PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Creighton, CJ				Creighton, C. J.			A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors	ONCOGENE			English	Article						akt pathway; mTOR; human breast cancer; gene expression pro. ling; meta-analysis	CELLS IN-VITRO; EXPRESSION SIGNATURE; TARGETED THERAPIES; CANCER; AKT; TAMOXIFEN; ACTIVATION; PATTERNS; ESTROGEN; SURVIVAL	The Akt pathway is commonly deregulated in many cancers. Clinical trials are currently underway to test the effectiveness of breast cancer treatment by inhibition of various Akt pathway intermediates. A set of genes induced by Akt in a transgenic mouse model, a subset of which were sensitive to mammalian target of rapamycin (mTOR) inhibitor RAD001, was examined in five public gene expression pro. le data sets of clinical breast tumor specimens (representing > 1000 different samples in all). In each of the clinical data sets, the Akt mouse model genes as a group were significantly overexpressed in human tumors having high levels of AKT1 mRNA. The subset of genes both upregulated by Akt and dependent on mTOR activity were associated with estrogen receptor-negative status, higher grade, increasing tumor size and poor prognosis in multiple patient cohorts; these associations were either not present or not as strong for the Akt-induced, mTOR-independent genes or for AKT1 expression alone. The genes shown here to be relevant to Akt-mTOR both experimentally and pathologically have the potential for use in a molecular diagnostic to determine which patients should receive mTOR antagonist treatment.	Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, Houston, TX 77030 USA	Baylor College of Medicine	Creighton, CJ (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, 1 Baylor Plaza MS 305, Houston, TX 77030 USA.	creighto@bcm.tmc.edu						Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tian L, 2005, P NATL ACAD SCI USA, V102, P13544, DOI 10.1073/pnas.0506577102; Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	23	51	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4648	4655		10.1038/sj.onc.1210245	http://dx.doi.org/10.1038/sj.onc.1210245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17213801				2022-12-25	WOS:000248037900005
J	Grinstein, E; Du, YH; Santourlidis, S; Christ, J; Uhrberg, M; Wernet, P				Grinstein, Edgar; Du, Yihua; Santourlidis, Simeon; Christ, Julia; Uhrberg, Markus; Wernet, Peter			Nucleolin regulates gene expression in CD34-positive hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; BCL-2 MESSENGER-RNA; HUMAN CD34 GENE; ACUTE MYELOGENOUS LEUKEMIA; AU-RICH ELEMENT; STEM-CELLS; C-MYB; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN	CD34 glycoprotein in human hematopoiesis is expressed on a subset of progenitor cells capable of self-renewal, multilineage differentiation, and hematopoietic reconstitution. Nucleolin is an abundant multifunctional phosphoprotein of growing eukaryotic cells, involved in regulation of gene transcription, chromatin remodeling, and RNA metabolism, whose transcripts are enriched in murine hematopoietic stem cells, as opposed to differentiated tissue. Here we show that, in human CD34-positive hematopoietic cells, nucleolin activates endogenous CD34 and Bcl-2 gene expression, and cell surface CD34 protein expression is thereby enhanced by nucleolin. Nucleolin-mediated activation of CD34 gene transcription results from direct sequence-specific interactions with the CD34 promoter region. Nucleolin expression prevails in CD34-positive cells mobilized into peripheral blood ( PB), as opposed to CD34-negative peripheral blood mononuclear cells ( PBMCs). Therefore, in intact CD34-positive mobilized PB cells, a recruitment of nucleolin to the CD34 promoter region takes place, accompanied by nucleosomal determinants of gene activity, which are absent from the CD34 promoter region in CD34-negative PBMCs. Our data show that nucleolin acts as a component of the gene regulation program of CD34-positive hematopoietic cells and provide further insights into processes by which human CD34-positive hematopoietic stem/progenitor cells are maintained.	Univ Dusseldorf, Med Ctr, Inst Transplantat Diagnost & Cellular Therapeut, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Grinstein, E (corresponding author), Univ Dusseldorf, Med Ctr, Inst Transplantat Diagnost & Cellular Therapeut, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@web.de		Santourlidis, Simeon/0000-0002-0743-5336				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; BURN TC, 1992, BLOOD, V80, P3051; CAMPOS L, 1993, BLOOD, V81, P3091; CIVIN CI, 1984, J IMMUNOL, V133, P157; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; DERENZINI M, 1995, LAB INVEST, V73, P497; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Drew E, 2005, IMMUNITY, V22, P43, DOI 10.1016/j.immuni.2004.11.014; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Graffmann N, 2006, ANAL BIOCHEM, V354, P308, DOI 10.1016/j.ab.2006.03.039; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Grinstein E, 2006, J BIOL CHEM, V281, P22223, DOI 10.1074/jbc.M513335200; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HE XY, 1992, BLOOD, V79, P2296; HE XY, 1994, BLOOD, V83, P1822, DOI 10.1182/blood.V83.7.1822.bloodjournal8371822; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Huddleson JP, 2006, J BIOL CHEM, V281, P15121, DOI 10.1074/jbc.M513406200; KASTAN MB, 1991, CANCER RES, V51, P4279; KOEFFLER HP, 1980, BLOOD, V56, P265; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Krause DS, 1996, BLOOD, V87, P1; KRAUSE DS, 1994, BLOOD, V84, P691; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lee SJ, 2004, BLOOD, V104, P2194, DOI 10.1182/blood-2003-07-2430; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Masumi A, 2006, ONCOGENE, V25, P5113, DOI 10.1038/sj.onc.1209522; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MORRIS JF, 1995, BLOOD, V86, P3640; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Orelio C, 2004, BLOOD, V103, P4084, DOI 10.1182/blood-2003-06-1827; Otake Y, 2005, MOL PHARMACOL, V67, P319, DOI 10.1124/mol.104.006080; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; Perrotti D, 1996, BLOOD, V88, P3336, DOI 10.1182/blood.V88.9.3336.bloodjournal8893336; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Radomska HS, 1999, BLOOD, V94, P3772, DOI 10.1182/blood.V94.11.3772.423k19_3772_3780; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; Roger B, 2002, J BIOL CHEM, V277, P10209, DOI 10.1074/jbc.M106412200; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Trompeter HI, 2005, J IMMUNOL, V174, P4135, DOI 10.4049/jimmunol.174.7.4135; Unwin RD, 2006, BLOOD, V107, P4687, DOI 10.1182/blood-2005-12-4995; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006	64	38	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12439	12449		10.1074/jbc.M608068200	http://dx.doi.org/10.1074/jbc.M608068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17255095	hybrid			2022-12-25	WOS:000245942800012
J	Ishida, H; Li, K; Yi, M; Lemon, SM				Ishida, Hisashi; Li, Kui; Yi, MinKyung; Lemon, Stanley M.			p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis c virus in human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBGENOMIC RNA REPLICATION; RIBOSOME ENTRY SITE; IFN-BETA PROMOTER; PROTEIN-KINASE; ADAPTER PROTEIN; B ACTIVITY; IDENTIFICATION; TRANSLATION; CULTURE; PHOSPHORYLATION	Cellular mechanisms that regulate the replication of hepatitis C virus ( HCV) RNA are poorly understood. p21-activated kinase 1 ( PAK1) is a serine/threonine kinase that has been suggested to participate in antiviral signaling. We studied its role in the cellular control of HCV replication. Transfection of PAK1-specific small interfering RNA enhanced viral RNA and protein abundance in established replicon cell lines as well as cells infected with chimeric genotype 1a/2a HCV, despite reducing cellular proliferation, suggesting specific regulation of HCV replication. PAK1 knockdown did not reduce interferon regulatory factor 3-dependent gene expression, indicating that this regulation is independent of the retinoic acid-inducible gene I/interferon regulatory factor 3 pathway. On the other hand, LY294002 and rapamycin abolished PAK1 phosphorylation and enhanced HCV abundance, suggesting that the mammalian target of rapamycin ( mTOR) is involved in PAK1 regulation of HCV. Small interfering RNA knockdown of the mTOR substrate p70 S6 kinase abrogated PAK1 phosphorylation and enhanced HCV RNA abundance, whereas overexpression of a constitutively active alternate substrate, eukaryotic translation initiation factor 4E-binding protein 1, increased cap-independent viral translation and viral RNA abundance without influencing PAK1 phosphorylation. Similar data indicated that mTOR is regulated by both phosphatidylinositol 3-kinase/Akt and ERK. Taken together, the data indicate that p70 S6 kinase activates PAK1 and contributes to phosphatidylinositol 3-kinase- and ERK-mediated regulation of HCV RNA replication.	Univ Texas, Med Branch, Ctr Hepatitis Res, Inst Human Infect & Immun, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lemon, SM (corresponding author), Univ Texas, Med Branch, Ctr Hepatitis Res, Inst Human Infect & Immun, 4-104 Blocker Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	smlemon@utmb.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035, R21AI063451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018054] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI063451, U19-AI40035] Funding Source: Medline; NIDA NIH HHS [R21-DA018054] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bost AG, 2003, J VIROL, V77, P4401, DOI 10.1128/JVI.77.7.4401-4408.2003; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Coito C, 2004, J VIROL, V78, P3502, DOI 10.1128/JVI.78.7.3502-3513.2004; Conzelmann KK, 2005, J VIROL, V79, P5241, DOI 10.1128/JVI.79.9.5241-5248.2005; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ishii N, 2006, J VIROL, V80, P4510, DOI 10.1128/JVI.80.9.4510-4520.2006; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Murata T, 2005, VIROLOGY, V340, P105, DOI 10.1016/j.virol.2005.06.015; Murata T, 2005, VIROLOGY, V331, P407, DOI 10.1016/j.virol.2004.10.036; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; Noyce RS, 2006, J VIROL, V80, P226, DOI 10.1128/JVI.80.1.226-235.2006; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Pause A, 2003, J BIOL CHEM, V278, P20374, DOI 10.1074/jbc.M210785200; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Quintavalle M, 2006, J VIROL, V80, P11305, DOI 10.1128/JVI.01465-06; Randall G, 2003, P NATL ACAD SCI USA, V100, P235, DOI 10.1073/pnas.0235524100; Scholle F, 2004, J VIROL, V78, P1513, DOI 10.1128/JVI.78.3.1513-1524.2004; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; Sharrard RM, 2007, CELL SIGNAL, V19, P129, DOI 10.1016/j.cellsig.2006.05.029; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang TH, 2000, J VIROL, V74, P11347, DOI 10.1128/JVI.74.23.11347-11358.2000; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Yi MK, 2007, J VIROL, V81, P629, DOI 10.1128/JVI.01890-06; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zhu HZ, 2003, J VIROL, V77, P5493, DOI 10.1128/JVI.77.9.5493-5498.2003	60	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11836	11848		10.1074/jbc.M610106200	http://dx.doi.org/10.1074/jbc.M610106200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17255101	hybrid			2022-12-25	WOS:000245941900026
J	Beck, V; Jaburek, M; Demina, T; Rupprecht, A; Porter, RK; Jezek, P; Pohl, EE				Beck, Valeri; Jaburek, Martin; Demina, Tatiana; Rupprecht, Anne; Porter, Richard K.; Jezek, Petr; Pohl, Elena E.			Polyunsaturated fatty acids activate human uncoupling proteins 1 and 2 in planar lipid bilayers	FASEB JOURNAL			English	Article						mitochondria; anion transporter; proton transport; artificial bilayer membranes; reactive oxygen species	MITOCHONDRIAL PROTON CONDUCTANCE; FLIP-FLOP; TRANSPORT MECHANISM; PURINE NUCLEOTIDES; H+ TRANSPORT; UCP2; MEMBRANES; LONG; MICE; RECONSTITUTION	Uncoupling proteins 1 (UCP1) and 2 (UCP2) belong to the family of mitochondrial anion transporters and share 59% sequence identity with each other. Whereas UCP1 was shown to be responsible for the rapid production of heat in brown adipose tissue, the primary function and transport properties of ubiquitously expressed UCP2 are controversially discussed. Here, for the first time, the activation pattern of the recombinant human UCP2 in comparison to the recombinant human UCP1 are studied using a well-defined system of planar lipid bilayers. It is shown that despite apparently different physiological functions, hUCP2 exhibited its protonophoric function similar to hUCP1-exclusively in the presence of long-chain fatty acids ( FA). The calculated hUCP2 transport rate of 4.5 s(-1) is the same order of magnitude, as shown previously for UCP1. It leads to the conclusion that the differences in the activity of both proteins in living mitochondria are based exclusively on their different expression level. Both proteins are activated much more effectively by polyunsaturated than by saturated FA. The proton and total membrane conductances increased in the range palmitic < oleic < eicosatrienoic < linoleic < retinoic < arachidonic acids. The higher uncoupling protein (UCP)-dependent conductance in the presence of polyunsaturated FA is explained on the basis of the FA cycling hypothesis.	Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Charitepl 1, D-10117 Berlin, Germany; Acad Sci Czech Republic, Inst Physiol, Dept Membrane Transport Biophys, Prague, Czech Republic; Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Trinity College Dublin	Pohl, EE (corresponding author), Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Charitepl 1, D-10117 Berlin, Germany.	elena.pohl@charite.de	Jaburek, Martin/B-9652-2012; Pohl, Elena E./A-4025-2009; Beck, Valeri/B-6658-2015; Jezek, Petr/B-9264-2012; Jabůrek, Martin/H-1114-2019	Pohl, Elena E./0000-0002-0604-5950; Beck, Valeri/0000-0003-1866-6559; Jezek, Petr/0000-0002-2720-9395; Jabůrek, Martin/0000-0002-4357-1116; Porter, Richard/0000-0001-9854-5161				Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Armstrong VT, 2003, ARCH BIOCHEM BIOPHYS, V414, P74, DOI 10.1016/S0003-9861(03)00159-0; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Beck V, 2006, BBA-BIOENERGETICS, V1757, P474, DOI 10.1016/j.bbabio.2006.03.006; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Breen EP, 2006, J BIOL CHEM, V281, P2114, DOI 10.1074/jbc.M511575200; Brunaldi K, 2005, J LIPID RES, V46, P245, DOI 10.1194/jlr.M400155-JLR200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Carroll AM, 2005, J BIOL CHEM, V280, P15534, DOI 10.1074/jbc.M413315200; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; Feller SE, 2002, J AM CHEM SOC, V124, P318, DOI 10.1021/ja0118340; FUKS B, 1994, BIOPHYS J, V66, P1404, DOI 10.1016/S0006-3495(94)80931-2; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; Hagen T, 2002, Minerva Med, V93, P41; HEATON GM, 1976, BIOCHEM J, V156, P635, DOI 10.1042/bj1560635; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Horvath B, 2002, BIOCHEM PHARMACOL, V64, P369, DOI 10.1016/S0006-2952(02)01167-X; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 2004, PHYSIOL RES, V53, pS199; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Nedergaard J, 1999, J BIOENERG BIOMEMBR, V31, P475, DOI 10.1023/A:1005400507802; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Paradis E, 2003, TRENDS MOL MED, V9, P522, DOI 10.1016/j.molmed.2003.10.009; Pohl EE, 2000, BIOCHEMISTRY-US, V39, P1834, DOI 10.1021/bi9919549; Porter Jr, 2001, POPTRONICS, V2, P3; Rial E, 2004, BBA-BIOENERGETICS, V1608, P122, DOI 10.1016/j.bbabio.2003.11.001; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 1999, J INTERN MED, V245, P637, DOI 10.1046/j.1365-2796.1999.00492.x; Ruzicka M, 2005, INT J BIOCHEM CELL B, V37, P809, DOI 10.1016/j.biocel.2004.10.016; Schmider W, 2000, J LIPID RES, V41, P775; Separovic F, 1996, BIOPHYS J, V71, P274, DOI 10.1016/S0006-3495(96)79223-8; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Urbankova E, 2003, J BIOL CHEM, V278, P32497, DOI 10.1074/jbc.M303721200; Vogler S, 2005, J MOL MED, V83, P806, DOI 10.1007/s00109-005-0661-5; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200; Zackova M, 2002, BIOSCIENCE REP, V22, P33, DOI 10.1023/A:1016009022186; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	68	79	82	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1137	1144		10.1096/fj.06-7489com	http://dx.doi.org/10.1096/fj.06-7489com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242157				2022-12-25	WOS:000245650400018
J	Zarse, K; Schulz, TJ; Birringer, M; Ristow, M				Zarse, Kim; Schulz, Tim J.; Birringer, Marc; Ristow, Michael			Impaired respiration is positively correlated with decreased life span in Caenorhabditis elegans models of Friedreich Ataxia	FASEB JOURNAL			English	Article						mitochondria; oxygen; frataxin; hormesis	OXIDATIVE STRESS; FRATAXIN; LONGEVITY; RESTRICTION; INTERFERENCE; EXPRESSION; EXTENDS	Impaired expression of mitochondrial genes causes alterations in life span of the nematode Caenorhabditis elegans. Intriguingly, although some of these genes have been shown to extend life expectancy and reduce aging processes, others are known to shorten life span in the same model organism. Reduced expression of a mitochondrial protein called frataxin causes a neurodegenerative disorder named Friedreich Ataxia, which decreases life span in humans. Surprisingly, reduced expression of the C. elegans frataxin homologue frh-1 has been associated with both increased as well as decreased life span by different laboratories. To further elucidate these conflicting findings, here we show that different RNA interference (RNAi) constructs directed against frh-1 reduce C. elegans life span. Moreover, we show that frh-1-inhibiting RNAi impairs oxygen consumption and that respiratory rate is positively correlated with life span in this multicellular eukaryote (r = 0.8566), suggesting that > 73% of life span variance in C. elegans is explained by changes in respiratory rate. Taken together, impaired mitochondrial metabolism due to RNAi-mediated inhibition of the frataxin homologue frh-1 causes both impaired respiration as well as decreased life span in the multicellular eukaryote C. elegans.	Univ Jena, Dept Human Nutr, Inst Nutr, D-07743 Jena, Germany; German Inst Human Nutr, Nuethetal, Germany	Friedrich Schiller University of Jena; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Ristow, M (corresponding author), Univ Jena, Dept Human Nutr, Inst Nutr, 29 Dornburger St, D-07743 Jena, Germany.	mristow@mristow.org	Ristow, Michael/O-9858-2014; Schulz, Tim/F-4842-2013; Zarse, Kim/D-2133-2016	Ristow, Michael/0000-0003-2109-2453; Schulz, Tim/0000-0002-8413-3972; Zarse, Kim/0000-0003-2542-6123; Birringer, Marc/0000-0003-0343-4704				Anson RM, 2004, AGING CELL, V3, P29, DOI 10.1111/j.1474-9728.2003.00077.x; Ausubel F, 1997, SHORT PROTOCOLS MOL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Isaya G, 2004, ACTA PAEDIATR, V93, P68, DOI 10.0180/08035320310021318; Johnson TE, 2002, J INHERIT METAB DIS, V25, P197, DOI 10.1023/A:1015677828407; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; McKusick V. A., 2006, ONLINE MENDELIAN INH; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nemoto S, 2006, J BIOL CHEM, V281, P10555, DOI 10.1074/jbc.M511626200; Pearl R., 1928, RATE LIVING BEING AC; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Rea SL, 2005, NAT GENET, V37, P894, DOI 10.1038/ng1608; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Southam CM, 1943, PHYTOPATHOLOGY, V33, P517; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; Ventura N, 2006, FASEB J, V20, P1029, DOI 10.1096/fj.06-0505ufm; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; Weindruch R., 1988, RETARDATION AGING DI	35	41	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1271	1275		10.1096/fj.06-6994com	http://dx.doi.org/10.1096/fj.06-6994com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215485				2022-12-25	WOS:000245650400031
J	Basu, S; Jala, VR; Mathis, S; Rajagopal, ST; Del Prete, A; Maturu, P; Trent, JO; Haribabu, B				Basu, Sudeep; Jala, Venkatakrishna R.; Mathis, Steven; Rajagopal, Soujanya T.; Del Prete, Annalisa; Maturu, Paramahamsa; Trent, John O.; Haribabu, Bodduluri			Critical role for polar residues in coupling leukotriene B-4 binding to signal transiduction in BLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; LIGAND-BINDING; RECEPTOR ACTIVATION; MOLECULAR-MECHANISMS; PARTIAL AGONISTS; GPCR FUNCTION; AMINO-ACIDS; RHODOPSIN; SITE; MUTAGENESIS	Leukotriene B-4 (LTB4) mediates a variety of inflammatory diseases such as asthma, arthritis, atherosclerosis, and cancer through activation of the G-protein-coupled receptor, BLT1. Using in silica molecular dynamics simulations combined with site-directed mutagenesis we characterized the ligand binding site and activation mechanism for BLT1. Mutation of residues predicted as potential ligand contact points in transmembrane domains (TMs) III (H94A and Y102A), V (E185A), and VI (N241A) resulted in reduced binding affinity. Analysis of arginines in extracellular loop 2 revealed that mutating arginine 156 but not arginine 171 or 178 to alanine resulted in complete loss of LTB4 binding to BLT1. Structural models for the ligand-free and ligand-bound states of BLT1 revealed an activation core formed around Asp-64, displaying multiple dynamic interactions with Asn-36, Ser-100, and Asn-281 and a triad of serines, Ser-276, Ser-277, and Ser-278. Mutagenesis of many of these residues in BLT1 resulted in loss of signaling capacity while retaining normal LTB4 binding function. Thus, polar residues within TMs III, V, and VI and extracellular loop 2 are critical for ligand binding, whereas polar residues in TMs II, III, and VII play a central role in transducing the ligand-induced conformational change to activation. The delineation of a validated binding site and activation mechanism should facilitate structurebased design of inhibitors targeting BLT1.	Univ Louisville, James Graham Brown Canc Ctr, Tumor Immunobiol Program, Louisville, KY 40202 USA; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Haribabu, B (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Tumor Immunobiol Program, 529 S Jackson St, Louisville, KY 40202 USA.	H0bodd01@gwise.louisville.edu	Bodduluri, Haribabu/A-2584-2010; Jala, Venkatakrishna R/K-7255-2018; Del Prete, Annalisa/Z-1368-2019	Bodduluri, Haribabu/0000-0002-8261-3294; Jala, Venkatakrishna R/0000-0002-4206-7305; Del Prete, Annalisa/0000-0002-3738-412X; Mathis, Steven/0000-0001-7704-1220; trent, John/0000-0002-7346-4231	NIAID NIH HHS [AI52381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gao ZG, 2002, J BIOL CHEM, V277, P19056, DOI 10.1074/jbc.M110960200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hata AN, 2005, J BIOL CHEM, V280, P32442, DOI 10.1074/jbc.M502563200; Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liu W, 2004, J MOL BIOL, V337, P713, DOI 10.1016/j.jmb.2004.02.001; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Ogilvie P, 2004, J IMMUNOL, V172, P6715, DOI 10.4049/jimmunol.172.11.6715; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Rao JVK, 2000, EUR J BIOCHEM, V267, P5967, DOI 10.1046/j.1432-1327.2000.01667.x; Sabirsh A, 2006, BIOCHEMISTRY-US, V45, P5733, DOI 10.1021/bi060076t; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shao WH, 2006, J IMMUNOL, V176, P6254, DOI 10.4049/jimmunol.176.10.6254; Shin N, 2002, MOL PHARMACOL, V62, P38, DOI 10.1124/mol.62.1.38; Spijker P, 2006, P NATL ACAD SCI USA, V103, P4882, DOI 10.1073/pnas.0511329103; Steeber DA, 1997, J IMMUNOL, V159, P952; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; Urizar E, 2005, J BIOL CHEM, V280, P17135, DOI 10.1074/jbc.M414678200; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHOU W, 1994, MOL PHARMACOL, V45, P165	58	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10005	10017		10.1074/jbc.M609552200	http://dx.doi.org/10.1074/jbc.M609552200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17237498	Green Published, hybrid			2022-12-25	WOS:000245421700075
J	Chen, KH; Liu, S; Bankston, LA; Liddington, RC; Leppla, SH				Chen, Kuang-Hua; Liu, Shihui; Bankston, Laurie A.; Liddington, Robert C.; Leppla, Stephen H.			Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY MORPHOGENESIS PROTEIN-2; CRYSTAL-STRUCTURE; BACILLUS-ANTHRACIS; LETHAL FACTOR; DOMAIN; UROKINASE; BINDING; IDENTIFICATION; ENDOTHELIUM; SPECIFICITY	Anthrax toxin, a three-component protein toxin secreted by Bacillus anthracis, assembles into toxic complexes at the surface of receptor-bearing eukaryotic cells. The protective antigen (PA) protein binds to receptors, either tumor endothelial cell marker 8 (TEM8) or CMG2 (capillary morphogenesis protein 2), and orchestrates the delivery of the lethal and edema factors into the cytosol. TEM8 is reported to be overexpressed during tumor angiogenesis, whereas CMG2 is more widely expressed in normal tissues. To extend prior work on targeting of tumor with modified anthrax toxins, we used phage display to select PA variants that preferentially bind to TEM8 as compared with CMG2. Substitutions were randomly introduced into residues 605-729 of PA, within the C-terminal domain 4 of PA, which is the principal region that contacts receptor. Candidates were characterized in cellular cytotoxicity assays with Chinese hamster ovary (CHO) cells expressing either TEM8 or CMG2. A PA mutant having the substitutions R659S and M662R had enhanced specificity toward TEM8-overexpressing CHO cells. This PA variant also displayed broad and potent tumoricidal activity to various human tumor cells, especially to HeLa and A549/ATCC cells. By contrast, the substitution N657Q significantly reduced toxicity to TEM8 but not CMG2-overexpressing CHO cells. Our results indicate that certain amino acid substitutions within PA domain 4 create anthrax toxins that selectively kill human tumor cells. The PA R659S/M662R protein may be useful as a therapeutic agent for cancer treatment.	NIAID, NIH, Lab Bacterial Dis, Bethesda, MD 20892 USA; Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Sanford Burnham Prebys Medical Discovery Institute	Leppla, SH (corresponding author), NIAID, NIH, Lab Bacterial Dis, Bldg 33,Rm 1W20B, Bethesda, MD 20892 USA.	sleppla@niaid.nih.gov		Liu, Shihui/0000-0003-3444-1069	Intramural NIH HHS [Z01 AI000929-05] Funding Source: Medline; NIAID NIH HHS [AI055789, P01 AI055789, P01 AI055789-040001] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055789, Z01AI001031, Z01AI000929] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 2005, TRENDS MICROBIOL, V13, P72, DOI 10.1016/j.tim.2004.12.004; ARORA N, 1993, J BIOL CHEM, V268, P3334; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brossier F, 1999, INFECT IMMUN, V67, P964, DOI 10.1128/IAI.67.2.964-967.1999; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 2006, COMPREHENSIVE SOURCE, P323; LIU S, 2006, CELL MICROB; Liu SH, 2000, CANCER RES, V60, P6061; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Ramirez DM, 2002, J IND MICROBIOL BIOT, V28, P232, DOI 10.1038/sj/jim/700239; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SINGH Y, 1989, J BIOL CHEM, V264, P19103; St Croix B, 2000, SCIENCE, V289, P1197; Varughese M, 1999, INFECT IMMUN, V67, P1860; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	33	30	35	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9834	9845		10.1074/jbc.M611142200	http://dx.doi.org/10.1074/jbc.M611142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251181	hybrid, Green Accepted			2022-12-25	WOS:000245421700058
J	Murray, IVJ; Liu, L; Komatsu, H; Uryu, K; Xiao, G; Lawson, JA; Axelsen, PH				Murray, Ian V. J.; Liu, Liu; Komatsu, Hiroaki; Uryu, Kunihiro; Xiao, Gang; Lawson, John A.; Axelsen, Paul H.			Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; FIBRIL FORMATION; GENE-EXPRESSION; PEROXIDATION; STRESS; PEPTIDES	Evidence of oxidative stress and the accumulation of fibrillar amyloid beta proteins (A beta) in senile plaques throughout the cerebral cortex are consistent features in the pathology of Alzheimer disease. To define a mechanistic link between these two processes, various aspects of the relationship between oxidative lipid membrane damage and amyloidogenesis were characterized by chemical and physical techniques. Earlier studies of this relationship demonstrated that oxidatively damaged synthetic lipid membranes promoted amyloidogenesis. The studies reported herein specify that 4-hydroxy-2-nonenal (HNE) is produced in both synthetic lipids and human brain lipid extracts by oxidative lipid damage and that it can account for accelerated amyloidogenesis. A beta promotes the copper-mediated generation of HNE from polyunsaturated lipids, and in turn, HNE covalently modifies the histidine side chains of A beta. HNE-modified A beta have an increased affinity for lipid membranes and an increased tendency to aggregate into amyloid fibrils. Thus, the prooxidant activity of A beta leads to its own covalent modification and to accelerated amyloidogenesis. These results illustrate how lipid membranes may be involved in templating the pathological misfolding of A beta, and they suggest a possible chemical mechanism linking oxidative stress with amyloid formation.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Proteom Core Facil, Penn Genom Inst, Philadelphia, PA 19104 USA; Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Axelsen, PH (corresponding author), Univ Penn, Dept Pharmacol, 105 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	axe@pharm.med.upenn.edu	Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360	NIA NIH HHS [R03 AG027893-02, R03 AG027893-01, P30 AG010124, R03 AG027893-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010124, R03AG027893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alderton AL, 2003, BIOCHEMISTRY-US, V42, P4398, DOI 10.1021/bi0271695; Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Bassett CN, 1999, LIPIDS, V34, P1273, DOI 10.1007/s11745-999-0478-1; Bayer TA, 2006, CLIN NEUROPATHOL, V25, P163; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bieschke J, 2005, BIOCHEMISTRY-US, V44, P4977, DOI 10.1021/bi0501030; Bolgar MS, 1996, J BIOL CHEM, V271, P27999, DOI 10.1074/jbc.271.45.27999; Bolgar MS, 1996, ANAL CHEM, V68, P2325, DOI 10.1021/ac9601021; Boutaud O, 2002, J NEUROCHEM, V82, P1003, DOI 10.1046/j.1471-4159.2002.01064.x; Boutaud O, 2001, ADV EXP MED BIOL, V500, P133; Boyd-Kimball D, 2005, BRAIN RES, V1044, P206, DOI 10.1016/j.brainres.2005.02.086; Bradbury Lisa E, 2004, Methods Mol Biol, V264, P245; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; Butterfield DA, 2004, BRAIN PATHOL, V14, P426; Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012; Carini M, 2004, MASS SPECTROM REV, V23, P281, DOI 10.1002/mas.10076; CHRISTIE WW, 2003, LIPID ANAL, P96; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Fenaille F, 2003, J AM SOC MASS SPECTR, V14, P215, DOI 10.1016/S1044-0305(02)00911-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galbusera C, 2004, CURR ALZHEIMER RES, V1, P103, DOI 10.2174/1567205043332171; HALLIWELL B, 1999, FREE RADIC BIOL MED; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Koppaka V, 2003, J BIOL CHEM, V278, P36277, DOI 10.1074/jbc.M301334200; Koppaka V, 2001, LANGMUIR, V17, P6309, DOI 10.1021/la010731s; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lewczuk P, 2004, BIOL PSYCHIAT, V55, P524, DOI 10.1016/j.biopsych.2003.10.014; Lewis HD, 2004, NEUROBIOL AGING, V25, P1175, DOI 10.1016/j.neurobiolaging.2003.12.009; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; Loeffler DA, 1996, BRAIN RES, V738, P265, DOI 10.1016/S0006-8993(96)00782-2; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Magni F, 2002, RAPID COMMUN MASS SP, V16, P1485, DOI 10.1002/rcm.743; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8; McGowan E, 1999, NEUROBIOL DIS, V6, P231, DOI 10.1006/nbdi.1999.0243; McGrath LT, 2001, QJM-MON J ASSOC PHYS, V94, P485, DOI 10.1093/qjmed/94.9.485; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Murray IVJ, 2005, BIOCHEMISTRY-US, V44, P12606, DOI 10.1021/bi050926p; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Puglielli L, 2005, J CLIN INVEST, V115, P2556, DOI 10.1172/JCI23610; Pype S, 2003, J NEUROCHEM, V84, P602, DOI 10.1046/j.1471-4159.2003.01556.x; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rofina JE, 2004, AMYLOID, V11, P90, DOI 10.1080/13506120412331285779; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SCHAUR RJ, 2006, MOL ASPECTS MED, V24, P149; Schippling S, 2000, FREE RADICAL BIO MED, V28, P351, DOI 10.1016/S0891-5849(99)00247-6; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Smith MA, 2002, FREE RADICAL BIO MED, V33, P1194, DOI 10.1016/S0891-5849(02)01021-3; Standridge John B., 2006, Current Alzheimer Research, V3, P95, DOI 10.2174/156720506776383068; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2006, FREE RADICAL BIO MED, V41, P202, DOI 10.1016/j.freeradbiomed.2006.01.021; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; WHITE DA, 1973, PHOSPHOLIPID COMPOSI, P441; Wu Yanjue, 2005, Current Alzheimer Research, V2, P37, DOI 10.2174/1567205052772768; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yao Y, 2003, NEUROLOGY, V61, P475, DOI 10.1212/01.WNL.0000070185.02546.5D; Yoshimoto N, 2005, J BIOSCI BIOENG, V100, P455, DOI 10.1263/jbb.100.455; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	82	94	96	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9335	9345		10.1074/jbc.M608589200	http://dx.doi.org/10.1074/jbc.M608589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255094	Green Accepted, hybrid			2022-12-25	WOS:000245421700005
J	Yang, W; Zheng, CY; Song, QL; Yang, XJ; Qiu, S; Liu, CQ; Chen, Z; Duan, SM; Luo, JH				Yang, Wei; Zheng, Chanying; Song, Qilin; Yang, Xiujuan; Qiu, Shuang; Liu, Chunqing; Chen, Zhong; Duan, Shumin; Luo, Jianhong			A three amino acid tail following the TM4 region of the N-methyl-D-aspartate receptor (NR) 2 subunits is sufficient to overcome endoplasmic reticulum retention of NR1-1a subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; CELL-SURFACE EXPRESSION; NMDA RECEPTOR; ER RETENTION; CHANNEL; TRAFFICKING; GLUTAMATE; SIGNAL; PREASSOCIATION; STOICHIOMETRY	The cytoplasmic C-terminal domains of NR2 subunits have been proposed to modulate the assembly and trafficking of NMDA receptors. However, questions remain concerning which domains in the C terminus of NR2 subunits control the assembly of receptor complexes and how the assembled complexes are selectively trafficked through the various cellular compartments such as endoplasmic reticulum (ER) to the cell surface. In the present study, we found that the three amino acid tail after the TM4 region of NR2 subunits is necessary for surface expression of functional NMDA receptors, while truncations with only two amino acids following the TM4 region (NR2 Delta 2) completely eliminated surface expression of the NMDA receptor on co-expression with NR1-1a in HEK293 cells. FRET (fluorescence resonance energy transfer) analysis showed that these NR2 Delta 2 truncations are able to form homomers and heteromers on co-expression with NR1-1a. Furthermore, when NR2 Delta 2 subunits were cotransfected with either the NR1-4a or NR1-1a(AAA) mutant, lacking the ER retention motif (RRR), functional NMDA receptors were detected in the transfected HEK293 cells. Unexpectedly, we found that the replacement of five residues after TM4 with alanines gave results indistinguishable from those of NR2B Delta 5 (EHLFY), demonstrating the short tail following the TM4 of NR2 subunits is not sequence-specific-dependent. Taken together, our results show that the C terminus of the NR2 subunits is not necessary for the assembly of NMDA receptor complexes, whereas a three amino acid long cytoplasmic tail following the TM4 of NR2 subunits is sufficient to overcome the ER retention existing in the C terminus of NR1, allowing the assembled NMDA receptors to reach the cell surface.	Zhejiang Univ, Sch Med, Inst Neurosci, Dept Neurobiol, Hangzhou 3100058, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China	Zhejiang University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, JH (corresponding author), Zhejiang Univ, Sch Med, Inst Neurosci, Dept Neurobiol, Hangzhou 3100058, Peoples R China.	luojianhong@zju.edu.cn	Luo, jian/HGE-7331-2022					CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; de Armentia ML, 2003, J NEUROSCI, V23, P6876; Dingledine R, 1999, PHARMACOL REV, V51, P7; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Hawkins LM, 2004, J BIOL CHEM, V279, P28903, DOI 10.1074/jbc.M402599200; Holmes KD, 2002, J BIOL CHEM, V277, P1457, DOI 10.1074/jbc.M107809200; Khalil H, 2005, J CELL SCI, V118, P4679, DOI 10.1242/jcs.02592; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; McIlhinney RAJ, 1996, NEUROSCIENCE, V70, P989, DOI 10.1016/0306-4522(95)00419-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; Mohrmann R, 2002, J NEUROSCI RES, V68, P265, DOI 10.1002/jnr.10219; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Okabe S, 1999, J NEUROSCI, V19, P7781; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Qiu S, 2005, J BIOL CHEM, V280, P24923, DOI 10.1074/jbc.M413915200; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rossi P, 2002, J NEUROSCI, V22, P9687; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Steigerwald F, 2000, J NEUROSCI, V20, P4573, DOI 10.1523/JNEUROSCI.20-12-04573.2000; Thompson SM, 2000, CURR BIOL, V10, pR218, DOI 10.1016/S0960-9822(00)00370-5; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	34	37	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9269	9278		10.1074/jbc.M700050200	http://dx.doi.org/10.1074/jbc.M700050200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255096	hybrid			2022-12-25	WOS:000245780300074
J	Scarselli, M; Li, B; Kim, SK; Wess, J				Scarselli, Marco; Li, Bo; Kim, Soo-Kyung; Wess, Juergen			Multiple residues in the second extracellular loop are critical for M-3 muscarinic acetylcholine receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 3RD CYTOPLASMIC LOOP; RANDOM MUTAGENESIS; TRANSMEMBRANE SEGMENTS; MOLECULAR-MECHANISMS; BINDING-SITE; YEAST; IDENTIFICATION; MUTATIONS; LOCALIZATION	Recent studies suggest that the second extracellular loop (o2 loop) of bovine rhodopsin and other class I G protein-coupled receptors (GPCRs) targeted by biogenic amine ligands folds deeply into the transmembrane receptor core where the binding of cis-retinal and biogenic amine ligands is known to occur. In the past, the potential role of the o2 loop in agonist-dependent activation of biogenic amine GPCRs has not been studied systematically. To address this issue, we used the M-3 muscarinic acetylcholine receptor (M3R), a prototypic class I GPCR, as a model system. Specifically, we subjected the o2 loop of the M3R to random mutagenesis and subsequently applied a novel yeast genetic screen to identity single amino acid substitutions that interfered with M3R function. This screen led to the recovery of about 20 mutant M3Rs containing single amino acid changes in the o2 loop that were inactive in yeast. In contrast, application of the same strategy to the extracellular N-terminal domain of the M3R did not yield any single point mutations that disrupted M3R function. Pharmacological characterization of many of the recovered mutant M3Rs in mammalian cells, complemented by site-directed mutagenesis studies, indicated that the presence of several o2 loop residues is important for efficient agonist-induced M3R activation. Besides the highly conserved Cys(220) residue, Gln(207), Gly(211), Arg(213), Gly(218), Ile(222), Phe(224), Leu(225), and Pro(228) were found to be of particular functional importance. In general, mutational modification of these residues had little effect on agonist binding affinities. Our findings are therefore consistent with a model in which multiple o2 loop residues are involved in stabilizing the active state of the M3R. Given the high degree of structural homology found among all biogenic amine GPCRs, our findings should be of considerable general relevance.	NIDDK, Mol Signaling Sect, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Recognit Sect, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Lab Bioorgan Chem, NIH, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov		Scarselli, Marco/0000-0001-5087-3182	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031130] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Behrendt HJ, 2004, BRIT J PHARMACOL, V141, P737, DOI 10.1038/sj.bjp.0705652; Beukers MW, 2005, TRENDS PHARMACOL SCI, V26, P533, DOI 10.1016/j.tips.2005.08.005; Birdsall NJM, 2005, MINI-REV MED CHEM, V5, P523, DOI 10.2174/1389557054023251; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bradley KN, 2000, PHARMACOL THERAPEUT, V85, P87, DOI 10.1016/S0163-7258(99)00064-9; CADWELL RC, 1994, PCR METH APPL, V3, pS136; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Dowell SJ, 2002, RECEPTOR CHANNEL, V8, P343, DOI 10.1080/10606820214647; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Herold CL, 2004, J BIOL CHEM, V279, P11456, DOI 10.1074/jbc.M301734200; Karlsson E, 2000, BIOCHIMIE, V82, P793, DOI 10.1016/S0300-9084(00)01176-7; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Kukkonen A, 2004, J BIOL CHEM, V279, P50923, DOI 10.1074/jbc.M406424200; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; Li B, 2005, J BIOL CHEM, V280, P5664, DOI 10.1074/jbc.M411623200; Li B, 2007, NAT METHODS, V4, P169, DOI 10.1038/nmeth990; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; Minic J, 2005, CURR MED CHEM, V12, P961, DOI 10.2174/0929867053507261; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pausch Mark H., 1998, P196; Pausch MH, 1997, TRENDS BIOTECHNOL, V15, P487, DOI 10.1016/S0167-7799(97)01119-0; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Schmidt C, 2003, J BIOL CHEM, V278, P30248, DOI 10.1074/jbc.M304991200; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; SOMMERS CM, 1999, REC BIOCH M, P141; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x	48	94	101	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7385	7396		10.1074/jbc.M610394200	http://dx.doi.org/10.1074/jbc.M610394200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213190	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000245080900050
J	Webb, DJ; Zhang, HY; Majumdar, D; Horwitz, AF				Webb, Donna J.; Zhang, Huaye; Majumdar, Devi; Horwitz, Alan F.			alpha 5 integrin signaling regulates the formation of spines and synapses in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED PLASTICITY; DENDRITIC SPINES; SYNAPTIC PLASTICITY; MENTAL-RETARDATION; ADHESION; RECEPTOR; GIT1; SRC; IDENTIFICATION; MORPHOGENESIS	The actin-based dynamics of dendritic spines play a key role in synaptic plasticity, which underlies learning and memory. Although it is becoming increasingly clear that modulation of actin is critical for spine dynamics, the upstream molecular signals that regulate the formation and plasticity of spines are poorly understood. In non-neuronal cells, integrins are critical modulators of the actin cytoskeleton, but their function in the nervous system is not well characterized. Here we show that alpha 5 integrin regulates spine morphogenesis and synapse formation in hippocampal neurons. Knockdown of alpha S integrin expression using small interfering RNA decreased the number of dendritic protrusions, spines, and synapses. Expression of constitutively active or dominant negative alpha 5 integrin also resulted in alterations in the number of dendritic protrusions, spines, and synapses. alpha 5 integrin signaling regulates spine morphogenesis and synapse formation by a mechanism that is dependent on Src kinase, Rac, and the signaling adaptor GIT1. Alterations in the activity or localization of these molecules result in a significant decrease in the number of spines and synapses. Thus, our results point to a critical role for integrin signaling in regulating the formation of dendritic spines and synapses in hippocampal neurons.	Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37235 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	Vanderbilt University; Vanderbilt University; University of Virginia	Webb, DJ (corresponding author), Vanderbilt Univ, Dept Biol Sci, VU Stn B,Box 35-1634, Nashville, TN 37235 USA.	donna.webb@vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023244, R37GM023244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071674] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM023244, GM23244, R37 GM023244] Funding Source: Medline; NIMH NIH HHS [R01 MH071674, R01 MH071674-02, MH071674] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BAHR BA, 1992, BIOCHEM J, V281, P137, DOI 10.1042/bj2810137; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; Bienvenu T, 2000, AM J MED GENET, V93, P294, DOI 10.1002/1096-8628(20000814)93:4<294::AID-AJMG8>3.0.CO;2-F; Cao ZJ, 1998, J BIOL CHEM, V273, P31670, DOI 10.1074/jbc.273.48.31670; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dunaevsky A, 2003, TRENDS NEUROSCI, V26, P155, DOI 10.1016/S0166-2236(03)00028-6; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Goslin K., 1998, CULTURING NERVE CELL, P339; GRAY EG, 1959, NATURE, V183, P1592, DOI 10.1038/1831592a0; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Manabe R, 2002, J CELL SCI, V115, P1497; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Shattil SJ, 2005, TRENDS CELL BIOL, V15, P399, DOI 10.1016/j.tcb.2005.06.005; Shi Y, 2006, J NEUROSCI, V26, P1813, DOI 10.1523/JNEUROSCI.4091-05.2006; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; Webb DJ, 2006, J CELL SCI, V119, P2847, DOI 10.1242/jcs03044; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Zhang HY, 2003, J CELL BIOL, V161, P131, DOI 10.1083/jcb.200211002; Zhang HY, 2005, J NEUROSCI, V25, P3379, DOI 10.1523/JNEUROSCI.3553-04.2005	33	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6929	6935		10.1074/jbc.M610981200	http://dx.doi.org/10.1074/jbc.M610981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213186	Green Accepted, hybrid			2022-12-25	WOS:000245080900004
J	Chosed, R; Tomchick, DR; Brautigam, CA; Mukherjee, S; Negi, VS; Machius, M; Orth, K				Chosed, Renee; Tomchick, Diana R.; Brautigam, Chad A.; Mukherjee, Sohini; Negi, Veera S.; Machius, Mischa; Orth, Kim			Structural analysis of Xanthomonas XopD provides insights into substrate specificity of ubiquitin-like protein proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO; EFFECTOR; SYSTEM; ARABIDOPSIS; ENZYMES; DIVERSITY; TRANSPORT	XopD (Xanthomonas outer protein D), a type III secreted effector from Xanthomonas campestris pv. vesicatoria, is a desumoylating enzyme with strict specificity for its plant small ubiquitin-like modifier (SUMO) substrates. Based on SUMO sequence alignments and peptidase assays with various plant, yeast, and mammalian SUMOs, we identified residues in SUMO that contribute to XopD/SUMO recognition. Further predictions regarding the enzyme/substrate specificity were made by solving the XopD crystal structure. By incorporating structural information with sequence alignments and enzyme assays, we were able to elucidate determinants of the rigid SUMO specificity exhibited by the Xanthomonas virulence factor XopD.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Orth, K (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Kim.Orth@utsouthwestern.edu	Orth, Kim/AAV-4421-2021; Tomchick, Diana/HGV-2018-2022	Orth, Kim/0000-0002-0678-7620; Brautigam, Chad/0000-0001-6563-1338; Tomchick, Diana/0000-0002-7529-4643; Chosed, Renee/0000-0002-0442-0833	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI056404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; Bailey J.L., 1967, TECHNIQUES PROTEIN C; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Chosed R, 2006, BIOCHEM J, V398, P521, DOI 10.1042/BJ20060426; Colby T, 2006, PLANT PHYSIOL, V142, P318, DOI 10.1104/pp.106.085415; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hotson A, 2003, MOL MICROBIOL, V50, P377, DOI 10.1046/j.1365-2958.2003.03730.x; Jones JB, 1998, ANNU REV PHYTOPATHOL, V36, P41, DOI 10.1146/annurev.phyto.36.1.41; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Misaghi S, 2006, MOL MICROBIOL, V61, P142, DOI 10.1111/j.1365-2958.2006.05199.x; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Mudgett MB, 2005, ANNU REV PLANT BIOL, V56, P509, DOI 10.1146/annurev.arplant.56.032604.144218; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murtas G, 2003, PLANT CELL, V15, P2308, DOI 10.1105/tpc.015487; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Roden J, 2004, MOL PLANT MICROBE IN, V17, P633, DOI 10.1094/MPMI.2004.17.6.633; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	39	61	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6773	6782		10.1074/jbc.M608730200	http://dx.doi.org/10.1074/jbc.M608730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204475	hybrid			2022-12-25	WOS:000244867200087
J	Li, P; Jiang, N; Nagarajan, S; Wohlhueter, R; Selvaraj, P; Zhu, C				Li, Ping; Jiang, Ning; Nagarajan, Shanmugam; Wohlhueter, Robert; Selvaraj, Periasamy; Zhu, Cheng			Affinity and kinetic analysis of Fc gamma receptor IIIa (CD16a) binding to IgG ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; RIII; CELLS; IDENTIFICATION; CONCURRENT; ANTIBODIES; FRAGMENT; ADHESION; ISOFORMS; COMPLEX	Binding of pathogen-bound immunoglobulin IS (IgG) to cell surface Fc gamma receptors (FcyRs) triggers a wide variety of effector functions. The binding kinetics and affinities of IgG-Fc gamma R interactions are hence important parameters for understanding Fc gamma R-mediated immune functions. We have measured the kinetic rates and equilibrium dissociation constants of IgG binding to a soluble Fc gamma RIIIa fused with Ig Fc (sCD16a) using the surface plasmon resonance technique. sCE116a interacted with monomeric human IgG and its subtypes IgG1 and IgG3 as well as rabbit IgG with on-rates of 6.5 X 10(3) 8.2 X 10(3), 1.1 X 10(4) and 1.8 X 10(4)M(-1) s(-1), off-rates of 4.7 X 10(-3), 5.7 X 10(-3) 5.9 X 10(-3), and 1.9 X 10(-2) s(-1), and equilibrium dissociation constants of 0.72, 0.71, 0.56, and 1.1 mu m, respectively. The kinetics and affinities measured by surface plasmon resonance agreed with those obtained from real time flow cytometry and competition inhibition binding experiments using cell surface CD16a. These data add to our understanding of IgG-Fc gamma R interactions.	Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University; Centers for Disease Control & Prevention - USA	Zhu, C (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	cheng.zhu@bme.gatech.edu	Jiang, Ning/M-5448-2017; Zhu, Cheng/A-5724-2011	Jiang, Ning/0000-0003-1103-5922; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038282, R29AI038282, R01AI049400] Funding Source: NIH RePORTER; NIAID NIH HHS [AI049400, AI38282] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Chang KC, 1999, BIOPHYS J, V76, P1280, DOI 10.1016/S0006-3495(99)77291-7; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAPPEL MS, 1993, J BIOL CHEM, V268, P25124; Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; FRIDMAN WH, 1997, CELL MEDIATED EFFECT; Galon J, 1997, EUR J IMMUNOL, V27, P1928, DOI 10.1002/eji.1830270816; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; Huang J, 2004, J BIOL CHEM, V279, P44915, DOI 10.1074/jbc.M407039200; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; Li P, 2002, MOL IMMUNOL, V38, P527, DOI 10.1016/S0161-5890(01)00088-8; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; PROPERT D, 1995, EXP CLIN IMMUNOGENET, V12, P198; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Riper JW, 1998, BIOPHYS J, V74, P492, DOI 10.1016/S0006-3495(98)77807-5; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, BIOCHEMISTRY-US, V38, P8469, DOI 10.1021/bi982889q; Tamm A, 1996, J IMMUNOL, V157, P1576; van de Winkel JG, 1996, HUMAN IGG FC RECEPTO; VANCE BA, 1993, J IMMUNOL, V151, P6429; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Williams TE, 2000, BIOPHYS J, V79, P1867, DOI 10.1016/S0006-3495(00)76436-8; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Zhang F, 2005, J BIOL CHEM, V280, P42207, DOI 10.1074/jbc.M510407200	36	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6210	6221		10.1074/jbc.M609064200	http://dx.doi.org/10.1074/jbc.M609064200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202140	hybrid			2022-12-25	WOS:000244867200027
J	de la Vega, MR; Sevilla, RG; Hermoso, A; Lorenzo, J; Tanco, S; Diez, A; Fricker, LD; Bautista, JM; Aviles, FX				de la Vega, Monica Rodriguez; Sevilla, Rafael G.; Hermoso, Antoni; Lorenzo, Julia; Tanco, Sebastian; Diez, Amalia; Fricker, Lloyd D.; Bautista, Jose M.; Aviles, Francesc X.			Nna1-like proteins are active metallocarboxypeptidases of a new and diverse M14 subfamily	FASEB JOURNAL			English	Article						peptidase classification; CCP; tubulin processing degradome; tubulinyl-Tyr carboxypeptidase	TUBULIN-TYROSINE-LIGASE; CARBOXYPEPTIDASE-A; ALPHA-TUBULIN; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENT; SUBSTRATE-BINDING; FOLD RECOGNITION; GENE-TRANSFER; ASSAY; CLONING	Nna1 has some sequence similarity to metallocarboxypeptidases, but the biochemical characterization of Nna1 has not previously been reported. In this work we performed a detailed genomic scan and found > 100 Nna1 homologues in bacteria, Protista, and Animalia, including several paralogs in most eukaryotic species. Phylogenetic analysis of the Nna1-like sequences demonstrates a major divergence between Nna1-like peptidases and the previously known metallocarboxypeptidases subfamilies: M14A, M14B, and M14C. Conformational modeling of representative Nna1-like proteins from a variety of species indicates an unusually open active site, a property that might facilitate its action on a wide variety of peptide and protein substrates. To test this, we expressed a recombinant form of one of the Nna1-like peptidases from Caenorhabditis elegans and demonstrated that this protein is a fully functional metallocarboxypeptidase that cleaves a range of C-terminal amino acids from synthetic peptides. The enzymatic activity is activated by ATP/ADP and salt-inactivated, and is preferentially inhibited by Z-Glu-Tyr dipeptide, which is without precedent in metallocarboxypeptidases and resembles tubulin carboxypeptidase functioning; this hypothesis is strongly reinforced by the results depicted in Kalinina et aL published as accompanying paper in this journal (1). Our findings demonstrate that the M14 family of metaBocarboxypeptidases is more complex and diverse than expected, and that Nna1-like peptidases are functional variants of such enzymes, representing a novel subfamily (we propose the name M14D) that contributes substantially to such diversity.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Complutense Madrid, Fac Vet, Dept Biochem & Mol Biol 4, Madrid, Spain; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; Complutense University of Madrid; Yeshiva University; Albert Einstein College of Medicine	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain.	jmbau@vet.ucm.es; FrancescXavier.Aviles@uab.es	Avilés, Francesc Xavier/A-2664-2015; Tanco, Sebastian Martin/R-2528-2016; Pulido, Toni Hermoso/K-3701-2015; Rodriguez de la Vega Otazo, Monica Margarita/H-7008-2015; Bautista, José M./B-7899-2013; Diez, Amalia/AAG-4274-2021; Aviles, Francesc Xavier/F-3482-2019; Diez, Amalia/I-4852-2014; Lorenzo, Julia/E-9015-2011	Avilés, Francesc Xavier/0000-0002-1399-6789; Tanco, Sebastian Martin/0000-0003-2130-4401; Pulido, Toni Hermoso/0000-0003-2016-6465; Rodriguez de la Vega Otazo, Monica Margarita/0000-0002-1061-3471; Bautista, José M./0000-0001-8926-881X; Diez, Amalia/0000-0002-2619-9252; Aviles, Francesc Xavier/0000-0002-1399-6789; Diez, Amalia/0000-0002-2619-9252; Lorenzo, Julia/0000-0001-5659-6008				Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; ALFA CE, 1991, CELL MOTIL CYTOSKEL, V18, P86, DOI 10.1002/cm.970180203; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; Badin-Larcon AC, 2004, P NATL ACAD SCI USA, V101, P5577, DOI 10.1073/pnas.0307917101; Barrett A.J., 1999, HDB PROTEOLYTIC ENZY; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bayes A, 2005, P NATL ACAD SCI USA, V102, P16602, DOI 10.1073/pnas.0505489102; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Bloom K, 2004, P NATL ACAD SCI USA, V101, P6839, DOI 10.1073/pnas.0401266101; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Cho JH, 2001, BIOCHEMISTRY-US, V40, P10197, DOI 10.1021/bi010807j; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; Contin MA, 2000, NEUROCHEM RES, V25, P27, DOI 10.1023/A:1007579113813; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Durbin R., 1998, BIOL SEQUENCE ANAL P; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Erck C, 2005, P NATL ACAD SCI USA, V102, P7853, DOI 10.1073/pnas.0409626102; Estebanez-Perpina E, 2001, J MOL BIOL, V313, P629, DOI 10.1006/jmbi.2001.5076; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; Han PJ, 2004, EXP NEUROL, V189, P293, DOI 10.1016/j.expneurol.2004.03.010; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HOURDOU ML, 1993, BIOCHEM J, V292, P563, DOI 10.1042/bj2920563; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KALININA E, 2007, IN PRESS FASEB J, V20; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Mock WL, 1996, ANAL BIOCHEM, V239, P218, DOI 10.1006/abio.1996.0318; Mock WL, 2002, BIOORG MED CHEM LETT, V12, P1193, DOI 10.1016/S0960-894X(02)00128-2; MULLINS FH, 1994, J NEUROCHEM, V62, P227; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; PETERSON LM, 1982, ANAL BIOCHEM, V125, P420, DOI 10.1016/0003-2697(82)90024-0; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Snell EA, 2006, P ROY SOC B-BIOL SCI, V273, P401, DOI 10.1098/rspb.2005.3263; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Too CKL, 2001, ENDOCRINOLOGY, V142, P1357, DOI 10.1210/en.142.3.1357; Vendrell J., 2004, HDB METALLOPROTEINS, P167; Ventura S, 1999, J BIOL CHEM, V274, P19925, DOI 10.1074/jbc.274.28.19925; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; WEBSTER DR, 1992, BIOCHEMISTRY-US, V31, P5849, DOI 10.1021/bi00140a021; WEBSTER DR, 2004, HDB PROTEOLYTIC ENZY, P2111; WEHLAND J, 1987, J CELL SCI, V88, P185; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200; Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040	74	78	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					851	865		10.1096/fj.06-7330com	http://dx.doi.org/10.1096/fj.06-7330com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17244817				2022-12-25	WOS:000244686400022
J	Glisic-Milosavljevic, S; Waukau, J; Jailwala, P; Jana, S; Khoo, HJ; Albertz, H; Woodliff, J; Koppen, M; Alemzadeh, R; Hagopian, W; Ghosh, S				Glisic-Milosavljevic, Sanja; Waukau, Jill; Jailwala, Parthav; Jana, Srikanta; Khoo, Huoy-Jii; Albertz, Hope; Woodliff, Jeffrey; Koppen, Marilyn; Alemzadeh, Ramin; Hagopian, William; Ghosh, Soumitra			At-Risk and Recent-Onset Type 1 Diabetic Subjects Have Increased Apoptosis in the CD4+CD25+(high) T-Cell Fraction	PLOS ONE			English	Article								Background. In experimental models, Type 1 diabetes (T1D) can be prevented by adoptive transfer of CD4+CD25+ (FoxP3+) suppressor or regulatory T cells. Recent studies have found a suppression defect of CD4+CD25+(high) T cells in human disease. In this study we measure apoptosis of CD4+CD25+(high) T cells to see if it could contribute to reduced suppressive activity of these cells. Methods and Findings. T-cell apoptosis was evaluated in children and adolescent (35 females/40 males) subjects comprising recent-onset and long-standing T1D subjects and their first-degree relatives, who are at variable risk to develop T1D. YOPRO1/7AAD and intracellular staining of the active form of caspase 3 were used to evaluate apoptosis. Isolated CD4+CD25+(high) and CD4+CD25- T cells were co-cultured in a suppression assay to assess the function of the former cells. We found that recent-onset T1D subjects show increased apoptosis of CD4+CD25+(high) T cells when compared to both control and long-standing T1D subjects (p<0.0001 for both groups). Subjects at high risk for developing T1D ( 2-3Ab+ve) show a similar trend (p<0.02 and p<0.01, respectively). On the contrary, in long-standing T1D and T2D subjects, CD4+CD25+(high) T cell apoptosis is at the same level as in control subjects (p = NS). Simultaneous intracellular staining of the active form of caspase 3 and FoxP3 confirmed recent-onset FoxP3+ve CD4+CD25+(high) T cells committed to apoptosis at a higher percentage (15.3 +/- 2.2) compared to FoxP3+ve CD4+CD25+(high) T cells in control subjects (6.1 +/- 1.7) (p<0.002). Compared to control subjects, both recent-onset T1D and high at-risk subjects had significantly decreased function of CD4+CD25+(high) T cells (p = 0.0007 and p = 0.007, respectively). Conclusions. There is a higher level of ongoing apoptosis in CD4+CD25+(high) T cells in recent-onset T1D subjects and in subjects at high risk for the disease. This high level of CD4+CD25+(high) T-cell apoptosis could be a contributing factor to markedly decreased suppressive potential of these cells in recent-onset T1D subjects.	[Glisic-Milosavljevic, Sanja; Waukau, Jill; Jailwala, Parthav; Jana, Srikanta; Khoo, Huoy-Jii; Koppen, Marilyn; Ghosh, Soumitra] Med Coll Wisconsin, Max McGee Natl Ctr Juvenile Diabet, Milwaukee, WI 53226 USA; [Glisic-Milosavljevic, Sanja; Waukau, Jill; Jailwala, Parthav; Jana, Srikanta; Khoo, Huoy-Jii; Koppen, Marilyn; Ghosh, Soumitra] Med Coll Wisconsin, Human Mol Genet Ctr, Milwaukee, WI 53226 USA; [Glisic-Milosavljevic, Sanja; Waukau, Jill; Jailwala, Parthav; Jana, Srikanta; Khoo, Huoy-Jii; Koppen, Marilyn; Ghosh, Soumitra] Childrens Hosp Wisconsin, Childrens Res Inst, Milwaukee, WI 53201 USA; [Albertz, Hope] Med Coll Wisconsin, Blood Ctr Wisconsin, Milwaukee, WI 53226 USA; [Woodliff, Jeffrey] Med Coll Wisconsin, Dept Pediat, Flow Cytometry Core Facil, Milwaukee, WI 53226 USA; [Alemzadeh, Ramin] Childrens Hosp Wisconsin, Med Coll Wisconsin, Diabet Ctr Pediat Endocrinol & Metab, Milwaukee, WI 53201 USA; [Hagopian, William] Pacific NW Res Inst, Seattle, WA USA	Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin	Ghosh, S (corresponding author), Med Coll Wisconsin, Max McGee Natl Ctr Juvenile Diabet, Milwaukee, WI 53226 USA.	sghosh@mcw.edu			Max McGee National Center for Juvenile Diabetes; Children's Research Institute; National Institutes of Health [M01-RR00058]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000058] Funding Source: NIH RePORTER	Max McGee National Center for Juvenile Diabetes; Children's Research Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Part of the study was funded through The Max McGee National Center for Juvenile Diabetes private fund and The Children's Research Institute. The study was also funded through GCRC Grant M01-RR00058 from the National Institutes of Health. The funding source didn't have any role or influence on study design, collection of data, analysis and interpretation of results.	Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Baecher-Allan C, 2005, CLIN IMMUNOL, V115, P10, DOI 10.1016/j.clim.2005.02.018; Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brusko TM, 2005, DIABETES, V54, P1407, DOI 10.2337/diabetes.54.5.1407; Buckner JH, 2004, ARTHRITIS RES THER, V6, P215, DOI 10.1186/ar1226; Dosch HM, 1999, J IMMUNOL, V163, P6933; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fritzsching B, 2005, J IMMUNOL, V175, P32, DOI 10.4049/jimmunol.175.1.32; GIORDANO C, 1995, DIABETOLOGIA, V38, P1449, DOI 10.1007/BF00400606; GIORDANO C, 1995, DIABETOLOGIA, V38, P953, DOI 10.1007/BF00400585; Glisic-Milosavljevic S, 2005, CELL PROLIFERAT, V38, P301, DOI 10.1111/j.1365-2184.2005.00351.x; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Hori S, 2004, MICROBES INFECT, V6, P745, DOI 10.1016/j.micinf.2004.02.020; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Liston A, 2004, IMMUNITY, V21, P817, DOI 10.1016/S1074-7613(04)00313-9; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lundsgaard D, 2005, DIABETES, V54, P1040, DOI 10.2337/diabetes.54.4.1040; Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6; Otton R, 2004, J ENDOCRINOL, V182, P145, DOI 10.1677/joe.0.1820145; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Putnam AL, 2005, J AUTOIMMUN, V24, P55, DOI 10.1016/j.jaut.2004.11.004; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Woo W, 2000, J IMMUNOL METHODS, V244, P91, DOI 10.1016/S0022-1759(00)00259-3; World Health Organization, 1999, DIAGN CLASS DIAB MEL	35	51	53	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e146	10.1371/journal.pone.0000146	http://dx.doi.org/10.1371/journal.pone.0000146			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206281	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443800008
J	Chikhlikar, P; de Arruda, LB; Maciel, M; Silvera, P; Lewis, MG; August, JT; Marques, ETA				Chikhlikar, Priya; de Arruda, Luciana Barros; Maciel, Milton; Silvera, Peter; Lewis, Mark G.; August, J. Thomas; Marques, Ernesto T. A.			DNA Encoding an HIV-1 Gag/Human Lysosome-Associated Membrane Protein-1 Chimera Elicits a Broad Cellular and Humoral Immune Response in Rhesus Macaques	PLOS ONE			English	Article								Previous studies of HIV-1 p55Gag immunization of mice have demonstrated the usefulness of targeting antigens to the cellular compartment containing the major histocompatibility complex type II (MHC II) complex molecules by use of a DNA antigen formulation encoding Gag as a chimera with the mouse lysosome-associated membrane protein (mLAMP/gag). In the present study, we have analyzed the magnitude and breadth of Gag-specific T-lymphocyte and antibody responses elicited in Rhesus macaques after immunization with DNA encoding a human LAMP/gag(hLAMP/gag) chimera. ELISPOT analyses indicated that the average Gag-specific IFN-gamma response elicited by the hLAMP/gag chimera was detectable after only two or three naked DNA immunizations in all five immunized macaques and reached an average of 1000 spot-forming cells (SFC)/10(6) PBMCs. High IFN-gamma ELISPOT responses were detected in CD8(+)-depleted cells, indicating that CD4(+) T-cells play a major role in these responses. The T-cell responses of four of the macaques were also tested by use of ELISPOT to 12 overlapping 15-amino acids (aa) peptide pools containing ten peptides each, encompassing the complete Gag protein sequence. The two Mamu 08 immunized macaques responded to eight and twelve of the pools, the Mamu B01 to six, and the other macaque to five pools indicating that the hLAMP/gag DNA antigen formulation elicits a broad T-cell response against Gag. Additionally, there was a strong HIV-1-specific IgG response. The IgG antibody titers increased after each DNA injection, indicating a strong amnestic B-cell response, and were highly elevated in all the macaques after three immunizations. Moreover, the serum of each macaque recognized 13 of the 49 peptides of a 20-aa peptide library covering the complete Gag amino acid sequence. In addition, HIV-1-specific IgA antibodies were present in the plasma and external secretions, including nasal washes. These data support the findings of increased immunogenicity of genetic vaccines encoded as LAMP chimeras, including the response to DNA vaccines by non-human primates.	[Chikhlikar, Priya; Maciel, Milton; August, J. Thomas; Marques, Ernesto T. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA; [de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil; [Silvera, Peter; Lewis, Mark G.] So Res Inst, Frederick, MD USA; [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil; [Marques, Ernesto T. A.] Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Johns Hopkins University; Johns Hopkins Medicine	Marques, ETA (corresponding author), Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.	emarques@jhmi.edu	Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana/B-5806-2014; Arruda, Luciana B/N-9086-2013	Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358; 	National Institute of Allergy and Infectious Disease, National Institutes of Health, USA [R37-AI41908, R21-AI44317, N01-AI-15429]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI041908, R01AI015429, R21AI044317] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by Grants R37-AI41908, R21-AI44317 and N01-AI-15429 "Simian Vaccine Evaluation Unit'' contract from the National Institute of Allergy and Infectious Disease, National Institutes of Health, USA	Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022; Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265; BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133; Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250; CARPIO E, 1991, AIDS RES HUM RETROV, V7, P97, DOI 10.1089/aid.1991.7.97; Casimiro DR, 2003, J VIROL, V77, P7663, DOI 10.1128/JVI.77.13.7663-7668.2003; Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025; De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x; Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005; Drake JR, 1999, J IMMUNOL, V162, P1150; DUBEY C, 1995, J IMMUNOL, V155, P45; FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; GUPTA V, 2005, VIROLOGY; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4; Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200; MATHIESEN T, 1989, IMMUNOLOGY, V67, P453; MATSUO K, 1992, J GEN VIROL, V73, P2445, DOI 10.1099/0022-1317-73-9-2445; Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657; MAZANEC MB, 1992, VIRUS RES, V23, P1, DOI 10.1016/0168-1702(92)90063-F; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; NIEDRIG M, 1991, J VIROL, V65, P4529, DOI 10.1128/JVI.65.8.4529-4533.1991; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136; Robinson HL, 1995, ANN NY ACAD SCI, V772, P209, DOI 10.1111/j.1749-6632.1995.tb44746.x; ROWELL JF, 1995, J IMMUNOL, V155, P1818; Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; Su Z, 2002, CANCER RES, V62, P5041; Su Z, 2005, J IMMUNOL, V174, P3798, DOI 10.4049/jimmunol.174.6.3798; SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671	44	27	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e135	10.1371/journal.pone.0000135	http://dx.doi.org/10.1371/journal.pone.0000135			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205139	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700029
J	Fabre, C; Carvalho, G; Tasdemir, E; Braun, T; Ades, L; Grosjean, J; Boehrer, S; Metivier, D; Souquere, S; Pierron, G; Fenaux, P; Kroemer, G				Fabre, C.; Carvalho, G.; Tasdemir, E.; Braun, T.; Ades, L.; Grosjean, J.; Boehrer, S.; Metivier, D.; Souquere, S.; Pierron, G.; Fenaux, P.; Kroemer, G.			NF-kappa B inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; autophagy; caspases; chemotherapy; mitochondria	THERAPEUTIC TARGET; APOPTOSIS; AUTOPHAGY; CANCER; PATHWAY; LINE	CD34(+) bone marrow blasts from high-risk myelodysplastic syndrome (MDS) patients as well as MDS patient-derived cell lines (P39 and MOLM13) constitutively activate the nuclear factor-kappa B (NF-kappa B) pathway and undergo apoptosis when NF-kappa B is inhibited. Here, we show that the combination of conventional chemotherapeutic agents (daunorubicin, mitoxantrone, 5-azacytidine or camptothecin) with the NF-kappa B inhibitor BAY11-7082 did not yield a synergistic cytotoxicity. In contrast, BAY11-7082 (which targets the NF-kappa B-activating I-kappa B kinase (IKK) complex) or knockdown of essential components of the NF-kappa B system (such as the IKK1 and IKK2 subunits of the IKK complex and the p65 subunit of NF-kappa B), by small interfering RNAs sensitized MDS cell lines to starvation-induced apoptosis. The combination of BAY11-7082 and nutrient depletion synergistically killed the acute myeloid leukemia (AML) cell line U937 as well as primary CD34+ bone marrow blasts from AML and high-risk MDS patients. The synergistic killing by BAY11-7082, combined with nutrient depletion, led to cell death accompanied by all hallmarks of apoptosis, including an early loss of the mitochondrial transmembrane potential, the release of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria, activation of caspase-3, phosphatidylserine exposure on the plasma membrane surface and nuclear chromatin condensation. Transmission electron microscopy revealed the presence of numerous autophagic vacuoles in the cytoplasm before cells underwent nuclear apoptosis. Nonetheless, cell death was neither inhibited by the pan-caspase inhibitor z-VAD-fmk nor by knockdown of AIF or of essential components of the autophagy pathway (ATG5, ATG6/ Beclin-1, ATG10, ATG12). In contrast, external supply of glucose, insulin or insulin-like growth factor-I could retard the cell death induced by BAY11-7082 combined with starvation. These results suggest that in MDS cells, NF-kappa B inhibition can precipitate a bioenergetic crisis that leads to an autophagic stress response followed by apoptotic cell death.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, F-94800 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM U542, F-94800 Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; Inst Andre Lwoff, CNRS, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ades, lionel/T-6882-2019; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; CARVALHO G, 2006, ONCOGENE        1016; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Israel A, 2006, CELL DEATH DIFFER, V13, P685, DOI 10.1038/sj.cdd.4401891; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; NAGAI M, 1984, GANN, V75, P1100; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Ribrag V, 2003, LEUKEMIA, V17, P319, DOI 10.1038/sj.leu.2402726; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Silverman Lewis R, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS12, DOI 10.1038/ncponc0347; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	36	80	92	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4071	4083		10.1038/sj.onc.1210187	http://dx.doi.org/10.1038/sj.onc.1210187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213804				2022-12-25	WOS:000247252700003
J	Jansen, PL; Kever, M; Rosch, R; Krott, E; Jansen, M; Alfonso-Jaume, A; Dooley, S; Klinge, U; Lovett, DH; Mertens, PR				Jansen, Petra Lynen; Kever, Mona; Rosch, Raphael; Krott, Ellen; Jansen, Marc; Alfonso-Jaume, Alexandra; Dooley, Steven; Klinge, Uwe; Lovett, David H.; Mertens, Peter R.			Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts	FASEB JOURNAL			English	Article						polymers; wound healing; cell-specific gene regulation; transgene	GLOMERULAR MESANGIAL CELLS; GELATINASE-A TRANSCRIPTION; Y-BOX PROTEIN-1; IV COLLAGENASE; ENHANCER; YB-1; ACTIVATION; MMP-2; INHIBITION; HERNIA	Matrix metalloproteinase-2 (MMP-2) is a key regulator in wound healing that orchestrates tissue remodeling. In the present study the spatial and temporal distribution of MMP-2 gene transcription, protein synthesis, and enzymatic activity were analyzed following polymeric mesh (polyglactin, polypropylene) implantation in transgenic reporter mice harboring MMP-2 regulatory sequences -1686/+423 or -1241/+423. Polymers induced MMP-2 promoter activity in macrophages within the foreign body granuloma via sequences -1686/+423 with concomitantly up-regulated protein synthesis and enzymatic activity. Macrophages distant from mesh filaments exhibited low MMP-2 expression levels. Fibroblasts surrounding mesh material displayed strong MMP-2 gene transcription independent of the included promoter sequences, whereas fibroblasts without close contact to mesh material had low MMP-2 synthesis rates due to silencing activity of sequences -1686/+1241. In vitro studies support a cellular crosstalk concept, as macrophages trans-repressed MMP-2 gene transcription in fibroblasts. The zonal and cell-specific regulation of MMP-2 gene transcription illuminates an intimate cellular crosstalk in foreign body reaction that may provide a new approach for mesh modification.	Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, D-52074 Aachen, Germany; Univ Hosp, RWTH Aachen, Dept Surg, Aachen, Germany; William Middleton Mem Univ Wisconsin, Dept Med, Madison, WI USA; Univ Hosp, Dept Med 2, Mannheim, Germany; Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA; Univ Hosp, Dept Nephrol & Clin Immunol, Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University of Wisconsin System; Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; RWTH Aachen University; RWTH Aachen University Hospital	Jansen, PL (corresponding author), Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, Pauwelsstr 30, D-52074 Aachen, Germany.	plynen@ukaachen.de	Dooley, Steven/T-6491-2018; Mertens, Peter/AAI-7310-2020	Dooley, Steven/0000-0002-4840-6240; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK039776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGREN MS, 1994, BRIT J DERMATOL, V131, P634, DOI 10.1111/j.1365-2133.1994.tb04974.x; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baum CL, 2005, DERMATOL SURG, V31, P674; Bellon JM, 2001, ANN SURG, V233, P287, DOI 10.1097/00000658-200102000-00020; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006; Cheng SF, 2002, BIOCHEM J, V366, P807, DOI 10.1042/BJ20020202; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Dooley S, 2006, J BIOL CHEM, V281, P1784, DOI 10.1074/jbc.M510215200; Ecrola LM, 2005, J HEART LUNG TRANSPL, V24, P426, DOI 10.1016/j.healun.2004.01.013; En-Nia A, 2002, BIOCHEM J, V362, P693, DOI 10.1042/0264-6021:3620693; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Inagaki Y, 2005, GASTROENTEROLOGY, V129, P259, DOI 10.1053/j.gastro.2005.03.088; Ishikawa T, 2005, BRIT J PHARMACOL, V144, P133, DOI 10.1038/sj.bjp.0706054; Jansen PL, 2004, SURGERY, V136, P1, DOI 10.1016/j.surg.2004.01.004; Junge K, 2004, LANGENBECK ARCH SURG, V389, P17, DOI 10.1007/s00423-003-0429-8; Junge K, 2002, WORLD J SURG, V26, P1472, DOI 10.1007/s00268-002-6444-z; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Klinge U, 1999, EUR J SURG, V165, P665; Klinge U, 1999, BIOMATERIALS, V20, P613, DOI 10.1016/S0142-9612(98)00211-7; Klinge U, 2001, BIOMATERIALS, V22, P1415, DOI 10.1016/S0142-9612(00)00299-4; Kuzuya Masafumi, 2003, J Atheroscler Thromb, V10, P275; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lee JG, 2005, P NATL ACAD SCI USA, V102, P16345, DOI 10.1073/pnas.0508085102; Mandal M, 2003, MOL CELL BIOCHEM, V252, P305, DOI 10.1023/A:1025526424637; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; Witte MB, 1998, SURGERY, V124, P464, DOI 10.1016/S0039-6060(98)70154-0; Woessner JF, 2002, MOL BIOTECHNOL, V22, P33, DOI 10.1385/MB:22:1:033; Zhu P, 2005, ARTHRITIS RES THER, V7, pR1023, DOI 10.1186/ar1778; ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4	48	21	22	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1047	1057		10.1096/fj.06-6755com	http://dx.doi.org/10.1096/fj.06-6755com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215487				2022-12-25	WOS:000245650400009
J	Nishimasu, H; Fushinobu, S; Shoun, H; Wakagi, T				Nishimasu, Hiroshi; Fushinobu, Shinya; Shoun, Hirofumi; Wakagi, Takayoshi			Crystal structures of an ATP-dependent hexokinase with broad substrate specificity from the hyperthermophilic archaeon Sulfolobus tokodaii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN HEXOKINASE; INDUCED CONFORMATIONAL-CHANGE; N-ACETYLGLUCOSAMINE KINASE; ENTNER-DOUDOROFF PATHWAY; YEAST HEXOKINASE; SUGAR KINASES; GLUCOSE PHOSPHORYLATION; PYROCOCCUS-FURIOSUS; COMPLETE GENOME; ACTIVE-SITE	Hexokinase catalyzes the phosphorylation of glucose to glucose 6-phosphate by using ATP as a phosphoryl donor. Recently, we identified and characterized an ATP-dependent hexokinase (StHK) from the hyperthermophilic archaeon Sulfolobus tokodaii, which can phosphorylate a broad range of sugar substrates, including glucose, mannose, glucosamine, and N-acetylglucosamine. Here we present the crystal structures of StHK in four different forms: (i) apo-form, (ii) binary complex with glucose, (iii) binary complex with ADP, and i quaternary complex with xylose, Mg2+, and ADP. Forms i and iii are in the open state, and forms ii and iv are in the closed state, indicating that sugar binding induces a large conformational change, whereas ADP binding does not. The four different crystal structures of the same enzyme provide "snapshots" of the conformational. changes during the catalytic cycle. StHK exhibits a core fold characteristic of the hexokinase family, but the structures of several loop regions responsible for substrate binding are significantly different from those of other known hexokinase family members. Structural comparison of StHK with human N-acetylglucosamine kinase and other hexokinases provides an explanation for the ability of StHK to phosphorylate both glucose and N-acetylglucosamine. A Mg2+ ion and coordinating water molecules are well defined in the electron density of the quaternary complex structure. This structure represents the first direct visualization of the binding mode for magnesium to hexokinase and thus allows for a better understanding of the catalytic mechanism proposed for the entire hexokinase family.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Wakagi, T (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	atwakag@mail.ecc.u-tokyo.jp	Wakagi, Takayoshi/AAJ-4145-2021; Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435				Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BORK P, 1993, PROTEIN SCI, V2, P31; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Chen LM, 2005, J BACTERIOL, V187, P4992, DOI 10.1128/JB.187.14.4992-4999.2005; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; Dorr C, 2003, J BIOL CHEM, V278, P18744, DOI 10.1074/jbc.M301914200; Grueninger D, 2006, J MOL BIOL, V359, P787, DOI 10.1016/j.jmb.2006.04.013; Hansen T, 2002, J BACTERIOL, V184, P5955, DOI 10.1128/JB.184.21.5955-5965.2002; Hinderlich S, 2000, EUR J BIOCHEM, V267, P3301, DOI 10.1046/j.1432-1327.2000.01360.x; Hinderlich S, 1998, EUR J BIOCHEM, V252, P133, DOI 10.1046/j.1432-1327.1998.2520133.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; Ito S, 2003, J MOL BIOL, V331, P871, DOI 10.1016/S0022-2836(03)00792-7; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; Kim SH, 2005, BIOCHEM J, V387, P271, DOI 10.1042/BJ20041053; Koga S, 2000, J BIOCHEM-TOKYO, V128, P1079, DOI 10.1093/oxfordjournals.jbchem.a022836; Kuser PR, 2000, J BIOL CHEM, V275, P20814, DOI 10.1074/jbc.M910412199; Labes A, 2003, ARCH MICROBIOL, V180, P69, DOI 10.1007/s00203-003-0563-2; Lamble HJ, 2005, FEBS LETT, V579, P6865, DOI 10.1016/j.febslet.2005.11.028; Lamble HJ, 2003, J BIOL CHEM, V278, P34066, DOI 10.1074/jbc.M305818200; Lunin VV, 2004, J BACTERIOL, V186, P6915, DOI 10.1128/JB.186.20.6915-6927.2004; Matte A, 1998, STRUCT FOLD DES, V6, P413, DOI 10.1016/S0969-2126(98)00043-4; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; Milburn CC, 2006, J BIOL CHEM, V281, P14796, DOI 10.1074/jbc.M601334200; Mukai T, 2004, J BIOL CHEM, V279, P50591, DOI 10.1074/jbc.M408126200; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; Nishimasu H, 2006, J BACTERIOL, V188, P2014, DOI 10.1128/JB.188.5.2014-2019.2006; OLSEN LR, 1993, ARCH BIOCHEM BIOPHYS, V304, P242, DOI 10.1006/abbi.1993.1345; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rosano C, 1999, STRUCT FOLD DES, V7, P1427, DOI 10.1016/S0969-2126(00)80032-5; Sakuraba H, 2002, J BIOL CHEM, V277, P12495, DOI 10.1074/jbc.C200059200; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Theodossis A, 2004, J BIOL CHEM, V279, P43886, DOI 10.1074/jbc.M407702200; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; Tsuge H, 2002, PROTEIN SCI, V11, P2456, DOI 10.1110/ps.0215602; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Valiev M, 2003, J AM CHEM SOC, V125, P9926, DOI 10.1021/ja029618u; Verhees CH, 2002, BIOCHEM J, V366, P121, DOI 10.1042/BJ20011597; Weihofen WA, 2006, J MOL BIOL, V364, P388, DOI 10.1016/j.jmb.2006.08.085; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zhang ZL, 2005, J BIOL CHEM, V280, P9698, DOI 10.1074/jbc.M411211200	62	41	41	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9923	9931		10.1074/jbc.M610678200	http://dx.doi.org/10.1074/jbc.M610678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17229727	hybrid			2022-12-25	WOS:000245421700067
J	Stempelj, M; Kedinger, M; Augenlicht, L; Klampfer, L				Stempelj, Mateja; Kedinger, Michele; Augenlicht, Leonard; Klampfer, Lidija			Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL ULCERATIVE-COLITIS; ABERRANT CRYPT FOCI; FACTOR-KAPPA-B; IFN-GAMMA; TUMOR ANGIOGENESIS; COLORECTAL-CANCER; GENE-EXPRESSION; ACTIVATION; CYCLOOXYGENASE-2; PROTEIN	Nitric oxide (NO) is a highly reactive free radical that modulates tumorigenesis through its ability to regulate cell proliferation, cell death, migration and angiogenesis. Although the role of NO has been well studied in inflammatory cells, much less is known about the regulation of NO production in epithelial cells. We demonstrated that in intestinal epithelial cells the expression of inducible NO synthase (iNOS), the critical enzyme in the synthesis of NO, is synergistically stimulated by bacterial lipopolysaccharide (LPS) and interferon gamma (IFN gamma) or by the combination of tumor necrosis factor (TNF) and IFN gamma at the transcriptional level. Expression of iNOS and the production of NO in response to LPS/IFN gamma were significantly increased upon induction of oncogenic K-Ras, underlying frequently elevated expression of iNOS in colon cancer. Silencing of STAT1, a major transcription factor involved in signaling by IFN gamma, or pharmacological inhibition of JAKs, kinases that phosphorylate STATs, prevented the induction of iNOS and the production of NO in response to stimulation of cells with LPS/IFN gamma or TNF/IFN gamma, underscoring the importance of the intact JAK/STAT signaling in the regulation of iNOS expression in intestinal epithelial cells. Butyrate, a histone deacetylase (HDAC) inhibitor and a dietary chemopreventive agent, decreased NO production in macrophages and in intestinal myofibroblasts, consistent with its anti-inflammatory activity. In contrast, in intestinal epithelial cells, butyrate significantly enhanced the expression of iNOS and the production of NO in response to treatment with LPS/IFN gamma. Despite the fact that, like butyrate, three structurally unrelated inhibitors of HDAC activity, trichostatin A, suberoylanilide hydroxamic acid, and apicidin, induced acetylation of H3 and H4 in epithelial cells, they failed to increase the production of NO, demonstrating that butyrate regulates NO production in epithelial cells in an HDAC-independent manner. The ability of butyrate to regulate the production of NO in a variety of cell types is likely to underlie its potent chemopreventive and anti-inflammatory activity.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Univ Strasbourg 1, INSERM, U682, F-67200 Strasbourg, France	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI NIH HHS [U54 CA100926, R01 CA111361] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn B, 2001, CANCER RES, V61, P8357; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1998, CANCER RES, V58, P334; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; COBBS CS, 1995, CANCER RES, V55, P727; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Edwards P, 1996, J SURG RES, V63, P49, DOI 10.1006/jsre.1996.0221; Ellerhorst JA, 2006, ONCOGENE, V25, P3956, DOI 10.1038/sj.onc.1209419; Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Hao XP, 2001, CANCER RES, V61, P419; Heigold S, 2002, CARCINOGENESIS, V23, P929, DOI 10.1093/carcin/23.6.929; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Kitano H, 1999, THYROID, V9, P113, DOI 10.1089/thy.1999.9.113; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Lanas A, 2000, NEW ENGL J MED, V343, P834, DOI 10.1056/NEJM200009213431202; Loibl S, 2005, EUR J CANCER, V41, P265, DOI 10.1016/j.ejca.2004.07.010; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Nam KT, 2004, GUT, V53, P1250, DOI 10.1136/gut.2003.030684; Plateroti M, 1998, AM J PHYSIOL-GASTR L, V274, pG945, DOI 10.1152/ajpgi.1998.274.5.G945; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; Rao CV, 2002, CANCER RES, V62, P165; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sasahara Y, 2002, CANCER LETT, V177, P155, DOI 10.1016/S0304-3835(01)00778-9; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SCHEPPACH W, 1997, SCAND J GASTROENTE S, V222, P53; Scott DJ, 2001, GASTROENTEROLOGY, V121, P889, DOI 10.1053/gast.2001.27994; Sheng HM, 2001, CANCER RES, V61, P2670; Sparmann A, 2005, CELL CYCLE, V4, P735, DOI 10.4161/cc.4.6.1714; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Takahashi M, 2003, ONCOGENE, V22, P7667, DOI 10.1038/sj.onc.1207051; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; Vernia P, 2003, EUR J CLIN INVEST, V33, P244, DOI 10.1046/j.1365-2362.2003.01130.x; Yamaguchi S, 2002, BRIT J NEUROSURG, V16, P567	47	98	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9797	9804		10.1074/jbc.M609426200	http://dx.doi.org/10.1074/jbc.M609426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251186	hybrid			2022-12-25	WOS:000245421700054
J	Phimister, AJ; Lango, J; Lee, EH; Ernst-Russell, MA; Takeshima, H; Ma, JJ; Allen, PD; Pessah, IN				Phimister, Andrew J.; Lango, Jozsef; Lee, Eun Hui; Ernst-Russell, Michael A.; Takeshima, Hiroshi; Ma, Jianjie; Allen, Paul D.; Pessah, Isaac N.			Conformation-dependent stability of junctophilin 1 (JP1) and ryanodine receptor type 1 (RyRl) channel complex is mediated by their hyper-reactive thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; DISULFIDE-BOND; SKELETAL-TYPE; REDOX SENSOR; HYPERREACTIVE CYSTEINES; S-GLUTATHIONYLATION; TRIADIN; BINDING; DOMAIN	Junctophilin 1 (JP1), a 72-kDa protein localized at the skeletal muscle triad, is essential for stabilizing the close apposition of T-tubule and sarcoplasmic reticulum membranes to form junctions. In this study we report that rapid and selective labeling of hyper-reactive thiols found in both JP1 and ryanodine receptor type 1 (RyR1) with 7-diethylamino-3-(4'-mateimidylphenyl)-4-methylcoumarin, a fluorescent thiol-reactive probe, proceeded 12-fold faster under conditions that minimize RyR1 gating (e,g. 10 mm Mg2+) compared with conditions that promote high channel activity (e.g. 100 mu m Ca2+, 10 mm caffeine, 5 mm ATP). The reactivity of these thiol groups was very sensitive to oxidation by naphthoquinone, H2O2, NO, or O-2, all known modulators of the RyR1 channel complex. Using preparative SDS-PAGE, in-get tryptic digestion, high pressure liquid chromatography, and mass spectrometry-based peptide sequencing, we identified 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin-thioether adducts on three cysteine residues of JP1 (101, 402, and 627); the remaining five cysteines of JP1 were unlabeled. Co-immunoprecipitation experiments demonstrated a physical interaction between JP1 and RyR1 that, like thiol reactivity, was sensitive to RyR1 conformation and chemical status of the hyper-reactive cysteines of JP1 and RyR1. These findings support a model in which JP1 interacts with the RyR1 channel complex in a conformationally sensitive manner and may contribute integral redox-sensing properties through reactive sulfhydryl chemistry.	Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA; Catholic Univ Korea, Dept Physiol, Coll Med, Seoul 137701, South Korea; Tohoku Univ, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	University of California System; University of California Davis; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital; Catholic University of Korea; Tohoku University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pessah, IN (corresponding author), Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Lee, Eun Hui/0000-0003-4555-1730; Takeshima, Hiroshi/0000-0003-4525-3725	NCRR NIH HHS [P20 RR16464] Funding Source: Medline; NIAMS NIH HHS [2R01-AR43140, 2P01-AR17605] Funding Source: Medline; NIEHS NIH HHS [P42-ES04699, 1P01-ES11269] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269, P42ES004699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELLATIF Y, 2007, IN PRESS CELL CALCIU; Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Chelu MG, 2004, TRENDS CARDIOVAS MED, V14, P227, DOI 10.1016/j.tcm.2004.06.003; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; Di Biase V, 2005, J CELL BIOL, V171, P695, DOI 10.1083/jcb.200503077; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Feng W, 1999, MOL PHARMACOL, V55, P821; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Finehout EJ, 2003, ELECTROPHORESIS, V24, P3508, DOI 10.1002/elps.200305615; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; Fomenko DE, 2003, ANTIOXID REDOX SIGN, V5, P397, DOI 10.1089/152308603768295131; Franzini-Armstrong C, 2005, ANN NY ACAD SCI, V1047, P76, DOI 10.1196/annals.1341.007; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; Gao J, 2005, TOXICOL SCI, V87, P419, DOI 10.1093/toxsci/kfi265; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Hirata Y, 2006, BIOPHYS J, V90, P4418, DOI 10.1529/biophysj.105.076570; Hurne AM, 2005, J BIOL CHEM, V280, P36994, DOI 10.1074/jbc.M506441200; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Komazaki S, 2002, FEBS LETT, V524, P225, DOI 10.1016/S0014-5793(02)03042-9; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Ma H, 2006, CELL RES, V16, P466, DOI 10.1038/sj.cr.7310058; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Moriguchi S, 2006, P NATL ACAD SCI USA, V103, P10811, DOI 10.1073/pnas.0509863103; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Nishi M, 2000, BIOCHEM BIOPH RES CO, V273, P920, DOI 10.1006/bbrc.2000.3011; Nishi M, 2003, MOL BRAIN RES, V118, P102, DOI 10.1016/S0169-328X(03)00341-3; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Pessah IN, 2001, MOL PHARMACOL, V59, P506, DOI 10.1124/mol.59.3.506; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Voss AA, 2004, J BIOL CHEM, V279, P34514, DOI 10.1074/jbc.M404290200; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	50	48	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8667	8677		10.1074/jbc.M609936200	http://dx.doi.org/10.1074/jbc.M609936200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237236	hybrid			2022-12-25	WOS:000245780300013
J	Shi, J; Kandror, KV				Shi, Jun; Kandror, Konstantin V.			The luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; GLUT4 GLUCOSE-TRANSPORTER; NEWLY SYNTHESIZED GLUT4; TRANS-GOLGI NETWORK; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; LYSOSOMAL TRAFFICKING; STORAGE COMPARTMENTS; REGULATED TRANSPORT; CYTOPLASMIC TAIL	-In fat and skeletal muscle cells, insulin-responsive vesicles, or IRVs, deliver glucose transporter Glut4 and several associated proteins to the plasma membrane in response to hormonal stimulation. Although the protein composition of the IRVs is well studied, the mechanism of their formation is unknown. It is believed, however, that the cytoplasmic tails of the IRV component proteins carry targeting information to this compartment. To test this hypothesis, we have studied targeting of sortilin, one of the major IRV constituents. We have found that the reporter protein consisting of the cytoplasmic tail of sortilin and EGFP is co-localized with ectopically expressed Glut4 in the perinuclear compartment of undifferentiated 3T3-L1 cells that do not form insulin-responsive vesicles. Upon cell differentiation, this reporter protein does not enter the IRVs; moreover, it loses its perinuclear localization and becomes randomly distributed throughout the whole intracellular space. In contrast, the tagged luminal Vps10p domain of sortilin demonstrates partial co-localization with Glut4 in both undifferentiated and differentiated cells and is targeted to the IRVs upon cell differentiation. Using chemical cross-linking and the yeast two-hybrid system, we show that sortilin interacts with Glut4 and IRAP in the vesicular lumen. Our results suggest that luminal interactions between component proteins play an important role in the process of IRV biogenesis.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K124D,715 Albany St, Boston, MA 02118 USA.	kandror@biochem.bumc.bu.edu		Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052057, R01DK056736, R56DK052057] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56736, DK52057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belfort GM, 2005, J BIOL CHEM, V280, P7262, DOI 10.1074/jbc.M404851200; Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Khan AH, 2004, J BIOL CHEM, V279, P37505, DOI 10.1074/jbc.M405694200; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampson MA, 2000, J CELL SCI, V113, P4065; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Malide D, 2000, J CELL SCI, V113, P4203; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Ni XY, 2006, TRAFFIC, V7, P889, DOI 10.1111/j.1600-0854.2006.00429.x; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Shi J, 2005, DEV CELL, V9, P99, DOI 10.1016/j.devcel.2005.04.004; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	42	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9008	9016		10.1074/jbc.M608971200	http://dx.doi.org/10.1074/jbc.M608971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17220298	hybrid			2022-12-25	WOS:000245780300048
J	Meng, FY; Henson, R; Wehbe-Janek, H; Smith, H; Ueno, Y; Patel, T				Meng, Fanyin; Henson, Roger; Wehbe-Janek, Hania; Smith, Heather; Ueno, Yoshiyuki; Patel, Tushar			The microRNA let-7a modulates interieukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ACTIVATION; CELL-SURVIVAL; EXPRESSION; CANCER; GROWTH; CHOLANGIOCARCINOMA; SUPPRESSOR; RESISTANCE; APOPTOSIS; MYELOMA	The inflammation-associated cytokine interleukin-6 (IL-6) can contribute to tumor growth and resistance to therapy by the activation of survival mechanisms. In several human cancers, IL-6-activated survival signaling involves the signal transducers and activators of transcription (Stat) factors or protein kinase cascades. microRNAs (miRNAs) are endogenous regulators of gene expression that are altered in expression in many cancers. However, the effect of inflammatory cytokines on miRNA expression and the role of miRNA in modulating IL-6-mediated cell survival are unknown. We investigated the involvement of miRNA in malignant cholangiocytes stably transfected to overexpress IL-6, which enhances tumor growth in vivo by inhibition of apoptosis. We provide evidence that (i) miRNA expression both in vitro and in vivo is altered by overexpression of IL-6; (ii) selective miRNAs including let-7a are up-regulated and contribute to the survival effects of enforced IL-6 activity; and (iii) let-7a contributes to the constitutively increased phosphorylation of Stat-3 by a mechanism involving the neurofibromatosis 2 (NF2) gene. These findings reveal a novel mechanism by which IL-6 mediates tumor cell survival that may be therapeutically targeted and emphasize the presence of complex interrelationships between deregulated expression of miRNA and transcription factors in human cancers.	Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Div Gastroenterol,Scott & White Clin, Temple, TX 76508 USA; Tohoku Univ, Div Gastroenterol, Sendai, Miyagi 9808577, Japan	Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Tohoku University	Patel, T (corresponding author), Ohio State Univ, Med Ctr, Div Gastroenterol & Hepatol, N201 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA.	patel.lab@gmail.com	patel, tushar/J-3976-2013; patel, tushar/A-6382-2008; Ueno, Yoshiyuki/R-9242-2019	patel, tushar/0000-0001-7021-9532; Ueno, Yoshiyuki/0000-0001-5623-4250	NIDDK NIH HHS [R01 DK069370, R01 DK069370-02, DK069370] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069370] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Javle MM, 2004, HEPATO-GASTROENTEROL, V51, P1653; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Shah M, 2006, J BIOL CHEM, V281, P7302, DOI 10.1074/jbc.M508527200; Tadlock L, 2003, AM J PHYSIOL-GASTR L, V284, pG924, DOI 10.1152/ajpgi.00355.2002; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Xu L, 1998, EXP CELL RES, V238, P231, DOI 10.1006/excr.1997.3843; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	31	169	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8256	8264		10.1074/jbc.M607712200	http://dx.doi.org/10.1074/jbc.M607712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17220301	hybrid			2022-12-25	WOS:000245081000058
J	Fagone, P; Sriburi, R; Ward-Chapman, C; Frank, M; Wang, J; Gunter, C; Brewer, JW; Jackowski, S				Fagone, Paolo; Sriburi, Rungtawan; Ward-Chapman, Cheryl; Frank, Matthew; Wang, Jina; Gunter, Christopher; Brewer, Joseph W.; Jackowski, Suzanne			Phospholipid biosynthesis program underlying membrane expansion during B-lymphocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; UNFOLDED PROTEIN RESPONSE; PLASMA-CELL DIFFERENTIATION; RAT-LIVER CTP; TRANSCRIPTION FACTOR XBP-1; FARNESOL-INDUCED APOPTOSIS; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; NUCLEAR-LOCALIZATION; ANTIGEN-SPECIFICITY	Stimulated B-lymphocytes differentiate into plasma cells committed to antibody production. Expansion of the endoplasmic reticulum and Golgi compartments is a prerequisite for high rate synthesis, assembly, and secretion of immunoglobulins. The bacterial cell wall component lipopolysaccharide (LPS) stimulates murine B-cells to proliferate and differentiate into antibody-secreting cells that morphologically resemble plasma cells. LPS activation of CH12 B-cells augmented phospholipid production and initiated a genetic program, including elevated expression of the genes for the synthesis, elongation, and desaturation of fatty acids that supply the phospholipid acyl moieties. Likewise, many of the genes in phospholipid biosynthesis were up-regulated, most notably those encoding Lipin1 and choline phosphotransferase. In contrast, CTP:phosphocholine cytidylyltransferase alpha (CCT alpha) protein, a key control point in phosphatidylcholine biosynthesis, increased because of stabilization of protein turnover rather than transcriptional activation. Furthermore, an elevation in cellular diacylglycerol and fatty acid correlated with enhanced allosteric activation of CCTa by the membrane lipids. This work defines a genetic and biochemical program for membrane phospholipid biogenesis that correlates with an increase in the phospholipid components of the endoplasmic reticulum and Golgi compartments in LPS-stimulated B-cells.	St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA	St Jude Children's Research Hospital; Loyola University Chicago	Jackowski, S (corresponding author), St Jude Childrens Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429; Frank, Matthew/0000-0002-4914-1440; Fagone, Paolo/0000-0002-0102-3701; sriburi, Rungtawan/0000-0002-8900-9233	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737, GM 61970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agassandian M, 2005, J BIOL CHEM, V280, P21577, DOI 10.1074/jbc.M412409200; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brewer JW, 2005, NAT IMMUNOL, V6, P23, DOI 10.1038/ni1149; Carter JM, 2003, J BIOL CHEM, V278, P44988, DOI 10.1074/jbc.M307336200; Cenci S, 2006, EMBO J, V25, P1104, DOI 10.1038/sj.emboj.7601009; CHARLES J, 1980, ANAL BIOCHEM, V104, P10; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Gunn KE, 2006, J IMMUNOL, V177, P3791, DOI 10.4049/jimmunol.177.6.3791; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; Hirabayashi Y, 2004, PFLUG ARCH EUR J PHY, V447, P760, DOI 10.1007/s00424-003-1071-6; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 2005, J BIOL CHEM, V280, P853, DOI 10.1074/jbc.R400031200; Jackowski S, 2004, MOL CELL BIOL, V24, P4720, DOI 10.1128/MCB.24.11.4720-4733.2004; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; JAMIL H, 1992, J BIOL CHEM, V267, P1752; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOCASCIO NJ, 1984, P NATL ACAD SCI-BIOL, V81, P2466, DOI 10.1073/pnas.81.8.2466; LOCASCIO NJ, 1984, J MOL CELL IMMUNOL, V1, P177; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; OVNIC M, 1987, J IMMUNOL, V138, P3075; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RANDALL TD, 1993, MOL CELL BIOL, V13, P3929, DOI 10.1128/MCB.13.7.3929; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; RUSH JS, 1991, ARCH BIOCHEM BIOPHYS, V284, P63, DOI 10.1016/0003-9861(91)90264-J; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; SRIBURI R, 2007, IN PRESS J BIOL CHEM, V282; STOCKDALE AM, 1987, J IMMUNOL, V139, P3527; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Wadham C, 2004, CIRCULATION, V109, P2116, DOI 10.1161/01.CIR.0000127419.45975.26; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Zhou JM, 2003, J BIOL CHEM, V278, P37032, DOI 10.1074/jbc.M304316200	63	68	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7591	7605		10.1074/jbc.M608175200	http://dx.doi.org/10.1074/jbc.M608175200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213195	hybrid			2022-12-25	WOS:000245080900072
J	Zhou, J; Damdimopoulos, AE; Spyrou, G; Brune, B				Zhou, Jie; Damdimopoulos, Anastassios E.; Spyrou, Giannis; Bruene, Bernhard			Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR EXPRESSION; REDOX STATE; MAMMALIAN THIOREDOXIN; TRANSCRIPTION FACTOR; CELL-DEATH; HIF-1-ALPHA; OXYGEN; ACTIVATION; APOPTOSIS	Hypoxia inducible factor 1 (HIF-1), a key regulator for adaptation to hypoxia, is composed of HIF-1 alpha and HIF-1 beta. In this study, we present evidence that overexpression of mitochondria-located thioredoxin 2 (Trx2) attenuated hypoxia-evoked HIF-1 alpha accumulation, whereas cytosolic thioredoxin 1 (Trx1) enhanced HIF-1 alpha protein amount. Transactivation of HIF-1 is decreased by overexpression of Trx2 but stimulated by Trx1. Inhibition of proteasomal degradation of HIF-1 alpha in Trx2-overexpressing cells did not fully restore HIF-1 alpha protein levels, while HIF-1 alpha accumulation was enhanced in Trx1-overexpressing cells. Reporter assays showed that cap-dependent translation is increased by Trx1 and decreased by Trx2, whereas HIF-1 alpha mRNA levels remained unaltered. These data suggest that thioredoxins affect the synthesis of HIF-1 alpha. Trx1 facilitated synthesis of HIF-1a by activating Akt, p70S6K, and eIF-4E, known to control cap-dependent translation. In contrast, Trx2 attenuated activities of Akt, p70S6K, and eIF-4E and provoked an increase in mitochondrial reactive oxygen species production. MitoQ, a mitochondria specific antioxidant, reversed HIF-1 alpha accumulation as well as Akt activation under hypoxia in Trx2 cells, supporting the notion of translation control mechanisms in affecting HIF-1 alpha protein accumulation.	Univ Frankfurt, Fac Med, Inst Biochem 1, D-60590 Frankfurt, Germany; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Acad Athens, Fdn Biomed Res, Athens 11527, Greece	Goethe University Frankfurt; Karolinska Institutet; Academy of Athens	Brune, B (corresponding author), Univ Frankfurt, Fac Med, Inst Biochem 1, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@zbc.kgu.de		Damdimopoulos, Anastasios/0000-0003-4425-1189				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Cadenas Enrique, 2004, Molecular Aspects of Medicine, V25, P17, DOI 10.1016/j.mam.2004.02.005; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jezek P, 2005, INT J BIOCHEM CELL B, V37, P2478, DOI 10.1016/j.biocel.2005.05.013; Kim A, 2005, FREE RADICAL BIO MED, V38, P644, DOI 10.1016/j.freeradbiomed.2004.10.030; Kim WJ, 2005, INT J ONCOL, V26, P1049; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Psarra AMG, 2005, INT J BIOCHEM CELL B, V37, P2544, DOI 10.1016/j.biocel.2005.06.015; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanjuan-Pla A, 2005, FEBS LETT, V579, P2669, DOI 10.1016/j.febslet.2005.03.088; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; Wei SJ, 2000, CANCER RES, V60, P6688; Welsh SJ, 2002, CANCER RES, V62, P5089; Xu D, 2006, AM J PHYSIOL-LUNG C, V291, pL966, DOI 10.1152/ajplung.00045.2006; Zhou J, 2004, CANCER RES, V64, P9041, DOI 10.1158/0008-5472.CAN-04-1437; Zhou Jie, 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P189, DOI 10.2174/187152506777698344; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	47	56	60	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7482	7490		10.1074/jbc.M608289200	http://dx.doi.org/10.1074/jbc.M608289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17220299	hybrid			2022-12-25	WOS:000245080900061
J	Clarke, SL; Betts, GJ; Plant, A; Wright, KL; El-Shanawany, TM; Harrop, R; Torkington, J; Rees, BI; Williams, GT; Gallimore, AM; Godkin, AJ				Clarke, Sarah L.; Betts, Gareth J.; Plant, Andrea; Wright, Kate L.; El-Shanawany, Tariq M.; Harrop, Richard; Torkington, Jared; Rees, Brian I.; Williams, Geraint T.; Gallimore, Awen M.; Godkin, Andrew J.			CD4(+) CD25(+) FOXP3(+) Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer	PLOS ONE			English	Article								Background. A wealth of evidence obtained using mouse models indicates that CD4(+) CD25(+) FOXP3(+) regulatory T cells (Treg) maintain peripheral tolerance to self-antigens and also inhibit anti-tumor immune responses. To date there is limited information about CD4(+) T cell responses in patients with colorectal cancer (CRC). We set out to measure T cell responses to a tumor-associated antigen and examine whether Treg impinge on those anti-tumor immune responses in CRC patients. Methodology and Principal Findings. Treg were identified and characterized as CD4(+) CD25(+) FOXP3(+) using flow cytometry. An increased frequency of Treg was demonstrated in both peripheral blood and mesenteric lymph nodes of patients with colorectal cancer (CRC) compared with either healthy controls or patients with inflammatory bowel disease (IBD). Depletion of Treg from peripheral blood mononuclear cells (PBMC) of CRC patients unmasked CD4(+) T cell responses, as observed by IFN gamma release, to the tumor associated antigen 5T4, whereas no effect was observed in a healthy age-matched control group. Conclusions/Significance. Collectively, these data demonstrate that Treg capable of inhibiting tumor associated antigen-specific immune responses are enriched in patients with CRC. These results support a rationale for manipulating Treg to enhance cancer immunotherapy.	[Clarke, Sarah L.; Betts, Gareth J.; Plant, Andrea; Wright, Kate L.; El-Shanawany, Tariq M.; Gallimore, Awen M.; Godkin, Andrew J.] Cardiff Univ, Dept Med Biochem & Immunol, Cardiff, Wales; [Harrop, Richard] Oxford Biomedica, Oxford, England; [Torkington, Jared; Rees, Brian I.] Univ Wales Hosp, Dept Surg, Cardiff, Wales; [Williams, Geraint T.] Cardiff Univ, Dept Pathol, Cardiff, Wales	Cardiff University; Oxford Biomedica (UK) Ltd; Cardiff University; Cardiff University	Clarke, SL (corresponding author), Cardiff Univ, Dept Med Biochem & Immunol, Cardiff, Wales.	godkinaj@cf.ac.uk		Godkin, Andrew/0000-0002-1910-7567; Gallimore, Awen/0000-0001-6675-7004	Tenovus Cancer Charity, Cardiff; Cardiff and Vale NHS Trust; Wellcome Trust project; Association of International Cancer Research; MRC senior research fellow; MRC [G0500617, G117/488] Funding Source: UKRI; Medical Research Council [G117/488, G0500617] Funding Source: researchfish	Tenovus Cancer Charity, Cardiff; Cardiff and Vale NHS Trust; Wellcome Trust project(Wellcome Trust); Association of International Cancer Research; MRC senior research fellow(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by funding from the Tenovus Cancer Charity, Cardiff, and a small grant award from Cardiff and Vale NHS Trust. KLW was funded by a Wellcome Trust project grant and the Association of International Cancer Research. AMG is an MRC senior research fellow.	Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; GODKIN A, 2006, MICROBES IN IN PRESS; Godkin AJ, 1998, J IMMUNOL, V161, P850; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Griffiths RW, 2005, BRIT J CANCER, V93, P670, DOI 10.1038/sj.bjc.6602776; Harris R., 2005, CANC IMMUNOL IM 1126, P1; HOLE N, 1988, BRIT J CANCER, V57, P239, DOI 10.1038/bjc.1988.53; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Jones Emma, 2002, Cancer Immun, V2, P1; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; MYERS KA, 1994, J BIOL CHEM, V269, P9319; Naito Y, 1998, CANCER RES, V58, P3491; Newcombe RG, 2001, STAT MED, V20, P2885, DOI 10.1002/sim.925; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; PARKIN DM, 2002, IARC SCI PUB, P1; Penn I, 1999, TRANSPLANT P, V31, P1260, DOI 10.1016/S0041-1345(98)01987-3; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Schramm C, 2004, INT IMMUNOL, V16, P1241, DOI 10.1093/intimm/dxh126; STARZYNSKA T, 1992, BRIT J CANCER, V66, P867, DOI 10.1038/bjc.1992.375; STARZYNSKA T, 1994, BRIT J CANCER, V69, P899, DOI 10.1038/bjc.1994.173; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; WRIGLEY E, 1995, INT J GYNECOL CANCER, V5, P269, DOI 10.1046/j.1525-1438.1995.05040269.x	29	178	186	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e129	10.1371/journal.pone.0000129	http://dx.doi.org/10.1371/journal.pone.0000129			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205133	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700023
J	Zhang, YL; McEwen, AE; Crothers, DM; Levene, SD				Zhang, Yongli; McEwen, Abbye E.; Crothers, Donald M.; Levene, Stephen D.			Analysis of In-Vivo LacR-Mediated Gene Repression Based on the Mechanics of DNA Looping	PLOS ONE			English	Article							TRANSCRIPTIONAL REGULATION; CRYSTAL-STRUCTURE; HELICAL REPEAT; PROTEIN; FLEXIBILITY; BINDING; DYNAMICS; HU; COMPLEXES; OPERATORS	Interactions of E. coli lac repressor (LacR) with a pair of operator sites on the same DNA molecule can lead to the formation of looped nucleoprotein complexes both in vitro and in vivo. As a major paradigm for loop-mediated gene regulation, parameters such as operator affinity and spacing, repressor concentration, and DNA bending induced by specific or non-specific DNA-binding proteins (e.g., HU), have been examined extensively. However, a complete and rigorous model that integrates all of these aspects in a systematic and quantitative treatment of experimental data has not been available. Applying our recent statistical-mechanical theory for DNA looping, we calculated repression as a function of operator spacing (58-156 bp) from first principles and obtained excellent agreement with independent sets of in-vivo data. The results suggest that a linear extended, as opposed to a closed v-shaped, LacR conformation is the dominant form of the tetramer in vivo. Moreover, loop-mediated repression in wild-type E. coli strains is facilitated by decreased DNA rigidity and high levels of flexibility in the LacR tetramer. In contrast, repression data for strains lacking HU gave a near-normal value of the DNA persistence length. These findings underscore the importance of both protein conformation and elasticity in the formation of small DNA loops widely observed in vivo, and demonstrate the utility of quantitatively analyzing gene regulation based on the mechanics of nucleoprotein complexes.	[Zhang, Yongli; Crothers, Donald M.] Yale Univ, Dept Chem, New Haven, CT 06520 USA; [Zhang, Yongli; Crothers, Donald M.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA; [McEwen, Abbye E.; Levene, Stephen D.] Univ Texas Dallas, Inst Biomed Sci & Technol, Richardson, TX 75083 USA; [Levene, Stephen D.] Univ Texas Dallas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	Yale University; Yale University; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Zhang, YL (corresponding author), Yale Univ, Dept Chem, New Haven, CT 06520 USA.	ylzhang@lbl.gov; sdlevene@utdallas.edu	Levene, Stephen/G-3100-2010	Levene, Stephen/0000-0003-2778-5162	NIH [GM 67242, GM 21966]; National Foundation for Cancer Research through the Yale-NFCR Center for Protein and Nucleic Acid Chemistry; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM067242, R01GM021966] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Foundation for Cancer Research through the Yale-NFCR Center for Protein and Nucleic Acid Chemistry; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Joint DMS/NIGMS Mathematical Biology Initiative (NIH GM 67242 to SDL and I. K. Darcy), by NIH grant GM 21966 to DMC, and by the National Foundation for Cancer Research through the Yale-NFCR Center for Protein and Nucleic Acid Chemistry.	[Anonymous], 1987, LINEAR AGGREGATION T; Azam TA, 2000, GENES CELLS, V5, P613, DOI 10.1046/j.1365-2443.2000.00350.x; Becker NA, 2005, J MOL BIOL, V349, P716, DOI 10.1016/j.jmb.2005.04.035; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Bintu L, 2005, CURR OPIN GENET DEV, V15, P125, DOI 10.1016/j.gde.2005.02.006; Bintu L, 2005, CURR OPIN GENET DEV, V15, P116, DOI 10.1016/j.gde.2005.02.007; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE, V1st ed.; Bryant Z, 2003, NATURE, V424, P338, DOI 10.1038/nature01810; Cloutier TE, 2005, P NATL ACAD SCI USA, V102, P3645, DOI 10.1073/pnas.0409059102; Cloutier TE, 2004, MOL CELL, V14, P355, DOI 10.1016/S1097-2765(04)00210-2; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; Edelman LM, 2003, BIOPHYS J, V84, P1131, DOI 10.1016/S0006-3495(03)74929-7; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; FINZI L, 1995, SCIENCE, V267, P378, DOI 10.1126/science.7824935; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; Fried MG, 2001, J BIOL CHEM, V276, P11226, DOI 10.1074/jbc.M009087200; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Geanacopoulos M, 2001, NAT STRUCT BIOL, V8, P432, DOI 10.1038/87595; Gemmen GJ, 2006, NUCLEIC ACIDS RES, V34, P2864, DOI 10.1093/nar/gkl382; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; LAW SM, 1993, J MOL BIOL, V230, P161, DOI 10.1006/jmbi.1993.1133; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; LEVENE SD, 2001, NATURE ENCY LIFE SCI; Lewis M, 2005, CR BIOL, V328, P521, DOI 10.1016/j.crvi.2005.04.004; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; Mehta RA, 1999, J MOL BIOL, V294, P67, DOI 10.1006/jmbi.1999.3244; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; Muller J, 1996, J MOL BIOL, V257, P21, DOI 10.1006/jmbi.1996.0143; OEHLER S, 1994, EMBO J, V13, P3348, DOI 10.1002/j.1460-2075.1994.tb06637.x; Pastre D, 2006, EUR BIOPHYS J BIOPHY, V35, P214, DOI 10.1007/s00249-005-0025-7; PORSCHKE D, 1991, BIOPHYS CHEM, V40, P169, DOI 10.1016/0301-4622(91)87006-Q; Rippe K, 2001, TRENDS BIOCHEM SCI, V26, P733, DOI 10.1016/S0968-0004(01)01978-8; Ross ED, 2001, MOL CELL BIOL, V21, P6598, DOI 10.1128/MCB.21.19.6598-6605.2001; Ruben GC, 1997, MICROSC RES TECHNIQ, V36, P400, DOI 10.1002/(SICI)1097-0029(19970301)36:5<400::AID-JEMT10>3.0.CO;2-W; Saiz L, 2005, P NATL ACAD SCI USA, V102, P17642, DOI 10.1073/pnas.0505693102; SAIZ L, IN VIVO EVIDENCE ALT; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; Skoko D, 2004, BIOCHEMISTRY-US, V43, P13867, DOI 10.1021/bi048428o; Swigon D, 2006, P NATL ACAD SCI USA, V103, P9879, DOI 10.1073/pnas.0603557103; van den Broek B, 2006, NUCLEIC ACIDS RES, V34, P167, DOI 10.1093/nar/gkj432; van Noort J, 2004, P NATL ACAD SCI USA, V101, P6969, DOI 10.1073/pnas.0308230101; Vilar JMG, 2005, CURR OPIN GENET DEV, V15, P136, DOI 10.1016/j.gde.2005.02.005; Vilar JMG, 2003, J MOL BIOL, V331, P981, DOI 10.1016/S0022-2836(03)00764-2; Villa E, 2005, P NATL ACAD SCI USA, V102, P6783, DOI 10.1073/pnas.0409387102; von Hippel P. H, 1979, BIOL REGULATION DEV, V1, P279; Vossen KM, 1996, J MOL BIOL, V255, P44, DOI 10.1006/jmbi.1996.0005; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; Watson MA, 2000, J MOL BIOL, V298, P461, DOI 10.1006/jmbi.2000.3676; Wiggins PA, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021909; Wiggins PA, 2006, NAT NANOTECHNOL, V1, P137, DOI 10.1038/nnano.2006.63; Yan J, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061905; Yan J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.108108; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623; Zhang Y, 2006, BIOPHYS J, V90, P1903, DOI 10.1529/biophysj.105.070490; Zhang YL, 2004, P NATL ACAD SCI USA, V101, P8337, DOI 10.1073/pnas.0402319101; Zhang YL, 2003, P NATL ACAD SCI USA, V100, P3161, DOI 10.1073/pnas.0530189100; Zhang YL, 2003, BIOPHYS J, V84, P136, DOI 10.1016/S0006-3495(03)74838-3; Zhou HX, 2001, BIOCHEMISTRY-US, V40, P15069, DOI 10.1021/bi015795g	69	54	55	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e136	10.1371/journal.pone.0000136	http://dx.doi.org/10.1371/journal.pone.0000136			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205140	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443700030
J	Schwartz, B; Melnikova, VO; Tellez, C; Mourad-Zeidan, A; Blehm, K; Zhao, YJ; McCarty, M; Adam, L; Bar-Eli, M				Schwartz, B.; Melnikova, V. O.; Tellez, C.; Mourad-Zeidan, A.; Blehm, K.; Zhao, Y-J; McCarty, M.; Adam, L.; Bar-Eli, M.			Loss of AP-2 alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo	ONCOGENE			English	Review						AP-2 alpha; colon cancer; MMP-9; E-cadherin; transcriptional regulation	TRANSCRIPTION FACTOR AP-2; GENE-EXPRESSION; HUMAN-MELANOMA; COLORECTAL-CARCINOMA; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION; TUMOR-GROWTH; METASTASIS; CLONING	Activator protein-2 (AP-2) is a transcription factor that regulates proliferation and differentiation in mammalian cells and has been implicated in the acquisition of the metastatic phenotype in several types of cancer. Herein, we examine the role of AP-2 alpha in colon cancer progression. We provide evidence for the lack of AP-2 alpha expression in the late stages of colon cancer cells. Re-expression of the AP-2 alpha gene in the AP-2 alpha-negative SW480 colon cancer cells suppressed their tumorigenicity following orthotopic injection into the cecal wall of nude mice. The inhibition of tumor growth could be attributed to the increased expression of E-cadherin and decreased expression and activity of matrix-metalloproteinase-9 (MMP-9) in the transfected cells, as well as a substantial loss of their in vitro invasive properties. Conversely, targeting constitutive expression of AP-2 alpha in AP-2-positive KM12C colon cancer cells with small interfering RNA resulted in an increase in their invasive potential, downregulation of E-cadherin and increased expression of MMP-9. In SW480 cells, re-expression of AP-2 alpha resulted in a fourfold increase in the activity of E-cadherin promoter, and a 5-14-fold decrease in the activity of MMP-9 promoter, indicating transcriptional regulation of these genes by AP-2 alpha. Chromatin immunoprecipitation assay showed that re-expressed AP-2 alpha directly binds to the promoter of E-cadherin, where it has been previously reported to act as a transcriptional activator. Furthermore, chromatin immunoprecipitation assay revealed AP-2 alpha binding to the MMP-9 promoter, which ensued by decreased binding of transcription factor Sp-1 and changes in the recruitment of transcription factors to a distal AP-1 element, thus, contributing to the overall downregulation of MMP-9 promoter activity. Collectively, our data provide evidence that AP-2 alpha acts as a tumor suppressor gene in colon cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA-76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Boedefeld WM, 2003, ANN SURG ONCOL, V10, P839, DOI 10.1245/ASO.2003.02.021; Bosher JM, 1996, ONCOGENE, V13, P1701; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang WH, 2002, J MOL MODEL, V8, P8, DOI 10.1007/s00894-001-0060-y; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORIKAWA K, 1988, CANCER RES, V48, P6863; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rozen P, 2004, EUR J CANCER PREV, V13, P71, DOI 10.1097/00008469-200402000-00011; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SATO H, 1993, ONCOGENE, V8, P395; Sumigama S, 2004, ONCOGENE, V23, P5496, DOI 10.1038/sj.onc.1207723; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vainio H, 2003, ACTA ONCOL, V42, P809, DOI 10.1080/02841860310010673; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	35	59	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4049	4058		10.1038/sj.onc.1210193	http://dx.doi.org/10.1038/sj.onc.1210193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224907				2022-12-25	WOS:000247252700001
J	Goldman, J; Rutkowski, JM; Shields, JD; Pasquier, MC; Cui, YJ; Schmokel, HG; Willey, S; Hicklin, DJ; Pytowski, B; Swartz, MA				Goldman, Jeremy; Rutkowski, Joseph M.; Shields, Jacqueline D.; Pasquier, Miriella C.; Cui, Yingjie; Schmoekel, Hugo G.; Willey, Stephen; Hicklin, Daniel J.; Pytowski, Bronislaw; Swartz, Melody A.			Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis	FASEB JOURNAL			English	Article						VEGF-C; mouse; in vitro wound healing; vasculogenesis	ENDOTHELIAL GROWTH-FACTOR; FACTOR-C; LYMPHATIC REGENERATION; FACTOR RECEPTOR-3; TYROSINE KINASES; TRANSGENIC MICE; HYPERPLASIA; METASTASIS; ACTIVATION; ANTIBODY	Activation of vascular endothelial growth factor ( VEGF) receptor-3 (VEGFR-3) by VEGF-C initiates lymphangiogenesis by promoting lymphatic proliferation and migration. However, it is unclear whether VEGFR-3 signaling is required beyond these initial stages, namely during the organization of new lymphatic endothelial cells (LECs) into functional capillaries. Furthermore, the role of VEGFR-2, which is also expressed on LECs and binds VEGF-C, is unclear. We addressed these questions by selectively neutralizing VEGFR-3 and/or VEGFR-2 for various time periods in an adult model of lymphangiogenesis in regenerating skin. While blocking either VEGFR-2 or VEGFR-3 with specific antagonist mAbs (DC101 and mF4-31C1, respectively) prior to lymphatic migration prevented lymphangiogenesis, blocking VEGFR-3 subsequent to migration did not affect organization into functional capillaries, and VEGFR-2 blocking had only a small hindrance on organization. These findings were confirmed in vitro using human LECs and anti-human antagonist mAbs (IMC-1121a and hF4-3C5): both VEGFR-2 and VEGFR-3 signaling were required for migration and proliferation, but tubulogenesis in 3D cultures was unaffected by VEGFR-3 blocking and partially hindered by VEGFR-2 blocking. Furthermore, both in vitro and in vivo, while VEGFR-3 blocking had no effect on LEC organization, coneutralization of VEGFR-2, and VEGFR- 3 completely prevented lymphatic organization. Our findings demonstrate that cooperative signaling of VEGFR-2 and -3 is necessary for lymphatic migration and proliferation, but VEGFR-3 is redundant with VEGFR-2 for LEC organization into functional capillaries.	Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Life Sci, LMBM, CH-1015 Lausanne, Switzerland; Tumor Biol ImClone Syst, New York, NY USA; ImClone Syst, Expt Therapeut, New York, NY USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Eli Lilly; Eli Lilly	Swartz, MA (corresponding author), Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Life Sci, LMBM, Stn 15, CH-1015 Lausanne, Switzerland.	melody.swartz@epfl.ch	Swartz, Melody A./F-9563-2011; Swartz, Melody/B-7633-2009	Rutkowski, Joseph/0000-0002-4197-0236	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075217] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL075217-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Alam A, 2004, BIOCHEM BIOPH RES CO, V324, P909, DOI 10.1016/j.bbrc.2004.08.237; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Aoki Y, 2005, JNCI-J NATL CANCER I, V97, P2, DOI 10.1093/jnci/dji015; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; Dixelius J, 2003, J BIOL CHEM, V278, P40973, DOI 10.1074/jbc.M304499200; Goldman J, 2005, CIRC RES, V96, P1193, DOI 10.1161/01.RES.0000168918.27576.78; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karpanen T, 2001, CANCER RES, V61, P1786; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Mimura T, 2001, EXP EYE RES, V72, P71, DOI 10.1006/exer.2000.0925; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Oliver G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI 10.1146/annurev.cellbio.21.012704.132338; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Pytowski B, 2005, JNCI-J NATL CANCER I, V97, P14, DOI 10.1093/jnci/dji003; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Rutkowski JM, 2006, AM J PHYSIOL-HEART C, V291, pH1402, DOI 10.1152/ajpheart.00038.2006; Saaristo A, 2004, FASEB J, V18, P1707, DOI 10.1096/fj.04-1592fje; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Swartz MA, 2001, MICROSC RES TECHNIQ, V55, P92, DOI 10.1002/jemt.1160; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Tammela T, 2005, BLOOD, V105, P4642, DOI 10.1182/blood-2004-08-3327; WITTE K, 1998, HLTH RISK COMMUNICAT, V2, P1; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Yuan L, 2002, DEVELOPMENT, V129, P4797	37	112	123	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1003	1012		10.1096/fj.06-6656com	http://dx.doi.org/10.1096/fj.06-6656com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17210781				2022-12-25	WOS:000245650400005
J	Huang, RQ; Qu, YH; Ke, WL; Zhu, JH; Pei, YY; Jiang, C				Huang, Rong-Qin; Qu, Ying-Hua; Ke, Wei-Lun; Zhu, Jian-Hua; Pei, Yuan-Ying; Jiang, Chen			Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer	FASEB JOURNAL			English	Article						brain targeting; PAMAM; transferrin	DRUG-DELIVERY; IN-VIVO; PAMAM DENDRIMER; BARRIER; LIPOSOMES; RECEPTOR; DNA; TRANSFECTION; ENDOCYTOSIS; TRANSPORT	The blood-brain barrier (BBB) poses great difficulties for gene delivery to the brain. To circumvent the BBB, we investigated a novel brain-targeting gene vector based on the nanoscopic high-branching dendrimer, polyamidoamine ( PAMAM), in vitro and in vivo. Transferrin (Tf) was selected as a brain-targeting ligand conjugated to PAMAM via bifunctional polyethyleneglycol ( PEG), yielding PAMAM-PEG-Tf. UV and nuclear magnetic resonance (NMR) spectroscopy were used to evaluate the synthesis of vectors. The characteristics and biodistribution of gene vectors were evaluated by fluorescent microscopy, flow cytometry, and a radiolabeling method. The transfection efficiency of vector/DNA complexes in brain capillary endothelial cells (BCECs) was evaluated by fluorescent microscopy and determination of luciferase activity. The potency of vector/DNA complexes was evaluated by using frozen sections and measuring tissue luciferase activity in Balb/c mice after i.v. administration. UV and NMR results demonstrated the successful synthesis of PAMAM-PEG-Tf. This vector showed a concentration- dependent manner in cellular uptake study and a 2.25-fold brain uptake compared with PAMAM and PAMAM-PEG in vivo. Transfection efficiency of PAMAM-PEG-Tf/DNA complex was much higher than PAMAM/DNA and PAMAM-PEG/DNA complexes in BCECs. Results of tissue expression experiments indicated the widespread expression of an exogenous gene in mouse brain after i.v. administration. With a PAMAM/DNA weight ratio of 10: 1, the brain gene expression of the PAMAM-PEG-Tf/DNA complex was similar to 2-fold higher than that of the PAMAM/DNA and PAMAM-PEG/DNA complexes. These results suggested that PAMAM-PEG-Tf can be exploited as a potential nonviral gene vector targeting to brain via noninvasive administration.	Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 200032, Peoples R China	Fudan University	Jiang, C (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmaceut, POB 130, Shanghai 200032, Peoples R China.	jiangchen@shmu.edu.cn	Huang, Rongqin/C-4165-2014					Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7; Bielinska AU, 1999, BIOCONJUGATE CHEM, V10, P843, DOI 10.1021/bc990036k; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun CS, 2005, J PHARM SCI-US, V94, P423, DOI 10.1002/jps.20251; Cheng YY, 2005, EUR J MED CHEM, V40, P1390, DOI 10.1016/j.ejmech.2005.08.002; Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027; Ding Jun-Jun, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P499; Eichman, 2000, Pharm Sci Technol Today, V3, P232, DOI 10.1016/S1461-5347(00)00273-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Harashima H, 2001, EUR J PHARM SCI, V13, P85, DOI 10.1016/S0928-0987(00)00211-6; Hatakeyama H, 2004, INT J PHARMACEUT, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; Kang HM, 2005, PHARM RES-DORDR, V22, P2099, DOI 10.1007/s11095-005-8330-5; Kitchens KM, 2005, ADV DRUG DELIVER REV, V57, P2163, DOI 10.1016/j.addr.2005.09.013; Kobayashi H, 1999, BIOCONJUGATE CHEM, V10, P103, DOI 10.1021/bc980091d; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027; Luo D, 2002, MACROMOLECULES, V35, P3456, DOI 10.1021/ma0106346; Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863; Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P223; Pardridge WM, 2001, JPN J PHARMACOL, V87, P97, DOI 10.1254/jjp.87.97; Pardridge WM, 2001, DRUG DISCOV TODAY, V6, P1, DOI 10.1016/S1359-6446(00)01583-X; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Sako K, 2005, J NEUROIMMUNOL, V158, P40, DOI 10.1016/j.jneuroim.2004.08.013; Schlachetzki F, 2004, NEUROLOGY, V62, P1275, DOI 10.1212/01.WNL.0000120551.38463.D9; Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497; Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086; Xie Y, 2005, J CONTROL RELEASE, V105, P106, DOI 10.1016/j.jconrel.2005.03.005; XU YQ, 1996, NUCL TECHNOL, V19, P309; Youk HJ, 2005, J CONTROL RELEASE, V107, P43, DOI 10.1016/j.jconrel.2005.05.014; Zhang Y, 2003, MOL THER, V7, P11, DOI 10.1016/S1525-0016(02)00018-7	34	272	294	2	89	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1117	1125		10.1096/fj.06-7380com	http://dx.doi.org/10.1096/fj.06-7380com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218540				2022-12-25	WOS:000245650400016
J	Nakada, T; Westhoff, CM; Kato, A; Hirose, S				Nakada, Tsutomu; Westhoff, Connie M.; Kato, Akira; Hirose, Shigehisa			Ammonia secretion from fish gill depends on a set of Rh glycoproteins	FASEB JOURNAL			English	Article						RhAG; rhesus glycoprotein; ammonium transporter; mitochondria-rich cell; teleost	TRANSPORTER; EXCRETION; KIDNEY; OSMOREGULATION; IDENTIFICATION; EXPRESSION; CELLS	Ammonia excretion from the gill in teleost fish is essential for nitrogen elimination. Although numerous physiological studies have measured ammonia excretion, the mechanism of ammonia movement through the membranes of gill epithelial cells is still unknown. Mammalian Rh glycoproteins are members of a family of proteins that mediate ammonia transport in bacteria, yeast, and plants. We identified the Rh glycoprotein homologs, fRhag, fRhbg, fRhcg1, and fRhcg2, of the pufferfish, Takifugu rubripes. Northern blot, in situ hybridization, and immunohistochemistry revealed that the pufferfish erythroid Rh glycoprotein homologue fRhag was present in red blood cells and the hematological organs ( spleen and kidney) in fish. All four pufferfish Rh glycoproteins are specifically localized in the gill and line the pillar cells, pavement cells, and the mitochondrion-rich cells. Heterologous expression in Xenopus oocytes showed that they mediate methylammonium ( an analog of ammonium) transport. These results suggest that pufferfish Rh glycoproteins are involved in ammonia excretion from the gill. These findings challenge the classic view that ammonia excretion in the fish gill occurs by passive diffusion.	Tokyo Inst Technol, Dept Sci Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Amer Red Cross, Philadelphia, PA USA	Tokyo Institute of Technology; University of Pennsylvania; American Red Cross	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Sci Biol, Midori Ku, 4259-B-19 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; GARVIN JL, 1988, AM J PHYSIOL, V255, pF56; KUDO H, 2007, IN PRESS J HISTOCHEM; KURTZ I, 1986, AM J PHYSIOL, V250, pF497, DOI 10.1152/ajprenal.1986.250.3.F497; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ludewig U, 2004, J PHYSIOL-LONDON, V559, P751, DOI 10.1113/jphysiol.2004.067728; Mak DOD, 2006, AM J PHYSIOL-RENAL, V290, pF297, DOI 10.1152/ajprenal.00147.2005; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Mistry AC, 2001, AM J PHYSIOL-REG I, V281, pR1594, DOI 10.1152/ajpregu.2001.281.5.R1594; Nakada T, 2005, AM J PHYSIOL-REG I, V289, pR575, DOI 10.1152/ajpregu.00725.2004; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Quentin F, 2003, J AM SOC NEPHROL, V14, P545, DOI 10.1097/01.ASN.0000050413.43662.55; Randall DJ, 1999, AM J PHYSIOL-REG I, V277, pR1562, DOI 10.1152/ajpregu.1999.277.6.R1562; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; Westhoff CM, 2004, J BIOL CHEM, V279, P17443, DOI 10.1074/jbc.M311853200; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Wilkie MP, 2002, J EXP ZOOL, V293, P284, DOI 10.1002/jez.10123; Wood C, 2002, BBA-BIOMEMBRANES, V1566, P72, DOI 10.1016/S0005-2736(02)00595-3; WRIGHT PA, 1995, J EXP BIOL, V198, P273	22	150	159	2	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1067	1074		10.1096/fj.06-6834com	http://dx.doi.org/10.1096/fj.06-6834com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218543				2022-12-25	WOS:000245650400011
J	Bae, JS; Yang, LK; Manithody, C; Rezaie, AR				Bae, Jong-Sup; Yang, Likui; Manithody, Chandrashekhara; Rezaie, Alireza R.			Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; KAPPA-B ACTIVATION; ENDOTHELIAL-CELLS; FACTOR-VA; CRYSTAL-STRUCTURE; RECEPTOR; APOPTOSIS; EXPRESSION; EXOSITE; CA2+	In addition to an anticoagulant activity, activated protein C (APC) also exhibits anti-inflammatory and cytoprotective properties. These properties may contribute to the beneficial effect of APC in treating severe sepsis patients. A higher incidence of bleeding because of its anticoagulant function has been found to be a major drawback of APC as an effective anti-inflammatory drug. In this study, we have prepared a protein C variant in which an engineered disulfide bond between two beta-sheets stabilized the functionally critical Ca2+ -binding 70 - 80 loop of the molecule. The 70 - 80 loop of this mutant no longer bound Ca2+- and the activation of the mutant by thrombin was enhanced 60-80-fold independently of thrombomodulin. The anticoagulant activity of the activated protein C mutant was nearly eliminated as determined by a plasma-based clotting assay. However, the endothelial protein C receptor- and protease-activated receptor- l-dependent protective signaling properties of the mutant were minimally altered as determined by staurosporine-induced endothelial cell apoptosis, thrombin-induced endothelial cell permeability, and tumor necrosis-a-mediated neutrophil adhesion and migration assays. These results suggest that the mutant lost its ability to interact with the procoagulant cofactors but not with the protective signaling molecules; thus this mutant provides an important tool for in vivo studies to examine the role of anticoagulant versus anti-inflammatory function of activated protein C.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Bae, Jong-Sup/AAU-9724-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL 68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Friedrich U, 2001, J BIOL CHEM, V276, P23105, DOI 10.1074/jbc.M103138200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1986, J BIOL CHEM, V261, P4991; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; LIU LW, 1994, J BIOL CHEM, V269, P11807; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Manithody C, 2003, BLOOD, V101, P4802, DOI 10.1182/blood-2003-01-0126; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STENFLO J, 1984, SEMIN THROMB HEMOST, V10, P109, DOI 10.1055/s-2007-1004413; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; Yang LK, 2006, P NATL ACAD SCI USA, V103, P879, DOI 10.1073/pnas.0507700103; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r	35	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9251	9259		10.1074/jbc.M610547200	http://dx.doi.org/10.1074/jbc.M610547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255099	hybrid			2022-12-25	WOS:000245780300072
J	Graubner, W; Schierhorn, A; Bruser, T				Graubner, Wenke; Schierhorn, Angelika; Brueser, Thomas			DnaK plays a pivotal role in Tat targeting of CueO and functions beside SlyD as a general Tat signal binding chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PROTEIN TRANSLOCATION; TRIGGER FACTOR; LYSIS PROTEIN; SYSTEM; STEP; IDENTIFICATION; SECRETION; INSERTION; PEPTIDE	The Tat (twin-arginine translocation) system from Escherichia coli transports folded proteins with N-terminal twin-arginine signal peptides across the cytoplasmic membrane. The influence of general chaperones on Tat substrate targeting has not been clarified so far. Here we show that the chaperones SlyD and DnaK bind to a broad range of different Tat signal sequences in vitro and in vivo. initially, SlyD and GroEL were purified from DnaK-deficient extracts by their affinity to various Tat signal sequences. Of these, only SlyD bound Tat signal sequences also in the presence of DnaK. SlyD and DnaK also co-purified with Tat substrate precursors, demonstrating the binding to Tat signal sequences in vivo. Deletion of dnaKcompletely abolished Tat-dependent translocation of CueO, but not of DmsA, YcdB, or HiPIP, indicating that DnaK has an essential role specifically for CueO. DnaK was not required for stability of the CueO precursor and thus served in some essential step after folding. A CueO signal sequence fusion to HiPIP was Tat-dependently transported without the need of DnaK, indicating that the mature domain of CueO is responsible for the DnaK dependence. The overall results suggest that SlyD and DnaK are in the set of chaperones that can serve as general Tat signal-binding proteins. DnaK has additional functions that are indispensable for the targeting of CueO.	Univ Halle Wittenberg, Inst Microbiol, D-06120 Halle, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Max Planck Society	Bruser, T (corresponding author), Univ Halle Wittenberg, Inst Microbiol, Kurt Mothes Str 3, D-06120 Halle, Germany.	t.brueser@mikrobiologie.uni-halle.de		Bruser, Thomas/0000-0002-5889-8306				Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; Bernhardt TG, 2002, MOL MICROBIOL, V45, P99, DOI 10.1046/j.1365-2958.2002.02984.x; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; Bruser T, 1998, FEMS MICROBIOL LETT, V164, P329; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dubini A, 2003, FEBS LETT, V549, P141, DOI 10.1016/S0014-5793(03)00802-0; Genest O, 2006, BIOCHEM BIOPH RES CO, V339, P991, DOI 10.1016/j.bbrc.2005.11.107; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Grass G, 2004, J BACTERIOL, V186, P5826, DOI 10.1128/JB.186.17.5826-5833.2004; Gutensohn M, 2004, MOL GENET GENOMICS, V272, P379, DOI 10.1007/s00438-004-1068-7; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Hou B, 2006, J MOL BIOL, V355, P957, DOI 10.1016/j.jmb.2005.11.029; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Jong WSP, 2004, EUR J BIOCHEM, V271, P4779, DOI 10.1111/j.1432-1033.2004.04442.x; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Kipping M, 2003, FEBS LETT, V550, P18, DOI 10.1016/S0014-5793(03)00804-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mitterauer T, 1999, BIOCHEM J, V342, P33, DOI 10.1042/0264-6021:3420033; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; Richter S, 2005, J BIOL CHEM, V280, P42723, DOI 10.1074/jbc.M509570200; ROOF WD, 1993, J BACTERIOL, V175, P3909, DOI 10.1128/JB.175.12.3909-3912.1993; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Sambasivarao D, 2001, J BIOL CHEM, V276, P20167, DOI 10.1074/jbc.M010369200; Scholz C, 2006, BIOCHEMISTRY-US, V45, P20, DOI 10.1021/bi051922n; Shanmugham A, 2006, BIOCHEMISTRY-US, V45, P2243, DOI 10.1021/bi052188a; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Sturm A, 2006, J BIOL CHEM, V281, P13972, DOI 10.1074/jbc.M511891200; Tree JJ, 2005, BIOCHEM BIOPH RES CO, V328, P1205, DOI 10.1016/j.bbrc.2005.01.084; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Walter S, 2002, CELL MOL LIFE SCI, V59, P1589, DOI 10.1007/PL00012485; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; Wilms B, 2001, BIOTECHNOL BIOENG, V73, P95, DOI 10.1002/bit.1041	43	68	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7116	7124		10.1074/jbc.M608235200	http://dx.doi.org/10.1074/jbc.M608235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215254	hybrid			2022-12-25	WOS:000245080900023
J	Meissner, JD; Chang, KC; Kubis, HP; Nebreda, AR; Gros, G; Scheibe, RJ				Meissner, Joachim D.; Chang, Kin-Chow; Kubis, Hans-Peter; Nebreda, Angel R.; Gros, Gerolf; Scheibe, Renate J.			The p38 alpha/beta mitogen-activated protein kinases mediate recruitment of CREB-binding protein to preserve fast myosin heavy chain IId/x gene activity in myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; SKELETAL-MUSCLE DIFFERENTIATION; TO-SLOW TRANSFORMATION; P38 MAP KINASE; TRANSCRIPTION FACTOR; RETINOIC ACID; CALCINEURIN; CALCIUM; MEF2; EXPRESSION	In skeletal muscle, the transformation of fast into slow fib type is accompanied by shifts in fiber type-specific gene expression that includes down-regulation of the adult fast fiber myosin heavy chain Ild/x (MyHCIId/x) gene. Here, we report that the mitogen-activated protein kinases (MAPKs) p38 alpha/beta regulate MyHCIId/x gene expression. Electrical stimulation of rabbi skeletal muscle cells with a slow fiber type activity pattern an treatment of C2C12 myotubes with Ca2+-ionophore inhibited p38 alpha/beta MAPKs and reduced fast fiber type MyHC protein expression and promoter activity. Pharmacological inhibition of p38 alpha/beta also down-regulated MyHCII gene expression. In controls, binding of the myocyte enhancer factor-2 (MEF-2) isoforms C and D as a heterodimer to a proximal consensus site within the MyHCIId/x promoter and recruitment of a transcriptional coactivator, the CREB-binding protein CBP, were observed. Overexpression of wild type MEF-2C but not of a MEF-2C mutant that cannot be phosphorylated by p38 induced promoter activity. Mutation of the MEF-2-binding site decreased the inducing effect of overexpressed CBP. Inhibition of p38 alpha/beta MAPKs abolished CBP binding, whereas enforced induction of p38 by activated MAPK kinase 6 (MKK6EE) enhanced binding of CBP and increased promoter activity. Furthermore, knockdown of endogenous CBP by RNA interference eliminated promoter activation by MEF-2C or MKK6EE. In electrical stimulated and Ca2+-ionophore-treated myotubes, CBP was absent in complex formation at that site. Taken together, the data indicate that p38 alpha/beta MAPKs-mediated coactivator recruitment at a proximal MEF-2 site is important for MyHCIId/x gene regulation in skeletal muscle.	Hannover Med Sch, Dept Physiol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Biochem, D-30625 Hannover, Germany; Univ Glasgow, Sch Vet, Div Anim Prod & Publ Hlth, Glasgow G61 1QH, Lanark, Scotland; CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain	Hannover Medical School; Hannover Medical School; University of Glasgow; Centro Nacional de Investigaciones Oncologicas (CNIO)	Meissner, JD (corresponding author), Hannover Med Sch, Dept Physiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	meissner.joachim@mh-hannover.de	Nebreda, Angel Rodriguez/R-9594-2019; Chang, Kin Chow/H-1046-2011; Gros, Gerolf/K-8421-2012	Chang, Kin-Chow/0000-0002-6602-7447				Allen DL, 2005, J BIOL CHEM, V280, P17126, DOI 10.1074/jbc.M501207200; Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; Carroll S, 1999, AM J PHYSIOL-CELL PH, V277, pC1122, DOI 10.1152/ajpcell.1999.277.6.C1122; Chan HM, 2001, J CELL SCI, V114, P2363; Chin ER, 2004, P NUTR SOC, V63, P279, DOI 10.1079/PNS2004335; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Goldspink G, 2002, BIOCHEM SOC T, V30, P285, DOI 10.1042/bst0300285; Goodman RH, 2000, GENE DEV, V14, P1553; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Kubis HP, 2002, J PHYSIOL-LONDON, V541, P835, DOI 10.1113/jphysiol.2002.017574; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Meissner JD, 2000, J PHYSIOL-LONDON, V523, P19, DOI 10.1111/j.1469-7793.2000.t01-1-00019.x; Meissner JD, 2007, J CELL PHYSIOL, V211, P138, DOI 10.1002/jcp.20916; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Puri PL, 2000, GENE DEV, V14, P574; Sakamoto K, 2002, J APPL PHYSIOL, V93, P369, DOI 10.1152/japplphysiol.00167.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHEIBE RJ, 1991, J BIOL CHEM, V266, P21300; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Smith JL, 2003, J BIOL CHEM, V278, P41034, DOI 10.1074/jbc.M305615200; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Terada H, 2003, J NEUROCHEM, V87, P1145, DOI 10.1046/j.1471-4159.2003.02098.x; Tran NQ, 2004, BIOCHEM J, V381, P267, DOI 10.1042/BJ20031653; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21; [No title captured]	58	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7265	7275		10.1074/jbc.M609076200	http://dx.doi.org/10.1074/jbc.M609076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210568	hybrid			2022-12-25	WOS:000245080900038
J	Paul, BD; Buchholz, DR; Fu, LZ; Shi, YB				Paul, Bindu D.; Buchholz, Daniel R.; Fu, Liezhen; Shi, Yun-Bo			SRC-p300 coactivator complex is required for thyroid hormone-induced amphibian metamorphosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS METAMORPHOSIS; STEROID-RECEPTOR COACTIVATOR-1; CREB-BINDING PROTEIN; IN-VIVO ANALYSIS; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; FROG METAMORPHOSIS; P160 COACTIVATOR; GLUCOCORTICOID-RECEPTOR	Gene activation by the thyroid hormone (T3) receptor (TR) involves the recruitment of specific coactivator complexes to T3-responsive promoters. A large number of coactivators for TR have been isolated and characterized in vitro. However, their roles and functions in vivo during development have remained largely unknown. We have utilized metamorphosis in Xenopus laevis to study the role of these coactivators during post-embryonic development. Metamorphosis is totally dependent on the thyroid hormone, and TR mediates a vast majority, if not all, of the developmental effects of the hormone. We have previously shown that TR recruits the coactivator SRC3 (steroid receptor coactivator-3) and that coactivator recruitment is essential for metamorphosis. To determine whether SRCs are indeed required, we have analyzed the in vivo role of the histone acetyltransferase p300/CREB-binding protein (CBP), which was reported to be a component of the SRC-coactivator complexes. Chromatin immunoprecipitation revealed that p300 is recruited to T3-responsive promoters, implicating a role of p300 in TR function. Further, transgenic tadpoles overexpressing a dominant negative form of p300, F-dnp300, containing only the SRC-interacting domain, displayed arrested or delayed metamorphosis. Molecular analyses of the transgenic F-dnp300 animals showed that F-dnp300 was recruited by TR (displacing endogenous p300) and inhibited the expression of T3-responsive genes. Our results thus suggest that p300 and/or its related CBP is an essential component of the TR-signaling pathway in vivo and support the notion that p300/CBP and SRC proteins are part of the same coactivator complex in vivo during postembryonic development.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shi, YB (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 18T,Room 106,LGRD, Bethesda, MD 20892 USA.	shi@helix.nih.gov		Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amano T, 2002, DEV DYNAM, V223, P526, DOI 10.1002/dvdy.10075; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Buchholz DR, 2003, MOL CELL BIOL, V23, P6750, DOI 10.1128/MCB.23.19.6750-6758.2003; Buchholz DR, 2006, GEN COMP ENDOCR, V145, P1, DOI 10.1016/j.ygcen.2005.07.009; Buchholz DR, 2005, J BIOL CHEM, V280, P41222, DOI 10.1074/jbc.M509593200; Buchholz DR, 2004, MOL CELL BIOL, V24, P9026, DOI 10.1128/MCB.24.20.9026-9037.2004; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Demarest SJ, 2004, PROTEIN SCI, V13, P203, DOI 10.1110/ps.03366504; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DODD MHI, 1976, BIOL METAMORPHOSIS, P467; Fu LZ, 2006, J BIOL CHEM, V281, P16870, DOI 10.1074/jbc.M603041200; Fu LZ, 2002, MOL REPROD DEV, V62, P470, DOI 10.1002/mrd.10137; Fujii G, 1998, BBA-GENE STRUCT EXPR, V1443, P41, DOI 10.1016/S0167-4781(98)00179-1; Furlow JD, 1999, MOL ENDOCRINOL, V13, P2076, DOI 10.1210/me.13.12.2076; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Havis E, 2003, EMBO REP, V4, P883, DOI 10.1038/sj.embor.embor908; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Ishizuya-Oka A, 1997, DEV BIOL, V192, P149, DOI 10.1006/dbio.1997.8749; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jepsen K, 2002, J CELL SCI, V115, P689; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Laudet V., 2002, NUCL RECEPTOR FACTS; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Y, 2006, MOL ENDOCRINOL, V20, P483, DOI 10.1210/me.2005-0101; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Parker D, 1996, MOL CELL BIOL, V16, P694; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; Paul BD, 2005, J BIOL CHEM, V280, P27165, DOI 10.1074/jbc.M503999200; Paul BD, 2005, MOL CELL BIOL, V25, P5712, DOI 10.1128/MCB.25.13.5712-5724.2005; Paul DB, 2003, CELL RES, V13, P459, DOI 10.1038/sj.cr.7290188; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Schreiber AM, 2001, P NATL ACAD SCI USA, V98, P10739, DOI 10.1073/pnas.191361698; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	78	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7472	7481		10.1074/jbc.M607589200	http://dx.doi.org/10.1074/jbc.M607589200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218308	hybrid			2022-12-25	WOS:000245080900060
J	Takeda, K; Shimozono, R; Noguchi, T; Umeda, T; Morimoto, Y; Naguro, I; Tobiume, K; Saitoh, M; Matsuzawa, A; Ichijo, H				Takeda, Kohsuke; Shimozono, Rieko; Noguchi, Takuya; Umeda, Tsuyoshi; Morimoto, Yoshifumi; Naguro, Isao; Tobiume, Kei; Saitoh, Masao; Matsuzawa, Atsushi; Ichijo, Hidenori			Apoptosis signal-regulating kinase (ASK) 2 functions as a mitogen-activated protein kinase kinase kinase in a heteromeric complex with ASK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; MOLECULAR-CLONING; MAP KINASES; B-RAF; STRESS; FAMILY; PATHWAYS; IMMUNITY; ERK	Apoptosis signal-regulating kinase (ASK) 1 is a mitogen-activated protein kinase kinase kinase (MAP3K) in the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase pathways that play multiple important roles in cytokine and stress responses. Here we show that ASK2, a highly related serine/threonine kinase to ASK1, also functions as a MAP3K only in a heteromeric complex with ASK1. We found that endogenous ASK2 was constitutively degraded in ASK1-deficient cells, suggesting that ASK1 is required for the stability of ASK2. ASK2 in a heteromeric complex with a kinase-negative mutant of ASK1 (ASK1-KN) effectively activated MAP2K and was more competent to respond to oxidative stress than ASK2 alone. Knockdown of ASK2 revealed that ASK2 was required for oxidative stress-induced JNK activation. These results suggest that ASK2 forms a functional MAP3K complex with ASK1, in which ASK1 supports the stability and the active configuration of ASK2. Moreover, ASK2 was found to activate ASK1 by direct phosphorylation, suggesting that ASK1 and ASK2 in a heteromeric complex facilitate their activities to each other by distinct mechanisms. Such a formation of functional heteromeric complex between different MAP3Ks may be advantageous for cells to cope with a wide variety of stimuli by fine regulation of cellular responses.	Univ Tokyo, Lab Cell Signaling, Grad Sch Pharmaceut Sci, CREST,Japan Sci & Technol Corp,Bunkyo Ku, Tokyo 1130033, Japan; Ctr Excellence Program, Strateg Approach Durg Discovery & Dev Pharmaceut, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Hiroshima Univ, Sch Biomed Sci, Dept Mucosal Immunol, Hiroshima 7348553, Japan	Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; Hiroshima University	Ichijo, H (corresponding author), Univ Tokyo, Lab Cell Signaling, Grad Sch Pharmaceut Sci, CREST,Japan Sci & Technol Corp,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ichijo@mol.f.u-tokyo.ac.jp	Naguro, Isao/P-1337-2019; Matsuzawa, Atsushi/GLU-1387-2022; Noguchi, Takuya/T-6767-2019	Noguchi, Takuya/0000-0001-6187-6645; Takeda, Kohsuke/0000-0002-8359-8399; Matsuzawa, Atsushi/0000-0001-8303-3905; Ichijo, Hidenori/0000-0002-5005-6438; Naguro, Isao/0000-0002-0338-8026				Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakagami H, 2005, J BIOL CHEM, V280, P23084, DOI 10.1074/jbc.M413438200; Stronach B, 2005, DEV DYNAM, V232, P575, DOI 10.1002/dvdy.20283; Su B, 2005, NAT IMMUNOL, V6, P541, DOI 10.1038/ni0605-541; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	28	87	114	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7522	7531		10.1074/jbc.M607177200	http://dx.doi.org/10.1074/jbc.M607177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210579	hybrid			2022-12-25	WOS:000245080900065
J	Shanware, NP; Trinh, AT; Williams, LM; Tibbetts, RS				Shanware, Naval P.; Trinh, Anthony T.; Williams, Leah M.; Tibbetts, Randal S.			Coregulated ataxia telangiectasia-mutated and casein kinase sites modulate cAMP-response element-binding protein-coactivator interactions in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED PHOSPHORYLATION; MEDIATED GENE-EXPRESSION; GENOME-WIDE ANALYSIS; NUCLEAR FACTOR CREB; GENOTOXIC STRESS; KIX DOMAIN; ATM KINASE; ACTIVATION; P53; TRANSCRIPTION	The cyclic AMP-response element-binding protein (CREB) is a bZIP family transcription factor implicated as an oncoprotein and neuron survival factor. CREB is activated in response to cellular stimuli, including cAMP and Ca2+, via phosphorylation of Ser-133, which promotes interaction between the kinase-inducible domain (KID) of CREB and the KID-interacting domain of CREB-binding protein (CBP). We previously demonstrated that the interaction between CREB and CBP is inhibited by DNA-damaging stimuli through a mechanism whereby CREB is phosphorylated by the ataxia telangiectasia-mutated (ATM) protein kinase. We now show that the ATM phosphorylation sites in CREB are functionally intertwined with a cluster of coregulated casein kinase (CK) sites. We demonstrate that DNA damage-induced phosphorylation of CREB occurs in three steps. The initial event in the CREB phosphorylation cascade is the phosphorylation of Ser111, which is carried out by CK1 and CK2 under basal conditions and by ATM in response to ionizing radiation. The phosphorylation of Ser-111 triggers the CK2-dependent phosphorylation of Ser-108 and the CK1-dependent phosphorylation of Ser-114 and Ser-117. The phosphorylation of Ser-114 and Ser-117 by CK1 then renders CREB permissive for ATM-dependent phosphorylation on Ser-121. Mutation of Ser-121 alone abrogates ionizing radiation-dependent repression of CREB-CBP complexes, which can be recapitulated using a CK1 inhibitor. Our findings outline a complex mechanism of CREB phosphorylation in which coregulated ATM and CK sites control CREB transactivation potential by modulating its CBP-binding affinity. The coregulated ATM and CK sites identified in CREB may constitute a signaling motif that is common to other DNA damage-regulated substrates.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067868-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Garat CV, 2006, MOL CELL BIOL, V26, P4934, DOI 10.1128/MCB.02477-05; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Horiuchi J, 2004, J BIOL CHEM, V279, P12117, DOI 10.1074/jbc.M212839200; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Parker D, 1996, MOL CELL BIOL, V16, P694; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Riccio A, 2006, MOL CELL, V21, P283, DOI 10.1016/j.molcel.2005.12.006; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; SHILOH Y, 2003, TRENDS BIOCHEM SCI, V31, P402; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	50	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6283	6291		10.1074/jbc.M610674200	http://dx.doi.org/10.1074/jbc.M610674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17209043	hybrid			2022-12-25	WOS:000244867200034
J	Pulliam, JRC; Dushoff, JG; Levin, SA; Dobson, AP				Pulliam, Juliet R. C.; Dushoff, Jonathan G.; Levin, Simon A.; Dobson, Andrew P.			Epidemic Enhancement in Partially Immune Populations	PLOS ONE			English	Article							INFECTIOUS-DISEASES; SPREAD	We observe that a pathogen introduced into a population containing individuals with acquired immunity can result in an epidemic longer in duration and/or larger in size than if the pathogen were introduced into a naive population. We call this phenomenon "epidemic enhancement,'' and use simple dynamical models to show that it is a realistic scenario within the parameter ranges of many common infectious diseases. This finding implies that repeated pathogen introduction or intermediate levels of vaccine coverage can lead to pathogen persistence in populations where extinction would otherwise be expected.	[Pulliam, Juliet R. C.; Dushoff, Jonathan G.; Levin, Simon A.; Dobson, Andrew P.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Dushoff, Jonathan G.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA	Princeton University; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Pulliam, JRC (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	pulliam@princeton.edu	Levin, Simon A/J-1218-2014; Pulliam, Juliet RC/A-6516-2008	Levin, Simon A/0000-0002-8216-5639; Pulliam, Juliet RC/0000-0003-3314-8223	NIH/NSF [R01-TW05869]; NIH [P50 GM071508]; Pew Charitable Trusts; FOGARTY INTERNATIONAL CENTER [R01TW005869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER	NIH/NSF(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pew Charitable Trusts; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was funded by an NIH/NSF "Ecology of Infectious Disease'' grant (R01-TW05869), by an NIH grant to the Center for Quantitative Biology at Princeton University (P50 GM071508), and by a grant from the Pew Charitable Trusts (2000-002558). The funding bodies have had no role in the conception or performance of the study nor in the preparation of the manuscript.	ANDERSON RM, 1986, PHILOS T ROY SOC B, V314, P533, DOI 10.1098/rstb.1986.0072; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Dobson A, 2001, PHILOS T R SOC B, V356, P1001, DOI 10.1098/rstb.2001.0900; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; May RM, 2001, PHILOS T R SOC B, V356, P901, DOI 10.1098/rstb.2001.0866; Savill NJ, 2006, NATURE, V442, P757, DOI 10.1038/442757a	7	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e165	10.1371/journal.pone.0000165	http://dx.doi.org/10.1371/journal.pone.0000165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225866	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444000015
J	Coleman, SW; Rosenthal, GG				Coleman, Seth W.; Rosenthal, Gil G.			Swordtail Fry Attend to Chemical and Visual Cues in Detecting Predators and Conspecifics	PLOS ONE			English	Article							XIPHOPHORUS; RESPONSES; RISK	Predation pressure and energy requirements present particularly salient opposing selective pressures on young fish. Thus, fry are expected to possess sophisticated means of detecting predators and resources. Here we tested the hypotheses that fry of the swordtail fish Xiphophorus birchmanni use chemical and visual cues in detection of predators and conspecifics. To test these hypotheses we presented young (<7 day-old) fry with combinations of visual and chemical stimuli from adult conspecifics and predators. We found that exposure to predator odors resulted in shoal tightening similar to that observed when fry were presented with visual cues alone. In trials with conspecific stimuli, fry were particularly attracted to adult conspecifics when presented simultaneous visual and chemical stimuli compared to the visual stimulus alone. These results show that fry attend to the odors of adult conspecifics, whose presence in a particular area may signal the location of resources as well as an absence of predators. This is one of the first studies to show that such young fish use chemical and visual cues in predator detection and in interactions with conspecifics. Previous research in X. birchmanni has shown that anthropogenic alteration of the chemical environment disrupts intraspecific chemical communication among adults; we suggest that because fry use the same chemosensory pathways to detect predators and conspecifics, alteration of the chemical environment may critically disrupt predator and resource detection.	[Coleman, Seth W.; Rosenthal, Gil G.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; [Coleman, Seth W.; Rosenthal, Gil G.] Ctr Invest Cient Huastecas Aguazarca, Calnali, Hidalgo, Mexico	Texas A&M University System; Texas A&M University College Station	Coleman, SW (corresponding author), Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA.	sethcoleman@tamu.edu	Rosenthal, Gil/E-6924-2015	Rosenthal, Gil/0000-0003-0342-9024	National Institutes of Health, USA; National Science Foundation, USA [IOB-063712]	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation, USA(National Science Foundation (NSF))	SWC is supported by an individual National Research Service Award from the National Institutes of Health, USA. GGR is supported by a grant (IOB-063712) from the National Science Foundation, USA.	Curio E., 1976, ETHOLOGY PREDATION; ELGAR MA, 1989, BIOL REV, V64, P13, DOI 10.1111/j.1469-185X.1989.tb00636.x; Endler J.A., 1991, P169; Endler J.A., 1986, Monographs in Population Biology, pviii; Ferrari MCO, 2006, BEHAV ECOL SOCIOBIOL, V60, P522, DOI 10.1007/s00265-006-0195-z; Fisher HS, 2006, ANIM BEHAV, V72, P721, DOI 10.1016/j.anbehav.2006.02.009; Fisher HS, 2006, P ROY SOC B-BIOL SCI, V273, P1187, DOI 10.1098/rspb.2005.3406; FREISEN RG, 2005, ETHOL, V112, P339; Hirvonen H, 2000, OIKOS, V88, P191, DOI 10.1034/j.1600-0706.2000.880121.x; Kats LB, 1998, ECOSCIENCE, V5, P361, DOI 10.1080/11956860.1998.11682468; Lima SL, 1998, BIOSCIENCE, V48, P25, DOI 10.2307/1313225; LIMA SL, 1990, CAN J ZOOL, V68, P619, DOI 10.1139/z90-092; Mikheev VN, 2006, ECOL FRESHW FISH, V15, P111, DOI 10.1111/j.1600-0633.2006.00140.x; Morris MR, 2001, COPEIA, P65, DOI 10.1643/0045-8511(2001)001[0065:PRAPON]2.0.CO;2; NEILL SRS, 1974, J ZOOL, V172, P549, DOI 10.1111/j.1469-7998.1974.tb04385.x; RAUCHENBERGER M, 1990, AM MUS NOVIT, P1; Rosenthal GG, 2001, AM NAT, V158, P146, DOI 10.1086/321309; Rosenthal GG, 2003, COPEIA, P299, DOI 10.1643/0045-8511(2003)003[0299:DOSSCI]2.0.CO;2; ROSENTHAL GG, 2000, THESIS U TEXAS AUSTI; Smith R.J.F., 1992, Reviews in Fish Biology and Fisheries, V2, P33, DOI 10.1007/BF00042916; Smith R. Jan F., 1997, P163; Sokal RR, 1995, BIOMETRY; TAMARU CS, 2001, MANUAL COMMERCIAL PR; Utne-Palm AC, 2001, MAR ECOL PROG SER, V218, P267, DOI 10.3354/meps218267; Wong BBM, 2006, AM NAT, V167, P136, DOI 10.1086/498278; Wong BBM, 2005, BEHAV ECOL, V16, P818, DOI 10.1093/beheco/ari058; WYATT TD, 2003, PHEROMONES ANIMAL BE, P410	27	12	12	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e118	10.1371/journal.pone.0000118	http://dx.doi.org/10.1371/journal.pone.0000118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205122	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700012
J	Crone, TJ; Wilcock, WSD; Barclay, AH; Parsons, JD				Crone, Timothy J.; Wilcock, William S. D.; Barclay, Andrew H.; Parsons, Jeffrey D.			The Sound Generated by Mid-Ocean Ridge Black Smoker Hydrothermal Vents	PLOS ONE			English	Article								Hydrothermal flow through seafloor black smoker vents is typically turbulent and vigorous, with speeds often exceeding 1 m/s. Although theory predicts that these flows will generate sound, the prevailing view has been that black smokers are essentially silent. Here we present the first unambiguous field recordings showing that these vents radiate significant acoustic energy. The sounds contain a broadband component and narrowband tones which are indicative of resonance. The amplitude of the broadband component shows tidal modulation which is indicative of discharge rate variations related to the mechanics of tidal loading. Vent sounds will provide researchers with new ways to study flow through sulfide structures, and may provide some local organisms with behavioral or navigational cues.	[Crone, Timothy J.; Wilcock, William S. D.; Barclay, Andrew H.; Parsons, Jeffrey D.] Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Crone, TJ (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.	tjc@ocean.washing-ton.edu	Crone, Timothy/A-9360-2009	Crone, Timothy/0000-0002-8100-5633; Wilcock, William/0000-0001-7224-7246	University of Washington Royalty Research Fund; W. M. Keck Foundation	University of Washington Royalty Research Fund(University of Washington); W. M. Keck Foundation(W.M. Keck Foundation)	This work was supported by the University of Washington Royalty Research Fund, and by a grant from the W. M. Keck Foundation.	BAKER ET, 1994, J GEOPHYS RES-SOL EA, V99, P4889, DOI 10.1029/93JB01030; BIBEE LD, 1986, GEOPHYS RES LETT, V13, P957, DOI 10.1029/GL013i009p00957; BISCHOFF JL, 1985, AM J SCI, V285, P725, DOI 10.2475/ajs.285.8.725; Blake W.K., 1986, MECH FLOW INDUCED SO; Blake W.K., 1986, MECH FLOW INDUCED SO, V2; Butterfield DA, 1997, PHILOS T R SOC A, V355, P369, DOI 10.1098/rsta.1997.0013; CONVERSE DR, 1984, EARTH PLANET SC LETT, V69, P159, DOI 10.1016/0012-821X(84)90080-3; Crone TJ, 2005, GEOCHEM GEOPHY GEOSY, V6, P1, DOI 10.1029/2004GC000905; Delaney JR, 1998, SCIENCE, V281, P222, DOI 10.1126/science.281.5374.222; DELANEY JR, 1992, J GEOPHYS RES-SOL EA, V97, P19663, DOI 10.1029/92JB00174; Desbruyeres D, 2006, DENISIA; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Fornari DJ, 1998, EARTH PLANET SC LETT, V160, P419, DOI 10.1016/S0012-821X(98)00101-0; HARRIS FJ, 1978, P IEEE, V66, P51, DOI 10.1109/PROC.1978.10837; Howe M., 1998, ACOUSTICS FLUID STRU; Johnson HP, 2000, NATURE, V407, P174, DOI 10.1038/35025040; Jupp TE, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002583; KOSKI RA, 1994, J GEOPHYS RES-SOL EA, V99, P4813, DOI 10.1029/93JB02871; LIGHTHILL MJ, 1952, PROC R SOC LON SER-A, V211, P564, DOI 10.1098/rspa.1952.0060; Lilley MD, 2003, NATURE, V422, P878, DOI 10.1038/nature01569; LITTLE SA, 1990, J GEOPHYS RES-SOLID, V95, P12927, DOI 10.1029/JB095iB08p12927; LITTLE SA, 1987, J GEOPHYS RES-SOLID, V92, P2587, DOI 10.1029/JB092iB03p02587; Melchior P. J. O., 1983, TIDES PLANET EARTH; MOFJELD HO, 1995, J GEOPHYS RES-OCEANS, V100, P10789, DOI 10.1029/95JC00687; MORFEY CL, 1973, J SOUND VIB, V31, P391, DOI 10.1016/S0022-460X(73)80255-X; PACKARD A, 1990, J COMP PHYSIOL A, V166, P501; PLETT EG, 1975, J ACOUST SOC AM, V57, P755, DOI 10.1121/1.380630; PLETT EG, 1974, J ACOUST SOC AM, V56, P516, DOI 10.1121/1.1903285; Popper AN, 2001, J COMP PHYSIOL A, V187, P83, DOI 10.1007/s003590100184; POWELL A, 1990, J VIB ACOUST, V112, P145, DOI 10.1115/1.2930107; Pruis MJ, 2004, EARTH PLANET SC LETT, V217, P379, DOI 10.1016/S0012-821X(03)00607-1; RIEDESEL M, 1982, J GEOPHYS RES, V87, P613, DOI 10.1029/JB087iB13p10613; ROCKWELL D, 1979, ANNU REV FLUID MECH, V11, P67, DOI 10.1146/annurev.fl.11.010179.000435; ROCKWELL D, 1978, J FLUID ENG-T ASME, V100, P152, DOI 10.1115/1.3448624; Ross D., 1976, MECH UNDERWATER NOIS; SCHUIJF A, 1976, DEV AQUACULTURE FISH, V5; Schultz A, 1996, GEOPHYS RES LETT, V23, P3471, DOI 10.1029/96GL02081; THOMSON RE, 1990, J GEOPHYS RES-OCEANS, V95, P7261, DOI 10.1029/JC095iC05p07261; Thomson RE, 2003, NATURE, V424, P545, DOI 10.1038/nature01824; Tolimieri N, 2000, MAR ECOL PROG SER, V207, P219, DOI 10.3354/meps207219; VANDOVER CL, 1989, NATURE, V337, P458, DOI 10.1038/337458a0; von Frisch Karl., 1923, BIOL ZBL, V43, P439; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wolff T, 2005, CAH BIOL MAR, V46, P97; YE IN, 1991, FLUID MECH SOV RES, V20, P108	45	18	18	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e133	10.1371/journal.pone.0000133	http://dx.doi.org/10.1371/journal.pone.0000133			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205137	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443700027
J	Kaphzan, H; O'Riordan, KJ; Mangan, KP; Levenson, JM; Rosenblum, K				Kaphzan, Hanoch; O'Riordan, Kenneth J.; Mangan, Kile P.; Levenson, Jonathan M.; Rosenblum, Kobi			NMDA and Dopamine Converge on the NMDA-Receptor to Induce ERK Activation and Synaptic Depression in Mature Hippocampus	PLOS ONE			English	Article								The formation of enduring internal representation of sensory information demands, in many cases, convergence in time and space of two different stimuli. The first conveys the sensory input, mediated via fast neurotransmission. The second conveys the meaning of the input, hypothesized to be mediated via slow neurotransmission. We tested the biochemical conditions and feasibility for fast (NMDA) and slow (dopamine) neurotransmission to converge on the Mitogen Activated Protein Kinase signaling pathways, crucial in several forms of synaptic plasticity, and recorded its effects upon synaptic transmission. We detected differing kinetics of ERK2 activation and synaptic strength changes in the CA1 for low and high doses of neurotransmitters in hippocampal slices. Moreover, when weak fast and slow inputs are given together, they converge on ERK2, but not on p38 or JNK, and induce strong short-term synaptic depression. Surprisingly, pharmacological analysis revealed that a probable site of such convergence is the NMDA receptor itself, suggesting it serves as a detector and integrator of fast and slow neurotransmission in the mature mammalian brain, as revealed by ERK2 activation and synaptic function.	[Kaphzan, Hanoch; Rosenblum, Kobi] Univ Haifa, Dept Neurobiol & Ethol, Ctr Brain & Behav, IL-31999 Haifa, Israel; [O'Riordan, Kenneth J.; Mangan, Kile P.; Levenson, Jonathan M.] Univ Wisconsin, Dept Pharmacol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [O'Riordan, Kenneth J.; Mangan, Kile P.; Levenson, Jonathan M.] Univ Wisconsin, Waisman Ctr, Sch Med & Publ Hlth, Madison, WI 53705 USA	University of Haifa; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rosenblum, K (corresponding author), Univ Haifa, Dept Neurobiol & Ethol, Ctr Brain & Behav, IL-31999 Haifa, Israel.	kobir@psy.haifa.ac.il	O'Riordan, Kenneth J./H-6467-2019	O'Riordan, Kenneth J./0000-0003-0081-6010	ISF; Psychobiology	ISF(Israel Science Foundation); Psychobiology	This research was supported by ISF and Psychobiology grants to KR.	Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377; Ajay SM, 2004, EUR J NEUROSCI, V20, P2671, DOI 10.1111/j.1460-9568.2004.03725.x; Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bailey CH, 2000, NAT REV NEUROSCI, V1, P11, DOI 10.1038/35036191; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Belelovsky K, 2005, EUR J NEUROSCI, V22, P2560, DOI 10.1111/j.1460-9568.2005.04428.x; Berman DE, 1998, J NEUROSCI, V18, P10037; Borsello T, 2004, TRENDS MOL MED, V10, P239, DOI 10.1016/j.molmed.2004.03.008; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; BULLER AL, 1994, J NEUROSCI, V14, P5471; Chan ASL, 2005, J NEUROCHEM, V94, P1457, DOI 10.1111/j.1471-4159.2005.03304.x; Chan GCK, 2005, J NEUROSCI, V25, P9913, DOI 10.1523/JNEUROSCI.2376-05.2005; Chang Anne B, 2005, Cough, V1, P7; Chen J, 2004, J BIOL CHEM, V279, P39317, DOI 10.1074/jbc.M403891200; COYLE JT, 2006, CELL MOL NEUROBIOL; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1990, BRAIN RES, V522, P69, DOI 10.1016/0006-8993(90)91578-5; Gerdjikov TV, 2004, BEHAV NEUROSCI, V118, P740, DOI 10.1037/0735-7044.118.4.740; Gisabella B, 2003, NEUROSCIENCE, V121, P297, DOI 10.1016/S0306-4522(03)00440-8; Gomez-Santos C, 2003, J NEUROSCI RES, V73, P341, DOI 10.1002/jnr.10663; Guerrero C, 2002, AM J PHYSIOL-LUNG C, V282, pL1099, DOI 10.1152/ajplung.00178.2001; Gurden H, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0003.2000; Ho OH, 2004, J NEUROCHEM, V91, P1344, DOI 10.1111/j.1471-4159.2004.02815.x; HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Ko HW, 1998, J NEUROCHEM, V71, P1390; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Lee MY, 2006, J CELL PHYSIOL, V208, P399, DOI 10.1002/jcp.20674; Li SM, 2003, NAT NEUROSCI, V6, P526, DOI 10.1038/nn1049; Luo YQ, 1998, J NEUROCHEM, V71, P980; Mao LM, 2004, EUR J NEUROSCI, V19, P1207, DOI 10.1111/j.1460-9568.2004.03223.x; Matthies H, 1997, NEUROREPORT, V8, P3533, DOI 10.1097/00001756-199711100-00023; MURPHY BP, 2006, SCHIZOPHR RES; Opazo P, 2003, J NEUROSCI, V23, P3679; Papadeas ST, 2004, J NEUROSCI, V24, P5863, DOI 10.1523/JNEUROSCI.0528-04.2004; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Rosenblum K, 2002, J NEUROSCI, V22, P5432; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rubinfeld Hadara, 2004, Methods Mol Biol, V250, P1; Sajikumar S, 2004, NEUROBIOL LEARN MEM, V82, P12, DOI 10.1016/j.nlm.2004.03.003; Scott L, 2006, P NATL ACAD SCI USA, V103, P762, DOI 10.1073/pnas.0505557103; Scott L, 2002, P NATL ACAD SCI USA, V99, P1661, DOI 10.1073/pnas.032654599; Smith WB, 2005, NEURON, V45, P765, DOI 10.1016/j.neuron.2005.01.015; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Valjent E, 2000, J NEUROSCI, V20, P8701; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; Wang HB, 2004, NAT NEUROSCI, V7, P635, DOI 10.1038/nn1248; Wang HB, 2003, MOL PHARMACOL, V63, P463, DOI 10.1124/mol.63.3.463; Waxman EA, 2005, J BIOL CHEM, V280, P29322, DOI 10.1074/jbc.M502080200; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607; Zhao ML, 2005, J NEUROSCI, V25, P7032, DOI 10.1523/JNEUROSCI.1579-05.2005; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zhen XC, 2001, J NEUROSCI, V21, P5513, DOI 10.1523/JNEUROSCI.21-15-05513.2001; Zhu YH, 2005, NEURON, V46, P905, DOI 10.1016/j.neuron.2005.04.037	68	23	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e138	10.1371/journal.pone.0000138	http://dx.doi.org/10.1371/journal.pone.0000138			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205142	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443700032
J	Maqbool, T; Soler, C; Jagla, T; Daczewska, M; Lodha, N; Palliyil, S; VijayRaghavan, K; Jagla, K				Maqbool, Tariq; Soler, Cedric; Jagla, Teresa; Daczewska, Malgorzata; Lodha, Neha; Palliyil, Sudhir; VijayRaghavan, K.; Jagla, Krzysztof			Shaping Leg Muscles in Drosophila: Role of ladybird, a Conserved Regulator of Appendicular Myogenesis	PLOS ONE			English	Article								Legs are locomotor appendages used by a variety of evolutionarily distant vertebrates and invertebrates. The primary biological leg function, locomotion, requires the formation of a specialised appendicular musculature. Here we report evidence that ladybird, an orthologue of the Lbx1 gene recognised as a hallmark of appendicular myogenesis in vertebrates, is expressed in leg myoblasts, and regulates the shape, ultrastructure and functional properties of leg muscles in Drosophila. ladybird expression is progressively activated in myoblasts associated with the imaginal leg disc and precedes that of the founder cell marker dumbfounded. The RNAi-mediated attenuation of ladybird expression alters properties of developing myotubes, impairing their ability to grow and interact with the internal tendons and epithelial attachment sites. It also affects sarcomeric ultrastructure, resulting in reduced leg muscle performance and impaired mobility in surviving flies. The overexpression of ladybird also results in an abnormal pattern of dorsally located leg muscles, indicating different requirements for ladybird in dorsal versus ventral muscles. This differential effect is consistent with the higher level of Ladybird in ventrally located myoblasts and with positive ladybird regulation by extrinsic Wingless signalling from the ventral epithelium. In addition, ladybird expression correlates with that of FGF receptor Heartless and the read-out of FGF signalling downstream of FGF. FGF signals regulate the number of leg disc associated myoblasts and are able to accelerate myogenic differentiation by activating ladybird, leading to ectopic muscle fibre formation. A key role for ladybird in leg myogenesis is further supported by its capacity to repress vestigial and to down-regulate the vestigial-governed flight muscle developmental programme. Thus in Drosophila like in vertebrates, appendicular muscles develop from a specialised pool of myoblasts expressing ladybird/Lbx1. The ladybird/Lbx1 gene family appears as a part of an ancient genetic circuitry determining leg-specific properties of myoblasts and making an appendage adapted for locomotion.	[Maqbool, Tariq; Soler, Cedric; Jagla, Teresa; Daczewska, Malgorzata; Lodha, Neha; Palliyil, Sudhir; VijayRaghavan, K.; Jagla, Krzysztof] Fac Med, U384, INSERM, Clermont Ferrand, France; [Lodha, Neha; Palliyil, Sudhir; VijayRaghavan, K.] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore, Karnataka, India; [Daczewska, Malgorzata] Univ Wroclaw, Dept Gen Zool, PL-50138 Wroclaw, Poland	Institut National de la Sante et de la Recherche Medicale (Inserm); Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Wroclaw	Jagla, K (corresponding author), Fac Med, U384, INSERM, Clermont Ferrand, France.	christophe.jagla@u-clermont1.fr	Jagla, Krzysztof/E-4144-2016; Daczewska, Małgorzata/E-9383-2017; Lodha, Neha/AAG-9581-2020	Jagla, Krzysztof/0000-0003-4965-8818; Daczewska, Małgorzata/0000-0001-7208-1012; soler, cedric/0000-0002-2312-5370; Teresa, Jagla/0000-0002-9277-6089	Institut National de la Sante et da la Recherche Medicale; Association Francaise contre les Myopathies; Association pour la Recherche sur le Cancer; Department of Biotechnology, Govt. Of India; Indo-French research programme (CEFIPRA);  [LSHG-CT2004-511978]	Institut National de la Sante et da la Recherche Medicale; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Department of Biotechnology, Govt. Of India(Department of Biotechnology (DBT) India); Indo-French research programme (CEFIPRA)(French National Research Agency (ANR)); 	This work was supported by the Institut National de la Sante et da la Recherche Medicale, the Association Francaise contre les Myopathies, the Association pour la Recherche sur le Cancer, and European Grant LSHG-CT2004-511978 to the MYORES Network of Excellence. Research support from the Department of Biotechnology, Govt. Of India and the Indo-French research programme (CEFIPRA) are gratefully acknowledged.	Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Anakwe K, 2003, DEVELOPMENT, V130, P3503, DOI 10.1242/dev.00538; BATE M, 1991, DEVELOPMENT, V113, P79; Bernard F, 2003, DEV BIOL, V260, P391, DOI 10.1016/S0012-1606(03)00255-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brohmann H, 2000, DEVELOPMENT, V127, P437; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Carmena A, 1998, GENE DEV, V12, P3910, DOI 10.1101/gad.12.24.3910; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CONDIC ML, 1991, DEVELOPMENT, V111, P23; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; COSTELLO WJ, 1996, DEV BIOL, V118, P247; De Graeve F, 2004, DEV BIOL, V270, P122, DOI 10.1016/j.ydbio.2004.02.014; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; Dutta D, 2005, PLOS BIOL, V3, P1789, DOI 10.1371/journal.pbio.0030337; Dutta D, 2004, DEVELOPMENT, V131, P3761, DOI 10.1242/dev.01249; FERNANDES J, 1991, DEVELOPMENT, V113, P67; Frasch M, 1999, CURR OPIN GENET DEV, V9, P522, DOI 10.1016/S0959-437X(99)00014-3; Fristrom Dianne, 1993, P843; Ghazi A, 2000, DEVELOPMENT, V127, P5309; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Gross MK, 2000, DEVELOPMENT, V127, P413; Hollway GE, 2003, EMBO REP, V4, P855, DOI 10.1038/sj.embor.embor920; Jagla K, 1997, DEVELOPMENT, V124, P3471; Jagla K, 1997, DEVELOPMENT, V124, P91; Jagla K, 2001, BIOESSAYS, V23, P125, DOI 10.1002/1521-1878(200102)23:2<125::AID-BIES1019>3.3.CO;2-3; Jagla T, 1998, DEVELOPMENT, V125, P3699; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Kojima T, 2004, DEV GROWTH DIFFER, V46, P115; Kraus P, 2006, AM J MED GENET A, V140A, P1366, DOI 10.1002/ajmg.a.31252; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; Marics I, 2002, DEVELOPMENT, V129, P4559; Neyt C, 2000, NATURE, V408, P82, DOI 10.1038/35040549; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Panganiban G, 2000, DEV DYNAM, V218, P554, DOI 10.1002/1097-0177(200008)218:4<554::AID-DVDY1023>3.0.CO;2-#; Relaix F, 2004, GENE DEV, V18, P1088, DOI 10.1101/gad.301004; Roy S, 1999, BIOESSAYS, V21, P486, DOI 10.1002/(SICI)1521-1878(199906)21:6&lt;486::AID-BIES5&gt;3.0.CO;2-M; Soler C, 2004, DEVELOPMENT, V131, P6041, DOI 10.1242/dev.01527; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Vasyutina E, 2005, GENE DEV, V19, P2187, DOI 10.1101/gad.346205; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; Volk T, 1999, TRENDS GENET, V15, P448, DOI 10.1016/S0168-9525(99)01862-4; Weigmann K, 1999, DEVELOPMENT, V126, P3823	48	43	43	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e122	10.1371/journal.pone.0000122	http://dx.doi.org/10.1371/journal.pone.0000122			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205126	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443700016
J	Cui, X; Zhang, L; Luo, J; Rajasekaran, A; Hazra, S; Cacalano, N; Dubinett, SM				Cui, X.; Zhang, L.; Luo, J.; Rajasekaran, A.; Hazra, S.; Cacalano, N.; Dubinett, S. M.			Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer	ONCOGENE			English	Article						STAT6; COX-2; NSCLC	TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; APOPTOSIS; TRANSCRIPTION; ACTIVATION; RESISTANCE; P300/CBP; IL-4	Cyclooxygenase-2 (COX-2) is frequently overexpressed in human cancers and contributes to the malignant phenotype. Our data indicate unphosphorylated signal transducers and activators of transcription 6 (STAT6) may transcriptionally upregulate COX-2 expression and protect against apoptosis in NSCLC cells. In A427 and H2122, NSCLC cell lines that constitutively express COX-2, only unphosphorylated STAT6 was detectable by western blot, thus, all of the following STAT6-dependent effects are attributed to the unphosphorylated protein. In both cell lines, small-interfering RNA-mediated knockdown of STAT6 or stable expression of dominant-negative STAT6 decreased COX-2 expression. In contrast, transfection with a phosphorylation-deficient mutant STAT6 increased COX-2 levels. Immunofluorescent staining revealed the presence of STAT6 in H2122 nuclei, suggesting a direct role in gene regulation for the unphosphorylated protein. Consistent with this hypothesis, unphosphorylated STAT6 increased luciferase expression from a COX-2 promoter reporter construct. STAT6 co-immunoprecipitated with the transcriptional co-activator, p300, and chromatin immunoprecipitation assays demonstrated that these proteins bind a consensus STAT6 binding site located within the COX-2 promoter. STAT6 DNA-binding specificity was confirmed by electrophoretic mobility shift assay. As COX-2 over-expression has been clearly linked to apoptosis resistance and other hallmarks of malignancy, these findings suggest a novel role of unphosphorylated STAT6 in the pathogenesis of non-small cell lung cancer.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, 37-131 CHS 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu			NCI NIH HHS [R01 CA111851, P50 CA90388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111851, P50CA090388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Gagarin D, 2005, J MOL CELL CARDIOL, V39, P453, DOI 10.1016/j.yjmcc.2005.01.015; Galka E, 2004, J SURG RES, V122, P14, DOI 10.1016/j.jss.2004.05.004; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Herschman HR, 1999, ADV EXP MED BIOL, V469, P3; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; Sheng HM, 1998, CANCER RES, V58, P362; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang J, 2005, CANCER RES, V65, P939; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567; Zhang MS, 2006, CANCER LETT, V243, P38, DOI 10.1016/j.canlet.2005.11.020	26	52	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4253	4260		10.1038/sj.onc.1210222	http://dx.doi.org/10.1038/sj.onc.1210222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237818				2022-12-25	WOS:000247619900008
J	Nunoda, K; Tauchi, T; Takaku, T; Okabe, S; Akahane, D; Sashida, G; Ohyashiki, JH; Ohyashiki, K				Nunoda, K.; Tauchi, T.; Takaku, T.; Okabe, S.; Akahane, D.; Sashida, G.; Ohyashiki, J. H.; Ohyashiki, K.			Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors	ONCOGENE			English	Article						BCR-ABL; tyrosine kinase inhibitor; imatinib; dasatinib	BCR-ABL; CELL-PROLIFERATION; LEUKEMIA-CELLS; IMATINIB; RESISTANCE; EXPRESSION; INDEPENDENCE; P27(KIP1); MECHANISM; BINDING	Dasatinib is an ATP-competitive, multi-targeted SRC and ABL kinase inhibitor that can bind BCR-ABL in both the active and inactive conformations. From a clinical standpoint, dasatinib is particularly attractive because it has been shown to induce hematologic and cytogenetic responses in imatinib-resistant chronic myeloid leukemia patients. The fact because the combination of imatinib and dasatinib shows the additive/synergistic growth inhibition on wild-type p210 BCR-ABL-expressing cells, we reasoned that these ABL kinase inhibitors might induce the different molecular pathways. To address this question, we used DNA microarrays to identify genes whose transcription was altered by imatinib and dasatinib. K562 cells were cultured with imatinib or dasatinib for 16 h, and gene expression data were obtained from three independent microarray hybridizations. Almost all of the imatinib-and dasatinib-responsive genes appeared to be similarly increased or decreased in K562 cells; however, small subsets of genes were identified as selectively altered expression by either imatinib or dasatinib. The distinct genes that are selectively modulated by dasatinib are cyclin-dependent kinase 2 (CDK2) and CDK8, which had a maximal reduction of <5-fold in microarray screen. To assess the functional importance of dasatinib regulated genes, we used RNA interference to determine whether reduction of CDK2 and CDK8 affected the growth inhibition. K562 and TF-1BCR-ABL cells, pretreated with CDK2 or CDK8 small interfering RNA, showed additive growth inhibition with imatinib, but not with dasatinib. These findings demonstrate that the additive/ synergistic growth inhibition by imatinib and dasatinib may be mediated in part by CDK2 and CDK8.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo, Japan	Tokyo Medical University; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishinhijuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Gambacorti-Passerini C, 2005, LEUKEMIA, V19, P1267, DOI 10.1038/sj.leu.2403775; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Nakajima A, 2003, MOL CANCER THER, V2, P219; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Ohyashiki JH, 2005, BIOCHEM BIOPH RES CO, V329, P11, DOI 10.1016/j.bbrc.2005.01.090; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; Takaku T, 2005, BIOCHEM BIOPH RES CO, V336, P469, DOI 10.1016/j.bbrc.2005.08.104; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Zhang Y, 2006, BRIT J CANCER, V94, P599, DOI 10.1038/sj.bjc.6602968	27	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4179	4188		10.1038/sj.onc.1210179	http://dx.doi.org/10.1038/sj.onc.1210179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213809				2022-12-25	WOS:000247252700013
J	Marsche, G; Semlitsch, M; Hammer, A; Frank, S; Weigle, B; Demling, N; Schmidt, K; Windischhofer, W; Waeg, G; Sattler, W; Malle, E				Marsche, Gunther; Semlitsch, Michaela; Hammer, Astrid; Frank, Sasa; Weigle, Bernd; Demling, Nina; Schmidt, Kurt; Windischhofer, Werner; Waeg, Georg; Sattler, Wolfgang; Malle, Ernst			Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway	FASEB JOURNAL			English	Article						AOPP; hypochlorous acid; inflammation; myeloperoxidase	GLYCATION END-PRODUCTS; OXIDATION PROTEIN PRODUCTS; HIGH-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN ATHEROSCLEROTIC LESIONS; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; WHHL RABBITS; MYELOPEROXIDASE; INFLAMMATION	Signal transduction via the endothelial receptor for advanced glycation end products ( RAGE) plays a key role in vascular inflammation. Recent observations have shown that the myeloperoxidase-H2O2-chloride system of activated phagocytes is highly up-regulated under inflammatory conditions where hypochlorous acid (HOCl) is formed as the major oxidant. Albumin, an in vivo carrier for myeloperoxidase is highly vulnerable to oxidation and a major representative of circulating advanced oxidized proteins during inflammatory diseases. Immunohistochemical studies performed in the present study revealed marked colocalization of HOCl-modified epitopes with RAGE and albumin in sections of human atheroma, mainly at the endothelial lining. We show that albumin modified with physiologically relevant concentrations of HOCl, added as reagent or generated by the myeloperoxidase-H2O2-chloride system, is a high affinity ligand for RAGE. Albumin, modified by HOCl in the absence of free amino acids/carbohydrates/lipids to exclude formation of AGE-like structures, induced a rapid, RAGE-dependent activation of extracellular signal-regulated kinase 1/2 and up-regulation of the proinflammatory mediator monocyte chemoattractant protein-1. Cellular activation could be blocked either by a specific polyclonal anti-RAGE IgG and/or a specific mitogen-activated protein-kinase kinase inhibitor. The present study demonstrates that HOCl-modified albumin acts as a ligand for RAGE and promotes RAGE-mediated inflammatory complications.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria; Inst Mol Biol & Biochem, Graz, Austria; Inst Cell Biol Histol & Embryol, Graz, Austria; Univ Childrens Hosp, Res Unit Osteol Res & Analyt Mass Spect, Graz, Austria; Tech Univ Dresden, Inst Immunol, D-8027 Dresden, Germany; Karl Franzens Univ Graz, Graz, Austria; Inst Pharmaceut Sci, Dept Pharmacol & Toxicol, Graz, Austria; Inst Mol Biosci, Graz, Austria	Medical University of Graz; Technische Universitat Dresden; University of Graz	Malle, E (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@meduni-graz.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	Austrian Science Fund FWF [P 19074, P 17013] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Brasen JH, 2003, ATHEROSCLEROSIS, V166, P13, DOI 10.1016/S0021-9150(02)00130-2; Capeillere-Blandin C, 2004, BBA-MOL BASIS DIS, V1689, P91, DOI 10.1016/j.bbadis.2004.02.008; Chen DR, 1999, J NANOPART RES, V1, P115, DOI 10.1023/A:1010087311616; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lau D, 2005, P NATL ACAD SCI USA, V102, P431, DOI 10.1073/pnas.0405193102; Liu SX, 2006, ARTERIOSCL THROM VAS, V26, P1156, DOI 10.1161/01.ATV.0000214960.85469.68; Liu Y, 2002, IMMUNOL LETT, V80, P27, DOI 10.1016/S0165-2478(01)00291-7; Malle E, 2006, ARCH BIOCHEM BIOPHYS, V445, P245, DOI 10.1016/j.abb.2005.08.008; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 2001, BIOCHEM BIOPH RES CO, V289, P894, DOI 10.1006/bbrc.2001.6074; Marsche G, 2001, FASEB J, V15, P1095, DOI 10.1096/fj.00-0532fje; Marsche G, 2004, ARTERIOSCL THROM VAS, V24, P2302, DOI 10.1161/01.ATV.0000148703.43429.25; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; Murakami S, 2002, ATHEROSCLEROSIS, V163, P79, DOI 10.1016/S0021-9150(01)00764-X; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Peters W, 2001, CURR OPIN LIPIDOL, V12, P175, DOI 10.1097/00041433-200104000-00011; RITTHALER U, 1995, AM J PATHOL, V146, P688; Rodriguez-Ayala E, 2005, ATHEROSCLEROSIS, V180, P333, DOI 10.1016/j.atherosclerosis.2004.12.007; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; Strauss JG, 2003, BIOCHEM J, V371, P981, DOI 10.1042/BJ20021437; TAKATA K, 1988, J BIOL CHEM, V263, P14819; Tiruppathi C, 2004, P NATL ACAD SCI USA, V101, P7699, DOI 10.1073/pnas.0401712101; Valencia JV, 2004, ANAL BIOCHEM, V324, P68, DOI 10.1016/j.ab.2003.09.013; Wautier JL, 2004, CIRC RES, V95, P233, DOI 10.1161/01.RES.0000137876.28454.64; Witko-Sarsat V, 1998, J IMMUNOL, V161, P2524; Witko-Sarsat W, 2003, KIDNEY INT, V64, P82, DOI 10.1046/j.1523-1755.2003.00044.x; WitkoSarsat V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/ki.1996.186; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	40	46	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1145	1152		10.1096/fj.06-7439com	http://dx.doi.org/10.1096/fj.06-7439com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218539	Green Accepted			2022-12-25	WOS:000245650400019
J	Perfetti, A; Oriente, F; Iovino, S; Alberobello, AT; Barbagallo, APM; Esposito, I; Fiory, F; Teperino, R; Ungaro, P; Miele, C; Formisano, P; Beguinot, F				Perfetti, Anna; Oriente, Francesco; Iovino, Salvatore; Alberobello, A. Teresa; Barbagallo, Alessia P. M.; Esposito, Iolanda; Fiory, Francesca; Teperino, Raffaele; Ungaro, Paola; Miele, Claudia; Formisano, Pietro; Beguinot, Francesco			Phorbol esters induce intracellular accumulation of the anti-apoptotic protein PED/PEA-15 by preventing ubiquitinylation and proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; DEATH-EFFECTOR DOMAIN; MALIGNANT GLIOMA-CELLS; ERK MAP KINASE; PKC-ZETA; GLUCOSE-TRANSPORT; FLIP EXPRESSION; MUSCLE-CELLS; PEA-15; PHOSPHORYLATION	Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (PED/PEA)-15 is an anti-apoptotic protein whose expression is increased in several cancer cells and following experimental skin carcinogenesis. Exposure of untransfected C5N keratinocytes and transfected HEK293 cells to phorbol esters (12-O-tetradecanoylphorbol-13-acetate (TPA)) increased PED/PEA-15 cellular content and enhanced its phosphorylation at serine 116 in a time-dependent fashion. Ser-116 -> Gly (PEDSS116G) but not Ser-104 -> Gly (PEDS104G) substitution almost completely abolished TPA regulation of PED/PEA-15 expression. TPA effect was also prevented by antisense inhibition of protein kinase C (PKC)-zeta and by the expression of a dominant-negative PKC-zeta mutant cDNA in HEK293 cells. Similar to long term TPA treatment, overexpression of wild-type PKC-zeta increased cellular content and phosphorylation of WT-PED/PEA-15 and PEDS101G but not of PEDS116G. These events were accompanied by the activation of Ca2+-calmodulin kinase (CaMK) II and prevented by the CaMK blocker, KN-93. At variance, the proteasome inhibitor lactacystin mimicked TPA action on PED/PEA-15 intracellular accumulation and reverted the effects of PKC-zeta and CaMK inhibition. Moreover, we show that PED/PEA-15 bound ubiquitin in intact cells. PED/PEA-15 ubiquitinylation was reduced by TPA and PKC-zeta overexpression and increased by KN-93 and PKC-zeta block. Furthermore, in HEK293 cells expressing PEDS116G, TPA failed to prevent ubiquitin-dependent degradation of the protein. Accordingly, in the same cells, TPA-mediated protection from apoptosis was blunted. Taken together, our results indicate that TPA increases PED/PEA-15 expression at the post-translational level by inducing phosphorylation at serine 116 and preventing ubiquitinylation and proteosomal degradation.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini,5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870; Teperino, Raffaele/0000-0001-8815-1409	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Condorelli G, 2001, DIABETES, V50, P1244, DOI 10.2337/diabetes.50.6.1244; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; de Thonel A, 2001, BLOOD, V98, P3770, DOI 10.1182/blood.V98.13.3770; Dong G, 2001, CANCER RES, V61, P4797; Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Hao CH, 2001, CANCER RES, V61, P1162; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; Kubes M, 1998, J NEUROCHEM, V71, P1307; Leroy I, 2005, CELL SIGNAL, V17, P1149, DOI 10.1016/j.cellsig.2004.12.013; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Sharif A, 2003, ANN NY ACAD SCI, V1010, P43, DOI 10.1196/annals.1299.006; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; Spitaler M, 1999, ANTICANCER RES, V19, P3969; Stassi G, 2005, CANCER RES, V65, P6668, DOI 10.1158/0008-5472.CAN-04-4009; Sur R, 2005, BIOCHEM J, V387, P315, DOI 10.1042/BJ20041713; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Vaidyanathan H, 2003, J BIOL CHEM, V278, P32367, DOI 10.1074/jbc.M303988200; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xiao C, 2005, EXP CELL RES, V304, P244, DOI 10.1016/j.yexcr.2004.11.002; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; ZICK Y, 2005, SCI STKE 2005, V25, P268	45	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8648	8657		10.1074/jbc.M608359200	http://dx.doi.org/10.1074/jbc.M608359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17227770	hybrid			2022-12-25	WOS:000245780300011
J	Matas, D; Juknat, A; Pier, M; Klin, Y; Vogel, Z				Matas, Devorah; Juknat, Ana; Pier, Maciej; Klin, Yael; Vogel, Zvi			Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL CANNABINOID RECEPTOR; ENDOCANNABINOID SYSTEM; VANILLOID RECEPTOR-1; ADENYLATE-CYCLASE; DNA-SYNTHESIS; HUMAN TUMORS; CELL-DEATH; INHIBITION; BRAIN; PHOSPHATIDYLETHANOLAMINE	Anandamide (AEA) is a lipid molecule belonging to the family of endocannabinoids. Various studies report neuroprotective activity of AEA against toxic insults, such as ischemic conditions and excitotoxicity, whereas some show that AEA has pro-apoptotic effects. Here we have shown that AEA confers a protective activity in N18TG2 murine neuroblastoma cells subjected to low serum-induced apoptosis. We have demonstrated that the protection from apoptosis by AEA is not mediated via the CB1 receptor, the CB2 receptor, or the vanilloid receptor 1. Interestingly, breakdown of AEA by fatty acid amide hydrolase is required for the protective effect of AEA. Furthermore, the ethanolamine (EA) generated in this reaction is the metabolite responsible for the protective response. The elevation in the levels of reactive oxygen species during low serum-induced apoptosis is not affected by AEA or EA. On the other hand, AEA and EA reduce caspase 3/7 activity, and AEA attenuates the cleavage of PARP-1. Taken together, our results demonstrate a role for AEA and EA in the protection against low serum-induced apoptosis.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	zvi.vogel@weizmann.ac.il						Abood ME, 1997, BIOCHEM PHARMACOL, V53, P207, DOI 10.1016/S0006-2952(96)00727-7; BASS DA, 1983, J IMMUNOL, V130, P1910; BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Brand A, 2000, J NEUROCHEM, V74, P1596, DOI 10.1046/j.1471-4159.2000.0741596.x; Contassot E, 2004, J NEUROPATH EXP NEUR, V63, P956, DOI 10.1093/jnen/63.9.956; Contassot E, 2004, GYNECOL ONCOL, V93, P182, DOI 10.1016/j.ygyno.2003.12.040; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Derocq JM, 1998, FEBS LETT, V425, P419, DOI 10.1016/S0014-5793(98)00275-0; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Guzman M, 2005, HANDB EXP PHARMACOL, V168, P627; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Hillard CJ, 1997, J LIPID RES, V38, P2383; Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53; Jackson SJ, 2005, J NEUROL SCI, V233, P21, DOI 10.1016/j.jns.2005.03.002; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kiss Z, 1997, EUR J BIOCHEM, V250, P395, DOI 10.1111/j.1432-1033.1997.0395a.x; Kiss Z, 1996, FEBS LETT, V381, P67, DOI 10.1016/0014-5793(96)00084-1; Kiss Z, 1997, BIOCHEM J, V328, P383, DOI 10.1042/bj3280383; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Lopez-Rodriguez ML, 2005, MINI-REV MED CHEM, V5, P97, DOI 10.2174/1389557053402819; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Malewicz B, 1998, EUR J BIOCHEM, V253, P10, DOI 10.1046/j.1432-1327.1998.2530010.x; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; McIntosh HH, 1998, MOL BRAIN RES, V53, P163, DOI 10.1016/S0169-328X(97)00294-5; Milton NGN, 2002, NEUROSCI LETT, V332, P127, DOI 10.1016/S0304-3940(02)00936-9; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; NAUJOKAITIS SA, 1984, J PHARM SCI, V73, P34, DOI 10.1002/jps.2600730109; NEGENDANK W, 1992, NMR BIOMED, V5, P303, DOI 10.1002/nbm.1940050518; Petersen G, 2005, J NEUROCHEM, V93, P299, DOI 10.1111/j.1471-4159.2005.03013.x; RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Sarne Y, 2005, CNS NEUROL DISORD-DR, V4, P677, DOI 10.2174/156800705774933005; Satoh T, 1996, BRAIN RES, V733, P9, DOI 10.1016/0006-8993(96)00527-6; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; Shire D, 1996, BBA-GENE STRUCT EXPR, V1307, P132, DOI 10.1016/0167-4781(96)00047-4; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; Wiley JL, 2002, CHEM PHYS LIPIDS, V121, P57, DOI 10.1016/S0009-3084(02)00146-9; Yamaji K, 2003, THROMB HAEMOSTASIS, V89, P875, DOI 10.1055/s-0037-1613475	47	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7885	7892		10.1074/jbc.M608646200	http://dx.doi.org/10.1074/jbc.M608646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227767	hybrid			2022-12-25	WOS:000245081000018
J	Santiago-Josefat, B; Esselens, C; Bech-Serra, JJ; Arribas, J				Santiago-Josefat, Belen; Esselens, Cary; Bech-Serra, Joan Josep; Arribas, Joaquin			Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast turnors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; MESSENGER-RNA EXPRESSION; AMYLOID PRECURSOR PROTEIN; RENAL-CELL CARCINOMA; INTRACELLULAR MATURATION; SECRETASE CLEAVAGE; TUMOR; EGFR; DISINTEGRIN; METALLOPROTEASES	ADAM17 is a transmembrane metalloprotease involved in the proteolytic release of the extracellular domain of many cell surface molecules, a process known as ectodomain shedding. Despite its likely participation in tumor progression and its current consideration as a therapeutic target, very little is known about the regulation of the expression of ADAM17. Here we show that long term treatment with epidermal growth factor (EGF) leads to a marked increase in the levels of ADAM17. EGF receptor activation does not affect the levels of the mRNA that encodes for, or the rate of synthesis of, ADAM17 but increases its half-life. The effect of EGF is biologically relevant because it increases the shedding of several substrates of ADAM17, including the desmosomal cadherin Dsg-2. Analysis of protein and mRNA levels in mammary tumor samples shows that in vivo the levels of ADAM17 can also be controlled post-transcriptionally. Finally, we show that both the shed extracellular domains of Dsg-2 and ADAM 17 are frequently expressed in tumors, further supporting the participation of the metalloprotease in malignant progression.	Vall Hebron Univ Hosp, Inst Res, Med Oncol Res Program, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Arribas, J (corresponding author), Vall Hebron Univ Hosp, Inst Res, Med Oncol Res Program, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	jarribas@ir.vhebron.net	Arribas, Joaquin/M-4482-2014; Bech-Serra, Joan Josep/AAA-2330-2020	Arribas, Joaquin/0000-0002-0504-0664; Bech-Serra, Joan Josep/0000-0003-3486-781X; Esselens, Cary/0000-0001-8876-634X				Arribas J, 2006, CANCER METAST REV, V25, P57, DOI 10.1007/s10555-006-7889-6; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Bech-Serra JJ, 2006, MOL CELL BIOL, V26, P5086, DOI 10.1128/MCB.02380-05; Blanchot-Jossic F, 2005, J PATHOL, V207, P156, DOI 10.1002/path.1814; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; de la Torre TV, 2004, BIOCHEM BIOPH RES CO, V314, P1028, DOI 10.1016/j.bbrc.2003.12.186; Ding X, 2004, WORLD J GASTROENTERO, V10, P2735, DOI 10.3748/wjg.v10.i18.2735; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hynes NE, 2006, CANCER CELL, V10, P7, DOI 10.1016/j.ccr.2006.06.012; Karan D, 2003, INT J ONCOL, V23, P1365; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lorch JH, 2004, J BIOL CHEM, V279, P37191, DOI 10.1074/jbc.M405123200; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Moasser MM, 2001, CANCER RES, V61, P7184; Obeid D, 2007, ONCOGENE, V26, P102, DOI 10.1038/sj.onc.1209779; Peiretti F, 2003, EXP CELL RES, V285, P278, DOI 10.1016/S0014-4827(03)00052-1; Roemer A, 2004, J UROLOGY, V172, P2162, DOI 10.1097/01.ju.0000144602.01322.49; Roemer A, 2004, ONCOL REP, V11, P529; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Slack BE, 1997, BIOCHEM J, V327, P245, DOI 10.1042/bj3270245; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yoshimura T, 2002, J INFECT DIS, V185, P332, DOI 10.1086/338191; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	38	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8325	8331		10.1074/jbc.M608826200	http://dx.doi.org/10.1074/jbc.M608826200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227756	hybrid			2022-12-25	WOS:000245081000066
J	Tanaka, SI; Saito, K; Chon, H; Matsumura, H; Koga, Y; Takano, K; Kanaya, S				Tanaka, Shun-ichi; Saito, Kenji; Chon, Hyongi; Matsumura, Hiroyoshi; Koga, Yuichi; Takano, Kazufumi; Kanaya, Shigenori			Crystal structure of unautoprocessed precursor of subtilisin from a hyperthermophilic Archaeon - Evidence for Ca2+-induced folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; INTRAMOLECULAR CHAPERONE; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; SERINE PROTEASES; PRO-SUBTILISIN; EGLIN-C; PROPEPTIDE; CALCIUM; COMPLEX	The crystal structure of an active site mutant of pro-Tk-subtilisin (pro-S324A) from the hyperthermophilic archaeon Thermococcus kodakaraensis was determined at 2.3 angstrom resolution. The overall structure of this protein is similar to those of bacterial subtilisin-propeptide complexes, except that the peptide bond linking the propeptide and mature domain contacts with the active site, and the mature domain contains six Ca2+ binding sites. The Ca-1 site is conserved in bacterial subtilisins but is formed prior to autoprocessing, unlike the corresponding sites of bacterial subtilisins. All other Ca2+-binding sites are unique in the pro-S324A structure and are located at the surface loops. Four of them apparently contribute to the stability of the central alpha beta alpha substructure of the mature domain. The CD spectra, 1-anilino-8-naphthalenesulfonic acid fluorescence spectra, and sensitivities to chymotryptic digestion of this protein indicate that the conformation of pro-S324A is changed from an unstable molten globule-like structure to a stable native one upon Ca2+ binding. Another active site mutant, pro-S324C, was shown to be autoprocessed to form a propeptide-mature domain complex in the presence of Ca2+. The CD spectra of this protein indicate that the structure of pro-S324C is changed upon Ca2+ -binding like pro-S324A but is not seriously changed upon subsequent autoprocessing. These results suggest that the maturation process of Tk-subtilisin is different from that of bacterial subtilisins in terms of the requirement of Ca2+ for folding of the mature domain and completion of the folding process prior to autoprocessing.	Osaka Univ, Dept Mat & Life Sci, Grad Sch Engn, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Appl Chem, Grad Sch Engn, Suita, Osaka 5650871, Japan; JST, CREST Sosho Project, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Kanaya, S (corresponding author), Osaka Univ, Dept Mat & Life Sci, Grad Sch Engn, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	kanaya@mls.eng.osaka-u.ac.jp		Takano, Kazufumi/0000-0002-7548-7314; Matsumura, Hiroyoshi/0000-0003-0361-3796				Almog O, 2003, J MOL BIOL, V332, P1071, DOI 10.1016/j.jmb.2003.07.011; Atomi Haruyuki, 2004, Archaea, V1, P263, DOI 10.1155/2004/204953; Baier K, 1996, EUR J BIOCHEM, V241, P750, DOI 10.1111/j.1432-1033.1996.00750.x; Basak A, 2003, BIOCHEM J, V373, P231, DOI 10.1042/BJ20030120; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYAN P, 1992, BIOCHEMISTRY-US, V31, P4937, DOI 10.1021/bi00136a003; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Comellas-Bigler M, 2004, STRUCTURE, V12, P1313, DOI 10.1016/j.str.2004.04.013; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Exterkate FA, 1999, APPL ENVIRON MICROB, V65, P1390; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GALLAGHER T, 1993, PROTEINS, V16, P205, DOI 10.1002/prot.340160207; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang HW, 1997, PROTEIN ENG, V10, P1227, DOI 10.1093/protein/10.10.1227; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannan Y, 2001, APPL ENVIRON MICROB, V67, P2445, DOI 10.1128/AEM.67.6.2445-2452.2001; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Nirasawa S, 1999, BIOCHEM J, V341, P25, DOI 10.1042/0264-6021:3410025; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; Shinde U, 1996, ADV EXP MED BIOL, V379, P147; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Smith CA, 1999, J MOL BIOL, V294, P1027, DOI 10.1006/jmbi.1999.3291; SMITH SM, 1989, J BIOL CHEM, V264, P20487; STRAUSBERG SL, 1995, BIO-TECHNOL, V13, P669, DOI 10.1038/nbt0795-669; Subbian E, 2005, J MOL BIOL, V347, P367, DOI 10.1016/j.jmb.2005.01.028; Tanaka S, 2006, ACTA CRYSTALLOGR F, V62, P902, DOI 10.1107/S1744309106030454; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VOORDOUW G, 1976, BIOCHEMISTRY-US, V15, P3716, DOI 10.1021/bi00662a012; WINTHER JR, 1991, NUCLEIC ACIDS RES, V11, P7911; Yabuta Y, 2002, J BIOCHEM, V131, P31, DOI 10.1093/oxfordjournals.jbchem.a003074; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200	49	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8246	8255		10.1074/jbc.M610137200	http://dx.doi.org/10.1074/jbc.M610137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237225	hybrid			2022-12-25	WOS:000245081000057
J	Wang, YM; Singh, U; Mueller, DM				Wang, Yamin; Singh, Usha; Mueller, David M.			Mitochondrial genome integrity mutations uncouple the yeast Saccharomyces cerevisiae ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; KLUYVEROMYCES-LACTIS; ESCHERICHIA-COLI; OXIDATIVE-PHOSPHORYLATION; PERIPHERAL STALK; BETA-SUBUNIT; F-1-ATPASE; GENE; PROTEIN; PURIFICATION	The mitochondrial ATP synthase is a molecular motor, which couples the flow of protons with phosphorylation of ADP. Rotation of the central stalk within the core of ATP synthase effects conformational changes in the active sites driving the synthesis of ATP. Mitochondrial genome integrity (mgi) mutations have been previously identified in the alpha-, beta-, and gamma-subunits of ATP synthase in yeast Kluyveromyces lactis and trypanosome Trypanosoma brucei. These mutations reverse the lethality of the loss of mitochondrial DNA in petite negative strains. Introduction of the homologous mutations in Saccharomyces cerevisiae results in yeast strains that lose mitochondrial DNA at a high rate and accompanied decreases in the coupling of the ATP synthase. The structure of yeast F-1-ATPase reveals that the mgi residues cluster around the gamma-subunit and selectively around the collar region of F-1. These results indicate that residues within the mgi complementation group are necessary for efficient coupling of ATP synthase, possibly acting as a support to fix the axis of rotation of the central stalk.	Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Chicago Med Sch, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Mueller, DM (corresponding author), 3333 Greenbay Rd, N Chicago, IL USA.	David.Mueller@RosalindFranklin.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067091, R01GM066223] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066223, R01-GM067091, R01 GM066223-01, R01 GM066223-02, R01 GM066223-04, R01 GM067091, R01-GM066223, R01 GM066223-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Cabezon E, 2003, NAT STRUCT BIOL, V10, P744, DOI 10.1038/nsb966; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chen XJ, 2000, INT REV CYTOL, V194, P197; CHEN XJ, 1995, EMBO J, V14, P3277, DOI 10.1002/j.1460-2075.1995.tb07331.x; Chen XJ, 1996, GENETICS, V144, P1445; Clark-Walker GD, 2003, MITOCHONDRION, V2, P257, DOI 10.1016/S1567-7249(02)00107-1; Clark-Walker GD, 2000, BBA-PROTEIN STRUCT M, V1478, P125, DOI 10.1016/S0167-4838(00)00003-0; DeLano W, 2002, PYMOL 0 99; Dickson VK, 2006, EMBO J, V25, P2911, DOI 10.1038/sj.emboj.7601177; Dunn CD, 2003, GENETICS, V165, P35; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DW, 2000, BBA-BIOENERGETICS, V1458, P343, DOI 10.1016/S0005-2728(00)00085-2; Guerin B, 1979, Methods Enzymol, V55, P149; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; Kabaleeswaran V, 2006, EMBO J, V25, P5433, DOI 10.1038/sj.emboj.7601410; Kominsky DJ, 2000, GENETICS, V154, P147; Kominsky DJ, 2002, GENETICS, V162, P1595; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; KUKI M, 1988, J BIOL CHEM, V263, P17437; Mueller DM, 2004, PROTEIN EXPRES PURIF, V37, P479, DOI 10.1016/j.pep.2004.06.035; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; Mueller DM, 2000, J BIOENERG BIOMEMBR, V32, P391, DOI 10.1023/A:1005532104617; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PITTMAN D, 1960, GENETICS, V45, P1023; PULLMAN ME, 1986, METHOD ENZYMOL, V126, P460; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Schnaufer A, 2005, EMBO J, V24, P4029, DOI 10.1038/sj.emboj.7600862; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Silvester JA, 2006, ACTA CRYSTALLOGR F, V62, P530, DOI 10.1107/S1744309106015338; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001; WEBER ER, 1995, GENETICS, V140, P435; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	47	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8228	8236		10.1074/jbc.M609635200	http://dx.doi.org/10.1074/jbc.M609635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244612	hybrid, Green Accepted			2022-12-25	WOS:000245081000055
J	Cohen, RO; Nixon, PJ; Diner, BA				Cohen, Rachel O.; Nixon, Peter J.; Diner, Bruce A.			Participation of the C-terminal region of the D1-polypeptide in the first steps in the assembly of the Mn4Ca cluster of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY-CHARGE SEPARATION; AMINO-ACID-RESIDUES; OXYGEN-EVOLVING COMPLEX; MANGANESE CLUSTER; CRYSTAL-STRUCTURE; D1 POLYPEPTIDE; ELECTRON-TRANSFER; REACTION CENTERS; SYNECHOCYSTIS; OXIDATION	Amino acid residue D1-Asp(170) of the D1-polypeptide of photo-system II was previously shown to be implicated in the binding and oxidation of the first manganese to be assembled into the Mn4Ca cluster of the oxygen-evolving complex (OEC). According to recent x-ray crystallographic structures of photosystem II, D1-Glu(333) is proposed to participate with D1-Asp(170) in the coordination of Mn4 of the OEC. Other residues in the C-terminal region of the D1-polypeptide are proposed to coordinate nearby manganese of the cluster. Site-directed replacements in Synechocystis sp. PCC 6803 at D1-His(332), D1-Glu(333), D1-Asp(342), D1-Ala(344), and D1-Ser(345) were examined with regard to their ability to influence the binding and oxidation of the first manganese in manganese-depleted photosystem II core complexes. Direct and indirect measurements reveal in all mutants, but most marked in D1-Glu(333) replaced by His, an impaired ability of Mn2+ to reduce Y-Z center dot, indicating a reduced ability (elevated K-m) compared with WT to bind and oxidize the first manganese of the OEC. The effect on the K-m of these mutations is, however, considerably weaker than some of those constructed at D1-Asp(170) (replacement by Asn, Ala, and Ser). These observations imply that the C-terminal residues ultimately involved in manganese coordination contribute to the high affinity binding at D1-Asp(170) likely through electrostatic interactions. That these residues are far from D1-Asp(170) in the primary structure of the D1-polypeptide, imply that the C terminus of the D1-polypeptide is already close to its mature conformation at the first stages of assembly of the Mn4Ca cluster.	EI duPont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Univ London Imperial Coll Sci Technol & Med, Div Biol, Fac Nat Sci, London SW7 2AZ, England	DuPont; Imperial College London	Diner, BA (corresponding author), EI duPont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA.	bruce.a.diner@usa.dupont.com		Nixon, Peter/0000-0003-1952-6937	Biotechnology and Biological Sciences Research Council [BB/C507037/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ananyev GA, 2002, BIOCHEMISTRY-US, V41, P974, DOI 10.1021/bi011528z; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; Britt RD, 2004, BBA-BIOENERGETICS, V1655, P158, DOI 10.1016/j.bbabio.2003.11.009; BUTLER WL, 1973, BIOCHIM BIOPHYS ACTA, V292, P140, DOI 10.1016/0005-2728(73)90258-2; Campbell KA, 2000, J AM CHEM SOC, V122, P3754, DOI 10.1021/ja000142t; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; Debus RJ, 2005, ADV PHOTO RESPIRAT, V22, P261; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; Dekker JP, 2000, PHOTOSYNTH RES, V63, P195, DOI 10.1023/A:1006468024245; Diner BA, 2005, ADV PHOTO RESPIRAT, V22, P207; Diner BA, 1998, METHOD ENZYMOL, V297, P337; DINER BA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P134, DOI 10.1016/0005-2728(92)90196-9; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Grabolle M, 2006, J BIOL CHEM, V281, P4580, DOI 10.1074/jbc.M509724200; Graige MS, 1996, J AM CHEM SOC, V118, P9005, DOI 10.1021/ja960056m; Groot ML, 2005, P NATL ACAD SCI USA, V102, P13087, DOI 10.1073/pnas.0503483102; Haumann M, 2005, BIOCHEMISTRY-US, V44, P1894, DOI 10.1021/bi048697e; Holzwarth AR, 2006, P NATL ACAD SCI USA, V103, P6895, DOI 10.1073/pnas.0505371103; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MAUZERAL.D, 1972, P NATL ACAD SCI USA, V69, P1358, DOI 10.1073/pnas.69.6.1358; Messinger J, 2001, J AM CHEM SOC, V123, P7804, DOI 10.1021/ja004307+; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; NUIJS AM, 1986, BIOCHIM BIOPHYS ACTA, V848, P167, DOI 10.1016/0005-2728(86)90038-1; Petrouleas V, 2005, ADV PHOTO RESPIRAT, V22, P177; Renger G, 2005, ADV PHOTO RESPIRAT, V22, P139; Robinson HH, 1984, ADV PHOTOSYNTHESIS R, V1, P477; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sauer K, 2005, PHOTOSYNTH RES, V85, P73, DOI 10.1007/s11120-005-0638-9; Sproviero EM, 2006, J CHEM THEORY COMPUT, V2, P1119, DOI 10.1021/ct060018l; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; VANGORKOM HJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P439, DOI 10.1016/0005-2728(74)90081-4; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yachandra VK, 2005, ADV PHOTO RESPIRAT, V22, P235; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	49	22	22	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7209	7218		10.1074/jbc.M606255200	http://dx.doi.org/10.1074/jbc.M606255200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17202088	hybrid			2022-12-25	WOS:000245080900033
J	Evrin, C; Straut, M; Slavova-Azmanova, N; Bucurenci, N; Onu, A; Assairi, L; Ionescu, M; Palibroda, N; Barzu, O; Gilles, AM				Evrin, Cecile; Straut, Monica; Slavova-Azmanova, Neli; Bucurenci, Nadia; Onu, Adrian; Assairi, Liliane; Ionescu, Mihaela; Palibroda, Nicolae; Barzu, Octavian; Gilles, Anne-Marie			Regulatory mechanisms differ in UMP kinases from gram-negative and gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE MONOPHOSPHATE KINASES; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ASPARTATE-TRANSCARBAMYLASE; GLUTAMINE HYDROLYSIS; PYROCOCCUS-FURIOSUS; PROVIDES INSIGHT; ADENYLATE KINASE; CTP SYNTHESIS	In this work, we examined the regulation by GTP and UTP of the UMP kinases from eight bacterial species. The enzyme from Gram-positive organisms exhibited cooperative kinetics with ATP as substrate. GTP decreased this cooperativity and increased the affinity for ATP. UTP had the opposite effect, as it decreased the enzyme affinity for ATP. The nucleotide analogs 5-bromo-UTP and 5-iodo-UTP were 5-10 times stronger inhibitors than the parent compound. On the other hand, UMP kinases from the Gram-negative organisms did not show cooperativity in substrate binding and catalysis. Activation by GTP resulted mainly from the reversal of inhibition caused by excess UMP, and inhibition by UTP was accompanied by a strong increase in the apparent K-m for UMP. Altogether, these results indicate that, depending on the bacteria considered, GTP and UTP interact with different enzyme recognition sites. In Gram-positive bacteria, GTP and UTP bind to a single site or largely overlapping sites, shifting the T reversible arrow R equilibrium to either the R or T form, a scenario corresponding to almost all regulatory proteins, commonly called K systems. In Gram-negative organisms, the GTP-binding site corresponds to the unique allosteric site of the Gram-positive bacteria. In contrast, UTP interacts cooperatively with a site that overlaps the catalytic center, i.e. the UMP-binding site and part of the ATP-binding site. These characteristics make UTP an original regulator of UMP kinases from Gram-negative organisms, beyond the common scheme of allosteric control.	Inst Pasteur, Unite Genet Genomes Bacteriens, F-75724 Paris 15, France; Cantacuzino Inst, Lab Enzymol & Appl Microbiol, Bucharest 050096, Romania; Ctr Univ Paris Sud, INSERM, Inst Curie Rech, U759, F-91405 Orsay, France; Inst Isotop & Mol Technol, Cluj Napoca 400293, Romania	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cantacuzino Institute Bucharest; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; National Institute for Research & Development of Isotopic & Molecular Technologies Cluj-Napoca	Gilles, AM (corresponding author), Inst Pasteur, Unite Genet Genomes Bacteriens, 28 Rue Dr Roux, F-75724 Paris 15, France.	amgilles@pasteur.fr	Onu, Adrian/AAP-8415-2021; Onu, Adrian/G-1858-2016; Ionescu, Mihaela Ileana/S-9516-2017	Onu, Adrian/0000-0001-8724-9754; Onu, Adrian/0000-0001-8724-9754; Ionescu, Mihaela Ileana/0000-0002-8019-118X; Slavova-Azmanova, Neli/0000-0003-0800-2943				ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ALBERTY RA, 1968, J BIOL CHEM, V243, P1337; BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326; BRABSON JS, 1975, J BIOL CHEM, V250, P8664; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briozzo P, 2005, J BIOL CHEM, V280, P25533, DOI 10.1074/jbc.M501849200; Bucurenci N, 1996, J BIOL CHEM, V271, P2856, DOI 10.1074/jbc.271.5.2856; Bucurenci N, 1998, J BACTERIOL, V180, P473, DOI 10.1128/JB.180.3.473-477.1998; Crowe J, 1994, Methods Mol Biol, V31, P371; DANCHIN A, 1984, MOL GEN GENET, V193, P473, DOI 10.1007/BF00382086; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; EVRIN C, 2006, THESIS U PARIS 7 PAR; Fassy F, 2004, BIOCHEM J, V384, P619, DOI 10.1042/BJ20040440; Gagyi C, 2004, CURR MICROBIOL, V48, P62, DOI 10.1007/s00284-003-4117-2; Gagyi C, 2003, EUR J BIOCHEM, V270, P3196, DOI 10.1046/j.1432-1033.2003.03702.x; GILLES AM, 1988, J BIOL CHEM, V263, P8204; Iyengar A, 2003, BIOCHEM J, V369, P497, DOI 10.1042/BJ20021110; Labesse G, 2002, BIOCHEM BIOPH RES CO, V294, P173, DOI 10.1016/S0006-291X(02)00450-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landais S, 1999, J BACTERIOL, V181, P833, DOI 10.1128/JB.181.3.833-840.1999; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; Marco-Marin C, 2005, J MOL BIOL, V352, P438, DOI 10.1016/j.jmb.2005.07.045; MOLLGAARD H, 1980, J BIOL CHEM, V255, P8216; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUNIER H, 1991, EUR J BIOCHEM, V196, P469, DOI 10.1111/j.1432-1033.1991.tb15838.x; Picard V, 1997, Methods Mol Biol, V67, P183; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; Sakamoto H, 2004, MICROBIOL-SGM, V150, P2153, DOI 10.1099/mic.0.26996-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; Serina L, 1996, BIOCHEMISTRY-US, V35, P7003, DOI 10.1021/bi960062v; Sinev MA, 1996, FEBS LETT, V397, P273, DOI 10.1016/S0014-5793(96)01195-7; SNAVELY MD, 1990, MET IONS BIOL SYST, V26, P155; Willemoes M, 2002, EUR J BIOCHEM, V269, P4772, DOI 10.1046/j.1432-1033.2002.03175.x	37	17	26	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7242	7253		10.1074/jbc.M606963200	http://dx.doi.org/10.1074/jbc.M606963200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210578	hybrid			2022-12-25	WOS:000245080900036
J	Shaw, AW; Pureza, VS; Sligar, SG; Morrissey, JH				Shaw, Andrew W.; Pureza, Vincent S.; Sligar, Stephen G.; Morrissey, James H.			The local phospholipid environment modulates the activation of blood clotting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR ACTIVITY; FACTOR-X; COAGULATION FACTOR; FACTOR VIIA; PROTEIN-BINDING; SUBSTRATE; SURFACE; EXPRESSION; MEMBRANES; FUSION	Examples abound of membrane-bound enzymes for which the local membrane environment plays an important role, including the ectoenzyme that triggers blood clotting, the plasma serine protease, factor VIIa, bound to the integral membrane protein, tissue factor. The activity of this enzyme complex is markedly influenced by lipid bilayer composition and further by tissue factor partitioning into membrane microdomains on some cell surfaces. Unfortunately, little is known about how membrane microdomain composition controls factor VIIa-tissue factor activity, as reactions catalyzed by membrane-tethered enzymes are typically studied under conditions in which the experimenter cannot control the composition of the membrane in the immediate vicinity of the enzyme. To overcome this problem, we used a nanoscale approach that afforded complete control over the membrane environment surrounding tissue factor by assembling the factor VIIa-tissue factor complex on stable bilayers containing 67 +/- 1 phospholipid molecules/leaflet (Nanodiscs). We investigated how local changes in phospholipid bilayer composition modulate the activity of the factor VIIa-tissue factor complex. We also addressed whether this enzyme requires a pool of membrane-bound protein substrate (factor X) for efficient catalysis, or alternatively if it could efficiently activate factor X, which binds directly to the membrane nanodomain adjacent to tissue factor. We have shown that full proteolytic activity of the factor VIIa-tissue factor complex requires extremely high local concentrations of anionic phospholipids and further that a large pool of membrane-bound factor X is not required to support sustained catalysis.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 417 Med Sci Bldg MC-714,506 S Mathews, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NHLBI NIH HHS [R01 HL047014-15, HL47014, R01 HL047014] Funding Source: Medline; NIGMS NIH HHS [GM33775] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Denisov IG, 2005, J PHYS CHEM B, V109, P15580, DOI 10.1021/jp051385g; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; FORD NC, 1985, DYNAMIC LIGHT SCATTE, P7; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; HATCHCOCK JJ, 2006, CELL MOL DIS, V36, P194; Hathcock JJ, 2005, BIOCHEMISTRY-US, V44, P8187, DOI 10.1021/bi050338b; HAVERSTICK DM, 1987, P NATL ACAD SCI USA, V84, P4475, DOI 10.1073/pnas.84.13.4475; HEYSEL S, 1995, PROTEIN SCI, V4, P2532, DOI 10.1002/pro.5560041210; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Lagerholm BC, 2005, ANNU REV PHYS CHEM, V56, P309, DOI 10.1146/annurev.physchem.56.092503.141211; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; Mandal SK, 2005, BLOOD, V105, P153, DOI 10.1182/blood-2004-03-0990; Morrissey J. H., 2006, HEMOSTASIS THROMBOSI, P91; Morrissey JH, 1997, THROMB HAEMOSTASIS, V78, P112; Mouritsen OG, 2004, LIPIDS, V39, P1101, DOI 10.1007/s11745-004-1336-x; Mulder AB, 1996, BLOOD, V88, P3667, DOI 10.1182/blood.V88.9.3667.bloodjournal8893667; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Shaw AW, 2004, FEBS LETT, V556, P260, DOI 10.1016/S0014-5793(03)01400-5; SMALL DM, 1967, J LIPID RES, V8, P551; Smith SA, 2004, J THROMB HAEMOST, V2, P1155, DOI 10.1111/j.1538-7836.2004.00772.x; TERRETTAZ S, 1993, LANGMUIR, V9, P1361, DOI 10.1021/la00029a033; Waters EK, 2006, BIOCHEMISTRY-US, V45, P3769, DOI 10.1021/bi052600m; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P8, DOI 10.1021/bi00322a002; Yang L, 1996, BIOCHEMISTRY-US, V35, P13966, DOI 10.1021/bi9610008	38	119	126	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6556	6563		10.1074/jbc.M607973200	http://dx.doi.org/10.1074/jbc.M607973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200119	hybrid			2022-12-25	WOS:000244867200064
J	Yoshihama, M; Nguyen, HD; Kenmochi, N				Yoshihama, Maki; Nguyen, Hung D.; Kenmochi, Naoya			Intron Dynamics in Ribosomal Protein Genes	PLOS ONE			English	Article							SPLICEOSOMAL INTRON; EVOLUTION; GAIN; POSITIONS; ORIGIN; GENOME	The role of spliceosomal introns in eukaryotic genomes remains obscure. A large scale analysis of intron presence/absence patterns in many gene families and species is a necessary step to clarify the role of these introns. In this analysis, we used a maximum likelihood method to reconstruct the evolution of 2,961 introns in a dataset of 76 ribosomal protein genes from 22 eukaryotes and validated the results by a maximum parsimony method. Our results show that the trends of intron gain and loss differed across species in a given kingdom but appeared to be consistent within subphyla. Most subphyla in the dataset diverged around 1 billion years ago, when the "Big Bang" radiation occurred. We speculate that spliceosomal introns may play a role in the explosion of many eukaryotes at the Big Bang radiation.	[Yoshihama, Maki; Nguyen, Hung D.; Kenmochi, Naoya] Miyazaki Univ, Frontier Sci Res Ctr, Miyazaki, Japan	University of Miyazaki	Kenmochi, N (corresponding author), Miyazaki Univ, Frontier Sci Res Ctr, Miyazaki, Japan.	kenmochi@med.miyazaki-u.ac.jp	Kenmochi, Naoya/ABF-3564-2021		Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [14035103, 17770207, 188093]; Japan Society for the Promotion of Science (JSPS)	Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by Grants-in-Aid for Scientific Research (14035103, 17770207, and 188093) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and the Japan Society for the Promotion of Science (JSPS). HDN is a research fellow of the JSPS (17-05174).	Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; Babenko VN, 2004, NUCLEIC ACIDS RES, V32, P3724, DOI 10.1093/nar/gkh686; Battistuzzi FU, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-44; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Csuros M, 2005, LECT NOTES COMPUT SC, V3678, P47; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Jeffares DC, 2006, TRENDS GENET, V22, P16, DOI 10.1016/j.tig.2005.10.006; KENMOCHI N, 2003, NATURE ENCY HUMAN GE, P77; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Nakao A, 2004, NUCLEIC ACIDS RES, V32, pD168, DOI 10.1093/nar/gkh004; Nguyen HD, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-69; Nguyen HD, 2005, PLOS COMPUT BIOL, V1, P631, DOI 10.1371/journal.pcbi.0010079; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Philippe H, 2000, CURR OPIN GENET DEV, V10, P596, DOI 10.1016/S0959-437X(00)00137-4; Rogozin IB, 2003, CURR BIOL, V13, P1512, DOI 10.1016/S0960-9822(03)00558-X; Roy SW, 2005, P NATL ACAD SCI USA, V102, P5773, DOI 10.1073/pnas.0500383102; Roy SW, 2003, P NATL ACAD SCI USA, V100, P7158, DOI 10.1073/pnas.1232297100; Russell AG, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-45; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Yoshihama M, 2002, GENOME RES, V12, P379, DOI 10.1101/gr.214202; Yoshihama M, 2006, PLOS GENET, V2, P237, DOI 10.1371/journal.pgen.0020025; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061	28	18	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e141	10.1371/journal.pone.0000141	http://dx.doi.org/10.1371/journal.pone.0000141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206276	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443800003
J	Puccini, GD; Compte, A; Maravall, M				Puccini, Gabriel D.; Compte, Albert; Maravall, Miguel			Stimulus Dependence of Barrel Cortex Directional Selectivity	PLOS ONE			English	Article								Neurons throughout the rat vibrissa somatosensory pathway are sensitive to the angular direction of whisker movement. Could this sensitivity help rats discriminate stimuli? Here we use a simple computational model of cortical neurons to analyze the robustness of directional selectivity. In the model, directional preference emerges from tuning of synaptic conductance amplitude and latency, as in recent experimental findings. We find that directional selectivity during stimulation with random deflection sequences is strongly dependent on the mean deflection frequency: Selectivity is weakened at high frequencies even when each individual deflection evokes strong directional tuning. This variability of directional selectivity is due to generic properties of synaptic integration by the neuronal membrane, and is therefore likely to hold under very general physiological conditions. Our results suggest that directional selectivity depends on stimulus context. It may participate in tasks involving brief whisker contact, such as detection of object position, but is likely to be weakened in tasks involving sustained whisker exploration (e.g., texture discrimination).	[Puccini, Gabriel D.; Compte, Albert; Maravall, Miguel] UMH, Inst Neurociencias Alicante, CSIC, Alicante, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Maravall, M (corresponding author), UMH, Inst Neurociencias Alicante, CSIC, Campus San Juan, Alicante, Spain.	mmaravall@umh.es	Maravall, Miguel/AAW-4328-2021; Compte, Albert/A-2491-2009	Maravall, Miguel/0000-0002-8869-7206; Compte, Albert/0000-0001-6594-6946	Human Frontier Science Program [RG0043/2004-C]; European Community Marie Curie International Reintegration [MIRG-CT-2004-511273]; Royal Society Joint Project; Spanish Ministry of Education [BFI2002-02378]; Volkswagen-Stiftung; European Regional Development Fund	Human Frontier Science Program(Human Frontier Science Program); European Community Marie Curie International Reintegration(European Commission); Royal Society Joint Project; Spanish Ministry of Education(Spanish Government); Volkswagen-Stiftung(Volkswagen); European Regional Development Fund(European Commission)	This work was supported by: Human Frontier Science Program Grant RG0043/2004-C (to M.M.), European Community Marie Curie International Reintegration Grant MIRG-CT-2004-511273 (to M.M.), Royal Society Joint Project Grant (to M.M.), Spanish Ministry of Education Grant BFI2002-02378 (to A.C.), Volkswagen-Stiftung (to A.C.) and European Regional Development Fund (to M.M. and A.C.). M.M. and A.C. are Ramon y Cajal Research Fellows (Spanish Ministry of Education and Science). Funders played no role in the research presented.	Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Andermann ML, 2006, NAT NEUROSCI, V9, P543, DOI 10.1038/nn1671; Arabzadeh E, 2005, PLOS BIOL, V3, P155, DOI 10.1371/journal.pbio.0030017; Bruno RM, 2006, SCIENCE, V312, P1622, DOI 10.1126/science.1124593; Bruno RM, 2003, J NEUROSCI, V23, P9565; Castro-Alamancos MA, 2004, PROG NEUROBIOL, V74, P213, DOI 10.1016/j.pneurobio.2004.09.002; Castro-Alamancos MA, 2004, NEURON, V41, P455, DOI 10.1016/S0896-6273(03)00853-5; Crochet S, 2006, NAT NEUROSCI, V9, P608, DOI 10.1038/nn1690; Erchova IA, 2004, J NEUROSCI, V24, P5931, DOI 10.1523/JNEUROSCI.1202-04.2004; Erchova IA, 2002, EUR J NEUROSCI, V15, P744, DOI 10.1046/j.0953-816x.2002.01898.x; Fanselow EE, 1999, J NEUROSCI, V19, P7603, DOI 10.1523/JNEUROSCI.19-17-07603.1999; Fiser J, 2004, NATURE, V431, P573, DOI 10.1038/nature02907; Gabernet L, 2005, NEURON, V48, P315, DOI 10.1016/j.neuron.2005.09.022; Hentschke H, 2006, CEREB CORTEX, V16, P1142, DOI 10.1093/cercor/bhj056; Higley MJ, 2006, J NEUROSCI, V26, P448, DOI 10.1523/JNEUROSCI.3506-05.2006; Hipp J, 2006, J NEUROPHYSIOL, V95, P1792, DOI 10.1152/jn.01104.2005; Jones LM, 2004, SCIENCE, V304, P1986, DOI 10.1126/science.1097779; Kleinfeld D, 2006, CURR OPIN NEUROBIOL, V16, P435, DOI 10.1016/j.conb.2006.06.009; Lee SH, 2004, J NEUROPHYSIOL, V91, P223, DOI 10.1152/jn.00541.2003; LICHTENSTEIN SH, 1990, SOMATOSENS MOT RES, V7, P47, DOI 10.3109/08990229009144697; MARAVALL M, 2007, PLOS BIOL IN PRESS; Minnery BS, 2003, J NEUROPHYSIOL, V90, P1556, DOI 10.1152/jn.00111.2003; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158, DOI 10.1152/jn.2000.83.3.1158; Polley DB, 2005, NEUROBIOL LEARN MEM, V83, P134, DOI 10.1016/j.nlm.2004.10.005; Shoykhet M, 2003, J NEUROPHYSIOL, V90, P1432, DOI 10.1152/jn.00419.2003; SIMONS DJ, 1983, BRAIN RES, V276, P178, DOI 10.1016/0006-8993(83)90561-9; SIMONS DJ, 1978, J NEUROPHYSIOL, V41, P798, DOI 10.1152/jn.1978.41.3.798; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311, DOI 10.1152/jn.1989.61.2.311; Temereanca S, 2003, J NEUROPHYSIOL, V89, P2137, DOI 10.1152/jn.00582.2002; Timofeeva E, 2003, J NEUROSCI, V23, P10717; Tuckwell H.C., 1988, INTRO THEORETICAL NE, DOI [10.1017/CBO9780511623202, DOI 10.1017/CBO9780511623202]; Wilent WB, 2005, NAT NEUROSCI, V8, P1364, DOI 10.1038/nn1545; Wilent WB, 2005, J NEUROSCI, V25, P2983, DOI 10.1523/JNEUROSCI.4906-04.2005; Wilent WB, 2004, J NEUROSCI, V24, P3985, DOI 10.1523/JNEUROSCI.5782-03.2004	35	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e137	10.1371/journal.pone.0000137	http://dx.doi.org/10.1371/journal.pone.0000137			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205141	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443700031
J	Rangrez, AY; Dayananda, KM; Atanur, S; Joshi, R; Patole, MS; Shouche, YS				Rangrez, Ashraf Yusuf; Dayananda, Kannayakanahalli Maheshwarappa; Atanur, Santosh; Joshi, Rajendra; Patole, Milind S.; Shouche, Yogesh S.			Detection of Conjugation Related Type Four Secretion Machinery in Aeromonas culicicola	PLOS ONE			English	Article							IV SECRETION; AGROBACTERIUM-TUMEFACIENS; DNA; SYSTEMS; TRANSPORT; VIRB9; PROTEINS; SUBSTRATE; VIRULENCE; MEMBRANES	Background. Aeromonas sp. can now be considered relatively common enteropathogens due to the increase of diseases in humans. Aeromonas culicicola is a gram negative rod-shaped bacterium isolated for the first time from the mosquito mid-gut, but subsequently detected in other insects and waters also. Our previous study discovered that A. culicicola harbors three plasmids, which we designated as pAc3249A, pAc3249B and pAc3249C. We investigated and report here the existence and genetic organization of a Conjugal Type IV Secretion System (TFSS) in pAc3249A. Methodology/Principle Finding. The complete operon is 11,061 bp in length and has G+C content of 47.20% code for 12 ORFs. The gene order and orientation were similar to those found in other bacteria with some differences. We have designated this system as AcTra for Aeromonas culicicola transfer system. BLAST results of ORFs and phylogenetic analysis showed significant similarity towards the respective proteins of the IncI2 plasmid R721 of E. coli. Other bioinformatics studies have been performed to predict conserved motifs/domains, signal peptides, transmembrane helices, etc. of the ORFs. Conclusions/Significance. BLAST results of ORFs and phylogenetic analysis showed significant similarity towards the respective proteins of the IncI2 plasmid R721 of E. coli.	[Rangrez, Ashraf Yusuf; Dayananda, Kannayakanahalli Maheshwarappa; Patole, Milind S.; Shouche, Yogesh S.] Natl Ctr Cell Sci, Mol Biol Unit, Pune, Maharashtra, India; [Atanur, Santosh; Joshi, Rajendra] Ctr Dev & Adv Comp, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Centre for Development of Advanced Computing (C-DAC)	Shouche, YS (corresponding author), Natl Ctr Cell Sci, Mol Biol Unit, Pune Univ Campus, Pune, Maharashtra, India.	yogesh@nccs.res.in	Rangrez, Ashraf/H-4988-2016	Rangrez, Ashraf/0000-0003-2630-9754	CSIR (Council of Scientific and Industrial Research), India	CSIR (Council of Scientific and Industrial Research), India(Council of Scientific & Industrial Research (CSIR) - India)	We are kindly thankful to CSIR (Council of Scientific and Industrial Research), India for providing research fellowship to Dayananda KM.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baron C, 1997, J BACTERIOL, V179, P1211, DOI 10.1128/jb.179.4.1211-1218.1997; Baron C, 2002, MOL MICROBIOL, V43, P1359, DOI 10.1046/j.1365-2958.2002.02816.x; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bayer M, 2001, J BACTERIOL, V183, P3176, DOI 10.1128/JB.183.10.3176-3183.2001; Beaupre CE, 1997, J BACTERIOL, V179, P78, DOI 10.1128/jb.179.1.78-89.1997; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; Boschiroli ML, 2002, VET MICROBIOL, V90, P341, DOI 10.1016/S0378-1135(02)00219-5; Burns DL, 2003, CURR OPIN MICROBIOL, V6, P29, DOI 10.1016/S1369-5274(02)00006-1; Cao TB, 2001, MICROBIOL-SGM, V147, P3201, DOI 10.1099/00221287-147-12-3201; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; Christie PJ, 2001, MOL MICROBIOL, V40, P294, DOI 10.1046/j.1365-2958.2001.02302.x; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Das A, 2000, J BACTERIOL, V182, P758, DOI 10.1128/JB.182.3.758-763.2000; Figueras MJ, 2000, CLIN INFECT DIS, V30, P988, DOI 10.1086/313839; Grohmann E, 2003, MICROBIOL MOL BIOL R, V67, P277, DOI 10.1128/MMBR.67.2.277-301.2003; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; Jakubowski SJ, 2005, J BACTERIOL, V187, P3486, DOI 10.1128/JB.187.10.3486-3495.2005; Jakubowski SJ, 2004, J MOL BIOL, V341, P961, DOI 10.1016/j.jmb.2004.06.052; Janda JM, 1998, CLIN INFECT DIS, V27, P332, DOI 10.1086/514652; JANDA JM, 2001, MOL MED MICROBIOLOGY, P1237; Joseph SW, 2000, ASM NEWS, V66, P218; Koraimann G, 2003, CELL MOL LIFE SCI, V60, P2371, DOI 10.1007/s00018-003-3056-1; Krause S, 2000, J BACTERIOL, V182, P2761, DOI 10.1128/JB.182.10.2761-2770.2000; Li KB, 2003, BIOINFORMATICS, V19, P1585, DOI 10.1093/bioinformatics/btg192; Maniatis T, MOL CLONING LAB MANU; Rhodes G, 2004, APPL ENVIRON MICROB, V70, P7497, DOI 10.1128/AEM.70.12.7497-7510.2004; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Roy CR, 2002, J CELL BIOL, V158, P415, DOI 10.1083/jcb.200205011; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Schmidt-Eisenlohr H, 1999, J BACTERIOL, V181, P5563, DOI 10.1128/JB.181.18.5563-5571.1999; Shamaei-Tousi A, 2004, J BACTERIOL, V186, P4796, DOI 10.1128/JB.186.14.4796-4801.2004; SONNHAMMER ELL, 1994, PROTEIN SCI, V3, P482; Spudich GM, 1996, P NATL ACAD SCI USA, V93, P7512, DOI 10.1073/pnas.93.15.7512; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x	37	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e115	10.1371/journal.pone.0000115	http://dx.doi.org/10.1371/journal.pone.0000115			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205119	Green Published, gold			2022-12-25	WOS:000207443700009
J	Oricchio, E; Sciamanna, I; Beraldi, R; Tolstonog, GV; Schumann, GG; Spadafora, C				Oricchio, E.; Sciamanna, I.; Beraldi, R.; Tolstonog, G. V.; Schumann, G. G.; Spadafora, C.			Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression	ONCOGENE			English	Article						retrotransposons; endogenous retroviruses; cell proliferation; differentiation; tumorigenesis	ENDOGENOUS REVERSE-TRANSCRIPTASE; NUCLEAR LAMINA; EXPRESSION; ENVELOPE; GROWTH; RETROVIRUS; MICE	Transformed cells express high levels of non-telomeric reverse-transcriptase (RT) activity of retrotransposon and endogenous retrovirus origin. We previously reported that RT inhibition, either pharmacological or through transient silencing of RT-encoding LINE-1 (L1) elements by RNA interference (RNAi), reduced proliferation, induced differentiation and reprogrammed gene expression in human tumorigenic cell lines. Moreover, the antiretroviral drug efavirenz antagonized tumor progression in animal models in vivo. To get insight into the role of retroelements in tumorigenesis, we have now produced two cell lines derived from A-375 melanoma, in which the expression of either L1 retrotransposon, or HERV-K endogenous retrovirus, was stably suppressed by RNAi. Compared to the parental A-375 cell line, cells with stably interfered L1 expression show a lower proliferation rate, a differentiated morphology and lower tumorigenicity when inoculated in nude mice. L1 silencing modulates expression of several genes and, unexpectedly, also downregulates HERV-K expression. In HERV-K interfered cells, instead, L1 expression was unaffected, and cell proliferation and differentiation remained unchanged compared to parental A-375 cells. In vivo, however, their tumorigenic potential was found to be reduced after inoculation in nude mice. These results suggest that L1 and HERV-K play specific and distinct roles in cell transformation and tumor progression.	Ist Super Sanita, Serv BGSA, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Siena, Dept Pediat & Obstet, I-53100 Siena, Italy; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; Paul Ehrlich Inst, Div Med Biotechnol, D-6070 Langen, Germany	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Siena; Heinrich Pette Institute; University of Hamburg; Paul Ehrlich Institute	Spadafora, C (corresponding author), Ist Super Sanita, Serv BGSA, Viale Regina Elena 299, I-00161 Rome, Italy.	cspadaf@tin.it		Sciamanna, Ilaria/0000-0002-5629-6184; Oricchio, Elisa/0000-0002-1690-0447; Spadafora, Corrado/0000-0002-5743-3224				Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Blaise S, 2001, J GEN VIROL, V82, P1597, DOI 10.1099/0022-1317-82-7-1597; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Gruenbaum Y, 2003, INT REV CYTOL, V226, P1, DOI 10.1016/S0074-7696(03)01001-5; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; HASUI M, 1989, CELL IMMUNOL, V120, P230, DOI 10.1016/0008-8749(89)90190-1; Humer J, 2006, CANCER RES, V66, P1658, DOI 10.1158/0008-5472.CAN-05-2452; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367; Mangeney M, 2005, CANCER RES, V65, P2588, DOI 10.1158/0008-5472.CAN-04-4231; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mangeney M, 2001, J GEN VIROL, V82, P2515, DOI 10.1099/0022-1317-82-10-2515; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Ross DA, 2006, EJSO-EUR J SURG ONC, V32, P80, DOI 10.1016/j.ejso.2005.08.005; Sauter ER, 2002, CANCER RES, V62, P3200; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Shapiro JA, 2005, BIOL REV, V80, P227, DOI 10.1017/S1464793104006657; Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802	30	99	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4226	4233		10.1038/sj.onc.1210214	http://dx.doi.org/10.1038/sj.onc.1210214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237820				2022-12-25	WOS:000247619900005
J	Camus, S; Menendez, S; Cheok, CF; Stevenson, LF; Lain, S; Lane, DP				Camus, S.; Menendez, S.; Cheok, C. F.; Stevenson, L. F.; Lain, S.; Lane, D. P.			Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6	ONCOGENE			English	Article						ubiquitination; p53; human papillomavirus; E6; degradation; proteasome	MDM2 PROMOTES; ORNITHINE-DECARBOXYLASE; PROTEASOMAL DEGRADATION; GROWTH SUPPRESSION; CONJUGATING ENZYME; DNA-BINDING; CELL-LINES; C-TERMINUS; ONCOPROTEIN; E6-AP	In vitro, high-risk human papillomavirus E6 proteins have been shown, in conjunction with E6-associated protein (E6AP), to mediate ubiquitination of p53 and its degradation by the 26S proteasome by a pathway that is thought to be analogous to Mdm2-mediated p53 degradation. However, differences in the requirements of E6/E6AP and Mdm2 to promote the degradation of p53, both in vivo and in vitro, suggest that these two E3 ligases may promote p53 degradation by distinct pathways. Using tools that disrupt ubiquitination and degradation, clear differences between E6-and Mdm2-mediated p53 degradation are presented. The consistent failure to fully protect p53 protein from E6-mediated degradation by disrupting the ubiquitin-degradation pathway provides the first evidence of an E6-dependent, ubiquitin-independent, p53 degradation pathway in vivo.	Inst Mol & Cell Biol, Dept Cell Cycle Control, Proteos 138673, Singapore; Univ Dundee, Dept Surg & Mol Oncol, Dundee DD1 4HN, Scotland; Ninewells Hosp & Med Sch, Dundee, Scotland	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of Dundee; University of Dundee	Camus, S (corresponding author), Inst Mol & Cell Biol, Dept Cell Cycle Control, 61 Biopolis Dr, Proteos 138673, Singapore.	scamus@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Menendez, Sergio/0000-0002-7929-8641; Lane, David/0000-0003-0551-3545	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5; BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; Camus S, 2003, FEBS LETT, V536, P220, DOI 10.1016/S0014-5793(03)00054-1; Chen Z, 2004, SHOCK, V21, P1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hoyt MA, 2005, METHOD ENZYMOL, V398, P399, DOI 10.1016/S0076-6879(05)98033-6; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Kahana Chaim, 2005, V301, P83; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kretz-Remy C, 2003, BIOL CHEM, V384, P589, DOI 10.1515/BC.2003.066; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lagrange M, 2005, J GEN VIROL, V86, P1001, DOI 10.1099/vir.0.80607-0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Nakamura S, 2002, ONCOGENE, V21, P2605, DOI 10.1038/sj.onc.1205343; Ness GC, 2005, FEBS LETT, V579, P3126, DOI 10.1016/j.febslet.2005.05.001; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PENA MM, 2005, BIOCHEM J, V394, P355; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Saeki Y, 2004, GENES GENET SYST, V79, P77, DOI 10.1266/ggs.79.77; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stewart D, 2005, J VIROL, V79, P8773, DOI 10.1128/JVI.79.14.8773-8783.2005; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	55	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4059	4070		10.1038/sj.onc.1210188	http://dx.doi.org/10.1038/sj.onc.1210188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224909	Green Accepted			2022-12-25	WOS:000247252700002
J	Mohankumar, KM; Xu, XQ; Zhu, T; Kannan, N; Miller, LD; Liu, ET; Gluckman, PD; Sukumar, S; Emerald, BS; Lobie, PE				Mohankumar, K. M.; Xu, X. Q.; Zhu, T.; Kannan, N.; Miller, L. D.; Liu, E. T.; Gluckman, P. D.; Sukumar, S.; Emerald, B. S.; Lobie, P. E.			HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells	ONCOGENE			English	Article						HOXA1; gene expression; p44/42 MAP kinase; MEK; oncogenicity	HUMAN GROWTH-HORMONE; GENE-EXPRESSION; BREAST; PHOSPHORYLATION; TRANSACTIVATION; TRANSFORMATION; PROLIFERATION; ACTIVATION; SURVIVAL; HOXA1	Expression of homeobox A1 ( HOXA1) results in oncogenic transformation of immortalized human mammary epithelial cells with aggressive tumor formation in vivo. However, the mechanisms by which HOXA1 mediates oncogenic transformation is not well defined. To identify molecules that could potentially be involved in HOXA1-mediated oncogenic transformation, microarray analysis was utilized to characterize and compare the gene expression pattern in response to forced expression or depletion of HOXA1 in human mammary carcinoma cells. Gene expression pro. ling identified that genes involved in the p44/42 mitogen-activated protein ( MAP) kinase activation pathway ( GRB2, MAP kinase kinase ( MEK1) and SDFR1) or p44/42 MAP kinase-regulated genes ( IER3, EPAS1, PCNA and catalase) are downstream expression targets of HOXA1. Forced expression of HOXA1 increased GRB2 and MEK1 mRNA and protein expression and increased p44/42 MAP kinase phosphorylation, activity and Elk-1-mediated transcription. Use of a MEK1 inhibitor demonstrated that increased p44/42 MAP kinase activity is required for the HOXA1-mediated increase in cell proliferation, survival, oncogenicity and oncogenic transformation. Thus, modulation of the p44/42 MAP kinase pathway is one mechanism by which HOXA1 mediates oncogenic transformation of the human mammary epithelial cell.	Univ Auckland, Liggins Inst, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland, New Zealand; Genome Inst Singapore, Singapore, Singapore; Johns Hopkins Univ, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University of Auckland; University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Johns Hopkins University; Johns Hopkins Medicine	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland, New Zealand.	p.lobie@auckland.ac.nz	Miller, Lance/A-5633-2009; David, Starling Emerald Bright/R-6034-2019; Liu, Edison/C-4141-2008; Kumarasamypet Murugesan, Mohankumar/F-4231-2012	David, Starling Emerald Bright/0000-0001-6875-2258; Miller, Lance/0000-0003-3799-2528; KM, Mohankumar/0000-0001-9407-1800; Kannan, Nagarajan/0000-0002-8825-2178				Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clark JH, 1999, GREEN CHEM, V1, P1, DOI 10.1039/a807961g; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salh B, 1999, ANTICANCER RES, V19, P731; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Wang CX, 2006, CELL DEATH DIFFER, V13, P1203, DOI 10.1038/sj.cdd.4401804; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yu FQ, 2005, FRONT BIOSCI-LANDMRK, V10, P896, DOI 10.2741/1584; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317; Zhu Z, 2005, ONCOGENE, V24, P3774, DOI 10.1038/sj.onc.1208541	30	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3998	4008		10.1038/sj.onc.1210180	http://dx.doi.org/10.1038/sj.onc.1210180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213808				2022-12-25	WOS:000247144500010
J	Yang, J; Runeberg-Roos, P; Leppanen, VM; Saarma, M				Yang, J.; Runeberg-Roos, P.; Leppanen, V-M; Saarma, M.			The mouse soluble GFR alpha 4 receptor activates RET independently of its ligand persephin	ONCOGENE			English	Article						GFR alpha 4; RET; PSPN; neurite outgrowth; survival	NEURONAL SURVIVAL; LIPID RAFTS; GDNF; BINDING; DIFFERENTIATION; PROTOONCOGENE; MECHANISM; FAMILY; MODEL	Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) all signal through the transmembrane receptor tyrosine kinase RET. The signalling complex consists of GFLs, GPI-anchored ligand binding GDNF family receptor alphas (GFRas) and RET. Signalling via RET is required for the development of the nervous system and the kidney, as well as for spermatogenesis. However, constitutive activation of RET is implicated as a cause in several diseases. Mutations of the RET proto-oncogene cause the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). Recently, it has been suggested that mutations in the persephin binding GFR alpha 4 receptor may have a potentially modifying role in MEN 2. Several naturally occurring, different splice variants of the mammalian GFRa4 have been reported. A 7 bp insertion - mutation in the human GFRa4 gene causes a shift of reading frame and thereby changes the balance between the transcripts encoding GPI-anchored and soluble GFRa4 receptors. We report here that the mammalian soluble GFRa4 can activate RET independently of its preferential ligand, persephin. Our data show that soluble GFRa4 can associate with, and induce, phosphorylation of RET. In addition, our data show that this isoform of GFRa4 can induce downstream signalling, as well as neuronal survival and differentiation, in the absence of persephin. These results suggest that, in line with the previous report, GFRa4 may be a candidate gene for, or modi. er of, the MEN 2 diseases.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Saarma, M (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	mart.saarma@helsinki.fi		Leppanen, Veli-Matti/0000-0001-7100-965X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lindfors PH, 2006, ENDOCRINOLOGY, V147, P2237, DOI 10.1210/en.2005-1620; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhorne JB, 2005, ONCOGENE, V24, P1091, DOI 10.1038/sj.onc.1207826; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257; Wang XQ, 2006, STRUCTURE, V14, P1083, DOI 10.1016/j.str.2006.05.010; Yang JM, 2004, FEBS LETT, V569, P267, DOI 10.1016/j.febslet.2004.06.007	21	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3892	3898		10.1038/sj.onc.1210161	http://dx.doi.org/10.1038/sj.onc.1210161			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213820				2022-12-25	WOS:000247026400012
J	Rachakonda, PS; Veit, M; Korte, T; Ludwig, K; Bottcher, C; Huang, Q; Schmidt, MFG; Herrmann, A				Rachakonda, P. Sivaramakrishna; Veit, Michael; Korte, Thomas; Ludwig, Kai; Boettcher, Christoph; Huang, Qiang; Schmidt, Michael F. G.; Herrmann, Andreas			The relevance of salt bridges for the stability of the influenza virus hemagglutinin	FASEB JOURNAL			English	Article						conformational change; fusion; ectodomain; influenza virus HA; stability	MEMBRANE-FUSION ACTIVITY; COILED-COIL REGION; CONFORMATIONAL-CHANGE; RECEPTOR-BINDING; DISULFIDE BONDS; PH; GLYCOPROTEIN; PROTEINS; SUBTYPES; PEPTIDE	Hemagglutinin ( HA) of influenza virus undergoes an irreversible conformational change at acidic pH, mediating viral fusion with the host endosomal membrane. To unravel the molecular basis of the pH-dependent stability of HA, we demonstrate by mutagenesis of the prototype HA of virus strain X31 (H3 subtype) that salt bridges, especially a tetrad salt bridge within the monomers, are crucial for folding and stability of the trimeric ectodomain. This complex ( tetrad) salt bridge is highly conserved among influenza virus subtypes. Introducing additional sites of electrostatic attraction between monomers in the distal region enhanced the stability of ectodomain at low pH mimicking the natural variant H2 subtype. We propose that distinct salt bridges in the distal domain may contribute to the enhanced stability of HA of natural virus variants. This hypothesis may provide clues to understanding adaptations of virus strains ( for example, avian influenza viruses) in order to preserve stability of the protein in the host-specific environment.	Humboldt Univ, Mat Naturwissensch Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany; Free Univ Berlin, Inst Immunol & Mol Biol, Vet Med Fak, Berlin, Germany; Free Univ Berlin, Forsch Zentrum Elek Mikroskopie, Berlin, Germany; Fudan Univ, State Key Lab Genet Engn, Sch Life Sci, Shanghai 200433, Peoples R China	Humboldt University of Berlin; Free University of Berlin; Free University of Berlin; Fudan University	Herrmann, A (corresponding author), Humboldt Univ, Mat Naturwissensch Fak 1, Inst Biol Biophys, Invalidenstr 43, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de	Ludwig, Kai/AAA-9017-2022; Veit, Michael/G-6492-2010	Ludwig, Kai/0000-0001-6808-8107; Rachakonda, Sivaramakrishna/0000-0002-2319-2821; Veit, Michael/0000-0002-7638-1829				BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Crowley PB, 2005, PROTEINS, V59, P231, DOI 10.1002/prot.20417; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; Gamblin SJ, 2004, SCIENCE, V303, P1838, DOI 10.1126/science.1093155; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Gruenke JA, 2002, J VIROL, V76, P4456, DOI 10.1128/JVI.76.9.4456-4466.2002; Ha Y, 2002, EMBO J, V21, P865, DOI 10.1093/emboj/21.5.865; Hoffman LR, 1997, J VIROL, V71, P8808, DOI 10.1128/JVI.71.11.8808-8820.1997; Huang Q, 2003, BBA-BIOMEMBRANES, V1614, P3, DOI 10.1016/S0005-2736(03)00158-5; Huang Q, 2002, BIOPHYS J, V82, P1050, DOI 10.1016/S0006-3495(02)75464-7; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; Isin B, 2002, BIOPHYS J, V82, P569, DOI 10.1016/S0006-3495(02)75422-2; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; Korte T, 1999, J VIROL, V73, P4567, DOI 10.1128/JVI.73.6.4567-4574.1999; Korte T, 1997, J BIOL CHEM, V272, P9764; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mayne L, 1998, J AM CHEM SOC, V120, P10643, DOI 10.1021/ja981592c; Mittal A, 2002, BIOPHYS J, V83, P2652, DOI 10.1016/S0006-3495(02)75275-2; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; PROESCH S, 1990, Febs Letters, V267, P19; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335; Russell RJ, 2004, VIROLOGY, V325, P287, DOI 10.1016/j.virol.2004.04.040; SCHOLTISSEK C, 1988, ARCH VIROL, V101, P119, DOI 10.1007/BF01314656; Shangguan T, 1998, BIOPHYS J, V74, P54, DOI 10.1016/S0006-3495(98)77766-5; Shental-Bechor D, 2002, BBA-BIOMEMBRANES, V1565, P81, DOI 10.1016/S0005-2736(02)00511-4; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Staschke KA, 1998, VIROLOGY, V248, P264, DOI 10.1006/viro.1998.9273; STEINHAUER DA, 1991, P NATL ACAD SCI USA, V88, P11525, DOI 10.1073/pnas.88.24.11525; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	47	57	58	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					995	1002		10.1096/fj.06-7052hyp	http://dx.doi.org/10.1096/fj.06-7052hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218542				2022-12-25	WOS:000245650400004
J	Lucarelli, D; Russo, S; Garman, E; Milano, A; Meyer-Klaucke, W; Pohl, E				Lucarelli, Debora; Russo, Santina; Garman, Elspeth; Milano, Anna; Meyer-Klaucke, Wolfram; Pohl, Ehmke			Crystal structure and function of the zinc uptake regulator FurB from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATOR; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; PSEUDOMONAS-AERUGINOSA; IRON HOMEOSTASIS; PROTEIN; VIRULENCE; ZUR; IDENTIFICATION; MECHANISMS	Members of the ferric/zinc uptake regulator (Fur/Zur) family are the central metal-dependent regulator proteins in many Gram-negative and -positive bacteria. They are responsible for the control of a wide variety of basic physiological processes and the expression of important virulence factors in human pathogens. Therefore, Fur has gathered significant interest as a potential target for novel antibiotics. Here we report the crystal structure of FurB from Mycobacterium tuberculosis at a resolution of 2.7 angstrom, and we present biochemical and spectroscopic data that allow us to propose the functional role of this protein. Although the overall fold of FurB with an N-terminal DNA binding domain and a C-terminal dimerization domain is conserved among the Zur/Fur family, large differences in the spatial arrangement of the two domains with respect to each other can be observed. The biochemical and spectroscopic analysis presented here reveals that M. tuberculosis FurB is Zn(II)-dependent and is likely to control genes involved in the bacterial zinc uptake. The combination of the structural, spectroscopic, and biochemical results enables us to determine the structural basis for functional differences in this important family of bacterial regulators.	Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany; Univ Oxford, Lab Mol Biophys, Dept Biochem, Oxford OX1 3QU, England; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Paul Scherrer Inst, Swiss Light Source, CH-5232 Villigen, Switzerland	European Molecular Biology Laboratory (EMBL); University of Oxford; University of Pavia; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Meyer-Klaucke, W (corresponding author), Hamburg Outstn, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	wolfram@embl-hamburg.de; ehmke.pohl@psi.ch	Meyer-Klaucke, Wolfram/G-1148-2010; Pohl, Ehmke/I-2408-2012	Pohl, Ehmke/0000-0002-9949-4471; Garman, Elspeth/0000-0001-8329-5665	EPSRC [EP/D032210/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/D032210/1] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015940, R01AI015940] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15940] Funding Source: Medline	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiyama S, 2004, J MOL BIOL, V341, P651, DOI 10.1016/j.jmb.2004.06.040; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canneva F, 2005, J BACTERIOL, V187, P5837, DOI 10.1128/JB.187.16.5837-5840.2005; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Diaz-Mireles E, 2004, MICROBIOL-SGM, V150, P1447, DOI 10.1099/mic.0.26961-0; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Garman EF, 2005, PROG BIOPHYS MOL BIO, V89, P173, DOI 10.1016/j.pbiomolbio.2004.09.005; Gelfand MS, 2006, CURR OPIN STRUC BIOL, V16, P420, DOI 10.1016/j.sbi.2006.04.001; GRIME GW, 1991, NUCL INSTRUM METH B, V54, P52, DOI 10.1016/0168-583X(91)95490-5; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hantke K, 2005, CURR OPIN MICROBIOL, V8, P196, DOI 10.1016/j.mib.2005.02.001; Harding MM, 2004, ACTA CRYSTALLOGR D, V60, P849, DOI 10.1107/S0907444904004081; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P797; Kaufmann SHE, 2006, IMMUNITY, V24, P351, DOI 10.1016/j.immuni.2006.04.003; Korbas M, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2209954; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; Maciag A, 2007, J BACTERIOL, V189, P730, DOI 10.1128/JB.01190-06; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Mills SA, 2005, BIOCHEMISTRY-US, V44, P13553, DOI 10.1021/bi0507579; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Outten CE, 2001, BIOCHEMISTRY-US, V40, P10417, DOI 10.1021/bi0155448; Patzer SI, 2000, J BIOL CHEM, V275, P24321, DOI 10.1074/jbc.M001775200; Patzer SI, 2001, J BACTERIOL, V183, P4806, DOI 10.1128/JB.183.16.4806-4813.2001; Pecqueur L, 2006, J BIOL CHEM, V281, P21286, DOI 10.1074/jbc.M601278200; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Pohl E, 1999, J MOL BIOL, V285, P1145, DOI 10.1006/jmbi.1998.2339; Pym AS, 2001, MOL MICROBIOL, V40, P879, DOI 10.1046/j.1365-2958.2001.02427.x; Rodriguez GM, 2003, MOL MICROBIOL, V47, P1485, DOI 10.1046/j.1365-2958.2003.03384.x; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; Wilderman PJ, 2004, P NATL ACAD SCI USA, V101, P9792, DOI 10.1073/pnas.0403423101; Wisedchaisri G, 2004, J MOL BIOL, V342, P1155, DOI 10.1016/j.jmb.2004.07.083; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877	51	107	111	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9914	9922		10.1074/jbc.M609974200	http://dx.doi.org/10.1074/jbc.M609974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17213192	hybrid, Green Published			2022-12-25	WOS:000245421700066
J	Michalik, L; Zoete, V; Krey, G; Grosdidier, A; Gelman, L; Chodanowski, P; Feige, JN; Desvergne, B; Wahli, W; Michielin, O				Michalik, Liliane; Zoete, Vincent; Krey, Grigorios; Grosdidier, Aurelien; Gelman, Laurent; Chodanowski, Pierre; Feige, Jerome N.; Desvergne, Beatrice; Wahli, Walter; Michielin, Olivier			Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING-DOMAIN; MOLECULAR-FORCE FIELD; CONSTITUTIVE ANDROSTANE RECEPTOR; FREE-ENERGY DECOMPOSITION; PROTEIN DATA-BANK; PPAR-GAMMA; NUCLEAR RECEPTORS; FATTY-ACIDS; CRYSTAL-STRUCTURE; TRANSACTIVATION DOMAIN	The dynamic properties of helix 12 in the ligand binding domain of nuclear receptors are a major determinant of AF-2 domain activity. We investigated the molecular and structural basis of helix 12 mobility, as well as the involvement of individual residues with regard to peroxisome proliferator-activated receptor alpha (PPAR alpha) constitutive and ligand-dependent transcriptional activity. Functional assays of the activity of PPARa helix 12 mutants were combined with free energy molecular dynamics simulations. The agreement between the results from these approaches allows us to make robust claims concerning the mechanisms that govern helix 12 functions. Our data support a model in which PPAR alpha helix 12 transiently adopts a relatively stable active conformation even in the absence of a ligand. This conformation provides the interface for the recruitment of a coactivator and results in constitutive activity. The receptor agonists stabilize this conformation and increase PPAR alpha transcription activation potential. Finally, we disclose important functions of residues in PPAR alpha AF-2, which determine the positioning of helix 12 in the active conformation in the absence of a ligand. Substitution of these residues suppresses PPAR alpha constitutive activity, without changing PPARa ligand-dependent activation potential.	Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Lausanne, Natl Res Ctr Frontier Genet, CH-1015 Lausanne, Switzerland; Univ Lausanne, Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland; Agr Res Fdn, Fisheries Res Inst, GR-64007 Kavala, Greece; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; Natl Res Ctr Mol Oncol, CH-1066 Epalinges, Switzerland; Univ Lausanne Hosp, CePO, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Swiss Institute of Bioinformatics; University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Wahli, W (corresponding author), Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland.	walter.wahli@unil.ch; olivier.michielin@unil.ch	Michielin, Olivier/ABE-7924-2020; Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Grosdidier, Aurelien/0000-0001-9873-3461; Michalik, Liliane/0000-0003-2963-2100; Desvergne, Beatrice/0000-0001-5483-288X; Gelman, Laurent/0000-0003-3277-3115				AMIDON GL, 1975, J PHYS CHEM-US, V79, P2239, DOI 10.1021/j100588a008; Andersin T, 2003, MOL ENDOCRINOL, V17, P234, DOI 10.1210/me.2002-0263; Auwerx J, 1999, CELL, V97, P161; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brelivet Y, 2004, EMBO REP, V5, P423, DOI 10.1038/sj.embor.7400119; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Diradourian C, 2005, BIOCHIMIE, V87, P33, DOI 10.1016/j.biochi.2004.11.010; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Elhaji YA, 2006, HUM MOL GENET, V15, P921, DOI 10.1093/hmg/ddl009; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Frank C, 2004, J BIOL CHEM, V279, P33558, DOI 10.1074/jbc.M403946200; Fyffe SA, 2006, J MOL BIOL, V356, P1005, DOI 10.1016/j.jmb.2005.12.047; Fyffe SA, 2006, MOL CELL, V21, P1, DOI 10.1016/j.molcel.2005.12.001; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; GROSDIDIER A, 2007, IN PRESS PROTEINS; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Halgren TA, 1996, J COMPUT CHEM, V17, P616, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Halgren TA, 1996, J COMPUT CHEM, V17, P553, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO;2-T; Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-Q; Hasel W., 1988, TETRAHEDRON COMPUT M, V1, P103, DOI DOI 10.1016/0898-5529(88)90015-2; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; HERMANN RB, 1972, J PHYS CHEM-US, V76, P2754, DOI 10.1021/j100663a023; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Keller H, 1997, BIOL CHEM, V378, P651, DOI 10.1515/bchm.1997.378.7.651; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kuhn B, 2006, BIOORG MED CHEM LETT, V16, P4016, DOI 10.1016/j.bmcl.2006.05.007; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Leaver MJ, 2005, ENDOCRINOLOGY, V146, P3150, DOI 10.1210/en.2004-1638; Lee MS, 2003, J COMPUT CHEM, V24, P1348, DOI 10.1002/jcc.10272; Lee MS, 2002, J CHEM PHYS, V116, P10606, DOI 10.1063/1.1480013; Lu IL, 2006, J MED CHEM, V49, P2703, DOI 10.1021/jm051129s; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahindroo N, 2006, J MED CHEM, V49, P6421, DOI 10.1021/jm060663c; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Molnar F, 2005, J BIOL CHEM, V280, P26543, DOI 10.1074/jbc.M502463200; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; REIHER WE, 1985, THESIS HARVARD U CAM; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; THOMPSON SK, 1994, J MED CHEM, V37, P3100, DOI 10.1021/jm00045a015; TONE Y, 1994, J BIOL CHEM, V269, P31157; Tsukahara T, 2006, J BIOL CHEM, V281, P3398, DOI 10.1074/jbc.M510843200; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Yu CY, 2004, EUR J BIOCHEM, V271, P386, DOI 10.1046/j.1432-1033.2003.03937.x; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zoete V, 2005, PROTEINS, V61, P79, DOI 10.1002/prot.20528; Zoete V, 2006, J COMPUT CHEM, V27, P1843, DOI 10.1002/jcc.20512	91	32	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9666	9677		10.1074/jbc.M610523200	http://dx.doi.org/10.1074/jbc.M610523200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17200111	hybrid			2022-12-25	WOS:000245421700040
J	Jasuja, R; Ge, GX; Voss, NG; Lyman-Gingerich, J; Branam, AM; Pelegri, FJ; Greenspan, DS				Jasuja, Reema; Ge, Gaoxiang; Voss, Nikolas G.; Lyman-Gingerich, Jamie; Branam, Amanda M.; Pelegri, Francisco J.; Greenspan, Daniel S.			Bone morphogenetic protein 1 prodomain specifically binds and regulates signaling by bone morphogenetic proteins 2 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWISTED GASTRULATION; GROWTH-FACTOR; VERTEBRATE DEVELOPMENT; ZEBRAFISH; EXPRESSION; CHORDIN; SKIN; METALLOPROTEINASES; XENOPUS; EMBRYO	Highly purified fractions of bone extracts capable of inducing ectopic bone formation have been reported to contain peptides corresponding to the mature active regions of the TGF-beta-like bone morphogenetic proteins (BMPs) 2-7, and to the prodomain region of the metalloproteinase BMP1. Co-purification of BMPs 2-7 with BMP1 prodomain sequences through the multiple biochemical steps used in these previous reports has suggested the possibility of interactions between the BMP1 prodomain and BMPs 2-7. Here we demonstrate that the BMP1 prodomain binds BMPs 2 and 4 with high specificity and with a K-D of similar to 11 nM, in the physiological range. It is further demonstrated that the BMP1 prodomain is capable of modulating signaling by BMPs 2 and 4 in vitro and in vivo, and that endogenous BMP1 prodomain-BMP4 complexes exist in cell culture media and in tissues.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu		Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060; Hillger F, 2005, J BIOL CHEM, V280, P14974, DOI 10.1074/jbc.M414413200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Jasuja R, 2004, J BIOL CHEM, V279, P51289, DOI 10.1074/jbc.M408129200; Jasuja R, 2006, MECH DEVELOP, V123, P548, DOI 10.1016/j.mod.2006.05.004; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Mullins MC, 1996, DEVELOPMENT, V123, P81; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	42	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9053	9062		10.1074/jbc.M610929200	http://dx.doi.org/10.1074/jbc.M610929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255107	hybrid			2022-12-25	WOS:000245780300052
J	Kim, SJ; Nian, C; McIntosh, CHS				Kim, Su-Jin; Nian, Cuilan; McIntosh, Christopher H. S.			Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes - A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; RAT ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; BETA-CELL; PEPTIDE RECEPTOR; GLUCAGON; PHOSPHORYLATION; GIP; EXPRESSION; METABOLISM	Glucose-dependent insulinotropic polypeptide (GIP) has been mainly studied because of its glucose-dependent insulinotropic action and its ability to regulate beta-cell proliferation and survival. Considerably less is known about the effects of GIP on fat metabolism, and the present study was directed at identifying the mechanisms underlying its stimulatory action on lipoprotein lipase (LPL). In differentiated 3T3-L1 adipocytes, GIP, in the presence of insulin, increased LPL activity and triglyceride accumulation through a pathway involving increased phosphorylation of protein kinase B (PKB) and reductions in phosphorylated LKB1 and AMP-activated protein kinase (AMPK). Knockdown of AMPK using RNA interference and application of the AMPK inhibitor, Compound C, supported this conclusion. In contrast, the other major incretin hormone, glucagon-like peptide-1, exhibited no significant effects on LPL activity or PKB, LKB1, or AMPK phosphorylation. Cultured subcutaneous human adipocytes showed similar responses to GIP but with greater sensitivity. Chronic elevation of circulating GIP levels in the Vancouver diabetic fatty Zucker rat in vivo resulted in increased LPL activity and elevated triglyceride accumulation in epidydimal fat tissue, combined with a modulation of PKB, LKB1, and AMPK phosphorylation similar to that observed in vitro. This appears to be the first demonstration of a GIP-stimulated signal transduction pathway involved in increasing fat storage in adipocytes.	Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An D, 2005, AM J PHYSIOL-ENDOC M, V288, pE246, DOI 10.1152/ajpendo.00211.2004; BECK B, 1983, REGUL PEPTIDES, V7, P3, DOI 10.1016/0167-0115(83)90276-8; BERBO M, 2002, J BIOL CHEM, V277, P11927; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; BROWN JC, 1989, HDB PHYSL 6, P403; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; Drucker DJ, 2003, ENDOCRINOLOGY, V144, P5145, DOI 10.1210/en.2003-1147; DUPRE J, 1976, METABOLISM, V25, P1197, DOI 10.1016/S0026-0495(76)80002-9; ECKEL RH, 1981, INT J OBESITY, V5, P571; ECKEL RH, 1979, DIABETES, V28, P1141, DOI 10.2337/diabetes.28.12.1141; Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002-0068; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200; Kim SJ, 2005, J BIOL CHEM, V280, P22297, DOI 10.1074/jbc.M500540200; KIM WH, 2006, IN PRESS CELL SIGNAL; King TD, 2006, BIOCHEM PHARMACOL, V71, P1637, DOI 10.1016/j.bcp.2006.03.005; KNAPPER JME, 1995, J NUTR, V125, P183; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; Meier JJ, 2005, DIABETES-METAB RES, V21, P91, DOI 10.1002/dmrr.538; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; MontroseRafizadeh C, 1997, J CELL PHYSIOL, V172, P275, DOI 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L; Morgan LM, 1996, BIOCHEM SOC T, V24, P585, DOI 10.1042/bst0240585; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; OHNEDA A, 1984, REGUL PEPTIDES, V8, P123, DOI 10.1016/0167-0115(84)90167-8; Pederson RA, 1993, GUT PEPTIDES, P217; PEDERSON RA, 2004, ENCY ENDOCRINE DIS, V2, P202; Pospisilik JA, 2002, DIABETES, V51, P943, DOI 10.2337/diabetes.51.4.943; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Sambandam N, 1999, ARTERIOSCL THROM VAS, V19, P1526, DOI 10.1161/01.ATV.19.6.1526; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Sponarova J, 2005, FEBS LETT, V579, P6105, DOI 10.1016/j.febslet.2005.09.078; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WASADA T, 1981, J CLIN INVEST, V68, P1106, DOI 10.1172/JCI110335; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yip RGC, 1998, ENDOCRINOLOGY, V139, P4004, DOI 10.1210/en.139.9.4004; Yip RGC, 1999, LIFE SCI, V66, P91, DOI 10.1016/S0024-3205(99)00314-8; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	56	142	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8557	8567		10.1074/jbc.M609088200	http://dx.doi.org/10.1074/jbc.M609088200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244606	hybrid			2022-12-25	WOS:000245780300001
J	Oo, ML; Thangada, S; Wu, MT; Liu, CH; Macdonald, TL; Lynch, KR; Lin, CY; Hla, T				Oo, Myat Lin; Thangada, Shobha; Wu, Ming-Tao; Liu, Catherine H.; Macdonald, Timothy L.; Lynch, Kevin R.; Lin, Chen-Yong; Hla, Timothy			Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubipuitinylation and proteasomal degradation of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXTRACELLULAR EXPORT; VASCULAR MATURATION; LYMPHOCYTE EGRESS; CELL-MIGRATION; BETA-ARRESTIN; T-CELLS; FTY720; SPHINGOSINE-1-PHOSPHATE; UBIQUITINATION	Sphingosine 1-phosphate (SIP), a multifunctional lipid mediator, regulates lymphocyte trafficking, vascular permeability, and angiogenesis by activation of the SIP1 receptor. This receptor is activated by FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720. However, in contrast to the natural ligand SIP, FTY720-P appears to act as a functional antagonist, even though the mechanisms involved are poorly understood. In this study, we investigated the fate of endogenously expressed SIP1 receptor in agonist-activated human umbilical vein endothelial cells and human embryonic kidney 293 cells expressing green fluorescent protein-tagged SIP1. We show that FTY720-P is more potent than SIP at inducing receptor degradation. Pretreatment with an antagonist of S1P(1), VPC 44116, prevented receptor internalization and degradation. FTY720-P did not induce degradation of internalization-deficient SIP1 receptor mutants. Further, small interfering RNA-mediated down-regulation of G protein-coupled receptor kinase-2 and beta-arrestins abolished FTY720-P-induced SIP1 receptor degradation. These data suggest that agonist-induced phosphorylation of SIP1 and subsequent endocytosis are required for FTY720-P-induced degradation of the receptor. S1P(1) degradation is blocked by MG132, a proteasomal inhibitor. Indeed, FTY720-P strongly induced polyubiquitinylation of SIP1 receptor, whereas SIP at concentrations that induced complete internalization was not as efficient, suggesting that receptor internalization is required but not sufficient for ubiquitinylation and degradation. We propose that the ability of FTY720-P to target the S1P(1) receptor to the ubiquitinylation and proteasomal degradation pathway may at least in part underlie its immunosuppressive and anti-angiogenic properties.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Washington, DC 20007 USA	University of Connecticut; University of Virginia; University of Virginia; Georgetown University	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA.	hla@nso2.uchc.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL CANCER INSTITUTE [R01CA096851, R01CA104944] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL067330, P01HL070694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067958] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA104944, R01-CA096851] Funding Source: Medline; NHLBI NIH HHS [R37-HL67330, P01 HL70694] Funding Source: Medline; NIGMS NIH HHS [R01-GM67958] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Bohler T, 2005, TRANSPLANTATION, V79, P492, DOI 10.1097/012.TP.0000151773.43266.17; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P976, DOI 10.1161/01.ATV.0000162171.30089.f6; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Foss FW, 2007, BIOORGAN MED CHEM, V15, P663, DOI 10.1016/j.bmc.2006.10.060; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; HLA T, 1990, J BIOL CHEM, V265, P9308; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Marchese Adriano, 2004, Methods Mol Biol, V259, P299; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; TANG TK, 1993, J CELL SCI, V104, P237; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Whetzel AM, 2006, CIRC RES, V99, P731, DOI 10.1161/01.RES.0000244088.33375.52; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Zhan B, 2005, ATHEROSCLEROSIS, V178, P199, DOI 10.1016/j.atherosclerosis.2004.08.024	49	316	337	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9082	9089		10.1074/jbc.M610318200	http://dx.doi.org/10.1074/jbc.M610318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237497	hybrid			2022-12-25	WOS:000245780300055
J	Currie, JC; Fortier, S; Sina, A; Galipeau, J; Cao, J; Annabi, B				Currie, Jean-Christophe; Fortier, Simon; Sina, Asmaa; Galipeau, Jacques; Cao, Jian; Annabi, Borhane			MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells - A molecular link between pro-MMP-2 activation, chemotaxis, and cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; DISEASE TYPE 1B; GROWTH-FACTOR; 1-MATRIX METALLOPROTEINASE; MORPHOGENIC DIFFERENTIATION; SPHINGOSINE 1-PHOSPHATE; NEUTROPHIL DYSFUNCTION; APOPTOTIC DEATH; GENE-THERAPY	Bone marrow-derived stromal cells (BMSC) are avidly recruited by experimental vascularizing tumors, which implies that they must respond to tumor-derived growth factor cues. In fact, BMSC chemotaxis and cell survival are regulated, in part, by the membrane type-1 matrix metalloproteinase (MT1-MMP), an MMP also involved in pro-MMP-2 activation and in degradation of the extracellular matrix (ECM). Given that impaired chemotaxis was recently observed in bone marrow cells isolated from a glucose 6-phosphate transporter-deficient (G6PT(-/-)) mouse model, we sought to investigate the potential MT1-MMP/G6PT signaling axis in BMSC. We show that MT1-MMP-mediated activation of pro-MMP-2 by concanavalin A (ConA) correlated with an increase in the sub-G(1) cell cycle phase as well as with cell necrosis, indicative of a decrease in BMSC survival. BMSC isolated from Egr-1(-/-) mouse or MT1-MMP gene silencing in BMSC with small interfering RNA (siMT1-MMP) antagonized both the ConA-mediated activation of pro-MMP-2 and the induction of cell necrosis. Overexpression of recombinant full-length MT1-MMP triggered necrosis and this was signaled through the cytoplasmic domain of MT1-MMP. ConA inhibited both the gene and protein expression of G6PT, while overexpression of recombinant G6PT inhibited MT1-MMP-mediated pro-MMP-2 activation but could not rescue BMSC from ConA-induced cell necrosis. Cell chemotaxis in response to the tumorigenic growth factor sphingosine 1-phosphate was significantly abrogated in siMT1-MMP BMSC and in chlorogenic acid-treated BMSC. Altogether, we provide evidence for an MT1-MMP/G6PT signaling axis that regulates BMSC survival, ECM degradation, and mobilization. This may lead to optimized clinical applications that use BMSC as a platform for the systemic delivery of therapeutic or anti-cancer recombinant proteins in vivo.	Univ Quebec, Oncol Mol Lab, Dept Chim, Ctr Biomed, Montreal, PQ H3C 3P8, Canada; Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	University of Quebec; University of Quebec Montreal; Lady Davis Institute; McGill University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Annabi, B (corresponding author), Univ Quebec, Oncol Mol Lab, Dept Chim, Ctr Biomed, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	annabi.borhane@uclam.ca	Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996; Fortier, Simon/0000-0002-3492-0759				Abraham R, 2005, J BIOL CHEM, V280, P34123, DOI 10.1074/jbc.M508155200; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Annabi B, 2004, J BIOL CHEM, V279, P21888, DOI 10.1074/jbc.M313694200; Annabi B, 2003, EXP HEMATOL, V31, P640, DOI 10.1016/S0301-472X(03)00090-0; Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Annabi B, 2004, J CELL BIOCHEM, V91, P1146, DOI 10.1002/jcb.10763; Bandyopadhyay G, 2004, BLOOD, V104, P2514, DOI 10.1182/blood-2003-11-4065; Belkaid A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-7; Belkaid A, 2006, FEBS LETT, V580, P3746, DOI 10.1016/j.febslet.2006.05.071; Biswas MHU, 2006, BIOCHEM BIOPH RES CO, V348, P1145, DOI 10.1016/j.bbrc.2006.07.173; Calderwood S, 2001, BLOOD, V97, P376, DOI 10.1182/blood.V97.2.376; Cao J, 2005, THROMB HAEMOSTASIS, V93, P770, DOI 10.1160/TH04-08-0555; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Chen LY, 2002, HUM MOL GENET, V11, P3199, DOI 10.1093/hmg/11.25.3199; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070; Ding L, 1999, GENE THER, V6, P1611, DOI 10.1038/sj.gt.3300973; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Gumin J, 2006, CANCER RES, V66; Hamada H, 2005, CANCER SCI, V96, P149, DOI 10.1111/j.1349-7006.2005.00032.x; Hinoue A, 2005, ANAT REC PART A, V282A, P130, DOI 10.1002/ar.a.20150; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hurwitz DR, 1997, HUM GENE THER, V8, P137, DOI 10.1089/hum.1997.8.2-137; KIM M, 1993, GLYCOBIOLOGY, V3, P447, DOI 10.1093/glycob/3.5.447; Kim SY, 2006, J BIOL CHEM, V281, P28794, DOI 10.1074/jbc.M604964200; Kurukulasuriya R, 2003, CURR MED CHEM, V10, P123, DOI 10.2174/0929867033368556; Langlois S, 2005, EXP CELL RES, V307, P452, DOI 10.1016/j.yexcr.2005.04.007; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Leuzzi R, 2003, BLOOD, V101, P2381, DOI 10.1182/blood-2002-08-2576; McLaughlin N, 2006, J NEURO-ONCOL, V80, P111, DOI 10.1007/s11060-006-9171-8; McLennan SV, 2000, DIABETOLOGIA, V43, P642, DOI 10.1007/s001250051353; Meriane M, 2006, STEM CELLS, V24, P2557, DOI 10.1634/stemcells.2006-0209; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Mohle R, 2001, ANN NY ACAD SCI, V938, P26; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005-0503; Preaux AM, 2002, HEPATOLOGY, V36, P615, DOI 10.1053/jhep.2002.35279; Saadane N, 2001, CAN J PHYSIOL PHARM, V79, P533, DOI 10.1139/cjpp-79-6-533; Sabbadini RA, 2006, BRIT J CANCER, V95, P1131, DOI 10.1038/sj.bjc.6603400; Sato H, 2005, CANCER GENE THER, V12, P757, DOI 10.1038/sj.cgt.7700827; Schichor C, 2006, EXP NEUROL, V199, P301, DOI 10.1016/j.expneurol.2005.11.027; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Ueno H, 1997, CANCER RES, V57, P2055; Vaananen HK, 2005, ANN MED, V37, P469, DOI 10.1080/07853890500371957; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Meter TE, 2004, NEURO-ONCOLOGY, V6, P188, DOI 10.1215/S1152851703000486; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yatomi Y, 2006, CURR PHARM DESIGN, V12, P575, DOI 10.2174/138161206775474404; Yiu WH, 2007, GENE THER, V14, P219, DOI 10.1038/sj.gt.3302869; Yu M, 1997, FEBS LETT, V412, P568, DOI 10.1016/S0014-5793(97)00849-1; Zhang L, 1999, CANCER LETT, V142, P129, DOI 10.1016/S0304-3835(99)00107-X; Zhang XY, 2002, MOL THER, V5, P555, DOI 10.1006/mthe.2002.0585; Zhu W, 2006, EXP MOL PATHOL, V80, P267, DOI 10.1016/j.yexmp.2005.07.004; Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005-0121; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	69	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8142	8149		10.1074/jbc.M610894200	http://dx.doi.org/10.1074/jbc.M610894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229722	hybrid			2022-12-25	WOS:000245081000046
J	Hepburn, NJ; Williams, AS; Nunn, MA; Chamberlain-Banoub, JC; Hamer, J; Morgan, BP; Harris, CL				Hepburn, Natalie J.; Williams, Anwen S.; Nunn, Miles A.; Chamberlain-Banoub, Jayne C.; Hamer, John; Morgan, B. Paul; Harris, Claire L.			In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE MYASTHENIA-GRAVIS; ACUTE MYOCARDIAL-INFARCTION; MEMBRANE ATTACK; COMPLEMENT INHIBITOR; DISEASE SEVERITY; DEMYELINATION; PEXELIZUMAB; ECULIZUMAB; DEFICIENCY; ACTIVATION	The involvement of complement (C) in inflammatory diseases has driven the search for agents capable of inhibiting dysregulated complement activation. Many of these reagents inhibit the C3 convertases during the early stages of the cascade. However, a drawback of total systemic C inhibition, particularly in long-term treatment of chronic disease, is potentiation of infection and immune complex disease due to an inability to opsonize complexes and foreign cells and to lyse pathogens. Recent identification of a CS-binding protein in the salivary gland of the soft tick Ornithodoros moubata has enabled development of a terminal pathway-specific reagent, OmCl, with potential to ameliorate disease while leaving key physiological processes unaffected. Here we demonstrated that OmCl has broad cross-species activity. When given intravenously to rodents, OmCl totally ablated complement hemolytic activity, which gradually restored as C5 was resynthesized. The circulating half-life of OmCl was 30 h, demonstrating a much slower clearance than other small, biological agents. Using C5-sufficient and C5-deficient mice we showed that prolonged half-life was due to binding to plasma C5. Surface plasmon resonance analysis of C5 binding to OmCl confirmed a high binding affinity with a slow dissociation rate. OmCl was effective in preventing experimental autoimmune myasthenia gravis induced by passive transfer in normal Lewis rats. OmCI ablated clinical disease reduced C3 and C9 deposition at the neuro-muscular junction, and effected a marked reduction in cellular infiltration at this site. These data offer exciting prospects for targeted treatment of complement-mediated diseases without the detrimental inhibition of the opsonic roles of complement.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales; NERC, Ctr Ecol & Hydrol, Oxford OX1 3SR, England; Evolutec Grp Plc, Reading RG2 6UG, Berks, England	Cardiff University; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Harris, CL (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Henry Wellcome Bldg,Heath Pk, Cardiff CF14 4XN, Wales.	HarrisCL@cardiff.ac.uk	Nunn, Miles/E-9233-2010	Morgan, Paul/0000-0003-4075-7676	Natural Environment Research Council [CEH010021] Funding Source: researchfish; Wellcome Trust [068590, 068823] Funding Source: Medline	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Chamberlain-Banoub J, 2006, CLIN EXP IMMUNOL, V146, P278, DOI 10.1111/j.1365-2249.2006.03198.x; Fleisig AJ, 2005, EXPERT OPIN BIOL TH, V5, P833, DOI 10.1517/14712598.5.6.833; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x; Harrison R. A., 1996, WEIRS HDBH EXPT IMMU, VII; Hill A, 2005, BLOOD, V106, P2559, DOI 10.1182/blood-2005-02-0564; Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688; Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2; Kaplan Mariana, 2002, Curr Opin Investig Drugs, V3, P1017; Lazar HL, 2004, CIRCULATION, V110, pII274, DOI 10.1161/01.CIR.0000138315.99788.eb; Mahaffey KW, 2006, AM HEART J, V152, P291, DOI 10.1016/j.ahj.2006.03.027; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Morgan BP, 2006, CLIN EXP IMMUNOL, V146, P294, DOI 10.1111/j.1365-2249.2006.03205.x; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; Morgan BP., 1999, COMPLEMENT REGULATOR; Nunn MA, 2005, J IMMUNOL, V174, P2084, DOI 10.4049/jimmunol.174.4.2084; Piddlesden SJ, 1996, J NEUROIMMUNOL, V71, P173, DOI 10.1016/S0165-5728(96)00144-0; Quigg RJ, 1998, J IMMUNOL, V160, P4553; RIBEIRO JMC, 1987, EXP PARASITOL, V64, P347, DOI 10.1016/0014-4894(87)90046-4; SISSONS JGP, 1977, J CLIN INVEST, V59, P704, DOI 10.1172/JCI108689; Szebeni J, 2003, SHOCK, V20, P347, DOI 10.1097/01.shk.0000082444.66379.17; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; TZARTOS S, 1987, J NEUROIMMUNOL, V15, P185, DOI 10.1016/0165-5728(87)90092-0; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; WALLER D, 1994, PRINCIPLES MED PHARM, P26; Williams AS, 2004, ARTHRITIS RHEUM-US, V50, P3035, DOI 10.1002/art.20478	33	73	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8292	8299		10.1074/jbc.M609858200	http://dx.doi.org/10.1074/jbc.M609858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17215252	hybrid			2022-12-25	WOS:000245081000062
J	Hernandez-Pigeon, H; Jean, C; Charruyer, A; Haure, MJ; Baudouin, C; Charveron, M; Quillet-Mary, A; Laurent, G				Hernandez-Pigeon, Helene; Jean, Christine; Charruyer, Alexandra; Haure, Marie-Jose; Baudouin, Caroline; Charveron, Marie; Quillet-Mary, Anne; Laurent, Guy			UVA induces granzyme B in human keratinocytes through MIF - Implication in extracellular matrix remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION INHIBITORY FACTOR; ACQUIRE CELLULAR CYTOTOXICITY; P38 MAP KINASE; SIGNALING PATHWAYS; LEUKEMIC-CELLS; HAIRLESS MICE; SKIN; ACTIVATION; PERFORIN; TRANSCRIPTION	In a previous study, we have described that UVB induces granzyme B (GrB) in human keratinocyte cells, and that confers potent cellular cytotoxicity against various cellular models, including immune cells (Hernandez-Pigeon, H., Jean, C., Charruyer, A., Hall M. J., Titeux, M., Tonasso, L., Quillet-Mary, A., Baudouin, C., Charveron, M., and Laurent, G. (2006) J. Biol. Chem. 281, 13525-13532). Herein, we have found that, in contrast to UVB, UVA failed to enhance keratinocyte cellular cytotoxicity but was still able to trigger GrB production. We show that GrB is accumulated through a p38 MAPK-dependent transcriptional mechanism stimulated by redox-dependent migration inhibitory factor release. Moreover, GrB purified from UVA-treated cellular extracts was found to degrade fibronectin in vitro. Treatment with antisense oligonucleotide directed against GrB resulted in the inhibition of UVA-induced cell detachment and cell death and facilitated cell migration through fibronectin and vitronectin matrix upon UVA exposure. Altogether, these results suggest another function for GrB in the context of the UV response. Indeed, combined with our previous study, it appears that, whereas this enzyme mediates keratinocyte cellular cytotoxicity following UVB irradiation, GrB supports the capacity of keratinocyte to degrade extracellular matrix components following UVA irradiation. UV-medlated GrB production may thus have important consequences in photoaging and photocarcinogenesis.	Ctr Hosp Univ Purpan, INSERM, U563, CPTP, F-31024 Toulouse 3, France; Hop Hotel Dieu, Lab Biol Cellulaire Cutanee, Inst Rech Pierre Fabre, CERPER, F-31025 Toulouse 3, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jean, C (corresponding author), Ctr Hosp Univ Purpan, INSERM, U563, CPTP, Bat B,Pavillon Lefebvre,Pl Dr Baylac,BP 3028, F-31024 Toulouse 3, France.	christine.jean@toulouse.inserm.fr	jean, christine/P-2920-2014; QUILLET-MARY, Anne/H-4690-2013	jean, christine/0000-0002-6936-289X; QUILLET-MARY, Anne/0000-0002-1849-6388				Babichuk CK, 1996, J BIOL CHEM, V271, P16485, DOI 10.1074/jbc.271.28.16485; Berthou C, 1997, J IMMUNOL, V159, P5293; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BOYER B, 1992, J PHOTOCH PHOTOBIO B, V14, P247, DOI 10.1016/1011-1344(92)85102-Z; Bruno AP, 2000, BLOOD, V96, P1914, DOI 10.1182/blood.V96.5.1914.h8001914_1914_1920; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Choy JC, 2004, ARTERIOSCL THROM VAS, V24, P2245, DOI 10.1161/01.ATV.0000147162.51930.b7; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FROELICH CJ, 1993, J IMMUNOL, V151, P7161; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Hernandez-Pigeon H, 2006, J BIOL CHEM, V281, P13525, DOI 10.1074/jbc.M512694200; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McIlroy D, 2003, P NATL ACAD SCI USA, V100, P2562, DOI 10.1073/pnas.0437935100; Ronday HK, 2001, RHEUMATOLOGY, V40, P55, DOI 10.1093/rheumatology/40.1.55; Santos LL, 2004, J RHEUMATOL, V31, P1038; SCHWARTZ E, 1988, J INVEST DERMATOL, V91, P158, DOI 10.1111/1523-1747.ep12464405; Shimizu T, 2005, J DERMATOL SCI, V37, P65, DOI 10.1016/j.jdermsci.2004.08.007; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; Watanabe H, 2004, J BIOL CHEM, V279, P1676, DOI 10.1074/jbc.M303650200; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	24	52	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8157	8164		10.1074/jbc.M607436200	http://dx.doi.org/10.1074/jbc.M607436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224449	hybrid			2022-12-25	WOS:000245081000048
J	Sano, H; Ishino, M; Kramer, H; Shimizu, T; Mitsuzawa, H; Nishitani, C; Kuroki, Y				Sano, Hitomi; Ishino, Masaho; Kramer, Helmut; Shimizu, Takeyuki; Mitsuzawa, Hiroaki; Nishitani, Chiaki; Kuroki, Yoshio			The microtubule-binding protein hook3 interacts with a cytoplasmic domain of scavenger receptor A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC TRAFFICKING; ALVEOLAR MACROPHAGES; CELLULAR TRAFFICKING; SURFACE EXPRESSION; SR-A; PHAGOCYTOSIS; ADHESION; DROSOPHILA; INFECTION; ENDOSOMES	The class A scavenger receptor (SR-A) is a multifunctional transmembrane glycoprotein that is implicated in atherogenesis, innate immunity, and cell adhesion. Despite extensive structure-function studies of the receptor, intracellar molecules that directly interact with SR-A and regulate the receptor trafficking have not been determined. In the current study, we have identified a microtubule-binding protein, Hook3, as a novel interacting partner of SR-A. The association between a rat Hook3 isoform and SR-A was suggested by yeast two-hybrid screening and mass spectrometry analysis of SR-A-cytoplasmic domain-bound proteins in rat alveolar macrophages. The binding of overexpressed and endogenous human Hook3 to SR-A was demonstrated by pull-down assay and co-immunoprecipitations. Furthermore, endogenous murine SR-A and HK3 co-sedimented from cell lysates isolated from Raw264.7 murine macrophage cells. The interaction of Hook3 with SR-A was significantly stimulated after SR-A had recognized the extracellular ligand. Studies using truncations demonstrated that the positively charged C-terminal Val(614)-Ala(717) region of human Hook3 was required for the interaction with the negatively charged residues, Glu(12), Asp(13), and Asp(15) in the human SR-A cytoplasmic domain. By transfecting small interfering RNA targeting Hook3, total and surface expression, receptor-mediated ligand uptake and protein stability of SR-A were significantly promoted, whereas the protein synthesis and maturation were not altered. We propose for the first time that Hook3 may participate in the turnover of the endocytosed scavenger receptor.	Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Hyg, Sapporo, Hokkaido 0608556, Japan; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; CREST, Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan	Sapporo Medical University; Sapporo Medical University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST)	Sano, H (corresponding author), South 1,West 17,Chuo Ku, Sapporo, Hokkaido 0608556, Japan.	sanohito@sapmed.ac.jp		Kramer, Helmut/0000-0002-1167-2676	NINDS NIH HHS [NS43406] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043406] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alarcon R, 2005, J BIOL CHEM, V280, P30406, DOI 10.1074/jbc.M414686200; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; Daugherty A, 2000, J LIPID RES, V41, P1568; de Winther MPJ, 2000, ARTERIOSCL THROM VAS, V20, P290, DOI 10.1161/01.ATV.20.2.290; DOI T, 1993, J BIOL CHEM, V268, P2126; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Heider H, 2001, FEBS LETT, V505, P185, DOI 10.1016/S0014-5793(01)02819-8; Ishiguro T, 2001, AM J PATHOL, V158, P179, DOI 10.1016/S0002-9440(10)63956-9; Kaiser F, 2004, J CELL SCI, V117, P1747, DOI 10.1242/jcs.01039; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kosswig N, 2003, J BIOL CHEM, V278, P34219, DOI 10.1074/jbc.M303465200; Kramer H, 1999, GENETICS, V151, P675; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuronuma K, 2004, J BIOL CHEM, V279, P21421, DOI 10.1074/jbc.M312490200; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MORI T, 1994, LAB INVEST, V71, P409; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Santiago-Garcia J, 2003, J BIOL CHEM, V278, P6942, DOI 10.1074/jbc.M208358200; Shotland Y, 2003, MOL MICROBIOL, V49, P1565, DOI 10.1046/j.1365-2958.2003.03668.x; Sunio A, 1999, MOL BIOL CELL, V10, P847, DOI 10.1091/mbc.10.4.847; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Tian G, 2004, J BIOL CHEM, V279, P39303, DOI 10.1074/jbc.M405219200; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923	37	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7973	7981		10.1074/jbc.M611537200	http://dx.doi.org/10.1074/jbc.M611537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237231	hybrid			2022-12-25	WOS:000245081000027
J	Jaubert, M; Lavergne, J; Fardoux, J; Hannibal, L; Vuillet, L; Adriano, JM; Bouyer, P; Pignol, D; Giraud, E; Vermeglio, A				Jaubert, Marianne; Lavergne, Jerome; Fardoux, Joel; Hannibal, Laure; Vuillet, Laurie; Adriano, Jean-Marc; Bouyer, Pierre; Pignol, David; Giraud, Eric; Vermeglio, Andre			A singular bacteriophytochrome acquired by lateral gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-TUMEFACIENS; BILIVERDIN CHROMOPHORE; HISTIDINE KINASES; PHYTOCHROME AGP1; BACTERIA; REVEALS; PHYCOCYANOBILIN; PHOTORECEPTORS; CYANOBACTERIAL; PERCEPTION	Bacteriophytochromes are phytochrome-like proteins that mediate photosensory responses in various bacteria according to their light environment. The genome of the photosynthetic and plant-symbiotic Bradyrhizobium sp. strain ORS278 revealed the presence of a genomic island acquired by lateral transfer harboring a bacteriophytochrome gene, BrBphP3.ORS278, and genes involved in the synthesis of phycocyanobilin and gas vesicles. The corresponding protein BrBphP3.ORS278 is phylogenetically distant from the other (bacterio)phytochromes described thus far and displays a series of unusual properties. It binds phycocyanobilin as a chromophore, a unique feature for a bacteriophytochrome. Moreover, its C-terminal region is short and displays no homology with any known functional domain. Its dark-adapted state absorbs maximally around 610 nm, an unusually short wavelength for (bacterio)phytochromes. This form is designated as Po for orange-absorbing form. Upon illumination, a photo-reversible switch occurs between the Po form and a red (670 nm)-absorbing form (Pr), which rapidly back-reacts in the dark. Because of this instability, illumination results in a mixture of the Po and Pr states in proportions that depend on the intensity. These uncommon features suggest that BrBphP3.ORS278 could be fitted to measure light intensity rather than color.	CEA, Cadarache DEVM, CNRS, Lab Bioenerget Cellulaire,UMR 6191, F-13108 St Paul Les Durance, France; INRA, Lab Symbioses Trop & Mediterraneennes, IRD, CIRAD,AGROM, F-34398 Montpellier, France	CEA; Centre National de la Recherche Scientifique (CNRS); CIRAD; INRAE; Institut Agro; Montpellier SupAgro; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Vermeglio, A (corresponding author), CEA, Cadarache DEVM, CNRS, Lab Bioenerget Cellulaire,UMR 6191, F-13108 St Paul Les Durance, France.	avermeglio@cea.fr	Giraud, Eric/GLS-1036-2022	PIGNOL, David/0000-0002-8070-0319				Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; DAMERVAL T, 1991, PLANT CELL, V3, P191; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Evans K, 2006, J MOL BIOL, V364, P655, DOI 10.1016/j.jmb.2006.09.045; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Froehlich AC, 2005, EUKARYOT CELL, V4, P2140, DOI 10.1128/EC.4.12.2140-2152.2005; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Giraud E, 2005, J BIOL CHEM, V280, P32389, DOI 10.1074/jbc.M506890200; Giraud E, 2004, PHOTOSYNTH RES, V82, P115, DOI 10.1007/s11120-004-1768-1; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Giraud E, 2000, P NATL ACAD SCI USA, V97, P14795, DOI 10.1073/pnas.250484097; Goller AH, 2005, CHEMPHYSCHEM, V6, P1259, DOI 10.1002/cphc.200400667; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Inomata K, 2005, J BIOL CHEM, V280, P24491, DOI 10.1074/jbc.M504710200; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; Lamparter T, 2004, FEBS LETT, V573, P1, DOI 10.1016/j.febslet.2004.07.050; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Li N, 1998, J BACTERIOL, V180, P2450, DOI 10.1128/JB.180.9.2450-2458.1998; Pfeifer F, 2002, J MOL MICROB BIOTECH, V4, P175; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; SINESHCHEKOV VA, 1995, BBA-BIOENERGETICS, V1228, P125, DOI 10.1016/0005-2728(94)00173-3; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; WALSBY AE, 1994, MICROBIOL REV, V58, P94, DOI 10.1128/MMBR.58.1.94-144.1994; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	31	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7320	7328		10.1074/jbc.M611173200	http://dx.doi.org/10.1074/jbc.M611173200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218312	hybrid			2022-12-25	WOS:000245080900043
J	Kawana, K; Quayle, AJ; Ficarra, M; Ibana, JA; Shen, L; Kawana, Y; Yang, HX; Marrero, L; Yavagal, S; Greene, SJ; Zhang, YX; Pyles, RB; Blumberg, RS; Schust, DJ				Kawana, Kei; Quayle, Alison J.; Ficarra, Mercedes; Ibana, Joyce A.; Shen, Li; Kawana, Yukiko; Yang, Huixia; Marrero, Luis; Yavagal, Sujata; Greene, Sheila J.; Zhang, You-Xun; Pyles, Richard B.; Blumberg, Richard S.; Schust, Danny J.			CD1d degradation in Chlamydia trachomatis-infected epithelial cells is the result of both cellular and chlamydial proteasomal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NKT CELLS; EXPRESSION; RECOGNITION; COMPLEX; ACTIVATION; PARADIGM	Chlamydia trachomatis is an obligate intracellular pathogen that can persist in the urogenital tract. Mechanisms by which C. trachomatis evades clearance by host innate immune responses are poorly described. CD1d is MHC-like, is expressed by epithelial cells, and can signal innate immune responses by NK and NKT cells. Here we demonstrate that C. trachomatis infection down-regulates surface-expressed CD1d in human penile urethral epithelial cells through proteasomal degradation. A chlamydial proteasome-like activity factor (CPAF) interacts with the CD1d heavy chain, and CPAF-associated CD1d heavy chain is then ubiquitinated and directed along two distinct proteolytic pathways. The degradation of immature glycosylated CD1d was blocked by the proteasome inhibitor lactacystin but not by MG132, indicating that degradation was not via the conventional proteasome. In contrast, the degradation of non-glycosylated CD1d was blocked by lactacystin and MG132, consistent with conventional cellular cytosolic degradation of N-linked glycoproteins. Immunofluorescent microscopy confirmed the interruption of CD1d trafficking to the cell surface, and the dislocation of CD1d heavy chains into both the cellular cytosol and the chlamydial inclusion along with cytosolic CPAF. C. trachomatis targeted CD1d toward two distinct proteolytic pathways. Decreased CD1d surface expression may help C. trachomatis evade detection by innate immune cells and may promote C. trachomatis persistence.	Boston Univ, Med Ctr, Div Reprod Biol, Dept Obstet & Gynecol,Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; Boston Univ, Sch Med, Div Infect Dis, Dept Med, Boston, MA 02118 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70112 USA; Univ Texas, Med Branch, Dept Pediat & Expt Pathol, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, Boston, MA 02115 USA	Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Boston University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Schust, DJ (corresponding author), Univ Missouri, Div Reprod Endocrinol & Fertil, Dept Obstet Gynecol & Womens Hlth, Sch Med,Columbia Reg Hosp, 402 Keene St,3rd Floor, Columbia, MO 65201 USA.	schustd@health.missouri.edu			NIAID NIH HHS [AI046518, R01 AI055869, U19AI061972] Funding Source: Medline; PHS HHS [KD44319] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI061972, P01AI046518] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BEATTY WL, 1994, MICROBIOL REV, V58, P686, DOI 10.1128/MMBR.58.4.686-699.1994; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; Cho S, 2005, VIROLOGY, V337, P242, DOI 10.1016/j.virol.2005.04.020; Dong F, 2004, MOL MICROBIOL, V52, P1487, DOI 10.1111/j.1365-2958.2004.04072.x; Fichorova RN, 1997, BIOL REPROD, V57, P847, DOI 10.1095/biolreprod57.4.847; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hogan RJ, 2004, INFECT IMMUN, V72, P1843, DOI 10.1128/IAI.72.4.1843-1855.2004; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Sanchez DJ, 2005, J CLIN INVEST, V115, P1369, DOI 10.1172/JCI200524041; Skold M, 2003, INFECT IMMUN, V71, P5447, DOI 10.1128/IAI.71.10.5447-5455.2003; Taniguchi M, 2000, SEMIN IMMUNOL, V12, P543, DOI 10.1006/smim.2000.0270; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yuan WM, 2006, NAT IMMUNOL, V7, P835, DOI 10.1038/ni1364; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931; Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935; Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525	22	54	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7368	7375		10.1074/jbc.M610754200	http://dx.doi.org/10.1074/jbc.M610754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215251	hybrid			2022-12-25	WOS:000245080900048
J	Lemmers, B; Salmena, L; Bidere, N; Su, H; Matysiak-Zablocki, E; Murakami, K; Ohashi, PS; Jurisicova, A; Lenardo, M; Hakem, R; Hakem, A				Lemmers, Benedicte; Salmena, Leonardo; Bidere, Nicolas; Su, Helen; Matysiak-Zablocki, Elzvieta; Murakami, Kiichi; Ohashi, Pamela S.; Jurisicova, Andrea; Lenardo, Michael; Hakem, Razqallah; Hakem, Anne			Essential role for caspase-8 in toll-like receptors and NF kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; BCL-2 FAMILY; ACTIVATION; APOPTOSIS; INNATE; KINASE; FADD; PHOSPHORYLATION; MITOCHONDRIA; STIMULATION	In addition to its pro-apoptotic function in the death receptor pathway, roles for caspase-8 in mediating T-cell proliferation, maintaining lymphocyte homeostasis, and suppressing immunodeficiency have become evident. Humans with a germline point mutation of CASPASE-8 have multiple defects in T cells, B cells, and NK cells, most notably attenuated activation and immunodeficiency. By generating mice with B-cell-specific inactivation of caspase-8 (bcasp8(-/-)), we show that caspase-8 is dispensable for B-cell development, but its loss in B cells results in attenuated antibody production upon in vivo viral infection. We also report an important role for caspase-8 in maintaining B-cell survival following stimulation of the Toll-like receptor (TLR)2,-3, and -4. In response to TLR4 stimulation, caspase-8 is recruited to a complex containing IKK alpha beta, and its loss resulted in delayed NF kappa B nuclear translocation and impaired NF kappa B transcriptional activity. Our study supports dual roles for caspase-8 in apoptotic and nonapoptotic functions and demonstrates its requirement for TLR signaling and in the regulation of NF kappa B function.	Univ Toronto, Adv Med Discovery Inst, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; NIAID, Lab Immunol, NIH, Bethesda, MD 20892 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 2X1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Hakem, R (corresponding author), Univ Toronto, Adv Med Discovery Inst, Ontario Canc Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.	rhakem@uhnres.utoronto.ca	Jurisicova, Andrea/E-4580-2013; Bidère, Nicolas/K-8887-2015	Bidère, Nicolas/0000-0001-9177-0008; Ohashi, Pamela S./0000-0003-2915-9317; Hakem, Razqallah/0000-0001-5948-7931; Salmena, Leonardo/0000-0003-4023-658X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000769, ZIAAI000565, Z01AI000769, Z01AI000565] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1; Bannerman DD, 2002, J CLIN INVEST, V109, P419, DOI 10.1172/JCI14774; Barnhart BC, 2005, CELL DEATH DIFFER, V12, P25, DOI 10.1038/sj.cdd.4401509; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Bertram EM, 2002, EUR J IMMUNOL, V32, P3376, DOI 10.1002/1521-4141(200212)32:12<3376::AID-IMMU3376>3.0.CO;2-Y; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Boatright KM, 2003, BIOCHEM SOC SYMP, V70, P233, DOI 10.1042/bss0700233; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Falk M, 2004, J IMMUNOL, V173, P5077, DOI 10.4049/jimmunol.173.8.5077; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; Fehr T, 2000, INT IMMUNOL, V12, P1275, DOI 10.1093/intimm/12.9.1275; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Krakauer T, 2004, CLIN DIAGN LAB IMMUN, V11, P621, DOI 10.1128/CDLI.11.3.621-624.2004; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Mack A, 2002, EUR J IMMUNOL, V32, P1986, DOI 10.1002/1521-4141(200207)32:7<1986::AID-IMMU1986>3.0.CO;2-#; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Takeda K, 2004, J DERMATOL SCI, V34, P73, DOI 10.1016/j.jdermsci.2003.10.002; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Vos Q, 2000, IMMUNOL REV, V176, P154; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang XD, 2001, GENE DEV, V15, P2922; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	52	125	127	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7416	7423		10.1074/jbc.M606721200	http://dx.doi.org/10.1074/jbc.M606721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213198	Green Published, hybrid			2022-12-25	WOS:000245080900053
J	Uemura, T; Kashiwagi, K; Igarashi, K				Uemura, Takeshi; Kashiwagi, Keiko; Igarashi, Kazuei			Polyamine uptake by DUR3 and SAM3 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES SPERMINE UPTAKE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; S-ADENOSYLMETHIONINE; VACUOLAR MEMBRANE; TRANSPORT PROTEIN; UPTAKE SYSTEM; PUTRESCINE; GENE; IDENTIFICATION	It has been reported that GAPI and AGP2 catalyze the uptake of polyamines together with amino acids in Saccharomyces cerevisiae. We have looked for polyamine-preferential uptake proteins in S. cerevisiae. DUR3 catalyzed the uptake of polyamines together with urea, and SAM3 was found to catalyze the uptake of polyamines together with S-adenosylmethionine, glutamic acid, and lysine. Polyamine uptake was greatly decreased in both DUR3- and SAM3-deficient cells. The K-m values for putrescine and spermidine of DUR3 were 479 and 21.2 mu m, respectively, and those of SAM3 were 433 and 20.7 mu m, respectively. Polyamine stimulation of cell growth of a polyamine requiring mutant, which is deficient in ornithine decarboxylase, was not influenced by the disruption of GAP1 and AGP2, but it was diminished by the disruption of DUR3 and SAM3. Furthermore, the polyamine stimulation of cell growth of a polyamine-requiring mutant was completely inhibited by the disruption of both DUR3 and SAM3. The results indicate that DUR3 and SAM3 are major polyamine uptake proteins in yeast. We previously reported that polyamine transport protein kinase 2 regulates polyamine transport. It was found that DUR3 (but not SAM3) was activated by phosphorylation of Thr(250), Ser(251), and Thr(684) by polyamine transport protein kinase 2.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Chiba Inst Sci, Fac Pharm, Choshi, Chiba 2880025, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Albertsen M, 2003, J BIOL CHEM, V278, P12820, DOI 10.1074/jbc.M210715200; Antognoni F, 1999, J BIOL CHEM, V274, P1942, DOI 10.1074/jbc.274.4.1942; Aouida M, 2005, J BIOL CHEM, V280, P24267, DOI 10.1074/jbc.M503071200; BALASUNDARAM D, 1994, J BACTERIOL, V176, P7126, DOI 10.1128/JB.176.22.7126-7128.1994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE RL, 1983, J BIOL CHEM, V258, P2193; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Graschopf A, 2001, J BIOL CHEM, V276, P16216, DOI 10.1074/jbc.M101504200; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Igarashi K, 2006, J BIOCHEM, V139, P11, DOI 10.1093/jb/mvj020; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; KAISER C, 1994, METHODS YEAST GENETI, P1; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; Kashiwagi K, 2002, J BIOL CHEM, V277, P24212, DOI 10.1074/jbc.M202849200; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; ROUSSELET G, 1995, FEBS LETT, V359, P215, DOI 10.1016/0014-5793(95)00038-B; Schreve JL, 2004, BIOCHEM BIOPH RES CO, V313, P745, DOI 10.1016/j.bbrc.2003.11.172; Soksawatmaekhin W, 2004, MOL MICROBIOL, V51, P1401, DOI 10.1046/j.1365-2958.2003.03913.x; Soksawatmaekhin W, 2006, J BIOL CHEM, V281, P29213, DOI 10.1074/jbc.M600754200; SUZUKI T, 1993, EUR J BIOCHEM, V215, P247, DOI 10.1111/j.1432-1033.1993.tb18029.x; Tachihara K, 2005, J BIOL CHEM, V280, P12637, DOI 10.1074/jbc.M410778200; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Uemura T, 2005, J BIOL CHEM, V280, P9646, DOI 10.1074/jbc.M410274200; Uemura T, 2005, BIOCHEM BIOPH RES CO, V328, P1028, DOI 10.1016/j.bbrc.2005.01.064; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604	39	71	75	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7733	7741		10.1074/jbc.M611105200	http://dx.doi.org/10.1074/jbc.M611105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218313	hybrid			2022-12-25	WOS:000245080900085
J	Agrewala, JN; Brown, DM; Lepak, NM; Duso, D; Huston, G; Swain, SL				Agrewala, Javed N.; Brown, Deborah M.; Lepak, Nancy M.; Duso, Debra; Huston, Gail; Swain, Susan L.			Unique ability of activated CD4(+) T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY VIRUS-INFECTIONS; SELECTIN GLYCOPROTEIN LIGAND-1; MEMORY CELLS; IN-VIVO; P-SELECTIN; T-HELPER-2 CELLS; INFLAMED SKIN; CLASS-II; ANTIGEN; SUBSETS	Recent studies suggest that effector T cells generated by immune responses migrate to multiple non-lymphoid sites, even those without apparent expression of antigen or inflammation. To investigate the ability of distinct CD4(+) T lymphocyte subsets to enter and persist in non-lymphoid, noninflamed compartments, we examined the migration and persistence of naive, effector, and rested effector CD4(+) T cells generated in vitro following transfer to nonimmunized adoptive hosts. Th1 and Th2 effectors migrated to both lymphoid and non-lymphoid organs (peritoneum, fat pads, and lung). In contrast, rested effectors and naive cells migrated only to lymphoid areas. Adhesion molecule expression, but not chemokine receptor expression, correlated with the ability to enter non-lymphoid sites. Donor cells persisted longer in lymphoid than in non-lymphoid sites. When hosts with naive and memory donor cells were challenged with antigen, effectors developed in situ, which also migrated to non-lymphoid sites. Memory cells showed an accelerated shift to non-lymphoid migration, in keeping. with memory effector formation. These results suggest that only recently activated effector T cells can disperse to non-lymphoid sites in the absence of antigen and inflammation, and as effectors return to rest, they lose this ability. These data also argue that memory cells in lymphoid sites are longer lived and not in equilibrium with those in non-lymphoid sites.	Trudeau Inst Inc, Saranac Lake, NY 12983 USA	Trudeau Institute	Swain, SL (corresponding author), Trudeau Inst Inc, 154 Algonquin Ave, Saranac Lake, NY 12983 USA.	sswain@northnet.org	Agrewala, Javed Naim/AAS-8449-2021		NIAID NIH HHS [P01AI46530, T32AI49823] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046530, T32AI049823] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRADLEY LM, 1991, J EXP MED, V174, P547, DOI 10.1084/jem.174.3.547; Bradley LM, 1999, EUR J IMMUNOL, V29, P3273, DOI 10.1002/(SICI)1521-4141(199910)29:10<3273::AID-IMMU3273>3.0.CO;2-2; Bradley LM, 2003, CURR OPIN IMMUNOL, V15, P343, DOI 10.1016/S0952-7915(03)00043-8; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Campbell DJ, 2001, NAT IMMUNOL, V2, P876, DOI 10.1038/ni0901-876; Cerwenka A, 1999, J IMMUNOL, V163, P5535; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Ely KH, 2003, J IMMUNOL, V170, P1423, DOI 10.4049/jimmunol.170.3.1423; Haddad W, 2003, J EXP MED, V198, P369, DOI 10.1084/jem.20020691; Hirata T, 2002, J IMMUNOL, V169, P4307, DOI 10.4049/jimmunol.169.8.4307; Hogan RJ, 2001, J EXP MED, V193, P981, DOI 10.1084/jem.193.8.981; Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643; Iezzi G, 2001, J EXP MED, V193, P987, DOI 10.1084/jem.193.8.987; Jelley-Gibbs DM, 2000, J IMMUNOL, V165, P5017, DOI 10.4049/jimmunol.165.9.5017; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Li JC, 2003, J EXP MED, V198, P1807, DOI 10.1084/jem.20030725; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Marshall DR, 2001, P NATL ACAD SCI USA, V98, P6313, DOI 10.1073/pnas.101132698; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Reinhardt RL, 2003, J EXP MED, V197, P751, DOI 10.1084/jem.20021690; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Rogers PR, 2000, J IMMUNOL, V164, P2338, DOI 10.4049/jimmunol.164.5.2338; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Swain SL, 2002, ADV EXP MED BIOL, V512, P113; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Swain SL, 2000, PHILOS T ROY SOC B, V355, P407, DOI 10.1098/rstb.2000.0581; Topham DJ, 2001, J IMMUNOL, V167, P6983, DOI 10.4049/jimmunol.167.12.6983; Unsoeld H, 2002, J IMMUNOL, V169, P638, DOI 10.4049/jimmunol.169.2.638; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Woodland DL, 2001, IMMUNOL RES, V24, P53, DOI 10.1385/IR:24:1:53; Xu BH, 2003, J EXP MED, V197, P1255, DOI 10.1084/jem.20010685; Zinkernagel RM, 2002, CURR OPIN IMMUNOL, V14, P523, DOI 10.1016/S0952-7915(02)00367-9	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6106	6115		10.1074/jbc.M608266200	http://dx.doi.org/10.1074/jbc.M608266200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197446	hybrid			2022-12-25	WOS:000244867200016
J	Deeb, TZ; Carland, JE; Cooper, MA; Livesey, MR; Lambert, JJ; Peters, JA; Hales, TG				Deeb, Tarek Z.; Carland, Jane E.; Cooper, Michelle A.; Livesey, Matthew R.; Lambert, Jeremy J.; Peters, John A.; Hales, Tim G.			Dynamic modification of a mutant cytoplasmic cysteine residue modulates the conductance of the human 5-HT3A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SINGLE-CHANNEL CONDUCTANCE; ANGSTROM RESOLUTION; AMINO-ACIDS; ION-CHANNEL; DETERMINANTS; LOOP; PORE	Structural models suggest that Are 36 lies within five cytoplasmic portals of the 5-HT3A receptor. We tested both the accessibility of residue 436 and the influence of its charge on single channel conductance (gamma) by substituting Arg(436) with Cys and examining the effect of methanethiosulfonate (MTS) reagents on gamma. Inclusion of positively charged 2-aminoethyl-MTS (MTSEA) within the electrode solution reduced gamma of 5-HT3A(R436C) receptors in outside-out patches from 7.8 +/- 0.5 to 5.0 +/- 0.5 picosiemens (pS). To increase gamma, we substituted Arg(436) by Cys in the 5-HT3A(R432Q,R440A) mutant, yielding the 5-HT3A(QCA) construct with a gamma of 17.7 +/- 0.4 pS. Modification of 5-HT3A(QCA) receptors by MTSEA or 2-(trimethylammonium) ethyl-MTS reduced gamma to 8.7 +/- 0.5 and 6.7 +/- 0.4 pS, respectively, both significantly below that of channels exposed to nonpolar propyl-MTS. Extracellular MTSEA, but not 2-(trimethylammonium) ethyl-MTS, crossed the membrane and in so doing slowly (tau=94s) reduced gamma. MTSEA more rapidly (tau=15s) reduced the gamma of 5-HT3A(QCA) receptors in inside-out patches, an effect reversed by the reducing agent dithiothreitol. Cys(436) modification by negatively charged 2-carboxyethyl-MTS and 2-sulfconatoethyl-MTS increased gamma to 23 +/- 1.0 and 26 +/- 0.7 pS, respectively. MTS reagents did not affect gamma values for 5-HT3A(QDA) constructs with Cys substituted for Lys(431) predicted to be outside the entrance to the portals. Collectively, the data demonstrate that the dynamic modification of the charge of a cytoplasmic residue regulates gamma, consistent with the existence of cytoplasmic portals that impose a rate-limiting barrier to ion conduction in Cys loop receptors.	George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA; Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland	George Washington University; George Washington University; University of Dundee	Hales, TG (corresponding author), George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, 2300 Eye St,NW, Washington, DC 20037 USA.	phmtgh@gwumc.edu		Livesey, Matthew/0000-0002-3441-7977; Carland, Jane/0000-0002-1456-876X	Wellcome Trust [073388] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLELI D, 1995, MOL PHARM, V48, P1054; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Hales TG, 2006, J BIOL CHEM, V281, P8062, DOI 10.1074/jbc.M513222200; Hanna MC, 2000, J NEUROCHEM, V75, P240, DOI 10.1046/j.1471-4159.2000.0750240.x; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; KIENKER P, 1994, BIOPHYS J, V66, P325, DOI 10.1016/S0006-3495(94)80781-7; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Peters JA, 2005, TRENDS PHARMACOL SCI, V26, P587, DOI 10.1016/j.tips.2005.09.011; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	20	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6172	6182		10.1074/jbc.M607698200	http://dx.doi.org/10.1074/jbc.M607698200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200121	hybrid			2022-12-25	WOS:000244867200023
J	Easlon, E; Tsang, F; Dilova, I; Wang, C; Lu, SP; Skinner, C; Lin, SJ				Easlon, Erin; Tsang, Felicia; Dilova, Ivanka; Wang, Chen; Lu, Shu-Ping; Skinner, Craig; Lin, Su-Ju			The dihydrolipoamide acetyltransferase is a novel metabolic longevity factor and is required for calorie restriction-mediated life span extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; ACETYL-COA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; GENE DISRUPTION; PROTEIN SIR2; BAKERS-YEAST; EXPRESSION; MITOCHONDRIA	Calorie restriction (CR) extends life span in a wide variety of species. Recent studies suggest that an increase in mitochondrial metabolism mediates CR-induced life span extension. Here we present evidence that Lat1 (dihydrolipoamide acetyltransferase), the E2 component of the mitochondrial pyruvate dehydrogenase complex, is a novel metabolic longevity factor in the CR pathway. Deleting the LAT1 gene abolishes life span extension induced by CR. Overexpressing Lat1 extends life span, and this life span extension is not further increased by CR. Similar to CR, life span extension by Lat1 overexpression largely requires mitochondrial respiration, indicating that mitochondrial metabolism plays an important role in CR. Interestingly, Lat1 overexpression does not require the Sir2 family to extend life span, suggesting that Lat1 mediates a branch of the CR pathway that functions in parallel to the Sir2 family. Lat1 is also a limiting longevity factor in nondividing cells in that overexpressing Lat1 extends cell survival during prolonged culture at stationary phase. Our studies suggest that Lat1 overexpression extends life span by increasing metabolic fitness of the cell. CR may therefore also extend life span and ameliorate age-associated diseases by increasing metabolic fitness through regulating central metabolic enzymes.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Lin, SJ (corresponding author), Univ Calif Davis, Microbiol Sect, 323 Briggs Hall,1 Shields Ave, Davis, CA 95616 USA.	slin@ucdavis.edu			NIA NIH HHS [R01 AG024351-02, R01 AG024351-03, R01 AG024351, R01 AG024351-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG024351] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Barros MH, 2004, J BIOL CHEM, V279, P49883, DOI 10.1074/jbc.M408918200; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brachmann CB, 1998, YEAST, V14, P115; Bubber P, 2005, ANN NEUROL, V57, P695, DOI 10.1002/ana.20474; Burke D., 2000, METHODS YEAST GENETI, P171; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Choi CH, 2005, CELL MOL LIFE SCI, V62, P625, DOI 10.1007/s00018-005-4516-6; Choi CH, 2004, CELL CYCLE, V3, P114; Cruz F, 2001, J NEUROSCI RES, V66, P771, DOI 10.1002/jnr.10048; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Gallo CA, 2004, MOL CELL BIOL, V24, P1301, DOI 10.1128/MCB.24.3.1301-1312.2004; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Guarente L, 2000, GENE DEV, V14, P1021; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Harmych S, 2002, MOL BIOCHEM PARASIT, V125, P135, DOI 10.1016/S0166-6851(02)00221-9; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JAMES AG, 1995, FEBS LETT, V373, P111, DOI 10.1016/0014-5793(95)01020-F; Jiang JC, 2000, FASEB J, V14, P2135; Jiang JC, 2002, EXP GERONTOL, V37, P1023, DOI 10.1016/S0531-5565(02)00064-5; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Krause-Buchholz U, 2006, FEBS LETT, V580, P2553, DOI 10.1016/j.febslet.2006.04.002; KRESZE GB, 1981, EUR J BIOCHEM, V119, P573, DOI 10.1111/j.1432-1033.1981.tb05646.x; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2003, J BIOL CHEM, V278, P13390, DOI 10.1074/jbc.M212818200; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Liu JK, 2002, ANN NY ACAD SCI, V959, P133, DOI 10.1111/j.1749-6632.2002.tb02090.x; Long JG, 2006, LIFE SCI, V79, P1466, DOI 10.1016/j.lfs.2006.04.024; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Park PU, 2002, METHOD ENZYMOL, V351, P468; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Perluigi M, 2005, MOL CELL PROTEOMICS, V4, P1849, DOI 10.1074/mcp.M500090-MCP200; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; UHLINGER DJ, 1986, BIOCHEMISTRY-US, V25, P5673, DOI 10.1021/bi00367a049; Wang YM, 2006, MECH AGEING DEV, V127, P48, DOI 10.1016/j.mad.2005.09.005; WARBURG O, 1956, SCIENCE, V124, P269; WEINDRUCH W, 1998, RETARDATION AGING DI; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	77	44	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6161	6171		10.1074/jbc.M607661200	http://dx.doi.org/10.1074/jbc.M607661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200108	Green Accepted, hybrid			2022-12-25	WOS:000244867200022
J	MacDonald, MJ				MacDonald, Michael J.			Synergistic potent insulin release by combinations of weak secretagogues in pancreatic islets and INS-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR ISOTOPOMER ANALYSIS; PERIFUSED RAT ISLETS; BETA-CELLS; MITOCHONDRIAL METABOLISM; GLYCERALDEHYDE PHOSPHATE; METHYL SUCCINATE; GLUCOSE; SECRETION; PYRUVATE; DEHYDROGENASE	Insulin secretion by the beta cell depends on anaplerosis in which insulin secretagogues are metabolized by mitochondria into molecules that are most likely exported to the extramitochondrial space where they have signaling roles. However, very little is known about the products of anaplerosis. We discovered an experimental paradigm that has begun to provide new information about these products. When various intracellular metabolites were applied in combination to overnight-cultured rat or human pancreatic islets or to INS-1 832/13 cells, they interacted synergistically to strongly stimulate insulin release. When these same metabolites were applied individually to these cells, insulin stimulation was poor. Discerning the contributions of the individual compounds to metabolism has begun to allow us to dissect some of the pathways involved in insulin secretion, which was not possible from studying individual secretagogues. Monomethyl succinate (MMS) combined with a barely stimulatory concentration of a-ketoisocaproate (KIC) (2 mm) stimulated insulin release in cultured rat islets 18-fold (versus 21-fold for 16.7 mM glucose). MMS plus low glucose (2 mm) or pyruvate (5 mM) gave 11- and 9-fold stimulations. These agents also potentiated MMS-induced insulin release in fresh islets, and KIC plus MMS gave synergistic insulin release in cultured human islets. In INS-1 cells, neither MMS nor KIC (10 mm) was an insulin secretagogue, but when added together KIC (2 mm) and MMS stimulated insulin release 7-fold (versus 12-fold for glucose). In islets and INS-1 cells, conditions that stimulated insulin release caused large relative increases in acetoacetate, which is a precursor of pathways to short chain acyl-CoAs. Liquid chromatography-tandem mass spectrometry measurements of acetyl-CoA, acetoacetyl-CoA, succinyl-CoA, hydroxymethyl-glutaryl-CoA, and malonyl-CoA confirmed that they were increased by insulin secretagogues. The results suggest a new mechanism of insulin secretion in which anaplerosis increases short chain acyl-CoAs that have roles in insulin exocytosis.	Univ Wisconsin, Sch Med, Childrens Diabet Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), 3459 Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	mjmacdon@wisc.edu			NIDDK NIH HHS [DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Brunengraber H, 2006, J INHERIT METAB DIS, V29, P327, DOI 10.1007/s10545-006-0320-1; Cline GW, 2004, J BIOL CHEM, V279, P44370, DOI 10.1074/jbc.M311842200; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Fahien LA, 2002, DIABETES, V51, P2669, DOI 10.2337/diabetes.51.9.2669; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Flamez D, 2002, DIABETES, V51, P2018, DOI 10.2337/diabetes.51.7.2018; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; GRILL V, 1991, ENDOCRINOLOGY, V128, P2195, DOI 10.1210/endo-128-4-2195; Gunawardana SC, 2004, AM J PHYSIOL-ENDOC M, V287, pE828, DOI 10.1152/ajpendo.00381.2003; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; HELLMAN B, 1974, ARCH BIOCHEM BIOPHYS, V162, P448, DOI 10.1016/0003-9861(74)90204-5; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LENZEN S, 1979, AM J PHYSIOL, V236, pE391, DOI 10.1152/ajpendo.1979.236.4.E391; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MacDonald MJ, 2004, MOL CELL BIOCHEM, V258, P201, DOI 10.1023/B:MCBI.0000012856.31929.91; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MacDonald MJ, 2003, BBA-GEN SUBJECTS, V1619, P77, DOI 10.1016/S0304-4165(02)00443-9; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MALAISSE WJ, 1993, AM J PHYSIOL, V264, P434; Reszko AE, 2003, J BIOL CHEM, V278, P34959, DOI 10.1074/jbc.M302013200; Rocheleau JV, 2002, J BIOL CHEM, V277, P30914, DOI 10.1074/jbc.M202314200; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843	39	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6043	6052		10.1074/jbc.M606652200	http://dx.doi.org/10.1074/jbc.M606652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17210580	hybrid			2022-12-25	WOS:000244867200009
J	Stella, L; Pallottini, V; Moreno, S; Leoni, S; De Maria, F; Turella, P; Federici, G; Fabrini, R; Dawood, KF; Lo Bello, M; Pedersen, JZ; Ricci, G				Stella, Lorenzo; Pallottini, Valentina; Moreno, Sandra; Leoni, Silvia; De Maria, Francesca; Turella, Paola; Federici, Giorgio; Fabrini, Raffaele; Dawood, Kutayba F.; Lo Bello, Mario; Pedersen, Jens Z.; Ricci, Giorgio			Electrostatic association of glutathione transferase to the nuclear membrane - Evidence of an enzyme defense barrier at the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; HUMAN-LIVER; PEROXIDASE ACTIVITY; NITRIC-OXIDE; CLASS-MU; EXPRESSION; LOCALIZATION; AGGREGATION; PRODUCTS; CARRIERS	The possible nuclear compartmentalization of glutathione S-transferase (GST) isoenzymes has been the subject of contradictory reports. The discovery that the dinitrosyl-diglutathionyl-iron complex binds tightly to Alpha class GSTs in rat hepatocytes and that a significant part of the bound complex is also associated with the nuclear fraction (Pedersen, J. Z., De Maria, F., Turella, P., Federici, G., Mattei, M., Fabrini, R., Dawood, K. F., Massimi, M., Caccuri, A. M., and Ricci, G. (2007) 1. BioL Chem. 282, 6364 - 637 1) prompted us to reconsi-der the nuclear localization of GSTs in these cells. Surprisingly, we found that a considerable amount of GSTs corresponding to 10% of the cytosolic pool is electrostatically associated with the outer nuclear membrane, and a similar quantity is compartmentalized inside the nucleus. Mainly Alpha class GSTs, in particular GSTA1-1, GSTA2-2, and GSTA3-3, are involved in this double modality of interaction. Confocal microscopy, immunofluorescence experiments, and molecular modeling have been used to detail the electrostatic association in hepatocytes and liposomes. A quantitative analysis of the membrane-bound Alpha GSTs suggests the existence of a multilayer assembly of these enzymes at the outer nuclear envelope that could represent an amazing novelty in cell physiology. The interception of potentially noxious compounds to prevent DNA damage could be the possible physiological role of the perinuclear and intranuclear localization of Alpha GSTs.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Univ Roma La Sapienza, Dept Cellular & Dev Biol, I-00185 Rome, Italy; Childrens Hosp Bambin Gesu, I-00165 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Roma Tre University; Sapienza University Rome; IRCCS Bambino Gesu; University of Rome Tor Vergata	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Pallottini, Valentina/AAA-3218-2021; Dawood, Kutayba/E-1505-2019; Stella, Lorenzo/A-7996-2010; Moreno, Sandra/D-4254-2014; Leoni, Silvia/AAS-2786-2021	Pallottini, Valentina/0000-0003-2511-6168; Dawood, Kutayba/0000-0002-0762-9632; Stella, Lorenzo/0000-0002-5489-7381; Ricci, Giorgio/0000-0002-7108-2846; moreno, sandra/0000-0002-1079-3222				ABEI M, 1989, BIOCHIM BIOPHYS ACTA, V995, P279, DOI 10.1016/0167-4838(89)90047-2; Ai H, 2003, CELL BIOCHEM BIOPHYS, V39, P23, DOI 10.1385/CBB:39:1:23; Alberts B, 2002, MOL BIOL CELL, P661; Albi E, 1997, CELL BIOCHEM FUNCT, V15, P181; ARNOLD K, 1990, CHEM PHYS LIPIDS, V55, P301, DOI 10.1016/0009-3084(90)90168-Q; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BENNETT CF, 1986, J CELL BIOL, V102, P600, DOI 10.1083/jcb.102.2.600; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; Boese M, 1997, J BIOL CHEM, V272, P21767, DOI 10.1074/jbc.272.35.21767; CAMPBELL JAH, 1991, CANCER, V67, P1608, DOI 10.1002/1097-0142(19910315)67:6<1608::AID-CNCR2820670623>3.0.CO;2-S; CARUSO F, 2004, COLLOIDS COLLOID ASS, P246; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Estes DJ, 2005, COLLOID SURFACE B, V42, P115, DOI 10.1016/j.colsurfb.2005.01.016; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; Mannervik B, 2005, METHOD ENZYMOL, V401, P1, DOI 10.1016/S0076-6879(05)01001-3; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; MCCUSKER FM, 1990, GLUTATHIONE S TRANFE; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; MORGENSTERN R, 1985, J BIOL CHEM, V260, P3976; Pedersen JZ, 2007, J BIOL CHEM, V282, P6364, DOI 10.1074/jbc.M609905200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Rogers LK, 2002, TOXICOL SCI, V69, P279, DOI 10.1093/toxsci/69.1.279; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; ROZELL B, 1993, XENOBIOTICA, V23, P835, DOI 10.3109/00498259309059412; SANDEEP K, 2001, BIOCHEM J, V360, P345; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; SOBOLL S, 1995, BIOCHEM J, V311, P889, DOI 10.1042/bj3110889; Stella L, 2004, BIOPHYS J, V86, P936, DOI 10.1016/S0006-3495(04)74169-7; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; STOCKMAN PK, 1987, BIOCHEM J, V244, P55, DOI 10.1042/bj2440055; Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903; Turella P, 2006, J BIOL CHEM, V281, P23725, DOI 10.1074/jbc.M604372200; VIRTANEN I, 1978, CELL BIOL INT REP, V2, P33, DOI 10.1016/0309-1651(78)90082-6; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069	41	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6372	6379		10.1074/jbc.M609906200	http://dx.doi.org/10.1074/jbc.M609906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197701	hybrid			2022-12-25	WOS:000244867200044
J	Tao, JC; Wang, HY; Malbon, CC				Tao, Jiangchuan; Wang, Hsien-yu; Malbon, Craig C.			Src docks to A-kinase anchoring protein gravin, regulating beta 2-adrenergic receptor resensitization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTORS; AGONIST-INDUCED DESENSITIZATION; TYROSINE KINASE; BETA(2)-ADRENERGIC RECEPTOR; C-SRC; SIGNALING COMPLEXES; MEMBRANE INTERACTIONS; COUPLED RECEPTORS; LINKED RECEPTORS; AKAP250 GRAVIN	Gravin (AKAP12) is a membrane-associated scaffold that provides docking for protein kinases, phosphatases, and adaptor molecules obligate for resensitization and recycling of beta(2)-adrenergic receptors. Gravin binds to the cell membrane in a Ca2+ sensitive manner and to receptors through well characterized protein-protein interactions. Although the interaction of serine/threonine, cyclic AMP-dependent protein kinase with protein kinase A-anchoring proteins is well described and involves a kinase regulatory subunit binding domain in the C terminus of these proteins, far less is known about tyrosine kinase docking to members of this family of scaffolds. The non-receptor-tyrosine kinase Src regulates resensitization of beta(2)-adrenergic receptors and docks to gravin. Gravin displays nine proline-rich domains distributed throughout the molecule. One class I ligand for Src homology domain 3 docking, found in the N terminus ((RXPXXP15)-R-10) of gravin, is shown to bind Src. Binding of Src to gravin activates the intrinsic tyrosine kinase of Src. Mutagenesis/deletion of the class I ligand (P15A,P16A) on the N terminus of gravin abolishes both the docking of Src to gravin as well as the receptor resensitization and recycling catalyzed by gravin. The Src-binding peptide-(1-51) of gravin behaves as a dominant-negative for AKAP gravin regulation of receptor resensitization/recycling. The tyrosine kinase Src plays an essential role in the AKAP gravin-mediated receptor resensitization and recycling, an essential aspect of receptor biology.	SUNY Stony Brook, Sch Med, Dept Pharmacol, Hlth Sci Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Hlth Sci Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Sch Med, Dept Pharmacol, Hlth Sci Ctr, Stony Brook, NY 11794 USA.	craig@pharm.sunysb.edu	malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK25410, T32 DK007521] Funding Source: Medline; NIGMS NIH HHS [GM69375] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410, T32DK007521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; DELAVIERKLUTCHKO C, 1984, FEBS LETT, V169, P151, DOI 10.1016/0014-5793(84)80308-7; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Karoor V, 1998, Adv Pharmacol, V42, P425; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Malbon CC, 2004, BIOCHEM J, V379, P1, DOI 10.1042/BJ20031648; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Shih ML, 1998, CELL SIGNAL, V10, P575, DOI 10.1016/S0898-6568(97)00195-2; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Shumay E, 2004, J CELL SCI, V117, P593, DOI 10.1242/jcs.00890; Shumay E, 2002, MOL BIOL CELL, V13, P3943, DOI 10.1091/mbc.E02-03-0174; Streb JW, 2005, J BIOL CHEM, V280, P28007, DOI 10.1074/jbc.M414017200; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Tao JC, 2006, J BIOL CHEM, V281, P23932, DOI 10.1074/jbc.M601813200; Wang HY, 2006, EUR J CELL BIOL, V85, P643, DOI 10.1016/j.ejcb.2005.12.003; WANG HY, 1991, INT J BIOCHEM, V23, P7; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527	42	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6597	6608		10.1074/jbc.M608927200	http://dx.doi.org/10.1074/jbc.M608927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200117	hybrid			2022-12-25	WOS:000244867200069
J	Yamashita, T; Nakamaru-Ogiso, E; Miyoshi, H; Matsuno-Yagi, A; Yagi, T				Yamashita, Tetsuo; Nakamaru-Ogiso, Eiko; Miyoshi, Hideto; Matsuno-Yagi, Akemi; Yagi, Takao			Roles of bound quinone in the single subunit NADH-quinone oxidoreductase (Ndi1) from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTENONE-INSENSITIVE NADH; COMPLEX-I DEFECTS; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; INTERNAL NADH; UBIQUINONE OXIDOREDUCTASE; OXIDATIVE-PHOSPHORYLATION; GLUCOSE-DEHYDROGENASE; PLANT-MITOCHONDRIA; ELECTRON-TRANSFER	To understand the biochemical basis for the function of the rotenone-insensitive internal NADH-quinone (ID) oxidoreductase (Ndil), we have overexpressed mature Ndi1- in Escherichia coli membranes. The Ndil purified from the membranes contained one FAD and showed enzymatic activities comparable with the original Ndil isolated from Saccharomyces cerevisiae. When extracted with Triton X-100, the isolated Ndil did not contain Q. The Q-bound form was easily reconstituted by incubation of the Q-free Ndil enzyme with ubiquinone-6. We compared the properties of Q-bound Ndil enzyme with those of Q-free Ndil enzyme, with higher activity found in the Q-bound enzyme. Although both are inhibited by low concentrations of ACO-11 (IC50 = 0.2 mu m), the inhibitory mode of ACO-11 on Q-bound Ndil was distinct from that of Q-free Ndil. The bound Q was slowly released from Ndil by treatment with NADH or dithionite under anaerobic conditions. This release of Q was prevented when Ndil was kept in the reduced state by NADH. When Ndil was incorporated into bovine heart: submitochondrial particles, the Q-bound form, but not the Q-free form, established the NADH-linked respiratory activity, which was insensitive to piericidin A but inhibited by KCN. Furthermore, Ndil produces H2O2 as isolated regardless of the presence of bound Q, and this H2O2 was eliminated when the Q-bound Ndil, but not the Q-free Ndil, was incorporated into submitochondrial particles. The data suggest that Ndil bears at least two distinct Q sites: one for bound Q and the other for catalytic Q.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Scripps Research Institute; Kyoto University	Yagi, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, MEM 256, La Jolla, CA 92037 USA.	yagi@scripps.edu		Tetsuo, Yamashita/0000-0002-4076-991X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM033712] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Elias MD, 2004, J BIOL CHEM, V279, P3078, DOI 10.1074/jbc.M310163200; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P3621, DOI 10.1021/bi00515a049; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Kobayashi K, 2005, BIOCHEMISTRY-US, V44, P13567, DOI 10.1021/bi051347n; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; Maklashina E, 2006, J BIOL CHEM, V281, P26655, DOI 10.1074/jbc.M602938200; MASSEY V, 1963, BIOCHEM Z, V338, P474; Matsumoto H, 2000, INT REV CYTOL, V200, P1, DOI 10.1016/S0074-7696(00)00001-2; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Menz RI, 1996, J BIOL CHEM, V271, P23117, DOI 10.1074/jbc.271.38.23117; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P1076, DOI 10.1021/bi00003a044; Miyoshi H, 1999, J BIOCHEM, V125, P138, DOI 10.1093/oxfordjournals.jbchem.a022250; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Nantapong N, 2005, BIOSCI BIOTECH BIOCH, V69, P149, DOI 10.1271/bbb.69.149; Richardson JR, 2007, TOXICOL SCI, V95, P196, DOI 10.1093/toxsci/kfl133; Romagnoli S, 1996, BIOCHEM MOL BIOL INT, V39, P671; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; Schnermann MJ, 2006, J AM CHEM SOC, V128, P11799, DOI 10.1021/ja0632862; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; Seo BB, 2006, FEBS LETT, V580, P6105, DOI 10.1016/j.febslet.2006.10.008; Seo BB, 2006, J BIOL CHEM, V281, P14250, DOI 10.1074/jbc.M600922200; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Shestopalov AI, 1997, FEBS LETT, V404, P272, DOI 10.1016/S0014-5793(97)00143-9; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; VIOLA RE, 1982, BIOCHEMISTRY-US, V21, P1295, DOI 10.1021/bi00535a029; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; Yagi T, 2006, REJUV RES, V9, P191, DOI 10.1089/rej.2006.9.191; YAGI T, 2004, RESP ARCHAEA BACTERI, P15; Yagi T, 2006, BBA-BIOENERGETICS, V1757, P708, DOI 10.1016/j.bbabio.2006.01.011; Yano T, 2006, J BIOL CHEM, V281, P11456, DOI 10.1074/jbc.M508844200	45	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6012	6020		10.1074/jbc.M610646200	http://dx.doi.org/10.1074/jbc.M610646200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200125	hybrid			2022-12-25	WOS:000244867200006
J	Yao, JH; Kim, TW; Qin, JZ; Jiang, ZF; Qian, YC; Xiao, H; Lu, Y; Qian, W; Gulen, MF; Sizemore, N; DiDonato, J; Sato, S; Akira, S; Su, B; Li, XX				Yao, Jianhong; Kim, Tae Whan; Qin, Jinzhong; Jiang, Zhengfan; Qian, Youcun; Xiao, Hui; Lu, Yi; Qian, Wen; Gulen, Muhammet Fatih; Sizemore, Nywana; DiDonato, Joseph; Sato, Shintaro; Akira, Shizuo; Su, Bing; Li, Xiaoxia			Interleukin-1 (IL-1)-induced TAK1-dependent versus MEKK3-dependent NF kappa B activation pathways bifurcate at IL-1 receptor-associated kinase modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA SUBUNIT; SIGNALING PATHWAY; ACCESSORY PROTEIN; JNK ACTIVATION; MICE LACKING; TAK1; IRAK; TAB2; PHOSPHORYLATION; COMPLEX	Interleukin-1 (IL-1) receptor-associated kinase (IRAK) is phosphorylated after it is recruited to the receptor, subsequently ubiquitinated, and eventually degraded upon IL-1 stimulation. Although a point mutation changing lysine 134 to arginine (K134R) in IRAK abolished IL-1-induced IRAK ubiquitination and degradation, mutations of serines and threonines adjacent to lysine 134 to alanines ((S/T)A (131-144)) reduced IL-1-induced IRAK phosphorylation and abolished IRAK ubiquitination. Through the study of these IRAK modification mutants, we uncovered two parallel IL-1-mediated signaling pathways for NF kappa B activation, TAKI-dependent and MEKK3-dependent, respectively. These two pathways bifurcate at the level of IRAK modification. The TAKI-dependent pathway leads to IKK alpha/beta phosphorylation and IKK beta activation, resulting in classical NF kappa B activation through I kappa B alpha phosphorylation and degradation. The TAK1-independent MEKK3-dependent pathway involves IKK gamma phosphorylation and IKK alpha activation, resulting in NF kappa B activation through I kappa B alpha phosphorylation and subsequent dissociation from NF kappa B but without I kappa B alpha degradation. These results provide significant insight to our further understanding of NF kappa B activation pathways.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Osaka Univ, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77054 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Japan Science & Technology Agency (JST); Osaka University; University of Texas System; UTMD Anderson Cancer Center; Case Western Reserve University	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	lix@ccf.org	Hazen, Stanley L/ABD-5845-2021; Akira, Shizuo/C-3134-2009	Gulen, Muhammet/0000-0002-7139-6781; Sato, Shintaro/0000-0001-5156-3354				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Li QT, 2000, GENE DEV, V14, P1729; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LORD KA, 1990, ONCOGENE, V5, P1095; Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Qin JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	50	86	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6075	6089		10.1074/jbc.M609039200	http://dx.doi.org/10.1074/jbc.M609039200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197697	hybrid			2022-12-25	WOS:000244867200013
J	Bain, MB; Haley, N; Peterson, DL; Arend, KK; Mills, KE; Sullivan, PJ				Bain, Mark B.; Haley, Nancy; Peterson, Douglas L.; Arend, Kristin K.; Mills, Kathy E.; Sullivan, Patrick J.			Recovery of a US Endangered Fish	PLOS ONE			English	Article							STURGEON ACIPENSER-BREVIROSTRUM; SPECIES-ACT; SHORTNOSE STURGEON; LIFE-HISTORY; CLASSIFICATION; CRITERIA; RIVER	Background. More fish have been afforded US Endangered Species Act protection than any other vertebrate taxonomic group, and none has been designated as recovered. Shortnose sturgeon (Acipenser brevirostrum) occupy large rivers and estuaries along the Atlantic coast of North America, and the species has been protected by the US Endangered Species Act since its enactment. Methodology/Principal Findings. Data on the shortnose sturgeon in the Hudson River (New York to Albany, NY, USA) were obtained from a 1970s population study, a population and fish distribution study we conducted in the late 1990s, and a fish monitoring program during the 1980s and 1990s. Population estimates indicate a late 1990s abundance of about 60,000 fish, dominated by adults. The Hudson River population has increased by more than 400% since the 1970s, appears healthy, and has attributes typical for a long-lived species. Our population estimates exceed the government and scientific population recovery criteria by more than 500%, we found a positive trend in population abundance, and key habitats have remained intact despite heavy human river use. Conclusions/Significance. Scientists and legislators have called for changes in the US Endangered Species Act, the Act is being debated in the US Congress, and the Act has been characterized as failing to recover species. Recovery of the Hudson River population of shortnose sturgeon suggests the combination of species and habitat protection with patience can yield successful species recovery, even near one of the world's largest human population centers.	[Bain, Mark B.; Haley, Nancy; Peterson, Douglas L.; Arend, Kristin K.; Mills, Kathy E.; Sullivan, Patrick J.] Cornell Univ, Dept Nat Resources, Ithaca, NY 14853 USA	Cornell University	Bain, MB (corresponding author), Cornell Univ, Dept Nat Resources, Fernow Hall, Ithaca, NY 14853 USA.	Mark.Bain@Cornell.edu		Arend, Kristin/0000-0003-1115-1050	Hudson River Foundation; US Army Corps of Engineers via the National Marine Fisheries Service; US Geological Survey	Hudson River Foundation; US Army Corps of Engineers via the National Marine Fisheries Service; US Geological Survey(United States Geological Survey)	Supported by grants to MBB from the Hudson River Foundation and the New York District of the US Army Corps of Engineers via the National Marine Fisheries Service and the US Geological Survey. None of the sponsors specified or influenced the study design, findings, and interpretations. The conclusions do not imply agency concurrence or policy positions.	*APPL SCI ASS, 1999, 1996 YEAR CLASS REP; Bain MB, 1997, ENVIRON BIOL FISH, V48, P347, DOI 10.1023/A:1007325814893; Bean MJ, 2006, BIOSCIENCE, V56, P98, DOI 10.1641/0006-3568(2006)056[0098:TESAUT]2.0.CO;2; Brook BW, 2000, NATURE, V404, P385, DOI 10.1038/35006050; BUCKLEY J, 1981, PROG FISH CULT, V43, P74, DOI 10.1577/1548-8659(1981)43[74:SAROSS]2.0.CO;2; Campbell SP, 2002, ECOL APPL, V12, P674, DOI 10.1890/1051-0761(2002)012[0674:AAOMEI]2.0.CO;2; Carroll R, 1996, ECOL APPL, V6, P1; COCH NK, 1986, NE GEOL, V8, P96; *CONN DEP ENV PROT, 2003, WORK NAT SHORTN STUR; Cooper J.C., 1988, AM FISHERIES SOC MON, V4, P11; CROCKER J, 2006, COMMUNICATION    NOV; Curran H.W., 1937, BIOL SURVEY LOWER HU, P124; Dadswell M. J., 1984, 14 NMFS NAT OC ATM A; Doremus H, 2001, CONSERV BIOL, V15, P1258, DOI 10.1046/j.1523-1739.2001.00178.x; Dovel W. L., 1981, ENDANGERED SHORTNOSE; DOVEL WL, 1992, ESTUARINE RESEARCH IN THE 1980S, P187; Foin TC, 1998, BIOSCIENCE, V48, P177, DOI 10.2307/1313263; Franklin I., 1980, CONSERVATION BIOL EV; FRIEDLAND KD, 2004, 2006 IUCN RED LIST T; GEOGHEGAN P, 1992, ESTUARINE RESEARCH IN THE 1980S, P217; Gerber LR, 2002, ECOL APPL, V12, P668; Gerber LR, 1999, CONSERV BIOL, V13, P1203, DOI 10.1046/j.1523-1739.1999.98277.x; GIBBONS A, 1992, SCIENCE, V256, P1386, DOI 10.1126/science.256.5062.1386; Hoekstra JM, 2002, ECOL APPL, V12, P630, DOI 10.2307/3060971; Hoff T.B., 1988, P171; JOHNSON L, 1976, J FISH RES BOARD CAN, V33, P2459, DOI 10.1139/f76-293; Klauda R.J., 1988, P7; Krebs C. J., 2014, ECOLOGICAL METHODOLO; Kynard B, 1997, ENVIRON BIOL FISH, V48, P319, DOI 10.1023/A:1007372913578; LANDE R, 1995, CONSERV BIOL, V9, P782, DOI 10.1046/j.1523-1739.1995.09040782.x; LIMBURG K E, 1989, Canadian Special Publication of Fisheries and Aquatic Sciences, V106, P265; MACE GM, 1991, CONSERV BIOL, V5, P148, DOI 10.1111/j.1523-1739.1991.tb00119.x; Male TD, 2005, ECOL LETT, V8, P986, DOI 10.1111/j.1461-0248.2005.00806.x; Manly BFJ, 1997, RANDOMIZATION BOOTST; MCDOWALL RM, 1987, AM FISH SOC S, V1, P1; MILLER RR, 1989, FISHERIES, V14, P22, DOI 10.1577/1548-8446(1989)014<0022:EONAFD>2.0.CO;2; *NAT MAR FISH SERV, 2002, C REC PROGR THREAT E; *NAT MAR FISH SERV, 1987, STAT REV SHORTN STUR; *NAT MAR FISH SERV, 2004, C REC PROGR THREAT E; *NOAA NAT MAR FISH, 1998, FIN REC PLAN SHORTN; *NOAA NAT MAR FISH, 1996, STAT REV SHORTN STUR; PEKOVITCH AW, 1979, DISTRIBUTION SOME LI; Ralls K, 1996, CONSERV BIOL, V10, P1528, DOI 10.1046/j.1523-1739.1996.10061528.x; RICKER W E, 1975, P382; Scott JM, 2005, FRONT ECOL ENVIRON, V3, P383, DOI 10.1890/1540-9295(2005)003[0383:ROISUT]2.0.CO;2; Shelden KEW, 2001, CONSERV BIOL, V15, P1300, DOI 10.1046/j.1523-1739.2001.99380.x; Stokstad E, 2005, SCIENCE, V309, P2150, DOI 10.1126/science.309.5744.2150; TAUBERT BD, 1980, COPEIA, P114; TEAR TH, 1993, SCIENCE, V262, P976, DOI 10.1126/science.262.5136.976; TEAR TH, 1995, CONSERV BIOL, V9, P182, DOI 10.1046/j.1523-1739.1995.09010182.x; THOMAS CD, 1990, CONSERV BIOL, V4, P324, DOI 10.1111/j.1523-1739.1990.tb00295.x; THOMPSON GG, 1991, FNWC198 NMFS NAT OC; TOWNES AK, 1937, BIOL SURVEY LOWER HU, P217; *US FISH WILDL SER, 2002, C REC THREAT END SPE; *US FISH WILDL SER, 2006, THREAT END SPEC SYST; Walsh MG, 2001, ESTUARIES, V24, P41, DOI 10.2307/1352811; WILCOVE DS, 1993, CONSERV BIOL, V7, P87, DOI 10.1046/j.1523-1739.1993.07010087.x; WILLIAMS JE, 1989, FISHERIES, V14, P2, DOI 10.1577/1548-8446(1989)014<0002:FONAET>2.0.CO;2; 1996, FED REG, V61, P53893	59	22	23	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e168	10.1371/journal.pone.0000168	http://dx.doi.org/10.1371/journal.pone.0000168			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245444	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444100005
J	Zhang, C; Carl, TF; Trudeau, ED; Simmet, T; Klymkowsky, MW				Zhang, Chi; Carl, Timothy F.; Trudeau, Evan D.; Simmet, Thomas; Klymkowsky, Michael W.			An NF-kappa B and Slug Regulatory Loop Active in Early Vertebrate Mesoderm	PLOS ONE			English	Article							TRANSCRIPTION FACTOR SLUG; NEURAL CREST DEVELOPMENT; ACETYL-BOSWELLIC ACIDS; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; ZINC-FINGER PROTEINS; REPRESSES E-CADHERIN; VIRUS TYPE-1 TAX; GENE-EXPRESSION; XENOPUS HOMOLOG	Background. In both Drosophila and the mouse, the zinc finger transcription factor Snail is required for mesoderm formation; its vertebrate paralog Slug (Snai2) appears to be required for neural crest formation in the chick and the clawed frog Xenopus laevis. Both Slug and Snail act to induce epithelial to mesenchymal transition (EMT) and to suppress apoptosis. Methodology & Principle Findings. Morpholino-based loss of function studies indicate that Slug is required for the normal expression of both mesodermal and neural crest markers in X. laevis. Both phenotypes are rescued by injection of RNA encoding the antiapoptotic protein Bcl-xL; Bcl-xL's effects are dependent upon I kappa B kinase-mediated activation of the bipartite transcription factor NF-kappa B. NF-kappa B, in turn, directly up-regulates levels of Slug and Snail RNAs. Slug indirectly up-regulates levels of RNAs encoding the NF-kappa B subunit proteins RelA, Rel2, and Rel3, and directly down-regulates levels of the pro-apopotic Caspase-9 RNA. Conclusions/Significance. These studies reveal a Slug/Snail-NF-kappa B regulatory circuit, analogous to that present in the early Drosophila embryo, active during mesodermal formation in Xenopus. This is a regulatory interaction of significance both in development and in the course of inflammatory and metastatic disease.	[Zhang, Chi; Carl, Timothy F.; Trudeau, Evan D.; Klymkowsky, Michael W.] Univ Colorado, Boulder, CO 80309 USA; [Simmet, Thomas] Univ Ulm, Inst Pharmacol Nat Prod & Clin Pharmacol, Ulm, Germany	University of Colorado System; University of Colorado Boulder; Ulm University	Klymkowsky, MW (corresponding author), Univ Colorado, Boulder, CO 80309 USA.	klym@spot.colorado.edu		Syrovets, Tatiana/0000-0002-6751-2233; Klymkowsky, Mike/0000-0001-5816-9771	March of Dimes Birth Defects Foundation, Inc.; National Institutes of Health [GM54001]; American Heart Association; German Cancer Foundation (Deutsche Krebshilfe); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054001] Funding Source: NIH RePORTER	March of Dimes Birth Defects Foundation, Inc.(March of Dimes); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); German Cancer Foundation (Deutsche Krebshilfe)(Deutsche Krebshilfe); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was initiated with support from the March of Dimes Birth Defects Foundation, Inc., and completed with support from the National Institutes of Health (GM54001) and the American Heart Association. TS was supported by the German Cancer Foundation (Deutsche Krebshilfe).	Ashraf SI, 1999, EMBO J, V18, P6426, DOI 10.1093/emboj/18.22.6426; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Baker CVH, 1997, MECH DEVELOP, V69, P3, DOI 10.1016/S0925-4773(97)00132-9; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck CW, 1998, INT J DEV BIOL, V42, P67; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bonstein L, 1998, DEV BIOL, V193, P156, DOI 10.1006/dbio.1997.8795; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cai Y, 2001, EMBO J, V20, P1704, DOI 10.1093/emboj/20.7.1704; Campbell KJ, 2006, BIOCHEM SOC SYMP, V73, P165, DOI 10.1042/bss0730165; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carl T, 1999, ADV MOLEC BIOL, P291; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; CRUZREYES J, 1995, GENE, V158, P171, DOI 10.1016/0378-1119(95)00159-4; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; DENT JA, 1989, DEVELOPMENT, V105, P61; Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; ENTNER N, 1973, J PROTOZOOL, V20, P160, DOI 10.1111/j.1550-7408.1973.tb06025.x; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; Finkielstein CV, 2001, P NATL ACAD SCI USA, V98, P1006, DOI 10.1073/pnas.98.3.1006; Fritzenwanker JH, 2004, DEV BIOL, V275, P389, DOI 10.1016/j.ydbio.2004.08.014; Ganguly A, 2005, DEVELOPMENT, V132, P3419, DOI 10.1242/dev.01903; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gordon MD, 2005, NATURE, V437, P746, DOI 10.1038/nature04073; GRAU Y, 1984, GENETICS, V108, P347; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Hajra KM, 2002, CANCER RES, V62, P1613; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2004, DEV BIOL, V269, P411, DOI 10.1016/j.ydbio.2004.01.029; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; Hensey C, 1998, DEV BIOL, V203, P36, DOI 10.1006/dbio.1998.9028; Hoernlein RF, 1999, J PHARMACOL EXP THER, V288, P613; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JIANG J, 1992, EMBO J, V11, P3147, DOI 10.1002/j.1460-2075.1992.tb05387.x; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; Kao KR, 1996, MECH DEVELOP, V58, P129, DOI 10.1016/S0925-4773(96)00565-5; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KENGAKU M, 1993, DEVELOPMENT, V119, P1067; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; Kishi M, 2000, DEVELOPMENT, V127, P791; KOLM PJ, 1995, DEV BIOL, V171, P267, DOI 10.1006/dbio.1995.1279; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kumano G, 2002, MECH DEVELOP, V118, P45, DOI 10.1016/S0925-4773(02)00186-7; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Lake BB, 2001, DEVELOPMENT, V128, P263; Lespinet O, 2002, DEV GENES EVOL, V212, P186, DOI 10.1007/s00427-002-0228-1; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li LJ, 2003, J CELL SCI, V116, P3687, DOI 10.1242/jcs.00644; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Locascio A, 2002, P NATL ACAD SCI USA, V99, P16841, DOI 10.1073/pnas.262525399; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Mayor R, 2000, MECH DEVELOP, V97, P47, DOI 10.1016/S0925-4773(00)00412-3; Mayor R, 1999, CURR TOP DEV BIOL, V43, P85; MAYOR R, 1995, DEVELOPMENT, V121, P767; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Meulemans D, 2004, DEV CELL, V7, P291, DOI 10.1016/j.devcel.2004.08.007; Monsoro-Burq AH, 2003, DEVELOPMENT, V130, P3111, DOI 10.1242/dev.00531; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Murray SA, 2006, P NATL ACAD SCI USA, V103, P10300, DOI 10.1073/pnas.0602234103; Nakakura EK, 2001, P NATL ACAD SCI USA, V98, P4010, DOI 10.1073/pnas.051014098; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Penzel R, 1997, INT J DEV BIOL, V41, P667; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; RICHARDSON JC, 1994, MECH DEVELOP, V45, P173, DOI 10.1016/0925-4773(94)90031-0; ROARK M, 1995, GENE DEV, V9, P2384, DOI 10.1101/gad.9.19.2384; SAFAYHI H, 1995, MOL PHARMACOL, V47, P1212; Saint-Germain N, 2004, DEVELOPMENT, V131, P1755, DOI 10.1242/dev.01066; Sakai D, 2006, DEVELOPMENT, V133, P1323, DOI 10.1242/dev.02297; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; SIMPSON P, 1983, GENETICS, V105, P615; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spokony RF, 2002, DEVELOPMENT, V129, P421; Stack JH, 1997, DEVELOPMENT, V124, P3185; Stennard F, 1999, MECH DEVELOP, V86, P87, DOI 10.1016/S0925-4773(99)00119-7; Su CC, 2006, ANTICANCER RES, V26, P1281; Suzuki K, 1998, GENE, V206, P1, DOI 10.1016/S0378-1119(97)00561-1; SUZUKI K, 1995, NUCLEIC ACIDS RES, V23, P4664, DOI 10.1093/nar/23.22.4664; Syrovets T, 2005, J BIOL CHEM, V280, P6170, DOI 10.1074/jbc.M409477200; Syrovets T, 2000, MOL PHARMACOL, V58, P71, DOI 10.1124/mol.58.1.71; Syrovets T, 2005, J IMMUNOL, V174, P498, DOI 10.4049/jimmunol.174.1.498; Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127; Takayama E, 2004, BIOCHEM BIOPH RES CO, V325, P1367, DOI 10.1016/j.bbrc.2004.10.179; TANNAHILL D, 1995, INT J DEV BIOL, V39, P549; Technau U, 2003, INT J DEV BIOL, V47, P531; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tribulo C, 2004, DEV BIOL, V275, P325, DOI 10.1016/j.ydbio.2004.07.041; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Vallin J, 2001, J BIOL CHEM, V276, P30350, DOI 10.1074/jbc.M103167200; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504; Vickaryous MK, 2006, BIOL REV, V81, P425, DOI 10.1017/S1464793106007068; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhang C, 2005, DEV DYNAM, V234, P878, DOI 10.1002/dvdy.20565; Zhang C, 2005, DEV BIOL, V278, P526, DOI 10.1016/j.ydbio.2004.11.008; Zhang C, 2003, DEVELOPMENT, V130, P5609, DOI 10.1242/dev.00798; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	143	42	43	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e106	10.1371/journal.pone.0000106	http://dx.doi.org/10.1371/journal.pone.0000106			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205110	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443700002
J	Berenjeno, IM; Nunez, F; Bustelo, XR				Berenjeno, I. M.; Nunez, F.; Bustelo, X. R.			Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases	ONCOGENE			English	Article						Rho/Rac GTPases; microarray; proliferation; gene expression; transcription; rock; c-Myc	FACTOR-KAPPA-B; C-MYC; ACTIVATION; EXPRESSION; PROTEINS; KINASES; BIOLOGY; PHOSPHORYLATION; METASTASIS; GADD153	We have used microarray technology to identify the transcriptional targets of Rho subfamily guanosine 5'-triphosphate (GTP)ases in NIH3T3 cells. This analysis indicated that murine fibroblasts transformed by these proteins show similar transcriptomal profiles. Functional annotation of the regulated genes indicate that Rho subfamily GTPases target a wide spectrum of functions, although loci encoding proteins linked to proliferation and DNA synthesis/transcription are upregulated preferentially. Rho proteins promote four main networks of interacting proteins nucleated around E2F, c-Jun, c-Myc and p53. Of those, E2F, c-Jun and c-Myc are essential for the maintenance of cell transformation. Inhibition of Rock, one of the main Rho GTPase targets, leads to small changes in the transcriptome of Rho-transformed cells. Rock inhibition decreases c-myc gene expression without affecting the E2F and c-Jun pathways. Loss-of-function studies demonstrate that c-Myc is important for the blockage of cell-contact inhibition rather than for promoting the proliferation of Rho-transformed cells. However, c-Myc overexpression does not bypass the inhibition of cell transformation induced by Rock blockage, indicating that c-Myc is essential, but not sufficient, for Rock-dependent transformation. These results reveal the complexity of the genetic program orchestrated by the Rho subfamily and pinpoint protein networks that mediate different aspects of the malignant phenotype of Rho-transformed cells.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NCI NIH HHS [R01 CA073735, 5R01-CA73735-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bolstad BM, 2004, INT REV NEUROBIOL, V60, P25; Budzyn K, 2006, TRENDS PHARMACOL SCI, V27, P97, DOI 10.1016/j.tips.2005.12.002; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chen CH, 1996, ONCOGENE, V13, P1659; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Parrish Rudolph S, 2004, J Biopharm Stat, V14, P575, DOI 10.1081/BIP-200025650; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van der Eb A J, 1980, Methods Enzymol, V65, P826; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu M, 2004, BREAST CANCER RES TR, V84, P3, DOI 10.1023/B:BREA.0000018426.76893.21	28	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4295	4305		10.1038/sj.onc.1210194	http://dx.doi.org/10.1038/sj.onc.1210194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17213802	Green Accepted, Green Submitted			2022-12-25	WOS:000247619900012
J	Jackson, KA; Helston, RM; McKay, JA; O'Neill, ED; Mathers, JC; Ford, D				Jackson, Kelly A.; Helston, Rachel M.; McKay, Jill A.; O'Neill, Elaine D.; Mathers, John C.; Ford, Dianne			Splice variants of the human zinc transporter ZnT5 (SLC30A5) are differentially localized and regulated by zinc through transcription and mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DIETARY ZINC; ALKALINE-PHOSPHATASES; PEPTIDE TRANSPORTER; VERTEBRATE CELLS; FACTOR MTF-1; PROTEINS; RATS; COMPLEXES; MEMBRANE	Maintenance of cellular zinc homeostasis includes regulating the expression of cell membrane zinc transporters. Knowledge about the mechanisms underlying changes in mammalian zinc transporter mRNA abundance is poor. We demonstrated that when expressed in Chinese hamster ovary cells as N-terminal fusions to green fluorescent protein, two splice variants of ZnT5 adopt different subcellular locations ( either in the Golgi apparatus or throughout the cell, including at the plasma membrane) indicating discrete roles in cellular zinc homeostasis. We demonstrated, using a beta-galactosidase reporter gene, that both splice variants were expressed from a promoter region that was transcriptionally repressed by increased extracellular zinc ( 150 mu M compared with 3 mu M; similar to 40%) and by extracellular zinc depletion, using the chelator N, N, N', N'-tetrakis( 2- pyridylmethyl) ethylenediamine (similar to 20%). We mapped the zinc- responsive element to the region -154 to +50, relative to the predicted start of transcription, and showed that a consensus metal response element sequence (-410 to -404) was not responsible for these effects. Changes in ZnT5 mRNA abundance in Caco- 2 cells at different zinc concentrations were in parallel to the changes in promoter activity (similar to 40% reduction at 150 mu M zinc) but in the presence of actinomycin D, to prevent transcription, we observed a marked stabilization ( 1.7 - 2- fold accumulation over 24 h) of ZnT5 mRNA. We conclude that effects of zinc on ZnT5 transcription and mRNA stability act in opposition to balance mRNA abundance for cellular zinc homeostasis. To our knowledge, this is the first report that zinc affects the stability of a transcript with a direct role in cellular zinc homeostasis.	Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Ford, D (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	dianne.ford@ncl.ac.uk		Mathers, John/0000-0003-3406-3002; McKay, Jill Ann/0000-0002-2711-0301; Helston, Rachel/0000-0001-6022-6755; Jackson, Kelly/0000-0001-9116-3769	Biotechnology and Biological Sciences Research Council [D18271] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j; Bird AJ, 2004, EMBO J, V23, P1123, DOI 10.1038/sj.emboj.7600122; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Blasie CA, 2002, BIOCHEMISTRY-US, V41, P15068, DOI 10.1021/bi026621h; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Cragg RA, 2005, GUT, V54, P469, DOI 10.1136/gut.2004.041962; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Devergnas S, 2004, BIOCHEM PHARMACOL, V68, P699, DOI 10.1016/j.bcp.2004.05.024; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; HELSTON RM, 2006, PLACENTA; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Howard A, 2004, J NUTR, V134, P2957, DOI 10.1093/jn/134.11.2957; Ishihara K, 2006, J BIOL CHEM, V281, P17743, DOI 10.1074/jbc.M602470200; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kim JR, 2002, ARCH BIOCHEM BIOPHYS, V397, P414, DOI 10.1006/abbi.2001.2691; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Liuzzi JP, 2003, J NUTR, V133, P342, DOI 10.1093/jn/133.2.342; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Suzuki T, 2005, J BIOL CHEM, V280, P637, DOI 10.1074/jbc.M411247200; Suzuki T, 2005, J BIOL CHEM, V280, P30956, DOI 10.1074/jbc.M506902200; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; Tsui KH, 2006, INT J CANCER, V118, P609, DOI 10.1002/ijc.21411; Walker D, 1998, J PHYSIOL-LONDON, V507, P697, DOI 10.1111/j.1469-7793.1998.697bs.x; Wimmer U, 2005, NUCLEIC ACIDS RES, V33, P5715, DOI 10.1093/nar/gki881; Zoller H, 2002, BLOOD CELL MOL DIS, V29, P488, DOI 10.1006/bcmd.2002.0587	29	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10423	10431		10.1074/jbc.M610535200	http://dx.doi.org/10.1074/jbc.M610535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17234632	hybrid			2022-12-25	WOS:000245941000033
J	MacRitchie, AN; Gardner, AA; Prescott, SM; Stafforini, DM				MacRitchie, Amy N.; Gardner, Alison A.; Prescott, Stephen M.; Stafforini, Diana M.			Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation	FASEB JOURNAL			English	Article						PAF acetylhydrolase; phospholipase A(2); oxidant stress; peroxynitrite; reactive oxygen species; protein oxidation	APOLIPOPROTEIN-A-I; NITRIC-OXIDE; CARDIOVASCULAR-DISEASE; PHOSPHOLIPASE A(2); REPERFUSION INJURY; LIPID MEDIATORS; PAF-AH; PEROXYNITRITE; NITRATION; LIPOPROTEIN	Platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that inactivates potent lipid messengers, such as PAF and modified phospholipids generated in settings of oxidant stress. The catalytic activity of PAF-AH is sensitive to oxidants, a feature that may have pathological consequences. We report that peroxynitrite, an oxidant species generated after cellular activation, mediates oxidative inactivation of PAF-AH. We found that peroxynitrite inactivated and derivatized the recombinant protein and obtained evidence supporting a role for a methionine and two tyrosine residues in this process. We employed inter-species comparisons and site-directed mutagenesis and identified a role for M-117, and a smaller contribution of Y-307 and Y-335 as targets of oxidant attack using free and lipoprotein-associated recombinant proteins. M-117 is adjacent to W-115 and L-116, which are essential for association of PAF-AH with LDL. Oxidation of LDL-associated PAF-AH partially dissociated the enzyme from the particles. Similarly, oxidation of the purified enzyme in the absence of lipoproteins prevented subsequent association with LDL. These results provide new insights into the molecular mechanisms that mediate inactivation of PAF-AH in settings of oxidant stress and the consequences of oxidation on the ability of this enzyme to associate with LDL.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Cir Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akarasereenont Pravit, 2001, Journal of the Medical Association of Thailand, V84, pS730; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bielicki JK, 2001, ATHEROSCLEROSIS, V155, P71, DOI 10.1016/S0021-9150(00)00539-6; Blankenberg S, 2003, J LIPID RES, V44, P1381, DOI 10.1194/jlr.M300086-JLR200; Boyle J. J., 2005, Current Vascular Pharmacology, V3, P63, DOI 10.2174/1570161052773861; Caplan Michael S, 2005, Semin Pediatr Surg, V14, P145, DOI 10.1053/j.sempedsurg.2005.05.002; Caslake MJ, 2005, NAT CLIN PRACT CARD, V2, P529, DOI 10.1038/ncpcardio0321; Caslake MJ, 2003, CURR OPIN LIPIDOL, V14, P347, DOI 10.1097/00041433-200308000-00002; Chen CH, 2004, CURR OPIN LIPIDOL, V15, P337, DOI 10.1097/00041433-200406000-00015; Clements MK, 2003, J LEUKOCYTE BIOL, V73, P344, DOI 10.1189/jlb.0802401; DENTAN C, 1994, ARTERIOSCLER THROMB, V14, P353, DOI 10.1161/01.ATV.14.3.353; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Gaylord MS, 1996, AM J MED SCI, V312, P149, DOI 10.1097/00000441-199610000-00001; Godecke A, 2003, CARDIOVASC RES, V60, P215, DOI 10.1016/j.cardiores.2003.09.005; Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413; Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Holvoet P, 1999, Expert Opin Investig Drugs, V8, P527, DOI 10.1517/13543784.8.5.527; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; IMAIZUMI T-A, 1990, Heart and Vessels, V5, P81, DOI 10.1007/BF02058322; Ji YB, 2006, J BIOL CHEM, V281, P1986, DOI 10.1074/jbc.M509480200; Kuhn DM, 2002, J BIOL CHEM, V277, P14336, DOI 10.1074/jbc.M200290200; LASKIN DL, 1994, J LEUKOCYTE BIOL, V56, P751, DOI 10.1002/jlb.56.6.751; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; MIYAURA S, 1992, CIRC RES, V70, P341, DOI 10.1161/01.RES.70.2.341; Moriel P, 2002, BRAZ J MED BIOL RES, V35, P1301, DOI 10.1590/S0100-879X2002001100007; MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RABINOVICI R, 1993, J APPL PHYSIOL, V74, P1791, DOI 10.1152/jappl.1993.74.4.1791; Rohn TT, 1998, EUR J PHARMACOL, V353, P329, DOI 10.1016/S0014-2999(98)00399-9; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; SHAO B, 2006, J BIOL CHEM; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Souza DG, 2003, BRIT J PHARMACOL, V139, P733, DOI 10.1038/sj.bjp.0705296; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; Suckling Keith E, 2002, Expert Opin Ther Targets, V6, P309; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tsukahara Y, 1996, J SURG RES, V66, P43, DOI 10.1006/jsre.1996.0370; Vassalle C, 2002, CLIN CHEM LAB MED, V40, P802, DOI 10.1515/CCLM.2002.139; Wu B, 2003, FASEB J, V17, P1156, DOI 10.1096/fj.02-0499fje; Yamada Y, 2000, ATHEROSCLEROSIS, V150, P209, DOI 10.1016/S0021-9150(99)00385-8; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	58	30	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1164	1176		10.1096/fj.06-6743com	http://dx.doi.org/10.1096/fj.06-6743com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17210780				2022-12-25	WOS:000245650400021
J	Ballottari, M; Dall'Osto, L; Morosinotto, T; Bassi, R				Ballottari, Matteo; Dall'Osto, Luca; Morosinotto, Tomas; Bassi, Roberto			Contrasting behavior of higher plant photosystem I and II antenna systems during acclimation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; CHLOROPHYLL FLUORESCENCE; PHOTOSYNTHETIC APPARATUS; ENERGY-DISSIPATION; LIGHT ENVIRONMENT; LOW-TEMPERATURE; PHOTOOXIDATIVE STRESS; ELECTRON-TRANSPORT; XANTHOPHYLL CYCLE; STATE TRANSITIONS	In this work we analyzed the photosynthetic apparatus in Arabidopsis thaliana plants acclimated to different light intensity and temperature conditions. Plants showed the ability to acclimate into different environments and avoid photoinhibition. When grown in high light, plants had a faster activation rate for energy dissipation (qE). This ability was correlated to higher accumulation levels of a specific photosystem II subunit, PsbS. The photosystem II antenna size was also regulated according to light exposure; smaller antenna size was observed in high light-acclimated plants with respect to low light plants. Different antenna polypeptides did not behave similarly, and Lhcb1, Lchb2, and Lhcb6 (CP24) are shown to undergo major levels of regulation, whereas Lhcb4 and Lhcb5 (CP29 and CP26) maintained their stoichiometry with respect to the reaction center in all growth conditions. The effect of acclimation on photosystem I antenna was different; in fact, the stoichiometry of any Lhca antenna proteins with respect to photosystem I core complex was not affected by growth conditions. Despite this stability in antenna stoichiometry, photosystem I light harvesting function was shown to be regulated through different mechanisms like the control of photosystem I to photosystem II ratio and the association or dissociation of Lhcb polypeptides to photosystem I.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, Lab Genet & Biophys Plantes, F-13009 Marseille, France; Univ Padua, Dipartimento Biol, I-35131 Padua, Italy	University of Verona; CEA; UDICE-French Research Universities; Aix-Marseille Universite; University of Padua	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str Grazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	Morosinotto, Tomas/AAC-3188-2019; Ballottari, Matteo/N-1916-2019; Dall'Osto, Luca/A-9384-2010	Morosinotto, Tomas/0000-0002-0803-7591; Ballottari, Matteo/0000-0001-8410-3397; bassi, roberto/0000-0002-4140-8446; Dall'Osto, Luca/0000-0001-9497-5156				ALLEN JF, 1992, TRENDS BIOCHEM SCI, V17, P12, DOI 10.1016/0968-0004(92)90418-9; ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; Aspinall-O'Dea M, 2002, P NATL ACAD SCI USA, V99, P16331, DOI 10.1073/pnas.252500999; Bailey S, 2004, PLANTA, V218, P793, DOI 10.1007/s00425-003-1158-5; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; Ballottari M, 2004, EUR J BIOCHEM, V271, P4659, DOI 10.1111/j.1432-1033.2004.04426.x; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; Bellafiore S, 2005, NATURE, V433, P892, DOI 10.1038/nature03286; Ben-Shem A, 2004, PHOTOSYNTH RES, V81, P239, DOI 10.1023/B:PRES.0000036881.23512.42; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bergantino E, 2003, P NATL ACAD SCI USA, V100, P15265, DOI 10.1073/pnas.2533072100; Boekema EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/bi9827161; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Crouchman S, 2006, FEBS LETT, V580, P2053, DOI 10.1016/j.febslet.2006.03.005; DAINESE P, 1992, RES PHOTOSYNTHESIS, V1, P287; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; Demmig-Adams B, 1998, PLANT CELL PHYSIOL, V39, P474, DOI 10.1093/oxfordjournals.pcp.a029394; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, PHYSIOL PLANTARUM, V98, P253, DOI 10.1034/j.1399-3054.1996.980206.x; Finazzi G, 2004, P NATL ACAD SCI USA, V101, P12375, DOI 10.1073/pnas.0404798101; Garcia-Plazaola JI, 1999, PHYTOCHEM ANALYSIS, V10, P307, DOI 10.1002/(SICI)1099-1565(199911/12)10:6&lt;307::AID-PCA477&gt;3.0.CO;2-L; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Gray GR, 1996, PLANT PHYSIOL, V110, P61, DOI 10.1104/pp.110.1.61; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2004, J BIOL CHEM, V279, P13878, DOI 10.1074/jbc.M311154200; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; HURRY VM, 1994, PLANT PHYSIOL, V106, P983, DOI 10.1104/pp.106.3.983; Klimmek F, 2005, BIOCHEMISTRY-US, V44, P3065, DOI 10.1021/bi047873g; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG TY, 1984, PHOTOSYNTH RES, V5, P105, DOI 10.1007/BF00028524; Li XP, 2004, J BIOL CHEM, V279, P22866, DOI 10.1074/jbc.M402461200; Li XP, 2002, J BIOL CHEM, V277, P33590, DOI 10.1074/jbc.M204797200; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; LICHTENTHALER HK, 1982, PHYSIOL PLANTARUM, V56, P183, DOI 10.1111/j.1399-3054.1982.tb00322.x; Lindahl M, 1997, PHOTOSYNTH RES, V54, P227, DOI 10.1023/A:1005920730947; MAENPAA P, 1989, Z NATURFORSCH C, V44, P403; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Morosinotto T, 2005, J BIOL CHEM, V280, P31050, DOI 10.1074/jbc.M502935200; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Morosinotto T, 2006, FEBS J, V273, P4616, DOI 10.1111/j.1742-4658.2006.05465.x; Muller-Moule P, 2004, PLANT PHYSIOL, V134, P1163, DOI 10.1104/pp.103.032375; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OQUIST G, 1993, PLANT PHYSIOL, V101, P245, DOI 10.1104/pp.101.1.245; PETER GF, 1991, J BIOL CHEM, V266, P16745; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; POLLOCK CJ, 1988, SYM SOC EXP BIOL, V42, P157; Rockholm DC, 1996, PLANT PHYSIOL, V110, P697, DOI 10.1104/pp.110.2.697; Rorat T, 2001, PHYSIOL PLANTARUM, V113, P72, DOI 10.1034/j.1399-3054.2001.1130110.x; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; SEEMANN JR, 1987, PLANT PHYSIOL, V84, P796, DOI 10.1104/pp.84.3.796; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; Standfuss J, 2004, J BIOL CHEM, V279, P36884, DOI 10.1074/jbc.M402348200; Svensson JT, 2006, PLANT PHYSIOL, V141, P257, DOI 10.1104/pp.105.072645; Thomashow MF, 2001, PLANT PHYSIOL, V125, P89, DOI 10.1104/pp.125.1.89; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623	69	226	236	5	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8947	8958		10.1074/jbc.M606417200	http://dx.doi.org/10.1074/jbc.M606417200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17229724	hybrid			2022-12-25	WOS:000245780300041
J	Ghiorghi, YK; Zeller, KI; Dang, CV; Kaminski, PA				Ghiorghi, Yoan Konto; Zeller, Karen I.; Dang, Chi V.; Kaminski, P. Alexandre			The c-Myc target gene Rcl (C6orf108) encodes a novel enzyme, deoxynucleoside 5 '-monophosphate N-glycosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE; ACTIVE-SITE; LACTOBACILLUS-HELVETICUS; PYRIMIDINE NUCLEOTIDES; BLASTICIDIN-S; IDENTIFICATION; STREPTOMYCES; EXPRESSION; BIOSYNTHESIS; DEGRADATION	RCL is a c-Myc target with tumorigenic potential. Genome annotation predicted that RCL belonged to the N-deoxyribosyltransferase family. However, its putative relationship to this class of enzymes did not lead to its precise biochemical function. The purified native or N-terminal His-tagged recombinant rat RCL protein expressed in Escherichia coli exhibits the same enzyme activity, deoxynucleoside 5'-monophosphate N-glycosidase, never before described. dGMP appears to be the best substrate. RCL opens a new route in the nucleotide catabolic pathways by cleaving the N-glycosidic bond of deoxynucleoside 5'-monophosphates to yield two reaction products, deoxyribose 5-phosphate and purine or pyrimidine base. Biochemical studies show marked differences in the terms of the structure and catalytic mechanism between RCL and of its closest enzyme family neighbor, N-deoxyribosyltransferase. The reaction products of this novel enzyme activity have been implicated in purine or pyrimidine salvage, glycolysis, and angiogenesis, and hence are all highly relevant for tumorigenesis.	Inst Pasteur, Unite Chim Organ, CNRS, URA 2128, F-75724 Paris 15, France; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johns Hopkins University	Kaminski, PA (corresponding author), Inst Pasteur, Unite Chim Organ, CNRS, URA 2128, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	akaminsk@pasteur.fr	Dang, Chi/Y-3375-2019	Kaminski, Pierre Alexandre/0000-0001-9841-6837; Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA54197] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama S, 2004, CANCER SCI, V95, P851, DOI 10.1111/j.1349-7006.2004.tb02193.x; Anand R, 2004, BIOCHEMISTRY-US, V43, P2384, DOI 10.1021/bi035723k; Armstrong SR, 1996, STRUCTURE, V4, P97, DOI 10.1016/S0969-2126(96)00013-5; Cone MC, 2003, CHEMBIOCHEM, V4, P821, DOI 10.1002/cbic.200300583; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Grochowski LL, 2006, CHEMBIOCHEM, V7, P957, DOI 10.1002/cbic.200600026; HOLGUINH.J, 1972, FEBS LETT, V20, P171, DOI 10.1016/0014-5793(72)80785-3; IMADA A, 1967, J GEN APPL MICROBIOL, V13, P267, DOI 10.2323/jgam.13.267; IMADA A, 1967, J GEN APPL MICROBIOL, V13, P255, DOI 10.2323/jgam.13.255; JYSSUM S, 1989, APMIS, V97, P343, DOI 10.1111/j.1699-0463.1989.tb00797.x; Kaminski PA, 2002, J BIOL CHEM, V277, P14400, DOI 10.1074/jbc.M111995200; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KUNINAKA A, 1957, KOSO KAGAKU SHINPOJI, V12, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG HB, 1984, J BIOL CHEM, V259, P6972; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; Lewis BC, 2000, CANCER RES, V60, P6178; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MACNUTT WS, 1952, BIOCHEM J, V50, P384, DOI 10.1042/bj0500384; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PORTER DJT, 1995, J BIOL CHEM, V270, P15551, DOI 10.1074/jbc.270.26.15551; Rhodes DR, 2002, CANCER RES, V62, P4427; Short SA, 1996, J BIOL CHEM, V271, P4978; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; UERKVITZ W, 1971, EUR J BIOCHEM, V23, P387, DOI 10.1111/j.1432-1033.1971.tb01632.x; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	30	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8150	8156		10.1074/jbc.M610648200	http://dx.doi.org/10.1074/jbc.M610648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234634	hybrid			2022-12-25	WOS:000245081000047
J	Meredith, TC; Mamat, U; Kaczynski, Z; Lindner, B; Holst, O; Woodard, RW				Meredith, Timothy C.; Mamat, Uwe; Kaczynski, Zbigniew; Lindner, Buko; Holst, Otto; Woodard, Ronald W.			Modification of lipopolysaccharide with colanic acid (M-antigen) repeats in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABINOSE 5-PHOSPHATE ISOMERASE; CAPSULAR POLYSACCHARIDE SYNTHESIS; ENTEROBACTERIAL COMMON ANTIGEN; LIPID A-CORE; O-ANTIGEN; STRUCTURAL-ANALYSIS; RCS PHOSPHORELAY; OUTER CORE; SALMONELLA-TYPHIMURIUM; BIOFILM FORMATION	Colanic acid (CA) or M-antigen is an exopolysaccharide produced by many enterobacteria, including the majority of Escherichia coli strains. Unlike other capsular polysaccharides, which have a close association with the bacterial surface, CA forms a loosely associated saccharide mesh that coats the bacteria, often within biofilms. Herein we show that a highly mucoid strain of E. coli K-12 ligates CA repeats to a significant proportion of lipopolysaccharide (LPS) core acceptor molecules, forming the novel LPS glycoform we call M-LPS.M-LPS biosynthesis is dependent upon (i) CA induction, (ii) LPS core biosynthesis, and (iii) the O-antigen ligase WaaL. Compositional analysis, mass spectrometry, and nuclear magnetic resonance spectroscopy of a purified MLPS sample confirmed the presence of a CA repeat unit identical in carbohydrate sequence, but differing at multiple positions in anomeric configuration and linkage, from published structures of extracellular CA. The attachment point was identified as O-7 of the L-glycero-D-manno-heptose of the outer LPS core, the same position used for O-antigen ligation. When O-antigen biosynthesis was restored in the K-12 background and grown under conditions meeting the above specifications, only MLPS was observed, suggesting E. coli can reversibly change its proximal covalently linked cell surface polysaccharide coat from O-antigen to CA in response to certain environmental stimuli. The identification of M-LPS has implications for potential underlying mechanisms coordinating the synthesis of various surface polysaccharides.	Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Leibniz Ctr Med & Biosci, Div Struct Biochem, D-23845 Borstel, Germany; Leibniz Ctr Med & Biosci, Div Immunochem, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Gdansk, Fac Chem, PL-80952 Gdansk, Poland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Forschungszentrum Borstel; Fahrenheit Universities; University of Gdansk	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.	rww@umich.edu	Lindner, Buko/G-9731-2014; Meredith, Timothy/X-2713-2019	Meredith, Timothy/0000-0002-1901-6841; Woodard, Ronald/0000-0002-7472-3653; Kaczynski, Zbigniew/0000-0002-4590-4690	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061531] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI61531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abeyrathne PD, 2005, J BACTERIOL, V187, P3002, DOI 10.1128/JB.187.9.3002-3012.2005; Agladze K, 2005, J BACTERIOL, V187, P8237, DOI 10.1128/JB.187.24.8237-8246.2005; Cescutti P, 1999, CARBOHYD RES, V315, P159, DOI 10.1016/S0008-6215(98)00318-8; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Danese PN, 2000, J BACTERIOL, V182, P3593, DOI 10.1128/JB.182.12.3593-3596.2000; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DISCHE Z, 1948, J BIOL CHEM, V175, P595; El-Kazzaz W, 2004, MOL MICROBIOL, V51, P1117, DOI 10.1046/j.1365-2958.2003.03888.x; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; GAREGG PJ, 1971, ACTA CHEM SCAND, V25, P2103, DOI 10.3891/acta.chem.scand.25-2103; GAREGG PJ, 1980, CARBOHYD RES, V78, P127, DOI 10.1016/S0008-6215(00)83666-6; GOTTESMAN S, 1985, J BACTERIOL, V162, P1111, DOI 10.1128/JB.162.3.1111-1119.1985; GRANT WD, 1969, J BACTERIOL, V100, P1187, DOI 10.1128/JB.100.3.1187-1193.1969; Hagiwara D, 2003, J BACTERIOL, V185, P5735, DOI 10.1128/JB.185.19.5735-5746.2003; Haseley SR, 1997, EUR J BIOCHEM, V247, P815, DOI 10.1111/j.1432-1033.1997.00815.x; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; JANSSON PE, 1993, ACTA CHEM SCAND, V47, P711, DOI 10.3891/acta.chem.scand.47-0711; Kaczynski Z, 2006, CARBOHYD RES, V341, P285, DOI 10.1016/j.carres.2005.10.020; KANG S, 1967, J BACTERIOL, V93, P584, DOI 10.1128/JB.93.2.584-591.1967; Kaniuk NA, 2004, J BIOL CHEM, V279, P36470, DOI 10.1074/jbc.M401366200; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; LAWSON CJ, 1969, BIOCHEM J, V115, P947, DOI 10.1042/bj1150947; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; LINDBERG AA, 1973, ANNU REV MICROBIOL, V27, P205, DOI 10.1146/annurev.mi.27.100173.001225; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; MACLACHLAN PR, 1993, J BACTERIOL, V175, P7515, DOI 10.1128/JB.175.23.7515-7522.1993; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Majdalani N, 2005, J BACTERIOL, V187, P6770, DOI 10.1128/JB.187.19.6770-6778.2005; Mao Y, 2006, LETT APPL MICROBIOL, V42, P642, DOI 10.1111/j.1472-765X.2006.01875.x; Marolda CL, 2004, MICROBIOL-SGM, V150, P4095, DOI 10.1099/mic.0.27456-0; Meredith TC, 2006, BIOCHEM J, V395, P427, DOI 10.1042/BJ20051828; Meredith TC, 2005, J BACTERIOL, V187, P6936, DOI 10.1128/JB.187.20.6936-6942.2005; Meredith TC, 2003, J BIOL CHEM, V278, P32771, DOI 10.1074/jbc.M303661200; Meredith TC, 2006, ACS CHEM BIOL, V1, P33, DOI 10.1021/cb0500015; Muller-Loennies S, 2003, J BIOL CHEM, V278, P34090, DOI 10.1074/jbc.M303985200; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OPHIR T, 1994, APPL ENVIRON MICROB, V60, P740, DOI 10.1128/AEM.60.2.740-745.1994; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PETERS H, 1985, INFECT IMMUN, V50, P459, DOI 10.1128/IAI.50.2.459-466.1985; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rajagopal S, 2002, APPL ENVIRON MICROB, V68, P4117, DOI 10.1128/AEM.68.8.4117-4121.2002; Reid AN, 2005, J BACTERIOL, V187, P5470, DOI 10.1128/JB.187.15.5470-5481.2005; Sailer FC, 2003, FEMS MICROBIOL LETT, V226, P245, DOI 10.1016/S0378-1097(03)00616-5; Sledjeski DD, 1996, J BACTERIOL, V178, P1204, DOI 10.1128/jb.178.4.1204-1206.1996; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; Stout V, 1996, J BACTERIOL, V178, P4273, DOI 10.1128/jb.178.14.4273-4280.1996; SUTHERLAND IW, 1969, BIOCHEM J, V115, P935, DOI 10.1042/bj1150935; Sutherland IW, 2001, MICROBIOL-UK, V147, P3, DOI 10.1099/00221287-147-1-3; Tan L, 2006, MOL MICROBIOL, V61, P861, DOI 10.1111/j.1365-2958.2006.05265.x; Theilacker C, 2006, INFECT IMMUN, V74, P5703, DOI 10.1128/IAI.00570-06; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; Wang X, 2004, J BACTERIOL, V186, P2724, DOI 10.1128/JB.186.9.2724-2734.2004; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Whitfield C, 2003, J ENDOTOXIN RES, V9, P244, DOI 10.1179/096805103225001440; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; Whitfield C, 2006, ANNU REV BIOCHEM, V75, P39, DOI 10.1146/annurev.biochem.75.103004.142545; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x	65	68	70	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7790	7798		10.1074/jbc.M611034200	http://dx.doi.org/10.1074/jbc.M611034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227761	hybrid			2022-12-25	WOS:000245081000007
J	Tyurina, YY; Basova, LV; Konduru, NV; Tyurin, VA; Potapovich, AI; Cai, P; Bayir, H; Stoyanovsky, D; Pitt, BR; Shvedova, AA; Fadeel, B; Kagan, VE				Tyurina, Yulia Y.; Basova, Liana V.; Konduru, Nagarjun V.; Tyurin, Vladimir A.; Potapovich, Ala I.; Cai, Peter; Bayir, Hulya; Stoyanovsky, Detcho; Pitt, Bruce R.; Shvedova, Anna A.; Fadeel, Bengt; Kagan, Valerian E.			Nitrosative stress inhibits the aminophospholipid translocase resulting in phosphatidylserine externalization and macrophage engulfment - Implications for the resolution of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID SCRAMBLASE; RED-BLOOD-CELLS; NITRIC-OXIDE; APOPTOTIC CELLS; S-NITROSYLATION; TRANSBILAYER MOVEMENT; PLASMA-MEMBRANE; PHAGOCYTE RECOGNITION; NEUTROPHIL APOPTOSIS; REACTIVE OXYGEN	Macrophage recognition of apoptotic cells depends on externalization of phosphatidylserine (PS), which is normally maintained within the cytosolic leaflet of the plasma membrane by aminophospholipid translocase (APLT). APLT is sensitive to redox modifications of its -SH groups. Because activated macrophages produce reactive oxygen and nitrogen species, we hypothesized that macrophages can directly participate in apoptotic cell clearance by S-nitrosylation/oxidation and inhibition of APLT causing PS externalization. Here we report that exposure of target HL-60 cells to nitrosative stress inhibited APLT, induced PS externalization, and enhanced recognition and elimination of "nitrosatively" modified cells by RAW 264.7 macrophages. Using S-nitroso-L-cysteine-ethyl ester (SNCEE) and S-nitrosoglutathione (GSNO) that cause intracellular and extracellular trans-nitrosylation of proteins, respectively, we found that SNCEE (but not GSNO) caused significant S-nitrosylation/ oxidation of thiols in HL-60 cells. SNCEE also strongly inhibited APLT, activated scramblase, and caused PS externalization. However, SNCEE did not induce caspase activation or nuclear condensation/fragmentation suggesting that PS externalization was dissociated from the common apoptotic pathway. Dithiothreitol reversed SNCEE-induced S-nitrosylation, APLT inhibition, and PS externalization. SNCEE but not GSNO stimulated phagocytosis of HL-60 cells. Moreover, phagocytosis of target cells by lipopolysaccharide-stimulated macrophages was significantly suppressed by an NO center dot scavenger, DAF-2. Thus, macrophage-induced nitrosylation/oxidation plays an important role in cell clearance, and hence in the resolution of inflammation.	Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15219 USA; NIOSH, Morgantown, WV 26505 USA; Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, S-17177 Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Karolinska Institutet	Kagan, VE (corresponding author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA.	kagan@pitt.edu		Tyurin, Vladimir/0000-0002-3474-1697; Tyurina, Yulia/0000-0003-0287-2091; Stoyanovsky, Detcho/0000-0001-5591-4780; Kagan, Valerian E./0000-0002-7245-1885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070755, P01HL070807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009648] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070807, HL70755] Funding Source: Medline; NIAID NIH HHS [U19 AI068021] Funding Source: Medline; NIEHS NIH HHS [ES09648] Funding Source: Medline; NIOSH CDC HHS [OH008282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS		Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bianco Alberto, 2005, Current Drug Delivery, V2, P253, DOI 10.2174/1567201054367959; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Bottcher A, 2006, ARTHRITIS RHEUM-US, V54, P927, DOI 10.1002/art.21660; Boullerne AI, 2002, J NEUROSCI, V22, P123, DOI 10.1523/JNEUROSCI.22-01-00123.2002; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brown SB, 1999, J IMMUNOL, V162, P480; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Chang QL, 2004, BIOCHEMISTRY-US, V43, P10710, DOI 10.1021/bi049063a; Clancy R, 2001, J MED CHEM, V44, P2035, DOI 10.1021/jm000463f; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1990, BIOCHEMISTRY-US, V29, P37, DOI 10.1021/bi00453a005; Corradi M, 2001, AM J RESP CRIT CARE, V163, P854, DOI 10.1164/ajrccm.163.4.2001108; Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006; Crow J P, 1995, Adv Pharmacol, V34, P17; Cvetanovic M, 2006, J BIOL CHEM, V281, P20055, DOI 10.1074/jbc.M603920200; Daleke DL, 2007, J BIOL CHEM, V282, P821, DOI 10.1074/jbc.R600035200; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; Davies NM, 1997, ALIMENT PHARM THER, V11, P69, DOI 10.1046/j.1365-2036.1997.115286000.x; de Jong K, 2006, BRIT J HAEMATOL, V133, P427, DOI 10.1111/j.1365-2141.2006.06045.x; deJong K, 1997, BIOCHEMISTRY-US, V36, P6768, DOI 10.1021/bi962973a; Demedts IK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-53; Devaux PF, 2006, CHEM PHYS LIPIDS, V141, P119, DOI 10.1016/j.chemphyslip.2006.02.007; Diaz C, 1999, CELL DEATH DIFFER, V6, P218, DOI 10.1038/sj.cdd.4400484; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Fabisiak JP, 2000, BIOCHEMISTRY-US, V39, P127, DOI 10.1021/bi9912544; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadeel B, 2003, CELL MOL LIFE SCI, V60, P2575, DOI 10.1007/s00018-003-3145-1; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fischer K, 2006, BLOOD, V108, P4094, DOI 10.1182/blood-2006-03-011742; FOLCH J, 1957, J BIOL CHEM, V226, P497; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Forsberg AJ, 2004, ANTIOXID REDOX SIGN, V6, P203, DOI 10.1089/152308604322899279; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gaipl US, 2006, CURR DIRECT AUTOIMMU, V9, P173; Gardai SJ, 2006, J LEUKOCYTE BIOL, V79, P896, DOI 10.1189/jlb.1005550; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Golpon HA, 2004, FASEB J, V18, P1716, DOI 10.1096/fj.04-1853fje; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Hanayama R, 2006, CURR DIRECT AUTOIMMU, V9, P162; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Iyer R, 2000, CANCER RES, V60, P1290; Jourd'Heuil D, 2002, FREE RADICAL BIO MED, V33, P676, DOI 10.1016/S0891-5849(02)00955-3; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kahlos K, 2003, MOL CELL BIOCHEM, V254, P47, DOI 10.1023/A:1027380828645; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; KONDURU NV, 2006, 1 INT C NAN BIOM ASP; Lucas M, 2006, J IMMUNOL, V177, P4047, DOI 10.4049/jimmunol.177.6.4047; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Meguro M, 2001, NAT GENET, V28, P19, DOI 10.1038/ng0501-19; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Narayanan PK, 1997, CANCER RES, V57, P3963; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Pritchard MT, 2005, J LEUKOCYTE BIOL, V78, P630, DOI 10.1189/jlb.0404220; Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serinkan BF, 2005, CELL DEATH DIFFER, V12, P1141, DOI 10.1038/sj.cdd.4401619; Shao C, 2003, CANCER RES, V63, P8437; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6; Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135; Torok NJ, 2002, CANCER RES, V62, P1648; Tyurin VA, 2002, METHOD ENZYMOL, V352, P347; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Tyurina YY, 2006, MOL PHARMACOL, V70, P706, DOI 10.1124/mol.106.022731; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; Uthaisang W, 2003, FEBS LETT, V545, P110, DOI 10.1016/S0014-5793(03)00508-8; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Verhoeven AJ, 2006, VOX SANG, V91, P244, DOI 10.1111/j.1423-0410.2006.00822.x; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wallace John L., 2006, Inflammation & Allergy Drug Targets, V5, P133, DOI 10.2174/187152806776383116; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Wolfs JLN, 2005, CELL MOL LIFE SCI, V62, P1514, DOI 10.1007/s00018-005-5099-y; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P831, DOI 10.1016/j.freeradbiomed.2004.12.016; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	99	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8498	8509		10.1074/jbc.M606950200	http://dx.doi.org/10.1074/jbc.M606950200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229723	hybrid			2022-12-25	WOS:000245081000082
J	Kittur, FS; Lalgondar, M; Yu, HY; Bevan, DR; Esen, A				Kittur, Farooqahmed S.; Lalgondar, Mallikarjun; Yu, Hyun Young; Bevan, David R.; Esen, Asim			Maize beta-glucosidase-aggregating factor is a polyspecific jacalin-related chimeric lectin, and its lectin domain is responsible for beta-glucosidase aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; AGLYCONE SPECIFICITY; DISEASE-RESISTANCE; CRYSTAL-STRUCTURES; CALYSTEGIA-SEPIUM; DIRIGENT PROTEIN; PRISM FOLD; AGGLUTININ; REVEALS; COMPLEX	In certain maize genotypes, called "null," beta-glucosidase does not enter gels and therefore cannot be detected on zymograms after electrophoresis. Such genotypes were originally thought to be homozygous for a null allele at the glu1 gene and thus devoid of enzyme. We have shown that a beta-glucosidase-aggregating factor (BGAF) is responsible for the "null" phenotype. BGAF is a chimeric protein consisting of two distinct domains: the disease response or "dirigent" domain and the jacalin-related lectin (JRL) domain. First, it was not known whether the lectin domain in BGAF is functional. Second, it was not known which of the two BGAF domains is involved in beta-glucosidase binding and aggregation. To this end, we purified BGAF to homogeneity from a maize null inbred line called H95. The purified protein gave a single band on SDS-PAGE, and the native protein was a homodimer of 32-kDa monomers. Native and recombinant BGAF (produced in Escherichia coli) agglutinated rabbit erythrocytes, and various carbohydrates and glycoproteins inhibited their hemagglutination activity. Sugars did not have any effect on the binding of BGAF to the beta-glucosidase isozyme 1 (Glu 1), and the BGAF-Glu1 complex could still bind lactosyl-agarose, indicating that the sugar-binding site of BGAF is distinct from the beta-glucosidase-binding site. Neither the dirigent nor the JRL domains alone (produced separately in E. coli) produced aggregates of Glu1 based on results from pull-down assays. However, gel shift and competitive binding assays indicated that the JRL domain binds beta-glucosidase without causing it to aggregate. These results with those from deletion mutagenesis and replacement of the JRL domain of a BGAF homolog from sorghum, which does not bind Glul, with that from maize allowed us to conclude that the JRL domain of BGAF is responsible for its lectin and beta-glucosidase binding and aggregating activities.	Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Esen, A (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA.	aevatan@vt.edu	Kittur, Farooqahmed S/G-3832-2012	Kittur, Farooqahmed/0000-0002-2272-3387; Bevan, David/0000-0001-9974-1105				Astoul CH, 2002, BIOCHEM J, V367, P817, DOI 10.1042/BJ20020856; BAENZIGER JU, 1979, J BIOL CHEM, V254, P789; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; Beyreuther K, 1980, BIOCHEM SOC T, V8, P675, DOI 10.1042/bst0080675; Blanchard DJ, 2001, J BIOL CHEM, V276, P11895, DOI 10.1074/jbc.M008872200; Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; Bourne Y, 2004, J BIOL CHEM, V279, P527, DOI 10.1074/jbc.M308218200; Chisholm ST, 2001, PLANT PHYSIOL, V127, P1667, DOI 10.1104/pp.010479; Cicek M, 1999, BIOTECHNOL BIOENG, V63, P392, DOI 10.1002/(SICI)1097-0290(19990520)63:4&lt;392::AID-BIT2&gt;3.0.CO;2-M; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; CULLEY DE, 1995, PLANT PHYSIOL, V107, P301, DOI 10.1104/pp.107.1.301; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESEN A, 1990, BIOCHEM GENET, V28, P319, DOI 10.1007/BF02401422; Esen A, 2000, PLANT PHYSIOL, V122, P563, DOI 10.1104/pp.122.2.563; ESEN A, 1992, BETA GLUCOSIDASE, P1; Gallego De Sol F, 2005, J MOL BIOL, V353, P574, DOI [10.1016/j.jmb.2005.08.055, DOI 10.1016/J.JMB.2005.08.055]; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; Halls SC, 2002, BIOCHEMISTRY-US, V41, P9455, DOI 10.1021/bi0259709; Hopkins TL, 2001, ARCH INSECT BIOCHEM, V47, P100, DOI 10.1002/arch.1040; HOSEL W, 1978, EUR J BIOCHEM, V84, P487, DOI 10.1111/j.1432-1033.1978.tb12190.x; HUI Y, 1993, J BIOL CHEM, V268, P5905; KAHLER AL, 1986, THEOR APPL GENET, V72, P15, DOI 10.1007/BF00261448; Kittur FS, 2003, FEBS LETT, V549, P147, DOI 10.1016/S0014-5793(03)00803-2; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; KOES RE, 1994, BIOESSAYS, V16, P123, DOI 10.1002/bies.950160209; KOSHTE VL, 1990, BIOCHEM J, V272, P721, DOI 10.1042/bj2720721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont V, 1996, J LEUKOCYTE BIOL, V59, P691, DOI 10.1002/jlb.59.5.691; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; MASSARDO F, 1994, PHYTOCHEMISTRY, V35, P873, DOI 10.1016/S0031-9422(00)90629-0; Meagher JL, 2005, GLYCOBIOLOGY, V15, P1033, DOI 10.1093/glycob/cwi088; Molina J, 2004, BBA-GEN SUBJECTS, V1674, P299, DOI 10.1016/j.bbagen.2004.07.002; Peumans WJ, 2000, FEBS LETT, V477, P186, DOI 10.1016/S0014-5793(00)01801-9; PHILLIPS DA, 1996, PLANT MICROBE INTERA, P236; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; Pratap JV, 2002, J MOL BIOL, V317, P237, DOI 10.1006/jmbi.2001.5432; Rosa JC, 1999, PROTEIN SCI, V8, P13; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; Takahashi N, 1998, ANAL BIOCHEM, V255, P183, DOI 10.1006/abio.1997.2463; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; VanDamme EJM, 1996, FEBS LETT, V397, P352, DOI 10.1016/S0014-5793(96)01211-2; Williams CE, 2002, J CHEM ECOL, V28, P1411, DOI 10.1023/A:1016200619766; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	49	37	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7299	7311		10.1074/jbc.M607417200	http://dx.doi.org/10.1074/jbc.M607417200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210577	hybrid			2022-12-25	WOS:000245080900041
J	Merten, N; Lindner, D; Rabe, N; Rompler, H; Morl, K; Schoneberg, T; Beck-Sickinger, AG				Merten, Nicole; Lindner, Diana; Rabe, Nadine; Roempler, Holger; Moerl, Karin; Schoeneberg, Torsten; Beck-Sickinger, Annette G.			Receptor subtype-specific docking of Asp(6.59) with C-terminal arginine residues in Y receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHOLECYSTOKININ-1 RECEPTOR; PANCREATIC-POLYPEPTIDE RECEPTOR; PROTEIN-COUPLED RECEPTORS; HUMAN NEUROPEPTIDE-Y; PEPTIDE-YY; GUINEA-PIG; BINDING-SITE; Y-1 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR EVOLUTION	Y receptors (YRs) are G protein-coupled receptors whose Y,R, Y2R, and Y5R subtypes preferentially bind neuropeptide Y (NPY) and peptide YY, whereas mammalian Y(4)Rs show a higher affinity for pancreatic polypeptide (PP). Comparison of YR orthologs; and paralogs; revealed Asp(6.59) to be fully conserved throughout all of the YRs reported so far. By replacing this conserved aspartic acid residue with alanine, asparagine, glutamate, and arginine, we now show that this residue plays a crucial role in binding and signal transduction of NPY/PP at all YRs. Sensitivity to distinct replacements is, however, receptor subtype-specific. Next, we performed a complementary mutagenesis approach to identify the contact site of the ligand. Surprisingly, this conserved residue interacts with two different ligand arginine residues by ionic interactions; although in Y2R and Y5R, Arg(33) is the binding partner of Asp(6.59), in Y1R and Y4R Arg(35) of human PP and NPY interacts with Asp(6.59). Furthermore, Arg(25) of PP and NPY is involved in ligand binding only at Y2R and Y5R. This suggests significant differences in the docking of YR ligands between Y1/4R and Y2/5R and provides new insights into the molecular binding mode of peptide agonists at GPCRs. Furthermore, the proposed model of a subtype-specific binding mode is in agreement with the evolution of YRs.	Univ Leipzig, Inst Biochem, Fac Biosci Pharm & Psychol, D-04103 Leipzig, Germany; Univ Leipzig, Fac Med, Inst Biochem Mol Biochem, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Beck-Sickinger, AG (corresponding author), Univ Leipzig, Inst Biochem, Fac Biosci Pharm & Psychol, Bruderstr 34, D-04103 Leipzig, Germany.	beck-sickinger@uni-leipzig.de	Lindner, Diana/AAL-9856-2021; Bernhardt, Nadine/C-1779-2017	Lindner, Diana/0000-0001-5477-769X; Bernhardt, Nadine/0000-0002-3188-8431				Abrahamsson C, 2000, J CARDIOVASC PHARM, V36, P451, DOI 10.1097/00005344-200010000-00006; Archer-Lahlou E, 2005, J BIOL CHEM, V280, P10664, DOI 10.1074/jbc.M409451200; Bader R, 2001, J MOL BIOL, V305, P307, DOI 10.1006/jmbi.2000.4264; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; BECKSICKINGER AG, 1994, EUR J BIOCHEM, V225, P947, DOI 10.1111/j.1432-1033.1994.0947b.x; BECKSICKINGER AG, 1995, BIOPOLYMERS, V37, P123, DOI 10.1002/bip.360370207; Berglund MM, 2001, PEPTIDES, V22, P351, DOI 10.1016/S0196-9781(01)00337-0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Cabrele C, 2002, BIOCHEMISTRY-US, V41, P8043, DOI 10.1021/bi0201421; Cabrele C, 2000, J BIOL CHEM, V275, P36043, DOI 10.1074/jbc.M000626200; Capurro D, 1999, EUR J PHARMACOL, V376, P251, DOI 10.1016/S0014-2999(99)00392-1; Cerda-Reverter JM, 2000, BIOCHEM CELL BIOL, V78, P371, DOI 10.1139/bcb-78-3-371; CLEARY J, 1994, BRAIN RES, V653, P210, DOI 10.1016/0006-8993(94)90391-3; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Dinger MC, 2003, J BIOL CHEM, V278, P10562, DOI 10.1074/jbc.M205747200; Eckard CP, 2000, CURR MED CHEM, V7, P897, DOI 10.2174/0929867003374552; El Bahh B, 2005, EUR J NEUROSCI, V22, P1417, DOI 10.1111/j.1460-9568.2005.04338.x; Eriksson H, 1998, REGUL PEPTIDES, V75-6, P29, DOI 10.1016/S0167-0115(98)00050-0; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Flanagan CA, 2000, BIOCHEMISTRY-US, V39, P8133, DOI 10.1021/bi000085g; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gregor P, 1996, J BIOL CHEM, V271, P27776, DOI 10.1074/jbc.271.44.27776; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Henin J, 2006, BIOPHYS J, V90, P1232, DOI 10.1529/biophysj.105.070599; Hofliger MM, 2003, J RECEPT SIG TRANSD, V23, P351, DOI 10.1081/RRS-120026974; Kane JK, 2000, BIOCHEM BIOPH RES CO, V272, P959, DOI 10.1006/bbrc.2000.2880; Koglin N, 2003, J MED CHEM, V46, P4369, DOI 10.1021/jm0341251; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Larhammar D, 2004, NEUROPEPTIDES, V38, P141, DOI 10.1016/j.npep.2004.06.002; Larhammar D, 2001, PEPTIDES, V22, P295, DOI 10.1016/S0196-9781(01)00331-X; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; Lecklin A, 2002, BRIT J PHARMACOL, V135, P2029, DOI 10.1038/sj.bjp.0704667; Lundell I, 2002, J MOL ENDOCRINOL, V28, P225, DOI 10.1677/jme.0.0280225; Matsumoto M, 1996, J BIOL CHEM, V271, P27217, DOI 10.1074/jbc.271.44.27217; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Monks SA, 1996, J BIOMOL NMR, V8, P379; NAKAJIMA M, 1994, J PHARMACOL EXP THER, V268, P1010; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAU MYC, 1988, PHYSIOL BEHAV, V44, P797, DOI 10.1016/0031-9384(88)90065-0; Porter JE, 2000, J PHARMACOL EXP THER, V292, P440; Rist B, 1996, FEBS LETT, V394, P169, DOI 10.1016/0014-5793(96)00943-X; Robin-Jagerschmidt C, 1998, MOL CELL ENDOCRINOL, V139, P187, DOI 10.1016/S0303-7207(98)00060-4; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; Sautel M, 1996, MOL PHARMACOL, V50, P285; SAUTEL M, 1995, MOL CELL ENDOCRINOL, V112, P215, DOI 10.1016/0303-7207(95)03603-5; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WALKER P, 1994, J BIOL CHEM, V269, P2863; Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435	56	74	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7543	7551		10.1074/jbc.M608902200	http://dx.doi.org/10.1074/jbc.M608902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17204471	hybrid			2022-12-25	WOS:000245080900067
J	Urra, S; Escudero, CA; Ramos, P; Lisbona, F; Allende, E; Covarrubias, P; Parraguez, JI; Zampieri, N; Chao, MV; Annaert, W; Bronfman, FC				Urra, Soledad; Escudero, Claudia A.; Ramos, Patricio; Lisbona, Fernanda; Allende, Edgardo; Covarrubias, Paulina; Parraguez, Jose I.; Zampieri, Niccolo; Chao, Moses V.; Annaert, Wim; Bronfman, Francisca C.			TrkA receptor activation by nerve growth factor induces shedding of the p75 neurotrophin receptor followed by endosomal gamma-secretase-mediated release of the p75 intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; REGULATED INTRAMEMBRANE PROTEOLYSIS; ALPHA-CONVERTING-ENZYME; ALZHEIMERS-DISEASE; NUCLEAR TRANSLOCATION; RETROGRADE TRANSPORT; SYMPATHETIC NEURONS; TERMINAL FRAGMENT; TRANSGENIC MICE; BETA PRODUCTION	Neurotrophins are trophic factors that regulate important neuronal functions. They bind two unrelated receptors, the Trk family of receptor-tyrosine kinases and the p75 neurotrophin receptor (p75). p75 was recently identified as a new substrate for gamma-secretase-mediated intramembrane proteolysis, generating a p75-derived intracellular domain (p75-ICD) with signaling capabilities. Using PC12 cells as a model, we studied how neurotrophins activate p75 processing and where these events occur in the cell. We demonstrate that activation of the TrkA receptor upon binding of nerve growth factor (NGF) regulates the metalloprotease-mediated shedding of p75 leaving a membrane-bound p75 C-terminal fragment (p75-CTF). Using subcellular fractionation to isolate a highly purified endosomal fraction, we demonstrate that p75-CTF ends up in endosomes where gamma-secretase-mediated p75-CTF cleavage occurs, resulting in the release of a p75-ICD. Moreover, we show similar structural requirements for gamma-secretase processing of p75 and amyloid precursor protein-derived CTFs. Thus, NGF-induced endocytosis regulates both signaling and proteolytic processing of p75.	Pontif Univ Catolica, Fac Biol Sci, Dept Physiol, Ctr Cellular Regulat & Pathol Joaquin V Luco, Santiago 8320000, Chile; NYU, Sch Med, Mol Neurobiol Program, Skirball Inst Biomol, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Gasthuisberg Katholieke Univ Leuven VIB, Ctr Human Genet, Lab Membrane Trafficking, B-3000 Louvain, Belgium	Pontificia Universidad Catolica de Chile; New York University; New York University; Flanders Institute for Biotechnology (VIB); KU Leuven	Annaert, W (corresponding author), Pontif Univ Catolica, Fac Biol Sci, Dept Physiol, Ctr Cellular Regulat & Pathol Joaquin V Luco, Alameda 340, Santiago 8320000, Chile.	Willem.Annaert@med.kuleuven.be; fbronfman@bio.puc.cl	Ramos, Patricio/ABE-5961-2021; Ramos, Patricio/B-6665-2017	Ramos, Patricio/0000-0001-8341-314X; Chao, Moses/0000-0002-6969-3744; Urra, Soledad/0000-0003-4432-6582; Zampieri, Niccolo/0000-0002-2228-9453				AHMED Z, 2006, FASEB J; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERG MM, 1992, J BIOL CHEM, V267, P13; Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Bronfman FC, 2004, EMBO REP, V5, P867, DOI 10.1038/sj.embor.7400219; Bronfman FC, 2000, NEUROBIOL DIS, V7, P152, DOI 10.1006/nbdi.2000.0283; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chao MV, 2004, J ALZHEIMERS DIS, V6, pS7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deinhardt K, 2006, NEURON, V52, P293, DOI 10.1016/j.neuron.2006.08.018; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Domeniconi M, 2005, NEURON, V46, P849, DOI 10.1016/j.neuron.2005.05.029; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Frade JM, 2005, J NEUROSCI, V25, P1407, DOI 10.1523/JNEUROSCI.3798-04.2005; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; Georgakopoulos A, 2006, EMBO J, V25, P1242, DOI 10.1038/sj.emboj.7601031; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1996, J NEUROSCI, V16, P7950; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Hibbert AP, 2006, MOL CELL NEUROSCI, V32, P387, DOI 10.1016/j.mcn.2006.06.001; Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kaether C, 2006, TRAFFIC, V7, P408, DOI 10.1111/j.1600-0854.2006.00396.x; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Kenchappa RS, 2006, NEURON, V50, P219, DOI 10.1016/j.neuron.2006.03.011; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lalli G, 2002, J CELL BIOL, V156, P233, DOI 10.1083/jcb.200106142; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Majdan M, 1997, J NEUROSCI, V17, P6988; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Morohashi Y, 2006, J BIOL CHEM, V281, P14670, DOI 10.1074/jbc.M513012200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyborg AC, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-3; Pal A, 2006, J CELL BIOL, V172, P605, DOI 10.1083/jcb.200509091; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pasternak SH, 2004, J ALZHEIMERS DIS, V6, P53; Paul CE, 2004, J NEUROSCI, V24, P1917, DOI 10.1523/JNEUROSCI.5397-03.2004; Podlesniy P, 2006, AM J PATHOL, V169, P119, DOI 10.2353/ajpath.2006.050787; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Salehi A, 2006, NEURON, V51, P29, DOI 10.1016/j.neuron.2006.05.022; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Saxena S, 2004, MOL CELL NEUROSCI, V26, P292, DOI 10.1016/j.mcn.2004.02.006; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Spasic D, 2006, J BIOL CHEM, V281, P26569, DOI 10.1074/jbc.M600592200; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tcherpakov M, 2002, J BIOL CHEM, V277, P49101, DOI 10.1074/jbc.C200533200; Tuszynski MH, 2004, PROG BRAIN RES, V146, P441; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Yano H, 2004, J NEUROBIOL, V58, P244, DOI 10.1002/neu.10321; Yoon SO, 1997, J BIOL CHEM, V272, P23231, DOI 10.1074/jbc.272.37.23231; Zampieri N, 2005, J BIOL CHEM, V280, P14563, DOI 10.1074/jbc.M412957200; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2006, FASEB J, V20, P1176, DOI 10.1096/fj.05-5531fje; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	87	68	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7606	7615		10.1074/jbc.M610458200	http://dx.doi.org/10.1074/jbc.M610458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215246	hybrid, Green Published			2022-12-25	WOS:000245080900073
J	Adams, KW; Cooper, GM				Adams, Kenneth W.; Cooper, Geoffrey M.			Rapid turnover of Mcl-1 couples translation to cell survival and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3; MEDIATED MITOCHONDRIAL APOPTOSIS; CYCLOHEXIMIDE-INDUCED APOPTOSIS; INITIATION-FACTOR 2B; HUMAN MYELOMA CELLS; BCL-2 FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION SITES; SIGNALING PATHWAYS	Inhibition of translation plays a role in apoptosis induced by a variety of stimuli, but the mechanism by which it promotes apoptosis has not been established. We have investigated the hypothesis that selective degradation of anti-apoptotic regulatory protein(s) is responsible for apoptosis resulting from translation inhibition. Induction of apoptosis by cycloheximide was detected within 2-4 hand blocked by proteasome inhibitors, indicating that degradation of shortlived protein(s) was required. Caspase inhibition and overexpression of Bcl-x(L) blocked cycloheximide-induced apoptosis. In addition, cycloheximide induced rapid activation of Bak and Bax, which required proteasome activity. Mcl-1 was degraded by the proteasome with a half-life of similar to 30 min following inhibition of protein synthesis, preceding Bak/Bax activation and the onset of apoptosis. Overexpression of Mcl-1 blocked apoptosis induced by cycloheximide, whereas RNA interference knockdown of Mcl-1 induced apoptosis. Knockdown of Bim and Bak, downstream targets of Mcl-1, inhibited cycloheximide-induced apoptosis, as did knockdown of Bax. Apoptosis resulting from inhibition of translation thus involves the rapid degradation of Mcl-1, leading to activation of Bim, Bak, and Bax. Because of its rapid turnover, Mcl-1 may serve as a convergence point for signals that affect global translation, coupling translation to cell survival and the apoptotic machinery.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Cooper, GM (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gmcooper@bu.edu			NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689, R01 CA018689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Alessenko AV, 1997, FEBS LETT, V416, P113, DOI 10.1016/S0014-5793(97)01161-7; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Blom WM, 1999, BIOCHEM PHARMACOL, V58, P1891, DOI 10.1016/S0006-2952(99)00268-3; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pavitt GD, 2005, BIOCHEM SOC T, V33, P1487, DOI 10.1042/BST0331487; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Wei MC, 2000, GENE DEV, V14, P2060; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; YANG L, 1995, AUDIT NEUROSCI, V1, P1; Yao R, 1996, ONCOGENE, V13, P343; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	69	126	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6192	6200		10.1074/jbc.M610643200	http://dx.doi.org/10.1074/jbc.M610643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200126	Green Accepted, hybrid			2022-12-25	WOS:000244867200025
J	Rellos, P; Ivins, FJ; Baxter, JE; Pike, A; Nott, TJ; Parkinson, DM; Das, S; Howell, S; Fedorov, O; Shen, QY; Fry, AM; Knapp, S; Smerdon, SJ				Rellos, Peter; Ivins, Frank J.; Baxter, Joanne E.; Pike, Ashley; Nott, Timothy J.; Parkinson, Donna-Marie; Das, Sanjan; Howell, Steven; Fedorov, Oleg; Shen, Qi Yu; Fry, Andrew M.; Knapp, Stefan; Smerdon, Stephen J.			Structure and regulation of the human Nek2 centrosomal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIMA-RELATED KINASE; CELL-CYCLE REGULATION; PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; TYROSINE KINASE; PHOSPHORYLATION; EXPRESSION; INHIBITION; DEPENDS; MITOSIS	The dimeric Ser/Thr kinase Nek2 regulates centrosome cohesion and separation through phosphorylation of structural components of the centrosome, and aberrant regulation of Nek2 activity can lead to aneuploid defects characteristic of cancer cells. Mutational analysis of autophosphorylation sites within the kinase domain identified by mass spectrometry shows a complex pattern of positive and negative regulatory effects on kinase activity that are correlated with effects on centrosomal splitting efficiency in vivo. The 2.2-angstrom resolution x-ray structure of the Nek2 kinase domain in complex with a pyrrole-indolinone inhibitor reveals an inhibitory helical motif within the activation loop. This helix presents a steric barrier to formation of the active enzyme and generates a surface that may be exploitable in the design of specific inhibitors that selectively target the inactive state. Comparison of this "auto-inhibitory" conformation with similar arrangements in cyclin-dependent kinase 2 and epidermal growth factor receptor kinase suggests a role for dimerization-dependent allosteric regulation that combines with autophosphorylation and protein phosphatase 1c phosphatase activity to generate the precise spatial and temporal control required for Nek2 function in centrosomal maturation.	Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England; Natl Inst Med Res, Med Res Council, Div Mol Struct, London NW7 1AA, England	University of Leicester; University of Oxford; MRC National Institute for Medical Research; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England.	amf5@leicester.ac.uk; Stefan.Knapp@sgc.ox.ac.uk; stephen.smerdon@nimr.mrc.ac.uk	Knapp, Stefan/AAG-2347-2019; Fedorov, Oleg Y./B-6412-2014	Knapp, Stefan/0000-0001-5995-6494; Fedorov, Oleg Y./0000-0001-9004-1815; Smerdon, Stephen/0000-0001-5688-8465; Nott, Timothy/0000-0002-5210-4931	MRC [MC_U117584228] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C000013/1] Funding Source: Medline; Medical Research Council [MC_U117584228] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bahe S, 2005, J CELL BIOL, V171, P27, DOI 10.1083/jcb.200504107; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; de Vos S, 2003, LAB INVEST, V83, P271, DOI 10.1097/01.LAB.0000053913.85892.E9; Di Agostino S, 2004, MOL BIOL CELL, V15, P1224, DOI 10.1091/mbc.E03-09-0638; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fletcher L, 2005, BBA-MOL CELL RES, V1744, P89, DOI 10.1016/j.bbamcr.2005.01.007; Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Graf R, 2002, J CELL SCI, V115, P1919; Grallert A, 2004, GENE DEV, V18, P1007, DOI 10.1101/gad.296204; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Heryanto B, 2003, REPRODUCTION, V125, P337, DOI 10.1530/reprod/125.3.337; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Liao AT, 2002, BLOOD, V100, P585, DOI 10.1182/blood-2001-12-0350; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; LU KP, 1994, J BIOL CHEM, V269, P6603; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; Mayor T, 2002, J CELL SCI, V115, P3275; Meraldi P, 2001, J CELL SCI, V114, P3749; MORRIS NR, 1989, BIOESSAYS, V10, P196; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; Prigent C, 2005, EXP CELL RES, V303, P1, DOI 10.1016/j.yexcr.2004.04.052; Quarmby LM, 2005, J CELL SCI, V118, P5161, DOI 10.1242/jcs.02681; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Roig J, 2005, MOL BIOL CELL, V16, P4827, DOI 10.1091/mbc.E05-04-0315; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sun L, 2003, J MED CHEM, V46, P1116, DOI 10.1021/jm0204183; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Wai DH, 2002, INT J ONCOL, V20, P441; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Zhang W, 2005, J BIOL CHEM, V280, P42994, DOI 10.1074/jbc.M505450200; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	53	80	98	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6833	6842		10.1074/jbc.M609721200	http://dx.doi.org/10.1074/jbc.M609721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197699	Green Published, hybrid			2022-12-25	WOS:000244867200093
J	Wilson, EM; Rotwein, P				Wilson, Elizabeth M.; Rotwein, Peter			Selective control of skeletal muscle differentiation by Akt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOXO TRANSCRIPTION FACTORS; GROWTH-FACTOR-II; KINASE-B; PROTEIN-KINASE; SIGNALING PATHWAYS; MYOCYTE MATURATION; MAMMALIAN TARGET; CELL-SURVIVAL; MICE LACKING; ATROPHY	The phosphatidylinositol 3-kinase-Akt pathway plays a central role in growth, development, and metabolism in both normal and neoplastic cells. In skeletal muscle, Akt has been implicated in regulating regeneration and hypertrophy and in counteracting atrophy. Here we provide evidence that Akt1 and not Akt2 is essential for muscle differentiation. Using a robust model of MyoD-mediated muscle development, in which dominant-negative Akt blocked differentiation, we show that targeted loss of Akt1 was equally inhibitory. Selective elimination of Akt1 had no effect on myoblast viability or proliferation but prevented differentiation by impairing the transcriptional actions of Myol). In contrast, knockdown of Akt2 had no effect on myoblast survival or differentiation and minimally inhibited MyoD-regulated transcription. Our results define isoform-specific Akt-regulated signaling pathways in muscle cells that act through Akt1 to sustain muscle gene activation and promote differentiation.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Rd,Mail Code L224, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [R01 DK042748, R01 DK42748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Hoffman EP, 2004, NAT MED, V10, P584, DOI 10.1038/nm0604-584; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kuninger D, 2004, HUM GENE THER, V15, P1287, DOI 10.1089/hum.2004.15.1287; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Miller BS, 2005, CANCER RES, V65, P10123, DOI 10.1158/0008-5472.CAN-05-2752; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Park IH, 2005, J BIOL CHEM, V280, P32009, DOI 10.1074/jbc.M506120200; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wilson EM, 2006, J BIOL CHEM, V281, P29962, DOI 10.1074/jbc.M605445200; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wilson EM, 2003, J BIOL CHEM, V278, P41109, DOI 10.1074/jbc.C300299200; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	37	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5106	5110		10.1074/jbc.C600315200	http://dx.doi.org/10.1074/jbc.C600315200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17218321	hybrid			2022-12-25	WOS:000244482300003
J	Levin, MH; de la Fuente, R; Verkman, AS				Levin, Marc H.; de la Fuente, Ricardo; Verkman, A. S.			Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B	FASEB JOURNAL			English	Article						urea transport; UT-B; kidney; diuretic; drug discovery; small-molecule discovery; aquaporin	URINARY CONCENTRATING ABILITY; MICE LACKING AQUAPORIN-1; WATER CHANNEL; KNOCKOUT MICE; ERYTHROCYTES; HYPONATREMIA; PROTEIN; DEFECT	Functional studies in knockout mice indicate a critical role for urea transporters (UTs) in the urinary concentrating mechanism and in renal urea clearance. However, potent and specific urea transport blockers have not been available. Here, we used high-throughput screening to discover high-affinity, small molecule inhibitors of the UT-B urea transporter. A collection of 50,000 diverse, drug like compounds was screened using a human erythrocyte lysis assay based on UT-B-facilitated acetamide transport. Primary screening yielded similar to 30 UT-B inhibitors belonging to the phenylsulfoxyoxazole, benzenesulfonanilide, phthalazinamine, and aminobenzimidazole chemical classes. Screening of similar to 700 structurally similar analogs gave many active compounds, the most potent of which inhibited UT-B urea transport with an EC50 of similar to 10 nM, and similar to 100% inhibition at higher concentrations. Phenyl-sulfoxyoxazoles and phthalazinamines also blocked rodent UT-B and had good UT-B vs. UT-A specificity. The UT-B inhibitors did not reduce aquaporin-1 (AQP1)-facilitated water transport. In AQP1-null erythrocytes, "chemical UT-B knockout" by UT-B inhibitors reduced by similar to 3-fold UT-B-mediated water transport, supporting an aqueous pore pathway through UT-B. UT-B inhibitors represent a new class of diuretics, "urearetics," which are predicted to increase renal water and solute clearance in water-retaining states.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Grad Grp Biophys, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574, P30EY002162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; BANKIR L, 2000, KIDNEY; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Fenton RA, 2005, J AM SOC NEPHROL, V16, P1583, DOI 10.1681/ASN.2005010031; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; FROEHLICH O, 2006, AM J PHYSIOL, V291, pC600; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; Goldsmith SR, 2005, AM J CARDIOL, V95, p14B, DOI 10.1016/j.amjcard.2005.03.004; Klein JD, 2004, J AM SOC NEPHROL, V15, P1161, DOI 10.1097/01.ASN.0000125617.19799.72; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; MARTIAL S, 1993, PFLUG ARCH EUR J PHY, V423, P51, DOI 10.1007/BF00374960; MASILAMANI S, 2000, KIDNEY; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; Mazeron P, 2000, PHOTOCHEM PHOTOBIOL, V72, P172, DOI 10.1562/0031-8655(2000)072<0172:ATAOTM>2.0.CO;2; Miller M, 2006, J AM GERIATR SOC, V54, P345, DOI 10.1111/j.1532-5415.2005.00609.x; OLDENBURG KR, 2001, HDB DRUG SCREENING; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Shayakul C, 2004, PFLUG ARCH EUR J PHY, V447, P603, DOI 10.1007/s00424-003-1124-x; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 2002, J BIOL CHEM, V277, P36782, DOI 10.1074/jbc.M206948200	26	51	57	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					551	563		10.1096/fj.06-6979com	http://dx.doi.org/10.1096/fj.06-6979com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202246				2022-12-25	WOS:000244686300028
J	Finn, RN; Kristoffersen, BA				Finn, Roderick Nigel; Kristoffersen, Borge A.			Vertebrate Vitellogenin Gene Duplication in Relation to the "3R Hypothesis": Correlation to the Pelagic Egg and the Oceanic Radiation of Teleosts	PLOS ONE			English	Article							WHOLE-GENOME DUPLICATION; FREE AMINO-ACIDS; YOLK-SAC LARVAE; DEDUCED PRIMARY-STRUCTURE; OOCYTE MATURATION; 2 FORMS; BARFIN FLOUNDER; MARINE TELEOST; HOX CLUSTERS; MULTIPLE VITELLOGENINS	The spiny ray-finned teleost fishes (Acanthomorpha) are the most successful group of vertebrates in terms of species diversity. Their meteoric radiation and speciation in the oceans during the late Cretaceous and Eocene epoch is unprecedented in vertebrate history, occurring in one third of the time for similar diversity to appear in the birds and mammals. The success of marine teleosts is even more remarkable considering their long freshwater ancestry, since it implies solving major physiological challenges when freely broadcasting their eggs in the hyper-osmotic conditions of seawater. Most extant marine teleosts spawn highly hydrated pelagic eggs, due to differential proteolysis of vitellogenin (Vtg)-derived yolk proteins. The maturational degradation of Vtg involves depolymerization of mainly the lipovitellin heavy chain (LvH) of one form of Vtg to generate a large pool of free amino acids (FAA 150-200 m M). This organic osmolyte pool drives hydration of the ooctye while still protected within the maternal ovary. In the present contribution, we have used Bayesian analysis to examine the evolution of vertebrate Vtg genes in relation to the "3R hypothesis'' of whole genome duplication (WGD) and the functional end points of LvH degradation during oocyte maturation. We find that teleost Vtgs have experienced a post-R3 lineage-specific gene duplication to form paralogous clusters that correlate to the pelagic and benthic character of the eggs. Neo-functionalization allowed one paralogue to be proteolyzed to FAA driving hydration of the maturing oocytes, which pre-adapts them to the marine environment and causes them to float. The timing of these events matches the appearance of the Acanthomorpha in the fossil record. We discuss the significance of these adaptations in relation to ancestral physiological features, and propose that the neo-functionalization of duplicated Vtg genes was a key event in the evolution and success of the teleosts in the oceanic environment.	[Finn, Roderick Nigel; Kristoffersen, Borge A.] Univ Bergen, Dept Biol, Bergen, Norway	University of Bergen	Finn, RN (corresponding author), Univ Bergen, Dept Biol, Bergen, Norway.	nigel.finn@bio.uib.no	Finn, Roderick Nigel/Y-2916-2019	Finn, Roderick Nigel/0000-0002-8776-3945				Abi-Rached L, 2002, NAT GENET, V31, P100, DOI 10.1038/ng855; Allendorf F.W., 1984, P1; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Amores A, 2004, GENOME RES, V14, P1, DOI 10.1101/gr.1717804; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; [Anonymous], 1966, VERTEBRATE PALEONTOL; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Buisine N, 2002, MOL GENET GENOMICS, V268, P535, DOI 10.1007/s00438-002-0771-5; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Carnevali O, 2006, GEN COMP ENDOCR, V146, P195, DOI 10.1016/j.ygcen.2005.12.007; Carnevali O, 1999, BIOL REPROD, V60, P140, DOI 10.1095/biolreprod60.1.140; Chen JS, 1997, J MOL EVOL, V44, P440, DOI 10.1007/PL00006164; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; CRAIK JCA, 1987, J MAR BIOL ASSOC UK, V67, P169, DOI 10.1017/S0025315400026436; Crow KD, 2006, MOL BIOL EVOL, V23, P121, DOI 10.1093/molbev/msj020; de Pinna Mario C.C., 1996, P147; Dehal P, 2005, PLOS BIOL, V3, P1700, DOI 10.1371/journal.pbio.0030314; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; Donoghue PCJ, 2005, TRENDS ECOL EVOL, V20, P312, DOI 10.1016/j.tree.2005.04.008; Dosch R, 2004, DEV CELL, V6, P771, DOI 10.1016/j.devcel.2004.05.002; Evans David H., 2004, P247; Evans David H., 1993, P315; Fabra M, 2005, SCIENCE, V307, P545, DOI 10.1126/science.1106305; Fabra M, 2004, MOL REPROD DEV, V67, P282, DOI 10.1002/mrd.20018; Fabra M, 2006, DEV BIOL, V295, P250, DOI 10.1016/j.ydbio.2006.03.034; Ferrier DE, 2005, CURR BIOL, V15, pR820, DOI 10.1016/j.cub.2005.10.014; Ferrier DEK, 2001, NAT REV GENET, V2, P33, DOI 10.1038/35047605; Fink SV, 1996, INTERRELATIONSHIPS F, P251; Finn RN, 1996, COMP BIOCHEM PHYS A, V115, P133, DOI 10.1016/0300-9629(96)00026-6; Finn RN, 1995, MAR BIOL, V124, P355, DOI 10.1007/BF00363909; Finn RN, 2002, MAR ECOL PROG SER, V237, P217, DOI 10.3354/meps237217; Finn RN, 2002, J EXP BIOL, V205, P211; Force A, 2002, J EXP ZOOL, V294, P30, DOI 10.1002/jez.10091; Fujiwara Y, 2005, GEN COMP ENDOCR, V143, P267, DOI 10.1016/j.ygcen.2005.03.014; Fulton T.W., 1898, 16 FISH BOARD SCOT 3, P83; Furlong RF, 2004, BIOL J LINN SOC, V82, P425, DOI 10.1111/j.1095-8312.2004.00329.x; Furlong RF, 2002, PHILOS T R SOC B, V357, P531, DOI 10.1098/rstb.2001.1035; Gardiner BG, 2005, ZOOL J LINN SOC-LOND, V144, P511, DOI 10.1111/j.1096-3642.2005.00181.x; GERBERHUBER S, 1987, NUCLEIC ACIDS RES, V15, P4737, DOI 10.1093/nar/15.12.4737; Glenner H, 2004, CURR BIOL, V14, P1644, DOI 10.1016/j.cub.2004.09.027; Gray J, 1932, J EXP BIOL, V9, P277; GREELEY MS, 1991, COMP BIOCHEM PHYS A, V100, P639, DOI 10.1016/0300-9629(91)90383-N; GRIFFITH RW, 1987, COMP BIOCHEM PHYS A, V87, P523, DOI 10.1016/0300-9629(87)90355-0; Haldane J. B. S., 1932, CAUSES EVOLUTION; Hayakawa H, 2006, BIOCHEM BIOPH RES CO, V344, P173, DOI 10.1016/j.bbrc.2006.03.116; Hiramatsu N, 2005, BIOCH MOLEC, V6, P431; Hiramatsu N, 2002, FISHERIES SCI, V68, P694, DOI 10.2331/fishsci.68.sup1_694; Hochachka P. W., 2002, BIOCH ADAPTATION MEC, DOI 10.1002/bmb.2002.494030030071; Hoegg S, 2004, J MOL EVOL, V59, P190, DOI 10.1007/s00239-004-2613-z; Holder M, 2003, NAT REV GENET, V4, P275, DOI 10.1038/nrg1044; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; Hughes AL, 1999, J MOL EVOL, V48, P565, DOI 10.1007/PL00006499; Hurley I, 2005, EVOL DEV, V7, P556, DOI 10.1111/j.1525-142X.2005.05059.x; Inoue JG, 2005, GENE, V349, P227, DOI 10.1016/j.gene.2005.01.008; Inoue JG, 2004, MOL PHYLOGENET EVOL, V32, P274, DOI 10.1016/j.ympev.2003.11.009; Inoue JG, 2003, MOL PHYLOGENET EVOL, V26, P110, DOI 10.1016/S1055-7903(02)00331-7; Irvine SQ, 2002, J EXP ZOOL, V294, P47, DOI 10.1002/jez.10090; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; JORGENSEN NC, 1984, CELL TISSUE RES, V235, P643; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Keller G, 2001, PLANET SPACE SCI, V49, P817, DOI 10.1016/S0032-0633(01)00032-0; Kendall A.W. Jr, 1984, American Society of Ichthyologists and Herpetologists Special Publication, P11; KORMANIK GA, 1993, ENVIRON BIOL FISH, V38, P233, DOI 10.1007/BF00842919; Krogh A, 1937, J EXP BIOL, V14, P35; Kumazawa Y, 2000, MOL BIOL EVOL, V17, P1869, DOI 10.1093/oxfordjournals.molbev.a026288; Kumazawa Y, 1999, BIOL BIODIVERSITY, P35; LAFLEUR GJ, 1991, J EXP ZOOL, V258, P126, DOI 10.1002/jez.1402580114; LAFLEUR GJ, 1995, J MOL EVOL, V41, P505, DOI 10.1007/BF00160323; LaFleur GJ, 2005, BIOL REPROD, V73, P815, DOI 10.1095/biolreprod.105.041335; Liberles DA, 2001, MOL BIOL EVOL, V18, P2040, DOI 10.1093/oxfordjournals.molbev.a003745; LOEFFLER CA, 1970, J EXP BIOL, V52, P291; LONG JA, 1995, RISE FISHES 500 MILL; Lynch M, 2001, GENETICS, V159, P1789; Marshall William S., 2006, P177; Matsubara T, 2003, FISH PHYSIOL BIOCHEM, V28, P295, DOI 10.1023/B:FISH.0000030559.71954.37; Matsubara T, 1997, J EXP ZOOL, V278, P189, DOI 10.1002/(SICI)1097-010X(19970615)278:3<189::AID-JEZ8>3.0.CO;2-K; Matsubara T, 1999, DEV BIOL, V213, P18, DOI 10.1006/dbio.1999.9365; McInerney JO, 2006, TRENDS ECOL EVOL, V21, P230, DOI 10.1016/j.tree.2006.03.008; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Meyer A, 1999, CURR BIOL, V9, pR210, DOI 10.1016/S0960-9822(99)80131-6; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Mikawa N, 2006, COMP BIOCHEM PHYS B, V143, P404, DOI 10.1016/j.cbpb.2005.12.013; Milroy T. H., 1898, 16th Rep Fish Board Scotland, P135; Miracle A, 2006, ECOTOX ENVIRON SAFE, V63, P337, DOI 10.1016/j.ecoenv.2005.12.002; Mossel E, 2005, SCIENCE, V309, P2207, DOI 10.1126/science.1115493; Mulley J, 2004, NATURE, V431, P916, DOI 10.1038/431916a; Needham J, 1930, J EXP BIOL, V7, P7; Nelson JS, 1984, FISHES WORLD; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; O'Sullivan O, 2004, J MOL BIOL, V340, P385, DOI 10.1016/j.jmb.2004.04.058; Ohkubo N, 2004, GEN COMP ENDOCR, V137, P19, DOI 10.1016/j.ygcen.2004.02.019; Ohkubo N, 2002, MAR BIOL, V140, P187, DOI 10.1007/s002270100647; Ohkubo N, 2003, GEN COMP ENDOCR, V131, P353, DOI 10.1016/S0016-6480(03)00035-2; Ohkubo N, 2006, FISHERIES SCI, V72, P620, DOI 10.1111/j.1444-2906.2006.01192.x; Ohno S, 1999, CELL MOL LIFE SCI, V55, P824, DOI 10.1007/s000180050336; Ohno S., 1970, EVOLUTION GENE DUPLI; OKUMURA H, 1995, FISHERIES SCI, V61, P529, DOI 10.2331/fishsci.61.529; PEREZ LE, 1991, COMP BIOCHEM PHYS B, V100, P821, DOI 10.1016/0305-0491(91)90297-Q; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; POTTS WTW, 1969, J EXP BIOL, V50, P223; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Raldua D, 2006, AM J PHYSIOL-REG I, V290, pR456, DOI 10.1152/ajpregu.00528.2005; Reith M, 2001, J EXP ZOOL, V291, P58, DOI 10.1002/jez.5; Robinson-Rechavi M, 2001, CURR BIOL, V11, pR458, DOI 10.1016/S0960-9822(01)00280-9; Romano M, 2004, MOL REPROD DEV, V69, P109, DOI 10.1002/mrd.20146; RONNESTAD I, 1992, MAR ECOL PROG SER, V88, P195, DOI 10.3354/meps088195; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Saitoh K, 2003, J MOL EVOL, V56, P464, DOI 10.1007/s00239-002-2417-y; Sawaguchi S, 2006, MOL REPROD DEV, V73, P719, DOI 10.1002/mrd.20446; Sawaguchi S, 2005, BIOL REPROD, V72, P1045, DOI 10.1095/biolreprod.104.037895; SCHMIDTKE J, 1977, NATURE, V266, P532, DOI 10.1038/266532a0; Selman K, 2001, J EXP ZOOL, V290, P265, DOI 10.1002/jez.1057; Seoka M, 2003, AQUACULTURE, V216, P355, DOI 10.1016/S0044-8486(02)00459-3; Siltberg J, 2002, J EVOLUTION BIOL, V15, P588, DOI 10.1046/j.1420-9101.2002.00416.x; SILVA R, 1989, MOL CELL BIOL, V9, P3557, DOI 10.1128/MCB.9.8.3557; Skibinski DOF, 2004, MOL BIOL EVOL, V21, P1753, DOI 10.1093/molbev/msh193; Skrabanek L, 1998, CURR OPIN GENET DEV, V8, P694, DOI 10.1016/S0959-437X(98)80039-7; Smith HW, 1953, FISH PHILOS STORY OU; Steele SL, 2004, J EXP BIOL, V207, P2021, DOI 10.1242/jeb.00959; Steinke D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-20; Steinke D, 2006, J MOL EVOL, V62, P772, DOI 10.1007/s00239-005-0170-8; STEINMANN G, 1906, BER NATF GES FREIBUR, V16, P1; Swafford D. L., 2002, PAUP PHYLOGENETIC AN; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tauber E, 2004, J BIOL RHYTHM, V19, P445, DOI 10.1177/0748730404268775; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; Thorsen A, 1996, J FISH BIOL, V48, P1195; Thorsen Anders, 1993, P94; Tingaud-Sequeira A, 2007, GENE, V386, P98, DOI 10.1016/j.gene.2006.08.018; Van de Peer Yves, 2003, Journal of Structural and Functional Genomics, V3, P65, DOI 10.1023/A:1022652814749; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Venkatesh B, 2003, CURR OPIN GENET DEV, V13, P588, DOI 10.1016/j.gde.2003.09.001; von Schantz M, 2006, J MOL EVOL, V62, P701, DOI 10.1007/s00239-005-0185-1; WALLACE RA, 1992, J COMP PHYSIOL B, V162, P241, DOI 10.1007/BF00357530; Wang H, 2000, GENE, V256, P303, DOI 10.1016/S0378-1119(00)00376-0; Wang H, 2005, GENE, V356, P91, DOI 10.1016/j.gene.2005.03.041; WATANABE WO, 1986, J FISH BIOL, V28, P425, DOI 10.1111/j.1095-8649.1986.tb05180.x; Wilkie MP, 2002, J EXP ZOOL, V293, P284, DOI 10.1002/jez.10123; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009; Woltering JM, 2006, NAT GENET, V38, P601, DOI 10.1038/ng0606-601; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Wright P.A., 2001, Fish Physiology, V20, P149; Yoshitome S, 2003, DEV GROWTH DIFFER, V45, P283; Zmasek CM, 2001, BIOINFORMATICS, V17, P383, DOI 10.1093/bioinformatics/17.4.383; Zmasek CM, 2001, BIOINFORMATICS, V17, P821, DOI 10.1093/bioinformatics/17.9.821; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	158	165	172	4	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e169	10.1371/journal.pone.0000169	http://dx.doi.org/10.1371/journal.pone.0000169			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245445	Green Published, gold, Green Submitted, Green Accepted			2022-12-25	WOS:000207444100006
J	Krystkowiak, P; Gaura, V; Labalette, M; Rialland, A; Remy, P; Peschanski, M; Bachoud-Levi, AC				Krystkowiak, Pierre; Gaura, Veronique; Labalette, Myriam; Rialland, Amandine; Remy, Philippe; Peschanski, Marc; Bachoud-Levi, Anne-Catherine			Alloimmunisation to Donor Antigens and Immune Rejection Following Foetal Neural Grafts to the Brain in Patients with Huntington's Disease	PLOS ONE			English	Article								Background. The brain is deemed "immunologically privileged'' due to sparse professional antigen-presenting cells and lymphatic drainage, and to the blood-brain barrier. Although the actual extent of this privilege is controversial, there is general consensus about the limited need in intracerebral neural grafts for immunosuppressive regimens comparable to those used in other cases of allotransplantation. This has led over the past fifteen years to the use of either short-term or even no immunosuppression in most clinical trials with foetal neural transplant in patients with Parkinson's and Huntington's disease. Methodology/Principal Findings. We report biological demonstration of alloimmunisation without signs of rejection in four grafted patients out of 13 studied during the course of a clinical trial involving fetal neural transplantation in patients with Huntington's Disease. Biological, radiological and clinical demonstration of an ongoing rejection process was observed in a fifth transplanted patient. The rejection process was, however, fully reversible under immunosuppressive treatment and graft activity recovered within six months. Conclusions/Significance. There had been, up to date, no report of documented cases that could have cast a doubt on those procedures. Our results underline the need for a reconsideration of the extent of the so-called immune privilege of the brain and of the follow-up protocols of patients with intracerebral grafts. It also suggests that some of the results obtained in past studies with foetal neural transplants may have been biased by an unrecognized immune response to donor cells.	[Krystkowiak, Pierre] Ctr Hosp Reg & Univ Lille, Hosp R Salengro, Equipe Associee 2683, Dept Neurol & Movement Disorders, F-59037 Lille, France; [Gaura, Veronique; Remy, Philippe] CEA, Serv Hosp Frederic Joliot, CNRS, Unite Rech Associee 2210, F-91406 Orsay, France; [Labalette, Myriam] Fac Med Lille, Serv Immunol, F-59045 Lille, France; [Rialland, Amandine; Remy, Philippe; Bachoud-Levi, Anne-Catherine] CHU Henri Mondor, AP HP, Serv Neurol, F-94010 Creteil, France; [Rialland, Amandine; Remy, Philippe; Bachoud-Levi, Anne-Catherine] CHU Henri Mondor, Fac Med Paris 12, F-94010 Creteil, France; [Peschanski, Marc; Bachoud-Levi, Anne-Catherine] Hop Henri Mondor, INSERM, Fac Med Creteil, U421, F-94010 Creteil, France	Universite de Lille - ISITE; CHU Lille; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Peschanski, M (corresponding author), Inst Stem Cell Therapy & Explorat Monogen Dis I S, Evry, France.	mpeschanski@istem.genethon.fr	Peschanski, Marc/N-5769-2017; Bachoud-Lévi, Anne-Catherine/GYU-8680-2022; LABALETTE, Myriam/M-4203-2018	Bachoud-Lévi, Anne-Catherine/0000-0003-3000-2210; LABALETTE, Myriam/0000-0002-1524-9891; Remy, Philippe/0000-0003-2150-2563	Assistance-Publique/Hopitaux de Paris [NCT00190450]; Association Francaise contre les Myopathies; INSERM	Assistance-Publique/Hopitaux de Paris; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	These results have been obtained as an ancillary study to the MIG-HD clinical trial (Multicentric Intracerebral Grafting in Huntington's Disease, NCT00190450) sponsored by Assistance-Publique/Hopitaux de Paris, with additional support from Association Francaise contre les Myopathies and INSERM. The study sponsors have had no role either in study design, collection, analysis and interpretation of data, writing of the paper nor in decision to submit.	Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; DEFER GL, 1994, BRAIN, V119, P41; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; Hourmant M, 2005, J AM SOC NEPHROL, V16, P2804, DOI 10.1681/ASN.2004121130; Lee PC, 2002, TRANSPLANTATION, V74, P1192, DOI 10.1097/00007890-200210270-00025; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; McKenna RM, 2000, TRANSPLANTATION, V69, P319, DOI 10.1097/00007890-200002150-00001; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; Wood MJA, 1996, TRENDS NEUROSCI, V19, P497, DOI 10.1016/S0166-2236(96)10060-6	14	97	102	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e166	10.1371/journal.pone.0000166	http://dx.doi.org/10.1371/journal.pone.0000166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245442	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444100003
J	Williams, KT; Young, SP; Negus, A; Young, LS; Adams, DH; Afford, SC				Williams, Kevin T.; Young, Steven P.; Negus, Alison; Young, Lawrence S.; Adams, David H.; Afford, Simon C.			C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell Survival	PLOS ONE			English	Article								Activation of CD40 on hepatocytes and cholangiocytes is critical for amplifying Fas-mediated apoptosis in the human liver. C4b-Binding Protein (C4BP) has been reported to act as a potential surrogate ligand for CD40, suggesting that it could be involved in modulating liver epithelial cell survival. Using surface plasmon resonance (BiaCore) analysis supported by gel filtration we have shown that C4BP does not bind CD40, but it forms stable high molecular weight complexes with soluble CD40 ligand (sCD154). These C4BP/sCD154 complexes bound efficiently to immobilised CD40, but when applied to cholangiocytes they failed to induce apoptosis or proliferation or to activate NFkB, AP-1 or STAT 3, which are activated by sCD154 alone. Thus C4BP can modulate CD40/sCD154 interactions by presenting a high molecular weight multimeric sCD154/C4BP complex that suppresses critical intracellular signalling pathways, permitting cell survival without inducing proliferation. Immunohistochemistry demonstrated co-localisation and enhanced expression of C4BP and CD40 in human liver cancers. These findings suggest a novel pathway whereby components of the complement system and TNF ligands and receptors might be involved in modulating epithelial cell survival in chronic inflammation and malignant disease.	[Williams, Kevin T.; Negus, Alison; Adams, David H.; Afford, Simon C.] Univ Birmingham, Liver Res Grp, Birmingham, W Midlands, England; [Williams, Kevin T.; Negus, Alison; Adams, David H.; Afford, Simon C.] Univ Birmingham, MRC Ctr Immune Regulat, Inst Biomed Res, Birmingham, W Midlands, England; [Young, Steven P.] Univ Birmingham, Sch Med, Dept Rheumatol, Birmingham, W Midlands, England; [Young, Lawrence S.] Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; Cancer Research UK; University of Birmingham	Afford, SC (corresponding author), Univ Birmingham, Liver Res Grp, Birmingham, W Midlands, England.	s.c.afford@bham.ac.uk	Young, Lawrence S/B-7213-2009; Adams, David H/C-9092-2009; Young, Stephen P/A-7380-2008	Young, Lawrence S/0000-0003-3919-4298; Adams, David H/0000-0001-6776-0336; Young, Stephen P/0000-0002-6355-3361	Biotechnology and Biological Science Research Council; Medical Research Council [G9818340B] Funding Source: researchfish	Biotechnology and Biological Science Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Financial support was received in the form of a project grant (Ref 6/C19953) from the Biotechnology and Biological Science Research Council. The sponsor played no role in the design or conduct of the study and BBSRC approval to submit the manuscript was a precondition of accepting the award.	Adams DH, 2005, SEMIN LIVER DIS, V25, P281, DOI 10.1055/s-2005-916320; Adams DH, 2002, FRONT BIOSCI-LANDMRK, V7, pE276; Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; AFFORD SC, 1995, J PATHOL, V176, P373, DOI 10.1002/path.1711760408; Afford SC, 2001, FASEB J, V15, P2345, DOI 10.1096/fj.01-0088com; Ahmed-Choudhury J, 2006, CELL SIGNAL, V18, P456, DOI 10.1016/j.cellsig.2005.05.015; Armitage R J, 1993, Semin Immunol, V5, P401; Baxendale AJ, 2005, ONCOGENE, V24, P7913, DOI 10.1038/sj.onc.1208929; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Choudhury JA, 2003, MOL BIOL CELL, V14, P1334, DOI 10.1091/mbc.E02-07-0378; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DE FRUTOS PG, 1995, J BIOL CHEM, V270, P26950, DOI 10.1074/jbc.270.45.26950; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Hayward AR, 1997, J IMMUNOL, V158, P977; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HESSING M, 1990, J IMMUNOL, V144, P204; Hill SC, 2005, J IMMUNOL, V174, P41, DOI 10.4049/jimmunol.174.1.41; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Johnsson E, 1996, J IMMUNOL, V157, P3021; Komichi D, 2003, DIGEST DIS SCI, V48, P2315, DOI 10.1023/B:DDAS.0000007869.67105.27; KUSADAFUNAKOSHI M, 1991, BIOCHEM MED METAB B, V45, P350, DOI 10.1016/0885-4505(91)90040-R; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LAPPIN DF, 1990, BIOCHEM J, V271, P767, DOI 10.1042/bj2710767; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MOFFAT GJ, 1992, J BIOL CHEM, V267, P20400; Murakami K, 1999, J IMMUNOL, V163, P2667; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SHAKIR A, 2005, LIVER DIS BIOCH MECH; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Stephens J, 1999, HEPATOLOGY, V30, P27, DOI 10.1002/hep.510300138; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209	36	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e159	10.1371/journal.pone.0000159	http://dx.doi.org/10.1371/journal.pone.0000159			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225862	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444000010
J	Angevine, CM; Herold, KAG; Vincent, OD; Fillingame, RH				Angevine, Christine M.; Herold, Kelly A. G.; Vincent, Owen D.; Fillingame, Robert H.			Aqueous access pathways in ATP synthase subunit a - Reactivity of cysteine substituted into transmembrane helices 1, 3, AND 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CROSS-LINKING; ROTARY MOTOR; PROTON TRANSLOCATION; POTASSIUM CHANNEL; ALPHA-SUBUNIT; C-RING; MEMBRANE; MUTAGENESIS; MUTATIONS	Subunit a is thought to play a key role in H+ transport-driven rotation of the subunit c ring in Escherichia coli F1F0 ATP synthase. In the membrane-traversing F-0 sector of the enzyme, H+ binding and release occurs at Asp-61 in the middle of the second transmembrane helix (TMH) of subunit c. Protons are thought to reach Asp-61 via aqueous channels formed at least in part by one or more of the five TMHs of subunit a. Aqueous access to surfaces of TMHs 2, 4, and 5 was previously suggested based upon the chemical reactivity of cysteine residues substituted into these helices. Here we have substituted Cys into TMH1 and TMH3 and extended the substitutions in TMH5 to the cytoplasmic surface. One region of TMH3 proved to be moderately Ag+-sensitive and may connect with the Ag+-sensitive region found previously on the periplasmic side of TMH2. A single Cys substitution in TMH1 proved to be both N-ethylmaleimide (NEM)-sensitive and Ag+-sensitive and suggests a possible packing interaction of TMH1 with TMH2 and TMH3. New Ag+- and NEM-sensitive residues were found at the cytoplasmic end of TMH5 and suggest a possible connection of this region to the NEM- and Ag+-sensitive region of TMH4 described previously. From the now complete pattern of TMH residue reactivity, we conclude that aqueous access from the periplasmic side of F-0 to cAsp-61 at the center of the membrane is likely to be mediated by residues of TMHs 2, 3, 4, and 5 at the center of a four-helix bundle. Further, aqueous access between cAsp-61 and the cytoplasmic surface is likely to be mediated by residues in TMH4 and TMH5 at the exterior of the four-helix bundle that are in contact with the c-ring.	Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; Barik S, 1996, Methods Mol Biol, V57, P203; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Dimroth P, 2006, EMBO REP, V7, P276, DOI 10.1038/sj.embor.7400646; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Fillingame RH, 2000, J EXP BIOL, V203, P9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P2187, DOI 10.1093/nar/9.9.2187; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; Li J, 2002, P NATL ACAD SCI USA, V99, P11605, DOI 10.1073/pnas.192439299; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Schwem BE, 2006, J BIOL CHEM, V281, P37861, DOI 10.1074/jbc.M607453200; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9001	9007		10.1074/jbc.M610848200	http://dx.doi.org/10.1074/jbc.M610848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17234633	hybrid			2022-12-25	WOS:000245780300047
J	Ball, JR; Dimaano, C; Bilak, A; Kurchan, E; Zundel, MT; Ullman, KS				Ball, Jennifer R.; Dimaano, Christian; Bilak, Amber; Kurchan, Eydiejo; Zundel, M. Tracy; Ullman, Katharine S.			Sequence preference in RNA recognition by the nucleoporin Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA; NUCLEOCYTOPLASMIC TRANSPORT; BINDING DOMAIN; PROTEIN NUP153; EXPORT; IMPORT; BETA; ORGANIZATION; CYTOPLASM	The vertebrate nuclear pore protein Nup153 contains a novel RNA binding domain. This 150-amino acid region was previously found to bind preferentially to a panel of mRNAs when compared with structured RNAs, such as tRNA, U snRNA, and double-stranded RNA. The ability to broadly recognize mRNA led to the conclusion that the Nup153 RNA binding domain confers a general affinity for single-stranded RNA. Here, we have probed Nup153 RNA recognition to decipher how this unique RNA binding domain discriminates between potential targets. We first mapped the binding determinant within an RNA fragment that associates relatively robustly with the Nup153 RNA binding domain. We next designed synthetic RNA oligonucleotides to systematically delineate the features within this minimal RNA fragment that are key to Nup153 RNA-binding domain binding and demonstrated that the binding preferences of Nup153 do not reflect general preferences of an mRNA/single-stranded RNA-binding protein. We further found that the association between Nup153 and a cellular mRNA can be attributed to an interaction with specific subregions of the RNA. These results indicate that Nup153 can discriminate between mRNA and other classes of RNA transcripts due in part to direct recognition of a loose sequence motif. This information adds a new dimension to the interfaces that can contribute to recognition in mRNA export cargo selection and fate.	Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ullman, KS (corresponding author), Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	katharine.ullman@hci.utah.edu		Ullman, Katharine/0000-0003-3693-2830	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061275] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA421014] Funding Source: Medline; NIGMS NIH HHS [R01 GM061275-07, R01 GM061275, GM61275] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Ball JR, 2005, CHROMOSOMA, V114, P319, DOI 10.1007/s00412-005-0019-3; Ball JR, 2004, RNA, V10, P19, DOI 10.1261/rna.5109104; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Cole CN, 2006, CURR OPIN CELL BIOL, V18, P299, DOI 10.1016/j.ceb.2006.04.006; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Dimaano C, 2001, J BIOL CHEM, V276, P45349, DOI 10.1074/jbc.M102592200; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Griffis ER, 2004, MOL BIOL CELL, V15, P1991, DOI 10.1091/mbc.e03-10-0743; Hase ME, 2003, MOL BIOL CELL, V14, P1923, DOI 10.1091/mbc.E02-09-0620; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Lim RYH, 2006, CURR OPIN CELL BIOL, V18, P342, DOI 10.1016/j.ceb.2006.03.006; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Masuyama K, 2004, GENE DEV, V18, P2074, DOI 10.1101/gad.1216204; Menon BB, 2005, P NATL ACAD SCI USA, V102, P5749, DOI 10.1073/pnas.0501768102; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ohno M, 2002, MOL CELL, V9, P659, DOI 10.1016/S1097-2765(02)00454-9; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Taddei A, 2006, NATURE, V441, P774, DOI 10.1038/nature04845; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027; Ullman KS, 2002, CURR BIOL, V12, pR461, DOI 10.1016/S0960-9822(02)00946-6; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451	42	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8734	8740		10.1074/jbc.M608477200	http://dx.doi.org/10.1074/jbc.M608477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242408	hybrid			2022-12-25	WOS:000245780300019
J	Otero-Cruz, JD; Baez-Pagan, CA; Caraballo-Gonzalez, IM; Lasalde-Dominicci, JA				David Otero-Cruz, Jose; Alberto Baez-Pagan, Carlos; Manuel Caraballo-Gonzalez, Ivan; Antonio Lasalde-Dominicci, Jose			Tryptophan-scanning mutagenesis in the alpha M3 transmembrane domain of the muscle-type acetylcholine receptor - A spring model revealed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERFACE; GATED ION CHANNELS; SHAKER K+ CHANNEL; VOLTAGE-SENSING DOMAINS; CYTOCHROME-C-OXIDASE; TORPEDO-CALIFORNICA; ANGSTROM RESOLUTION; NICOTINIC RECEPTOR; CRYSTAL-STRUCTURE; HELICAL STRUCTURE	Membrane proteins constitute a large fraction of all proteins, yet very little is known about their structure and conformational transitions. A fundamental question that remains obscure is how protein domains that are in direct contact with the membrane lipids move during the conformational change of the membrane protein. Important structural and functional information of several lipid-exposed transmembrane domains of the acetylcholine receptor (AChR) and other ion channel membrane proteins have been provided by the tryptophan-scanning mutagenesis. Here, we use the tryptophan-scanning mutagenesis to monitor the conformational change of the aM3 domain of the muscle-type AChR. The perturbation produced by the systematic tryptophan substitution along the aM3 domain were characterized through two-electrode voltage clamp and I-125-labeled a-bungarotoxin binding. The periodicity profiles of the changes in AChR expression (closed state) and ACh EC50 (open-channel state) disclose two different helical structures; a thinner-elongated helix for the closed state and a thicker-shrunken helix for the open-channel state. The existence of two different helical structures suggest that the conformational transition of the aM3 domain between both states resembles a spring motion and reveals that the lipid-AChR interface plays a key role in the propagation of the conformational wave evoked by agonist binding. In addition, the present study also provides evidence about functional and structural differences between the aM3 domains of the Torpedo and muscle-type receptors AChR.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, Rio Piedras Campus, San Juan, PR 00931 USA.	joseal@coqui.net			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056371, R25GM061151] Funding Source: NIH RePORTER; NIGMS NIH HHS [R25GM61151, GM08102-27, 2R01GM56371-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Blanton MP, 1998, BIOCHEMISTRY-US, V37, P14545, DOI 10.1021/bi981435q; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; CamposCaro A, 1997, BIOCHEMISTRY-US, V36, P2709, DOI 10.1021/bi9623486; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COCKCROFT VB, 1990, MOL NEUROBIOL, V4, P129, DOI 10.1007/BF02780338; Collins A, 1997, P NATL ACAD SCI USA, V94, P5456, DOI 10.1073/pnas.94.10.5456; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Cruz-Martin A, 2001, J MEMBRANE BIOL, V183, P61, DOI 10.1007/s00232-001-0051-z; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; daCosta CJB, 2002, J BIOL CHEM, V277, P201, DOI 10.1074/jbc.M108341200; De Rosa MJ, 2002, MOL PHARMACOL, V62, P406, DOI 10.1124/mol.62.2.406; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; Engel AG, 2002, MOL NEUROBIOL, V26, P347, DOI 10.1385/MN:26:2-3:347; Garbus I, 2002, NEUROPHARMACOLOGY, V43, P65, DOI 10.1016/S0028-3908(02)00068-0; Guzman GR, 2003, BIOCHEMISTRY-US, V42, P12243, DOI 10.1021/bi034764d; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Honse Y, 2004, NEUROPHARMACOLOGY, V46, P647, DOI 10.1016/j.neuropharm.2003.11.006; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; IWATA T, 1994, J BIOL CHEM, V269, P4928; Jenkins A, 2002, NEUROPHARMACOLOGY, V43, P669, DOI 10.1016/S0028-3908(02)00175-2; Jung SW, 2005, J BIOL CHEM, V280, P308, DOI 10.1074/jbc.M409871200; Kandasamy SK, 2006, BIOPHYS J, V90, P2326, DOI 10.1529/biophysj.105.073395; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kashlan OB, 2006, J BIOL CHEM, V281, P30455, DOI 10.1074/jbc.M604615200; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Lasalde JA, 1996, BIOCHEMISTRY-US, V35, P14139, DOI 10.1021/bi961583l; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LI L, 1990, BIOCHEMISTRY-US, V29, P5428, DOI 10.1021/bi00475a003; LI L, 1992, BIOPHYS J, V62, P61, DOI 10.1016/S0006-3495(92)81779-4; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; Mitra A, 2004, STRUCTURE, V12, P1909, DOI 10.1016/j.str.2004.08.004; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Navedo M, 2004, BIOCHEMISTRY-US, V43, P78, DOI 10.1021/bi0356496; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Ortiz-Acevedo A, 2004, J BIOL CHEM, V279, P42250, DOI 10.1074/jbc.M405132200; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Panchenko VA, 2001, J GEN PHYSIOL, V117, P345, DOI 10.1085/jgp.117.4.345; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5713, DOI 10.1021/bi047338g; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Santiago J, 2004, BIOCHEMISTRY-US, V43, P10064, DOI 10.1021/bi0362368; Santiago J, 2001, J BIOL CHEM, V276, P46523, DOI 10.1074/jbc.M104563200; Shen XM, 2006, ANN NEUROL, V60, P128, DOI 10.1002/ana.20861; Silberberg SD, 2005, J GEN PHYSIOL, V125, P347, DOI 10.1085/jgp.200409221; Smith DK, 2003, PROTEIN SCI, V12, P1060, DOI 10.1110/ps.0236203; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Subbiah RN, 2005, J PHYSIOL-LONDON, V569, P367, DOI 10.1113/jphysiol.2005.097386; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamamizu S, 1999, J MEMBRANE BIOL, V170, P157, DOI 10.1007/s002329900545; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wang SY, 2003, BIOPHYS J, V85, P911, DOI 10.1016/S0006-3495(03)74530-5; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798	82	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9162	9171		10.1074/jbc.M607492200	http://dx.doi.org/10.1074/jbc.M607492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242410	hybrid			2022-12-25	WOS:000245780300063
J	Shiraishi, S; Zhou, C; Aoki, T; Sato, N; Chiba, T; Tanaka, K; Yoshida, S; Nabeshima, Y; Nabeshima, Y; Tamura, T				Shiraishi, Seiji; Zhou, Chang; Aoki, Tsutomu; Sato, Naruki; Chiba, Tomoki; Tanaka, Keiji; Yoshida, Shosei; Nabeshima, Yoko; Nabeshima, Yo-ichi; Tamura, Taka-aki			TBP-interacting protein 120B (TIP120B)/cullin-associated and neddylation-dissociated 2 (CAND2) inhibits SCF-dependent ubiquitination of myogenin and accelerates myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TBP-INTERACTING PROTEIN; LIGASE COMPLEX; MEDIATED DEGRADATION; NEDD8 MODIFICATION; SKELETAL-MUSCLE; E3 LIGASE; MYOD; GENE; CUL1; TRANSCRIPTION	Despite fast protein degradation in muscles, protein concentrations remain constant during differentiation and maintenance of muscle tissues. Myogenin, a basic helix-loop-helix-type myogenic transcription factor, plays a critical role through transcriptional activation in myogenesis as well as muscle maintenance. TBP-interacting protein 120/cullin-associated neddylation-dissociated (TIP 120/CAND) is known to bind to cullin and negatively regulate SCF (Skp1-Cullin1-F-box protein) ubiquitin ligase, although its physiological role has not been elucidated. We have identified a muscle-specific isoform of TIP120, named TIP120B/CAND2. In this study, we found that TIP120B is not only induced in association with myogenic differentiation but also actively accelerates the myogenic differentiation of C2C12 cells. Although myogenin is a short lived protein and is degraded by a ubiquitin-proteasome system, TIP120B suppressed its ubiquitination and subsequent degradation of myogenin. TIP120B bound to cullin family proteins, especially Cullin 1 (CULL), and was associated with SCF complex in cells. It was demonstrated that myogenin was also associated with SCF and that CULL small interference RNA treatment inhibited ubiquitination of myogenin and stabilized it. TIP120B was found to break down the SCF-myogenin complex. Consequently suppression of SCF-dependent ubiquitination of myogenin by TIP 120B, which leads to stabilization of myogenin, can account for the TIP1208-directed accelerated differentiation of C2C12 cells. TIP120B is proposed to be a novel regulator for myogenesis.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan; Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan	Chiba University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Tamura, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.	ttamura@faculty.chiba-u.jp		Yoshida, Shosei/0000-0001-8861-1866				Aoki T, 2002, BIOCHEM BIOPH RES CO, V296, P1097, DOI 10.1016/S0006-291X(02)02031-4; Aoki T, 1999, BIOCHEM BIOPH RES CO, V261, P911, DOI 10.1006/bbrc.1999.1147; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2006, EXP BIOL MED, V231, P1197; Di Carlo A, 2004, J BIOL CHEM, V279, P16332, DOI 10.1074/jbc.M313931200; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hatoum Ossama Abu, 1998, Molecular and Cellular Biology, V18, P5670; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Kayukawa K, 2001, GENES CELLS, V6, P165, DOI 10.1046/j.1365-2443.2001.00407.x; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Min KW, 2005, BIOCHEM BIOPH RES CO, V334, P867, DOI 10.1016/j.bbrc.2005.06.188; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakadai T, 2004, J BIOL CHEM, V279, P7447, DOI 10.1074/jbc.M305412200; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Sato S, 2006, EMBO J, V25, P211, DOI 10.1038/sj.emboj.7600774; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; You JX, 2003, J BIOL CHEM, V278, P23369, DOI 10.1074/jbc.M212887200; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	50	35	35	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9017	9028		10.1074/jbc.M611513200	http://dx.doi.org/10.1074/jbc.M611513200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242400	hybrid			2022-12-25	WOS:000245780300049
J	Uemura, S; Kihara, A; Iwaki, S; Inokuchi, JI; Igarashi, Y				Uemura, Satoshi; Kihara, Akio; Iwaki, Soichiro; Inokuchi, Jin-ichi; Igarashi, Yasuyuki			Regulation of the transport and protein levels of the inositol phosphorylceramide mannosyltransferases Csg1 and Csh1 by the Ca2+ binding protein Csg2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE; SPHINGOLIPID BIOSYNTHESIS; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; LINKED GLYCOSYLATION; GOLGI-APPARATUS; PLANT DEFENSIN; AUR1 GENE	Complex sphingolipids in yeast are known to function in cellular adaptation to environmental changes. One of the yeast complex sphingolipids, mannosylinositol phosphorylceramide (MIPC), is produced by the redundant inositol phosphorylceramide (IPC) mannosyltransferases Csg1 and Csh1. The Ca2+-binding protein Csg2 can form a complex with either Csg1 or Csh1 and is considered to act as a regulatory subunit. However, the role of Csg2 in MIPC synthesis has remained unclear. In this study, we found that Csg1 and Csh1 are N-glycosylated with core-type and mannan-type structures, respectively. Further identification of the glycosylated residues suggests that both Csg1 and Csh1 exhibit membrane topology with their C termini in the cytosol and their mannosyltransferase domains in the lumen. After complexing with Csg2, both Csg1 and Csh1 function in the Golgi, and then are delivered to the vacuole for degradation. However, uncomplexed Csh1 cannot exit from the endoplasmic reticulum. We also demonstrated that Ca2+ stimulates IPC-to-MIPC conversion, because of a Csg2-dependent increase in Csg1 levels. Thus, Csg2 has several regulatory functions for Csg1 and Csh1, including stability, transport, and gene expression.	Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Tohoku Pharmaceut Univ, Div Glycopathol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan; Japan Sci & Technol Agcy, CREST Program, Kawaguchi, Saitama 3320012, Japan; Hokkaido Univ, Fac Adv Life Sci, Lab Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University; Tohoku Medical & Pharmaceutical University; Japan Science & Technology Agency (JST); Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Chome, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	Inokuchi, Jin-ichi/AAW-9964-2020; KIHARA, AKIO/A-3802-2012	Inokuchi, Jin-ichi/0000-0002-0703-5746; KIHARA, AKIO/0000-0001-5889-0788				Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Aerts AM, 2006, FEBS LETT, V580, P1903, DOI 10.1016/j.febslet.2006.02.061; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Brachmann CB, 1998, YEAST, V14, P115; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; HEIDLER SA, 1995, ANTIMICROB AGENTS CH, V39, P2765, DOI 10.1128/AAC.39.12.2765; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kobayashi T, 2005, J BIOL CHEM, V280, P18087, DOI 10.1074/jbc.M414138200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Lisman Q, 2004, J BIOL CHEM, V279, P1020, DOI 10.1074/jbc.M306119200; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Markovich S, 2004, ANTIMICROB AGENTS CH, V48, P3871, DOI 10.1128/AAC.48.10.3871-3876.2004; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Reggiori F, 1998, J BIOL CHEM, V273, P30550, DOI 10.1074/jbc.273.46.30550; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stock SD, 2000, ANTIMICROB AGENTS CH, V44, P1174, DOI 10.1128/AAC.44.5.1174-1180.2000; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; Tani M, 2006, BIOCHEM J, V394, P237, DOI 10.1042/BJ20051354; Thevissen K, 2000, P NATL ACAD SCI USA, V97, P9531, DOI 10.1073/pnas.160077797; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zink S, 2005, EUKARYOT CELL, V4, P879, DOI 10.1128/EC.4.5.879-889.2005	42	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8613	8621		10.1074/jbc.M606649200	http://dx.doi.org/10.1074/jbc.M606649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17220303	Green Published, hybrid			2022-12-25	WOS:000245780300007
J	Vaughan, RA; Sakrikar, DS; Parnas, ML; Adkins, S; Foster, JD; Duval, RA; Lever, JR; Kulkarni, SS; Hauck-Newman, A				Vaughan, Roxanne A.; Sakrikar, Dhananjay S.; Parnas, M. Laura; Adkins, Steven; Foster, James D.; Duval, Romain A.; Lever, John R.; Kulkarni, Santosh S.; Hauck-Newman, Amy			Localization of cocaine analog [I-125]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOAFFINITY LIGANDS; DOMAINS; RECOGNITION; RECEPTOR; SITE; ANTIDEPRESSANTS; ACCESSIBILITY; CONFORMATION; MUTAGENESIS; INHIBITORS	The site of cocaine binding on the dopamine transporter (DAT) was investigated using the photoactivatable irreversible cocaine analog [I-125]3 beta-(p-chlorophenyl)tropane-2 beta-carboxylic acid, 4'-azido-3'-iodophenylethyl ester ([I-125]RTI 82). The incorporation site of this compound was mapped to transmembrane domains (TMs) 4-6 using epitope-specific immunoprecipitation of trypsin fragments and further localized using cyanogen bromide (CNBr), which hydrolyzes proteins on the C-terminal side of methionine residues. CNBr hydrolysis of [I-125]RTI 82-labeled rat striatal and expressed human DATs produced fragments of similar to 5-10 kDa consistent with labeling between Met(271/272) or Met(290) in TM5 to Met(370/371) in TM7. To further define the incorporation site, substitution mutations were made that removed endogenous methionines and inserted exogenous methionines in combinations that would generate labeled CNBr fragments of distinct masses depending on the labeling site. The results obtained were consistent with the presence of TM6 but not TMs 4, 5, or 7 in the labeled fragments, with additional support for these conclusions obtained by epitopespecific immunoprecipitation and secondary digestion of CNBr fragments with endoproteinase Lys-C. The final localization of [I-125]RTI 82 incorporation to rat DAT Met(290)-Lys(336) and human DAT I291M to R344M provides positive evidence for the proximity of cocaine binding to TM6. Residues in and near DAT TM6 regulate transport and transport-dependent conformational states, and TM6 forms part of the substrate permeation pathway in the homologous Aquifex aeolicus leucine transporter. Cocaine binding near TM6 may thus overlap the dopamine translocation pathway and function to inhibit TM6 structural rearrangements necessary for transport.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Univ Missouri, Dept Radiol, Columbia, MO 65212 USA; Univ Missouri, Dept Med Pharmacol, Columbia, MO 65212 USA; Univ Missouri, Dept Physiol, Columbia, MO 65212 USA; Harry S Truman Mem Vet Hosp, Columbia, MO 65212 USA; NIDA, Med Chem Sect, Intramural Res Program, Baltimore, MD 21224 USA	University of North Dakota Grand Forks; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Vaughan, RA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 501 N Columbia Rd, Grand Forks, ND 58203 USA.	rvaughan@medicine.nodak.edu	Duval, Romain A/K-2299-2016	Duval, Romain A/0000-0002-0125-506X; Sakrikar, Dhananjay/0000-0001-8430-0120	Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [P20 RR 016741] Funding Source: Medline; NIDA NIH HHS [DA15175] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015175] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CARROLL FI, 1992, J MED CHEM, V35, P1813, DOI 10.1021/jm00088a017; CARROLL FI, 1992, J MED CHEM, V35, P969, DOI 10.1021/jm00084a001; Chen NH, 2004, J NEUROCHEM, V89, P853, DOI 10.1111/j.1471-4159.2004.02386.x; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Chen NH, 1998, J NEUROSCI, V18, P10257; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; CRIMMINS DL, 2005, CURRENT PROTOCOLS PR, V1, P2; ESHLEMAN AJ, 1995, J PHARMACOL EXP THER, V274, P276; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Gaffaney JD, 2004, MOL PHARMACOL, V65, P692, DOI 10.1124/mol.65.3.692; GIROS B, 1994, J BIOL CHEM, V269, P15985; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Henry LK, 2006, J BIOL CHEM, V281, P2012, DOI 10.1074/jbc.M505055200; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; KOTZYBAHIBERT F, 1989, ANGEW CHEM INT EDIT, V34, P1296; Lee SH, 2002, EXP MOL MED, V34, P90, DOI 10.1038/emm.2002.13; Lever JR, 2005, BIOCONJUGATE CHEM, V16, P644, DOI 10.1021/bc0497214; LEVER JR, 1993, J LABELLED COMPD RAD, V33, P1131, DOI 10.1002/jlcr.2580331207; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; PARNAS ML, 2006, ABSTR VIEW IT PLANN; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; Surratt CK, 2005, AAPS J, V7, pE739, DOI 10.1208/aapsj070374; Varano F, 2002, J MED CHEM, V45, P1035, DOI 10.1021/jm010995b; Vaughan RA, 1996, J BIOL CHEM, V271, P21672, DOI 10.1074/jbc.271.35.21672; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Vaughan RA, 2005, J NEUROSCI METH, V143, P33, DOI 10.1016/j.jneumeth.2004.09.022; Vaughan RA, 1999, J NEUROSCI, V19, P630; Vaughan RA, 2001, MOL PHARMACOL, V59, P1157, DOI 10.1124/mol.59.5.1157; Volz TJ, 2005, SYNAPSE, V58, P72, DOI 10.1002/syn.20183; Xing DX, 2000, J MED CHEM, V43, P639, DOI 10.1021/jm9902234; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zou MF, 2001, J MED CHEM, V44, P4453, DOI 10.1021/jm0101904	40	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8915	8925		10.1074/jbc.M610633200	http://dx.doi.org/10.1074/jbc.M610633200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255098	hybrid			2022-12-25	WOS:000245780300038
J	Wang, CH; Su, LH; Sun, CH				Wang, Chih-Hung; Su, Li-Hsin; Sun, Chin-Hung			A novel ARID/bright-like protein involved in transcriptional activation of cyst wall protein 1 gene in Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; DEAD RINGER GENE; PRIMITIVE EUKARYOTE; ARID FAMILY; ENCYSTATION; PROMOTER; SEQUENCE; EXPRESSION; IDENTIFICATION; COMPLEX	The capability of protozoan parasite Giardia lamblia to encyst is critical for survival outside the host and its transmission. AT-rich interaction domain (ARID) or Bright homologs constitute a large family of transcription factors in higher eukaryotes that regulate cell proliferation, development, and differentiation. We asked whether Giardia has ARID-like genes and whether they influence gene expression during Giardia encystation. Blast searches of the Giardia genome data base identified two genes with putative ARID/Bright domains (gARID1 and 2). Epitope-tagged gARID1 was found to localize to nuclei. Recombinant gARID1 specifically bound to the encystation-induced cyst wall protein (cwp) gene promoters. Mutation analysis revealed that AT-rich initiators were required for binding of gARID1 to the cwp promoters. gARID1 contains several key residues for DNA binding, and its binding sequences are similar to those of the known ARID family proteins. The gARID1 binding sequences were positive cis-acting elements of the cwp1 promoter during both vegetative growth and encystation. We also found that gARID1 transactivated the cwp1 promoter through its binding sequences in vivo. Our results suggest that the ARID family has been conserved during evolution and that gARID1 is an important transactivator in regulation of the Giardia cwp1 gene, which is key to Giardia differentiation into cysts.	Natl Taiwan Univ, Coll Med, Dept Parasitol, Taipei 100, Taiwan	National Taiwan University	Sun, CH (corresponding author), Natl Taiwan Univ, Coll Med, Dept Parasitol, Taipei 100, Taiwan.	chsun@ha.mc.ntu.edu.tw	Shin, Jerry/AAO-2515-2021	SUN, CHIN-HUNG/0000-0002-8604-8085				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Best AA, 2004, GENOME RES, V14, P1537, DOI 10.1101/gr.2256604; Bruderer T, 1996, MOL BIOCHEM PARASIT, V77, P225, DOI 10.1016/0166-6851(96)02605-9; BURATOWSKI S, 2000, CURRENT PROTOCOLS MO, P9; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Davis-Hayman SR, 2003, INT J PARASITOL, V33, P1005, DOI 10.1016/S0020-7519(03)00177-2; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Eichinger D, 2001, CURR OPIN MICROBIOL, V4, P421, DOI 10.1016/S1369-5274(00)00229-0; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; Inagaki Y, 2003, NUCLEIC ACIDS RES, V31, P4227, DOI 10.1093/nar/gkg440; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Kim TG, 2003, J BIOL CHEM, V278, P42247, DOI 10.1074/jbc.M307386200; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Nixon JC, 2004, J BIOL CHEM, V279, P52465, DOI 10.1074/jbc.M403028200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Seshadri V, 2003, J BIOL CHEM, V278, P27804, DOI 10.1074/jbc.M303316200; Shandala T, 1999, DEVELOPMENT, V126, P4341; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 2003, J BIOL CHEM, V278, P21701, DOI 10.1074/jbc.M302023200; Sun CH, 2006, MOL BIOCHEM PARASIT, V146, P45, DOI 10.1016/j.molbiopara.2005.10.017; Sun CH, 2005, MOL BIOCHEM PARASIT, V142, P1, DOI 10.1016/j.molbiopara.2005.03.003; Sun CH, 1999, J BIOL CHEM, V274, P19699, DOI 10.1074/jbc.274.28.19699; Sun CH, 2002, MOL MICROBIOL, V46, P971, DOI 10.1046/j.1365-2958.2002.03233.x; Sun CH, 1998, MOL BIOCHEM PARASIT, V92, P123, DOI 10.1016/S0166-6851(97)00239-9; Van Keulen H, 1998, J EUKARYOT MICROBIOL, V45, P637, DOI 10.1111/j.1550-7408.1998.tb04560.x; Watanabe M, 2002, CIRC RES, V91, P382, DOI 10.1161/01.RES.0000033593.05545.7B; Whitson RH, 1999, BIOCHEM BIOPH RES CO, V258, P326, DOI 10.1006/bbrc.1999.0643; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; WOLFE MS, 1992, CLIN MICROBIOL REV, V5, P93, DOI 10.1128/CMR.5.1.93-100.1992; Worgall TS, 2004, J LIPID RES, V45, P981, DOI 10.1194/jlr.M400024-JLR200; Yee J, 2000, J BIOL CHEM, V275, P11432, DOI 10.1074/jbc.275.15.11432	46	33	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8905	8914		10.1074/jbc.M611170200	http://dx.doi.org/10.1074/jbc.M611170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244608	hybrid			2022-12-25	WOS:000245780300037
J	Yatsunyk, LA; Rosenzweig, AC				Yatsunyk, Liliya A.; Rosenzweig, Amy C.			Cu(I) binding and transfer by the N terminus of the Wilson disease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; MENKES-DISEASE; REGULATED TRAFFICKING; ATX1 METALLOCHAPERONE; BICINCHONINIC ACID; CATALYTIC-ACTIVITY; PRION PROTEIN; GENE HOMOLOG; APO FORMS; DOMAIN	Wilson and Menkes diseases are genetic disorders of copper metabolism caused by mutations in the Wilson (WND) and Menkes (MNK) copper-transporting P-1B-type ATPases. The N termini of these ATPases consist of six metal binding domains (MBDs). The MBDs interact with the copper chaperone Atox1 and are believed to play roles in catalysis and in copper-mediated cellular relocalization of WND and MNK. Although all six MBDs have similar folds and bind one Cu(I) ion via a conserved CXXC motif, biochemical and genetic data suggest that they have distinct functions. Most studies aimed at characterizing the MBDs have employed smaller polypeptides consisting of one or two domains. The role of each MBD is probably defined by its environment within the six-domain N terminus, however. To study the properties of the individual domains within the context of the intact Wilson N terminus (N-WND), a series of variants in which five of the six metal binding CXXC motifs are mutated to SXXS was generated. For each variant, the Cu(I) binding affinity and the ability to exchange Cu(I) with Atox1 were investigated. The results indicate that Atox1 can deliver Cu(I) to and remove Cu(I) from each MBD, that each MBD has stronger Cu(I) retention properties than Atox1, and that all of the MBDs as well as Atox1 have similar K-Cu. values of (2.2-6.3) x 10(10) (-1)(M). Therefore, the specific role of each MBD is not conferred by its position within the intact N-WND but may be related to interactions with other domains and partner proteins.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58518] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achila D, 2006, P NATL ACAD SCI USA, V103, P5729, DOI 10.1073/pnas.0504472103; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 2005, J BIOL CHEM, V280, P38259, DOI 10.1074/jbc.M506219200; Banci L, 2005, FEBS J, V272, P865, DOI 10.1111/j.1742-4658.2004.04526.x; Banci L, 2004, BIOCHEMISTRY-US, V43, P3396, DOI 10.1021/bi036042s; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Bunce J, 2006, BBA-GEN SUBJECTS, V1760, P907, DOI 10.1016/j.bbagen.2006.02.005; Cater MA, 2007, BIOCHEM J, V401, P143, DOI 10.1042/BJ20061055; Chen XH, 2000, J BIOL INORG CHEM, V5, P93, DOI 10.1007/s007750050012; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lim CM, 2006, J BIOL CHEM, V281, P14006, DOI 10.1074/jbc.M512745200; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Norgate M, 2006, MOL BIOL CELL, V17, P475, DOI 10.1091/mbc.E05-06-0492; OSTERBERG R, 1979, J INORG BIOCHEM, V10, P341, DOI 10.1016/S0162-0134(00)80200-7; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Ralle M, 2004, J INORG BIOCHEM, V98, P765, DOI 10.1016/j.jinorgbio.2004.02.009; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; Thompsett AR, 2005, J BIOL CHEM, V280, P42750, DOI 10.1074/jbc.M506521200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Walker JM, 2004, J BIOL CHEM, V279, P15376, DOI 10.1074/jbc.M400053200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	50	102	103	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8622	8631		10.1074/jbc.M609533200	http://dx.doi.org/10.1074/jbc.M609533200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17229731	hybrid			2022-12-25	WOS:000245780300008
J	Yu, JS; Bippes, CA; Hand, GM; Muller, DJ; Sosinsky, GE				Yu, Jinshu; Bippes, Christian A.; Hand, Galen M.; Muller, Daniel J.; Sosinsky, Gina E.			Aminosulfonate modulated pH-induced conformational changes in connexin26 hemichannels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION; 3-DIMENSIONAL STRUCTURE; CHANNELS; TAURINE; INHIBITION; CALCIUM; COMMUNICATION; SURFACE; CONDUCTANCE; ISCHEMIA	Gap junction channels regulate cell-cell communication by passing metabolites, ions, and signaling molecules. Gap junction channel closure in cells by acidification is well documented; however, it is unknown whether acidification affects connexins or modulating proteins or compounds that in turn act on connexins. Protonated aminosulfonates directly inhibit connexin channel activity in an isoform-specific manner as shown in previously published studies. High-resolution atomic force microscopy of force-dissected connexin26 gap junctions revealed that in HEPES buffer, the pore was closed at pH < 6.5 and opened reversibly by increasing the pH to 7.6. This pH effect was not observed in non-aminosulfonate buffers. Increasing the protonated HEPES concentration did not close the pore, indicating that a saturation of the binding sites occurs at 10 mm HEPES. Analysis of the extracellular surface topographs reveals that the pore diameter increases gradually with pH. The outer connexon diameter remains unchanged, and there is a similar to 6.5 degrees rotation in connexon lobes. These observations suggest that the underlying mechanism closing the pore is different from an observed Ca2+-induced closure.	Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, Dept Neurosci, La Jolla, CA 92093 USA; Tech Univ Dresden, Ctr Biotechnol, D-01307 Dresden, Germany	University of California System; University of California San Diego; Technische Universitat Dresden	Sosinsky, GE (corresponding author), Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, Dept Neurosci, 1070 Basic Sci Bldg,MC 0608,9500 Gilman Dr, La Jolla, CA 92093 USA.	gsosinsky@ucsd.edu	Müller, Daniel J./A-5967-2010	Müller, Daniel J./0000-0003-3075-0665	NCRR NIH HHS [RR04050] Funding Source: Medline; NIGMS NIH HHS [GM065937, R01 GM065937, GM072881] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072881, R01GM065937] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TS, 1983, J CELL BIOL, V96, P204, DOI 10.1083/jcb.96.1.204; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; Bukauskas FF, 1997, BIOPHYS J, V72, P2137, DOI 10.1016/S0006-3495(97)78856-8; BURT JM, 1987, AM J PHYSIOL, V253, pC607, DOI 10.1152/ajpcell.1987.253.4.C607; Chang EH, 2003, EAR HEARING, V24, P314, DOI 10.1097/01.AUD.0000079801.55588.13; Delmar M, 2000, CURR TOP MEMBR, V49, P223; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Fotiadis D, 2002, MICRON, V33, P385, DOI 10.1016/S0968-4328(01)00026-9; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; Hand GM, 2002, J MOL BIOL, V315, P587, DOI 10.1006/jmbi.2001.5262; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HOH JH, 1993, BIOPHYS J, V65, P149, DOI 10.1016/S0006-3495(93)81074-9; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; IKEDA K, 1989, ACTA OTO-LARYNGOL, V108, P88, DOI 10.3109/00016488909107397; JACOBSEN JG, 1968, PHYSIOL REV, V48, P424, DOI 10.1152/physrev.1968.48.2.424; Kamasawa N, 2005, NEUROSCIENCE, V136, P65, DOI 10.1016/j.neuroscience.2005.08.027; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; KLEBER AG, 1987, CIRC RES, V61, P271, DOI 10.1161/01.RES.61.2.271; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Liu F, 2006, J BIOL CHEM, V281, P23207, DOI 10.1074/jbc.M605048200; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Muller DJ, 1997, J STRUCT BIOL, V119, P172, DOI 10.1006/jsbi.1997.3875; Nagy JI, 2001, J COMP NEUROL, V441, P302, DOI 10.1002/cne.1414; Nattel S, 2004, HEART RHYTHM, V1, P234, DOI 10.1016/j.hrthm.2004.04.003; NOMA A, 1987, J PHYSIOL-LONDON, V382, P193, DOI 10.1113/jphysiol.1987.sp016363; Owens LM, 1996, CIRCULATION, V94, P10, DOI 10.1161/01.CIR.94.1.10; PAPARELLA MM, 1984, ANN OTO RHINOL LARYN, V93, P623, DOI 10.1177/000348948409300616; PASANTESMORALES H, 1985, BIOCHEM PHARMACOL, V34, P2205, DOI 10.1016/0006-2952(85)90419-8; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Peracchia C, 2004, BBA-BIOMEMBRANES, V1662, P61, DOI 10.1016/j.bbamem.2003.10.020; Peracchia C, 2003, CELL COMMUN ADHES, V10, P233, DOI 10.1080/15419060390262958; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; Perkins GA, 1998, J MOL BIOL, V277, P171, DOI 10.1006/jmbi.1997.1580; Petit C, 2001, ANNU REV GENET, V35, P589, DOI 10.1146/annurev.genet.35.102401.091224; Pfahnl A, 1998, BIOPHYS J, V75, P2323, DOI 10.1016/S0006-3495(98)77676-3; Pottek M, 2003, J COMP NEUROL, V466, P468, DOI 10.1002/cne.10897; PUTMAN CAJ, 1992, SPIE, V1639, P198; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; Saltman AE, 2002, J THORAC CARDIOV SUR, V124, P371, DOI 10.1067/mtc.2002.124239; SAXTON WO, 1984, ULTRAMICROSCOPY, V13, P57, DOI 10.1016/0304-3991(84)90057-3; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Tao L, 2005, BIOPHYS J, V88, p201A; Tao L, 2004, J BIOL CHEM, V279, P38544, DOI 10.1074/jbc.M405654200; Tappaz ML, 2004, NEUROCHEM RES, V29, P83, DOI 10.1023/B:NERE.0000010436.44223.f8; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Trexler EB, 1999, J GEN PHYSIOL, V113, P721; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; UNWIN PNT, 1983, J CELL BIOL, V97, P1459, DOI 10.1083/jcb.97.5.1459; Van Nhieu GT, 2003, NAT CELL BIOL, V5, P720, DOI 10.1038/ncb1021; Verselis VK, 2000, BRAZ J MED BIOL RES, V33, P379, DOI 10.1590/S0100-879X2000000400003; WRIGHT CE, 1986, ANNU REV BIOCHEM, V55, P427, DOI 10.1146/annurev.bi.55.070186.002235; Yokota H, 2000, CRIT CARE MED, V28, P3275, DOI 10.1097/00003246-200009000-00025; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	73	55	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8895	8904		10.1074/jbc.M609317200	http://dx.doi.org/10.1074/jbc.M609317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17227765	hybrid			2022-12-25	WOS:000245780300036
J	Maines, MD; Miralem, T; Lerner-Marmarosh, N; Shen, J; Gibbs, PEM				Maines, Mahin D.; Miralem, Tihomir; Lerner-Marmarosh, Nicole; Shen, Jenny; Gibbs, Peter E. M.			Human biliverdin reductase, a previously unknown activator of protein kinase C beta II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; IX-ALPHA REDUCTASE; HEME OXYGENASE-1; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; PLASMA-MEMBRANE; BINDING PROTEIN; MUSCLE CELLS; RAT-KIDNEY; IN-VIVO	Human biliverdin reductase (hBVR), a dual specificity kinase (Ser/Thr/Tyr) is, as protein kinase C (PKC) beta II, activated by insulin and free radicals (Miralem, T., Hu, Z., Torno, M. D., Lelli, K. M., and Maines, M. D. (2005) J. Biol. Chem. 280, 17084-17092; Lerner-Marmarosh, N., Shen, J., Torno, M. D., Kravets, A., Hu, Z., and Maines, M. D. (2005) Proc. Natl. Acad Sci. U.S.A. 102, 7109-7114). Here, by using 293A cells co-transfected with pcDNA3-hBVR and PKC beta II plasmids, we report the co-immunoprecipitation of the proteins and co-purification in the glutathione S-transferase (GST) pulldown assay. hBVR and PKC beta II, but not the reductase and PKC zeta, transphosphorylated in assay systems supportive of activity of only one of the kinases. PKC beta II K371R mutant protein ("kinase-dead") was also a substrate for hBVR. The reductase increased the V-max but not the apparent K-m values of PKC beta II for myelin basic protein; activation was independent of phospholipids and extended to the phosphorylation of S2, a PKC-specific substrate. The increase in substrate phosphorylation was blocked by specific inhibitors of conventional PKCs and attenuated by sihBVR. The effect of the latter could be rescued by subsequent overexpression of hBVR. To a large extent, the activation was a function of the hBVR N-terminal chain of valines and intact ATP-binding site and the cysteine-rich C-terminal segment. The cobalt protoporphyrin-activated hBVR phosphorylated a threonine in a peptide corresponding to the Thr(500) in the human PKC beta II activation loop. Neither serine nor threonine residues in peptides corresponding to other phosphorylation sites of the PKC beta II nor PKC C activation loop-derived peptides were substrates. The phosphorylation of Thr(500) was confirmed by immunoblotting of hBVR center dot PKC beta II immunocomplex. The potential biological relevance of the hBVR activation of PKC beta II was suggested by the finding that in cells transfected with the PKC beta II, hBVR augmented phorbol myristate acetate-mediated c-fos expression, and infection with sihBVR attenuated the response. Also, in cells overexpressing hBVR and PKC beta II, as well as in untransfected cells, upon treatment with phorbol myristate acetate, the PKC translocated to the plasma membrane and co-localized with hBVR. hBVR activation of PKC beta II underscores its potential function in propagation of signals relayed through PKCs.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14624 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14624 USA.	mahin_maines@urmc.rochester.edu	; Miralem, Tihomir/F-7576-2013	Shen, Jenny/0000-0003-0956-7209; Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [ES12187, ES004066] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012187, R01ES004066] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; BEALE SI, 1984, ARCH BIOCHEM BIOPHYS, V235, P371, DOI 10.1016/0003-9861(84)90210-8; BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; Borowski P, 1999, ARCH VIROL, V144, P687, DOI 10.1007/s007050050536; Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; CURRAN T, 1987, ONCOGENE, V2, P79; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Huang TJ, 2001, ANTIOXID REDOX SIGN, V3, P685, DOI 10.1089/15230860152543023; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Johnson LA, 2005, J BIOL CHEM, V280, P10914, DOI 10.1074/jbc.M413887200; Kawakami T, 2002, J BIOCHEM, V132, P677, DOI 10.1093/oxfordjournals.jbchem.a003273; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; McDonagh AF, 2001, NAT STRUCT BIOL, V8, P198, DOI 10.1038/84915; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Nakamura J, 2001, DIABETOLOGIA, V44, P480, DOI 10.1007/s001250051646; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1990, J BIOL CHEM, V265, P6296; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Schluchter WM, 1997, J BIOL CHEM, V272, P13562, DOI 10.1074/jbc.272.21.13562; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Watterson JM, 2002, BRAIN RES, V934, P69, DOI 10.1016/S0006-8993(02)02362-4; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911	61	40	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8110	8122		10.1074/jbc.M513427200	http://dx.doi.org/10.1074/jbc.M513427200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227757	hybrid			2022-12-25	WOS:000245081000043
J	Yamamoto, H; Nakashima, N; Ikeda, Y; Uchiumi, T				Yamamoto, Hiroshi; Nakashima, Nobuhiko; Ikeda, Yuka; Uchiumi, Toshio			Binding mode of the first aminoacyl-tRNA in translation initiation mediated by Plautia stali intestine virus internal ribosorne entry site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC RIBOSOMES; STRUCTURAL ELEMENTS; CROSS-LINKING; HYGROMYCIN-B; ELONGATION; PROTEIN; LIVER; NUCLEOTIDES; ANTIBIOTICS; COMPLEX	Eukaryotic ribosomes directly bind to the intergenic region-internal ribosome entry site (IGR-IRES) of Plautia stali intestine virus (PSIV) and initiate translation without either initiation factors or initiator Met-tRNA. We have investigated the mode of binding of the first aminoacyl-tRNA in translation initiation mediated by the IGR-IRES. Binding ability of aminoacyl-tRNA to the first codon within the IGR-IRES/80 S ribosome complex was very low in the presence of eukaryotic elongation factor 1A (eEF1A) alone but markedly enhanced by the translocase eEF2. Moreover, eEF2-dependent GTPase activity of the IRES/80 S ribosome complex was 3-fold higher than that of the free 80 S ribosome. This activation was suppressed by addition of the antibiotics pactamycin and hygromycin B, which are inhibitors of translocation. The results suggest that translocation by the action of eEF2 is essential for stable tRNA binding to the first codon of the PSIV-IRES in the ribosome. Chemical probing analysis showed that IRES binding causes a conformational. change in helix 18 of 18 S rRNA at the A site such that IRES destabilizes the conserved pseudoknot within the helix. This conformational change caused by the PSIV-IRES may be responsible for the activation of eEF2 action and stimulation of the first tRNA binding to the P site without initiation factors.	Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058634, Japan; Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan	Niigata University; National Institute of Agrobiological Sciences - Japan; Shinshu University	Uchiumi, T (corresponding author), Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan.	uchiumi@bio.sc.niigata-u.ac.jp	Yamamoto, Hiroshi/Z-5912-2019	Ikeda-Iwabu, Yuka/0000-0003-3550-7891				Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; DIONS G, 2004, MOL CELL, V16, P113; Dorner S, 2006, NAT STRUCT MOL BIOL, V13, P234, DOI 10.1038/nsmb1060; FOLK WR, 1971, BIOCHEMISTRY-US, V10, P1728, DOI 10.1021/bi00785a034; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; Hatakeyama Y, 2004, RNA, V10, P779, DOI 10.1261/rna.5208104; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Iwasaki K, 1979, Methods Enzymol, V60, P657; Jan E, 2003, P NATL ACAD SCI USA, V100, P15410, DOI 10.1073/pnas.2535183100; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; MIZUMOTO K, 1974, J BIOCHEM-TOKYO, V76, P1269, DOI 10.1093/oxfordjournals.jbchem.a130680; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NISHIMURA S, 1967, BIOCHIM BIOPHYS ACTA, V142, P133, DOI 10.1016/0005-2787(67)90522-9; Nishiyama T, 2003, NUCLEIC ACIDS RES, V31, P2434, DOI 10.1093/nar/gkg336; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pestova TV, 2004, EMBO REP, V5, P906, DOI 10.1038/sj.embor.7400240; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Pisarev AV, 2005, CR BIOL, V328, P589, DOI 10.1016/j.crvi.2005.02.004; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; Sarnow P, 2005, BIOCHEM SOC T, V33, P1479, DOI 10.1042/BST0331479; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; Sasaki J, 1999, J VIROL, V73, P1219, DOI 10.1128/JVI.73.2.1219-1226.1999; Schuler M, 2006, NAT STRUCT MOL BIOL, V13, P1092, DOI 10.1038/nsmb1177; Sergiev PV, 2005, NUCLEIC ACIDS RES, V33, P6048, DOI 10.1093/nar/gki910; Spahn CMT, 2004, CELL, V118, P465, DOI 10.1016/j.cell.2004.08.001; Takyar S, 2005, CELL, V120, P49, DOI 10.1016/j.cell.2004.11.042; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; Uchiumi T, 2000, J BIOL CHEM, V275, P35116, DOI 10.1074/jbc.M004596200; UCHIUMI T, 1986, J BIOL CHEM, V261, P9668; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; WOESE CR, 1989, P NATL ACAD SCI USA, V86, P3119, DOI 10.1073/pnas.86.9.3119; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1	39	41	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7770	7776		10.1074/jbc.M610887200	http://dx.doi.org/10.1074/jbc.M610887200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17209036	hybrid			2022-12-25	WOS:000245081000004
J	Solforosi, L; Bellon, A; Schaller, M; Cruite, JT; Abalos, GC; Williamson, RA				Solforosi, Laura; Bellon, Anne; Schaller, Monica; Cruite, Justin T.; Abalos, Gil C.; Williamson, R. Anthony			Toward molecular dissection of PrPC-PrPSc interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN; MONOCLONAL-ANTIBODIES; CELLULAR PRP; N-TERMINUS; REPLICATION; PROPAGATION; CONVERSION; STRAIN; CONFORMATION; DISEASE	Direct interaction between endogenous cellular prion protein (PrPC) and misfolded, disease-associated (PrPSc) conformers is a key event in prion propagation, which precedes templated conversion of PrPC into nascent PrPSc and prion infectivity. Although almost none of the molecular details of this pivotal process are understood, the persistence of individual prion strains suggests that assembly of the prion replicative complex is mechanistically precise. To systematically map defined regions of PrPC sequence that bind tightly to PrPSc, we have generated a comprehensive panel of over 45 motif-grafted antibodies containing overlapping peptide grafts collectively spanning PrP residues 19-231. Grafted antibody binding experiments, performed under stringent conditions, clearly identified only three distinct and independent high affinity PrPSc recognition motifs. The first of these binding motifs lies at the very N-terminal region of the mature PrP molecule within PrP-(23-33); the second motif lies within PrP-(98-110); and the third is contained within PrP-(136-158). Mutational analyses of these PrPSc-binding regions revealed that reactivity of the 23-33 and 98-110 segments are largely dependent upon the presence of multiple positively charged amino acid residues. These studies yield new insight into critical peptidic components composing one side of the prion replicative interface.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Williamson, RA (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	anthony@scripps.edu		Schaller, Monica/0000-0002-5002-2238	NIA NIH HHS [AG004243] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Morel N, 2004, J BIOL CHEM, V279, P30143, DOI 10.1074/jbc.M403896200; Moroncini G, 2004, P NATL ACAD SCI USA, V101, P10404, DOI 10.1073/pnas.0403522101; Moroncini G, 2006, NEUROBIOL DIS, V23, P717, DOI 10.1016/j.nbd.2006.06.008; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; Novitskaya V, 2006, J BIOL CHEM, V281, P15536, DOI 10.1074/jbc.M601349200; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Shaked Y, 2002, J NEUROCHEM, V82, P1, DOI 10.1046/j.1471-4159.2002.00995.x; Speare JO, 2003, J BIOL CHEM, V278, P12522, DOI 10.1074/jbc.M211599200; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-222; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457	29	74	76	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7465	7471		10.1074/jbc.M610051200	http://dx.doi.org/10.1074/jbc.M610051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218310	hybrid			2022-12-25	WOS:000245080900059
J	Yuan, CB; O'Connell, RJ; Jacob, RF; Mason, RP; Treistman, SN				Yuan, Chunbo; O'Connell, Robert J.; Jacob, Robert F.; Mason, R. Preston; Treistman, Steven N.			Requiation of the gating of BKCa channel by lipid bilayer thickness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNELS; PHOSPHOLIPID SURFACE-CHARGE; N-ACYL SPHINGOMYELINS; X-RAY; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MODEL MEMBRANES; CHAIN-LENGTH; CONDUCTANCE	Transmembrane segments of ion channels tend to match the hydrophobic thickness of lipid bilayers to minimize mismatch energy and to maintain their proper organization and function. To probe how ion channels respond to mismatch with lipid bilayers of different thicknesses, we examined the single channel activities of BKCa (hSlo alpha-subunit) channels in planar bilayers of binary mixtures of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) with phosphatidylcholines (PCs) of varying chain lengths, including PC 14:1, PC 18:1, PC 22:1, PC 24:1, and with porcine brain sphingomyelin. Bilayer thickness and structure was measured with small angle x-ray diffraction and atomic force microscopy. The open probability (P-o) of the BKCa channel was finely tuned by bilayer thickness, first decreasing with increases in bilayer thickness from PC 14:1 to PC 22:1 and then increasing from PC 22:1 to PC 24:1 and to porcine brain sphingomyelin. Single channel kinetic analyses revealed that the mean open time of the channel increased monotonically with bilayer thickness and, therefore, could not account for the biphasic changes in P-o. The mean closed time increased with bilayer thickness from PC 14:1 up to PC 22:1 and then decreased with further increases in bilayer thickness to PC 24:1 and sphingomyelin, correlating with changes in P-o. This is consistent with the proposition that bilayer thickness affects channel activity mainly through altering the stability of the closed state. We suggest a simple mechanical model that combines forces of lateral stress within the lipid bilayer with local hydrophobic mismatch between lipids and the protein to account for the biphasic modulation of BKCa gating.	Univ Massachusetts, Brudnick Neuropsychiat Res Inst, Sch Med, Worcester, MA 01604 USA; Elucida Res, Beverly, MA 01915 USA	University of Massachusetts System; University of Massachusetts Worcester	Treistman, SN (corresponding author), Univ Massachusetts, Brudnick Neuropsychiat Res Inst, Sch Med, 303 Belmont St, Worcester, MA 01604 USA.	Steven.Treistman@umassmed.edu	Yuan, Chunbo/E-9627-2011		NIAAA NIH HHS [AA12054] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA012054] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; Alvarez O., 1986, ION CHANNEL RECONSTI, P115; BALDWIN PA, 1985, BIOCHEMISTRY-US, V24, P2633, DOI 10.1021/bi00332a007; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; BELL JE, 1984, BIOPHYS J, V45, P279, DOI 10.1016/S0006-3495(84)84154-5; BERS DM, 1994, PRACTICAL GUIDE STUD, P3; BRAVOZEHNDER M, 1997, P NATL ACAD SCI USA, V37, P319; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CAFFREY M, 1981, BIOCHEMISTRY-US, V20, P1949, DOI 10.1021/bi00510a034; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P6901, DOI 10.1021/bi00321a096; CHANG HM, 1995, J MEMBRANE BIOL, V143, P51; Cornelius F, 2003, BIOCHEMISTRY-US, V42, P8541, DOI 10.1021/bi034532e; Crowley JJ, 2005, MOL PHARMACOL, V68, P4, DOI 10.1124/mol.105.012971; Crowley JJ, 2003, MOL PHARMACOL, V64, P365, DOI 10.1124/mol.64.2.365; Cui JM, 2000, BIOCHEMISTRY-US, V39, P15612, DOI 10.1021/bi001509+; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; ELLIOTT JR, 1983, BIOCHIM BIOPHYS ACTA, V735, P95, DOI 10.1016/0005-2736(83)90264-X; Gillis KD, 2000, PFLUG ARCH EUR J PHY, V439, P655, DOI 10.1007/s004240050990; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; HERBETTE L, 1985, BIOCHIM BIOPHYS ACTA, V817, P103, DOI 10.1016/0005-2736(85)90073-2; Jakab M, 1997, J MEMBRANE BIOL, V157, P237, DOI 10.1007/PL00005895; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; KILLIAN JA, 1909, BIOCHIM BIOPHYS ACTA, V1376, P40; Kuikka M, 2001, BIOPHYS J, V80, P2327, DOI 10.1016/S0006-3495(01)76203-0; Kunze WAA, 2000, J PHYSIOL-LONDON, V526, P375, DOI 10.1111/j.1469-7793.2000.00375.x; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lundbaek JA, 1996, BIOCHEMISTRY-US, V35, P3825, DOI 10.1021/bi952250b; Magleby RL, 2003, J GEN PHYSIOL, V121, P81, DOI 10.1085/jgp.20028721; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Maulik PR, 1995, BIOPHYS J, V69, P1909, DOI 10.1016/S0006-3495(95)80061-5; MAULIK PR, 1986, BIOPHYS J, V50, P1071, DOI 10.1016/S0006-3495(86)83551-2; MCMANUS OB, 1988, J PHYSIOL-LONDON, V402, P79, DOI 10.1113/jphysiol.1988.sp017195; Mobashery N, 1997, FEBS LETT, V412, P15, DOI 10.1016/S0014-5793(97)00709-6; MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701; Niu XW, 2004, NEURON, V42, P745, DOI 10.1016/j.neuron.2004.05.001; OCONNELL RJ, 2007, IN PRESS J MEMBR BIO; Oliver D, 2003, J NEUROSCI, V23, P2141; Park JB, 2003, J GEN PHYSIOL, V121, P375, DOI 10.1085/jgp.200208746; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Pilot JD, 2001, BIOCHEMISTRY-US, V40, P8188, DOI 10.1021/bi0103258; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5713, DOI 10.1021/bi047338g; Qi Z, 2005, MOL MEMBR BIOL, V22, P519, DOI 10.1080/09687860500370703; Rezzonico R, 2003, J BONE MINER RES, V18, P1863, DOI 10.1359/jbmr.2003.18.10.1863; Rothberg BS, 2000, J GEN PHYSIOL, V116, P75, DOI 10.1085/jgp.116.1.75; Rothberg BS, 1998, J GEN PHYSIOL, V111, P751, DOI 10.1085/jgp.111.6.751; Rothberg BS, 1999, J GEN PHYSIOL, V114, P93, DOI 10.1085/jgp.114.1.93; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Schmidt D, 2006, NATURE, V444, P775, DOI 10.1038/nature05416; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; Turnheim K, 1999, AM J PHYSIOL-CELL PH, V277, pC83, DOI 10.1152/ajpcell.1999.277.1.C83; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Walters FS, 2000, AM J PHYSIOL-CELL PH, V279, pC1107, DOI 10.1152/ajpcell.2000.279.4.C1107; Williamson IM, 2002, BIOPHYS J, V83, P2026, DOI 10.1016/S0006-3495(02)73964-7; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6; WOOD WG, 1990, BIOCHIM BIOPHYS ACTA, V1025, P243, DOI 10.1016/0005-2736(90)90103-U; Yuan CB, 2004, BIOPHYS J, V86, P3620, DOI 10.1529/biophysj.103.029678	63	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7276	7286		10.1074/jbc.M607593200	http://dx.doi.org/10.1074/jbc.M607593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209047	hybrid			2022-12-25	WOS:000245080900039
J	Alford, KA; Glennie, S; Turrell, BR; Rawlinson, L; Saklatvala, J; Dean, JLE				Alford, Kate A.; Glennie, Sarah; Turrell, Bryony R.; Rawlinson, Lesley; Saklatvala, Jeremy; Dean, Jonathan L. E.			Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HEAT-SHOCK-PROTEIN; CYCLOOXYGENASE-2 MESSENGER-RNA; FACTOR INCREASE PHOSPHORYLATION; INDUCED CELL-DEATH; AU-RICH ELEMENTS; KAPPA-B PATHWAY; HUMAN HSP27; PROTECTIVE ACTIVITY; OXIDATIVE STRESS	Heat shock protein (HSP) 27 has long been known to be a component of the p38 mitogen-activated protein kinase (MAPK) signaling pathway. p38 MAPK has important functions in the inflammatory response, but the role of HSP27 in inflammation has remained unknown. We have used small interfering RNAs to suppress HSP27 expression in HeLa cells and fibroblasts and found that it is required for pro-inflammatory cell signaling and the expression of pro-inflammatory genes. HSP27 is needed for the activation by interleukin (IL)-1 of TAK1 and downstream signaling by p38 MAPK, JNK, and their activators (MKK-3, -4, -6, -7) and IKK beta. IL-1-induced ERK activation appears to be independent of HSP27. HSP27 is required for both IL-1 and TNF-induced signaling pathways for which the most upstream common signaling protein is TAK1. HSP27 is also required for IL-1-induced expression of the pro-inflammatory mediators, cyclooxygenase-2, IL-6, and IL-8. FISP27 functions to drive cyclooxygenase-2 and IL-6 expression by augmenting the activation of the kinase downstream of p38 MAPK, MK2, resulting in stabilization of cyclooxygenase-2 and IL-6 mRNAs. The mechanism may not occur in cells of myeloid lineage because HSP27 protein was undetectable in human monocytes and murine macrophages.	Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, London W6 8LH, England	Imperial College London; University of Oxford	Dean, JLE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, 1 Aspenlea Rd, London W6 8LH, England.	jonathan.dean@imperial.ac.uk		Dean, Jonathan/0000-0002-0703-2756	MRC [G8623776] Funding Source: UKRI; Medical Research Council [G8623776] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD R, 1995, SCIENCE, V267, P682; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Finch A, 2001, BIOCHEM J, V353, P275, DOI 10.1042/0264-6021:3530275; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Garrido C, 1997, CANCER RES, V57, P2661; Guay J, 1997, J CELL SCI, V110, P357; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HUOT J, 1991, CANCER RES, V51, P5245; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sato S, 2006, INT IMMUNOL, V18, P1405, DOI 10.1093/intimm/dxl082; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	53	104	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6232	6241		10.1074/jbc.M610987200	http://dx.doi.org/10.1074/jbc.M610987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202147	hybrid			2022-12-25	WOS:000244867200029
J	Bruns, JB; Carattino, MD; Sheng, SH; Maarouf, AB; Weisz, OA; Pilewski, JM; Hughey, RP; Kleyman, TR				Bruns, James B.; Carattino, Marcelo D.; Sheng, Shaohu; Maarouf, Ahmad B.; Weisz, Ora A.; Pilewski, Joseph M.; Hughey, Rebecca P.; Kleyman, Thomas R.			Epithelial Na+ channels are fully activated by furin- and prostasin-dependent release of an inhibitory peptide from the gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; MEMBRANE TOPOLOGY; SURFACE EXPRESSION; ALPHA-SUBUNIT; PORE REGION; ENAC; MCAP1	Epithelial sodium channels (ENaC) are expressed in the apical membrane of high resistance Na+ transporting epithelia and have a key role in regulating extracellular fluid volume and the volume of airway surface liquids. Maturation and activation of ENaC subunits involves furin-dependent cleavage of the ectodomain at two sites in the alpha subunit and at a single site within the gamma subunit. We now report that the serine protease prostasin further activates ENaC by inducing cleavage of the gamma subunit at a site distal to the furin cleavage site. Dual cleavage of the gamma subunit is predicted to release a 43-amino acid peptide. Channels with a gamma subunit lacking this 43-residue tract have increased activity due to a high open probability. A synthetic peptide corresponding to the fragment cleaved from the gamma subunit is a reversible inhibitor of endogenous ENaCs in mouse corticalcollecting duct cells and in primary cultures of human airway epithelial cells. Our results suggest that multiple proteases cleave ENaC gamma subunits to fully activate the channel.	Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Div Pulm & Crit Care Med, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, S933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu	Sheng, Shaohu/G-7052-2016; Pilewski, Joseph/AAF-5149-2021	Sheng, Shaohu/0000-0002-7198-1702; 	NIDDK NIH HHS [P50 DK54690, P30 DK072506, DK065161] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK065161, R01DK065161, P30DK072506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; Adebamiro A, 2005, J GEN PHYSIOL, V126, P339, DOI 10.1085/jgp.200509285; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Andreasen D, 2006, J AM SOC NEPHROL, V17, P968, DOI 10.1681/ASN.2005060637; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Carattino MD, 2005, J BIOL CHEM, V280, P4393, DOI 10.1074/jbc.M413123200; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Harris M, 2007, J BIOL CHEM, V282, P58, DOI 10.1074/jbc.M605125200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Iwashita K, 2003, J AM SOC NEPHROL, V14, P11, DOI 10.1097/01.ASN.0000043900.39397.48; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Liu L, 2002, HYPERTENSION, V39, P860, DOI 10.1161/01.HYP.0000013055.48885.8D; Myerburg MM, 2006, J BIOL CHEM, V281, P27942, DOI 10.1074/jbc.M606449200; Narikiyo T, 2002, J CLIN INVEST, V109, P401, DOI 10.1172/JCI13229; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wakida N, 2006, KIDNEY INT, V70, P1432, DOI 10.1038/sj.ki.5001787	41	255	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6153	6160		10.1074/jbc.M610636200	http://dx.doi.org/10.1074/jbc.M610636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17199078	hybrid			2022-12-25	WOS:000244867200021
J	Gerber, R; Tahiri-Alaoui, A; Hore, PJ; James, W				Gerber, Remo; Tahiri-Alaoui, Abdessamad; Hore, P. J.; James, William			Oligomerization of the human prion protein proceeds via a molten globule intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR DIFFUSION MEASUREMENTS; CREUTZFELDT-JAKOB-DISEASE; MOLECULAR-BIOLOGY; CULTURED-CELLS; SCRAPIE; RECOMBINANT; SUSCEPTIBILITY; CONFORMATIONS; SPECTROSCOPY; TRANSITION	The conformational transition of the human prion protein from an alpha-helical to a beta-sheet-rich structure is believed to be the critical event in prion pathogenesis. The molecular mechanism of misfolding and the role of intermediate states during this transition remain poorly understood. To overcome the obstacle of insolubility of amyloid fibrils, we have studied a beta-sheet-rich misfolded isoform of the prion protein, the 6-oligomer, which shares some structural properties with amyloid, including partial proteinase resistance. We demonstrate here that the beta-oligomer can be studied by solution-state NMR spectroscopy and obtain insights into the misfolding mechanism via its transient monomeric precursor. It is often assumed that misfolding into beta-sheet-rich isoforms proceeds via a compatible precursor with a beta-sheet subunit structure. We show here, on the contrary, evidence for an almost natively alpha-helix-rich monomeric precursor state with molten globule characteristics, converting in vitro into the beta-oligomer. We propose a possible mechanism for the formation of the beta-oligomer, triggered by intermolecular contacts between constantly rearranging structures. It is concluded that the beta-oligomer is not preceded by precursors with beta-sheet structure but by a partially unfolded clearly distinguishable alpha-helical state.	Univ Oxford, Dept Chem, Phys & Theoret Chem Lab, Oxford OX1 3QZ, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; University of Oxford	Gerber, R (corresponding author), Univ Oxford, Dept Chem, Phys & Theoret Chem Lab, S Parks Rd, Oxford OX1 3QZ, England.	remo.gerber@chem.ox.ac.uk	Hore, Peter/R-1923-2017; james, william/H-4289-2013	Hore, Peter/0000-0002-8863-570X; james, william/0000-0002-2506-1198				Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; ARNOLD JE, 1995, J PATHOL, V176, P403, DOI 10.1002/path.1711760412; Baskakov I, 2005, FEBS LETT, V579, P2589, DOI 10.1016/j.febslet.2005.03.075; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, PROTEIN SCI, V13, P586, DOI 10.1110/ps.03457204; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Keller R., 2004, COMPUTER AIDED RESON, V1; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MERRILL MR, 1993, J MAGN RESON SER A, V103, P223, DOI 10.1006/jmra.1993.1157; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; Novitskaya V, 2006, J BIOL CHEM, V281, P13828, DOI 10.1074/jbc.M511174200; OESCH B, 1985, CELL, V40, P7385; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Redfield C, 2004, METHODS, V34, P121, DOI 10.1016/j.ymeth.2004.03.009; Redfield C, 1999, CURR BIOL, V9, pR313, DOI 10.1016/S0960-9822(99)80199-7; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Tahiri-Alaoui A, 2005, PROTEIN SCI, V14, P942, DOI 10.1110/ps.041000905; Tahiri-Alaoui A, 2004, J BIOL CHEM, V279, P31390, DOI 10.1074/jbc.M401754200; Tahiri-Alaoui A, 2006, J BIOL CHEM, V281, P34171, DOI 10.1074/jbc.M606606200; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	46	69	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6300	6307		10.1074/jbc.M608926200	http://dx.doi.org/10.1074/jbc.M608926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17210575	hybrid			2022-12-25	WOS:000244867200036
J	Lee, JG; Kay, EP				Lee, Jeong Goo; Kay, EunDuck P.			Two populations of p27 use differential kinetics to phosphorylate Ser-10 and Thr-187 via phosphatidylinositol 3-kinase in response to fibroblast growth factor-2 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL ENDOTHELIAL-CELLS; DEPENDENT KINASE INHIBITOR; MESENCHYMAL TRANSFORMATION; CYTOPLASMIC LOCALIZATION; CYCLE PROGRESSION; REGULATORY ROLE; NUCLEAR EXPORT; I COLLAGEN; P27(KIP1); DEGRADATION	The cyclin-dependent kinase inhibitor p27 regulates cell cycle progression. We investigated whether FGF-2 uses PI 3-kinase to facilitate phosphorylation of p27 on serine 10 (Ser-10) and threonine 187 (Thr-187) and whether the two phosphorylation sites were differentially regulated. FGF-2 stimulation dramatically increased p27 phosphorylation at Ser-10 and Thr-187 using differential kinetics, and the FGF-2-induced p27 phosphorylation was completely blocked at both sites by LY294002. We determined the physical and biochemical interaction of p27 with the Cdk2-cyclin E complex in response to FGF-2 stimulation. Maximal p27 binding to Cdk2-cyclin E occurred at 12 h; the maximal level of p27 phosphorylation at Thr-187 in the ternary complex was observed at 16 h; ubiquitination of the Thr-187-phosphorylated p27 (pp27Thr-187) was observed starting at 12 h and continuing up to 24 h. However, maximum p27 phosphorylation at Ser-10 occurred in the nucleus 6 h after FGF-2 stimulation; maximal export of Ser-10-phosphorylated p27 (pp27Ser-10) occurred 8 h after FGF-2 treatment, and pp27Ser-10 was simultaneously ubiquitinated. We further investigated which of the two phosphorylated p27 was involved in G(1)/S progression. LY294002 blocked 64% of the cell proliferation stimulated by FGF-2. Use of leptomycin B to block nuclear export of pp27Ser-10 greatly decreased the FGF-2-stimulated cell proliferation (44%), suggesting that phosphorylation of p27 at Ser-10 is the major mechanism for G(1)/S transition. Our results suggest that differential kinetics are observed in p27 phosphorylation at Ser-10 and Thr-187 and that pp27Thr-187 and pp27Ser-10 may represent two populations of p27 observed in the G(1) phase of the cell cycle.	Univ So Calif, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90089 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Kay, EP (corresponding author), Univ So Calif, Doheny Eye Inst, Keck Sch Med, 1450 San Pablo St,DVRC 203, Los Angeles, CA 90089 USA.	ekay@usc.edu			NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHS [EY03040, EY06431] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; BROWN SI, 1966, ARCH OPHTHALMOL-CHIC, V75, P518; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Joyce NC, 1996, INVEST OPHTH VIS SCI, V37, P1566; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KAY EDP, 1994, INVEST OPHTH VIS SCI, V35, P2427; KAY EP, 1982, J BIOL CHEM, V257, P7116; KAY EP, 1993, INVEST OPHTH VIS SCI, V34, P663; KAY EP, 1982, INVEST OPHTH VIS SCI, V22, P200; Ko MK, 2005, INVEST OPHTH VIS SCI, V46, P4495, DOI 10.1167/iovs.05-0818; Ko MK, 2001, EXP CELL RES, V264, P363, DOI 10.1006/excr.2000.5155; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P1521, DOI 10.1167/iovs.02-0637; Lee JG, 2006, INVEST OPHTH VIS SCI, V47, P2358, DOI 10.1167/iovs.05-1490; Lee JG, 2006, INVEST OPHTH VIS SCI, V47, P1376, DOI 10.1167/iovs.05-1223; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Senoo T, 2000, INVEST OPHTH VIS SCI, V41, P660; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713	36	35	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6444	6454		10.1074/jbc.M607808200	http://dx.doi.org/10.1074/jbc.M607808200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17209046	hybrid			2022-12-25	WOS:000244867200052
J	Beard, DA; Qian, H				Beard, Daniel A.; Qian, Hong			Relationship between Thermodynamic Driving Force and One-Way Fluxes in Reversible Processes	PLOS ONE			English	Article								Chemical reaction systems operating in nonequilibrium open-system states arise in a great number of contexts, including the study of living organisms, in which chemical reactions, in general, are far from equilibrium. Here we introduce a theorem that relates forward and reverse fluxes and free energy for any chemical process operating in a steady state. This relationship, which is a generalization of equilibrium conditions to the case of a chemical process occurring in a nonequilibrium steady state in dilute solution, provides a novel equivalent definition for chemical reaction free energy. In addition, it is shown that previously unrelated theories introduced by Ussing and Hodgkin and Huxley for transport of ions across membranes, Hill for catalytic cycle fluxes, and Crooks for entropy production in microscopically reversible systems, are united in a common framework based on this relationship.	[Beard, Daniel A.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Qian, Hong] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA	Medical College of Wisconsin; University of Washington; University of Washington Seattle	Beard, DA (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	dbeard@mcw.edu			NIH [GM0680610]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant GM0680610.	Crooks GE, 1999, PHYS REV E, V60, P2721, DOI 10.1103/PhysRevE.60.2721; Frank T, 1996, FOKKER PLANCK EQUATI; GALLAVOTTI G, 1995, PHYS REV LETT, V74, P2694, DOI 10.1103/PhysRevLett.74.2694; Hill T.L., 1977, FREE ENERGY TRANSDUC; HILL TL, 1975, P NATL ACAD SCI USA, V72, P1291, DOI 10.1073/pnas.72.4.1291; HILL TL, 1988, P NATL ACAD SCI USA, V85, P5345, DOI 10.1073/pnas.85.15.5345; HILL TL, 1966, J THEOR BIOL, V10, P442, DOI 10.1016/0022-5193(66)90137-8; Hill TL, 2004, FREE ENERGY TRANSDUC; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P449, DOI 10.1113/jphysiol.1952.sp004717; KOHLER HH, 1980, J MATH BIOL, V9, P275, DOI 10.1007/BF00276029; Lewis GN, 1925, P NATL ACAD SCI USA, V11, P179, DOI 10.1073/pnas.11.3.179; Onsager L, 1931, PHYS REV, V37, P405, DOI 10.1103/PhysRev.37.405; Onsager L, 1931, PHYS REV, V38, P2265, DOI 10.1103/PhysRev.38.2265; QIAN C, 1981, SCI SINICA, V24, P1431; Qian H, 2005, BIOPHYS CHEM, V114, P213, DOI 10.1016/j.bpc.2004.12.001; Qian H, 2003, EUR J BIOCHEM, V270, P415, DOI 10.1046/j.1432-1033.2003.03357.x; Qian H, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.022101; Qian H, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.010902; USSING HH, 1949, ACTA PHYSIOL SCAND, V19, P43, DOI 10.1111/j.1748-1716.1949.tb00633.x; Wiechert W, 1997, BIOTECHNOL BIOENG, V55, P101, DOI 10.1002/(SICI)1097-0290(19970705)55:1<101::AID-BIT12>3.0.CO;2-P	20	112	113	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e144	10.1371/journal.pone.0000144	http://dx.doi.org/10.1371/journal.pone.0000144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206279	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443800006
J	Koivusilta, LK; Ojanlatva, A				Koivusilta, Leena K.; Ojanlatva, Ansa			To Have or Not To Have a Pet for Better Health?	PLOS ONE			English	Article								Background. Pet ownership is thought to have health benefits, but not all scientific explorations have been founded on proper applications of representative samples or statistically correct methodologies. Databanks have been too small for proper statistical analyses; or, instead of a random sample, participation has been voluntary. The direction of causality has been evaluated incorrectly or control of relevant factors noted deficient. This study examined the associations of pet ownership with perceived health and disease indicators by taking into account socio-demographic background factors together with health risk factors, including exercise. Methodology/Principal Findings. The present study used baseline data from the 15-year Health and Social Support Study (the HeSSup Study). The Finnish Population Register Centre was used to draw population-based random samples stratified according to gender and four age groups (20-24, 30-34, 40-44, and 50-54 years). A total of 21,101 working-aged Finns responded to the baseline survey questionnaire of the 15-year HeSSup Study in 1998. Ordinal and binary logistic regression was used to analyze the cross-sectional data. Pet ownership was associated with poor rather than good perceived health. BMI surfaced as the risk factor most strongly associated with pet ownership. Conclusions/Significance. Pet owners set in their ways and getting older were found to have a slightly higher BMI than the rest. Additional research is needed for the testing of hypotheses involving effects of pet ownership with various health dimensions within population groups that are composed of different kinds of background characteristics.	[Ojanlatva, Ansa] Univ Turku, Dept Teacher Educ, Turku, Finland; [Ojanlatva, Ansa] Univ Turku, Inst Biomed, Ctr Reprod & Dev Med, Turku, Finland; [Ojanlatva, Ansa] Turku City Hosp, Turku, Finland; [Koivusilta, Leena K.] Univ Turku, Inst & Social Mech IASM Consortium, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku	Ojanlatva, A (corresponding author), Univ Turku, Dept Teacher Educ, Turku, Finland.	ansa.ojanlatva@utu.fi						ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; ANDERSON WP, 1992, MED J AUSTRALIA, V157, P298, DOI 10.5694/j.1326-5377.1992.tb137178.x; [Anonymous], 1984, BIOPHILIA HUMAN BOND; *APPMA, US PET OWN STAT 2005; Argyle M., 1994, PSYCHOL SOCIAL CLASS; AROMAA A, 2002, HLTH FUNCTIONAL CAPA; Bauman AE, 2001, MED J AUSTRALIA, V175, P632, DOI 10.5694/j.1326-5377.2001.tb143757.x; BECK AM, 1984, J AM VET MED ASSOC, V184, P414; DOBSON A, 1998, AN COMM HLTH PUBL PO; Elo IT, 1996, SOC SCI MED, V42, P47, DOI 10.1016/0277-9536(95)00062-3; Friedmann E, 2003, AM J CARDIOL, V91, P718, DOI 10.1016/S0002-9149(02)03412-4; FRIEDMANN E, 1995, AM J CARDIOL, V76, P1213, DOI 10.1016/S0002-9149(99)80343-9; FRIEDMANN E, 1980, PUBLIC HEALTH REP, V95, P307; Friedmann E., 1995, WALTHAM BOOK HUMAN A; Frumkin P, 2001, AM J PREV MED, V20, P234, DOI 10.1016/S0749-3797(00)00317-2; Headey B, 2003, MED J AUSTRALIA, V179, P460, DOI 10.5694/j.1326-5377.2003.tb05646.x; Headey B, 1999, SOC INDIC RES, V47, P233, DOI 10.1023/A:1006892908532; HEADEY B, 2003, C 20 ANN GERM SOC PA; HEADEY B, 1995, HLTH COST SAVINGS IM; HEADEY B, 1999, DO PET OWNERS ENJOY; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jorm AF, 1997, MED J AUSTRALIA, V166, P376, DOI 10.5694/j.1326-5377.1997.tb123170.x; Kingwell BA, 2001, CLIN AUTON RES, V11, P313, DOI 10.1007/BF02332977; Korkeila K, 2001, EUR J EPIDEMIOL, V17, P991, DOI 10.1023/A:1020016922473; KOSKENVUO M, 1986, SOC SCI MED, V23, P605, DOI 10.1016/0277-9536(86)90154-1; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; McHarg M., 1995, NATL PEOPLE PETS SUR; Parslow RA, 2005, GERONTOLOGY, V51, P40, DOI 10.1159/000081433; Parslow RA, 2003, MED J AUSTRALIA, V179, P466, DOI 10.5694/j.1326-5377.2003.tb05649.x; Putnam RD., 2000, BOWLING ALONE COLLAP; Raina P, 1999, J AM GERIATR SOC, V47, P323, DOI 10.1111/j.1532-5415.1999.tb02996.x; RAINA P, 1998, RELATIONSHIP PET OWN; ROWAN AN, 1994, ANTHROZOOS, V7, P85, DOI 10.2752/089279394787001916; SERPELL J, 1991, J ROY SOC MED, V84, P717, DOI 10.1177/014107689108401208; Siegel JM, 1999, AIDS CARE, V11, P157, DOI 10.1080/09540129948054; SIEGEL JM, 1990, J PERS SOC PSYCHOL, V58, P1081, DOI 10.1037/0022-3514.58.6.1081; Simons LA, 1997, MED J AUSTRALIA, V167, P231, DOI 10.5694/j.1326-5377.1997.tb138864.x; *STAT FINL, STAT YB FINL 1998; Virtanen P, 2003, INT J EPIDEMIOL, V32, P1015, DOI 10.1093/ije/dyg319; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WRIGHT JC, 1982, PUBLIC HEALTH REP, V97, P380; 2000, OUR DOGS MAGAZINE, P16	44	34	34	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e109	10.1371/journal.pone.0000109	http://dx.doi.org/10.1371/journal.pone.0000109			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205113	gold, Green Published			2022-12-25	WOS:000207443700004
J	Cuerrier, D; Moldoveanu, T; Campbell, RL; Kelly, J; Yoruk, B; Verhelst, SHL; Greenbaum, D; Bogyo, M; Davies, PL				Cuerrier, Dominic; Moldoveanu, Tudor; Campbell, Robert L.; Kelly, Jacqueline; Yoruk, Bilge; Verhelst, Steven H. L.; Greenbaum, Doron; Bogyo, Matthew; Davies, Peter L.			Development of calpain-specific inactivators by screening of positional scanning epoxide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; CYSTEINE PROTEASES; CATHEPSIN-B; ACTIVE-SITE; CRYSTAL-STRUCTURES; ELECTRON-DENSITY; PEPTIDE EPOXIDES; IN-VITRO; INHIBITORS; CRYSTALLOGRAPHY	Calpains are calcium-dependent proteases that are required for numerous intracellular processes but also play an important role in the development of pathologies such as ischemic injury and neurodegeneration. Many current small molecule calpain inhibitors also inhibit other cysteine proteases, including cathepsins, and need improved selectivity. The specificity of inhibition of several calpains and papain was profiled using synthetic positional scanning libraries of epoxide-based compounds that target the active-site cysteine. These peptidomimetic libraries probe the P4, P3, and P2 positions, display (SS)- or (RR)-epoxide stereochemistries, and incorporate both natural and nonnatural amino acids. To facilitate library screening, an SDS-PAGE assay that measures the extent of hydrolysis of an inactive recombinant m-calpain was developed. Individual epoxide inhibitors were synthesized guided by calpain-specific preferences observed from the profiles and tested for inhibition against calpain. The most potent compounds were assayed for specificity against cathepsins B, L, and K. Several compounds demonstrated high inhibition specificity for calpains over cathepsins. The best of these inhibitors, WRH(RR), irreversibly inactivates m- and mu-calpain rapidly (k(2)/K-i = 131,000 and 16,500 M-1 s(-1), respectively) but behaves exclusively as a reversible and less potent inhibitor toward the cathepsins. X-ray crystallography of the proteolytic core of rat mu-calpain inactivated by the epoxide compounds WR gamma-cyano-alpha-aminobutyric acid (SS) and WR allylglycine (RR) reveals that the stereochemistry of the epoxide influences positioning and orientation of the P2 residue, facilitating alternate interactions within the S2 pocket. Moreover, the WR gamma-cyano-alpha-aminobutyric acid (SS)-complexed structure defines a novel hydrogen-bonding site within the S2 pocket of calpains.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Funct Discovery Grp, Kingston, ON K7L 3N6, Canada; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Queens University - Canada; Queens University - Canada; Stanford University	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Botterell Hall, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X; Campbell, Robert/0000-0002-5473-5876; Verhelst, Steven/0000-0002-7400-1319; Bogyo, Matthew/0000-0003-3753-4412	NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005011] Funding Source: NIH RePORTER; NCRR NIH HHS [U54 RR20843] Funding Source: Medline; NIBIB NIH HHS [R01-EB005011] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Chatterjee S, 1998, J MED CHEM, V41, P2663, DOI 10.1021/jm980035y; Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200; Chou FL, 1999, NEUROLOGY, V52, P1015, DOI 10.1212/WNL.52.5.1015; Cox NJ, 2004, DIABETES, V53, pS19, DOI 10.2337/diabetes.53.2007.S19; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; Cuerrier D, 2006, BIOCHEMISTRY-US, V45, P7446, DOI 10.1021/bi060425j; Cuerrier D, 2005, J BIOL CHEM, V280, P40632, DOI 10.1074/jbc.M506870200; Delano W. L., 2003, PYMOL MOL GENETICS G; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Greenbaum D, 2002, MOL CELL PROTEOMICS, V1, P60, DOI 10.1074/mcp.T100003-MCP200; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Greenbaum DC, 2002, CHEM BIOL, V9, P1085, DOI 10.1016/S1074-5521(02)00238-7; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; James KE, 2004, J MED CHEM, V47, P1553, DOI 10.1021/jm0305016; Janossy J, 2004, BIOCHEM PHARMACOL, V67, P1513, DOI 10.1016/j.bcp.2003.12.021; Kambe A, 2005, BRAIN RES, V1040, P36, DOI 10.1016/j.brainres.2005.01.080; Katunuma N, 1999, FEBS LETT, V458, P6, DOI 10.1016/S0014-5793(99)01107-2; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Li QS, 2006, BIOCHEMISTRY-US, V45, P701, DOI 10.1021/bi052077b; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; Mathur P, 2000, CURR EYE RES, V21, P926, DOI 10.1076/ceyr.21.6.926.6990; Matsumoto K, 1999, BIOPOLYMERS, V51, P99, DOI 10.1002/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moldoveanu T, 2004, J MOL BIOL, V343, P1313, DOI 10.1016/j.jmb.2004.09.016; Moldoveanu T, 2004, J BIOL CHEM, V279, P6106, DOI 10.1074/jbc.M310460200; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2001, BBA-PROTEIN STRUCT M, V1545, P245, DOI 10.1016/S0167-4838(00)00286-7; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; PARKES C, 1985, BIOCHEM J, V230, P509, DOI 10.1042/bj2300509; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Schaschke N, 1998, FEBS LETT, V421, P80, DOI 10.1016/S0014-5793(97)01538-X; Schaschke N, 1997, BIOORGAN MED CHEM, V5, P1789, DOI 10.1016/S0968-0896(97)00105-3; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; Verhelst SHL, 2005, CHEMBIOCHEM, V6, P824, DOI 10.1002/cbic.200400377; Wang K K, 1997, Adv Pharmacol, V37, P117; Wieczerzak E, 2005, J PEPT RES, V66, P1, DOI 10.1111/j.1747-0285.2006.00329.x; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x	57	34	35	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9600	9611		10.1074/jbc.M610372200	http://dx.doi.org/10.1074/jbc.M610372200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17218315	hybrid			2022-12-25	WOS:000245421700033
J	Mercer, AE; Maggs, JL; Sun, XM; Cohen, GM; Chadwick, J; O'Neill, PM; Park, BK				Mercer, Amy E.; Maggs, James L.; Sun, Xiao-Ming; Cohen, Gerald M.; Chadwick, James; O'Neill, Paul M.; Park, B. Kevin			Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-TRAPPING EVIDENCE; LEUKEMIC HL60 CELLS; QINGHAOSU ARTEMISININ; TRANSFERRIN RECEPTOR; TUMOR-CELLS; IN-VITRO; ANTIMALARIAL ENDOPEROXIDE; MONOCLONAL-ANTIBODY; BILIARY METABOLITES; SELECTIVE TOXICITY	Artemisinin and its derivatives are currently recommended as first-line antimalarials in regions where Plasmodium-falciparum is resistant to traditional drugs. The cytotoxic activity of these endoperoxides toward rapidly dividing human carcinoma cells and cell lines has been reported, and it is hypothesized that activation of the endoperoxide bridge by an iron(II) species, to form C-centered radicals, is essential for cytotoxicity. The studies described here have utilized artemisinin derivatives, dihydroartemisinin, 10 beta-(p-bromophenoxy)dihydroartemisinin, and 10 beta-(p-fluorophenoxy)dihydroartemisinin, to determine the chemistry of endoperoxide bridge activation to reactive intermediates responsible for initiating cell death and to elucidate the molecular mechanism of cell death. These studies have demonstrated the selective cytotoxic activity of the endoperoxides toward leukemia cell lines (HL-60 and Jurkat) over quiescent peripheral blood mononuclear cells. Deoxy10 beta-(p-fluorophenoxy)dihydroartemisinin, which lacks the endoperoxide bridge, was 50- and 130-fold less active in HL-60 and jurkat cells, respectively, confirming the importance of this functional group for cytotoxicity. We have shown that chemical activation is responsible for cytotoxicity by using liquid chromatography-mass spectrometry analysis to monitor endoperoxide activation by measurement of a stable rearrangement product of endoperoxide-derived radicals, which was formed in sensitive HL-60 cells but not in insensitive peripheral blood mononuclear cells. In HL-60 cells the endoperoxides induce caspase-dependent apoptotic cell death characterized by concentration- and time-dependent mitochondrial membrane depolarization, activation of caspases-3 and -7, sub-G(0)/G(1), DNA formation, and attenuation by benzyloxycarbonyl-VAD-fluoromethyI ketone, a caspase inhibitor. Overall, these results indicate that endoperoxide-induced cell death is a consequence of activation of the endoperoxide bridge to radical species, which triggers caspase-dependent apoptosis.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Chem, Liverpool L69 3GE, Merseyside, England; MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Liverpool; University of Liverpool; University of Leicester	Park, BK (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Sherrington Bldgs, Liverpool L69 3GE, Merseyside, England.	b.k.park@liv.ac.uk	Chadwick, Amy E/D-8633-2015; Cohen, Gerald M/A-1687-2008; Chadwick, James/A-7574-2017	Chadwick, Amy E/0000-0002-7399-8655; Chadwick, James/0000-0003-4456-0117	MRC [MC_U132615750] Funding Source: UKRI; Medical Research Council [MC_U132615750] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Beekman AC, 1998, PLANTA MED, V64, P615, DOI 10.1055/s-2006-957533; Beekman AC, 1997, J NAT PROD, V60, P325, DOI 10.1021/np9605495; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; CHITAMBAR CR, 1990, J LAB CLIN MED, V116, P345; Clark RL, 2004, BIRTH DEFECTS RES B, V71, P380, DOI 10.1002/bdrb.20027; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Creek DJ, 2005, J PHARM SCI-US, V94, P1820, DOI 10.1002/jps.20400; deVries PJ, 1996, DRUGS, V52, P818, DOI 10.2165/00003495-199652060-00004; Dinsdale D, 1999, AM J PATHOL, V155, P607, DOI 10.1016/S0002-9440(10)65156-5; Disbrow GL, 2005, CANCER RES, V65, P10854, DOI 10.1158/0008-5472.CAN-05-1216; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Efferth T, 2001, INT J ONCOL, V18, P767; Furtmuller PG, 2000, FEBS LETT, V484, P139, DOI 10.1016/S0014-5793(00)02143-8; GALLAGHER R, 1979, BLOOD, V54, P713; Hachiya M, 2000, BBA-MOL CELL RES, V1495, P237, DOI 10.1016/S0167-4889(99)00168-8; Haynes RK, 2004, MICROBES INFECT, V6, P1339, DOI 10.1016/j.micinf.2004.09.002; Haynes RK, 1996, TETRAHEDRON LETT, V37, P253, DOI 10.1016/0040-4039(95)02141-8; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Jahaniani F, 2005, PHYTOCHEMISTRY, V66, P1581, DOI 10.1016/j.phytochem.2005.04.035; Jeyadevan JP, 2004, J MED CHEM, V47, P1290, DOI 10.1021/jm030974c; Jung M, 1997, BIOORG MED CHEM LETT, V7, P1091, DOI 10.1016/S0960-894X(97)00169-8; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kumar P, 2002, J MED MICROBIOL, V51, P832, DOI 10.1099/0022-1317-51-10-832; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; LAI H, 1995, CANCER LETT, V91, P41, DOI 10.1016/0304-3835(94)03716-V; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; LEBMAN D, 1982, BLOOD, V59, P671; Li W, 2005, PLOS GENET, V1, P329, DOI 10.1371/journal.pgen.0010036; Li Y, 2001, BIOORG MED CHEM LETT, V11, P5, DOI 10.1016/S0960-894X(00)00578-3; Longo M, 2006, REPROD TOXICOL, V21, P83, DOI 10.1016/j.reprotox.2005.05.005; Maggs JL, 2000, DRUG METAB DISPOS, V28, P209; Maggs JL, 1997, DRUG METAB DISPOS, V25, P1200; O'Neill PM, 2004, J MED CHEM, V47, P2945, DOI 10.1021/jm030571c; O'Neill PM, 2000, J ORG CHEM, V65, P1578, DOI 10.1021/jo991585m; O'Neill PM, 2001, J MED CHEM, V44, P58, DOI 10.1021/jm000987f; Park BK, 1998, BRIT J CLIN PHARMACO, V46, P521, DOI 10.1046/j.1365-2125.1998.00838.x; PILARSKI LM, 1995, AM J HEMATOL, V49, P323, DOI 10.1002/ajh.2830490411; Posner GH, 2003, J MED CHEM, V46, P1060, DOI 10.1021/jm020461q; Posner GH, 1999, J MED CHEM, V42, P4275, DOI 10.1021/jm990363d; POSNER GH, 1992, J AM CHEM SOC, V114, P8328, DOI 10.1021/ja00047a076; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; RIBIERIO IR, 1998, MED TROP, V58, P50; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; Sadava D, 2002, CANCER LETT, V179, P151, DOI 10.1016/S0304-3835(02)00005-8; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schmuck G, 2002, ANTIMICROB AGENTS CH, V46, P821, DOI 10.1128/AAC.46.3.821-827.2002; SEARLE J, 1982, PATHOL ANNU, V17, P229; Singh NP, 2001, LIFE SCI, V70, P49, DOI 10.1016/S0024-3205(01)01372-8; Smith SL, 1997, BIOCHEM PHARMACOL, V53, P5, DOI 10.1016/S0006-2952(96)00591-6; Smith SL, 1998, NEUROTOXICOLOGY, V19, P557; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki F, 2005, ANTICANCER RES, V25, P887; TAETLE R, 1985, J CLIN INVEST, V75, P1061, DOI 10.1172/JCI111768; TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRUMP BF, 1984, DRUG METABOLISM DRUG, P261; van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4; Wang DY, 2000, CHEM COMMUN, P2193, DOI 10.1039/b006906j; Williams DP, 1997, J PHARMACOL EXP THER, V283, P1375; WOERDENBAG HJ, 1993, J NAT PROD, V56, P849, DOI 10.1021/np50096a007; Wu GD, 2004, VASC PHARMACOL, V41, P205, DOI 10.1016/j.vph.2004.11.001; Wu WM, 1998, J AM CHEM SOC, V120, P3316, DOI 10.1021/ja973080o; Wu WM, 1996, CHEM COMMUN, P2213, DOI 10.1039/cc9960002213; Wu YK, 2003, HELV CHIM ACTA, V86, P3074, DOI 10.1002/hlca.200390249; Wu YK, 2003, CHEM RES TOXICOL, V16, P1202, DOI 10.1021/tx034133k; Wu YK, 1999, ANGEW CHEM INT EDIT, V38, P2580, DOI 10.1002/(SICI)1521-3773(19990903)38:17&lt;2580::AID-ANIE2580&gt;3.0.CO;2-J; YANG YZ, 1993, BIOCHEM PHARMACOL, V46, P336, DOI 10.1016/0006-2952(93)90425-V; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	76	153	175	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9372	9382		10.1074/jbc.M610375200	http://dx.doi.org/10.1074/jbc.M610375200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17227762	hybrid			2022-12-25	WOS:000245421700009
J	Vigneux, F; Zumbihl, R; Jubelin, G; Ribeiro, C; Poncet, J; Baghdiguian, S; Givaudan, A; Brehelin, M				Vigneux, Fabienne; Zumbihl, Robert; Jubelin, Gregory; Ribeiro, Carlos; Poncet, Joel; Baghdiguian, Stephen; Givaudan, Alain; Brehelin, Michel			The xaxAB genes encoding a new apoptotic toxin from the insect pathogen Xenorhabdus nematophila are present in plant and human pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM PHOTORHABDUS-LUMINESCENS; ESCHERICHIA-COLI; GENOME SEQUENCE; FULL VIRULENCE; FAMILY; CELLS; HEMOLYSIN; CLOSTRIDIUM; ACTIVATION; EXPRESSION	Xenorhabdus nematophila, a member of the Enterobacteriaceae, kills many species of insects by strongly depressing the immune system and colonizing the entire body. A peptide cytotoxin has been purified from X. nematophila broth growth, and the cytolytic effect on insect immunocytes and hemolytic effect on mammalian red blood cells of this toxin have been described (Ribeiro, C., Vignes, M., and Brehelin, M. (2003) J. Mal. Chem. 278, 3030-3039). We show here that this toxin, Xenorhabdus alpha-xenorhabdolysin (Xax), triggers apoptosis in both insect and mammalian cells. We also report the cloning and sequencing of two genes, xaxAB, encoding this toxin in X. nematophila. The expression of both genes in recombinant Escherichia coli led to the production of active cytotoxin/hemolysin. However, hemolytic activity was observed only if the two peptides were added in the appropriate order. Furthermore, we report here that inactivation of xaxAB genes in X. nematophila abolished the major cytotoxic activity present in broth growth, called C I. We also show that these genes are present in various entomopathogenic bacteria of the genera Xenorhabdus and Photorhabdus, in Pseudomonas entomophila, in the human pathogens Yersinia enterocolitica and Proteus mirabilis, and in the plant pathogen Pseudomonas syringae. This toxin cannot be classified in any known family of cytotoxins on the basis of amino acid sequences, locus organization, and activity features. It is, therefore, probably the prototype of a new family of binary toxins.	Univ Montpellier 2, INRA, UMR 1133, F-34095 Montpellier, France; Univ Montpellier 1, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5554, Inst Sci Evolut, F-34095 Montpellier, France	INRAE; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Givaudan, A (corresponding author), Univ Montpellier 2, INRA, UMR 1133, Pl Eugene Bataillon, F-34095 Montpellier, France.	givaudan@univ-montp2.fr; brehelin@univ-montp2.fr		Baghdiguian, Stephen/0000-0002-2992-9708; JUBELIN, Gregory/0000-0002-9902-0663				Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; BREHELIN M, 1989, INSECT BIOCHEM, V19, P301, DOI 10.1016/0020-1790(89)90076-0; Brillard J, 2003, FEMS MICROBIOL LETT, V218, P107, DOI 10.1111/j.1574-6968.2003.tb11505.x; Brillard J, 2002, J BACTERIOL, V184, P3871, DOI 10.1128/JB.184.14.3871-3878.2002; Brillard J, 2001, APPL ENVIRON MICROB, V67, P2515, DOI 10.1128/AEM.67.6.2515-2525.2001; Coburn PS, 2004, SCIENCE, V306, P2270, DOI 10.1126/science.1103996; Cowles KN, 2005, CELL MICROBIOL, V7, P209, DOI 10.1111/j.1462-5822.2004.00448.x; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; Feil H, 2005, P NATL ACAD SCI USA, V102, P11064, DOI 10.1073/pnas.0504930102; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; Forst S, 1996, MICROBIOL REV, V60, P21, DOI 10.1128/MMBR.60.1.21-43.1996; Givaudan A, 2000, J BACTERIOL, V182, P107, DOI 10.1128/JB.182.1.107-115.2000; Gravet A, 1998, FEBS LETT, V436, P202, DOI 10.1016/S0014-5793(98)01130-2; Hertle R, 2005, CURR PROTEIN PEPT SC, V6, P313, DOI 10.2174/1389203054546370; Hwang SY, 2003, INT J ONCOL, V22, P151; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; MENESTRINA G, 1994, MOL ASPECTS MED, V15, P79, DOI 10.1016/0098-2997(94)90043-4; Miyata S, 2003, INFECT IMMUN, V71, P2404, DOI 10.1128/IAI.71.5.2404-2413.2003; Morgan JAW, 2001, APPL ENVIRON MICROB, V67, P2062, DOI 10.1128/AEM.67.5.2062-2069.2001; Park Y, 2000, J INSECT PHYSIOL, V46, P1469, DOI 10.1016/S0022-1910(00)00071-8; Ribeiro C, 1999, J INSECT PHYSIOL, V45, P677, DOI 10.1016/S0022-1910(99)00043-8; Ribeiro C, 2003, J BIOL CHEM, V278, P3030, DOI 10.1074/jbc.M210353200; Ribeiro C, 2006, J INSECT PHYSIOL, V52, P417, DOI 10.1016/j.jinsphys.2006.01.005; Sicard M, 2004, APPL ENVIRON MICROB, V70, P6473, DOI 10.1128/AEM.70.11.6473-6480.2004; Stiles BG, 2000, INFECT IMMUN, V68, P3475, DOI 10.1128/IAI.68.6.3475-3484.2000; Tennant SM, 2005, INFECT IMMUN, V73, P6860, DOI 10.1128/IAI.73.10.6860-6867.2005; Vodovar N, 2006, NAT BIOTECHNOL, V24, P673, DOI 10.1038/nbt1212; Waterfield NR, 2004, NAT REV MICROBIOL, V2, P833, DOI 10.1038/nrmicro1008; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	34	89	92	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9571	9580		10.1074/jbc.M604301200	http://dx.doi.org/10.1074/jbc.M604301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17229739	Green Published, hybrid			2022-12-25	WOS:000245421700030
J	Fan, WQ; Yanase, T; Morinaga, H; Okabe, T; Nomura, M; Daitoku, H; Fukamizu, A; Kato, S; Takayanagi, R; Nawata, H				Fan, WuQiang; Yanase, Toshihiko; Morinaga, Hidetaka; Okabe, Taijiro; Nomura, Masatoshi; Daitoku, Hiroaki; Fukamizu, Akiyoshi; Kato, Shigeaki; Takayanagi, Ryoichi; Nawata, Hajime			Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; NUCLEAR RECEPTOR; INHIBITS PROLIFERATION; FACTOR-I; EXPRESSION; TRANSACTIVATION; TRANSCRIPTION; SUPPRESSES; RESISTANCE; PROTEIN	The androgen-androgen receptor (AR) system plays vital roles in a wide array of biological processes, including prostate cancer development and progression. Several growth factors, such as insulin-like growth factor 1 (IGF1), can induce AR activation, whereas insulin resistance and hyperinsulinemia are correlated with an elevated incidence of prostate cancer. Here we report that Foxo1, a downstream molecule that becomes phosphorylated and inactivated by phosphatidylinositol 3-kinase/Akt kinase in response to IGF1 or insulin, suppresses ligand-mediated AR transactivation. Foxo1 reduces androgen-induced AR target gene expressions and suppresses the in vitro growth of prostate cancer cells. These inhibitory effects of Foxo1 are attenuated by IGF1 but are enhanced when it is rendered Akt-nonphosphorylatable. Foxo1 interacts directly with the C terminus of AR in a ligand-dependent manner and disrupts ligand-induced AR subnuclear compartmentalization. Foxo1 is recruited by liganded AR to the chromatin of AR target gene promoters, where it interferes with AR-DNA interactions. IGF1 or insulin abolish the Foxo1 occupancy of these promoters. Of interest, a positive feedback circuit working locally in an autocrine/intracrine manner may exist, because liganded AR up-regulates IGF1 receptor expression in prostate cancer cells, presumably resulting in higher IGF1 signaling tension and further enhancing the functions of the receptor itself. Thus, Foxo1 is a novel corepressor for AR, and IGF1/insulin signaling may confer stimulatory effects on AR by attenuating Foxo1 inhibition. These results highlight the potential involvement of metabolic syndrome and hyperinsulinemia in prostate diseases and further suggest that intervention of IGF1/insulin-phosphatidyl-inositol 3-kinase-Akt signaling may be of clinical value for prostate diseases.	Kyushu Univ, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Grad Sch Agr & Life Sci, Tokyo 1130032, Japan	Kyushu University; University of Tsukuba; University of Tokyo	Yanase, T (corresponding author), Kyushu Univ, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	yanase@intmed3.med.kyushu-u.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				Amling CL, 2005, CURR OPIN UROL, V15, P167, DOI 10.1097/01.mou.0000165550.94663.fb; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Brinkmann AO, 2000, ADV PHARMACOL, V47, P317; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen GC, 2005, J BIOL CHEM, V280, P36355, DOI 10.1074/jbc.M506147200; CULIG Z, 1994, CANCER RES, V54, P5474; Fan WQ, 2005, DIABETES, V54, P1000, DOI 10.2337/diabetes.54.4.1000; Fan WQ, 2005, ENDOCRINOLOGY, V146, P85, DOI 10.1210/en.2004-1046; Fan WQ, 2004, MOL ENDOCRINOL, V18, P127, DOI 10.1210/me.2003-0110; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Grzmil M, 2004, J PATHOL, V202, P50, DOI 10.1002/path.1492; Hellawell GO, 2002, CANCER RES, V62, P2942; Hsing AW, 2003, J NATL CANCER I, V95, P67, DOI 10.1093/jnci/95.1.67; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McMenamin ME, 1999, CANCER RES, V59, P4291; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Nickerson T, 2001, CANCER RES, V61, P6276; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Santos AF, 2004, STEROIDS, V69, P79, DOI 10.1016/j.steroids.2003.10.005; Stattin P, 2003, J NATL CANCER I, V95, P1086, DOI 10.1093/jnci/95.14.1086; Tao RH, 2006, MOL CELL ENDOCRINOL, V247, P150, DOI 10.1016/j.mce.2005.12.052; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Verras M, 2005, MOL ENDOCRINOL, V19, P391, DOI 10.1210/me.2004-0208; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Wu Y, 2006, MOL CELL BIOL, V26, P6633, DOI 10.1128/MCB.01534-05; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	41	125	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7329	7338		10.1074/jbc.M610447200	http://dx.doi.org/10.1074/jbc.M610447200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17202144	hybrid			2022-12-25	WOS:000245080900044
J	Fraser, DA; Arora, M; Bohlson, SS; Lozano, E; Tenner, AJ				Fraser, Deborah A.; Arora, Meenakshi; Bohlson, Suzanne S.; Lozano, Encarnacion; Tenner, Andrea J.			Generation of inhibitory NF kappa B complexes and phosphorylated cAMP response element-binding protein correlates with the anti-inflammatory activity of complement protein C1q in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA TRANSCRIPTION; GENE-EXPRESSION; CYTOKINE SYNTHESIS; APOPTOTIC CELLS; IN-VITRO; ACTIVATION; CLQ; SUBCOMPONENT; ASSOCIATION; DISEASE	The interaction of C1q with specific cells of the immune system induces activities, such as enhancement of phagocytosis in monocytes and stimulation of superoxide production in neutrophils. In contrast to some other monocyte activators, C1q itself does not induce pro-inflammatory cytokine production, but rather inhibits the lipopolysaccharide (LPS)-stimulated induction of certain pro-inflammatory cytokines and induces expression of interleukin-10. To investigate the molecular mechanism by which C1q exerts this effect on gene expression, the influence of C1q on the activation of transcription factors of the NF kappa B family and cAMP response element-binding protein (CREB) was assessed. C1q treatment increased kappa B binding activity in freshly isolated human monocytes in a time-dependent fashion as assessed by electrophoretic mobility shift assays. In antibody supershift experiments, anti-p50 antibody supershifted the C1q-induced NF kappa B complex, whereas anti-p65 antibody had little effect, suggesting that C1q induced the translocation of NF kappa B p50p50 homodimers. This is in contrast to the dominant induction of p65 containing complexes in parallel monocyte cultures stimulated with LPS. C1q treatment also induced cAMP response element (CRE)-binding activity as demonstrated by electrophoretic mobility shift assay, increased phosphorylation of CREB, and induction of CRE driven gene expression. In contrast, CREB activation was not detected in LPS-treated monocytes. These results suggest that C1q may modulate the cytokine profile expressed in response to inflammatory stimuli (e.g. LPS), by triggering inhibitory and/or competing signals. Because C1q and other defense collagens have been shown to enhance clearance of apoptotic cells, this regulatory pathway may be beneficial in avoiding autoimmunity and/or resolving inflammation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Ctr Immunol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tenner, AJ (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Ctr Immunol, 3205 McGaugh Hall, Irvine, CA 92697 USA.	atenner@uci.edu	Lozano, Encarnacion/C-5161-2008	Lozano, Encarnacion/0000-0003-0254-0935	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041090] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00827] Funding Source: Medline; NIAID NIH HHS [AI41090] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; BOBAK DA, 1988, EUR J IMMUNOL, V18, P2001, DOI 10.1002/eji.1830181220; BOBAK DA, 1987, J IMMUNOL, V138, P1150; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DIETZSCHOLD B, 1995, J NEUROL SCI, V130, P11, DOI 10.1016/0022-510X(94)00269-T; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan R, 2004, EXP NEUROL, V185, P241, DOI 10.1016/j.expneurol.2003.09.023; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Fraser DA, 2006, J LEUKOCYTE BIOL, V80, P107, DOI 10.1189/jlb.1105683; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gee K, 2006, J BIOL CHEM, V281, P31647, DOI 10.1074/jbc.M512109200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goldsmith SK, 1997, J NEUROCHEM, V68, P2046; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kingsley-Kallesen ML, 1999, J BIOL CHEM, V274, P34020, DOI 10.1074/jbc.274.48.34020; Korb LC, 1997, J IMMUNOL, V158, P4525; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200; Lionetti F. J., 1980, METHODS CELL SEPARAT; MALEFYT RD, 1991, J EXP MED, V174, P1209; Mitchell DA, 2002, J IMMUNOL, V168, P2538, DOI 10.4049/jimmunol.168.5.2538; Miura-Shimura Y, 2002, J IMMUNOL, V169, P1334, DOI 10.4049/jimmunol.169.3.1334; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nauta AJ, 2004, INT ARCH ALLERGY IMM, V134, P310, DOI 10.1159/000079261; Nauta AJ, 2004, J IMMUNOL, V173, P3044, DOI 10.4049/jimmunol.173.5.3044; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Platzer C, 1999, EUR J IMMUNOL, V29, P3098, DOI 10.1002/(SICI)1521-4141(199910)29:10<3098::AID-IMMU3098>3.0.CO;2-H; REID KBM, 1972, BIOCHEM J, V130, P749, DOI 10.1042/bj1300749; Rosseau S, 1999, J IMMUNOL, V163, P4495; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; Stamme C, 2000, AM J RESP CELL MOL, V23, P772, DOI 10.1165/ajrcmb.23.6.4083; TENNER AJ, 1981, J IMMUNOL, V127, P648; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6; Walport MJ, 1998, IMMUNOBIOLOGY, V199, P265, DOI 10.1016/S0171-2985(98)80032-6; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YOUNG KR, 1991, J IMMUNOL, V146, P3356; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhong WJ, 1998, J IMMUNOL, V161, P2533	63	53	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7360	7367		10.1074/jbc.M605741200	http://dx.doi.org/10.1074/jbc.M605741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209050	hybrid			2022-12-25	WOS:000245080900047
J	Li, YP; Zeng, SX; Landais, I; Lu, H				Li, Yanping; Zeng, Shelya X.; Landais, Igor; Lu, Hua			Human SSRP1 has Spt16-dependent and -independent roles in gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SERUM RESPONSE FACTOR; GROUP BOX PROTEIN; SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; DNA-BINDING; FACT COMPLEX; IN-VIVO; C-FOS; CHROMATIN	The facilitating chromatin transcription (FACT) complex, a heterodimer of SSRP1 and Spt16, has been shown to regulate transcription elongation through a chromatin template in vitro and on specific genes in cells. However, its global role in transcription regulation in human cells remains largely elusive. We conducted spotted microarray analyses using arrays harboring 8308 human genes to assess the gene expression profile after knocking down SSRP1 or Spt16 levels in human non-small cell lung carcinoma (H1299) cells. Although the changes of these transcripts were surprisingly subtle, there were similar to 170 genes whose transcript levels were either reduced or induced > 1.5fold. Approximately 106 genes with > 1.2-fold change at the level of transcripts were the common targets of both SSRP1 and Spt16 (similar to 1.3%). A subset of genes was regulated by SSRP1 independent of Spt16. Further analyses of some of these genes not only verified this observation but also identified the serum-responsive gene, egr1, as a novel target for both SSRP1 and Spt16. We further showed that SSRP1 and Spt16 are important for the progression of elongation RNA pol II on the egr1 gene. These results suggest that SSRPI has Spt16-dependent and -independent roles in regulating gene transcription in human cells.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [CA095441, CA93614, CA079721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA093614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Aida M, 2006, MOL CELL BIOL, V26, P6094, DOI 10.1128/MCB.02366-05; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Belotserkovskaya R, 2004, CURR OPIN GENET DEV, V14, P139, DOI 10.1016/j.gde.2004.02.004; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Biswas D, 2005, MOL CELL BIOL, V25, P5812, DOI 10.1128/MCB.25.14.5812-5822.2005; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Cao S, 2003, MOL CELL BIOL, V23, P5301, DOI 10.1128/MCB.23.15.5301-5307.2003; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Evans DRH, 1998, GENETICS, V150, P1393; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2003, CURR TOP MICROBIOL, V274, P171; Formosa T, 2002, GENETICS, V162, P1557; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Hertel L, 1997, BIOCHIMIE, V79, P717, DOI 10.1016/S0300-9084(97)86929-5; Jimeno-Gonzalez S, 2006, MOL CELL BIOL, V26, P8710, DOI 10.1128/MCB.01129-06; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; Kuninger D, 2004, HUM GENE THER, V15, P1287, DOI 10.1089/hum.2004.15.1287; Landais I, 2006, CELL DEATH DIFFER, V13, P1866, DOI 10.1038/sj.cdd.4401878; Li YP, 2005, J BIOL CHEM, V280, P11869, DOI 10.1074/jbc.M413944200; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; PAULSSON Y, 1987, EXP CELL RES, V171, P186, DOI 10.1016/0014-4827(87)90261-8; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Reinberg D, 2006, J BIOL CHEM, V281, P23297, DOI 10.1074/jbc.R600007200; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schlesinger MB, 2000, GENETICS, V155, P1593; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Singer RA, 2004, BIOCHEM CELL BIOL, V82, P419, DOI 10.1139/O04-050; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Svejstrup JQ, 2002, CURR OPIN GENET DEV, V12, P156, DOI 10.1016/S0959-437X(02)00281-2; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540	52	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6936	6945		10.1074/jbc.M603822200	http://dx.doi.org/10.1074/jbc.M603822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209051	hybrid			2022-12-25	WOS:000245080900005
J	Onoguchi, K; Yoneyama, M; Takemura, A; Akira, S; Taniguchi, T; Namiki, H; Fujita, T				Onoguchi, Kazuhide; Yoneyama, Mitsutoshi; Takemura, Azumi; Akira, Shizuo; Taniguchi, Tardatsugu; Namiki, Hideo; Fujita, Takashi			Viral infections activate types I and III interferon genes through a common mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIG-I; ANTIVIRAL ACTIVITY; ADAPTER PROTEIN; DENDRITIC CELLS; IFN-LAMBDA; KAPPA-B; VIRUS; INDUCTION; ROLES; IDENTIFICATION	Viral infections trigger innate immune responses, including the production of type I interferons (IFN-alpha and -beta) and other proinflammatory cytokines. Novel antiviral cytokines IFN-lambda 1, IFN-lambda 2, and IFN-lambda 3 are classified as type III IFNs and have evolved independently of type I IFNs. Type III IFN genes are regulated at the level of transcription and induced by viral infection. Although the regulatory mechanism of type I IFNs is well elucidated, the expression mechanism of IFN-lambda s is not well understood. Here, we analyzed the mechanism by which IFN-lambda gene expression is induced by viral infections. Loss- and gain-of-function experiments revealed the involvement of RIG-I (retinoic acid-inducible gene 1), IPS-1, TBK1, and interferon regulatory factor-3, key regulators of the virus-induced activation of type I IFN genes. Consistent with this, a search for the cis-regulatory element of the human ifn lambda 1 revealed a cluster of interferon regulatory factor-binding sites and a NF-kappa B-binding site. Functional analysis demonstrated that all of these sites are essential for gene activation by the virus. These results strongly suggest that types I and III IFN genes are regulated by a common mechanism.	Kyoto Univ, Inst Virus Res, Lab Mol Genet, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068507, Japan; Waseda Univ, Sch Educ, Dept Biol, Tokyo 1690051, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Osaka 5650871, Japan; Univ Tokyo, Dept Immunol, Grad Sch Med, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Tokyo 1130033, Japan	Kyoto University; Kyoto University; Waseda University; Osaka University; University of Tokyo; University of Tokyo	Fujita, T (corresponding author), Kyoto Univ, Inst Virus Res, Lab Mol Genet, Kyoto 6068507, Japan.	tfujita@virus.kyoto-u.ac.jp	Akira, Shizuo/C-3134-2009; Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Osterlund P, 2005, J VIROL, V79, P9608, DOI 10.1128/JVI.79.15.9608-9617.2005; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	23	273	302	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7576	7581		10.1074/jbc.M608618200	http://dx.doi.org/10.1074/jbc.M608618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17204473	hybrid			2022-12-25	WOS:000245080900070
J	Perreault, A; Lemieux, C; Bachand, F				Perreault, Audrey; Lemieux, Caroline; Bachand, Francois			Regulation of the nuclear poly(A)-binding protein by arginine methylation in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; POLY(A) BINDING-PROTEIN; TAIL LENGTH CONTROL; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; GENE-EXPRESSION; IN-VITRO; EXPORT FACTORS; METHYLTRANSFERASE	Two structurally different poly(A)-binding proteins (PABP) bind the poly(A) tract of mRNAs in most mammalian cells: PABPC in the cytoplasm and PABP2/PABPN1 in the nucleus. Whereas yeast orthologs of the cytoplasmic PABP are characterized, a gene product homologous to mammalian PABP2 has not been identified in yeast. We report here the identification of a homolog of PABP2 as an arginine methyltransferase 1 (RMT1)-associated protein in fission yeast. The product of the Schizosaccharomyces pombe pab2 gene encodes a nonessential nuclear protein and demonstrates specific poly(A) binding in vitro. Consistent with a functional role in poly(A) tail metabolism, mRNAs from pab2-null cells displayed hyperaderylated 3'-ends. We also show that arginine residues within the C-terminal arginine-rich domain of Pab2 are modified by RMT1-dependent methylation. Whereas the arginine methylated and unmethylated forms of Pab2 behaved similarly in terms of subcellular localization, poly(A) binding, and poly(A) tail length control; Pab2 oligomerization levels were markedly increased when Pab2 was not methylated. Significantly, Pab2 overexpression reduced growth rate, and this growth inhibitory effect was exacerbated in rmt1-null cells. Our results indicate that the main cellular function of Pab2 is in poly(A) tail length control and support a biological role for arginine methylation in the regulation of Pab2 oligomerization.	Univ Sherbrooke, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bachand, F (corresponding author), Univ Sherbrooke, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada.	f.bachand@usherbrooke.ca						Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bachand F, 2006, MOL CELL BIOL, V26, P1731, DOI 10.1128/MCB.26.5.1731-1742.2006; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Benoit B, 1999, NUCLEIC ACIDS RES, V27, P3771, DOI 10.1093/nar/27.19.3771; Benoit B, 2005, DEV CELL, V9, P511, DOI 10.1016/j.devcel.2005.09.002; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Bird G, 2005, MOL CELL, V20, P747, DOI 10.1016/j.molcel.2005.11.009; Blanchet F, 2005, J EXP MED, V202, P371, DOI 10.1084/jem.20050176; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; Boisvert FM, 2002, J CELL BIOL, V159, P957, DOI 10.1083/jcb.200207028; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Brodsky AS, 2000, RNA, V6, P1737, DOI 10.1017/S1355838200001059; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Brune C, 2005, RNA, V11, P517, DOI 10.1261/rna.7291205; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Chartier A, 2006, EMBO J, V25, P2253, DOI 10.1038/sj.emboj.7601117; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Corbeil-Girard LP, 2005, NEUROBIOL DIS, V18, P551, DOI 10.1016/j.nbd.2004.10.019; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Cote J, 2005, J BIOL CHEM, V280, P28476, DOI 10.1074/jbc.M414328200; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Dheur S, 2005, J BIOL CHEM, V280, P24532, DOI 10.1074/jbc.M504720200; Dower K, 2004, RNA, V10, P1888, DOI 10.1261/rna.7166704; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Dunn EF, 2005, GENE DEV, V19, P90, DOI 10.1101/gad.1267005; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hammell CM, 2002, MOL CELL BIOL, V22, P6441, DOI 10.1128/MCB.22.18.6441-6457.2002; Hector RE, 2002, EMBO J, V21, P1800, DOI 10.1093/emboj/21.7.1800; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Hilleren P, 2001, RNA, V7, P753, DOI 10.1017/S1355838201010147; Hosoda N, 2006, MOL CELL BIOL, V26, P3085, DOI 10.1128/MCB.26.8.3085-3097.2006; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Kerwitz Y, 2003, EMBO J, V22, P3705, DOI 10.1093/emboj/cdg347; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Mangus DA, 2004, MOL CELL BIOL, V24, P5521, DOI 10.1128/MCB.24.12.5521-5533.2004; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Marfatia KA, 2003, J BIOL CHEM, V278, P6731, DOI 10.1074/jbc.M207571200; Matsuyama A, 2006, NAT BIOTECHNOL, V24, P841, DOI 10.1038/nbt1222; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Meaux S, 2006, RNA, V12, P1323, DOI 10.1261/rna.46306; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; Mowen KA, 2004, MOL CELL, V15, P559, DOI 10.1016/j.molcel.2004.06.042; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Proudfoot N, 2002, CURR BIOL, V12, pR855, DOI 10.1016/S0960-9822(02)01353-2; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Thakurta AG, 2002, YEAST, V19, P795, DOI 10.1002/yea.876; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wang QS, 2005, HUM MOL GENET, V14, P3673, DOI 10.1093/hmg/ddi395; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhelkovsky A, 1998, MOL CELL BIOL, V18, P5942, DOI 10.1128/MCB.18.10.5942	75	52	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7552	7562		10.1074/jbc.M610512200	http://dx.doi.org/10.1074/jbc.M610512200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213188	hybrid			2022-12-25	WOS:000245080900068
J	Chen, JX; Enns, CA				Chen, Juxing; Enns, Caroline A.			The cytoplasmic domain of transferrin receptor 2 dictates its stability and response to holo-transferrin in Hep3B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HEREDITARY HEMOCHROMATOSIS; IRON OVERLOAD; JUVENILE HEMOCHROMATOSIS; EXPRESSION; HEPCIDIN; INTERNALIZATION; BINDING; TFR2; DEGRADATION	Transferrin receptor 2 (TfR2) is a homolog of transferrin receptor 1 (TfR1), the receptor responsible for the uptake of iron-loaded transferrin (holo-Tf) into cells. Unlike the ubiquitous TfR1, TfR2 is predominantly expressed in the liver. Mutations in TfR2 gene cause a rare autosomal recessive form of the iron overload disease, hereditary hemochromatosis. Previous studies demonstrated that holo-Tf increases TfR2 levels by stabilizing TfR2 at the protein level. In this study we constructed two chimeras, one of which had the cytoplasmic domain of TfR2 and the remaining portion of TfR1 and the other with the cytoplasmic and transmembrane domain of TfR1 joined to the ectodomain of TfR2. Similar to TfR2, the levels of the chimera containing only the cytoplasmic domain of TfR2 increased in a time- and dose-dependent manner after the addition of holo-Tf to the medium. The half-life of the chimera increased 2.7-fold in cells exposed to holo-Tf like the endogenous TfR2 in HepG2 cells. Like TfR2 and unlike TfR1, the levels of the chimera did not respond to intracellular iron content. These results suggest that although holo-Tf binding to the ectodomain is necessary, the cytoplasmic domain of TfR2 is largely responsible for its stabilization by holo-Tf.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, Portland, OR 97239 USA	Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, 3181 SW Sam Jackson Pk Blvd, Portland, OR 97239 USA.	ennsca@ohsu.edu			NIDDK NIH HHS [R01-DK072166] Funding Source: Medline; NIGMS NIH HHS [GM-192837] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; Andrews NC, 2000, CURR OPIN PEDIATR, V12, P596, DOI 10.1097/00008480-200012000-00015; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; COX TM, 1989, EUR J HAEMATOL, V42, P113; Deaglio S, 2002, BLOOD, V100, P3782, DOI 10.1182/blood-2002-01-0076; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Johnson MB, 2004, BLOOD, V104, P4287, DOI 10.1182/blood-2004-06-2477; JOHNSON MB, 2007, IN PRESS MOL BIOL CE; Kawabata H, 2005, BLOOD, V105, P376, DOI 10.1182/blood-2004-04-1416; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kawabata H, 2000, J BIOL CHEM, V275, P16618, DOI 10.1074/jbc.M908846199; Kawabata H, 2004, BRIT J HAEMATOL, V127, P464, DOI 10.1111/j.1365-2141.2004.05224.x; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Nemeth E, 2005, BLOOD, V105, P1803, DOI 10.1182/blood-2004-08-3042; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Robb A, 2004, BLOOD, V104, P4294, DOI 10.1182/blood-2004-06-2481; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Syed BA, 2006, HEMOGLOBIN, V30, P69, DOI 10.1080/03630260500455318; Vogt TM, 2003, BLOOD, V101, P2008, DOI 10.1182/blood-2002-09-2742; Wallace DF, 2005, GUT, V54, P980, DOI 10.1136/gut.2004.062018; Wallace DF, 2002, BLOOD, V100, P692, DOI 10.1182/blood.V100.2.692; Warren RA, 1997, J BIOL CHEM, V272, P2116; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643	40	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6201	6209		10.1074/jbc.M610127200	http://dx.doi.org/10.1074/jbc.M610127200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202145	hybrid			2022-12-25	WOS:000244867200026
J	Greenstein, RJ; Su, LY; Haroutunian, V; Shahidi, A; Brown, ST				Greenstein, Robert J.; Su, Liya; Haroutunian, Vahram; Shahidi, Azra; Brown, Sheldon T.			On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis	PLOS ONE			English	Article								Background. Clinical improvement in inflammatory bowel disease (IBD) treated with methotrexate and 6-mercaptopurine (6-MP) is associated with a decrease in pro-inflammatory cytokines. This has been presumed to indicate the mechanism of action of methotrexate and 6-MP. Although controversial, there are increasingly compelling data that Mycobacterium avium subspecies paratuberculosis(MAP) may be an etiological agent in some or all of IBD. We hypothesized that the clinical efficacy of methotrexate and 6-MP in IBD may be to simply inhibit the growth of MAP. Methodology. The effect on MAP growth kinetics by methotrexate and 6-MP were evaluated in cell culture of two strains each of MAP and M. avium using a radiometric ((CO2)-C-14 BACTEC (R)) detection system that quantifies mycobacterial growth as arbitrary "growth index units'' (GI). Efficacy data are presented as "percent decrease in cumulative GI'' (% -Delta cGI). Principal Findings. The positive control antibiotic (clarithromycin) has >= 85% -Delta cGI at a concentration of 0.5 mu g/ml. The negative control (ampicillin) has minimal inhibition at 64 mu g/ml. MAP ATCC 19698 shows >= 80% -Delta cGI for both agents by 4 mu g/ml. With the other three isolates, although more effective than ampicillin, 6-MP is consistently less effective than methotrexate. Conclusions. We show that methotrexate and 6-MP inhibit MAP growth in vitro. Each of the four isolates manifests different % -Delta cGI. These data are compatible with the hypothesis that the clinical improvement in patients with IBD treated with methotrexate and 6-MP could be due to treating a MAP infection. The decrease in pro-inflammatory cytokines, thought to be the primary mechanism of action, may simply be a normal, secondary, physiological response. We conclude that henceforth, in clinical studies that evaluate the effect of anti-MAP agents in IBD, the use of methotrexate and 6-MP should be excluded from any control groups.	[Greenstein, Robert J.; Su, Liya] VA Med Ctr, Lab Mol Surg Res, Bronx, NY USA		Greenstein, RJ (corresponding author), VA Med Ctr, Lab Mol Surg Res, Bronx, NY USA.	BGAxis@aol.com						Autschbach F, 2005, GUT, V54, P944, DOI 10.1136/gut.2004.045526; Baumgart DC, 2005, SCAND J GASTROENTERO, V40, P958, DOI 10.1080/00365520510015854; BERNSTEIN CN, 1994, DIGEST DIS SCI, V39, P1638, DOI 10.1007/BF02087769; BERTRAM MA, 1986, J INFECT DIS, V154, P194, DOI 10.1093/infdis/154.1.194; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHIODINI RJ, 1986, J CLIN MICROBIOL, V24, P357, DOI 10.1128/JCM.24.3.357-363.1986; COGGIN JH, 1966, J BACTERIOL, V92, P446, DOI 10.1128/JB.92.2.446-454.1966; DAMATO JJ, 1990, VET MICROBIOL, V22, P31, DOI 10.1016/0378-1135(90)90122-C; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; FINDLEY RS, 1996, TXB THERAPEUTICS DRU, P1509; Greenstein RJ, 2004, LANCET, V364, P396, DOI 10.1016/S0140-6736(04)16781-0; Greenstein RJ, 2003, LANCET INFECT DIS, V3, P507, DOI 10.1016/S1473-3099(03)00724-2; GROSS V, 1991, KLIN WOCHENSCHR, V69, P981, DOI 10.1007/BF01645143; Hermon-Taylor J, 2004, PATHOGENIC MYCOBACTE, P74; JOHNE HA, 1895, DTSCH Z TIERMED PATH, V21, P438; Kleinsmith LJ, 2006, PRINCIPLES CANC BIOL; KUNZE ZM, 1991, MOL MICROBIOL, V5, P2265, DOI 10.1111/j.1365-2958.1991.tb02157.x; KUNZE ZM, 1992, J CLIN MICROBIOL, V30, P2366, DOI 10.1128/JCM.30.9.2366-2372.1992; Mishina D, 1996, P NATL ACAD SCI USA, V93, P9816, DOI 10.1073/pnas.93.18.9816; Naser SA, 2004, LANCET, V364, P1039, DOI 10.1016/S0140-6736(04)17058-X; Peifer C, 2006, CURR TOP MED CHEM, V6, P113, DOI 10.2174/156802606775270323; RASTOGI N, 1992, ANTIMICROB AGENTS CH, V36, P2843, DOI 10.1128/AAC.36.12.2843; *RTI INT, 2006, TUB ANT ACQ COORD FA; URBA W J, 1990, Journal of the National Cancer Institute Monographs, P29; WOLTERS FL, 2005, GUT; ZIMMERMAN EF, 1964, J BIOL CHEM, V239, P293	26	63	64	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e161	10.1371/journal.pone.0000161	http://dx.doi.org/10.1371/journal.pone.0000161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17252054	Green Published, gold			2022-12-25	WOS:000207444100002
J	Okuyama, R; Ogawa, E; Nagoshi, H; Yabuki, M; Kurihara, A; Terui, T; Aiba, S; Obinata, M; Tagami, H; Ikawa, S				Okuyama, R.; Ogawa, E.; Nagoshi, H.; Yabuki, M.; Kurihara, A.; Terui, T.; Aiba, S.; Obinata, M.; Tagami, H.; Ikawa, S.			p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity	ONCOGENE			English	Article						p51/p63; Notch; keratinocyte; stem cell; p53; tumor suppressor	NF-KAPPA-B; SPONTANEOUS TUMORS; MICE LACKING; IKK-ALPHA; P63; DIFFERENTIATION; EXPRESSION; MECHANISM; ONCOGENE; KINASE	p53 homologue, p51/p63, predominantly expressed in keratinocyte stem cells, is indispensable for the formation of epidermis. Notch1, another such gene indispensable for the process, induces growth arrest and differentiation in keratinocytes. We found that exogenous expression of Delta Np51B (Delta Np63 alpha), one of the isoforms of p51 specifically expressed in basal keratinocytes, blocked Notch 1-dependent growth arrest and differentiation in mouse keratinocytes by inhibiting p21 expression and maintaining integrins expression. Furthermore, DNp51B by itself was found to have ability to induce expression of integrin alpha 6 beta 4, which promotes attachment of basal cells to basal membrane thereby keeping the cells in immature state. Therefore, we conclude that DNp51B expression warrants integrin expression even under the influence of Notch1 and that Delta Np51B is a long-sought factor required to maintain basal cell keratinocytes immaturity by inhibiting Notch1 activity. We will postulate a plausible model explaining the maintenance of the squamous epithelium architectures as well as offering mechanistic explanations for pathological features of skin diseases, including cancers, psoriasis along with physiological wound healings.	Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Ikawa Grp, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Grad Sch Life Sci, Lab Cell Differentiat, Aoba Ku, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Ikawa, S (corresponding author), Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Aramaki,6-3 Aoba, Sendai, Miyagi 9808578, Japan.	sikawa@cir.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; CUI R, 2005, IN PRESS BIOCH BIOPH; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Hagiwara K, 1999, CANCER RES, V59, P4165; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stiewe T, 2002, CANCER RES, V62, P3598; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Uyttendaele H, 2004, DIFFERENTIATION, V72, P396, DOI 10.1111/j.1432-0436.2004.07208006.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	57	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4478	4488		10.1038/sj.onc.1210235	http://dx.doi.org/10.1038/sj.onc.1210235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237812				2022-12-25	WOS:000247836100002
J	Kim, M; Egan, C; Alain, T; Urbanski, SJ; Lee, PW; Forsyth, PA; Johnston, RN				Kim, M.; Egan, C.; Alain, T.; Urbanski, S. J.; Lee, P. W.; Forsyth, P. A.; Johnston, R. N.			Acquired resistance to reoviral oncolysis in Ras-transformed brosarcoma cells	ONCOGENE			English	Article						reovirus; Ras; oncolysis; resistance	CATHEPSIN-B; PERSISTENT INFECTION; CANCER-THERAPY; INTERFERON; PATHWAY; VIRUS; GENE; MACROPHAGES; ACTIVATION; EXPRESSION	Reovirus shows considerable potential as an oncolytic agent for Ras- activated tumors and is currently in clinical trials. Here we ask whether such tumor cell lines can acquire resistance to reoviral oncolysis. We challenged human HT1080. fibrosarcoma cells that carry a Ras mutation by prolonged exposure to reovirus, thereby yielding highly virus- resistant HTR1 cells. These cells are persistently infected with reovirus, exhibit high Ras activity and retain the original Ras gene mutation, showing that resistance to reovirus can be displayed in cells with active Ras. The HTR1 cells also exhibit reduced cellular cathepsin B activity, which normally contributes to viral entry and activation. Persistently infected HTR1 cells were not tumorigenic in vivo, whereas immunologically cured virus- free HTR1 cells were highly tumorigenic. Thus, acquisition of resistance to reovirus may constrain therapeutic strategies. To determine whether reoviral resistance is associated with a general reduction in apoptotic potential, we challenged the HTR1 cells with apoptotic inducers and E1B- defective adenovirus, resulting in significant apoptosis and cell death following both approaches. Therefore, even if resistance to reoviral oncolysis should arise in tumor cells in vivo, other therapeutic strategies may nevertheless remain effective.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pathol, Calgary, AB T2N 4N1, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 3J5, Canada	University of Calgary; University of Calgary; University of Calgary; Dalhousie University	Johnston, RN (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Room HMRB 371,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rnjohnst@ucalgary.ca	Johnston, Randal/B-9247-2009					AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; Danis C, 1997, VIRUS RES, V51, P139, DOI 10.1016/S0168-1702(97)00088-9; Dermody TS, 1998, CURR TOP MICROBIOL, V233, P1; DERMODY TS, 1995, VIROLOGY, V212, P272, DOI 10.1006/viro.1995.1483; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Duursma AM, 2003, SEMIN CANCER BIOL, V13, P267, DOI 10.1016/S1044-579X(03)00040-3; Ebert DH, 2004, J BIOL CHEM, V279, P3837, DOI 10.1074/jbc.M310048200; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; Langland JO, 2006, VIRUS RES, V119, P100, DOI 10.1016/j.virusres.2005.10.014; Loken SD, 2004, CANCER BIOL THER, V3, P734, DOI 10.4161/cbt.3.8.963; Meusel TR, 2003, J IMMUNOL, V171, P3768, DOI 10.4049/jimmunol.171.7.3768; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA L, 1984, NUCLEIC ACIDS RES, V12, P8699, DOI 10.1093/nar/12.22.8699; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Samuel CE, 1998, CURR TOP MICROBIOL, V233, P125; Schotte P, 2001, J BIOL CHEM, V276, P21153, DOI 10.1074/jbc.M102239200; Shiratsuchi A, 2000, J VIROL, V74, P9240, DOI 10.1128/JVI.74.19.9240-9244.2000; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Steele TA, 2005, EXP BIOL MED, V230, P487; Steele TA, 1996, P SOC EXP BIOL MED, V212, P63; Stewart MJ, 2005, J VIROL, V79, P2979, DOI 10.1128/JVI.79.5.2979-2987.2005; Stoeckel J, 2006, CURR OPIN MOL THER, V8, P249; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; TABER R, 1976, J VIROL, V17, P513, DOI 10.1128/JVI.17.2.513-524.1976; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TYLER KL, 2001, LIPPINCOTT FIELDS VI, P1729; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860	38	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4124	4134		10.1038/sj.onc.1210189	http://dx.doi.org/10.1038/sj.onc.1210189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213803				2022-12-25	WOS:000247252700008
J	Riz, I; Akimov, SS; Eaker, SS; Baxter, KK; Lee, HJ; Marino-Ramirez, L; Landsman, D; Hawley, TS; Hawley, RG				Riz, I.; Akimov, S. S.; Eaker, S. S.; Baxter, K. K.; Lee, H. J.; Marino-Ramirez, L.; Landsman, D.; Hawley, T. S.; Hawley, R. G.			TLX1/HOX11-induced hematopoietic differentiation blockade	ONCOGENE			English	Article						TLX1/HOX11 oncogene; erythropoiesis; conditional differentiation block; CBP; GATA-1; repressive chromatin domains	TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; T-CELL LEUKEMIA; THYMOCYTE DIFFERENTIATION; ERYTHROID-CELLS; HOX11 INTERACTS; HOMEOBOX GENES; CBP; ACETYLATION; ONCOPROTEIN	Aberrant expression of the human homeobox-containing proto-oncogene TLX1/HOX11 inhibits hematopoietic differentiation programs in a number of murine model systems. Here, we report the establishment of a murine erythroid progenitor cell line, iEBHX1S-4, developmentally arrested by regulatable TLX1 expression. Extinction of TLX1 expression released the iEBHX1S-4 differentiation block, allowing erythropoietin-dependent acquisition of erythroid markers and hemoglobin synthesis. Coordinated activation of erythroid transcriptional networks integrated by the acetyltransferase co-activator CREB-binding protein (CBP) was suggested by bioinformatic analysis of the upstream regulatory regions of several conditionally induced iEBHX1S-4 gene sets. In accord with this notion, CBP-associated acetylation of GATA-1, an essential regulator of erythroid differentiation, increased concomitantly with TLX1 downregulation. Coimmunoprecipitation experiments and glutathione-S-transferase pull-down assays revealed that TLX1 directly binds to CBP, and confocal laser microscopy demonstrated that the two proteins partially colocalize at intranuclear sites in iEBHX1S-4 cells. Notably, the distribution of CBP in conditionally blocked iEBHX1S-4 cells partially overlapped with chromatin marked by a repressive histone methylation pattern, and downregulation of TLX1 coincided with exit of CBP from these heterochromatic regions. Thus, we propose that TLX1-mediated differentiation arrest may be achieved in part through a mechanism that involves redirection of CBP and/or its sequestration in repressive chromatin domains.	George Washington Univ, Dept Anat & Cell Biol, Med Ctr, Washington, DC 20037 USA; NanoDetect Technol, Knoxville, TN USA; George Washington Univ, Mol Med Program, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Genom & Bioinformat Program, Med Ctr, Washington, DC 20037 USA; Natl Ctr Biotechnol Informat, Computat Biol Branch, Natl Lib Med, NIH, Bethesda, MD USA; George Washington Univ, Flow Cytometry Core Facil, Med Ctr, Washington, DC 20037 USA	George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); George Washington University	Hawley, TS (corresponding author), George Washington Univ, Dept Anat & Cell Biol, Med Ctr, 2300 I St NW, Washington, DC 20037 USA.	rghawley@gwu.edu	Mariño-Ramírez, Leonardo/N-5395-2019; Landsman, David/GZK-5496-2022; Landsman, David/C-5923-2009; Mariño-Ramírez, Leonardo/I-5759-2013	Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Landsman, David/0000-0002-9819-6675; Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Hawley, Robert/0000-0003-3512-5818	Intramural NIH HHS [Z99 LM999999] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305-05, R01 HL065519-04, R01 HL066305-02, R01 HL065519-01A1, R01 HL065519-02, R01 HL065519, R01 HL065519-06, R01 HL065519-03, R01 HL066305-04, R01 HL066305-03, R01 HL065519-05, R01 HL066305, R01 HL066305-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000084] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Akimov SS, 2005, STEM CELLS, V23, P1423, DOI 10.1634/stemcells.2005-0390; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Berger LC, 1997, BLOOD, V89, P261, DOI 10.1182/blood.V89.1.261.261_261_271; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Choi YJ, 2006, CANCER RES, V66, P2990, DOI 10.1158/0008-5472.CAN-05-2944; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Greer L, 1998, INT J NON-EQUILIB PR, V11, P1; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Heidari M, 2006, LEUKEMIA, V20, P304, DOI 10.1038/sj.leu.2404071; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; LARSON RC, 1995, ONCOGENE, V11, P853; Owens BM, 2006, BRIT J HAEMATOL, V132, P216, DOI 10.1111/j.1365-2141.2005.05850.x; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Popratiloff A, 2003, J COMP NEUROL, V461, P466, DOI 10.1002/cne.10702; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Watabiki Y, 2003, J HIGH ENERGY PHYS; Wen J, 2005, J BIOL CHEM, V280, P12956, DOI 10.1074/jbc.M412721200; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; YOSHIDA M, 1987, CANCER RES, V47, P3688; Zhang N, 1999, ONCOGENE, V18, P2273, DOI 10.1038/sj.onc.1202545	55	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4115	4123		10.1038/sj.onc.1210185	http://dx.doi.org/10.1038/sj.onc.1210185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213805	Green Accepted			2022-12-25	WOS:000247252700007
J	Karagiannis, TC; Kn, H; El-Osta, A				Karagiannis, T. C.; Kn, H.; El-Osta, A.			Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments	ONCOGENE			English	Article						histone acetylation; HDAC inhibitor; trichostatin A; radiation sensitivity; gamma H2AX; ChIP	NUCLEOTIDE EXCISION-REPAIR; ACTIVE CHROMATIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TUMOR RADIOSENSITIVITY; HUMAN-CELLS; ENHANCEMENT; METHYLATION; PHOTOLYASE; CANCER	Epigenetic regulation of chromatin structure is central to the process of DNA repair. A well-characterized epigenetic feature is the dynamic phosphorylation of the histone H2AX ( gamma H2AX) and mobilization of double strand break ( DSB) recognition and repair factors to the site. How chromatin structure is altered in response to DNA damage and how such alterations influence DSB repair mechanisms are currently relevant issues. Despite the clear link between histone deacetylases ( HDACs) and radiosensitivity, how histone hyperacetylation influence DSB repair remains poorly understood. We have determined the structure of chromatin is a major factor determining radiosensitivity and repair in human cells. Trichostatin A ( TSA) enhances radiosensitivity with dose modi. cation factors of 1.2 and 1.9 at 0.2 and 1 mu M, respectively. Cells treated with TSA causing hyperacetylation and remodelling on euchromatic alleles coexist with gamma H2AX accumulation in radiosensitized cells. Formation of gamma H2AX on heterochromatin was significantly reduced even when cells were treated with TSA, suggesting that chromatin structure and histone hyperacetylation are pronounced features of radiation sensitivity and repair in euchromatic regions.	Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, Melbourne, Vic 3004, Australia; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Dept Mol Radiat Biol, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; University of Melbourne	El-Osta, A (corresponding author), Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, 2nd Floor,Commercial Rd, Melbourne, Vic 3004, Australia.	assam.el-osta@baker.edu.au		Kaipananickal, Harikrishnan/0000-0002-4662-659X; El-Osta, Assam/0000-0001-7968-7375; El-Osta, Assam/0000-0003-2969-9137; Karagiannis, Tom/0000-0002-9967-1546				Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537; Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Livingstone-Zatchej M, 2003, J BIOL CHEM, V278, P37471, DOI 10.1074/jbc.M306335200; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	38	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3963	3971		10.1038/sj.onc.1210174	http://dx.doi.org/10.1038/sj.onc.1210174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213813				2022-12-25	WOS:000247144500006
J	Kashkevich, K; Humeny, A; Ziegler, U; Groschup, MH; Nicken, P; Leeb, T; Fischer, C; Becker, CM; Schiebel, K				Kashkevich, Kseniya; Humeny, Andreas; Ziegler, Ute; Groschup, Martin H.; Nicken, Petra; Leeb, Tosso; Fischer, Christine; Becker, Cord-Michael; Schiebel, Katrin			Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection	FASEB JOURNAL			English	Article						PRNP; German bovine breeds; haplotype; expression; single nucleotide polymorphism	BOVINE SPONGIFORM ENCEPHALOPATHY; GERMAN CATTLE BREEDS; HAPLOTYPE RECONSTRUCTION; SEQUENCE VARIATION; NATURAL SCRAPIE; PRNP GENES; PRP GENE; SHEEP; SUSCEPTIBILITY; EXPRESSION	Transmissible spongiform encephalopathies ( TSEs) are a group of neurodegenerative diseases that can occur spontaneously or can be caused by infection or mutations within the prion protein gene PRNP. Nonsynonymous DNA polymorphisms within the PRNP gene have been shown to influence susceptibility/ resistance to infection in sheep and humans. Analysis of DNA polymorphisms within the core promoter region of the PRNP gene in four major German bovine breeds resulted in the identification of both SNPs and insertion/ deletion ( indel) polymorphisms. Comparative genotyping of both controls and animals that tested positive for bovine spongiform encephalopathy ( BSE) revealed a significantly different distribution of two indel polymorphisms and two SNPs within Braunvieh animals, suggesting an association of these polymorphisms with BSE susceptibility. The functional relevance of these polymorphisms was analyzed using reporter gene constructs in neuronal cells. A specific haplotype near exon 1 was identified that exhibited a significantly lower expression level. Genotyping of nine polymorphisms within the promoter region and haplotype calculation revealed that the haplotype associated with the lowest expression level was underrepresented in the BSE group of all breeds compared to control animals, indicating a correlation of reduced PRNP expression and increased resistance to BSE.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Friedrich Loeffler Inst, Inst Novel & Emerging Infect Dis, Insel Riems, Germany; Univ Vet Med, Inst Anim Breeding & Genet, Hannover, Germany; Univ Heidelberg, Inst Human Genet, Heidelberg, Germany	University of Erlangen Nuremberg; Friedrich Loeffler Institute; University of Veterinary Medicine Hannover, Foundation; Ruprecht Karls University Heidelberg	Schiebel, K (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	katrin.schiebel@biochem.uni-erlangen.de	Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880; Nicken, Petra/0000-0002-8535-1453				Balbus N, 2005, MAMM GENOME, V16, P884, DOI 10.1007/s00335-005-0052-9; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; Bonk T, 2002, CLIN BIOCHEM, V35, P87, DOI 10.1016/S0009-9120(02)00279-5; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Geldermann H, 2006, ANIM GENET, V37, P469, DOI 10.1111/j.1365-2052.2006.01519.x; Geldermann H, 2003, ANIM GENET, V34, P283, DOI 10.1046/j.1365-2052.2003.01006.x; Heaton MP, 2003, MAMM GENOME, V14, P765, DOI 10.1007/s00335-003-2283-y; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; Hills D, 2003, ANIM GENET, V34, P183, DOI 10.1046/j.1365-2052.2003.00977.x; Humeny A, 2002, NEUROGENETICS, V4, P59, DOI 10.1007/s10048-001-0126-0; Hunter N, 1996, ARCH VIROL, V141, P809, DOI 10.1007/BF01718157; Inoue S, 1997, J VET MED SCI, V59, P175, DOI 10.1292/jvms.59.175; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Juling K, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-33; KLEBE RJ, 1969, J CELL BIOL, V43, P69; Kretzschmar HA, 1999, EUR ARCH PSY CLIN N, V249, P56; MANSON JC, 1994, NEURODEGENERATION, V3, P331; NEIBERGS HL, 1994, ANIM GENET, V25, P313, DOI 10.1111/j.1365-2052.1994.tb00364.x; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Sander P, 2005, J BIOL CHEM, V280, P37408, DOI 10.1074/jbc.M506361200; Sander P, 2004, NEUROGENETICS, V5, P19, DOI 10.1007/s10048-003-0171-y; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tranulis MA, 2002, APMIS, V110, P33, DOI 10.1034/j.1600-0463.2002.100105.x; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; Windl O, 1999, HUM GENET, V105, P244, DOI 10.1007/s004390051096; Zhang C, 2004, GENETICS, V167, P1863, DOI 10.1534/genetics.104.026401	29	34	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1547	1555		10.1096/fj.06-7522com	http://dx.doi.org/10.1096/fj.06-7522com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255470				2022-12-25	WOS:000246117000029
J	Rodrigues, AJ; Coppola, G; Santos, C; Costa, MD; Ailion, M; Sequeiros, J; Geschwind, DH; Maciel, P				Rodrigues, Ana-Joao; Coppola, Giovanni; Santos, Claudia; Costa, Maria do Carmo; Ailion, Michael; Sequeiros, Jorge; Geschwind, Daniel H.; Maciel, Patricia			Functional genomics and biochemical characterization of the C-elegans orthologue of the Machado-Joseph disease protein ataxin-3	FASEB JOURNAL			English	Article						polyglutamine disorders; ubiquitin-proteasome pathway; microarray; ataxia; knockout	VALOSIN-CONTAINING PROTEIN; CAENORHABDITIS-ELEGANS; NEUROLOGICAL DISEASE; RNA INTERFERENCE; AZORES ISLANDS; GENE-PRODUCT; F-BOX; EXPRESSION; LOCALIZATION; PROTEOLYSIS	Machado-Joseph disease (MJD) is the most common dominant spinocerebellar ataxia. MJD is caused by a CAG trinucleotide expansion in the ATXN3 gene, which encodes a protein named ataxin-3. Ataxin-3 has been proposed to act as a deubiquitinating enzyme in the ubiquitin-proteasome pathway and to be involved in transcriptional repression; nevertheless, its precise biological function(s) remains unknown. To gain further insight into the function of ataxin-3, we have identified the Caenorhabditis elegans orthologue of the ATXN3 gene and characterized its pattern of expression, developmental regulation, and subcellular localization. We demonstrate that, analogous to its human orthologue, C. elegans ataxin-3 has deubiquitinating activity in vitro against polyubiquitin chains with four or more ubiquitins, the minimum ubiquitin length for proteasomal targeting. To further evaluate C. elegans ataxin-3, we characterized the first known knockout animal models both phenotypically and biochemically, and found that the two C. elegans strains were viable and displayed no gross phenotype. To identify a molecular phenotype, we performed a large-scale microarray analysis of gene expression in both knockout strains. The data revealed a significant deregulation of core sets of genes involved in the ubiquitin-proteasome pathway, structure/motility, and signal transduction. This gene identification provides important clues that can help elucidate the specific biological role of ataxin-3 and unveil some of the physiological effects caused by its absence or diminished function.	Univ Minho, Life & Hlth Sci Res Inst, Hlth Sci Sch, P-4710057 Braga, Portugal; Univ Calif Los Angeles, Program Neurogenet, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA; UnIGENe, Inst Mol & Cell Biol, Oporto, Portugal; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Universidade do Minho; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Universidade do Porto; Utah System of Higher Education; University of Utah	Maciel, P (corresponding author), Univ Minho, Life & Hlth Sci Res Inst, Hlth Sci Sch, Campus Gualtar, P-4710057 Braga, Portugal.	pmaciel@ecsaude.uminho.pt	Maciel, Patricia/AAH-2102-2020; Rodrigues, Ana/GYQ-6273-2022; Maciel, Patrícia/B-5989-2009; Ailion, Michael/ABE-6210-2021; Rodrigues, Ana João/D-3782-2012	Maciel, Patricia/0000-0002-0920-6350; Maciel, Patrícia/0000-0002-0920-6350; Ailion, Michael/0000-0002-8070-1362; Rodrigues, Ana João/0000-0003-1968-7968; Sequeiros, Jorge/0000-0002-9846-1037; Pereira da Costa, Maria do Carmo/0000-0001-8466-4864	Fundação para a Ciência e a Tecnologia [POCI/SAU-MMO/60412/2004] Funding Source: FCT	Fundação para a Ciência e a Tecnologia		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Berke SJS, 2005, J BIOL CHEM, V280, P32026, DOI 10.1074/jbc.M506084200; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; BRENNER S, 1974, GENETICS, V77, P71; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Cope Gregory A., 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-1; COUTINHO P, 1978, NEUROLOGY, V28, P703, DOI 10.1212/WNL.28.7.703; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; DOCARMO CM, 2004, GENOMICS, V84, P361; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Evert BO, 2003, J NEUROPATH EXP NEUR, V62, P1006, DOI 10.1093/jnen/62.10.1006; Gales L, 2005, J MOL BIOL, V353, P642, DOI 10.1016/j.jmb.2005.08.061; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Inoue T, 2005, P NATL ACAD SCI USA, V102, P4972, DOI 10.1073/pnas.0408122102; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; LANG AE, 1994, ANN NEUROL, V36, P443, DOI 10.1002/ana.410360318; LASPADA AR, 1994, ANN NEUROL, V36, P814, DOI 10.1002/ana.410360604; Lee J, 2001, GENES CELLS, V6, P899, DOI 10.1046/j.1365-2443.2001.00471.x; Lerer I, 1996, EUR J HUM GENET, V4, P3; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller MA, 2001, SCIENCE, V291, P2144, DOI 10.1126/science.1057586; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piekny AJ, 2003, DEVELOPMENT, V130, P5695, DOI 10.1242/dev.00807; Reinke V, 2004, DEVELOPMENT, V131, P311, DOI 10.1242/dev.00914; Restituito S, 2000, J NEUROSCI, V20, P6394, DOI 10.1523/JNEUROSCI.20-17-06394.2000; Rosenberg R N, 1978, Adv Neurol, V21, P33; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; TAKIYAMA Y, 1993, NAT GENET, V4, P300, DOI 10.1038/ng0793-300; Tops BBJ, 2005, NUCLEIC ACIDS RES, V33, P347, DOI 10.1093/nar/gki183; Trottier Y, 1998, NEUROBIOL DIS, V5, P335, DOI 10.1006/nbdi.1998.0208; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhong WW, 2006, SCIENCE, V311, P1481, DOI 10.1126/science.1123287; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6	55	52	54	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1126	1136		10.1096/fj.06-7002com	http://dx.doi.org/10.1096/fj.06-7002com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17234717				2022-12-25	WOS:000245650400017
J	Sun, Y; Breydo, L; Makarava, N; Yang, QY; Bocharova, OV; Baskakov, IV				Sun, Ying; Breydo, Leonid; Makarava, Natallia; Yang, Qingyuan; Bocharova, Olga V.; Baskakov, Ilia V.			Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CONVERSION; SYNTHETIC PRIONS; SCRAPIE PRIONS; M-VALUES; STRAIN; THERMODYNAMICS; DENATURATION; STABILITY; DISEASE; POLYMORPHISM	Despite the ability of most proteins to form amyloid, very little is know about amyloid fibril structures and the factors that govern their stability. Using amyloid fibrils produced from full-length prion protein (PrP), we describe a reliable approach for determining both site-specific and global conformational stability of the fibrillar form. To measure site-specific stability, we produced six variants of PrP by replacing the residues at positions 88, 98, 127, 144, 196, and 230 with cysteine, labeled the new cysteines with the fluorescent dye acrylodan, and investigated their conformational status within the amyloid form in guanidine hydrochloride-induced denaturation experiments. We found that the fibrils labeled at positions 127, 144, 196, and 230 displayed cooperative unfolding and showed a very high C-1/2 value similar to that observed for the global unfolding of the amyloid structure. The unfolding at residue 98 was also cooperative; however, it showed a C-1/2 value substantially lower than that of global unfolding, whereas the unfolding of fibrils labeled at residue 88 was non-cooperative. These data illustrate that there are at least two independent cooperative folding domains within the amyloid structure of the full-length PrP. In addition, kinetic experiments revealed only a partial overlap between the region that constituted the fibrillar cross-beta core and the regions that were involved in nucleation. This result illustrates that separate PrP regions accounted for the nucleation and for the formation of the conformationally most stable fibrillar core.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Breydo, Leo/AAJ-7996-2020; Bocharova, Olga V./J-8284-2018; Breydo, Leonid/E-6119-2010	Bocharova, Olga V./0000-0002-5056-1506; Breydo, Leonid/0000-0003-4666-2301				Anderson M, 2006, J MOL BIOL, V358, P580, DOI 10.1016/j.jmb.2006.02.007; Baskakov IV, 2005, BIOCHEMISTRY-US, V44, P2339, DOI 10.1021/bi048322t; Baskakov IV, 2004, PROTEIN SCI, V13, P586, DOI 10.1110/ps.03457204; Baskakov IV, 1998, BIOCHEMISTRY-US, V37, P18010, DOI 10.1021/bi981849j; BASKAKOV IV, 2007, IN PRESS BIOCH BIOPH; Bocharova OV, 2006, J BIOL CHEM, V281, P2373, DOI 10.1074/jbc.M510840200; Bocharova OV, 2005, BIOCHEMISTRY-US, V44, P6776, DOI 10.1021/bi050251q; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Breydo L, 2005, BIOCHEMISTRY-US, V44, P15534, DOI 10.1021/bi051369+; Breydo L, 2007, BIOCHEMISTRY-US, V46, P852, DOI 10.1021/bi061923v; Carra JH, 1996, FASEB J, V10, P67, DOI 10.1096/fasebj.10.1.8566550; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Dima RI, 2004, P NATL ACAD SCI USA, V101, P15335, DOI 10.1073/pnas.0404235101; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Englander SW, 1997, PROTEIN SCI, V6, P1101, DOI 10.1002/pro.5560060517; Ferreon ACM, 2004, BIOCHEMISTRY-US, V43, P13357, DOI 10.1021/bi048666j; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Haire LF, 2004, J MOL BIOL, V336, P1175, DOI 10.1016/j.jmb.2003.12.059; Hosszu LLP, 2005, BIOCHEMISTRY-US, V44, P16649, DOI 10.1021/bi051277k; Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014-5793(00)01888-3; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Legname G, 2005, P NATL ACAD SCI USA, V102, P2168, DOI 10.1073/pnas.0409079102; Legname G, 2006, P NATL ACAD SCI USA, V103, P19105, DOI 10.1073/pnas.0608970103; Leliveld SR, 2006, J BIOL CHEM, V281, P3268, DOI 10.1074/jbc.M510606200; Moore RA, 2006, PROTEIN SCI, V15, P609, DOI 10.1110/ps.051822606; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Narimoto T, 2004, FEBS LETT, V576, P313, DOI 10.1016/j.febslet.2004.09.024; Novitskaya V, 2006, J BIOL CHEM, V281, P15536, DOI 10.1074/jbc.M601349200; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Podrabsky JE, 2001, AM J PHYSIOL-REG I, V280, pR123, DOI 10.1152/ajpregu.2001.280.1.R123; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Williams AD, 2006, J MOL BIOL, V357, P1283, DOI 10.1016/j.jmb.2006.01.041; Ziegler J, 2003, J BIOL CHEM, V278, P50175, DOI 10.1074/jbc.M305234200	49	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9090	9097		10.1074/jbc.M608623200	http://dx.doi.org/10.1074/jbc.M608623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244617	hybrid			2022-12-25	WOS:000245780300056
J	Fiala, KA; Suo, ZC				Fiala, Kevin A.; Suo, Zucai			Sloppy bypass of an abasic lesion catalyzed by a Y-family DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS; CRYSTAL-STRUCTURE; ERROR-PRONE; ACTIVE-SITE; DUPLEX DNA; FIDELITY; MECHANISM; DPO4; ETA; IV	DNA damage that eludes cellular repair pathways can arrest the replication machinery and stall the cell cycle. However, this damage can be bypassed by the Y-family DNA polymerases. Here, Dpo4, an archetypal Y-family member from the thermophilic Sulfolobus solfataricus, was used to extend our kinetic studies of the bypass of an abasic site, one of the most mutagenic and ubiquitous cellular lesions. A short oligonucleotide sequencing assay is developed to directly sequence DNA bypass products synthesized by Dpo4. Our results show that incorporation upstream of the abasic lesion is replicated error-free; yet dramatically, once Dpo4 encounters the lesion, synthesis became sloppy, with bypass products containing a myriad of mutagenic events. Incorporation of dAMP (29%) and dCMP (53%) opposite the abasic lesion at 37 degrees C correlates exceptionally well with our kinetic results and demonstrates two dominant bypass pathways via the A-rule and the lesion loop-out mechanism. Interestingly, the percentage of overall frameshift mutations increased from 71 (37 degrees C) to 87% (75 degrees). Further analysis indicates that lesion bypass via the A-rule is strongly preferred over the lesion loop-out mechanism at higher temperatures and concomitantly reduces the occurrence of "-1 deletion" mutations observed opposite the lesion at lower temperatures. The bypass percentage via the latter pathway is confirmed by an enzymatic digestion assay, verifying the reliability of our sequencing assay. Our results demonstrate that an abasic lesion causes Dpo4 and possibly all Y-family members to switch from a normal to a very mutagenic mode of replication.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Suo, ZC (corresponding author), 740 Biol Sci,484 W 12th Ave, Columbus, OH 43210 USA.	suo.3@osu.edu						Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Efrati E, 1997, J BIOL CHEM, V272, P2559; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P6751, DOI 10.1021/bi049975c; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Fiala KA, 2007, J BIOL CHEM, V282, P8188, DOI 10.1074/jbc.M610718200; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Mizukami S, 2006, BIOCHEMISTRY-US, V45, P2772, DOI 10.1021/bi051961z; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Nakamura J, 1999, CANCER RES, V59, P2522; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Rechkoblit O, 2006, PLOS BIOL, V4, P25, DOI 10.1371/journal.pbio.0040011; SCHAAPER RM, 1981, P NATL ACAD SCI-BIOL, V78, P1773, DOI 10.1073/pnas.78.3.1773; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; STRAUSS B, 1982, BIOCHIMIE, V64, P829, DOI 10.1016/S0300-9084(82)80138-7; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200	42	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8199	8206		10.1074/jbc.M610719200	http://dx.doi.org/10.1074/jbc.M610719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234630	hybrid			2022-12-25	WOS:000245081000052
J	Sengupta, P; Ruano, MJ; Tebar, F; Golebiewska, U; Zaitseva, I; Enrich, C; McLaughlin, S; Villalobo, A				Sengupta, Parijat; Jose Ruano, Maria; Tebar, Francesc; Golebiewska, Urszula; Zaitseva, Irina; Enrich, Carlos; McLaughlin, Stuart; Villalobo, Antonio			Membrane-permeable calmodulin inhibitors (e.g. W-7/W-13) bind to membranes, changing the electrostatic surface potential - Dual effect of W-13 on epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; MAPK SIGNALING PATHWAY; PROTEIN KINASE-C; PLASMA-MEMBRANE; EGF RECEPTOR; PHOSPHOLIPID-VESICLES; TARGET RECOGNITION; SPHINGOSINE KINASE; TYROSINE KINASES; DOWN-REGULATION	Membrane-permeable calmodulin inhibitors, such as the napthalenesulfonamide derivatives W-7/W-13, trifluoperazine, and calmidazolium, are used widely to investigate the role of calcium/calmodulin (Ca2+/CaM) in living cells. If two chemically different inhibitors (e.g. W-7 and trifluoperazine) produce similar effects, investigators often assume the effects are due to CaM inhibition. Zeta potential measurements, however, show that these amphipathic weak bases bind to phospholipid vesicles at the same concentrations as they inhibit Ca2+/CaM; this suggests that they also bind to the inner leaflet of the plasma membrane, reducing its negative electrostatic surface potential. This change will cause electrostatically bound clusters of basic residues on peripheral (e.g. Src and K-Ras4B) and integral (e.g. epidermal growth factor receptor (EGFR)) proteins to translocate from the membrane to the cytoplasm. We measured inhibitor-mediated translocation of a simple basic peptide corresponding to the calmodulin-binding juxtamembrane region of the EGFR on model membranes; W-7/W-13 causes translocation of this peptide from membrane to solution, suggesting that caution must be exercised when interpreting the results obtained with these inhibitors in living cells. We present evidence that they exert dual effects on autophosphorylation of EGFR; W-13 inhibits epidermal growth factor-dependent EGFR autophosphorylation under different experimental conditions, but in the absence of epidermal growth factor, W-13 stimulates autophosphorylation of the receptor in four different cell types. Our interpretation is that the former effect is due to W-13 inhibition of Ca2+/CaM, but the latter results could be due to binding of W-13 to the plasma membrane.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Autonoma Madrid, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, CSIC, E-28029 Madrid, Spain; Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, E-08036 Barcelona, Spain	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona	McLaughlin, S (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	Stuart.McLaughlin@stonybrook.edu; antonio.villalobo@iib.uam.es	Villalobo, Antonio/O-9621-2019; Tebar, Francesc/H-1498-2015; Villalobo, Antonio/K-2902-2017	Villalobo, Antonio/0000-0002-4200-374X; Tebar, Francesc/0000-0002-9522-9726; Enrich, Carlos/0000-0003-0382-2993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024971, R01GM024971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aifa S, 2006, PROTEINS, V62, P1036, DOI 10.1002/prot.20780; Aifa S, 2002, CELL SIGNAL, V14, P1005, DOI 10.1016/S0898-6568(02)00034-7; Anfinogenova YJ, 2001, CELL PHYSIOL BIOCHEM, V11, P295, DOI 10.1159/000047816; APODACA G, 1994, J BIOL CHEM, V269, P19005; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Buser CA, 1998, METH MOL B, V84, P267; CAFISO D, 1989, METHOD ENZYMOL, V171, P342; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHANDLER WK, 1965, J PHYSIOL-LONDON, V180, P821, DOI 10.1113/jphysiol.1965.sp007733; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; CHEYETTE TE, 1991, CELL REGUL, V2, P827, DOI 10.1091/mbc.2.10.827; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DILL K, 2003, MOL DRIVING FORCES, P369; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; Elson EL, 2004, J BIOMED OPT, V9, P857, DOI 10.1117/1.1779234; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Golebiewska U, 2006, BIOPHYS J, V91, P588, DOI 10.1529/biophysj.106.081562; Helmholtz H., 1879, ANN PHYS CHEM, V243, P337, DOI DOI 10.1002/ANDP.18792430702; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Hubbard SR, 2004, NAT REV MOL CELL BIO, V5, P464, DOI 10.1038/nrm1399; Hubbard SR, 2006, CELL, V125, P1029, DOI 10.1016/j.cell.2006.05.028; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Jan CR, 2000, PHARMACOL RES, V42, P323, DOI 10.1006/phrs.2000.0703; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Li HB, 2004, FEBS LETT, V559, P175, DOI 10.1016/S0014-5793(04)00067-5; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Li WP, 2004, J BIOL CHEM, V279, P4570, DOI 10.1074/jbc.M304334200; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND KA, 1990, J BIOL CHEM, V265, P20517; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; MCLAUGHLIN S, 1988, J PHYSIOL-LONDON, V396, P189, DOI 10.1113/jphysiol.1988.sp016958; McLaughlin S, 2005, J GEN PHYSIOL, V126, P41, DOI 10.1085/jgp.200509274; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; McLaughlin S, 2006, SCIENCE, V314, P1402, DOI 10.1126/science.1136314; NISHIKAWA M, 1982, J CLIN INVEST, V69, P1348, DOI 10.1172/JCI110574; Okeley NM, 2004, J BIOL CHEM, V279, P21833, DOI 10.1074/jbc.M313469200; Osawa M, 1999, FEBS LETT, V442, P173, DOI 10.1016/S0014-5793(98)01637-8; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Pellicena P, 2006, CURR OPIN STRUC BIOL, V16, P702, DOI 10.1016/j.sbi.2006.10.007; Pike LJ, 2005, J BIOL CHEM, V280, P26796, DOI 10.1074/jbc.M503805200; Rusu L, 2004, BIOPHYS J, V87, P1044, DOI 10.1529/biophysj.104.039958; Sato T, 2006, BIOCHEMISTRY-US, V45, P12704, DOI 10.1021/bi061264m; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sengupta P, 2002, METHODS, V27, P374, DOI 10.1016/S1046-2023(02)00096-8; SHEETZ MP, 1976, J CELL BIOL, V70, P247, DOI 10.1083/jcb.70.1.247; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOROKIN A, 1995, ONCOGENE, V11, P1531; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; Tebar F, 2002, FEBS LETT, V517, P206, DOI 10.1016/S0014-5793(02)02624-8; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; Uyemura T, 2005, BIOPHYS J, V88, P3720, DOI 10.1529/biophysj.104.053330; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; Watanabe H, 1999, BIOCHEM BIOPH RES CO, V265, P697, DOI 10.1006/bbrc.1999.1755; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	86	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8474	8486		10.1074/jbc.M607211200	http://dx.doi.org/10.1074/jbc.M607211200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227773	hybrid, Green Accepted			2022-12-25	WOS:000245081000080
J	Turu, G; Simon, A; Gyombolai, P; Szidonya, L; Bagdy, G; Lenkei, Z; Hunyady, L				Turu, Gabor; Simon, Anne; Gyombolai, Pal; Szidonya, Laszlo; Bagdy, Gyorgy; Lenkei, Zsolt; Hunyady, Laszlo			The role of diacylglycerol lipase in constitutive and angiotensin AT(1) receptor-stimulated cannabinoid CB1 receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERSE AGONIST; ENDOCANNABINOID SYSTEM; SIGNALING PATHWAYS; EXPRESSION; PROTEIN; BRAIN; BINDS; MODEL; CELL	The cannabinoid CB1 receptor (CB1R) is,a G protein-coupled receptor, which couples to the G(i/o) family of heterotrimeric G proteins. The receptor displays both basal and agonist-induced signaling and internalization. Although basal activity of CBIRs is attributed to constitutive (agonist-independent) receptor activity, studies in neurons suggested a role of postsynaptic endocannabinoid (eCB) release in the persistent activity of presynaptic CB1Rs. To elucidate the role of eCBs in basal CB1R activity, we have investigated the role of diacylglycerol lipase (DAGL) in this process in Chinese hamster ovary (CHO) cells, which are not targeted specifically with I Agonist-induced G protein activation was determined by detecting dissociation G protein subunits expressed in CHO cells with bioluminescence resonance energy transfer (BRET), after labeling the alpha and beta subunits with Renilla luciferase and enhanced yellow fluorescent protein (EYFP), respectively. Pre-incubation of the cells with tetrahydrolipstatin (THL), a known inhibitor of DAGLs, caused inhibition of the basal activity of CBIR. Moreover, preincubation of CHO and cultured hippocampal neurons with THL increased the number of CBIRs on the cell membrane, which reflects its inhibitory action on CB1R internalization in non-simulated cells. In CHO cells co-expressing CB1R and angiotensin AT(1) receptors, angiotensin II-induced Go protein activation that was blocked by both a CBIR antagonist and THL. These data indicate that cell-derived I mediators have a general role in the basal activity of CB1Rs in non-neural cells and neurons, and that this mechanism can be stimulated by AT(1) receptor activation.	Semmelweis Univ, Dept Physiol, Fac Med, H-1444 Budapest, Hungary; Hungarian Acad Sci, Lab Neurobiochem & Mol Physiol, H-1444 Budapest, Hungary; Ecole Super Phys & Chim Ind Ville Paris, CNRS, Lab Neurobiol & Divers Cellulaire, UMR 7637, F-75013 Paris, France; Natl Inst Psychiat & Neurol, Lab Neurochem & Expt Med, H-1021 Budapest, Hungary; Hungarian Acad Sci, Grp Neuropsychopharmacol, H-1089 Budapest, Hungary	Semmelweis University; Hungarian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Hunyady, L (corresponding author), Semmelweis Univ, Dept Physiol, Fac Med, POB 259, H-1444 Budapest, Hungary.	Hunyady@puskin.sote.hu	Bagdy, György/O-3893-2017; Szidonya, Laszlo/A-2271-2010; Lenkei, Zsolt/G-4369-2013	Bagdy, György/0000-0001-8141-3410; Lenkei, Zsolt/0000-0002-1142-5931; Turu, Gabor/0000-0002-4421-3812; Gyombolai, Pal/0000-0001-7117-6351				Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Bisogno T, 2006, BBA-MOL CELL BIOL L, V1761, P205, DOI 10.1016/j.bbalip.2005.12.009; Bisogno T, 2005, PHARMACOL BIOCHEM BE, V81, P224, DOI 10.1016/j.pbb.2005.01.027; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Hentges ST, 2005, J NEUROSCI, V25, P9746, DOI 10.1523/JNEUROSCI.2769-05.2005; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; MacLennan SJ, 1998, BRIT J PHARMACOL, V124, P619, DOI 10.1038/sj.bjp.0701915; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Neu A, 2007, J PHYSIOL-LONDON, V578, P233, DOI 10.1113/jphysiol.2006.115691; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pan XH, 1998, MOL PHARMACOL, V54, P1064, DOI 10.1124/mol.54.6.1064; Pertwee RG, 2005, LIFE SCI, V76, P1307, DOI 10.1016/j.lfs.2004.10.025; Randall MD, 2004, BRIT J PHARMACOL, V142, P20, DOI 10.1038/sj.bjp.0705725; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V287, P1038; Spat A, 2004, PHYSIOL REV, V84, P489, DOI 10.1152/physrev.00030.2003; Turu G, 2006, FEBS LETT, V580, P41, DOI 10.1016/j.febslet.2005.11.044; Vasquez C, 1999, J NEUROSCI, V19, P9271; Vinod KY, 2006, TRENDS PHARMACOL SCI, V27, P539, DOI 10.1016/j.tips.2006.08.006; Zhu PJ, 2005, J NEUROSCI, V25, P6199, DOI 10.1523/JNEUROSCI.1148-05.2005	27	58	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7753	7757		10.1074/jbc.C600318200	http://dx.doi.org/10.1074/jbc.C600318200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227758	Green Published, hybrid			2022-12-25	WOS:000245081000002
J	Denisov, IG; Baas, BJ; Grinkova, YV; Sligar, SG				Denisov, Ilia G.; Baas, Bradley J.; Grinkova, Yelena V.; Sligar, Stephen G.			Cooperativity in cytochrome P450 3A4 - Linkages in substrate binding, spin state, uncoupling, and product formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NANOSCALE LIPID-BILAYERS; MOLECULE HEIGHT MEASUREMENTS; P450 REDUCTASE; RECOGNITION SITE; LIGAND-BINDING; MICROSOMAL CYTOCHROME-P450; SCANNING MUTAGENESIS; CATALYTIC-ACTIVITY; MEMBRANE-PROTEINS; ESCHERICHIA-COLI	Understanding the detailed metabolic mechanisms of membrane-associated cytochromes P450 is often hampered by heterogeneity, ill-defined oligomeric state of the enzyme, and variation in the stoichiometry of the functional P450(.)reductase complexes in various reconstituted systems. Here, we describe the detailed characterization of a functionally homogeneous 1:1 complex of cytochrome P450 3A4 (CYP3A4) and cytochrome P450 reductase solubilized via self-assembly in a nanoscale phospholipid bilayer. CYP3A4 in this complex showed a nearly complete conversion from the low- to high-spin state when saturated with testosterone (TS) and no noticeable modulation due to the presence of cytochrome P450 reductase. Global analysis of equilibrium substrate binding and steady-state NADPH consumption kinetics provided precise resolution of the fractional contributions to turnover of CYP3A4 intermediates with one, two, or three TS molecules bound. The first binding event accelerates NADPH consumption but does not result in significant product formation due to essentially complete uncoupling. Binding of the second substrate molecule is critically important for catalysis, as the product formation rate reaches a maximum value with two TS molecules bound, whereas the third binding event significantly improves the coupling efficiency of redox equivalent usage with no further increase in product formation rate. The resolution of the fractional contributions of binding intermediates of CYP3A4 into experimentally observed overall spin shift and the rates of steady-state NADPH oxidation and product formation provide new detailed insight into the mechanisms of cooperativity and allosteric regulation in this human cytochrome P450.	Univ Illinois, Dept Biochem, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, Coll Med, 116 Morrill Hall,MC-119,505 S Goodwin Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Denisov, Ilia G/J-6590-2013	Denisov, Ilia G/0000-0002-7878-2626	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM033775] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM33775, R37 GM31756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARLOTTO MP, 1991, METHOD ENZYMOL, V206, P454; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; Bayburt TH, 2000, LANGMUIR, V16, P5993, DOI 10.1021/la991449c; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Bayburt TH, 2006, ARCH BIOCHEM BIOPHYS, V450, P215, DOI 10.1016/j.abb.2006.03.013; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Boldog T, 2006, P NATL ACAD SCI USA, V103, P11509, DOI 10.1073/pnas.0604988103; BONOMO EA, 1988, J LIPID RES, V29, P380; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Civjan NR, 2003, BIOTECHNIQUES, V35, P556, DOI 10.2144/03353rr02; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Davydov DR, 2003, BIOCHEM BIOPH RES CO, V312, P121, DOI 10.1016/j.bbrc.2003.09.247; Denisov IG, 2005, J PHYS CHEM B, V109, P15580, DOI 10.1021/jp051385g; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Denisov IG, 2006, J BIOL CHEM, V281, P23313, DOI 10.1074/jbc.M605511200; Di Cera E., 1995, THERMODYNAMIC THEORY; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Domanski TL, 2001, BIOCHEMISTRY-US, V40, P10150, DOI 10.1021/bi010758a; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103; Fernando H, 2006, BIOCHEMISTRY-US, V45, P4199, DOI 10.1021/bi052491b; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gilep AA, 2001, ARCH BIOCHEM BIOPHYS, V390, P215, DOI 10.1006/abbi.2001.2372; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Harlow GR, 1997, J BIOL CHEM, V272, P5396, DOI 10.1074/jbc.272.9.5396; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Hosea NA, 1998, ARCH BIOCHEM BIOPHYS, V353, P365, DOI 10.1006/abbi.1998.0659; Houston JB, 2005, ARCH BIOCHEM BIOPHYS, V433, P351, DOI 10.1016/j.abb.2004.09.010; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; Kim KH, 2003, BIOCHEMISTRY-US, V42, P15377, DOI 10.1021/bi035280k; Krauser JA, 2004, EUR J BIOCHEM, V271, P3962, DOI 10.1111/j.1432-1033.2004.04339.x; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; Makris TM., 2005, CYTOCHROME P450, P149; NAKANO R, 1995, BBA-PROTEIN STRUCT M, V1252, P245, DOI 10.1016/0167-4838(95)00143-I; OMURA T, 1964, J BIOL CHEM, V239, P2379; Perret A, 1998, BIOCHEMISTRY-US, V37, P11412, DOI 10.1021/bi980908q; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; SCHENKMAN JB, 2005, CYTOCHROME P450 PROT, V320, P11; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Scott EE, 2005, TRENDS BIOCHEM SCI, V30, P5, DOI 10.1016/j.tibs.2004.11.004; SHEN ES, 1989, BIOCHEM PHARMACOL, V38, P4075, DOI 10.1016/0006-2952(89)90689-8; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; Shimada T, 2005, ARCH BIOCHEM BIOPHYS, V435, P207, DOI 10.1016/j.abb.2004.12.008; Shou MG, 1999, BIOCHEM J, V340, P845, DOI 10.1042/0264-6021:3400845; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	61	164	166	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7066	7076		10.1074/jbc.M609589200	http://dx.doi.org/10.1074/jbc.M609589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213193	hybrid			2022-12-25	WOS:000245080900018
J	Ranjith-Kumar, CT; Miller, W; Jin, XO; Russell, WK; Lamb, R; Santos, J; Duffy, KE; Cleveland, L; Parv, M; Bhardwaj, K; Wu, ZX; Russell, DH; Sarisky, RT; Mbow, ML; Kao, CC				Ranjith-Kumar, C. T.; Miller, William; Jin Xiong; Russell, William K.; Lamb, Roberta; Santos, Jonathan; Duffy, Karen E.; Cleveland, Larissa; Parv, Mary; Bhardwaj, Kanchan; Wu, Zhaoxiang; Russell, David H.; Sarisky, Robert T.; Mbow, M. Lamine; Kao, C. Cheng			Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; RECOGNITION; RESIDUES; LOCALIZATION; ACTIVATION	The structure of the human Toll-like receptor 3 (TLR3) ectodomain (ECD) was recently solved by x-ray crystallography, leading to a number of models concerning TLR3 function (Choe, J., Kelker, M. S., and Wilson, I. A. (2005) Science 309, 581-585; Bell, J. K., Botos, I., Hall, P. R., Askins, J., Shiloach, J., Segal, D. M., and Davies, D. R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10976-10980) The structure revealed four pairs of cysteines that are putatively involved in disulfide bond formation, several residues that are predicted to be involved in dimerization between ECD subunits, and surfaces that could bind to poly(I:C). In addition, there are two loops that protrude from the central solenoid structure of the protein. We examined the recombinant TLR3 ECD for disulfide bond formation, poly(I:Q binding, and protein-protein interaction. We also made over 80 mutations in the residues that could affect these features in the full-length TLR3 and examined their effects in TLR3-mediated NF-kappa B activation. A number of mutations that affected TLR3 activity also affected the ability to act as dominant negative inhibitors of wild type TLR3. Loss of putative RNA binding did not necessarily affect dominant negative activity. All of the results support a model where a dimer of TLR3 is the form that binds RNA and activates signal transduction.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, Lab Biol Mass Spectrometry, College Stn, TX 77843 USA; Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Johnson & Johnson; Johnson & Johnson USA	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Kumar CT, Ranjith/J-5701-2016; Wu, Zhaoxiang/D-5678-2012; Bhardwaj, Kanchan/CAH-2291-2022; Russell, David H/C-3618-2015	Bhardwaj, Kanchan/0000-0002-7331-7717; Russell, David H/0000-0003-0830-3914; Miller, William/0000-0002-1518-2973	NCRR NIH HHS [RR019587] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR019587] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; Gorman JJ, 2002, MASS SPECTROM REV, V21, P183, DOI 10.1002/mas.10025; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Guarino LA, 2005, J MOL BIOL, V353, P1106, DOI 10.1016/j.jmb.2005.09.007; Kim CH, 2000, NAT STRUCT BIOL, V7, P415, DOI 10.1038/75202; Lancaster GI, 2005, J PHYSIOL-LONDON, V563, P945, DOI 10.1113/jphysiol.2004.081224; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Park ZY, 2000, ANAL CHEM, V72, P2667, DOI 10.1021/ac991444k; RUIZ M, 2004, EUR J IMMUNOL, V34, P2541; Salio M, 2005, CURR BIOL, V15, pR336, DOI 10.1016/j.cub.2005.04.025; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Uematsu S, 2006, EXPERT OPIN BIOL TH, V6, P203, DOI 10.1517/14712598.6.3.203; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	28	49	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7668	7678		10.1074/jbc.M610946200	http://dx.doi.org/10.1074/jbc.M610946200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209042	hybrid			2022-12-25	WOS:000245080900079
J	Wang, JH; Barke, RA; Roy, S				Wang, Jinghua; Barke, Roderick A.; Roy, Sabita			Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-EARLY REPRESSOR; PANCREATIC BETA-CELLS; MU-OPIOID RECEPTOR; CYCLIC-AMP; IL-2 GENE; MOLECULAR-BASIS; THE-180 SITE; DRUG-USERS; EXPRESSION; PROMOTER	Chronic morphine inhibits interleukin-2 (IL-2) at both the transcriptional and protein synthesis levels. The molecular mechanisms by which morphine decreases IL-2 are not fully understood. The production of IL-2 is tightly regulated by several transcription factors that bind to the IL-2 promoter. Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/ cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells. Furthermore, ICER competes for p-CREB binding to the cAMP-responsive elements (CREs) site. This leads to the uncoupling of CBP/p300 thereby abrogating IL-2 transcription. Overexpression of either antisense CREM or CREB plasmid rescued morphine-induced inhibition of IL-2 promoter activity and protein production. In addition, we also found that chronic morphine treatment inhibited the acetylation and trimethylation of histories and decreased both DNA demethylation and accessibility of the IL-2 promoter. These findings suggest that chronic morphine treatment may function through both transcriptional and epigenetic mechanisms to inhibit IL-2 production.	Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Dept Surg, Minneapolis, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Roy, S (corresponding author), Univ Minnesota, Dept Pharmaceut, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	royxx002@umn.edu			NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007097, P50DA011806, K02DA015349, R01DA012104] Funding Source: NIH RePORTER; NIDA NIH HHS [T32DA07097, KO2DA015349, P50DA11806, R01DA12104] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bird A, 2003, NAT IMMUNOL, V4, P208, DOI 10.1038/ni0303-208; Bodor J, 2002, EUR J IMMUNOL, V32, P203, DOI 10.1002/1521-4141(200201)32:1<203::AID-IMMU203>3.0.CO;2-C; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Bodor J, 2000, J LEUKOCYTE BIOL, V67, P774, DOI 10.1002/jlb.67.6.774; Bodor J, 2001, J LEUKOCYTE BIOL, V69, P1053; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; Daniel PB, 2000, ENDOCRINOLOGY, V141, P3923, DOI 10.1210/en.141.11.3923; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DellaFazia MA, 1997, FEBS LETT, V410, P22, DOI 10.1016/S0014-5793(97)00445-6; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Friedman H, 2003, CLIN MICROBIOL REV, V16, P209, DOI 10.1128/CMR.16.2.209-219.2003; Georges H, 1999, INTENS CARE MED, V25, P198, DOI 10.1007/s001340050816; Gordon RJ, 2005, NEW ENGL J MED, V353, P1945, DOI 10.1056/NEJMra042823; Hussain MA, 2000, DIABETES, V49, P1681, DOI 10.2337/diabetes.49.10.1681; Inada A, 2004, MOL CELL BIOL, V24, P2831, DOI 10.1128/MCB.24.7.2831-2841.2004; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Liu Y, 2006, J NEUROENDOCRINOL, V18, P42, DOI 10.1111/j.1365-2826.2005.01383.x; Mioduszewska B, 2003, J NEUROCHEM, V87, P1313, DOI 10.1046/j.1471-4159.2003.02116.x; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012; Nath A, 2002, JAIDS-J ACQ IMM DEF, V31, pS62, DOI 10.1097/00126334-200210012-00006; Powell JD, 1999, J IMMUNOL, V163, P6631; Quaglio G, 2002, SCAND J INFECT DIS, V34, P574, DOI 10.1080/00365540110080791; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Roy S, 1997, CELL IMMUNOL, V179, P1, DOI 10.1006/cimm.1997.1147; Roy S, 2005, J IMMUNOL, V175, P6361, DOI 10.4049/jimmunol.175.10.6361; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Roy S, 2004, J NEUROIMMUNOL, V147, P78, DOI 10.1016/j.jneuroim.2003.10.016; Roy S, 2001, SURGERY, V130, P304, DOI 10.1067/msy.2001.116033; Roy S, 2006, J NEUROIMMUNE PHARM, V1, P77, DOI 10.1007/s11481-005-9009-8; Sacerdote P, 2003, ADV EXP MED BIOL, V521, P106; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Sharp BM, 1998, J NEUROIMMUNOL, V83, P45, DOI 10.1016/S0165-5728(97)00220-8; Solomou EE, 2001, J IMMUNOL, V166, P4216, DOI 10.4049/jimmunol.166.6.4216; Solomou EE, 2001, J IMMUNOL, V166, P5665, DOI 10.4049/jimmunol.166.9.5665; Thomas RM, 2005, J IMMUNOL, V174, P4639, DOI 10.4049/jimmunol.174.8.4639; TSURUTA L, 1995, J IMMUNOL, V154, P5255; Wang JH, 2005, J IMMUNOL, V174, P426, DOI 10.4049/jimmunol.174.1.426; Wang JH, 2003, J BIOL CHEM, V278, P37622, DOI 10.1074/jbc.M301224200; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; Wang JH, 2001, J LEUKOCYTE BIOL, V70, P527; Wang L, 2005, BIOCHEM BIOPH RES CO, V331, P589, DOI 10.1016/j.bbrc.2005.03.216; Ward SB, 1998, NUCLEIC ACIDS RES, V26, P2923, DOI 10.1093/nar/26.12.2923	47	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7164	7171		10.1074/jbc.M604367200	http://dx.doi.org/10.1074/jbc.M604367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17227776	hybrid			2022-12-25	WOS:000245080900028
J	Niu, JG; Chang, Z; Peng, BL; Xia, QH; Lu, WQ; Huang, P; Tsao, MS; Chiao, PJ				Niu, Jiangong; Chang, Zhe; Peng, Bailu; Xia, Qianghua; Lu, Weiqin; Huang, Peng; Tsao, Ming-Sound; Chiao, Paul J.			Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappa B transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EXPRESSION; PANCREATIC ADENOCARCINOMA; GENE-EXPRESSION; ALPHA; PROTEINS; RECEPTOR; OVEREXPRESSION; AUTOREGULATION; IDENTIFICATION; SPECIFICITY	Keratinocyte growth factor (KGF)/fibroblast growth factor-7 (FGF-7) is a paracrine- and epithelium-specific growth,factor produced by cells of mesenchymal origin. It acts exclusively through FGF-7 receptor (FGFR2/IIIb), which is expressed predominantly by epithelial cells, but not by fibroblasts, suggesting that it might function as a paracrine mediator of mesenchymal-epithelial interactions. KGF/FGF-7 plays an essential role in the growth of epithelial cells and is frequently overexpressed in cancers of epithelial origin such as pancreatic cancer, switching paracrine stimulation of KGF/FGF-7 to an autocrine loop. Less is known, however, about the signaling pathways by which KGF/FGF-7 regulates the response of epithelial cells. To delineate the signaling pathways activated by KGF/FGF-7 and examine cellular response to KGF/ FGF-7 stimulation, we performed functional analysis of KGF/ FGF-7 action. In this report, we show that KGF/FGF-.7 activated nuclear factor kappa B (NF-kappa B), which in turn induced expression of VEGF, NIMP-9, and urokinase-type plasminogen activator and increased migration and invasion of KGF/FGF-7-stimulated human pancreatic ductal epithelial cells. Expression of phosphorylation-defective I kappa B alpha (I kappa B alpha S32A,S36A), which blocked NF-kappa B activation, inhibited KGF/FGF-7-induced gene expression and cell migration and invasion. Our results demonstrate for the first time that KGF/FGF-7 induces NF-kappa B activation and that NF-kappa B plays an essential role in regulation of KGF/FGF-7-inducible gene expression and KGF/FGF-7-initiated cellular responses. Thus, these findings identify one signaling pathway for KGF/FGF-7-regulated cell migration and invasion and suggest that paracrine sources of KGF/FGF-7 are one of the malignancy-contributing factors from tumor stroma.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Univ Toronto, Hlth Network, Princess Margaret Hosp, Ontario Canc Inst,Dept Lab Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Hlth Network, Princess Margaret Hosp, Ontario Canc Inst,Dept Pathobiol, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol Mol & Cellular Oncol, Unit 107,1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mdanderson.org	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405	NATIONAL CANCER INSTITUTE [R01CA109405, R01CA097159] Funding Source: NIH RePORTER; NCI NIH HHS [CA097159, CA109405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Florin L, 2004, ONCOGENE, V23, P7005, DOI 10.1038/sj.onc.1207938; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Furukawa T, 1996, AM J PATHOL, V148, P1763; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1996, ONCOGENE, V13, P1367; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keller UAD, 2004, EUR J CELL BIOL, V83, P607; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maas-Szabowski N, 1999, J CELL SCI, V112, P1843; Maas-Szabowski N, 2000, J INVEST DERMATOL, V114, P1075, DOI 10.1046/j.1523-1747.2000.00987.x; MaasSzabowski N, 1996, J INVEST DERMATOL, V107, P849, DOI 10.1111/1523-1747.ep12331158; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Niu JG, 2004, J BIOL CHEM, V279, P16452, DOI 10.1074/jbc.M309789200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozes ON, 1999, NATURE, V401, P82; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Ray Prabir, 2005, Proc Am Thorac Soc, V2, P221, DOI 10.1513/pats.200502-012AC; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; VAN AD, 1996, SCIENCE, V274, P787; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; YI ES, 1994, AM J PATHOL, V145, P1015	44	74	85	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6001	6011		10.1074/jbc.M606878200	http://dx.doi.org/10.1074/jbc.M606878200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200110	hybrid			2022-12-25	WOS:000244867200005
J	Pedersen, JZ; De Maria, F; Turella, P; Federici, G; Mattei, M; Fabrini, R; Dawood, KF; Massimi, M; Caccuri, AM; Ricci, G				Pedersen, Jens Z.; De Maria, Francesca; Turella, Paola; Federici, Giorgio; Mattei, Maurizio; Fabrini, Raffaele; Dawood, Kutayba F.; Massimi, Mara; Caccuri, Anna Maria; Ricci, Giorgio			Glutathione transferases sequester toxic dinitrosyl-iron complexes in cells - A protection mechanism against excess nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; S-TRANSFERASES; RAT HEPATOCYTES; IN-VIVO; LIVER; IDENTIFICATION; RELEASE; P1-1; SUPERFAMILY; SENSITIVITY	It is now well established that exposure of cells and tissues to nitric oxide leads to the formation of a dinitrosyl-iron complex bound to intracellular proteins, but little is known about how the complex is formed, the identity of the proteins, and the physiological role of this process. By using EPR spectroscopy and enzyme activity measurements to study the mechanism in hepatocytes, we here identify the complex as a dinitrosyl-diglutathionyl-iron complex (DNDGIC) bound to Alpha class glutathione S-transferases (GSTs) with extraordinary high affinity (K-D = 10(-10) m). This complex is formed spontaneously through NO-mediated extraction of iron from ferritin and transferrin, in a reaction that requires only glutathione. In hepatocytes, DNDGIC may reach concentrations of 0.19 mM, apparently entirely bound to Alpha class GSTs, present in the cytosol at a concentration of about 0.3 mM. Surprisingly, about 20% of the dinitrosyl-glutathionyl-iron complex-GST is found to be associated with subcellular components, mainly the nucleus, as demonstrated in the accompanying paper (Stella, L., Pallottini, V., Moreno, S., Leoni, S., De Maria, F., Turella, P., Federici, G., Fabrini, R., Dawood, K. F., Lo Bello, M., Pedersen, J. Z., and Ricci, G. (2007) J. Biol. Chem. 282, 6372-6379). DNDGIC is a potent irreversible inhibitor of glutathione reductase, but the strong complex-GST interaction ensures full protection of glutathione reductase activity in the cells, and in vitro experiments show that damage to the reductase only occurs when the DNDGIC concentration exceeds the binding capacity of the intracellular GST pool. Because Pi class GSTs may exert a similar role in other cell types, we suggest that specific sequestering of DNDGIC by GSTs is a physiological protective mechanism operating in conditions of excessive levels of nitric oxide.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Childrens Hosp Bambin Gesu, I-00165 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; Univ Aquila, Dept Appl Biol, I-67010 Laquila, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu; University of Rome Tor Vergata; University of L'Aquila	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy.	riccig@uniroma2.it	Mattei, Maurizio/AAC-1303-2019; Dawood, Kutayba/E-1505-2019; massimi, mara/I-6076-2012; CACCURI, ANNA MARIA/AFU-2643-2022; Massimi, Mara/R-6836-2019	Mattei, Maurizio/0000-0002-0814-8873; Dawood, Kutayba/0000-0002-0762-9632; massimi, mara/0000-0002-9569-816X; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846				ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; Boese M, 1997, J BIOL CHEM, V272, P21767, DOI 10.1074/jbc.272.35.21767; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Cesareo E, 2005, J BIOL CHEM, V280, P42172, DOI 10.1074/jbc.M507916200; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; HARRIS LR, 1994, BIOCHEM J, V301, P385, DOI 10.1042/bj3010385; Incerpi S, 1996, AM J PHYSIOL-CELL PH, V270, pC841, DOI 10.1152/ajpcell.1996.270.3.C841; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mannervik B, 2005, METHOD ENZYMOL, V401, P1, DOI 10.1016/S0076-6879(05)01001-3; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; OPPENHEIMER JH, 1985, J CLIN INVEST, V75, P147, DOI 10.1172/JCI111667; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; ROUIMI P, 1995, ANAL BIOCHEM, V229, P304, DOI 10.1006/abio.1995.1417; Sergent O, 1997, HEPATOLOGY, V25, P122, DOI 10.1002/hep.510250123; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; Stella L, 2007, J BIOL CHEM, V282, P6372, DOI 10.1074/jbc.M609906200; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; VANIN A F, 1967, Biofizika, V12, P829; Vanin AF, 1998, NITRIC OXIDE-BIOL CH, V2, P224, DOI 10.1006/niox.1998.0180; Watts RN, 2006, P NATL ACAD SCI USA, V103, P7670, DOI 10.1073/pnas.0602515103; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069	36	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6364	6371		10.1074/jbc.M609905200	http://dx.doi.org/10.1074/jbc.M609905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197702	hybrid			2022-12-25	WOS:000244867200043
J	Viola, A; Saywell, V; Villard, L; Cozzone, PJ; Lutz, NW				Viola, Angele; Saywell, Veronique; Villard, Laurent; Cozzone, Patrick J.; Lutz, Norbert W.			Metabolic Fingerprints of Altered Brain Growth, Osmoregulation and Neurotransmission in a Rett Syndrome Model	PLOS ONE			English	Article								Background. Rett syndrome (RS) is the leading cause of profound mental retardation of genetic origin in girls. Since RS is mostly caused by mutations in the MECP2 gene, transgenic animal models such as the Mecp2-deleted ("Mecp2-null'') mouse have been employed to study neurological symptoms and brain function. However, an interdisciplinary approach drawing from chemistry, biology and neuroscience is needed to elucidate the mechanistic links between the genotype and phenotype of this genetic disorder. Methodology/Principal Findings. We performed, for the first time, a metabolomic study of brain extracts from Mecp2-null mice by using high-resolution magnetic resonance spectroscopy. A large number of individual water-soluble metabolites and phospholipids were quantified without prior selection for specific metabolic pathways. Results were interpreted in terms of Mecp2 gene deletion, brain cell function and brain morphology. This approach provided a "metabolic window'' to brain characteristics in Mecp2-null mice (n = 4), revealing (i) the first metabolic evidence of astrocyte involvement in RS (decreased levels of the astrocyte marker, myo-inositol, vs. wild-type mice; p = 0.034); (ii) reduced choline phospholipid turnover in Mecp2-null vs. wild-type mice, implying a diminished potential of cells to grow, paralleled by globally reduced brain size and perturbed osmoregulation; (iii) alterations of the platelet activating factor (PAF) cycle in Mecp2-null mouse brains, where PAF is a bioactive lipid acting on neuronal growth, glutamate exocytosis and other processes; and (iv) changes in glutamine/glutamate ratios (p = 0.034) in Mecp2-null mouse brains potentially indicating altered neurotransmitter recycling. Conclusions/Significance. This study establishes, for the first time, detailed metabolic fingerprints of perturbed brain growth, osmoregulation and neurotransmission in a mouse model of Rett syndrome. Combined with morphological and neurological findings, these results are crucial elements in providing mechanistic links between genotype and phenotype of Rett syndrome. Ultimately, this information can be used to identify novel molecular targets for pharmacological RS treatment.	[Viola, Angele; Cozzone, Patrick J.; Lutz, Norbert W.] Univ Mediterranee, Fac Med, CNRS, UMR 6612,CRMBM, Marseille, France; [Saywell, Veronique; Villard, Laurent] Fac Med Timone, INSERM, U491, Marseille, France; [Saywell, Veronique; Villard, Laurent] Univ Mediterranee, Fac Med Timone, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lutz, NW (corresponding author), Univ Mediterranee, Fac Med, CNRS, UMR 6612,CRMBM, Marseille, France.	Norbert.Lutz@medecine.univ-mrs.fr	Villard, Laurent/E-3941-2016	Villard, Laurent/0000-0001-6657-5008	CNRS (Centre National de la Recherche Scientifique); Programme Interdisciplinaire CNRS-CEA Imagerie du Petit Animal, Institut Universitaire de France, ACI 2003	CNRS (Centre National de la Recherche Scientifique)(Centre National de la Recherche Scientifique (CNRS)); Programme Interdisciplinaire CNRS-CEA Imagerie du Petit Animal, Institut Universitaire de France, ACI 2003	Financial support from the following institutions is gratefully acknowledged: CNRS (Centre National de la Recherche Scientifique), Programme Interdisciplinaire CNRS-CEA Imagerie du Petit Animal, Institut Universitaire de France, ACI 2003 (Action Concertee Initiative Plates-formes d'explorations fonctionnelles thematisees). These sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.	Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Armstrong DD, 2001, BRAIN DEV-JPN, V23, pS72, DOI 10.1016/S0387-7604(01)00332-1; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Bazan NG, 2003, J LIPID RES, V44, P2221, DOI 10.1194/jlr.R300013-JLR200; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; Gokcay A, 2002, COMPUT MED IMAG GRAP, V26, P271, DOI 10.1016/S0895-6111(02)00016-2; Gotoh H, 2001, BRAIN DEV-JPN, V23, pS118, DOI 10.1016/S0387-7604(01)00355-2; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1986, AM J MED GENET, V24, P47; Hagberg Bengt, 2002, Eur J Paediatr Neurol, V6, P293, DOI 10.1053/ejpn.2002.0612; Hagberg G, 2000, ACTA PAEDIATR, V89, P198, DOI 10.1080/080352500750028834; Ham AL, 2005, J CHILD NEUROL, V20, P768; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; JOHNSTON MV, 1995, NEUROPEDIATRICS, V26, P119, DOI 10.1055/s-2007-979740; Johnston R, 2001, POLIT BEHAV, V23, P1, DOI 10.1023/A:1017684329835; Kimelberg HK, 2004, NEUROCHEM INT, V45, P191, DOI 10.1016/j.neuint.2003.08.015; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; Lekman A Y, 1999, Eur J Paediatr Neurol, V3, P119, DOI 10.1016/S1090-3798(99)90099-5; LEKMAN AY, 1991, PEDIATR NEUROL, V7, P186, DOI 10.1016/0887-8994(91)90082-V; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lutz NW, 2005, METABOLOMICS, V1, P251, DOI 10.1007/s11306-005-0005-z; Lutz NW, 2002, NMR BIOMED, V15, P356, DOI 10.1002/nbm.790; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACALA LJ, 1995, GLYCOBIOLOGY, V5, P67, DOI 10.1093/glycob/5.1.67; Nagai K, 2005, DEV BRAIN RES, V157, P103, DOI 10.1016/j.devbrainres.2005.03.011; Naidu S, 2001, BRAIN DEV-JPN, V23, pS62, DOI 10.1016/S0387-7604(01)00381-3; Nelson ED, 2006, CURR BIOL, V16, P710, DOI 10.1016/j.cub.2006.02.062; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Nuber UA, 2005, HUM MOL GENET, V14, P2247, DOI 10.1093/hmg/ddi229; Pan JW, 1999, J CHILD NEUROL, V14, P524, DOI 10.1177/088307389901400808; PAPADIMITRIOU JM, 1988, AM J MED GENET, V29, P365, DOI 10.1002/ajmg.1320290216; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Picker JD, 2006, NEUROREPORT, V17, P541, DOI 10.1097/01.wnr.0000208995.38695.2f; Purves D., 2001, NEUROSCIENCE; REISS AL, 1993, ANN NEUROL, V34, P227, DOI 10.1002/ana.410340220; Rett A, 1966, Wien Med Wochenschr, V116, P723; Rice SQJ, 1998, BIOCHEM J, V330, P1309; Saywell W, 2006, BIOCHEM BIOPH RES CO, V340, P776, DOI 10.1016/j.bbrc.2005.12.080; Segovia G, 1999, NEUROCHEM RES, V24, P779, DOI 10.1023/A:1020787714940; Shahbazian MD, 2002, AM J HUM GENET, V71, P1259, DOI 10.1086/345360; Shokati T, 2005, NEUROCHEM RES, V30, P1269, DOI 10.1007/s11064-005-8798-8; Sokal RR, 1995, BIOMETRY; Stanimirovic DB, 1997, GLIA, V19, P123, DOI 10.1002/(SICI)1098-1136(199702)19:2<123::AID-GLIA4>3.0.CO;2-1; Subramaniam B, 1997, NEUROLOGY, V48, P399, DOI 10.1212/WNL.48.2.399; Tome ME, 2003, BBA-MOL CELL RES, V1642, P149, DOI 10.1016/j.bbamcr.2003.08.002; Viemari JC, 2005, J NEUROSCI, V25, P11521, DOI 10.1523/JNEUROSCI.4373-05.2005; Viola A, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.0000019549.97278.EF; WESTERGAARD N, 1991, J NEUROCHEM, V56, P59, DOI 10.1111/j.1471-4159.1991.tb02562.x; Wu GS, 2005, J NEUROSCI, V25, P11014, DOI 10.1523/JNEUROSCI.3635-05.2005; Zhang XH, 2006, J CELL SCI, V119, P1005, DOI 10.1242/jcs.02821; Zoghbi HY, 2005, J CHILD NEUROL, V20, P736, DOI 10.1177/08830738050200090701; ZWINGMANN C, NEUROCHEM R IN PRESS	55	42	42	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e157	10.1371/journal.pone.0000157	http://dx.doi.org/10.1371/journal.pone.0000157			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17237885	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444000008
J	Li, CY; Stanton, JAL; Robertson, TM; Suttie, JM; Sheard, PW; Harris, AJ; Clark, DE				Li, Chunyi; Stanton, Jo-Ann L.; Robertson, Tracy M.; Suttie, James M.; Sheard, Philip W.; Harris, A. John; Clark, Dawn E.			Nerve Growth Factor mRNA Expression in the Regenerating Antler Tip of Red Deer (Cervus elaphus)	PLOS ONE			English	Article								Deer antlers are the only mammalian organs that can fully regenerate each year. During their growth phase, antlers of red deer extend at a rate of approximately 10 mm/day, a growth rate matched by the antler nerves. It was demonstrated in a previous study that extracts from deer velvet antler can promote neurite outgrowth from neural explants, suggesting a possible role for Nerve Growth Factor (NGF) in antler innervation. Here we showed using the techniques of Northern blot analysis, denervation, immunohistochemistry and in situ hybridization that NGF mRNA was expressed in the regenerating antler, principally in the smooth muscle of the arteries and arterioles of the growing antler tip. Regenerating axons followed the route of the major blood vessels, located at the interface between the dermis and the reserve mesenchyme of the antler. Denervation experiments suggested a causal relationship exists between NGF mRNA expression in arterial smooth muscle and sensory axons in the antler tip. We hypothesize that NGF expressed in the smooth muscle of the arteries and arterioles promotes and maintains antler angiogenesis and this role positions NGF ahead of axons during antler growth. As a result, NGF can serve a second role, attracting sensory axons into the antler, and thus it can provide a guidance cue to define the nerve track. This would explain the phenomenon whereby re-innervation of the regenerating antler follows vascular ingrowth. The annual growth of deer antler presents a unique opportunity to better understand the factors involved in rapid nerve regeneration.	[Li, Chunyi; Robertson, Tracy M.; Suttie, James M.; Clark, Dawn E.] AgRes, Invermay Agr Ctr, Mosgiel, New Zealand; [Stanton, Jo-Ann L.] Univ Otago, Dept Anat & Struct Biol, Dunedin, New Zealand; [Robertson, Tracy M.; Sheard, Philip W.; Harris, A. John] Univ Otago, Dept Physiol, Dunedin, New Zealand	AgResearch - New Zealand; University of Otago; University of Otago	Li, CY (corresponding author), AgRes, Invermay Agr Ctr, Mosgiel, New Zealand.	chunyi.li@agresearch.co.nz	Coates, Dawn Elizabeth/B-5134-2012; Stanton, Jo-Ann L/C-6621-2009	Coates, Dawn Elizabeth/0000-0003-4242-6846; Stanton, Jo-Ann L/0000-0001-8139-4694	New Zealand Foundation for Research and Technology [C10X0207]; Department of Physiology, University of Otago, New Zealand	New Zealand Foundation for Research and Technology(New Zealand Foundation for Research, Science and Technology); Department of Physiology, University of Otago, New Zealand	This research was funded by New Zealand Foundation for Research and Technology (Grant number: C10X0207) through AgResearch and the Department of Physiology, University of Otago, New Zealand.	Allen SP, 2002, DEV BIOL, V251, P409, DOI 10.1006/dbio.2002.0816; ANGELETT.RH, 1971, P NATL ACAD SCI USA, V68, P2417, DOI 10.1073/pnas.68.10.2417; BUBENIK GA, 1982, DEER ANTLER DEV CERV, P73; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark DE, 1996, HUM REPROD, V11, P1090; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DISSEN GA, 1995, ENDOCRINOLOGY, V136, P4681, DOI 10.1210/en.136.10.4681; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; Fiorentini C, 2002, EUR J ENDOCRINOL, V147, P371, DOI 10.1530/eje.0.1470371; Garcia RL, 1997, J MOL ENDOCRINOL, V19, P173, DOI 10.1677/jme.0.0190173; Gibran NS, 2003, SHOCK, V19, P127, DOI 10.1097/00024382-200302000-00007; Goss R.J., 1983, DEER ANTLERS REGENER; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; GRAY C, 1992, NEUROSCIENCE, V50, P953, DOI 10.1016/0306-4522(92)90218-Q; HUMPHREY MF, 1992, EXP BRAIN RES, V60, P630; Huo Y, 1997, Biomed Sci Instrum, V33, P541; IDE C, 1996, J NEUROSCI RES, V25, P101; Lee JW, 2002, BIOTECHNOL LETT, V24, P2035, DOI 10.1023/A:1021363203406; Li C., 2003, RECENT ADV RES UPDAT, V4, P255; Li CY, 2002, ANAT REC, V268, P125, DOI 10.1002/ar.10120; LI CY, 1993, J EXP ZOOL, V267, P188, DOI 10.1002/jez.1402670212; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; NITHYA M, 2003, BIOCHIM BIOPHYS ACTA, V1620, P23; Reimer MK, 2003, PANCREAS, V26, P392, DOI 10.1097/00006676-200305000-00014; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SCULLY JL, 1995, CELL BIOL INT, V19, P459, DOI 10.1006/cbir.1995.1089; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SELBY MJ, 1987, MOL CELL BIOL, V7, P3057, DOI 10.1128/MCB.7.9.3057; Takeuchi T, 2003, BIOCHEM PHARMACOL, V65, P1507, DOI 10.1016/S0006-2952(03)00116-3; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0; WISLOCKI GB, 1946, J COMP NEUROL, V85, P1, DOI 10.1002/cne.900850102	34	39	44	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2007	2	1							e148	10.1371/journal.pone.0000148	http://dx.doi.org/10.1371/journal.pone.0000148			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DE	17215957	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443900002
J	Caley, P; Becker, NG; Philp, DJ				Caley, Peter; Becker, Niels G.; Philp, David J.			The Waiting Time for Inter-Country Spread of Pandemic Influenza	PLOS ONE			English	Article								Background. The time delay between the start of an influenza pandemic and its subsequent initiation in other countries is highly relevant to preparedness planning. We quantify the distribution of this random time in terms of the separate components of this delay, and assess how the delay may be extended by non-pharmaceutical interventions. Methods and Findings. The model constructed for this time delay accounts for: (i) epidemic growth in the source region, (ii) the delay until an infected individual from the source region seeks to travel to an at-risk country, (iii) the chance that infected travelers are detected by screening at exit and entry borders, (iv) the possibility of in-flight transmission, (v) the chance that an infected arrival might not initiate an epidemic, and (vi) the delay until infection in the at-risk country gathers momentum. Efforts that reduce the disease reproduction number in the source region below two and severe travel restrictions are most effective for delaying a local epidemic, and under favourable circumstances, could add several months to the delay. On the other hand, the model predicts that border screening for symptomatic infection, wearing a protective mask during travel, promoting early presentation of cases arising among arriving passengers and moderate reduction in travel volumes increase the delay only by a matter of days or weeks. Elevated in-flight transmission reduces the delay only minimally. Conclusions. The delay until an epidemic of pandemic strain influenza is imported into an at-risk country is largely determined by the course of the epidemic in the source region and the number of travelers attempting to enter the at-risk country, and is little affected by non-pharmaceutical interventions targeting these travelers. Short of preventing international travel altogether, eradicating a nascent pandemic in the source region appears to be the only reliable method of preventing country-to-country spread of a pandemic strain of influenza.	[Caley, Peter; Becker, Niels G.; Philp, David J.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia	Australian National University	Caley, P (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.	Peter.Caley@anu.edu.au	Caley, Peter/D-8638-2011	Caley, Peter/0000-0002-8077-6460	Australian National Health & Medical Research Council [358425, 410224]; Australia Research Council [DP0558357]; Australian Department of Health and Ageing	Australian National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australia Research Council(Australian Research Council); Australian Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing)	Funding by Australian National Health & Medical Research Council grants (358425, 410224), an Australia Research Council grant (DP0558357) and the Australian Department of Health and Ageing is gratefully acknowledged.	BECKER NG, 1989, ANAL INFECT DIS DATA; Caswell H, 2000, MATRIX POPULATION MO, V2nd; Cooper BS, 2006, PLOS MED, V3, P845, DOI 10.1371/journal.pmed.0030212; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Harris T. E., 1963, THEORY BRANCHING PRO; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hollingsworth TD, 2006, NAT MED, V12, P497, DOI 10.1038/nm0506-497; John RKS, 2005, EMERG INFECT DIS, V11, P6, DOI 10.3201/eid1101.040835; Liao CM, 2005, RISK ANAL, V25, P1097, DOI 10.1111/j.1539-6924.2005.00663.x; Lloyd-Smith JO, 2005, TRENDS ECOL EVOL, V20, P511, DOI 10.1016/j.tree.2005.07.004; Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; Mangili A, 2005, LANCET, V365, P989, DOI 10.1016/S0140-6736(05)71089-8; Marsden AG, 2003, MED J AUSTRALIA, V179, P172, DOI 10.5694/j.1326-5377.2003.tb05483.x; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; Pitman RJ, 2005, BRIT MED J, V331, P1242, DOI 10.1136/bmj.38573.696100.3A	19	41	42	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e143	10.1371/journal.pone.0000143	http://dx.doi.org/10.1371/journal.pone.0000143			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206278	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443800005
J	Apatoff, A; Kim, E; Kliger, Y				Apatoff, Avihay; Kim, Eddo; Kliger, Yossef			Towards Alignment Independent Quantitative Assessment of Homology Detection	PLOS ONE			English	Article								Identification of homologous proteins provides a basis for protein annotation. Sequence alignment tools reliably identify homologs sharing high sequence similarity. However, identification of homologs that share low sequence similarity remains a challenge. Lowering the cutoff value could enable the identification of diverged homologs, but also introduces numerous false hits. Methods are being continuously developed to minimize this problem. Estimation of the fraction of homologs in a set of protein alignments can help in the assessment and development of such methods, and provides the users with intuitive quantitative assessment of protein alignment results. Herein, we present a computational approach that estimates the amount of homologs in a set of protein pairs. The method requires a prevalent and detectable protein feature that is conserved between homologs. By analyzing the feature prevalence in a set of pairwise protein alignments, the method can estimate the number of homolog pairs in the set independently of the alignments' quality. Using the HomoloGene database as a standard of truth, we implemented this approach in a proteome-wide analysis. The results revealed that this approach, which is independent of the alignments themselves, works well for estimating the number of homologous proteins in a wide range of homology values. In summary, the presented method can accompany homology searches and method development, provides validation to search results, and allows tuning of tools and methods.	[Apatoff, Avihay; Kim, Eddo; Kliger, Yossef] Compugen Ltd, Tel Aviv, Israel; [Apatoff, Avihay; Kim, Eddo] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Bar Ilan University	Kliger, Y (corresponding author), Compugen Ltd, Tel Aviv, Israel.	kliger@compugen.co.il						Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Finlay BB, 2006, CELL, V124, P767, DOI 10.1016/j.cell.2006.01.034; FISCHELGHODSIAN F, 1990, PROTEIN ENG, V3, P577, DOI 10.1093/protein/3.7.577; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Hadley C, 1999, STRUCT FOLD DES, V7, P1099, DOI 10.1016/S0969-2126(99)80177-4; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Kim E, 2005, BIOINFORMATICS, V21, P4216, DOI 10.1093/bioinformatics/bti706; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158; Zhang ZM, 2004, PROTEIN SCI, V13, P2819, DOI 10.1110/ps.04682504	22	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e113	10.1371/journal.pone.0000113	http://dx.doi.org/10.1371/journal.pone.0000113			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205117	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700007
J	Nakazawa, Y; Suzuki, M; Manabe, N; Yamada, T; Kihara-Negishi, F; Sakurai, T; Tenen, DG; Iwama, A; Mochizuki, M; Oikawa, T				Nakazawa, Y.; Suzuki, M.; Manabe, N.; Yamada, T.; Kihara-Negishi, F.; Sakurai, T.; Tenen, D. G.; Iwama, A.; Mochizuki, M.; Oikawa, T.			Cooperative interaction between ETS1 and GFI1 transcription factors in the repression of Bax gene expression	ONCOGENE			English	Article						ETS1; GFI1; Bax; transcription; cross-talk	ZINC-FINGER PROTEIN; T-CELL DEATH; TERNARY COMPLEX; DIFFERENTIATION; ACTIVATION; PU.1; FAMILY; DNA; HEMATOPOIESIS; LEUKEMIA	The proto-oncoproteins ETS1 and growth factor independent-1 (GFI1) are implicated in cell growth and differentiation in various types of cells, and their deregulated expression is involved in malignant transformation. Here, we report that ETS1 and GFI1 interact and affect gene expression through their cross-talk. Co-immunoprecipitation analyses and glutathione-S-transferase pull-down assays revealed that ETS1 bound directly to GFI1 via its Ets domain, and GFI1 bound to ETS1 via its zinc-finger domain. Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner. However, in the Bax promoter where the Ets- and Gfi-binding sites (EBS and GBS) are adjacent, ETS1 and GFI1 cooperatively reduced activation. Site-directed mutagenesis on the EBS and GBS of the Bax promoter showed that both binding sites were necessary for full repression. Chromatin immunoprecipitation analyses con. rmed that an ETS1-GFI1 complex formed on the Bax promoter even when either EBS or GBS was mutated. Introduction of small interfering RNA against ETS1 and/ or GFI1 enhanced endogenous Bax gene expression. Our results suggest that the interaction between ETS1 and GFI1 facilitates their binding to speci. c sites on the Bax promoter and represses Bax expression in vivo.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Kyoritsu Coll Pharmaceut Sci, Div Organ & Bioorgan Chem, Minato Ku, Tokyo, Japan; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan	Harvard University; Harvard Medical School; Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawat@hoku-iryo-u.dc.jp		Tenen, Daniel/0000-0002-6423-3888				BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Duan Zhijun, 2003, Hematology, V8, P339, DOI 10.1080/10245330310001612116; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HELLE JP, 1997, MOL CELL BIOL, V17, P4220; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; OIKAWA T, 2005, MOL GENETICS CANC, P119; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sledz CA, 2005, BLOOD, V106, P787, DOI 10.1182/blood-2004-12-4643; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	40	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3541	3550		10.1038/sj.onc.1210140	http://dx.doi.org/10.1038/sj.onc.1210140			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17213822				2022-12-25	WOS:000246799200010
J	Lehman, N; Ledford, B; Di Fulvio, M; Frondorf, K; McPhail, LC; Gomez-Cambronero, J				Lehman, Nicholas; Ledford, Bill; Di Fulvio, Mauricio; Frondorf, Kathleen; McPhail, Linda C.; Gomez-Cambronero, Julian			Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR	FASEB JOURNAL			English	Article						signal transduction; network phospholipases and kinases; small interfering RNA; protein/lipid binding; immunofluorescence colocalization	MAMMALIAN TARGET; HUMAN NEUTROPHILS; NADPH OXIDASE; IN-VIVO; SUPEROXIDE GENERATION; SIGNALING PATHWAY; PROTEIN-SYNTHESIS; PLASMA-MEMBRANE; PHOSPHORYLATION; RAPAMYCIN	The product of phospholipase D (PLD) enzymatic action in cell membranes, phosphatidic acid (PA), regulates kinases implicated in NADPH oxidase activation, as well as the mammalian target of rapamycin ( mTOR) kinase. However, other protein targets for this lipid second messenger must exist in order to explain other key PA-mediated cellular functions. In this study, PA was found to specifically and saturably bind to and activate recombinant and immunoprecipitated endogenous ribosomal S6 kinase (S6K) with a stoichiometry of 94:1 lipid/protein. Polyphosphoinositides PI4-P and PI4,5P(2) and cardiolipin could also bind to and activate S6K, albeit with different kinetics. Conversely, PA with at least one acyl side chain saturated ( 10: 0) was ineffective in binding or activating the enzyme. Transfection of COS-7 cells with a wild-type myc-(pcDNA)-PLD2 construct resulted in high PLD activity, concomitantly with an increase in ribosomal p70S6K enzyme activity and phosphorylation in T-389 and T-421/S-424 as well as phosphorylation of p70S6K's natural substrate S6 protein in S-235/S-236. Overexpression of a lipase inactive mutant (K758R), however, failed to induce an increase in both PLD and S6K activity or phosphorylation, indicating that the enzymatic activity of PLD2 (i.e., synthesis of PA) must be present to affect S6K. Neither inhibiting mTOR kinase activity with rapamycin nor silencing mTOR gene expression altered the augmentative effect of PLD2 exerted on p70S6K activity. This finding indicates that PA binds to and activates p70S6K, even in the absence of mTOR. Lastly, COS-7 transfection with PLD2 changed the pattern of subcellular expression, and a colocalization of S6K and PLD2 was observed by immunofluorescence microscopy. These results show for the first time a direct (mTOR-independent) participation of PLD in the p70S6K pathway and implicate PA as a nexus that brings together cell phospholipases and kinases.	Wright State Univ, Sch Med, Dept Neurosci Cell Biol & Physiol, Dayton, OH 45435 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27109 USA	University System of Ohio; Wright State University Dayton; Wake Forest University	Gomez-Cambronero, J (corresponding author), Wright State Univ, Sch Med, Dept Neurosci Cell Biol & Physiol, 3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.	julian.cambronero@wright.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X; Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL056653] Funding Source: Medline; NIAID NIH HHS [AI22564, R01 AI022564] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Al-Shami R, 2005, J CELL BIOCHEM, V94, P1218, DOI 10.1002/jcb.20379; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Bannister P, 2001, TREE PHYSIOL SER, V1, P3; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cho DH, 2006, AM J PHYSIOL-CELL PH, V291, pC317, DOI 10.1152/ajpcell.00491.2005; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Di Fulvio M, 2006, ONCOGENE, V25, P3032, DOI 10.1038/sj.onc.1209340; DING JB, 1994, FEBS LETT, V348, P149, DOI 10.1016/0014-5793(94)00593-1; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eliasson J, 2006, AM J PHYSIOL-ENDOC M, V291, pE1197, DOI 10.1152/ajpendo.00141.2006; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones JA, 2005, BIOCHEMISTRY-US, V44, P13235, DOI 10.1021/bi0505159; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kusner DJ, 2002, J BIOL CHEM, V277, P50683, DOI 10.1074/jbc.M209221200; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lehman N, 2006, BLOOD, V108, P3564, DOI 10.1182/blood-2006-02-005959; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Miles DJC, 2003, DIS AQUAT ORGAN, V55, P77, DOI 10.3354/dao055077; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; Picq M, 2002, J MED CHEM, V45, P1678, DOI 10.1021/jm011032f; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rebholz H, 2006, FEBS J, V273, P2023, DOI 10.1111/j.1742-4658.2006.05219.x; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; Sekulic A, 2000, CANCER RES, V60, P3504; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Talvas J, 2006, J NUTR, V136, P1466, DOI 10.1093/jn/136.6.1466; TORTORELLA D, 1993, BIOCHEMISTRY-US, V32, P9181, DOI 10.1021/bi00086a025; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Zheng XJ, 2003, MOL CELL ENDOCRINOL, V206, P113, DOI 10.1016/S0303-7207(03)00211-9	77	87	91	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1075	1087		10.1096/fj.06-6652com	http://dx.doi.org/10.1096/fj.06-6652com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242159				2022-12-25	WOS:000245650400012
J	Perotti, MA; Allen, JM; Reed, DL; Braig, HR				Perotti, M. Alejandra; Allen, Julie M.; Reed, David L.; Braig, Henk R.			Host-symbiont interactions of the primary endosymbiont of human head and body lice	FASEB JOURNAL			English	Article						host-pathogen interaction; host-symbiont evolution; organ-forming bacteria; immune evasion; bacteriotome	PLEBEJUS FALL HOMOPTERA; PEDICULUS-HUMANUS; PHYLOGENETIC ANALYSIS; HORIZONTAL TRANSFER; EMBRYONIC MYCETOME; RATIO DISTORTION; FINE-STRUCTURE; RIBOSOMAL-RNA; LOUSE; ARSENOPHONUS	The first mycetome was discovered more than 340 yr ago in the human louse. Despite the remarkable biology and medical and social importance of human lice, its primary endosymbiont has eluded identification and characterization. Here, we report the host-symbiont interaction of the mycetomic bacterium of the head louse Pediculus humanus capitis and the body louse P. h. humanus. The endosymbiont represents a new bacterial lineage in the gamma-Proteobacteria. Its closest sequenced relative is Arsenophonus nasoniae, from which it differs by more than 10%. A. nasoniae is a male-killing endosymbiont of jewel wasps. Using microdissection and multiphoton confocal microscopy, we show the remarkable interaction of this bacterium with its host. This endosymbiont is unique because it occupies sequentially four different mycetomes during the development of its host, undergoes three cycles of proliferation, changes in length from 2-4 mu m to more than 100 mu m, and has two extracellular migrations, during one of which the endosymbionts have to outrun its host's immune cells. The host and its symbiont have evolved one of the most complex interactions: two provisional or transitory mycetomes, a main mycetome and a paired filial mycetome. Despite the close relatedness of body and head lice, differences are present in the mycetomic provisioning and the immunological response.	Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Florida, Florida Museum Nat Hist, Gainesville, FL USA; Univ Florida, Dept Zool, Gainesville, FL 32611 USA	Bangor University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Braig, HR (corresponding author), Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	h.braig@bangor.ac.uk	Braig, Henk/I-5477-2013; Reed, David/A-6296-2008	Braig, Henk/0000-0001-9592-1141; 				Aschner M., 1933, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V26, P529, DOI 10.1007/BF00446386; ASCHNER MANFRED, 1934, PARASITOLOGY, V26, P309, DOI 10.1017/S0031182000023611; Batut J, 2004, NAT REV MICROBIOL, V2, P933, DOI 10.1038/nrmicro1044; Baudisch K., 1958, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V47, P436, DOI 10.1007/BF00411810; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Burgess IE, 2004, ANNU REV ENTOMOL, V49, P457, DOI 10.1146/annurev.ento.49.061802.123253; Dale C, 2006, APPL ENVIRON MICROB, V72, P2997, DOI 10.1128/AEM.72.4.2997-3004.2006; Drancourt M, 2005, NAT REV MICROBIOL, V3, P23, DOI 10.1038/nrmicro1063; EBERLE MW, 1983, CAN J MICROBIOL, V29, P755, DOI 10.1139/m83-123; EBERLE MW, 1982, J INSECT PHYSIOL, V28, P417, DOI 10.1016/0022-1910(82)90068-3; Foucault C, 2006, J INFECT DIS, V193, P474, DOI 10.1086/499279; GHERNA RL, 1991, INT J SYST BACTERIOL, V41, P563, DOI 10.1099/00207713-41-4-563; Grimaldi D, 2006, P ROY SOC B-BIOL SCI, V273, P625, DOI 10.1098/rspb.2005.3337; Grindle N, 2003, J INVERTEBR PATHOL, V83, P264, DOI 10.1016/S0022-2011(03)00080-6; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Hinton H.E., 1981, BIOL INSECT EGGS, VI; Hooke Robert, 1665, MICROGRAPHIA SOME PH; Houhamdi L, 2006, AM J TROP MED HYG, V74, P521, DOI 10.4269/ajtmh.2006.74.521; Hurst GDD, 2000, EMERG INFECT DIS, V6, P329, DOI 10.3201/eid0604.000402; Hypsa V, 1997, INT J SYST BACTERIOL, V47, P1140, DOI 10.1099/00207713-47-4-1140; Johnson KP, 2004, P ROY SOC B-BIOL SCI, V271, P1771, DOI 10.1098/rspb.2004.2798; Kittler R, 2004, CURR BIOL, V14, P2309, DOI 10.1016/j.cub.2004.12.024; Kittler R, 2003, CURR BIOL, V13, P1414, DOI 10.1016/S0960-9822(03)00507-4; KORNER HK, 1974, Z PARASITENKD, V44, P149, DOI 10.1007/BF02433467; KORNER HK, 1972, Z PARASITENKD, V40, P203; Kyei-Poku GK, 2005, MOL ECOL, V14, P285, DOI 10.1111/j.1365-294X.2004.02409.x; Leo NP, 2005, PARASITOL RES, V98, P44, DOI 10.1007/s00436-005-0013-y; Leo NP, 2005, HEREDITY, V95, P34, DOI 10.1038/sj.hdy.6800663; Leo NP, 2002, INSECT MOL BIOL, V11, P651, DOI 10.1046/j.1365-2583.2002.00367.x; Leo NP, 2002, J MED ENTOMOL, V39, P662, DOI 10.1603/0022-2585-39.4.662; LEVENE H, 1959, AM NAT, V93, P347, DOI 10.1086/282094; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; McMeniman CJ, 2006, HEREDITY, V96, P63, DOI 10.1038/sj.hdy.6800760; Murrell A, 2005, PARASITOL RES, V97, P274, DOI 10.1007/s00436-005-1413-8; Perotti MA, 2006, FASEB J, V20, P2372, DOI 10.1096/fj.06-5870fje; Perotti MA, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-10; Puchta O., 1955, Zeitschrift fuer Parasitenkunde, V17, P1; Raoult D, 2006, J INFECT DIS, V193, P112, DOI 10.1086/498534; Reed DL, 2004, PLOS BIOL, V2, P1972, DOI 10.1371/journal.pbio.0020340; Ries E., 1931, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V20, P233, DOI 10.1007/BF00444101; Russell JA, 2005, APPL ENVIRON MICROB, V71, P7987, DOI 10.1128/AEM.71.12.7987-7994.2005; Russell JA, 2003, MOL ECOL, V12, P1061, DOI 10.1046/j.1365-294X.2003.01780.x; Spaulding AW, 2001, INSECT MOL BIOL, V10, P57, DOI 10.1046/j.1365-2583.2001.00231.x; SWAMMERDAM J, 1737, BYBEL NATUURE HIST I, V2; Thao ML, 2000, CURR MICROBIOL, V41, P300, DOI 10.1007/s002840010138; Thao MLL, 2004, CURR MICROBIOL, V48, P140, DOI 10.1007/s00284-003-4157-7; Trowbridge RE, 2006, J INVERTEBR PATHOL, V91, P64, DOI 10.1016/j.jip.2005.08.009; Veneti Z, 2005, SCIENCE, V307, P1461, DOI 10.1126/science.1107182; Yong Z, 2003, CR BIOL, V326, P565, DOI 10.1016/S1631-0691(03)00153-7; YOSHIZAWA K, 2006, ZOOL J LINN SOC, V146; Zawadzka M, 1997, TISSUE CELL, V29, P665, DOI 10.1016/S0040-8166(97)80042-0; Zinsser Hans., 1935, RATS LICE HIST	53	71	73	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1058	1066		10.1096/fj.06-6808com	http://dx.doi.org/10.1096/fj.06-6808com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227954				2022-12-25	WOS:000245650400010
J	Boggs, K; Reisman, D				Boggs, Kristy; Reisman, David			C/EBP beta participates in regulating transcription of the p53 gene in response to mitogen stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; SIGNAL-TRANSDUCTION; EXPRESSION; DIFFERENTIATION; PROMOTER; ISOFORMS; PROLIFERATION; DEFICIENT; MUTATION; ANTIGEN	The tightly regulated expression of p53 contributes to genomic stability, and transcription of the p53 gene is induced prior to cells entering S phase, possibly as a mechanism to ensure a rapid p53 response in the event of DNA damage. We have previously described the cloning of an additional 1000 bp of upstream p53 sequences that we have demonstrated play a role in the regulated expression of p53. As described in an earlier report, we preliminarily identified that a member of the CAAT/enhancer-binding protein (C/EPB) family of transcription factors may play a role in regulating p53. Here we have demonstrated that a particular C/EB beta isoform, C/EB beta 6-2, efficiently binds to the p53 promoter and induces its expression in a fashion that reflects the pattern of p53 expression seen as cells are induced to enter S phase and is absent from cells that are defective in proper p53 regulation. We conclude from these findings that C/EBP beta-2 plays a central role in the regulating of p53 transcription during the transition into S phase.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.	reisman@biol.sc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016461] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16461] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boggs K, 2006, ONCOGENE, V25, P555, DOI 10.1038/sj.onc.1209076; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen XN, 1997, BLOOD, V90, P156; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Freedman DA, 1999, CANCER RES, V59, P1; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hussain SP, 1998, CANCER RES, V58, P4023; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Reisman D, 2001, GENE, V274, P129, DOI 10.1016/S0378-1119(01)00623-0; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	50	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7982	7990		10.1074/jbc.M611675200	http://dx.doi.org/10.1074/jbc.M611675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244625	hybrid			2022-12-25	WOS:000245081000028
J	Fuse, C; Ishida, Y; Hikita, T; Asai, T; Oku, N				Fuse, Chiaki; Ishida, Yuuki; Hikita, Tomoya; Asai, Tomohiro; Oku, Naoto			Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; PROTEIN; FAMILY; IDENTIFICATION; MIGRATION; INTERACTS; INVASION; MEMBER; JAM-1; PET	The junctional adhesion molecule (JAM) family is a key molecule in a process called transendothelial migration or diapedesis. Here, we report implications of JAM-C in cancer metastasis. We first determined the mRNA expression of JAMs in 19 kinds of cancer cell lines. JAM-C was expressed in most of tumors having potent metastatic properties. Especially in murine K-1735 melanoma cell lines, the highly metastatic sublines (M2 and X21) strongly expressed JAM-C when compared with the poorly metastatic ones (C-10 and C23). Next, we investigated the role of JAM-C in cancer metastasis by using human JAM-C (hJAM-C) gene-transfected HT1080 fibrosarcoma cells. In comparison with mock-transfected HT 1080 cells, these cells showed a significant increase in the adhesion to various extracellular substrates and the invasion across a Matrigel(TM)-coated membrane. The knockdown of hJAM-C using small interfering RNA resulted in the suppression of both the adhesion and the invasion of HT1080 cells, suggesting that endogenous hJAM-C might be involved in tumor metastasis. Finally, we studied the role of hJAM-C in an in vivo experimental metastatic model. The results showed that the overexpression of hJAM-C in HT 1080 cells significantly decreased the life spans of the tumor-bearing mice. In contrast, the knockdown of hJAM-C in HT1080 cells suppressed the weight gain of the lungs with metastatic colonies. We conclude that the expression of JAM-C promotes metastasis by enhancing both the adhesion of cancer cells to extracellular matrices and the subsequent invasion.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Ctr Excellence Program 21st Century, Shizuoka 4228526, Japan	University of Shizuoka; University of Shizuoka	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp						Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Babinska A, 2002, THROMB HAEMOSTASIS, V88, P843, DOI 10.1055/s-0037-1613312; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; FIDLER IJ, 1981, J NATL CANCER I, V67, P947; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kikkawa H, 2002, CLIN EXP METASTAS, V19, P717, DOI 10.1023/A:1021356019563; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOIKE C, 1995, BBA-BIOMEMBRANES, V1238, P99, DOI 10.1016/0005-2736(95)00123-K; Lamagna C, 2005, CANCER RES, V65, P5703, DOI 10.1158/0008-5472.CAN-04-4012; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; Liu Y, 2000, J CELL SCI, V113, P2363; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Santoso S, 2005, J BIOL CHEM, V280, P36326, DOI 10.1074/jbc.M505059200; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yamakawa S, 2000, BIOL PHARM BULL, V23, P1264	37	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8276	8283		10.1074/jbc.M608836200	http://dx.doi.org/10.1074/jbc.M608836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227766	hybrid			2022-12-25	WOS:000245081000060
J	Gray, JP; Heck, DE; Mishin, V; Smith, PJS; Hong, JY; Thiruchelvam, M; Cory-Slechta, DA; Laskin, DL; Laskin, JD				Gray, Joshua P.; Heck, Diane E.; Mishin, Vladimir; Smith, Peter J. S.; Hong, Jun-Yan; Thiruchelvam, Mona; Cory-Slechta, Deborah A.; Laskin, Debra L.; Laskin, Jeffrey D.			Paraquat increases cyanide-insensitive respiration in murine lung epithelial cells by activating an NAD(P)H : paraquat oxidoreductase - Identification of the enzyme as thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT ALVEOLAR MACROPHAGES; HYPOXIA-INDUCIBLE FACTOR; PANCREATIC BETA-CELLS; OXIDATIVE STRESS; LIPID-PEROXIDATION; OXYGEN-CONSUMPTION; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; II CELLS; SUPEROXIDE-PRODUCTION	Pulmonary fibrosis is one of the most severe consequences of exposure to paraquat, an herbicide that causes rapid alveolar inflammation and epithelial cell damage. Paraquat is known to induce toxicity in cells by stimulating oxygen utilization via redox cycling and the generation of reactive oxygen intermediates. However, the enzymatic activity mediating this reaction in lung cells is not completely understood. Using self-referencing microsensors, we measured the effects of paraquat on oxygen flux into murine lung epithelial cells. Paraquat (10-100 mu m) was found to cause a 2-4-fold increase in cellular oxygen flux. The mitochondrial poisons cyanide, rotenone, and antimycin A prevented mitochondrial-but not paraquat-mediated oxygen flux into cells. In contrast, diphenyleneiodonium (10 mu m), an NADPH oxidase inhibitor, blocked the effects of paraquat without altering mitochondrial respiration. NADPH oxidases, enzymes that are highly expressed in lung epithelial cells, utilize molecular oxygen to generate superoxide anion. We discovered that lung epithelial cells possess a distinct cytoplasmic diphenyleneiodonium-sensitive NAD(P)H:paraquat oxidoreductase. This enzyme utilizes oxygen, requires NADH or NADPH, and readily generates the reduced paraquat radical. Purification and sequence analysis identified this enzyme activity as thioredoxin reductase. Purified paraquat reductase from the cells contained thioredoxin reductase activity, and purified rat liver thioredoxin reductase or recombinant enzyme possessed paraquat reductase activity. Reactive oxygen intermediates and subsequent oxidative stress generated from this enzyme are likely to contribute to paraquat-induced lung toxicity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Marine Biol Lab, Biocurrents Res Ctr, Woods Hole, MA 02543 USA; Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Marine Biological Laboratory - Woods Hole; Rutgers State University New Brunswick; Rutgers State University Medical Center	Laskin, JD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	jlaskin@eohsi.rutgers.edu		Smith, Peter/0000-0003-4400-6853; Laskin, Debra/0000-0003-1832-7311; Gray, Joshua/0000-0002-9704-3845; Gray, Joshua/0000-0003-4146-7902	NCI NIH HHS [CA100994, CA093798] Funding Source: Medline; NCRR NIH HHS [RR001395] Funding Source: Medline; NIAMS NIH HHS [U54AR055073] Funding Source: Medline; NIEHS NIH HHS [ES004738, ES005022, ES006897, ES010791, ES003647] Funding Source: Medline; NIGMS NIH HHS [GM034310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA093798, R01CA100994, R01CA093798] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR055073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006897, R01ES010791, R01ES003647, R01ES004738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM A, 1990, BIOCHEM PHARMACOL, V40, P1533, DOI 10.1016/0006-2952(90)90451-P; ADAM A, 1990, ENVIRON HEALTH PERSP, V85, P113, DOI 10.2307/3430673; Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; AUTOR AP, 1977, BIOCH MECH PARAQUAT, P21; Barros Paulo S. M., 1998, Veterinary Ophthalmology, V1, P119, DOI 10.1046/j.1463-5224.1998.00026.x; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; CLEJAN LA, 1993, BIOCHEM J, V295, P781, DOI 10.1042/bj2950781; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; DICKER E, 1991, BIOCHEM PHARMACOL, V42, P529, DOI 10.1016/0006-2952(91)90315-V; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Fenton H.J.H., 1876, CHEM NEWS, V33; GAGE JC, 1968, BIOCHEM J, V109, P757, DOI 10.1042/bj1090757; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GAUDU P, 1994, EUR J BIOCHEM, V226, P459, DOI 10.1111/j.1432-1033.1994.tb20070.x; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 2002, J BIOL CHEM, V277, P9701, DOI 10.1074/jbc.M109234200; HAGEN TM, 1986, BIOCHEM PHARMACOL, V35, P4537, DOI 10.1016/0006-2952(86)90776-8; Han JF, 2006, TOXICOL SCI, V91, P42, DOI 10.1093/toxsci/kfj139; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; Higuchi A, 2003, TOXICOLOGY, V183, P143, DOI 10.1016/S0300-483X(02)00512-7; HIRAI KI, 1992, TOXICOLOGY, V72, P1, DOI 10.1016/0300-483X(92)90081-O; Hoffer E, 1996, TOXICOL LETT, V84, P7, DOI 10.1016/0378-4274(95)03446-3; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; Johnson DK, 2002, ENDOTHELIUM-J ENDOTH, V9, P191, DOI 10.1080/10623320213638; Jung SK, 2000, BIOL BULL, V199, P197, DOI 10.2307/1542895; Jung SK, 2001, ANAL CHEM, V73, P3759, DOI 10.1021/ac010247u; Kang HJ, 2006, MOL CELLS, V22, P113; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; Karakashev P, 2000, NEOPLASMA, V47, P122; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; KIMBROUGH RD, 1970, TOXICOL APPL PHARM, V17, P679, DOI 10.1016/0041-008X(70)90042-6; Kuo WY, 1998, FREE RADICAL BIO MED, V24, P1130, DOI 10.1016/S0891-5849(97)00413-9; Land SC, 1999, J EXP BIOL, V202, P211; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; MASON HS, 1957, ADV ENZYMOL REL S BI, V19, P79; MASON RP, 1990, ENVIRON HEALTH PERSP, V87, P237, DOI 10.2307/3431031; McCarthy S, 2004, TOXICOL APPL PHARM, V201, P21, DOI 10.1016/j.taap.2004.04.019; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Michaelis L, 1933, J AM CHEM SOC, V55, P1481, DOI 10.1021/ja01331a027; Mishin VA, 2004, BIOCHEM PHARMACOL, V68, P747, DOI 10.1016/j.bcp.2004.05.004; Mostert V, 2003, FEBS LETT, V541, P85, DOI 10.1016/S0014-5793(03)00309-0; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Porterfield DM, 2001, AM J PHYSIOL-LUNG C, V281, pL904, DOI 10.1152/ajplung.2001.281.4.L904; Porterfield DM, 2000, DIABETES, V49, P1511, DOI 10.2337/diabetes.49.9.1511; Pouyssegur J, 2006, BIOL CHEM, V387, P1337, DOI 10.1515/BC.2006.167; Prabhakar NR, 2004, BIOL CHEM, V385, P217, DOI 10.1515/BC.2004.015; RANNELS DE, 1989, AM J PHYSIOL, V257, pL346, DOI 10.1152/ajplung.1989.257.6.L346; RASHBASTEP J, 1994, MOL PHARMACOL, V45, P150; ROSSOUW DJ, 1979, S AFR MED J, V55, P558; ROSSOUW DJ, 1979, S AFR MED J, V55, P20; ROSSOUW DJ, 1978, S AFR MED J, V54, P1101; ROSSOUW DJ, 1978, S AFR MED J, V54, P199; SCHWEICH MD, 1994, BIOCHEM PHARMACOL, V47, P1395, DOI 10.1016/0006-2952(94)90339-5; SENN H, 1987, EUR BIOPHYS J BIOPHY, V14, P301, DOI 10.1007/BF00254895; Shimada H, 2002, ARCH BIOCHEM BIOPHYS, V402, P149, DOI 10.1016/S0003-9861(02)00059-0; Sittipunt Chanchai, 2005, Respir Care, V50, P383; SMITH LL, 1982, BIOCHEM PHARMACOL, V31, P3029, DOI 10.1016/0006-2952(82)90075-2; SMITH LL, 1987, HUM TOXICOL, V6, P31, DOI 10.1177/096032718700600105; Spyrou G, 1996, BIOCHEM BIOPH RES CO, V220, P42, DOI 10.1006/bbrc.1996.0353; Tampo Y, 1999, FREE RADICAL BIO MED, V27, P588, DOI 10.1016/S0891-5849(99)00110-0; Tanaka Reiko, 2000, Journal of Toxicological Sciences, V25, P199; Towne V, 2004, ANAL BIOCHEM, V334, P290, DOI 10.1016/j.ab.2004.07.037; Turanov AA, 2006, J BIOL CHEM, V281, P22953, DOI 10.1074/jbc.M604326200; VANDERWAL NAA, 1990, BIOCHEM PHARMACOL, V39, P1665, DOI 10.1016/0006-2952(90)90109-X; Vetrano AM, 2005, J BIOL CHEM, V280, P35372, DOI 10.1074/jbc.M503991200; WADDELL WJ, 1980, TOXICOL APPL PHARM, V56, P127, DOI 10.1016/0041-008X(80)90138-6; Weidauer E, 2002, ARCH TOXICOL, V76, P89, DOI 10.1007/s00204-001-0303-9; Wenger RH, 1997, BIOL CHEM, V378, P609; WINTERBOURN CC, 1981, FEBS LETT, V128, P339, DOI 10.1016/0014-5793(81)80112-3; WITSCHI H, 1977, CHEM-BIOL INTERACT, V19, P143, DOI 10.1016/0009-2797(77)90027-8; Wolff DJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P73, DOI 10.1006/abbi.1996.9811; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhao HT, 2005, P NATL ACAD SCI USA, V102, P5727, DOI 10.1073/pnas.0501719102; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	82	52	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7939	7949		10.1074/jbc.M611817200	http://dx.doi.org/10.1074/jbc.M611817200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229725	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000245081000024
J	Kang, KR; Kim, YS; Wolff, EC; Park, MH				Kang, Kee Ryeon; Kim, Yeon Sook; Wolff, Edith C.; Park, Myung Hee			Specificity of the deoxyhypusine hydroxylase-eukaryotic translation initiation factor (eIF5A) interaction - Identification of amino acid residues of the enzyme required for binding of its substrate, deoxyhypusine-containing eIF5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; HUMAN CANCER-CELLS; FACTOR 5A EIF5A; PROTEIN-SYNTHESIS; POSTTRANSLATIONAL SYNTHESIS; HYPUSINE FORMATION; NUCLEAR EXPORT; MESSENGER-RNA; RAT TESTIS; IN-VIVO	Deoxyhypusine hydroxylase (DOHH) is a novel metalloenzyme that catalyzes the final step of the post-translational synthesis of hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine) in the eukaryotic translation initiation factor 5A (6175A). Hypusine synthesis is unique in that it occurs in only one protein, denoting the strict specificity of the modification enzymes toward the substrate protein. The specificity of the interaction between eIF5A and DOHH was investigated using human eIF5A (eIF5A-1 isoform) and human recombinant DOHH. DOHH displayed a strong preference for binding the deoxyhypusine-containing form of eIF5A, over the eIF5A precursor or the hypusine-containing eIF5A, indicating a role for the deoxyhypusine residue in binding. In addition to the deoxyhypusine residue, a large portion of the eIF5A polypeptide 1(> 20-90 amino acids) is required for effective modification by DOHH. We have identified the amino acid residues of DOHH that are critical for substrate binding by alanine substitution of 36 conserved amino 90 acid residues. Of these, alanilne substitution at Glu(57), Glu(90), GIU(208), GIU(241), Gly(63), or Gly(214) caused a severe impairment in eIF5A(Dhp) binding, with a complete loss of binding and activity in the E57A and E208A mutant enzymes. Only aspartate substitution mutants, E57D or E208D, retained partial activity and substrate binding, whereas alanine, glutamine, or asparagine mutants did not. These findings support a proposed model of DOHH-eIF5A binding in which the amino group(s) of the deoxyhypusine side chain of the substrate is primarily anchored by gamma-carboxyl groups of Glu(57) and Glu(208) at the DOHH active site.	NIDCR, OPCB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Park, MH (corresponding author), NIDCR, OPCB, NIH, Bldg 30,Rm 211, Bethesda, MD 20892 USA.	mhpark@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DE999999] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; BENNE R, 1978, J BIOL CHEM, V253, P3070; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Caraglia M, 2003, J BIOCHEM, V133, P757, DOI 10.1093/jb/mvg097; Chatterjee I, 2006, MOL GENET GENOMICS, V275, P264, DOI 10.1007/s00438-005-0086-4; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chen KY, 1997, BIOL SIGNAL, V6, P105; Clement PMJ, 2006, FEBS J, V273, P1102, DOI 10.1111/j.1742-4658.2006.05135.x; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Facchiano AM, 2001, PROTEIN ENG, V14, P881, DOI 10.1093/protein/14.11.881; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; Hanauske-Abel HM, 2003, CURR MED CHEM, V10, P1005, DOI 10.2174/0929867033457601; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hanawa-Suetsugu K, 2004, P NATL ACAD SCI USA, V101, P9595, DOI 10.1073/pnas.0308667101; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; JAKUS J, 1993, J BIOL CHEM, V268, P13151; Jao DLE, 2006, J CELL BIOCHEM, V97, P583, DOI 10.1002/jcb.20658; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Jorgensen R, 2006, BIOCHEM SOC T, V34, P1; KANG HA, 1994, J BIOL CHEM, V269, P3934; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Kim YS, 2006, J BIOL CHEM, V281, P13217, DOI 10.1074/jbc.M601081200; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Nishimura K, 2005, BIOCHEM J, V385, P779, DOI 10.1042/BJ20041477; Park JH, 2006, P NATL ACAD SCI USA, V103, P51, DOI 10.1073/pnas.0509348102; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034; PARK MH, 1984, J BIOL CHEM, V259, P2123; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Spradling AC, 1999, GENETICS, V153, P135; Sugimoto A, 2004, DIFFERENTIATION, V72, P81, DOI 10.1111/j.1432-0436.2004.07202004.x; Thompson GM, 2003, FEBS LETT, V555, P464, DOI 10.1016/S0014-5793(03)01305-X; Valentini SR, 2002, GENETICS, V160, P393; Weir BA, 2004, MOL BIOL CELL, V15, P1656, DOI 10.1091/mbc.E03-06-0371; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Xu AG, 2004, BIOCHEM J, V384, P585, DOI 10.1042/BJ20041232; Zanelli CF, 2005, GENETICS, V171, P1571, DOI 10.1534/genetics.105.048082; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	55	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8300	8308		10.1074/jbc.M607495200	http://dx.doi.org/10.1074/jbc.M607495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17213197	hybrid, Green Accepted			2022-12-25	WOS:000245081000063
J	Wang, CH; Mao, XM; Wang, LX; Liu, ML; Wetzel, MD; Guan, KL; Dong, LQ; Liu, F				Wang, Changhua; Mao, Xuming; Wang, Lixin; Liu, Meilian; Wetzel, Michael D.; Guan, Kun-Liang; Dong, Lily Q.; Liu, Feng			Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE; RHEB GTPASE; MTOR; ACTIVATION; INHIBITION; RESISTANCE; TSC1/TSC2; ADIPOCYTE; TARGET	Adiponectin functions as an insulin sensitizer, and yet the underlying molecular mechanism(s) remains largely unknown. We found that treating C2C12 myotubes with adiponectin or rapamycin enhanced the ability of insulin to stimulate IRS-1 tyrosine phosphorylation and Akt phosphorylation, concurrently with reduced p70 S6 kinase phosphorylation at Thr(389) as well as IRS-1 phosphorylation at Ser(302) and Ser(636/639). Overexpression of dominant-negative AMP kinase (AMPK), but not dominant-negative p38 MAPK, reduced the insulin-sensitizing effect of adiponectin. Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin. Finally, overexpression of wild-type Rheb (Ras homology-enriched in brain) or the TSC2 mutant lacking the AMPK phosphorylation. site (TSC2(S1345A)) inhibited the insulin-sensitizing effect of adiponectin in C2C12 cells. These results indicate that activation of the LKB1/AMPK/TSC1/2 pathway alleviates the p70 S6 kinase-mediated negative regulation of insulin signaling, providing a mechanism by which adiponectin increases insulin sensitivity in cells.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Michigan System; University of Michigan	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Guan, Kun-Liang/ADK-7088-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069930] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK069930] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bouskila M, 2005, INT J OBESITY, V29, pS17, DOI 10.1038/sj.ijo.0802908; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Danielsson A, 2005, J BIOL CHEM, V280, P34389, DOI 10.1074/jbc.C500230200; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Faried LS, 2006, EUR J CANCER, V42, P934, DOI 10.1016/j.ejca.2005.12.018; Fujii R, 2000, J CELL BIOL, V150, P1335, DOI 10.1083/jcb.150.6.1335; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; HARDIE D, 2007, ANN REV PHARM TOXICO, V47; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ju JS, 2007, AM J PHYSIOL-CELL PH, V292, pC564, DOI 10.1152/ajpcell.00269.2006; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2; Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Nawrocki AR, 2005, DRUG DISCOV TODAY, V10, P1219, DOI 10.1016/S1359-6446(05)03569-5; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Ueno M, 2005, DIABETOLOGIA, V48, P506, DOI 10.1007/s00125-004-1662-6; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	36	161	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7991	7996		10.1074/jbc.M700098200	http://dx.doi.org/10.1074/jbc.M700098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244624	hybrid			2022-12-25	WOS:000245081000029
J	Yang, ZY; Zheng, CY; Hayes, JJ				Yang, Zungyoon; Zheng, Chunyang; Hayes, Jeffrey J.			The core histone tail domains contribute to sequence-dependent nucleosome positioning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; TRANSCRIPTION FACTOR IIIA; YEAST PHO5 PROMOTER; N-TERMINAL TAIL; 5S RNA GENE; ORDERED RECRUITMENT; LINKER HISTONES; IN-VIVO; DNA; MECHANISM	The precise positioning of nucleosomes plays a critical role in the regulation of gene expression by modulating the DNA binding activity of trans-acting factors. However, molecular determinants responsible for positioning are not well understood. We examined whether the removal of the core histone tail domains from nucleosomes reconstituted with specific DNA fragments led to alteration of translational positions. Remarkably, we find that removal of tail domains from a nucleosome assembled on a DNA fragment containing a Xenopus borealis somatic-type 5S RNA gene results in repositioning of nucleosomes along the DNA, including two related major translational positions that move about 20 bp further upstream with respect to the 5S gene. In a nucleosome reconstituted with a DNA fragment containing the promoter of a Drosophila alcohol dehydrogenase gene, several translational positions shifted by about 10 bp along the DNA upon tail removal. However, the positions of nucleosomes assembled with a DNA fragment known to have one of the highest binding affinities for core histone proteins in the mouse genome were not altered by removal of core histone tail domains. Our data support the notion that the basic tail domains bind to nucleosomal DNA and influence the selection of the translational position of nucleosomes and that once tails are removed movement between translational positions occurs in a facile manner on some sequences. However, the effect of the N-terminal tails on the positioning and movement of a nucleosome appears to be dependent on the DNA sequence such that the contribution of the tails can be masked by very high affinity DNA sequences. Our results suggest a mechanism whereby sequence-dependent nucleosome positioning can be specifically altered by regulated changes in histone tail-DNA interactions in chromatin.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Hayes, JJ (corresponding author), Univ Rochester, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	jjhs@mail.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; Anderson JD, 2002, MOL CELL BIOL, V22, P7147, DOI 10.1128/MCB.22.20.7147-7157.2002; Aoyagi S, 2003, J BIOL CHEM, V278, P30562, DOI 10.1074/jbc.M304148200; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Badenhorst P, 2005, GENE DEV, V19, P2540, DOI 10.1101/gad.1342605; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Davey CA, 2002, P NATL ACAD SCI USA, V99, P11169, DOI 10.1073/pnas.172271399; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Fazzio TG, 2003, MOL CELL, V12, P1333, DOI 10.1016/S1097-2765(03)00436-2; Flaus A, 2003, BIOPOLYMERS, V68, P563, DOI 10.1002/bip.10323; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Ioshikhes IP, 2006, NAT GENET, V38, P1210, DOI 10.1038/ng1878; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Kassabov SR, 2002, MOL CELL BIOL, V22, P7524, DOI 10.1128/MCB.22.21.7524-7534.2002; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Lee KM, 1999, METHOD ENZYMOL, V304, P231; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; Thiriet C, 1998, J BIOL CHEM, V273, P21352, DOI 10.1074/jbc.273.33.21352; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Holde KE., 1989, SPRINGER SERIES MOL; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Whitehouse I, 2006, NAT STRUCT MOL BIOL, V13, P633, DOI 10.1038/nsmb1111; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; Widlund HR, 1999, J BIOL CHEM, V274, P31847, DOI 10.1074/jbc.274.45.31847; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; Yang ZY, 2005, MOL CELL BIOL, V25, P241, DOI 10.1128/MCB.25.1.241-249.2005; Yang ZY, 2004, METHODS, V33, P25, DOI 10.1016/j.ymeth.2003.10.017; Zheng CY, 2005, J BIOL CHEM, V280, P33552, DOI 10.1074/jbc.M507241200	69	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7930	7938		10.1074/jbc.M610584200	http://dx.doi.org/10.1074/jbc.M610584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234628	hybrid			2022-12-25	WOS:000245081000023
J	Li, G; Elder, RT; Qin, KF; Park, HU; Liang, D; Zhao, RY				Li, Ge; Elder, Robert T.; Qin, Kefeng; Park, Hyeon Ung; Liang, Doing; Zhao, Richard Y.			Phosphatase type 2A-dependent and -independent pathways for ATR phosphorylation of Chk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE-RESPONSE; CELL-CYCLE ARREST; YEAST SCHIZOSACCHAROMYCES-POMBE; PROTEIN PHOSPHATASE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; OKADAIC ACID; VPR ARRESTS; G(2) PHASE; 2A	ATM and Rad3-related (ATR) is a regulatory kinase that, when activated by hydroxyurea, UV, or human immunodeficiency virus-1 Vpr, causes cell cycle arrest through Chk1-Ser(345) phosphorylation. We demonstrate here that of these three agents only Vpr requires protein phosphatase type 2A (PP2A) to activate ATR for Chk1-Ser(345) phosphorylation. A requirement for PP2A by Vpr was first shown with the PP2A-specific inhibitor okadaic acid, which reduced Vpr-induced G(2) arrest and Cdk1-Tyr(15) phosphorylation. Using small interference RNA to down-regulate specific subunits of PP2A indicated that the catalytic beta-isoform PP2A(C beta) and the A regulatory alpha-isoform PP2A(A alpha) are involved in the G(2) induction, and these down-regulations decreased the Vpr-induced, ATR-dependent phosphorylations of Cdk1-Tyr(15) and Chk1-Ser(345). In contrast, the same down-regulations had no effect on hydroxyurea- or UV-activated ATR-dependent Chk1-Ser(345) phosphorylation. Vpr and hydroxyurea/UV all induce ATR-mediated gamma H2AX-Ser(139) phosphorylation and foci formation, but down-regulation of PP2A(A alpha) or PP2A(C beta) did not decrease gamma H2AX-Ser(139) phosphorylation by any of these agents or foci formation by Vpr. Conversely, H2AX down-regulation had little effect on PP2A(A alpha/C beta)-mediated G(2) arrest and Chk1-Ser(345) phosphorylation by Vpr. The expression of vpr increases the amount and phosphorylation of Claspin, an activator of Chk1 phosphorylation. Down-regulation of either PP2A(C,6) or PP2A(Act) had little effect on Claspin phosphorylation, but the amount of Claspin was reduced. Claspin may then be one of the phosphoproteins through which PP2A(A alpha/C beta) affects Chk1 phosphorylation when ATR is activated by human immunodeficiency virus-1 Vpr.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Chicago, IL 60614 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Northwestern University; Feinberg School of Medicine	Zhao, RY (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF700A, Baltimore, MD 21201 USA.	rzhao@som.umaryland.edu		Zhao, Richard Y./0000-0003-3424-2852	NIAID NIH HHS [AI40891] Funding Source: Medline; NIGMS NIH HHS [GM63080] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040891, R29AI040891, R21AI040891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063080] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Baumgartner M, 1999, MICROBES INFECT, V1, P1181, DOI 10.1016/S1286-4579(99)00244-0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hrimech M, 2000, EMBO J, V19, P3956, DOI 10.1093/emboj/19.15.3956; Hrimech M, 2002, EMBO J, V21, P3918; Ikehara T, 2006, PROTEIN EXPRES PURIF, V45, P150, DOI 10.1016/j.pep.2005.06.002; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lai MY, 2005, J VIROL, V79, P15443, DOI 10.1128/JVI.79.24.15443-15451.2005; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Liu QH, 2000, GENE DEV, V14, P1448; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; Morita E, 2001, J VIROL, V75, P7555, DOI 10.1128/JVI.75.16.7555-7563.2001; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; Zhao LJ, 2003, GENE, V316, P137, DOI 10.1016/S0378-1119(03)00750-9; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhou J, 2003, J BIOL CHEM, V278, P8617, DOI 10.1074/jbc.M211181200; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244; Zhou Y, 2001, VIROLOGY, V287, P133, DOI 10.1006/viro.2001.1031; Zimmerman ES, 2004, MOL CELL BIOL, V24, P9286, DOI 10.1128/MCB.24.21.9286-9294.2004; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	67	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7287	7298		10.1074/jbc.M607951200	http://dx.doi.org/10.1074/jbc.M607951200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210576	hybrid			2022-12-25	WOS:000245080900040
J	Mao, XQ; Kim, BE; Wang, FD; Eide, DJ; Petris, MJ				Mao, Xiaoqing; Kim, Byung-Eun; Wang, Fudi; Eide, David J.; Petris, Michael J.			A histidine-rich cluster mediates the ubiquitination and degradation of the human zinc transporter, hZIP4, and protects against zinc cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL EXPRESSION; GENE ENCODES; ENDOCYTOSIS; YEAST; FAMILY; PROTEINS; RECEPTOR; ZIP4; IDENTIFICATION	Zinc is an essential nutrient. Genetic evidence for this nutritional requirement in humans is the zinc deficiency disease, acrodermatitis enteropathica. This disorder is caused by mutations in hZIP4 (SLC39A4), a zinc importer required for zinc uptake in enterocytes and other cell types. Studies in mice have demonstrated that levels of the mZIP4 mRNA are reduced by elevated dietary zinc, resulting in a decreased abundance of the ZIP4 protein at the plasma membrane. Moreover, studies in cultured cells have demonstrated that low micromolar concentrations of zinc stimulate the endocytosis of the mZIP4 protein resulting in a reduction in cellular zinc uptake. In this study, we demonstrate an additional level of hZIP4 regulation involving ubiquitination and degradation of this transporter in elevated zinc concentrations. Mutational analysis identified a cytoplasmic histidine-rich domain that was essential for ubiquitin-dependent degradation of ZIP4 and protection against zinc toxicity. However, this motif was dispensable for zinc-induced endocytosis. These findings indicate that ubiquitin-mediated degradation of the ZIP4 protein is critical for regulating zinc homeostasis in response to the upper tier of physiological zinc concentrations, via a process that is distinct from zinc-stimulated endocytosis.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Wisconsin System; University of Wisconsin Madison	Petris, MJ (corresponding author), Univ Missouri, Dept Biochem, 540D Life Sci Ctr, Columbia, MO 65211 USA.	petrism@missouri.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NIDDK NIH HHS [DK66333] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK066333, R01DK066333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao J, 2001, J LEUKOCYTE BIOL, V70, P559; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Huang ZL, 2006, DEV BIOL, V295, P571, DOI 10.1016/j.ydbio.2006.03.045; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Kury Sebastien, 2003, Hum Mutat, V22, P337, DOI 10.1002/humu.9178; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liuzzi JP, 2004, P NATL ACAD SCI USA, V101, P14355, DOI 10.1073/pnas.0406216101; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Nakano A, 2003, J INVEST DERMATOL, V120, P963, DOI 10.1046/j.1523-1747.2003.12243.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wang FD, 2004, HUM MOL GENET, V13, P563, DOI 10.1093/hmg/ddh049; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	35	130	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6992	7000		10.1074/jbc.M610552200	http://dx.doi.org/10.1074/jbc.M610552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17202136	hybrid			2022-12-25	WOS:000245080900011
J	Strehl, A; Munnix, ICA; Kuijpers, MJE; van der Meijden, PEJ; Cosemans, JMEM; Feijge, MAH; Nieswandt, B; Heemskerk, JWM				Strehl, Amrei; Munnix, Imke C. A.; Kuijpers, Marijke J. E.; van der Meijden, Paola E. J.; Cosemans, Judith M. E. M.; Feijge, Marion A. H.; Nieswandt, Bernhard; Heemskerk, Johan W. M.			Dual role of platelet protein kinase C in thrombus formation - Stimulation of pro-aggregatory and suppression of procoagulant activity in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN RECEPTOR ACTIVATION; GLYCOPROTEIN-VI; IN-VIVO; INTEGRIN ALPHA(IIB)BETA(3); REVERSIBLE EXPOSURE; P2Y(12) RECEPTORS; FREE CALCIUM; COLLAGEN; ADHESION; ALPHA	Protein kinase C (PKC) isoforms regulate many platelet responses in a still incompletely understood manner. Here we investigated the roles of PKC in the platelet reactions implicated in thrombus formation as follows: secretion aggregate formation and coagulation-stimulating activity, using inhibitors with proven activity in plasma. In human and mouse platelets, PKC regulated aggregation by mediating secretion and contributing to alpha IIb beta 3 activation. Strikingly, PKC suppressed Ca2+ signal generation and Ca2+-dependent exposure of procoagulant phosphatidylserine. Furthermore, under coagulant conditions, PKC suppressed the thrombin-generating capacity of platelets. In flowing human and mouse blood, PKC contributed to platelet adhesion and controlled secretion-dependent thrombus formation, whereas it down-regulated Ca2+ signaling and procoagulant activity. In murine platelets lacking G(q)alpha, where secretion reactions were reduced in comparison with wild type mice, PKC still positively regulated platelet aggregation and down-regulated procoagulant activity. We conclude that platelet PKC isoforms have a dual controlling role in thrombus formation as follows: (i) by mediating secretion and integrin activation required for platelet aggregation under flow, and (ii) by suppressing Ca2+-dependent phosphatidylserine exposure, and consequently thrombin generation and coagulation. This platelet signaling protein is the first one identified to balance the pro-aggregatory and procoagulant functions of thrombi.	Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Human Biol, NL-6200 MD Maastricht, Netherlands; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany	Maastricht University; Maastricht University; University of Wurzburg	Nieswandt, B (corresponding author), Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands.	bernhard.nieswandt@virchow.uni-wuerzburg.de	Cosemans, Judith MEM/C-8161-2016; Heemskerk, Johan/AAM-8323-2021; Kuijpers, Marijke/AAN-9876-2021	Cosemans, Judith MEM/0000-0001-7429-0109; Heemskerk, Johan/0000-0002-2848-5121; van der Meijden, Paola/0000-0002-6532-2583				Auger JM, 2005, FASEB J, V19, P825, DOI 10.1096/fj.04-1940fje; Bernardi B, 2006, BLOOD, V107, P2728, DOI 10.1182/blood-2005-07-3023; Buensuceso CS, 2005, J BIOL CHEM, V280, P644, DOI 10.1074/jbc.M410229200; Cauwenberghs S, 2006, TRANSFUSION, V46, P1018, DOI 10.1111/j.1537-2995.2006.00837.x; Chen H, 2003, MOL CELL BIOL, V23, P4764, DOI 10.1128/MCB.23.14.4764-4777.2003; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; Giuliano S, 2003, BIOCHEM J, V372, P163, DOI 10.1042/BJ20020868; Gruner S, 2004, CIRCULATION, V110, P2946, DOI 10.1161/01.CIR.0000146341.63677.3C; Gruner S, 2003, BLOOD, V102, P4021, DOI 10.1182/blood-2003-05-1391; Hardy AR, 2005, BLOOD, V105, P3552, DOI 10.1182/blood-2004-07-2893; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Heemskerk JWM, 2001, J PHYSIOL-LONDON, V535, P625, DOI 10.1111/j.1469-7793.2001.00625.x; Hers I, 2000, ARTERIOSCL THROM VAS, V20, P1651, DOI 10.1161/01.ATV.20.6.1651; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; KING WG, 1989, J BIOL CHEM, V264, P6070; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Lecut C, 2004, ARTERIOSCL THROM VAS, V24, P1727, DOI 10.1161/01.ATV.0000137974.85068.93; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Munnix ICA, 2005, ARTERIOSCL THROM VAS, V25, P2673, DOI 10.1161/01.ATV.0000193568.71980.4a; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; ORR JW, 1992, J BIOL CHEM, V267, P15263; PACKHAM MA, 1993, BIOCHEM J, V290, P849, DOI 10.1042/bj2900849; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Polanowska-Grabowska R, 1999, ARTERIOSCL THROM VAS, V19, P3044, DOI 10.1161/01.ATV.19.12.3044; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; Pula G, 2005, J BIOL CHEM, V280, P7194, DOI 10.1074/jbc.M409212200; Quinton TM, 2002, BIOCHEM J, V368, P535, DOI 10.1042/BJ20020226; Quinton TM, 2002, BLOOD, V99, P3228, DOI 10.1182/blood.V99.9.3228; Reither G, 2006, J CELL BIOL, V174, P521, DOI 10.1083/jcb.200604033; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SIESS W, 1988, BIOCHEM J, V255, P309; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Tabuchi A, 2003, J BIOL CHEM, V278, P26374, DOI 10.1074/jbc.M212407200; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; van der Meijden PEJ, 2005, THROMB HAEMOSTASIS, V93, P1128, DOI 10.1160/TH04-09-0597; Vanschoonbeek K, 2004, J THROMB HAEMOST, V2, P476, DOI 10.1111/j.1538-7933.2004.00618.x; VANWILLIGEN G, 1991, BIOCHEM J, V273, P115, DOI 10.1042/bj2730115; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Yacoub D, 2006, J BIOL CHEM, V281, P30024, DOI 10.1074/jbc.M604504200; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200	50	52	55	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7046	7055		10.1074/jbc.M611367200	http://dx.doi.org/10.1074/jbc.M611367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210570	hybrid			2022-12-25	WOS:000245080900016
J	Tossidou, I; Kardinal, C; Peters, I; Kriz, W; Shaw, A; Dikic, I; Tkachuk, S; Dumler, I; Haller, H; Schiffer, M				Tossidou, Irini; Kardinal, Christian; Peters, Imke; Kriz, Wilhelm; Shaw, Andrey; Dikic, Ivan; Tkachuk, Sergej; Dumler, Inna; Haller, Hermann; Schiffer, Mario			CD2AP/CIN85 balance determines receptor tyrosine kinase signaling response in podocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD2-ASSOCIATED PROTEIN; DOWN-REGULATION; ADAPTER PROTEIN; SLIT DIAPHRAGM; CD2AP; BINDING; PATHWAY; IDENTIFICATION; REARRANGEMENTS; CYTOSKELETON	Defects in podocyte signaling are the basis of many inherited glomerular diseases leading to glomerulosclerosis. CD2-associated protein (CD2AP) is highly expressed in podocytes and is considered to play an important role in the maintenance of the glomerular slit diaphragm. Mice deficient for CD2AP (CD2AP(-/-)) appear normal at birth but develop a rapid onset nephrotic syndrome at 3 weeks of age. We demonstrate that impaired intracellular signaling with subsequent podocyte damage is the reason for this delayed podocyte injury in CD2AP(-/-) mice. We document that CD2AP deficiency in podocytes leads to diminished signal initiation and termination of signaling pathways mediated by receptor tyrosine kinases (RTKs). In addition, we demonstrate that CIN85, a paralog of CD2AP, is involved in termination of RTK signaling in podocytes. CIN85 protein expression is increased in CD2AP(-/-) podocytes in vitro. Stimulation of CD2AP(-/-) podocytes with various growth factors, including insulin-like growth factor 1, vascular endothelial growth factor, and fibroblast growth factor, resulted in a significantly decreased phosphatidylinositol 3-kinase/AKT and ERK signaling response. Moreover, increased CIN85 protein is detectable in podocytes in diseased CD2AP(-/-) mice, leading to decreased base-line activation of ERK and decreased phosphorylation after growth factor stimulation in vivo. Because repression of CIN85 protein leads to a restored RTK signaling response, our results support an important role of CD2AP/CIN85 protein balance in the normal signaling response of podocytes.	Hannover Med Sch, Div Nephrol, Dept Med, D-30625 Hannover, Germany; Hannover Med Sch, Div Pediat Hematol & Oncol, D-30625 Hannover, Germany; Univ Heidelberg, Dept Anat & Cell Biol, D-69120 Heidelberg, Germany; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Goethe Univ, Sch Med, Dept Biochem 2, Mol Signaling Grp, D-60590 Frankfurt, Germany	Hannover Medical School; Hannover Medical School; Ruprecht Karls University Heidelberg; Washington University (WUSTL); Goethe University Frankfurt	Schiffer, M (corresponding author), Hannover Med Sch, Div Nephrol, Dept Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	schiffer.mario@mh-hannover.de	Schiffer, Mario/U-7050-2019; Dikic, Ivan/O-4650-2015	Schiffer, Mario/0000-0002-8414-1470; Dikic, Ivan/0000-0001-8156-9511				Aissouni Y, 2005, BIOCHEM BIOPH RES CO, V338, P808, DOI 10.1016/j.bbrc.2005.10.032; Bridgewater DJ, 2005, KIDNEY INT, V67, P1308, DOI 10.1111/j.1523-1755.2005.00208.x; Bruck S, 2006, J BIOL CHEM, V281, P19196, DOI 10.1074/jbc.M600166200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cormont M, 2003, TRAFFIC, V4, P97, DOI 10.1034/j.1600-0854.2003.40205.x; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Foster RR, 2006, AM J PHYSIOL-RENAL, V291, pF196, DOI 10.1152/ajprenal.00431.2005; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Grunkemeyer JA, 2005, J BIOL CHEM, V280, P29677, DOI 10.1074/jbc.M504004200; Guan FX, 2006, AM J PHYSIOL-RENAL, V291, pF422, DOI 10.1152/ajprenal.00448.2005; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Peters I, 2006, J AM SOC NEPHROL, V17, P1644, DOI 10.1681/ASN.2005111209; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	29	33	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7457	7464		10.1074/jbc.M608519200	http://dx.doi.org/10.1074/jbc.M608519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213204	hybrid			2022-12-25	WOS:000245080900058
J	Huang, WQ; Horvath, E; Eklund, EA				Huang, Weiqi; Horvath, Elizabeth; Eklund, Elizabeth A.			PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TARGETED DISRUPTION; TYPE-1 NEUROFIBROMATOSIS; GP91(PHOX) EXPRESSION; MYELOGENOUS LEUKEMIA; GENE; PROMOTER; PHOSPHORYLATION; MUTATIONS; GROWTH	Nfl (neurofibromin 1) is a Ras-GAP protein that regulates cytokine-induced proliferation of myeloid cells. In previous studies, we found that the interferon consensus sequence-binding protein (ICSBP; also referred to as interferon regulatory factor 8) activates transcription of the gene encoding Nfl (the NF1 gene) in differentiating myeloid cells. We also found that NF1 activation requires cytokine-stimulated phosphorylation of a conserved tyrosine residue in the interferon regulatory factor (IRF) domain of ICSBP/IRF8. In this study, we found that ICSBP/IRF8 cooperates with PU.1 and interferon regulatory factor 2 to activate a composite ets/IRF-cis element in the NF1 promoter. We found that PU.1 binds directly to the NF1-cis element, and DNA-bound PU.1 interacts with IRF2, recruiting IRF2 to the cis element. This interaction requires cytokine-induced phosphorylation of specific serine residues in the PUA PEST domain and of a conserved tyrosine residue in the IRF domain of IRF2. We found that ICSBP/IRF8 interaction with the NF1-cis element requires pre-binding of PUA and IRF2. The conserved IRF domain tyrosine in ICSBP/IRF8 is required for interaction with the DNA-bound PU.1-IRF2 heterodimer. NF1 deficiency in myeloid progenitor cells results in cytokine hypersensitivity and myeloproliferation. Therefore, these studies identify a target gene for the previously observed tumor-suppressor effect of PU.1. Additionally, these studies identify a tumor-suppressor function for the "oncogenic" transcription factor, IRF2.	Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Dept Med, Feinberg Sch Med, 710 N Fairbanks Ct,Olson 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu	Huang, Weiqi/E-4341-2010					Alter-Koltunoff M, 2003, J BIOL CHEM, V278, P44025, DOI 10.1074/jbc.M307954200; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Gross P, 1998, BIOCHEMISTRY-US, V37, P9802, DOI 10.1021/bi9731448; Guyot B, 2003, J LEUKOCYTE BIOL, V73, P263, DOI 10.1189/jlb.0502244; Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Huang WQ, 2006, MOL CELL BIOL, V26, P6311, DOI 10.1128/MCB.00036-06; Iida H, 2000, INT J HEMATOL, V71, P153; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LARRICK JW, 1980, J IMMUNOL, V125, P6; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; Li SL, 2002, BLOOD, V99, P4578, DOI 10.1182/blood.V99.12.4578; Liang MD, 2006, J BIOL CHEM, V281, P9227, DOI 10.1074/jbc.M510700200; Lu D, 2003, CANCER-AM CANCER SOC, V97, P441, DOI 10.1002/cncr.11037; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sharf R, 1997, J BIOL CHEM, V272, P9785; Throm SL, 2003, J LEUKOCYTE BIOL, V74, P111, DOI 10.1189/jlb.0203061; Xi HK, 2003, MOL IMMUNOL, V39, P677, DOI 10.1016/S0161-5890(02)00214-6; Zhang YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/jem.187.11.1893; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	47	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6629	6643		10.1074/jbc.M607760200	http://dx.doi.org/10.1074/jbc.M607760200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200120	hybrid			2022-12-25	WOS:000244867200072
J	Lu, H; Wu, JY; Beswick, EJ; Ohno, T; Odenbreit, S; Haas, R; Reyes, VE; Kita, M; Graham, DY; Yamaoka, Y				Lu, Hong; Wu, Jeng Yih; Beswick, Ellen J.; Ohno, Tomoyuki; Odenbreit, Stefan; Haas, Rainer; Reyes, Victor E.; Kita, Masakazu; Graham, David Y.; Yamaoka, Yoshio			Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; NF-KAPPA-B; OUTER-MEMBRANE PROTEINS; CAG PATHOGENICITY ISLAND; HISTIDINE-DECARBOXYLASE PROMOTER; INFLAMMATION-ASSOCIATED CANCER; INTERLEUKIN-8 PRODUCTION; TYROSINE PHOSPHORYLATION; ACTIVATOR PROTEIN-1; EXPRESSION	Following adhesion of Helicobacterpylori to gastric epithelial cells, intracellular signaling leads to cytokine production, which causes H. pylori-related gastric injury. Two adjacent homologous genes (alpA and alpB), which encode H. pylori outer membrane proteins, are thought to be associated with adhesion and cytokine induction. We co-cultured gastric epithelial cells with wild type H. pylori strains and their corresponding alpA/alpB-deleted mutants (Delta alpAB). Results were confirmed by complementation. Flow cytometry confirmed that AlpAB was involved in cellular adhesion. Deletion of alpAB reduced interleukin (IL)-6 induction in gastric epithelial cells. Deletion of alpAB reduced IL-8 induction with East Asian but not with Western strains. All AlpAB-positive strains tested activated the extracellular signal-regulated kinase, c-Fos, and cAMP-responsive element-binding protein. Activation of the Jun-N-terminal kinase, c-Jun, and NF-kappa B was exclusive to AlpAB from East Asian strains. Delta alpAB mutants poorly colonized the stomachs of C57BL/6 mice and were associated with lower mucosal levels of KC and IL-6. Our results suggest that AlpAB may induce gastric injury by mediating adherence to gastric epithelial cells and by modulating proinflammatory intracellular signaling cascades. Known geographical differences in H. pylori-related clinical outcomes may relate to differential effects of East Asian and Western types of AlpAB on NF-kappa B-related proinflammatory signaling pathways.	Baylor Coll Med, Dept Med Gastroenterol, Houston, TX 77030 USA; Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Dept Gastroenterol,Renji Hosp, Shanghai 200001, Peoples R China; Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung 807, Taiwan; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto 6028566, Japan	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Shanghai Jiao Tong University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Munich; Kyoto Prefectural University of Medicine	Yamaoka, Y (corresponding author), Baylor Coll Med, Dept Med Gastroenterol, 2002 Holcombe Blvd, Houston, TX 77030 USA.	yyamaoka@bcm.tmc.edu	Wu, Jeng-Yih/D-4520-2009; Graham, David/AAL-2165-2021	Yamaoka, Yoshio/0000-0002-1222-5819	NIDDK NIH HHS [DK62813, R01 DK062813-03, DK50669, P30 DK056338, DK56338, R01 DK062813, R01 DK050669] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338, R01DK050669, R01DK062813] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; Beswick EJ, 2006, INFECT IMMUN, V74, P1148, DOI 10.1128/IAI.74.2.1148-1155.2006; Beswick EJ, 2005, J IMMUNOL, V175, P171, DOI 10.4049/jimmunol.175.1.171; Beswick EJ, 2005, INFECT IMMUN, V73, P2736, DOI 10.1128/IAI.73.5.2736-2743.2005; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; de Jonge R, 2004, J MED MICROBIOL, V53, P375, DOI 10.1099/jmm.0.45551-0; Evans DJ, 2000, HELICOBACTER, V5, P183, DOI 10.1046/j.1523-5378.2000.00029.x; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Gan LM, 2000, FEBS LETT, V477, P89, DOI 10.1016/S0014-5793(00)01788-9; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kudo T, 2005, INFECT IMMUN, V73, P7602, DOI 10.1128/IAi.73.11.7602-7612.2005; Kudo T, 2004, J CLIN MICROBIOL, V42, P2279, DOI 10.1128/JCM.42.5.2279-2281.2004; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Lu H, 2005, MOL BIOL CELL, V16, P4954, DOI 10.1091/mbc.E05-05-0426; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; McDaniel TK, 2001, HELICOBACTER, V6, P15, DOI 10.1046/j.1523-5378.2001.00001.x; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Naumann M, 2004, TRENDS MICROBIOL, V12, P29, DOI 10.1016/j.tim.2003.11.005; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Odenbreit S, 2005, INT J MED MICROBIOL, V295, P317, DOI 10.1016/j.ijmm.2005.06.003; Odenbreit S, 2002, INT J MED MICROBIOL, V292, P257, DOI 10.1078/1438-4221-00205; Odenbreit S, 2002, INT J MED MICROBIOL, V292, P247, DOI 10.1078/1438-4221-00204; Odenbreit S, 1999, MOL MICROBIOL, V31, P1537, DOI 10.1046/j.1365-2958.1999.01300.x; Peck B, 1999, NUCLEIC ACIDS RES, V27, P3325, DOI 10.1093/nar/27.16.3325; Pikarsky E, 2006, EUR J CANCER, V42, P779, DOI 10.1016/j.ejca.2006.01.011; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; Selbach M, 2002, INFECT IMMUN, V70, P665, DOI 10.1128/IAI.70.2.665-671.2002; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wu JY, 2006, CANCER RES, V66, P5111, DOI 10.1158/0008-5472.CAN-06-0383; Yamaoka Y, 2006, GUT, V55, P775, DOI 10.1136/gut.2005.083014; Yamaoka Y, 2000, P NATL ACAD SCI USA, V97, P7533, DOI 10.1073/pnas.130079797; Yamaoka Y, 2004, GASTROENTEROLOGY, V126, P1030, DOI 10.1053/j.gastro.2003.12.048; Yamaoka Y, 2002, GASTROENTEROLOGY, V123, P1992, DOI 10.1053/gast.2002.37074	41	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6242	6254		10.1074/jbc.M611178200	http://dx.doi.org/10.1074/jbc.M611178200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202133	Green Accepted, hybrid			2022-12-25	WOS:000244867200030
J	Kalinina, E; Biswas, R; Berezniuk, I; Hermoso, A; Aviles, FX; Fricker, LD				Kalinina, Elena; Biswas, Reeta; Berezniuk, Iryna; Hermoso, Antoni; Aviles, Francesc X.; Fricker, Lloyd D.			A novel subfamily of mouse cytosolic carboxypeptidases	FASEB JOURNAL			English	Article						posttranslational processing; Nna1; Purkinje cell degeneration; CCP	PURKINJE-CELL DEGENERATION; TUBULIN-TYROSINE-LIGASE; METALLOCARBOXYPEPTIDASE GENE FAMILY; CEREBELLAR MUTANT MOUSE; RETINAL DEGENERATION; PROTEIN STRUCTURES; PCD; IDENTIFICATION; NNA1; DIFFERENTIATION	Nna1 is a recently described gene product that has sequence similarity with metallocarboxypeptidases. In the present study, five additional Nna1-like genes were identified in the mouse genome and named cytosolic carboxypeptidase (CCP) 2 through 6. Modeling suggests that the carboxypeptidase domain folds into a structure that resembles metallocarboxypeptidases of the M14 family, with all necessary residues for catalytic activity and broad substrate specificity. All CCPs are abundant in testis and also expressed in brain, pituitary, eye, and other mouse tissues. In brain, Nna1/CCP1, CCP5, and CCP6 are broadly distributed, whereas CCP2 and 3 exhibit restricted patterns of expression. Nna1/CCP1, CCP2, CCP5, and CCP6 were found to exhibit a cytosolic distribution, with a slight accumulation of CCP5 in the nucleus. Based on the above results, we hypothesized that Nna1/CCP1 and CCP2-6 function in the processing of cytosolic proteins such as alpha-tubulin, which is known to be modified by the removal of a C-terminal tyrosine. Analysis of the forms of alpha tubulin in the olfactory bulb of mice lacking Nna1/CCP1 showed the absence of the detyrosinylated form in the mitral cells. Taken together, these results are consistent with a role for Nna1/CCP1 and the related CCPs in the processing of tubulin.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Autonomous Univ Barcelona, Inst Biotecnol I Biomed, Bellaterra, Barcelona, Spain; Autonomous Univ Barcelona, Dept Bioquim & Biol Mol, Bellaterra, Barcelona, Spain	Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Barcelona; Autonomous University of Barcelona	Fricker, LD (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu	Aviles, Francesc Xavier/F-3482-2019; Kalinina, Elena/D-9252-2012; Avilés, Francesc Xavier/A-2664-2015; Pulido, Toni Hermoso/K-3701-2015	Aviles, Francesc Xavier/0000-0002-1399-6789; Kalinina, Elena/0000-0003-0180-090X; Avilés, Francesc Xavier/0000-0002-1399-6789; Pulido, Toni Hermoso/0000-0003-2016-6465	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [DA-04494] Funding Source: Medline; NIDDK NIH HHS [DK-051271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROLAS JL, 2006, IN PRESS CURR PHARM; AULD DS, 2004, HDB PROTEOLYTIC ENZY, P821; AULD DS, 2004, HDB PROTEOLYTIC ENZY, P812; AVILES FX, 2004, HDB PROTEOLYTIC ENZY, P831; BARRA HS, 1988, MOL NEUROBIOL, V2, P133, DOI 10.1007/BF02935343; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; Chakrabarti L, 2006, MAMM GENOME, V17, P103, DOI 10.1007/s00335-005-0096-x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DELAVEGA R, 2007, IN PRESS FASEB J; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Erck C, 2005, P NATL ACAD SCI USA, V102, P7853, DOI 10.1073/pnas.0409626102; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; Estebanez-Perpina E, 2001, J MOL BIOL, V313, P629, DOI 10.1006/jmbi.2001.5076; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Fontenele-Neto JD, 2005, MOL BRAIN RES, V137, P132, DOI 10.1016/j.molbrainres.2005.02.026; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, P844; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V1, P848, DOI 10.1016/B978-0-12-079611-3.50259-7; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V8, P840; GREER CA, 1982, BRAIN RES, V235, P156, DOI 10.1016/0006-8993(82)90206-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HENDRIKS DF, 2004, HDB PROTEOLYTIC ENZY, P825; Huang HJ, 1999, CANCER RES, V59, P2981; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Kato C, 2004, INT J CANCER, V112, P365, DOI 10.1002/ijc.20431; Lafanechere L, 1998, J CELL SCI, V111, P171; LANDIS SC, 1978, J COMP NEUROL, V177, P125, DOI 10.1002/cne.901770109; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAVAIL MM, 1982, J COMP NEUROL, V212, P217, DOI 10.1002/cne.902120302; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rong YQ, 2004, MOL BRAIN RES, V132, P128, DOI 10.1016/j.molbrainres.2004.10.015; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P851; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P837; Springman EB, 2004, HDB PROTEOLYTIC ENZY, P828; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; WEBSTER DR, 2004, HDB PROTEOLYTIC ENZY, P2111; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897	48	94	102	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					836	850		10.1096/fj.06-7329com	http://dx.doi.org/10.1096/fj.06-7329com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17244818				2022-12-25	WOS:000244686400021
J	Griffin, MJ; Wong, RHF; Pandya, N; Sul, HS				Griffin, Michael J.; Wong, Roger H. F.; Pandya, Niyati; Sul, Hei Sook			Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; HELIX-LOOP-HELIX; TANDEM AFFINITY PURIFICATION; ATP-CITRATE-LYASE; LIPOPROTEIN RECEPTOR GENE; ACETYL-COA CARBOXYLASE; UPSTREAM STIMULATORY FACTORS; NUCLEAR FACTOR-Y; BINDING PROTEIN; TRANSCRIPTION FACTOR	To understand the molecular mechanisms underlying transcriptional activation of fatty-acid synthase (FAS), we examined the relationship between upstream stimulatory factor (USF) and SREBP-1c, two transcription factors that we have shown previously to be critical for FAS induction by feeding/insulin. Here, by using a combination of tandem affinity purification and coinummoprecipitation, we demonstrate, for the first time, that USF and SREBP-1 interact in vitro and in vivo. Glutathione S-transferase pulldown experiments with various USF and sterol regulatory element-binding protein (SREBP) deletion constructs indicate that the basic helix-loop-helix domain of USF interacts directly with the basic helix-loop-helix and an N-terminal region of SREBP-1c. Furthermore, cotransfection of USF and SREBP-1c with an FAS promoter-luciferase reporter construct in Drosophila SL2 cells results in highly synergistic activation of the FAS promoter. We also show similar cooperative activation of the mitochondrial glycerol-3-phosphate acyltransferase promoter by USF and SREBP-1c. Chromatin immunoprecipitation analysis of mouse liver demonstrates that USF binds constitutively to the mitochondrial glycerol 3-phosphate acyltransferase promoter during fasting/refeeding in vivo, whereas binding of SREBP-1 is observed only during refeeding, in a manner identical to that of the FAS promoter. In addition, we show that the synergy we have observed depends on the activation domains of both proteins and that mutated USF or SREBP lacking the N-terminal activation domain could inhibit the transactivation of the other. Closely positioned E-boxes and sterol regulatory elements found in the promoters of several lipogenic genes suggest a common mechanism of induction by feeding/insulin.	Univ Calif Berkeley, Dept Nutrit Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutrit Sci & Toxicol, 219 Morgan Hall, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Wong, Hoi Fung Roger/F-2044-2013; Han, Zaiqi/AAI-2233-2019	Griffin, Michael/0000-0003-4252-2803	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Barber MC, 2003, BIOCHEM J, V375, P489, DOI 10.1042/BJ20030480; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Drakas R, 2005, PROTEOMICS, V5, P132, DOI 10.1002/pmic.200400919; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Gibson D M, 1972, Adv Enzyme Regul, V10, P187, DOI 10.1016/0065-2571(72)90014-3; Gould KL, 2004, METHODS, V33, P239, DOI 10.1016/j.ymeth.2003.11.019; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Guan GM, 1997, J BIOL CHEM, V272, P10295; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KIM KS, 1994, BIOCHEM J, V302, P759, DOI 10.1042/bj3020759; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Knuesel M, 2003, MOL CELL PROTEOMICS, V2, P1225, DOI 10.1074/mcp.T300007-MCP200; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Makaula S, 2006, ARCH BIOCHEM BIOPHYS, V446, P91, DOI 10.1016/j.abb.2005.10.025; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MISRA S, 1994, BIOCHEM J, V298, P575, DOI 10.1042/bj2980575; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; Moore AW, 2000, P NATL ACAD SCI USA, V97, P10436, DOI 10.1073/pnas.170301897; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NEPOKROEFF CM, 1974, ARCH BIOCHEM BIOPHYS, V162, P340, DOI 10.1016/0003-9861(74)90191-X; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rishi V, 2004, J BIOL CHEM, V279, P11863, DOI 10.1074/jbc.M308000200; Roder K, 2002, J BIOL CHEM, V277, P30543, DOI 10.1074/jbc.M111891200; Rosenfeld JM, 1998, J BIOL CHEM, V273, P16112, DOI 10.1074/jbc.273.26.16112; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; SUL HS, 1984, J BIOL CHEM, V259, P1201; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; SUL HS, 1984, J BIOL CHEM, V259, P555; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; VOLPE JJ, 1974, P NATL ACAD SCI USA, V71, P889, DOI 10.1073/pnas.71.3.889; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	75	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5453	5467		10.1074/jbc.M610566200	http://dx.doi.org/10.1074/jbc.M610566200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17197698	hybrid			2022-12-25	WOS:000244482300040
J	Hetzer, C; Bisgrove, D; Cohen, MS; Pedal, A; Kaehlcke, K; Speyerer, A; Bartscherer, K; Taunton, J; Ott, M				Hetzer, Claudia; Bisgrove, Dwayne; Cohen, Michael S.; Pedal, Angelika; Kaehlcke, Katrin; Speyerer, Anja; Bartscherer, Kerstin; Taunton, Jack; Ott, Melanie			Recruitment and Activation of RSK2 by HIV-1 Tat	PLOS ONE			English	Article								The transcriptional activity of the integrated HIV provirus is dependent on the chromatin organization of the viral promoter and the transactivator Tat. Tat recruits the cellular pTEFb complex and interacts with several chromatin-modifying enzymes, including the histone acetyltransferases p300 and PCAF. Here, we examined the interaction of Tat with activation-dependent histone kinases, including the p90 ribosomal S6 kinase 2 (RSK2). Dominant-negative RSK2 and treatment with a small-molecule inhibitor of RSK2 kinase activity inhibited the transcriptional activity of Tat, indicating that RSK2 is important for Tat function. Reconstitution of RSK2 in cells from subjects with a genetic defect in RSK2 expression (Coffin-Lowry syndrome) enhanced Tat transactivation. Tat interacted with RSK2 and activated RSK2 kinase activity in cells. Both properties were lost in a mutant Tat protein (F38A) that is deficient in HIV transactivation. Our data identify a novel reciprocal regulation of Tat and RSK2 function, which might serve to induce early changes in the chromatin organization of the HIV LTR.	[Bisgrove, Dwayne; Pedal, Angelika; Kaehlcke, Katrin; Ott, Melanie] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; [Hetzer, Claudia; Speyerer, Anja; Bartscherer, Kerstin] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; [Cohen, Michael S.; Taunton, Jack] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; Helmholtz Association; German Cancer Research Center (DKFZ); University of California System; University of California San Francisco	Ott, M (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.	mott@gladstone.ucsf.edu		Ott, Melanie/0000-0002-5697-1274	Searle Scholars Foundation; NIH; Helmholtz-Gemeinschaft deutscher Forschungszentren; Public Health Service [NIAID AI057179-02, NIAID AI065248-02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI057179, R21AI065248] Funding Source: NIH RePORTER	Searle Scholars Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helmholtz-Gemeinschaft deutscher Forschungszentren(Helmholtz Association); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the Searle Scholars Foundation and the NIH to J. T. and grants from the Helmholtz-Gemeinschaft deutscher Forschungszentren and Public Health Service grants (NIAID AI057179-02 and NIAID AI065248-02) to M. O. The sponsors had no role in the study design, collection, analysis, and interpretation of data or the writing and submission of the manuscript.	Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Davie James R, 2003, Sci STKE, V2003, pPE33; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Emiliani S, 1996, P NATL ACAD SCI USA, V93, P6377, DOI 10.1073/pnas.93.13.6377; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hanauer A, 2002, J MED GENET, V39, P705, DOI 10.1136/jmg.39.10.705; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Morshead KB, 2003, P NATL ACAD SCI USA, V100, P11577, DOI 10.1073/pnas.1932643100; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; YANG J, 1999, P INT S WEAR COMP SA, V1, P73; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	72	16	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e151	10.1371/journal.pone.0000151	http://dx.doi.org/10.1371/journal.pone.0000151			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225856	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444000003
J	Warsame, M; Kimbute, O; Machinda, Z; Ruddy, P; Melkisedick, M; Peto, T; Ribeiro, I; Kitua, A; Tomson, G; Gomes, M				Warsame, Marian; Kimbute, Omari; Machinda, Zena; Ruddy, Patricia; Melkisedick, Majaha; Peto, Thomas; Ribeiro, Isabela; Kitua, Andrew; Tomson, Goran; Gomes, Melba			Recognition, Perceptions and Treatment Practices for Severe Malaria in Rural Tanzania: Implications for Accessing Rectal Artesunate as a Pre-Referral	PLOS ONE			English	Article							CLINICAL-FEATURES; INTEGRATED MANAGEMENT; PROGNOSTIC INDICATORS; TRADITIONAL HEALERS; CHILDHOOD MALARIA; TREATMENT SEEKING; TECHNICAL BASIS; HEALTH-WORKERS; CHILDREN; DISTRICT	Objectives. Preparatory to a community trial investigating how best to deliver rectal artesunate as pre-referral treatment for severe malaria; local understanding, perceptions of signs/symptoms of severe malaria and treatment-seeking patterns for and barriers to seeking biomedical treatment were investigated. Methodology/Principal Findings. 19 key informant interviews, 12 in-depth interviews and 14 focus group discussions targeting care-givers, opinion leaders, and formal and informal health care providers were conducted. Monthly fever episodes and danger signs or symptoms associated with severe malaria among under-fives were recorded. Respondents recognized convulsions, altered consciousness and coma, and were aware of their risks if not treated. But, these symptoms were perceived to be caused by supernatural forces, and traditional healers were identified as primary care providers. With some delay, mothers eventually visited a health facility when convulsions were part of the illness, despite pressures against this. Although vomiting and failure to eat/suck/drink were associated with malaria, they were not considered as indicators of danger signs unless combined with another more severe symptom. Study communities were familiar with rectal application of medicines. Conclusions/Significance. Communities' recognition and awareness of major symptoms of severe malaria could encourage action, but perceptions of their causes and poor discrimination of other danger signs - vomiting and failure to feed - might impede early treatment. An effective health education targeting parents/guardians, decision-makers/advisors, and formal and informal care providers might be a prerequisite for successful introduction of rectal artemisinins as an emergency treatment. Role of traditional healers in delivering such medication to the community should be explored.	[Warsame, Marian; Tomson, Goran] Karolinska Inst, Div Int Hlth IHCAR, Stockholm, Sweden; [Warsame, Marian; Kimbute, Omari; Machinda, Zena; Melkisedick, Majaha; Peto, Thomas] Natl Inst Med Res, Rectal Artesunate Study Team, Dar Es Salaam, Tanzania; [Ribeiro, Isabela; Gomes, Melba] United Nations Dev Programme UNDP World Bank WHO, Geneva, Switzerland	Karolinska Institutet; National Institute of Medical Research; World Health Organization	Warsame, M (corresponding author), Karolinska Inst, Div Int Hlth IHCAR, Stockholm, Sweden.	dahan2004@hotmail.com		Peto, Thomas/0000-0003-3197-9891; Tomson, Goran/0000-0001-9222-3604; Kimbute, Omari/0000-0002-0067-5783	UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) Geneva, Switzerland	UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) Geneva, Switzerland	This study received financial support from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) Geneva, Switzerland. Melba Gomes and Isabela Ribeiro are employed by this organization. Patricia Ruddy was provided with financial support as an external consultant to the study by the sponsor.	Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x; AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M; [Anonymous], 2006, PLoS Med, V3, pe83; Armspach D, 2004, J IRAN CHEM SOC, V1, P10, DOI 10.1007/BF03245765; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Comoro C, 2003, ACTA TROP, V87, P305, DOI 10.1016/S0001-706X(03)00113-X; de Savigny D, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-27; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Gilroy K, 2004, PATIENT EDUC COUNS, V54, P35, DOI 10.1016/s0738-3991(03)00189-7; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Gove S, 1999, ARCH DIS CHILD, V81, P473, DOI 10.1136/adc.81.6.473; Hardon A.P., 2001, APPL HLTH RES ANTHR, V3rd; Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013; Kaona FAD, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-28; KENGEYAKAYONDO JF, 1994, ACTA TROP, V58, P267, DOI 10.1016/0001-706X(94)90020-5; Makundi EA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-58; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; McCombie SC, 2002, HEALTH POLICY PLANN, V17, P333, DOI 10.1093/heapol/17.4.333; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; MOLYNEUX ME, 1989, Q J MED, V71, P441; *MORB MORT PROJ PH, 1997, POL IMPL AD MORB MOR, P197; MWENESI HA, 1995, J BIOSOC SCI, V27, P235, DOI 10.1017/S0021932000022720; Newton P, 2000, ANTIMICROB AGENTS CH, V44, P972, DOI 10.1128/AAC.44.4.972-977.2000; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Okeke TA, 2006, J BIOSOC SCI, V38, P491, DOI 10.1017/S002193200502660X; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Simoes EAF, 2003, B WORLD HEALTH ORGAN, V81, P522; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; WALLER D, 1995, CLIN INFECT DIS, V21, P577, DOI 10.1093/clinids/21.3.577; WARRELL DA, 1989, J ROY SOC MED, V82, P44; *WHO, 2006, WHOHTMMAL20061108; Winch PJ, 2005, HEALTH POLICY PLANN, V20, P199, DOI 10.1093/heapol/czi027; Winch PJ, 1996, SOC SCI MED, V42, P1057, DOI 10.1016/0277-9536(95)00293-6; Winch PJ, 2002, HEALTH POLICY PLANN, V17, P345, DOI 10.1093/heapol/17.4.345; Zucker JR, 1997, B WORLD HEALTH ORGAN, V75, P97	35	32	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e149	10.1371/journal.pone.0000149	http://dx.doi.org/10.1371/journal.pone.0000149			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225854	Green Published, gold, Green Submitted, Green Accepted			2022-12-25	WOS:000207444000001
J	Martinez-Diez, M; Santamaria, G; Ortega, AD; Cuezva, JM				Martinez-Diez, Marta; Santamaria, Gema; Ortega, Alvaro D.; Cuezva, Jose M.			Biogenesis and Dynamics of Mitochondria during the Cell Cycle: Significance of 3 ' UTRs	PLOS ONE			English	Article								Nowadays, we are facing a renaissance of mitochondria in cancer biology. However, our knowledge of the basic cell biology and on the timing and mechanisms that control the biosynthesis of mitochondrial constituents during progression through the cell cycle of mammalian cells remain largely unknown. Herein, we document the in vivo changes on mitochondrial morphology and dynamics that accompany cellular mitosis, and illustrate the following key points of the biogenesis of mitochondria during progression of liver cells through the cycle: (i) the replication of nuclear and mitochondrial genomes is synchronized during cellular proliferation, (ii) the accretion of OXPHOS proteins is asynchronously regulated during proliferation being the synthesis of beta-F1-ATPase and Hsp60 carried out also at G2/M and, (iii) the biosynthesis of cardiolipin is achieved during the S phase, although full development of the mitochondrial membrane potential (Delta Psi m) is attained at G2/M. Furthermore, we demonstrate using reporter constructs that the mechanism regulating the accretion of beta-F1-ATPase during cellular proliferation is controlled at the level of mRNA translation by the 3'UTR of the transcript. The 3'UTR-driven synthesis of the protein at G2/M is essential for conferring to the daughter cells the original phenotype of the parental cell. Our findings suggest that alterations on this process may promote deregulated beta-F1-ATPase expression in human cancer.	[Martinez-Diez, Marta; Santamaria, Gema; Ortega, Alvaro D.; Cuezva, Jose M.] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Cuezva, JM (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, Madrid, Spain.	jmcuezva@cbm.uam.es	Ortega, Alvaro Dario/K-5394-2018; Cuezva, Jose M/F-8381-2011; Cuezva, Jose M/AAR-5392-2020	Ortega, Alvaro Dario/0000-0003-0691-7154; Martinez Diez, Marta/0000-0001-5410-7207; Santamaria, Gema/0000-0002-5455-2754; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X; Martinez-Diez, Marta/0000-0002-4095-8673	Ministerio de Sanidad [Pl041255]; Educacion y Ciencia [SAF-2005-4001, BMC2001-0710]; Fundacion Mutua Madrilena, Spain; Fundacion Ramon Areces	Ministerio de Sanidad(Instituto de Salud Carlos IIISpanish Government); Educacion y Ciencia; Fundacion Mutua Madrilena, Spain; Fundacion Ramon Areces	M-D, G. S. and A. D. O are/were recipients of predoctoral fellowships from the Ministerio de Educacion/Ciencia, Spain. This work was supported by grants from the Ministerio de Sanidad (Pl041255), Educacion y Ciencia SAF-2005-4001 and BMC2001-0710) and Fundacion Mutua Madrilena, Spain. The CBMSO is the recipient of an institutional grant from Fundacion Ramon Areces.	ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Cuezva JM, 1997, J BIOENERG BIOMEMBR, V29, P365, DOI 10.1023/A:1022450831360; Cuezva JM, 2002, CANCER RES, V62, P6674; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; de Heredia ML, 2000, J BIOL CHEM, V275, P7430, DOI 10.1074/jbc.275.10.7430; de Mena IR, 2000, J BIOL CHEM, V275, P13628, DOI 10.1074/jbc.275.18.13628; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Di Liegro CM, 2000, BIOCHEM J, V352, P109, DOI 10.1042/0264-6021:3520109; Egea G, 1997, BIOCHEM J, V322, P557, DOI 10.1042/bj3220557; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; Isidoro A, 2005, CARCINOGENESIS, V26, P2095, DOI 10.1093/carcin/bgi188; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Izquierdo JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P481, DOI 10.1016/j.abb.2004.10.007; Izquierdo JM, 2000, BIOCHEM J, V346, P849, DOI 10.1042/0264-6021:3460849; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim H, 2001, EXP CELL RES, V265, P339, DOI 10.1006/excr.2001.5207; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Lefebvre-Legendre L, 2003, MOL MICROBIOL, V47, P1329, DOI 10.1046/j.1365-2958.2003.03371.x; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUIS AM, 1993, J BIOL CHEM, V268, P1868; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Margeot A, 2002, EMBO J, V21, P6893, DOI 10.1093/emboj/cdf690; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; Neutzner A, 2005, J BIOL CHEM, V280, P18598, DOI 10.1074/jbc.M500807200; Nishida K, 2005, MOL BIOL CELL, V16, P2493, DOI 10.1091/mbc.e05-01-0068; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; RADSAK K, 1978, EUR J BIOCHEM, V89, P3, DOI 10.1111/j.1432-1033.1978.tb20889.x; Reinke H, 2006, TRENDS BIOCHEM SCI, V31, P189, DOI 10.1016/j.tibs.2006.02.001; Ricart J, 1997, BIOCHEM J, V324, P635, DOI 10.1042/bj3240635; Ricart J, 2002, BIOCHEM J, V365, P417, DOI 10.1042/BJ20011726; Rojo G, 1998, J VIROL, V72, P7583, DOI 10.1128/JVI.72.9.7583-7588.1998; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Sweet S, 1999, J CELL PHYSIOL, V180, P91, DOI 10.1002/(SICI)1097-4652(199907)180:1<91::AID-JCP10>3.0.CO;2-6; Sylvestre J, 2003, MOL BIOL CELL, V14, P3848, DOI 10.1091/mbc.E03-02-0074; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tu BP, 2006, NAT REV MOL CELL BIO, V7, P696, DOI 10.1038/nrm1980; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; TVRDIK P, 1992, FEBS LETT, V313, P23, DOI 10.1016/0014-5793(92)81175-L; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; VANDENBOGERT C, 1988, EXP CELL RES, V178, P143, DOI 10.1016/0014-4827(88)90385-0; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	77	89	93	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e107	10.1371/journal.pone.0000107	http://dx.doi.org/10.1371/journal.pone.0000107			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17205111	Green Published, gold			2022-12-25	WOS:000207443600104
J	Yao, JJ; Liu, Y; Lacorazza, HD; Soslow, RA; Scandura, JM; Nimer, SD; Hedvat, CV				Yao, J. J.; Liu, Y.; Lacorazza, H. D.; Soslow, R. A.; Scandura, J. M.; Nimer, S. D.; Hedvat, C. V.			Tumor promoting properties of the ETS protein MEF in ovarian cancer	ONCOGENE			English	Article						MEF; ELF4; RNA interference; ovarian cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; PHOSPHORYLATION	We have previously shown that MEF ( myeloid ELF1-like factor, also known as ELF4) functions as a transcriptional activator of the interleukin ( IL)-8, perforin, granulocyte macrophage-colonyst imulating factor ( GM-CSF) and IL-3 genes in hematopoietic cells. MEF is also expressed in non-hematopoietic tissues including certain ovarian cancer cells. To de. ne the function of MEF in these cells, we examined primary human ovarian epithelial tumors and found that MEF is expressed in a significant proportion of ovarian carcinomas, and in the CAOV3 and SKOV3 ovarian cancer cell lines, but not in normal ovarian surface epithelium. Manipulating MEF levels in these cell lines altered their behavior; reducing MEF levels, using short hairpin RNA expressing vectors, significantly inhibited the proliferation of SKOV3 and CAOV3 cells in culture, and impaired the anchorage-independent growth of CAOV3 cells. Overexpression of MEF in SKOV3 cells ( via retroviral transduction) significantly increased their growth rate, enhanced colony formation in soft agar and promoted tumor formation in nude mice. The oncogenic activity of MEF was further shown by the ability of MEF to transform NIH3T3 cells, and induce their tumor formation in nude mice. MEF is an important regulator of the tumorigenic properties of ovarian cancer cells and could be used a therapeutic target in ovarian cancer.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Haematopoiesis, Mol Pharmacol & Chem Program, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA.	nimers@mskcc.org		HEDVAT, CYRUS/0000-0003-0045-3491; Soslow, Robert/0000-0002-7269-5898; Yao, JinJuan/0000-0003-4692-9969; Scandura, Joseph/0000-0002-9525-143X	NATIONAL CANCER INSTITUTE [P01CA052477, K01CA099156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA099156, CA052477] Funding Source: Medline; NHLBI NIH HHS [K08 HL4478] Funding Source: Medline; NIDDK NIH HHS [R01 DK052208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aryee DNT, 1998, GENE, V210, P71, DOI 10.1016/S0378-1119(98)00022-5; Choi C, 1997, GENE CHROMOSOME CANC, V20, P234; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; Hedvat CV, 2004, J BIOL CHEM, V279, P6395, DOI 10.1074/jbc.M307524200; Lacorazza HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017; Lacorazza HD, 2003, BLOOD CELL MOL DIS, V31, P342, DOI 10.1016/S1079-9796(03)00162-1; Lacorazza HD, 2002, IMMUNITY, V17, P437, DOI 10.1016/S1074-7613(02)00422-3; Liu Y, 2006, MOL CELL BIOL, V26, P3114, DOI 10.1128/MCB.26.8.3114-3123.2006; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Seki Y, 2002, CANCER RES, V62, P6579; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Takai N, 2003, INT J MOL MED, V12, P349; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	19	27	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4032	4037		10.1038/sj.onc.1210170	http://dx.doi.org/10.1038/sj.onc.1210170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213815				2022-12-25	WOS:000247144500014
J	Levy, V; Lindon, C; Zheng, Y; Harfe, BD; Morgan, BA				Levy, Vered; Lindon, Catherine; Zheng, Ying; Harfe, Brian D.; Morgan, Bruce A.			Epidermal stem cells arise from the hair follicle after wounding	FASEB JOURNAL			English	Article						infundibulum; epidermis; follicular bulge; wound healing	LABEL-RETAINING CELLS; MOUSE EPIDERMIS; PROLIFERATIVE UNIT; SKIN; IDENTIFICATION; EPITHELIA; KINETICS; BEHAVIOR; HEDGEHOG	During normal development, the epidermis and hair follicle are distinct lineage compartments maintained by independent stem cell populations. Both epidermal and follicular keratinocytes are recruited to participate in epidermal repair in response to injury. However, it is generally thought that follicular cells contribute to the wound epidermis only transiently and are ultimately replaced by the progeny of stem cells derived from the original epidermal compartment prior to wounding. Here we use inducible and constitutive cre recombinase expressed from the Sonic hedgehog locus ( Shh) for in vivo lineage tracing. This analysis confirms that follicular cells participate in the initial resurfacing of the wound but also reveals that their progeny persist in wound epidermis for months after the wound is healed. It further demonstrates that Shh is not induced in keratinocytes during the wound healing process. We conclude that follicular cells can undergo reprogramming to become long-term repopulating epidermal progenitors following wounding.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA	Harvard University; Massachusetts General Hospital; Harvard University; State University System of Florida; University of Florida	Morgan, BA (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	bruce.morgan@cbrc2.mgh.harvard.edu						ALLEN TD, 1974, J CELL SCI, V15, P291; ARGYRIS TS, 1977, AM J PATHOL, V88, P575; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; Bickenbach JR, 1998, EXP CELL RES, V244, P184, DOI 10.1006/excr.1998.4163; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Gambardella L, 2003, CURR OPIN CELL BIOL, V15, P771, DOI 10.1016/j.ceb.2003.10.011; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Kaur P, 2006, J INVEST DERMATOL, V126, P1450, DOI 10.1038/sj.jid.5700184; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; MACKENZIE IC, 1985, CELL TISSUE RES, V242, P551; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; MORRIS RJ, 1994, CELL PROLIFERAT, V27, P279, DOI 10.1111/j.1365-2184.1994.tb01425.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORRIS RJ, 1986, CANCER RES, V46, P3061; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; POTTEN CS, 1975, J CELL SCI, V17, P413; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Schneider TE, 2003, P NATL ACAD SCI USA, V100, P11412, DOI 10.1073/pnas.2034935100; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Tudor D, 2004, J INVEST DERM SYMP P, V9, P208, DOI 10.1111/j.1087-0024.2004.09310.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436	28	290	307	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1358	1366		10.1096/fj.06-6926com	http://dx.doi.org/10.1096/fj.06-6926com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255473				2022-12-25	WOS:000246117000011
J	Rigby, K; Zhang, LM; Cobine, PA; George, GN; Winge, DR				Rigby, Kevin; Zhang, Limei; Cobine, Paul A.; George, Graham N.; Winge, Dennis R.			Characterization of the cytochrome c oxidase assembly factor Cox19 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER METALLOCHAPERONE COX17; THIOLATE POLYNUCLEAR CLUSTER; MITOCHONDRIAL INNER MEMBRANE; INTERMEMBRANE SPACE; STRUCTURAL CHEMISTRY; PROTEIN IMPORT; BIOGENESIS; BINDING; EXPRESSION; OXIDATION	Cox19 is an important accessory protein in the assembly of cytochrome c oxidase in yeast. The protein is functional when tethered to the mitochondrial inner membrane, suggesting its functional role within the intermembrane space. Cox19 resembles Cox17 in having a twin CX9C sequence motif that adopts a helical hairpin in Cox17. The function of Cox17 appears to be a Cu(I) donor protein in the assembly of the copper centers in cytochrome c oxidase. Cox19 also resembles Cox17 in its ability to coordinate Cu(I). Recombinant Cox19 binds 1 mol eq of Cu(I) per monomer and exists as a dimeric protein. Cox19 isolated from the mitochondrial intermembrane space contains variable quantities of copper, suggesting that Cu(I) binding may be a transient property. Cysteinyl residues important for Cu(I) binding are also shown to be important for the in vivo function of Cox19. Thus, a correlation exists in the ability to bind Cu(I) and in vivo function.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84312 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84312 USA; Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Saskatchewan	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Cobine, Paul A/G-3107-2011; George, Graham N/E-3290-2013; Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010	Cobine, Paul A/0000-0001-6012-0985; Cobine, Paul/0000-0001-6012-0985; George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057375] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NIGMS NIH HHS [GM57375] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abajian C, 2004, J BIOL CHEM, V279, P53584, DOI 10.1074/jbc.M408099200; Arnesano F, 2005, STRUCTURE, V13, P713, DOI 10.1016/j.str.2005.02.015; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barros MH, 2004, J BIOL CHEM, V279, P31943, DOI 10.1074/jbc.M405014200; BOWMAKER GA, 1984, POLYHEDRON, V3, P535, DOI 10.1016/S0277-5387(00)88084-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Herrmann JM, 2005, GENE, V354, P43, DOI 10.1016/j.gene.2005.03.017; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; REHR JJ, 1992, PHYS REV LETT, V69, P3397, DOI 10.1103/PhysRevLett.69.3397; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	30	48	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10233	10242		10.1074/jbc.M610082200	http://dx.doi.org/10.1074/jbc.M610082200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17237235	hybrid			2022-12-25	WOS:000245941000013
J	Lei, HT; Venkatakrishnan, A; Yu, SY; Kaziauskas, A				Lei, Hetian; Venkatakrishnan, Annapurna; Yu, Soyoung; Kaziauskas, Andrius			Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY-DISEASE; IN-VIVO; OXIDATIVE STRESS; CELLS; PHOSPHORYLATION; HSP90; DYSFUNCTION; ACTIVATION; COMPLEX; ENOS	Diabetes mellitus (DM) and high glucose (HG) are known to reduce the bioavailability of nitric oxide (NO) by modulating endothelial nitric-oxide synthase (eNOS) activity. eNOS is regulated by several mechanisms including its interaction with heat shock protein (Hsp) 90. We previously discovered that DM in vivo and HG in vitro induced the translocation of Hsp90 alpha to the outside of aortic endothelial cells. In this report we tested the hypothesis that translocation of Hsp90a is responsible for the decline in NO production observed in HG-treated cells. We found that HG increased phosphorylation of Hsp90 alpha in a cAMP-dependent protein kinase A-dependent manner, and that this event was required for translocation of Hsp90a in porcine aortic endothelial cells. Furthermore, preventing translocation of Hsp90a protected from the HG-induced decline in eNOS-Hsp90a complex and NO production. Notably, DM increased phosphorylation of Hsp90ce and reduced its association with eNOS in the aortic endothelium of diabetic rats. These studies suggest that translocation of Hsp90a is a novel mechanism by which HG and DM impair eNOS activity and thereby reduce NO production.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School	Kaziauskas, A (corresponding author), 20 Staniford St, Boston, MA 02114 USA.	ak@eri.harvard.edu		Lei, Hetian/0000-0003-4091-1936				Boo YC, 2006, FREE RADICAL BIO MED, V41, P144, DOI 10.1016/j.freeradbiomed.2006.03.024; Booth G, 2002, DIABETES, V51, P1556, DOI 10.2337/diabetes.51.5.1556; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Davis BJ, 2006, DIABETES, V55, P496, DOI 10.2337/diabetes.55.02.06.db05-1064; ERKELLERYUKSEL FM, 1992, J AUTOIMMUN, V5, P803, DOI 10.1016/0896-8411(92)90194-U; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Felaco M, 2001, ANN CLIN LAB SCI, V31, P179; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JACKOWSKI MM, 1978, J CYCLIC NUCL PROT, V4, P323; Lash JM, 1999, AM J PHYSIOL-HEART C, V277, pH1513, DOI 10.1152/ajpheart.1999.277.4.H1513; Lei HT, 2004, CIRC RES, V94, P902, DOI 10.1161/01.RES.0000124979.46214.E3; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Oess S, 2006, BIOCHEM J, V396, P401, DOI 10.1042/BJ20060321; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Salt IP, 2003, J BIOL CHEM, V278, P18791, DOI 10.1074/jbc.M210618200; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Stalker TJ, 2005, DIABETES, V54, P1132, DOI 10.2337/diabetes.54.4.1132; Stalker TJ, 2003, FASEB J, V17, P1511, DOI 10.1096/fj.02-1213fje; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Tayebjee MH, 2005, DIABETIC MED, V22, P1628, DOI 10.1111/j.1464-5491.2005.01675.x; Tayebjee MH, 2005, AM J CARDIOL, V96, P339, DOI 10.1016/j.amjcard.2005.03.072; Tayebjee MH, 2005, CURR MED CHEM, V12, P917, DOI 10.2174/0929867053507270; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; Wang Hwei-Zu, 1997, Kaohsiung Journal of Medical Sciences, V13, P566; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Xu YZ, 2005, AM J PHYSIOL-RENAL, V289, pF1040, DOI 10.1152/ajprenal.00076.2005; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZAWALICH WS, 1975, DIABETOLOGIA, V11, P231, DOI 10.1007/BF00422327; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200; Zimmerman UJP, 1996, BBA-MOL CELL RES, V1311, P117, DOI 10.1016/0167-4889(95)00181-6; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	58	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9364	9371		10.1074/jbc.M608985200	http://dx.doi.org/10.1074/jbc.M608985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17202141	hybrid			2022-12-25	WOS:000245421700008
J	ter Haar, E; Prabakhar, P; Liu, X; Lepre, C				ter Haar, Ernst; Prabakhar, Prakash; Liu, Xun; Lepre, Christopher			Crystal structure of the P38 alpha-MAPKAP kinase 2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; HIGH-AFFINITY BINDING; DOCKING SITES; NUCLEAR EXPORT; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; PATHWAY; SIGNAL; PROTEIN-KINASE-2	The p38 signaling pathway is activated in response to cell stress and induces production of proinflammatory cytokines. P38 alpha is phosphorylated and activated in response to cell stress by MKK3 and MKK6 and in turn phosphorylates a number of substrates, including MAPKAP kinase 2 (MK2). We have determined the crystal structure of the unphosphorylated p38 alpha-MK2 heterodimer. The C-terminal regulatory domain of MK2 binds in the docking groove of p38 alpha, and the ATP-binding sites of both kinases are at the heterodimer interface. The conformation suggests an extra mechanism in addition to the regulation of the p38 alpha and MK2 phosphorylation states that prevents phosphorylation of substrates in the absence of cell stress. Addition of constitutively active MKK6-DD results in rapid phosphorylation of the p38 alpha-MK2 heterodimer.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	ter Haar, E (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	ernst_terhaar@vrtx.com						Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lukas SM, 2004, BIOCHEMISTRY-US, V43, P9950, DOI 10.1021/bi049508v; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Neininger A, 2001, EMBO REP, V2, P703, DOI 10.1093/embo-reports/kve157; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Salituro FG, 1999, CURR MED CHEM, V6, P807; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Underwood KW, 2003, STRUCTURE, V11, P627, DOI 10.1016/S0969-2126(03)00092-3; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566; ZU YL, 1995, J BIOL CHEM, V270, P202, DOI 10.1074/jbc.270.1.202	40	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9733	9739		10.1074/jbc.M611165200	http://dx.doi.org/10.1074/jbc.M611165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255097	hybrid			2022-12-25	WOS:000245421700047
J	Zegarra-Moran, O; Monteverde, M; Galietta, LJV; Moran, O				Zegarra-Moran, Olga; Monteverde, Martino; Galietta, Luis J. V.; Moran, Oscar			Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators - Interaction between activation and inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE CORRECTORS; CL-CHANNELS; DELTA-F508 MUTATION; CRYSTAL-STRUCTURE; CFTR CHANNEL; WILD-TYPE; GENISTEIN; DOMAIN; PHOSPHORYLATION; MECHANISM	An increasing number of compounds able to potentiate the activity of mutants of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel have been identified by high throughput screening or by individual search of derivatives of known active compounds. Several lines of evidence suggest that most CFTR potentiators act through the same mechanism, probably by binding to the nucleotide binding domains to promote the activity of the protein and then, with lower affinity, to an inhibitory site. With the aim of identifying the activating binding site, we recently modeled the nucleotide binding domain dimer and predicted a common binding site for potentiators in its interface. To validate this model experimentally, we mutated some of the residues involved in the putative binding site, i.e. Arg(553), Ala(554), and Val(1293). The activity of CFTR potentiators was measured as apical membrane currents on polarized cells stably expressing wild type or mutated proteins. CFTR activity was elicited by application of a membrane-permeable cAMP analogue followed by increasing concentrations of potentiators. We found that all three mutants responded to cAMP, although the affinity of R553Q was higher than that of wild type CFTR. In R553Q and V1293G mutants, the dissociation constant of potentiators for the activating site was increased, whereas the dissociation constant for the inhibitory site was reduced. Our results show that the mutated residues are part of the activating binding site for potentiators, as suggested by the molecular model. In addition, these results suggest that the activating and inhibitory sites are not independent of each other.	Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; CNR, Inst Biofis, I-16149 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR)	Zegarra-Moran, O (corresponding author), Ist Giannina Gaslini, Genet Mol Lab, Largo Gerolamo Gaslini 5, I-16148 Genoa, Italy.	ozegarra@unige.it	Moran, Oscar/W-4277-2019; Galietta, Luis JV/HCG-8692-2022	Monteverde, Martino/0000-0003-2623-414X; Galietta, Luis/0000-0001-8686-3461				Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Caci E, 2003, AM J PHYSIOL-LUNG C, V285, pL180, DOI 10.1152/ajplung.00351.2002; Cai ZW, 2006, J BIOL CHEM, V281, P1970, DOI 10.1074/jbc.M510576200; Cai ZW, 2002, J BIOL CHEM, V277, P19546, DOI 10.1074/jbc.M108023200; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Derand R, 2001, AM J PHYSIOL-CELL PH, V281, pC1657, DOI 10.1152/ajpcell.2001.281.5.C1657; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Ma TH, 2002, J BIOL CHEM, V277, P37235, DOI 10.1074/jbc.M205932200; Marivingt-Mounir C, 2004, J MED CHEM, V47, P962, DOI 10.1021/jm0308848; Mense M, 2006, EMBO J, V25, P4728, DOI 10.1038/sj.emboj.7601373; Moran O, 2005, FEBS LETT, V579, P3979, DOI 10.1016/j.febslet.2005.06.026; Moran O, 2005, CELL MOL LIFE SCI, V62, P446, DOI 10.1007/s00018-004-4422-3; Pedemonte N, 2005, MOL PHARMACOL, V68, P1736, DOI 10.1124/mol.105.015149; Pedemonte N, 2005, MOL PHARMACOL, V67, P1797, DOI 10.1124/mol.105.010959; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Springsteel MF, 2003, BIOORGAN MED CHEM, V11, P4113, DOI 10.1016/S0968-0896(03)00435-8; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zegarra-Moran O, 2002, BRIT J PHARMACOL, V137, P504, DOI 10.1038/sj.bjp.0704882	34	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9098	9104		10.1074/jbc.M611411200	http://dx.doi.org/10.1074/jbc.M611411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244607	hybrid			2022-12-25	WOS:000245780300057
J	Ding, HG; Yang, JJ; Coleman, LC; Yeung, S				Ding, Huangen; Yang, Juanjuan; Coleman, Liana C.; Yeung, Simon			Distinct iron binding property of two putative iron donors for the iron-sulfur cluster assembly - IscA and the bacterial frataxin ortholog CyaY under physiological and oxidative stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLET-REPEAT EXPANSION; ESCHERICHIA-COLI CYAY; FRIEDREICH ATAXIA; YEAST FRATAXIN; CRYSTAL-STRUCTURE; THIOREDOXIN REDUCTASE; 2FE-2S CLUSTERS; SACCHAROMYCES-CEREVISIAE; AZOTOBACTER-VINELANDII; TRANSCRIPTION FACTOR	Frataxin, a small mitochondrial protein linked to the neurodegenerative disease Friedreich ataxia, has recently been proposed as an iron donor for the iron-sulfur cluster assembly. An analogous function has also been attributed to IscA, a key member of the iron-sulfur cluster assembly machinery found in bacteria, yeast, and humans. Here we have compared the iron binding property of IscA and the frataxin ortholog CyaY from Escherichia coli under physiological and oxidative stress conditions. In the presence of the thioredoxin reductase system, which emulates the intracellular redox potential, CyaY fails to bind any iron even at a 10-fold excess of iron in the incubation solution. Under the same physiologically relevant conditions, IscA efficiently recruits iron and transfers the iron for the iron-sulfur cluster assembly in a proposed scaffold IscU. In the presence of hydrogen peroxide, however, IscA completely loses its iron binding activity, whereas CyaY becomes a competent iron-binding protein and attenuates the iron-mediated production of hydroxyl free radicals. Hydrogen peroxide appears to oxidize the iron binding thiol groups in IscA, thus blocking the iron binding in the protein. Once the oxidized thiol groups in IscA are re-reduced with the thioredoxin reductase system, the iron binding activity of IscA is fully restored. On the other hand, hydrogen peroxide has no effect on the iron binding carboxyl groups in CyaY, allowing the protein to bind iron under oxidative stress conditions. The results suggest that IscA is capable of recruiting intracellular iron for the iron-sulfur cluster assembly under normal physiological conditions, whereas CyaY may serve as an iron chaperon to sequester redox active free iron and alleviate cellular oxidative damage under oxidative stress conditions.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, HG (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	hding@lsu.edu	Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336	NATIONAL CANCER INSTITUTE [R01CA107494] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; AISEN P, 1978, J BIOL CHEM, V253, P1930; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Aslund F, 1999, J BACTERIOL, V181, P1375; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Bou-Abdallah F, 2004, J MOL BIOL, V341, P605, DOI 10.1016/j.jmb.2004.05.072; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Condo I, 2006, J BIOL CHEM, V281, P16750, DOI 10.1074/jbc.M511960200; Cook JD, 2006, BIOCHEMISTRY-US, V45, P7767, DOI 10.1021/bi060424r; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; Cozar-Castellano I, 2004, BBA-PROTEINS PROTEOM, V1700, P179, DOI 10.1016/j.bbapap.2004.05.004; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Ding BJ, 2005, BIOCHEM J, V389, P797, DOI 10.1042/BJ20050405; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Ding HG, 2005, J BIOL CHEM, V280, P30432, DOI 10.1074/jbc.M504638200; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fontecave M, 2006, NAT CHEM BIOL, V2, P171, DOI 10.1038/nchembio0406-171; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; He YN, 2004, BIOCHEMISTRY-US, V43, P16254, DOI 10.1021/bi0488193; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irazusta V, 2006, J BIOL CHEM, V281, P12227, DOI 10.1074/jbc.M511649200; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Johnson DC, 2006, J BACTERIOL, V188, P7551, DOI 10.1128/JB.00596-06; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Layer G, 2006, J BIOL CHEM, V281, P16256, DOI 10.1074/jbc.M513569200; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Morimoto K, 2006, J MOL BIOL, V360, P117, DOI 10.1016/j.jmb.2006.04.067; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Nair M, 2004, STRUCTURE, V12, P2037, DOI 10.1016/j.str.2004.08.012; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; O'Neill HA, 2005, J MOL BIOL, V345, P433, DOI 10.1016/j.jmb.2004.10.074; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Veine DM, 1998, PROTEIN SCI, V7, P1441, DOI 10.1002/pro.5560070621; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; VIVAS E, 2006, J BACTERIOL, V188, P1475; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Yang JJ, 2006, J BIOL CHEM, V281, P27956, DOI 10.1074/jbc.M601356200; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	72	39	45	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7997	8004		10.1074/jbc.M609665200	http://dx.doi.org/10.1074/jbc.M609665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244611	hybrid			2022-12-25	WOS:000245081000030
J	Romero, S; Didry, D; Larquet, E; Boisset, N; Pantaloni, D; Carlier, MF				Romero, Stephane; Didry, Dominique; Larquet, Eric; Boisset, Nicolas; Pantaloni, Dominique; Carlier, Marie-France			How ATP hydrolysis controls filament assembly from profilin-actin - Implication for formin processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBED END ELONGATION; F-ACTIN; STRUCTURAL BASIS; CAPPING PROTEIN; FISSION YEAST; ACANTHAMOEBA PROFILIN; BUNDLING ACTIVITY; HOMOLOGY PROTEIN; MOUSE FORMIN; NUCLEATION	Formins catalyze rapid filament growth from profilin-actin, by remaining processively bound to the elongating barbed end. The sequence of elementary reactions that describe filament assembly from profilin-actin at either free or formin-bound barbed ends is not fully understood. Specifically, the identity of the transitory complexes between profilin and actin terminal subunits is not known; and whether ATP hydrolysis is directly or indirectly coupled to profilin-actin assembly is not clear. We have analyzed the effect of profilin on actin assembly at free and FH1-FH2-bound barbed ends in the presence of ADP and non-hydrolyzable CrATP. Profilin blocked filament growth by capping the barbed ends in ADP and CrATP/ADP-P-i states, with a higher affinity when formin is bound. We confirm that, in contrast, profilin accelerates depolymerization of ADP-F-actin, more efficiently when FH1-FH2 is bound to barbed ends. To reconcile these data with effective barbed end assembly from profilin-MgATP-actin, the nature of nucleotide bound to both terminal and subterminal subunits must be considered. All data are accounted for quantitatively by a model in which a barbed end whose two terminal subunits consist of profilin-ATP-actin cannot grow until ATP has been hydrolyzed and P-1 released from the penultimate subunit, thus promoting the release of profilin and allowing further elongation. Formin does not change the activity of profilin but simply uses it for its processive walk at barbed ends. Finally, if profilin release from actin is prevented by a chemical cross-link, formin processivity is abolished.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 06, Inst Mineral & Phys Mat Condensee, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	Romero, Stephane/K-5998-2017; Romero, Stephane/GLR-3472-2022; larquet, eric/ABB-3063-2021	Romero, Stephane/0000-0002-7358-3871; Romero, Stephane/0000-0002-7358-3871; larquet, eric/0000-0002-9994-6845				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Blanchoin L, 2002, BIOCHEMISTRY-US, V41, P597, DOI 10.1021/bi011214b; Bubb MR, 2003, J BIOL CHEM, V278, P24629, DOI 10.1074/jbc.M302796200; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; DEPAMPHILIS ML, 1973, BIOCHEMISTRY-US, V12, P3714, DOI 10.1021/bi00743a022; Dickinson RB, 2004, BIOPHYS J, V87, P2838, DOI 10.1529/biophysj.104.045211; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; GIESELMANN R, 1995, EUR J BIOCHEM, V229, P621, DOI 10.1111/j.1432-1033.1995.tb20506.x; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Harris ES, 2006, J BIOL CHEM, V281, P14383, DOI 10.1074/jbc.M510923200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kato T, 2001, J CELL SCI, V114, P775; Kinosian HJ, 2002, BIOCHEMISTRY-US, V41, P6734, DOI 10.1021/bi016083t; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; Michelot A, 2005, PLANT CELL, V17, P2296, DOI 10.1105/tpc.105.030908; Mogilner A, 2006, CURR OPIN CELL BIOL, V18, P32, DOI 10.1016/j.ceb.2005.11.001; Narita A, 2006, EMBO J, V25, P5626, DOI 10.1038/sj.emboj.7601395; Nyman T, 2002, J BIOL CHEM, V277, P15828, DOI 10.1074/jbc.M112195200; OHM T, 1994, BBA-PROTEIN STRUCT M, V1208, P8, DOI 10.1016/0167-4838(94)90153-8; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; Vavylonis D, 2006, MOL CELL, V21, P455, DOI 10.1016/j.molcel.2006.01.016; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899; Yarmola EG, 2006, TRENDS BIOCHEM SCI, V31, P197, DOI 10.1016/j.tibs.2006.02.006; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	58	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8435	8445		10.1074/jbc.M609886200	http://dx.doi.org/10.1074/jbc.M609886200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17210567	hybrid			2022-12-25	WOS:000245081000076
J	Santarelli, VP; Eastwood, AL; Dougherty, DA; Horn, R; Ahern, CA				Santarelli, Vincent P.; Eastwood, Amy L.; Dougherty, Dennis A.; Horn, Richard; Ahern, Christopher A.			A cation-pi interaction discriminates among sodium channels that are either sensitive or resistant to tetrodotoxin block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNNATURAL AMINO-ACIDS; BINDING-SITE; POTASSIUM CHANNEL; OUTER VESTIBULE; PORE REGION; NICOTINIC RECEPTOR; RAT SKELETAL; MUTAGENESIS; SAXITOXIN; SELECTIVITY	Voltage-gated sodium channels control the upstroke of the action potential in excitable cells of nerve and muscle tissue, making them ideal targets for exogenous toxins that aim to squelch electrical excitability. One such toxin, tetrodotoxin (TTX), blocks sodium channels with nanomolar affinity only when an aromatic Phe or Tyr residue is present at a specific location in the external vestibule of the ion-conducting pore. To test whether TTX is attracted to Tyr(401) of Na(V)1.4 through a cation-pi interaction, this aromatic residue was replaced with fluorinated derivatives of Phe using in vivo nonsense suppression. Consistent with a cation-pi interaction, increased fluorination of Phe, which reduces the negative electrostatic potential on the aromatic face, caused a monotonic increase in the inhibitory constant for block. Trifluorination of the aromatic ring decreased TTX affinity by similar to 50-fold, a reduction similar to that caused by replacement with the comparably hydrophobic residue Leu. Furthermore, we show that an energetically equivalent cation-pi interaction underlies both use-dependent and tonic block by TTX. Our results are supported by high level ab initio quantum mechanical calculations applied to a model of TTX binding to benzene. Our analysis suggests that the aromatic side chain faces the permeation pathway where it orients TTX optimally and interacts with permeant ions. These results are the first of their kind to show the incorporation of unnatural amino acids into a voltage-gated sodium channel and demonstrate that a cation-pi interaction is responsible for the obligate nature of an aromatic at this position in TTX-sensitive sodium channels.	Thomas Jefferson Univ, Jefferson Med Coll, Inst Hyperexcitabil, Dept Mol Physiol & Biophys, Philadelphia, PA 19107 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Jefferson University; California Institute of Technology	Santarelli, VP (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Inst Hyperexcitabil, Dept Mol Physiol & Biophys, Philadelphia, PA 19107 USA.	Christopher.Ahern@jefferson.edu	Tuluc, Petronel/C-2527-2011	Ahern, Christopher/0000-0002-7975-2744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034407, R01NS034407] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM079427] Funding Source: Medline; NINDS NIH HHS [NS34407] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern CA, 2006, J GEN PHYSIOL, V128, P649, DOI 10.1085/jgp.200609654; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Boccaccio A, 1999, BIOPHYS J, V77, P229, DOI 10.1016/S0006-3495(99)76884-0; Bruhova I, 2005, BIOPHYS J, V89, P1020, DOI 10.1529/biophysj.105.062240; Camacho CJ, 1999, BIOPHYS J, V76, P1166, DOI 10.1016/S0006-3495(99)77281-4; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; Conti F, 1996, BIOPHYS J, V71, P1295, DOI 10.1016/S0006-3495(96)79330-X; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1962, Biophys J, V2, P259; ESCOBAR L, 1993, BIOCHEMISTRY-US, V32, P6982, DOI 10.1021/bi00078a024; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; Gallivan JP, 2000, J AM CHEM SOC, V122, P870, DOI 10.1021/ja991755c; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1971, J GEN PHYSIOL, V58, P599, DOI 10.1085/jgp.58.6.599; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; Hui KY, 2003, J GEN PHYSIOL, V122, P63, DOI 10.1085/jgp.200308842; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; KONTIS KJ, 1993, MOL PHARMACOL, V43, P635; Lange A, 2006, NATURE, V440, P959, DOI 10.1038/nature04649; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Lipkind GM, 2005, MOL PHARMACOL, V68, P1611, DOI 10.1124/mol.105.014803; Lummis SCR, 2005, CHEM BIOL, V12, P993, DOI 10.1016/j.chembiol.2005.06.012; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; McMenimen KA, 2006, ACS CHEM BIOL, V1, P227, DOI 10.1021/cb6000944; Mecozzi S, 1996, J AM CHEM SOC, V118, P2307, DOI 10.1021/ja9539608; Moran O, 2003, BIOPHYS J, V84, P2999, DOI 10.1016/S0006-3495(03)70026-5; Morikubo N, 2006, J AM CHEM SOC, V128, P13184, DOI 10.1021/ja063358p; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Penzotti JL, 2001, BIOPHYS J, V80, P698, DOI 10.1016/S0006-3495(01)76049-3; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P4538, DOI 10.1021/bi00412a047; SALGADO VL, 1986, ANN NY ACAD SCI, V479, P84, DOI 10.1111/j.1749-6632.1986.tb15563.x; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Schlief T, 1996, EUR BIOPHYS J BIOPHY, V25, P75, DOI 10.1007/s002490050020; Shahidullah M, 2003, BIOCHEMISTRY-US, V42, P11243, DOI 10.1021/bi034738f; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; Tikhonov DB, 2005, BIOPHYS J, V88, P184, DOI 10.1529/biophysj.104.048173; WILLIAMS JH, 1993, ACCOUNTS CHEM RES, V26, P593, DOI 10.1021/ar00035a005; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	53	70	72	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8044	8051		10.1074/jbc.M611334200	http://dx.doi.org/10.1074/jbc.M611334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237232	hybrid, Green Accepted			2022-12-25	WOS:000245081000036
J	Farhan, H; Reiterer, V; Korkhov, VM; Schmid, JA; Freissmuth, M; Sitte, HH				Farhan, Hesso; Reiterer, Veronika; Korkhov, Vladimir M.; Schmid, Johannes A.; Freissmuth, Michael; Sitte, Harald H.			Concentrative export from the endoplasmic reticulum of the gamma-aminobutyric acid transporter 1 requires binding to SEC24D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; OLIGOMER FORMATION; ORTHOSTATIC INTOLERANCE; FUNCTIONAL EXPRESSION; CARBOXYL-TERMINUS; C-TERMINUS; COPII; CARGO; PROTEINS; RECONSTITUTION	Re-uptake of gamma-aminobutyric acid (GABA) into presynaptic specializations is mediated by the GABA transporter 1 (GAT1), a member of the SLC6 gene family. Here, we show that a motif in the COOH terminus of GATI ((566) RL (567)), which is conserved in SLC6 family members, is a binding site for the COPII coat component Sec24D. We also identified residues in Sec24D (733 DD 734) that are required to support the interaction with GAT1 and two additional family members, i.e. the transporters for serotonin and dopamine. We used three strategies to prevent recruitment of Sec24D to GATI: knock-down of Sec24D by RNA interference, overexpression of Sec24D-VN (replacement of (DD734)-D-733 by (VN734)-V-733), and mutation of (RL567)-R-566 to (566)AS(567) (GATI-RL/AS). In each instance, endoplasmic reticulum (ER) export of GAT 1 was impaired: in the absence of Sec24D or upon coexpression of dominant negative Sec24D-VN, GAT1 failed to undergo concentrative ER export; GAT1-RL/AS also accumulated in the ER and exerted a dominant negative effect on cell surface targeting of wild type GATI. Our observations show that concentrative ER-export is contingent on a direct interaction of GATI with Sec24D; this also provides a mechanistic explanation for the finding that oligomeric assembly of transporters is required for their ER export: transporter oligomerization supports efficient recruitment of COPII components.	Ctr Biomol Med & Pharmacol, Inst Pharmacol, A-1090 Vienna, Austria; Ctr Biomol Med & Pharmacol, Inst Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria		Freissmuth, M (corresponding author), Ctr Biomol Med & Pharmacol, Inst Pharmacol, Waehringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Schmid, Johannes A./C-7659-2009; Farhan, Hesso/C-7997-2012; Sitte, Harald/N-2681-2013; Sitte, Harald/O-7025-2019	Schmid, Johannes A./0000-0002-6586-3507; Farhan, Hesso/0000-0002-0889-8463; Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Freissmuth, Michael/0000-0001-9398-1765; Korkhov, Volodymyr/0000-0002-0962-9433				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bjerggaard C, 2004, J NEUROSCI, V24, P7024, DOI 10.1523/JNEUROSCI.1863-04.2004; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Cai YQ, 2006, J NEUROSCI RES, V84, P255, DOI 10.1002/jnr.20884; Chiu CS, 2005, J NEUROSCI, V25, P3234, DOI 10.1523/JNEUROSCI.3364-04.2005; Farhan H, 2004, J BIOL CHEM, V279, P28553, DOI 10.1074/jbc.M307325200; Farhan H, 2006, HANDB EXP PHARM, V175, P233; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Hahn MK, 2003, J NEUROSCI, V23, P4470; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; Korkhov VM, 2006, J BIOL CHEM, V281, P13439, DOI 10.1074/jbc.M511382200; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; Larsen MB, 2006, BIOCHEMISTRY-US, V45, P1331, DOI 10.1021/bi0508688; McHugh EM, 2004, MOL CELL NEUROSCI, V26, P406, DOI 10.1016/j.mcn.2004.03.006; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Miranda M, 2004, J BIOL CHEM, V279, P30760, DOI 10.1074/jbc.M312774200; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Sato K, 2004, J BIOL CHEM, V279, P1330, DOI 10.1074/jbc.C300457200; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Xu DL, 2004, J CELL BIOL, V167, P997, DOI 10.1083/jcb.200408135	33	85	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7679	7689		10.1074/jbc.M609720200	http://dx.doi.org/10.1074/jbc.M609720200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210573	hybrid			2022-12-25	WOS:000245080900080
J	Fok, PT; Huang, KC; Holland, PC; Nalbantoglu, J				Fok, Patrick T.; Huang, Kuo-Cheng; Holland, Paul C.; Nalbantoglu, Josephine			The coxsackie and adenovirus receptor binds microtubules and plays a role in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLADDER-CANCER; TIGHT JUNCTIONS; GENE-TRANSFER; B VIRUSES; EXPRESSION; CAR; ADHESION; DOMAIN; PROTEIN; CARCINOMA	The Coxsackie and adenovirus receptor (CAR), a cell adhesion molecule of the immunoglobulin superfamily, inhibits cell growth of a variety of tumors. The cytoplasmic domain of CAR has been implicated in decreased invasion and intracerebral growth of human U87 glioma cells. Using affinity binding, we identified tubulin as an interaction partner for the cytoplasmic domain of CAR. The interaction was specific; CAR and tubulin co-immunoprecipitated in cells expressing endogenous CAR and partially co-localized in situ. The binding of CAR to tubulin heterodimers and to microtubules was direct, with dissociation constants of similar to 1 mu M for tubulin and similar to 32 nM for in vitro assembled microtubules. Whereas CAR-expressing U87 glioma cells had decreased migration in a chemotactic assay in Boyden chambers as compared with control cells, an effect that depended on the presence of the cytoplasmic domain of CAR, the difference was abrogated at low, non-cytotoxic doses of the taxane paclitaxel, a microtubule-stabilizing agent. These results indicate that CAR may affect cell migration through its interaction with microtubules.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Nalbantoglu, J (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	Josephine.nalbantoglu@mcgill.ca						Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2005, J CELL SCI, V118, P623, DOI 10.1242/jcs.01661; Belotti D, 1996, CLIN CANCER RES, V2, P1725; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; CAHAN MA, 1994, CANCER CHEMOTH PHARM, V33, P441, DOI 10.1007/s002800050079; Cao TT, 2004, MOL BIOL CELL, V15, P151, DOI 10.1091/mbc.E03-07-0504; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Cohen CJ, 2001, J BIOL CHEM, V276, P25392, DOI 10.1074/jbc.M009531200; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Excoffon KJDA, 2004, J CELL SCI, V117, P4401, DOI 10.1242/jcs.01300; Felgner H, 1997, J CELL BIOL, V138, P1067, DOI 10.1083/jcb.138.5.1067; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Huang KC, 2005, INT J CANCER, V113, P738, DOI 10.1002/ijc.20623; Jee YS, 2002, ANTICANCER RES, V22, P2629; Kim M, 2003, BRIT J CANCER, V88, P1411, DOI 10.1038/sj.bjc.6600932; Kirby I, 2000, J VIROL, V74, P2804, DOI 10.1128/JVI.74.6.2804-2813.2000; Korn WM, 2006, CANCER GENE THER, V13, P792, DOI 10.1038/sj.cgt.7700947; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Li YM, 1999, CANCER RES, V59, P325; Matsumoto K, 2005, UROLOGY, V66, P441, DOI 10.1016/j.urology.2005.02.033; Mirza M, 2005, EXP CELL RES, V309, P110, DOI 10.1016/j.yexcr.2005.05.023; Nalbantoglu J, 1999, HUM GENE THER, V10, P1009, DOI 10.1089/10430349950018409; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Okegawa T, 2000, CANCER RES, V60, P5031; Okegawa T, 2001, CANCER RES, V61, P6592; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; Pellegrini F, 2005, CANCER INVEST, V23, P264, DOI 10.1081/CNV-200055970; Perego C, 2002, J CELL SCI, V115, P3331; Raschperger E, 2004, J BIOL CHEM, V279, P796, DOI 10.1074/jbc.M308249200; Raschperger E, 2006, EXP CELL RES, V312, P1566, DOI 10.1016/j.yexcr.2006.01.025; Rauen KA, 2002, CANCER RES, V62, P3812; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Shaw CA, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-42; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Strohmaier AR, 2000, CELLS TISSUES ORGANS, V167, P1, DOI 10.1159/000016760; Suzu S, 2002, BIOCHEM BIOPH RES CO, V296, P1215, DOI 10.1016/S0006-291X(02)02025-9; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; van't Hof W, 2002, J VIROL, V76, P6382, DOI 10.1128/JVI.76.12.6382-6386.2002; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; Watanabe T, 2005, TRENDS CELL BIOL, V15, P76, DOI 10.1016/j.tcb.2004.12.006; Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036	60	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7512	7521		10.1074/jbc.M607230200	http://dx.doi.org/10.1074/jbc.M607230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210569	hybrid			2022-12-25	WOS:000245080900064
J	Katayama, H; Kusaka, Y; Yokota, H; Akao, T; Kojima, M; Nakamura, O; Mekada, E; Mizuki, E				Katayama, Hideki; Kusaka, Yoshitomo; Yokota, Haruo; Akao, Tetsuyuki; Kojima, Masayasu; Nakamura, Osamu; Mekada, Eisuke; Mizuki, Eiich			Parasporin-1, a novel cytotoxic protein from Bacillus thuringiensis, induces Ca2+ influx and a sustained elevation of the cytoplasmic Ca2+ concentration in toxin-sensitive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; FACTOR RECEPTOR-BINDING; PLASMA-MEMBRANE; GROWTH-FACTOR; SF9 CELLS; CALCIUM-CHANNELS; CRYSTAL PROTEINS; DIPHTHERIA-TOXIN; SURAMIN ANALOGS; INHIBITS GROWTH	Parasporin-1 is a novel non-insecticidal inclusion protein from Bacillus thuringiensis that is cytotoxic to specific mammalian cells. In this study, we investigated the effects of parasporin-1 on toxinsensitive cell lines to elucidate the cytotoxic mechanism of parasporin-1. Parasporin-1 is not a membrane pore-forming toxin as evidenced by measurements of lactate dehydrogenase release, propidium iodide penetration, and membrane potential in parasporin-l-treated cells. Parasporin-1 decreased the level of cellular protein and DNA synthesis in parasporin-l-sensitive HeLa cells. The earliest change observed in cells treated with this toxin was a rapid elevation of the intracellular free-Ca2+ concentration; increases in the intracellular Ca2+ levels were observed 1-3 min following parasporin-1 treatment. Using four different cell lines, we found that the degree of cellular sensitivity to parasporin-1 was positively correlated with the size of the increase in the intracellular Ca2+ concentration. The toxin-induced elevation of the intracellular Ca2+ concentration was markedly decreased in low-Ca2+ buffer and was not observed in Ca2+-free buffer. Accordingly, the cytotoxicity of parasporin-1 decreased in the low-Ca2+ buffer and was restored by the addition of Ca2+ to the extracellular medium. Suramin, which inhibits trimeric G-protein signaling, suppressed both the Ca 21 influx and the cytotoxicity of parasporin-1. In parasporin-1-treated HeLa cells, degradation of pro-caspase-3 and poly(ADPribose) polymerase was observed. Furthermore, synthetic caspase inhibitors blocked the cytotoxic activity of parasporin-1. These results indicate that parasporin-1 activates apoptotic signaling in these cells as a result of the increased Ca2+ level and that the Ca2+ influx is the first step in the pathway that underlies parasporin-1 toxicity.	Fukuoka Ind Technol Ctr, Biotechnol & Food Res Inst, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390864, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Cell Biol, Suita, Osaka 5650871, Japan	Kurume University; Osaka University	Katayama, H (corresponding author), Fukuoka Ind Technol Ctr, Biotechnol & Food Res Inst, Kurume, Fukuoka 8390861, Japan.	hkatayam@fitc.pref.fukuoka.jp		Mekada, Eisuke/0000-0001-8858-4781				Beindl W, 1996, MOL PHARMACOL, V50, P415; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; CAHILL AL, 1988, NEUROSCI LETT, V84, P345, DOI 10.1016/0304-3940(88)90533-2; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guihard G, 2000, J MEMBRANE BIOL, V175, P115, DOI 10.1007/s002320001060; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HOFTE H, 1989, MICROBIOL REV, V53, P242; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; Itagaki K, 2005, J LEUKOCYTE BIOL, V77, P181, DOI 10.1189/jlb.0704390; Ito A, 2004, J BIOL CHEM, V279, P21282, DOI 10.1074/jbc.M401881200; Katayama H, 2005, J BIOCHEM, V137, P17, DOI 10.1093/jb/mvi003; Kitada S, 2006, J BIOL CHEM, V281, P26350, DOI 10.1074/jbc.M602589200; KLOEN P, 1994, EUR J CANCER, V30A, P678, DOI 10.1016/0959-8049(94)90544-4; KOPP R, 1990, CANCER RES, V50, P6490; Krause KH, 1998, J BIOL CHEM, V273, P18122, DOI 10.1074/jbc.273.29.18122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DW, 2000, BIOCHEM BIOPH RES CO, V272, P218, DOI 10.1006/bbrc.2000.2765; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MCCARTHY RT, 1992, J NEUROSCI, V12, P2225; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MEADOWS MP, 1992, APPL ENVIRON MICROB, V58, P1344, DOI 10.1128/AEM.58.4.1344-1350.1992; Mizuki E, 1999, J APPL MICROBIOL, V86, P477, DOI 10.1046/j.1365-2672.1999.00692.x; Mizuki E, 2000, CLIN DIAGN LAB IMMUN, V7, P625, DOI 10.1128/CDLI.7.4.625-634.2000; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHBA M, 1986, J INVERTEBR PATHOL, V47, P12, DOI 10.1016/0022-2011(86)90158-8; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; SPIGELMAN Z, 1987, CANCER RES, V47, P4694; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; VACHON V, 1995, J MEMBRANE BIOL, V148, P57, DOI 10.1007/BF00234156; Villalon M, 1998, BBA-BIOMEMBRANES, V1368, P27, DOI 10.1016/S0005-2736(97)00184-3; VILLARROYA M, 1995, BRIT J PHARMACOL, V114, P369, DOI 10.1111/j.1476-5381.1995.tb13236.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Yamashita S, 2000, CAN J MICROBIOL, V46, P913, DOI 10.1139/cjm-46-10-913	52	35	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7742	7752		10.1074/jbc.M611382200	http://dx.doi.org/10.1074/jbc.M611382200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17204466	hybrid			2022-12-25	WOS:000245080900086
J	Watanabe, S; Yamada, M; Ohtsu, I; Makino, K				Watanabe, Seiya; Yamada, Masaki; Ohtsu, Iwao; Makino, Keisuke			alpha-Ketoglutaric semialclehyde dehydrogenase isozymes involved in metabolic pathways of D-glucarate, D-galactarate, and hydroxy-L-proline - Molecular and metabolic convergent evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARABINOSE METABOLISM; METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALTERNATIVE PATHWAY; VIBRIO-HARVEYI; BACILLUS-SUBTILIS; IDENTIFICATION; PSEUDOMONAS; CLONING; ENZYME	Azospirillum brasilense possesses an alternative pathway of L-arabinose metabolism in which alpha-ketoglutaric semialdehyde (alpha KGSA) dehydrogenase (KGSADH) is involved in the last step, the conversion of alpha KGSA to alpha-ketoglutarate. In the preceding studies, we identified a set of metabolic genes of the L-arabinose pathway including the KGSADH gene (Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 2612-2623; Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 28876-28888; Watanabe, S., Shimada, N., Tajima, K., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 3352133536). Here, we describe that A. brasilense possesses two different KGSADH isozymes from L-arabinose-related enzyme (KGSADH-I); that is, D-glucarate/D-galactarate-inducible KGSADH-II and hydroxy-L-proline-inducible KGSADH-III. They were purified homogeneously from A. brasilense cells grown on D-galactarate or hydroxy-L-proline, respectively. When compared with KGSADH-I, amino acid sequences of KGSADH-II and KGSADH-III were significantly similar but not totally identical. Physiological characterization using recombinant enzymes revealed that KGSADH-II and KGSADH-III showed similar high substrate specificity for alpha KGSA and different coenzyme specificity; that is, NAD(+)-dependent KGSADH-II and NADP(+)-dependent KGSADH-III. In the phylogenetic tree of the aldehyde dehydrogenase (ALDH) superfamily, KGSADH-II and KGSADH-III were poorly related to the known ALDH subclasses including KGSADH-I. On the other hand, ALDH-like ycbD protein involved in D-glucarate/D-galactarate operon from Bacillus subtilis is closely related to the methylmalonyl semialdehyde dehydrogenase subclass but not A. brasilense KGSADH isozymes. To estimate the correct function, the corresponding gene was expressed, purified, and characterized. Kinetic analysis revealed the physiological role as NADP(+)-dependent KGSADH. We conclude that three different types of KGSADH appeared in the bacterial evolutional stage convergently. Furthermore, even the same pathway such as L-arabinose and D-glucarate/D-galactarate metabolism also evolved by the independent involvement of KGSADH.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan; Japan Sci & Technol Agcy, CREST, Uji, Kyoto 6110011, Japan; Shimadzu Co Ltd, Analyt & Measuring Instruments Div, Life Sci Lab, Nakagyo Ku, Kyoto 6048511, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Shimadzu Corporation; Kyoto University	Watanabe, S (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	irab@iae.kyoto-u.ac.jp; kmak@iae.kyoto-u.ac.jp		Ohtsu, Iwao/0000-0002-3553-0306				ADAMS E, 1967, J BIOL CHEM, V242, P1802; ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; BOGNAR AL, 1978, J BIOL CHEM, V253, P446; Brouns SJJ, 2006, J BIOL CHEM, V281, P27378, DOI 10.1074/jbc.M605549200; CHANG YF, 1977, J BIOL CHEM, V252, P7979; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; GENNADY PM, 2002, HDB DETECTION ENZYME, P27; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hosoya S, 2002, FEMS MICROBIOL LETT, V210, P193, DOI 10.1111/j.1574-6968.2002.tb11180.x; Hottes AK, 2004, J BACTERIOL, V186, P1448, DOI 10.1128/JB.186.5.1448-1461.2004; Hubbard BK, 1998, BIOCHEMISTRY-US, V37, P14369, DOI 10.1021/bi981124f; IMANAKA T, 1993, J FERMENT BIOENG, V76, P161, DOI 10.1016/0922-338X(93)90001-O; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOO PH, 1974, J BIOL CHEM, V249, P1704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; PEDROSA FO, 1974, J BACTERIOL, V119, P336, DOI 10.1128/JB.119.1.336-338.1974; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; SINGH RMM, 1964, SCIENCE, V144, P67, DOI 10.1126/science.144.3614.67; STEPHENS C, 2007, IN PRESS J BACTERIOL; Stines-Chaumeil C, 2006, BIOCHEM J, V395, P107, DOI 10.1042/BJ20051525; STRYER L, 1988, BIOCHEMISTRY-US, P805; Vedadi M, 1995, BIOCHEMISTRY-US, V34, P16725, DOI 10.1021/bi00051a022; Watanabe S, 2006, J BIOL CHEM, V281, P2612, DOI 10.1074/jbc.M506477200; Watanabe S, 2006, J BIOL CHEM, V281, P33521, DOI 10.1074/jbc.M606727200; Watanabe S, 2006, J BIOL CHEM, V281, P28876, DOI 10.1074/jbc.M602585200; WELMBERG R, 1955, J BIOL CHEM, V217, P607; Zhang L, 1999, BIOCHEMISTRY-US, V38, P11440, DOI 10.1021/bi991101g	39	42	49	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6685	6695		10.1074/jbc.M611057200	http://dx.doi.org/10.1074/jbc.M611057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202142	hybrid			2022-12-25	WOS:000244867200078
J	Sendi, P; Gunthard, HF; Simcock, M; Ledergerber, B; Schupbach, J; Battegay, M				Sendi, Pedram; Guenthard, Huldrych F.; Simcock, Mathew; Ledergerber, Bruno; Schuepbach, Joerg; Battegay, Manuel		Swiss HIV Cohort Study	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure	PLOS ONE			English	Article								Background. Genotypic antiretroviral resistance testing (GRT) in HIV infection with drug resistant virus is recommended to optimize antiretroviral therapy, in particular in patients with virological failure. We estimated the clinical effect, cost and cost-effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure. Methods. We developed a mathematical model of HIV disease to describe disease progression in HIV-infected patients with treatment failure and compared the incremental impact of GRT versus expert opinion to guide antiretroviral therapy. The analysis was conducted from the health care (discount rate 4%) and societal (discount rate 2%) perspective. Outcome measures included life-expectancy, quality-adjusted life-expectancy, health care costs, productivity costs and cost-effectiveness in US Dollars per quality-adjusted life-year (QALY) gained. Clinical and economic data were extracted from the large Swiss HIV Cohort Study and clinical trials. Results. Patients whose treatment was optimized with GRT versus expert opinion had an increase in discounted life-expectancy and quality-adjusted life-expectancy of three and two weeks, respectively. Health care costs with and without GRT were $US 421,000 and $US 419,000, leading to an incremental cost-effectiveness ratio of $US 35,000 per QALY gained. In the analysis from the societal perspective, GRT versus expert opinion led to an increase in discounted life-expectancy and quality-adjusted life-expectancy of three and four weeks, respectively. Health care costs with and without GRT were $US 551,000 and $US 549,000, respectively. When productivity changes were included in the analysis, GRT was cost-saving. Conclusions. GRT for treatment optimization in HIV-infected patients with treatment failure is a cost-effective use of scarce health care resources and beneficial to the society at large.	[Sendi, Pedram; Simcock, Mathew; Battegay, Manuel] Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland; [Sendi, Pedram; Simcock, Mathew] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland; [Guenthard, Huldrych F.; Ledergerber, Bruno] Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; [Schuepbach, Joerg] Univ Zurich, Swiss Natl Ctr Retroviruses, Zurich, Switzerland	University of Basel; University of Basel; University of Zurich; University Zurich Hospital; University of Zurich	Sendi, P (corresponding author), Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland.	pedram.sendi@unibas.ch; mbattegay@uhbs.ch	Pantaleo, Giuseppe/K-6163-2016; gunthard, huldrych f/F-1724-2011; Sendi, Pedram/AAC-2067-2019; Ledergerber, Bruno/B-5656-2009; Schüpbach, Jörg/G-4209-2016; VALLET, Yannick/F-9979-2011; SHCS, social sciences/G-4093-2011; Sendi, Parham/R-3286-2018	gunthard, huldrych f/0000-0002-1142-6723; Ledergerber, Bruno/0000-0002-6881-4401; Schüpbach, Jörg/0000-0002-8074-5891; Sendi, Parham/0000-0002-7347-6312	Swiss National Science Foundation [3345CO-103560/1]; Stiftung Forschung Infektionskrankheiten Basel; Swiss HIV Cohort Study (SHCS) [400]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Stiftung Forschung Infektionskrankheiten Basel; Swiss HIV Cohort Study (SHCS)	This cost-effectiveness analysis was financially supported by the Swiss National Science Foundation (SNF project # 3345CO-103560/1), the Stiftung Forschung Infektionskrankheiten Basel and the Swiss HIV Cohort Study (SHCS project # 400), supported by the Swiss National Science Foundation.	Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; Briggs AH, 1999, HEALTH ECON, V8, P257, DOI 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E; Briggs AH, 2003, MED DECIS MAKING, V23, P341, DOI 10.1177/0272989X03255922; Briggs AH, 2002, MED DECIS MAKING, V22, P290, DOI 10.1177/027298902400448867; Chaix C, 2000, J ACQ IMMUN DEF SYND, V24, P227; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Clevenbergh P, 2000, ANTIVIR THER, V5, P65; Corzillius M, 2004, ANTIVIR THER, V9, P27; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Drummond MF, 2015, METHODS EC EVALUATIO; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Ena J, 2006, ENFERM INFEC MICR CL, V24, P232, DOI 10.1016/S0213-005X(06)73768-5; Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181; Haupts S, 2003, ANTIVIR THER, V8, P443; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Hirsch HH, 2005, EUR J CLIN MICROBIOL, V24, P733, DOI 10.1007/s10096-005-0044-4; Hirsch Martin S, 2003, Top HIV Med, V11, P150; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hunink MGM, 1998, MED DECIS MAKING, V18, P337, DOI 10.1177/0272989X9801800312; Jiang HY, 2003, J INFECT DIS, V188, P1001, DOI 10.1086/378355; Johannesson M, 1998, HEALTH ECON, V7, P1, DOI 10.1002/(SICI)1099-1050(199802)7:1<1::AID-HEC327>3.0.CO;2-U; Johannesson M, 1997, MED DECIS MAKING, V17, P382, DOI 10.1177/0272989X9701700403; Kaiser C, 2005, LANCET, V366, P921, DOI 10.1016/S0140-6736(05)67221-2; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; Krol M, 2006, PHARMACOECONOMICS, V24, P401, DOI 10.2165/00019053-200624040-00009; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; MCCARTHY BD, 1993, ARCH INTERN MED, V153, P1107, DOI 10.1001/archinte.153.9.1107; Meltzer D, 1999, MED DECIS MAKING, V19, P371, DOI 10.1177/0272989X9901900401; Mrus JM, 2003, MED DECIS MAKING, V23, P414, DOI 10.1177/0272989X03256884; OCHOA DE, 2005, AIDS, V19, P1385; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panidou ET, 2004, AIDS, V18, P2153, DOI 10.1097/00002030-200411050-00007; Sanders GD, 2005, NEW ENGL J MED, V353, P1471, DOI 10.1056/NEJMsa051989; Sax PE, 2005, CLIN INFECT DIS, V41, P1316, DOI 10.1086/496984; Sendi P, 2005, HEALTH ECON, V14, P643, DOI 10.1002/hec.971; Sendi P, 2004, CLIN THER, V26, P791, DOI 10.1016/S0149-2918(04)90080-X; Sendi PP, 1999, AIDS, V13, P1115, DOI 10.1097/00002030-199906180-00016; Sendi PP, 1999, J ACQ IMMUN DEF SYND, V20, P376, DOI 10.1097/00042560-199904010-00008; Sendi PP, 1999, J EVAL CLIN PRACT, V5, P283, DOI 10.1046/j.1365-2753.1999.00174.x; Sendi PP, 1999, J ANTIMICROB CHEMOTH, V44, P811, DOI 10.1093/jac/44.6.811; Simcock M, 2006, ANTIVIR THER, V11, P305; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300; Torre Donato, 2002, HIV Clin Trials, V3, P1, DOI 10.1310/FY66-NVWJ-3332-HW3C; Vandamme AM, 2004, ANTIVIR THER, V9, P829; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251; Zinkernagel C, 1999, AIDS, V13, P1587, DOI 10.1097/00002030-199908200-00024	53	20	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e173	10.1371/journal.pone.0000173	http://dx.doi.org/10.1371/journal.pone.0000173			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245449	Green Published, gold			2022-12-25	WOS:000207444100010
J	De Souza, CT; Araujo, EP; Stoppiglia, LF; Pauli, JR; Ropelle, E; Rocco, SA; Marin, RM; Franchini, KG; Carvalheira, JB; Saad, MJ; Boschero, AC; Carneiro, EM; Velloso, LA				De Souza, Claudio T.; Araujo, Eliana P.; Stoppiglia, Luiz F.; Pauli, Jose R.; Ropelle, Eduardo; Rocco, Silvana A.; Marin, Rodrigo M.; Franchini, Kleber G.; Carvalheira, Jose B.; Saad, Mario J.; Boschero, Antonio C.; Carneiro, Everardo M.; Velloso, Licio A.			Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action	FASEB JOURNAL			English	Article						short-term inhibition of UCP2; antisense oligonucleotide; ATP synthase; anti-UCP2 antibody	BETA-CELL DYSFUNCTION; UNCOUPLING PROTEINS UCP2; PANCREATIC-ISLETS; RECEPTOR SUBSTRATE-1; OXIDATIVE STRESS; OBESITY; RESISTANCE; MICE; OVEREXPRESSION; HYPERINSULINEMIA	Recent characterization of the ability of uncoupling protein 2 (UCP2) to reduce ATP production and inhibit insulin secretion by pancreatic beta-cells has placed this mitochondrial protein as a candidate target for therapeutics in diabetes mellitus. In the present study we evaluate the effects of short-term treatment of two animal models of type 2 diabetes mellitus with an antisense oligonucleotide to UCP2. In both models, Swiss mice ( made obese and diabetic by a hyperlipidic diet) and ob/ob mice, the treatment resulted in a significant improvement in the hyperglycemic syndrome. This effect was due not only to an improvement of insulin secretion, but also to improved peripheral insulin action. In isolated pancreatic islets, the partial inhibition of UCP2 increased ATP content, followed by increased glucose-stimulated insulin secretion. This was not accompanied by increased expression of enzymes involved in protection against oxidative stress. The evaluation of insulin action in peripheral tissues revealed that the inhibition of UCP2 expression significantly improved insulin signal transduction in adipose tissue. In conclusion, short-term inhibition of UCP2 expression ameliorates the hyperglycemic syndrome in two distinct animal models of obesity and diabetes. Metabolic improvement is due to a combined effect on insulin-producing pancreatic islets and in at least one peripheral tissue that acts as a target for insulin.	Univ Estadual Campinas, Dept Internal Med, Campinas, SP, Brazil; Univ Estadual Campinas, Dept Phys & Biophys, Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas	Velloso, LA (corresponding author), Univ Estadual Campinas, Dept Clin Med, Fac Ciencias Med, Campinas, SP, Brazil.	lavelloso@fcm.unicamp.br	Carvalheira, Jose Barreto Campello/E-8562-2013; Marin, Rodrigo Miguel/M-5687-2013; Carneiro, Everardo/D-4758-2012; Velloso, Licio/AAJ-3778-2020; Araujo, EP/D-9231-2013; Pauli, José Rdrigo/AAD-2763-2021; Rocco, Silvana Aparecida/Q-3828-2019; Boschero, Antonio/O-7525-2014; Carvalheira, Jose B/H-8405-2012; Stoppiglia, Luiz F/C-4963-2015; Rocco, Silvana Aparecida/H-6300-2014; Ropelle, Eduardo R/C-3977-2012; Saad, Mario/ABD-8262-2020	Carvalheira, Jose Barreto Campello/0000-0002-0136-0943; Araujo, EP/0000-0002-7539-8477; Pauli, José Rdrigo/0000-0002-6129-1521; Rocco, Silvana Aparecida/0000-0003-4551-3443; Boschero, Antonio/0000-0003-3829-8570; Stoppiglia, Luiz F/0000-0002-5202-5395; Rocco, Silvana Aparecida/0000-0003-4551-3443; Ropelle, Eduardo R/0000-0003-1655-9557; 				ANDERSSON A, 1978, DIABETOLOGIA, V14, P397, DOI 10.1007/BF01228134; Araujo EP, 2006, CURR CANCER DRUG TAR, V6, P77, DOI 10.2174/156800906775471734; Araujo EP, 2005, ENDOCRINOLOGY, V146, P1428, DOI 10.1210/en.2004-0778; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Babinet C, 2000, J AM SOC NEPHROL, V11, pS88; BONORA E, 1987, DIABETES METAB, V13, P116; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; Branchi I, 2002, GENES BRAIN BEHAV, V1, P135, DOI 10.1034/j.1601-183X.2002.10301.x; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; De Souza CT, 2003, DIABETOLOGIA, V46, P1522, DOI 10.1007/s00125-003-1222-5; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Fujikawa T, 2005, ENDOCRINOLOGY, V146, P3471, DOI 10.1210/en.2004-1528; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Nicholls DG, 2006, BBA-BIOENERGETICS, V1757, P459, DOI 10.1016/j.bbabio.2006.02.005; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; OPALINSKA JB, 2003, SCI STKE; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Robertson JA, 2002, INT J SYST EVOL MICR, V52, P587, DOI 10.1099/00207713-52-2-587; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Ronner P, 1999, ANAL BIOCHEM, V275, P208, DOI 10.1006/abio.1999.4317; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Rydstrom J, 2006, TRENDS BIOCHEM SCI, V31, P355, DOI 10.1016/j.tibs.2006.05.003; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; Simoneau JA, 1998, FASEB J, V12, P1739, DOI 10.1096/fasebj.12.15.1739; Sluse FE, 2006, BBA-BIOENERGETICS, V1757, P480, DOI 10.1016/j.bbabio.2006.02.004; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Tonkonogi M, 1997, ACTA PHYSIOL SCAND, V161, P345, DOI 10.1046/j.1365-201X.1997.00222.x; TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	45	71	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1153	1163		10.1096/fj.06-7148com	http://dx.doi.org/10.1096/fj.06-7148com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17209127				2022-12-25	WOS:000245650400020
J	Ke, PY; Hu, CM; Chang, YC; Chang, ZF				Ke, Po-Yuan; Hu, Chun-Mei; Chang, Yi-Chang; Chang, Zee-Fen			Hiding human thymidine kinase 1 from APC/C-mediated destruction by thymidine binding	FASEB JOURNAL			English	Article						cell cycle; proteolysis; ubiquitination; dTTP synthesis	MOUSE RIBONUCLEOTIDE REDUCTASE; SERUM-STIMULATED CELLS; MESSENGER-RNA; MITOTIC PHOSPHORYLATION; SUBSTRATE-BINDING; MAMMALIAN-CELLS; GENE-EXPRESSION; TUMOR-MARKER; HELA-CELLS; DEGRADATION	Thymidine kinase 1 (TK1) is a key cytosolic enzyme in the salvage pathway for dTTP synthesis. In mitotic exit, human TK1 (hTK1) is degraded via the anaphase-promoting complex/cyclosome (APC/C)-Cdh1 pathway to limit dTTP production. In this study, we show that thymidine binding stabilizes hTK1 during growth arrest. By in vitro degradation, ubiquitination, and Cdh1 binding analyses, we provide direct evidence that thymidine binding protects wild-type hTK1 protein from APC/C-Cdh1-mediated destruction. In contrast, mutant-type hTK1 protein defective in thymidine binding ability could still be polyubiquitinated by APC/CCdh1 in the presence of thymidine. These results suggest that the status of thymidine binding to hTK1 protein determines its susceptibility to degradation due to APC/C targeting. Our in vivo experimental data also demonstrated that thymidine treatment abolished Cdh1/proteasome-responsive suppression of hTK1 expression. Moreover, exposure of mitotic-arrested K562 cells to thymidine (100 mu M) stabilized endogenous TK1, causing nucleotide imbalance in the early G(1) phase and an increase of S phase accumulation. In conclusion, thymidine is not only a substrate of TK1 but also acts as its expression regulator by modulating its proteolytic control during mitotic exit, conferring a feed-forward regulation of dTTP formation.	Natl Taiwan Univ, Grad Inst Biochem & Mol Biol, Coll Med, Taipei, Taiwan	National Taiwan University	Chang, ZF (corresponding author), Natl Taiwan Univ, Grad Inst Biochem & Mol Biol, Coll Med, 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.	zfchang@ha.mc.ntu.edu.tw	Ke, Po-Yuan/AAQ-6324-2021	Ke, Po-Yuan/0000-0002-0471-0806				Berenstein D, 2000, J BIOL CHEM, V275, P32187, DOI 10.1074/jbc.M005325200; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; BRADLEY MO, 1978, NATURE, V274, P607, DOI 10.1038/274607a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CHANG ZF, 1990, BIOCHEM BIOPH RES CO, V169, P780, DOI 10.1016/0006-291X(90)90399-8; CHANG ZF, 1994, J BIOL CHEM, V269, P21249; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; Chimploy K, 2001, J BIOL CHEM, V276, P7093, DOI 10.1074/jbc.M006232200; Chou WL, 2001, BBA-GENE STRUCT EXPR, V1519, P209, DOI 10.1016/S0167-4781(01)00241-X; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gilles SI, 2003, INT J BIOL MARKER, V18, P1; HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117; He QM, 2004, INT J ONCOL, V25, P945; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; ITO M, 1990, J BIOL CHEM, V265, P6954; JI JP, 1991, J BIOL CHEM, V266, P16289; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Ke PY, 2005, GENE DEV, V19, P1920, DOI 10.1101/gad.1322905; Ke PY, 2004, MOL CELL BIOL, V24, P514, DOI 10.1128/MCB.24.2.514-526.2004; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; Li CL, 2004, BIOCHEM BIOPH RES CO, V313, P587, DOI 10.1016/j.bbrc.2003.11.147; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Posch M, 2000, J MOL BIOL, V300, P493, DOI 10.1006/jmbi.2000.3876; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; Sutterluety H, 1997, J MOL BIOL, V265, P153, DOI 10.1006/jmbi.1996.0721; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Welin M, 2004, P NATL ACAD SCI USA, V101, P17970, DOI 10.1073/pnas.0406332102; Wintersberger E, 1997, BIOCHEM SOC T, V25, P303, DOI 10.1042/bst0250303	43	11	13	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1276	1284		10.1096/fj.06-7272com	http://dx.doi.org/10.1096/fj.06-7272com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227951	Green Submitted			2022-12-25	WOS:000245650400032
J	Lao, DH; Yusoff, P; Chandramouli, S; Philp, RJ; Fong, CW; Jackson, RA; Saw, TY; Yu, CY; Guy, GR				Lao, Dieu-Hung; Yusoff, Permeen; Chandramouli, Sumana; Philp, Robin J.; Fong, Chee Wai; Jackson, Rebecca A.; Saw, Tzuen Yih; Yu, Chye Yun; Guy, Graeme R.			Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; TYROSINE PHOSPHORYLATION; KINASE; ACTIVATION; PATHWAY; FAMILY; RAF-1; CBL	In the context of fibroblast growth factor (FGF) signaling, Sprouty2 (Spry2) is the most profound inhibitor of the Ras/ERK pathway as compared with other Spry isoforms. An exclusive, necessary, but cryptic PXXPXR motif in the C terminus of Spry2 is revealed upon stimulation. The activation of Spry2 appears to be linked to sequences in the N-terminal half of the protein and correlated with a bandshifting seen on SDS-PAGE. The bandshifting is likely caused by changes in the phosphorylation status of key Ser and Thr residues following receptor stimulation. Dephosphorylation of at least two conserved Ser residues (Ser112 and Ser-115) within a conserved Ser/Thr sequence is accomplished upon stimulation by a phosphatase that binds to Spry2 around residues 50-60. We show that human Spry2 coimmunoprecipitates with both the catalytic and the regulatory subunits of protein phosphatase 2A (PP2A-C and PP2A-A, respectively) in cells upon FGF receptor (FGFR) activation. PP2A-A binds directly to Spry2, but not to Spry2 Delta 50 - 60 (Delta 50-60), and the activity of PP2A increases with both FGF treatment and FGFR1 overexpression. c-Cb1 and PP2A-A compete for binding centered around Tyr-55 on Spry2. We show that there are at least two distinct pools of Spry2, one that binds PP2A and another that binds c-Cb1. c-Cb1 binding likely targets Spry2 for ubiquitin-linked destruction, whereas the phosphatase binding and activity are necessary to dephosphorylate specific Ser/Thr residues. The resulting change in tertiary structure enables the Pro-rich motif to be revealed with subsequent binding of Grb2, a necessary step for Spry2 to act as a Ras/ERK pathway inhibitor in FGF signaling.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 138673, Singapore; Bioproc Technol Inst, Singapore 138668, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, Rm 6-01A,61 Biopolis Dr, Singapore 138673, Singapore.	mcbgg@imcb.a-star.edu.sg		Chandramouli, Sumana/0000-0001-6994-506X				BOS JL, 1989, CANCER RES, V49, P4682; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03-07-0503; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Rubin C, 2005, J BIOL CHEM, V280, P9735, DOI 10.1074/jbc.M408308200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	27	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9117	9126		10.1074/jbc.M607563200	http://dx.doi.org/10.1074/jbc.M607563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255109	hybrid			2022-12-25	WOS:000245780300059
J	Solt, LA; Madge, LA; Orange, JS; May, MJ				Solt, Laura A.; Madge, Lisa A.; Orange, Jordan S.; May, Michael J.			Interleukin-1-induced NF-kappa B activation is NEMO-dependent but does not require IKK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; GENE-EXPRESSION; INCONTINENTIA PIGMENTI; SELECTIVE-INHIBITION; KINASE-ALPHA; PATHWAYS; SUBUNIT; LACKING; DOMAIN	Activation of NF-kappa B by the pro-inflammatory cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1) requires the I kappa B kinase (IKK) complex, which contains two kinases named IKK alpha and IKK beta and a critical regulatory subunit named NEMO. Although we have previously demonstrated that NEMO associates with both IKKs, genetic studies reveal that only its interaction with IKK beta is required for TNF-induced NF-kappa B activation. To determine whether NEMO and IKK alpha can form a functional IKK complex capable of activating the classical NF-kappa B pathway in the absence of IKK beta, we utilized a panel of mouse embryonic fibroblasts (MEFs) lacking each of the IKK complex subunits. This confirmed that TNF-induced I kappa B alpha degradation absolutely requires NEMO and IKK beta. In contrast, we consistently observed intact I kappa B alpha degradation and NF-kappa B activation in response to IL-1 in two separate cell lines lacking IKK beta. Furthermore, exogenously expressed, catalytically inactive IKK beta blocked TNF- but not IL-1-induced I kappa B alpha degradation in wild-type MEFs, and reconstitution of IKK alpha/beta double knockout cells with IKK alpha rescued IL-1- but not TNF-induced NF-kappa B activation. Finally, we have shown that incubation of IKK beta-deflcient MEFs with a cell-permeable peptide that blocks the interaction of NEMO with the IKKs inhibits IL-1-induced NF-kappa B activation. Our results therefore demonstrate that NEMO and IKK alpha can form a functional IKK complex that activates the classical NF-kappa B pathway in response to IL-1 but not TNF. These findings further suggest NEMO differentially regulates the fidelity of the IKK subunits activated by distinct upstream signaling pathways.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu	Orange, Jordan S/D-5239-2009	May, Michael/0000-0002-2485-3716; orange, jordan/0000-0001-7117-7725	NHLBI NIH HHS [R01 HL080612-01A1, R01 HL080612, 1R01HL080612-01A1] Funding Source: Medline; NIAID NIH HHS [T32 AI055428, R01 AI022070, N01AI-22070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022070, T32AI055428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Correa RG, 2005, CURR BIOL, V15, P1291, DOI 10.1016/j.cub.2005.06.023; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Supprian M, 2003, IMMUNITY, V19, P377, DOI 10.1016/S1074-7613(03)00237-1; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	39	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8724	8733		10.1074/jbc.M609613200	http://dx.doi.org/10.1074/jbc.M609613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244613	hybrid, Green Accepted			2022-12-25	WOS:000245780300018
J	Altenburg, M; Johnson, L; Wilder, J; Maeda, N				Altenburg, Michael; Johnson, Lance; Wilder, Jennifer; Maeda, Nobuyo			Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III HYPERLIPOPROTEINEMIA; CHOLESTEROL EFFLUX; MICE; ATHEROSCLEROSIS; LDL; HYPERCHOLESTEROLEMIA; INHIBITION; METABOLISM; APOE; REPLACEMENT	Apolipoprotein E (apoE) and the low density lipoprotein receptor (LDLr) are well recognized determinants of atherosclerosis. In addition to hepatocytes, where both are highly expressed and contribute to plasma lipoprotein clearance, they are expressed in vascular cells and macrophages. In this study, we examined the effects of human apoE isoforms and LDLr levels in atherogenic pathways in primary macrophages ex vivo and atherosclerosis development after bone marrow transfer in vivo using mice expressing human apoE isoformis and different levels of LDLr expression. Increases in LDLr expression significantly increased cholesterol delivery into macrophages in culture, and the effects were more prominent with lipoproteins containing apoE4 than those containing apoE3. Conversely, increased LDLr expression reduced cholesterol efflux in macrophages expressing apoE4 but not in macrophages expressing apoE3. Furthermore, apoE3 protected VLDL from oxidation in vitro more than did apoE4. In LDLr-deficient mice expressing the human apoE4 isoform, Apoe(4/4) Ldlr(-/-), the replacement of bone marrow cells with those expressing LDLr increased atherosclerotic lesions in a dose-dependent manner compared with mice transplanted with cells having no LDLr. In contrast, atherosclerosis in Apoe(3/3) Ldlr(-/-) mice, expressing the human apoE3 isoform, did not differ by the levels of macrophage LDLr expression. Our results demonstrate that apoE4, but not apoE3, in macrophages enhances atherosclerotic plaque development in mice in an LDLr-dependent manner and suggests that this interaction may contribute to the association of apoE4 with an increased cardiovascular risk in humans.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Maeda, N (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, 701 Brinkhous Bulitt Bldg, Chapel Hill, NC 27599 USA.	nobuyo@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042630, R01HL042630, T32HL069768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL042630, HL42630, R37 HL042630, T32HL69768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bohnet K, 1996, J LIPID RES, V37, P1316; Costet P, 2000, J BIOL CHEM, V275, P28240; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; Hara M, 2003, ARTERIOSCL THROM VAS, V23, P269, DOI 10.1161/01.ATV.0000054199.78458.4B; Hasty AH, 2005, J LIPID RES, V46, P1433, DOI 10.1194/jlr.M400418-JLR200; Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200; Herijgers N, 1997, ARTERIOSCL THROM VAS, V17, P1995, DOI 10.1161/01.ATV.17.10.1995; Herijgers N, 2000, ARTERIOSCL THROM VAS, V20, P1961, DOI 10.1161/01.ATV.20.8.1961; Ishigami M, 2000, ARTERIOSCL THROM VAS, V20, P1020, DOI 10.1161/01.ATV.20.4.1020; Knouff C, 2004, BBA-MOL CELL BIOL L, V1684, P8, DOI 10.1016/j.bbalip.2004.03.004; Knouff C, 2001, J BIOL CHEM, V276, P3856, DOI 10.1074/jbc.M009423200; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; Linton MF, 1999, J BIOL CHEM, V274, P19204, DOI 10.1074/jbc.274.27.19204; Lucic D, 2007, J LIPID RES, V48, P366, DOI 10.1194/jlr.M600259-JLR200; Mabile L, 2003, J CELL BIOCHEM, V90, P766, DOI 10.1002/jcb.10697; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Malloy SI, 2004, ARTERIOSCL THROM VAS, V24, P91, DOI 10.1161/01.ATV.0000094963.07902.FB; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacre SM, 2003, FEBS LETT, V540, P181, DOI 10.1016/S0014-5793(03)00261-8; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Zeleny M, 2002, BIOCHEMISTRY-US, V41, P11820, DOI 10.1021/bi026202k; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	35	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7817	7824		10.1074/jbc.M610712200	http://dx.doi.org/10.1074/jbc.M610712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234631	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000245081000010
J	Block, K; Gorin, Y; Hoover, P; Williams, P; Chelmicki, T; Clark, RA; Yoneda, T; Abboud, HE				Block, Karen; Gorin, Yves; Hoover, Paul; Williams, Paul; Chelmicki, Tomasz; Clark, Robert A.; Yoneda, Toshiyuki; Abboud, Hanna E.			NAD(P)H Oxidases regulate HIF-2 alpha protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RENAL-CARCINOMA CELLS; GROWTH SUPPRESSION; NADPH OXIDASES; UP-REGULATION; CANCER CELLS; OXYGEN; ACTIVATION; NOX4	Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene (VHL) is linked to the development of hereditary and sporadic renal cell carcinoma (RCC). In the absence of VHL, the alpha subunits of heterodimeric hypoxia-inducible transcription factors (HIT-1 alpha and HIF-2 alpha) are stabilized. Reactive oxygen species, generated by NAD(P)H oxidases, are involved in signaling cascades of malignant growth. We show that in VHL-deficient cells p22(phox), Nox4 protein levels and NADPH-dependent superoxide generation are increased. Reintroduction of VHL into the VHL-deficient cells down-regulates the expression of p22(phox) and NADPH-dependent superoxide generation. Inhibition of the 26 S proteasome in VHL-expressing cells increased p22(phox) protein levels, which correlated with an increase of NADPH-dependent superoxide generation. We also show that p22(phox) co-immunoprecipitates with VHL in vivo. Moreover, p22(phox) is a target of ubiquitination. Importantly, in VHL-deficient cells, diphenyleneiodonium chloride (DPI), an inhibitor of Nox oxidases, decreased the expression of HIF-2a. Down-regulation of Nox1, Nox4, and p22(phox) expression by small interfering RNA also decreased HIF-2 alpha protein expression and inhibited Akt and 4E-BP1 phosphorylation, suggesting that a translational mechanism is involved in maintaining HIF-2 alpha in VHL-deficient cells. Colony formation by RCC 786-O in soft agar was markedly inhibited by DPI. Moreover, DPI significantly inhibited RCC 786-O tumor formation in athymic mice. Collectively, the data demonstrate that VHL protein exerts its tumor suppressor action, at least partially, via inhibition of p22(phox)-based Nox4/Nox1 NADPH oxidase-dependent reactive oxygen species generation.	Univ Texas, Hlth Sci Ctr, George OBrien Kidney Res Ctr, Dep Med,Div Nephrol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, George OBrien Kidney Res Ctr, Dep Med,Div Endocrinol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Block, K (corresponding author), Univ Texas, Hlth Sci Ctr, George OBrien Kidney Res Ctr, Dep Med,Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	block@uthscsa.edu	Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Chelmicki, Tomasz/0000-0003-0502-7360; Gorin, Yves/0000-0003-4048-6925				Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2001, AM J PHYSIOL-CELL PH, V280, pC659, DOI 10.1152/ajpcell.2001.280.3.C659; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; CHEN F, 1995, CANCER RES, V55, P4804; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Gorin Y, 2005, J BIOL CHEM, V280, P39616, DOI 10.1074/jbc.M502412200; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Kanno H, 1997, CANCER RES, V57, P1035; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Kim NH, 2006, AM J PHYSIOL-RENAL, V290, pF741, DOI 10.1152/ajprenal.00313.2005; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zimmer M, 2004, MOL CANCER RES, V2, P89	31	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8019	8026		10.1074/jbc.M611569200	http://dx.doi.org/10.1074/jbc.M611569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17200123	hybrid			2022-12-25	WOS:000245081000033
J	Wallis, R; Dodds, AW; Mitchell, DA; Sim, RB; Reid, KBM; Schwaeble, WJ				Wallis, Russell; Dodds, Alister W.; Mitchell, Daniel A.; Sim, Robert B.; Reid, Kenneth B. M.; Schwaeble, Wilhelm J.			Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; SURFACE-PLASMON RESONANCE; SERINE-PROTEASE; INTERNAL THIOESTER; SUBSTRATE SPECIFICITIES; CLASSICAL PATHWAY; COMPONENT C4; SYSTEM; RECOGNITION; COMPLEXES	Activation of component C3 is central to the pathways of complement and leads directly to neutralization of pathogens and stimulation of adaptive immune responses. The convertases that catalyze this reaction assemble from fragments of complement components via multistep reactions. In the lectin pathway, mannose-binding lectin (MBL) and ficolins bind to pathogens and activate MBL-associated serine protease-2 (MASP-2). MASP-2 cleaves C4 releasing C4a and generating C4b, which attaches covalently to the pathogen surface upon exposure of its reactive thioester. C2 binds to C4b and is also cleaved by MASP-2 to form the C3 convertase (C4b2a). To understand how this complex process is coordinated, we have analyzed the interactions between MASP-2, C4, C2, and their activation fragments and have compared MASP-2-catalyzed cleavage of C4b2 and C2. The data show that C2 binds tightly to C4b but not to C4, implying that C4 and C2 do not circulate as preformed complexes but that C2 is recruited only after prior activation of C4. Following cleavage of C4, C4b still binds to MASP-2 (K-D similar to 0.6 mu m) and dissociates relatively slowly (k(off) similar to 0.06 s(-1)) compared with the half-life of the thioester (<= 0.7 s) (Sepp, A., Dodds, A. W., Anderson, M. J., Campbell, R. D., Willis, A. C., and Law, S. K. (1993) Protein Sci. 2, 706 716). We propose that the C4b-MASP-2 interaction favors attachment of C4b near to the activating MBL.MASP complex on the bacterial surface so that, following recruitment of C2, the proximity of enzyme and substrate (C4b2) combined with more favorable reaction kinetics drive the formation of the C3 convertase, promoting complement activation.	Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; Univ Leicester, Dept Biochem, Leicester, Leics, England; Univ Oxford, Dept Biochem, Immunochem Unit, MRC, Oxford OX1 3QU, England; Warwick Med Sch, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England	University of Leicester; University of Leicester; University of Oxford; University of Warwick	Wallis, R (corresponding author), Univ Leicester, Dept Infect Immun & Inflammat, Med Sci Bldg,Univ Rd, Leicester, Leics, England.	rw73@le.ac.uk	Mitchell, Daniel A/A-6580-2009; Sim, Bob/A-1354-2008	Mitchell, Daniel A/0000-0003-0936-6212; Sim, Bob/0000-0002-2855-7455; Schwaeble, Wilhelm/0000-0001-8927-0864; Wallis, Russell/0000-0002-8705-5295; Dodds, Alister William/0000-0003-3396-1257	Wellcome Trust [077400, 060574] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Chen CB, 2004, J BIOL CHEM, V279, P26058, DOI 10.1074/jbc.M401318200; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; DODDS AW, 1990, BIOCHEM J, V265, P495, DOI 10.1042/bj2650495; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Harmat V, 2004, J MOL BIOL, V342, P1533, DOI 10.1016/j.jmb.2004.07.014; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4479, DOI 10.1021/bi00560a015; KERR MA, 1980, BIOCHEM J, V189, P173, DOI 10.1042/bj1890173; Laich A, 2001, BBA-PROTEIN STRUCT M, V1544, P96, DOI 10.1016/S0167-4838(00)00208-9; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Law SKA, 1997, PROTEIN SCI, V6, P263; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Minton AP, 1997, PROG COLL POL SCI S, V107, P11; Moller-Kristensen M, 2003, SCAND J IMMUNOL, V57, P556, DOI 10.1046/j.1365-3083.2003.01270.x; PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Rossi V, 2005, J BIOL CHEM, V280, P41811, DOI 10.1074/jbc.M503813200; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; Schwaeble W, 2002, IMMUNOBIOLOGY, V205, P455, DOI 10.1078/0171-2985-00146; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Whaley K, 1997, SEMIN LIVER DIS, V17, P297, DOI 10.1055/s-2007-1007206; Yu HN, 2005, BBA-GEN SUBJECTS, V1726, P168, DOI 10.1016/j.bbagen.2005.08.003; ZICCARDI RJ, 1981, J IMMUNOL, V126, P1769; Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342	35	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7844	7851		10.1074/jbc.M606326200	http://dx.doi.org/10.1074/jbc.M606326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17204478	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000245081000013
J	Alexander, RT; Malevanets, A; Durkan, AM; Kocinsky, HS; Aronson, PS; Orlowski, J; Grinstein, S				Alexander, R. Todd; Malevanets, Anatoly; Durkan, Anne M.; Kocinsky, Hetal S.; Aronson, Peter S.; Orlowski, John; Grinstein, Sergio			Membrane curvature alters the activation kinetics of the epithelial Na+/H+ exchanger, NHE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; HCO3-ABSORPTION; PH; AMILORIDE; ISOFORMS; CELLS; INHIBITION; MECHANISM; PHOSPHORYLATION; DEPENDENCE	The epithelial Na+/H+ exchanger, NHE3, was found to activate slowly following an acute cytosolic acidification. The sigmoidal course of activation could not be explained by the conventional two-state model, which postulates that activation results from protonation of an allosteric modifier site. Instead, mathematical modeling predicted the existence of three distinct states of the exchanger: two different inactive states plus an active form. The interconversion of the inactive states is rapid and dependent on pH, whereas the conversion between the second inactive state and the active conformation is slow and pH-independent but subject to regulation by other stimuli. Accordingly, exposure of epithelial cells to hypoosmolar solutions activated NHE3 by accelerating this latter transition. The number of surface-exposed exchangers and their association with the cytoskeleton were not affected by hypoosmolarity. Instead, NHE3 is activated by the membrane deformation, a result of cell swelling. This was suggested by the stimulatory effects of amphiphiles that induce a comparable positive (convex) deformation of the membrane. We conclude that NHE3 exists in multiple states and that different physiological parameters control the transitions between them.	Hosp Sick Children, Program Cell Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Yale University; Yale University; Yale University; McGill University; University of Toronto	Grinstein, S (corresponding author), Hosp Sick Children, Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca	Durkan, Anne/AAP-4205-2020; Alexander, R. Todd/G-1373-2012	Durkan, Anne/0000-0003-3739-2290; Orlowski, John/0000-0001-7371-175X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK017433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander RT, 2005, P NATL ACAD SCI USA, V102, P12253, DOI 10.1073/pnas.0409197102; Ambuhl P, 1998, J CLIN INVEST, V101, P170, DOI 10.1172/JCI62; AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Di Sole F, 2004, J BIOL CHEM, V279, P2962, DOI 10.1074/jbc.M306838200; Fuster D, 2004, P NATL ACAD SCI USA, V101, P10482, DOI 10.1073/pnas.0403930101; Garnovskaya MN, 2003, J BIOL CHEM, V278, P16908, DOI 10.1074/jbc.M209883200; Good DW, 2000, AM J PHYSIOL-CELL PH, V279, pC1443, DOI 10.1152/ajpcell.2000.279.5.C1443; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1985, FED PROC, V44, P2508; Hayashi H, 2004, J GEN PHYSIOL, V123, P491, DOI 10.1085/jgp.200308979; Hayashi H, 2002, J BIOL CHEM, V277, P11090, DOI 10.1074/jbc.M111868200; Hwang TC, 2003, BIOCHEMISTRY-US, V42, P13646, DOI 10.1021/bi034887y; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kocinsky HS, 2005, AM J PHYSIOL-RENAL, V289, pF249, DOI 10.1152/ajprenal.00082.2004; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lacroix J, 2004, EMBO REP, V5, P91, DOI 10.1038/sj.embor.7400035; Lee EM, 2003, AM J PHYSIOL-RENAL, V285, pF748, DOI 10.1152/ajprenal.00442.2002; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lorenz JN, 1999, AM J PHYSIOL-RENAL, V277, pF447, DOI 10.1152/ajprenal.1999.277.3.F447; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; OTSU K, 1989, P NATL ACAD SCI USA, V86, P4818, DOI 10.1073/pnas.86.13.4818; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; Ritter M, 2001, CELL PHYSIOL BIOCHEM, V11, P1, DOI 10.1159/000047787; SHEETZ MP, 1976, J CELL BIOL, V70, P247, DOI 10.1083/jcb.70.1.247; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; Turner JR, 2001, AM J PHYSIOL-CELL PH, V281, pC1533, DOI 10.1152/ajpcell.2001.281.5.C1533; VIGNE P, 1984, EMBO J, V3, P1865, DOI 10.1002/j.1460-2075.1984.tb02060.x; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 2003, J BIOL CHEM, V278, P43580, DOI 10.1074/jbc.M306690200; Watts BA, 1999, J CLIN INVEST, V104, P1593, DOI 10.1172/JCI7332; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101	42	29	29	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7376	7384		10.1074/jbc.M608557200	http://dx.doi.org/10.1074/jbc.M608557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218318	Green Published, hybrid			2022-12-25	WOS:000245080900049
J	Okino, N; Ito, M				Okino, Nozomu; Ito, Makoto			Ceramidase enhances phospholipase C-induced hemolysis by Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL CERAMIDASE; MOLECULAR-CLONING; BACTERIAL PHOSPHOLIPASES; ALKALINE CERAMIDASE; GENE; VIRULENCE; EXPRESSION; ERYTHROCYTES; LOCALIZATION; PURIFICATION	We previously reported the purification, molecular cloning, and characterization of a neutral ceramidase from Pseudomonas aeruginosa strain AN17 (Okino, N., Tani, M., Imayama, S., and Ito, M. (1998) J. Biol. Chem. 273,14368-14373; Okino, N., Ichinose, S., Omori, A., Imayama, S., Nakamura, T., and Ito, M. (1999) J. Biol. Chem. 274,36616-36622). Interestingly, the gene encoding the enzyme is adjacent to that encoding hemolytic phospholipase C (plcH) in the genome of Pseudomonas aeruginosa, which is a well known pathogen for opportunistic infections. We report here that simultaneous production of PlcH and ceramidase was induced by several lipids and PlcH-induced hemolysis was significantly enhanced by the action of the ceramidase. When the strain was cultured with sphingomyelin or phosphatidylcholine, production of both enzymes drastically increased, causing the increase of hemolytic activity in the cell-free culture supernatant. Ceramide and sphingosine were also effective in promoting the production of ceramidase but not that of PlcH. Furthermore, we found that the hemolytic activity of a Bacillus cereus sphingomyelinase was significantly enhanced by addition of a recombinant Pseudomonas ceramidase. TLC analysis of the erythrocytes showed that ceramide produced from sphingomyelin by the sphingomyelinase was partly converted to sphingosine by the ceramidase. A ceramidase-null mutant strain caused much less hemolysis of sheep erythrocytes than did the wild-type strain. Sphingosine was detected in the erythrocytes co-cultured with the wild-type strain but not the mutant strain. Finally, we found that the enhancement of PlcH-induced hemolysis by the ceramidase occurred in not only sheep but also human erythrocytes. These results may indicate that the ceramidase enhances the PlcH-induced cytotoxicity and provide new insights into the role of sphingolipid-degrading enzymes in the pathogenicity of P. aeruginosa.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Okino, N (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1,Hakozaki, Fukuoka 8128581, Japan.	nokino@agr.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818				Acharya U, 2004, P NATL ACAD SCI USA, V101, P1922, DOI 10.1073/pnas.0308693100; Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Barker AP, 2004, MOL MICROBIOL, V53, P1089, DOI 10.1111/j.1365-2958.2004.04189.x; BODEY GP, 1983, REV INFECT DIS, V5, P279; CHIN JC, 1988, J GEN MICROBIOL, V134, P2567; COLLEY CM, 1973, BIOCHIM BIOPHYS ACTA, V307, P74, DOI 10.1016/0005-2736(73)90026-6; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; FUJITA K, 1988, INFECT IMMUN, V56, P1385, DOI 10.1128/IAI.56.5.1385-1387.1988; Garcia-Sanchez A, 2004, VET MICROBIOL, V99, P67, DOI 10.1016/j.vetmic.2003.10.028; GATT S, 1963, J BIOL CHEM, V238, P3131; He XX, 2002, ANAL BIOCHEM, V306, P115, DOI 10.1006/abio.2002.5686; HOLLSING AE, 1987, J CLIN MICROBIOL, V25, P1868, DOI 10.1128/JCM.25.10.1868-1874.1987; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; IGISU H, 1988, LIPIDS, V23, P345, DOI 10.1007/BF02537346; ITO M, 2003, CERAMIDE SIGNALING, P41; Komori H, 1999, J BIOL CHEM, V274, P8981, DOI 10.1074/jbc.274.13.8981; Komori H, 2000, FEBS LETT, V475, P247, DOI 10.1016/S0014-5793(00)01696-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MEYERS DJ, 1992, TOXICON, V30, P161, DOI 10.1016/0041-0101(92)90469-L; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Monjusho H, 2003, BIOCHEM J, V376, P473, DOI 10.1042/BJ20030652; Nakagawa T, 2005, J LIPID RES, V46, P1103, DOI 10.1194/jlr.M400516-JLR200; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; OSTROFF RM, 1990, J BACTERIOL, V172, P5915, DOI 10.1128/jb.172.10.5915-5923.1990; OSTROFF RM, 1989, INFECT IMMUN, V57, P1369, DOI 10.1128/IAI.57.5.1369-1373.1989; PRITCHARD AE, 1986, J BACTERIOL, V167, P291, DOI 10.1128/jb.167.1.291-298.1986; Rahme LG, 2000, P NATL ACAD SCI USA, V97, P8815, DOI 10.1073/pnas.97.16.8815; Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; Stonehouse MJ, 2002, MOL MICROBIOL, V46, P661, DOI 10.1046/j.1365-2958.2002.03194.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TAKETOMI T, 1970, J BIOCHEM-TOKYO, V68, P475, DOI 10.1093/oxfordjournals.jbchem.a129378; Tani M, 2005, J BIOL CHEM, V280, P36592, DOI 10.1074/jbc.M506827200; Tani M, 2004, J BIOL CHEM, V279, P29351, DOI 10.1074/jbc.M404012200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; VASIL ML, 1986, J PEDIATR-US, V108, P800, DOI 10.1016/S0022-3476(86)80748-X; VASIL ML, 1982, J BACTERIOL, V152, P431; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	48	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6021	6030		10.1074/jbc.M603088200	http://dx.doi.org/10.1074/jbc.M603088200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202150	hybrid			2022-12-25	WOS:000244867200007
J	Ye, YZ; Quijano, C; Robinson, KM; Ricart, KC; Strayer, AL; Sahawneh, MA; Shacka, JJ; Kirk, M; Barnes, S; Accavitti-Loper, MA; Radi, R; Beckman, JS; Estevez, AG				Ye, Yaozu; Quijano, Celia; Robinson, Kristine M.; Ricart, Karina C.; Strayer, Amy L.; Sahawneh, Mary Anne; Shacka, John J.; Kirk, Marion; Barnes, Stephen; Accavitti-Loper, Mary Ann; Radi, Rafael; Beckman, Joseph S.; Estevez, Alvaro G.			Prevention of peroxynitrite-induced apoptosis of motor neurons and PC12 cells by tyrosine-containing peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NERVE GROWTH-FACTOR; MANGANESE-SUPEROXIDE-DISMUTASE; CARBONATE RADICAL-ANION; HEAT-SHOCK PROTEINS; NITRIC-OXIDE; IN-VIVO; OXIDATIVE STRESS; DNA-DAMAGE; NITROTYROSINE RESIDUES; CATALYZED OXIDATION	Although peroxynitrite stimulates apoptosis in many cell types, whether peroxynitrite acts directly as an oxidant or the induction of apoptosis is because of the radicals derived from peroxynitrite decomposition remains unknown. Before undergoing apoptosis because of trophic factor deprivation, primary motor neuron cultures become immunoreactive for nitrotyrosine. We show here using tyrosine-containing peptides that free radical processes mediated by peroxynitrite decomposition products were required for triggering apoptosis in primary motor neurons and in PC12 cells cultures. The same concentrations of tyrosine-containing peptides required to prevent the nitration and apoptosis of motor neurons induced by trophic factor deprivation and of PC12 cells induced by peroxynitrite also prevented peroxynitrite-mediated nitration, of motor neurons, brain homogenates, and PC12 cells. The heat shock protein 90 chaperone was nitrated in both trophic factor-deprived motor neurons and PC12 cells incubated with peroxynitrite. Tyrosine-containing peptides did not affect the induction of PC12 cell death by hydrogen peroxide. Tyrosine-containing peptides should protect by scavenging peroxynitrite-derived radicals and not by direct reactions with peroxynitrite as they neither increase the rate of peroxynitrite decomposition nor decrease the bimolecular peroxynitrite-mediated oxidation of thiols. These results reveal an important role for free radical-mediated nitration of tyrosine residues, in apoptosis induced by endogenously produced and exogenously added peroxynitrite; moreover, tyrosine-containing peptides may offer a novel strategy to neutralize the toxic effects of peroxynitrite.	Burke Med Res Inst, White Plains, NY 10605 USA; Univ Republica, Dept Bioquim, Fac Med, Montevideo, Uruguay; Univ Republica, Ctr Free Rad & Biomed Res, Fac Med, Montevideo, Uruguay; Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Mass Spectrometry Facil, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med Genet & Translat Med, Birmingham, AL 35294 USA; Cornell Univ, Dept Neurol & Neurosci, Weill Med Coll, New York, NY 10021 USA	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Oregon State University; Oregon State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cornell University	Estevez, AG (corresponding author), Burke Med Res Inst, White Plains, NY 10605 USA.	age2002@med.cornell.edu			NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT002034] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487, S10RR013795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036761] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT02034] Funding Source: Medline; NCI NIH HHS [P30 CA13148] Funding Source: Medline; NCRR NIH HHS [RR06487, RR13795] Funding Source: Medline; NIEHS NIH HHS [ES00040] Funding Source: Medline; NINDS NIH HHS [NS36761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez B, 2001, FREE RADICAL RES, V34, P467, DOI 10.1080/10715760100300411; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Batulan Z, 2006, NEUROBIOL DIS, V24, P213, DOI 10.1016/j.nbd.2006.06.017; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Cappelletti G, 2003, EXP CELL RES, V288, P9, DOI 10.1016/S0014-4827(03)00209-X; Chang W, 2002, J BIOL CHEM, V277, P30690, DOI 10.1074/jbc.M204930200; COMELLA JX, 1994, J NEUROSCI, V14, P2674; Crow JP, 1996, METHOD ENZYMOL, V269, P185; Crow JP, 1998, AM HEART MONOGR S, P315; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crow JP, 1997, J NEUROCHEM, V69, P1945; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Didelot C, 2006, HANDB EXP PHARM, V172, P171; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Espey MG, 2002, P NATL ACAD SCI USA, V99, P3481, DOI 10.1073/pnas.062604199; Estevez AG, 1998, J NEUROSCI, V18, P923; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Estevez AG, 2000, FREE RADICAL BIO MED, V28, P437, DOI 10.1016/S0891-5849(99)00261-0; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 2002, METHOD ENZYMOL, V349, P23, DOI 10.1016/S0076-6879(02)49318-4; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; Ferrer-Sueta G, 2006, FREE RADICAL BIO MED, V41, P503, DOI 10.1016/j.freeradbiomed.2006.04.028; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Gow AJ, 1998, METH MOL B, V100, P291; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; GROVES JT, 1995, J AM CHEM SOC, V117, P9578, DOI 10.1021/ja00142a032; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Johnson BD, 2000, J BIOL CHEM, V275, P32499, DOI 10.1074/jbc.M005195200; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.3.CO;2-R; Martin LJ, 2005, J NEUROSCI, V25, P6449, DOI 10.1523/JNEUROSCI.0911-05.2005; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2002, NEUROCHEM RES, V27, P1093, DOI 10.1023/A:1020961006216; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; Nauser T, 2002, J PHYS CHEM A, V106, P4084, DOI 10.1021/jp025518z; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Peluffo H, 2004, J NEUROCHEM, V89, P602, DOI 10.1046/j.1471-4159.2004.02363.x; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Quijano C, 2005, FREE RADICAL BIO MED, V39, P728, DOI 10.1016/j.freeradbiomed.2005.04.014; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 1996, METHOD ENZYMOL, V269, P354; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ramezanian MS, 1996, CHEM RES TOXICOL, V9, P232, DOI 10.1021/tx950135w; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Robinson KM, 2005, METHOD ENZYMOL, V396, P207, DOI 10.1016/S0076-6879(05)96019-9; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Ross A. B., 1998, NDRL NIST SOLUTION K; Sacksteder CA, 2006, BIOCHEMISTRY-US, V45, P8009, DOI 10.1021/bi060474w; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Spear N, 1997, J NEUROCHEM, V69, P53; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Spear Nathan, 1997, P32; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Ugolini G, 2003, J NEUROSCI, V23, P8526; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Viera L, 1999, METHOD ENZYMOL, V301, P373; Viera L., 1999, METHODS MOL MED SEPT, P159; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; YAN Q, 1988, J NEUROSCI, V8, P3481; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang YM, 2004, EUR J NEUROSCI, V20, P1727, DOI 10.1111/j.1460-9568.2004.03651.x	107	51	52	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6324	6337		10.1074/jbc.M610800200	http://dx.doi.org/10.1074/jbc.M610800200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200124	hybrid			2022-12-25	WOS:000244867200039
J	Tohami, T; Drucker, L; Shapiro, H; Radnay, J; Lishner, M				Tohami, Tali; Drucker, Liat; Shapiro, Hava; Radnay, Judith; Lishner, Michael			Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential	FASEB JOURNAL			English	Article						CD82; CD81; CAG; RPMI 8226	MICRODOMAINS; EXPRESSION; PROTEINS; CD82; ADHESION; GROWTH; AKT; CD9; METASTASIS; ACTIVATION	Cellular interactions with microenvironmental components are critical in multiple myeloma (MM) and impede effective disease treatment. Membranal-embedded tetraspanins, associated with metastasis suppression, are underexpressed in MM. We aimed to investigate the consequences of CD81/CD82 tetraspanins over-expression in MM cell lines. CAG and RPMI 8226 were transfected with pEGFP-N1/C1 fusion vectors of CD81/CD82. Employing flow cytometry, immunocytochemistry, and activity assays we assessed transfected cells for: morphology, survival, death, caspases, cell cycle, proliferation, oxidative stress, adhesion, motility and invasion. Overexpressed CD81/CD82 pEGFP-N1 vectors reduced survival without elevation of pre-G1 or AnnexinV+/7AAD- and independently of caspases. Decreased Ki67 and elevated intracellular glutathione were detected. No perturbations in cell cycle distribution were observed. The pEGFP-C1 vectors of CD81/CD82 caused reduction of MM cell adherence with/without fibronectin, insulin-like growth factor (IGF)-I, and matrigel. They also reduced cell motility and attenuated invasion potential, expressed by reduced secreted MMP-9 activity. These novel findings delineate the significance of CD81/CD82 expression to MM cell survival and their negative effects on cell adhesion, motility, and invasion thus, supporting their role as tumor metastasis suppressors.	Meir Med Ctr, Oncogenet Lab, IL-44281 Kefar Sava, Israel; Meir Med Ctr, Hematol Lab, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Meir Med Ctr, Dept Internal Med, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Kfar Saba, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Sackler Fac Med, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Drucker, L (corresponding author), Meir Med Ctr, Oncogenet Lab, IL-44281 Kefar Sava, Israel.	druckerl@clalit.org.il						Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Boucheix C., 2001, EXPERT REV MOL MED, V2001, P1; Bruno B, 2005, LEUKEMIA, V19, P1729, DOI 10.1038/sj.leu.2403905; Cacciotti P, 2005, CANCER RES, V65, P5256, DOI 10.1158/0008-5472.CAN-05-0127; Csordas A, 2006, EXP CELL RES, V312, P1753, DOI 10.1016/j.yexcr.2006.02.005; Delaguillaumie A, 2004, J CELL SCI, V117, P5269, DOI 10.1242/jcs.01380; Drucker L, 2006, CARCINOGENESIS, V27, P197, DOI 10.1093/carcin/bgi209; Epstein Joshua, 2003, Hematol J, V4, P310, DOI 10.1038/sj.thj.6200313; Guo XZ, 2005, ONCOL REP, V14, P59; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hong IK, 2005, EXP MOL MED, V37, P230, DOI 10.1038/emm.2005.31; Kanavaros P, 2000, ANTICANCER RES, V20, P4619; Kelly T, 2000, LEUKEMIA LYMPHOMA, V37, P273, DOI 10.3109/10428190009089428; Mazzocca A, 2005, J BIOL CHEM, V280, P11329, DOI 10.1074/jbc.M410161200; OCONNOR JE, 1988, CYTOMETRY, V9, P529, DOI 10.1002/cyto.990090604; Oliver L, 2005, DRUG RESIST UPDATE, V8, P163, DOI 10.1016/j.drup.2005.05.001; Ono M, 1999, CANCER RES, V59, P2335; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Tai YT, 2003, CANCER RES, V63, P5850; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; Tohami T, 2004, TISSUE ANTIGENS, V64, P235, DOI 10.1111/j.1399-0039.2004.00271.x; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Wright MD, 2004, TISSUE ANTIGENS, V64, P533, DOI 10.1111/j.1399-0039.2004.00321.x; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	30	45	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					691	699		10.1096/fj.06-6610com	http://dx.doi.org/10.1096/fj.06-6610com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17210782				2022-12-25	WOS:000244686400008
J	Mulder, WJM; van der Schaft, DWJ; Hautvast, PAI; Strijkers, GJ; Koning, GA; Storm, G; Mayo, KH; Griffioen, AW; Nicolay, K				Mulder, Willem J. M.; van der Schaft, Daisy W. J.; Hautvast, Petra A. I.; Strijkers, Gustav J.; Koning, Gerben A.; Storm, Gert; Mayo, Kevin H.; Griffioen, Aijan W.; Nicolay, Klaas			Early in vivo assessment of angiostatic therapy efficacy by molecular MRI	FASEB JOURNAL			English	Article						molecular imaging; tumor angiogenesis; a nu beta 3-integrin	TUMOR-GROWTH; ANGIOGENESIS INHIBITORS; 1.5 TESLA; ENDOSTATIN; ANGINEX; NANOPARTICLE; MICROSCOPY; PEPTIDE; TARGETS; CANCER	Noninvasive diagnostic imaging methods to establish the efficacy of angiostatic therapies are becoming increasingly important with the first Food and Drug Administration approvals of such agents. Magnetic resonance molecular imaging is an imaging technique that allows the visualization of pathological processes in vivo with a better spatial resolution as compared with nuclear methods, such as photon emission tomography and single photon emission computed tomography. In this study, we used alpha v beta 3 targeted bimodal liposomes to quantitate angiogenesis in a tumor mouse model with magnetic resonance imaging (MRI) and to evaluate the therapeutic efficacy of the angiogenesis inhibitors anginex and endostatin. The MRI findings were validated with fluorescence microscopy and showed a very good correlation with the microvessel density. In conclusion, this study provides evidence that molecular MRI can be used to noninvasively measure the efficacy of angiogenesis inhibitors during the course of therapy.	Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; Maastricht Univ, Angiogenesis Lab, Res Inst Growth & Dev, Dept Pathol Internal Med, Maastricht, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands; Delft Univ Technol, Dept Radiat Radioisotopes & Reactors, Fac Sci Appl, Delft, Netherlands; Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA	Eindhoven University of Technology; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Delft University of Technology; Utrecht University; University of Minnesota System; University of Minnesota Twin Cities	Mulder, WJM (corresponding author), Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, POB 513, NL-5600 MB Eindhoven, Netherlands.	w.j.m.mulder@tue.nl	Nicolay, Klaas/F-4192-2010; Storm, Gerrit/O-8696-2016; Mulder, Willem J.M./B-7232-2009; Koning, Gerben A/K-2326-2012; Strijkers, Gustav J/H-3158-2011	Mulder, Willem J.M./0000-0001-8665-3878; Koning, Gerben A/0000-0003-3090-2403; Strijkers, Gustav/0000-0001-6700-5058; Nicolay, Klaas/0000-0002-4179-616X				Abdollahi A, 2005, DRUG RESIST UPDATE, V8, P59, DOI 10.1016/j.drup.2005.03.001; Beliveau R, 2002, CLIN CANCER RES, V8, P1242; Benezra R, 2004, CANCER CELL, V5, P205, DOI 10.1016/S1535-6108(04)00057-1; Dafni H, 2002, CANCER RES, V62, P6731; de Lussanet QG, 2004, EUR J CANCER, V40, P1262, DOI 10.1016/j.ejca.2004.01.020; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 2001, BIOCHEM J, V354, P233, DOI 10.1042/0264-6021:3540233; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kracht LW, 2003, EUR J NUCL MED MOL I, V30, P868, DOI 10.1007/s00259-003-1148-7; MATTHEWS K, 2006, NAT CLIN PRACT ONCOL, V3, P119; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Mulder WJM, 2004, BIOCONJUGATE CHEM, V15, P799, DOI 10.1021/bc049949r; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; ROCCARO AM, 2005, ALLERGY, V4, P27; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; van der Schaft DWJ, 2002, FASEB J, V16, P1991, DOI 10.1096/fj.02-0509fje; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Winter PM, 2003, CANCER RES, V63, P5838; Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241	25	73	77	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					378	383		10.1096/fj.06-6791com	http://dx.doi.org/10.1096/fj.06-6791com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202248				2022-12-25	WOS:000244686300011
J	Gemmell, NJ; Slate, J				Gemmell, Neil J.; Slate, Jon			Heterozygote Advantage for Fecundity	PLOS ONE			English	Article								Heterozygote advantage, or overdominance, remains a popular and persuasive explanation for the maintenance of genetic variation in natural populations in the face of selection. However, despite being first proposed more than 80 years ago, there remain few examples that fit the criteria for heterozygote advantage, all of which are associated with disease resistance and are maintained only in the presence of disease or other gene-by-environment interaction. Here we report five new examples of heterozygote advantage, based around polymorphisms in the BMP15 and GDF9 genes that affect female fecundity in domesticated sheep and are not reliant on disease for their maintenance. Five separate mutations in these members of the transforming growth factor beta (TGF beta) superfamily give phenotypes with fitness differentials characteristic of heterozygous advantage. In each case, one copy of the mutant allele increases ovulation rate, and ultimately litter size per ewe lambing, relative to the wildtype. However, homozygous ewes inheriting mutant alleles from both parents have impaired oocyte development and maturation, which results in small undeveloped ovaries and infertility. Using data collected over many years on ovulation rates, litter size, and lambing rates, we have calculated the equilibrium solution for each of these polymorphisms using standard population genetic theory. The predicted equilibrium frequencies obtained for these mutant alleles range from 0.11 to 0.23, which are amongst the highest yet reported for a polymorphism maintained by heterozygote advantage. These are amongst the most frequent and compelling examples of heterozygote advantage yet described and the first documented examples of heterozygote advantage that are not reliant on a disease interaction for their maintenance.	[Gemmell, Neil J.] Univ Canterbury, Sch Biol Sci, Christchurch 1, New Zealand; [Slate, Jon] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Canterbury; University of Sheffield	Gemmell, NJ (corresponding author), Univ Canterbury, Sch Biol Sci, Christchurch 1, New Zealand.	neil.gemmell@canterbury.ac.nz	Gemmell, Neil J/C-6774-2009; Slate, Jon/D-2925-2012	Gemmell, Neil J/0000-0003-0671-3637; Slate, Jon/0000-0003-3356-5123	University of Canterbury Erskine	University of Canterbury Erskine	This collaboration was facilitated by a University of Canterbury Erskine Grant to J.S.	ALLISON AC, 1954, BRIT MED J, V1, P290, DOI 10.1136/bmj.1.4857.290; Amer PR, 1999, LIVEST PROD SCI, V58, P75, DOI 10.1016/S0301-6226(98)00192-4; Clutton-Brock T.H., 2004, SOAY SHEEP DYNAMICS; Davis GH, 2005, GENET SEL EVOL, V37, pS11, DOI 10.1051/gse:2004026; DAVIS GH, 1992, LIVESTOCK PRODUCTION, V34, P83; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Fisher R.A., 1930, GENETICAL THEORY NAT; Fisher RA., 1922, P ROY SOC EDINB B, V42, P321, DOI [10.1017/S0370164600023993, DOI 10.1007/BF02459576]; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Galloway SM, 2002, MOL CELL ENDOCRINOL, V191, P15, DOI 10.1016/S0303-7207(02)00047-3; Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68; Hanrahan J. P., 1982, 2nd World Congress on Genetics applied to Livestock Production, 4th-8th October 1982. 5. Plenary sessions, P294; Hanrahan JP, 2004, BIOL REPROD, V70, P900, DOI 10.1095/biolreprod.103.023093; Hedrick P. W., 2011, GENETICS POPULATIONS; Kreitman M, 2004, TRENDS GENET, V20, P300, DOI 10.1016/j.tig.2004.05.002; Lassoued N, 2004, SMALL RUMINANT RES, V52, P117, DOI 10.1016/S0921-4488(03)00250-5; O'Callaghan D, 1999, ANIM SCI, V68, P299, DOI 10.1017/S1357729800050311; ROBERTSON A, 1962, GENETICS, V47, P1291; Robinson JJ, 1996, ANIM REPROD SCI, V42, P25, DOI 10.1016/0378-4320(96)01526-6; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; Williams TN, 2005, NAT GENET, V37, P1253, DOI 10.1038/ng1660	22	60	63	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e125	10.1371/journal.pone.0000125	http://dx.doi.org/10.1371/journal.pone.0000125			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205129	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000207443700019
J	Demichelis, F; Fall, K; Perner, S; Andren, O; Schmidt, F; Setlur, SR; Hoshida, Y; Mosquera, JM; Pawitan, Y; Lee, C; Adami, HO; Mucci, LA; Kantoff, PW; Andersson, SO; Chinnaiyan, AM; Johansson, JE; Rubin, MA				Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S. R.; Hoshida, Y.; Mosquera, J-M; Pawitan, Y.; Lee, C.; Adami, H-O; Mucci, L. A.; Kantoff, P. W.; Andersson, S-O; Chinnaiyan, A. M.; Johansson, J-E; Rubin, M. A.			TMPRSS2 : ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort	ONCOGENE			English	Article						prostate cancer; cancer-specific death; prognosis; TMPRSS2 : ETS; ERG	RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; NATURAL-HISTORY; SURVIVAL; SWEDEN; DEATH	The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may de. ne risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio = 2.7, P < 0.01, 95% confidence interval = 1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2: ERG fusion (P < 0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; ITCirst, SRA, Bioinformat Grp, Trenton, NJ USA; Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; Univ Hosp Ulm, Inst Pathol, Ulm, Germany; Orebro Univ Hosp, Dept Urol, Orebro, Sweden; Dana Farber Canc Inst, Boston, MA 02115 USA; Broad Inst MIT & Harvard, Cambridge, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Univ Michigan, Sch Med, Dept Urol AMC, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Pathol AMC, Ann Arbor, MI USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; SRA International; Karolinska Institutet; Ulm University; Orebro University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rubin, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 221 Longwood Ave,EBRC 442A, Boston, MA 02115 USA.	marubin@partners.org	Jackson, Benjamin L/C-4297-2012; Fall, Katja/AAE-1876-2021; Fall, Katja/A-9186-2012; Demichelis, Francesca/J-9829-2016; Hoshida, Yujin/R-7513-2019	Fall, Katja/0000-0002-3649-2639; Demichelis, Francesca/0000-0002-8266-8631; Rubin, Mark/0000-0002-8321-9950; Kantoff, Philip/0000-0001-7275-0597	NATIONAL CANCER INSTITUTE [U01CA113913, P50CA090381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021404] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090381, UO1CA113913] Funding Source: Medline; NIA NIH HHS [R01AG21404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andren O, 2006, J UROLOGY, V175, P1337, DOI 10.1016/S0022-5347(05)00734-2; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Carver BS, 2006, J UROLOGY, V176, P564, DOI 10.1016/j.juro.2006.03.093; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; PERNER S, AM J SURG PATHOL; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Porter CR, 2006, J UROLOGY, V176, P569, DOI 10.1016/j.juro.2006.03.094; R Development Core Team, 2006, R LANG ENV STAT COMP; Rubin MA, 2005, CANCER EPIDEM BIOMAR, V14, P1424, DOI 10.1158/1055-9965.EPI-04-0801; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Ward JF, 2003, J UROLOGY, V170, P1872, DOI 10.1097/01.ju.0000091876.13656.2e; Warlick C, 2006, JNCI-J NATL CANCER I, V98, P355, DOI 10.1093/jnci/djj072	21	473	525	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4596	4599		10.1038/sj.onc.1210237	http://dx.doi.org/10.1038/sj.onc.1210237			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237811				2022-12-25	WOS:000247836100014
J	Schild-Poulter, C; Shih, A; Tantin, D; Yarymowich, NC; Soubeyrand, S; Sharp, PA; Hache, RJG				Schild-Poulter, C.; Shih, A.; Tantin, D.; Yarymowich, N. C.; Soubeyrand, S.; Sharp, P. A.; Hache, R. J. G.			DNA-PK phosphorylation sites on Oct-1 promote cell survival following DNA damage	ONCOGENE			English	Article						Ku; DNA-dependent protein kinase; Oct-1; DNA damage; phosphorylation	DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR OCT-1; DOUBLE-STRAND BREAKS; CATALYTIC SUBUNIT; HISTONE H2B; MULTISITE PHOSPHORYLATION; IONIZING-RADIATION; DOWN-REGULATION; POU DOMAIN; IN-VITRO	Octamer transcription factor-1 ( Oct-1) has recently been shown to function as a stress sensor that promotes cell survival subsequent to DNA damage. Here, we show that the survival signal imparted by Oct-1 following exposure to ionizing radiation ( IR) is dependent upon DNA-dependent protein kinase ( DNA-PK)-dependent phosphorylation of a cluster of 13 specific ser/thr residues within the N-terminal transcriptional regulatory domain of Oct-1. Although IR treatment did not affect the recruitment of Oct-1 to the histone H2B promoter, the recruitment of RNA polymerase II, TATA-binding protein and histone H4 acetylation were strongly reduced, consistent with a decrease in Oct-1 transcriptional regulatory potential following IR exposure. Ser/Thr-Ala substitution of 13 sites present in Oct-1 transcriptional regulatory domain eliminated Oct-1 phosphorylation subsequent to IR exposure. Further, these substitutions prevented Oct-1 from rescuing the survival of IR-treated Oct-1(-/-) murine embryonic fibroblasts, providing a direct link between DNA-PK- dependent phosphorylation and the contribution of Oct-1 to cell survival. These results implicate Oct-1 as a primary effector in a DNA-PK-dependent cell survival pathway that is activated by double-stranded DNA breaks.	Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schild-Poulter, C (corresponding author), Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, 725 Parkdale Rd, Ottawa, ON K1Y 4E9, Canada.	cschild-poulter@robarts.ca; rhache@ohri.ca	Schild-Poulter, Caroline/K-4476-2013	soubeyrand, sebastien/0000-0002-9317-301X				Bailey SM, 2004, CYTOGENET GENOME RES, V104, P109, DOI 10.1159/000077474; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; EBLE MJ, 1994, INT J RADIAT BIOL, V65, P193, DOI 10.1080/09553009414550231; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Gunawardena J, 2005, P NATL ACAD SCI USA, V102, P14617, DOI 10.1073/pnas.0507322102; HECKMAN CA, 2005, ONCOGENE, V26, P26; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Loong SLE, 2004, ONCOGENE, V23, P5562, DOI 10.1038/sj.onc.1207771; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Maiti NR, 2005, J INTERF CYTOK RES, V25, P553, DOI 10.1089/jir.2005.25.553; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Soubeyrand S, 2003, CANCER RES, V63, P1198; STRONG CB, 1996, ADV ENVIRONM MANAG, V1, P1; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Takahashi S, 2001, CANCER RES, V61, P1187; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Zhao HC, 2000, CANCER RES, V60, P6276; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	54	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3980	3988		10.1038/sj.onc.1210165	http://dx.doi.org/10.1038/sj.onc.1210165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213819				2022-12-25	WOS:000247144500008
J	Fan, XD; Patera, AC; Pong-Kennedy, A; Deno, G; Gonsiorek, W; Manfra, DJ; Vassileva, G; Zeng, M; Jackson, C; Sullivan, L; Sharif-Rodriguez, W; Opdenakker, G; Van Damme, J; Hedrick, JA; Lundell, D; Lira, SA; Hipkin, RW				Fan, Xuedong; Patera, Andriani C.; Pong-Kennedy, Amy; Deno, Gregory; Gonsiorek, Waldemar; Manfra, Denise J.; Vassileva, Galya; Zeng, Ming; Jackson, Craig; Sullivan, Lee; Sharif-Rodriguez, Wanda; Opdenakker, Ghislain; Van Damme, Jo; Hedrick, Joseph A.; Lundell, Daniel; Lira, Sergio A.; Hipkin, R. William			Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULOCYTE CHEMOTACTIC PROTEIN-2; COLLAGEN-INDUCED ARTHRITIS; BIOLOGICAL CHARACTERIZATION; CHEMOKINE RECEPTOR; IL-8 RECEPTOR; MOUSE HOMOLOG; CC-CHEMOKINE; IN-VITRO; NEUTROPHIL; CLONING	Functional interleuin-8 ( IL-8) receptors ( IL-8RA and IL-8RB: CXCR1 and CXCR2, respectively) have been described in human, monkey, dog, rabbit, and guinea pig. Although three IL-8R homologues have been found in rat, only one of these, rat CXCR2, appears to be functional based on responsiveness to ligands. Similarly, CXC chemokines induce biological responses through the murine homolog of CXCR2, but the identification of functional rodent CXCR1 homologues has remained elusive. We have identified and characterized the mouse CXCR1 homologue ( mCXCR1). Murine CXCR1 shares 68 and 88% amino acid identity with its human and rat counterparts, respectively. Similar to the tissue distribution pattern of rat CXCR1, we found murine CXCR1 mRNA expression predominantly in lung, stomach, bone marrow, and leukocyte-rich tissues. In contrast to previous reports, we determined that mCXCR1 is a functional receptor. We show predominant engagement of this receptor by mouse GCP-2/CXCL6, human GCP-2, and IL-8/CXCL8 by binding, stimulation of GTP gamma S exchange, and chemotaxis of mCXCR1-transfected cells. Furthermore, murine CXCR1 is not responsive to the human CXCR2 ligands ENA-78/CXCL5, NAP-2/CXCL7, GRO-alpha, -beta, -gamma/CXCL1-3, or rat CINC-1-3. In addition, we show concomitant elevation of mCXCR1 and its proposed major ligand, GCP-2, positively correlated with paw swelling in murine collagen-induced arthritis. This report represents the first description of a functional CXCR1-like receptor in rodents.	Schering Plough Res Inst, Dept Inflammat, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Discovery Technol Dept, Kenilworth, NJ 07033 USA; Univ Louvain, Lab Mol Immunol, Rega Inst Med Res, B-3000 Louvain, Belgium; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute; KU Leuven; Icahn School of Medicine at Mount Sinai	Hipkin, RW (corresponding author), Schering Plough Res Inst, Dept Inflammat, K15 E332C-3945, Kenilworth, NJ 07033 USA.	william.hipkin@spcorp.com	Zeng, Ming/GXF-3628-2022; Vassileva, Galya/A-6807-2009; Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017	Zeng, Ming/0000-0003-2836-9240; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Van Damme, Jo/0000-0002-6707-1167				BOZIC CR, 1994, J BIOL CHEM, V269, P29355; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Campbell IK, 2000, EUR J IMMUNOL, V30, P1568, DOI 10.1002/1521-4141(200006)30:6<1568::AID-IMMU1568>3.0.CO;2-R; Catusse J, 2004, BIOCHEM PHARMACOL, V68, P1947, DOI 10.1016/j.bcp.2004.07.003; Catusse J, 2003, BIOCHEM PHARMACOL, V66, P1171, DOI 10.1016/S0006-2952(03)00459-3; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CHATHAM WW, 1993, ARTHRITIS RHEUM, V36, P51; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chou CC, 2002, BRIT J PHARMACOL, V137, P663, DOI 10.1038/sj.bjp.0704907; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Cuzzocrea S, 2003, ARTHRITIS RHEUM-US, V48, P3544, DOI 10.1002/art.11351; Cuzzocrea S, 2005, ARTHRITIS RHEUM, V52, P940, DOI 10.1002/art.20875; Dunstan CAN, 1996, J BIOL CHEM, V271, P32770, DOI 10.1074/jbc.271.51.32770; Froyen G, 1997, EUR J BIOCHEM, V243, P762, DOI 10.1111/j.1432-1033.1997.00762.x; Fu WX, 2005, CYTOKINE, V31, P9, DOI 10.1016/j.cyto.2005.02.005; Goczalik IM, 2005, J NEUROIMMUNOL, V161, P49, DOI 10.1016/j.jneuroim.2004.12.004; Godaly G, 2000, J IMMUNOL, V165, P5287, DOI 10.4049/jimmunol.165.9.5287; Gonsiorek W, 2003, J IMMUNOL METHODS, V273, P15, DOI 10.1016/S0022-1759(02)00415-5; HARADA A, 1994, GENE, V142, P297, DOI 10.1016/0378-1119(94)90278-X; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEE J, 1995, J IMMUNOL, V155, P2158; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Moepps B, 2006, MOL IMMUNOL, V43, P897, DOI 10.1016/j.molimm.2005.06.043; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nomiyama H, 2003, J INTERF CYTOK RES, V23, P37, DOI 10.1089/10799900360520432; Struyf S, 2001, BLOOD, V97, P2197, DOI 10.1182/blood.V97.8.2197; Svanborg C, 2001, ANN MED, V33, P563, DOI 10.3109/07853890109002101; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Van Coillie E, 2001, AM J PATHOL, V159, P1405, DOI 10.1016/S0002-9440(10)62527-8; Wuyts A, 2000, BIOCHEMISTRY-US, V39, P14549, DOI 10.1021/bi0011227; Wuyts A, 1999, J IMMUNOL, V163, P6155; Wuyts A, 1996, J IMMUNOL, V157, P1736; Wuyts A, 1997, BIOCHEMISTRY-US, V36, P2716, DOI 10.1021/bi961999z	36	155	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11658	11666		10.1074/jbc.M607705200	http://dx.doi.org/10.1074/jbc.M607705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17197447	hybrid			2022-12-25	WOS:000245941900007
J	DiCara, D; Rapisarda, C; Sutcliffe, JL; Violette, SM; Weinreb, PH; Hart, IR; Howard, MJ; Marshall, JF				DiCara, Danielle; Rapisarda, Chiara; Sutcliffe, Julie L.; Violette, Shelia M.; Weinreb, Paul H.; Hart, Ian R.; Howard, Mark J.; Marshall, John F.			Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE-VIRUS; TRANSFER DIFFERENCE NMR; SQUAMOUS CARCINOMA-CELLS; NEUTRALIZING ANTIBODY; EXPRESSION; RECEPTOR; PROTEIN; LOOP; RECOGNITION; BINDING	Data relating to the structural basis of ligand recognition by integrins are limited. Here we describe the physical requirements for high affinity binding of ligands to alpha v beta 6. By combining a series of structural analyses with functional testing, we show that 20-mer peptide ligands, derived from high affinity ligands of alpha v beta 6 (foot-and-mouth-disease virus, latency associated peptide), have a common structure comprising an Arg-Gly-Asp motif at the tip of a hairpin turn followed immediately by a C-terminal helix. This arrangement allows two conserved Leu/Ile residues at Asp(+1) and Asp(+4) to be presented on the outside face of the helix enabling a potential hydrophobic interaction with the alpha v beta 6 integrin, in addition to the Arg-Gly-Asp interaction. The extent of the helix determines peptide affinity for alpha v beta 6 and potency as an alpha v beta 6 antagonist. A major role of this C-terminal helix is likely to be the correct positioning of the Asp(+1) and Asp(+4) residues. These data suggest an explanation for several biological functions of alpha v beta 6 and provide a structural platform for design of alpha v beta 6 antagonists.	Univ Kent, Prot Sci Grp, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Queen Marys Coll, Tumor Biol Ctr, Canc Res UK Clin Ctr, London EC1M 6BQ, England; London Med & Dent Sch, John Vane Sci Ctr, London EC1M 6BQ, England; Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; Biogen Idec Inc, Cambridge Ctr, Cambridge, MA 02142 USA	University of Kent; Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London; University of California System; University of California Davis; Biogen	Howard, MJ (corresponding author), Univ Kent, Prot Sci Grp, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	m.j.howard@kent.ac.uk; john.marshall@cancer.org.uk	Rapisarda, Chiara/E-8028-2013	Rapisarda, Chiara/0000-0002-1867-1385; Weinreb, Paul/0000-0002-0802-0052; Howard, Mark/0000-0002-0762-2887				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Annes JP, 2002, FEBS LETT, V511, P65, DOI 10.1016/S0014-5793(01)03280-X; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Burman A, 2006, J VIROL, V80, P9798, DOI 10.1128/JVI.00577-06; Cavanagh John, 1996, P532; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; Goodman SL, 2002, J MED CHEM, V45, P1045, DOI 10.1021/jm0102598; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hakkinen L, 2004, AM J PATHOL, V164, P229, DOI 10.1016/S0002-9440(10)63113-6; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kraft S, 1999, J BIOL CHEM, V274, P1979, DOI 10.1074/jbc.274.4.1979; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meinecke R, 2001, J MED CHEM, V44, P3059, DOI 10.1021/jm0109154; Monaghan P, 2005, J GEN VIROL, V86, P2769, DOI 10.1099/vir.0.81172-0; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Ochoa WF, 2000, J GEN VIROL, V81, P1495, DOI 10.1099/0022-1317-81-6-1495; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Thomas GJ, 2006, J ORAL PATHOL MED, V35, P1, DOI 10.1111/j.1600-0714.2005.00374.x; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; VANGUNSTEREN WF, 1994, METHOD ENZYMOL, V239, P619; Verdaguer N, 1998, J VIROL, V72, P739, DOI 10.1128/JVI.72.1.739-748.1998; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Weinreb PH, 2004, J BIOL CHEM, V279, P17875, DOI 10.1074/jbc.M312103200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan JL, 2003, J MAGN RESON, V163, P270, DOI 10.1016/S1090-7807(03)00106-X	41	72	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9657	9665		10.1074/jbc.M610461200	http://dx.doi.org/10.1074/jbc.M610461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244604	hybrid			2022-12-25	WOS:000245421700039
J	Morita, T; Mayanagi, T; Yoshio, T; Sobue, K				Morita, Tsuyoshi; Mayanagi, Taira; Yoshio, Toshiyuki; Sobue, Kenji			Changes in the balance between caldesmon regulated by p21-activated kinases and the Arp2/3 complex govern podosome formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; VIRUS-TRANSFORMED FIBROBLASTS; ALDRICH-SYNDROME PROTEIN; ACTIN-FILAMENTS; N-WASP; NONERYTHROID SPECTRIN; NONMUSCLE CALDESMON; BINDING PROTEIN; ALPHA-ACTININ; F-ACTIN	Podosomes are dynamic cell adhesion structures that degrade the extracellular matrix, permitting extracellular matrix remodeling. Accumulating evidence suggests that actin and its associated proteins play a crucial role in podosome dynamics. Caldesmon is localized to the podosomes, and its expression is down-regulated in transformed and cancer cells. Here we studied the regulatory mode of caldesmon in podosome formation in Rous sarcoma virus-transformed fibroblasts. Exogenous expression analyses revealed that caldesmon represses podosome formation triggered by the N-WASP-Arp2/3 pathway. Conversely, depletion of caldesmon by RNA interference induces numerous small-sized podosomes with high dynamics. Caldesmon competes with the Arp2/3 complex for actin binding and thereby inhibits podosome formation. p21-activated kinases (PAK) 1 and 2 are also repressors of podosome formation via phosphorylation of caldesmon. Consequently, phosphorylation of caldesmon by PAK1/2 enhances this regulatory mode of caldesmon. Taken together, we conclude that in Rous sarcoma virus-transformed cells, changes in the balance between PAK 1/2-regulated caldesmon and the Arp2/3 complex govern the formation of podosomes.	Osaka Univ, Grad Sch Med, Dept Neurosci, Suita, Osaka 5650871, Japan	Osaka University	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Neurosci, D13,Yamadaoka 2-2, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp	Yoshio, Toshiyuki/ABC-4723-2021	Yoshio, Toshiyuki/0000-0002-6546-0329				ASHINO N, 1987, J BIOCHEM-TOKYO, V101, P609, DOI 10.1093/jb/101.3.609; BOKOCH GM, 2003, ANNU REV BIOCHEM, V72, P30781; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Eppinga RD, 2006, CELL MOTIL CYTOSKEL, V63, P543, DOI 10.1002/cm.20144; Eves R, 2006, J CELL SCI, V119, P1691, DOI 10.1242/jcs.02881; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; Hedges JC, 1998, AM J PHYSIOL-CELL PH, V275, pC527, DOI 10.1152/ajpcell.1998.275.2.C527; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOJIOWADA M, 1984, P NATL ACAD SCI USA, V81, P3133; Konno D, 2005, J BIOL CHEM, V280, P5082, DOI 10.1074/jbc.M408251200; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Lorenz M, 2004, CURR BIOL, V14, P697, DOI 10.1016/j.cub.2004.04.008; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mizutani K, 2002, CANCER RES, V62, P669; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NOMURA M, 1987, EUR J BIOCHEM, V163, P467, DOI 10.1111/j.1432-1033.1987.tb10892.x; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Ory S, 2000, J CELL SCI, V113, P1177; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SOBUE K, 1989, EXP CELL RES, V181, P256, DOI 10.1016/0014-4827(89)90199-7; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1988, P NATL ACAD SCI USA, V85, P482, DOI 10.1073/pnas.85.2.482; SOBUE K, 1990, NEUROSCI RES, V13, P80; Takenawa T, 2001, J CELL SCI, V114, P1801; TANAKA J, 1993, J CELL SCI, V104, P595; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; VOROTNIKOV AV, 1988, FEBS LETT, V236, P321, DOI 10.1016/0014-5793(88)80047-4; Webb BA, 2005, AM J PHYSIOL-CELL PH, V289, pC898, DOI 10.1152/ajpcell.00095.2005; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamakita Y, 2003, J BIOL CHEM, V278, P17937, DOI 10.1074/jbc.M208739200; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121	49	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8454	8463		10.1074/jbc.M609983200	http://dx.doi.org/10.1074/jbc.M609983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224451	hybrid			2022-12-25	WOS:000245081000078
J	Spink, E; Cosgrove, S; Rogers, L; Hewage, C; Malthouse, JPG				Spink, Edward; Cosgrove, Sonya; Rogers, Louis; Hewage, Chandralal; Malthouse, J. Paul G.			C-13 and H-1 NMR studies of ionizations and hydrogen bonding in chymotrypsin-glyoxal inhibitor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MAGNETIC-RESONANCE; ACTIVE-CENTER HISTIDINE; CHLOROMETHYL KETONE INHIBITOR; OPTICAL BIOSENSOR TECHNOLOGY; ALPHA-CHYMOTRYPSIN; SERINE-PROTEASE; DELTA-CHYMOTRYPSIN; TRIFLUOROMETHYL KETONE; PEPTIDEBORONIC ACIDS; TETRAHEDRAL ADDUCTS	Benzyloxycarbonyl (Z)-Ala-Pro-Phe-glyoxal and Z-Ala-AlaPhe-glyoxal have both been shown to be inhibitors of a-chymotrypsin with minimal K-i values of 19 and 344 nm, respectively, at neutral pH. These Ki values increased at low and high pH with pK(alpha), values of similar to 4.0 and similar to 10.5, respectively. By using surface plasmon resonance, we show that the apparent association rate constant for Z-Ala-Pro-Phe-glyoxal is much lower than the value expected for a diffusion-controlled reaction. C-13 NMR has been used to show that at low pH the glyoxal keto carbon is sp(3)-hybridized with a chemical shift of similar to 100.7 ppm and that the aldehyde carbon is hydrated with a chemical shift of similar to 91.6 ppm. The signal at similar to 100.7 ppm is assigned to the hemiketal formed between the hydroxy group of serine 195 and the keto carbon of the glyoxal. In a slow exchange process controlled by a p, of similar to 4.5, the aldehyde carbon dehydrates to give a signal at similar to 205.5 ppm and the hemiketal forms an oxyanion at similar to 107.0 ppm. At higher pH, the re-hydration of the glyoxal aldehyde carbon leads to the signal at 107 ppm being replaced by a signal at 104 ppm (pK(a) similar to 9.2). On binding either Z-Ala-Pro-Phe-glyoxal or Z-AlaAla-Phe-glyoxal to alpha-chymotrypsin at 4 and 25 degrees C, H-1 NMR is used to show that the binding of these glyoxal inhibitors raises the pK(a) value of the imidazolium ion of histidine 57 to a value of > 11 at both 4 and 25 degrees C. We discuss the mechanistic significance of these results, and we propose that it is ligand binding that raises the pK(a) value of the imidazolium ring of histidine 57 allowing it to enhance the nucleophilicity of the hydroxy group of the active site serine 195 and lower the pK(a) value of the oxyanion forming a zwitterionic tetrahedral intermediate during catalysis.	Univ Coll Dublin, Conway Inst, Ctr Synth & Chem Biol, Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Malthouse, JPG (corresponding author), Univ Coll Dublin, Conway Inst, Ctr Synth & Chem Biol, Sch Biomol & Biomed Sci, Dublin 4, Ireland.	J.Paul.G.Malthouse@ucd.ie	Malthouse, Jonathan/AAP-8357-2020	HEWAGE, CHANDRALAL/0000-0002-6626-3829; Malthouse, Jonathan/0000-0002-8372-6549	Wellcome Trust [055637/Z/98] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEBODUN F, 1989, J CELL BIOCHEM, V40, P249, DOI 10.1002/jcb.240400213; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; Bao DH, 1999, J AM CHEM SOC, V121, P4684, DOI 10.1021/ja990180g; Bao DH, 1998, J AM CHEM SOC, V120, P3485, DOI 10.1021/ja972937e; BAUER CA, 1976, BIOCHEMISTRY-US, V15, P1291, DOI 10.1021/bi00651a019; BELL RP, 1956, T FARADAY SOC, V52, P1093, DOI 10.1039/tf9565201093; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7600, DOI 10.1021/bi00485a009; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cassidy CS, 2000, BIOCHEM BIOPH RES CO, V273, P789, DOI 10.1006/bbrc.2000.2986; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; Djurdjevic-Pahl A, 2005, BBA-PROTEINS PROTEOM, V1749, P33, DOI 10.1016/j.bbapap.2005.02.001; Djurdjevic-Pahl A, 2002, BIOCHEM J, V362, P339, DOI 10.1042/0264-6021:3620339; FEENEY J, 1979, J MAGN RESON, V33, P519, DOI 10.1016/0022-2364(79)90163-X; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; FINUCANE MD, 1992, BIOCHEM J, V286, P889, DOI 10.1042/bj2860889; FINUCANE MD, 1989, BIOCHEM J, V258, P853, DOI 10.1042/bj2580853; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; GAREL JR, 1970, J MOL BIOL, V47, P41, DOI 10.1016/0022-2836(70)90400-6; Kahyaoglu A, 2002, PROTEIN SCI, V11, P965, DOI 10.1110/ps.3890102; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; Lin J, 1998, BIOCHEMISTRY-US, V37, P11940, DOI 10.1021/bi980278s; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Lynas JF, 1998, BIOORG MED CHEM LETT, V8, P373, DOI 10.1016/S0960-894X(98)00030-4; Mac Sweeney A, 2000, ACTA CRYSTALLOGR D, V56, P280, DOI 10.1107/S0907444999016583; MALTHOUSE JPG, 1983, J AM CHEM SOC, V105, P1685, DOI 10.1021/ja00344a062; MALTHOUSE JPG, 1985, BIOCHEMISTRY-US, V24, P3478, DOI 10.1021/bi00335a014; Markgren PO, 2001, ANAL BIOCHEM, V291, P207, DOI 10.1006/abio.2001.5025; Markgren PO, 1998, ANAL BIOCHEM, V265, P340, DOI 10.1006/abio.1998.2927; Markley JL, 1996, BIOCHEMISTRY-US, V35, P11092, DOI 10.1021/bi961366k; OConnell TP, 1997, BIOCHEM J, V326, P861, DOI 10.1042/bj3260861; OCONNELL TP, 1995, BIOCHEM J, V307, P353, DOI 10.1042/bj3070353; Pol E, 2006, BIOCHEMISTRY-US, V45, P513, DOI 10.1021/bi0515523; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROBILLAR.G, 1974, J MOL BIOL, V86, P519, DOI 10.1016/0022-2836(74)90178-8; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Stratton JR, 2001, BIOCHEMISTRY-US, V40, P10411, DOI 10.1021/bi015542n; WALKER B, 1993, BIOCHEM J, V293, P321, DOI 10.1042/bj2930321; WEHRLI FW, 1988, INTERPRETATION CARBO, P33; ZHONG S, 1995, J AM CHEM SOC, V117, P7048, DOI 10.1021/ja00132a002	41	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7852	7861		10.1074/jbc.M611394200	http://dx.doi.org/10.1074/jbc.M611394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17213185	hybrid			2022-12-25	WOS:000245081000014
J	Ohnishi, N; Kashino, Y; Satoh, K; Ozawa, S; Takahashi, Y				Ohnishi, Norikazu; Kashino, Yasuhiro; Satoh, Kazuhiko; Ozawa, Shin-ichiro; Takahashi, Yuichiro			Chloroplast-encoded polypeptide PsbT is involved in the repair of primary electron acceptor Q(A) of photosystem II during photoinhibition in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D1 PROTEIN; QUINONE ACCEPTOR; LIGHT; COMPLEX; OXYGEN; FTSH; PHOTODAMAGE; MECHANISM; SITE; PHOTOACTIVATION	PsbT is a small chloroplast-encoded hydrophobic polypeptide associated with the D1/D2 heterodimer of the photosystem II (PSII) reaction center and is required for the efficient posttranslational repair of photodamaged PSII. Here we addressed that role in detail in Chlamydomonas reinhardtii wild type and Delta psbT cells by analyzing the activities of PSII, the assembly of PSII proteins, and the redox components of PSII during photoinhibition and repair. Strong illumination of cells for 15 min decreased the activities of electron transfer through PSII and Q, photoreduction by 50%, and it reduced the amount of atomic manganese by 20%, but it did not affect the steadystate level of PSII proteins, photoreduction of pheophytin (pheo(D1)), and the amount of bound plastoquinone (Q,), indicating that the decrease in PSII activity resulted mainly from inhibition of the electron transfer from pheo(D1) to Q(A). In wild type cells, we observed parallel recovery of electron transfer activity through PSII and Q, photoreduction, suggesting that the recovery of Q, activity is one of the rate-limiting steps of PSII repair. In Delta psbT cells, the repairs of electron transfer activity through PSII and of QA photoreduction activity were both impaired, but PSII protein turnover was unaffected. Moreover, about half the QA was lost from the PSI1 core complex during purification. Since PsbT is intimately associated with the QA-binding region on D2, we propose that this polypeptide enhances the efficient recovery of QA photoreduction by stabilizing the structure of the Q.A-binding region.	Okayama Univ, Fac Sci, Dept Biol, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan	Okayama University	Takahashi, Y (corresponding author), Okayama Univ, Fac Sci, Dept Biol, Grad Sch Nat Sci & Technol, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	taka@cc.okayama-u.ac.jp	Takahashi, Yuichiro/B-2062-2011; Ozawa, Shin-Ichiro/O-7408-2015	Takahashi, Yuichiro/0000-0001-6410-0447; Ozawa, Shin-Ichiro/0000-0001-7698-5350				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Bailey S, 2002, J BIOL CHEM, V277, P2006, DOI 10.1074/jbc.M105878200; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARR R, 1971, PHOTOSYNTHESIS, P372; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hakala M, 2005, BBA-BIOENERGETICS, V1706, P68, DOI 10.1016/j.bbabio.2004.09.001; Haussuhl K, 2001, EMBO J, V20, P713, DOI 10.1093/emboj/20.4.713; Hoshida H, 1997, BIOCHEMISTRY-US, V36, P12053, DOI 10.1021/bi9710885; ISOGAI Y, 1987, PLANT CELL PHYSIOL, V28, P1301; IWAI M, 2001, PS2001, pS22; JONES LW, 1966, PLANT PHYSIOL, V41, P1037, DOI 10.1104/pp.41.6.1037; JUNG J, 1990, PHOTOCHEM PHOTOBIOL, V52, P1003, DOI 10.1111/j.1751-1097.1990.tb01817.x; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kanervo E, 2003, BBA-BIOENERGETICS, V1607, P131, DOI 10.1016/j.bbabio.2003.09.007; Kashino Yasuhiro, 2003, Phycological Research, V51, P168, DOI 10.1111/j.1440-1835.2003.tb00184.x; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KEREN N, 1998, MOL BIOL CHLOROPLAST, P569; KITAMURA K, 1994, FEBS LETT, V354, P113, DOI 10.1016/0014-5793(94)01089-7; KLIMOV VV, 1977, FEBS LETT, V82, P183, DOI 10.1016/0014-5793(77)80580-2; KLIMOV VV, 1980, FEBS LETT, V112, P97, DOI 10.1016/0014-5793(80)80137-2; KOIVUNIEMI A, 1993, FEBS LETT, V327, P343, DOI 10.1016/0014-5793(93)81017-T; Lindahl M, 2000, PLANT CELL, V12, P419, DOI 10.1105/tpc.12.3.419; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MONOD C, 1994, EMBO J, V13, P2747, DOI 10.1002/j.1460-2075.1994.tb06568.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEALE PJ, 1986, J PHYCOL, V22, P531, DOI 10.1111/j.1529-8817.1986.tb02497.x; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Nishiyama Y, 2001, EMBO J, V20, P5587, DOI 10.1093/emboj/20.20.5587; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; Noguchi T, 2002, PLANT CELL PHYSIOL, V43, P1112, DOI 10.1093/pcp/pcf137; Ohnishi N, 2005, BIOCHEMISTRY-US, V44, P8494, DOI 10.1021/bi047518q; Ohnishi N, 2001, J BIOL CHEM, V276, P33798, DOI 10.1074/jbc.M104454200; Rova EM, 1996, J BIOL CHEM, V271, P28918, DOI 10.1074/jbc.271.46.28918; Rova M, 1998, BIOCHEMISTRY-US, V37, P11039, DOI 10.1021/bi980381h; Sakamoto W, 2003, PLANT CELL, V15, P2843, DOI 10.1105/tpc.017319; SATOH K, 1995, PLANT CELL PHYSIOL, V36, P597; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Sugimoto I, 2003, J BIOL CHEM, V278, P45004, DOI 10.1074/jbc.M307537200; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TAKAHASHI Y, 1986, BIOCHIM BIOPHYS ACTA, V848, P183, DOI 10.1016/0005-2728(86)90040-X; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; Tyystjarvi E, 1996, P NATL ACAD SCI USA, V93, P2213, DOI 10.1073/pnas.93.5.2213; VANGORKOM HJ, 1975, BIOCHIM BIOPHYS ACTA, V408, P331, DOI 10.1016/0005-2728(75)90134-6; VANGORKOM HJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P439, DOI 10.1016/0005-2728(74)90081-4; VANWIJK KJ, 1994, J BIOL CHEM, V269, P28382; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Zhang LX, 2001, J BIOL CHEM, V276, P37809; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	51	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7107	7115		10.1074/jbc.M606763200	http://dx.doi.org/10.1074/jbc.M606763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215255	hybrid			2022-12-25	WOS:000245080900022
J	Zissimopoulos, S; Docrat, N; Lai, FA				Zissimopoulos, Spyros; Docrat, Naadiya; Lai, F. Anthony			Redox sensitivity of the ryanodine receptor interaction with FK506-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; KINASE-A PHOSPHORYLATION; SKELETAL-MUSCLE; CA2+ RELEASE; HEART-FAILURE; CALMODULIN-BINDING; OXIDATIVE STRESS; FKBP12.6-MEDIATED STABILIZATION; HYPERREACTIVE SULFHYDRYLS	The ryanodine receptor (RyR) calcium release channel functions as a redox sensor that is sensitive to channel modulators. The FK506-binding protein (FKBP) is an important regulator of channel activity, and disruption of the RyR2-FKBP12.6 association has been implicated in cardiac disease. In the present study, we investigated whether the RyR-FKBP association is redox-regulated. Using co-immunoprecipitation assays of solubilized native RyR2 from cardiac muscle sarcoplasmic reticulum (SR) with recombinant [S-35]FKBP12.6, we found that the sulfydryloxidizing agents, H2O2 and diamide, result in diminished RyR2FKBP12.6 binding. Co-sedimentation experiments of cardiac SR vesicles with [35S]FKBP12.6 also demonstrated that oxidizing reagents decreased FKBP binding. Matching results were obtained with skeletal muscle SR. Notably, H2O2 and diamide differentially affected the RyR2-FKBP12.6 interaction, decreasing binding to similar to 75 and similar to 50% of control, respectively. In addition, the effect of H2O2 was negligible when the channel was in its closed state or when applied after FKBP binding had occurred, whereas diamide was always effective. A cysteine-null mutant FKBP12.6 retained redox-sensitive interaction with RyR2, suggesting that the effect of the redox reagents is exclusively via sites on the ryanodine receptor. K201 (or JTV519), a drug that has been proposed to prevent FKBP12.6 dissociation from the RyR2 channel complex, did not restore normal FKBP binding under oxidizing conditions. Our results indicate that the redox state of the RyR is intimately connected with FKBP binding affinity.	Univ Cardiff Wales, Sch Med, Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, Wales	Cardiff University	Zissimopoulos, S (corresponding author), Univ Cardiff Wales, Sch Med, Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, Wales.	zissimopouloss@cardiff.ac.uk	Zissimopoulos, Spyros/GSD-9824-2022	Lai, Tony/0000-0003-2852-8547; Zissimopoulos, Spyros/0000-0001-5196-9450				ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; Danila C, 2004, BIOPHYS J, V86, p242A; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Doi M, 2002, CIRCULATION, V105, P1374, DOI 10.1161/hc1102.105270; Eager KR, 1997, AM J PHYSIOL-CELL PH, V272, pC1908, DOI 10.1152/ajpcell.1997.272.6.C1908; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; George CH, 2003, BIOCHEM J, V370, P579, DOI 10.1042/BJ20021433; Hidalgo C, 2004, BIOL RES, V37, P539, DOI 10.4067/S0716-97602004000400007; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; KANEKO N, 1994, DRUG DEVELOP RES, V33, P429, DOI 10.1002/ddr.430330406; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Luo YQ, 2000, ANTIOXID REDOX SIGN, V2, P449, DOI 10.1089/15230860050192224; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Oba T, 1998, AM J PHYSIOL-CELL PH, V274, pC914, DOI 10.1152/ajpcell.1998.274.4.C914; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Prestle J, 2001, CIRC RES, V88, P188; Qi Y, 1998, J BIOL CHEM, V273, P34813, DOI 10.1074/jbc.273.52.34813; Sanchez G, 2005, J MOL CELL CARDIOL, V39, P982, DOI 10.1016/j.yjmcc.2005.08.010; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Singal PK, 1998, CARDIOVASC RES, V40, P426, DOI 10.1016/S0008-6363(98)00244-2; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; Suko J, 2000, J MEMBRANE BIOL, V174, P105, DOI 10.1007/s002320001036; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; TATSUMI R, 1995, ANAL BIOCHEM, V224, P28, DOI 10.1006/abio.1995.1004; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Xiao BL, 2005, CIRC RES, V96, P847, DOI 10.1161/01.RES.0000163276.26083.e8; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yano M, 2005, CIRCULATION, V112, P3633, DOI 10.1161/CIRCULATIONAHA.105.555623; Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zheng YM, 2004, CELL CALCIUM, V35, P345, DOI 10.1016/j.ceca.2003.09.006; Zima AV, 2004, J PHYSIOL-LONDON, V555, P727, DOI 10.1113/jphysiol.2003.055848; Zima AV, 2004, J PHYSIOL-LONDON, V555, P607, DOI 10.1113/jphysiol.2003.058529; Zissimopoulos S, 2006, BIOCHEM SOC T, V34, P919, DOI 10.1042/BST0340919; Zissimopoulos S, 2005, CELL BIOCHEM BIOPHYS, V43, P203, DOI 10.1385/CBB:43:2:203; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	68	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6976	6983		10.1074/jbc.M607590200	http://dx.doi.org/10.1074/jbc.M607590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17200109	hybrid			2022-12-25	WOS:000245080900009
J	Akimzhanov, AM; Yang, XXO; Dong, C				Akimzhanov, Askar M.; Yang, Xuexian O.; Dong, Chen			Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAGES; DISTINCT	During differentiation of naive CD4+ helper T (TH) cells into effector cells, specific cytokine gene loci undergo extensive changes in chromatin modification. A novel lineage of TH cells that is regulated by transforming growth factor-beta (TGFO) and interleukin-6 (IL-6) has been identified recently as promoting tissue inflammation. These inflammatory TH (THi) cells, also called TH17 or THIL-17 produce IL-17 and IL-17F, two highly homologous cytokines that have genes located in the same chromosomal region. Here, using chromatin immunoprecipitation techniques, we have demonstrated that similar to the regulation in TH1 and TH2 cell lineages, polarization of THi cells was accompanied by selective chromatin remodeling events. Histone H3 acetylation. and Lys-4 tri-methylation were specifically associated with IL-17 and IL-17F gene promoters in THi lineage. At an early stage of T cell activation, histone acetylation on these promoters was greatly promoted by a combination of TGFP and IL-6, suggesting their synergistic role in initiating chromatin accessibility for transcription factors. Furthermore, we identified multiple noncoding sequences within the IL-17-IL-17F locus conserved across species. These elements were also associated with hyperacetylated histone 3 in a lineage-specific manner and may thus serve as potential regulatory regions. In summary, our results demonstrate for the first time that THi cell differentiation is associated with epigenetic changes in the IL-17-IL-17F locus, which suggests novel mechanisms in T cell functional regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Dong, C (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 7455 Fannin,Unit 906, Houston, TX 77030 USA.	cdong@mdanderson.org	Yang, Xuexian/Y-2472-2019; dong, chen/B-3181-2009	Yang, Xuexian/0000-0001-6816-7024; dong, chen/0000-0002-0084-9130; Akimzhanov, Askar/0000-0002-5592-8215				Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001	13	215	219	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					5969	5972		10.1074/jbc.C600322200	http://dx.doi.org/10.1074/jbc.C600322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17218320	hybrid			2022-12-25	WOS:000244867200001
J	Gao, L; Balakrishnan, M; Roques, BP; Bambara, RA				Gao, Lu; Balakrishnan, Mini; Roques, Bernard P.; Bambara, Robert A.			Insights into the multiple roles of pausing in HIV-1 reverse transcriptase-promoted strand transfers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NUCLEOCAPSID PROTEIN; RNA SECONDARY STRUCTURE; PRIMER BINDING-SITE; VIRAL-DNA SYNTHESIS; STRONG-STOP DNA; RETROVIRAL RECOMBINATION; IN-VITRO; ACCEPTOR RNA; GENETIC-RECOMBINATION	We previously analyzed the role of pausing induced by hairpin structures within RNA templates in facilitating, strand transfer by HIV-1 RT (reverse transcriptase). We proposed a multistep transfer mechanism in which pause-induced RNase H cuts within the initial RNA template (donor) expose regions of cDNA. A second homologous RNA template (acceptor) can interact with the cDNA at such sites, initiating transfer. The acceptor-cDNA hybrid is thought to then propagate by branch-migration, eventually catching up with the primer terminus and completing the transfer. The prominent pause site in the template system facilitated acceptor invasion; however, very few of the transfers terminated at this pause. To examine the effects of homology on pause-promoted transfer, we increased template homology before the pause site, from 19 nucleotides (nt) in the initial template system to 52 nt in the new system. Significantly, the increased homology enhanced transfers 3-fold, with 32% of the transfers now terminating at the pause site. Additionally, the acceptor cleavage profile indicated the creation of a new invasion site in the added region of homology. NC (nucleocapsid) increased the strand transfer throughout the whole template. However, the prominent hot spot for internal transfer remained, which was still at the pause site. We interpret the new results to mean that pause sites can also serve to stall DNA synthesis, allowing acceptor invasions initiated earlier in the template to catch up with the primer terminus.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; CNRS, INSERM, Dept Pharmacochim Mol & Struct, U266,UMR 8600,Fac Pharm 4, F-75270 Paris 06, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An WF, 2002, J VIROL, V76, P7897, DOI 10.1128/JVI.76.15.7897-7902.2002; Anderson JA, 1998, J VIROL, V72, P1186, DOI 10.1128/JVI.72.2.1186-1194.1998; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Chen Y, 2005, J BIOL CHEM, V280, P14443, DOI 10.1074/jbc.M412190200; Chen Y. H., 2003, J BIOL CHEM; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COLICELLI J, 1987, VIROLOGY, V160, P518, DOI 10.1016/0042-6822(87)90030-4; Dang Q, 2004, P NATL ACAD SCI USA, V101, P632, DOI 10.1073/pnas.0307636100; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1994, J MOL BIOL, V243, P558, DOI 10.1016/0022-2836(94)90030-2; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DeStefano JJ, 1997, ARCH VIROL, V142, P1797, DOI 10.1007/s007050050198; Dykes C, 2004, VIROLOGY, V326, P262, DOI 10.1016/j.virol.2004.02.033; Galetto R, 2006, J BIOL CHEM, V281, P2711, DOI 10.1074/jbc.M505457200; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GU ZX, 1995, J GEN VIROL, V76, P2601, DOI 10.1099/0022-1317-76-10-2601; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Hanson MN, 2005, J MOL BIOL, V353, P772, DOI 10.1016/j.jmb.2005.08.065; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; Heath MJ, 2005, BIOCHEMISTRY-US, V44, P3915, DOI 10.1021/bi0477945; Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HU WS, 1992, J VIROL, V66, P4457, DOI 10.1128/JVI.66.7.4457-4463.1992; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; Lanciault C, 2006, J VIROL, V80, P2483, DOI 10.1128/JVI.80.5.2483-2494.2006; Lanciault C, 2005, J BIOL CHEM, V280, P2413, DOI 10.1074/jbc.M410718200; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; Lee R, 1998, BIOCHEMISTRY-US, V37, P900, DOI 10.1021/bi972197m; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; Peeters M, 1999, J VIROL, V73, P7368, DOI 10.1128/JVI.73.9.7368-7375.1999; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Song M, 2006, J BIOL CHEM, V281, P24227, DOI 10.1074/jbc.M603097200; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; Telesnitsky A., 1997, P121; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wooley DP, 1997, J VIROL, V71, P9650, DOI 10.1128/JVI.71.12.9650-9653.1997; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	72	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6222	6231		10.1074/jbc.M610056200	http://dx.doi.org/10.1074/jbc.M610056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204480	hybrid			2022-12-25	WOS:000244867200028
J	Kim, W; Yoo, TK; Kim, SJ; Shin, DJ; Tyler-Smith, C; Jin, HJ; Kwak, KD; Kim, ET; Bae, YS				Kim, Wook; Yoo, Tag-Keun; Kim, Sung-Joo; Shin, Dong-Jik; Tyler-Smith, Chris; Jin, Han-Jun; Kwak, Kyoung-Don; Kim, Eun-Tak; Bae, Yoon-Sun			Lack of Association between Y-Chromosomal Haplogroups and Prostate Cancer in the Korean Population	PLOS ONE			English	Article								The Y chromosome has recently been suggested to have an association with prostate cancer risk in human populations. Since this chromosome is haploid and lacks recombination over most of its length, haplotypes constructed from binary markers throughout the chromosome can be used for association studies. To assess the possible Y-chromosomal contribution to prostate cancer risk, we have therefore analyzed 14 Y-chromosomal binary markers in 106 prostate cancer cases and 110 controls from the Korean population. In contrast to previous findings in the Japanese population, no statistically significant difference in the distribution of Y-chromosomal haplogroup frequencies was observed between the case and control groups of Koreans. Thus, our data imply that the previously reported associations between Y-chromosomal lineages and a predisposition to, or protection against, prostate cancer might be explained by statistical fluctuations, or by genetic effects that are seen only in some environments.	[Kim, Wook; Jin, Han-Jun; Kwak, Kyoung-Don] Dankook Univ, Dept Biol Sci, Cheonan, South Korea; [Yoo, Tag-Keun] Eulji Univ, Sch Med, Eulji Med Ctr, Dept Urol, Seoul, South Korea; [Kim, Sung-Joo] Catholic Res Inst Med Sci, Res Inst Mol Genet, Seoul, South Korea; [Shin, Dong-Jik; Bae, Yoon-Sun] Yonsei Univ, Coll Med, Cardiovasc Genome Ctr, Seoul, South Korea; [Tyler-Smith, Chris] Wellcome Trust Sanger Inst, Cambridge, England; [Kim, Eun-Tak] Eulji Univ, Sch Med, Dept Urol, Taejon, South Korea	Dankook University; Eulji University; Catholic University of Korea; Yonsei University; Yonsei University Health System; Wellcome Trust Sanger Institute; Eulji University	Kim, W (corresponding author), Dankook Univ, Dept Biol Sci, Cheonan, South Korea.	wookkim@dankook.ac.kr	Yoo, Tag/M-8852-2019		Korean Science and Engineering Foundation (KOSEF), Republic of Korea [R01-2005-000-10534-0]; The Wellcome Trust	Korean Science and Engineering Foundation (KOSEF), Republic of Korea(Korea Science and Engineering Foundation); The Wellcome Trust(Wellcome TrustEuropean Commission)	WK is supported by a grant from the Korean Science and Engineering Foundation (KOSEF R01-2005-000-10534-0), Republic of Korea. CTS is supported by The Wellcome Trust.	Bergen AW, 1999, ANN HUM GENET, V63, P63, DOI 10.1046/j.1469-1809.1999.6310063.x; Brothman AR, 1999, PROSTATE, V38, P303; Dagnelie PC, 2004, BJU INT, V93, P1139, DOI 10.1111/j.1464-410X.2004.04795.x; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Ellis N, 2002, GENOME RES, V12, P339; Ewis AA, 2006, PROSTATE CANCER P D, V9, P303, DOI 10.1038/sj.pcan.4500876; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; Hammer MF, 2006, J HUM GENET, V51, P47, DOI 10.1007/s10038-005-0322-0; HAMMER MF, 1995, AM J HUM GENET, V56, P951; Hammer MF, 1997, GENETICS, V145, P787; Hammer MF, 2001, MOL BIOL EVOL, V18, P1189, DOI 10.1093/oxfordjournals.molbev.a003906; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Horai S, 1996, AM J HUM GENET, V59, P579; Hsing AW, 2000, CANCER EPIDEM BIOMAR, V9, P1335; Jin HJ, 2003, HUM GENET, V114, P27, DOI 10.1007/s00439-003-1019-0; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; JOBLING MA, 1995, TRENDS GENET, V11, P449, DOI 10.1016/S0168-9525(00)89144-1; Jordan JJ, 2001, CANCER GENET CYTOGEN, V124, P122, DOI 10.1016/S0165-4608(00)00340-X; Kayser M, 2001, AM J HUM GENET, V68, P990, DOI 10.1086/319510; Kutach LS, 1999, ELECTROPHORESIS, V20, P1204, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1204::AID-ELPS1204>3.3.CO;2-J; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; McElreavey K, 2000, Results Probl Cell Differ, V28, P211; Paracchini S, 2003, J MED GENET, V40, P815, DOI 10.1136/jmg.40.11.815; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Sambrook J., 2002, MOL CLONING LAB MANU; Santos FR, 2000, HUM MOL GENET, V9, P421, DOI 10.1093/hmg/9.3.421; Schneider S., 2000, ARLEQUIN SOFTWARE PO, V2, P2496; Shinka T, 1999, J HUM GENET, V44, P240, DOI 10.1007/s100380050151; Sim HG, 2005, EUR J CANCER, V41, P834, DOI 10.1016/j.ejca.2004.12.033; Su B, 1999, AM J HUM GENET, V65, P1718, DOI 10.1086/302680; Tajima A, 2002, HUM GENET, V110, P80, DOI 10.1007/s00439-001-0651-9; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Whittemore AS, 1999, AM J HUM GENET, V65, P254, DOI 10.1086/302457; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200	38	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e172	10.1371/journal.pone.0000172	http://dx.doi.org/10.1371/journal.pone.0000172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245448	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444100009
J	Lehrmann, E; Colantuoni, C; Deep-Soboslay, A; Becker, KG; Lowe, R; Huestis, MA; Hyde, TM; Kleinman, JE; Freed, WJ				Lehrmann, Elin; Colantuoni, Carlo; Deep-Soboslay, Amy; Becker, Kevin G.; Lowe, Ross; Huestis, Marilyn A.; Hyde, Thomas M.; Kleinman, Joel E.; Freed, William J.			Transcriptional Changes Common to Human Cocaine, Cannabis and Phencyclidine Abuse	PLOS ONE			English	Article								A major goal of drug abuse research is to identify and understand drug-induced changes in brain function that are common to many or all drugs of abuse. As these may underlie drug dependence and addiction, the purpose of the present study was to examine if different drugs of abuse effect changes in gene expression that converge in common molecular pathways. Microarray analysis was employed to assay brain gene expression in postmortem anterior prefrontal cortex ( aPFC) from 42 human cocaine, cannabis and/or phencyclidine abuse cases and 30 control cases, which were characterized by toxicology and drug abuse history. Common transcriptional changes were demonstrated for a majority of drug abuse cases (N = 34), representing a number of consistently changed functional classes: Calmodulin-related transcripts (CALM1, CALM2, CAMK2B) were decreased, while transcripts related to cholesterol biosynthesis and trafficking (FDFT1, APOL2, SCARB1), and Golgi/endoplasmic reticulum (ER) functions (SEMA3B, GCC1) were all increased. Quantitative PCR validated decreases in calmodulin 2 (CALM2) mRNA and increases in apolipoprotein L, 2 (APOL2) and semaphorin 3B (SEMA3B) mRNA for individual cases. A comparison between control cases with and without cardiovascular disease and elevated body mass index indicated that these changes were not due to general cellular and metabolic stress, but appeared specific to the use of drugs. Therefore, humans who abused cocaine, cannabis and/or phencyclidine share a decrease in transcription of calmodulin-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function. These changes represent common molecular features of drug abuse, which may underlie changes in synaptic function and plasticity that could have important ramifications for decision-making capabilities in drug abusers.	[Lehrmann, Elin; Freed, William J.] NIDA, Cellular Neurobiol Res Branch, Intramural Res Program, NIH,Dept Hlth & Human Serv, Baltimore, MD USA; [Colantuoni, Carlo; Deep-Soboslay, Amy; Hyde, Thomas M.; Kleinman, Joel E.] NIMH, Clin Brain Disorders Branch, GCAP, Intramural Res Program,NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Becker, Kevin G.] NIA, Res Resources Branch, Intramural Res Program, NIH,Dept Hlth & Human Serv, Baltimore, MD 21224 USA; [Lehrmann, Elin; Lowe, Ross; Huestis, Marilyn A.] NIDA, Chem & Drug Metab Sect, Intramural Res Program, NIH,Dept Hlth & Human Serv, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Lehrmann, E (corresponding author), NIDA, Cellular Neurobiol Res Branch, Intramural Res Program, NIH,Dept Hlth & Human Serv, Baltimore, MD USA.	elehrman@intra.nida.nih.gov		Colantuoni, Carlo/0000-0001-6818-6380; Lehrmann, Elin/0000-0002-9869-9475; Becker, Kevin/0000-0002-6794-6656	Intramural Research Programs at the NIDA, NIMH; NIA, NIH, DHHS; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002399, Z01MH002399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000411, Z01DA000411] Funding Source: NIH RePORTER	Intramural Research Programs at the NIDA, NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)NIH National Institute on Drug Abuse (NIDA)); NIA, NIH, DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was funded by the Intramural Research Programs at the NIDA, NIMH and NIA, NIH, DHHS.	Albertson DN, 2004, J NEUROCHEM, V88, P1211, DOI 10.1046/j.1471-4159.2003.02247.x; Bahi A, 2005, MOL CELL NEUROSCI, V28, P275, DOI 10.1016/j.mcn.2004.09.011; Bartzokis G, 2002, BIOL PSYCHIAT, V51, P605, DOI 10.1016/S0006-3223(02)01315-X; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136; Evans SJ, 2004, P NATL ACAD SCI USA, V101, P15506, DOI 10.1073/pnas.0406788101; Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033; Ferrer-Alcon M, 2004, J NEUROCHEM, V90, P220, DOI 10.1111/j.1471-4159.2004.02473.x; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hashimoto E, 1998, ALCOHOL CLIN EXP RES, V22, p88S, DOI 10.1111/acer.1998.22.s3_part1.88s; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Horton AC, 2003, J NEUROSCI, V23, P6188; Jacobs B, 2001, CEREB CORTEX, V11, P558, DOI 10.1093/cercor/11.6.558; Kolb B, 2003, P NATL ACAD SCI USA, V100, P10523, DOI 10.1073/pnas.1834271100; Kufahl PR, 2005, NEUROIMAGE, V28, P904, DOI 10.1016/j.neuroimage.2005.06.039; Lehrmann E, 2003, PHARMACOGENOMICS J, V3, P27, DOI 10.1038/sj.tpj.6500146; Lipska BK, 2006, BIOL PSYCHIAT, V60, P650, DOI 10.1016/j.biopsych.2006.06.019; Lowe RH, 2006, J MASS SPECTROM, V41, P175, DOI 10.1002/jms.975; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; Merrill MA, 2005, TRENDS PHARMACOL SCI, V26, P645, DOI 10.1016/j.tips.2005.10.003; Mimmack ML, 2002, P NATL ACAD SCI USA, V99, P4680, DOI 10.1073/pnas.032069099; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Monajemi H, 2002, GENOMICS, V79, P539, DOI 10.1006/geno.2002.6729; Morita A, 2006, J NEUROSCI, V26, P2971, DOI 10.1523/JNEUROSCI.5453-05.2006; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Robinson TE, 2001, SYNAPSE, V39, P257; Robinson TE, 2002, SYNAPSE, V46, P271, DOI 10.1002/syn.10146; Rounsaville BJ, 2003, DRUG ALCOHOL DEPEN, V70, P117, DOI 10.1016/S0376-8716(03)00033-4; Sahay A, 2005, J NEUROSCI, V25, P3613, DOI 10.1523/JNEUROSCI.5255-04.2005; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; SCHLAEPFER TE, 2005, INT J NEUROPSYCHOPH, V8, P1; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shichinohe S, 2001, J NEURAL TRANSM, V108, P335, DOI 10.1007/s007020170079; Sohma H, 1999, BBA-MOL BASIS DIS, V1454, P11, DOI 10.1016/S0925-4439(99)00018-6; Sokolov BP, 2003, J NEUROSCI RES, V72, P756, DOI 10.1002/jnr.10631; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suemaru J, 2000, SYNAPSE, V36, P155, DOI 10.1002/(SICI)1098-2396(20000601)36:3<155::AID-SYN1>3.0.CO;2-N; Tang WX, 2003, J NEUROCHEM, V85, P911, DOI 10.1046/j.1471-4159.2003.01740.x; Vawter MP, 2002, SCHIZOPHR RES, V58, P11, DOI 10.1016/S0920-9964(01)00377-2; Xia ZG, 2005, NAT REV NEUROSCI, V6, P267, DOI 10.1038/nrn1647	46	39	44	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e114	10.1371/journal.pone.0000114	http://dx.doi.org/10.1371/journal.pone.0000114			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205118	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700008
J	Perchepied, L; Kroj, T; Tronchet, M; Loudet, O; Roby, D				Perchepied, Laure; Kroj, Thomas; Tronchet, Maurice; Loudet, Olivier; Roby, Dominique			Natural Variation in Partial Resistance to Pseudomonas syringae Is Controlled by Two Major QTLs in Arabidopsis thaliana	PLOS ONE			English	Article							POWDERY MILDEW RESISTANCE; MEDIATED DISEASE RESISTANCE; INBRED LINE POPULATION; RECEPTOR-LIKE KINASE; TRAIT LOCI ANALYSIS; ORYZA-SATIVA L.; GENETIC ARCHITECTURE; INNATE IMMUNITY; NONHOST RESISTANCE; DEFENSE RESPONSES	Background. Low-level, partial resistance is pre-eminent in natural populations, however, the mechanisms underlying this form of resistance are still poorly understood. Methodology/Principal Findings. In the present study, we used the model pathosystem Pseudomonas syringae pv. tomato DC3000 (Pst) - Arabidopsis thaliana to study the genetic basis of this form of resistance. Phenotypic analysis of a set of Arabidopsis accessions, based on evaluation of in planta pathogen growth revealed extensive quantitative variation for partial resistance to Pst. It allowed choosing a recombinant inbred line (RIL) population derived from a cross between the accessions Bayreuth and Shahdara for quantitative genetic analysis. Experiments performed under two different environmental conditions led to the detection of two major and two minor quantitative trait loci (QTLs) governing partial resistance to Pst and called PRP-Ps1 to PRP-Ps4. The two major QTLs, PRP-Ps1 and PRP-Ps2, were confirmed in near isogenic lines (NILs), following the heterogeneous inbred families (HIFs) strategy. Analysis of marker gene expression using these HIFs indicated a negative correlation between the induced amount of transcripts of SA-dependent genes PR1, ICS and PR5, and the in planta bacterial growth in the HIF segregating at PRP-Ps2 locus, suggesting an implication of PRP-Ps2 in the activation of SA dependent responses. Conclusions/Significance. These results show that variation in partial resistance to Pst in Arabidopsis is governed by relatively few loci, and the validation of two major loci opens the way for their fine mapping and their cloning, which will improve our understanding of the molecular mechanisms underlying partial resistance.	[Perchepied, Laure; Kroj, Thomas; Tronchet, Maurice; Roby, Dominique] Natl Inst Agron Res, CNRS, UMR 2594, LIPM, Castanet Tolosan, France; [Loudet, Olivier] INRA, F-78026 Versailles, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Roby, D (corresponding author), Natl Inst Agron Res, CNRS, UMR 2594, LIPM, Castanet Tolosan, France.	Dominique.roby@toulouse.inra.fr	Loudet, Olivier/K-8266-2012; Loudet, Olivier/CAF-7559-2022; Kroj, Thomas/ABG-3249-2020	Loudet, Olivier/0000-0003-3717-0137; kroj, thomas/0000-0002-3752-1788	GABI-Genoplante-MCyt contract on Plant Genome Research	GABI-Genoplante-MCyt contract on Plant Genome Research	This work has been financially supported by a GABI-Genoplante-MCyt contract on Plant Genome Research.	Abramovitch RB, 2006, NAT REV MOL CELL BIO, V7, P601, DOI 10.1038/nrm1984; Al-Chaarani G, 2002, THEOR APPL GENET, V104, P490, DOI 10.1007/s001220100742; Alonso-Blanco C, 2000, TRENDS PLANT SCI, V5, P22, DOI 10.1016/S1360-1385(99)01510-1; Alonso-Blanco C, 1998, METH MOL B, V82, P137; Alonso-Blanco C, 1998, GENETICS, V149, P749; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Arahana VS, 2001, CROP SCI, V41, P180, DOI 10.2135/cropsci2001.411180x; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Bai YL, 2003, MOL PLANT MICROBE IN, V16, P169, DOI 10.1094/MPMI.2003.16.2.169; Bartsch M, 2006, PLANT CELL, V18, P1038, DOI 10.1105/tpc.105.039982; Buell CR, 1997, PLANT J, V12, P21, DOI 10.1046/j.1365-313X.1997.12010021.x; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Collins NC, 2003, NATURE, V425, P973, DOI 10.1038/nature02076; de Torres M, 2006, PLANT J, V47, P368, DOI 10.1111/j.1365-313X.2006.02798.x; Denby KJ, 2004, PLANT J, V38, P473, DOI 10.1111/j.0960-7412.2004.02059.x; Falk A, 1999, P NATL ACAD SCI USA, V96, P3292, DOI 10.1073/pnas.96.6.3292; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Feys BJ, 2005, PLANT CELL, V17, P2601, DOI 10.1105/tpc.105.033910; Foulongne M, 2003, MOL BREEDING, V12, P33, DOI 10.1023/A:1025417507358; Gallais A, 1990, THEORIE SELECTION AM; Gebhardt C, 2001, ANNU REV PHYTOPATHOL, V39, P79, DOI 10.1146/annurev.phyto.39.1.79; Glazebrook J, 2003, PLANT J, V34, P217, DOI 10.1046/j.1365-313X.2003.01717.x; Glazebrook J, 1997, ANNU REV GENET, V31, P547, DOI 10.1146/annurev.genet.31.1.547; Godiard L, 2003, PLANT J, V36, P353, DOI 10.1046/j.1365-313X.2003.01877.x; Gu YQ, 2002, PLANT CELL, V14, P817, DOI 10.1105/tpc.000794; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Hulbert SH, 2001, ANNU REV PHYTOPATHOL, V39, P285, DOI 10.1146/annurev.phyto.39.1.285; Inukai T, 2006, MOL PLANT MICROBE IN, V19, P1034, DOI 10.1094/MPMI-19-1034; Jirage D, 1999, P NATL ACAD SCI USA, V96, P13583, DOI 10.1073/pnas.96.23.13583; Jones JDG, 2001, CURR OPIN PLANT BIOL, V4, P281, DOI 10.1016/S1369-5266(00)00174-6; Kamoun S, 1999, TRENDS PLANT SCI, V4, P196, DOI 10.1016/S1360-1385(99)01404-1; Katagiri Fumiaki, 2002, Arabidopsis Book, V1, pe0039, DOI 10.1199/tab.0039; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Kliebenstein DJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-308; Koornneef M, 2004, ANNU REV PLANT BIOL, V55, P141, DOI 10.1146/annurev.arplant.55.031903.141605; Kover PX, 2005, HEREDITY, V94, P507, DOI 10.1038/sj.hdy.6800651; Kover PX, 2002, P NATL ACAD SCI USA, V99, P11270, DOI 10.1073/pnas.102288999; Kroymann J, 2003, P NATL ACAD SCI USA, V100, P14587, DOI 10.1073/pnas.1734046100; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; LAMB CJ, 1992, BIO-TECHNOL, V10, P1436, DOI 10.1038/nbt1192-1436; Li XY, 2005, P NATL ACAD SCI USA, V102, P12990, DOI 10.1073/pnas.0502425102; Li ZK, 2006, P NATL ACAD SCI USA, V103, P7994, DOI 10.1073/pnas.0507492103; Liao CY, 2001, THEOR APPL GENET, V103, P104, DOI 10.1007/s001220000528; Lipka V, 2005, SCIENCE, V310, P1180, DOI 10.1126/science.1119409; Llorente F, 2005, PLANT J, V43, P165, DOI 10.1111/j.1365-313X.2005.02440.x; Lorrain S, 2004, PLANT CELL, V16, P2217, DOI 10.1105/tpc.104.022038; Loudet O, 2005, THEOR APPL GENET, V110, P742, DOI 10.1007/s00122-004-1900-9; Loudet O, 2002, THEOR APPL GENET, V104, P1173, DOI 10.1007/s00122-001-0825-9; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; Mauricio R, 2005, GENETICA, V123, P75, DOI 10.1007/s10709-002-2714-9; McKhann HI, 2004, PLANT J, V38, P193, DOI 10.1111/j.1365-313X.2004.02034.x; Meyers BC, 2003, PLANT CELL, V15, P809, DOI 10.1105/tpc.009308; Mitchell-Olds T, 2006, NATURE, V441, P947, DOI 10.1038/nature04878; Mouille G, 2006, PLANT PHYSIOL, V141, P1035, DOI 10.1104/pp.106.079384; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; Nguyen HQ, 2006, RARE METAL MAT ENG, V35, P188; Nomura K, 2005, CURR OPIN PLANT BIOL, V8, P361, DOI 10.1016/j.pbi.2005.05.005; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; PARLEVLIET JE, 1979, ANNU REV PHYTOPATHOL, V17, P203, DOI 10.1146/annurev.py.17.090179.001223; Perchepied L, 2005, THEOR APPL GENET, V111, P65, DOI 10.1007/s00122-005-1991-y; Quirino BF, 2003, MOL PLANT PATHOL, V4, P517, DOI 10.1046/J.1364-3703.2003.00198.X; ROBERTSON A, 1989, DEV APPL MOL MARKERS, P81; Stein M, 2006, PLANT CELL, V18, P731, DOI 10.1105/tpc.105.038372; Tao Y, 2003, PLANT CELL, V15, P317, DOI 10.1105/tpc.007591; Thomma BPHJ, 2001, CURR OPIN IMMUNOL, V13, P63, DOI 10.1016/S0952-7915(00)00183-7; Tuinstra MR, 1997, THEOR APPL GENET, V95, P1005, DOI 10.1007/s001220050654; Wang GL, 1998, PLANT CELL, V10, P765, DOI 10.1105/tpc.10.5.765; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; Williams KJ, 2003, AUST J AGR RES, V54, P1065, DOI 10.1071/AR02219; Wilson IW, 2001, GENETICS, V158, P1301; Young ND, 1996, ANNU REV PHYTOPATHOL, V34, P479, DOI 10.1146/annurev.phyto.34.1.479; ZENG ZB, 1994, GENETICS, V136, P1457; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	75	32	32	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e123	10.1371/journal.pone.0000123	http://dx.doi.org/10.1371/journal.pone.0000123			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205127	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443700017
J	Allende-Vega, N; Saville, MK; Meek, DW				Allende-Vega, N.; Saville, M. K.; Meek, D. W.			Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53	ONCOGENE			English	Article						p53; Mdm2; TAFII250; transcription factor; ubiquitylation	IN-VIVO; ACIDIC DOMAIN; BINDING-SITE; DNA-DAMAGE; CELL-LINE; MDM2; TAF(II)250; PHOSPHORYLATION; UBIQUITINATION; PROTEIN	The p53 tumour suppressor is regulated mainly by Mdm2, an E3 ubiquitin ligase that promotes the ubiquitylation and proteasome-mediated degradation of p53. Many agents that induce p53 are inhibitors of transcription, suggesting that the p53 pathway can detect a signal(s) arising from transcriptional malfunction. Mdm2 associates with TAFII250, a component of the general transcription factor TFIID. Inactivation of TAFII250 in ts13 cells, which express a temperature-sensitive mutant of TAFII250, leads to the induction of p53 and cell cycle arrest. In the present study, we show that TAFII250 stimulates the ubiquitylation and degradation of p53 in a manner that is dependent upon Mdm2 and requires its acidic domain. Mechanistically, TAFII250 downregulates Mdm2 auto-ubiquitylation, leading to Mdm2 stabilization, and promotes p53-Mdm2 association through a recently defined second binding site in the acidic domain of Mdm2. These data provide a novel route through which TAFII250 can directly influence p53 levels and are consistent with the idea that the maintenance of p53 turnover is coupled to the integrity of RNA polymerase II transcription.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Div Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk		Allende-Vega, Nerea/0000-0001-5569-6461	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buchmann AM, 2004, MOL CELL BIOL, V24, P5332, DOI 10.1128/MCB.24.12.5332-5339.2004; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wassarman DA, 2001, J CELL SCI, V114, P2895; Wasylyk C, 2000, MOL CELL BIOL, V20, P5554, DOI 10.1128/MCB.20.15.5554-5570.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; Zhu Y, 2001, Respir Res, V2, P300, DOI 10.1186/rr73	34	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4234	4242		10.1038/sj.onc.1210209	http://dx.doi.org/10.1038/sj.onc.1210209			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237821	Green Accepted			2022-12-25	WOS:000247619900006
J	Shi, Q; Bao, S; Song, L; Bigner, DD; Hjelmeland, AB; Rich, JN				Shi, Q.; Bao, S.; Song, L.; Bigner, D. D.; Hjelmeland, A. B.; Rich, J. N.			Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases	ONCOGENE			English	Article						SPARC; AKT; glioma; invasion; siRNA	HUMAN-MELANOMA CELLS; BREAST-CANCER; GENE-EXPRESSION; TUMOR-GROWTH; IN-VITRO; PROTEIN; RICH; GLIOBLASTOMA; OSTEONECTIN; METASTASIS	Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and survival under stress, the latter process dependent on SPARC activation of AKT. Here we demonstrate that downregulation of SPARC expression with short interfering RNA (siRNA) in glioma cells decreased tumor cell survival and invasion. SPARC siRNA reduced the activating phosphorylation of AKT and two cytoplasmic kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK). We determined the contributions of FAK and ILK to SPARC effects using SPARC protein and cell lines engineered to overexpress SPARC. SPARC activated FAK and ILK in glioma cells previously characterized as responsive to SPARC. Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone. Decreased SPARC-mediated AKT activation correlated with a reduction in SPARC-dependent invasion and survival upon the downregulation of FAK and/or ILK expression. These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers.	Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, POB 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu	Rich, Jeremy/AAM-1445-2021		NATIONAL CANCER INSTITUTE [P50CA108786, R01CA116659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054276, K02NS047409] Funding Source: NIH RePORTER; NCI NIH HHS [CA 108786, CA 116659] Funding Source: Medline; NINDS NIH HHS [NS047409, NS054276] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez MJ, 2005, CANCER RES, V65, P5123, DOI 10.1158/0008-5472.CAN-04-1102; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; CHICOINE MR, 1995, J NEUROSURG, V82, P615, DOI 10.3171/jns.1995.82.4.0615; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gradishar WJ, 2006, EXPERT OPIN PHARMACO, V7, P1041, DOI 10.1517/14656566.7.8.1041; Hecker TP, 2002, CANCER RES, V62, P2699; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; KENNEY J, 1992, MAGNET RESON MED, V27, P68, DOI 10.1002/mrm.1910270108; Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807; Lal A, 1999, CANCER RES, V59, P5403; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Schultz C, 2002, CANCER RES, V62, P6270; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	25	113	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4084	4094		10.1038/sj.onc.1210181	http://dx.doi.org/10.1038/sj.onc.1210181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213807				2022-12-25	WOS:000247252700004
J	Sutton, KM; Hayat, S; Chau, NM; Cook, S; Pouyssegur, J; Ahmed, A; Perusinghe, N; Le Floch, R; Yang, J; Ashcroft, M				Sutton, K. M.; Hayat, S.; Chau, N-M; Cook, S.; Pouyssegur, J.; Ahmed, A.; Perusinghe, N.; Le Floch, R.; Yang, J.; Ashcroft, M.			Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1	ONCOGENE			English	Article						hypoxia-inducible factor 1(HIF-1); hypoxia; growth factor; ERK1/2 signalling; small molecule inhibitor	INDUCIBLE FACTOR 1-ALPHA; GROWTH-FACTOR EXPRESSION; ACTIVATED PROTEIN-KINASE; MAP KINASE; FACTOR-I; FACTOR (HIF)-1-ALPHA; CANCER-THERAPY; BREAST-CANCER; FACTOR-1-ALPHA; ANGIOGENESIS	The transcription factor hypoxia-inducible factor 1 (HIF-1) plays a pivotal role in tumour growth and progression, and HIF-1 is regulated through a number of signalling pathways. Here, we investigated the involvement of the mitogen-activated protein kinase (MAPK) signalling pathway in HIF-1 regulation. We found that overexpression of wild-type (WT) extracellular signal regulated protein kinase 1 (ERK1) greatly potentiated HIF-1 activation in hypoxia and HIF-1 alpha induced in response to insulin growth-like factor 1 (IGF-1). Conversely, treatment of tumour cells with the MEK1/2 inhibitors PD98059 or U0216, or expression of a dominant-negative form of ERK1 blocked HIF-1 activation in hypoxia without affecting HIF-1 alpha induction, localization or binding of HIF-1 beta. Interestingly however, the highly selective MEK1/2 inhibitor PD184352 did not inhibit HIF-1 activity or vascular endothelial growth factor (VEGF) induced in response to hypoxia but blocked HIF-1a protein and HIF-1 activity induced by IGF-1 stimulation without affecting HIF-1 alpha mRNA levels. Finally, we found that ERK5 phosphorylation status was not significantly affected by hypoxia in the presence or absence of PD184352. Taken together, our data suggest that although ERK1/2 signalling is important for HIF-1 alpha induction and HIF-1 activity in response to IGF-1, it is dispensable for the induction of HIF-1 alpha and activation of HIF-1 in response to hypoxia.	Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; Babraham Inst, MAP Kinase Grp, Mol Signalling Lab, Signalling Programme, Cambridge, England; Inst Signalling Dev Biol & Canc Res, Nice, France; Inst Canc Res, Microscopy Facil, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cancer Research UK; University of London; Institute of Cancer Research - UK	Ashcroft, M (corresponding author), Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	margaret.ashcroft@icr.ac.uk	Yang, Jun/N-2309-2018	Yang, Jun/0000-0002-4233-3220				Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Carroll Veronica A., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009117; Chau NM, 2005, CANCER RES, V65, P4918, DOI 10.1158/0008-5472.CAN-04-4453; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee E, 2002, MOL CELLS, V14, P9; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 2003, CURR PHARM DESIGN, V9, P531, DOI 10.2174/1381612033391469; Michiels C, 2001, IUBMB LIFE, V52, P49, DOI 10.1080/15216540252774766; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830	40	51	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3920	3929		10.1038/sj.onc.1210168	http://dx.doi.org/10.1038/sj.onc.1210168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213817				2022-12-25	WOS:000247144500002
J	Szafranska, AE; Davison, TS; John, J; Cannon, T; Sipos, B; Maghnouj, A; Labourier, E; Hahn, SA				Szafranska, A. E.; Davison, T. S.; John, J.; Cannon, T.; Sipos, B.; Maghnouj, A.; Labourier, E.; Hahn, S. A.			MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; chronic pancreatitis; microRNA; expression profiling	PROGNOSIS; SIGNATURE; PROFILES; MIRNAS; TARGET; CANCER; HOXB8; SET	Pancreatic ductal adenocarcinoma (PDAC) is known for its very poor overall prognosis. Accurate early diagnosis and new therapeutic modalities are therefore urgently needed. We used 377 feature microRNA (miRNA) arrays to investigate miRNA expression in normal pancreas, chronic pancreatitis, and PDAC tissues as well as PDAC- derived cell lines. A pancreatic miRNome was established comparing the data from normal pancreas with a reference set of 33 human tissues. The expression of miR-216 and -217 and lack of expression of miR- 133a were identifi. ed as characteristic of pancreas tissue. Unsupervised clustering showed that the three pancreatic tissues types can be classifi. ed according to their respective miRNA expression pro. files. We identified 26 miRNAs most prominently misregulated in PDAC and a relative quantitative reverse transcriptase- polymerase chain reaction index using only miR-217 and -196a was found to discriminate normal pancreas, chronic pancreatitis and cancerous tissues, establishing a potential utility for miRNAs in diagnostic procedures. Lastly, comparing differentially expressed genes from PDAC with predicted miRNA target genes for the top 26 miRNAs, we identifi. ed potential novel links between aberrant miRNA expression and known target genes relevant to PDAC biology. Our data provides novel insights into the miRNA-driven pathophysiological mechanisms involved in PDAC development and offers new candidate targets to be exploited both for diagnostic and therapeutic strategies.	Ruhr Univ Bochum, Dept Internal Med, MGO, ZKF, D-44780 Bochum, Germany; Asuragen Inc, Austin, TX USA; Univ Kiel, Dept Pathol, D-2300 Kiel, Germany; Ruhr Univ Bochum, Knappschafts Krankenhaus, D-4630 Bochum, Germany	Ruhr University Bochum; Asuragen; University of Kiel; Ruhr University Bochum	Hahn, SA (corresponding author), Ruhr Univ Bochum, Dept Internal Med, MGO, ZKF, Univ Str 150, D-44780 Bochum, Germany.	elabourier@asuragen.com; stephan.hahn@rub.de	Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741; Labourier, Emmanuel/0000-0001-8010-0674				Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Davison TS, 2006, METHOD ENZYMOL, V411, P14, DOI 10.1016/S0076-6879(06)11002-2; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heidenblut AM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh130; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hu YX, 2000, PANCREAS, V21, P226, DOI 10.1097/00006676-200010000-00002; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu CD, 1999, CANCER, V85, P1250, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1250::AID-CNCR6>3.3.CO;2-R; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yeo Theresa Pluth, 2002, Curr Probl Cancer, V26, P176, DOI 10.1067/mcn.2002.129579; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607	38	521	588	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4442	4452		10.1038/sj.onc.1210228	http://dx.doi.org/10.1038/sj.onc.1210228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237814				2022-12-25	WOS:000247620000012
J	Ellison, GM; Torella, D; Karakikes, I; Purushothaman, S; Curcio, A; Gasparri, C; Indolfi, C; Cable, NT; Goldspink, DF; Nadal-Ginard, B				Ellison, Georgina M.; Torella, Daniele; Karakikes, Ioannis; Purushothaman, Saranya; Curcio, Antonio; Gasparri, Cosimo; Indolfi, Ciro; Cable, N. Tim; Goldspink, David F.; Nadal-Ginard, Bernardo			Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; HEART-FAILURE; MYOCARDIAL-INFARCTION; PKA PHOSPHORYLATION; FAILING HEARTS; REGENERATION; APOPTOSIS; RELEASE; DEATH; HYPERTROPHY	A hyperadrenergic state is a seminal aspect of chronic heart failure. Also, " Takotsubo stress cardiomyopathy," is associated with increased plasma catecholamine levels. The mechanisms of myocyte damage secondary to excess catecholamine exposure as well as the consequence of this neurohumoral burst on cardiac stem cells ( CSCs) are unknown. Cardiomyocytes and CSCs were exposed to high doses of isoproterenol ( ISO), in vivo and in vitro. Male Wistar rats received a single injection of ISO ( 5 mg kg(-1)) and were sacrificed 1, 3, and 6 days later. In comparison with controls, LV function was impaired in rats 1 day after ISO and started to improve at 3 days. The fraction of dead myocytes peaked 1 day after ISO and decreased thereafter. ISO administration resulted in significant ryanodine receptor 2 ( RyR2) hyperphosphorylation and RyR2- calstabin dissociation. JTV519, a RyR2 stabilizer, prevented the ISO- induced death of adult myocytes in vitro. In contrast, CSCs were resistant to the acute neurohumoral overload. Indeed, CSCs expressed a decreased and inverted complement of beta(1)/beta(2)-adrenoreceptors and absence of RyR2, which may explain their survival to ISO insult. Thus, a single injection of ISO causes diffuse myocyte death through Ca2+ leakage secondary to the acutely dysfunctional RyR2. CSCs are resistant to the noxious effects of an acute hyperadrenergic state and through their activation participate in the response to the ISO- induced myocardial injury. The latter could contribute to the ability of the myocardium to rapidly recover from acute hyperadrenergic damage.	Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; Mt Sinai Sch Med, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA; Liverpool John Moores Univ, Sport & Exercise Sci Res Inst, Liverpool L3 2ET, Merseyside, England; Magna Graecia Univ Catanzaro, Lab Mol & Cellular Cardiol, I-88100 Catanzaro, Italy; Ctr Nacl Invest Cardiovasc, E-28029 Madrid, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Liverpool John Moores University; Magna Graecia University of Catanzaro; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Nadal-Ginard, B (corresponding author), Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Box 1030,1 Gustave L Levy Pl, New York, NY 10029 USA.	bernardo.nadal-ginard@mssm.edu	Torella, Daniele/A-3296-2009; Curcio, Antonio/K-4822-2018; Ellison-Hughes, Georgina M./B-4597-2016	Ellison-Hughes, Georgina M./0000-0002-2733-3361; INDOLFI, Ciro/0000-0003-1241-6487; Curcio, Antonio/0000-0003-3213-4436; TORELLA, Daniele/0000-0002-4915-5084; Cable, Nigel/0000-0003-3766-9835; Karakikes, Ioannis/0000-0002-4348-600X	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; British Heart Foundation [PG/06/053/20650] Funding Source: Medline; NCI NIH HHS [5R24 CA095823-04, R24 CA095823] Funding Source: Medline; NCRR NIH HHS [1 S10 RR0 9145-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); British Heart Foundation(British Heart Foundation); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bybee KA, 2004, ANN INTERN MED, V141, P858, DOI 10.7326/0003-4819-141-11-200412070-00010; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Goldspink DF, 2004, EXP PHYSIOL, V89, P407, DOI 10.1113/expphysiol.2004.027482; Jaffe AS, 2000, CIRCULATION, V102, P1216, DOI 10.1161/01.CIR.102.11.1216; Lehnart SE, 2006, P NATL ACAD SCI USA, V103, P7906, DOI 10.1073/pnas.0602133103; Liu N, 2006, CIRC RES, V99, P292, DOI 10.1161/01.RES.0000235869.50747.e1; Maron BJ, 2006, CIRCULATION, V113, P1807, DOI 10.1161/CIRCULATIONAHA.106.174287; MARUYAMA R, 2006, AM J PHYSIOL, V290, P41493; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Mouquet F, 2005, CIRC RES, V97, P1090, DOI 10.1161/01.RES.0000194330.66545.f5; Nadal-Ginard B, 2003, J CLIN INVEST, V111, P1457, DOI 10.1172/JCI200318611; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; SHANNON RP, 1993, AM J PHYSIOL, V265, pH801, DOI 10.1152/ajpheart.1993.265.3.H801; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; TAM SKC, 1995, ANN NY ACAD SCI, V752, P72, DOI 10.1111/j.1749-6632.1995.tb17407.x; TEERLINK JR, 1994, CIRC RES, V75, P105, DOI 10.1161/01.RES.75.1.105; Torella D, 2007, CELL MOL LIFE SCI, V64, P661, DOI 10.1007/s00018-007-6519-y; Torella D, 2005, TRENDS CARDIOVAS MED, V15, P229, DOI 10.1016/j.tcm.2005.06.006; Torella D, 2004, AM J PHYSIOL-HEART C, V287, pH2850, DOI 10.1152/ajpheart.01119.2003; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Torella Daniele, 2006, Nat Clin Pract Cardiovasc Med, V3 Suppl 1, pS8, DOI 10.1038/ncpcardio0409; Urbanek K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI 10.1073/pnas.1832855100; Wehrens XHT, 2006, P NATL ACAD SCI USA, V103, P511, DOI 10.1073/pnas.0510113103; Wehrens XHT, 2005, ANNU REV PHYSIOL, V67, P69, DOI 10.1146/annurev.physiol.67.040403.114521; Wehrens XHT, 2005, P NATL ACAD SCI USA, V102, P9607, DOI 10.1073/pnas.0500353102; Wehrens XHT, 2004, NAT REV DRUG DISCOV, V3, P565, DOI 10.1038/nrd1440; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; Zaugg M, 2000, CIRCULATION, V102, P344; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215	38	127	133	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11397	11409		10.1074/jbc.M607391200	http://dx.doi.org/10.1074/jbc.M607391200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17237229	Green Accepted, hybrid			2022-12-25	WOS:000245941500062
J	Otu, HH; Naxerova, K; Ho, K; Can, H; Nesbitt, N; Libermann, TA; Karp, SJ				Otu, Hasan H.; Naxerova, Kamila; Ho, Karen; Can, Handan; Nesbitt, Nicole; Libermann, Towia A.; Karp, Seth J.			Restoration of liver mass after injury requires proliferative and not embryonic transcriptional patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HEPATOCYTE PROLIFERATION; REGENERATION; PROGENITORS; DELETION; REVEALS; PROTEIN; SYSTEM; GROWTH; TISSUE	Normal adult liver is uniquely capable of renewal and repair after injury. Whether this response represents simple hyperplasia of various liver elements or requires recapitulation of the genetic program of the developing liver is not known. To study these possibilities, we examined transcriptional programs of adult liver after partial hepatectomy and contrasted these with developing embryonic liver. Principal component analysis demonstrated that the time series of gene expression during liver regeneration does not segregate according to developmental transcription patterns. Gene ontology analysis revealed that liver restoration after hepatectomy and liver development differ dramatically with regard to transcription factors and chromatin structure modification. In contrast, the tissues are similar with regard to proliferation-associated genes. Consistent with these findings, real-time polymerase chain reaction showed transcription factors known to be important in liver development are not induced during liver regeneration. These three lines of evidence suggest that at a transcriptional level restoration of liver mass after injury is best described as hepatocyte hyperplasia and not true regeneration. We speculate this novel pattern of gene expression may underlie the unique capacity of the liver to repair itself after injury.	Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Genom Core, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Yeditepe Univ, Dept Genet & Bioengn, TR-34755 Istanbul, Turkey; Childrens Hosp, Informat Program, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Yeditepe University; Harvard University; Boston Children's Hospital	Karp, SJ (corresponding author), Transplant Ctr, 110 Francis St,7th Floor, Boston, MA 02215 USA.	skarp@bidmc.harvard.edu	Libermann, Towia/F-9866-2010; Ho, Karen/AHC-8328-2022	Libermann, Towia/0000-0002-4006-8179; Otu, Hasan/0000-0002-9253-8152; Naxerova, Kamila/0000-0001-7744-5110	NHLBI NIH HHS [2T32HL007734-11] Funding Source: Medline; NIDDK NIH HHS [DK64648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai M, 2003, J BIOL CHEM, V278, P29813, DOI 10.1074/jbc.M212648200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 2002, DEVELOPMENT, V129, P1829; Fukuhara Y, 2003, J HEPATOL, V38, P784, DOI 10.1016/S0168-8278(03)00077-1; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; Holtzinger A, 2005, DEVELOPMENT, V132, P4005, DOI 10.1242/dev.01978; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jochheim A, 2003, DIFFERENTIATION, V71, P62, DOI 10.1046/j.1432-0436.2003.700606.x; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Ju WJ, 2006, MOL CELL BIOL, V26, P654, DOI 10.1128/MCB.26.2.654-667.2006; Kelley-Loughnane N, 2002, HEPATOLOGY, V35, P525, DOI 10.1053/jhep.2002.31351; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Laurson J, 2005, INT J EXP PATHOL, V86, P1, DOI 10.1111/j.0959-9673.2005.00410.x; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Maglott D, 2005, NUCLEIC ACIDS RES, V33, pD54, DOI 10.1093/nar/gki031; Motoyama J, 1997, MECH DEVELOP, V66, P27, DOI 10.1016/S0925-4773(97)00082-8; Muravyova E, 2001, SCIENCE, V291, P495, DOI 10.1126/science.291.5503.495; Palis J, 1999, DEVELOPMENT, V126, P5073; Petkov PM, 2004, HEPATOLOGY, V39, P617, DOI 10.1002/hep.20088; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reimold AM, 2000, GENE DEV, V14, P152; Sasaki K, 2000, ARCH HISTOL CYTOL, V63, P137, DOI 10.1679/aohc.63.137; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; Shedden K, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-26; Sinclair DAR, 1998, DEVELOPMENT, V125, P1207; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Su AI, 2002, P NATL ACAD SCI USA, V99, P11181, DOI 10.1073/pnas.122359899; Sumazaki R, 2004, NAT GENET, V36, P83, DOI 10.1038/ng1273; Tornte LT, 2006, J HISTOCHEM CYTOCHEM, V54, P593, DOI 10.1369/jhc.5A6810.2006; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200	41	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11197	11204		10.1074/jbc.M608441200	http://dx.doi.org/10.1074/jbc.M608441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17227769	hybrid			2022-12-25	WOS:000245941500041
J	Wang, Q; Wei, XC; Zhu, TH; Zhang, M; Shen, R; Xing, LP; O'Keefe, RJ; Chen, D				Wang, Qing; Wei, Xiaochao; Zhu, Tianhui; Zhang, Ming; Shen, Run; Xing, Lianping; O'Keefe, Regis J.; Chen, Di			Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; BETA INTERACTS; CBFA1; BINDING; EXPRESSION; CONTRIBUTES; INDUCTION; PROMOTER; DOMAIN	BMP-2 plays an essential role in osteoblast and chondrocyte differentiation, but its signaling mechanism has not been fully defined. In the present studies, we investigated the mechanism through which BMP-2 activates the Smad6 gene. A - 2006/ + 45 Smad6 promoter-luciferase construct was generated along with deletions and Runx2 binding site mutations to examine the role of Smad1 and Runx2 signaling following BMP-2 stimulation in osteoblasts. Transfection of Runx2 or treatment with BMP-2-stimulated promoter activity of the - 2006/ + 45 and - 1191/ + 45 reporters but not the - 829/ + 45 and - 374/ + 45 reporters. No Smad1/5 binding site is present in the - 1191/ + 829 region of the Smad6 promoter. Mutation of the OSE2-a site ( - 1036/ - 1031) completely abolished the stimulatory effect of Runx2 as well as BMP-2 on the - 2006/ + 45 and - 1191/ + 45 Smad6 reporters. Gel shift and chromatin immunoprecipitation ( ChIP) assays showed that Runx2 binds the OSE2-a element. ChIP assays demonstrated that Smad1 also interacts with the OSE2-a site at the Smad6 promoter through Runx2. The protein degradation of Runx2 is mediated by the E3 ubiquitin ligase Smurf1. In the present studies, we found that Smurf1 binds the OSE2-a site through Runx2 and inhibits Smad6 gene transcription. Treatment with BMP-2 and transfection of Smad1 abolished Smurf1 binding to the OSE2 site. These results show that Smad1 binding excludes Smurf1 interaction with the OSE2 site and promotes Smad6 gene transcription.	Univ Rochester, Med Ctr, Dept Orthopaed, Sch Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14642 USA; Nankai Univ, Coll Med, Tianjin 300071, Peoples R China	University of Rochester; University of Rochester; Nankai University	Chen, D (corresponding author), Univ Rochester, Med Ctr, Dept Orthopaed, Sch Med, Rochester, NY 14642 USA.	di_chen@urmc.rochester.edu	Zhang, Ming/H-6467-2011		NIAMS NIH HHS [R01 AR051189-03, R01 AR054465-01, R01 AR051189, R01 AR054465, K02 AR052411-01A2, K02 AR052411, R01 AR051189-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR052411, R01AR054465, R01AR051189] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bae JS, 2007, J CELL BIOCHEM, V100, P434, DOI 10.1002/jcb.21039; Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	31	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10742	10748		10.1074/jbc.M610997200	http://dx.doi.org/10.1074/jbc.M610997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17215250	Green Accepted, hybrid			2022-12-25	WOS:000245941000068
J	Liberman, AC; Refojo, D; Druker, J; Toscano, M; Rein, T; Holsboer, F; Arzt, E				Liberman, Ana C.; Refojo, Damian; Druker, Jimena; Toscano, Marta; Rein, Theo; Holsboer, Florian; Arzt, Eduardo			The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction	FASEB JOURNAL			English	Article						transrepression; T helper inhibition; immunosupression	NF-KAPPA-B; IFN-GAMMA; INTERFERON-GAMMA; DNA-BINDING; ANTIINFLAMMATORY ACTION; TH1 DEVELOPMENT; NUCLEAR-FACTOR; ZINC-FINGER; CROSS-TALK; IN-VITRO	Glucocorticoids (GCs) immunosuppression acts via regulation of several transcription factors (TF), including activating protein (AP)-1, NF-kappa B, and NFAT. GCs inhibit Th1 cytokines and promote a shift toward Th2 differentiation. Th1 phenotype depends on TF T-bet. In this study, we examined GC regulation of T-bet. We found that GCs inhibit T-bet transcriptional activity. We show that glucocorticoid receptor (GR) physically interacts with T-bet both in transfected cell lines and in primary splenocyte cultures with endogenous GR and T-bet. This interaction also blocks GR-dependent transcription. We show both in vitro and in vivo at endogenous binding sites that the mechanism underlying T-bet inhibition further involves reduction of T-bet binding to DNA. Using specific mutations of GR, we demonstrate that the first zinc finger region of GR is required for T-bet inhibition. GCs additionally inhibit T-bet both at mRNA and protein expression levels, revealing another layer of GR action on T-bet. Finally, we examined the functional consequences of GR/T-bet interaction on IFN-gamma, showing that GCs inhibit transcriptional activity of T-bet on its promoter. In view of the crucial role of T-bet in T cell differentiation and inflammation, we propose that GR inhibitory interaction with T-bet may be an important mechanism underlying the immunosuppressive properties of GCs.	Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, RA-1428 Buenos Aires, DF, Argentina; IFIBYNE CONICET, Buenos Aires, DF, Argentina; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Buenos Aires, Hosp Clin Jose De San Martin, Fac Med, Div Immunogenet, Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; University of Buenos Aires	Arzt, E (corresponding author), Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	earzt@fbmc.fcen.uba.ar		Rein, Theo/0000-0003-2850-4289; Refojo, Damian/0000-0002-9798-6413				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Blotta MH, 1997, J IMMUNOL, V158, P5589; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; FOX HS, 1991, J IMMUNOL, V146, P4362; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Hwang ES, 2002, J IMMUNOL, V169, P248, DOI 10.4049/jimmunol.169.1.248; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Kovalovsky D, 1998, EUR J IMMUNOL, V28, P2075; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Novac N, 2006, FASEB J, V20, P1074, DOI 10.1096/fj.05-5457com; O'Shea JJ, 2005, CURR OPIN RHEUMATOL, V17, P305, DOI 10.1097/01.bor.0000160781.07174.db; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; RAIDEN S, 1995, J CLIN IMMUNOL, V15, P242, DOI 10.1007/BF01540881; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Robinson DS, 2002, IMMUNITY, V16, P755, DOI 10.1016/S1074-7613(02)00331-X; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yin ZN, 2002, J IMMUNOL, V168, P1566, DOI 10.4049/jimmunol.168.4.1566; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; Yudt MR, 2003, MOL CELL BIOL, V23, P4319, DOI 10.1128/MCB.23.12.4319-4330.2003	66	76	85	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1177	1188		10.1096/fj.06-7452com	http://dx.doi.org/10.1096/fj.06-7452com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215482				2022-12-25	WOS:000245650400022
J	Bohl, J; Brimer, N; Lyons, C; Pol, SBV				Bohl, Joanna; Brimer, Nicole; Lyons, Charles; Pol, Scott B. Vande			The stardust family protein MPP7 forms a tripartite complex with LIN7 and DLG1 that regulates the stability and localization of DLG1 to cell junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS E6 PROTEINS; LARGE TUMOR-SUPPRESSOR; ADENOVIRUS TYPE 9; HUMAN DISCS LARGE; DROSOPHILA-MELANOGASTER; POLARITY DEFECTS; EPITHELIAL-CELLS; MAMMARY-TUMORS; BINDING; DEGRADATION	MPP7, a previously uncharacterized member of the p55 Stardust family of membrane-associated guanylate kinase (MAGUK) proteins, was found in a tripartite complex with DLG1 and LIN7A or LIN7C. MPP7 dimerizes with all three LIN7 family members (LIN7A, -B, and -C) through interaction of the single L27 domain of LIN7 with the carboxyl-terminal L27 domain of MPP7, thereby stabilizing both proteins. The dimer of MPP7 with LIN7A or LIN7C associates with DLG I through an interaction requiring the amino-terminal L27 domain of MPP7. The amino-terminal L27 domain of MPP7 is not sufficient for interaction with DLG1 but interacts efficiently only if MPP7 is in a complex with LIN7A or -C. Thus the specificity of interaction of DLG I with the LIN7-MPP7 complex is determined by L27 interactions with both MPP7 and LIN7. The tripartite complex forms in a ratio of 1:1:1 and localizes to epithelial adherens junctions in a manner dependent upon MPP7. Expression of MPP7 stabilizes DLG1 in an insoluble compartment. Expression of MPP7 deleted of the PDZ or Src homology 3 domain redistributes MPP7, DLG1, and LIN7 out of adherens junctions and into the soluble cytoplasmic fraction without changing the localization of E-cadherin. Thus, the stability and localization of DLG1 to cell-cell junctions are complex functions determined by the expression and association of particular Stardust family members together with particular LIN7 family members.	Univ Virginia, Dept Pathol, Sch Med, Charlottesville, VA 22908 USA	University of Virginia	Pol, SBV (corresponding author), Univ Virginia, Dept Pathol, Sch Med, POB 800904, Charlottesville, VA 22908 USA.	vandepol@virginia.edu	Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NCI NIH HHS [CA69292, R01 CA069292-11, R01 CA069292, R01 CA120352, R01 CA120352-01A2, CA80931] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069292, R01CA120352, R29CA069292, R01CA080931] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Flores ER, 1999, VIROLOGY, V262, P344, DOI 10.1006/viro.1999.9868; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Hall WW, 2005, ONCOGENE, V24, P5965, DOI 10.1038/sj.onc.1208975; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER R, 1992, SCIENCE, V257, P1267, DOI 10.1126/science.1519063; Jeong KW, 2007, ONCOGENE, V26, P487, DOI 10.1038/sj.onc.1209837; Jing M, 2007, J VIROL, V81, P2231, DOI 10.1128/JVI.01979-06; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Katoh M, 2004, INT J MOL MED, V13, P333; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Olsen O, 2005, J CELL BIOL, V170, P1127, DOI 10.1083/jcb.200503011; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; Straight SW, 2006, J BIOL CHEM, V281, P37738, DOI 10.1074/jbc.M607059200; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Wu HJ, 1998, J CELL SCI, V111, P2365; Xie L, 2006, BLOOD, V107, P1980, DOI 10.1182/blood-2005-03-1333	38	46	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9392	9400		10.1074/jbc.M610002200	http://dx.doi.org/10.1074/jbc.M610002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17237226	hybrid			2022-12-25	WOS:000245421700011
J	Kim, M; Hersh, LB; Leissring, MA; Ingelsson, M; Matsui, T; Farris, W; Lu, A; Hyman, BT; Selkoe, DJ; Bertram, L; Tanzi, RE				Kim, Minji; Hersh, Louis B.; Leissring, Malcolm A.; Ingelsson, Martin; Matsui, Toshifumi; Farris, Wesley; Lu, Alice; Hyman, Bradley T.; Selkoe, Dennis J.; Bertram, Lars; Tanzi, Rudolph E.			Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; NEURODEGENERATIVE DISEASES; EXTRACELLULAR LEVELS; APOLIPOPROTEIN-E; PEPTIDE LEVELS; IN-VIVO; BRAIN; DEGRADATION; PROTEOLYSIS; INSULYSIN	Insulin-degrading enzyme (IDE) is a zinc metalloprotease that degrades the amyloid beta-peptide, the key component of Alzheimer disease (AD)-associated senile plaques. We have previously reported evidence for genetic linkage and association of AD on chromosome 10q23-24 in the region harboring the IDE gene. Here we have presented the first functional assessment of IDE in AD families showing the strongest evidence of the genetic linkage. We have examined the catalytic activity and expression of IDE in lymphoblast samples from 12 affected and unaffected members of three chromosome 10-linked AD pedigrees in the National Institute of Mental Health AD Genetics Initiative family sample. We have shown that the catalytic activity of cytorsolic IDE to degrade insulin is reduced in affected versus unaffected subjects of these families. Further, we have shown the decrease in activity is not due to reduced IDE expression, suggesting the possible defects in IDE function in these AD families. In attempts to find potential mutations in the IDE gene in these families, we have found no coding region substitutions or alterations in splicing of the canonical exons and exon 15b of IDE. We have also found that total IDE mRNA levels are not significantly different in sporadic AD versus age-matched control brains. Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.	Massachusetts Gen Hosp, Inst Neurodegenerat, Genet & Aging Res Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02129 USA; Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Neurodegenerat, Alzheimer Res Unit, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Kentucky; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Tanzi, RE (corresponding author), Massachusetts Gen Hosp, Inst Neurodegenerat, Genet & Aging Res Unit, Bldg 114,16th St,C3009, Boston, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Bertram, Lars/K-3889-2015; LEISSRING, MALCOLM/AAW-5361-2021; Tanzi, Rudolph/AAE-9622-2019	Bertram, Lars/0000-0002-0108-124X; LEISSRING, MALCOLM/0000-0001-7185-4255; Tanzi, Rudolph/0000-0002-7032-1454; Matsui, Toshifumi/0000-0002-8478-2809				BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; Bennett RG, 2000, J BIOL CHEM, V275, P36621, DOI 10.1074/jbc.M006170200; Bernstein HG, 1999, NEUROSCI LETT, V263, P161, DOI 10.1016/S0304-3940(99)00135-4; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Blomqvist MEL, 2004, NEUROGENETICS, V5, P115, DOI 10.1007/s10048-004-0173-4; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; Edland SD, 2003, NEUROSCI LETT, V345, P21, DOI 10.1016/S0304-3940(03)00488-9; Farris W, 2005, BIOCHEMISTRY-US, V44, P6513, DOI 10.1021/bi0476578; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Gutala RV, 2004, J NEUROSCI METH, V132, P101, DOI 10.1016/j.jneumeth.2003.09.005; Hamel FG, 2003, ENDOCRINOLOGY, V144, P2404, DOI 10.1210/en.2002-0007; Huang J, 2004, NEUROSCI LETT, V367, P85, DOI 10.1016/j.neulet.2004.05.085; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; INGELSSON M, 2006, ACTA NEUROPATHOL BER; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morelli L, 2004, J BIOL CHEM, V279, P56004, DOI 10.1074/jbc.M407283200; OGAWA W, 1992, J BIOL CHEM, V267, P1310; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Prince JA, 2003, HUM MUTAT, V22, P363, DOI 10.1002/humu.10282; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; Savage MJ, 1998, J NEUROSCI, V18, P1743; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Song ES, 2005, J MOL NEUROSCI, V25, P201, DOI 10.1385/JMN:25:3:201; Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Udrisar Daniel Pedro, 1992, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V42, P183; Vekrellis K, 2000, J NEUROSCI, V20, P1657	47	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7825	7832		10.1074/jbc.M609168200	http://dx.doi.org/10.1074/jbc.M609168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244626	hybrid			2022-12-25	WOS:000245081000011
J	Bentley, ML; Gaweska, H; Kielec, JM; McCafferty, DG				Bentley, Matthew L.; Gaweska, Helena; Kielec, Joseph M.; McCafferty, Dewey G.			Engineering the substrate specificity of Staphylococcurs aureus sortase A - The beta 6/beta 7 loop from SrtB confers NPQTN recognition to SrtA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PROTEINS; CELL-WALL; LISTERIA-MONOCYTOGENES; TRANSPEPTIDASE; GENE; IRON; SEQUENCE; DEHYDROGENASE; INACTIVATION; INTERNALIN	The Staphylococcus aureus transpepticlase Sortase A (SrtA) anchors virulence and colonization-associated surface proteins to the cell wall. SrtA selectively recognizes a C-terminal LPXTG motif, whereas the related transpeptidase Sortase B (SrtB) recognizes a C-terminal NPQTN motif. In both enzymes, cleavage occurs after the conserved threonine, followed by amide bond formation between threonine and the pentaglycine cross-bridge of cell wall peptidoglycan. Genetic and biochemical studies strongly suggest that SrtA and SrtB exhibit exquisite specificity for their recognition motifs. To better understand the origins of substrate specificity within these two isoforms, we used sequence and structural analysis to predict residues and domains likely to be involved in conferring substrate specificity. Mutational analyses and domain swapping experiments were conducted to test their function in substrate recognition and specificity. Marked changes in the specificity profile of SrtA were obtained by replacing the beta 6/beta 7 loop in SrtA with the corresponding domain from SrtB. The chimeric beta 6/beta 7 loop swap enzyme (SrtLS) conferred the ability to acylate NPQTN-containing substrates, with a k(cat)/K-mapp of 0.0062 +/- 0.003 M-1 s(-1). This enzyme was unable to perform the transpeptidation stage of the reaction, suggesting that additional domains are required for transpepticlation to occur. The overall catalytic specificity profile (k(cat)/K-m(app) (NPQTN)/k(cat)/K-m(app) (LPETG)) of SrtLS was altered 700,000-fold from SrtA. These results indicate that the beta 6/beta 7 loop is an important site for substrate recognition in sortases.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA	Duke University; University of Pennsylvania; University of Pennsylvania	McCafferty, DG (corresponding author), Duke Univ, Dept Chem, B120 LSRC Bldg,Box 90317, Durham, NC 27708 USA.	dewey@duke.edu			NIAID NIH HHS [AI46611, R01 AI046611] Funding Source: Medline; NIGMS NIH HHS [T32 GM008275] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Barnett TC, 2002, J BACTERIOL, V184, P2181, DOI 10.1128/JB.184.8.2181-2191.2002; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; BULLEN JJ, 1981, REV INFECT DIS, V3, P1127; Cazzola M, 2004, CURR OPIN PULM MED, V10, P204, DOI 10.1097/00063198-200405000-00010; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; Frankel BA, 2005, BIOCHEMISTRY-US, V44, P11188, DOI 10.1021/bi050141j; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; Kruger RG, 2004, ANAL BIOCHEM, V326, P42, DOI 10.1016/j.ab.2003.10.023; Lalioui L, 2005, INFECT IMMUN, V73, P3342, DOI 10.1128/IAI.73.6.3342-3350.2005; Lee SF, 2003, INFECT IMMUN, V71, P676, DOI 10.1128/IAI.71.2.676-681.2003; Ma HC, 1999, P NATL ACAD SCI USA, V96, P11161, DOI 10.1073/pnas.96.20.11161; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Marraffini LA, 2005, J BIOL CHEM, V280, P16263, DOI 10.1074/jbc.M500071200; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MITTL PRE, 1994, PROTEIN SCI, V3, P1504, DOI 10.1002/pro.5560030916; Naik MT, 2006, J BIOL CHEM, V281, P1817, DOI 10.1074/jbc.M506123200; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Osaki M, 2002, J BACTERIOL, V184, P971, DOI 10.1128/jb.184.4.971-982.2002; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Paterson GK, 2006, MICROBES INFECT, V8, P145, DOI 10.1016/j.micinf.2005.06.009; Paterson GK, 2004, TRENDS MICROBIOL, V12, P89, DOI 10.1016/j.tim.2003.12.007; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Sabet C, 2005, INFECT IMMUN, V73, P6912, DOI 10.1128/IAI.73.10.6912-6922.2005; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Tendolkar PM, 2006, J BACTERIOL, V188, P2063, DOI 10.1128/JB.188.6.2063-2072.2006; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Yamaguchi M, 2006, MICROBES INFECT, V8, P2791, DOI 10.1016/j.micinf.2006.08.010; Zhang RG, 2004, STRUCTURE, V12, P1147, DOI 10.1016/j.str.2004.06.001; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	44	59	62	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6571	6581		10.1074/jbc.M610519200	http://dx.doi.org/10.1074/jbc.M610519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200112	hybrid			2022-12-25	WOS:000244867200066
J	Valnickova, Z; Petersen, SV; Nielsen, SB; Otzen, DE; Enghild, JJ				Valnickova, Zuzana; Petersen, Steen V.; Nielsen, Soren B.; Otzen, Daniel E.; Enghild, Jan J.			Heparin binding induces a conformational change in pigment epithelium-derived factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC ACTIVITY; I COLLAGEN; PEDF; SERPIN; CELLS; SITE; ANGIOGENESIS; PURIFICATION; INHIBITOR; PROTEINS	Pigment epithelium-derived factor (PEDF) is a noninhibitory serpin found in plasma and in the extracellular space. The protein is involved in different biological processes including cell differentiation and survival. In addition, it is a potent inhibitor of angiogenesis. The function is likely associated with binding to cell surface receptors in a heparin-dependent way (Alberdi, E. M., Weldon, J. E., and Becerra, S. P. (2003) BMC Biochem. 4, 1). We have investigated the structural basis for this observation and show that heparin induces a conformational change in the vicinity of Lys(178). This structural change was evident both when binding to intact heparin and specific heparin-derived oligosaccharides at physiological conditions or simply when exposing PEDF to low ionic strength. Binding to other glycosaminoglycans, heparin-derived oligosaccharides smaller than hexadecasaccharides (dp16), or type I collagen did not affect the structure of PEDF. The conformational change is likely to expose the epitope involved in binding to the receptor and thus regulates the interactions with cell surface receptors.	Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Struct, inSPIN, DK-8000 Aarhus C, Denmark; Univ Aalborg, Dept Life Sci, DK-9000 Aalborg, Denmark	Aarhus University; Aalborg University	Enghild, JJ (corresponding author), Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Struct, inSPIN, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk		Otzen, Daniel/0000-0002-2918-8989; Vang Petersen, Steen/0000-0002-9338-911X; Enghild, Jan Johannes/0000-0001-9292-9172				Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Alberdi Elena M, 2003, BMC Biochem, V4, P1, DOI 10.1186/1471-2091-4-1; Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; Maik-Rachline G, 2005, BLOOD, V105, P670, DOI 10.1182/blood-2004-04-1569; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Mogensen JE, 2004, BIOCHEMISTRY-US, V43, P3357, DOI 10.1021/bi0358622; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; Petersen SV, 2004, J BIOL CHEM, V279, P13705, DOI 10.1074/jbc.M310217200; Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; Yasui N, 2003, BIOCHEMISTRY-US, V42, P3160, DOI 10.1021/bi0206558	24	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6661	6667		10.1074/jbc.M610471200	http://dx.doi.org/10.1074/jbc.M610471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202143	hybrid			2022-12-25	WOS:000244867200075
J	Wu, LJ; Ko, SW; Toyoda, H; Zhao, MG; Xu, H; Vadakkan, KI; Ren, M; Knifed, E; Shum, F; Quan, J; Zhang, XH; Zhuo, M				Wu, Long-Jun; Ko, Shanelle W.; Toyoda, Hiroki; Zhao, Ming-Gao; Xu, Hui; Vadakkan, Kunjumon I.; Ren, Ming; Knifed, Eva; Shum, Fanny; Quan, Jessica; Zhang, Xue-Han; Zhuo, Min			Increased Anxiety-Like Behavior and Enhanced Synaptic Efficacy in the Amygdala of GluR5 Knockout Mice	PLOS ONE			English	Article								GABAergic transmission in the amygdala modulates the expression of anxiety. Understanding the interplay between GABAergic transmission and excitatory circuits in the amygdala is, therefore, critical for understanding the neurobiological basis of anxiety. Here, we used a multi-disciplinary approach to demonstrate that GluR5-containing kainate receptors regulate local inhibitory circuits, modulate the excitatory transmission from the basolateral amygdala to the central amygdala, and control behavioral anxiety. Genetic deletion of GluR5 or local injection of a GluR5 antagonist into the basolateral amygdala increases anxiety-like behavior. Activation of GluR5 selectively depolarized inhibitory neurons, thereby increasing GABA release and contributing to tonic GABA current in the basolateral amygdala. The enhanced GABAergic transmission leads to reduced excitatory inputs in the central amygdala. Our results suggest that GluR5 is a key regulator of inhibitory circuits in the amygdala and highlight the potential use of GluR5-specific drugs in the treatment of pathological anxiety.	[Wu, Long-Jun; Ko, Shanelle W.; Toyoda, Hiroki; Zhao, Ming-Gao; Xu, Hui; Vadakkan, Kunjumon I.; Ren, Ming; Knifed, Eva; Shum, Fanny; Quan, Jessica; Zhang, Xue-Han; Zhuo, Min] Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Zhuo, M (corresponding author), Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada.	min.zhuo@utoronto.ca	Wu, Long-Jun/AAK-7113-2020; Zhuo, Min/A-2072-2008; Wu, Long-Jun/E-2684-2012; Vadakkan, Kunjumon/A-3254-2008	Wu, Long-Jun/0000-0001-8019-3380; Zhuo, Min/0000-0001-9062-3241; Vadakkan, Kunjumon/0000-0002-2721-6931; Zhao, Ming-gao/0000-0002-7539-3887; Toyoda, Hiroki/0000-0002-9907-7176	NINDS [NS42722]; Canadian Institutes of Health Research; EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health; Canada Research Chair; Fragile X Research Foundation of Canada; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042722] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Fragile X Research Foundation of Canada; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from NINDS NS42722, the Canadian Institutes of Health Research, the EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health, and the Canada Research Chair to M.Z. L.-J.W. is supported by postdoctoral fellowships from the Canadian Institutes of Health Research and Fragile X Research Foundation of Canada.	BAHN S, 1994, J NEUROSCI, V14, P5525; Braga MFM, 2003, J NEUROSCI, V23, P442, DOI 10.1523/JNEUROSCI.23-02-00442.2003; Caraiscos VB, 2004, P NATL ACAD SCI USA, V101, P3662, DOI 10.1073/pnas.0307231101; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; De Armentia ML, 2004, J NEUROPHYSIOL, V92, P1285, DOI 10.1152/jn.00211.2004; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; Fu Y, 2005, J NEUROPHYSIOL, V93, P3012, DOI 10.1152/jn.00871.2004; Goddard AW, 2001, ARCH GEN PSYCHIAT, V58, P556, DOI 10.1001/archpsyc.58.6.556; Greenberg PE, 1999, J CLIN PSYCHIAT, V60, P427, DOI 10.4088/JCP.v60n0702; Gross C, 2004, NAT REV NEUROSCI, V5, P545, DOI 10.1038/nrn1429; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Kash SF, 1999, P NATL ACAD SCI USA, V96, P1698, DOI 10.1073/pnas.96.4.1698; Kent JM, 2002, BIOL PSYCHIAT, V52, P1008, DOI 10.1016/S0006-3223(02)01672-4; Kerchner GA, 2002, J NEUROSCI, V22, P8010; Kerchner GA, 2001, NEURON, V32, P477, DOI 10.1016/S0896-6273(01)00479-2; Khalilov I, 2002, J NEUROPHYSIOL, V88, P523, DOI 10.1152/jn.2002.88.1.523; Ko S, 2005, J NEUROSCI, V25, P977, DOI 10.1523/JNEUROSCI.4059-04.2005; Lawrence JJ, 2003, TRENDS NEUROSCI, V26, P631, DOI 10.1016/j.tins.2003.09.007; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lerma J, 2003, NAT REV NEUROSCI, V4, P481, DOI 10.1038/nrn1118; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li H, 2001, NAT NEUROSCI, V4, P612, DOI 10.1038/88432; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; Mulle C, 2000, NEURON, V28, P475, DOI 10.1016/S0896-6273(00)00126-4; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Rogawski MA, 2001, NEUROPHARMACOLOGY, V40, P28, DOI 10.1016/S0028-3908(00)00112-X; Rosen JB, 1998, PSYCHOL REV, V105, P325, DOI 10.1037/0033-295X.105.2.325; Royer S, 1999, J NEUROSCI, V19, P10575; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Salin PA, 1996, J NEUROPHYSIOL, V75, P1573, DOI 10.1152/jn.1996.75.4.1573; Sandford JJ, 2000, PHARMACOL THERAPEUT, V88, P197, DOI 10.1016/S0163-7258(00)00082-6; Savander V, 1996, J COMP NEUROL, V374, P291, DOI 10.1002/(SICI)1096-9861(19961014)374:2<291::AID-CNE10>3.0.CO;2-Y; Semyanov A, 2001, NAT NEUROSCI, V4, P718, DOI 10.1038/89506; Semyanov A, 2003, NAT NEUROSCI, V6, P484, DOI 10.1038/nn1043; Simmons RMA, 1998, NEUROPHARMACOLOGY, V37, P25, DOI 10.1016/S0028-3908(97)00188-3; Singewald N, 2003, BIOL PSYCHIAT, V53, P275, DOI 10.1016/S0006-3223(02)01574-3; Smolders I, 2002, NAT NEUROSCI, V5, P796, DOI 10.1038/nn880; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Tsvetkov E, 2002, NEURON, V34, P289, DOI 10.1016/S0896-6273(02)00645-1; Wieronska JM, 2005, PHARMACOL REP, V57, P734; WISDEN W, 1993, J NEUROSCI, V13, P3582; Wu LJ, 2005, J NEUROSCI, V25, P11107, DOI 10.1523/JNEUROSCI.1678-05.2005; Wu LJ, 2005, J NEUROPHYSIOL, V94, P1805, DOI 10.1152/jn.00091.2005; WU LJ, J NEUROBIOL IN PRESS; Xu H, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-29; Zhao MG, 2005, NEURON, V47, P859, DOI 10.1016/j.neuron.2005.08.014	56	62	62	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e167	10.1371/journal.pone.0000167	http://dx.doi.org/10.1371/journal.pone.0000167			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245443	gold, Green Published			2022-12-25	WOS:000207444100004
J	Zajitschek, F; Hunt, J; Zajitschek, SRK; Jennions, MD; Brooks, R				Zajitschek, Felix; Hunt, John; Zajitschek, Susanne R. K.; Jennions, Michael D.; Brooks, Robert			No Intra-Locus Sexual Conflict over Reproductive Fitness or Ageing in Field Crickets	PLOS ONE			English	Article							LIFE-HISTORY; DROSOPHILA-MELANOGASTER; ANTAGONISTIC PLEIOTROPY; GENETIC CORRELATION; MATE CHOICE; SELECTION; EVOLUTION; AGE; PERSPECTIVE; ADAPTATION	Differences in the ways in which males and females maximize evolutionary fitness can lead to intra-locus sexual conflict in which genes delivering fitness benefits to one sex are costly when expressed in the other. Trade-offs between current reproductive effort and future reproduction and survival are fundamental to the evolutionary biology of ageing. This leads to the prediction that sex differences in the optimization of age-dependent reproductive effort may generate intra-locus sexual conflict over ageing rates. Here we test for intra-locus sexual conflict over age-dependent reproductive effort and longevity in the black field cricket, Teleogryllus commodus. Using a half-sib breeding design, we show that the most important components of male and female reproductive effort (male calling effort and the number of eggs laid by females) were positively genetically correlated, especially in early adulthood. However, the genetic relationships between longevity and reproductive effort were different for males and females, leading to low genetic covariation between male and female longevity. The apparent absence of intra-locus sexual conflict over ageing suggests that male and female longevity can evolve largely independently of one another.	[Zajitschek, Felix; Hunt, John; Zajitschek, Susanne R. K.; Brooks, Robert] Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia; [Hunt, John] Univ Exeter, Ctr Ecol & Conservat, Cornwall, Penryn, England; [Jennions, Michael D.] Australian Natl Univ, Sch Bot & Zool, Canberra, ACT, Australia	University of New South Wales Sydney; University of Exeter; Australian National University	Zajitschek, F (corresponding author), Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia.	felix.zajitschek@student.unsw.edu.au	Zajitschek, Felix/B-2596-2010; Brooks, Robert/A-1251-2008; Jennions, Michael D/C-7560-2009; Hunt, John/F-1279-2014; Zajitschek, Susanne/E-2958-2012	Zajitschek, Felix/0000-0001-6010-6112; Brooks, Robert/0000-0001-6926-0781; Jennions, Michael D/0000-0001-9221-2788; Zajitschek, Susanne/0000-0003-4676-9950; Hunt, John/0000-0002-4962-8750	Australian Research Council	Australian Research Council(Australian Research Council)	J.H., R. B. and M.D.J. were funded by the Australian Research Council.	Arnqvist Goran, 2005, pUnpaginated; Bentsen CL, 2006, AM NAT, V167, pE102, DOI 10.1086/501376; Bonduriansky R, 2005, EVOLUTION, V59, P1965; Bussiere LF, 2006, EVOLUTION, V60, P792, DOI 10.1554/05-378.1; Chippindale AK, 2001, P NATL ACAD SCI USA, V98, P1671, DOI 10.1073/pnas.041378098; Day T, 2004, GENETICS, V167, P1537, DOI 10.1534/genetics.103.026211; Falconer D. S, 1996, INTRO QUANTITATIVE G; Fedorka KM, 2004, NATURE, V429, P65, DOI 10.1038/nature02492; Fisher R.A., 1930, GENETICAL THEORY NAT; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FRY JD, 1993, EVOLUTION, V47, P327, DOI 10.1111/j.1558-5646.1993.tb01224.x; FRY JD, 1990, AM NAT, V136, P569, DOI 10.1086/285116; Hansen TF, 1995, J EVOLUTION BIOL, V8, P759, DOI 10.1046/j.1420-9101.1995.8060759.x; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; HOULE D, 1991, EVOLUTION, V45, P630, DOI 10.1111/j.1558-5646.1991.tb04334.x; Hunt J, 2004, NATURE, V432, P1024, DOI 10.1038/nature03084; Hunt J, 2005, AM NAT, V166, P79, DOI 10.1086/430672; Hunt J, 2006, AM NAT, V168, pE72, DOI 10.1086/506918; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; Kotiaho JS, 2001, BIOL REV, V76, P365, DOI 10.1017/S1464793101005711; LANDE R, 1980, EVOLUTION, V34, P292, DOI 10.1111/j.1558-5646.1980.tb04817.x; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Lynch M., 1998, GENETICS ANAL QUANTI; Maklakov AA, 2005, P ROY SOC B-BIOL SCI, V272, P2485, DOI 10.1098/rspb.2005.3240; Matos M, 2001, AM NAT, V158, P655, DOI 10.1086/323591; Moore SL, 2002, SCIENCE, V297, P2015, DOI 10.1126/science.1074196; Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; PEASE CM, 1988, J EVOLUTION BIOL, V1, P293, DOI 10.1046/j.1420-9101.1988.1040293.x; Pischedda A, 2006, PLOS BIOL, V4, P2099, DOI 10.1371/journal.pbio.0040356; Pizzari T, 2003, EVOLUTION, V57, P1223, DOI 10.1111/j.0014-3820.2003.tb00331.x; Promislow D, 2003, BEHAV GENET, V33, P191, DOI 10.1023/A:1022562103669; Promislow DEL, 2002, MECH AGEING DEV, V123, P841, DOI 10.1016/S0047-6374(02)00021-0; PROMISLOW DEL, 1990, J ZOOL, V220, P417, DOI 10.1111/j.1469-7998.1990.tb04316.x; Rice WR, 2001, J EVOLUTION BIOL, V14, P685, DOI 10.1046/j.1420-9101.2001.00319.x; Roff Derek A., 1992; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; ROSE MR, 1982, HEREDITY, V48, P63, DOI 10.1038/hdy.1982.7; ROSE MR, 1981, GENETICS, V97, P172; ROSE MR, 1981, GENETICS, V97, P187; SERVICE PM, 1985, EVOLUTION, V39, P943, DOI [10.2307/2408694, 10.1111/j.1558-5646.1985.tb00436.x]; Sgro CM, 1999, SCIENCE, V286, P2521, DOI 10.1126/science.286.5449.2521; Shanley DP, 2000, EVOLUTION, V54, P740, DOI 10.1111/j.0014-3820.2000.tb00076.x; Simons AM, 1996, EVOLUTION, V50, P267, DOI 10.1111/j.1558-5646.1996.tb04490.x; Stearns S.C., 1992, pi; Tregenza T, 2006, PHILOS T R SOC B, V361, P229, DOI 10.1098/rstb.2005.1796; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.2307/2410318	51	35	35	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e155	10.1371/journal.pone.0000155	http://dx.doi.org/10.1371/journal.pone.0000155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225859	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444000006
J	Reina, JH; Azzouz, TN; Hernandez, N				Reina, Jaime H.; Azzouz, Teldja N.; Hernandez, Nouria			Maf1, a New Player in the Regulation of Human RNA Polymerase III Transcription	PLOS ONE			English	Article								Background. Human RNA polymerase III (pol III) transcription is regulated by several factors, including the tumor suppressors P53 and Rb, and the proto-oncogene c-Myc. In yeast, which lacks these proteins, a central regulator of pol III transcription, called Maf1, has been described. Maf1 is required for repression of pol III transcription in response to several signal transduction pathways and is broadly conserved in eukaryotes. Methodology/Principal Findings. We show that human endogenous Maf1 can be co-immunoprecipitated with pol III and associates in vitro with two pol III subunits, the largest subunit RPC1 and the alpha-like subunit RPAC2. Maf1 represses pol III transcription in vitro and in vivo and is required for maximal pol III repression after exposure to MMS or rapamycin, treatments that both lead to Maf1 dephosphorylation. Conclusions/Significance. These data suggest that Maf1 is a major regulator of pol III transcription in human cells.	[Reina, Jaime H.; Azzouz, Teldja N.; Hernandez, Nouria] Univ Lausanne, CIG, Lausanne, Switzerland	University of Lausanne	Hernandez, N (corresponding author), Univ Lausanne, CIG, Lausanne, Switzerland.	Nouria.Hernandez@unil.ch		Hernandez, Nouria/0000-0003-1465-4585	University of Lausanne, SNSF [3100A0-109941/1]; NIH [GM38810]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	University of Lausanne, SNSF(Swiss National Science Foundation (SNSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	University of Lausanne, SNSF grant 3100A0-109941/1, NIH grant GM38810	Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Desai N, 2005, J BIOL CHEM, V280, P6455, DOI 10.1074/jbc.M412375200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Geiduschek EP, 2006, CURR BIOL, V16, pR849, DOI 10.1016/j.cub.2006.08.071; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GREEN CJ, 1990, J BIOL CHEM, V265, P12139; Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; Hu P, 2002, MOL CELL BIOL, V22, P8044, DOI 10.1128/MCB.22.22.8044-8055.2002; Kuhlman TC, 1999, MOL CELL BIOL, V19, P2130; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; MACPHERSON JM, 1986, GENE, V42, P101, DOI 10.1016/0378-1119(86)90155-1; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MOIR RD, 2006, P NATL ACAD SCI US; Murawski Marcin, 1994, Acta Biochimica Polonica, V41, P441; Oficjalska-Pham D, 2006, MOL CELL, V22, P623, DOI 10.1016/j.molcel.2006.04.008; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Pluta K, 2001, MOL CELL BIOL, V21, P5031, DOI 10.1128/MCB.21.15.5031-5040.2001; Roberts DN, 2006, MOL CELL, V22, P633, DOI 10.1016/j.molcel.2006.04.009; Saxena A, 2005, MOL CELL BIOL, V25, P9406, DOI 10.1128/MCB.25.21.9406-9418.2005; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Stein T, 2002, ONCOGENE, V21, P5540, DOI 10.1038/sj.onc.1205739; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Willis IM, 2004, PROG NUCLEIC ACID RE, V77, P323, DOI 10.1016/S0079-6603(04)77009-9; YUO CY, 1985, CELL, V42, P193, DOI 10.1016/S0092-8674(85)80115-X	41	80	83	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e134	10.1371/journal.pone.0000134	http://dx.doi.org/10.1371/journal.pone.0000134			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205138	Green Published, gold			2022-12-25	WOS:000207443700028
J	Murata-Kamiya, N; Kurashima, Y; Teishikata, Y; Yamahashi, Y; Saito, Y; Higashi, H; Aburatani, H; Akiyama, T; Peek, RM; Azuma, T; Hatakeyama, M				Murata-Kamiya, N.; Kurashima, Y.; Teishikata, Y.; Yamahashi, Y.; Saito, Y.; Higashi, H.; Aburatani, H.; Akiyama, T.; Peek, R. M., Jr.; Azuma, T.; Hatakeyama, M.			Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells	ONCOGENE			English	Article						Helicobacter pylori CagA; gastric adenocarcinoma; intestinal metaplasia; E-cadherin; beta-catenin	ATROPHIC GASTRITIS; WNT PATHWAY; PROTEIN; ACTIVATION; CANCER; EXPRESSION; CDX1; INFECTION; TARGET; GENE	Infection with Helicobacter pylori cagA-positive strains is associated with gastric adenocarcinoma. Intestinal metaplasia is a precancerous lesion of the stomach characterized by transdifferentiation of the gastric mucosa to an intestinal phenotype. The H. pylori cagA gene product, CagA, is delivered into gastric epithelial cells, where it undergoes tyrosine phosphorylation by Src family kinases. Tyrosine-phosphorylated CagA specifically binds to and activates SHP-2 phosphatase, thereby inducing cell-morphological transformation. We report here that CagA physically interacts with E-cadherin independently of CagA tyrosine phosphorylation. The CagA/E-cadherin interaction impairs the complex formation between E-cadherin and beta-catenin, causing cytoplasmic and nuclear accumulation of beta-catenin. CagA-deregulated beta-catenin then transactivates beta-catenin-dependent genes such as cdx1, which encodes intestinal specific CDX1 transcription factor. In addition to b-catenin signal, CagA also transactivates p21(WAF1/Cip1), again, in a phosphorylation-independent manner. Consequently, CagA induces aberrant expression of an intestinal-differentiation marker, goblet-cell mucin MUC2, in gastric epithelial cells that have been arrested in G1 by p21(WAF1/Cip1). These results indicate that perturbation of the E-cadherin/beta-catenin complex by H. pylori CagA plays an important role in the development of intestinal metaplasia, a premalignant transdifferentiation of gastric epithelial cells from which intestinal-type gastric adenocarcinoma arises.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan; Vanderbilt Univ, Sch Med, Dept Gastroenterol, Div Gastroenterol, Nashville, TN 37212 USA; Kobe Univ, Grad Sch Med, Int Ctr Med Res, Kobe, Hyogo, Japan	Hokkaido University; University of Tokyo; University of Tokyo; Vanderbilt University; Kobe University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012					Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Bailey T, 1998, AM J PATHOL, V152, P135; Bebb JR, 2006, J CLIN PATHOL, V59, P1261, DOI 10.1136/jcp.2006.036772; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; BLASER MJ, 1995, CANCER RES, V55, P2111; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Duman-Scheel M, 2004, P NATL ACAD SCI USA, V101, P3857, DOI 10.1073/pnas.0400526101; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Kenny PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-3; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Knudsen S., 2002, BIOL GUIDE ANAL DNA; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Lickert H, 2000, DEVELOPMENT, V127, P3805; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Mizoshita T, 2004, J CANCER RES CLIN, V130, P29, DOI 10.1007/s00432-003-0503-1; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Souaze F, 2006, CARCINOGENESIS, V27, P708, DOI 10.1093/carcin/bgi269; Sozzi M, 1998, AM J GASTROENTEROL, V93, P375, DOI 10.1111/j.1572-0241.1998.00375.x; Tago K, 2000, GENE DEV, V14, P1741; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Togawa K, 2000, J CELL PHYSIOL, V183, P129, DOI 10.1002/(SICI)1097-4652(200004)183:1<129::AID-JCP15>3.0.CO;2-S; Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013; Yokoyama K, 2005, P NATL ACAD SCI USA, V102, P9661, DOI 10.1073/pnas.0502529102	41	314	332	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4617	4626		10.1038/sj.onc.1210251	http://dx.doi.org/10.1038/sj.onc.1210251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237808				2022-12-25	WOS:000248037900002
J	Yu, J; Wang, P; Ming, L; Wood, MA; Zhang, L				Yu, J.; Wang, P.; Ming, L.; Wood, M. A.; Zhang, L.			SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events	ONCOGENE			English	Article						SMAC/Diablo; PUMA; apoptosis; mitochondria; DNA damage	STRESS-INDUCED APOPTOSIS; COLON-CANCER CELLS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; CASPASE ACTIVATION; INTERFERING RNAS; MAMMALIAN-CELLS; TUMOR-CELLS; IN-VIVO; SMAC	p53-upregulated modulator of apoptosis (PUMA) is a BH3-only Bcl-2 family protein and an essential mediator of DNA damage-induced apoptosis. PUMA is localized in the mitochondria and induces apoptosis through the mitochondrial pathway. However, the mechanisms of PUMA-induced apoptosis remain unclear. In this study, we found that second mitochondria- derived activator of caspase (SMAC)/Diablo, a mitochondrial apoptogenic protein, mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. SMAC is consistently released into the cytosol in colon cancer cells undergoing PUMA-induced apoptosis. In SMAC-deficient cells, execution of PUMA-induced apoptosis is abrogated, in company with decreases in caspase activation, cytosolic release of cytochrome c and collapse of mitochondrial membrane potential. Reconstituting SMAC expression restored these events in the SMAC-deficient cells. Furthermore, SMAC and agents that mimic the inhibitor of apoptosis proteins (IAPs) inhibition function of SMAC significantly sensitize cells to PUMA-induced apoptosis. These results demonstrate an important role of SMAC in executing DNA damage-induced and PUMA-mediated apoptosis and suggest that SMAC participates in a feedback amplification loop to promote cytochrome c release and other mitochondrial events in apoptosis.	Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Suite 2 42D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; Wood-Trageser, Michelle/GPG-1868-2022	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Wood-Trageser, Michelle/0000-0002-1880-4926	NATIONAL CANCER INSTITUTE [R01CA106348] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106348, CA106348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnt CR, 2003, CELL DEATH DIFFER, V10, P1118, DOI 10.1038/sj.cdd.4401294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hansen T, 2006, CELL DEATH DIFFER, V13, P1181, DOI 10.1038/sj.cdd.4401795; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Sun HY, 2004, J AM CHEM SOC, V126, P16686, DOI 10.1021/ja047438+; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XD, 2001, GENE DEV, V15, P2922; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038/sj.cgt.7700910; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	42	68	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4189	4198		10.1038/sj.onc.1210196	http://dx.doi.org/10.1038/sj.onc.1210196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237824				2022-12-25	WOS:000247619900001
J	Bagnasco, L; Tortolina, L; Biasotti, B; Castagnino, N; Ponassi, R; Tomati, V; Nieddu, E; Stier, G; Malacarne, D; Parodi, S				Bagnasco, L.; Tortolina, L.; Biasotti, B.; Castagnino, N.; Ponassi, R.; Tomati, V.; Nieddu, E.; Stier, G.; Malacarne, D.; Parodi, S.			Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest	FASEB JOURNAL			English	Article						inhibitors	MYC/MAX DIMERIZATION; CELL-GROWTH; DNA-BINDING; SEQUENCE; MAX; TRANSFORMATION; TRANSCRIPTION; APOPTOSIS	c-Myc is a transcription modulator protooncogene. When overexpressed, it becomes an important contributor to the multi-hit process of malignant transformation. In two earlier papers in this journal (see refs. 19, 20) we reported that retro-inverso peptidomimetic molecules inspired by the Helix-1 of c-Myc motif could be sequence-specific antiproliferative agents active in the low micromolar range. We also found that our peptides were not opening the four-alpha-helix Myc:Max bundle. Their antiproliferative activity in cancer cell lines needs the presence of side chains projecting outside of the bundle in the corresponding native H1 motif. This observation suggested interference with an external partner. In this study we investigated the INI1:Myc interaction. INI1 is a subunit of the SWI/SNF complex (component of the enhanceosome surrounding Myc:Max heterodimer). The INI1:Myc interaction was confirmed via pull down, ELISA, and fluorescence anisotropy assays. According to the length of INI1 fragments used, we calculated K(d)s ranging between 1.3 x 10(-6) and 4.8 x 10(-7) M. The three different techniques applied showed that the INI1:Myc interaction was also the target of our retro-inverso peptidomimetic molecules, which seem to bind specifically at INI1. A Myc binding, 21aa INI1 fragment (minimum interacting sequence), could inspire the synthesis of a new class of more selective c-Myc inhibitors.	Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; Natl Canc Inst, Expt Oncol Lab, IST, Genoa, Italy; ISO, Genoa, Italy; Univ Genoa, Dept Pharmaceut Sci, Genoa, Italy; EMBL Heidelberg, Struct & Computat Biol Unit, Heidelberg, Germany	University of Genoa; University of Genoa; European Molecular Biology Laboratory (EMBL)	Bagnasco, L (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, L go R Benzi 10, I-16132 Genoa, Italy.	luca.bagnasco@unige.it	Tomati, Valeria/AAB-4543-2021	Tomati, Valeria/0000-0003-3761-1916				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dang CV, 1999, MOL CELL BIOL, V19, P1; Giorello L, 1998, CANCER RES, V58, P3654; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; HENRIKSSON M, 1996, CANCER RES, V68, P109; Kiessling A, 2006, CHEM BIOL, V13, P745, DOI 10.1016/j.chembiol.2006.05.011; KOHN KW, 2003, ENCY HUMAN GENOME, P457; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mo H, 2006, P NATL ACAD SCI USA, V103, P6344, DOI 10.1073/pnas.0601418103; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nieddu E, 2005, FASEB J, V19, P632, DOI 10.1096/fj.04-2369fje; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pescarolo MP, 2001, FASEB J, V15, P31; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Xu Y, 2006, BIOORGAN MED CHEM, V14, P2660, DOI 10.1016/j.bmc.2005.11.052; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	23	23	25	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1256	1263		10.1096/fj.06-7082com	http://dx.doi.org/10.1096/fj.06-7082com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215484				2022-12-25	WOS:000245650400029
J	Jalota-Badhwar, A; Kaul-Ghanekar, R; Mogare, D; Boppana, R; Paknikar, KM; Chattopadhyay, S				Jalota-Badhwar, Archana; Kaul-Ghanekar, Ruchika; Mogare, Devraj; Boppana, Ramanamurthy; Paknikar, Kishore M.; Chattopadhyay, Samit			SMAR1-derived p44 peptide retains its tumor suppressor function through modulation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CELL-CYCLE PROGRESSION; PROTEIN TRANSDUCTION; IN-VIVO; MAMMALIAN-CELLS; FUSION PROTEINS; CANCER-CELLS; TAT PROTEIN; GROWTH; DELIVERY	The use of pharmacologically active short peptide sequences is a better option in cancer therapeutics than the full-length protein. Here we report one such 44-mer peptide sequence of SMAR1 (TAT-SMAR1 wild type, P44) that retains the tumor suppressor activity of the full-length protein. The protein transduction domain of human immunodeficiency virus, type 1, Tat protein was used here to deliver the 33-mer peptide of SMAR1 into the cells. P44 peptide could efficiently activate p53 by mediating its phosphorylation at serine 15, resulting in the activation of p21. and in effect regulating cell cycle checkpoint. In vitro phosphorylation assays with point-mutated P44-derived peptides suggested that serine 347 of SMAR1 was indispensable for its activity and represented the substrate motif for the protein kinase C family of proteins. Using xenograft nude mice models, we further demonstrate that P44 was capable of inhibiting tumor growth by preventing cellular proliferation. P44 treatment to tumor-bearing mice prevented the formation of poorly organized tumor vasculature and an increase in hypoxia-inducible factor-la expression, both being signatures of tumor progression. The chimeric TAT-SMAR1-derived peptide, P44, thus has a strong therapeutic potential as an anticancer drug.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Agharkar Res Inst, Pune 400004, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Department of Science & Technology (India); Agharkar Research Institute (ARI)	Chattopadhyay, S (corresponding author), Natl Ctr Cell Sci, Pune Univ Campus, Pune 411007, Maharashtra, India.	samit@nccs.res.in	Paknikar, Kishore/A-4963-2010	Paknikar, Kishore/0000-0001-5602-7518; Jalota-Badhwar, Archana/0000-0002-7785-0965				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Birner P, 2000, CANCER RES, V60, P4693; Bonfanti M, 1997, CANCER RES, V57, P1442; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chattopadhyay S, 2000, GENOMICS, V68, P93, DOI 10.1006/geno.2000.6279; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165; Donehower LA, 1997, CANCER SURV, V29, P329; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fujimoto K, 2000, CANCER LETT, V159, P151, DOI 10.1016/S0304-3835(00)00536-X; Giorello L, 1998, CANCER RES, V58, P3654; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harley CB, 1997, CANCER SURV, V29, P263; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; Ho A, 2001, CANCER RES, V61, P474; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jalota A, 2005, J BIOL CHEM, V280, P16019, DOI 10.1074/jbc.M413200200; Kaul R, 2003, INT J CANCER, V103, P606, DOI 10.1002/ijc.10881; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Lee K., 2003, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V1, P203, DOI 10.2174/1568016033477414; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Prives C, 1999, J PATHOL, V187, P112; Ryan HE, 2000, CANCER RES, V60, P4010; SCHELD WM, 1989, REV INFECT DIS S, V7, P1669; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seagroves T, 2002, CANCER CELL, V1, P211, DOI 10.1016/S1535-6108(02)00048-X; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Semenza GL, 2000, GENE DEV, V14, P1983; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani A, 2001, METHOD ENZYMOL, V332, P36; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	58	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9902	9913		10.1074/jbc.M608434200	http://dx.doi.org/10.1074/jbc.M608434200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17229733	hybrid			2022-12-25	WOS:000245421700065
J	Lagerstedt, JO; Budamagunta, MS; Oda, MN; Voss, JC				Lagerstedt, Jens O.; Budamagunta, Madhu S.; Oda, Michael N.; Voss, John C.			Electron paramagnetic resonance spectroscopy of site-directed spin labels reveals the structural heterogeneity in the N-terminal domain of ApoA-I in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; LOOP-GAP RESONATOR; LIPID-FREE; CRYSTAL-STRUCTURE; CONFORMATION; PROTEINS; BINDING; ORGANIZATION; CHOLESTEROL	Apolipoprotein A-I (apoA-I) is the major protein constituent of high density lipoprotein (HDL) and plays a central role in phospholipid and cholesterol metabolism. This 243-residue long protein is remarkably flexible and assumes numerous lipid-dependent conformations. Consequently, definitive structural determination of lipid-free apoA-I in solution has been difficult. Using electron paramagnetic spectroscopy of site-directed spin labels in the N-terminal domain of apoA-I (residues 1-98) we have mapped a mixture of secondary structural elements, the composition of which is consistent with findings from other insolution methods. Based on side chain mobility and their accessibility to polar and non-polar spin relaxers, the precise location of secondary elements for amino acids 14-98 was determined for both lipid-free and lipid-bound apoA-I. Based on intermolecular dipolar coupling at positions 26, 44, and 64, these secondary structural elements were arranged into a tertiary fold to generate a structural model for lipid-free apoA-I in solution.	Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of California System; University of California Davis; University of California System; University of California Davis; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Voss, JC (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA.	jcvoss@ucdavis.edu	Lagerstedt, Jens/AAF-9567-2021; Budamagunta, Madhu S/C-4628-2011	Lagerstedt, Jens/0000-0002-4313-2666	NCRR NIH HHS [C06 RR-12088-01] Funding Source: Medline; NHLBI NIH HHS [HL077268, HL078615] Funding Source: Medline; NIA NIH HHS [R01 AG029246] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012088] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077268, R01HL078615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG029246] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; Andreola A, 2003, J BIOL CHEM, V278, P2444, DOI 10.1074/jbc.M204801200; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brubaker G, 2006, BBA-MOL CELL BIOL L, V1761, P64, DOI 10.1016/j.bbalip.2006.01.007; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Dong JH, 2005, SCIENCE, V308, P1023, DOI 10.1126/science.1106592; Frank PG, 2000, J LIPID RES, V41, P853; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Joy T, 2003, CLIN BIOCHEM, V36, P641, DOI 10.1016/S0009-9120(03)00110-3; KOKORIN AI, 1972, BIOFIZIKA+, V17, P34; LI WH, 1988, J LIPID RES, V29, P245; LIKHTENSHTEIN GI, 1993, BIOPHYSICAL LABELING; Linsel-Nitschke P, 2005, NAT REV DRUG DISCOV, V4, P193, DOI 10.1038/nrd1658; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; Martin DDO, 2006, J BIOL CHEM, V281, P20418, DOI 10.1074/jbc.M602077200; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oh KJ, 2000, METH MOL B, V145, P147; Okon M, 2001, FEBS LETT, V487, P390, DOI 10.1016/S0014-5793(00)02375-9; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; VITELLO LB, 1976, J BIOL CHEM, V251, P1131	34	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9143	9149		10.1074/jbc.M608717200	http://dx.doi.org/10.1074/jbc.M608717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17204472	hybrid			2022-12-25	WOS:000245780300061
J	Chong, SAC; Lee, W; Arora, PD; Laschinger, C; Young, EWK; Simmons, CA; Manolson, M; Sodek, J; McCulloch, CA				Chong, Sandra A. C.; Lee, Wilson; Arora, Pam D.; Laschinger, Carol; Young, Edmond W. K.; Simmons, Craig A.; Manolson, Morris; Sodek, Jaro; McCulloch, Christopher A.			Methylglyoxal inhibits the binding step of collagen phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GINGIVAL FIBROBLASTS; CELL-MATRIX INTERACTIONS; AMINO-ACID-SEQUENCE; ADVANCED GLYCATION; ALPHA(2)BETA(1) INTEGRINS; PERIODONTAL TISSUES; ENDOTHELIAL-CELLS; PROTEIN GLYCATION; LIGAND-BINDING; BETA-1 SUBUNIT	Bacterial infection-induced fibrosis affects a wide variety of tissues, including the periodontium, but the mechanisms that dysregulate matrix turnover and mediate fibrosis are not defined. Since collagen turnover by phagocytosis is an important pathway for matrix remodeling, we studied the effect of the bacterial and eukaryotic cell metabolite, methylglyoxal. (NIGO), on the binding step of phagocytosis by periodontal fibroblasts. Type 1 collagen was treated with various concentrations of methylglyoxal, an important glucose metabolite that modifies Arg and Lys residues. The extent of MGO-induced modifications was authenticated by amino acid analysis, solubility, and cross-linking. Cells were incubated with fluorescent beads coated with collagen, and the percentage of phagocytic cells was estimated by flow cytometry. MGO inhibited collagen binding (20% of control for 10 mm MGO) in a time- and concentration-dependent manner. MGO-induced inhibition of binding was prevented by aminoguanidine, which blocks the formation of collagen cross-links. MGO reduced collagen binding strength and blocked intracellular calcium signaling. MGO modified the Arg residue in the critical alpha(2)beta(1) integrin-binding recognition sequence of triple helical collagen peptides, whereas MGO-induced cross-linking of Lys residues played only a small role in binding inhibition. Thus, MGO modifications of Arg residues in collagen could be a key factor in the impaired degradation of collagen that promotes fibrosis in chronic infections, such as periodontitis.	Univ Toronto, Canadian Inst, Hlth Res Grp, Dynam Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Mech & Ind Engn, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	McCulloch, CA (corresponding author), Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mccculloch@utoronto.ca	Young, Edmond/B-4915-2011; Simmons, Craig/ABA-2015-2020; Simmons, Craig/A-5880-2008; Young, Edmond/AFN-7180-2022	Simmons, Craig/0000-0001-7729-1772; Simmons, Craig/0000-0001-7729-1772; Young, Edmond/0000-0002-1274-5478; Manolson, Morris/0000-0001-8755-5460				Abdulhussein R, 2004, J BIOL CHEM, V279, P31462, DOI 10.1074/jbc.M400651200; Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Arora PD, 2004, MOL BIOL CELL, V15, P588, DOI 10.1091/mbc.E03-07-0468; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; Arora PD, 2001, J BIOL CHEM, V276, P14100, DOI 10.1074/jbc.M010298200; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; Baronas-Lowell D, 2004, J BIOL CHEM, V279, P952, DOI 10.1074/jbc.M305989200; Bhide VM, 2005, J BIOL CHEM, V280, P23103, DOI 10.1074/jbc.M410060200; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bishara NB, 2002, J CELL PHYSIOL, V193, P80, DOI 10.1002/jcp.10153; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; Chou DHI, 1996, J IMMUNOL, V156, P4354; da Silva APB, 2004, CELL MICROBIOL, V6, P485, DOI 10.1111/j.1462-5822.2004.00377.x; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dobler D, 2006, DIABETES, V55, P1961, DOI 10.2337/db05-1634; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Ferguson GP, 1998, J BACTERIOL, V180, P4314, DOI 10.1128/JB.180.16.4314-4318.1998; Glogauer M, 1997, J CELL SCI, V110, P11; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Kashket S, 2003, J CLIN PERIODONTOL, V30, P364, DOI 10.1034/j.1600-051X.2003.00322.x; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KNOWLES GC, 1991, J CELL SCI, V98, P551; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; MCKEOWN M, 1990, CELL TISSUE RES, V262, P523, DOI 10.1007/BF00305249; Mene P, 1999, J AM SOC NEPHROL, V10, P1478; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MOSKOW BS, 1991, J CLIN PERIODONTOL, V18, P534, DOI 10.1111/j.1600-051X.1991.tb00086.x; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NGO TT, 1981, J BIOL CHEM, V256, P1313; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Paul RG, 1999, INT J BIOCHEM CELL B, V31, P653, DOI 10.1016/S1357-2725(99)00023-0; Pedchenko VK, 2005, DIABETES, V54, P2952, DOI 10.2337/diabetes.54.10.2952; PENDER N, 1991, J CELL SCI, V100, P187; Phares DJ, 2000, J FLUID MECH, V418, P351, DOI 10.1017/S002211200000121X; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Segal G, 2001, J CELL SCI, V114, P119; Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SODEK J, 1988, COLLAGEN REL RES, V8, P11; SODEK J, 1978, J BIOL CHEM, V253, P1129; UITTO VJ, 1991, CRIT REV ORAL BIOL M, V2, P323, DOI 10.1177/10454411910020030301; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9	51	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8510	8520		10.1074/jbc.M609859200	http://dx.doi.org/10.1074/jbc.M609859200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229729	hybrid			2022-12-25	WOS:000245081000083
J	Kitagawa, H; Izumikawa, T; Mizuguchi, S; Dejima, K; Nomura, KH; Egusa, N; Taniguchi, F; Tamura, J; Gengyo-Ando, K; Mitani, S; Nomura, K; Sugahara, K				Kitagawa, Hiroshi; Izumikawa, Tomomi; Mizuguchi, Souhei; Dejima, Katsufumi; Nomura, Kazuko H.; Egusa, Noriyuki; Taniguchi, Fumiyasu; Tamura, Jun-ichi; Gengyo-Ando, Keiko; Mitani, Shohei; Nomura, Kazi; Sugahara, Kazuyuki			Expression of rib-1, a Caenorhabditis elegans homolog of the human tumor suppressor EXT genes, is indispensable for heparan sulfate synthesis and embryonic morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; N-ACETYLGLUCOSAMINE; MOLECULAR-CLONING; CHAIN INITIATION; CELL-DIVISION; TOUT-VELU; BIOSYNTHESIS; DROSOPHILA; PROTEOGLYCANS; PROTEINS	The proteins encoded by all of the five cloned human EXT family genes (EXT1, EXT2, EXTL1, EXTL2, and EXTL3), members of the hereditary multiple exostoses gene family of tumor suppressors, are glycosyltransferases required for the biosynthesis of heparan sulfate. In the Caenorhabditis elegans genome, only two genes, rib-1 and rib-2, homologous to the mammalian EXT genes have been identified. Although rib-2 encodes an N-acetylglucosaminyltransferase involved in initiating the biosynthesis and elongation of heparan sulfate, the involvement of the protein encoded by rib-1 in the biosynthesis of heparan sulfate remains unclear. Here we report that RIB-1 is indispensable for the biosynthesis and for embryonic morphogenesis. Despite little individual glycosyltransferase activity by RIB-1, the polymerization of heparan sulfate chains was demonstrated when RIB-1 was coexpressed with RIB-2 in vitro. In addition, RIB-1 and RIB-2 were demonstrated to interact by pultdown assays. To investigate the functions of RIB-1 in vivo, we depleted the expression of rib-1 by deletion mutagenesis. The null mutant worms showed reduced synthesis of heparan sulfate and embryonic lethality. Notably, the null mutant embryos showed abnormality at the gastrulation cleft formation stage or later and arrested mainly at the 1-fold stage. Nearly 100% of the embryos died before L1 stage, although the differentiation of some of the neurons and muscle cells proceeded normally. Similar phenotypes have been observed in rib-2 null mutant embryos. Thus, RIB-1 in addition to RIB-2 is indispensable for the biosynthesis of heparan sulfate in C elegans, and the two cooperate to synthesize heparan sulfate in vivo. These findings also show that heparan sulfate is essential for post-gastrulation morphogenic movement of embryonic cells and is indispensable for ensuring the normal spatial organization of differentiated tissues and organs.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyushu Univ, Fac Sci 33, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tottori Univ, Fac Reg Sci, Dept Reg Environm, Tottori 6808551, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan	Kobe Pharmaceutical University; Kyushu University; Japan Science & Technology Agency (JST); Tottori University; Tokyo Women's Medical University	Kitagawa, H (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	kitagawa@kobepharma-u.ac.jp; smizuscb@mbox.nc.kyushu-u.ac.jp; k-sugar@sci.hokudai.ac.jp	Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; Bornemann DJ, 2004, DEVELOPMENT, V131, P1927, DOI 10.1242/dev.01061; Brunner A, 2006, GLYCOCONJUGATE J, V23, P543, DOI 10.1007/s10719-006-7633-z; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Busse M, 2003, J BIOL CHEM, V278, P41333, DOI 10.1074/jbc.M308314200; Clines GA, 1997, GENOME RES, V7, P359, DOI 10.1101/gr.7.4.359; Dejima K, 2006, J BIOL CHEM, V281, P11431, DOI 10.1074/jbc.M601509200; Franks DM, 2006, DEV BIOL, V296, P409, DOI 10.1016/j.ydbio.2006.06.008; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Gengyo-Ando K, 2006, BIOCHEM BIOPH RES CO, V349, P1345, DOI 10.1016/j.bbrc.2006.08.183; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hudson ML, 2006, DEV BIOL, V294, P352, DOI 10.1016/j.ydbio.2006.02.036; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Izumikawa T, 2006, J BIOL CHEM, V281, P1929, DOI 10.1074/jbc.M509138200; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kim BT, 2002, J BIOL CHEM, V277, P13659, DOI 10.1074/jbc.M111630200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Lee JS, 2004, NEURON, V44, P947, DOI 10.1016/j.neuron.2004.11.029; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Mizumoto S, 2005, HANDBOOK OF CARBOHYDRATE ENGINEERING, P289; Morio H, 2003, BIOCHEM BIOPH RES CO, V301, P317, DOI 10.1016/S0006-291X(02)03031-0; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Poinat P, 2002, CURR BIOL, V12, P622, DOI 10.1016/S0960-9822(02)00764-9; Rhiner C, 2005, DEVELOPMENT, V132, P4621, DOI 10.1242/dev.02042; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Siekmann AF, 2005, DEV DYNAM, V232, P498, DOI 10.1002/dvdy.20248; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; Yamada S, 2004, J BIOL CHEM, V279, P32134, DOI 10.1074/jbc.M312624200	53	25	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8533	8544		10.1074/jbc.M611107200	http://dx.doi.org/10.1074/jbc.M611107200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237233	hybrid			2022-12-25	WOS:000245081000085
J	Kreutzenbeck, P; Kroger, C; Lausberg, F; Blaudeck, N; Sprenger, GA; Freudl, R				Kreutzenbeck, Peter; Kroeger, Carsten; Lausberg, Frank; Blaudeck, Natascha; Sprenger, Georg A.; Freudl, Roland			Escherichia coli twin arginine (Tat) mutant translocases possessing relaxed signal peptide recognition specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; GENETIC-ANALYSIS; EXPORT PATHWAY; MEMBRANE; MUTATIONS; SEQUENCE; COMPLEX; REQUIREMENT; SECRETION; EVOLUTION	The twin arginine (Tat) secretion pathway allows the translocation of folded proteins across the cytoplasmic membrane of bacteria. Tat-specific signal peptides contain a characteristic amino acid motif ((S/T)RRXFLK) including two highly conserved consecutive arginine residues that are thought to be involved in the recognition of the signal peptides by the Tat translocase. Here, we have analyzed the specificity of Tat signal peptide recognition by using a genetic approach. Replacement of the two arginine residues in a Tat-specific precursor protein by lysine-glutamine resulted in an export-defective mutant precursor that was no longer accepted by the wild-type translocase. Selection for restored export allowed for the isolation of Tat translocases possessing single mutations in either the amino-terminal domain of TatB or the first cytosolic domain of TatC. The mutant Tat translocases still efficiently accepted the unaltered precursor protein, indicating that the substrate specificity of the translocases was not strictly changed; rather, the translocases showed an increased tolerance toward variations of the amino acids occupying the positions of the twin arginine residues in the consensus motif of a Tat signal peptide.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Freudl, R (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	r.freudl@fz-juelich.de	Kröger, Carsten/D-1863-2014; Freudl, Roland/N-4179-2017; Sprenger, Georg A./E-2384-2011	Kröger, Carsten/0000-0003-0461-1530; Freudl, Roland/0000-0003-0743-1279; Sprenger, Georg A./0000-0002-7879-8978				Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BIEKER KL, 1990, TRENDS GENET, V6, P329, DOI 10.1016/0168-9525(90)90254-4; Blaudeck N, 2005, J BIOL CHEM, V280, P3426, DOI 10.1074/jbc.M411210200; Blaudeck N, 2003, J BACTERIOL, V185, P2811, DOI 10.1128/JB.185.9.2811-2819.2003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; Dassa E, 1997, RES MICROBIOL, V148, P389, DOI 10.1016/S0923-2508(97)83869-7; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DUPLAY P, 1984, J BIOL CHEM, V259, P606; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; Ize B, 2002, J MOL BIOL, V317, P327, DOI 10.1006/jmbi.2002.5431; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jaeger KE, 2001, APPL MICROBIOL BIOT, V55, P519, DOI 10.1007/s002530100643; MILLER JH, 1972, SHORT COURSE BACT GE; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; RYAN JP, 1985, J BIOL CHEM, V260, P4832; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Smith MA, 2005, J BACTERIOL, V187, P6454, DOI 10.1128/JB.187.18.6454-6465.2005; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179	36	57	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7903	7911		10.1074/jbc.M610126200	http://dx.doi.org/10.1074/jbc.M610126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229735	hybrid			2022-12-25	WOS:000245081000020
J	Spurny, R; Abdoulrahman, K; Janda, L; Runzler, D; Kohler, G; Castanon, MJ; Wiche, G				Spurny, Radovan; Abdoulrahman, Kamaran; Janda, Lubomir; Ruenzler, Dominik; Koehler, Gottfried; Castanon, Maria J.; Wiche, Gerhard			Oxidation and nitrosylation of cysteines proximal to the intermediate filament (IF)-binding site of plectin - Effects on structure and vimentin binding and involvement in if collapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S-NITROSYLATION; NITRIC-OXIDE SYNTHASE; EPIDERMOLYSIS-BULLOSA; KINASE; IDENTIFICATION; RECEPTOR; DESMIN; LOCALIZATION; INACTIVATION; ORGANIZATION	As an intermediate filament (IF)-based cytolinker protein, plectin plays a key role in the maintenance of cellular cytoarchitecture and serves at the same time as a scaffolding platform for signaling cascades. Consisting of six structural repeats (R1-6) and harboring binding sites for different IF proteins and proteins involved in signaling, the plectin C-terminal domain is of strategic functional importance. Depending on the species, it contains at least 13 cysteines, 4 of which reside in the R5 domain. To investigate the structural and biological functions of R5 cysteines, we used cysteine-to-serine mutagenesis and spectroscopic, biochemical, and functional analyses. Urea-induced unfolding experiments indicated that wild-type R5 in the oxidized, disulfide bond-mediated conformation was more stable than its cysteine-free mutant derivative. The binding affinity of R5 for vimentin was significantly higher, however, when the protein was in the reduced, more relaxed conformation. Of the four R5 cysteines, one (Cys4) was particularly reactive as reflected by its ability to form disulfide bridges with R5 Cys 1 and to serve as a target for nitrosylation in vitro. Using immortalized endothelial cell cultures from mice, we show that endogenous plectin is nitrosylated in vivo, and we found that NO donor-induced IF collapse proceeds dramatically faster in plectin-deficient compared with wild-type cells. Our data suggest an antagonistic role of plectin in nitrosylation (oxidative stress)mediated alterations of IF cytoarchitecture and a possible role of R5 Cys4 as a regulatory switch.	Univ Vienna, Dept Mol Cell Biol, Max F Perutz Labs, A-1030 Vienna, Austria; Univ Vienna, Dept Biomol Struct Chem, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Wiche, G (corresponding author), Univ Vienna, Dept Mol Cell Biol, Max F Perutz Labs, Campus Vienna Bioctr,Dr Bohr Gasse 9, A-1030 Vienna, Austria.	gerhard.wiche@univie.ac.at	WICHE, Gerhard/AAA-3227-2021; Rünzler, Dominik/G-9393-2014; Wiche-Castanon, Maria/AAA-9914-2021; Janda, Lubomir/D-8048-2012	Rünzler, Dominik/0000-0002-6020-3411; Wiche, Gerhard/0000-0001-9550-5463; Janda, Lubomir/0000-0002-5406-4208; Castanon, Maria J./0000-0002-3266-478X	Austrian Science Fund FWF [P 17862] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Callsen D, 1999, FREE RADICAL BIO MED, V26, P1544, DOI 10.1016/S0891-5849(99)00015-5; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; Choi HJ, 2002, NAT STRUCT BIOL, V9, P612, DOI 10.1038/nsb818; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; FOISNER R, 1987, J MOL BIOL, V198, P515, DOI 10.1016/0022-2836(87)90297-X; FRASER RDB, 1985, INT J BIOL MACROMOL, V7, P258, DOI 10.1016/0141-8130(85)90024-8; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Fuchs P, 1999, HUM MOL GENET, V8, P2461, DOI 10.1093/hmg/8.13.2461; GIESE G, 1986, EUR J CELL BIOL, V40, P266; Green Kathleen J., 1992, Journal of Dermatology (Tokyo), V19, P765; Gregor M, 2006, J CELL SCI, V119, P1864, DOI 10.1242/jcs.02891; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hijikata T, 2003, HISTOCHEM CELL BIOL, V119, P109, DOI 10.1007/s00418-003-0496-5; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Janda L, 2001, BIOESSAYS, V23, P1064, DOI 10.1002/bies.1151; Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8; KRIJNSELOCKER J, 1999, J CELL BIOL, V144, P267; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Lakowitz J., 1999, PRINCIPLES FLUORESCE; Lane P., 2001, SCI STKE, V86, pre1; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Liu CG, 1996, P NATL ACAD SCI USA, V93, P4278, DOI 10.1073/pnas.93.9.4278; Lunter PC, 2002, BIOCHEM BIOPH RES CO, V296, P904, DOI 10.1016/S0006-291X(02)02007-7; Maatta A, 2000, J BIOL CHEM, V275, P19857, DOI 10.1074/jbc.M001028200; Martinez-Ruiz A, 2004, ARCH BIOCHEM BIOPHYS, V423, P192, DOI 10.1016/j.abb.2003.12.006; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Osmanagic-Myers S, 2006, J CELL BIOL, V174, P557, DOI 10.1083/jcb.200605172; PARRY DAD, 1985, INT J BIOL MACROMOL, V7, P203, DOI 10.1016/0141-8130(85)90003-0; Peitsch WK, 2001, EUR J CELL BIOL, V80, P567, DOI 10.1078/0171-9335-00194; Pfendner E, 2005, EXP DERMATOL, V14, P241, DOI 10.1111/j.0906-6705.2005.00324.x; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Rogers KR, 1996, J STRUCT BIOL, V117, P55, DOI 10.1006/jsbi.1996.0069; ROGERS KR, 1991, BIOCHEM J, V275, P789, DOI 10.1042/bj2750789; ROGERS KR, 1989, INT J TISSUE REACT, V11, P309; Schroder R, 2002, J NEUROPATH EXP NEUR, V61, P520, DOI 10.1093/jnen/61.6.520; Sevcik J, 2004, EUR J BIOCHEM, V271, P1873, DOI 10.1111/j.1432-1033.2004.04095.x; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Stamatakis K, 2006, J AM SOC NEPHROL, V17, P89, DOI 10.1681/ASN.2005030329; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Steinbock FA, 2000, J CELL SCI, V113, P483; TRAUB P, 1993, J MOL BIOL, V230, P837, DOI 10.1006/jmbi.1993.1205; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; West MB, 2006, FASEB J, V20, P1715, DOI 10.1096/fj.06-5843fje; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; Wiche G, 1998, J CELL SCI, V111, P2477; Xian M, 2000, BIOCHEM BIOPH RES CO, V268, P310, DOI 10.1006/bbrc.2000.2117; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102	55	29	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8175	8187		10.1074/jbc.M608473200	http://dx.doi.org/10.1074/jbc.M608473200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224453	hybrid			2022-12-25	WOS:000245081000050
J	Eley, HL; Tisdale, MJ				Eley, Helen L.; Tisdale, Michael J.			Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED-RNA; UBIQUITIN-PROTEASOME PATHWAY; KINASE PKR; EUKARYOTIC INITIATION-FACTOR-2; MALIGNANT-TRANSFORMATION; CACHECTIC-FACTOR; MURINE MYOTUBES; IN-VITRO; ACTIVATION	Both proteolysis-inducing factor (PIF) and angiotensin II have been shown to produce a depression in protein synthesis in murine myotubes concomitant with an increased phosphorylation of eukaryotic initiation factor 2 (eIF2 alpha). Both PIF and angiotensin II were shown to induce autophosphorylation of the RNA-dependent protein kinase (PKR), and an inhibitor of this enzyme completely attenuated the depression in protein synthesis and prevented the induction of eIF2 alpha phosphorylation. The PKR inhibitor also completely attenuated the increase in protein degradation induced by PIF and angiotensin II and prevented the increase in proteasome expression and activity. To confirm these results myotubes were transfected with plasmids that express either wild-type PKR, or a catalytically inactive PKR variant, PKR Delta 6. Myotubes expressing PKRA6 showed no increase in eIF2 alpha phosphorylation in response to PIF or angiotensin II, no depression in protein synthesis, and no increase in protein degradation or increase in proteasome expression. Induction of the ubiquitin-proteasome pathway by PIF and angiotensin II has been linked to activation of the transcription factor nuclear factor-kappa B (NF-kappa B). Inhibition of PKR prevented nuclear migration of NF-kappa B in response to both PIF and angiotensin II, by preventing degradation of the inhibitor protein I-kappa B. Phosphorylation of PKR and eIF2 alpha was also significantly increased in the gastrocnemius muscle of weight losing mice bearing the MAC16 tumor, suggesting that a similar process may be operative in cancer cachexia. These results provide a link between the depression of protein synthesis in skeletal muscle and the increase in protein degradation.	Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	Aston University	Tisdale, MJ (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	m.j.tisdale@aston.ac.uk						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASHFORD AJ, 1986, J BIOL CHEM, V261, P4059; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Cooney RN, 1999, SHOCK, V11, P235, DOI 10.1097/00024382-199904000-00002; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; EMERY PW, 1984, BRIT MED J, V289, P584, DOI 10.1136/bmj.289.6445.584; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; Gomes-Marcondes MCC, 2002, BRIT J CANCER, V86, P1628, DOI 10.1038/sj/bjc/6600236; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jammi NV, 2003, BIOCHEM BIOPH RES CO, V308, P50, DOI 10.1016/S0006-291X(03)01318-4; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lawler JM, 2003, FREE RADICAL BIO MED, V35, P9, DOI 10.1016/S0891-5849(03)00186-2; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Lorite MJ, 2001, BRIT J CANCER, V85, P297, DOI 10.1054/bjoc.2001.1879; LUNDHOLM K, 1976, EUR J CANCER, V12, P465, DOI 10.1016/0014-2964(76)90036-0; NIXON DW, 1980, AM J MED, V68, P683, DOI 10.1016/0002-9343(80)90254-5; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Russell ST, 2006, CELL SIGNAL, V18, P1087, DOI 10.1016/j.cellsig.2005.09.009; Russell ST, 2006, CANCER LETT, V231, P290, DOI 10.1016/j.canlet.2005.02.007; Sanders PM, 2005, BRIT J CANCER, V93, P425, DOI 10.1038/sj.bjc.6602725; Smith HJ, 1999, CANCER RES, V59, P5507; Smith HJ, 2004, BRIT J CANCER, V91, P408, DOI 10.1038/sj.bjc.6601981; Smith HJ, 2004, BRIT J CANCER, V90, P1850, DOI 10.1038/sj.bjc.6601767; Smith HJ, 2003, APOPTOSIS, V8, P161, DOI 10.1023/A:1022970609579; SMITH KL, 1993, BRIT J CANCER, V67, P680, DOI 10.1038/bjc.1993.126; SVEN KCS, 2003, J BIOL CHEM, V278, P49819; Todorov PT, 1996, CANCER RES, V56, P1256; Whitehouse AS, 2003, BRIT J CANCER, V89, P1116, DOI 10.1038/sj.bjc.6601132; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; Wyke SM, 2005, BRIT J CANCER, V92, P711, DOI 10.1038/sj.bjc.6602402; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	45	104	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7087	7097		10.1074/jbc.M610378200	http://dx.doi.org/10.1074/jbc.M610378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213191	hybrid			2022-12-25	WOS:000245080900020
J	Wang, Y; Zhou, K; Zeng, XC; Lin, JX; Zhan, X				Wang, Ying; Zhou, Kang; Zeng, Xianchun; Lin, Jinxiu; Zhan, Xi			Tyrosine phosphorylation of missing in metastasis protein in implicated in platelet-derived growth factor-mediated cell shape changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEDGEHOG-RESPONSIVE GENE; SRC FAMILY; MIM-B; SIGNAL-TRANSDUCTION; SUPPRESSOR GENE; BLADDER-CANCER; ACTIN; RECEPTOR; EXPRESSION; KINASES	Missing in metastasis gene, or MTSS1, encodes an intracellular protein that is implicated in actin cytoskeleton reorganization and often down-regulated in certain types of tumor cells. In response to platelet-derived growth factor (PDGF), green fluorescent protein (GFP)-tagged murine Mtss1 (Mtss1-GFP) underwent redistribution from the cytoplasm to dorsal membrane ruffles along with phosphorylation at tyrosine residues in a time-dependent manner. Tyrosine phosphorylation of Mtss1-GFP was also elevated in cells where an oncogenic Src was activated but severely impaired in Src knock-out cells or cells treated with Src kinase inhibitor PP2. Mutagenesis analysis has revealed that phosphorylation occurs at multiple sites, including tyrosine residues Tyr-397 and Tyr-398. Mutation at both Tyr-397 and Tyr-398 abolished the PDGF-mediated tyrosine phosphorylation. Furthermore, recombinant Mtss1 protein was phosphorylated by recombinant Src in a manner dependent on Tyr-397 and Tyr-398. Efficient tyrosine phosphorylation of Mtss1 in response to PDGF also involves a coiled-coil domain, which is essential for a proper distribution to the cell leading edge and dorsal ruffles. Interestingly, overexpression of wild type Mtss1-GFP promoted the PDGF-induced dorsal ruffling, whereas overexpression of a mutant deficient in phosphorylation at Tyr-397 and Tyr-398 or a mutant with deletion of the coiled-coil domain impaired the formation of dorsal ruffles. These data indicate that Mtss1 represents a novel signaling pathway from PDGF receptor to the actin cytoskeleton via Src-related kinases.	Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Dept Pathol,Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Fujian Med Univ, Affiliated Hosp 1, Dept Cardiol, Fuzhou 350005, Peoples R China	University System of Maryland; University of Maryland Baltimore; Fujian Medical University	Zhan, X (corresponding author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Dept Pathol,Marlene & Stewart Greenebaum Canc Ctr, 800 W Baltimore St, Baltimore, MD 21201 USA.	Hxzhan@som.umaryland.edu		Zeng, Xian-Chun/0000-0003-2675-2596	NCI NIH HHS [R01CA113809, R01CA091984] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113809, R01CA091984] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; CATLING AD, 1994, J VIROL, V68, P4392, DOI 10.1128/JVI.68.7.4392-4399.1994; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Loberg RD, 2005, INT J ONCOL, V26, P1699; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Stradal TEB, 2006, CURR OPIN CELL BIOL, V18, P4, DOI 10.1016/j.ceb.2005.12.003; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106; Wang DW, 2006, J BIOL CHEM, V281, P32660, DOI 10.1074/jbc.M604588200; WANG Y, 2007, IN PRESS CANC INVEST; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x	29	29	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7624	7631		10.1074/jbc.M608448200	http://dx.doi.org/10.1074/jbc.M608448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17224454	hybrid			2022-12-25	WOS:000245080900075
J	Lee, MH; Atkinson, S; Murphy, G				Lee, Meng-Huee; Atkinson, Susan; Murphy, Gillian			Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CATALYTIC DOMAIN; PROTEIN	Tissue inhibitor of metalloproteinases (TIMPs) are the endogenous inhibitors of the zinc-dependent endopeptidases of the matrix metalloproteinase families. There are four mammalian TIMPs (TIMP-1 to -4) but only TIMP-3 is sequestered to the extracellular matrix (ECM). The molecular basis for the TIMP-3:ECM association has never been fully investigated until now. In this report, we identify the unique amino acid configuration that constitutes the basis of the ECM binding motif in TIMP-3. By systematically exchanging the subdomains of the TIMPs and exhaustive mutation of TIMP-3, we have identified the surface residues directly responsible for ECM association. Contrary to the accepted view, we have found that TIMP-3 interacts with the ECM via both its N- and C-terminal domains. The amino acids involved in ECM binding are all basic in nature: Lys-26, Lys-27, Lys-30, Lys-76 of the N-terminal domain and Arg-163, Lys-165 of the C-terminal domain. Replacement of these residues with glutamate (E) and glutamine (Q) (K26/27/30/76E + R163/K165Q) resulted in a soluble TIMP-3 devoid of ECM-adhering ability. Using the ECM binding motif derived from TIMP-3, we have also created a TIMP-1 mutant (K26/27/30 + K76 transplant) capable of ECM association. This is the first instance of TIMPs being intentionally rendered soluble or ECM-bound. The ability to prepare TIMPs in soluble or ECM-bound forms also opens new avenues for future TIMP research.	Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Res Inst, Cambridge CB2 0RE, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Res Inst, Robinson Way, Cambridge CB2 0RE, England.	gm290@cam.ac.uk			MRC [G0400637] Funding Source: UKRI; Medical Research Council [G0400637] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 1998, CANCER RES, V58, P2310; ALBERTS B, 2002, MOL BIOL CELL, P949; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BLENIS J, 1984, J BIOL CHEM, V259, P1563; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; Caterina NCM, 1998, BBA-PROTEIN STRUCT M, V1388, P21, DOI 10.1016/S0167-4838(98)00158-7; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Lee MH, 2005, J BIOL CHEM, V280, P15967, DOI 10.1074/jbc.M500897200; Lee MH, 2004, J BIOL CHEM, V279, P17562, DOI 10.1074/jbc.M312589200; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lorenz HM, 2002, ARTHRITIS RES THER, V4, pS17, DOI 10.1186/ar564; Majid MA, 2006, BRIT J OPHTHALMOL, V90, P1310, DOI 10.1136/bjo.2006.097246; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; van Deventer SJH, 2002, GUT, V51, P5, DOI 10.1136/gut.51.1.5; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	26	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6887	6898		10.1074/jbc.M610490200	http://dx.doi.org/10.1074/jbc.M610490200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202148	hybrid			2022-12-25	WOS:000244867200098
J	Ong, SJ; Hsu, HM; Liu, HW; Chu, CH; Tai, JH				Ong, Shiou-Jeng; Hsu, Hong-Ming; Liu, Hsing-Wei; Chu, Chien-Hsin; Tai, Jung-Hsiang			Activation of multifarious transcription of an adhesion protein ap65-1 gene by a novel Myb2 protein in the protozoan parasite Trichomonas vaginalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; REGULATORY ELEMENTS; EXPRESSION; IRON; ENZYMES; CELLS; ADHERENCE; PROMOTER; COMPLEX; LOCALIZATION	Multifarious transcription of the adhesion protein ap65-1 gene in the human pathogen, Trichomonas vaginalis, is critically regulated by the coordination of two similar but opposite oriented DNA regulatory regions, MRE-1/MRE-2r and MRE-2f, both of which are binding sites for multiple Myb-like proteins. In the present study, MRE-1/MRE-2r was demonstrated to be composed of multiple overlapping promoter elements, among which the entire region is required for growth-related ap65-1 transcription, and the 5'-MRE-1 antagonizes the suppressive activity of the 3'-MRE-2r in iron-inducible transcription. The recombinant Myb2 protein derived from a previously identified myb2 gene was demonstrated to recognize distinct sequence contexts in MRE-2r and MRE-2f, whereas Myb2 in the nuclear lysate preferentially binds to MRE-2f to MRE-2r. Iron repletion resulted in persistent repression of the myb2 gene, and temporal activation/deactivation of Myb2 promoter entry, which was also activated by prolonged iron depletion. The hemagglutinin-tagged Myb2 when overexpressed during iron-depleted conditions facilitated basal and growth-related ap65-1 transcription to a level that was achieved in iron-replete cells, whereas iron-inducible ap65-1 transcription was abolished with knockdown of Myb2. These findings demonstrated that Myb2 is involved in activation of growth-related and iron-inducible transcription of the ap65-1 gene, possibly through differential promoter selection in competition with other Myb proteins.	Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tai, JH (corresponding author), Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei 11529, Taiwan.	taijh@gate.sinica.edu.tw	Tai, Jung-Hsiang/S-7019-2018; Chu, Chu/T-6038-2019	Chu, Chien-Hsin/0000-0002-5490-8378; HSU, HONG-MING/0000-0002-7579-5106				ALDERETE JF, 1995, MOL MICROBIOL, V17, P69, DOI 10.1111/j.1365-2958.1995.mmi_17010069.x; Alderete JF, 2004, MICROB PATHOGENESIS, V36, P263, DOI 10.1016/j.micpath.2003.12.007; ALDERETE JF, 1995, MICROB PATHOGENESIS, V19, P93, DOI 10.1006/mpat.1995.0049; Alderete JF, 1999, INFECT IMMUN, V67, P4298, DOI 10.1128/IAI.67.8.4298-4302.1999; Alderete JF, 2001, CELL MICROBIOL, V3, P359, DOI 10.1046/j.1462-5822.2001.00126.x; Bastida-Corcuera FD, 2005, EUKARYOT CELL, V4, P1951, DOI 10.1128/EC.4.11.1951-1958.2005; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brugerolle G, 2000, PARASITOL RES, V86, P30, DOI 10.1007/PL00008503; Dolezal P, 2004, GENE, V329, P81, DOI 10.1016/j.gene.2003.12.022; Garcia AF, 2003, MOL MICROBIOL, V47, P1207, DOI 10.1046/j.1365-2958.2003.03366.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HRDY I, 1995, J EUKARYOT MICROBIOL, V42, P593, DOI 10.1111/j.1550-7408.1995.tb05913.x; Kucknoor AS, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-5; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Moreno-Brito V, 2005, CELL MICROBIOL, V7, P245, DOI 10.1111/j.1462-5822.2004.00455.x; Mundodi V, 2004, MOL MICROBIOL, V53, P1099, DOI 10.1111/j.1365-2958.2004.04192.x; Nilsson T, 2001, J VIROL, V75, P5796, DOI 10.1128/JVI.75.13.5796-5811.2001; Nishimura W, 2005, BIOCHEM J, V392, P181, DOI 10.1042/BJ20050970; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ong SJ, 2006, EUKARYOT CELL, V5, P391, DOI 10.1128/EC.5.2.391-399.2006; Ong SJ, 2004, MOL MICROBIOL, V52, P1721, DOI 10.1111/j.1365-2958.2004.04088.x; Ortiz D, 2003, MOL BIOCHEM PARASIT, V128, P43, DOI 10.1016/S0166-6851(03)00043-4; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; QU XM, 2004, J BIOL CHEM, V279, P21021; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Solano R, 1997, J BIOL CHEM, V272, P2889, DOI 10.1074/jbc.272.5.2889; Sorvillo F, 2001, EMERG INFECT DIS, V7, P927, DOI 10.3201/eid0706.010603; Stoffler D, 2006, CAN J PHYSIOL PHARM, V84, P499, DOI 10.1139/Y06-001; Sulentic CEW, 2004, TOXICOLOGY, V200, P235, DOI 10.1016/j.tox.2004.03.015; Tsai CD, 2002, J BIOL CHEM, V277, P5153, DOI 10.1074/jbc.M110234200; Vanacova S, 2005, P NATL ACAD SCI USA, V102, P4430, DOI 10.1073/pnas.0407500102; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6716	6725		10.1074/jbc.M610484200	http://dx.doi.org/10.1074/jbc.M610484200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202137	hybrid			2022-12-25	WOS:000244867200081
J	Beattie, JR; Maguire, C; Gilchrist, S; Barrett, LJ; Cross, CE; Possmayer, F; Ennis, M; Elborn, JS; Curry, WJ; McGarvey, JJ; Schock, BC				Beattie, J. Renwick; Maguire, Ciaran; Gilchrist, Sarah; Barrett, Lindsay J.; Cross, Carroll E.; Possmayer, Fred; Ennis, Madeleine; Elborn, J. Stuart; Curry, W. James; McGarvey, John J.; Schock, Bettina C.			The use of Raman microscopy to determine and localize vitamin E in biological samples	FASEB JOURNAL			English	Article						alpha-tocopherol; tissue distribution; lung tissue; Raman mapping	RAC-ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; MASS-SPECTROMETRY; TRANSFER PROTEIN; II CELLS; LUNG; SPECTROSCOPY; ANTIOXIDANT; PLASMA; CHROMATOGRAPHY	Alpha-tocopherol (aT), the predominant form of vitamin E in mammals, is thought to prevent oxidation of polyunsaturated fatty acids. In the lung, aT is perceived to be accumulated in alveolar type 11 cells and secreted together with surfactant into the epithelial lining fluid. Conventionally, determination of aT and related compounds requires extraction with organic solvents. This study describes a new method to determine and image the distribution of aT and related compounds within cells and tissue sections using the light-scattering technique of Raman microscopy to enable high spatial as well as spectral resolution. This study compared the nondestructive analysis by Raman microscopy of vitamin E, in particular aT, in biological samples with data obtained using conventional HPLC analysis. Raman spectra were acquired at spatial resolutions of 2-0.8 mu m. Multivariate analysis techniques were used for analyses and construction of corresponding maps showing the distribution of aT, alpha-tocopherol quinone (aTQ), and other constituents (hemes, proteins, DNA, and surfactant lipids). A combination of images enabled identification of colocalized constituents (heme/aTQ and aT/surfactant lipids). Our data demonstrate the ability of Raman microscopy to discriminate between different tocopherols and oxidation products in biological specimens without sample destruction. By enabling the visualization of lipid-protein interactions, Raman microscopy offers a novel method of investigating biological characterization of lipid-soluble compounds, including those that may be embedded in biological membranes such as aT.	Queens Univ Belfast, Sch Chem & Chem Engn, Dept Med, Resp Res Grp, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Sch Med & Dent, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Sch Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; Univ Calif Davis, Davis, CA 95616 USA; Univ Western Ontario, Dept Ob Gyn & Biochem, London, ON N6A 3K7, Canada	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of California System; University of California Davis; Western University (University of Western Ontario)	Schock, BC (corresponding author), Queens Univ Belfast, Sch Chem & Chem Engn, Dept Med, Resp Res Grp, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.	b.schock@qub.ac.uk	Beattie, Renwick/B-7810-2008; Ennis, Madeleine/GZG-4070-2022; Beattie, James Renwick/I-4506-2015	Beattie, James Renwick/0000-0002-0205-717X; elborn, joseph/0000-0002-2323-442X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011985] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES011985] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkinson JK, 2004, ANN NY ACAD SCI, V1031, P324, DOI 10.1196/annals.1331.032; Azzi A, 2002, FEBS LETT, V519, P8, DOI 10.1016/S0014-5793(02)02706-0; Barbas C, 1997, J CHROMATOGR A, V778, P415, DOI 10.1016/S0021-9673(97)00416-0; Beattie JR, 2006, LIPIDS, V41, P287, DOI 10.1007/s11745-006-5099-1; Beattie JR, 2005, MOL VIS, V11, P825; Beattie JR, 2004, LIPIDS, V39, P897, DOI 10.1007/s11745-004-1312-5; Beattie JR, 2004, LIPIDS, V39, P407, DOI 10.1007/s11745-004-1245-z; Blatt DH, 2001, NUTRITION, V17, P799, DOI 10.1016/S0899-9007(01)00637-2; Bouhafs RKL, 1999, LUNG, V177, P101, DOI 10.1007/PL00007629; Bouhafs RKL, 1999, PEDIATR PULM, V27, P322, DOI 10.1002/(SICI)1099-0496(199905)27:5<322::AID-PPUL5>3.3.CO;2-5; Bruno Richard S, 2006, Pathophysiology, V13, P143, DOI 10.1016/j.pathophys.2006.05.003; Celedon A, 2002, FOOD SCI TECHNOL INT, V8, P101, DOI 10.1106/108201302024208; CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; Everall NJ, 2000, APPL SPECTROSC, V54, P1515, DOI 10.1366/0003702001948439; Galli F, 2002, FREE RADICAL BIO MED, V32, P333, DOI 10.1016/S0891-5849(01)00800-0; Gille L, 2004, ANN NY ACAD SCI, V1031, P341, DOI 10.1196/annals.1331.039; Haka AS, 2006, CANCER RES, V66, P3317, DOI 10.1158/0008-5472.CAn-05-2815; IKENOYA S, 1979, CHEM PHARM BULL, V27, P1237; INGOLD KU, 1987, ARCH BIOCHEM BIOPHYS, V259, P224, DOI 10.1016/0003-9861(87)90489-9; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ITO Y, 1990, CLIN CHIM ACTA, V194, P131, DOI 10.1016/0009-8981(90)90128-F; Kolleck I, 2002, AM J RESP CRIT CARE, V166, pS62, DOI 10.1164/rccm.2206019; Kolleck I, 2002, AM J RESP CELL MOL, V27, P57, DOI 10.1165/ajrcmb.27.1.4774; Kraemer K, 2004, ANN NY ACAD SCI, V1031, P435, DOI 10.1196/annals.1331.066; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; Leonard SW, 2003, FREE RADICAL BIO MED, V35, P1560, DOI 10.1016/j.freeradbiomed.2003.09.010; LEVIN IW, 1988, BIOPHYS J, V53, pA244; MacNee W, 2000, CHEST, V117, p303S, DOI 10.1378/chest.117.5_suppl_1.303S-a; Min YK, 2005, J RAMAN SPECTROSC, V36, P73, DOI 10.1002/jrs.1280; Muller PY, 2005, J PLANT PHYSIOL, V162, P811, DOI 10.1016/j.jplph.2005.04.015; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; PACHT ER, 1986, J CLIN INVEST, V77, P789, DOI 10.1172/JCI112376; Panin L E, 1998, Membr Cell Biol, V11, P631; Podda M, 1996, J LIPID RES, V37, P893; PRYOR WA, 1991, AM J CLIN NUTR, V53, P702, DOI 10.1093/ajcn/53.3.702; PUPPELS GJ, 1990, NATURE, V347, P301, DOI 10.1038/347301a0; Qian J, 2004, ANN NY ACAD SCI, V1031, P330, DOI 10.1196/annals.1331.034; Qian JH, 2005, J LIPID RES, V46, P2072, DOI 10.1194/jlr.M500143-JLR200; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; RUSTOW B, 1993, AM J PHYSIOL, V265, pL133, DOI 10.1152/ajplung.1993.265.2.L133; Saito Y, 2004, ANN NY ACAD SCI, V1031, P368, DOI 10.1196/annals.1331.047; Schock BC, 2004, ARCH BIOCHEM BIOPHYS, V423, P162, DOI 10.1016/j.abb.2003.12.009; Sijtsema NM, 2000, BIOPHYS J, V78, P2606, DOI 10.1016/S0006-3495(00)76805-6; Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446; Sinha P, 2002, BBA-MOL CELL BIOL L, V1583, P91, DOI 10.1016/S1388-1981(02)00189-0; Smit HA, 1999, P NUTR SOC, V58, P309, DOI 10.1017/S0029665199000427; Song LMWK, 2002, GASTROENTEROLOGY, V122, pA288; SPIRO TG, 1986, BIOL APPL RAMAN SPEC, V1; Tabak C, 1999, THORAX, V54, P1021, DOI 10.1136/thx.54.11.1021; Tang Wei, 2005, Genomics Proteomics & Bioinformatics, V3, P169; Tolle A, 2005, FREE RADICAL BIO MED, V38, P1401, DOI 10.1016/j.freeradbiomed.2005.02.001; Touboul D, 2005, J LIPID RES, V46, P1388, DOI 10.1194/jlr.M500058-JLR200; TRABER MG, 2005, MODERN NUTR HLTH DIS, P396; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Tu A.T., 1982, RAMAN SPECTROSCOPY B; Yang H, 2002, J PHARM PHARMACOL, V54, P1247, DOI 10.1211/002235702320402099	56	33	33	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					766	776		10.1096/fj.06-7028com	http://dx.doi.org/10.1096/fj.06-7028com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17209128				2022-12-25	WOS:000244686400015
J	Waters, PD; Dobigny, G; Waddell, PJ; Robinson, TJ				Waters, Paul D.; Dobigny, Gauthier; Waddell, Peter J.; Robinson, Terence J.			Evolutionary History of LINE-1 in the Major Clades of Placental Mammals	PLOS ONE			English	Article								Background. LINE-1 constitutes an important component of mammalian genomes. It has a dynamic evolutionary history characterized by the rise, fall and replacement of subfamilies. Most data concerning LINE-1 biology and evolution are derived from the human and mouse genomes and are often assumed to hold for all placentals. Methodology. To examine LINE-1 relationships, sequences from the 39 region of the reverse transcriptase from 21 species (representing 13 orders across Afrotheria, Xenarthra, Supraprimates and Laurasiatheria) were obtained from whole genome sequence assemblies, or by PCR with degenerate primers. These sequences were aligned and analysed. Principal Findings. Our analysis reflects accepted placental relationships suggesting mostly lineage-specific LINE-1 families. The data provide clear support for several clades including Glires, Supraprimates, Laurasiatheria, Boreoeutheria, Xenarthra and Afrotheria. Within the afrotherian LINE-1 (AfroLINE) clade, our tree supports Paenungulata, Afroinsectivora and Afroinsectiphillia. Xenarthran LINE-1 (XenaLINE) falls sister to AfroLINE, providing some support for the Atlantogenata (Xenarthra+Afrotheria) hypothesis. Significance. LINEs and SINEs make up approximately half of all placental genomes, so understanding their dynamics is an essential aspect of comparative genomics. Importantly, a tree of LINE-1 offers a different view of the root, as long edges (branches) such as that to marsupials are shortened and/or broken up. Additionally, a robust phylogeny of diverse LINE-1 is essential in testing that site-specific LINE-1 insertions, often regarded as homoplasy-free phylogenetic markers, are indeed unique and not convergent.	[Waters, Paul D.; Dobigny, Gauthier; Robinson, Terence J.] Univ Stellenbosch, Dept Bot & Zool, Evolutionary Genom Grp, Matieland, South Africa; [Waters, Paul D.] Australian Natl Univ, Res Sch Biol Sci, Comparat Genom Grp, Canberra, ACT 2601, Australia; [Dobigny, Gauthier] Ctr Biol Gest Populat, Inst Rech Dev, Montferrier Sur Lez, France; [Waddell, Peter J.] Univ Tokyo, Lab Biometry & Bioinformat, Tokyo, Japan; [Waddell, Peter J.] Univ S Carolina, S Carolina Canc Ctr, Columbia, SC 29208 USA	Stellenbosch University; Australian National University; Institut de Recherche pour le Developpement (IRD); University of Tokyo; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Robinson, TJ (corresponding author), Univ Stellenbosch, Dept Bot & Zool, Evolutionary Genom Grp, Matieland, South Africa.	tjr@sun.ac.za	Waters, Paul/D-1044-2009; Waters, Paul D/B-7871-2015; Robinson, Terence J./K-7342-2017	Waters, Paul D/0000-0002-4689-8747; Robinson, Terence J./0000-0002-4298-4891	Wellcome Trust; University of Stellenbosch; National Research Foundation [GUN 2053812]; NIH [5R01LM8626]; NATIONAL LIBRARY OF MEDICINE [R01LM008626] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); University of Stellenbosch; National Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Financial support from the Wellcome Trust, the University of Stellenbosch and the National Research Foundation (GUN 2053812) to TJR is gratefully acknowledged. PJW thanks JSPS for support via their fellowship program, NIH grant 5R01LM8626.	Amrine-Madsen H, 2003, MOL PHYLOGENET EVOL, V28, P225, DOI 10.1016/S1055-7903(03)00118-0; Boissinot S, 2000, MOL BIOL EVOL, V17, P915, DOI 10.1093/oxfordjournals.molbev.a026372; Cabot EL, 1997, J MOL EVOL, V45, P412, DOI 10.1007/PL00006246; Delsuc F, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-11; Delsuc F, 2002, MOL BIOL EVOL, V19, P1656, DOI 10.1093/oxfordjournals.molbev.a003989; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Furano AV, 2004, TRENDS GENET, V20, P9, DOI 10.1016/j.tig.2003.11.006; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1; Kriegs JO, 2006, PLOS BIOL, V4, P537, DOI 10.1371/journal.pbio.0040091; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; MACPHEE RDE, 1993, MAMMAL PHYLOGENY : PLACENTALS, P13; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Nikaido M, 2003, MOL BIOL EVOL, V20, P522, DOI 10.1093/molbev/msg052; Nishihara H, 2005, MOL BIOL EVOL, V22, P1823, DOI 10.1093/molbev/msi179; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ohshima K, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r74; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Robinson TJ, 2004, P ROY SOC B-BIOL SCI, V271, P1477, DOI 10.1098/rspb.2004.2754; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; SCULLY M, 2001, J MAMM EVOL, V8, P239; Shoshani J, 1998, MOL PHYLOGENET EVOL, V9, P572, DOI 10.1006/mpev.1998.0520; SMIT AF, 1995, J MOL BIOL, V264, P401; Springer MS, 2004, MOL PHYLOGENET EVOL, V30, P883, DOI 10.1016/j.ympev.2003.09.019; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; SWOFFORD DL, 1996, MOL SYSTEMATICS, V2, P407; SWOFFORD DL, PAUP PHYLOGENETIC AN; Thomsen PD, 1996, MAMM GENOME, V7, P42, DOI 10.1007/s003359900010; Waddell P J, 2001, Genome Inform, V12, P141; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Waddell PJ, 1997, MOL PHYLOGENET EVOL, V8, P398, DOI 10.1006/mpev.1997.0452; Waddell PJ, 1999, SYST BIOL, V48, P31, DOI 10.1080/106351599260427; Waddell PJ, 2003, MOL PHYLOGENET EVOL, V28, P197, DOI 10.1016/S1055-7903(03)00115-5; WADDELL PJ, 1996, HDB SYMBOLIC EVOLUTI, P53; Waters PD, 2004, CHROMOSOMA, V113, P137, DOI 10.1007/s00412-004-0301-9; Wilcox TP, 2002, MOL PHYLOGENET EVOL, V25, P361, DOI 10.1016/S1055-7903(02)00244-0; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891	43	50	51	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e158	10.1371/journal.pone.0000158	http://dx.doi.org/10.1371/journal.pone.0000158			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225861	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444000009
J	Jiang, X; Ellison, SJ; Alarid, ET; Shapiro, DJ				Jiang, X.; Ellison, S. J.; Alarid, E. T.; Shapiro, D. J.			Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells	ONCOGENE			English	Article						estrogen; estrogen receptor; tamoxifen; proteinase inhibitor 9; natural killer cell; granzyme; breast cancer	INVASIVE BREAST-CANCER; B-MEDIATED APOPTOSIS; AROMATASE INHIBITORS; ALPHA CONCENTRATION; TARGET-CELLS; CYTOTOXICITY; PROTEASE; POSTMENOPAUSAL; EXPRESSION; MODULATORS	Estrogens promote cell proliferation and metastases in several human cancers. Here, we describe a different action of estrogens likely to contribute to tumor development-blocking immunosurveillance. In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor a (ER alpha) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERa, induct ion of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells. When the Erk pathway is activated with epidermal growth factor, the concentration of estrogen required to induce a protective level of PI-9 is reduced to 10 pM. Elevated concentrations of estrogen and ER may provide a dual selective advantage to breast cancer cells by controlling PI-9 levels and thereby blocking immunosurveillance. Expressing elevated levels of ERa reveals a potentially important difference in the effects of TAM, raloxifene and ICI 182,780 on immunosurveillance in breast cancer.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, B-4 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909, R01DK064034] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16720] Funding Source: Medline; NIDDK NIH HHS [DK64034, DK071909] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barrie MB, 2004, J IMMUNOL, V172, P6453, DOI 10.4049/jimmunol.172.10.6453; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Blomberg K, 1996, J IMMUNOL METHODS, V193, P199, DOI 10.1016/0022-1759(96)00063-4; Bots M, 2006, IMMUNOL CELL BIOL, V84, P79, DOI 10.1111/j.1440-1711.2005.01417.x; Bots M, 2005, BLOOD, V105, P1153, DOI 10.1182/blood-2004-03-0791; Bots M, 2006, BLOOD, V107, P4974, DOI 10.1182/blood-2006-01-0291; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Godal R, 2006, BLOOD, V107, P3205, DOI 10.1182/blood-2005-07-2880; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Gradishar WJ, 2006, JAMA-J AM MED ASSOC, V295, P2784, DOI 10.1001/jama.295.23.jed60037; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Hupperets PS, 1997, AM J CLIN ONCOL-CANC, V20, P546, DOI 10.1097/00000421-199712000-00002; Jiang XG, 2006, ENDOCRINOLOGY, V147, P1419, DOI 10.1210/en.2005-0996; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kannan-Thulasiraman P, 2002, J BIOL CHEM, V277, P41230, DOI 10.1074/jbc.M200379200; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Lamboley C, 2000, CELL MOL BIOL, V46, P13; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lonning PE, 1997, J STEROID BIOCHEM, V61, P255; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Mahrus S, 2004, J BIOL CHEM, V279, P54275, DOI 10.1074/jbc.M411482200; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MELDRUM DR, 1981, OBSTET GYNECOL, V57, P624; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Riera J, 1999, AM J CLIN PATHOL, V111, P329; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SANCHOGARNIER H, 1995, EUR J CANCER, V31A, P1851, DOI 10.1016/0959-8049(95)00387-X; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; ten Berge RL, 2003, J PATHOL, V200, P4, DOI 10.1002/path.1331; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; van Houdt IS, 2005, CLIN CANCER RES, V11, P6400, DOI 10.1158/1078-0432.CCR-05-0306; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Zhang ZH, 2006, MOL ECOL NOTES, V6, P24, DOI 10.1111/j.1471-8286.2005.01117.x	48	75	80	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4106	4114		10.1038/sj.onc.1210197	http://dx.doi.org/10.1038/sj.onc.1210197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237823				2022-12-25	WOS:000247252700006
J	John, CD; Sahni, V; Mehet, D; Morris, JF; Christian, HC; Perretti, M; Flower, RJ; Solito, E; Buckingham, JC				John, C. D.; Sahni, V.; Mehet, D.; Morris, J. F.; Christian, H. C.; Perretti, M.; Flower, R. J.; Solito, E.; Buckingham, J. C.			Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides	FASEB JOURNAL			English	Article						glucocorticoids; annexin 1; pituitary; HPA axis; formyl peptides	ANTERIOR-PITUITARY GLAND; N-FORMYLPEPTIDE RECEPTOR; METHIONYL-LEUCYL-PHENYLALANINE; RAT PANCREATIC-ISLETS; PROTEIN-KINASE-C; LIPOCORTIN 1; IN-VITRO; CORTICOTROPIN RELEASE; INSULIN-SECRETION; CELL-LINE	The N-formyl peptide receptors (FPRs) are a family of G-protein coupled receptors that respond to proinflammatory N-formylated bacterial peptides ( e. g., formyl-Met-Leu-Phe, fMLF) and, thus, contribute to the host response to bacterial infection. Paradoxically, a growing body of evidence suggests that some members of this receptor family may also be targets for certain anti-inflammatory molecules, including annexin A1 (ANXA1), which is an important mediator of glucocorticoid ( GC) action. To explore further the potential role of FPRs in mediating ANXA1 actions, we have focused on the pituitary gland, where ANXA1 has a well-defined role as a cell-cell mediator of the inhibitory effects of GCs on the secretion of corticotrophin ( ACTH), and used molecular, genetic, and pharmacological approaches to address the question in well-established rodent models. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis identified mRNAs for four FPR family members in the mouse anterior pituitary gland, Fpr-rs1, Fpr-rs2, Fpr-rs6, and Fpr-rs7. Functional studies confirmed that, like dexamethasone, ANXA1 and two ANXA1-derived peptides (ANXA1(1-188) and ANXA1(Ac2-26)) inhibit the evoked release of ACTH from rodent anterior pituitary tissue in vitro. Fpr1 gene deletion failed to modify the pituitary responses to dexamethasone or ANXA1(Ac2-26). However, lipoxin A4 (LXA4, 0.02-2 mu M, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 mu M) but not lower (10-100 nM) concentrations. Additionally, a nonselective FPR antagonist (Boc1, 100 mu M) overcame the effects of dexamethasone, ANXA1(1-188), ANXA1(Ac2-26), fMLF, and LXA4 on ACTH release, although at a lower concentration ( 50 mu M), it was without effect. Together, the results suggest that the actions of ANXA1 in the pituitary gland are independent of Fpr1 but may involve other FPR family members, in particular, Fpr-rs1 or a closely related receptor. They thus provide the first evidence for a role of the FPR family in the regulation of neuroendocrine function.	Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, Dept Cell Biol & Neurosci, London W12 0NN, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 2JD, England; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, London, England	Imperial College London; University of Oxford; University of London; Queen Mary University London	Buckingham, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, Dept Cell Biol & Neurosci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	j.buckingham@imperial.ac.uk		Solito, Egle/0000-0001-5279-0049	BBSRC [BB/E52708X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: Medline; Wellcome Trust [040269] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILERA G, 1983, J BIOL CHEM, V258, P8039; Altamura AC, 1999, EUR NEUROPSYCHOPHARM, V10, P1, DOI 10.1016/S0924-977X(99)00017-6; Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042; BUCK T, 1997, IEEE T EVOLUTIONARY, V1, P3; BUCKINGHAM JC, 1978, J PHYSL, V286, P331; CASTELLINO F, 1992, P NATL ACAD SCI USA, V89, P3775, DOI 10.1073/pnas.89.9.3775; Chapman L, 2002, ENDOCRINOLOGY, V143, P4330, DOI 10.1210/en.2002-220529; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Christian HC, 1997, ENDOCRINOLOGY, V138, P5341, DOI 10.1210/en.138.12.5341; COWELL AM, 1991, J ENDOCRINOL, V130, P21, DOI 10.1677/joe.0.1300021; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Fu HM, 2006, J LEUKOCYTE BIOL, V79, P247, DOI 10.1189/jlb.0905498; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; He R, 2000, J IMMUNOL, V165, P4598, DOI 10.4049/jimmunol.165.8.4598; Hetland G, 1998, J CLIN PATHOL-MOL PA, V51, P143, DOI 10.1136/mp.51.3.143; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; Hong SH, 2002, FEBS LETT, V532, P17, DOI 10.1016/S0014-5793(02)03613-X; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; KIM SJ, 1989, ANN NY ACAD SCI, V559, P461; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; OHNISHI M, 1995, ENDOCRINOLOGY, V136, P2421, DOI 10.1210/en.136.6.2421; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; Philip JG, 1997, NEUROREPORT, V8, P1871, DOI 10.1097/00001756-199705260-00016; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rabiet MJ, 2005, EUR J IMMUNOL, V35, P2486, DOI 10.1002/eji.200526338; REES LH, 1971, ENDOCRINOLOGY, V89, P254, DOI 10.1210/endo-89-1-254; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SEHRAN NC, 2005, CURR OPIN CLIN NUTR, V8, P115; SMITH ME, 1993, J ARCHAEOL RES, V1, P5; Smith T., 1993, Molecular Neuropharmacology, V3, P45; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; THEOGARAJ E, 2005, PERINATAL DEXAMETHAS; Traverso V, 1999, ENDOCRINOLOGY, V140, P4311, DOI 10.1210/en.140.9.4311; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang ZG, 2002, GENE, V299, P57, DOI 10.1016/S0378-1119(02)01012-0	52	29	29	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1037	1046		10.1096/fj.06-7299com	http://dx.doi.org/10.1096/fj.06-7299com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218541	Green Accepted			2022-12-25	WOS:000245650400008
J	Kimber, MJ; McKinney, S; McMaster, S; Day, TA; Fleming, CC; Maule, AG				Kimber, Michael J.; McKinney, Susan; McMaster, Steven; Day, Tim A.; Fleming, Colin C.; Maule, Aaron G.			flp gene disruption in a parasitic nematode reveals motor dysfunction and unusual neuronal sensitivity to RNA interference	FASEB JOURNAL			English	Article						FMRFamide-like peptide; neuropeptide; nervous system; locomotion; helminth parasite	DOUBLE-STRANDED-RNA; FUNCTIONAL GENOMIC ANALYSIS; FMRFAMIDE-RELATED PEPTIDES; FREE-LIVING NEMATODE; CAENORHABDITIS-ELEGANS; NEUROPEPTIDE GENE; GLOBODERA-ROSTOCHIENSIS; KSAYMRFAMIDE PF3/AF8; EXPRESSION; MUSCLE	The potato cyst nematode Globodera pallida is a serious pest of potato crops. Nematode FMRFamide-like peptides (FLPs) are one of the most diverse neuropeptide families known, and modulate sensory and motor functions. As neuromuscular function is a well-established target for parasite control, parasitic nematode FLP signaling has significant potential in novel control strategies. In the absence of transgenic parasitic nematodes and the reported ineffectiveness of neuronal gene RNAi in Caenorhabditis elegans, nothing is known about flp function in nematode parasites. In attempts to evaluate flp function in G. pallida, we have discovered that, unlike in C. elegans, these genes are readily susceptible to RNAi. Silencing any of the five characterized G. pallida flp genes (Gp-flp-1, -6, -12, -14, or -18) incurred distinct aberrant behavioral phenotypes consistent with key roles in motor function. Further delineation of these effects revealed that double-stranded RNA exposure time (>= 18 h) and concentration (>= 0.1 mu g/ml) were critical to the observed effects, which were reversible. G. pallida flp genes are essential to coordinated locomotory activities, do not display redundancy, and are susceptible to RNAi, paving the way for the investigation of RNAi-mediated flp gene silencing as a novel plant parasite control strategy.	Queens Univ Belfast, Sch Biol Sci, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland; Iowa State Univ, Dept Biomed Sci, Ames, IA USA; Agri Food & Biosci Inst, Belfast, Antrim, North Ireland	Queens University Belfast; Iowa State University; Agri-Food & Biosciences Institute	Maule, AG (corresponding author), Queens Univ Belfast, Sch Biol Sci, Ctr Med Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	a.maule@qub.ac.uk		Day, Tim/0000-0002-9037-6540; Maule, Aaron/0000-0003-0862-2667				Aboobaker AA, 2003, MOL BIOCHEM PARASIT, V129, P41, DOI 10.1016/S0166-6851(03)00092-6; Asikainen S, 2005, NEUROREPORT, V16, P1995, DOI 10.1097/00001756-200512190-00005; ATKINSON HJ, 1988, J ZOOL, V216, P663, DOI 10.1111/j.1469-7998.1988.tb02464.x; Bakhetia M, 2005, TRENDS PLANT SCI, V10, P362, DOI 10.1016/j.tplants.2005.06.007; Bakhetia M, 2005, MOL PLANT MICROBE IN, V18, P1099, DOI 10.1094/MPMI-18-1099; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Briese Michael, 2006, Invertebrate Neuroscience, V6, P5, DOI 10.1007/s10158-005-0011-x; Chen Q, 2005, MOL PLANT MICROBE IN, V18, P621, DOI 10.1094/MPMI-18-0621; Chitwood DJ, 2003, PEST MANAG SCI, V59, P748, DOI 10.1002/ps.684; COWDEN C, 1995, PEPTIDES, V16, P491, DOI 10.1016/0196-9781(94)00211-N; Day TA, 1999, PEPTIDES, V20, P999, DOI 10.1016/S0196-9781(99)00093-5; Fanelli E, 2005, GENE, V349, P87, DOI 10.1016/j.gene.2004.11.045; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GEARY TG, 1999, ANN NY ACAD SCI, V897, P213; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Greenwood K, 2005, PARASITOLOGY, V131, pS169, DOI 10.1017/S003118200500819X; Grishok A, 2005, FEBS LETT, V579, P5932, DOI 10.1016/j.febslet.2005.08.001; Hussein AS, 2002, MOL BIOCHEM PARASIT, V122, P91, DOI 10.1016/S0166-6851(02)00068-3; Husson S. J., 2005, Communications in Agricultural and Applied Biological Sciences, V70, P153; Issa Z, 2005, INT J PARASITOL, V35, P935, DOI 10.1016/j.ijpara.2005.06.001; Jiang GL, 2005, J BIOL CHEM, V280, P2065, DOI 10.1074/jbc.M408470200; Johnson NA, 2005, GENE, V359, P26, DOI 10.1016/j.gene.2005.05.034; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Kim K, 2004, J COMP NEUROL, V475, P540, DOI 10.1002/cne.20189; Kimber MJ, 2002, INT J PARASITOL, V32, P1095, DOI 10.1016/S0020-7519(02)00084-X; Kimber MJ, 2001, MOL BIOCHEM PARASIT, V116, P199, DOI 10.1016/S0166-6851(01)00323-1; Kotze AC, 2006, MOL BIOCHEM PARASIT, V145, P101, DOI 10.1016/j.molbiopara.2005.09.012; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Li C, 2005, PARASITOLOGY, V131, pS109, DOI 10.1017/S0031182005009376; Lilley CJ, 2005, INT J PARASITOL, V35, P1577, DOI 10.1016/j.ijpara.2005.07.017; Lustigmana S, 2004, MOL BIOCHEM PARASIT, V138, P165, DOI 10.1016/j.molbiopara.2004.08.003; Marks NJ, 1998, BIOCHEM BIOPH RES CO, V248, P422, DOI 10.1006/bbrc.1998.8982; Marks NJ, 1999, MOL BIOCHEM PARASIT, V100, P185, DOI 10.1016/S0166-6851(99)00057-2; Maule AG, 1995, INVERTEBR NEUROSCI, V1, P255, DOI 10.1007/BF02211027; Maule Aaron G., 2002, Current Topics in Medicinal Chemistry, V2, P733, DOI 10.2174/1568026023393697; MAULE AG, 1994, BIOCHEM BIOPH RES CO, V200, P973, DOI 10.1006/bbrc.1994.1545; McVeigh P, 2005, INT J PARASITOL, V35, P1043, DOI 10.1016/j.ijpara.2005.05.010; McVeigh P, 2006, TRENDS PARASITOL, V22, P385, DOI 10.1016/j.pt.2006.06.010; Mousley A, 2004, TRENDS PARASITOL, V20, P482, DOI 10.1016/j.pt.2004.07.011; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Rosso MN, 2005, MOL PLANT MICROBE IN, V18, P615, DOI 10.1094/MPMI-18-0615; Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439; Sasser J. N., 1987, Vistas on Nematology: A Commemoration of the Twenty-fifth Anniversary of the Society of Nematologists, P7; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TURNER SJ, 1981, NEMATOLOGICA, V27, P315, DOI 10.1163/187529281X00548; Urwin PE, 2002, MOL PLANT MICROBE IN, V15, P747, DOI 10.1094/MPMI.2002.15.8.747; van Roessel P, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-208; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Yadav BC, 2006, MOL BIOCHEM PARASIT, V148, P219, DOI 10.1016/j.molbiopara.2006.03.013; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6	57	97	115	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1233	1243		10.1096/fj.06-7343com	http://dx.doi.org/10.1096/fj.06-7343com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17200420				2022-12-25	WOS:000245650400027
J	Pal, S; Leger, RJS; Wu, LP				Pal, Subhamoy; Leger, Raymond J. St.; Wu, Louisa P.			Fungal peptide destruxin a plays a specific role in suppressing the innate immune response in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS SURFACE-ANTIGEN; METARHIZIUM-ANISOPLIAE; ENTOMOPATHOGENIC FUNGUS; DEGRADATION ESTABLISHES; ANTIMICROBIAL PEPTIDE; DEFICIENCY IMD; TOLL; ACTIVATION; DEFENSE; PROTEIN	Destruxins are a class of insecticidal, anti-viral, and phytotoxic cyclic depsipeptides that are also studied for their toxicity to cancer cells. They are produced by various fungi, and a direct relationship has been established between Destruxin production and the virulence of the entomopathogen Metarhizium anisopliae. Aside from opening calcium channels, their in vivo mode of action during pathogenesis remains largely uncharacterized. To better understand the effects of a Destruxin, we looked at changes in gene expression following injection of Destruxin A into the fruit fly Drosophila melanogaster. Microarray results revealed reduced expression of various antimicrobial peptides that play a major role in the humoral immune response of the fly. Flies co-injected with a non-lethal dose of Destruxin A and the normally innocuous Gram-negative bacteria Escherichia coli, showed increased mortality and an accompanying increase in bacterial titers. Mortality due to sepsis was rescued through ectopic activation of components in the IMD pathway, one of two signal transduction pathways that are responsible for antimicrobial peptide induction. These results demonstrate a novel role for Destruxin A in specific suppression of the humoral immune response in insects.	Univ Maryland, Inst Biotechnol, Ctr Biosyst Res, College Pk, MD 20742 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Wu, LP (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Biosyst Res, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.	wul@umbi.umd.edu	St. Leger, Raymond/N-3219-2013; Pal, Subhamoy/A-8025-2011; Pal, Subhamoy/H-3166-2019; Pal, Subhamoy/A-9526-2015	Pal, Subhamoy/0000-0003-0133-8444; Pal, Subhamoy/0000-0003-0133-8444; Wu, Louisa/0000-0001-8609-3081	NIGMS NIH HHS [R01 GM62316] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Blanford S, 2005, SCIENCE, V308, P1638, DOI 10.1126/science.1108423; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; Braun A, 1998, P NATL ACAD SCI USA, V95, P14337, DOI 10.1073/pnas.95.24.14337; Chen HC, 1997, ANTIVIR RES, V34, P137, DOI 10.1016/S0166-3542(97)01031-0; CHERTON JC, 1991, J CHROMATOGR-BIOMED, V566, P511, DOI 10.1016/0378-4347(91)80268-H; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; DUMAS C, 1994, COMP BIOCHEM PHYS C, V108, P195, DOI 10.1016/1367-8280(94)90031-0; Dumas C, 1996, COMP BIOCHEM PHYS C, V114, P213, DOI 10.1016/0742-8413(96)00041-2; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; FARGUES J, 1985, ENTOMOPHAGA, V30, P353, DOI 10.1007/BF02372341; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gregory PG, 2005, J INSECT SCI, V5, DOI 10.1093/jis/5.1.7; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Herndon JH, 2000, NEW ENGL J MED, V343, P503, DOI 10.1056/NEJM200008173430710; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hunter DM, 2001, B ENTOMOL RES, V91, P93; HUXHAM IM, 1989, J INSECT PHYSIOL, V35, P97, DOI 10.1016/0022-1910(89)90042-5; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Isaka M, 2005, ACCOUNTS CHEM RES, V38, P813, DOI 10.1021/ar040247r; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kershaw MJ, 1999, J INVERTEBR PATHOL, V74, P213, DOI 10.1006/jipa.1999.4884; KODAIRA Y, 1961, AGR BIOL CHEM TOKYO, V25, P261, DOI 10.1080/00021369.1961.10857803; LANGE C, 1992, RAPID COMMUN MASS SP, V6, P28, DOI 10.1002/rcm.1290060107; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Maniania NK, 2002, MYCOPATHOLOGIA, V155, P229, DOI 10.1023/A:1021177626246; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MOTTA I, 1991, EUR J IMMUNOL, V21, P551, DOI 10.1002/eji.1830210304; PAIS M, 1981, PHYTOCHEMISTRY, V20, P715, DOI 10.1016/0031-9422(81)85160-6; Pedras MSC, 2002, PHYTOCHEMISTRY, V59, P579, DOI 10.1016/S0031-9422(02)00016-X; QUIOT JM, 1980, CR ACAD SCI D NAT, V291, P763; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; RIZKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P6154, DOI 10.1073/pnas.81.19.6154; ROBERTS DW, 1966, J INVERTEBR PATHOL, V8, P222, DOI 10.1016/0022-2011(66)90132-7; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; SAMUELS RI, 1988, COMP BIOCHEM PHYS C, V90, P403, DOI 10.1016/0742-8413(88)90018-7; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SUZUKI A, 1971, AGR BIOL CHEM TOKYO, V35, P1641, DOI 10.1080/00021369.1971.10860127; Tzou P, 2002, P NATL ACAD SCI USA, V99, P2152, DOI 10.1073/pnas.042411999; Vey A, 2002, J INVERTEBR PATHOL, V80, P177, DOI 10.1016/S0022-2011(02)00104-0; VEY A, 1985, C R ACAD SCI  SER, V3, P229; Vilcinskas A, 1997, J INSECT PHYSIOL, V43, P1149, DOI 10.1016/S0022-1910(97)00066-8; Vilcinskas A, 1997, J INSECT PHYSIOL, V43, P475, DOI 10.1016/S0022-1910(96)00120-5; Wright MS, 2005, J ECON ENTOMOL, V98, P1451, DOI 10.1603/0022-0493-98.5.1451; Yeh SF, 1996, BIOCHEM BIOPH RES CO, V229, P65, DOI 10.1006/bbrc.1996.1758	57	120	131	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8969	8977		10.1074/jbc.M605927200	http://dx.doi.org/10.1074/jbc.M605927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17227774	hybrid			2022-12-25	WOS:000245780300043
J	Shao, CH; Shi, XM; Wehbi, H; Zambonelli, C; Head, JF; Seaton, BA; Roberts, MF				Shao, Chenghua; Shi, Xiaomeng; Wehbi, Hania; Zambonelli, Carlo; Head, James F.; Seaton, Barbara A.; Roberts, Mary F.			Dimer structure of an interfacially impaired phosphatidylinositol-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BACILLUS-CEREUS; ACTIVATION; BINDING; DIMERIZATION; MECHANISM; INSIGHT; COMPLEX; ENZYME	The crystal structure of the W47A/W242A mutant of phosphatidylinositol-specific phospholipase C (PI-PLC) from Bacillus thuringiensis has been solved to 1.8 angstrom resolution. The W47A/ W242A mutant is an interfacially challenged enzyme, and it has been proposed that one or both tryptophan side chains serve as membrane interfacial anchors (Feng, J., Wehbi, H., and Roberts, M. F. (2002) J. Biol. Chem. 277,19867-19875). The crystal structure supports this hypothesis. Relative to the crystal structure of the closely related (97% identity) wild-type PI-PLC from Bacillus cereus, significant conformational differences occur at the membrane-binding interfacial region rather than the active site. The Trp -> Ala mutations not only remove the membrane-partitioning aromatic side chains but also perturb the conformations of the so-called helix B and rim loop regions, both of which are implicated in interfacial binding. The crystal structure also reveals a homodimer, the first such observation for a bacterial PI-PLC, with pseudo-2-fold symmetry. The symmetric dimer interface is stabilized by hydrophobic and hydrogen-bonding interactions, contributed primarily by a central swath of aromatic residues arranged in a quasiherringbone pattern. Evidence that interfacially active wild-type PI-PLC enzymes may dimerize in the presence of phosphatidylcholine vesicles is provided by fluorescence quenching of PI-PLC mutants with pyrene-labeled cysteine residues. The combined data suggest that wild-type PI-PLC can form similar homodimers, anchored to the interface by the tryptophan and neighboring membrane-partitioning residues.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02465 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Boston College; Boston University	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02465 USA.	mary.roberts@bc.edu		Seaton, Barbara/0000-0003-4654-7709; Head, James/0000-0002-6226-4146	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060418] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60418] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apiyo D, 2005, BIOCHEMISTRY-US, V44, P9980, DOI 10.1021/bi047896v; Bahnson BJ, 2005, ARCH BIOCHEM BIOPHYS, V433, P96, DOI 10.1016/j.abb.2004.08.013; BRUENGER AT, 1909, ACTA CRYSTALLOGR, V54, P905; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Essen LO, 1997, BIOCHEMISTRY-US, V36, P1704, DOI 10.1021/bi962512p; Feng JW, 2003, J BIOL CHEM, V278, P24651, DOI 10.1074/jbc.M301207200; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Heinz DW, 1996, BIOCHEMISTRY-US, V35, P9496, DOI 10.1021/bi9606105; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENRICKSON HS, 1999, BIOCHIM BIOPHYS ACTA, V1440, P107; Hondal RJ, 1998, BIOCHEMISTRY-US, V37, P4568, DOI 10.1021/bi972646i; HU ML, 1994, METHOD ENZYMOL, V233, P380; Ilkaeva O, 2002, J BIOL CHEM, V277, P4294, DOI 10.1074/jbc.M109612200; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Jones T. A., 1992, MANUAL; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P248; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; Moser J, 1997, J MOL BIOL, V273, P269, DOI 10.1006/jmbi.1997.1290; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian XQ, 1998, BIOCHEMISTRY-US, V37, P6513, DOI 10.1021/bi972650u; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; ROBERTS MF, 1998, ACS SYM SER, V718, P137, DOI DOI 10.1021/BK-1999-0718.CH009; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; Wehbi H, 2003, BIOCHEMISTRY-US, V42, P9374, DOI 10.1021/bi034195+; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P11223, DOI 10.1021/bi971039s; Zhang X, 2004, J BIOL CHEM, V279, P20490, DOI 10.1074/jbc.M401016200; Zhang Y, 2006, MOL PHARMACOL, V70, P860, DOI 10.1124/mol.105.021923; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w; Zhou C, 1999, J BIOL CHEM, V274, P2786, DOI 10.1074/jbc.274.5.2786; Zhou C, 1997, BIOCHEMISTRY-US, V36, P10089, DOI 10.1021/bi970846o; Zhou C, 1998, BIOCHEMISTRY-US, V37, P16430, DOI 10.1021/bi980601r	40	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9228	9235		10.1074/jbc.M610918200	http://dx.doi.org/10.1074/jbc.M610918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17213187	hybrid			2022-12-25	WOS:000245780300069
J	Sun, XX; Dai, MS; Lu, H				Sun, Xiao-Xin; Dai, Mu-Shui; Lu, Hua			5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINES; AUTOREGULATORY FEEDBACK LOOP; HCT116 COLON-CANCER; COLORECTAL-CANCER; ANTICANCER AGENTS; ONCOPROTEIN MDM2; RIBOSOMAL-RNA; INHIBITION; CYCLE; L11	5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug for the treatment of a variety of solid tumors. The antitumor activity of 5-FU has been attributed in part to its ability to induce p53-dependent cell growth arrest and apoptosis. However, the molecular mechanisms underlying p53 activation by 5-FU remain largely obscure. Here we report that 5-FU treatment leads to p53 stabilization and activation by blocking MDM2 feedback inhibition through ribosomal proteins. 5-FU treatment increased the fraction of ribosome-free L5, L11, and L23 ribosomal proteins and their interaction with MDM2, leading to p53 activation and G,/S arrest. Conversely, individual knockdown of these ribosomal proteins by small interfering RNA prevented the 5-FU-induced p53 activation and reversed the 5-FU-induced G(1)/S arrest. These results demonstrate that 5-FU treatment triggers a ribosomal stress response so that ribosomal proteins L5, L11, and L23 are released from ribosome to activate p53 by ablating the MDM2-p53 feedback circuit.	Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR USA.	luh@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA093614] Funding Source: NIH RePORTER; NCI NIH HHS [CA079721, CA93614, CA095441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, CANCER RES, V58, P1149; ASCHROFT M, 2000, MOL CELL BIOL, V20, P3224; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; De Angelis PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-20; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; GEOFFROY FJ, 1994, ONCOL RES, V6, P581; GHOSHAL K, 1994, CANCER RES, V54, P632; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hernandez-Vargas H, 2006, INT J CANCER, V119, P1164, DOI 10.1002/ijc.21938; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Houghton JA, 1995, CLIN CANCER RES, V1, P723; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; KANAMARU R, 1986, CANCER CHEMOTH PHARM, V17, P43, DOI 10.1007/BF00299864; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li MH, 2004, ORAL ONCOL, V40, P63, DOI 10.1016/S1368-8375(03)00136-2; Liang JT, 2002, INT J CANCER, V101, P519, DOI 10.1002/ijc.10643; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAYBAUM J, 1980, CANCER RES, V40, P4209; OConnor PM, 1997, CANCER RES, V57, P4285; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIZZORNO G, 1995, BIOCHEM PHARMACOL, V49, P553, DOI 10.1016/0006-2952(94)00444-Q; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILKINSON DS, 1973, J BIOL CHEM, V248, P63; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	41	133	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8052	8059		10.1074/jbc.M610621200	http://dx.doi.org/10.1074/jbc.M610621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17242401	hybrid			2022-12-25	WOS:000245081000037
J	Choi, WT; Kaul, M; Kumar, S; Wang, J; Kumar, IMK; Dong, CZ; An, J; Lipton, SA; Huang, ZW				Choi, Won-Tak; Kaul, Marcus; Kumar, Santosh; Wang, Jun; Kumar, I. M. Krishna; Dong, Chang-Zhi; An, Jing; Lipton, Stuart A.; Huang, Ziwei			Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 INFECTION; HETEROLOGOUS DESENSITIZATION; RECEPTOR CXCR4; FACTOR-I; AKT; PROTEIN; EXPRESSION; SURVIVAL; DEMENTIA	As the main coreceptors for human immunodeficiency virus type 1 (HIV-1) entry CXCR4 and CCR5 play important roles in HIV-associated dementia (HAD). HIV-1 glycoprotein gp120 contributes to HAD by causing neuronal damage and death, either directly by triggering apoptotic pathways or indirectly by stimulating glial cells to release neurotoxins. Here, to understand the mechanism of CXCR4 or CCR5 signaling in neuronal apoptosis associated with HAD, we have applied synthetically and modularly modified (SMM)-chemokine analogs derived from natural stromal cell-derived factor-la or viral macrophage inflammatory protein-II as chemical probes of the mechanism(s) whereby these SMM-chemokines prevent or promote neuronal apoptosis. We show that inherently neurotoxic natural ligands of CXCR4, such as stromal cell-derived factor-la or viral macrophage inflammatory protein-II, can be modified to protect neurons from apoptosis induced by CXCR4-preferring gp120(IIIB), and that the inhibition of CCR5 by antagonist SMM-chemokines, unlike neuroprotective CCR5 natural ligands, leads to neurotoxicity by activating a p38 mitogen-activated protein kinase (MAPK)-dependent pathway. Furthermore, we discover distinct signaling pathways activated by different chemokine ligands that are either natural agonists or synthetic antagonists, thus demonstrating a chemical, biology strategy of using chemically engineered inhibitors of chemokine receptors to study the signaling mechanism of neuronal apoptosis and survival.	Burnham Inst Med Sci, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Burnham Inst Med Sci, Ctr Canc, La Jolla, CA 92037 USA; Chemokine Pharmaceut Inc, Raylight Corp, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Sanford Burnham Prebys Medical Discovery Institute	Huang, ZW (corresponding author), Burnham Inst Med Sci, Ctr Neurosci & Aging, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ziweihuang@burnham.org	Kaul, Marcus/AAS-8955-2020	Lipton, Stuart/0000-0002-3490-1259; Dong, Changzhi/0000-0001-7927-6306	NEI NIH HHS [R01 EY09024] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NIGMS NIH HHS [R01 GM5776105] Funding Source: Medline; NINDS NIH HHS [R01 NS050621, R01 NS41207] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041207, R01NS050621] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blair LAC, 1999, J NEUROSCI, V19, P1940; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bonini JA, 1997, DNA CELL BIOL, V16, P1023, DOI 10.1089/dna.1997.16.1023; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Choi WT, 2005, J VIROL, V79, P15398, DOI 10.1128/JVI.79.24.15398-15404.2005; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong CZ, 2005, J MED CHEM, V48, P7923, DOI 10.1021/jm050829u; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Forster R, 1998, J IMMUNOL, V160, P1522; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gartner S, 2000, SCIENCE, V287, P602, DOI 10.1126/science.287.5453.602; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hecht I, 2003, INT IMMUNOL, V15, P29, DOI 10.1093/intimm/dxg002; Heesen M, 1998, IMMUNOGENETICS, V47, P364, DOI 10.1007/s002510050371; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Honczarenko M, 2002, BLOOD, V100, P2321, DOI 10.1182/blood-2002-01-0248; KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kaul M, 2004, J NEUROVIROL, V10, P113; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kumar S, 2006, CHEM BIOL, V13, P69, DOI 10.1016/j.chembiol.2005.10.012; Lavi E, 1997, AM J PATHOL, V151, P1035; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109; McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meucci O, 1996, J NEUROSCI, V16, P4080; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohagen A, 1999, J VIROL, V73, P897, DOI 10.1128/JVI.73.2.897-906.1999; Oravecz T, 1996, J IMMUNOL, V157, P1329; Parolin C, 1998, J VIROL, V72, P1652, DOI 10.1128/JVI.72.2.1652-1656.1998; Pillarisetti K, 2001, INFLAMMATION, V25, P293, DOI 10.1023/A:1012808525370; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Rottman JB, 1997, AM J PATHOL, V151, P1341; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; Tian SM, 2005, J VIROL, V79, P12667, DOI 10.1128/JVI.79.20.12667-12673.2005; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	51	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7154	7163		10.1074/jbc.M611599200	http://dx.doi.org/10.1074/jbc.M611599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218311	hybrid			2022-12-25	WOS:000245080900027
J	Delprat, B; Schaert, D; Roy, S; Wang, J; Puel, JL; Geering, K				Delprat, Benjamin; Schaert, Daniele; Roy, Sophie; Wang, Jing; Puel, Jean-Luc; Geering, Kathi			FXYD6 is a novel regulator of Na,K-ATPase expressed in the inner ear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; BETA-SUBUNIT; STRIA VASCULARIS; ION-TRANSPORT; GAMMA-SUBUNIT; FUNCTIONAL INTERACTION; COCHLEAR POTENTIALS; INTERMEDIATE CELLS; ALPHA-SUBUNIT; GUINEA-PIG	The exquisite sensitivity of the cochlea, which mediates the transduction of sound waves into nerve impulses, depends on the endolymph ionic composition and the endocochlear potential. A key protein in the maintenance of the electrochemical composition of the endolymph is the Na,K-ATPase. In this study, we have looked for the presence in the rat inner ear of members of the FXYD protein family, recently identified as tissue-specific modulators of Na,K-ATPase. Only FXYD6 is detected at the protein level. FXYD6 is expressed in various epithelial cells bordering the endolymph space and in the auditory neurons. FXYD6 co-localizes with Na,K-ATPase in the stria vascularis and can be co-immunoprecipitated with Na,K-ATPase. After expression in Xenopus oocytes, FXYD6 associates with Na,K-ATPase alpha 1-beta 1 and alpha 1-beta 2 isozymes, which are preferentially expressed in different regions of the inner ear and also with gastric and non-gastric H,K-ATPases. The apparent K+ and Na+ affinities of alpha 1-beta 1 and alpha 1-beta 2 isozymes are different. Association of FXYD6 with Na,K-ATPase alpha 1-beta 1 isozymes slightly decreases their apparent K+ affinity and significantly decreases their apparent Na+ affinity. On the other hand, association with alpha 1-beta 2 isozymes increases their apparent K+ and Na+ affinity. The effects of FXYD6 on the apparent Na+ affinity of Na,K-ATPase and the voltage dependence of its K+ effect are distinct from other FXYD proteins. In conclusion, this study defines the last FXYD protein of unknown function as a modulator of Na,K-ATPase. Among FXYD protein, FXYD6 is unique in its expression in the inner ear, suggesting a role in endolymph composition.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Montpellier, F-34091 Montpellier, France; Inst Neurosci Montpellier, Inst Natl Sante & Rech Med, U583, F-34091 Montpellier, France	University of Lausanne; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Geering, K (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Kaethi.Geering@unil.ch	Delprat, Benjamin/O-3791-2018	Puel, jean-luc/0000-0002-3772-5190; Delprat, Benjamin/0000-0002-2457-6923				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BOSHER SK, 1968, PROC R SOC SER B-BIO, V171, P227, DOI 10.1098/rspb.1968.0066; Chen ZY, 2002, JARO-J ASSOC RES OTO, V3, P140, DOI 10.1007/s101620020029; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; Crambert G, 2002, BIOCHEMISTRY-US, V41, P6723, DOI 10.1021/bi016063r; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Crambert G, 2005, MOL BIOL CELL, V16, P2363, DOI 10.1091/mbc.E04-10-0878; CRAMBERT G, 2003, SCI STKE, pRE1; DALLOS P, 1992, J NEUROSCI, V12, P4575; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; EYBALIN M, 1990, CR ACAD SCI III-VIE, V310, P639; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Geering K, 2006, AM J PHYSIOL-RENAL, V290, pF241, DOI 10.1152/ajprenal.00126.2005; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; HINOJOSA R, 1966, AM J ANAT, V118, P631, DOI 10.1002/aja.1001180218; IKEDA K, 1989, HEARING RES, V39, P279, DOI 10.1016/0378-5955(89)90047-6; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Kadowaki K, 2004, MOL BRAIN RES, V125, P105, DOI 10.1016/j.molbrainres.2004.03.021; KUIJPERS W, 1970, PFLUG ARCH EUR J PHY, V320, P348, DOI 10.1007/BF00588213; KUIJPERS W, 1970, PFLUG ARCH EUR J PHY, V320, P359, DOI 10.1007/BF00588214; Marcus DC, 2002, AM J PHYSIOL-CELL PH, V282, pC403, DOI 10.1152/ajpcell.00312.2001; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORGENSTERN C, 1982, AM J OTOLARYNG, V3, P323, DOI 10.1016/S0196-0709(82)80004-5; Morris KA, 2005, JARO-J ASSOC RES OTO, V6, P75, DOI 10.1007/s10162-004-5046-x; Nie LP, 2005, J NEUROSCI, V25, P8671, DOI 10.1523/JNEUROSCI.1422-05.2005; Peters TA, 2001, EUR ARCH OTO-RHINO-L, V258, P67, DOI 10.1007/s004050000304; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Rose CR, 2002, NEUROSCIENTIST, V8, P532, DOI 10.1177/1073858402238512; Shibata T, 2006, AM J PHYSIOL-CELL PH, V291, pC1038, DOI 10.1152/ajpcell.00266.2006; SMITH CA, 1954, LARYNGOSCOPE, V64, P141; SONTHEIMER H, 1994, GLIA, V11, P156, DOI 10.1002/glia.440110210; Spicer SS, 2005, HEARING RES, V200, P87, DOI 10.1016/j.heares.2004.09.006; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Takeuchi S, 2000, BIOPHYS J, V79, P2572, DOI 10.1016/S0006-3495(00)76497-6; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Trigueiros-Cunha N, 2003, EUR J NEUROSCI, V18, P2653, DOI 10.1046/j.1460-9568.2003.02989.x	41	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7450	7456		10.1074/jbc.M609872200	http://dx.doi.org/10.1074/jbc.M609872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209044	Green Submitted, hybrid			2022-12-25	WOS:000245080900057
J	Hill, K; Schaefer, M				Hill, Kerstin; Schaefer, Michael			TRPA1 is differentially modulated by the amphipathic molecules trinitrophenol and chlorpromazine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL; ACTIVATION; RECEPTOR; COLD; INHIBITION; MECHANISM; HYPOXIA; TOXIN; CELLS	TRPA1, a poorly selective Ca2+-permeable cation channel, is expressed in peripheral sensory neurons, where it is considered to contribute to a variety of sensory processes such as the detection of painful stimuli. Furthermore, TRPA1 was also identified in hair cells of the inner ear, but its involvement in sensing mechanical forces is still being controversially discussed. Amphipathic molecules such as trinitrophenol and chlorpromazine have been shown to provide useful tools to study mechanosensitive channels. Depending on their charge, they partition in the inner or outer sheets of the lipid bilayer, causing a curvature of the membrane, which has been demonstrated to activate or inhibit mechanosensitive ion channels. In the present study, we investigated the effect of these molecules on TRPA1 gating. TRPA1 was robustly activated by the anionic amphipathic molecule trinitrophenol. The whole-cell and single channel properties resemble those previously described for TRPA1. Moreover, we could show that the toxin GsMTx-4 acts on TRPA1. In addition to its recently described role as an inhibitor of stretch-activated ion channels, it serves as a potent activator of TRPA1 channels. On the other hand, the positively charged drug chlorpromazine modulates activated TRPA1 currents in a voltage-dependent way. The exposure of activated TRPA1 channels to chlorpromazine led to a block at positive potentials and an increased open probability at negative potentials. The variability in the shape of the I-V curve gives a first indication that native mechanically activated TRPA1 currents must not necessarily exhibit the same biophysical properties as ligand-activated TRPA1 currents.	Univ Med Berlin, Inst Pharmakol, Charite, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schaefer, M (corresponding author), Univ Med Berlin, Inst Pharmakol, Charite, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	m.schaefer@charite.de						Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030; Buckler KJ, 2005, J PHYSIOL-LONDON, V562, P213, DOI 10.1113/jphysiol.2004.077503; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; Chen KH, 2002, ATHEROSCLEROSIS, V165, P5, DOI 10.1016/S0021-9150(01)00768-7; CHOI SY, 2001, BRIT J PHARMACOL, V2, P411; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Dreixler JC, 2000, EUR J PHARMACOL, V401, P1, DOI 10.1016/S0014-2999(00)00401-5; Fang J, 2006, NEUROSCI LETT, V404, P213, DOI 10.1016/j.neulet.2006.05.059; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Jung HJ, 2006, BIOCHEM BIOPH RES CO, V340, P633, DOI 10.1016/j.bbrc.2005.12.046; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Lue AJC, 2001, OTOLARYNG HEAD NECK, V125, P71, DOI 10.1067/mhn.2001.116446; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; Miller P, 2003, J PHYSIOL-LONDON, V548, P31, DOI 10.1113/jphysiol.2003.040048; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; O'Neil RG, 2005, PFLUG ARCH EUR J PHY, V451, P193, DOI 10.1007/s00424-005-1424-4; Qi Z, 2005, MOL MEMBR BIOL, V22, P519, DOI 10.1080/09687860500370703; SAH DWY, 1994, MOL PHARMACOL, V45, P84; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; Siemens J, 2006, NATURE, V444, P208, DOI 10.1038/nature05285; Sotomayor M, 2005, STRUCTURE, V13, P669, DOI 10.1016/j.str.2005.03.001; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Thomas D, 2003, BRIT J PHARMACOL, V139, P567, DOI 10.1038/sj.bjp.0705283; TSENG GN, 1992, AM J PHYSIOL, V262, pC1056, DOI 10.1152/ajpcell.1992.262.4.C1056; Zhang PC, 2001, NATURE, V413, P428, DOI 10.1038/35096578	38	80	86	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7145	7153		10.1074/jbc.M609600200	http://dx.doi.org/10.1074/jbc.M609600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218316	hybrid			2022-12-25	WOS:000245080900026
J	Yu, CF; Cresswell, J; Loffler, MG; Bogan, JS				Yu, Chenfei; Cresswell, James; Loffler, Michael G.; Bogan, Jonathan S.			The glucose transporter 4-regulating protein TUG is essential for highly insulin-responsive glucose uptake in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; GTPASE-ACTIVATING-PROTEIN; NEWLY SYNTHESIZED GLUT4; STORAGE COMPARTMENT; TRAFFICKING; VESICLES; CELLS; GLUCOSE-TRANSPORTER-4; FUSION; AMINOPEPTIDASE	Insulin stimulates glucose uptake in fat and muscle by redistributing GLUT4 glucose transporters from intracellular membranes to the cell surface. We previously proposed that, in 3T3-LI adipocytes, TUG retains GLUT4 within unstimulated cells and insulin mobilizes this retained GLUT4 by stimulating its dissociation from TUG. Yet the relative importance of this action in the overall control of glucose uptake remains uncertain. Here we report that transient, small interfering RNA-mediated depletion of TUG causes GLUT4 translocation and enhances glucose uptake in unstimulated 3T3-L1 adipocytes, similar to insulin. Stable TUG depletion or expression of a dominant negative fragment likewise stimulates GLUT4 redistribution and glucose uptake, and insulin causes a 2-fold further increase. Microscopy shows that TUG governs the accumulation of GLUT4 in perinuclear membranes distinct from endosomes and indicates that it is this pool of GLUT4 that is mobilized by TUG disruption. Interestingly, in addition to translocating GLUT4 and enhancing glucose uptake, TUG disruption appears to accelerate the degradation of GLUT4 in lysosomes. Finally, we find that TUG binds directly and specifically to a large intracellular loop in GLUT4. Together, these findings demonstrate that TUG is required to retain GLUT4 intracellularly in 3T3-L1 adipocytes in the absence of insulin and further implicate the insulin-stimulated dissociation of TUG and GLUT4 as an important action by which insulin stimulates glucose uptake.	Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol & Metab, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Bogan, JS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol & Metab, 333 Cedar St,POB 208020, New Haven, CT 06520 USA.	jonathan.bogan@yale.edu	Löffler, Michael/F-1748-2013; Bogan, Jonathan S/A-1575-2010	Löffler, Michael/0000-0002-6529-9723; Bogan, Jonathan S/0000-0001-6463-8466	NIDDK NIH HHS [R21 DK070812, P30 DK045735, R21 DK070812-02, P30 DK045735-159008, R21 DK070812-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R21DK070812] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2003, DIABETES MELLITUS FU, P917; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Coster ACF, 2004, TRAFFIC, V5, P763, DOI 10.1111/j.1600-0854.2004.00218.x; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Hosaka T, 2005, MOL BIOL CELL, V16, P2882, DOI 10.1091/mbc.E05-01-0072; HUANG X, 2004, KEYST S DIAB MELL BA; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Keller SR, 2002, J BIOL CHEM, V277, P17677, DOI 10.1074/jbc.M202037200; Khan AH, 2004, J BIOL CHEM, V279, P37505, DOI 10.1074/jbc.M405694200; KIM SS, 1994, AM J PHYSIOL, V267, pE132, DOI 10.1152/ajpendo.1994.267.1.E132; Koumanov F, 2005, CELL METAB, V2, P179, DOI 10.1016/j.cmet.2005.08.007; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Liao W, 2006, ENDOCRINOLOGY, V147, P2245, DOI 10.1210/en.2005-1638; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101; Maianu L, 2001, J CLIN ENDOCR METAB, V86, P5450, DOI 10.1210/jc.86.11.5450; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Sano H, 2005, BIOCHEM BIOPH RES CO, V332, P880, DOI 10.1016/j.bbrc.2005.05.027; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shi J, 2005, DEV CELL, V9, P99, DOI 10.1016/j.devcel.2005.04.004; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; VANDAM EM, 2005, MOL ENDOCRINOL; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Williams D, 2006, MOL BIOL CELL, V17, P5346, DOI 10.1091/mbc.E06-05-0386; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200; Yamada E, 2005, J CELL BIOL, V168, P921, DOI 10.1083/jcb.200408182	39	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7710	7722		10.1074/jbc.M610824200	http://dx.doi.org/10.1074/jbc.M610824200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17202135	Green Accepted, hybrid			2022-12-25	WOS:000245080900083
J	Hock, TD; Liby, K; Wright, MM; McConnell, S; Schorpp-Kistner, M; Ryan, TM; Agarwal, A				Hock, Thomas D.; Liby, Karen; Wright, Marcienne M.; McConnell, Sean; Schorpp-Kistner, Marina; Ryan, Thomas M.; Agarwal, Anupam			JunB and JunD regulate human herne oxygenase-1 gene expression in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEME OXYGENASE-1; ANTIOXIDANT RESPONSE ELEMENT; CADMIUM-MEDIATED INDUCTION; NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; IN-VIVO; BINDING PROTEIN; GROWTH-FACTORS	Heme oxygenase-1 is a highly inducible gene, the product of which catalyzes breakdown of the prooxidant heme. The purpose of this study was to investigate the regulation of the human heme oxygenase-1 gene in renal epithelial cells. DNase I hypersensitivity studies identified three distal sites (HS-2, -3, and -4) corresponding to approximately -4.0, -7.2, and -9.2 kb, respectively, of the heme oxygenase-1 promoter in addition to one proximal region, HS-1, which we have shown previously to be an E box. In vivo dimethyl sulfate footprinting of the HS-2 region revealed six individual protected guanines. Two mutations within HS-2 combined with a third mutation of the proximal E box abolished hemin- and cadmium-driven heme oxygenase-1 promoter activation, suggesting that these three sites synergized for maximal heme oxygenase-1 induction. Jun proteins bound to the antioxidant response element in the HS-2 region in vitro and associated with the heme oxygenase-1 promoter in vivo. JunB and JunD contribute opposing effects; JunB activated whereas JunD repressed heme oxygenase-1 expression in human renal epithelial cells, results that were corroborated in junB(-/-) and junD(-/-) cells. We propose that heme oxygenase-1 induction is controlled by a dynamic interplay of regulatory proteins, and we provide new insights into the molecular control of the human heme oxygenase-1 gene.	Univ Alabama, Dept Med, Nephrol Res & Training Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Dartmouth Coll Sch Med, Hanover, NH 03755 USA; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Dartmouth College; Helmholtz Association; German Cancer Research Center (DKFZ)	Agarwal, A (corresponding author), Univ Alabama, Div Nephrol, Zeigler Res Bldg,Rm 614,703 19th St S, Birmingham, AL 35294 USA.	agarwal@uab.edu		Ryan, Thomas/0000-0002-8982-0253; Liby, Karen/0000-0003-3317-3437; McConnell, Sean/0000-0002-0988-5373	NHLBI NIH HHS [HL068157] Funding Source: Medline; NIDDK NIH HHS [DK059600, DK067472] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067472, R01DK059600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bussolati B, 2004, BLOOD, V103, P761, DOI 10.1182/blood-2003-06-1974; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hilfiker-Kleiner D, 2005, CIRCULATION, V112, P1470, DOI 10.1161/CIRCULATIONAHA.104.518472; Hill-Kapturczak N, 2003, AM J PHYSIOL-RENAL, V285, pF515, DOI 10.1152/ajprenal.00137.2003; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hock TD, 2004, BIOCHEM J, V383, P209, DOI 10.1042/BJ20040794; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jeong WS, 2006, ANTIOXID REDOX SIGN, V8, P99, DOI 10.1089/ars.2006.8.99; Kronke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Liby K, 2005, CANCER RES, V65, P4789, DOI 10.1158/0008-5472.CAN-04-4539; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mellott JK, 2001, AM J PHYSIOL-LUNG C, V280, pL390, DOI 10.1152/ajplung.2001.280.3.L390; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nath KA, 2006, KIDNEY INT, V70, P432, DOI 10.1038/sj.ki.5001565; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ricci R, 2005, GENE DEV, V19, P208, DOI 10.1101/gad.327005; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; Sikorski EM, 2004, AM J PHYSIOL-RENAL, V286, pF425, DOI 10.1152/ajprenal.00297.2003; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Takahashi S, 1999, BBA-GENE STRUCT EXPR, V1447, P231, DOI 10.1016/S0167-4781(99)00156-6; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Volti GL, 2005, ANTIOXID REDOX SIGN, V7, P704, DOI 10.1089/ars.2005.7.704; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang HP, 2005, MOL CELL BIOL, V25, P5933, DOI 10.1128/MCB.25.14.5933-5946.2005; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003	61	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6875	6886		10.1074/jbc.M608456200	http://dx.doi.org/10.1074/jbc.M608456200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204476	hybrid			2022-12-25	WOS:000244867200097
J	Plaza-Menacho, I; van der Sluis, T; Hollema, H; Gimm, O; Buys, CHCM; Magee, AI; Isacke, CM; Hofstra, RMW; Eggen, BJL				Plaza-Menacho, Ivan; van der Sluis, Tineke; Hollema, Harry; Gimm, Oliver; Buys, Charles H. C. M.; Magee, Anthony I.; Isacke, Clare M.; Hofstra, Robert M. W.; Eggen, Bart J. L.			Ras/ERK1/2-mediated STAT3 Ser(727) phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; CANCER-CELLS; KINASE; PHENOTYPE; PATHWAYS	The precise role of STAT3 Ser 727 phosphorylation in RET-mediated cell transformation and oncogenesis is not well understood. In this study, we have shown that familial medullary thyroid carcinoma (FMTC) mutants RETY791F and RETS891A induced, in addition to Tyr(705) phosphorylation, constitutive STAT3 Ser 727 phosphorylation. Using inhibitors and dominant negative constructs, we have demonstrated that RETY791F and RETS891A induce STAT3 Ser 727 phosphorylation via a canonical Ras/ERK1/2 pathway and that integration of the Ras/ERKI/2/ELK-1 and STAT3 pathways was required for up-regulation of the c-fos promoter by FMTC-RET. Moreover, inhibition of ERK1/2 had a more severe effect on cell proliferation and cell phenotype in HEK293 cells expressing REVS891A compared with control and RETWT-transfected cells. The transforming activity of RETY791F and RETS891A in NIH-3T3 cells was also inhibited by U0126, indicating a role of the ERK1/2 pathway in RET-mediated transformation. To investigate the biological significance of Ras/ERK1/2-induced STAT3 Ser 727 phosphorylation for cell proliferation and transformation, N-Ras-transformed NIH-3T3 cells were employed. These cells displayed elevated levels of activated ERK1/2 and Ser(727)-phosphorylated STAT3, which were inhibited by treatment with U0126. Importantly, overexpression of STAT3, in which the Ser 717 was mutated into Ala (STAT3(S727A)), rescued the transformed phenotype of N-Ras-transformed cells. Immunohistochemistry in tumor samples from FMTC patients showed strong nuclear staining of phosphorylated ERK1/2 and Ser 727 STAT3. These data show that FMTC-RET mutants activate a Ras/ERK1/2/STAT3 Ser(727) pathway, which plays an important role in cell mitogenicity and transformation.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Univ Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands; Univ Groningen, Dept Pathol, Med Ctr, NL-9713 GZ Groningen, Netherlands; Univ Halle Wittenberg, Dept Surg, D-06097 Halle, Germany; Univ London Imperial Coll Sci Technol & Med, Sect Mol & Cellular Med, London SW7 2AZ, England; Univ Groningen, Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Groningen; University of Groningen; Martin Luther University Halle Wittenberg; Imperial College London; University of Groningen	Plaza-Menacho, I (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	ivan.plaza-menacho@icr.ac.uk	Piris, Alejandro/D-3830-2014; Magee, Anthony/V-8345-2019; Plaza-Menacho, Ivan/K-8517-2017	Plaza-Menacho, Ivan/0000-0003-4666-9431; Hofstra, Robert/0000-0001-7498-3829; Isacke, Clare/0000-0002-9222-3345	Medical Research Council [G0100471] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline; MRC [G0100471] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; de Groot JWB, 2006, SURGERY, V139, P806, DOI 10.1016/j.surg.2005.10.019; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Jimenez C, 2004, J CLIN ENDOCR METAB, V89, P4142, DOI 10.1210/jc.2004-0041; Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Marcos C, 1996, Int J Dev Biol, VSuppl 1, p137S; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Mise N, 2006, ONCOGENE, V25, P6637, DOI 10.1038/sj.onc.1209669; PASINI A, 1999, ONCOGENE, V24, P393; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schuringa JJ, 2001, ONCOGENE, V20, P5350, DOI 10.1038/sj.onc.1204715; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wierenga ATJ, 2003, EXP HEMATOL, V31, P398, DOI 10.1016/S0301-472X(03)00045-6; Yuan ZL, 2004, MOL CELL BIOL, V24, P9390, DOI 10.1128/MCB.24.21.9390-9400.2004	28	51	52	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6415	6424		10.1074/jbc.M608952200	http://dx.doi.org/10.1074/jbc.M608952200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17209045	hybrid			2022-12-25	WOS:000244867200049
J	Tanno, M; Sakamoto, J; Miura, T; Shimamoto, K; Horio, Y				Tanno, Masaya; Sakamoto, Jun; Miura, Tetsuji; Shimamoto, Kazuaki; Horio, Yoshiyuki			Nucleocytoplasmic shuttling of the NAD(+)-dependent histone deacrtylase SIRT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROMOTES CELL-SURVIVAL; NUCLEAR EXPORT SIGNAL; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; LIFE-SPAN; PROTEIN; P53; DEACETYLASE; LONGEVITY	Sir2 (silent information regulator 2) is an NAD(+)-dependent histone deacetylase that contributes to longevity in yeast. SIRT1, a mammalian Sir2 ortholog, deacetylates histones and various transcription factors, including p53, FOXO proteins, and peroxisome proliferator-activated receptor-gamma. We found that its subcellular localization varied in different tissues of the adult mouse. Some subsets of neurons predominantly expressed SIRT1 in the cytoplasm, but ependymal cells expressed it in both the nucleus and cytoplasm. On the other hand, spermatocytes expressed SIRT1 only in the nucleus. Cardiomyocytes in the day 12.5 mouse embryo expressed SIRT1 exclusively in the nucleus, but in the adult heart, they expressed it in both the cytoplasm and nucleus. C2C12 myoblast cells expressed SIRT1 in the nucleus, but it localized to the cytoplasm after differentiation. LY294002, an inhibitor of phosphoinositide 3-hydroxykinase, strongly inhibited the nuclear localization of SIRT1 in undifferentiated C2C12 cells. In a heterokaryon assay, SIRT1 shuttled between the nucleus and cytoplasm, and leptomycin B, an inhibitor of CRM1-mediated nuclear exportation, inhibited this shuttling. Two nuclear localization signals and two nuclear export signals were identified by deletion and site-directed mutation analyses. Overexpressed nuclear (but not cytoplasmic or dominant-negative) SIRT1 enhanced the deacetylation of histone H3 in C2C12 cells. Moreover, only the nuclear form suppressed the apoptosis of C2C12 cells induced by antimycin A, an oxidative stressor. These findings indicate that nucleocytoplasmic shuttling is a novel regulatory mechanism of SIRT1, which may participate in differentiation and in inhibition of cell death.	Sapporo Med Univ, Dept Pharmacol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Dept Internal Med 2, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Horio, Y (corresponding author), Sapporo Med Univ, Dept Pharmacol, Chuo Ku, S1W16, Sapporo, Hokkaido 0608556, Japan.	horio@sapmed.ac.jp		Horio, Yoshiyuki/0000-0002-5021-5929				Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen IY, 2006, J BIOL CHEM, V281, P19369, DOI 10.1074/jbc.M601443200; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; RINE J, 1987, GENETICS, V116, P9; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Selvetella G, 2004, CARDIOVASC RES, V63, P373, DOI 10.1016/j.cardiores.2004.04.031; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	36	549	582	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6823	6832		10.1074/jbc.M609554200	http://dx.doi.org/10.1074/jbc.M609554200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197703	hybrid			2022-12-25	WOS:000244867200092
J	Haddy, FJ				Haddy, Francis J.			NASA - Has its biological groundwork for a trip to Mars improved?	FASEB JOURNAL			English	Article						life sciences; mission; planet earth; US Space Program; deep space	RADIATION; HUMANS	In a 1991 editorial in The FASEB journal, Robert W. Krauss commented on a recent report of the Presidential Advisory Committee on the Future of the U.S. Space Program (Augustine report). He concluded that, although a maimed mission to Mars with life sciences as the priority was endorsed by the Committee, it failed to deal realistically with one huge gap; biological sciences have never been given high priority. According to Krauss, this left a void that will cripple, perhaps fatally, any early effort to ensure long-term survival on any mission of extended duration. The gap included insufficient flight time for fundamental biological space research and insufficient funds. Krauss expressed his opinions 15 years ago. Have we better knowledge of space biology now? This question becomes more acute now that President George W. Bush recently proposed a manned return to the moon by 2015 or 2020, with the moon to become our staging post for manned missions to Mars. Will we be ready so soon? A review of the progress in the last 15 years suggests that we will not. Because of the Columbia disaster, flight opportunities for biological sciences in shuttle spacelabs and in Space Station laboratories compete with time for engineering problems and construction. Thus, research on gravity, radiation, and isolation loses out to problems deemed to be of higher priority. Radiation in deep space and graded gravity in space with on board centrifuges are areas that must be studied before we undertake prolonged space voyages. Very recent budgetary changes within National Aeronautics and Space Administration threaten to greatly reduce the fundamental space biology funds. Are we ready for a trip to Mars? Like Krauss 15 years ago, I drink not for some time.	Mayo Coll Med, Mayo Grad Fac, Dept Physiol & Biomed Engn, Rochester, MN USA	Mayo Clinic	Haddy, FJ (corresponding author), 211 2nd St NW,1607, Rochester, MN 55901 USA.	tbhaddy@aol.com						*COMM SPAC BIOL ME, 1987, STRAT SPAC BIOL MED; KRAUSS RW, 1991, FASEB J, V5, P251, DOI 10.1096/fasebj.5.3.2001785; LONG ME, 2001, NATL GEOGR MAG, V199, P2; MAZZASCHI A, 1990, FASEB J, V4, P3; MOORE FD, 1992, FASEB J, V6, P2871; MOORE FD, 1992, FASEB J, V6, P2338, DOI 10.1096/fasebj.6.6.1544543; *NASA ADV COUNC, 1988, EXPL LIV U STRAT SPA; REYNOLDS RD, 1992, FASEB J, V6, P2870, DOI 10.1096/fasebj.6.10.1634053	8	5	5	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					643	646		10.1096/fj.06-7262LSF	http://dx.doi.org/10.1096/fj.06-7262LSF			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17200421				2022-12-25	WOS:000244686400003
J	Pickart, MA; Klee, EW; Nielsen, AL; Sivasubbu, S; Mendenhall, EM; Bill, BR; Chen, E; Eckfeldt, CE; Knowlton, M; Robu, ME; Larson, JD; Deng, Y; Schimmenti, LA; Ellis, LBM; Verfaillie, CM; Hammerschmidt, M; Farber, SA; Ekker, SC				Pickart, Michael A.; Klee, Eric W.; Nielsen, Aubrey L.; Sivasubbu, Sridhar; Mendenhall, Eric M.; Bill, Brent R.; Chen, Eleanor; Eckfeldt, Craig E.; Knowlton, Michelle; Robu, Mara E.; Larson, Jon D.; Deng, Yun; Schimmenti, Lisa A.; Ellis, Lynda B. M.; Verfaillie, Catherine M.; Hammerschmidt, Matthias; Farber, Steven A.; Ekker, Stephen C.			Genome-Wide Reverse Genetics Framework to Identify Novel Functions of the Vertebrate Secretome	PLOS ONE			English	Article								Background. Understanding the functional role(s) of the more than 20,000 proteins of the vertebrate genome is a major next step in the post-genome era. The approximately 4,000 co-translationally translocated (CTT) proteins - representing the vertebrate secretome - are important for such vertebrate-critical processes as organogenesis. However, the role(s) for most of these genes is currently unknown. Results. We identified 585 putative full-length zebrafish CTT proteins using cross-species genomic and EST-based comparative sequence analyses. We further investigated 150 of these genes (Figure 1) for unique function using morpholino-based analysis in zebrafish embryos. 12% of the CTT protein-deficient embryos resulted in specific developmental defects, a notably higher rate of gene function annotation than the 2%-3% estimate from random gene mutagenesis studies. Conclusion(s). This initial collection includes novel genes required for the development of vascular, hematopoietic, pigmentation, and craniofacial tissues, as well as lipid metabolism, and organogenesis. This study provides a framework utilizing zebrafish for the systematic assignment of biological function in a vertebrate genome.	[Nielsen, Aubrey L.; Sivasubbu, Sridhar; Mendenhall, Eric M.; Bill, Brent R.; Chen, Eleanor; Knowlton, Michelle; Robu, Mara E.; Larson, Jon D.; Schimmenti, Lisa A.; Ekker, Stephen C.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; [Nielsen, Aubrey L.; Sivasubbu, Sridhar; Mendenhall, Eric M.; Bill, Brent R.; Chen, Eleanor; Knowlton, Michelle; Robu, Mara E.; Larson, Jon D.; Ekker, Stephen C.] Univ Minnesota, Arnold & Mabel Beckman Ctr Transposon Res, Minneapolis, MN USA; [Pickart, Michael A.; Robu, Mara E.] Univ Minnesota, Dept Oral Sci, Minneapolis, MN USA; [Pickart, Michael A.; Robu, Mara E.] Univ Minnesota, MinnCResT, Minneapolis, MN USA; [Bill, Brent R.; Schimmenti, Lisa A.] Univ Minnesota, Dept Pediat Genet & Metab, Minneapolis, MN USA; [Bill, Brent R.; Schimmenti, Lisa A.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; [Klee, Eric W.; Ellis, Lynda B. M.] Univ Minnesota, Lab Med & Pathol & Comp Sci & Engn, Minneapolis, MN 55455 USA; [Mendenhall, Eric M.; Eckfeldt, Craig E.; Verfaillie, Catherine M.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; [Mendenhall, Eric M.; Eckfeldt, Craig E.; Verfaillie, Catherine M.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA; [Hammerschmidt, Matthias] Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; [Deng, Yun; Farber, Steven A.] Carnegie Inst Washington, Baltimore, MD USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Max Planck Society; Carnegie Institution for Science	Ekker, SC (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	ekker001@umn.edu	Farber, Steven A/G-5851-2012; Verfaillie, Catherine/H-5148-2013	Farber, Steven A/0000-0002-8037-7312; Verfaillie, Catherine/0000-0001-7564-4079; Eckfeldt, Craig/0000-0003-2834-0421; Schimmenti, Lisa/0000-0003-3154-4249; Ekker, Stephen/0000-0003-0726-4212; Mendenhall, Eric/0000-0002-7395-6295; Bill, Brent/0000-0002-3436-1969	NIH [T32-DE07288-07 (NIDCR), NLM TG-0704l, RO1 to SCE GM63904]; Arnold and Mabel Beckman Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM063904, R01GM063904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arnold and Mabel Beckman Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants: Postdoctoral traineeship to MAP NIH T32-DE07288-07 (NIDCR), a predoctoral traineeship to EWK (NLM TG-0704l), NIH RO1 to SCE GM63904 (NIH) and the Arnold and Mabel Beckman Foundation.	Amsterdam A, 2006, TRENDS GENET, V22, P473, DOI 10.1016/j.tig.2006.06.011; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen E, 2004, BLOOD, V103, P1710, DOI 10.1182/blood-2003-06-1783; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Chen E, 2006, BLOOD, V107, P4364, DOI 10.1182/blood-2005-02-0789; CHEN PS, 1956, ANAL CHEM, V28, P1758; Dosch R, 2004, DEV CELL, V6, P771, DOI 10.1016/j.devcel.2004.05.002; Driever W, 1996, DEVELOPMENT, V123, P37; Eckfeldt CE, 2005, PLOS BIOL, V3, P1449, DOI 10.1371/journal.pbio.0030254; Ekker SC, 2004, METHOD CELL BIOL, V77, P121; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Hermanson S, 2004, METHOD CELL BIOL, V77, P349; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Kenwrick S, 2004, DEV DYNAM, V229, P289, DOI 10.1002/dvdy.10440; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klee EW, 2005, NUCLEIC ACIDS RES, V33, pW506, DOI 10.1093/nar/gki453; Klee EW, 2004, NUCLEIC ACIDS RES, V32, P1414, DOI 10.1093/nar/gkh286; Klee EW, 2001, GENESIS, V30, P123, DOI 10.1002/gene.1045; Liang F, 2000, NUCLEIC ACIDS RES, V28, P3657, DOI 10.1093/nar/28.18.3657; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Pelegri F, 1999, METHOD CELL BIOL, V60, P1; Pickart MA, 2004, PIGM CELL RES, V17, P461, DOI 10.1111/j.1600-0749.2004.00189.x; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wagner DS, 2004, DEV CELL, V6, P781, DOI 10.1016/j.devcel.2004.04.001; Yamada L, 2003, DEVELOPMENT, V130, P6485, DOI 10.1242/dev.00847	32	61	64	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e104	10.1371/journal.pone.0000104	http://dx.doi.org/10.1371/journal.pone.0000104			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17218990	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600103
J	Hanel, P; Andreani, P; Graler, MH				Haenel, Petra; Andreani, Paul; Graeler, Markus H.			Erythrocytes store and release sphingosine 1-phosphate in blood	FASEB JOURNAL			English	Article						HPLC; plasma; sphingolipid; thrombocyte	PROTEIN-COUPLED RECEPTORS; LYMPHOCYTE EGRESS; T-CELLS; IN-VIVO; SPHINGOSINE-1-PHOSPHATE; FTY720; MODULATION; EXPRESSION; SPHINGOLIPIDS; EXTRACTION	The blood constituent sphingosine 1-phosphate (S1P) is a specific ligand for five G-protein-coupled receptors designated S1P(1-5). Expression of the S1P(1) receptor on lymphocytes is required for their exit from secondary lymphoid organs, suggesting that S1P serves as a stimulus for maintaining lymphocyte circulation in blood. Despite its potential role in immune surveillance, the regulatory system that controls blood S1P levels is not well understood. This report reveals that erythrocytes constitute a buffer system for S1P in blood. They efficiently incorporated and stored S1P, and protected it from cellular degradation. They also released S1P into plasma, but not into other serum-free media, indicating that S1P release was controlled by a plasma factor. Erythrocytes did not generate S1P since an increase in plasma S1P levels was always accompanied by a decrease in cellular S1P levels. Thrombocytes that were reported to generate and release S1P after activation did not contribute to the observed S1P release in blood. The amount of erythrocytes as well as the proportion of plasma in the medium determined the magnitude of S1P release. Adoptively transferred S1P-loaded and unloaded mouse erythrocytes displayed a normal life span and similar S1P levels 24 h after recovery, indicating that S1P incorporation and release are dynamically regulated in vivo.	Hannover Med Sch, Inst Immunol, D-30625 Hannover, Germany	Hannover Medical School	Graler, MH (corresponding author), Hannover Med Sch, Inst Immunol, Bldg K11,OE 9422,Carl Neuberg Str 1, D-30625 Hannover, Germany.	graeler.markus@mh-hannover.de	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Andreani P, 2006, ANAL BIOCHEM, V358, P239, DOI 10.1016/j.ab.2006.08.027; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Butter JJ, 2005, J CHROMATOGR B, V824, P65, DOI 10.1016/j.jchromb.2005.06.040; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deutschman DH, 2003, AM HEART J, V146, P62, DOI 10.1016/S0002-8703(03)00118-2; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Karliner JS, 2004, J CELL BIOCHEM, V92, P1095, DOI 10.1002/jcb.20129; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Van Veldhoven PP, 2005, CHEM PHYS LIPIDS, V136, P164; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Young N, 2006, THESCIENTIFICWORLDJO, V6, P946, DOI 10.1100/tsw.2006.182; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628	26	297	304	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1202	1209		10.1096/fj.06-7433com	http://dx.doi.org/10.1096/fj.06-7433com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215483				2022-12-25	WOS:000245650400024
J	Bouly, JP; Schleicher, E; Dionisio-Sese, M; Vandenbussche, F; Van Der Straeten, D; Bakrim, N; Meier, S; Batschauer, A; Galland, P; Bittl, R; Ahmad, M				Bouly, Jean-Pierre; Schleicher, Erik; Dionisio-Sese, Maribel; Vandenbussche, Fillip; Van Der Straeten, Dominique; Bakrim, Nadia; Meier, Stefan; Batschauer, Alfred; Galland, Paul; Bittl, Robert; Ahmad, Margaret			Cryptochrome blue light photoreceptors are activated through interconversion of flavin redox states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAPROTEIN ELECTRON-TRANSFER; DNA PHOTOLYASE; ARABIDOPSIS CRYPTOCHROMES; ESCHERICHIA-COLI; HYPOCOTYL GROWTH; UV-A; INHIBITION; MECHANISM; PHYCOMYCES; ELONGATION	Cryptochromes are blue light-sensing photoreceptors found in Plants, animals, and humans. They are known to play key roles in the regulation of the circadian clock and in development. However, despite striking structural similarities to photolyase DNA repair enzymes, cryptochromes do not repair double-stranded DNA, and their mechanism of action is unknown. Recently, a blue light-dependent intramolecular electron transfer to the excited state flavin was characterized and proposed as the primary mechanism of light activation. The resulting formation of a stable neutral flavin semiquinone intermediate enables the photoreceptor to absorb green/yellow light (500 - 630 nm) in addition to blue light in vitro. Here, we demonstrate that Arabidopsis cryptochrome activation by blue light can be inhibited by green light in vivo consistent with a change of the cofactor redox state. We further characterize light-dependent changes in the cryptochromel (cry1) protein in living cells, which match photoreduction of the purified cryl in vitro. These experiments were performed using fluorescence absorption/emission and EPR on whole cells and thereby represent one of the few examples of the active state of a known photoreceptor being monitored in vivo. These results indicate that cryl activation via blue light initiates formation of a flavosemiquinone signaling state that can be converted by green light to an inactive form. In summary, cryptochrome activation via flavin photoreduction is a reversible mechanism novel to blue light photoreceptors. This photocycle may have adaptive significance for sensing the quality of the light environment in multiple organisms.	Univ Paris 06, FRE 2846, CNRS, F-75005 Paris, France; Univ Philippines, Los Banos Coll, Coll Arts & Sci, Inst Biol Sci, Laguna 4031, Philippines; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; Univ Marburg, FB Biol Pflanzenphysiol, D-35032 Marburg, Germany; Univ Ghent, Unit Plant Hormone Signaling & Bioimaging, Dept Mol Genet, B-9000 Ghent, Belgium; Penn State Univ, Media, PA 19063 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of the Philippines System; University of the Philippines Los Banos; Free University of Berlin; Philipps University Marburg; Ghent University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Ahmad, M (corresponding author), Univ Paris 06, FRE 2846, CNRS, Casier 156,4 Pl Jussieu, F-75005 Paris, France.	ahmad@ccr.jussieu.fr	Van Der Straeten, Dominique/E-7385-2016; Bittl, Robert/I-8149-2013; Schleicher, Erik/C-9951-2010	Van Der Straeten, Dominique/0000-0002-7755-1420; Bittl, Robert/0000-0003-4103-3768; Ahmad, Margaret/0000-0003-4524-5813; Dionisio-Sese, Maribel/0000-0003-0954-0954; Schleicher, Erik/0000-0003-2953-050X				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; AHMAD M, 2006, PLANTA, V224, P995; Banerjee R, 2005, PLANTA, V220, P498, DOI 10.1007/s00425-004-1418-z; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Briggs W. R., 2006, PHOTOMORPHOGENESIS P, P171; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Byrdin M, 2004, BBA-BIOENERGETICS, V1655, P64, DOI 10.1016/j.bbabio.2003.07.001; Carell T, 2001, CURR OPIN CHEM BIOL, V5, P491, DOI 10.1016/S1367-5931(00)00239-8; Folta KM, 2004, PLANT PHYSIOL, V135, P1407, DOI 10.1104/pp.104.038893; Franklin KA, 2005, ANN BOT-LONDON, V96, P169, DOI 10.1093/aob/mci165; Frechilla S, 2000, PLANT CELL PHYSIOL, V41, P171, DOI 10.1093/pcp/41.2.171; Galland P, 2003, PLANTA, V217, P971, DOI 10.1007/s00425-003-1068-6; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; GOTO N, 1993, PHOTOCHEM PHOTOBIOL, V57, P867, DOI 10.1111/j.1751-1097.1993.tb09226.x; Green CB, 2004, CURR BIOL, V14, pR847, DOI 10.1016/j.cub.2004.09.040; Kavakli IH, 2004, BIOCHEMISTRY-US, V43, P15103, DOI 10.1021/bi0478796; Kleiner O, 1999, EUR J BIOCHEM, V264, P161, DOI 10.1046/j.1432-1327.1999.00590.x; Kottke T, 2006, BIOCHEMISTRY-US, V45, P2472, DOI 10.1021/bi051964b; LI QH, 2006, IN PRESS PHOTOCHEM P; LIN C, 1995, P NATL ACAD SCI USA, V92, P8423, DOI 10.1073/pnas.92.18.8423; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Lin CT, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-220; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; NEUMANN D, 1993, PLANTA, V190, P32, DOI 10.1007/BF00195672; Partch CL, 2005, PHOTOCHEM PHOTOBIOL, V81, P1291, DOI 10.1562/2005-07-08-IR-607; Partch CL, 2005, BIOCHEMISTRY-US, V44, P3795, DOI 10.1021/bi047545g; Sancar A, 2004, J BIOL CHEM, V279, P34079, DOI 10.1074/jbc.R400016200; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Saxena C, 2005, J AM CHEM SOC, V127, P7984, DOI 10.1021/ja0421607; Schmidt W, 1999, PLANTA, V208, P274, DOI 10.1007/s004250050559; Selby CP, 2006, P NATL ACAD SCI USA, V103, P17696, DOI 10.1073/pnas.0607993103; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; SPUDICH JL, 1984, NATURE, V312, P509, DOI 10.1038/312509a0; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Van Gelder RN, 2002, J BIOL RHYTHM, V17, P110, DOI 10.1177/074873002129002401; Vandenbussche F, 2005, CURR OPIN PLANT BIOL, V8, P462, DOI 10.1016/j.pbi.2005.07.007; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Weber S, 2005, BBA-BIOENERGETICS, V1707, P1, DOI 10.1016/j.bbabio.2004.02.010; Yang HQ, 2001, PLANT CELL, V13, P2573, DOI 10.1105/tpc.13.12.2573; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946; Zeugner A, 2005, J BIOL CHEM, V280, P19437, DOI 10.1074/jbc.C500077200	48	321	333	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9383	9391		10.1074/jbc.M609842200	http://dx.doi.org/10.1074/jbc.M609842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17237227	hybrid			2022-12-25	WOS:000245421700010
J	Ishiguro, A; Ideta, M; Mikoshiba, K; Chen, DJ; Aruga, J				Ishiguro, Akira; Ideta, Maki; Mikoshiba, Katsuhiko; Chen, David J.; Aruga, Jun			ZIC2-dependent transcriptional regulation is mediated by DNA-dependent protein kinase, poly(ADP-ribose) polymerase, and RNA helicase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; NEURAL CREST DEVELOPMENT; XENOPUS-ZIC FAMILY; V(D)J RECOMBINATION; KU-AUTOANTIGEN; MOLECULAR-PROPERTIES; IN-VITRO; GENE; MOUSE; BINDING	The Zic family of zinc finger proteins is essential for animal development, as demonstrated by the holoprosencephaly caused by mammalian Zic2 mutation. To determine the molecular mechanism of Zic-mediated developmental control, we characterized two types of high molecular weight complexes, including Zic2. Complex I was composed of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), Ku70/80, and poly(ADP-ribose) polymerase; complex II contained Ku70/80 and RNA helicase A; all the components interacted directly with Zic2 protein. Immunoprecipitation, submiclear localization, and in vitro phosphorylation analyses revealed that the DNAPKcs in complex I played an essential role in the assembly of complex II. Stepwise exchange from complex I to complex II depended on phosphorylation of Zic2 by DNA-PK and poly(ADP-ribose) polymerase. Phosphorylated Zic2 protein made a stable complex with RNA helicase A, and complex II could interact with RNA polymerase II. Phosphorylation-dependent transformation of Zic2-containing molecular complexes may occur in transcriptional regulation.	RIKEN, Brain Sci Inst, Lab Comparat Neurogenesis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Dev Neurobiol, Wako, Saitama 3510198, Japan; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA	RIKEN; RIKEN; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ishiguro, A (corresponding author), RIKEN, Brain Sci Inst, Lab Comparat Neurogenesis, Wako, Saitama 3510198, Japan.	akiraishiguro@brain.riken.go.jp; jaruga@brain.riken.go.jp	Aruga, Jun/H-5837-2011; Mikoshiba, Katsuhiko/N-7943-2015	Aruga, Jun/0000-0001-7936-1375; Ishiguro, Akira/0000-0003-1867-3134				Ame JC, 2001, J BIOL CHEM, V276, P11092, DOI 10.1074/jbc.M007870200; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Aratani S, 2003, INT J MOL MED, V12, P175; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Aruga J, 2002, J NEUROSCI, V22, P218, DOI 10.1523/JNEUROSCI.22-01-00218.2002; Aruga J, 2002, DEV BIOL, V244, P329, DOI 10.1006/dbio.2002.0598; Aruga J, 2004, MOL CELL NEUROSCI, V26, P205, DOI 10.1016/j.mcn.2004.01.004; Aruga J, 2006, GENOMICS, V87, P783, DOI 10.1016/j.ygeno.2006.02.011; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; DVIR A, 1993, J BIOL CHEM, V268, P10440; Fukumura R, 1998, J BIOL CHEM, V273, P13058, DOI 10.1074/jbc.273.21.13058; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grinberg I, 2005, CLIN GENET, V67, P290, DOI 10.1111/j.1399-0004.2005.00418.x; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hoshino J, 2003, MOL BRAIN RES, V120, P57, DOI 10.1016/j.molbrainres.2003.10.004; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; Inoue T, 2004, DEV BIOL, V270, P146, DOI 10.1016/j.ydbio.2004.02.017; Ishiguro A, 2004, BIOCHEM BIOPH RES CO, V324, P302, DOI 10.1016/j.bbrc.2004.09.052; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Koike M, 1999, J CELL SCI, V112, P4031; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; LIU SH, 1993, J BIOL CHEM, V268, P21147; Minakawa M, 1998, BRAIN RES, V813, P172, DOI 10.1016/S0006-8993(98)00979-2; Mizugishi K, 2004, BIOCHEM BIOPH RES CO, V320, P233, DOI 10.1016/j.bbrc.2004.05.158; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Salero E, 2001, J BIOL CHEM, V276, P1881, DOI 10.1074/jbc.M007008200; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schild-Poulter C, 2003, DNA CELL BIOL, V22, P65, DOI 10.1089/104454903321515887; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tzung TY, 1998, INT J RADIAT BIOL, V73, P469; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yagi K, 2004, DEV BIOL, V274, P478, DOI 10.1016/j.ydbio.2004.07.013; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhang QM, 2005, RADIAT RES, V164, P497, DOI 10.1667/RR3366.1; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933	65	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9983	9995		10.1074/jbc.M610821200	http://dx.doi.org/10.1074/jbc.M610821200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251188	hybrid			2022-12-25	WOS:000245421700073
J	Coyne, HJ; Ciofi-Baffoni, S; Banci, L; Bertini, I; Zhang, LM; George, GN; Winge, DR				Coyne, H. Jerome, III; Ciofi-Baffoni, Simone; Banci, Lucia; Bertini, Ivano; Zhang, Limei; George, Graham N.; Winge, Dennis R.			The characterization and role of zinc binding in yeast Cox4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MOLECULAR-DYNAMICS SIMULATIONS; NMR STRUCTURE DETERMINATION; PROTON-TRANSFER; IDENTIFICATION; MITOCHONDRIA; SITE	Yeast Cox4 is a zinc binding subunit of cytochrome c oxidase. Cox4 is the only cofactor-containing subunit that is not directly part of the catalytic core of the enzyme located in the mitochondrial inner membrane. The Zn(II) site is shown to be distinct from the bovine ortholog, as it results from the x-ray structure of the entire cytochrome c oxidase in having a single histidyl residue and three conserved cysteines residues in the coordination sphere. Substitutions at the Cys ligand positions result in nonfunctional Cox4 proteins that fail to lead to cytochrome oxidase assembly. Limited function exists in His-119 mutants when overexpressed. Zn(II) binding in Cox4 is, therefore, important for the stability of the complex. The solution structure of yeast Cox4 elucidated by multidimensional NMR reveals a C-terminal globular domain consisting of two beta sheets analogous to the bovine ortholog except the loop containing the coordinating His in the yeast protein and the fourth Cys in the bovine protein are in different positions in the two structures. The conformation of this loop is dictated by the different sequence position of the fourth coordinating zinc ligand. The Zn(II) ion is buried within the domain, consistent with its role in structural stability. Potential functions of this matrix-facing subunit are discussed.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Florence, Ctr Risonanze Magnet, I-50019 Florence, Italy; Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Florence; University of Saskatchewan	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Ciofi-Baffoni, Simone/AAH-9778-2021; George, Graham N/E-3290-2013; Winge, Dennis/G-3611-2010	Ciofi Baffoni, Simone/0000-0002-2376-3321; George, Graham/0000-0002-0420-7493; BANCI, LUCIA/0000-0003-0562-5774	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057375] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03817] Funding Source: Medline; NIGMS NIH HHS [GM57375] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard A, 2002, BBA-BIOENERGETICS, V1555, P133, DOI 10.1016/S0005-2728(02)00268-2; Banci L, 2003, CURR OPIN CHEM BIOL, V7, P143, DOI 10.1016/S1367-5931(02)00014-5; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Beauvoit B, 1999, EUR J BIOCHEM, V263, P118, DOI 10.1046/j.1432-1327.1999.00475.x; BERTINI I, 1984, ADV INORGANIC BIOCH; BISSON R, 1987, J BIOL CHEM, V262, P5992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; CHEN YL, 1995, BIOCHEMISTRY-US, V34, P12265, DOI 10.1021/bi00038a022; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Gilderson G, 2003, BIOCHEMISTRY-US, V42, P7400, DOI 10.1021/bi0341298; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Herrmann T, 2002, J BIOMOL NMR, V24, P171, DOI 10.1023/A:1021614115432; Hosler JP, 2006, ANNU REV BIOCHEM, V75, P165, DOI 10.1146/annurev.biochem.75.062003.101730; Ilbert M, 2006, ANTIOXID REDOX SIGN, V8, P835, DOI 10.1089/ars.2006.8.835; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Keller R., 2004, COMPUTER AIDED RESON, V1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.3.CO;2-E; MARET W, 1993, METHOD ENZYMOL, V226, P52; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; REHR JJ, 1992, PHYS REV LETT, V69, P3397, DOI 10.1103/PhysRevLett.69.3397; Suarez D, 2001, J AM CHEM SOC, V123, P3759, DOI 10.1021/ja003796a; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yoshikawa S, 2002, ADV PROTEIN CHEM, V60, P341; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	36	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8926	8934		10.1074/jbc.M610303200	http://dx.doi.org/10.1074/jbc.M610303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17215247	hybrid			2022-12-25	WOS:000245780300039
J	Maegawa, GHB; Tropak, M; Buttner, J; Stockley, T; Kok, F; Clarke, JTR; Mahuran, DJ				Maegawa, Gustavo H. B.; Tropak, Michael; Buttner, Justin; Stockley, Tracy; Kok, Fernando; Clarke, Joe T. R.; Mahuran, Don J.			Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-HEXOSAMINIDASE; TAY-SACHS-DISEASE; SANDHOFF-DISEASE; MOLECULAR-BASIS; ALPHA-SUBUNIT; ADULT FORM; GM2-GANGLIOSIDOSIS-B1 VARIANT; ENHANCEMENT THERAPIES; ENZYME REPLACEMENT; ACTIVATOR PROTEIN	Late-onset GM2 gangliosidosis is composed of two related, autosomal recessive, neurodegenerative diseases, both resulting from deficiency of lysosomal, heterodimeric beta-hexosaminidase A (Hex A, alpha beta). Pharmacological chaperones (PC) are small molecules that can stabilize the conformation of a mutant protein, allowing it to pass the quality control system of the endoplasmic reticulum. To date all successful PCs have also been competitive inhibitors. Screening for Hex A inhibitors in a library of 1040 Food Drug Administration-approved compounds identified pyrimethamine (PYR (2,4-diamino 5-(4-chlorophenyl)-6-ethylpyrimidine)) as the most potent inhibitor. Cell lines from 10 late-onset Tay-Sachs (11 a-mutations, 2 novel) and 7 Sandhoff (9 beta-mutations, 4 novel) disease patients, were cultured with PYR at concentrations corresponding to therapeutic doses. Cells carrying the most common late-onset mutation, alpha G269S, showed significant increases in residual Hex A activity, as did all 7 of the beta-mutants tested. Cells responding to PC treatment included those carrying mutants resulting in reduced Hex heat stability and partial splice junction mutations of the inherently less stable a-subunit. PYR, which binds to the active site in domain II, was able to function as PC even to domain I beta-mutants. We concluded that PYR functions as a mutation-specific PC, variably enhancing residual lysosomal Hex A levels in late-onset GM2 gangliosidosis patient cells.	Hosp Sick Children, Res Inst, Div Clin & Metab Genet, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1L5, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Sao Paulo, Fac Med, Dept Neurol, BR-01246903 Sao Paulo, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Universidade de Sao Paulo	Mahuran, DJ (corresponding author), Rm 9146,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.ca	Stockley, Tracy/AAW-6561-2021	Maegawa, Gustavo/0000-0001-6933-4138; Stockley, Tracy/0000-0002-4476-9722	NINDS NIH HHS [R21 NS051214-02, R21 NS051214-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS051214] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akerman B. R., 1992, Human Mutation, V1, P303, DOI 10.1002/humu.1380010407; AKLI S, 1993, HUM MOL GENET, V2, P61, DOI 10.1093/hmg/2.1.61; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; ARNOLD LA, 2006, SCI STKE, P13; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1993, AM J HUM GENET, V53, P497; Buxton IL, 2006, GOODMAN GILMANS PHAR; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DAZZO A, 1984, J BIOL CHEM, V259, P1070; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; Kaback MM, 2000, EUR J PEDIATR, V159, pS192, DOI 10.1007/PL00014401; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; Lemieux MJ, 2006, J MOL BIOL, V359, P913, DOI 10.1016/j.jmb.2006.04.004; Leport C, 1996, J INFECT DIS, V173, P91, DOI 10.1093/infdis/173.1.91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maegawa GHB, 2006, PEDIATRICS, V118, pE1550, DOI 10.1542/peds.2006-0588; MAHURAN D, 1980, CAN J BIOCHEM CELL B, V58, P287, DOI 10.1139/o80-038; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; Matsuda J, 2003, P NATL ACAD SCI USA, V100, P15912, DOI 10.1073/pnas.2536657100; MCINNES B, 1992, J CLIN INVEST, V90, P306, DOI 10.1172/JCI115863; Mules Emilie H., 1992, Human Mutation, V1, P298, DOI 10.1002/humu.1380010406; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAKANO T, 1989, J BIOL CHEM, V264, P5155; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; Neudorfer O, 2005, GENET MED, V7, P119, DOI 10.1097/01.GIM.0000154300.84107.75; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; PAW BH, 1990, J BIOL CHEM, V265, P9452; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; SAGHERIAN C, 1994, BIOCHEM BIOPH RES CO, V204, P135, DOI 10.1006/bbrc.1994.2436; SAGHERIAN C, 1993, BIOCHEM CELL BIOL, V71, P340, DOI 10.1139/o93-051; Sambrook J, 2001, MOL CLONING LAB MANU; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Sharma R, 2003, BBA-MOL BASIS DIS, V1637, P113, DOI 10.1016/S0925-4439(02)00221-1; SmiljanicGeorgijev N, 1997, BBA-PROTEIN STRUCT M, V1339, P192, DOI 10.1016/S0167-4838(97)00002-2; TANAKA A, 1990, AM J HUM GENET, V46, P329; Teichmann SA, 2001, TRENDS BIOTECHNOL, V19, P482, DOI 10.1016/S0167-7799(01)01813-3; Tominaga L, 2001, BRAIN DEV-JPN, V23, P284, DOI 10.1016/S0387-7604(01)00216-9; Tropak MB, 2004, J BIOL CHEM, V279, P13478, DOI 10.1074/jbc.M308523200; Verkman AS, 2006, CURR PHARM DESIGN, V12, P2235, DOI 10.2174/138161206777585148; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580; WEISS LM, 1992, AM J TROP MED HYG, V46, P288, DOI 10.4269/ajtmh.1992.46.288; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	54	126	127	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9150	9161		10.1074/jbc.M609304200	http://dx.doi.org/10.1074/jbc.M609304200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237499	Green Accepted, hybrid			2022-12-25	WOS:000245780300062
J	Roumy, M; Lorenzo, C; Mazeres, S; Bouchet, S; Zajac, JM; Mollereau, C				Roumy, Michel; Lorenzo, Corinne; Mazeres, Serge; Bouchet, Stephanie; Zajac, Jean-Marie; Mollereau, Catherine			Physical association between neuropeptide FF and mu-opioid receptors as a possible molecular basis for anti-opioid activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA SH-SY5Y; PROTEIN-COUPLED RECEPTOR; RAT DORSAL RAPHE; CHEMOKINE RECEPTORS; PEPTIDE RECEPTORS; FRAP EXPERIMENTS; NPFF2 RECEPTOR; HETERODIMERIZATION; MEMBRANE; DELTA	Neuropeptide FF (NPFF) modulates the opioid system by exerting functional anti-opioid activity on neurons, the mechanism of which is unknown. By using a model of SH-SY5Y cells, we recently postulated that anti-opioid activity likely takes place upstream from the signaling cascade, suggesting that NPFF receptors could block opioid receptors by physical interaction. In the present study, fluorescence techniques were used to monitor the physical association and the dynamic of NPFF, and mu-opioid (MOP) receptors tagged with variants of the green fluorescent protein. Importantly, cyan fluorescent protein-tagged NPFF, receptors retained their capacity to antagonize opioid receptors. Fluorescence resonance energy transfer (FRET) and coimmunoprecipitation studies indicate that NPFF and MOP receptors are close enough to generate a basal FRET signal. The opioid agonist Tyr-D-Ala-Gly-NMe-Phe-Gly-ol disrupts by 20-30% this FRET signal, mainly because it concomitantly induces 40% internalization of receptors. In contrast, the NPFF analog IDMe significantly increases by 10-15% the basal FRET signal, suggesting an association between both receptors. In addition, IDMe reduces, by half, MOP receptor internalization, indicating that, besides a functional blockade of opioid receptors, the NPFF analog also inhibits their internalization. Finally, as a first report showing the modulation of the mobility of a G-protein-coupled receptor by another one, fluorescence recovery after photobleaching analysis reveals that IDMe modifies the lateral diffusion of MOP receptors in the cell membrane, changing them from a confined to a freely diffusing state. By promoting NPFF-MOP receptor heteromerization, IDMe could disrupt the domain organization of MOP receptors in the membrane, resulting in a reduction of opioid response.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse 04, France; CNRS, UMR 5088, Lab Biol Cellulaire & Mol Controle Proliferat, F-31062 Toulouse 09, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Mollereau, C (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 04, France.	catherine.mollereau-manaute@ipbs.fr	Zajac, jean-marie/E-5129-2010	Mollereau, Catherine/0000-0003-1543-5624				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Butour JL, 2004, BIOCHEM BIOPH RES CO, V325, P915, DOI 10.1016/j.bbrc.2004.10.125; CESSELIN F, 1995, FUND CLIN PHARMACOL, V9, P409, DOI 10.1111/j.1472-8206.1995.tb00517.x; Cezanne L, 2004, J BIOL CHEM, V279, P45057, DOI 10.1074/jbc.M404811200; Chen CG, 2004, EUR J PHARMACOL, V483, P175, DOI 10.1016/j.ejphar.2003.10.033; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Daumas F, 2003, BIOPHYS J, V84, P356, DOI 10.1016/S0006-3495(03)74856-5; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Gouarderes C, 2002, NEUROSCIENCE, V115, P349, DOI 10.1016/S0306-4522(02)00419-0; Gregan B, 2004, J BIOL CHEM, V279, P27679, DOI 10.1074/jbc.M403601200; Gupta A, 2006, AAPS J, V8, pE153, DOI 10.1208/aapsj080118; Harrison LM, 1998, PEPTIDES, V19, P1603, DOI 10.1016/S0196-9781(98)00126-0; Horvat RD, 1999, BIOCHEM BIOPH RES CO, V255, P382, DOI 10.1006/bbrc.1999.0185; Jiao XM, 2005, MOL CELL BIOL, V25, P5752, DOI 10.1128/MCB.25.13.5752-5762.2005; JOHANSSON B, 1993, J CELL BIOL, V121, P1281, DOI 10.1083/jcb.121.6.1281; Jordan BA, 2003, MOL PHARMACOL, V64, P1317, DOI 10.1124/mol.64.6.1317; Kersante F, 2006, PEPTIDES, V27, P980, DOI 10.1016/j.peptides.2005.07.025; Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LOPEZ A, 1988, BIOPHYS J, V53, P963, DOI 10.1016/S0006-3495(88)83177-1; Marshall F H, 2001, Curr Opin Pharmacol, V1, P40, DOI 10.1016/S1471-4892(01)00001-7; Mauborgne A, 2001, EUR J PHARMACOL, V430, P273, DOI 10.1016/S0014-2999(01)01384-X; Mollereau C, 2005, CURR TOP MED CHEM, V5, P341, DOI 10.2174/1568026053544515; Mollereau C, 2005, MOL PHARMACOL, V67, P965, DOI 10.1124/mol.104.004614; Mouledous L, 2005, MOL PHARMACOL, V68, P467, DOI 10.1124/mol.105.013391; Panula P, 1999, BRAIN RES, V848, P191, DOI 10.1016/S0006-8993(99)02044-2; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Pfleger KDG, 2005, BIOCHEM J, V385, P625, DOI 10.1042/BJ20041361; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Pucadyil TJ, 2004, BIOCHEMISTRY-US, V43, P15852, DOI 10.1021/bi0480887; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Roumy M, 1999, BRAIN RES, V845, P208, DOI 10.1016/S0006-8993(99)01965-4; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Roumy M, 2003, NEUROSCI LETT, V348, P159, DOI 10.1016/S0304-3940(03)00791-2; Salome L, 1998, EUR BIOPHYS J BIOPHY, V27, P391, DOI 10.1007/s002490050146; Sauliere A, 2006, FEBS LETT, V580, P5227, DOI 10.1016/j.febslet.2006.08.056; Scott L, 2006, P NATL ACAD SCI USA, V103, P762, DOI 10.1073/pnas.0505557103; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Strock J, 2004, MOL PHARMACOL, V66, P1071, DOI 10.1124/mol.104.002261; Suzuki S, 2002, EXP CELL RES, V280, P192, DOI 10.1006/excr.2002.5638; Takeuchi T, 2001, JPN J PHARMACOL, V86, P417, DOI 10.1254/jjp.86.417; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Toselli M, 1997, PFLUG ARCH EUR J PHY, V433, P587, DOI 10.1007/s004240050318; Triller A, 2005, TRENDS NEUROSCI, V28, P133, DOI 10.1016/j.tins.2005.01.001; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VAUGHAN PFT, 1995, GEN PHARMACOL-VASC S, V26, P1191, DOI 10.1016/0306-3623(94)00312-B; VOGEL SS, 2006, SCI STKE, pRE2, DOI DOI 10.1126/STKE.3312006RE2; Wang HL, 2005, J NEUROCHEM, V92, P1285, DOI 10.1111/j.1471-4159.2004.02921.x; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zajac JM, 2006, PEPTIDES, V27, P941, DOI 10.1016/j.peptides.2005.12.005; Zajac JM, 2001, TRENDS PHARMACOL SCI, V22, P63, DOI 10.1016/S0165-6147(00)01610-2; Zhang X, 2006, TRENDS PHARMACOL SCI, V27, P324, DOI 10.1016/j.tips.2006.04.005	64	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8332	8342		10.1074/jbc.M606946200	http://dx.doi.org/10.1074/jbc.M606946200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224450	hybrid			2022-12-25	WOS:000245081000067
J	Tullman-Ercek, D; DeLisa, MP; Kawarasaki, Y; Iranpour, P; Ribnicky, B; Palmer, T; Georgiou, G				Tullman-Ercek, Danielle; DeLisa, Matthew P.; Kawarasaki, Yasuaki; Iranpour, Pooya; Ribnicky, Brian; Palmer, Tracy; Georgiou, George			Export pathway selectivity of Escherichia coli twin arginine translocation signal peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION; PERIPLASMIC PROTEIN; CYTOPLASMIC MEMBRANE; GENETIC-ANALYSIS; MATURE SEQUENCE; TAT PATHWAY; SPECIFICITY; SECRETION; REDUCTASE; RESIDUES	The Escherichia coli genome encodes at least 29 putative signal peptides containing a twin arginine motif characteristic of proteins exported via the twin arginine translocation (Tat) pathway. Fusions of the putative Tat signal peptides plus six to eight amino acids of the mature proteins to three reporter proteins (short-lived green fluorescent protein, maltose-binding protein (MBP), and alkaline phosphatase) and also data from the cell localization of epitope-tagged full-length proteins were employed to determine the ability of the 29 signal peptides to direct export through the Tat pathway, through the general secretory pathway (Sec), or through both. 27/29 putative signal peptides could export one or more reporter proteins through Tat. Of these, I I signal peptides displayed Tat specificity in that they could not direct the export of Sec-only reporter proteins. The rest (16/27) were promiscuous and were capable of directing export of the appropriate reporter either via Tat (green fluorescent protein, MBP) or via Sec (PhoA, MBP). Mutations that conferred a >=+1 charge to the N terminus of the mature protein abolished or drastically reduced routing through the Sec pathway without affecting the ability to export via the Tat pathway. These experiments demonstrate that the charge of the mature protein N terminus affects export promiscuity, independent of the effect of the folding state of the mature protein.	Univ Texas, Dept Chem, Austin, TX 78712 USA; Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY 14853 USA; John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Cornell University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, 1 Univ Stn C04000, Austin, TX 78712 USA.	gg@che.utexas.edu	Tullman-Ercek, Danielle/L-2792-2016; DeLisa, Matthew/AAE-7361-2019; Kawarasaki, Yasuaki/J-5910-2013	Kawarasaki, Yasuaki/0000-0002-7143-3159; Palmer, Tracy/0000-0001-9043-2592; DeLisa, Matthew/0000-0003-3226-1566	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069872] Funding Source: NIH RePORTER; MRC [G117/519] Funding Source: UKRI; Medical Research Council [G117/519] Funding Source: Medline; NIGMS NIH HHS [R01 GM069872, R01 GM069872-01A1, R0-01 GM069872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; Bendtsen JD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-167; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bernhardt TG, 2003, MOL MICROBIOL, V48, P1171, DOI 10.1046/j.1365-2958.2003.03511.x; Blaudeck N, 2003, J BACTERIOL, V185, P2811, DOI 10.1128/JB.185.9.2811-2819.2003; Blaudeck N, 2001, J BACTERIOL, V183, P604, DOI 10.1128/JB.183.2.604-610.2001; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Caldelari I, 2006, MOL PLANT MICROBE IN, V19, P200, DOI 10.1094/MPMI-19-0200; Chanal A, 2003, J MOL BIOL, V327, P563, DOI 10.1016/S0022-2836(03)00170-0; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; DeLisa MP, 2002, J BIOL CHEM, V277, P29825, DOI 10.1074/jbc.M201956200; DeLisa MP, 2003, P NATL ACAD SCI USA, V100, P6115, DOI 10.1073/pnas.0937838100; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; FISHER AC, 2006, PROTEIN SCI; GELLER B, 1993, J BIOL CHEM, V268, P9442; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gon S, 2000, J BACTERIOL, V182, P5779, DOI 10.1128/JB.182.20.5779-5786.2000; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ize B, 2004, J BIOL CHEM, V279, P47543, DOI 10.1074/jbc.M406910200; Ize B, 2003, MOL MICROBIOL, V48, P1183, DOI 10.1046/j.1365-2958.2003.03504.x; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Kajava AV, 2000, J BACTERIOL, V182, P2163, DOI 10.1128/JB.182.8.2163-2169.2000; Kebir MO, 2002, BIOCHEMISTRY-US, V41, P5573, DOI 10.1021/bi015798t; Lee PA, 2006, ANNU REV MICROBIOL, V60, P373, DOI 10.1146/annurev.micro.60.080805.142212; Lequette Y, 2004, J BACTERIOL, V186, P3695, DOI 10.1128/JB.186.12.3695-3702.2004; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Rose RW, 2002, MOL MICROBIOL, V45, P943, DOI 10.1046/j.1365-2958.2002.03090.x; Sambasivarao D, 2000, J BIOL CHEM, V275, P22526, DOI 10.1074/jbc.M909289199; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Sturm A, 2006, J BIOL CHEM, V281, P13972, DOI 10.1074/jbc.M511891200; Thomas G, 1999, FEMS MICROBIOL LETT, V174, P167, DOI 10.1111/j.1574-6968.1999.tb13564.x; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; YAMANE K, 1988, J BIOL CHEM, V263, P19690	47	100	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8309	8316		10.1074/jbc.M610507200	http://dx.doi.org/10.1074/jbc.M610507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17218314	Green Accepted, hybrid			2022-12-25	WOS:000245081000064
J	Yamada, Y; Suzuki, NN; Hanada, T; Ichimura, Y; Kumeta, H; Fujioka, Y; Ohsumi, Y; Inagaki, F				Yamada, Yuya; Suzuki, Nobuo N.; Hanada, Takao; Ichimura, Yoshinobu; Kumeta, Hiroyuki; Fujioka, Yuko; Ohsumi, Yoshinori; Inagaki, Fuyuhiko			The crystal structure of Atg3, an autophagy-related ubiquitin carrier protein (E2) enzyme that mediates Atg8 lipidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; CONJUGATING ENZYMES; SYSTEM; DOMAIN; CELLS; MICE	Atg3 is an E2-like enzyme that catalyzes the conjugation of Atg8 and phosphatidylethanolamine (PE). The Atg8-PE conjugate is essential for autophagy, which is the bulk degradation process of cytoplasmic components by the vacuolar/lysosomal system. We report here the crystal structure of Saccharomyces cerevisiae Atg3 at 2.5-angstrom resolution. Atg3 has an alpha/beta-fold, and its core region is topologically similar to canonical E2 enzymes. Atg3 has two regions inserted in the core region, one of which consists of similar to 80 residues and has a random coil structure in solution and another with a long a-helical structure that protrudes from the core region as far as 30 angstrom. In vivo and in vitro analyses suggested that the former region is responsible for binding Atg7, an E1-like enzyme, and that the latter is responsible for binding Atg8. A sulfate ion was bound near the catalytic cysteine of Atg3, suggesting a possible binding site for the phosphate moiety of PE. The structure of Atg3 provides a molecular basis for understanding the unique lipidation reaction that Atg3 carries out.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Natl Inst Basic Biol, Div Mol Cell Biol, Okazaki, Aichi 4448585, Japan	Hokkaido University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Ohsumi, Yoshinori/C-6449-2009; Noda, Nobuo/P-1397-2015	Ohsumi, Yoshinori/0000-0003-2384-2166; Fujioka, Yuko/0000-0002-6905-0669; Kumeta, Hiroyuki/0000-0003-3713-2122; Hanada, Takao/0000-0003-2732-4008; Noda, Nobuo/0000-0002-6940-8069				Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1997, TURBO FRODO VERSION; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Goddard T.D., SPARKY 3; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plafker SM, 2004, J CELL BIOL, V167, P649, DOI 10.1083/jcb.200406001; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; Sugawara K, 2005, J BIOL CHEM, V280, P40058, DOI 10.1074/jbc.M509158200; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Winn PJ, 2004, STRUCTURE, V12, P1563, DOI 10.1016/j.str.2004.06.017; Yamada Y, 2006, ACTA CRYSTALLOGR F, V62, P1016, DOI 10.1107/S1744309106036098	35	101	106	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8036	8043		10.1074/jbc.M611473200	http://dx.doi.org/10.1074/jbc.M611473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227760	hybrid			2022-12-25	WOS:000245081000035
J	Gonzalez-Cabrera, PJ; Hla, T; Rosen, H				Gonzalez-Cabrera, Pedro J.; Hla, Timothy; Rosen, Hugh			Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-PROMOTED UBIQUITINATION; DOWN-REGULATION; LYMPHOCYTE EGRESS; BETA-ARRESTIN; DEGRADATION; TRAFFICKING; INVOLVEMENT; INHIBITION; DISEASES	Sphingosine 1-phosphate subtype 1 (S1P(1)) receptor agonists alter lymphocyte trafficking and endothelial barrier integrity in vivo. Among these is the potent, non-selective agonist, FTY720-P, whose mechanism of action has been suggested to correlate with S1P(1) down-regulation. Discovery of the in vivo active S1P(1)-selective agonist, SEW2871, has broadened our understanding of minimal requirements for S1P(1) function while highlighting differences regarding agonist effect on S1P(1) fate, because SEW2871 does not degrade S1P(1). To further understand the mechanism of agonist-induced S1P(1) down-regulation, we compared signaling and fate of human S1P(1)-green fluorescent protein (GFP) in stable 293 cells, using AFD-R, a chiral analog of FTY720-P, SEW2871, and S1P. Although all agonists acutely internalized S1P(1) to late endosomal vesicles and activated GTP gamma S-35 binding and PERK to similar maxima, only AFD-R led to significant S1P(1) down-regulation, as shown by GFP immunoprecipitation studies. Down-regulation was time- and concentration-dependent, was partially blocked by proteasomal inhibition and reversed by chloroquine and an antagonist to S1P(1). All agonists induced a receptor-associated increase in ubiquitination, with AFD-R inducing 3-fold more accumulation than S1P and being 3-4 logs more potent than SEW2871. The formation of AFD-R-receptor ubiquitin complex was inhibited by antagonist and chloroquine and was enhanced by proteasomal inhibition. Identification of proteins by PAGE liquid chromatography-tandem mass spectrometry in cells treated with AFD-R confirmed the co-migration of ubiquitin peptides with those of S1P(1) and GFP, relative to vehicle alone. These data suggest that the hierarchy of ubiquitin recruitment to SIP1 (AFD-R > S1P > SEW2871) correlates with the efficiency of lysosomal receptor degradation and reflects intrinsic differences between agonists.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA	Scripps Research Institute; University of Connecticut	Rosen, H (corresponding author), Scripps Res Inst, Dept Immunol, ICND 118,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hrosen@scripps.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL70694] Funding Source: Medline; NIAID NIH HHS [R01 AI055509] Funding Source: Medline; NIMH NIH HHS [MH 074404] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH074404] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alfonso C, 2006, EUR J IMMUNOL, V36, P149, DOI 10.1002/eji.200535127; Bouley R, 2005, AM J PHYSIOL-CELL PH, V288, pC1390, DOI 10.1152/ajpcell.00353.2004; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Ciechanover A, 2006, EXP BIOL MED, V231, P1197; Dugast M, 2005, J BIOL CHEM, V280, P19656, DOI 10.1074/jbc.M501357200; Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828; Foss FW, 2007, BIOORGAN MED CHEM, V15, P663, DOI 10.1016/j.bmc.2006.10.060; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Lemieux B, 2004, ANAL BIOCHEM, V327, P247, DOI 10.1016/j.ab.2004.01.010; Liang W, 2004, J BIOL CHEM, V279, P46882, DOI 10.1074/jbc.M406501200; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Luttrell Louis M., 2006, V332, P3; MacLennan AJ, 2006, HEARING RES, V220, P38, DOI 10.1016/j.heares.2006.06.016; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese Adriano, 2004, Methods Mol Biol, V259, P299; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Prossnitz ER, 2004, LIFE SCI, V75, P893, DOI 10.1016/j.lfs.2004.04.003; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; Tulipano G, 2004, J BIOL CHEM, V279, P21374, DOI 10.1074/jbc.M313522200; Urbe S, 2005, ESSAYS BIOCHEM, V41, P81, DOI 10.1042/EB0410081; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Zaslavsky A, 2006, BBA-MOL CELL BIOL L, V1761, P1200, DOI 10.1016/j.bbalip.2006.08.011	32	68	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7254	7264		10.1074/jbc.M610581200	http://dx.doi.org/10.1074/jbc.M610581200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218309	hybrid			2022-12-25	WOS:000245080900037
J	Ouellet, H; Ranguelova, K; LaBarre, M; Wittenberg, JB; Wittenberg, BA; Magliozzo, RS; Guertin, M				Ouellet, Hugues; Ranguelova, Kalina; LaBarre, Marie; Wittenberg, Jonathan B.; Wittenberg, Beatrice A.; Magliozzo, Richard S.; Guertin, Michel			Reaction of Mycobacterium tuberculosis truncated hemoglobin O with hydrogen peroxide - Evidence for peroxidatic activity and formation of protein-based radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; ELECTRON-PARAMAGNETIC-RESONANCE; SPERM-WHALE MYOGLOBIN; NUCLEAR DOUBLE-RESONANCE; TYROSINE CROSS-LINK; HORSERADISH-PEROXIDASE; CATALASE-PEROXIDASE; CRYSTAL-STRUCTURE; COMPOUND-I; ASCORBATE PEROXIDASE	In this work, we investigated the reaction of ferric Mycobacterium tuberculosis truncated hemoglobin O (trHbO) with hydrogen peroxide. Stopped-flow spectrophotometric experiments under single turnover conditions showed that trHbO reacts with H,O, to give transient intermediate(s), among which is an oxyferryl heme, different from a typical peroxidase Compound I (oxyferryl heme pi-cation radical). EPR spectroscopy indicated evidence for both tryptophanyl and tyrosyl radicals, whereas redox titrations demonstrated that the peroxide-treated protein product retains 2 oxidizing eq. We propose that Compound I formed transiently is reduced with concomitant oxidation of Trp(G8) to give the detected oxoferryl heme and a radical on Trp(G8) (detected by EPR of the trHbO Tyr(CD1)Phe mutant). In the wild-type protein, the Trp(G8) radical is in turn reduced rapidly by Tyr(CD1). In a second cycle, Trp(G8) may be reoxidized by the ferryl heme to yield ferric heme and two protein radicals. In turn, these migrate to form tyrosyl radicals on Tyr(55) and Tyr(115), which lead, in the absence of a reducing substrate, to oligomerization of the protein. Steady-state kinetics in the presence of H2O2 and the one-electron donor 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) indicated that trHbO has peroxidase activity, in accord with the presence of typical peroxidase intermediates. These findings suggest an oxidation/reduction function for trHbO and, by analogy, for other Group II trHbs.	Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada; CUNY, Dept Chem, Brooklyn Coll, Brooklyn, NY 11210 USA; CUNY, Dept Chem, Grad Ctr, New York, NY 10016 USA; CUNY, Dept Biochem, Grad Ctr, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Phys & Biophys, Bronx, NY 10461 USA	Laval University; City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System; Yeshiva University; Albert Einstein College of Medicine	Guertin, M (corresponding author), Univ Laval, Dept Biochem & Microbiol, Pavillon Marchand,Room 3145, Quebec City, PQ G1K 7P4, Canada.	mguertin@bcm.ulaval.ca			NIAID NIH HHS [1-R01-AI052258, AI060014] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060014, R01AI052258, R56AI060014] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; Bhaskar B, 2003, J MOL BIOL, V328, P157, DOI 10.1016/S0022-2836(03)00179-7; Blodig W, 1999, ARCH BIOCHEM BIOPHYS, V370, P86, DOI 10.1006/abbi.1999.1365; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; Bravo J, 1997, PROTEIN SCI, V6, P1016, DOI 10.1002/pro.5560060507; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chartier FJM, 2004, BIOPHYS J, V87, P1939, DOI 10.1529/biophysj.104.042119; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3; Diaz A, 2004, J MOL BIOL, V342, P971, DOI 10.1016/j.jmb.2004.07.027; DUNFORD HB, 1999, HEME PEROXIDASES, P141; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Egawa T, 2003, J BIOL CHEM, V278, P41597, DOI 10.1074/jbc.M210383200; ERMAN JE, 1975, BIOCHIM BIOPHYS ACTA, V393, P350, DOI 10.1016/0005-2795(75)90061-6; ERMAN JE, 1975, BIOCHIM BIOPHYS ACTA, V393, P343, DOI 10.1016/0005-2795(75)90060-4; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Giangiacomo L, 2005, J BIOL CHEM, V280, P9192, DOI 10.1074/jbc.M407267200; GOODWIN DC, 1995, ANAL BIOCHEM, V231, P333, DOI 10.1006/abio.1995.0059; Hara I, 2001, J BIOL CHEM, V276, P36067, DOI 10.1074/jbc.C100371200; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Hiner ANP, 2002, J INORG BIOCHEM, V91, P27, DOI 10.1016/S0162-0134(02)00390-2; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; KEILIN D, 1950, NATURE, V166, P513, DOI 10.1038/166513a0; LaCount MW, 2000, J BIOL CHEM, V275, P18712, DOI 10.1074/jbc.M001194200; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Lardinois OM, 2003, J BIOL CHEM, V278, P36214, DOI 10.1074/jbc.M304726200; Lawrence A, 2003, J BIOL CHEM, V278, P29410, DOI 10.1074/jbc.M300054200; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; Liang ZX, 2004, J AM CHEM SOC, V126, P2785, DOI 10.1021/ja038163l; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; MOREAU S, 1995, BBA-PROTEIN STRUCT M, V1251, P17, DOI 10.1016/0167-4838(95)00087-B; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NOBLE RW, 1970, J BIOL CHEM, V245, P2409; Osborne RL, 2004, BIOCHEM BIOPH RES CO, V324, P1194, DOI 10.1016/j.bbrc.2004.09.174; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Ozaki S, 2001, BIOCHEMISTRY-US, V40, P1044, DOI 10.1021/bi001579g; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; Pogni R, 2006, J BIOL CHEM, V281, P9517, DOI 10.1074/jbc.M510424200; Pogni R, 2005, BIOCHEMISTRY-US, V44, P4267, DOI 10.1021/bi047474l; RAO SI, 1993, J BIOL CHEM, V268, P803; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Savenkova MI, 1996, J BIOL CHEM, V271, P24598, DOI 10.1074/jbc.271.40.24598; SELWYN MJ, 1965, BIOCHIM BIOPHYS ACTA, V105, P193, DOI 10.1016/S0926-6593(65)80190-4; Shi WJ, 2000, BIOCHEMISTRY-US, V39, P4112, DOI 10.1021/bi992561c; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SPIRO TG, 1988, BIOL APPLICATIONS RA, V3, P39; Svistunenko DA, 2005, BBA-BIOENERGETICS, V1707, P127, DOI 10.1016/j.bbabio.2005.01.004; TEW D, 1988, J BIOL CHEM, V263, P17880; Tsaprailis G, 2003, J BIOL INORG CHEM, V8, P248, DOI 10.1007/s00775-002-0407-6; TschirretGuth RA, 1996, ARCH BIOCHEM BIOPHYS, V335, P93, DOI 10.1006/abbi.1996.0485; WITTENBE.BA, 1967, BIOCHEMISTRY-US, V6, P1970, DOI 10.1021/bi00859a013; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YONETANI T, 1965, J BIOL CHEM, V240, P4509; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	64	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7491	7503		10.1074/jbc.M609155200	http://dx.doi.org/10.1074/jbc.M609155200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17218317	hybrid			2022-12-25	WOS:000245080900062
J	Huang, JH; Lu, L; Lu, H; Chen, X; Jiang, SB; Chen, YH				Huang, Jing-He; Lu, Lu; Lu, Hong; Chen, Xi; Jiang, Shibo; Chen, Ying-Hua			Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 GP41; MONOCLONAL-ANTIBODY; 6-HELIX BUNDLES; LIPID RAFTS; VIRAL ENTRY; INHIBITION; SUBDOMAIN; PROTEINS; MULTIPLE; ACTIN	The human immunodeficiency virus, type I (HIV-1) gp41 core plays an important role in fusion between viral and target cell membranes. A single chain polypeptide, N36(L8)C34, which forms a six-helix bundle in physiological solution, can be used as a model of gp41 core. Here we identified from a 12-mer phage peptide library a positive phage clone displaying a peptide sequence with high binding activity to the HIV-I gp41 core. The peptide sequence contains a putative gp41-binding motif, Phi XXXX Phi X Phi (X is any amino acid residue, and Phi is any one of the aromatic amino acid residues Trp, Phe, or Tyr). This motif also exists in the scaffolding domain of caveolin-1 (Cav-1), a known gp41-binding protein. Cav-1-(61-101) and Cav-l-(82-101), two recombinant fusion proteins containing the Cav-1 scaffolding domain, bound significantly to the gp41 expressed in mammalian cells and interacted with the polypeptide N36(L8)C34. These results suggest that the scaffolding domain of Cav-1 may bind to the gp41 core via the motif. This interaction may be essential for formation of fusion pore or endocytosis of HIV-I and affect the pathogenesis of HIV-1 infection. Further characterization of the gp41 core-binding motifs may shed light on the alternative mechanism by which HIV-1 enters into the target cell.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, New York, NY 10021 USA; Tsinghua Univ, Immunol Lab, Dept Biol, Prot Sci Lab,Minist Educ, Beijing 100084, Peoples R China	New York Blood Center; Tsinghua University	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, New York, NY 10021 USA.	sjiang@nybloodcenter.org; chenyh@mail.tsinghua.edu.cn	chen, ying/HHS-8254-2022; lu, lu/HII-7530-2022; Jiang, Shibo/L-4500-2014; lu, lu/HGA-0894-2022; Huang, Jinghe/P-8068-2019; Lu, Lu/K-7070-2014; Huang, Jinghe/O-1986-2015	Jiang, Shibo/0000-0001-8283-7135; Lu, Lu/0000-0002-2255-0391; Huang, Jinghe/0000-0002-1968-871X	NIAID NIH HHS [AI46221] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221, R21AI046221] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Becker KA, 1999, J CELL SCI, V112, P97; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; Fermin C, 2005, MICROSC RES TECHNIQ, V68, P149, DOI 10.1002/jemt.20228; Galli T, 2001, Sci STKE, V2001, pre1; Hovanessian AG, 2004, IMMUNITY, V21, P617, DOI 10.1016/j.immuni.2004.08.015; Huang JH, 2006, FEBS LETT, V580, P4807, DOI 10.1016/j.febslet.2006.07.067; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	34	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6143	6152		10.1074/jbc.M607701200	http://dx.doi.org/10.1074/jbc.M607701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197700	hybrid			2022-12-25	WOS:000244867200020
J	Wang, SZE; Narasanna, A; Whitell, CW; Wu, FY; Friedman, DB; Arteaga, CL				Wang, Shizhen Emily; Narasanna, Archana; Whitell, Corbin W.; Wu, Frederick Y.; Friedman, David B.; Arteaga, Carlos L.			Convergence of p53 and transforming growth factor beta (TGF beta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BREAST-CANCER; LUNG-CANCER; MUTANT P53; RECEPTOR; MOTILITY; ERBB2; PROGRESSION; ALPHA; TUMORIGENESIS; COOPERATION	Using two-dimensional difference gel electrophoresis, we identified the tumor suppressor gene maspin as a transforming growth factor beta (TGF beta) target gene in human mammary epithelial cells. TGF beta up-regulatesMaspin expression both at the RNA and protein levels. This up-regulation required Smad2/3 function and intact p53-binding elements in the Maspin promoter. DNA affinity immunoblot and chromatin immunoprecipitation revealed the presence of both Smads and p53 at the Maspin promoter in TGF beta-treated cells, suggesting that both transcription factors cooperate to induce Maspin transcription. TGF beta did not activate Maspin-luciferase reporter in p53-mutant MDA-MB-231 breast cancer cells, which exhibit methylation of the endogenous Maspin promoter. Expression of ectopic p53, however, restored ligand-induced association of Smad2/3 with a transfected Maspin promoter. Stable transfection of Maspin inhibited basal and TGF beta-stimulated MDA-MB-231 cell motility. Finally, knockdown of endogenous Maspin in p53 wild-type MCF10A/HER2 cells enhanced basal and TGF beta-stimulated motility. Taken together, these data support cooperation between the p53 and TGF beta tumor suppressor pathways in the induction of Maspin expression, thus leading to inhibition of cell migration.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, 2220 Poerce Ave,777 PRB, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu		Wang, Shizhen Emily/0000-0002-5036-8175	NCI NIH HHS [R01 CA062212, R01 CA080195, P50 CA98131, P50 CA098131, P30 CA068485, R01CA62212, P30 CA68485, R00 CA125892, R01CA80195, K99 CA125892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K99CA125892, R01CA080195, P30CA068485, R01CA062212, P50CA098131, R00CA125892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2006, CURR OPIN GENET DEV, V16, P30, DOI 10.1016/j.gde.2005.12.009; Bakin AV, 2002, J CELL SCI, V115, P3193; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016/j.canlet.2004.06.008; Ewan KB, 2002, CANCER RES, V62, P5627; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; FOEKENS JA, 1995, CANCER RES, V55, P1423; Friedman DB, 2006, PLOS PATHOG, V2, P777, DOI 10.1371/journal.ppat.0020087; Friedman DB, 2007, MOL CELL PROTEOMICS, V6, P150, DOI 10.1074/mcp.D600001-MCP200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; HAMILTON JA, 1993, J IMMUNOL, V151, P5154; Kim S, 2004, CANCER RES, V64, P6900, DOI 10.1158/0008-5472.CAN-04-1657; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471; Odero-Marah VA, 2002, BIOCHEM BIOPH RES CO, V295, P800, DOI 10.1016/S0006-291X(02)00764-7; OLIFF A, 1985, J VIROL, V54, P864, DOI 10.1128/JVI.54.3.864-868.1985; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Reddy KB, 2001, ONCOGENE, V20, P6538, DOI 10.1038/sj.onc.1204796; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Smith SL, 2003, ONCOGENE, V22, P8677, DOI 10.1038/sj.onc.1207127; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang SE, 2003, J VIROL, V77, P600, DOI 10.1128/JVI.77.1.600-623.2003; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhang WG, 2002, INT J ONCOL, V20, P1145; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	30	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5661	5669		10.1074/jbc.M608499200	http://dx.doi.org/10.1074/jbc.M608499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17204482	Green Accepted, hybrid			2022-12-25	WOS:000244482300063
J	Hamon, Y; Trompier, D; Ma, Z; Venegas, V; Pophillat, M; Mignotte, V; Zhou, Z; Chimini, G				Hamon, Yannick; Trompier, Doriane; Ma, Zhong; Venegas, Victor; Pophillat, Matthieu; Mignotte, Vincent; Zhou, Zheng; Chimini, Giovanna			Cooperation between Engulfment Receptors: The Case of ABCA1 and MEGF10	PLOS ONE			English	Article								The engulfment of dying cells is a specialized form of phagocytosis that is extremely conserved across evolution. In the worm, it is genetically controlled by two parallel pathways, which are only partially reconstituted in mammals. We focused on the recapitulation of the CED-1 defined pathway in mammalian systems. We first explored and validated MEGF10, a novel receptor bearing striking structural similarities to CED-1, as a bona fide functional ortholog in mammals and hence progressed toward the analysis of molecular interactions along the corresponding pathway. We ascertained that, in a system of forced expression by transfection, MEGF10 function can be modulated by the ATP binding cassette transporter ABCA1, ortholog to CED-7. Indeed, the coexpression of either a functional or a mutant ABCA1 exerted a transdominant positive or negative modulation on the MEGF10-dependent engulfment. The combined use of biochemical and biophysical approaches indicated that this functional cooperation relies on the alternate association of these receptors with a common partner, endogenously expressed in our cell system. We provide the first working model structuring in mammals the CED-1 dependent pathway.	[Hamon, Yannick; Trompier, Doriane; Pophillat, Matthieu; Chimini, Giovanna] Univ Aix Marseille 2, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France; [Ma, Zhong] Univ Virginia, Carter Immunol Ctr, Charlottesville, VA USA; [Ma, Zhong] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Venegas, Victor; Zhou, Zheng] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Mignotte, Vincent] Univ Paris 05, CNRS, INSERM, Inst Cochin,U567,UMR 8104, F-75270 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Virginia; University of Virginia; Baylor College of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chimini, G (corresponding author), Univ Aix Marseille 2, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France.	chimini@ciml.univ-mrs.fr	TROMPIER, Doriane/D-5862-2017; HAMON, Yannick/S-3118-2019; HAMON, Yannick YH/N-5372-2016	HAMON, Yannick/0000-0002-7636-2310; HAMON, Yannick YH/0000-0002-7636-2310; Trompier, Doriane/0000-0002-0746-1753	INSERM; CNRS; European Community-APOCLEAR; FLIPPASE; Nouvelle Societe Francaise d'Atherosclerose	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); European Community-APOCLEAR; FLIPPASE; Nouvelle Societe Francaise d'Atherosclerose	This work has been funded by institutional grants from INSERM and CNRS and specific grants from the European Community-APOCLEAR and FLIPPASE. DT was funded in part by a fellowship, allocated by the Nouvelle Societe Francaise d'Atherosclerose.	Abe-Dohmae S, 2006, FEBS LETT, V580, P1178, DOI 10.1016/j.febslet.2005.12.029; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; Broccardo C, 2001, CYTOGENET CELL GENET, V92, P264, DOI 10.1159/000056914; Callebaut I, 2003, BIOCHEM BIOPH RES CO, V300, P619, DOI 10.1016/S0006-291X(02)02904-2; Castellano F, 2000, J CELL SCI, V113, P2955; ELLIS RE, 1991, GENETICS, V129, P79; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Jehle AW, 2006, J CELL BIOL, V174, P547, DOI 10.1083/jcb.200601030; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kim WS, 2005, J BIOL CHEM, V280, P3989, DOI 10.1074/jbc.M412602200; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Kiss RS, 2006, J BIOL CHEM, V281, P12081, DOI 10.1074/jbc.M600621200; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mangahas PM, 2005, SEMIN CELL DEV BIOL, V16, P295, DOI 10.1016/j.semcdb.2004.12.005; PETER GF, 1991, J BIOL CHEM, V266, P16745; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; TROMPIER D, 2005, ABCA1 AFCS NATURE MO, DOI DOI 10.1038/MP.A002593.01; TROMPIER D, 2005, ABCA7 AFCS NATURE MO, DOI DOI 10.1038/MP.A002599.01; Trompier D, 2006, J BIOL CHEM, V281, P20283, DOI 10.1074/jbc.M601072200; Valentin G, 2005, NAT METHODS, V2, P801, DOI 10.1038/nmeth1105-801; Vallejo Abbe N., 1995, P603; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yu XM, 2006, DEV CELL, V10, P743, DOI 10.1016/j.devcel.2006.04.007; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	40	78	84	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e120	10.1371/journal.pone.0000120	http://dx.doi.org/10.1371/journal.pone.0000120			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205124	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443700014
J	Sun, HL; Liu, YN; Huang, YT; Pan, SL; Huang, DY; Guh, JH; Lee, FY; Kuo, SC; Teng, CM				Sun, H-L; Liu, Y-N; Huang, Y-T; Pan, S-L; Huang, D-Y; Guh, J-H; Lee, F-Y; Kuo, S-C; Teng, C-M			YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappa B signaling to HIF-1 alpha accumulation during hypoxia	ONCOGENE			English	Article						YC-1; HIF-1; Akt; NF-kappa B; prostate cancer	INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITE; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DOWN-REGULATION; TUMOR HYPOXIA; UP-REGULATION; FACTOR-1-ALPHA	Hypoxia-inducible factor 1 ( HIF-1), a transcription factor that is critical for tumor adaptation to microenvironmental stimuli, represents an attractive chemotherapeutic target. YC-1 is a novel antitumor agent that inhibits HIF-1 through previously unexplained mechanisms. In the present study, YC-1 was found to prevent HIF-1 alpha and HIF-1 beta accumulation in response to hypoxia or mitogen treatment in PC-3 prostate cancer cells. Neither HIF-1 alpha protein half-life nor mRNA level was affected by YC-1. However, YC-1 was found to suppress the PI3K/Akt/mTOR/4E-BP pathway, which serves to regulate HIF-1 alpha expression at the translational step. We demonstrated that YC-1 also inhibited hypoxia-induced activation of nuclear factor ( NF)-kappa B, a downstream target of Akt. Two modulators of the Akt/NF-kappa B pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1 alpha expression. Additionally, overexpression of NF-kappa B partly reversed the ability of wortmannin to inhibit HIF-1 alpha-dependent transcriptional activity, suggesting that NF-kappa B contributes to Akt-mediated HIF-1 alpha accumulation during hypoxia. Overall, we identify a potential molecular mechanism whereby YC-1 serves to reduce HIF-1 expression.	Natl Taiwan Univ, Inst Pharmacol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei 100, Taiwan; Yung Shin Pharmaceut Ind Co Ltd, China Med Coll, Taichung, Taiwan; China Med Coll, Grad Inst Pharmaceut Chem, Taichung, Taiwan	National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Taiwan	Teng, CM (corresponding author), Natl Taiwan Univ, Inst Pharmacol, Coll Med, 1 Jen Ai Rd,Sect 1, Taipei 100, Taiwan.	cmteng@ntumc.org	Pan, Shiow-Lin/C-1372-2010	Huang, Yao-Ting/0000-0001-5912-8090; GUH, JIH-HWA/0000-0002-6738-6054; TENG, CHE-MING/0000-0002-9719-7334				Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen EY, 2001, CANCER RES, V61, P2429; Chiang PC, 2005, J HEPATOL, V43, P679, DOI 10.1016/j.jhep.2005.02.049; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Domingo-Domenech J, 2005, BRIT J CANCER, V93, P1285, DOI 10.1038/sj.bjc.6602851; Figueroa YG, 2002, EXP HEMATOL, V30, P1419, DOI 10.1016/S0301-472X(02)00934-7; Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078-0432.CCR-04-0764; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang DM, 2005, J UROLOGY, V173, P256, DOI 10.1097/01.ju.0000141587.72429.e3; Huang YT, 2005, MOL CANCER THER, V4, P1628, DOI 10.1158/1535-7163.MCT-05-0090; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kim I, 2004, EXP CELL RES, V298, P229, DOI 10.1016/j.yexcr.2004.04.017; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; KOONG AC, 1994, CANCER RES, V54, P1425; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Lessard L, 2003, BJU INT, V91, P417, DOI 10.1046/j.1464-410X.2003.04104.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Pan SL, 2005, J PHARMACOL EXP THER, V314, P35, DOI 10.1124/jpet.105.085126; Powis G, 2004, MOL CANCER THER, V3, P647; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009; Zhong H, 2001, BIOCHEM BIOPH RES CO, V284, P352, DOI 10.1006/bbrc.2001.4981; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, CANCER RES, V64, P9041, DOI 10.1158/0008-5472.CAN-04-1437; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598; Zundel W, 2000, GENE DEV, V14, P391	53	149	155	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3941	3951		10.1038/sj.onc.1210169	http://dx.doi.org/10.1038/sj.onc.1210169			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213816				2022-12-25	WOS:000247144500004
J	Palmer, D; Jimmo, SL; Raymond, DR; Wilson, LS; Carter, RL; Maurice, DH				Palmer, Daniel; Jimmo, Sandra L.; Raymond, Daniel R.; Wilson, Lindsay S.; Carter, Rhonda L.; Maurice, Donald H.			Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MEDIATED ACTIVATION; EXPRESSION; HEART; CAMP; LOCALIZATION; ISOFORMS; DOMAINS; PDE3B	Recent studies confirm that intracellular cAMP concentrations are nonuniform and that localized subcellular cAMP hydrolysis by cyclic nucleotide phosphodiesterases (PDEs) is important in maintaining these cAMP compartments. Human phosphodiesterase 313 (HSPDE3B), a member of the PDE3 family of PDEs, represents the dominant particulate cAMP-PDE activity in many cell types, including adipocytes and cells of hematopoietic lineage. Although several previous reports have shown that phosphorylation of HSPDE3B by either protein kinase A (PKA) or protein kinase B (PKB) activates this enzyme, the mechanisms that allow cells to distinguish these two activated forms of HSPDE3B are unknown. Here we report that PKA phosphorylates HSPDE3B at several distinct sites (Ser-73, Ser-296, and Ser-318), and we show that phosphorylation of HSPDE3B at Ser-318 activates this PDE and stimulates its interaction with 14-3-3 proteins. In contrast, although PKB-catalyzed phosphorylation of HSPDE3B activates this enzyme, it does not promote 14-3-3 protein binding. Interestingly, we report that the PKA-phosphorylated, 14-3-3 protein-bound, form of HSPDE3B is protected from phosphatase-dependent dephosphorylation and inactivation. In contrast, PKA-phosphorylated HSPDE3B that is not bound to 14-3-3 proteins is readily dephosphorylated and inactivated. Our data are presented in the context that a selective interaction between PKA-activated HSPDE3B and 14-3-3 proteins represents a mechanism by which cells can protect this enzyme from deactivation. Moreover, we propose that this mechanism may allow cells to distinguish between PKA- and PKB-activated HSPDE3B.	Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Maurice, DH (corresponding author), Queens Univ, Dept Pharmacol & Toxicol, Botterell Hall,Rm 229, Kingston, ON K7L 3N6, Canada.	mauriced@post.queensu.ca	Palmer, Daniel/Q-7595-2016; Maurice, Donald/AAE-9332-2019; Palmer, Daniel/J-2967-2014	Palmer, Daniel/0000-0002-7954-9332; Palmer, Daniel/0000-0002-7954-9332				Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Dodge-Kafka KL, 2006, CIRC RES, V98, P993, DOI 10.1161/01.RES.0000218273.91741.30; Elbatarny HS, 2005, AM J PHYSIOL-ENDOC M, V289, pE695, DOI 10.1152/ajpendo.00125.2005; FELDMAN RD, 1993, BRIT J PHARMACOL, V110, P1640, DOI 10.1111/j.1476-5381.1993.tb14013.x; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hambleton R, 2005, J BIOL CHEM, V280, P39168, DOI 10.1074/jbc.M506760200; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Hutchins JRA, 2002, FEBS LETT, V528, P267, DOI 10.1016/S0014-5793(02)03327-6; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; MASTERS SC, 1999, BIOCHEM J, V38, P12499; Maurice DH, 2003, MOL PHARMACOL, V64, P533, DOI 10.1124/mol.64.3.533; McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008; Nilsson R, 2006, CELL SIGNAL, V18, P1713, DOI 10.1016/j.cellsig.2006.01.010; Onuma H, 2002, DIABETES, V51, P3362, DOI 10.2337/diabetes.51.12.3362; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Rose RJ, 1997, BRIT J PHARMACOL, V122, P233, DOI 10.1038/sj.bjp.0701376; Rubio MP, 2005, BIOCHEM J, V392, P163, DOI 10.1042/BJ20051103; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; TAYLOR P, 1988, PRINCIPLES DRUG ACTI, P144; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Wechsler J, 2002, J BIOL CHEM, V277, P38072, DOI 10.1074/jbc.M203647200; Zmuda-Trzebiatowska E, 2007, CELL SIGNAL, V19, P81, DOI 10.1016/j.cellsig.2006.05.024	41	40	45	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9411	9419		10.1074/jbc.M606936200	http://dx.doi.org/10.1074/jbc.M606936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255105	hybrid			2022-12-25	WOS:000245421700013
J	Schumacher, J; Joly, N; Rappas, M; Bradley, D; Wigneshweraraj, SR; Zhang, XD; Buck, M				Schumacher, Jorg; Joly, Nicolas; Rappas, Mathieu; Bradley, Dominic; Wigneshweraraj, Siva R.; Zhang, Xiaodong; Buck, Martin			Sensor I threonine of the AAA plus ATPase transcriptional activator PspF is involved in coupling nucleoticle triphosphate hydrolysis to the restructuring of sigma(54)-RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE FTSH; ENHANCER-BINDING PROTEINS; BACTERIAL RNA-POLYMERASE; PROMOTER DNA COMPLEX; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DOMAIN; MECHANISM; COMMUNICATION; SUBUNIT	Transcriptional initiation invariably involves the transition from a closed RNA polymerase (RNAP) promoter complex to a transcriptional competent open complex. Activators of the bacterial sigma(54)-RNAP are AAA+ proteins that couple ATP hydrolysis to restructure the sigma(54)-RNAP promoter complex. Structures of the sigma(54) activator PspF AAA+ domain (PspF(1-275)) bound to sigma(54) show two loop structures proximal to sigma(54) as follows: the w` contacting the GAFTGA loop 1 structure and loop 2 that classifies sigma(54) activators as pre-sensor 1 beta-hairpin AAA+ proteins. We report activities for PspF(1-275) mutated in the AAA+ conserved served sensor I threonine/asparagine motif (PspF(1-275)(T148A), PspF(1-275)(N149A), and PspF(1-275)(N149S)) within the second region of homology. We show that sensor I asparagine plays a direct role in ATP hydrolysis. However, low hydrolysis rates are sufficient for functional output in vitro. In contrast, PspF(1-275)(T148A) has severe defects at the distinct step of 0,54 promoter restructuring. This defect is not because of the failure of PspF(1-275)(T148A) to stably engage with the closed sigma(54) promoter, indicating (i) an important role in ATP hydrolysis-associated motions during energy coupling for remodeling and (ii) distinguishing PspF(1-275)(T148A) from PspF(1-275) variants involved in signaling to the GAFTGA loop I,which fail to stably engage with the promoter. Activities of loop 2 PspF(1-275) variants are similar to those of PspF(1-275)(T148A) suggesting a functional signaling link between Thr(148) and loop 2. In PspF(1-275) this link relies on the conserved nucleotide state-dependent interaction between the Walker B residue Glu(108) and Thr(148). We propose that hydrolysis is relayed via Thr(148) to loop 2 creating motions that provide mechanical force to the GAFTGA loop 1 that contacts sigma(54).	Univ London Imperial Coll Sci & Technol, Div Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Div Mol Biosci, London SW7 2AZ, England	Imperial College London; Imperial College London	Schumacher, J (corresponding author), Univ London Imperial Coll Sci & Technol, Div Biol, London SW7 2AZ, England.	j.schumacher@imperial.ac.uk; m.buck@imperial.ac.uk		Wigneshweraraj, Sivaramesh/0000-0002-1418-4029				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Besche H, 2004, FEBS LETT, V574, P161, DOI 10.1016/j.febslet.2004.08.021; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Cannon W, 2002, NUCLEIC ACIDS RES, V30, P886, DOI 10.1093/nar/30.4.886; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Cannon WV, 2004, NUCLEIC ACIDS RES, V32, P4596, DOI 10.1093/nar/gkh755; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gerega A, 2005, J BIOL CHEM, V280, P42856, DOI 10.1074/jbc.M510592200; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Han YW, 2001, J BIOL CHEM, V276, P35024, DOI 10.1074/jbc.M103611200; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hsu LLM, 2003, BIOCHEMISTRY-US, V42, P3777, DOI 10.1021/bi026954e; Huo YX, 2006, MOL MICROBIOL, V59, P168, DOI 10.1111/j.1365-2958.2005.04943.x; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Joly N, 2006, J BIOL CHEM, V281, P34997, DOI 10.1074/jbc.M606628200; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; Jovanovic G, 2006, J BIOL CHEM, V281, P21147, DOI 10.1074/jbc.M602323200; Kapanidis AN, 2006, SCIENCE, V314, P1144, DOI 10.1126/science.1131399; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Leach RN, 2006, J BIOL CHEM, V281, P33717, DOI 10.1074/jbc.M605731200; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin YC, 2005, NAT STRUCT MOL BIOL, V12, P603, DOI 10.1038/nsmb949; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Rappas M, 2006, J MOL BIOL, V357, P481, DOI 10.1016/j.jmb.2005.12.052; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; SARKAR G, 1985, J BIOL CHEM, V260, P3831; Schumacher J, 2004, J MOL BIOL, V338, P863, DOI 10.1016/j.jmb.2004.02.071; Schumacher J, 2006, J STRUCT BIOL, V156, P190, DOI 10.1016/j.jsb.2006.01.006; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Suno R, 2006, MOL CELL, V22, P575, DOI 10.1016/j.molcel.2006.04.020; Wigneshweraraj SR, 2004, EMBO J, V23, P4264, DOI 10.1038/sj.emboj.7600407; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	47	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9825	9833		10.1074/jbc.M611532200	http://dx.doi.org/10.1074/jbc.M611532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17242399	hybrid			2022-12-25	WOS:000245421700057
J	Paz, Y; Katz, A; Pick, U				Paz, Yakov; Katz, Adriana; Pick, Uri			Multicopper ferroxidase involved in iron binding to transferrins in Dunaliella salina plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGA DUNALIELLA; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; OXIDASE FET3P; PROTEIN; TRANSPORT; YEAST; HALOTOLERANCE; DEFICIENCY; PREDICTION	The halotolerant alga Dunaliella salina is unique among plants in that it utilizes a transferrin (TTf) to mediate iron acquisition (Fisher, M., Zamir, A., and Pick, U. (1998) J. Mal. Chem. 273, 17553-17558). Two new proteins that are induced by iron deprivation were identified in plasma membranes of D. salina as follows: a multicopper ferroxidase termed D-Fox and an internally duplicated glycoprotein (p130B). D-Fox and p130B are accessible to glycolytic, proteolytic, and biotin surface tagging treatments, suggesting that they are surface-exposed glycoproteins. Induction of D-Fox was also manifested by ferroxidase activity in plasma membrane preparations. These results are puzzling because ferroxidases in yeast and in Chlamydomonas reinhardtii function in redox-mediated iron uptake, a mechanism that is not known to operate in D. salina. Two lines of evidence suggest that D-Fox and p130B interact with D. salina triplicated transferrin (TTf). First, chemical cross-linking combined with mass spectroscopy analysis showed that D-Fox and p130B associate with TTf and with another plasma membrane transferrin. Second, detergent-solubilized D-Fox and p130B comigrated on blue native gels with plasma membrane transferrins. Fe-59 autoradiography indicated that this complex binds Fe3+ ions. Also, the induction of D-Fox and p130B is kinetically correlated with enhanced iron binding and uptake activities. These results suggest that D-Fox and p130B associate with plasma membrane transferrins forming a complex that enhances iron binding and iron uptake. We propose that the function of D-Fox in D. salina has been modified during evolution from redox-mediated to transferrin-mediated iron uptake, following a gene transfer event of transferrins from an ancestral animal cell.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Pick, U (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	uri.pick@weizmann.ac.il						ALLNUTT FCT, 1987, PLANT PHYSIOL, V85, P751, DOI 10.1104/pp.85.3.751; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; BENDERLIEV KM, 1994, PLANTA, V193, P163; Boye M, 2000, MAR CHEM, V70, P277, DOI 10.1016/S0304-4203(00)00032-3; CHIDAMBARAM MV, 1984, J INORG BIOCHEM, V22, P231, DOI 10.1016/0162-0134(84)85008-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; di Patti MCB, 2005, BIOCHEM BIOPH RES CO, V333, P432, DOI 10.1016/j.bbrc.2005.05.121; Eisenhaber B, 2003, PLANT PHYSIOL, V133, P1691, DOI 10.1104/pp.103.023580; Fisher M, 1997, J BIOL CHEM, V272, P1565, DOI 10.1074/jbc.272.3.1565; Fisher M, 1998, J BIOL CHEM, V273, P17553, DOI 10.1074/jbc.273.28.17553; FISHER M, 1994, PLANT PHYSIOL, V106, P1359, DOI 10.1104/pp.106.4.1359; GIBBS CR, 1976, ANAL CHEM, V48, P1197, DOI 10.1021/ac50002a034; Herbik A, 2002, PLANT PHYSIOL, V130, P2039, DOI 10.1104/pp.013060; Herbik A, 2002, PLANT SOIL, V241, P1, DOI 10.1023/A:1016037906516; Keshtacher-Liebson E, 1999, PLANT SOIL, V215, P175, DOI 10.1023/A:1004760613906; La Fontaine S, 2002, EUKARYOT CELL, V1, P736, DOI 10.1128/EC.1.5.736-757.2002; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Maurer-Stroh S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r55; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; Premikumar L, 2005, P NATL ACAD SCI USA, V102, P7493, DOI 10.1073/pnas.0502829102; Robinson NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schwarz M, 2003, J PLANT NUTR, V26, P2081, DOI 10.1081/PLN-120024266; Schwarz M, 2003, BBA-PROTEINS PROTEOM, V1649, P190, DOI 10.1016/S1570-9639(03)00185-7; SCHWARZ M, 2002, THESIS WEIZMANN I SC; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Varsano T, 2003, J PLANT NUTR, V26, P2197, DOI 10.1081/PLN-120024275; Wang TP, 2003, J BIOL INORG CHEM, V8, P611, DOI 10.1007/s00775-003-0456-5	29	31	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8658	8666		10.1074/jbc.M609756200	http://dx.doi.org/10.1074/jbc.M609756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17227764	hybrid			2022-12-25	WOS:000245780300012
J	Cho, YY; Yao, K; Bode, AM; Bergen, HR; Madden, BJ; Oh, SM; Ermakova, S; Kang, BS; Choi, HS; Shim, JH; Dong, ZG				Cho, Yong-Yeon; Yao, Ke; Bode, Ann M.; Bergen, H. Robert, III; Madden, Benjamin J.; Oh, Sang-Muk; Ermakova, Svetlana; Kang, Bong Seok; Choi, Hong Seok; Shim, Jung-Hyun; Dong, Zigang			RSK2 mediates muscle cell differentiation through regulation of NFAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFFIN-LOWRY-SYNDROME; ACTIVATED T-CELLS; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; NF-ATC; PROTEIN-KINASES; NUCLEAR FACTOR; CYCLOSPORINE-A	RSK2, an ERK downstream kinase, is a novel mediator of skeletal muscle cell differentiation through its regulation of NFAT3 activity. We found that the N-terminal (amino acids (aa) 1-68) and C-terminal (aa 416-674) kinase domains of RSK2 directly interacted with nuclear localization signal 1, the Ser/Pro repeat, and the polyproline domains (aa 261-365) of NFAT3. Upon A23187 stimulation, RSK2 induced nuclear localization of NFAT3. RSK2 phosphorylated NFAT3 in vitro (K-m = 3.559 mu M), and activation of NFAT3 by RSK2 enhanced the promoter activity of NFAT3 downstream target genes in vivo. Furthermore, nuclear accumulation of NFAT3 was attenuated markedly in RSK2(-/-) cells compared with wild-type RSK2(+/+) cells. Notably, RSK2 and NFAT3 induced a significant differentiation of C2C12 myoblasts to multinucleated myotubes. Multinucleated myotube differentiation was inhibited by small interfering RNA against RSK2, ERK1/2, or NFAT3. These results demonstrate that RSK2 is an important kinase for NFAT3 in mediating myotube differentiation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Mayo Clin, Coll Med, Mayo Proteom Res Ctr, Rochester, MN 55905 USA	University of Minnesota System; Mayo Clinic	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; Ermakova, Svetlana P/G-2766-2013	Shim, Jung-Hyun/0000-0002-4062-4016; Ermakova, Svetlana/0000-0002-5905-2046; Cho, Yong-Yeon/0000-0003-1107-2651	NATIONAL CANCER INSTITUTE [R01CA077646, P01CA027502, P01CA088961, R37CA081064, R01CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA88961, R37 CA081064, P01 CA088961-020003, P01 CA027502-270022, R01 CA077646, CA81064, R01 CA081064, P01 CA088961, CA27502, P01 CA027502, R01 CA077646-10, CA77646, R37 CA081064-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; Cho YY, 2005, CANCER RES, V65, P3596, DOI 10.1158/0008-5472.CAN-04-3935; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Ichida M, 2001, J BIOL CHEM, V276, P3524, DOI 10.1074/jbc.M004275200; ISHIDA Y, 1992, CLIN ORTHOP RELAT R, P144; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Massin MM, 1999, ACTA PAEDIATR, V88, P468, DOI 10.1080/08035259950169909; McCandless SE, 2000, AM J MED GENET, V95, P93, DOI 10.1002/1096-8628(20001113)95:2<93::AID-AJMG1>3.0.CO;2-B; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Nelson GB, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e197; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Penn BH, 2001, MOL CELL, V8, P245, DOI 10.1016/S1097-2765(01)00331-8; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; SHARMA KR, 1993, NEUROLOGY, V43, P527, DOI 10.1212/WNL.43.3_Part_1.527; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang T, 2001, J BIOL CHEM, V276, P39569, DOI 10.1074/jbc.M102961200; Yang TTC, 2005, MOL CELL BIOL, V25, P907, DOI 10.1128/MCB.25.3.907-920.2005; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	53	56	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8380	8392		10.1074/jbc.M611322200	http://dx.doi.org/10.1074/jbc.M611322200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17213202	Green Accepted, hybrid			2022-12-25	WOS:000245081000071
J	Todeschini, AR; Dos Santos, JN; Handa, K; Hakomori, S				Todeschini, Adriane Regina; Dos Santos, Jose Nilson; Handa, Kazuko; Hakomori, Sen-itiroh			Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM3 GANGLIOSIDE; CANCER-CELLS; MEMBRANE; RECEPTOR; MICRODOMAIN; METASTASIS; ADHESION; EXPRESSION; REVERSION; APOPTOSIS	Glycosphingolipids (GSLs) at the cell surface membrane are associated or complexed with signal transducers (Src family kinases and small G-proteins), tetraspanins, growth factor receptors, and integrins. Such organizational framework, defining GSL-modulated or -dependent cell adhesion, motility, and growth, is termed "glycosynapse" (Hakomori, S., and Handa, K. (2002) FEBS Lett. 531, 88-92; Hakomori, S. (2004) Ann, Braz. Acad. Sci. 76, 553-572). We describe here the functional organization of the glycosynaptic microdomain, and the mechanisms for control of cell motility and invasiveness, in normal bladder epithelial HCV29 cells versus highly invasive bladder cancer YTS1 cells, both derived from transitional epithelia. (i) Ganglioside GM2, but not GM3 or globoside, interacted specifically with tetraspanin CD82, and such a complex inhibited hepatocyte growth factor (HGF)-induced activation of Met tyrosine kinase in a dose-dependent manner. (ii) Depletion of GM2 in HCV29 cells by treatment with D-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4), or reduction of CD82 expression by RNA interference, significantly enhanced HGF-induced Met tyrosine kinase and cell motility. (iii) In contrast, YTS1 cells, lacking CD82, displayed HGF-independent activation of Met tyrosine kinase and high cell motility. Transfection of the CD82 gene to YTS1 inhibited HGF dose-dependent Met tyrosine kinase activity and cell motility, due to formation of the GM2-CD82 complex. (iv) Adhesion of YTS1 or YTS1/CD82 cells to laminin-5-coated plates, as compared with noncoated plates, strongly enhanced Met activation, and the degree of activation was further increased in association with GSL depletion by P4. Laminin-5-dependent Met activation was minimal in HCV29 cells. These findings indicate that GSL, particularly GM2, forms a complex with CD82, and that such complex interacts with Met and thereby inhibits HGF-induced Met tyrosine kinase activity, as well as integrin to Met cross-talk.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98122 USA; Univ Washington, Dept Microbiol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Todeschini, AR (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.	adrianet@biof.ufrg.br; hakomori@u.washington.edu	Todeschini, Adriane Regina/ABC-9165-2020; Todeschini, Adriane/AAG-8128-2020	Todeschini, Adriane Regina/0000-0002-6049-2751; 	NCI NIH HHS [CA080054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bektas M, 2003, ANAL BIOCHEM, V320, P259, DOI 10.1016/S0003-2697(03)00388-9; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DOHI T, 1988, CANCER RES, V48, P5680; FOLCH J, 1951, J BIOL CHEM, V191, P807; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Hakomori S, 2005, P JPN ACAD B-PHYS, V81, P189, DOI 10.2183/pjab.81.189; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kakizaki H., 1990, JPN J UROL, V81, P204; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kitamura S, 2000, BRIT J CANCER, V83, P668, DOI 10.1054/bjoc.2000.1301; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; MASTERS JRW, 1986, CANCER RES, V46, P3630; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; MIYAKE M, 1988, CANCER RES, V48, P6154; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Odintsova E, 2006, BIOCHEM J, V400, P315, DOI 10.1042/BJ20060259; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Papadopoulos N, 2006, NAT BIOTECHNOL, V24, P985, DOI 10.1038/nbt1234; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Scott WN, 2000, ANAL BIOCHEM, V287, P343, DOI 10.1006/abio.2000.4866; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sorice M, 1997, J LIPID RES, V38, P969; Sridhar SC, 2006, ONCOGENE, V25, P2367, DOI 10.1038/sj.onc.1209269; Toledo MS, 2005, J BIOL CHEM, V280, P16227, DOI 10.1074/jbc.M413713200; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Tsuji T, 2002, CLIN EXP METASTAS, V19, P127, DOI 10.1023/A:1014573204062; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yoon SJ, 2006, P NATL ACAD SCI USA, V103, P18987, DOI 10.1073/pnas.0609281103; YU RK, 1972, J LIPID RES, V13, P680; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	58	114	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8123	8133		10.1074/jbc.M611407200	http://dx.doi.org/10.1074/jbc.M611407200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17215249	hybrid			2022-12-25	WOS:000245081000044
J	Luttermann, C; Meyers, G				Luttermann, Christine; Meyers, Gregor			A bipartite sequence motif induces translation reinitiation in feline calicivirus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAMES; MESSENGER-RNA; RIBOSOMAL-RNA; COUPLED TRANSLATION; INITIATION; VIRUS; PROTEIN; EXPRESSION; ADENOVIRUS; MECHANISM	The mechanism leading to reinitiation of translation after termination of protein synthesis in eukaryotes has not yet been resolved in detail. One open question concerns the way the post-termination ribosome is tethered to the mRNA to allow binding of the necessary initiation factors. In caliciviruses, a family of positive strand RNA viruses, the capsid protein VP2 is translated via a termination/reinitiation process. VP2 of the feline calicivirus is encoded in the 3'-terminal open reading frame 3 (ORF3) that overlaps with the preceding ORF2 by four nucleotides. In transient expression studies, the efficiency of VP2 expression was 20 times lower than that of the ORF2 proteins. The close vicinity of the ORF2 termination signal and the ORF3 AUG codon was crucial, whereas the AUG could be replaced by alternative codons. Deletion mapping revealed that the 3'-terminal 69 nucleotides of ORF2 are crucial for VP2 expression. This sequence contains two essential sequence motifs. The first motif is conserved among caliciviruses and complementary to part of the 18 S rRNA. In conclusion, VP2 is expressed in a translation termination/reinitiation process that is special because it requires a sequence element that could prevent dissociation of post-termination ribosomes via hybridization with 18 S rRNA.	Friedrich Loeffler Inst, Inst Immunol, D-72001 Tubingen, Germany	Friedrich Loeffler Institute	Meyers, G (corresponding author), Friedrich Loeffler Inst, Inst Immunol, Paul Ehrlich Str 28, D-72076 Tubingen, Germany.	gregor.meyers@fli.bund.de	Luttermann, Christine/L-5440-2019	Luttermann, Christine/0000-0002-6977-9900				Ahmadian G, 2000, EMBO J, V19, P2681, DOI 10.1093/emboj/19.11.2681; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2006, P NATL ACAD SCI USA, V103, P9488, DOI 10.1073/pnas.0603597103; Chaudhry Y, 2006, J BIOL CHEM, V281, P25315, DOI 10.1074/jbc.M602230200; Cuesta R, 2001, COLD SPRING HARB SYM, V66, P259, DOI 10.1101/sqb.2001.66.259; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dresios J, 2006, NAT STRUCT MOL BIOL, V13, P30, DOI 10.1038/nsmb1031; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; Goodfellow I, 2005, EMBO REP, V6, P968, DOI 10.1038/sj.embor.7400510; Gould PS, 2005, J BIOL CHEM, V280, P21972, DOI 10.1074/jbc.M502276200; GOWDA S, 1989, P NATL ACAD SCI USA, V86, P9203, DOI 10.1073/pnas.86.23.9203; GREEN KY, 2000, VIRUS TAXONOMY, P725; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Herbert TP, 1996, J GEN VIROL, V77, P123, DOI 10.1099/0022-1317-77-1-123; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HORVATH CM, 1990, EMBO J, V9, P2639, DOI 10.1002/j.1460-2075.1990.tb07446.x; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 2001, NUCLEIC ACIDS RES, V29, P5226, DOI 10.1093/nar/29.24.5226; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Meyers G, 2003, J BIOL CHEM, V278, P34051, DOI 10.1074/jbc.M304874200; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Poyry TAA, 2004, GENE DEV, V18, P62, DOI 10.1101/gad.276504; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; Ryabova LA, 2006, VIRUS RES, V119, P52, DOI 10.1016/j.virusres.2005.10.017; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook J, 2001, MOL CLONING LAB MANU; Sarnow P, 2005, BIOCHEM SOC T, V33, P1479, DOI 10.1042/BST0331479; SCHEPER GC, 1994, FEBS LETT, V352, P271, DOI 10.1016/0014-5793(94)00975-9; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Sosnovtsev SV, 2000, VIROLOGY, V277, P193, DOI 10.1006/viro.2000.0579; Sosnovtsev SV, 2005, J VIROL, V79, P4012, DOI 10.1128/JVI.79.7.4012-4024.2005; Stacey SN, 2000, J VIROL, V74, P7284, DOI 10.1128/JVI.74.16.7284-7297.2000; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; Thumfart JO, 2002, J VIROL, V76, P6398, DOI 10.1128/JVI.76.12.6398-6407.2002; Tranque P, 1998, P NATL ACAD SCI USA, V95, P12238, DOI 10.1073/pnas.95.21.12238; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Yueh A, 2000, GENE DEV, V14, P414	58	49	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7056	7065		10.1074/jbc.M608948200	http://dx.doi.org/10.1074/jbc.M608948200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213194	hybrid			2022-12-25	WOS:000245080900017
J	Ostling, P; Bjork, JK; Roos-Mattjus, P; Mezger, V; Sistonen, L				Ostling, Paivi; Bjork, Johanna K.; Roos-Mattjus, Pia; Mezger, Valerie; Sistonen, Lea			Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; MOLECULAR CHAPERONES; TARGETED DISRUPTION; ERYTHROLEUKEMIA-CELLS; FACTOR-II; IN-VIVO; STRESS; DIFFERENTIATION; ACTIVATION	The heat shock response is a defense reaction activated by proteotoxic damage induced by physiological or environmental stress. Cells respond to the proteotoxic damage by elevated expression of heat shock proteins (Hsps) that function as molecular chaperones and maintain the vital homeostasis of protein folds. Heat shock factors (HSFs) are the main transcriptional regulators of the stress-induced expression of hsp genes. Mammalian HSF I was originally identified as the transcriptional regulator of the heat shock response, whereas HSF2 has not been implicated a role in the stress response. Previously, we and others have demonstrated that HSF1 and HSF2 interact through their trimerization domains, but the functional consequence of this interaction remained unclear. We have now demonstrated on chromatin that both HSF1 and HSF2 were able to bind the hsp70 promoter not only in response to heat shock but also during hemin-induced differentiation of K562 erythroleukernia cells. In both cases an intact HSF1 was required in order to reach maximal levels of promoter occupancy, suggesting that HSF1 influences the DNA binding activity of HSF2. The functional consequence of the HSFI-HSF2 interplay was demonstrated by real-time reverse transcription-PCR analyses, which showed that HSF2 was able to modulate the HSFI-mediated expression of major hsp genes. Our results reveal, contrary to the predominant model, that HSF2 indeed participates in the transcriptional regulation of the heat shock response.	Abo Akad Univ, Turku Ctr Biotechnol, FI-20521 Turku, Finland; Turku Univ, FI-20521 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FI-20521 Turku, Finland; Abo Akad Univ, Dept Biol, FI-20521 Turku, Finland; Ecole Normale Super, CNRS, UMR8541, Lab Biol Mol Stress, F-75005 Paris, France	Abo Akademi University; University of Turku; University of Turku; Abo Akademi University; Abo Akademi University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Sistonen, L (corresponding author), Abo Akad Univ, Turku Ctr Biotechnol, POB 123, FI-20521 Turku, Finland.	lea.sistonen@btk.fi		Roos-Mattjus, Pia/0000-0002-7187-2012; Ostling, Paivi/0000-0001-5501-466X; Sistonen, Lea/0000-0003-1341-2867				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; Alastalo TP, 2003, J CELL SCI, V116, P3557, DOI 10.1242/jcs.00671; Alastalo TP, 1998, EXP CELL RES, V240, P16, DOI 10.1006/excr.1997.3926; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Biamonti G, 2004, NAT REV MOL CELL BIO, V5, P493, DOI 10.1038/nrm1405; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Chang YH, 2006, GENE DEV, V20, P836, DOI 10.1101/gad.366906; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Eriksson M, 2000, INT J DEV BIOL, V44, P471; Gyrd-Hansen M, 2004, CELL CYCLE, V3, P1484, DOI 10.4161/cc.3.12.1287; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; Hilgarth RS, 2004, CELL STRESS CHAPERON, V9, P214, DOI 10.1379/CSC-8R.1; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Inouye S, 2003, MOL CELL BIOL, V23, P5882, DOI 10.1128/MCB.23.16.5882-5895.2003; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Morano KA, 1999, GENE EXPRESSION, V7, P271; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Paslaru L, 2003, J CELL MOL MED, V7, P425, DOI 10.1111/j.1582-4934.2003.tb00245.x; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pirkkala L, 1999, CELL STRESS CHAPERON, V4, P259, DOI 10.1379/1466-1268(1999)004<0259:ASAIIF>2.3.CO;2; Pirkkala L, 1999, FASEB J, V13, P1089, DOI 10.1096/fasebj.13.9.1089; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Somasundaram T, 2004, J BIOL CHEM, V279, P44497, DOI 10.1074/jbc.M405813200; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tonkiss J, 2005, INT J HYPERTHER, V21, P433, DOI 10.1080/02656730500165514; Trinklein ND, 2004, CELL STRESS CHAPERON, V9, P21, DOI 10.1379/1466-1268(2004)009<0021:TRABOH>2.0.CO;2; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Wang GH, 2003, GENESIS, V36, P48, DOI 10.1002/gene.10200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478; Yoshima T, 1998, J BIOL CHEM, V273, P25466, DOI 10.1074/jbc.273.39.25466; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232	61	162	167	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7077	7086		10.1074/jbc.M607556200	http://dx.doi.org/10.1074/jbc.M607556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213196	hybrid			2022-12-25	WOS:000245080900019
J	Sun, XH; Flynn, DC; Castranova, V; Millecchia, LL; Beardsley, AR; Liu, J				Sun, Xing-Hui; Flynn, Daniel C.; Castranova, Vincent; Millecchia, Lyndell L.; Beardsley, Andrew R.; Liu, Jun			Identification of a novel domain at the N terminus of caveolin-1 that controls rear polarization of the protein and caveolae formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; MDCK CELLS; CHOLESTEROL TRAFFICKING; ENDOTHELIAL-CELLS; GOLGI-COMPLEX; LIPID RAFTS; GENE FAMILY; NULL MICE; IN-VIVO	When cells are migrating, caveolin-1, the principal protein component of caveolae, is excluded from the leading edge and polarized at the cell rear. The dynamic feature depends on a specific sequence motif that directs intracellular trafficking of the protein. Deletion mutation analysis revealed a putative polarization domain at the N terminus of caveolin-1, between amino acids 32-60. Alanine substitution identified a minimal sequence of 10 residues ((TKEIDLVNRD55)-T-46) necessary for caveolin-1 rear polarization. Interestingly, deletion of amino acids 1-60 did not prevent the polarization of caveolin-1 in human umbilical vein endothelial cells or wild-type mouse embryonic fibroblasts because of an interaction of Cav(61-178) mutant with endogenous caveolin-1. Surprisingly, expression of the depolarization mutant in caveolin-1 null cells dramatically impeded caveolae formation. Furthermore, knockdown of caveolae formation by methyl-beta-cyclodextrin failed to prevent wild-type caveolin-1 rear polarization. Importantly, genetic depletion of caveolin-1 led to disoriented migration, which can be rescued by full-length caveolin-1 but not the depolarization mutant, indicating a role of caveolin-1 polarity in chemotaxis. Thus, we have identified a sequence motif that is essential for caveolin-1 rear polarization and caveolae formation.	W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; W Virginia Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; W Virginia Univ, Hlth Sci Ctr, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA	West Virginia University; West Virginia University; West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Liu, J (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, POB 9229, Morgantown, WV 26506 USA.	junliu@hsc.wvu.edu			NCRR NIH HHS [RR016440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Fielding CJ, 1997, J LIPID RES, V38, P1503; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Hailstones D, 1998, J LIPID RES, V39, P369; Isshiki M, 2002, J CELL SCI, V115, P475; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2001, J BIOL CHEM, V276, P38121; Ren XY, 2004, MOL BIOL CELL, V15, P4556, DOI 10.1091/mbc.E04-06-0480; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEVERS NJ, 1988, J CELL SCI, V90, P341; Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Spisni E, 2005, BIOCHEM BIOPH RES CO, V338, P1383, DOI 10.1016/j.bbrc.2005.10.099; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; Westermann M, 2005, HISTOCHEM CELL BIOL, V123, P613, DOI 10.1007/s00418-004-0750-5; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Zicha D, 1997, Methods Mol Biol, V75, P449	57	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7232	7241		10.1074/jbc.M607396200	http://dx.doi.org/10.1074/jbc.M607396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213184	hybrid, Green Submitted			2022-12-25	WOS:000245080900035
J	Yamashita, D; Komori, H; Higuchi, Y; Yamaguchi, T; Osumi, T; Hirose, F				Yamashita, Daisuke; Komori, Hirofumi; Higuchi, Yoshiki; Yamaguchi, Tomohiro; Osumi, Takashi; Hirose, Fumiko			Human DNA replication-related element binding factor (hDREF) self-association via hATC domain is necessary for its nuclear accumulation and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSABLE ELEMENTS; TRANSCRIPTION FACTOR; IMPORTIN-ALPHA; IMAGINAL DISC; DREF; PROTEIN; EXPRESSION; SEQUENCE; IDENTIFICATION; COMMON	We previously demonstrated that hDREF, a human homologue of Drosophila DNA replication-related element binding factor (dDREF), is a DNA-binding protein predominantly distributed with granular structures in the nucleus. Here, glutathione S-transferase pulldown and chemical cross-linking assays showed that the carboxyl-terminal hATC domain of hDREF, highly conserved among hAT transposase family members, possesses self-association activity. Immunoprecipitation analyses demonstrated that hDREF self-associates in vivo, dependent on hATC domain. Moreover, analyses using a series of hDREF mutants carrying amino acid substitutions in the hATC domain revealed that conserved hydrophobic amino acids are essential for self-association. Immunofluorescence studies further showed that all hDREF mutants lacking self-association activity failed to accumulate in the nucleus. Self-association-defective hDREF mutants also lost association with endogenous importin beta 1. Moreover, electrophoretic gel-mobility shift assays revealed that the mutations completely abolished the DNA binding activity of hDREF. These results suggest that self-association of hDREF via the hATC domain is necessary for its nuclear accumulation and DNA binding. We also found that ZBED4/KIAA0637, another member of the human hAT family, also self-associates, again dependent on the hATC domain, with deletion resulting in loss of efficient nuclear accumulation. Thus, hATC domains of human hAT family members appear to have conserved functions in self-association that are required for nuclear accumulation.	Univ Hyogo, Grad Sch Life Sci, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Hirose, F (corresponding author), Univ Hyogo, Grad Sch Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	fhirose@sci.u-hyogo.ac.jp		Hirose, Fumiko/0000-0003-4586-4892; Yamashita, Daisuke/0000-0001-6054-5617				Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P421, DOI 10.1016/S0968-0004(00)01620-0; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Esposito T, 1999, HUM MOL GENET, V8, P61, DOI 10.1093/hmg/8.1.61; Essers L, 2000, PLANT CELL, V12, P211, DOI 10.1105/tpc.12.2.211; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hart CM, 1999, CHROMOSOMA, V108, P375, DOI 10.1007/s004120050389; Hebert MD, 2000, MOL BIOL CELL, V11, P4159, DOI 10.1091/mbc.11.12.4159; Hickman AB, 2005, NAT STRUCT MOL BIOL, V12, P715, DOI 10.1038/nsmb970; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hirose F, 2002, MOL CELL BIOL, V22, P5182, DOI 10.1128/MCB.22.14.5182-5193.2002; Hirose F, 2001, MOL CELL BIOL, V21, P7231, DOI 10.1128/MCB.21.21.7231-7242.2001; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hyun JY, 2005, MOL CELL BIOL, V25, P5590, DOI 10.1128/MCB.25.13.5590-5598.2005; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kashino Y, 2003, J CHROMATOGR B, V797, P191, DOI 10.1016/S1570-0232(03)00428-8; Kempken F, 2001, CHROMOSOMA, V110, P1, DOI 10.1007/s004120000118; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Michel K, 2003, INSECT BIOCHEM MOLEC, V33, P959, DOI 10.1016/S0965-1748(03)00102-4; Ohshima N, 2003, J BIOL CHEM, V278, P22928, DOI 10.1074/jbc.M303109200; Okada M, 2002, GENES CELLS, V7, P985, DOI 10.1046/j.1365-2443.2002.00577.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAMBROOK J, 2001, MOL CLONING, V2; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Spector DL, 2001, J CELL SCI, V114, P2891; Tachibana T, 2000, CELL STRUCT FUNCT, V25, P115, DOI 10.1247/csf.25.115; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yoshida H, 2001, GENES CELLS, V6, P877, DOI 10.1046/j.1365-2443.2001.00473.x; Zhou LQ, 2004, NATURE, V432, P995, DOI 10.1038/nature03157	45	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7563	7575		10.1074/jbc.M607180200	http://dx.doi.org/10.1074/jbc.M607180200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209048	hybrid			2022-12-25	WOS:000245080900069
J	Isin, EM; Guengerich, FP				Isin, Emre M.; Guengerich, F. Peter			Multiple sequential steps involved in the binding of inhibitors to cytochrome p450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; SINGULAR VALUE DECOMPOSITION; DRUG-DRUG INTERACTIONS; HUMAN P-GLYCOPROTEIN; ACTIVE-SITE; LIGAND-BINDING; HUMAN-LIVER; IN-VITRO; ALPHA-NAPHTHOFLAVONE; ELECTRON-TRANSFER	Cytochrome P450 (P450) 3A4 is an extensively studied human enzyme involved in the metabolism of > 50% of drugs. The mechanism of the observed homotropic and heterotropic cooperativity in P450 3A4-catalyzed oxidations is not well understood, and together with the cooperative behavior, a detailed understanding of interaction of drug inhibitors with P450 3A4 is important in predicting clinical drug-drug interactions. The interactions of P450 3A4 with several structurally diverse inhibitors were investigated using both kinetic and thermodynamic approaches to resolve the steps involved in binding of these ligands. The results of pre-steady-state absorbance and fluorescence experiments demonstrate that inhibitor binding is clearly a multistep process, even more complex than the binding of substrates. Based on spectrophotometric equilibrium binding titrations as well as isothermal titration calorimetry experiments, the stoichiometry of binding appears to be 1:1 in the concentration ranges studied. Using a sequential-mixing stopped-flow approach, we were also able to show that the observed multiphasic binding kinetics is the result of sequential events as opposed to the existence of multiple enzyme populations in dynamic equilibrium that interact with ligands at different rates. We propose a three-step minimal model for inhibitor binding, developed with kinetic simulations, consistent with our previously reported model for the binding of substrates, although it is possible that even more steps are involved.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Isin, Emre/0000-0003-3402-7685	NCI NIH HHS [R37 CA090426] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2006, EXPERT OPIN DRUG MET, V2, P573, DOI 10.1517/17425255.2.4.573; Atkins WM, 2005, ANNU REV PHARMACOL, V45, P291, DOI 10.1146/annurev.pharmtox.45.120403.100004; Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BUENING MK, 1978, BIOCHEM BIOPH RES CO, V82, P348, DOI 10.1016/0006-291X(78)90616-2; Cameron MD, 2005, BIOCHEMISTRY-US, V44, P14143, DOI 10.1021/bi051689t; CHAN TF, 1982, ACM T MATH SOFTWARE, V8, P72, DOI 10.1145/355984.355990; Cliff MJ, 2003, J MOL RECOGNIT, V16, P383, DOI 10.1002/jmr.648; Cliff MJ, 2004, J MOL RECOGNIT, V17, P513, DOI 10.1002/jmr.714; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Ekins S, 1997, PHARMACOGENETICS, V7, P165, DOI 10.1097/00008571-199706000-00001; Ekins S, 2003, TRENDS PHARMACOL SCI, V24, P161, DOI 10.1016/S0165-6147(03)00049-X; Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fernando H, 2006, BIOCHEMISTRY-US, V45, P4199, DOI 10.1021/bi052491b; FERSHT A, 1999, STRUCTURE MECH PROTE, P158; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich FP, 2006, P NATL ACAD SCI USA, V103, P13565, DOI 10.1073/pnas.0606333103; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; He YA, 2003, ARCH BIOCHEM BIOPHYS, V409, P92, DOI 10.1016/S0003-9861(02)00484-8; HE YA, 2006, 16 INT S MICR DRUG O, P114; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Houston JB, 2005, ARCH BIOCHEM BIOPHYS, V433, P351, DOI 10.1016/j.abb.2004.09.010; Hummel MA, 2004, BIOCHEM PHARMACOL, V67, P1831, DOI 10.1016/j.bcp.2004.01.017; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Imai Y., 1978, CYTOCHROME P450, P37; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; KAPITULNIK J, 1977, CLIN PHARMACOL THER, V22, P475; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; Koley AP, 1996, BIOCHIMIE, V78, P706, DOI 10.1016/S0300-9084(97)82528-X; Koley AP, 1997, BIOCHEM PHARMACOL, V53, P455, DOI 10.1016/S0006-2952(96)00836-2; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Ladbury JE, 2004, BIOTECHNIQUES, V37, P885, DOI 10.2144/04376TE01; Lampe JN, 2006, BIOCHEMISTRY-US, V45, P12204, DOI 10.1021/bi060083h; Locuson CW, 2006, ARCH BIOCHEM BIOPHYS, V449, P115, DOI 10.1016/j.abb.2006.02.004; Loo TW, 2006, BIOCHEM J, V396, P537, DOI 10.1042/BJ20060012; Loo TW, 2005, J MEMBRANE BIOL, V206, P173, DOI 10.1007/s00232-005-0792-1; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2005, BIOCHEM BIOPH RES CO, V329, P419, DOI 10.1016/j.bbrc.2005.01.134; MAEDER M, 1990, ANAL CHEM, V62, P2220, DOI 10.1021/ac00219a013; MATHESON IBC, 1989, COMPUT CHEM, V13, P299, DOI 10.1016/0097-8485(89)80036-1; MATHESON IBC, 1987, ANAL INSTRUM, V16, P345; MATHESON IBC, 1990, COMPUT CHEM, V14, P49, DOI 10.1016/0097-8485(90)80007-O; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; Ortiz de Montellano P.R., 2005, CYTOCHROME P450 STRU, P183, DOI [10.1007/b139087, DOI 10.1007/B139087]; PALMER G, 1992, J BIOL CHEM, V267, P665; Pearson JT, 2006, BIOCHEMISTRY-US, V45, P6341, DOI 10.1021/bi0600042; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; Sauna ZE, 2006, J BIOL CHEM, V281, P26501, DOI 10.1074/jbc.M601917200; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Scott EE, 2005, TRENDS BIOCHEM SCI, V30, P5, DOI 10.1016/j.tibs.2004.11.004; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Shou MG, 2002, METHOD ENZYMOL, V357, P261; Stresser DM, 2000, DRUG METAB DISPOS, V28, P1440; UENG YF, 1997, BIOCHEMISTRY-US, V36, pS381; Venkatakrishnan K, 1998, J CLIN PHARMACOL, V38, P112, DOI 10.1002/j.1552-4604.1998.tb04399.x; Wanchana S, 2003, PHARM RES-DORDR, V20, P1401, DOI 10.1023/A:1025702009611; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhang QY, 1999, DRUG METAB DISPOS, V27, P804	74	61	61	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6863	6874		10.1074/jbc.M610346200	http://dx.doi.org/10.1074/jbc.M610346200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200113	hybrid			2022-12-25	WOS:000244867200096
J	Mazharian, A; Roger, S; Berrou, E; Adam, F; Kauskot, A; Nurden, P; Jandrot-Perrus, M; Bryckaert, M				Mazharian, Alexandra; Roger, Severine; Berrou, Eliane; Adam, Frederic; Kauskot, Alexandre; Nurden, Paquita; Jandrot-Perrus, Martine; Bryckaert, Marijke			Protease-activating receptor-4 induces full platelet spreading on a fibrinogen - Involvement of Erk2 and p38 and Ca2+ matrix mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; THROMBIN-RECEPTOR; MAP KINASE; AGGREGATION; COLLAGEN; SECRETION; KINETICS; ADHESION; PATHWAY; BINDING	Although the involvement of protease-activating receptor PAR I and PAR4 is well established in platelet aggregation, their role in platelet adhesion and spreading has yet to be characterized. We investigated platelet adhesion and spreading on a fibrinogen matrix after PARI and PAR4 stimulation in correlation with the activation of two MAPKs, ERK2 and p38. Of the two PAR-activating peptides (PAR-APs), PAR1-AP and PAR4-AP, which both induce adhesion, only PAR4-AP induced full platelet spreading. Although both PAR1-AP and PAR4-AP induced ADP secretion, which is required for platelet spreading, only PAR4-AP induced sustained Ca2+ mobilization. In these conditions of PAR4 induction, ERK2 and p38 activation were involved in platelet spreading but not in platelet adhesion. p38 phosphorylation was dependent on ADP signaling through P2Y12, its receptor. ERK2 phosphorylation was triggered through integrin aIIb beta 3 outside-in signaling and was dependent on the Rho pathway. ERK2 and p38 activation induced phosphorylation of the myosin light chain and actin polymerization, respectively, necessary for cytoskeleton reorganization. These findings provide the first evidence that thrombin requires PAR4 for the full spreading response. ERK2 and p38 and sustained Ca2+ mobilization, involved in PAR4-induced platelet spreading, contribute to the stabilization of platelet thrombi at sites of high thrombin production.	Hop Lariboisiere, INSERM, U689, IFR 139, F-75010 Paris, France; Hop Bichat Claude Bernard, INSERM, U698, F-75018 Paris, France; Hop Cardiol, Hematol Lab, IFR4, F-33604 Pessac, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Bryckaert, M (corresponding author), Hop Lariboisiere, INSERM, U689, IFR 139, 8 Rue Guy Patin, F-75010 Paris, France.	marijke.bryckaert@larib.inserm.fr	Jandrot-Perrus, Martine/GZM-1526-2022; Kauskot, Alexandre/J-6794-2015	Kauskot, Alexandre/0000-0002-4064-8114; Bryckaert, Marijke/0000-0003-3398-0976; ADAM, Frederic/0000-0001-6603-2687; JANDROT-PERRUS, Martine/0000-0002-8450-9247; Mazharian, Alexandra/0000-0002-0204-3325				Adam F, 2003, J THROMB HAEMOST, V1, P798, DOI 10.1046/j.1538-7836.2003.00138.x; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Canobbio I, 2004, THROMB HAEMOSTASIS, V91, P102, DOI 10.1160/TH03-02-0083; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Falker K, 2004, THROMB HAEMOSTASIS, V92, P114, DOI 10.1160/th03-12-0729; GANGULY P, 1979, BRIT J HAEMATOL, V42, P137, DOI 10.1111/j.1365-2141.1979.tb03706.x; Holinstat M, 2006, J BIOL CHEM, V281, P26665, DOI 10.1074/jbc.M602174200; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Mazharian A, 2005, J BIOL CHEM, V280, P26002, DOI 10.1074/jbc.M414083200; Minuz P, 2002, THROMB HAEMOSTASIS, V87, P888; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Nylander S, 2004, BRIT J PHARMACOL, V142, P1325, DOI 10.1038/sj.bjp.0705885; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Roger S, 2004, FEBS LETT, V556, P227, DOI 10.1016/S0014-5793(03)01430-3; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Sakurai K, 2004, J RECEPT SIG TRANSD, V24, P283, DOI 10.1081/RRS-200040324; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Simoes RL, 2005, J IMMUNOL, V175, P1843, DOI 10.4049/jimmunol.175.3.1843; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Vijayan KV, 2003, J BIOL CHEM, V278, P3860, DOI 10.1074/jbc.M208680200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Xiao DL, 2005, AM J PHYSIOL-HEART C, V288, pH2828, DOI 10.1152/ajpheart.01189.2004; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	43	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5478	5487		10.1074/jbc.M609881200	http://dx.doi.org/10.1074/jbc.M609881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17200114	hybrid			2022-12-25	WOS:000244482300042
J	Baxter-Roshek, JL; Petrov, AN; Dinman, JD				Baxter-Roshek, Jennifer L.; Petrov, Alexey N.; Dinman, Jonathan D.			Optimization of Ribosome Structure and Function by rRNA Base Modification	PLOS ONE			English	Article								Background. Translating mRNA sequences into functional proteins is a fundamental process necessary for the viability of organisms throughout all kingdoms of life. The ribosome carries out this process with a delicate balance between speed and accuracy. This work investigates how ribosome structure and function are affected by rRNA base modification. The prevailing view is that rRNA base modifications serve to fine tune ribosome structure and function. Methodology/Principal Findings. To test this hypothesis, yeast strains deficient in rRNA modifications in the ribosomal peptidyltransferase center were monitored for changes in and translational fidelity. These studies revealed allele-specific sensitivity to translational inhibitors, changes in reading frame maintenance, nonsense suppression and aa-tRNA selection. Ribosomes isolated from two mutants with the most pronounced phenotypic changes had increased affinities for aa-tRNA, and surprisingly, increased rates of peptidyltransfer as monitored by the puromycin assay. rRNA chemical analyses of one of these mutants identified structural changes in five specific bases associated with the ribosomal A-site. Conclusions/Significance. Together, the data suggest that modification of these bases fine tune the structure of the A-site region of the large subunit so as to assure correct positioning of critical rRNA bases involved in aa-tRNA accommodation into the PTC, of the eEF-1A.aa-tRNANGTP ternary complex with the GTPase associated center, and of the aa-tRNA in the A-site. These findings represent a direct demonstration in support of the prevailing hypothesis that rRNA modifications serve to optimize rRNA structure for production of accurate and efficient ribosomes.	[Baxter-Roshek, Jennifer L.; Petrov, Alexey N.; Dinman, Jonathan D.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Dinman, JD (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.	dinman@umd.edu		Dinman, Jonathan/0000-0002-2402-9698	National Institutes of Health [R01 GM58859, T32 AI051967]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058859] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant to JDD from the National Institutes of Health (R01 GM58859). JLB-R was supported in part by a Virology Training Grant from the National Institutes of Health (T32 AI051967).	Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; Bonnerot C, 2003, MOL CELL, V12, P1309, DOI 10.1016/S1097-2765(03)00435-0; Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6; Caldas T, 2000, J BIOL CHEM, V275, P16414, DOI 10.1074/jbc.M001854200; CARRASCO L, 1973, BIOCHIM BIOPHYS ACTA, V312, P368, DOI 10.1016/0005-2787(73)90381-X; Charette M, 2000, IUBMB LIFE, V49, P341; Decatur WA, 2002, TRENDS BIOCHEM SCI, V27, P344, DOI 10.1016/S0968-0004(02)02109-6; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; DINMAN JD, 1994, GENETICS, V136, P75; Green R, 1996, RNA, V2, P1011; GROLLMAN AP, 1967, J BIOL CHEM, V242, P3226; Gustafsson C, 1998, J BACTERIOL, V180, P359, DOI 10.1128/JB.180.2.359-365.1998; Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0022-2836(03)00668-5; Hansen TM, 2003, EMBO REP, V4, P499, DOI 10.1038/sj.embor.embor825; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; Helm M, 2006, NUCLEIC ACIDS RES, V34, P721, DOI 10.1093/nar/gkj471; HERNER AE, 1969, BIOCHEMISTRY-US, V8, P1335, DOI 10.1021/bi00832a006; Hirabayashi N, 2006, J BIOL CHEM, V281, P17203, DOI 10.1074/jbc.M511728200; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobs JL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh157; JAYARAMA.J, 1968, BIOCHEMISTRY-US, V7, P418, DOI 10.1021/bi00841a053; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; King TH, 2003, MOL CELL, V11, P425, DOI 10.1016/S1097-2765(03)00040-6; Kiparisov S, 2005, MOL GENET GENOMICS, V274, P235, DOI 10.1007/s00438-005-0020-9; Lapeyre B, 2004, MOL CELL, V16, P663, DOI 10.1016/j.molcel.2004.10.022; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075; Meskauskas A, 2005, MOL CELL BIOL, V25, P10863, DOI 10.1128/MCB.25.24.10863-10874.2005; Meskauskas A, 2001, RNA, V7, P1084, DOI 10.1017/S1355838201001480; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; Rakauskaite R, 2006, MOL CELL BIOL, V26, P8992, DOI 10.1128/MCB.01311-06; Raychaudhuri S, 1999, J BIOL CHEM, V274, P18880, DOI 10.1074/jbc.274.27.18880; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Samarsky DA, 1999, NUCLEIC ACIDS RES, V27, P161, DOI 10.1093/nar/27.1.161; Sanbonmatsu KY, 2005, P NATL ACAD SCI USA, V102, P15854, DOI 10.1073/pnas.0503456102; SCHINDLER D, 1974, NATURE, V249, P38, DOI 10.1038/249038a0; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sumita M, 2005, RNA, V11, P1420, DOI 10.1261/rna.2320605; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Williams DJ, 2001, RNA, V7, P44, DOI 10.1017/S1355838201001558; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	49	96	97	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e174	10.1371/journal.pone.0000174	http://dx.doi.org/10.1371/journal.pone.0000174			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245450	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444100011
J	Yamagishi, T; Ozawa, M; Ohtsuka, C; Ohyama-Goto, R; Kondo, T				Yamagishi, Takumi; Ozawa, Michiru; Ohtsuka, Chiho; Ohyama-Goto, Ritsuko; Kondo, Takashi			Evx2-Hoxd13 Intergenic Region Restricts Enhancer Association to Hoxd13 Promoter	PLOS ONE			English	Article								Expression of Hox genes is tightly regulated in spatial and temporal domains. Evx2 is located next to Hoxd13 within 8 kb on the opposite DNA strand. Early in development, the pattern of Hoxd13 expression resembles that of Evx2 in limb and genital buds. After 10 dpc, however, Evx2 begins to be expressed in CNS as well. We analyzed the region responsible for these differences using ES cell techniques, and found that the intergenic region between Evx2 and Hoxd13 behaves as a boundary element that functions differentially in space and time, specifically in the development of limbs, genital bud, and brain. This boundary element comprises a large sequence spanning several kilobases that can be divided into at least two units: a constitutive boundary element, which blocks transcription regulatory influences from the chromosomal environment, and a regulatory element, which controls the function of the constitutive boundary element in time and space.	[Yamagishi, Takumi; Ozawa, Michiru; Ohtsuka, Chiho; Ohyama-Goto, Ritsuko; Kondo, Takashi] RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Kondo Res Unit,Brain Dev Res Grp, Wako, Saitama 35101, Japan	RIKEN	Kondo, T (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Kondo Res Unit,Brain Dev Res Grp, Wako, Saitama 35101, Japan.	TKondo@brain.riken.jp		jin teng, long/0000-0002-1948-9331	Human Frontier Scientific Program Organization (HFSPO); The Ministry of Education, Culture, Sports, and Technology (MEXT) of Japan	Human Frontier Scientific Program Organization (HFSPO)(Human Frontier Science Program); The Ministry of Education, Culture, Sports, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a grant from the Human Frontier Scientific Program Organization (HFSPO) and Grant-in-Aid for Scientific Research on Priority Areas from The Ministry of Education, Culture, Sports, and Technology (MEXT) of Japan.	Akasaka T, 1996, DEVELOPMENT, V122, P1513; Archey WB, 1999, CANCER RES, V59, P2292; Barges S, 2000, DEVELOPMENT, V127, P779; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Core N, 1997, DEVELOPMENT, V124, P721; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GEORGIEV PG, 1995, P NATL ACAD SCI USA, V92, P5184, DOI 10.1073/pnas.92.11.5184; Ghosh D, 2001, EMBO J, V20, P2518, DOI 10.1093/emboj/20.10.2518; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2000, GENE DEV, V14, P198; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Kmita M, 2002, DEVELOPMENT, V129, P5521, DOI 10.1242/dev.00151; Kondo T, 1999, CELL, V97, P407, DOI 10.1016/S0092-8674(00)80749-7; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Monge I, 2003, DEV BIOL, V256, P212, DOI 10.1016/S0012-1606(02)00136-7; PEIFER M, 1986, EMBO J, V5, P2293, DOI 10.1002/j.1460-2075.1986.tb04497.x; Recillas-Targa F, 2002, P NATL ACAD SCI USA, V99, P6883, DOI 10.1073/pnas.102179399; Schweinsberg S, 2004, GENETICS, V168, P1371, DOI 10.1534/genetics.104.029561; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Tarchini B, 2006, DEV CELL, V10, P93, DOI 10.1016/j.devcel.2005.11.014; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	35	17	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e175	10.1371/journal.pone.0000175	http://dx.doi.org/10.1371/journal.pone.0000175			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245451	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444100012
J	Beke, L; Nuytten, M; Van Eynde, A; Beullens, M; Bollen, M				Beke, L.; Nuytten, M.; Van Eynde, A.; Beullens, M.; Bollen, M.			The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2	ONCOGENE			English	Article						EZH2; tumor suppressor; Polycomb group proteins; prostate cancer PSP94; epigenetics	SECRETORY PROTEIN; CANCER; METHYLATION; EXPRESSION; GROWTH; HYPERCALCEMIA; PROGRESSION; MALIGNANCY	PSP94, for prostatic secretory protein of 94 amino acids, is secreted by the prostate gland and functions as a suppressor of tumor growth and metastasis. The expression of PSP94 is lost in advanced, hormone-refractory prostate cancer and this correlates with an increased expression of the Polycomb protein EZH2 (enhancer of zeste homolog 2), which represses transcription via trimethylation of histone H3 on Lys27 (H3K27). We show here that these events are causally related and that the MSMB gene, which encodes PSP94, is trimethylated on H3K27 in androgen-refractory, but not in androgen-sensitive prostate cancer cells. Chromatin immunoprecipitation experiments confirmed an association of EZH2 with the MSMB gene. The RNAi-mediated knockdown of EZH2 resulted in a loss of H3K27 trimethylation and an increased expression of the MSMB gene. Conversely, the overexpression of EZH2 was associated with a decreased expression of the MSMB gene. We also demonstrate that MSMB is additionally repressed in androgen-refractory prostate cancer cells by the hypoacetylation of histone H3K9 and the hypermethylation of a CpG island in the promoter region. Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells.	Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Louvain, Belgium	KU Leuven	Van Eynde, A (corresponding author), Afdeling Biochem, Campus Gasthuisberg,O&N1,Herestr 49,Bus 901, B-3000 Louvain, Belgium.	Aleyde.VanEynde@med.kuleuven.be						Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Garde SV, 1999, PROSTATE, V38, P118, DOI 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-G; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Lamy S, 2006, INT J CANCER, V118, P2350, DOI 10.1002/ijc.21615; LaTulippe E, 2002, CANCER RES, V62, P4499; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Shukeir N, 2004, CANCER RES, V64, P5370, DOI 10.1158/0008-5472.CAN-04-0788; Shukeir N, 2003, CANCER RES, V63, P2072; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431	18	84	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4590	4595		10.1038/sj.onc.1210248	http://dx.doi.org/10.1038/sj.onc.1210248			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237810				2022-12-25	WOS:000247836100013
J	Kristian, SA; Timmer, AM; Liu, GY; Lauth, X; Sal-Man, N; Rosenfeld, Y; Shai, Y; Gallo, RL; Nizet, V				Kristian, Sascha A.; Timmer, Anjuli M.; Liu, George Y.; Lauth, Xavier; Sal-Man, Neta; Rosenfeld, Yosef; Shai, Yechiel; Gallo, Richard L.; Nizet, Victor			Impairment of innate immune killing mechanisms by bacteriostatic antibiotics	FASEB JOURNAL			English	Article						antimicrobial peptides; cathelicidin; complement	PLATELET MICROBICIDAL PROTEIN; HUMAN ANTIMICROBIAL PEPTIDE; STAPHYLOCOCCUS-AUREUS; INFECTIONS; RESISTANCE; ORGANISMS; MEMBRANES; BACTERIA; DEFENSIN; OPERON	Antibiotics are designed to support host defense in controlling infection. Here we describe a paradoxical inhibitory effect of bacteriostatic antibiotics on key mediators of mammalian innate immunity. When growth of species including Escherichia coli and Staphylococcus aureus is suppressed by chloramphenicol or erythromycin, the susceptibility of the bacteria to cathelicidin antimicrobial peptides or serum complement was markedly diminished. Survival of the bacteria in human whole blood, human wound fluid, or a mouse wound infection model was in turn increased after antibiotic-induced bacteriostasis. These findings provide a further rationale against the indiscriminate use of antibiotics.	Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Weizmann Institute of Science	Nizet, V (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat Cellular & Mol Med E1066, 9500 Gilman Dr, La Jolla, CA 92093 USA.	vnizet@ucsd.edu	Nizet, Victor/AAF-3190-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Sal-Man, Neta/0000-0002-1109-479X; Nizet, Victor/0000-0003-3847-0422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048176, R01AI048694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-048694, AI-48176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASMAR BI, 1983, PEDIATR INFECT DIS J, V2, P39, DOI 10.1097/00006454-198301000-00010; Barnes MG, 2002, INFECT IMMUN, V70, P403, DOI 10.1128/IAI.70.1.403-406.2002; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Finberg RW, 2004, CLIN INFECT DIS, V39, P1314, DOI 10.1086/425009; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Koo SP, 1996, INFECT IMMUN, V64, P1070, DOI 10.1128/IAI.64.3.1070-1074.1996; Lauth X, 2002, J BIOL CHEM, V277, P5030, DOI 10.1074/jbc.M109173200; Mulligan M J, 1989, Infect Dis Clin North Am, V3, P389; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Proctor RA, 2006, NAT REV MICROBIOL, V4, P295, DOI 10.1038/nrmicro1384; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Silphaduang U, 2001, NATURE, V414, P268, DOI 10.1038/35104690; Stratton CW, 2003, EMERG INFECT DIS, V9, P10; von Eiff C, 2006, INJURY, V37, P26, DOI 10.1016/j.injury.2006.04.006; Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563; Xiong YQ, 1999, ANTIMICROB AGENTS CH, V43, P1111, DOI 10.1128/AAC.43.5.1111; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	23	35	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1107	1116		10.1096/fj.06-6802com	http://dx.doi.org/10.1096/fj.06-6802com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215486				2022-12-25	WOS:000245650400015
J	Paclet, MH; Berthier, S; Kuhn, L; Garin, J; Morel, F				Paclet, Marie-Helene; Berthier, Sylvie; Kuhn, Lauriane; Garin, Jerome; Morel, Francoise			Regulation of phagocyte NADPH oxidase activity: identification of two cytochrome b(558) activation states	FASEB JOURNAL			English	Article						NADPH oxidase complex; MRP; p67-phox	CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; IMMORTALIZED B-LYMPHOCYTES; SODIUM DODECYL-SULFATE; RESPIRATORY BURST; NEUTROPHILS; P47(PHOX); COMPONENTS; P67(PHOX)	Activation of the phagocyte NADPH oxidase (phox) requires the association of cytosolic proteins (p67-phox, p47-phox, p40-phox, and Rac1/2) with the membrane cytochrome b558, leading to a hemoprotein conformation change. To clarify this mechanism, the phagocyte NADPH oxidase complex was isolated through cytochrome b558 purification after three chromatographic steps. The purified neutrophil complex was constitutively active in the absence of an amphiphile agent with a maximum turnover (125 mol O-2(-) . s(-1) . mol heme b(-1)), indicating that cytochrome b558 has been activated by cytosolic proteins and is in an "open conformation," able to transfer a maximum rate of electrons. In contrast, the phox complex prepared with B lymphocyte cytosol shows a lower constitutive turnover (similar to 50 mol O-2(-) . s(-1) . mol heme b(-1)). Analysis of phox complex components by Western blot and mass spectrometry showed the presence of cytosolic factors (especially p67-phox) and structural proteins (moesin, ezrin). To investigate the difference in activity of phox complexes, we evaluated the effect of MRP8 and MRP14, specifically expressed in neutrophils, on the activity of the B lymphocyte complex. MRPs induce the switch between the partially and the fully "open" cytochrome b558 conformation. Moreover, their effect was independent of p67-phox. Data point out two potential cytochrome b558 activation states.	CHU Grenoble, GREPI EA 2938, Lab Enzymol, DBPC, F-38043 Grenoble 9, France; ERIT M CEA Grenoble, Lab Chim Prot, Grenoble, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA	Paclet, MH (corresponding author), CHU Grenoble, GREPI EA 2938, Lab Enzymol, DBPC, BP 217, F-38043 Grenoble 9, France.	mhpaclet@chu-grenoble.fr	Paclet, Marie-Hélène/AAS-5029-2020	Kuhn, Lauriane/0000-0002-2637-1024				ABO A, 1992, J BIOL CHEM, V267, P16767; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; BELLAVITE P, 1984, BIOCHEM J, V223, P639, DOI 10.1042/bj2230639; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DOUSSIERE J, 1985, BIOCHEMISTRY-US, V24, P7231, DOI 10.1021/bi00346a032; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Grogan A, 1997, J CELL SCI, V110, P3071; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; REEVES EPL, 1999, BIOCHEM J, V15, P859; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ugolev Y, 2006, J BIOL CHEM, V281, P19204, DOI 10.1074/jbc.M600042200; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	35	29	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1244	1255		10.1096/fj.06-6852com	http://dx.doi.org/10.1096/fj.06-6852com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227953				2022-12-25	WOS:000245650400028
J	Chung, I; Karpf, AR; Muindi, JR; Conroy, JM; Nowak, NJ; Johnson, CS; Trump, DL				Chung, Ivy; Karpf, Adam R.; Muindi, Josephia R.; Conroy, Jeffrey M.; Nowak, Norma J.; Johnson, Candace S.; Trump, Donald L.			Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; VITAMIN-D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CANDIDATE ONCOGENE; D ANALOGS; IN-VITRO; METHYLATION; EXPRESSION; PREVENTION; THERAPY	Calcitriol (1,25-dihydroxycholecalciferol), the most active form of vitamin D, has selective anti-proliferative effects on tumor-derived endothelial cells (TDEC) compared with Matrigel-derived endothelial cells (MDEC). Although both cell types have an intact vitamin D receptor-signaling axis, this study demonstrates that upon treatment with calcitriol, 24-hydroxylase (CYP24) mRNA, protein and enzymatic activity were markedly induced in MDEC in a time-dependent manner but not in TDEC. Furthermore, treatment of MDEC with a CYP24 small interfering RNA restored sensitivity to calcitriol. To investigate the lack of CYP24 induction in TDEC, we examined methylation patterns in the promoter regions of the CYP24 gene in these two cell types. We identified two putative CpG island regions located at the 5' end. Using methylation-specific PCR and bisulfite sequencing, we determined that these CpG islands were hypermethylated in TDEC but not in MDEC. These data may explain the recruitment of vitamin D receptor to the promoter region in MDEC but not TDEC, as revealed by chromatin immunoprecipitation analyses. Treatment of TDEC with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine restored calcitriol-mediated induction of CYP24, which led to loss of sensitivity to calcitriol growth inhibitory effects. CYP24 promoter hypermethylation was also observed in endothelial cells isolated from other tumors but not in endothelial cells isolated from normal mouse tissues. These observations indicate that the methylation status of the CYP24 promoter differs in endothelial cells isolated from different microenvironments (tumor versus normal) and that methylation silencing of CYP24 contributes to selective calcitriol-mediated growth inhibition in endothelial cells.	Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Prevent, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Trump, DL (corresponding author), Roswell Pk Canc Inst, Dept Med, Elm & Carlton Sts, Buffalo, NY 14263 USA.	donald.trump@roswellpark.org	Chung, Ivy/C-3804-2012	Karpf, Adam/0000-0002-0866-0666	NATIONAL CANCER INSTITUTE [R01CA085142, R01CA067267, R01CA095045, R01CA116674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116674-02, CA95045, CA67267, R01 CA116674, CA85142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Anderson MG, 2006, CANCER CHEMOTH PHARM, V57, P234, DOI 10.1007/s00280-005-0059-7; Banwell CM, 2006, CLIN CANCER RES, V12, P2004, DOI 10.1158/1078-0432.CCR-05-1218; Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Chung I, 2006, CANCER RES, V66, P8565, DOI 10.1158/0008-5472.CAN-06-0905; Cross HS, 2004, J NUTR, V134, p1207S, DOI 10.1093/jn/134.5.1207S; Diaz GD, 2000, CANCER RES, V60, P2304; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fradette C, 2004, CURR DRUG METAB, V5, P257, DOI 10.2174/1389200043335577; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grover AC, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-13; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Hershberger PA, 1999, CANCER RES, V59, P2644; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; HONDA A, 1993, BIOCHEM J, V295, P509, DOI 10.1042/bj2950509; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Johnson CS, 2006, ANTICANCER RES, V26, P2543; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu Y, 2005, J BONE MINER RES, V20, P1680, DOI 10.1359/JBMR.050410; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Mimori K, 2004, ANN ONCOL, V15, P236, DOI 10.1093/annonc/mdh056; MODZELEWSKI RA, 1994, CANCER RES, V54, P336; Muindi JR, 2007, CANCER CHEMOTH PHARM, V59, P97, DOI 10.1007/s00280-006-0247-0; OHYAMA Y, 2002, NUCL ACIDS RES S, V2, P249; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; Sergeev IN, 2004, J STEROID BIOCHEM, V89-90, P419, DOI 10.1016/j.jsbmb.2004.03.010; Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200; Trump DL, 2006, ANTICANCER RES, V26, P2551; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	32	60	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8704	8714		10.1074/jbc.M608894200	http://dx.doi.org/10.1074/jbc.M608894200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244627	hybrid			2022-12-25	WOS:000245780300016
J	Del Re, DP; Miyamoto, S; Brown, JH				Del Re, Dominic P.; Miyamoto, Shigeki; Brown, Joan Heller			RhoA/Rho kinase up-regulate bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-ALPHA-Q; RAT VENTRICULAR MYOCYTES; CYTOCHROME-C RELEASE; MYOSIN LIGHT CHAIN-2; TUMOR-SUPPRESSOR P53; RHO-KINASE; GENE-EXPRESSION; CARDIAC MYOCYTES; CELL-DEATH; HEART-FAILURE	The small G-protein RhoA regulates the actin cytoskeleton, and its involvement in cell proliferation has also been established. In contrast, little is known about whether RhoA participates in cell survival or apoptosis. In cardiomyocytes in vitro, RhoA induces hypertrophic cell growth and gene expression. In vivo, however, RhoA expression leads to development of heart failure (Sah, V. P., Minamisawa, S., Tam, S. P., Wu, T. H., Dorn, G. W., Ross, J. Jr., Chien, K. R., and Brown, J. H. (1999) J. Clin. Investig. 103, 1627-1634), a condition widely associated with cardiomyocyte apoptosis. We demonstrate here that adenoviral overexpression of activated RhoA in cardiomyocytes induces hypertrophy, which transitions over time to apoptosis, as evidenced by caspase activation and nucleosomal DNA fragmentation. The Rho kinase inhibitors Y-27632 and HA-1077 and expression of a dominant negative Rho kinase block these responses. Caspase-9, but not caspase-8, is activated, and its inhibition prevents DNA fragmentation, consistent with involvement of a mitochondrial death pathway. Interestingly, RhoA expression induces a 3-4-fold up-regulation of the proapoptotic Bcl-2 family protein Bax. RhoA also increases levels of activated Bax and the amount of Bax protein localized at mitochondria. Bax mRNA is increased by RhoA, indicating transcriptional regulation, and the ability of a dominant negative p53 mutant to block Bax up-regulation implicates p53 in this response. The involvement of Bax in RhoA-induced apoptosis was examined by treatment with a Bax-inhibitory peptide, which was found to significantly attenuate DNA fragmentation and caspase-9 and -3 activation. The dominant negative p53 also prevents RhoA-induced apoptosis. We conclude that RhoA/Rho kinase activation up-regulates Bax through p53 to induce a mitochondrial death pathway and cardiomyocyte apoptosis.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu	Miyamoto, Shigeki/L-4004-2019	Del Re, Dominic/0000-0002-5504-9114	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Bao WK, 2004, CARDIOVASC RES, V61, P548, DOI 10.1016/j.cardiores.2003.12.004; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Capano M, 2006, BIOCHEM J, V395, P57, DOI 10.1042/BJ20051654; Chang J, 2006, P NATL ACAD SCI USA, V103, P14495, DOI 10.1073/pnas.0601911103; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; De Sarno L, 2005, BRAIN RES, V1041, P112, DOI 10.1016/j.brainres.2005.01.081; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hattori T, 2004, CIRCULATION, V109, P2234, DOI 10.1161/01.CIR.0000127939.16111.58; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Hou Q, 2005, AM J PHYSIOL-HEART C, V289, pH477, DOI 10.1152/ajpheart.00879.2004; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kacimi R, 2003, HYPERTENSION, V41, P968, DOI 10.1161/01.HYP.0000062465.60601.CC; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwahara K, 1999, FEBS LETT, V452, P314, DOI 10.1016/S0014-5793(99)00680-8; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LEE HR, 1988, J BIOL CHEM, V263, P7352; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Miao L, 2002, LIFE SCI, V71, P1175, DOI 10.1016/S0024-3205(02)01827-1; Miyamoto S, 2005, J BIOL CHEM, V280, P38505, DOI 10.1074/jbc.M505223200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Natori S, 1999, TRANSPLANTATION, V68, P89, DOI 10.1097/00007890-199907150-00018; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Regula KM, 2001, J MOL CELL CARDIOL, V33, P1435, DOI 10.1006/jmcc.2001.1405; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Satoh S, 2003, J MOL CELL CARDIOL, V35, P59, DOI 10.1016/S0022-2828(02)00278-X; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolfrum S, 2004, ARTERIOSCL THROM VAS, V24, P1842, DOI 10.1161/01.ATV.0000142813.33538.82; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200	56	119	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8069	8078		10.1074/jbc.M604298200	http://dx.doi.org/10.1074/jbc.M604298200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234627	hybrid			2022-12-25	WOS:000245081000039
J	Huster, D; Purnat, TD; Burkhead, JL; Ralle, M; Fiehn, O; Stuckert, F; Olson, NE; Teupser, D; Lutsenko, S				Huster, Dominik; Purnat, Tina D.; Burkhead, Jason L.; Ralle, Martina; Fiehn, Oliver; Stuckert, Franziska; Olson, N. Erik; Teupser, Daniel; Lutsenko, Svetlana			High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; FATTY-ACID SYNTHASE; GENE-EXPRESSION; STATISTICAL-MODEL; MICROARRAY DATA; LIVER; IDENTIFICATION; TRANSCRIPTION; BINDING; PROTEIN	Copper is essential for human physiology, but in excess it causes the severe metabolic disorder Wilson disease. Elevated copper is thought to induce pathological changes in tissues by stimulating the production of reactive oxygen species that damage multiple cell targets. To better understand the molecular basis of this disease, we performed genome-wide mRNA profiling as well as protein and metabolite analysis for Atp7b(-/-) mice, an animal model of Wilson disease. We found that at the presymptomatic stages of the disease, copper-induced changes are inconsistent with widespread radical-mediated damage, which is likely due to the sequestration of cytosolic copper by metallothioneins that are markedly up-regulated in Atp7b(-/-) livers. Instead, copper selectively up-regulates molecular machinery associated with the cell cycle and chromatin structure and down-regulates lipid metabolism, particularly cholesterol biosynthesis. Specific changes in the transcriptome are accompanied by distinct metabolic changes. Biochemical and mass spectroscopy measurements revealed a 3.6-fold decrease of very low density lipoprotein cholesterol in serum and a 33% decrease of liver cholesterol, indicative of a marked decrease in cholesterol biosynthesis. Consistent with low cholesterol levels, the amount of activated sterol regulatory-binding protein 2 (SREBP-2) is increased in Atp7b(-/-) nuclei. However, the SREBP-2 target genes are dysregulated suggesting that elevated copper alters SREBP-2 function rather than its processing or re-localization. Thus, in Atp7b(-/-) mice elevated copper affects specific cellular targets at the transcription and/or translation levels and has distinct effects on liver metabolic function, prior to appearance of histopathological changes. The identification of the network of specific copper-responsive targets facilitates further mechanistic analysis of human disorders of copper misbalance.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Leipzig, Dept Med 2, D-04103 Leipzig, Germany; Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; VizX Labs, Seattle, WA 98119 USA	Oregon Health & Science University; Leipzig University; Leipzig University; University of California System; University of California Davis	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,Sam Jackson Pk Rd, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Burkhead, Jason/C-9612-2013; Ralle, Martina/H-2936-2019	Burkhead, Jason/0000-0001-5457-311X; PURNAT, Tina/0000-0002-0257-6631	NIGMS NIH HHS [P01 GM 067166-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOTHMAN AA, 1992, J NUTR, V122, P1199, DOI 10.1093/jn/122.6.1199; Armendariz AD, 2004, PHYSIOL GENOMICS, V20, P45, DOI 10.1152/physiolgenomics.00196.2003; Bove KE, 2004, PEDIATR DEVEL PATHOL, V7, P315, DOI 10.1007/s10024-002-1201-8; Brewer GJ, 1998, AM J CLIN NUTR, V67, p1087S, DOI 10.1093/ajcn/67.5.1087S; Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214; Buiakova OI, 1999, HUM MOL GENET, V8, P1665, DOI 10.1093/hmg/8.9.1665; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Cherian MG, 2006, EXP BIOL MED, V231, P138; Compston A., 1912, BRAIN, V34, P295, DOI DOI 10.1093/BRAIN/34.4.295; COX D, 2006, WILSON DIS, P1601; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ferenci P, 2004, METAB BRAIN DIS, V19, P229, DOI 10.1023/B:MEBR.0000043973.10494.85; Foretz M, 1999, BIOCHEM J, V341, P371, DOI 10.1042/0264-6021:3410371; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hu R, 2006, LIFE SCI, V79, P1944, DOI 10.1016/j.lfs.2006.06.019; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Huster D, 2006, AM J PATHOL, V168, P423, DOI 10.2353/ajpath.2006.050312; Inoue N, 2005, MOL CELL BIOL, V25, P8938, DOI 10.1128/MCB.25.20.8938-8947.2005; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; KELLER A, 2005, MOL SYST BIOL, V1, pE1; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Klein D, 2003, ARCH TOXICOL, V77, P568, DOI 10.1007/s00204-003-0493-4; Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216; Leong HX, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-37; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loudianos G, 2000, SEMIN LIVER DIS, V20, P353, DOI 10.1055/s-2000-9389; Morozova N, 2003, GENES CELLS, V8, P963, DOI 10.1046/j.1365-2443.2003.00687.x; Mutlib A, 2006, CHEM RES TOXICOL, V19, P1270, DOI 10.1021/tx060093j; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Ng HH, 2005, GENOMICS, V86, P657, DOI 10.1016/j.ygeno.2005.07.005; Prabhu KS, 2003, ADV EXP MED BIOL, V525, P189; Riordan SM, 2001, J HEPATOL, V34, P165, DOI 10.1016/S0168-8278(00)00028-3; Rodo M, 2000, EUR J NEUROL, V7, P491; SCHEINBERG IH, 1984, WILSON DIS, P58; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; STREMMEL W, 1991, ANN INTERN MED, V115, P720, DOI 10.7326/0003-4819-115-9-720; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Teupser D, 2004, P NATL ACAD SCI USA, V101, P17795, DOI 10.1073/pnas.0408096101; Wilson J, 1997, AM J PHYSIOL-ENDOC M, V272, pE1124, DOI 10.1152/ajpendo.1997.272.6.E1124; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zhu QH, 2005, ENDOCRINOLOGY, V146, P3343, DOI 10.1210/en.2005-0204	48	169	173	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8343	8355		10.1074/jbc.M607496200	http://dx.doi.org/10.1074/jbc.M607496200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17205981	hybrid			2022-12-25	WOS:000245081000068
J	Taniguchi, M; Taoka, M; Itakura, M; Asada, A; Saito, T; Kinoshita, M; Takahashi, M; Isobe, T; Hisanaga, S				Taniguchi, Makoto; Taoka, Masato; Itakura, Makoto; Asada, Akiko; Saito, Taro; Kinoshita, Makoto; Takahashi, Masami; Isobe, Toshiaki; Hisanaga, Shin-ichi			Phosphorylation of adult type Sept5 (CDCrel-1) by cyclin-dependent kinase 5 inhibits interaction with syntaxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT-BRAIN SYNAPTOSOMES; MAMMALIAN SEPTINS; DOWN-REGULATION; NMDA RECEPTORS; CELL-DIVISION; BUDDING YEAST; MOUSE-BRAIN; CDK5; EXOCYTOSIS	Increasing evidence implicates cyclin-dependent kinase 5 (Cdk5) in neuronal synaptic function. We searched for Cdk5 substrates in synaptosomal fractions prepared from mouse brains. Mass spectrometric analysis after two-dimensional SDS-PAGE identified several synaptic proteins phosphorylated by Cdk5-p35; one protein identified was Sept5 (CDCrel-1). Although septins were isolated originally as cell division-related proteins in yeast, Sept5 is expressed predominantly in neurons and is implicated in exocytosis. We confirmed that Sept5 is phosphorylated by Cdk5p35 in vitro and identified Ser(17) of adult type Sept5 (Sept5_v1) as a major phosphorylation site. We found that Ser17 of Sept5_v1 is phosphorylated in mouse brains. Coimmunoprecipitation from synaptosomal fractions and glutathione S-transferase-syntaxin-1A pulldown assays of Sept5_v1 expressed in COS-7 cells showed that phosphorylation of Sept5_v1 by Cdk5-p35 decreases the binding to syntaxin-1. These results indicate that the interaction of Sept5 with syntaxin-1 is regulated by the phosphorylation of Sept_v1 at Ser(17) by Cdk5-p35.	Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920397, Japan; Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa 2288555, Japan; Kyoto Univ, Grad Sch Med, Biochem & Cell Biol Unit, HMRO, Kyoto 6068501, Japan	Tokyo Metropolitan University; Tokyo Metropolitan University; Kitasato University; Kyoto University	Taniguchi, M (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, 1-1 Minamiosawa, Hachioji, Tokyo 1920397, Japan.	taniguti-makoto@c.metro-u.ac.jp; hisanaga-shinichi@c.metro-u.ac.jp	Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beites CL, 2005, BIOCHEM J, V385, P347, DOI 10.1042/BJ20041090; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Cheung ZH, 2006, NEURON, V50, P13, DOI 10.1016/j.neuron.2006.02.024; Dent J, 2002, P NATL ACAD SCI USA, V99, P3064, DOI 10.1073/pnas.052715199; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dong ZZ, 2003, P NATL ACAD SCI USA, V100, P12438, DOI 10.1073/pnas.2132992100; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Gil C, 2005, BIOCHEM BIOPH RES CO, V329, P117, DOI 10.1016/j.bbrc.2005.01.111; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Hosokawa T, 2006, J NEUROSCI RES, V84, P747, DOI 10.1002/jnr.20975; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kinoshita M, 2006, CURR OPIN CELL BIOL, V18, P54, DOI 10.1016/j.ceb.2005.12.005; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Liu YX, 2006, J BIOL CHEM, V281, P9852, DOI 10.1074/jbc.M513496200; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Morabito MA, 2004, J NEUROSCI, V24, P865, DOI 10.1523/JNEUROSCI.4582-03.2004; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Nikolic M, 2004, TRENDS CELL BIOL, V14, P1, DOI 10.1016/j.tcb.2003.10.010; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rosales JL, 2004, J BIOL CHEM, V279, P53932, DOI 10.1074/jbc.M408467200; Sakaue F, 2005, J BIOL CHEM, V280, P31522, DOI 10.1074/jbc.M504792200; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; Shelton SB, 2004, J NEUROCHEM, V88, P1313, DOI 10.1111/j.1471-4159.2003.02328.x; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tang CSL, 2002, CELL CYCLE, V1, P42, DOI 10.4161/cc.1.1.99; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Toda S, 2000, BIOCHEM BIOPH RES CO, V273, P723, DOI 10.1006/bbrc.2000.3003; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; Versele M, 2004, J CELL BIOL, V164, P701, DOI 10.1083/jcb.200312070; Wang J, 2003, NAT NEUROSCI, V6, P1039, DOI 10.1038/nn1119; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Xin XN, 2004, J CELL SCI, V117, P4739, DOI 10.1242/jcs.01333; Xue J, 2004, BIOCHEM J, V381, P753, DOI 10.1042/BJ20040455; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	59	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7869	7876		10.1074/jbc.M609457200	http://dx.doi.org/10.1074/jbc.M609457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224448	hybrid			2022-12-25	WOS:000245081000016
J	Wang, LX; Srinivasan, S; Theiss, AL; Merlin, D; Sitaraman, SV				Wang, Lixin; Srinivasan, Shanthi; Theiss, Arianne L.; Merlin, Didier; Sitaraman, Shanthi V.			Interleukin-6 induces keratin expression in intestinal epithelial cells - Potential role of keratin-8 in interleukin-6-induced barrier function alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERMEDIATE-FILAMENT PROTEINS; INFLAMMATORY-BOWEL-DISEASE; EXPERIMENTAL COLITIS; HEMORRHAGIC-SHOCK; PLASMA-MEMBRANE; SHEAR-STRESS; IN-VITRO; MICE; IL-6	Keratin 8 1 and keratin-18 (K18) are the major intermediate filament proteins in the intestinal epithelia. The regulation and function of keratin in the intestinal epithelia is largely unknown. In this study we addressed the role and regulation of K8 and K18 expression by interleukin 6 (IL-6). Caco2-BBE cell line and IL-6 null mice were used to study the effect of IL-6 on keratin expression. Keratin expression was studied by Northern blot, Western blot, and confocal microscopy. Paracellular permeability was assessed by apical-to-basal transport of a fluorescein isothiocyanate dextran probe I K8 was silenced using the small interfering RNA approach. IL-6 significantly up-regulated mRNA and protein levels of K8 and K18. Confocal microscopy showed a reticular pattern of intracellular keratin localized to the subapical region after IL-6 treatment. IL-6 also induced serine phosphorylation of K8. IL-6 decreased paracellular flux of FD-4 compared with vehicle-treated monolayers. K8 silencing abolished the decrease in paracellular permeability induced by IL-6. Administration of dextran sodium sulfate (DSS) significantly increased intestinal permeability in IL-6(-/-) mice compared with wild type mice given DSS. Collectively, our data demonstrate that IL-6 regulates the colonic expression of K8 and K18, and K8/KI8 mediates barrier protection by IL-6 under conditions where intestinal barrier is compromised. Thus, our data uncover a novel function of these abundant cytoskeletal proteins, which may have implications in intestinal disorders such as inflammatory bowel disease wherein barrier dysfunction underlies the inflammatory response.	Emory Univ, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA	Emory University	Sitaraman, SV (corresponding author), Emory Univ, Div Digest Dis, Dept Med, Rm 201-F,615,Michael St,Whitehead Res Bldg, Atlanta, GA 30322 USA.	ssitar2@emory.edu	Srinivasan, Shanthi/A-6133-2013	Theiss, Arianne/0000-0003-2862-0933	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002831, K08DK067045, R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02831, 5R24DK064399-02, DK 067045, DK06411] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen NA, 2001, J CELL SCI, V114, P563; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; Brembeck FH, 2003, CANCER RES, V63, P2005; Buhler H, 2005, MOL CANCER RES, V3, P365, DOI 10.1158/1541-7786.MCR-04-0117; CASANOVA L, 1995, J CELL SCI, V108, P811; Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Dignass AU, 2004, ALIMENT PHARM THER, V20, P9, DOI 10.1111/j.1365-2036.2004.02047.x; Dube PH, 2004, INFECT IMMUN, V72, P3561, DOI 10.1128/IAI.72.6.3561-3570.2004; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Habtezion A, 2005, J CELL SCI, V118, P1971, DOI 10.1242/jcs.02316; Herrmann H, 2004, METHOD CELL BIOL, V78, P3; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Hesse M, 2001, J CELL SCI, V114, P2569; Jaquemar D, 2003, J CELL BIOL, V161, P749, DOI 10.1083/jcb.200210004; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Kimizuka K, 2004, AM J TRANSPLANT, V4, P482, DOI 10.1111/j.1600-6143.2004.00368.x; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Krizanac-Bengez L, 2003, BRAIN RES, V977, P239, DOI 10.1016/S0006-8993(03)02689-1; Ku NO, 2006, J CELL BIOL, V174, P115, DOI 10.1083/jcb.200602146; Ku NO, 2004, METHOD CELL BIOL, V78, P489; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; Ku NO, 2003, HEPATOLOGY, V37, P1006, DOI 10.1053/jhep.2003.50181; Ku NO, 1998, J CELL BIOL, V143, P2023, DOI 10.1083/jcb.143.7.2023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane EB, 2004, J PATHOL, V204, P355, DOI 10.1002/path.1643; Leonard M, 2000, PHARM RES-DORDR, V17, P1181, DOI 10.1023/A:1026454427621; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Mangan JK, 2006, ONCOGENE, V25, P2489, DOI 10.1038/sj.onc.1209280; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MOLL R, 1982, PATHOL RES PRACT, V175, P146, DOI 10.1016/S0344-0338(82)80105-2; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Owens DW, 2004, J CELL SCI, V117, P1989, DOI 10.1242/jcs.01043; Owens DW, 2004, J PATHOL, V204, P377, DOI 10.1002/path.1646; Panja A, 1998, J IMMUNOL, V161, P3675; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Paul R, 2003, BRAIN, V126, P1873, DOI 10.1093/brain/awg171; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Rockman SP, 2001, J GASTROEN HEPATOL, V16, P991, DOI 10.1046/j.1440-1746.2001.02588.x; Rollwagen FM, 1996, CYTOKINE, V8, P121, DOI 10.1006/cyto.1996.0017; Rollwagen FM, 1997, MIL MED, V162, P366, DOI 10.1093/milmed/162.5.366; Salas PJI, 1997, J CELL BIOL, V137, P359, DOI 10.1083/jcb.137.2.359; Shen L, 2006, AM J PHYSIOL-GASTR L, V290, pG577, DOI 10.1152/ajpgi.00439.2005; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Tao GZ, 2006, J CELL SCI, V119, P1425, DOI 10.1242/jcs.02861; Toivola DA, 2004, HEPATOLOGY, V40, P459, DOI 10.1002/hep.20277; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; Wald FA, 2005, MOL BIOL CELL, V16, P4096, DOI 10.1091/mbc.e05-03-0242; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; Wang LX, 2005, GASTROENTEROLOGY, V128, pA659; Wang LX, 2004, AM J PHYSIOL-GASTR L, V287, pG1100, DOI 10.1152/ajpgi.00164.2004; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Wang Q, 2000, CLIN SCI, V99, P489, DOI 10.1042/CS20000059; Wang XP, 2004, J INVEST DERMATOL, V123, P124, DOI 10.1111/j.0022-202X.2004.22736.x; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878; Yang RK, 2003, AM J PHYSIOL-GASTR L, V285, pG621, DOI 10.1152/ajpgi.00177.2003; Zhong BH, 2004, J CELL SCI, V117, P1709, DOI 10.1242/jcs.01016	68	72	79	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8219	8227		10.1074/jbc.M604068200	http://dx.doi.org/10.1074/jbc.M604068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17213200	hybrid			2022-12-25	WOS:000245081000054
J	Wei, EH; Gao, WH; Lehner, R				Wei, Enhui; Gao, Wenhui; Lehner, Richard			Attenuation of adipocyte triacylglycerol hydrolase activity decreases basal fatty acid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHOLESTERYL ESTER HYDROLASE; ADIPOSE-TISSUE; INSULIN-RESISTANCE; EXPRESSION; MOBILIZATION; IDENTIFICATION; LIPOLYSIS; CLONING; PHOSPHORYLATION	Fatty acids released from adipose triacylglycerol stores by lipolysis provide vertebrates with an important source of energy. We investigated the role of microsomal triacylglycerol hydrolase (TGH) in the mobilization of adipocyte triacylglycerols through inactivation of the TGH activity by RNA interference or chemical inhibition. Attenuation of TGH activity resulted in decreased basal but not isoproterenol-stimulated efflux of fatty acids from 3T3-L1 adipocytes. Lack of TGH activity was accompanied by accumulation of cellular triacylglycerols and cholesteryl esters without any changes in the expression of enzymes catalyzing triacylglycerol synthesis (diacylglycerol acyltransferases 1 and 2) or degradation (adipose triglyceride lipase and hormone-sensitive lipase). Inhibition of TGH-mediated lipolysis also did not affect insulin-stimulated Glut4 translocation from intracellular compartments to the plasma membrane or glucose uptake into adipocytes. These data suggest that TGH plays a role in adipose tissue triacylglycerol. metabolism and may be a suitable pharmacological target for lowering fatty acid efflux from adipose tissue without altering glucose import.	Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Lehner, R (corresponding author), Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Pediat, 328 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	richard.lehner@ualberta.ca		Lehner, Richard/0000-0002-6008-1805				Alam M, 2002, BIOCHEMISTRY-US, V41, P6679, DOI 10.1021/bi0255625; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Birner-Gruenberger R, 2005, MOL CELL PROTEOMICS, V4, P1710, DOI 10.1074/mcp.M500062-MCP200; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Dolinsky VW, 2004, BIOCHEM J, V378, P967, DOI 10.1042/BJ20031320; Dolinsky VW, 2003, BBA-MOL CELL BIOL L, V1635, P20, DOI 10.1016/j.bbalip.2003.09.007; Dolinsky VW, 2001, BBA-MOL CELL BIOL L, V1532, P162, DOI 10.1016/S1388-1981(01)00133-0; Frayn KN, 2002, DIABETOLOGIA, V45, P1201, DOI 10.1007/s00125-002-0873-y; Ghosh S, 2003, J LIPID RES, V44, P1833, DOI 10.1194/jlr.M300162-JLR200; Gilham D, 2005, BBA-MOL CELL BIOL L, V1736, P189, DOI 10.1016/j.bbalip.2005.08.013; Gilham D, 2005, METHODS, V36, P139, DOI 10.1016/j.ymeth.2004.11.003; Gilham D, 2005, MOL BIOL CELL, V16, P984, DOI 10.1091/mbc.e04-03-0224; Gilham D, 2003, FASEB J, V17, P1685, DOI 10.1096/fj.02-0728fje; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Horowitz JF, 2003, TRENDS ENDOCRIN MET, V14, P386, DOI 10.1016/S1043-2760(03)00143-7; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kershaw EE, 2006, DIABETES, V55, P148, DOI 10.2337/diabetes.55.01.06.db05-0982; Kraemer FB, 2002, ENDOCRINOLOGY, V143, P801, DOI 10.1210/en.143.3.801; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; Langin D, 2005, DIABETES, V54, P3190, DOI 10.2337/diabetes.54.11.3190; Langston TB, 2005, LIPIDS, V40, P31, DOI 10.1007/s11745-005-1357-5; Lee W, 2000, J BIOL CHEM, V275, P10041, DOI 10.1074/jbc.275.14.10041; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Milad-Kodsi E, 2005, BBA-MOL CELL BIOL L, V1734, P62, DOI 10.1016/j.bbalip.2005.02.008; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Sahoo D, 2004, J LIPID RES, V45, P1122, DOI 10.1194/jlr.M300529-JLR200; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Soni KG, 2004, J BIOL CHEM, V279, P40683, DOI 10.1074/jbc.M400541200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei E, 2005, BIOCHEM J, V388, P959, DOI 10.1042/BJ20041442; World Health Organization, 1997, OB PREV MAN GLOB EP; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	46	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8027	8035		10.1074/jbc.M605789200	http://dx.doi.org/10.1074/jbc.M605789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237500	hybrid			2022-12-25	WOS:000245081000034
J	Luo, B; Parker, GJ; Cooksey, RC; Soesanto, Y; Evans, M; Jones, D; McClain, DA				Luo, Bai; Parker, Glendon J.; Cooksey, Robert C.; Soesanto, Yucli; Evans, Mark; Jones, Deborah; McClain, Donald A.			Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; O-LINKED GLYCOSYLATION; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE; UPSTREAM KINASE; PATHWAY; BETA; ADIPONECTIN	The hexosamine biosynthesis pathway (HBP) serves as a nutrient sensor and has been implicated in the development of type 2 diabetes. We previously demonstrated that fatty acid oxidation was enhanced in transgenic mouse adipocytes, wherein the rate-limiting enzyme of the HBP, glutamine:fructose-6-phosphate amidotransferase (GFA), was overexpressed. To explore the molecular mechanism of the HBP-induced fatty acid oxidation in adipocytes, we studied AMP-activated protein kinase (AMPK), an energy sensor that stimulates fatty acid oxidation by regulating acetyl-CoA carboxylase (ACC) activity. Phosphorylation and activity of AMPK were increased in transgenic fat pads and in 3T3L1 adipocytes treated with glucosamine to stimulate hexosamine flux. Glucosamine also stimulated phosphorylation of ACC and fatty acid oxidation in 3T3L1 adipocytes, and these stimulatory effects were diminished by adenovirus-mediated expression of a dominant negative AMPK in 3T3L1 adipocytes. Conversely, blocking the HBP with a GFA inhibitor reduced AMPK activity, ACC phosphorylation, and fatty acid oxidation. These changes are not explained by alterations in the cellular AMP/ATP ratio. Further demonstrating that AMPK is regulated by the HBP, we found that AMPK was recognized by succinylated wheat germ agglutinin, which specifically binds O-GlcNAc. The levels of AMPK in succinylated wheat germ agglutinin precipitates correlated with hexosamine flux in mouse fat pads and 3T3L1 adipocytes. Moreover, removal of O-GlcNAc by hexosaminidase reduced AMPK activity. We conclude that chronically high hexosamine flux stimulates fatty acid oxidation by activating AMPK in adipocytes, in part through O-linked glycosylation.	Univ Utah, Div Endocrinol, Sch Med, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McClain, DA (corresponding author), Univ Utah, Div Endocrinol, Sch Med, 30 N 2030 E, Salt Lake City, UT 84132 USA.	donald.mcclain@hsc.utah.edu		McClain, Don/0000-0002-3310-2359	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043526, R01DK043526] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Cooksey RC, 2002, ANN NY ACAD SCI, V967, P102; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Goldberg HJ, 2006, ENDOCRINOLOGY, V147, P222, DOI 10.1210/en.2005-0523; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hazel M, 2004, ENDOCRINOLOGY, V145, P2118, DOI 10.1210/en.2003-0812; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; Matejkova O, 2004, FEBS LETT, V569, P245, DOI 10.1016/j.febslet.2004.06.002; McClain DA, 2005, AM J PHYSIOL-ENDOC M, V288, pE973, DOI 10.1152/ajpendo.00549.2004; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V8, P186; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Raile K, 2005, DIABETOLOGIA, V48, P1798, DOI 10.1007/s00125-005-1860-x; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Sakoda H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1239, DOI 10.1152/ajpendo.00455.2001; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016	54	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7172	7180		10.1074/jbc.M607362200	http://dx.doi.org/10.1074/jbc.M607362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17227772	hybrid			2022-12-25	WOS:000245080900029
J	Ranguelova, K; Girotto, S; Gerfen, GJ; Yu, SW; Suarez, J; Metlitsky, L; Magliozzo, RS				Ranguelova, Kalina; Girotto, Stefania; Gerfen, Gary J.; Yu, Shengwei; Suarez, Javier; Metlitsky, Leonid; Magliozzo, Richard S.			Radical sites in Mycobacterium tuberculosis KatG identified using electron paramagnetic resonance spectroscopy, the three-dimensional crystal structure, and electron transfer couplings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE KATG; HIGH-FIELD EPR; PROSTAGLANDIN-H SYNTHASE; CYTOCHROME-C PEROXIDASE; TRP CROSS-LINK; TYROSYL RADICALS; ISONIAZID ACTIVATION; HYDROGEN-PEROXIDE; BURKHOLDERIA-PSEUDOMALLEI; RIBONUCLEOTIDE REDUCTASE	Catalase-peroxidase (KatG) from Mycobacterium tuberculosis, a Class I peroxidase, exhibits high catalase activity and peroxidase activity with various substrates and is responsible for activation of the commonly used antitubercular drug, isoniazid (INH). KatG readily forms amino acid-based radicals during turnover with alkyl peroxides, and this work focuses on extending the identification and characterization of radicals forming on the millisecond to second time scale. Rapid freeze-quench electron paramagnetic resonance spectroscopy (RFQ-EPR) reveals a change in the structure of the initially formed radical in the presence of INK Heme pocket binding of the drug and knowledge that KatG[Y229F] lacks this signal provides evidence for radical formation on residue Tyr(229). High field RFQ-EPR spectroscopy confirmed a tryptophanyl radical signal, and new analyses of X-band RFQ-EPR spectra also established its presence. High field EPR spectroscopy also confirmed that the majority radical species is a tyrosyl radical. Site-directed mutagenesis, along with simulations of EPR spectra based on x-ray structural data for particular tyrosine and tryptophan residues, enabled assignments based on predicted hyperfine coupling parameters. KatG mutants W107F, Y229F, and the double mutant W107F/Y229F showed alteration in type and yield of radical species. Results are consistent with formation of a tyrosyl radical reasonably assigned to residue Tyr 229 within the first few milliseconds of turnover. This is followed by a mixture of tyrosyl and tryptophanyl radical species and finally to only a tyrosyl radical on residue Tyr 353, which lies more distant from the heme. The radical processing of enzyme lacking the Trp(107)Tyr(229) -Met(255) adduct (found as a unique structural feature of catalase-peroxidases) is suggested to be a reasonable assignment of the phenomena.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Dept Biochem, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; Yeshiva University; Albert Einstein College of Medicine	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.	rmaglioz@brooklyn.cuny.edu	Girotto, Stefania/F-5997-2012		NIAID NIH HHS [R01 AI060014, R01 AI043582-03, R56 AI060014, AI-43582, AI-060014] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582, R56AI060014, R01AI060014] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; Bhaskar B, 2003, J MOL BIOL, V328, P157, DOI 10.1016/S0022-2836(03)00179-7; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; BURGHAUS O, 1992, MEAS SCI TECHNOL, V3, P765, DOI 10.1088/0957-0233/3/8/013; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Deemagarn T, 2005, J MOL BIOL, V345, P21, DOI 10.1016/j.jmb.2004.10.020; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; FESSENDEN RW, 1963, J CHEM PHYS, V39, P2147, DOI 10.1063/1.1701415; Ghiladi RA, 2005, BIOCHEMISTRY-US, V44, P15093, DOI 10.1021/bi051463q; Ghiladi RA, 2005, J AM CHEM SOC, V127, P13428, DOI 10.1021/ja054366t; Ghiladi RA, 2005, J BIOL CHEM, V280, P22651, DOI 10.1074/jbc.M502486200; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Jakopitsch C, 2005, J BIOL CHEM, V280, P42411, DOI 10.1074/jbc.M508009200; Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3; Jakopitsch C, 2002, J INORG BIOCHEM, V91, P78, DOI 10.1016/S0162-0134(02)00374-4; Jakopitsch C, 2006, J INORG BIOCHEM, V100, P1091, DOI 10.1016/j.jinorgbio.2006.02.009; Janovsky I, 2004, CHEM-EUR J, V10, P5524, DOI 10.1002/chem.200400401; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Kapetanaki S, 2003, BIOCHEMISTRY-US, V42, P3835, DOI 10.1021/bi026992y; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; Liang ZX, 2004, J AM CHEM SOC, V126, P2785, DOI 10.1021/ja038163l; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; OMalley PJ, 1995, BBA-BIOENERGETICS, V1232, P175, DOI 10.1016/0005-2728(95)00102-6; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P1734, DOI 10.1021/bi00173a016; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; Sherman DR, 1999, BIOFACTORS, V10, P211, DOI 10.1002/biof.5520100219; Shi WJ, 2000, BIOCHEMISTRY-US, V39, P4112, DOI 10.1021/bi992561c; Sipe HJ, 2004, CHEM RES TOXICOL, V17, P226, DOI 10.1021/tx0341759; Smulevich G, 2006, J INORG BIOCHEM, V100, P568, DOI 10.1016/j.jinorgbio.2006.01.033; Svistunenko DA, 2004, BIOPHYS J, V87, P582, DOI 10.1529/biophysj.104.041046; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Todorovic S, 1999, J AM CHEM SOC, V121, P10962, DOI 10.1021/ja9918674; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; Zhao XB, 2006, BIOCHEMISTRY-US, V45, P4131, DOI 10.1021/bi051967o; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	50	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6255	6264		10.1074/jbc.M607309200	http://dx.doi.org/10.1074/jbc.M607309200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204474	Green Accepted, hybrid			2022-12-25	WOS:000244867200031
J	Rivard, CJ; Brown, LM; Almeida, NE; Maunsbach, AB; Pihakaski-Maunsbach, K; Andres-Hernando, A; Capasso, JM; Berl, T				Rivard, Christopher J.; Brown, Lewis M.; Almeida, Nestor E.; Maunsbach, Arvid B.; Pihakaski-Maunsbach, Kaarina; Andres-Hernando, Ana; Capasso, Juan M.; Berl, Tomas			Expression of the calcium-binding protein S100A4 is markedly up-regulated by osmotic stress and is involved in the renal osmoadaptive response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; NONMUSCLE MYOSIN; PLASMA-PROTEOME; HEAVY-CHAIN; CELL-LINE; RAT; METASTASIS; GENE; P9KA; KINASE	Proteomic analysis of Inner Medullary Collecting Duct (IMCD3) cells adapted to increasing levels of tonicity (300,600, and 900 mosmol/kg H2O) by two-dimensional. difference gel electrophoresis and mass spectrometry revealed several proteins as yet unknown to be up-regulated in response to hypertonic stress. Of these proteins, one of the most robustly up-regulated (22-fold) was S100A4. The identity of the protein was verified by high pressure liquid chromatography-mass spectrometry. Western blot analysis confirmed increased expression with increased tonicity, both acute and chronic. S10OA4 protein expression was further confirmed by immunocytochemical analysis. Cells grown in isotonic conditions showed complete absence of immunostaining, whereas chronically adapted IMCD3 cells had uniform cytoplasmic localization. The protein is also regulated in vivo as in mouse kidney tissues S10OA4 expression was many -fold greater in the papilla as compared with the cortex and increased further in the papilla upon 36 h of thirsting. Increased expression of S10OA4 was also observed in the medulla and papilla, but not the cortex of a human kidney. Data from Affymetrix gene chip analysis and quantitative PCR also revealed increased S10OA4 message in IMCD3 cells adapted to hypertonicity. The initial expression of message increased at 8-10 h following exposure to acute sublethal hypertonic stress (550 mosmol/kg H2O). Protein and message half-life in IMCD3 cells were 85.5 and 6.8 h, respectively. Increasing medium tonicity with NaCl, sucrose, mannitol, and choline-chloride stimulated S10OA4 expression, whereas urea did not. Silencing of S10OA4 expression using a stable siRNA vector (pSM2; Open Biosystems) resulted in a 48-h delay in adaptation of IMCD3 cells under sublethal osmotic stress, suggesting S10OA4 is involved in the osmoadaptive response. In summary, we describe the heretofore unrecognized up-regulation of a small calcium-binding protein, both in vitro and in vivo, whose absence profoundly delays osmoadaptation and slows cellular growth under hypertonic conditions.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Sch Med, Denver, CO 80262 USA; Aarhus Univ, Dept Anat, Walter & Salt Res Ctr, DK-8000 Aarhus, Denmark	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Aarhus University	Berl, T (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Sch Med, 4200 E 9th Ave,MS C-281, Denver, CO 80262 USA.	tomas.berl@uchsc.edu	Almeida, Nestor/AAJ-9569-2020	Almeida, Nestor/0000-0001-6907-6028; Andres-Hernando, Ana/0000-0002-0676-0188	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066544, P01DK019928] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK066544-01A1S1, R01 DK066544-02, DK-66544, R01 DK066544-03, P01 DK019928-280021, DK-19928, P01 DK019928-270021, P01 DK019928-26A10021, R01 DK066544-01A1, P01 DK019928, R01 DK066544, R01 DK066544-03S1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson NL, 2004, MOL CELL PROTEOMICS, V3, P311, DOI 10.1074/mcp.M300127-MCP200; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; Blake CA, 2005, EXP BIOL MED, V230, P800, DOI 10.1177/153537020523001104; Bustamante M, 2003, AM J PHYSIOL-RENAL, V285, pF336, DOI 10.1152/ajprenal.00003.2003; Capasso JM, 2001, P NATL ACAD SCI USA, V98, P13414, DOI 10.1073/pnas.231309198; Capasso JM, 2001, AM J PHYSIOL-RENAL, V280, pF768, DOI 10.1152/ajprenal.2001.280.5.F768; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ebner HL, 2005, AM J PHYSIOL-REG I, V289, pR877, DOI 10.1152/ajpregu.00170.2005; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kato C, 2005, BIOCHEM BIOPH RES CO, V326, P147, DOI 10.1016/j.bbrc.2004.11.010; KLAWITTER J, 2005, J AM SOC NEPHOL, V16, pA571; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Le Hir M, 2005, HISTOCHEM CELL BIOL, V123, P335, DOI 10.1007/s00418-005-0788-z; Levett D, 2002, AM J PATHOL, V160, P693, DOI 10.1016/S0002-9440(10)64889-4; Li XH, 2005, PROTEOMICS, V5, P3423, DOI 10.1002/pmic.200401226; Li ZH, 2003, BIOCHEMISTRY-US, V42, P14258, DOI 10.1021/bi0354379; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Mandinova A, 1998, J CELL SCI, V111, P2043; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Pisitkun T, 2006, PHYSIOL GENOMICS, V25, P263, DOI 10.1152/physiolgenomics.00214.2005; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Ravasi T, 2004, GENOMICS, V84, P10, DOI 10.1016/j.ygeno.2004.02.002; Rivard CJ, 2003, J AM SOC NEPHROL, V14, p56A; Robertson H, 2004, J AM SOC NEPHROL, V15, P390, DOI 10.1097/01.ASN.0000108521.39082.E1; Tian W, 2002, AM J PHYSIOL-RENAL, V283, pF388, DOI 10.1152/ajprenal.00031.2002; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2	36	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6644	6652		10.1074/jbc.M609432200	http://dx.doi.org/10.1074/jbc.M609432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200116	Green Accepted, hybrid			2022-12-25	WOS:000244867200073
J	Berchiche, YA; Chow, KY; Lagane, B; Leduc, M; Percherancier, Y; Fujii, N; Tamamura, H; Bachelerie, F; Heveker, N				Berchiche, Yamina A.; Chow, Ken Y.; Lagane, Bernard; Leduc, Martin; Percherancier, Yann; Fujii, Nobutaka; Tamamura, Hirokazu; Bachelerie, Francoise; Heveker, Nikolaus			Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G alpha(i) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; AGONIST; EFFICACY; MUTATION; MODELS	Ligand binding to G protein-coupled receptors (GPCRs) is thought to induce changes in receptor conformation that translate into activation of downstream effectors. The link between receptor conformation and activity is still insufficiently understood, as current models of GPCR activation fail to take an increasing amount of experimental data into account. To elucidate structure-function relationships in GPCR activation, we used bioluminescence resonance energy transfer to directly assess the conformation of mutants of the chemokine receptor CXCR4. We analyzed substitutions in the arginine cage DRY motif and in the conserved asparagine N(3.35)119, which are pivotal molecular switches for receptor conformation and activation. G alpha(i) activation of the mutants was either similar to wildtype CXCR4 (D133N, Y135A, and N119D) or resulted in loss of activity (R134A and N119K). Mutant N119S was constitutively active but further activated by agonist. Bioluminescence resonance energy transfer analysis suggested no simple correlation between conformational changes in response to ligand binding and activation of Gat by the mutants. Different conformations of active receptors were detected (for wild-type CXCR4, D133N, and N119S), suggesting that different receptor conformations are able to trigger Gai activity. Several conformations were also found for inactive mutants. These data provide biophysical evidence for different receptor conformations being active with respect to a single readout. They support models of GPCR structure-activity relationships that take this conformational flexibility of active receptors into account.	Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1J4, Canada; Inst Pasteur, Unite Pathogenie Virale Mol, F-75015 Paris, France; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Tokyo Med & Dent Univ, Dept Mol Recognit, Inst Biomat & Bioengn, Tokyo 1010062, Japan	Universite de Montreal; Universite de Montreal; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Kyoto University; Tokyo Medical & Dental University (TMDU)	Heveker, N (corresponding author), Hop St Justine, Ctr Rech, 6737,3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	nikolaus.heveker@recherche-ste-justine.qc.ca	Heveker, Nikolaus/G-5306-2012; BACHELERIE, FRANCOISE/F-8823-2013; Lagane, Bernard/AAA-2205-2019; Lagane, Bernard/K-8446-2016	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Lagane, Bernard/0000-0002-3459-7867; percherancier, yann/0000-0002-2410-5806; Berchiche, Yamina/0000-0002-9559-9209				Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Cotecchia S, 2003, ASSAY DRUG DEV TECHN, V1, P311, DOI 10.1089/15406580360545125; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kenakin T, 2002, TRENDS PHARMACOL SCI, V23, P275, DOI 10.1016/S0165-6147(02)02036-9; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; Onaran HO, 1997, ANN NY ACAD SCI, V812, P98, DOI 10.1111/j.1749-6632.1997.tb48150.x; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Springael JY, 2006, MOL PHARMACOL, V69, P1652, DOI 10.1124/mol.105.019414; Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	23	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5111	5115		10.1074/jbc.C600270200	http://dx.doi.org/10.1074/jbc.C600270200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17197449	hybrid			2022-12-25	WOS:000244482300004
J	Vandebrouck, A; Sabourin, J; Rivet, J; Balghi, H; Sebille, S; Kitzis, A; Raymond, G; Cognard, C; Bourmeyster, N; Constantin, B				Vandebrouck, Aurelie; Sabourin, Jessica; Rivet, Jerome; Balghi, Haouria; Sebille, Stephane; Kitzis, Alain; Raymond, Guy; Cognard, Christian; Bourmeyster, Nicolas; Constantin, Bruno			Regulation of capacitative calcium entries by alpha 1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha 1-syntrophin	FASEB JOURNAL			English	Article						dystrophic muscle; store-operated calcium entries; TRP channels; scaffolding proteins	ALPHA-SYNTROPHIN; CATION CHANNEL; MUSCLE-FIBERS; PROTEIN; MDX; BINDING; INFLUX; CA2+; DYSTROBREVIN; EXPRESSION	Calcium mishandling in Duchenne dystrophic muscle suggested that dystrophin, a membrane-associated cytoskeleton protein, might regulate calcium signaling cascade such as calcium influx pathway. It was previously shown that abnormal calcium entries involve uncontrolled stretch-activated currents and store-operated Ca2+ currents supported by TRPC1 channels. Moreover, our recent work demonstrated that reintroduction of minidystrophin in dystrophic myotubes restores normal capacitative calcium entries (CCEs). However, until now, no molecular link between the dystrophin complex and calcium entry channels has been described. This study is the first to show by coimmunoprecipitation assays the molecular association of TRPC1 with dystrophin and alpha 1-syntrophin in muscle cells. TRPC1 was also associated with alpha 1-syntrophin in dystrophic muscle cells independently of dystrophin. Furthermore, glutathione S-transferase (GST) pull-down assays showed that TRPC1 binds to the alpha 1-syntrophin PDZ domain. Transfected recombinant alpha 1-syntrophin formed a complex with TRPC1 channels and restored normal CCEs in dystrophic muscle cells. We suggest that normal regulation of CCEs in skeletal muscle depends on the association between TRPC1 channels and alpha 1-syntrophin that may anchor the store-operated channels to the dystrophin-associated protein complex (DAPC). The loss of this molecular association could participate in the calcium alterations observed in dystrophic muscle cells. This study provides a new model for the regulation of calcium influx by interaction with the scaffold of the DAPC in muscle cells.	Univ Poitiers, CNRS, UMR6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France; CHU Poitiers, LGCM, Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Constantin, B (corresponding author), Univ Poitiers, CNRS, UMR6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France.	bruno.constantin@univ-poitiers.fr	Sebille, Stéphane/P-7959-2016; Constantin, Bruno/AAH-6463-2021; COGNARD, Christian/P-5305-2016	Constantin, Bruno/0000-0003-1668-581X; Bourmeyster, Nicolas/0000-0002-9563-5142; Sabourin, Jessica/0000-0002-2980-8455				Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; Balghi H, 2006, J GEN PHYSIOL, V127, P171, DOI 10.1085/jgp.200509456; Compton AG, 2005, J NEUROPATH EXP NEUR, V64, P350, DOI 10.1093/jnen/64.4.350; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Ducret T, 2006, J PHYSIOL-LONDON, V575, P913, DOI 10.1113/jphysiol.2006.115154; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; Froehner SC, 1997, SOC GEN PHY, V52, P197; Gee SH, 1998, J NEUROSCI, V18, P128; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Marchand E, 2004, EXP CELL RES, V297, P363, DOI 10.1016/j.yexcr.2004.02.032; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Ou YJ, 2003, J BIOL CHEM, V278, P1915, DOI 10.1074/jbc.M209938200; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck A, 2005, FASEB J, V19, P136, DOI 10.1096/fj.04-3633fje; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vandebrouck C, 2001, NEUROMUSCULAR DISORD, V11, P72, DOI 10.1016/S0960-8966(00)00153-X; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275; Zhou YW, 2005, AM J PHYSIOL-CELL PH, V288, pC377, DOI 10.1152/ajpcell.00279.2004	40	90	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					608	617		10.1096/fj.06-6683com	http://dx.doi.org/10.1096/fj.06-6683com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202249				2022-12-25	WOS:000244686300033
J	Denning, G; Jean-Joseph, B; Prince, C; Durden, DL; Vogt, PK				Denning, G.; Jean-Joseph, B.; Prince, C.; Durden, D. L.; Vogt, P. K.			A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth	ONCOGENE			English	Article						PTEN; tumor suppressor; mutation; lipid binding; cytoplasmic localization signal	HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR; NUCLEAR-LOCALIZATION; CHROMOSOME-10 PTEN; PHOSPHATASE; PROTEIN; GENE; MEMBRANE; CANCER; CYCLE	Phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is an important negative regulator of cell growth and a tumor suppressor. Its growth-attenuating activity is based on the dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate ( PIP3), an essential second messenger for the phosphoinositide 3-kinase/Akt signaling pathway. This activity may require localization of PTEN to cytoplasmic membranes. Yet PTEN can also localize to the cell nucleus where its functions remain unclear. Here we present data that de. ne a short sequence in the N-terminal region of PTEN required for cytoplasmic localization. We will refer to this sequence as cytoplasmic localization signal ( CLS). It could function as a non-canonical signal for nuclear export or as a cytoplasmic retention signal of PTEN. Mutations within the CLS induce nuclear localization and impair growth suppressive activities of PTEN while preserving lipid phosphatase activity. We propose that nuclear localization of PTEN is not compatible with plasma membrane-targeted growth suppressive functions of PTEN.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, Atlanta, GA 30322 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Emory Univ, Sch Med, Dept Pediat,Div Pediat Hematol & Oncol, AFLAC Canc Ctr & Blood Disorder Serv, Atlanta, GA 30322 USA	Emory University; Scripps Research Institute; Emory University	Denning, G (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, 1365 Clifton Rd,Bldg C,Room 5054D, Atlanta, GA 30322 USA.	gabriela_denning@oz.ped.emory.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA094233, P01CA078045, R01CA078230, R56CA094233] Funding Source: NIH RePORTER; NCI NIH HHS [CA078230, CA078045, CA94233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Leslie NR, 2005, BIOCHEM SOC T, V33, P1507, DOI 10.1042/BST0331507; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su JD, 2003, CANCER RES, V63, P3585; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2006, CELL CYCLE, V5, P1523, DOI 10.4161/cc.5.14.3005; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798	31	81	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3930	3940		10.1038/sj.onc.1210175	http://dx.doi.org/10.1038/sj.onc.1210175			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213812				2022-12-25	WOS:000247144500003
J	Mitani, Y; Oue, N; Matsumura, S; Yoshida, K; Noguchi, T; Ito, M; Tanaka, S; Kuniyasu, H; Kamata, N; Yasui, W				Mitani, Y.; Oue, N.; Matsumura, S.; Yoshida, K.; Noguchi, T.; Ito, M.; Tanaka, S.; Kuniyasu, H.; Kamata, N.; Yasui, W.			Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy	ONCOGENE			English	Article						reg IV; apoptosis; 5-fluorouracil; serum tumor marker; SAGE; gastric cancer	DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; CELL-LINE TMK-1; GENE-EXPRESSION; COLONIC CARCINOMAS; SERIAL ANALYSIS; APOPTOSIS; SENSITIVITY; METASTASIS; SEARCH	Regenerating gene family, member 4 (Reg IV), a secreted protein, is overexpressed in several cancers, including gastric cancer (GC). In the present study, we measured Reg IV levels in sera from patients with GC by enzyme-linked immunosorbent assay. We also examined the effect of forced Reg IV expression on the apoptotic susceptibility to 5-fluorouracil(5-FU). Forced expression of Reg IV inhibited 5-FU-induced apoptosis. Induction of Bcl-2 and dihydropyrimidine dehydrogenase was involved in inhibition of apoptosis. Among 36 GC patients treated with a combination chemotherapy of low-dose 5-FU and cisplatin, all 14 Reg IV-positive patients showed no change or disease progression. The serum Reg IV concentration was similar between healthy individuals mean +/- s.e., (0.52 +/- 0.05 ng/ml) and patients with chronic-active gastritis (0.36 +/- 0.09 ng/ml). However, the serum Reg IV concentration in presurgical GC patients was signifi. cantly elevated (1.96 +/- 0.17 ng/ml), even at stage I. The diagnostic sensitivity of serum Reg IV (36.1%) was superior to that of serum carcinoembryonic antigen (11.5%) or carbohydrate antigen 19-9 (13.1%). These results indicate that expression of Reg IV is a marker for prediction of resistance to 5-FU-based chemotherapy in patients with GC. Serum Reg IV represents a novel biomarker for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Surg, Div Cervico Gnathostomatol, Hiroshima, Japan; Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Oita University; Hiroshima University; Nara Medical University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				ALLEY MC, 1988, CANCER RES, V48, P589; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bishnupuri KS, 2006, GASTROENTEROLOGY, V130, P137, DOI 10.1053/j.gastro.2005.10.001; Buckhaults P, 2001, CANCER RES, V61, P6996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS BE, 1990, CANCER RES, V50, P197; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Inada T, 2000, ANTICANCER RES, V20, P2457; Ishikawa Y, 2000, JPN J CANCER RES, V91, P105, DOI 10.1111/j.1349-7006.2000.tb00866.x; Kari C, 2003, CANCER RES, V63, P1; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim R, 1999, INT J ONCOL, V15, P921; Kochi Mitsugu, 2000, Gastric Cancer, V3, P177, DOI 10.1007/PL00011715; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393; Ukon K, 2005, CANCER RES, V65, P1055; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; YASUI W, 1988, CANCER RES, V48, P137	33	91	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4383	4393		10.1038/sj.onc.1210215	http://dx.doi.org/10.1038/sj.onc.1210215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237819	Green Submitted			2022-12-25	WOS:000247620000006
J	Schauble, S; King, CC; Darshi, M; Koller, A; Shah, K; Taylor, SS				Schauble, Sharmin; King, Charles C.; Darshi, Manjula; Koller, Antonius; Shah, Kavita; Taylor, Susan S.			Identification of ChChd3 as a novel substrate of the cAMP-dependent protein kinase (PKA) using an analog-sensitive catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNNATURAL NUCLEOTIDE SPECIFICITY; TYROSINE KINASE; CHEMICAL GENETICS; ESCHERICHIA-COLI; V-SRC; PHOSPHORYLATION; ACTIVATION; FAMILY; AUTOPHOSPHORYLATION; INHIBITOR	Due to the numerous kinases in the cell, many with overlapping substrates, it is difficult to find novel substrates for a specific kinase. To identify novel substrates of cAMP- dependent protein kinase ( PKA), the PKA catalytic subunit was engineered to accept bulky N-6-substituted ATP analogs, using a chemical genetics approach initially pioneered with v-Src ( 1). Methionine 120 was mutated to glycine in the ATP-binding pocket of the catalytic subunit. To express the stable mutant C-subunit in Escherichia coli required co-expression with PDK1. This mutant protein was active and fully phosphorylated on Thr(197) and Ser(338). Based on its kinetic properties, the engineered C-subunit preferred N-6( benzyl)-ATP and N-6( phenethyl)-ATP over other ATP analogs, but still retained a 30 mu M K-m for ATP. This mutant recombinant C-subunit was used to identify three novel PKA substrates. One protein, a novel mitochondrial ChChd protein, ChChd3, was identified, suggesting that PKA may regulate mitochondria proteins.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA.	staylor@ucsd.edu	Shah, Kavita/Y-9755-2019	Shah, Kavita/0000-0002-0451-1305	NCI NIH HHS [T32 CA009523] Funding Source: Medline; NIDDK NIH HHS [DK5441, DK071228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Dephoure N, 2005, P NATL ACAD SCI USA, V102, P17940, DOI 10.1073/pnas.0509080102; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee I, 2005, J BIOL CHEM, V280, P6094, DOI 10.1074/jbc.M411335200; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915	28	33	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14952	14959		10.1074/jbc.M609221200	http://dx.doi.org/10.1074/jbc.M609221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17242405	hybrid			2022-12-25	WOS:000246589000033
J	Novgorodov, AS; El-Alwani, M; Bielawski, J; Obeid, LM; Gudz, TI				Novgorodov, Alexander S.; El-Alwani, Mazen; Bielawski, Jacek; Obeid, Lina M.; Gudz, Tatyana I.			Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration	FASEB JOURNAL			English	Article						brain development; S1P2 receptor; FTY720; directional guidance cue	SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTORS; RHO FAMILY GTPASES; CELL-MIGRATION; GUIDANCE; FTY720; LYSOPHOSPHOLIPIDS; PROLIFERATION; MECHANISMS; INTEGRINS	Sphingosine-1-phosphate (S1P) acts as an extracellular ligand for a family of G-protein coupled receptors that are crucial in cell migration. S1P5 is exclusively expressed in oligodendrocytes and oligodendrocyte precursor cells (OPCs), which migrate considerable distances during brain development. The current studies suggest a physiological role for S1P and S1P5 in regulation of OPC migration. mRNA expression levels of S1P2 and S1P5 are comparable in OPCs, but S1P binding specifically to the S1P5 receptor blocked OPC migration (IC50 = 29 nM). Thus, knocking down S1P5 using siRNA prevented the S1P-induced decrease in OPC migration, whereas knocking down S1P2 did not have any effect. S1P-induced modulation of OPC migration was insensitive to pertussis toxin, suggesting that S1P5-initiated signaling is not mediated by the G alpha(i)-protein coupled pathway. Furthermore, S1P5 appears to engage the G alpha(12/13) protein coupled Rho/ROCK signaling pathway to impede OPC migration. To modulate OPC motility, extracellular S1P could be derived from the export of intracellular S1P generated in response to glutamate treatment of OPCs. These studies suggest that S1P could be a part of the neuron-oligodendroglial communication network regulating OPC migration and may provide directional guidance cues for migrating OPCs in the developing brain.	Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Gudz, TI (corresponding author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St, Charleston, SC 29425 USA.	gudz@musc.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; obeid, lina/0000-0002-0734-0847	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 17677-04] Funding Source: Medline; NIGMS NIH HHS [GM062887] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x; Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Bassi R, 2006, GLIA, V53, P621, DOI 10.1002/glia.20324; Behar TN, 1999, J NEUROSCI, V19, P4449; Behar TN, 1998, J NEUROSCI, V18, P6378; Belachew S, 1999, ACTA NEUROL BELG, V99, P21; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, YONSEI MED J, V45, P991, DOI 10.3349/ymj.2004.45.6.991; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Cohen RI, 2005, CELL MOL LIFE SCI, V62, P505, DOI 10.1007/s00018-004-4485-1; Deng WB, 2006, J NEUROCHEM, V98, P213, DOI 10.1111/j.1471-4159.2006.03861.x; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; GEISER T, 1993, J BIOL CHEM, V268, P15419; Goetzl EJ, 2004, J CELL BIOCHEM, V92, P867, DOI 10.1002/jcb.20186; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Gudz TI, 2006, J NEUROSCI, V26, P2458, DOI 10.1523/JNEUROSCI.4054-05.2006; Gudz TI, 2002, J NEUROSCI, V22, P7398; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, BIOCHEM BIOPH RES CO, V279, P139, DOI 10.1006/bbrc.2000.3933; Im DS, 2001, BIOCHEMISTRY-US, V40, P14053, DOI 10.1021/bi011606i; Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005; Jarjour AA, 2004, NEUROSCIENTIST, V10, P99, DOI 10.1177/1073858403260751; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawabata S, 2004, GENES CELLS, V9, P653, DOI 10.1111/j.1356-9597.2004.00749.x; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lepley D, 2005, CANCER RES, V65, P3788, DOI 10.1158/0008-5472.CAN-04-2311; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; MILNER R, 1994, DEVELOPMENT, V120, P3497; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spassky N, 2002, J NEUROSCI, V22, P5992; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sugimoto Y, 2001, DEVELOPMENT, V128, P3321; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Terai K, 2003, NEUROSCIENCE, V116, P1053, DOI 10.1016/S0306-4522(02)00791-1; Tsai HH, 2002, TRENDS NEUROSCI, V25, P173, DOI 10.1016/S0166-2236(00)02096-8; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106; Yu NC, 2004, GLIA, V45, P17, DOI 10.1002/glia.10297	66	136	150	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1503	1514		10.1096/fj.06-7420com	http://dx.doi.org/10.1096/fj.06-7420com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255471				2022-12-25	WOS:000246117000025
J	Greenstein, AE; Echols, N; Lombana, TN; King, DS; Alber, T				Greenstein, Andrew E.; Echols, Nathaniel; Lombana, T. Noelle; King, David S.; Alber, Tom			Allosteric activation by dimerization of the PknD receptor Ser/Thr protein kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASES; CRYSTAL-STRUCTURE; DOMAIN; SUBSTRATE; PHOSPHORYLATION; RECOGNITION; EMBR; AUTOPHOSPHORYLATION; IDENTIFICATION; PHOSPHATASE	To define how extracellular signals activate bacterial receptor Ser/Thr protein kinases, we characterized the regulatory functions of a weak dimer interface identified in the Mycobacterium tuberculosis PknB and PknE receptor kinases. Sequence comparisons revealed that the analogous interface is conserved in PknD orthologs from diverse bacterial species. To analyze the roles of dimerization, we constructed M. tuberculosis PknD kinase domain ( KD) fusion proteins that formed dimers upon addition of rapamycin. Dimerization of unphosphorylated M. tuberculosis PknD KD fusions stimulated phosphorylation activity. Mutations in the dimer interface reduced this activation, limited autophosphorylation, and altered substrate specificity. In contrast, an inactive catalytic site mutant retained the ability to stimulate the wild-type KD by dimerization. These results support the idea that dimer formation allosterically activates unphosphorylated PknD. The phosphorylated PknD KD was fully active even in the absence of dimerization, suggesting that phosphorylation provides an additional regulatory mechanism. The conservation of analogous dimers in diverse prokaryotic and eukaryotic Ser/Thr protein kinases implies that this mechanism of protein kinase regulation is ancient and broadly distributed.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Alber, T (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 339 Hildebrand Hall 3206, Berkeley, CA 94720 USA.	tom@ucxray.berkeley.edu		Greenstein, Andrew/0000-0002-1470-1970	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM70962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderwick LJ, 2006, P NATL ACAD SCI USA, V103, P2558, DOI 10.1073/pnas.0507766103; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Duran R, 2005, BIOCHEM BIOPH RES CO, V333, P858, DOI 10.1016/j.bbrc.2005.05.173; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P380, DOI 10.1093/nar/gkh180; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gay LM, 2006, J MOL BIOL, V360, P409, DOI 10.1016/j.jmb.2006.05.015; Good MC, 2004, J MOL BIOL, V339, P459, DOI 10.1016/j.jmb.2004.03.063; Greenstein AE, 2005, J MOL MICROB BIOTECH, V9, P167, DOI 10.1159/000089645; GREENSTEIN AE, 2007, IN PRESS PLOS PATHOG; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Madec E, 2002, MOL MICROBIOL, V46, P571, DOI 10.1046/j.1365-2958.2002.03178.x; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Ortiz-Lombardia M, 2003, J BIOL CHEM, V278, P13094, DOI 10.1074/jbc.M300660200; Padyana AK, 2005, J BIOL CHEM, V280, P29289, DOI 10.1074/jbc.M504096200; Perez J, 2006, BIOCHEM BIOPH RES CO, V348, P6, DOI 10.1016/j.bbrc.2006.06.164; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Pullen KE, 2004, STRUCTURE, V12, P1947, DOI 10.1016/j.str.2004.09.008; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharma K, 2006, FEBS J, V273, P2711, DOI 10.1111/j.1742-4658.2006.05289.x; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	31	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11427	11435		10.1074/jbc.M610193200	http://dx.doi.org/10.1074/jbc.M610193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17242402	hybrid			2022-12-25	WOS:000245941500064
J	Chen, S; Kim, JJP; Barbieri, JT				Chen, Sheng; Kim, Jung-Ja P.; Barbieri, Joseph T.			Mechanism of substrate recognition by botulinum neurotoxin serotype A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; CRYSTAL-STRUCTURE; STRUCTURAL-ANALYSIS; CLOSTRIDIUM-BOTULINUM; ANGSTROM RESOLUTION; TETANUS NEUROTOXIN; CATALYTIC DOMAIN; TOXIN; IDENTIFICATION; INHIBITORS	Botulinum neurotoxins (BoNTs) are zinc proteases that cleave SNARE proteins to elicit flaccid paralysis by inhibiting neurotransmitter-carrying vesicle fusion to the plasma membrane of peripheral neurons. Unlike other zinc proteases, BoNTs recognize extended regions of SNAP25 for cleavage; however, the molecular basis for this extended substrate recognition is unclear. Here, we define a multistep mechanism for recognition and cleavage of SNAP25 by BoNT/A. SNAP25 initially binds along the belt region of BoNT/A, which aligns the P5 residue to the S5 pocket at the periphery of the active site. Although the exact order of each step of recognition of SNAP25 by BoNT/A at the active site is not clear, the initial binding could subsequently orient the P4'-residue of SNAP25 to form a salt bridge with the S4'-residue, which opens the active site allowing the P1'-residue access to the S1'-pocket. Subsequent hydrophobic interactions between the P3 residue of SNAP25 and the S3 pocket optimize alignment of the scissile bond for cleavage. This explains how the BoNTs recognize and cleave specific coiled SNARE substrates and provides insight into the development of inhibitors to prevent botulism.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	jtb01@mcw.edu		Chen, Sheng/0000-0003-3526-7808	NIAID NIH HHS [U54 AI057153] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2005, BIOCHEMISTRY-US, V44, P8291, DOI 10.1021/bi050253a; Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; Ahmed SA, 2001, J PROTEIN CHEM, V20, P221, DOI 10.1023/A:1010952025677; Arndt JW, 2005, BIOCHEMISTRY-US, V44, P9574, DOI 10.1021/bi0505924; ARNON SS, 1978, LANCET, V1, P1273; Ascher B, 2004, Ann Chir Plast Esthet, V49, P537, DOI 10.1016/j.anplas.2004.09.002; Bajohrs M, 2004, EMBO REP, V5, P1090, DOI 10.1038/sj.embor.7400278; Baldwin MR, 2004, PROTEIN EXPRES PURIF, V37, P187, DOI 10.1016/j.pep.2004.05.009; Bhidayasiri R, 2005, J NEUROL SCI, V235, P1, DOI 10.1016/j.jns.2005.04.017; Binz T, 2002, BIOCHEMISTRY-US, V41, P1717, DOI 10.1021/bi0157969; Boldt GE, 2006, J COMB CHEM, V8, P513, DOI 10.1021/cc060010h; Breidenbach MA, 2005, BIOCHEMISTRY-US, V44, P7450, DOI 10.1021/bi050262j; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Chen S, 2006, J BIOL CHEM, V281, P10906, DOI 10.1074/jbc.M513032200; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Fu ZJ, 2006, BIOCHEMISTRY-US, V45, P8903, DOI 10.1021/bi060786z; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Klein AW, 2004, DERMATOL CLIN, V22, P197, DOI 10.1016/S0733-8635(03)00122-0; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Mandal A, 2001, EUR J GASTROEN HEPAT, V13, P603, DOI 10.1097/00042737-200105000-00024; Marvaud JC, 2002, CR BIOL, V325, P863, DOI 10.1016/S1631-0691(02)01498-1; Middlebrook JL, 1995, ADV EXP MED BIOL, V383, P93; Min D, 2004, P NATL ACAD SCI USA, V101, P14701, DOI 10.1073/pnas.0404107101; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Parpura V, 2005, CROAT MED J, V46, P491; Poulain B., 2003, Annales de Readaptation et de Medecine Physique, V46, P265, DOI 10.1016/S0168-6054(03)00114-4; Rao KN, 2005, TOXICON, V45, P929, DOI 10.1016/j.toxicon.2005.02.032; Robinson RF, 2003, ANN PHARMACOTHER, V37, P127, DOI 10.1345/aph.1C034; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Schmidt JJ, 2005, BIOCHEMISTRY-US, V44, P4067, DOI 10.1021/bi0477642; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; Sikorra S, 2006, J MOL BIOL, V357, P574, DOI 10.1016/j.jmb.2005.12.075; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8	39	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9621	9627		10.1074/jbc.M611211200	http://dx.doi.org/10.1074/jbc.M611211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244603	hybrid			2022-12-25	WOS:000245421700035
J	Jeyakumar, M; Liu, XF; Erdjument-Bromage, H; Tempst, P; Bagchi, MK				Jeyakumar, M.; Liu, Xue-feng; Erdjument-Bromage, Hediye; Tempst, Paul; Bagchi, Milan K.			Phosphorylation of thyroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; N-COR; PROGESTERONE-RECEPTOR; CATALYTIC SUBUNIT; BINDING DOMAIN; LIGASE-III; IN-VITRO; COMPLEX; TRANSCRIPTION; REPRESSION	It is well documented that unliganded thyroid hormone receptor (TR) functions as a transcriptional repressor of specific cellular target genes by acting in concert with a corepressor complex harboring histone deacetylase (HDAC) activity. To fully explore the cofactors that interact with the transcriptionally repressive form of TR, we biochemically isolated a multiprotein complex that assembles on a TR-retinoid X receptor (RXR) heterodimer in HeLa nuclear extracts and identified its polypeptide components by mass spectrometry. A subset of TR-RXRassociated polypeptides included NCoR, SMRT, TBLI, and HDAC3, which represent the core components of a previously described NCoR/SMRT corepressor complex. We also identified several polypeptides that constitute a DNA-dependent protein kinase (DNA-PK) enzyme complex, a regulator of DNA repair, recombination, and transcription. These polypeptides included the catalytic subunit DNA-PKcs, the regulatory subunits Ku70 and Ku86, and the poly(ADP-ribose) polymerase 1. Density gradient fractionation and immunoprecipitation analyses provided evidence for the existence of a high molecular weight TR-RXR-corepressor holocomplex containing both NCoR/SMRT and DNA-PK complexes. Chromatin immunoprecipitation studies confirmed that unliganded TR-RXR recruits both complexes to the triiodothyronine-responsive region of growth hormone gene in vivo. Interestingly, DNAPKcs, a member of the phosphatidylinositol 3-kinase family, was found to phosphorylate HDAC3 when the purified TR-RXR-corepressor holocomplex was incubated with ATP. This phosphorylation was accompanied by a significant enhancement of the HDAC activity of this complex. Collectively, our results indicated that DNA-PK promotes the establishment of a repressive chromatin at a TR target promoter by enhancing the HDAC activity of the receptor-bound NCoR/SMRT corepressor complex.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Illinois System; University of Illinois Urbana-Champaign; Memorial Sloan Kettering Cancer Center	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 534 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIDDK NIH HHS [DK50257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li QX, 2004, J BIOL CHEM, V279, P11570, DOI 10.1074/jbc.M311773200; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Mortusewicz O, 2006, NUCLEIC ACIDS RES, V34, P3523, DOI 10.1093/nar/gkl492; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Soubeyrand S, 2003, CANCER RES, V63, P1198; SUEN CS, 1994, J BIOL CHEM, V269, P1314; Tong GX, 1996, MOL CELL BIOL, V16, P1909; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Watrin E, 2006, EXP CELL RES, V312, P2687, DOI 10.1016/j.yexcr.2006.06.024; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yen PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI 10.1016/j.mce.2005.11.030; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005	59	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9312	9322		10.1074/jbc.M609009200	http://dx.doi.org/10.1074/jbc.M609009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17242407	hybrid			2022-12-25	WOS:000245421700003
J	Dupont, E; Prochiantz, A; Joliot, A				Dupont, Edmond; Prochiantz, Alain; Joliot, Alain			Identification of a signal peptide for unconventional secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; ISCHEMIC BRAIN INJURY; PLASMA-MEMBRANE; ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX; PROTEIN; TRANSCYTOSIS; PERMEATION; DELIVERY; PATHWAY	Homeoproteins are a class of transcription factors defined by the structure of their DNA-binding domain, the homeodomain. In addition to their nuclear cell-autonomous activities, homeoproteins transfer between cells, thanks to two separate steps of secretion and internalization, which both rely on unconventional mechanisms. Internalization is driven by the third helix of the homeodomain (Penetratin) through a non-vesicular and endocytosis-independent mechanism. In contrast, homeoprotein secretion involves vesicular compartments and requires the presence of a sequence of 11 amino acids (Sec sequence) spanning between the second and third helix of the homeodomain. In this study, we report that the SecPen polypeptide, which combines the two identified domains, Penetratin and Sec, bears all of the necessary information to go in and out of cells. We have analyzed key mechanisms and demonstrated that this peptide can efficiently cross a tight junction epithelium.	Ecole Normale Super, CNRS, UMR8542, Homeoprot Cell Biol Grp, F-75230 Paris 05, France; Ecole Normale Super, CNRS, UMR8542, Dev & Neuropharmacol Grp, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS)	Joliot, A (corresponding author), Ecole Normale Super, CNRS, UMR8542, Homeoprot Cell Biol Grp, 46 Rue Ulm, F-75230 Paris 05, France.	joliot@biologie.ens.fr						Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Brunet I, 2005, NATURE, V438, P94, DOI 10.1038/nature04110; Cao GD, 2002, J NEUROSCI, V22, P5423; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUPONT E, 2002, PHARM TOXIC, P23; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; Joliot A, 1997, DEVELOPMENT, V124, P1865; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760; Maizel A, 2002, DEVELOPMENT, V129, P3545; Maizel A, 1999, DEVELOPMENT, V126, P3183; Nedelec S, 2004, P NATL ACAD SCI USA, V101, P10815, DOI 10.1073/pnas.0403824101; NIBBERING PH, 1996, FRONT BIOSCI, V1, P25; Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SUGIYAMA S, 2005, SOC NEUROSCI; Tasssetto M, 2005, EMBO REP, V6, P885, DOI 10.1038/sj.embor.7400487; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Trehin R, 2004, PHARM RES-DORDR, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3; Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; WAN JS, 1992, J BIOL CHEM, V267, P13446; Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y	29	63	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8994	9000		10.1074/jbc.M609246200	http://dx.doi.org/10.1074/jbc.M609246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242404	hybrid			2022-12-25	WOS:000245780300046
J	East, CJ; Stanton, H; Golub, SB; Rogerson, FM; Fosang, AJ				East, Charlotte J.; Stanton, Heather; Golub, Suzanne B.; Rogerson, Fraser M.; Fosang, Amanda J.			ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-INDUCED ARTHRITIS; HUMAN ARTICULAR-CARTILAGE; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; INTERGLOBULAR DOMAIN; EXTRACELLULAR-MATRIX; PIVOTAL ROLE; IN-VITRO; PROTEOGLYCAN; DEGRADATION	In the mouse, proteolysis in the aggrecan interglobular domain is driven by ADAMTS-5, and mice deficient in ADAMTS-5 catalytic activity are protected against aggrecan loss and cartilage damage in experimental models of arthritis. Here we show that despite ablation of ADAMTS-5 activity, aggrecanolysis can still occur at two preferred sites in the chondroitin sulfate-rich region. Retinoic acid was more effective than interleukin-1 alpha (IL) in promoting cleavage at these sites in ADAMTS-5-deficient cartilage. These results suggest that cleavage at preferred sites in the chondroitin sulfate-rich region is mediated by ADAMTS-4 or an aggrecanase other than ADAMTS-5. Following retinoic acid or IL-1 alpha stimulation of cartilage explants, aggrecan fragments in medium and extracts contained SELE1279 orFREEE(1467) C-terminal sequences. Some SELE1279 and FREEE1467 fragments were retained in the cartilage, with intact G1 domains. Other SELE1279 fragments were released into the medium and co-migrated with the (374)ALGS neoepitope, indicating they were aggrecanase-derived fragments. In contrast none of the FREEE1467 fragments released into the medium co-migrated with the (374)ALGS neoepitope, suggesting that, despite their size, these fragments were not products of aggrecanase cleavage in the interglobular domain. ADAMTS-5, but not ADAMTS-1, -4, or -9, was up-regulated 8-fold by retinoic acid and 17-fold by IL-1 alpha treatment. The data show that whereas ADAMTS-5 is entirely responsible for cleavage in the interglobular domain, cleavage in the chondroitin sulfate-rich region is driven either by ADAMTS-4, which compensates for loss of ADAMTS-5 in this experimental system, or possibly by another aggrecanase. The data show that there are differential aggrecanase activities with preferences for separate regions of the core protein.	Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Fosang, AJ (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia.	amanda.fosang@mcri.edu.au		Fosang, Amanda/0000-0002-5523-5427; STANTON, HEATHER/0000-0002-3427-5614				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Chockalingam PS, 2004, ARTHRITIS RHEUM-US, V50, P2839, DOI 10.1002/art.20496; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; DENNIS JE, 1990, J BIOL CHEM, V265, P12098; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Hui W, 2005, ANN RHEUM DIS, V64, P1624, DOI 10.1136/ard.2004.028191; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Jones GC, 2005, ARTHRITIS RES THER, V7, P160, DOI 10.1186/ar1783; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Little CB, 2005, ARTHRITIS RHEUM-US, V52, P1461, DOI 10.1002/art.21022; Little CB, 2005, MOL CELL BIOL, V25, P3388, DOI 10.1128/MCB.25.8.3388-3399.2005; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; Mort JS, 2003, BIOCHEM SOC SYMP, V70, P107, DOI 10.1042/bss0700107; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Roughley PJ, 2003, BIOCHEM J, V375, P183, DOI 10.1042/BJ20030609; Sandy J.D., 2000, BIOCHEM J, V351, P1, DOI [10.1042/bj3510161, DOI 10.1042/BJ3510161]; Sandy JD, 1998, BIOCHEM J, V335, P59, DOI 10.1042/bj3350059; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Stewart MC, 2006, OSTEOARTHR CARTILAGE, V14, P392, DOI 10.1016/j.joca.2005.11.009; Sugimoto K, 2004, OSTEOARTHR CARTILAGE, V12, P1006, DOI 10.1016/j.joca.2004.09.003; Sztrolovics R, 2002, BIOCHEM J, V362, P473, DOI 10.1042/0264-6021:3620473; Sztrolovics R, 2002, BIOCHEM J, V362, P465, DOI 10.1042/0264-6021:3620465; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs J, 1999, J IMMUNOL, V163, P5633; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2	55	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8632	8640		10.1074/jbc.M605750200	http://dx.doi.org/10.1074/jbc.M605750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255106	hybrid			2022-12-25	WOS:000245780300009
J	Ivarsson, Y; Travaglini-Allocatelli, C; Jemth, P; Malatesta, F; Brunori, M; Gianni, S				Ivarsson, Ylva; Travaglini-Allocatelli, Carlo; Jemth, Per; Malatesta, Francesco; Brunori, Maurizio; Gianni, Stefano			An on-pathway intermediate in the folding of a PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATES; KINETIC-ANALYSIS; MECHANISM; BARNASE; BINDING; PROTEINS; EXCHANGE; REVEAL; MODEL	The folding pathways of some proteins include the population of partially structured species en route to the native state. Identification and characterization of these folding intermediates are particularly difficult as they are often only transiently populated and play different mechanistic roles, being either on-pathway productive species or off-pathway kinetic traps. To define the role of folding intermediates, a quantitative analysis of the folding and unfolding rate constants over a wide range of denaturant concentration is often required. Such a task is further complicated by the reversible nature of the folding reaction, which implies the observed kinetics to be governed by a complex combination of different microscopic rate constants. Here, we tackled this problem by measuring directly the folding rate constant under highly denaturing conditions, namely by inducing the folding of a PDZ domain through a quasi-irreversible binding reaction with a specific peptide. In analogy with previous works based on hydrogen exchange experiments, we present evidence that the folding pathway of the PDZ domain involves the formation of an obligatory on-pathway intermediate. The results presented exemplify a novel type of kinetic test to detect an on-pathway folding intermediate.	Univ Roma La Sapienza, Ist Biol & Patol Mol, CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Aquila, Dept Pure & Appl Biol, I-67010 Coppito, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Uppsala University; University of L'Aquila	Gianni, S (corresponding author), Univ Roma La Sapienza, Ist Biol & Patol Mol, CNR, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	stefano.gianni@uniromal.it	Malatesta, Francesco/AAT-4757-2020; Ivarsson, Ylva/HGE-0283-2022; gianni, stefano/C-8536-2009	Ivarsson, Ylva/0000-0002-7081-3846; Gianni, Stefano/0000-0003-1653-1925; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Brunori, Maurizio/0000-0002-7795-1635				BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Feng HQ, 2005, J MOL BIOL, V346, P345, DOI 10.1016/j.jmb.2004.11.040; Ferraro DM, 2004, BIOCHEMISTRY-US, V43, P587, DOI 10.1021/bi035943y; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P14121, DOI 10.1073/pnas.260502597; Gianni S, 2005, J BIOL CHEM, V280, P34805, DOI 10.1074/jbc.M506017200; Gianni S, 2005, PROTEIN ENG DES SEL, V18, P389, DOI 10.1093/protein/gzi047; Gianni S, 2007, P NATL ACAD SCI USA, V104, P128, DOI 10.1073/pnas.0602770104; Gianni S, 2006, STRUCTURE, V14, P1801, DOI 10.1016/j.str.2006.10.010; Hedberg L, 2004, P NATL ACAD SCI USA, V101, P7606, DOI 10.1073/pnas.0308497101; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Khan F, 2003, J MOL BIOL, V333, P169, DOI 10.1016/j.jmb.2003.08.024; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OLSON ST, 1981, J BIOL CHEM, V256, P1073; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; Sanchez IE, 2003, J MOL BIOL, V325, P367, DOI 10.1016/S0022-2836(02)01230-5; SANZ JM, 1994, FEBS LETT, V344, P216, DOI 10.1016/0014-5793(94)00384-X; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Takei L, 2000, P NATL ACAD SCI USA, V97, P10796, DOI 10.1073/pnas.190265797; Teilum K, 2002, P NATL ACAD SCI USA, V99, P9807, DOI 10.1073/pnas.152321499; Ternstrom T, 1999, P NATL ACAD SCI USA, V96, P14854, DOI 10.1073/pnas.96.26.14854	30	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8568	8572		10.1074/jbc.M611026200	http://dx.doi.org/10.1074/jbc.M611026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17251182	hybrid			2022-12-25	WOS:000245780300002
J	Matarrese, P; Falzano, L; Fabbri, A; Gambardella, L; Frank, C; Geny, B; Popoff, MR; Malorni, W; Fiorentini, C				Matarrese, Paola; Falzano, Loredana; Fabbri, Alessia; Gambardella, Lucrezia; Frank, Claudio; Geny, Blandine; Popoff, Michel R.; Malorni, Walter; Fiorentini, Carla			Clostridium difficile toxin B causes apoptosis in epithelial cells by thrilling mitochondria - Involvement of ATP-sensitive mitochondrial potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYLORI VACUOLATING CYTOTOXIN; CEREBELLAR GRANULE NEURONS; NECROSIS-FACTOR-ALPHA; HELICOBACTER-PYLORI; NEISSERIA-GONORRHOEAE; DEATH PATHWAY; LETHAL TOXIN; NITRIC-OXIDE; K+ CHANNELS; RHO-GTPASES	Targeting to mitochondria is emerging as a common strategy that bacteria utilize to interact with these central executioners of apoptosis. Several lines of evidence have in fact indicated mitochondria as specific targets for bacterial protein toxins, regarded as the principal virulence factors of pathogenic bacteria. This work shows, for the first time, the ability of the Clostridium difficile toxin B (TcdB), a glucosyltransferase that inhibits the Rho GTPases, to impact mitochondria. In living cells, TcdB provokes an early hyperpolarization of mitochondria that follows a calcium-associated signaling pathway and precedes the final execution step of apoptosis (i.e. mitochondria depolarization). Importantly, in isolated mitochondria, the toxin can induce a calcium-dependent mitochondrial swelling, accompanied by the release of the proapoptogenic factor cytochrome c. This is consistent with a mitochondrial targeting that does not require the Rho-inhibiting activity of the toxin. Of interest, the mitochondrial ATP-sensitive potassium channels are also involved in the apoptotic response to TcdB and appear to be crucial for the cell death execution phase, as demonstrated by using specific modulators of these channels. To our knowledge, the involvement of these mitochondrial channels in the ability of a bacterial toxin to control cell fate is a hitherto unreported finding.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; Inst Pasteur, Unite Toxines Microbiennes, F-75724 Paris 15, France	Istituto Superiore di Sanita (ISS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fiorentini, C (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	carla.fiorentini@iss.it	Matarrese, Paola/A-4369-2014; Malorni, Walter/G-5874-2016; FRANK, CLAUDIO/A-6642-2015; Fiorentini, Carla/Q-2088-2015; Fabbri, Alessia/AAA-4594-2019; FIORENTINI, CARLA/AAG-8005-2019	FRANK, CLAUDIO/0000-0002-6016-5750; Fiorentini, Carla/0000-0003-1707-6282; Fabbri, Alessia/0000-0002-3075-3367; FIORENTINI, CARLA/0000-0003-1707-6282; malorni, walter/0000-0002-1223-7000; falzano, loredana/0000-0003-4074-180X				Bantel H, 2001, J CELL BIOL, V155, P637, DOI 10.1083/jcb.200105081; Blanke SR, 2005, TRENDS MICROBIOL, V13, P64, DOI 10.1016/j.tim.2004.12.007; Boquet P, 2003, TRENDS MICROBIOL, V11, P410, DOI 10.1016/S0966-842X(03)00211-7; Buttner D, 2002, TRENDS MICROBIOL, V10, P186, DOI 10.1016/S0966-842X(02)02331-4; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Cover TL, 2005, NAT REV MICROBIOL, V3, P320, DOI 10.1038/nrmicro1095; Cover TL, 2003, CANCER RES, V63, P951; D HE, 2000, GASTROENTEROLOGY, V119, P139, DOI 10.1053/gast.2000.8526; Dahlem YA, 2004, BBA-BIOENERGETICS, V1656, P46, DOI 10.1016/j.bbabio.2004.01.003; Debska G, 2001, BRAIN RES, V892, P42, DOI 10.1016/S0006-8993(00)03187-5; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Eliseev RA, 2004, J BIOL CHEM, V279, P46748, DOI 10.1074/jbc.M406217200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiorentini C, 1998, INFECT IMMUN, V66, P2660, DOI 10.1128/IAI.66.6.2660-2665.1998; Fiorentini C, 2003, CELL DEATH DIFFER, V10, P147, DOI 10.1038/sj.cdd.4401151; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gerhard R, 2005, MICROB PATHOGENESIS, V38, P77, DOI 10.1016/j.micpath.2004.12.002; Giovannini C, 2002, FEBS LETT, V523, P200, DOI 10.1016/S0014-5793(02)02972-1; Gohil VM, 2004, J BIOL CHEM, V279, P42612, DOI 10.1074/jbc.M402545200; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Guichon A, 2001, J BACTERIOL, V183, P1269, DOI 10.1128/JB.183.4.1269-1276.2001; Hamm EE, 2006, P NATL ACAD SCI USA, V103, P14176, DOI 10.1073/pnas.0604725103; Haslinger B, 2003, CELL MICROBIOL, V5, P729, DOI 10.1046/j.1462-5822.2003.00317.x; He D, 2002, GASTROENTEROLOGY, V122, P1048, DOI 10.1053/gast.2002.32386; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kenny B, 2000, CELL MICROBIOL, V2, P579, DOI 10.1046/j.1462-5822.2000.00082.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lazebnik Y, 2001, CURR BIOL, V11, pR767, DOI 10.1016/S0960-9822(01)00465-1; Le SS, 2005, J NEUROCHEM, V94, P1025, DOI 10.1111/j.1471-4159.2005.03252.x; Liu D, 2003, J NEUROCHEM, V86, P966, DOI 10.1046/j.1471-4159.2003.01913.x; Liu HP, 2002, AM J PHYSIOL-HEART C, V282, pH1380, DOI 10.1152/ajpheart.00348.2001; Liu YG, 1999, ANN NY ACAD SCI, V874, P27, DOI 10.1111/j.1749-6632.1999.tb09222.x; Loucks FA, 2006, J NEUROCHEM, V97, P957, DOI 10.1111/j.1471-4159.2006.03802.x; Lucattini R, 2004, MOL BIOL EVOL, V21, P652, DOI 10.1093/molbev/msh058; Ma GZ, 2004, NEUROREPORT, V15, P1813, DOI 10.1097/01.wnr.0000135694.89237.3d; Malish HR, 2003, APOPTOSIS, V8, P179, DOI 10.1023/A:1022974710488; Matarrese P, 2003, J IMMUNOL, V170, P6006, DOI 10.4049/jimmunol.170.12.6006; Matarrese P, 2002, AM J PATHOL, V160, P1507, DOI 10.1016/S0002-9440(10)62577-1; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; Muller A, 2002, EMBO J, V21, P1916, DOI 10.1093/emboj/21.8.1916; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Perl A, 2004, METH MOLEC MED, V102, P87; Perry Mary Ellen, 2004, Cancer Res, V64, P7640, DOI 10.1158/0008-5472.CAN-04-1991; Petit P, 2003, CELL MICROBIOL, V5, P761, DOI 10.1046/j.1462-5822.2003.00309.x; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Pozniakovsky AI, 2005, J CELL BIOL, V168, P257, DOI 10.1083/jcb.200408145; Qa'Dan M, 2002, CELL MICROBIOL, V4, P425, DOI 10.1046/j.1462-5822.2002.00201.x; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Skulachev VP, 2005, IUBMB LIFE, V57, P305, DOI 10.1080/15216540500092161; Teshima Y, 2003, STROKE, V34, P1796, DOI 10.1161/01.STR.0000077017.60947.AE; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Wang YG, 2001, J MOL CELL CARDIOL, V33, P2037, DOI 10.1006/jmcc.2001.1468; Zamzami N, 2001, METHOD CELL BIOL, V65, P147, DOI 10.1016/S0091-679X(01)65009-X; Zhang AS, 2005, BLOOD, V105, P368, DOI 10.1182/blood-2004-06-2226	65	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9029	9041		10.1074/jbc.M607614200	http://dx.doi.org/10.1074/jbc.M607614200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17220295	hybrid			2022-12-25	WOS:000245780300050
J	Melchers, J; Dirdjaja, N; Ruppert, T; Krauth-Siegel, RL				Melchers, Johannes; Dirdjaja, Natalie; Ruppert, Thomas; Krauth-Siegel, R. Luise			Glutathionylation of trypanosomal thiol redox proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MONOTHIOL GLUTAREDOXIN; THIOLTRANSFERASE GLUTAREDOXIN; TRYPAREDOXIN PEROXIDASES; TRYPANOTHIONE REDUCTASE; CRITHIDIA-FASCICULATA; THIOREDOXIN REDUCTASE; AFRICAN TRYPANOSOMES; BRUCEI TRYPAREDOXIN; S-THIOLATION	Trypanosomatids, the causative agents of several tropical diseases, lack glutathione reductase and thioredoxin reductase but have a trypanothione reductase instead. The main low molecular weight thiols are trypanothione (N-1,N-8-bis(glutathionyl)spermidine) and glutathionyl-spermidine, but the parasites also contain free glutathione. To elucidate whether trypanosomes employ S-thiolation for regulatory or protection purposes, six recombinant parasite thiol redox proteins were studied by ESI-MS and MALDI-TOF-MS for their ability to form mixed disulfides with glutathione or glutathionylspermidine. Trypanosoma brucei mono-Cys-glutaredoxin 1 is specifically thiolated at Cys(181). Thiolation of this residue induced formation of an intramolecular disulfide bridge with the putative active site Cys(104). This contrasts with mono-Cys-glutaredoxins from other sources that have been reported to be glutathionylated at the active site cysteine. Both disulfide forms of the T. brucei protein were reduced by tryparedoxin and trypanothione, whereas glutathione cleaved only the protein disulfide. In the glutathione peroxidase-type tryparedoxin peroxidase III of T. brucei, either Cys(47) or Cys(95) became glutathionylated but not both residues in the same protein molecule. T. brucei thioredoxin contains a third cysteine (Cys(68)) in addition to the redox active dithiol/disulfide. Treatment of the reduced protein with GSSG caused glutathionylation of Cys(68), which did not affect its capacity to catalyze reduction of insulin disulfide. Reduced T. brucei tryparedoxin possesses only the redox active Cys(32)-Cys(35) couple, which upon reaction with GSSG formed a disulfide. Also glyoxalase II and Trypanosoma cruzi trypanothione reductase were not sensitive to thiolation at physiological GSSG concentrations.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.	krauth-siegel@bzh.uni-heidelberg.de	Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				Alves R, 2004, PROTEINS, V57, P481, DOI 10.1002/prot.20228; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Budde H, 2003, BIOL CHEM, V384, P1305, DOI 10.1515/BC.2003.146; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; Comini M, 2005, J BIOL CHEM, V280, P6850, DOI 10.1074/jbc.M404486200; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Deponte M, 2005, BIOL CHEM, V386, P33, DOI 10.1515/BC.2005.005; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Friemann R, 2003, FEBS LETT, V554, P301, DOI 10.1016/S0014-5793(03)01173-6; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Krauth-Siegel RL, 2005, ANGEW CHEM INT EDIT, V44, P690, DOI 10.1002/anie.200300639; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Motyka SA, 2006, J BIOL CHEM, V281, P18499, DOI 10.1074/jbc.M602880200; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Onn I, 2004, EUKARYOT CELL, V3, P277, DOI 10.1128/EC.3.2.277-287.2004; Oza SL, 2003, MOL BIOCHEM PARASIT, V131, P25, DOI 10.1016/S0166-6851(03)00176-2; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rist W, 2005, ANAL BIOCHEM, V342, P160, DOI 10.1016/j.ab.2004.11.043; Schlecker T, 2005, J BIOL CHEM, V280, P14385, DOI 10.1074/jbc.M413338200; Schmidt H, 2003, J BIOL CHEM, V278, P46329, DOI 10.1074/jbc.M305338200; Shahi SK, 2002, MOL MICROBIOL, V43, P1129, DOI 10.1046/j.1365-2958.2002.02831.x; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SHIM H, 1988, J GEN MICROBIOL, V134, P807; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TABOR H, 1975, J BIOL CHEM, V250, P2648; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	54	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8678	8694		10.1074/jbc.M608140200	http://dx.doi.org/10.1074/jbc.M608140200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242409	hybrid			2022-12-25	WOS:000245780300014
J	Hummel, S; Christian, S; Osanger, A; Heid, H; Nimpf, J; Schneider, WJ				Hummel, Susanna; Christian, Sabine; Osanger, Andreas; Heid, Hans; Nimpf, Johannes; Schneider, Wolfgang J.			Identification of a novel chondroitin-sulfated collagen in the membrane separating theca and granulosa cells in chicken ovarian follicles - The granulosa-theca cell interface is nota bona fide basement membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RAPID GROWTH-PHASE; OOCYTE RECEPTOR; BASAL LAMINA; APOLIPOPROTEIN-B; GALLUS-DOMESTICUS; YOLK DEPOSITION; PROTEOGLYCANS; BINDING; GLYCOSAMINOGLYCANS	The membranous structure separating the granulosa from theca cells in the developing ovarian follicles of birds is generally perceived as a genuine basement membrane (BM). Previously, we suggested that this membrane is unusual in that it lacks several typical BM components, e.g. collagen IV, laminin B, perlecan, and fibronectin (Hummel, S., Osanger, A., Bajari, T. M., Balasubramani, M., Halfter, W., Nimpf, J., and Schneider, W. J. (2004) J. Biol. Chem. 279, 23486 -23494). We have now identified a novel chondroitin sulfate-modified collagen, tentatively termed ggBM1 (Gallus gallus basement membrane protein I) as a major component of the border between the vascularized theca and the epitheloid granulosa cells. In biosynthetic experiments using [H-3]proline and [S-35] sulfate, ggBM1 was shown to be synthesized by and secreted from the granulosa cells that support the developing oocyte. The acidic heterogeneous 135-kDa proteoglycan was converted to a protein with an apparent M-r of 95,000 by treatment with chondroitinase ABC and was completely degraded by collagenase. Sequencing of tryptic fragments revealed peptides typical of collagens. The follicular BM accumulated apolipoprotein B and apo-VLDLII, the major resident proteins of the yolk precursor very low density lipoprotein. Interestingly, and likely indicating an analogous situation to the follicle, ggBM1 is also a component of Bruch's membrane of the eye, which separates the vascularized choroid from retinal pigmented epithelial cells. Based on our data we propose that in addition to thecal perlecan, ggBM1 is involved in the transfer of yolk precursors from the thecal capillary bed to oocyte surface lipoprotein receptors mediating their uptake into oocytes.	Med Univ Vienna, Max F Perutz Labs, Dept Biochem Med, A-1030 Vienna, Austria; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Helmholtz Association; German Cancer Research Center (DKFZ)	Schneider, WJ (corresponding author), Med Univ Vienna, Max F Perutz Labs, Dept Biochem Med, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wolfgang.schneider@meduniwien.ac.at		Nimpf, Johannes/0000-0002-9273-3492				Asem EK, 2000, COMP BIOCHEM PHYS C, V125, P189, DOI 10.1016/S0742-8413(99)00100-0; Asem EK, 2000, POULTRY SCI, V79, P589, DOI 10.1093/ps/79.4.589; BARBER DL, 1991, J BIOL CHEM, V266, P18761; Bausek N, 2000, J BIOL CHEM, V275, P28866, DOI 10.1074/jbc.275.37.28866; Bjornsson S, 2000, SCAND J CLIN LAB INV, V60, P27, DOI 10.1080/00365510050185010; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; Bujo H, 1997, J NUTR, V127, pS801, DOI 10.1093/jn/127.5.801S; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; EVANS AJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P184, DOI 10.1016/0005-2760(79)90185-1; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225; Hermann M, 1997, J LIPID RES, V38, P1308; Hollborn M, 2004, INVEST OPHTH VIS SCI, V45, P2033, DOI 10.1167/iovs.03-0656; Hummel S, 2004, J BIOL CHEM, V279, P23486, DOI 10.1074/jbc.M312694200; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; Mahley R W, 1980, Ann N Y Acad Sci, V348, P265, DOI 10.1111/j.1749-6632.1980.tb21306.x; Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102; Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9; Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; Olsson U, 2001, GLYCOCONJUGATE J, V18, P789, DOI 10.1023/A:1021155518464; PERRY MM, 1978, J ANAT, V125, P481; PERRY MM, 1979, J CELL SCI, V39, P257; Recheis B, 2005, CELL MOL LIFE SCI, V62, P1871, DOI 10.1007/s00018-005-5193-1; Schneider WJ, 1998, BIOL CHEM, V379, P965; Schonherr E, 2000, EUR J CELL BIOL, V79, P689, DOI 10.1078/0171-9335-00103; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1991, J BIOL CHEM, V266, P19079; Tovar AMF, 1996, ATHEROSCLEROSIS, V126, P185, DOI 10.1016/0021-9150(96)05897-2; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; Watanabe K, 2004, DNA SEQUENCE, V15, P251, DOI 10.1080/10425170410001723921	38	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8011	8018		10.1074/jbc.M606029200	http://dx.doi.org/10.1074/jbc.M606029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17204479	hybrid			2022-12-25	WOS:000245081000032
J	Jones, RJ; Dickerson, S; Bhende, PM; Delecluse, HJ; Kenney, SC				Jones, Richard J.; Dickerson, Sarah; Bhende, Prassana M.; Delecluse, Henri-Jacque; Kenney, Shannon C.			Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; EPITHELIAL-CELLS; VITAMIN-A; HUMAN CYTOMEGALOVIRUS; ZTA TRANSACTIVATOR; LATENT INFECTION; PLASMA-CELLS; EXPRESSION; DIFFERENTIATION; REPLICATION	Lytic Epstein-Barr virus (EBV) replication occurs in differentiated, but not undifferentiated, epithelial cells. Retinoic acid (RA) induces epithelial cell differentiation. The conversion of retinol into its active form, retinoic acid, requires retinol dehydrogenase enzymes. Here we show that AGS gastric carcinoma cells containing the lytic form of EBV infection have enhanced expression of a gene (DHRS9) encoding an enzyme that mediates conversion of retinol into RA. DHRS9 expression is also increased following induction of lytic viral infection in EBVpositive Burkitt lymphoma cells. We demonstrate that the EBV immediate-early protein, BZLF1, activates the DHRS9 promoter through a direct DNA binding mechanism. Furthermore, BZLF1 expression in AGS cells is sufficient to activate DHRS9 gene expression and increases the ability of retinol to induce the RA-responsive gene, CYP26A1. Production of RA during the lytic form of EBV infection may enhance viral replication by promoting keratinocyte differentiation.	Univ Wisconsin, McArdle Lab Canc Res, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA; German Canc Res Ctr, D-69009 Heidelberg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Helmholtz Association; German Cancer Research Center (DKFZ)	Kenney, SC (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Dept Med, Rm 421A,1400 Univ Ave, Madison, WI 53706 USA.	skenney@wisc.edu		Delecluse, Henri-Jacques/0000-0002-1744-6274	NCI NIH HHS [P01-CA19014, R01-CA66519, R01-CA58853] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066519, R01CA058853, P01CA019014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; Bhende PM, 2004, NAT GENET, V36, P1099, DOI 10.1038/ng1424; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Faluhelyi Z, 2004, ANTICANCER RES, V24, P807; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Feng WH, 2004, JNCI-J NATL CANCER I, V96, P1691, DOI 10.1093/jnci/djh313; Feng WH, 2004, J VIROL, V78, P1893, DOI 10.1128/JVI.78.4.1893-1902.2004; Ghazal P, 1997, REV MED VIROL, V7, P21, DOI 10.1002/(SICI)1099-1654(199704)7:1<21::AID-RMV179>3.0.CO;2-Q; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GONCZOL E, 1984, SCIENCE, V224, P159, DOI 10.1126/science.6322309; GREENSPAN D, 1984, LANCET, V2, P831; GUDAS LJ, 1994, RETINOIDS BIOL CHEM; Hong GK, 2005, J VIROL, V79, P13993, DOI 10.1128/JVI.79.22.13993-14003.2005; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; KARIMI L, 1995, J GEN VIROL, V76, P759, DOI 10.1099/0022-1317-76-4-759; Klaassen I, 2001, BRIT J CANCER, V85, P630, DOI 10.1054/bjoc.2001.1952; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Lampen A, 2000, J PHARMACOL EXP THER, V295, P979; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; Li YL, 2004, J VIROL, V78, P4197, DOI 10.1128/JVI.78.8.4197-4206.2004; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; Marill J, 2003, CURR DRUG METAB, V4, P1, DOI 10.2174/1389200033336900; Morikawa K, 2005, INT IMMUNOPHARMACOL, V5, P1830, DOI 10.1016/j.intimp.2005.06.002; Morrison TE, 2004, VIROLOGY, V328, P219, DOI 10.1016/j.virol.2004.07.020; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Neuhierl B, 2006, J VIROL, V80, P5078, DOI 10.1128/JVI.80.10.5078-5081.2006; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; RICKINSON AB, 2001, FIELDS VIROLOGY; Sarisky RT, 1996, J VIROL, V70, P8340, DOI 10.1128/JVI.70.12.8340-8347.1996; Shimizu N, 1996, J VIROL, V70, P7260, DOI 10.1128/JVI.70.10.7260-7263.1996; SHYU RY, 1995, EUR J CANCER, V31A, P237, DOI 10.1016/0959-8049(94)00481-J; SISTA ND, 1993, P NATL ACAD SCI USA, V90, P3894, DOI 10.1073/pnas.90.9.3894; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIZEMORE N, 1993, CANCER RES, V53, P4511; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; WOLFF D, 1994, VIROLOGY, V204, P101, DOI 10.1006/viro.1994.1514; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	48	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8317	8324		10.1074/jbc.M608667200	http://dx.doi.org/10.1074/jbc.M608667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244623	hybrid			2022-12-25	WOS:000245081000065
J	Bogush, A; Pedrini, S; Pelta-Heller, J; Chan, T; Yang, Q; Mao, ZX; Sluzas, E; Gieringer, T; Ehrlich, ME				Bogush, Alexey; Pedrini, Steve; Pelta-Heller, Joshua; Chan, Tung; Yang, Qian; Mao, Zixu; Sluzas, Emily; Gieringer, Tracy; Ehrlich, Michelle E.			AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; HUNTINGTONS-DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE; MOTOR-NEURONS; MOUSE MODEL; EXPRESSION; DOPAMINE; GENE; ACTIVATION; PHOSPHORYLATION	Mature striatal medium size spiny neurons express the dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa (DARPP-32), but little is known about the mechanisms regulating its levels or the specification of fully differentiated neuronal subtypes. Cell extrinsic molecules that increase DARPP-32 mRNA and/or protein levels include brain-derived neurotrophic factor (BDNF), retinoic acid, and estrogen. DARPP-32 induction by BDNF in vitro requires phosphatiaylinositide 3-kinase (PI3K), but inhibition of phosphorylation of protein kinase B/Akt does not entirely abolish expression of DARPP-32. Moreover, the requirement for Akt has not been established. Using pharmacologic inhibitors of PI3K, Akt, and cyclin-dependent kinase 5 (cdk5) and constitutively active and dominant negative PI3K, Akt, cdk5, and p35 viruses in cultured striatal neurons, we measured BDNF-induced levels of DARPP-32 protein and/or mRNA. We demonstrated that both the PI3K/Akt/mammalian target of rapamycin and the cdk5/p35 signal transduction pathways contribute to the induction of DARPP-32 protein levels by BDNF and that the effects are on both the transcriptional and translational levels. It also appears that PI3K is upstream of cdk5/p35, and its activation can lead to an increase in p35 protein levels. These data support the presence of multiple signal transduction pathways mediating expression of DARPP-32 in vitro, including a novel, important pathway via by which PI3K regulates the contribution of cdk5/p35.	Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Ctr Translat Res, Philadelphia, PA 19107 USA; Emory Univ, Sch Med, Dept Pharmacol & Neurol, Atlanta, GA 30322 USA	Jefferson University; Jefferson University; Jefferson University; Emory University	Ehrlich, ME (corresponding author), 900 Walnut St,JHN 411, Philadelphia, PA 19107 USA.	Michelle.Ehrlich@jefferson.edu		Chan, Tung/0000-0001-6574-9555; Pedrini, Steve/0000-0002-6409-8022	NIA NIH HHS [AG023695] Funding Source: Medline; NINDS NIH HHS [R01NS045942, R01NS048254] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048254, R01NS045942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023695] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bibb JA, 2000, P NATL ACAD SCI USA, V97, P6809, DOI 10.1073/pnas.120166397; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Bolanos CA, 2004, NEUROMOL MED, V5, P69, DOI 10.1385/NMM:5:1:069; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cheung ZH, 2006, NEURON, V50, P13, DOI 10.1016/j.neuron.2006.02.024; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Colin E, 2005, EUR J NEUROSCI, V21, P1478, DOI 10.1111/j.1460-9568.2005.03985.x; Corbin JG, 2000, DEVELOPMENT, V127, P5007; Cruz JC, 2004, CURR OPIN NEUROBIOL, V14, P390, DOI 10.1016/j.conb.2004.05.002; Dluzen DE, 2004, ANN NY ACAD SCI, V1025, P205, DOI 10.1196/annals.1316.026; Duman RS, 2004, NEUROMOL MED, V5, P11, DOI 10.1385/NMM:5:1:011; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; EHRLICH ME, 1990, DEV BRAIN RES, V54, P257, DOI 10.1016/0165-3806(90)90148-R; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Fienberg AA, 2000, BRAIN RES REV, V31, P313, DOI 10.1016/S0165-0173(99)00047-8; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Fryer HJL, 2000, J NEUROCHEM, V74, P582, DOI 10.1046/j.1471-4159.2000.740582.x; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Gerfen CR, 2000, ANN NEUROL, V47, pS42; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hansen C, 2006, EXP CELL RES, V312, P4011, DOI 10.1016/j.yexcr.2006.09.003; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Holleran JL, 2003, ANAL BIOCHEM, V323, P19, DOI 10.1016/j.ab.2003.08.030; Hu P, 2003, J NEUROCHEM, V84, P1421, DOI 10.1046/j.1471-4159.2003.01599.x; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Ivkovic S, 1997, NEUROSCIENCE, V79, P509, DOI 10.1016/S0306-4522(96)00684-7; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kesavapany S, 2004, BBA-PROTEINS PROTEOM, V1697, P143, DOI 10.1016/j.bbapap.2003.11.020; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Li Z, 2004, J BIOL CHEM, V279, P54438, DOI 10.1074/jbc.M411002200; Lindskog M, 2002, NATURE, V418, P774, DOI 10.1038/nature00817; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Nairn AC, 2004, NEUROPHARMACOLOGY, V47, P14, DOI 10.1016/j.neuropharm.2004.05.010; NAKAO N, 1994, EXP BRAIN RES, V101, P291, DOI 10.1007/BF00228749; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Sarker KP, 2004, ONCOGENE, V23, P6064, DOI 10.1038/sj.onc.1207819; Sinor AD, 2004, J NEUROSCI, V24, P8531, DOI 10.1523/JNEUROSCI.1470-04.2004; Soliman GA, 2005, CURR OPIN LIPIDOL, V16, P317, DOI 10.1097/01.mol.0000169352.35642.06; Stroppolo A, 2004, NEUROENDOCRINOLOGY, V79, P259, DOI 10.1159/000079320; Stroppolo A, 2001, J NEUROCHEM, V79, P1027, DOI 10.1046/j.1471-4159.2001.00651.x; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Svenningsson P, 2002, P NATL ACAD SCI USA, V99, P3182, DOI 10.1073/pnas.052712799; Takahashi K, 2003, J NEUROSCI RES, V73, P61, DOI 10.1002/jnr.10638; Takahashi S, 2005, P NATL ACAD SCI USA, V102, P1737, DOI 10.1073/pnas.0409456102; Tamura S, 2004, NEUROSCIENCE, V124, P261, DOI 10.1016/j.neuroscience.2003.11.036; Toresson H, 1999, DEVELOPMENT, V126, P1317; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang HF, 2005, NEUROSCIENCE, V134, P97, DOI 10.1016/j.neuroscience.2005.04.008; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Wang ZF, 2006, NEURON, V50, P443, DOI 10.1016/j.neuron.2006.04.010; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zuccato C, 2005, PHARMACOL RES, V52, P133, DOI 10.1016/j.phrs.2005.01.001	68	48	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7352	7359		10.1074/jbc.M606508200	http://dx.doi.org/10.1074/jbc.M606508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209049	hybrid			2022-12-25	WOS:000245080900046
J	Knosp, WM; Saneyoshi, C; Shou, SM; Bachinger, HP; Stadler, HS				Knosp, Wendy M.; Saneyoshi, Chie; Shou, Siming; Bachinger, Hans Peter; Stadler, H. Scott			Elucidation, quantitative refinement, and in vivo utilization of the HOXA13 DNA binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE INTERACTIONS; DEVELOPMENTAL BASIS; PROTEINS; GENE; LIMB; EXPRESSION; PBX; SPECIFICITY; BMP; ULTRABITHORAX	Mutations in Hoxa13 cause malformations of the appendicular skeleton and genitourinary tract, including digit loss, syndactyly, and hypospadias. To determine the molecular basis for these defects, the DNA sequences bound by HOXA13 were empirically determined, revealing a novel high affinity binding site. Correlating the utilization of this high affinity binding site with genes exhibiting perturbed expression in Hoxa13 mutant limbs, we identified that HOXA13 suppresses the expression of the BMP antagonist, Sostdc1. In the absence of HOXA13 function, Sostdc1 is ectopically expressed in the distal limb, causing reduced expression of BMP-activated genes and decreased SMAD phosphorylation. Limb chromatin immunoprecipitation revealed HOXA13 binding at its high affinity site in two conserved Sostdc1 regulatory sites in vivo. In vitro, HOXA13 represses gene expression through the Sostdc1 high affinity binding sites in a dosage-dependent manner. Together, these findings confirm that the high affinity HOXA13 binding site deduced by quantitative analyses is used in vivo to facilitate HOXA13 target gene regulation, providing a critical advance toward understanding the molecular basis for defects associated with the loss of HOXA13 function.	Shriners Hosp Children, Div Res, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94158 USA	Oregon Health & Science University; Oregon Health & Science University; University of California System; University of California San Francisco	Stadler, HS (corresponding author), Shriners Hosp Children, Div Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hss@shcc.org			NATIONAL CANCER INSTITUTE [P30CA069533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008617] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA69533] Funding Source: Medline; NIDDK NIH HHS [5R01DK066539-01] Funding Source: Medline; NIGMS NIH HHS [5T32GM008617-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON GV, 1995, MOL CELL BIOL, V15, P1591; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; BURKE AC, 1995, DEVELOPMENT, V121, P333; Burke AC, 1997, SCIENCE, V278, P666, DOI 10.1126/science.278.5338.666; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Capovilla M, 2001, DEVELOPMENT, V128, P1221; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Davis AP, 1996, DEVELOPMENT, V122, P1175; Favier B, 1996, DEVELOPMENT, V122, P449; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Galant R, 2002, DEVELOPMENT, V129, P3115; Godwin AR, 1998, P NATL ACAD SCI USA, V95, P13042, DOI 10.1073/pnas.95.22.13042; Guha U, 2002, DEV BIOL, V249, P108, DOI 10.1006/dbio.2002.0752; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Healy C, 1996, ANN NY ACAD SCI, V785, P261, DOI 10.1111/j.1749-6632.1996.tb56278.x; Hinchliffe JR, 2002, INT J DEV BIOL, V46, P835; Huang H, 2005, J BIOL CHEM, V280, P10119, DOI 10.1074/jbc.M413963200; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Kassai Y, 2005, SCIENCE, V309, P2067, DOI 10.1126/science.1116848; Knosp WM, 2004, DEVELOPMENT, V131, P4581, DOI 10.1242/dev.01327; Kobayashi T, 2005, P NATL ACAD SCI USA, V102, P18023, DOI 10.1073/pnas.0503617102; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; LEI H, 2006, P NATL CAD SCI US; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Maruyama M, 2005, J BIOL CHEM, V280, P24371, DOI 10.1074/jbc.M501423200; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032; Mohit P, 2006, DEV BIOL, V291, P356, DOI 10.1016/j.ydbio.2005.12.022; Morgan EA, 2003, DEVELOPMENT, V130, P3095, DOI 10.1242/dev.00530; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; PHELAN ML, 1994, MOL CELL BIOL, V14, P5066, DOI 10.1128/MCB.14.8.5066; Ruvinsky I, 2000, DEVELOPMENT, V127, P5233; Salsi V, 2006, J BIOL CHEM, V281, P1992, DOI 10.1074/jbc.M510900200; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Stadler HS, 2001, DEVELOPMENT, V128, P4177; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Tour E, 2005, DEVELOPMENT, V132, P5271, DOI 10.1242/dev.02138; TREISMAN J, 1989, CELL, V59, P553; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wang N, 2006, EMBO J, V25, P1469, DOI 10.1038/sj.emboj.7601037; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Williams TM, 2005, DEV BIOL, V279, P462, DOI 10.1016/j.ydbio.2004.12.015; Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004; Williams TM, 2005, NUCLEIC ACIDS RES, V33, P4475, DOI 10.1093/nar/gki761; Workman CT, 2005, NUCLEIC ACIDS RES, V33, pW389, DOI 10.1093/nar/gki439; Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075; Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102; Zhao YX, 2001, DEVELOPMENT, V128, P3197; Zwijsen A, 2003, FEBS LETT, V546, P133, DOI 10.1016/S0014-5793(03)00566-0	64	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6843	6853		10.1074/jbc.M610775200	http://dx.doi.org/10.1074/jbc.M610775200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200107	hybrid			2022-12-25	WOS:000244867200094
J	Minami, H; Dubouzet, E; Iwasa, K; Sato, F				Minami, Hiromichi; Dubouzet, Emilyn; Iwasa, Kinuko; Sato, Fumihiko			Functional analysis of norcoclaurine synthase in Coptis japonica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZYLISOQUINOLINE ALKALOID BIOSYNTHESIS; 1ST COMMITTED STEP; MOLECULAR-CLONING; HOMOSPERMIDINE SYNTHASE; 2-OXOGLUTARATE-DEPENDENT DIOXYGENASE; (S)-NORLAUDANOSOLINE SYNTHASE; STRICTOSIDINE SYNTHASE; CATHARANTHUS-ROSEUS; ESCHERICHIA-COLI; SENECIO-VULGARIS	(S)-Norcoclaurine is the entry compound in benzylisoquinoline alkaloid biosynthesis and is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS) (EC 4.2.1.78). Although cDNA of the pathogenesis-related (PR) 10 family, the translation product of which catalyzes NCS reaction, has been isolated from Thalictrumflavum, its detailed enzymological properties have not yet been characterized. We report here that a distinct cDNA isotated from Coptisjaponica (CjNCS1) also catalyzed NCS reaction as well as a PR10 homologue of C. japonica (CjPR10A). Both recombinant proteins stereo-specifically produced (S)norcoclaurine by the condensation of dopamine and 4-HPAA. Because a CjNCS1 cDNA that encoded 352 amino acids showed sequence similarity to 2-oxoglutarate-dependent dioxygenases of plant origin, we characterized the properties of the native enzyme. Sequence analysis indicated that CjNCS1 only contained a Fe2+-binding site and lacked the 2-oxoglutarate-binding domain. In fact, NCS reaction of native NCS isolated from cultured C japonica cells did not depend on 2-oxoglutarate or oxygen, but did require ferrous ion. On the other hand, CjPR10A showed no specific motif The addition of o-phenanthroline inhibited NCS reaction of both native NCS and recombinant CjNCS1, but not that of CjPR10A. In addition, native NCS and recombinant CjNCS1 accepted phenylacetaldehyde and 3,4-dihydroxyphenylacetaldehyde, as well as 4-HPAA, for condensation with dopamine, whereas recombinant CjPR10A could use 4-hydroxyphenylpyruvate and pyruvate in addition to the above aldehydes. These results suggested that CjNCS1 is the major NCS in C japonica, whereas native NCS extracted from cultured C. japonica cells was more active and formed a larger complex compared with recombinant CjNCS1.	Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Kobe Pharmaceut Univ, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kyoto University; Kobe Pharmaceutical University	Sato, F (corresponding author), Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.	fsato@lif.kyoto-u.ac.jp	Sato, Fumihiko/C-1078-2011	Sato, Fumihiko/0000-0001-9497-4452				Allen RS, 2004, NAT BIOTECHNOL, V22, P1559, DOI 10.1038/nbt1033; Borovok I, 1996, BIOCHEMISTRY-US, V35, P1981, DOI 10.1021/bi951534t; Bouin J C, 1976, Methods Enzymol, V44, P478; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; Christinet L, 2004, PLANT PHYSIOL, V134, P265, DOI 10.1104/pp.103.031914; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; Dubouzet JG, 2005, BIOSCI BIOTECH BIOCH, V69, P63, DOI 10.1271/bbb.69.63; Facchini PJ, 2005, CURR OPIN PLANT BIOL, V8, P657, DOI 10.1016/j.pbi.2005.09.008; HEDDEN P, 1992, BIOCHEM SOC T, V20, P373, DOI 10.1042/bst0200373; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ikezawa N, 2003, J BIOL CHEM, V278, P38557, DOI 10.1074/jbc.M302470200; Iwasa K, 2005, J NAT PROD, V68, P992, DOI 10.1021/np0402219; Kaiser A, 1999, PLANT J, V19, P195, DOI 10.1046/j.1365-313X.1999.00509.x; Kato N, 2007, PLANT CELL PHYSIOL, V48, P8, DOI 10.1093/pcp/pcl041; Kristensen C, 2005, P NATL ACAD SCI USA, V102, P1779, DOI 10.1073/pnas.0409233102; KUTCHAN TM, 1988, FEBS LETT, V237, P40, DOI 10.1016/0014-5793(88)80167-4; KUTCHAN TM, 1986, PLANT PHYSIOL, V81, P161, DOI 10.1104/pp.81.1.161; Liscombe DK, 2005, PHYTOCHEMISTRY, V66, P2500, DOI 10.1016/j.phytochem.2005.04.044; MATSUDA J, 1991, J BIOL CHEM, V266, P9460; MCKNIGHT TD, 1990, NUCLEIC ACIDS RES, V18, P4939, DOI 10.1093/nar/18.16.4939; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; Morishige T, 2002, EUR J BIOCHEM, V269, P5659, DOI 10.1046/j.1432-1033.2002.03275.x; Nurhayati N, 2005, PHYTOCHEMISTRY, V66, P1346, DOI 10.1016/j.phytochem.2005.04.013; Ober D, 2000, PHYTOCHEMISTRY, V55, P305, DOI 10.1016/S0031-9422(00)00267-3; PERRY D, 1988, BIOCHEM J, V255, P345; Prescott AG, 1996, ANNU REV PLANT PHYS, V47, P245, DOI 10.1146/annurev.arplant.47.1.245; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; ROBERTS MF, 1983, ARCH BIOCHEM BIOPHYS, V222, P599, DOI 10.1016/0003-9861(83)90558-1; RUEFFER M, 1981, FEBS LETT, V129, P5, DOI 10.1016/0014-5793(81)80742-9; Saito K, 1999, PLANT J, V17, P181, DOI 10.1046/j.1365-313X.1999.00365.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Samanani N, 2004, PLANT J, V40, P302, DOI 10.1111/j.1365-313X.2004.02210.x; Samanani N, 2002, J BIOL CHEM, V277, P33878, DOI 10.1074/jbc.M203051200; Samanani N, 2001, PLANTA, V213, P898, DOI 10.1007/s004250100581; SATO F, 1994, EUR J BIOCHEM, V225, P125, DOI 10.1111/j.1432-1033.1994.00125.x; SATO F, 1984, PHYTOCHEMISTRY, V23, P281, DOI 10.1016/S0031-9422(00)80318-0; Sato F, 2001, P NATL ACAD SCI USA, V98, P367, DOI 10.1073/pnas.011526398; SCHUMACHER HM, 1983, PLANTA MED, V48, P212, DOI 10.1055/s-2007-969923; Shitan N, 2003, P NATL ACAD SCI USA, V100, P751, DOI 10.1073/pnas.0134257100; STADLER R, 1989, PHYTOCHEMISTRY, V28, P1083, DOI 10.1016/0031-9422(89)80187-6; STADLER R, 1987, TETRAHEDRON LETT, V28, P1251, DOI 10.1016/S0040-4039(00)95338-3; STADLER R, 1990, LIEBIGS ANN CHEM, V6, P555; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VazquezFlota F, 1997, PLANT MOL BIOL, V34, P935, DOI 10.1023/A:1005894001516; WILSON ML, 1975, J AM CHEM SOC, V97, P431, DOI 10.1021/ja00835a040	47	96	107	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6274	6282		10.1074/jbc.M608933200	http://dx.doi.org/10.1074/jbc.M608933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204481	hybrid			2022-12-25	WOS:000244867200033
J	Ryan, JF; Mazza, ME; Pang, K; Matus, DQ; Baxevanis, AD; Martindale, MQ; Finnerty, JR				Ryan, Joseph F.; Mazza, Maureen E.; Pang, Kevin; Matus, David Q.; Baxevanis, Andreas D.; Martindale, Mark Q.; Finnerty, John R.			Pre-Bilaterian Origins of the Hox Cluster and the Hox Code: Evidence from the Sea Anemone, Nematostella vectensis	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; BAYESIAN PHYLOGENETIC INFERENCE; HOMEOBOX GENES; EXPRESSION PATTERNS; PARAHOX GENES; EVOLUTIONARY IMPLICATIONS; SCHISTOCERCA-GREGARIA; ANTENNAPEDIA COMPLEX; ACROPORA-MILLEPORA; MOLECULAR EVIDENCE	Background. Hox genes were critical to many morphological innovations of bilaterian animals. However, early Hox evolution remains obscure. Phylogenetic, developmental, and genomic analyses on the cnidarian sea anemone Nematostella vectensis challenge recent claims that the Hox code is a bilaterian invention and that no "true'' Hox genes exist in the phylum Cnidaria. Methodology/Principal Findings. Phylogenetic analyses of 18 Hox-related genes from Nematostella identify putative Hox1, Hox2, and Hox9+ genes. Statistical comparisons among competing hypotheses bolster these findings, including an explicit consideration of the gene losses implied by alternate topologies. In situ hybridization studies of 20 Hox-related genes reveal that multiple Hox genes are expressed in distinct regions along the primary body axis, supporting the existence of a pre-bilaterian Hox code. Additionally, several Hox genes are expressed in nested domains along the secondary body axis, suggesting a role in "dorsoventral'' patterning. Conclusions/Significance. A cluster of anterior and posterior Hox genes, as well as ParaHox cluster of genes evolved prior to the cnidarian-bilaterian split. There is evidence to suggest that these clusters were formed from a series of tandem gene duplication events and played a role in patterning both the primary and secondary body axes in a bilaterally symmetrical common ancestor. Cnidarians and bilaterians shared a common ancestor some 570 to 700 million years ago, and as such, are derived from a common body plan. Our work reveals several conserved genetic components that are found in both of these diverse lineages. This finding is consistent with the hypothesis that a set of developmental rules established in the common ancestor of cnidarians and bilaterians is still at work today.	[Ryan, Joseph F.; Finnerty, John R.] Boston Univ, Bioinformat Program, Boston, MA 02215 USA; [Mazza, Maureen E.; Finnerty, John R.] Boston Univ, Dept Biol, Boston, MA 02215 USA; [Pang, Kevin; Matus, David Q.; Martindale, Mark Q.] Univ Hawaii, Pacific Biosci Res Ctr, Kewalo Marine Lab, Honolulu, HI 96822 USA; [Ryan, Joseph F.; Baxevanis, Andreas D.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA	Boston University; Boston University; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Finnerty, JR (corresponding author), Boston Univ, Bioinformat Program, Boston, MA 02215 USA.	jrf3@bu.edu	Matus, David/E-9972-2010	Matus, David/0000-0002-1570-5025; Baxevanis, Andy/0000-0002-5370-0014; Ryan, Joseph/0000-0001-5478-0522	National Science Foundation [DEB51 9727244, IBN-0212773]; National Atmospheric and Space Administration [NAG2-1374, NAG2-1519]; National Human Genome Research Institute; National Institutes of Health; Boston University Women's Guild; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG021374] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Atmospheric and Space Administration; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boston University Women's Guild; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by the National Science Foundation and the National Atmospheric and Space Administration (NSF grant number DEB51 9727244 to M. Q. M. and J.R.F.; NSF grant number IBN-0212773 to J.R.F.; NASA grant number NAG2-1374 and NAG2-1519s to M. Q. M.) and by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. M. E. M. received financial support from the Boston University Women's Guild.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; AERNE BL, 1995, DEV BIOL, V169, P547, DOI 10.1006/dbio.1995.1168; [Anonymous], 2005, PHYLIP PHYLOGENY INF; Arenas-Mena C, 2000, DEVELOPMENT, V127, P4631; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BONCINELLI E, 1993, ANN GENET-PARIS, V36, P30; Bonneton F, 2003, M S-MED SCI, V19, P1265, DOI 10.1051/medsci/200319121265; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Brown SJ, 2002, GENETICS, V160, P1067; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; Burglin TR, 2005, ENCY MOL CELL BIOL M; BURKE AC, 1995, DEVELOPMENT, V121, P333; Cameron RA, 2006, J EXP ZOOL PART B, V306B, P45, DOI 10.1002/jez.b.21070; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chourrout D, 2006, NATURE, V442, P684, DOI 10.1038/nature04863; Collins AG, 2006, SYST BIOL, V55, P97, DOI 10.1080/10635150500433615; Collins AG, 1998, P NATL ACAD SCI USA, V95, P15458, DOI 10.1073/pnas.95.26.15458; Damen WGM, 1998, DEV GENES EVOL, V208, P586, DOI 10.1007/s004270050218; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; Dearden P, 2000, EVOL DEV, V2, P261, DOI 10.1046/j.1525-142x.2000.00065.x; Devenport MP, 2000, EVOL DEV, V2, P326, DOI 10.1046/j.1525-142x.2000.00074.x; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Edvardsen RB, 2005, CURR BIOL, V15, pR12, DOI 10.1016/j.cub.2004.12.010; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Ferrier DEK, 1996, P NATL ACAD SCI USA, V93, P13024, DOI 10.1073/pnas.93.23.13024; Ferrier DEK, 2002, MOL PHYLOGENET EVOL, V24, P412, DOI 10.1016/S1055-7903(02)00204-X; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Finnerty JR, 1998, CURR TOP DEV BIOL, V40, P211, DOI 10.1016/S0070-2153(08)60368-3; Finnerty JR, 1997, BIOL BULL-US, V193, P62, DOI 10.2307/1542736; Finnerty JR, 1999, EVOL DEV, V1, P16, DOI 10.1046/j.1525-142x.1999.99010.x; Finnerty JR, 2003, EVOL DEV, V5, P331, DOI 10.1046/j.1525-142X.2003.03041.x; Finnerty JR, 2001, AM ZOOL, V41, P608, DOI 10.1668/0003-1569(2001)041[0608:CRISIT]2.0.CO;2; Frobius AC, 2006, DEV GENES EVOL, V216, P81, DOI 10.1007/s00427-005-0049-0; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Galliot B, 2000, CURR OPIN GENET DEV, V10, P629, DOI 10.1016/S0959-437X(00)00141-6; Garcia-Fernandez J, 2005, HEREDITY, V94, P145, DOI 10.1038/sj.hdy.6800621; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GRAHAM A, 1991, DEVELOPMENT, V112, P255; Grienenberger A, 2003, DEVELOPMENT, V130, P5445, DOI 10.1242/dev.00760; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hayward DC, 2002, P NATL ACAD SCI USA, V99, P8106, DOI 10.1073/pnas.112021499; Hayward DC, 2001, DEV GENES EVOL, V211, P10; Hughes CL, 2004, EVOL DEV, V6, P393, DOI 10.1111/j.1525-142X.2004.04048.x; Hughes CL, 2002, DEVELOPMENT, V129, P1225; HUNT P, 1991, DEVELOPMENT, P63; Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030; Iimura T, 2006, NATURE, V442, P568, DOI 10.1038/nature04838; *JOINT GEN I, NEM VECT GEN PORT V1; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KAMM K, 2006, J EXP ZOOLOG B; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Kappen C, 1996, COMPUT CHEM, V20, P49, DOI 10.1016/S0097-8485(96)80007-6; Kawazoe Y, 2002, DEV GROWTH DIFFER, V44, P77; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Kortschak RD, 2003, CURR BIOL, V13, P2190, DOI 10.1016/j.cub.2003.11.030; Kourakis MJ, 1997, DEV BIOL, V190, P284, DOI 10.1006/dbio.1997.8689; Kourakis MJ, 2000, J EXP ZOOL, V288, P175, DOI 10.1002/1097-010X(20000815)288:2<175::AID-JEZ8>3.0.CO;2-N; Kozmik Z, 2005, CURR OPIN GENET DEV, V15, P430, DOI 10.1016/j.gde.2005.05.001; Kuhn K, 1999, J EXP ZOOL, V285, P63, DOI 10.1002/(SICI)1097-010X(19990415)285:1<63::AID-JEZ8>3.0.CO;2-X; Kuhn K, 1996, MOL PHYLOGENET EVOL, V6, P30, DOI 10.1006/mpev.1996.0055; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lee PN, 2003, NATURE, V424, P1061, DOI 10.1038/nature01872; Lichtneckert R, 2005, HEREDITY, V94, P465, DOI 10.1038/sj.hdy.6800664; MADDISON DR, 2000, MCCLADE 4 ANAL PHYLO; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; Magie CR, 2005, DEV GENES EVOL, V215, P618, DOI 10.1007/s00427-005-0022-y; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; Manzanares M, 2000, NATURE, V408, P854, DOI 10.1038/35048570; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; Masuda-Nakagawa LM, 2000, DEV GENES EVOL, V210, P151, DOI 10.1007/s004270050022; Matus DQ, 2006, P NATL ACAD SCI USA, V103, P11195, DOI 10.1073/pnas.0601257103; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; MAZZA ME, NEMATOSTELLA UNPUB; Medina M, 2001, P NATL ACAD SCI USA, V98, P9707, DOI 10.1073/pnas.171316998; Minguillon C, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r12; Minguillon C, 2005, INT J BIOL SCI, V1, P19; Monteiro AS, 2006, INT J BIOL SCI, V2, P95; Mullikin JC, 2003, GENOME RES, V13, P81, DOI 10.1101/gr.731003; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NAITO M, 1993, FEBS LETT, V333, P271, DOI 10.1016/0014-5793(93)80668-K; Negre B, 2005, GENOME RES, V15, P692, DOI 10.1101/gr.3468605; Negre B, 2003, MOL BIOL EVOL, V20, P2042, DOI 10.1093/molbev/msg238; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Peterson KJ, 2005, P NATL ACAD SCI USA, V102, P9547, DOI 10.1073/pnas.0503660102; Pierce RJ, 2005, MOL BIOL EVOL, V22, P2491, DOI 10.1093/molbev/msi239; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Powers TP, 2000, EVOL DEV, V2, P311, DOI 10.1046/j.1525-142x.2000.00072.x; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; RANDAZZO FM, 1993, GENETICS, V134, P319; RENTZSCH F, 2006, DEV BIOL; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Ruvinsky I, 2000, DEVELOPMENT, V127, P5233; RYAN JF, 2006, GENOME BIOL IN PRESS; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sakiyama J, 2001, MECH DEVELOP, V101, P233, DOI 10.1016/S0925-4773(00)00564-5; SCHIERWATER B, 1991, J EXP ZOOL, V260, P413, DOI 10.1002/jez.1402600316; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; Sekimoto T, 1998, GENES CELLS, V3, P51, DOI 10.1046/j.1365-2443.1998.00167.x; SHENK MA, 1993, DEV BIOL, V160, P108, DOI 10.1006/dbio.1993.1290; SHENK MA, 1993, DEVELOPMENT, V117, P657; Sinsheimer JS, 1996, BIOMETRICS, V52, P193, DOI 10.2307/2533156; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Spitz F, 2005, NAT GENET, V37, P889, DOI 10.1038/ng1597; Stauber M, 1999, P NATL ACAD SCI USA, V96, P3786, DOI 10.1073/pnas.96.7.3786; Stauber M, 2002, P NATL ACAD SCI USA, V99, P274, DOI 10.1073/pnas.012292899; *STELLABASE, NEM VECT GEN DAT; Stephenson T.A, 1928, BRIT SEA ANEMONES; Stephenson TA, 1935, BRIT SEA ANEMONES, VII; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; Sullivan JC, 2006, NUCLEIC ACIDS RES, V34, pD495, DOI 10.1093/nar/gkj020; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; TIONG SYK, 1987, DEVELOPMENT, V101, P135; Valentine JW, 2003, INT J DEV BIOL, V47, P517; Van Auken K, 2000, P NATL ACAD SCI USA, V97, P4499, DOI 10.1073/pnas.97.9.4499; van den Akker E, 2002, DEVELOPMENT, V129, P2181; VonAllmen G, 1996, NATURE, V380, P116, DOI 10.1038/380116a0; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Yang ZH, 1997, MOL BIOL EVOL, V14, P717, DOI 10.1093/oxfordjournals.molbev.a025811; Zhang JZ, 1996, GENETICS, V142, P295	129	178	180	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e153	10.1371/journal.pone.0000153	http://dx.doi.org/10.1371/journal.pone.0000153			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17252055	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444100001
J	Wu, JF; Xue, LX; Weng, M; Sun, Y; Zhang, ZY; Wang, WG; Tong, TJ				Wu, Junfeng; Xue, Lixiang; Weng, Mo; Sun, Ying; Zhang, Zongyu; Wang, Wengong; Tong, Tanjun			Sp1 Is Essential for p16(INK4a) Expression in Human Diploid Fibroblasts during Senescence	PLOS ONE			English	Article							REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; O-GLYCOSYLATION; GROWTH-FACTOR; CELLULAR SENESCENCE; PROTEIN; ACTIVATION; P16; PHOSPHORYLATION; BINDING	Background. p16(INK4a) tumor suppressor protein has been widely proposed to mediate entrance of the cells into the senescent stage. Promoter of p16(INK4a) gene contains at least five putative GC boxes, named GC-I to V, respectively. Our previous data showed that a potential Sp1 binding site, within the promoter region from 2466 to 2451, acts as a positive transcription regulatory element. These results led us to examine how Sp1 and/or Sp3 act on these GC boxes during aging in cultured human diploid fibroblasts. Methodology/Principal Findings. Mutagenesis studies revealed that GC-I, II and IV, especially GC-II, are essential for p16(INK4a) gene expression in senescent cells. Electrophoretic mobility shift assays (EMSA) and ChIP assays demonstrated that both Sp1 and Sp3 bind to these elements and the binding activity is enhanced in senescent cells. Ectopic overexpression of Sp1, but not Sp3, induced the transcription of p16(INK4a). Both Sp1 RNAi and Mithramycin, a DNA intercalating agent that interferes with Sp1 and Sp3 binding activities, reduced p16(INK4a) gene expression. In addition, the enhanced binding of Sp1 to p16(INK4a) promoter during cellular senescence appeared to be the result of increased Sp1 binding affinity, not an alteration in Sp1 protein level. Conclusions/Significance. All these results suggest that GC-II is the key site for Sp1 binding and increase of Sp1 binding activity rather than protein levels contributes to the induction of p16(INK4a) expression during cell aging.	[Wu, Junfeng; Xue, Lixiang; Weng, Mo; Sun, Ying; Zhang, Zongyu; Wang, Wengong; Tong, Tanjun] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Peking Univ Res Ctr Aging, Beijing 100871, Peoples R China	Peking University	Wang, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Peking Univ Res Ctr Aging, Beijing 100871, Peoples R China.	wwg@bjmu.edu.cn; ttj@bjmu.edu.cn			National Basic Research Programs of China [2007CB507400]; National Natural Science Foundation of China [30500082, 30671064]	National Basic Research Programs of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The National Basic Research Programs of China (No. 2007CB507400) and the National Natural Science Foundation of China (No. 30500082 and No. 30671064)	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Blander G, 2003, J BIOL CHEM, V278, P38966, DOI 10.1074/jbc.M307146200; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Guo SZ, 2004, EXP CELL RES, V298, P465, DOI 10.1016/j.yexcr.2004.04.044; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jarrard DF, 1999, CANCER RES, V59, P2957; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; Ma H, 2004, EXP GERONTOL, V39, P415, DOI 10.1016/j.exger.2003.11.012; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; Parkinson EK, 2000, BIOCHEM SOC T, V28, P226, DOI 10.1042/bst0280226; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sandhu C, 2000, CANCER RES, V60, P2616; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Wagner M, 2001, FEBS LETT, V499, P101, DOI 10.1016/S0014-5793(01)02524-8; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Xue LX, 2004, FEBS LETT, V564, P199, DOI 10.1016/S0014-5793(04)00352-7; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	39	35	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e164	10.1371/journal.pone.0000164	http://dx.doi.org/10.1371/journal.pone.0000164			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225865	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444000014
J	Nelson, XJ; Jackson, RR				Nelson, Ximena J.; Jackson, Robert R.			A Predator from East Africa that Chooses Malaria Vectors as Preferred Prey	PLOS ONE			English	Article								Background. All vectors of human malaria, a disease responsible for more than one million deaths per year, are female mosquitoes from the genus Anopheles. Evarcha culicivora is an East African jumping spider (Salticidae) that feeds indirectly on vertebrate blood by selecting blood-carrying female mosquitoes as preferred prey. Methodology/Principal Findings. By testing with motionless lures made from mounting dead insects in lifelike posture on cork discs, we show that E. culicivora selects Anopheles mosquitoes in preference to other mosquitoes and that this predator can identify Anopheles by static appearance alone. Tests using active (grooming) virtual mosquitoes rendered in 3-D animation show that Anopheles' characteristic resting posture is an important prey-choice cue for E. culicivora. Expression of the spider's preference for Anopheles varies with the spider's size, varies with its prior feeding condition and is independent of the spider gaining a blood meal. Conclusions/Significance. This is the first experimental study to show that a predator of any type actively chooses Anopheles as preferred prey, suggesting that specialized predators having a role in the biological control of disease vectors is a realistic possibility.	[Nelson, Ximena J.; Jackson, Robert R.] Univ Canterbury, Sch Biol Sci, Christchurch 1, New Zealand; [Jackson, Robert R.] Int Ctr Insect Physiol & Ecol, Mbita Point, Kenya	University of Canterbury; International Centre of Insect Physiology & Ecology (ICIPE)	Nelson, XJ (corresponding author), Macquarie Univ, Ctr Integrat Study Anim Behav, Sydney, NSW 2109, Australia.	ximena@galliform.bhs.mq.edu.au		Nelson, Ximena/0000-0003-4301-2928	Marsden Grant of New Zealand; University of Canterbury Doctoral Scholarship	Marsden Grant of New Zealand(Royal Society of New ZealandMarsden Fund (NZ)); University of Canterbury Doctoral Scholarship	This research was supported by the Marsden Grant of New Zealand (to RRJ) and a University of Canterbury Doctoral Scholarship (to XJN). No funding agency was involved in the design or interpretation of this study.	Alibu VP, 2003, PLOS BIOL, V1, P142, DOI 10.1371/journal.pbio.0000039; Beadle L.C., 1981, INLAND WATERS TROPIC; BLEST AD, 1981, J COMP PHYSIOL, V145, P227, DOI 10.1007/BF00605035; BLEST AD, 1990, CELL TISSUE RES, V262, P445, DOI 10.1007/BF00305241; Clements AN., 1999, SENSORY RECEPTION BE; COLLINS FH, 1995, ANNU REV ENTOMOL, V40, P195, DOI 10.1146/annurev.en.40.010195.001211; DEVOE RD, 1975, J GEN PHYSIOL, V66, P193, DOI 10.1085/jgp.66.2.193; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Jackson RR, 2005, P NATL ACAD SCI USA, V102, P15155, DOI 10.1073/pnas.0507398102; KRYWINSKI J, 2003, ANNU REV ENTOMOL, V48, P111; Land M.F., 1985, P53; LAND MF, 1969, J EXP BIOL, V51, P443; Land MF, 2002, ANIMAL EYES; Lehmann T, 1998, MOL BIOL EVOL, V15, P264, DOI 10.1093/oxfordjournals.molbev.a025923; Li DQ, 2003, BEHAV ECOL SOCIOBIOL, V55, P129, DOI 10.1007/s00265-003-0689-x; Lim MLM, 2006, J COMP PHYSIOL A, V192, P871, DOI 10.1007/s00359-006-0126-5; Minakawa N, 2001, J MED ENTOMOL, V38, P388, DOI 10.1603/0022-2585-38.3.388; Morse DH., 1980, BEHAV MECH ECOLOGY; Nelson XJ, 2005, J ARACHNOL, V33, P541, DOI 10.1636/05-3.1; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Wesolowska W, 2003, ANN ZOOL, V53, P335; WHO UNICEF, 2005, WORLD MALARIA REPORT; WILLIAMS DS, 1980, NATURE, V288, P578, DOI 10.1038/288578a0; YAMASHITA S, 1976, J COMP PHYSIOL, V105, P29, DOI 10.1007/BF01380051; [No title captured]	26	48	49	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e132	10.1371/journal.pone.0000132	http://dx.doi.org/10.1371/journal.pone.0000132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205136	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700026
J	Garcia-Saez, I; DeBonis, S; Lopez, R; Trucco, F; Rousseau, B; Thuery, P; Kozielski, F				Garcia-Saez, Isabel; DeBonis, Salvatore; Lopez, Roman; Trucco, Fernando; Rousseau, Bernard; Thuery, Pierre; Kozielski, Frank			Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE PROTEIN KSP; DIFFRACTION DATA; KINESIN EG5; DESIGN; CONFORMATION; ACTIVATION; MECHANISM; PROGRAM; POTENT	Drugs that target mitotic spindle proteins have been proven useful for tackling tumor growth. Eg5, a kinesin-5 family member, represents a potential target, since its inhibition leads to prolonged mitotic arrest through the activation of the mitotic checkpoint and apoptotic cell death. Monastrol, a specific dihydropyrimidine inhibitor of Eg5, shows stereo-specificity, since predominantly the (S)-, but not the (R)-, enantiomer has been shown to be the biologically active compound in vitro and in cell-based assays. Here, we solved the crystal structure (2.7 angstrom) of the complex between human Eg5 and a new keto derivative of monastrol (named mon-97), a potent antimitotic inhibitor. Surprisingly, we identified the (R)-enantiomer bound in the active site, and not, as for monastrol, the (S)-enantiomer. The absolute configuration of this more active (R)-enantiomer has been unambiguously determined via chemical correlation and x-ray analysis. Unexpectedly, both the R- and the S-forms inhibit Eg5 ATPase activity with IC50 values of 110 and 520 nM (basal assays) and 150 nm and 650 nm (microtubule-stimulated assays), respectively. However, the difference was large enough for the protein to select the (R)- over the (S)-enantiomer. Taken together, these results show that in this new monastrol family, both (R)- and (S)-enantiomers can be active as Eg5 inhibitors. This considerably broadens the alternatives for rational drug design.	UJF, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Moteurs Mol, F-38027 Grenoble, France; CEA Saclay, Grp Chim Combinatoire & Criblage Haut Debit, Serv Marquage Mol & Chim Bioorgan, F-91191 Gif Sur Yvette, France; CEA Saclay, Serv Chim Mol, DSM, DRECAM, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Kozielski, F (corresponding author), UJF, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Moteurs Mol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	frank.kozielski@ibs.fr	Thuery, Pierre/A-7429-2009					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bergnes G, 2005, CURR TOP MED CHEM, V5, P127, DOI 10.2174/1568026053507697; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Cochran JC, 2005, BIOCHEMISTRY-US, V44, P16633, DOI 10.1021/bi051724w; Cox CD, 2006, BIOORG MED CHEM LETT, V16, P3175, DOI 10.1016/j.bmcl.2006.03.040; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dondoni A, 2002, TETRAHEDRON LETT, V43, P5913, DOI 10.1016/S0040-4039(02)01269-8; FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762; Fraley ME, 2006, BIOORG MED CHEM LETT, V16, P1775, DOI 10.1016/j.bmcl.2006.01.030; Gartner M, 2005, CHEMBIOCHEM, V6, P171, DOI 10.1002/cbic.200400195; Huang YJ, 2005, J AM CHEM SOC, V127, P16386, DOI 10.1021/ja056092f; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kappe CO, 2000, EUR J MED CHEM, V35, P1043, DOI 10.1016/S0223-5234(00)01189-2; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kim KS, 2006, BIOORG MED CHEM LETT, V16, P3937, DOI 10.1016/j.bmcl.2006.05.037; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leizerman I, 2004, CELL MOL LIFE SCI, V61, P2060, DOI 10.1007/s00018-004-4074-3; LOPEZ R, 2005, Patent No. 02518; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Maliga Z, 2006, J BIOL CHEM, V281, P7977, DOI 10.1074/jbc.M511955200; Manju K, 1998, TETRAHEDRON-ASYMMETR, V9, P3365, DOI 10.1016/S0957-4166(98)00347-4; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nitta R, 2004, SCIENCE, V305, P678, DOI 10.1126/science.1096621; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81; Sheldrick G.M., 1997, SHELXS97 SHELXL97; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Tarby CM, 2006, BIOORG MED CHEM LETT, V16, P2095, DOI 10.1016/j.bmcl.2006.01.056; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	44	66	68	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9740	9747		10.1074/jbc.M608883200	http://dx.doi.org/10.1074/jbc.M608883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251189	hybrid			2022-12-25	WOS:000245421700048
J	Le, SB; Hailer, MK; Buhrow, S; Wang, Q; Flatten, K; Pediaditakis, P; Bible, KC; Lewis, LD; Sausville, EA; Pang, YP; Ames, MM; Lemasters, JJ; Holmuhamedov, EL; Kaufmann, SH				Le, Son B.; Hailer, M. Katie; Buhrow, Sarah; Wang, Qi; Flatten, Karen; Pediaditakis, Peter; Bible, Keith C.; Lewis, Lionel D.; Sausville, Edward A.; Pang, Yuan-Ping; Ames, Matthew M.; Lemasters, John J.; Holmuhamedov, Ekhson L.; Kaufmann, Scott H.			Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIA-CELLS; CARCINOMA-CELLS; MOLECULAR-DYNAMICS; CYTOCHROME BC(1); MAMMALIAN-CELLS; DT-DIAPHORASE; STEADY-STATE; COMPLEX-I; APOPTOSIS; RESISTANCE	Adaphostin is a dihydroquinone derivative that is undergoing extensive preclinical testing as a potential anticancer drug. Previous studies have suggested that the generation of reactive oxygen species (ROS) plays a critical role in the cytotoxicity of this agent. In this study, we investigated the source of these ROS. Consistent with the known chemical properties of dihydroquinones, adaphostin simultaneously underwent oxidation to the corresponding quinone and generated ROS under aqueous conditions. Interestingly, however, this quinone was not detected in intact cells. Instead, high performance liquid chromatography demonstrated that adaphostin was concentrated by up to 300-fold in cells relative to the extracellular medium and that the highest concentration of adaphostin (3000-fold over extracellular concentrations) was detected in mitochondria. Consistent with a mitochondrial site for adaphostin action, adaphostin-induced ROS production was diminished by >75% in MOLT-4 rho(o) cells, which lack mitochondrial electron transport, relative to parental MOLT-4 cells. In addition, inhibition of oxygen consumption was observed when intact cells were treated with adaphostin. Loading of isolated mitochondria to equivalent adaphostin concentrations caused inhibition of uncoupled oxygen consumption in mitochondria incubated with the complex I substrates pyruvate and malate or the complex II substrate succinate. Further analysis demonstrated that adaphostin had no effect on pyruvate or succinate dehydrogenase activity. Instead, adaphostin inhibited reduced decylubiquinone-induced cytochrome c reduction, identifying complex III as the site of inhibition by this agent. Moreover, adaphostin enhanced the production of ROS by succinate-charged mitochondria. Collectively, these observations demonstrate that mitochondrial respiration rather than direct redox cycling of the hydroquinone moiety is a source of adaphostin-induced ROS and identify complex III as a potential target for antineoplastic agents.	Mayo Clin, Div Oncol Res, Coll Med, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA; Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; Dartmouth College; University System of Maryland; University of Maryland Baltimore	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Coll Med, Dept Oncol, Guggenheim 1342C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu	Holmuhamedov, Ekhson L/P-5228-2016	Holmuhamedov, Ekhson L/0000-0002-0809-350X; Kaufmann, Scott/0000-0002-4900-7145; Pang, Yuan-Ping/0000-0003-0838-2560	NCI NIH HHS [R01 CA85972] Funding Source: Medline; NIDDK NIH HHS [R01 DK073336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Beall HD, 2000, FRONT BIOSCI-LANDMRK, V5, pD639, DOI 10.2741/Beall; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Chandra J, 2006, BLOOD, V107, P2501, DOI 10.1182/blood-2005-07-2966; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COVEY JM, 1989, CANCER RES, V49, P5016; DAWSON TL, 1993, AM J PHYSIOL, V264, P961; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Frisch M. J., 1999, GAUSSIAN 03; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gutierrez PL, 2000, FREE RADICAL BIO MED, V29, P263, DOI 10.1016/S0891-5849(00)00314-2; HAMILTON PB, 1969, APPL MICROBIOL, V17, P102, DOI 10.1128/AEM.17.1.102-105.1969; Holmuhamedov E, 2003, MITOCHONDRION, V3, P13, DOI 10.1016/S1567-7249(03)00053-9; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Hose C, 2005, CLIN CANCER RES, V11, P6370, DOI 10.1158/1078-0432.CCR-05-0291; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kaufmann SH, 1996, J NATL CANCER I, V88, P734, DOI 10.1093/jnci/88.11.734; Kowaltowski AJ, 1999, J BIOENERG BIOMEMBR, V31, P581, DOI 10.1023/A:1005421112345; LAMPIDIS TJ, 1985, BIOMED PHARMACOTHER, V39, P220; Laupeze B, 2002, BRIT J HAEMATOL, V116, P834, DOI 10.1046/j.0007-1048.2002.03350.x; Le SB, 2006, CELL DEATH DIFFER, V13, P151, DOI 10.1038/sj.cdd.4401732; Li H, 1997, J NEUROCHEM, V69, P1530; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Loegering D, 2004, J BIOL CHEM, V279, P18641, DOI 10.1074/jbc.M313536200; Long J, 2007, CANCER CHEMOTH PHARM, V59, P527, DOI 10.1007/s00280-006-0295-5; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; NADAKAVUKAREN KK, 1985, CANCER RES, V45, P6093; Okubo T, 1997, TOXICOL LETT, V90, P11, DOI 10.1016/S0378-4274(96)03823-4; Pang YP, 2001, J COMPUT CHEM, V22, P1750, DOI 10.1002/jcc.1129; Pang YP, 2004, PROTEINS, V57, P747, DOI 10.1002/prot.20249; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PETRONILLI V, 1986, EUR J BIOCHEM, V155, P423, DOI 10.1111/j.1432-1033.1986.tb09508.x; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; PORTEOUS JW, 1965, BIOCHEM J, V96, P159, DOI 10.1042/bj0960159; POTTER VR, 1952, J BIOL CHEM, V194, P287; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; RIESKE JS, 1976, BIOCHIM BIOPHYS ACTA, V456, P195, DOI 10.1016/0304-4173(76)90012-4; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Schwab MA, 2005, CLIN CHEM, V51, P151, DOI 10.1373/clinchem.2004.033852; Shanafelt TD, 2004, BLOOD, V103, P1202, DOI 10.1182/blood-2003-07-2281; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; Svingen PA, 2000, CLIN CANCER RES, V6, P237; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; Walter RB, 2003, BLOOD, V102, P1466, DOI 10.1182/blood-2003-02-0396; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444; Xu GP, 2001, NEUROSCI LETT, V300, P141, DOI 10.1016/S0304-3940(01)01575-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	61	59	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8860	8872		10.1074/jbc.M611777200	http://dx.doi.org/10.1074/jbc.M611777200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17213201	Green Published, hybrid			2022-12-25	WOS:000245780300033
J	Li, XL; Andersen, JB; Ezelle, HJ; Wilson, GM; Hassel, BA				Li, Xiao-Ling; Andersen, Jesper B.; Ezelle, Heather J.; Wilson, Gerald M.; Hassel, Bret A.			Post-transcriptional regulation of RNase-L expression is mediated by the 3 '-untranslated region of its mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL DIFFERENTIATION; AU-RICH ELEMENTS; INTERFERON ACTION; 2-5A-DEPENDENT RNASE; BINDING PROTEINS; 2-5A SYSTEM; L INHIBITOR; CYCLIN B1; UV-LIGHT; HUR	RNase-L mediates critical cellular functions including antiviral, pro-apoptotic, and tumor suppressive activities; accordingly, its expression must be tightly regulated. Little is known about the control of RNASEL expression; therefore, we examined the potential regulatory role of a conserved 3'-untranslated region (3'-UTR) in its mRNA. The 3'-UTR mediated a potent decrease in the stability of RNase-L mRNA, and of a chimeric beta-globin-3'-UTR reporter mRNA. AU-rich elements (AREs) are cis-acting regulatory regions that modulate mRNA stability. Eight AREs were identified in the RNase-L 3'-UTR, and deletion analysis identified positive and negative regulatory regions associated with distinct AREs. In particular, AREs 7 and 8 served a strong positive regulatory function. HuR is an ARE-binding protein that stabilizes ARE-containing mRNAs, and a predicted HuR binding site was identified in the region comprising AREs 7 and 8. Co-transfection of HuR and RNase-L enhanced RNase-L expression and mRNA stability in a manner that was dependent on this 3'-UTR region. Immunoprecipitation demonstrated that RNase-L mRNA associates with a HuR containing complex in intact cells. Activation of endogenous HuR by cell stress, or during myoblast differentiation, increased RNase-L expression, suggesting that RNase-L mRNA is a physiologic target for HuR. HuR-dependent regulation of RNase-L enhanced its antiviral activity demonstrating the functional significance of this regulation. These findings identify a novel mechanism of RNase-L regulation mediated by its 3'-UTR.	Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Grad Program Mol Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Hassel, BA (corresponding author), 655 W Baltimore St,9th Floor BRB, Baltimore, MD 21201 USA.	bhassel@som.umaryland.edu	Wilson, Gerald/AAF-3874-2019	Andersen, Jesper B/0000-0003-1760-5244; Wilson, Gerald/0000-0002-1273-7507				Bakheet T, 2006, NUCLEIC ACIDS RES, V34, pD111, DOI 10.1093/nar/gkj052; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chandrasekaran K, 2004, BIOCHEM BIOPH RES CO, V325, P18, DOI 10.1016/j.bbrc.2004.10.016; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cho NH, 2006, CANCER LETT, V232, P170, DOI 10.1016/j.canlet.2005.02.026; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fialcowitz EJ, 2005, J BIOL CHEM, V280, P22406, DOI 10.1074/jbc.M500618200; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gealy C, 2005, J VIROL, V79, P472, DOI 10.1128/JVI.79.1.472-485.2005; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kubota K, 2004, J BIOL CHEM, V279, P37832, DOI 10.1074/jbc.M400089200; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Le Roy F, 2005, NAT STRUCT MOL BIOL, V12, P505, DOI 10.1038/nsmb944; LEROY F, 2005, J BIOL CHEM, V102, P14533; Lewis JA, 1996, J BIOL CHEM, V271, P13184, DOI 10.1074/jbc.271.22.13184; Lu Z, 2006, CLIN CANCER RES, V12, P2404, DOI 10.1158/1078-0432.CCR-05-1036; Malathi K, 2005, P NATL ACAD SCI USA, V102, P14533, DOI 10.1073/pnas.0507551102; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Zhou AM, 2000, MAMM GENOME, V11, P989, DOI 10.1007/s003350010194; Zhou AM, 2005, J INTERF CYTOK RES, V25, P595, DOI 10.1089/jir.2005.25.595; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	48	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7950	7960		10.1074/jbc.M607939200	http://dx.doi.org/10.1074/jbc.M607939200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237228	hybrid			2022-12-25	WOS:000245081000025
J	Morita, T; Yamashita, A; Kashima, I; Ogata, K; Ishiura, S; Ohno, S				Morita, Tomoko; Yamashita, Akio; Kashima, Isao; Ogata, Kazuhiro; Ishiura, Shoichi; Ohno, Shigeo			Distant N- and C-terminal domains are required for intrinsic kinase activity of SMG-1, a critical component of nonsense-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DNA-PKCS; CATALYTIC SUBUNIT; TYROSINE KINASE; 3-DIMENSIONAL STRUCTURE; SURVEILLANCE PROTEIN; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; COMPLEX; ATM	Phosphatidylinositol 3-kinase-related kinases (PIKKs) consisting of SMG-1, ATM, ATR, DNA-PKcs, and mTOR are a family of proteins involved in the surveillance of gene expression in eukaryotic cells. They are involved in mechanisms responsible for genome stability, mRNA quality, and translation. They share a large N-terminal domain and a C-terminal FATC domain in addition to the unique serine/threonine protein kinase (PIKK) domain that is different from classical protein kinases. However, structure-function relationships of PIKKs remain unclear. Here we have focused on one of the PIKK members, SMG-1, which is involved in RNA surveillance, termed nonsense-mediated mRNA decay (NMD), to analyze the roles of conserved and SMG-1-specific sequences on the intrinsic kinase activity. Analyses of sets of point and deletion mutants of SMG-1 in a purified system and intact cells revealed that the long N-terminal region and the conserved leucine in the FATC domain were essential for SMG-1 kinase activity. However, the conserved tryptophan in the TOR SMG-1 (TS) homology domain and the FATC domain was not. In addition, the long insertion region between PIKK and FATC domains was not essential for SMG-1 kinase activity. These results indicated an unexpected feature of SMG-1, i.e. that distantly located N- and C-terminal sequences were essential for the intrinsic kinase activity.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Biochem, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Yokohama City University; Yokohama City University; University of Tokyo	Ohno, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fuku ura, Yokohama, Kanagawa 2360004, Japan.	ohnos@med.yokohama-cu.ac.jp	Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish HJ, 2000, NUCLEIC ACIDS RES, V28, P1506, DOI 10.1093/nar/28.7.1506; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Brewerton SC, 2004, J STRUCT BIOL, V145, P295, DOI 10.1016/j.jsb.2003.11.024; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen ZZ, 2005, GENETICS, V171, P403, DOI 10.1534/genetics.105.045674; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Grimson A, 2004, MOL CELL BIOL, V24, P7483, DOI 10.1128/MCB.24.17.7483-7490.2004; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Rivera-Calzada A, 2005, STRUCTURE, V13, P243, DOI 10.1016/j.str.2004.12.006; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takahara T, 2006, J BIOL CHEM, V281, P28605, DOI 10.1074/jbc.M606087200; Takahashi T, 2000, GENES CELLS, V5, P765, DOI 10.1046/j.1365-2443.2000.00365.x; Taylor SS, 2005, BBA-PROTEINS PROTEOM, V1754, P25, DOI 10.1016/j.bbapap.2005.08.024; Usuki F, 2006, MOL THER, V14, P351, DOI 10.1016/j.ymthe.2006.04.011; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yamashita A, 2005, BBA-PROTEINS PROTEOM, V1754, P305, DOI 10.1016/j.bbapap.2005.10.002	39	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7799	7808		10.1074/jbc.M610159200	http://dx.doi.org/10.1074/jbc.M610159200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229728	hybrid			2022-12-25	WOS:000245081000008
J	Sivakumar, S; Rajagopal, R; Venkatesh, GR; Srivastava, A; Bhatnagar, RK				Sivakumar, Swaminathan; Rajagopal, Raman; Venkatesh, G. Raja; Srivastava, Anand; Bhatnagar, Raj K.			Knockdown of aminopeptidase-N from Helicoverpla armigera larvae and in transfected Sf21 cells by RNA interference reveals its functional interaction with Bacillus thuringiensis insecticidal protein Cry1Ac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDUCA-SEXTA; DELTA-ENDOTOXIN; BOMBYX-MORI; COTTON BOLLWORM; BINDING; RECEPTOR; TOXIN; MIDGUT; MEMBRANE; IDENTIFICATION	Aminopeptidase-N (APN) and cadherin proteins located at the midgut epithelium of Helicoverpa armigera have been implicated as receptors for the Cry1A subfamily of insecticidal proteins of Bacillus thuringiensis. Ligand blot analysis with heterologously expressed and purified H. armigera Bt receptor with three closely related Cry1A proteins tentatively identified HaAPN1 as an interacting ligand. However, to date there is no direct evidence of APN being a functional receptor to Cry1Ac in H. armigera. Sf21. insect cells expressing HaAPN1 displayed aberrant cell morphology upon overlaying with Cry1Ac protein. Down-regulating expression of HaAPN1 by RNA interference using double-stranded RNA correlated with a corresponding reduction in the sensitivity of HaAPN1-expressing cells to Cry1Ac protein. This clearly establishes that insect cells expressing the receptor recruit sensitivity to the insecticidal protein Cry1Ac, and their susceptibility is directly dependent on the amount of HaAPN1 protein expressed. Most importantly, silencing of HaAPN1 in H. armigera in vivo by RNA interference resulted in reduced transcript levels and a corresponding decrease in the susceptibility of larvae to Cry1Ac. BIAcore analysis of HaAPN1/Cry1Ac interaction further established HaAPN1 as a ligand for Cry1Ac. This is the first functional demonstration of insect aminopeptidase-N of H. armigera being a receptor of Cry1Ac protein of B. thuringiensis.	ICGEB, Insect Resistance Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Bhatnagar, RK (corresponding author), ICGEB, Insect Resistance Grp, POB 10504, New Delhi 110067, India.	raj@icgeb.res.in	Srivastava, Anand/AFY-2073-2022; Srivastava, Anand/AAD-2166-2019; GUO, Zhaoyu/AAS-5699-2020; SRIVASTAVA, ANAND/C-9609-2012	Srivastava, Anand/0000-0002-2031-4643; SRIVASTAVA, ANAND/0000-0002-2031-4643				Agrawal N, 2004, BIOCHEM BIOPH RES CO, V320, P428, DOI 10.1016/j.bbrc.2004.05.184; Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Daniel A, 2002, APPL ENVIRON MICROB, V68, P2106, DOI 10.1128/AEM.68.5.2106-2112.2002; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Denolf P, 1997, EUR J BIOCHEM, V248, P748, DOI 10.1111/j.1432-1033.1997.t01-1-00748.x; ELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; Gill M, 2002, INSECT MOL BIOL, V11, P619, DOI 10.1046/j.1365-2583.2002.00373.x; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; Hellmich RL, 2001, P NATL ACAD SCI USA, V98, P11925, DOI 10.1073/pnas.211297698; Hua G, 2004, J BIOL CHEM, V279, P28051, DOI 10.1074/jbc.M400237200; Huang FN, 1999, J ECON ENTOMOL, V92, P547, DOI 10.1093/jee/92.3.547; JAMES C, 2005, 34 ISAAA; Jenkins JL, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-12; Jenkins JL, 1999, FEBS LETT, V462, P373, DOI 10.1016/S0014-5793(99)01559-8; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; JOHNSON DE, 1994, J INVERTEBR PATHOL, V63, P123, DOI 10.1006/jipa.1994.1024; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; Kwa MSG, 1998, J INVERTEBR PATHOL, V71, P121, DOI 10.1006/jipa.1997.4723; Lee MK, 2000, MOL MICROBIOL, V38, P289, DOI 10.1046/j.1365-2958.2000.02109.x; LEE MK, 1992, J BIOL CHEM, V267, P3115; Li HR, 2004, BIOCHEM BIOPH RES CO, V323, P52, DOI 10.1016/j.bbrc.2004.08.054; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; MCCARTHY WJ, 1994, INSECT CELL BIOTECHN, P71; MONETTE R, 1994, J INSECT PHYSIOL, V40, P273, DOI 10.1016/0022-1910(94)90067-1; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Rajagopal R, 2003, BIOCHEM J, V370, P971, DOI 10.1042/BJ20021741; Rajagopal R, 2002, J BIOL CHEM, V277, P46849, DOI 10.1074/jbc.C200523200; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; SINGH AK, 1992, INSECT SCI APPL, V13, P333, DOI 10.1017/S1742758400013588; Tsuda Y, 2003, BIOCHEM J, V369, P697, DOI 10.1042/BJ20021401; VACHON V, 1995, J MEMBRANE BIOL, V148, P57, DOI 10.1007/BF00234156; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Yaoi K, 1997, EUR J BIOCHEM, V246, P652, DOI 10.1111/j.1432-1033.1997.t01-1-00652.x	37	87	114	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7312	7319		10.1074/jbc.M607442200	http://dx.doi.org/10.1074/jbc.M607442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213205	hybrid			2022-12-25	WOS:000245080900042
J	Aguado, T; Carracedo, A; Julien, B; Velasco, G; Milman, G; Mechoulam, R; Alvarez, L; Guzman, M; Galve-Roperh, I				Aguado, Tania; Carracedo, Arkaitz; Julien, Boris; Velasco, Guillermo; Milman, Garry; Mechoulam, Raphael; Alvarez, Luis; Guzman, Manuel; Galve-Roperh, Ismael			Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN; NEURAL PROGENITORS; IN-VIVO; EXPRESSION; TUMORS; ANANDAMIDE; RECEPTOR; IDENTIFICATION; GLIOBLASTOMAS; ACTIVATION	Glioma stem-like cells constitute one of the potential origins of gliomas, and therefore, their elimination is an. essential factor for the development of efficient therapeutic strategies. Cannabinoids are known to exert an antitumoral action on gliomas that relies on at least two mechanisms: induction of apoptosis of transformed cells and inhibition of tumor angiogenesis. However, whether cannabinoids target human glioma stem cells and their potential impact in gliomagenesis are unknown. Here, we show that glioma stem-like cells derived from glioblastoma multiforme biopsies and the glioma cell lines U87MG and U373MG express cannabinoid type 1 (CB1) and type 2 (CB2) receptors and other elements of the endocannabinoid system. In gene array experiments, CB receptor activation altered the expression of genes involved in the regulation of stem cell proliferation and differentiation. The cannabinoid agonists HU-210 and JWH-133 promoted glial differentiation in a CB receptor-dependent manner as shown by the increased number of S-100 beta- and glial fibrillary acidic protein-expressing cells. In parallel, cannabinoids decreased the cell population expressing the neuroepithelial progenitor marker nestin. Moreover, cannabinoid challenge decreased the efficiency of glioma stem-like cells to initiate glioma formation in vivo, a finding that correlated with decreased neurosphere formation and cell proliferation in secondary xenografts. Gliomas derived from cannabinoid-treated cancer stem-like cells were characterized with a panel of neural markers and evidenced a more differentiated phenotype and a concomitant decrease in nestin expression. Overall, our results demonstrate that cannabinoids target glioma stem-like cells, promote their differentiation, and inhibit gliomagenesis, thus giving further support to their potential use in the management of malignant gliomas.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; La Paz Univ Hosp, Res Unit, E-28046 Madrid, Spain	Complutense University of Madrid; Hebrew University of Jerusalem; Hospital Universitario La Paz	Galve-Roperh, I (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais S-N, E-28040 Madrid, Spain.	igr@quim.ucm.es	Carracedo, Arkaitz/F-7029-2011; Galve-Roperh, Ismael/AAG-2369-2020; Velasco, Guillermo/H-5260-2012; AGUADO SANCHEZ, TANIA/ABD-6975-2021; Aguado, Tania/AAE-3972-2019; Velasco, Guillermo/AAU-9189-2020; Julien, Boris/E-2374-2012	Carracedo, Arkaitz/0000-0001-5957-1260; Velasco, Guillermo/0000-0002-1994-2386; AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Velasco, Guillermo/0000-0002-1994-2386; Guzman, Manuel/0000-0001-7475-118X				Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Daou MC, 2005, ACTA NEUROPATHOL, V110, P472, DOI 10.1007/s00401-005-1070-0; Englund C, 2005, NEUROPATH APPL NEURO, V31, P429, DOI 10.1111/j.1365-2990.2005.00665.x; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Jang TC, 2004, NEUROBIOL DIS, V15, P544, DOI 10.1016/j.nbd.2003.11.016; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Maccarrone M, 2001, J NEUROCHEM, V76, P594, DOI 10.1046/j.1471-4159.2001.00092.x; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Makriyannis A, 2005, NEUROPHARMACOLOGY, V48, P1068, DOI 10.1016/j.neuropharm.2005.03.012; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Petersen G, 2005, J NEUROCHEM, V93, P299, DOI 10.1111/j.1471-4159.2005.03013.x; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Rutka JT, 1999, INT J DEV NEUROSCI, V17, P503, DOI 10.1016/S0736-5748(99)00049-0; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanchez C, 2001, CANCER RES, V61, P5784; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034; Tunici P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-25; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	42	89	96	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6854	6862		10.1074/jbc.M608900200	http://dx.doi.org/10.1074/jbc.M608900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202146	hybrid			2022-12-25	WOS:000244867200095
J	Basile, JR; Holmbeck, K; Bugge, TH; Gutkind, JS				Basile, John R.; Holmbeck, Kenn; Bugge, Thomas H.; Gutkind, J. Silvio			MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; ENDOTHELIAL GROWTH-FACTOR; UP-REGULATION; CELL CARCINOMA; AXON GUIDANCE; EXPRESSION; PLEXIN; SURFACE; ACTIVATION; TRANSMEMBRANE	The semaphorins are a family of proteins originally identified as regulators of axon growth that recently have been implicated in blood vessel development. The plexins are high affinity receptors for the semaphorins and are responsible for initiation of signaling upon ligation. Emerging evidence indicates that many human cancers overexpress Semaphorin 4D, which promotes neovascularization upon stimulating its receptor, Plexin-B1, on endothelial cells. However, to exert its pro-angiogenic functions, Semaphorin 4D must be processed and released from its membrane bound form to act in a paracrine manner on endothelial cells. Here we show that Semaphorin 4D is a novel target for the membrane-tethered collagenase membrane type I-matrix metalloproteinase. We demonstrate that this metalloproteinase, which is not expressed in normal or immortal but non-tumorigenic epithelial cell lines, was present in several head and neck squamous cell carcinoma cell lines and was required for processing and release of Semaphorin 4D into its soluble form from these cells, thereby inducing endothelial cell chemotaxis in vitro and blood vessel growth in vivo. These results suggest that the proteolytic cleavage of Semaphorin 4D may provide a novel molecular mechanism by which membrane type 1-matrix metalloproteinase controls tumor-induced angiogenesis.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Matrix Metalloprot Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Basile, JR (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Rm 211, Bethesda, MD 20892 USA.	jbasile@mail.nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Holmbeck, Kenn/0000-0002-4472-3257	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676, ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Autiero M, 2005, CARDIOVASC RES, V65, P629, DOI 10.1016/j.cardiores.2004.09.013; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889-6898.2005; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown CB, 2001, DEVELOPMENT, V128, P3071; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; COLOMA MJ, 1992, J IMMUNOL METHODS, V152, P89, DOI 10.1016/0022-1759(92)90092-8; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Dalpe G, 2004, DEVELOPMENT, V131, P2073, DOI 10.1242/dev.01063; Deryugina EI, 2002, CANCER RES, V62, P580; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341; Fang JM, 2001, CANCER RES, V61, P5731; Feiner L, 2001, DEVELOPMENT, V128, P3061; Fujisawa H, 1997, DEV NEUROSCI-BASEL, V19, P101, DOI 10.1159/000111192; GALARDY RE, 1994, CANCER RES, V54, P4715; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Katayama A, 2004, CLIN CANCER RES, V10, P634, DOI 10.1158/1078-0432.CCR-0864-02; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumanogoh A, 2001, TRENDS IMMUNOL, V22, P670, DOI 10.1016/S1471-4906(01)02087-7; LAITINEN L, 1987, HISTOCHEM J, V19, P225, DOI 10.1007/BF01680633; LIOTTA LA, 1990, CANCER METAST REV, V9, P285, DOI 10.1007/BF00049519; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Noda K, 2005, INVEST OPHTH VIS SCI, V46, P3817, DOI 10.1167/iovs.04-1528; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; Ottino P, 2004, MOL VIS, V10, P341; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; SATODA M, 1995, J NEUROSCI, V15, P942; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105	52	132	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6899	6905		10.1074/jbc.M609570200	http://dx.doi.org/10.1074/jbc.M609570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204469	hybrid			2022-12-25	WOS:000244867200099
J	Takaluoma, K; Hyry, M; Lantto, J; Sormunen, R; Bank, RA; Kivirikko, KI; Myllyharju, J; Soininen, R				Takaluoma, Kati; Hyry, Marjo; Lantto, Juha; Sormunen, Raija; Bank, Ruud A.; Kivirikko, Kari I.; Myllyharju, Johanna; Soininen, Raija			Tissue-specific changes in the hydroxylysine content and cross-links of collagens and alterations in fibril morphology in lysyl hydroxylase 1 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; LEUCINE-RICH PROTEOGLYCANS; SYNDROME TYPE-VI; KYPHOSCOLIOTIC TYPE; MUSCULAR-DYSTROPHY; SKIN FRAGILITY; NULL MICE; IN-VITRO; GENE; IDENTIFICATION	We have generated mice with targeted inactivation of the Plod1 gene for lysyl hydroxylase 1 (LH1). Its human mutations cause Ehlers-Danlos syndrome VIA (EDS VIA) characterized by muscular hypotonia, joint laxity, and kyphoscoliosis. The Plod1(-/-) mice are flaccid and have gait abnormalities. About 15% of them died because of aortic rupture and smooth muscle cells in non-ruptured Plod1(-/-) aortas showed degenerative changes. Collagen fibrils in the Plod1(-/-) aorta and skin had an abnormal morphology. The LH activity level in the Plod1(-/-) skin and aorta samples was 35-45% of that in the wild type. The hydroxylysine content was decreased in all the Plod1(-/-) tissues, ranging from 22% of that in the wild type in the skin to 75 and 86% in the femur and lung. The hydroxylysylpyridinoline cross-links likewise showed decreases in all the Plod1(-/-) tissues, ranging from 28 and 33% of that in the wild type in the aorta and cornea to 47 and 59% in femur and tendon, while lysylpyridinolines were increased. The hydroxylysines found in the Plod1(-/-) collagens and their cross-links were evidently synthesized by the other two LH isoenzymes. Few data are available on abnormalities in EDS VIA tissues other than the skin. Plod1(-/-) mice offer an in vivo model for systematic analysis of the tissue-specific consequences of the lack of LH1 activity and may also provide a tool for analyzing the roles of connective tissue in muscle function and the complex interactions occurring in the proper assembly of the extracellular matrix.	Univ Oulu, Collagen Res Unit, Bioctr Oulu, Oulu 90014, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland; Univ Oulu, Dept Pathol, Oulu 90014, Finland; Acad Ctr Dent Amsterdam, Dept Oral Cell Biol, NL-1066 Amsterdam, Netherlands	University of Oulu; University of Oulu; University of Oulu; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam	Myllyharju, J (corresponding author), Univ Oulu, Collagen Res Unit, Bioctr Oulu, POB 5000, Oulu 90014, Finland.	johanna.myllyharju@oulu.fi						Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; Bank RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/abio.1996.0346; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; COLIGE A, 1999, AM J HUM GENET, V65, P9; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Eyre D, 2002, MOL GENET METAB, V76, P211, DOI 10.1016/S1096-7192(02)00036-7; Eyre DR, 2005, TOP CURR CHEM, V247, P207, DOI 10.1007/b103828; Giunta C, 2005, AM J MED GENET A, V133A, P158, DOI 10.1002/ajmg.a.30529; Graham HK, 2000, J MOL BIOL, V295, P891, DOI 10.1006/jmbi.1999.3384; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; Ha-Vinh R, 2004, AM J MED GENET A, V131A, P115, DOI 10.1002/ajmg.a.30231; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kirschner J, 2005, AM J MED GENET A, V132A, P296, DOI 10.1002/ajmg.a.30443; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kobayasi T, 2004, EUR J DERMATOL, V14, P221; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101; Ruotsalainen H, 2006, J CELL SCI, V119, P625, DOI 10.1242/jcs.02780; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Salo AM, 2006, MATRIX BIOL, V25, P475, DOI 10.1016/j.matbio.2006.08.260; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TEINMANN B, 2002, CONNECTIVE TISSUE IT, P431; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; van der Slot AJ, 2003, J BIOL CHEM, V278, P40967, DOI 10.1074/jbc.M307380200; Walker LC, 2005, J INVEST DERMATOL, V124, P914, DOI 10.1111/j.0022-202X.2005.23727.x; WATSON RB, 1992, J BIOL CHEM, V267, P9093; Wenstrup RJ, 2006, J BIOL CHEM, V281, P12888, DOI 10.1074/jbc.M511528200; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	46	61	65	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6588	6596		10.1074/jbc.M608830200	http://dx.doi.org/10.1074/jbc.M608830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197443	hybrid			2022-12-25	WOS:000244867200068
J	Immler, S; Moore, HDM; Breed, WG; Birkhead, TR				Immler, Simone; Moore, Harry D. M.; Breed, William G.; Birkhead, Tim R.			By Hook or by Crook? Morphometry, Competition and Cooperation in Rodent Sperm	PLOS ONE			English	Article							PLAINS MOUSE; EVOLUTION; SPERMATOZOA; SIZE; MIDPIECE; MOTILITY; HEAD	Background. Sperm design varies enormously across species and sperm competition is thought to be a major factor influencing this variation. However, the functional significance of many sperm traits is still poorly understood. The sperm of most murid rodents are characterised by an apical hook of the sperm head that varies markedly in extent across species. In the European woodmouse Apodemus sylvaticus(Muridae), the highly reflected apical hook of sperm is used to form sperm groups, or "trains,'' which exhibited increased swimming velocity and thrusting force compared to individual sperm. Methodology/Principal Findings. Here we use a comparative study of murine rodent sperm and demonstrate that the apical hook and sperm cooperation are likely to be general adaptations to sperm competition in rodents. We found that species with relatively larger testes, and therefore more intense sperm competition, have a longer, more reflected apical sperm hook. In addition, we show that sperm groups also occur in rodents other than the European woodmouse. Conclusions. Our results suggest that in rodents sperm cooperation is more widespread than assumed so far and highlight the importance of diploid versus haploid selection in the evolution of sperm design and function.	[Immler, Simone; Birkhead, Tim R.] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; [Breed, William G.] Univ Adelaide, Fac Hlth Sci, Sch Med Sci, Discipline Anat Sci, Adelaide, SA 5005, Australia	University of Sheffield; University of Adelaide	Immler, S (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.	s.immler@sheffield.ac.uk	Immler, Simone/F-8708-2014; Immler, Simone/A-1707-2014	Breed, William/0000-0003-1739-6593	Roche Research Foundation	Roche Research Foundation	This study was funded by a grant from the Roche Research Foundation to SI and TRB.	Anderson MJ, 2005, J ZOOL, V267, P135, DOI 10.1017/S0952836905007284; Anderson MJ, 2002, NATURE, V416, P496, DOI 10.1038/416496a; Breed WG, 2004, J MORPHOL, V261, P52, DOI 10.1002/jmor.10228; Breed WG, 2000, J MAMMAL, V81, P758, DOI 10.1644/1545-1542(2000)081&lt;0758:BMTMAS&gt;2.3.CO;2; COHEN J, 1977, REPRODUCTION; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed., DOI DOI 10.4324/9780203771587; FERSON S, 1985, SYST ZOOL, V34, P59, DOI 10.2307/2413345; FLAHERTY SP, 1983, J EXP ZOOL, V225, P497, DOI 10.1002/jez.1402250318; FLAHERTY SP, 1987, ANAT REC, V217, P240, DOI 10.1002/ar.1092170304; Freckleton RP, 2002, AM NAT, V160, P712, DOI 10.1086/343873; HAIG D, 1995, J EVOLUTION BIOL, V8, P265, DOI 10.1046/j.1420-9101.1995.8030265.x; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90039-6; HARCOURT AH, 1981, NATURE, V293, P55, DOI 10.1038/293055a0; Hayashi F, 1998, FUNCT ECOL, V12, P347, DOI 10.1046/j.1365-2435.1998.00205.x; HOLLOWAY AJ, 1990, FUND APPL TOXICOL, V14, P113, DOI 10.1016/0272-0590(90)90237-E; Hosken DJ, 2001, ECOL LETT, V4, P10, DOI 10.1046/j.1461-0248.2001.00198.x; Jamieson B.G., 1987, ULTRASTRUCTURE PHYLO; JAMIESON BGM, 1987, NEW HORIZONS SPERM C, P311; LESSELLS CM, 1987, AUK, V104, P116, DOI 10.2307/4087240; MCGREGOR L, 1989, GAMETE RES, V23, P279, DOI 10.1002/mrd.1120230305; Moore H, 2002, NATURE, V418, P174, DOI 10.1038/nature00832; MOORE HDM, 1995, BIOL REPROD, V52, P947, DOI 10.1095/biolreprod52.4.947; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; PARKER GA, 1993, P ROY SOC B-BIOL SCI, V253, P255, DOI 10.1098/rspb.1993.0111; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Pitnick S, 2001, P ROY SOC B-BIOL SCI, V268, P1071, DOI 10.1098/rspb.2001.1621; Pizzari T, 2002, BIOL REV, V77, P183, DOI 10.1017/S1464793101005863; Ramm SA, 2005, P ROY SOC B-BIOL SCI, V272, P949, DOI 10.1098/rspb.2004.3048; ROHLF FJ, 1992, EFA VERSION 1 33; Rohlf FJ, 2004, TPSUTIL FILE UTILITY; ROLDAN ERS, 1992, BIOL REV, V67, P551, DOI 10.1111/j.1469-185X.1992.tb01193.x; Sivinsky J., 1984, SPERM COMPETITION EV, P86; SMITH TT, 1990, BIOL REPROD, V42, P450, DOI 10.1095/biolreprod42.3.450; Snook RR, 2005, TRENDS ECOL EVOL, V20, P46, DOI 10.1016/j.tree.2004.10.011; VOSS R, 1979, Occasional Papers of the Museum of Zoology University of Michigan, P1; Woolley DM, 2003, REPRODUCTION, V126, P259, DOI 10.1530/rep.0.1260259	36	103	108	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e170	10.1371/journal.pone.0000170	http://dx.doi.org/10.1371/journal.pone.0000170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245446	Green Published, Green Accepted, gold			2022-12-25	WOS:000207444100007
J	Stevens, C; Lin, Y; Sanchez, M; Amin, E; Copson, E; White, H; Durston, V; Eccles, DM; Hupp, T				Stevens, Craig; Lin, Yao; Sanchez, Maria; Amin, Eliana; Copson, Ellen; White, Helen; Durston, Vicky; Eccles, Diana M.; Hupp, Ted			A germ line mutation in the death domain of DAPK-1 inactivates ERK-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-DEATH; P53 PATHWAY; EXPRESSION; POLYMORPHISM; TRANSCRIPTION; RECEPTOR; CANCER; PHOSPHORYLATION; ACETYLATION	p53 is activated genetically by a set of kinases that are components of the calcium calmodulin kinase superfamily, including CHK2, AMP kinase, and DAPK-1. In dissecting the mechanism of DAPK-1 control, a novel mutation (N1347S) was identified in the death domain of DAPK-1. The N1347S mutation prevented the death domain module binding stably to ERK in vitro and in vivo. Gel filtration demonstrated that the N1347S mutation disrupted the higher order oligomeric nature of the purified recombinant death domain miniprotein. Accordingly, the N1347S death domain module is defective in vivo in the formation of high molecular weight oligomeric intermediates after crosslinking with ethylene glycol bis(succinimidylsuccinate). Full-length DAPK-1 protein harboring a N1347S mutation in the death domain was also defective in binding to ERK in cells and was defective in formation of an ethylene glycol bis(succinimidylsuccinate)cross-linked intermediate in vivo. Full-length DAPK-1 encoding the N1347S mutation was attenuated in tumor necrosis factor receptor-induced apoptosis. However, the N1347S mutation strikingly prevented ERK: DAPK-1-dependent apoptosis as defined by poly(ADP-ribose) polymerase cleavage, Annexin V staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling imaging. Significant penetrance of the N1347S allele was identified in normal genomic DNA indicating the mutation is germ line, not tumor derived. The frequency observed in genomic DNA was from 37 to 45% for homozygous wild-type, 41 to 47% for heterozygotes, and 12 to 15% for homozygous mutant. These data highlight a naturally occurring DAPK-1 mutation that alters the oligomeric structure of the death domain, de-stabilizes DAPK-1 binding to ERK, and prevents ERK: DAPK-1-dependent apoptosis.	Univ Edinburgh, Canc Res UK P53 Signal Transduct Grp, Edinburgh EH4 2XR, Midlothian, Scotland; Univ Southampton, Southampton SO16 6YD, Hants, England; Salisbury District Hosp, Natl Genet Reference Lab Wessex, Salisbury SP2 8BJ, Wilts, England	University of Edinburgh; University of Southampton; Salisbury District Hospital	Hupp, T (corresponding author), Univ Edinburgh, Canc Res UK P53 Signal Transduct Grp, S Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	ted.hupp@ed.ac.uk	Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169; , yao/0000-0002-0493-0155				Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brooks LA, 2000, CANCER RES, V60, P6875; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie JJ, 2005, CANCER LETT, V217, P221, DOI 10.1016/j.canlet.2004.06.025; Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Levy D, 2004, CLIN CANCER RES, V10, P3124, DOI 10.1158/1078-0432.CCR-03-0213; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Murphy ME, 2006, CELL DEATH DIFFER, V13, P916, DOI 10.1038/sj.cdd.4401907; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Velentza AV, 2003, BIOORG MED CHEM LETT, V13, P3465, DOI 10.1016/S0960-894X(03)00733-9; VELENTZA AV, 2002, EXPERT OPIN THER TAR, V6, P497; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wethkamp N, 2006, EUR J CANCER, V42, P264, DOI 10.1016/j.ejca.2005.10.019; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	44	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13791	13803		10.1074/jbc.M605649200	http://dx.doi.org/10.1074/jbc.M605649200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17244621	hybrid			2022-12-25	WOS:000246060300069
J	Lee, JH; Richter, W; Namkung, W; Kim, KH; Kim, E; Conti, M; Lee, MG				Lee, Ji Hyun; Richter, Wito; Namkung, Wan; Kim, Kyung Hwan; Kim, Eunjoon; Conti, Marco; Lee, Min Goo			Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SHANK FAMILY; DIFFERENTIAL EXPRESSION; POSTSYNAPTIC DENSITY; EPITHELIAL-CELLS; EMERGING ROLE; CAMP; CFTR; PHOSPHODIESTERASES; MEMBRANE	Disorganized ion transport caused by hypo- or hyperfunctioning of the cystic fibrosis transmembrane conductance regulator ( CFTR) can be detrimental and may result in life-threatening diseases such as cystic fibrosis or secretory diarrhea. Thus, CFTR is controlled by elaborate positive and negative regulations for an efficient homeostasis. It has been shown that expression and activity of CFTR can be regulated either positively or negatively by PDZ ( PSD-95/ discs large/ ZO-1) domain-based adaptors. Although a positive regulation by PDZ domain-based adaptors such as EBP50/NHERF1 is established, the mechanisms for negative regulation of the CFTR by Shank2, as well as the effects of multiple adaptor interactions, are not known. Here we demonstrate a physical and physiological competition between EBP50-CFTR and Shank2-CFTR associations and the dynamic regulation of CFTR activity by these positive and negative interactions using the surface plasmon resonance assays and consecutive patch clamp experiments. Furthermore whereas EBP50 recruits a cAMP-dependent protein kinase ( PKA) complex to CFTR, Shank2 was found to be physically and functionally associated with the cyclic nucleotide phosphodiesterase PDE4D that precludes cAMP/PKA signals in epithelial cells and mouse brains. These findings strongly suggest that balanced interactions between the membrane transporter and multiple PDZ-based adaptors play a critical role in the homeostatic regulation of epithelial transport and possibly the membrane transport in other tissues.	Yonsei Univ, Coll Med, Dept Pharmacol, Inst Gastroenterol, Seoul 120752, South Korea; Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, Stanford, CA 94305 USA; Korea Adv Inst Sci & Technol, Creat Res Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Yonsei University; Yonsei University Health System; Stanford University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Inst Gastroenterol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Lee, Min Goo/D-5635-2012; Kim, Eunjoon/C-1566-2011; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Richter, Wito/0000-0001-5588-9060	NICHD NIH HHS [HD20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Barnes AP, 2005, J BIOL CHEM, V280, P7997, DOI 10.1074/jbc.M407521200; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P3, DOI 10.1113/jphysiol.2005.090399; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Han W, 2006, J BIOL CHEM, V281, P1461, DOI 10.1074/jbc.M509786200; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim JY, 2004, J BIOL CHEM, V279, P10389, DOI 10.1074/jbc.M312871200; Lamprecht G, 2006, AM J PHYSIOL-GASTR L, V291, pG766, DOI 10.1152/ajpgi.00135.2006; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Liu SS, 2005, J PHARMACOL EXP THER, V314, P846, DOI 10.1124/jpet.105.083519; McWilliams RR, 2004, BIOCHEM J, V380, P181, DOI 10.1042/BJ20031577; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Namkung W, 2005, GASTROENTEROLOGY, V129, P1979, DOI 10.1053/j.gastro.2005.08.049; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Sheng M, 2000, J CELL SCI, V113, P1851; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Taouil K, 2003, J BIOL CHEM, V278, P17320, DOI 10.1074/jbc.M212227200; Tateyama M, 2006, P NATL ACAD SCI USA, V103, P1124, DOI 10.1073/pnas.0505925103; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	35	73	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10414	10422		10.1074/jbc.M610857200	http://dx.doi.org/10.1074/jbc.M610857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17244609	hybrid, Green Published			2022-12-25	WOS:000245941000032
J	Liu, YD; Dore, J; Chen, XH				Liu, Yudan; Dore, Jules; Chen, Xihua			Calcium influx through L-type channels generates protein kinase M to induce burst firing of dopamine cells in the rat ventral tegmental area	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; FREE CATALYTIC SUBUNIT; METHYL-D-ASPARTATE; SUBSTANTIA-NIGRA; CA2+ CHANNELS; DEPENDENT FACILITATION; NONLINEAR RELATIONSHIP; NUCLEUS-ACCUMBENS; IMPULSE FLOW; IN-VIVO	Enhanced activity of the dopaminergic system originating in the ventral tegmental area is implicated in addictive and psychiatric disorders. Burst firing increases dopamine levels at the synapse to signal novelty and salience. We have previously reported a calcium-dependent burst firing of dopamine cells mediated by L-type channels following cholinergic stimulation; this paper describes a cellular mechanism resulting in burst firing following L-type channel activation. Calcium influx through L-type channels following FPL 64176 or (S)-(-)-Bay K8644 induced burst firing independent of dopamine, glutamate, or calcium from the internal stores. Burst firing induced as such was completely blocked by the substrate site protein kinase C (PKC) inhibitor chelerythrine but not by the diacylglycerol site inhibitor calphostin C. Western blotting analysis showed that FPL 64176 and (S)-(-)-Bay K8644 increased the cleavage of PKC to generate protein kinase M (PKM) and the specific calpain inhibitor MDL28170 blocked this increase. Prevention of PKM production by inhibiting calpain or depleting PKC blocked burst firing induction whereas direct loading of purified PKM into cells induced burst firing. Activation of the N-methyl-D-aspartic acid type glutamate or cholinergic receptors known to induce burst firing increased PKM expression. These results indicate that calcium influx through L-type channels activates a calcium dependent protease that cleaves PKC to generate constitutively active and labile PKM resulting in burst firing of dopamine cells, a pathway that is involved in glutamatergic or cholinergic modulation of the central dopamine system.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St John, NF A1B 3V6, Canada; Mem Univ Newfoundland, Fac Med, Discipline Psychiat, St John, NF A1B 3V6, Canada	Memorial University Newfoundland; Memorial University Newfoundland	Chen, XH (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St John, NF A1B 3V6, Canada.	xihuac@mun.ca						AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; Beckstead MJ, 2004, NEURON, V42, P939, DOI 10.1016/j.neuron.2004.05.019; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bonci A, 1998, J NEUROSCI, V18, P6693; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; CARDOZO DL, 1995, J NEUROPHYSIOL, V74, P1137, DOI 10.1152/jn.1995.74.3.1137; Chen BT, 2001, J NEUROSCI, V21, P7841, DOI 10.1523/JNEUROSCI.21-19-07841.2001; CHERGUI K, 1994, NEUROSCIENCE, V62, P641, DOI 10.1016/0306-4522(94)90465-0; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Durante P, 2004, J NEUROPHYSIOL, V91, P1450, DOI 10.1152/jn.01015.2003; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Fiorillo CD, 1998, NATURE, V394, P78, DOI 10.1038/27919; Floresco SB, 2003, NAT NEUROSCI, V6, P968, DOI 10.1038/nn1103; GARRIS PA, 1994, J NEUROSCI, V14, P6084; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7; GRACE AA, 1984, J NEUROSCI, V4, P2877; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; Hoogland TM, 2004, J NEUROSCI, V24, P8416, DOI 10.1523/JNEUROSCI.1677-04.2004; Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155; Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1; INOUE M, 1977, J BIOL CHEM, V252, P7610; Johnson SW, 2004, BRAIN RES, V1019, P293, DOI 10.1016/j.brainres.2004.06.022; JOHNSON SW, 1992, SCIENCE, V258, P665, DOI 10.1126/science.1329209; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x; LACEY MG, 1989, J NEUROSCI, V9, P1233; Lee TS, 2006, J BIOL CHEM, V281, P25560, DOI 10.1074/jbc.M508661200; Levitan IB, 2006, NAT NEUROSCI, V9, P305, DOI 10.1038/nn1647; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; MCARDLE CA, 1989, METHOD ENZYMOL, V168, P287; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mercuri NB, 1996, NEUROSCIENCE, V74, P785, DOI 10.1016/0306-4522(96)00189-3; MERCURI NB, 1994, BRIT J PHARMACOL, V113, P831, DOI 10.1111/j.1476-5381.1994.tb17068.x; Miranda M, 2005, J BIOL CHEM, V280, P35617, DOI 10.1074/jbc.M506618200; Namkung Y, 2004, J BIOL CHEM, V279, P49533, DOI 10.1074/jbc.M408319200; NEDERGAARD S, 1993, J PHYSIOL-LONDON, V466, P727; Osten P, 1996, J NEUROSCI, V16, P2444; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Seamans JK, 2004, PROG NEUROBIOL, V74, P1, DOI 10.1016/j.pneurobio.2004.05.006; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Steketee JD, 1997, BRAIN RES BULL, V43, P565, DOI 10.1016/S0361-9230(97)00089-0; Steketee JD, 1998, NEUROPHARMACOLOGY, V37, P339, DOI 10.1016/S0028-3908(98)00022-7; STEKETEE JD, 1994, NEUROREPORT, V6, P69, DOI 10.1097/00001756-199412300-00019; STEKETEE JD, 1993, NEUROPHARMACOLOGY, V32, P1289, DOI 10.1016/0028-3908(93)90023-V; SUAUDCHAGNY MF, 1992, NEUROSCIENCE, V49, P63, DOI 10.1016/0306-4522(92)90076-E; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Takada M, 2001, EUR J NEUROSCI, V13, P757, DOI 10.1046/j.1460-9568.2001.01435.x; Tobler PN, 2005, SCIENCE, V307, P1642, DOI 10.1126/science.1105370; van der Heyden MAG, 2005, CARDIOVASC RES, V65, P28, DOI 10.1016/j.cardiores.2004.09.028; Xu WF, 2001, J NEUROSCI, V21, P5944, DOI 10.1523/JNEUROSCI.21-16-05944.2001; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200; YOSHIHARA C, 1991, J NEUROSCI, V11, P690; Young CE, 2004, J NEUROSCI, V24, P8, DOI 10.1523/JNEUROSCI.1650-03.2004; Zhang L, 2005, J PHYSIOL-LONDON, V568, P469, DOI 10.1113/jphysiol.2005.094722	59	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8594	8603		10.1074/jbc.M610230200	http://dx.doi.org/10.1074/jbc.M610230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237234	hybrid			2022-12-25	WOS:000245780300005
J	Ong, HL; Cheng, KT; Liu, XB; Bandyopadhyay, BC; Paria, BC; Soboloff, J; Pani, B; Gwack, Y; Srikanth, S; Singh, BB; Gill, D; Ambudkar, IS				Ong, Hwei Ling; Cheng, Kwong Tai; Liu, Xibao; Bandyopadhyay, Bidhan C.; Paria, Biman C.; Soboloff, Jonathan; Pani, Biswaranjan; Gwack, Yousang; Srikanth, Sonal; Singh, Brij B.; Gill, Donald; Ambudkar, Indu S.			Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx - Evidence for similarities in store-operated and calcium release-activated calcium channel components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; CRAC CHANNEL; GLAND CELLS; STIM1; PROTEIN; TRPC1; DEPLETION; RECEPTOR; ORAI1; CURRENTS	Store-operated calcium entry (SOCE) is a ubiquitous mechanism that is mediated by distinct SOC channels, ranging from the highly selective calcium release-activated Ca2+ (CRAG) channel in rat basophilic leukemia and other hematopoietic cells to relatively Ca2+-selective or non-selective SOC channels in other cells. Although the exact composition of these channels is not yet established, TRPC1 contributes to SOC channels and regulation of physiological function of a variety of cell types. Recently, Orai1 and STIM1 have been suggested to be sufficient for generating CRAC channels. Here we show that Orai1 and STIM1 are also required for TRPC1-SOC channels. Knockdown of TRPC1, Orai1, or STIM1 attenuated, whereas overexpression of TRPC1, but not Orai1 or STIM1, induced an increase in SOC entry and I-SOC in human salivary gland cells. All three proteins were co-localized in the plasma membrane region of cells, and thapsigargin increased co-immunoprecipitation of TRPC1 with STIM1, and Orai1 in human salivary gland cells as well as dispersed mouse submandibular gland cells. In aggregate, the data presented here reveal that all three proteins are essential for generation of I-SOC in these cells and that dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in activation of SOC channel in response to internal Ca2+ store depletion. Thus, these data suggest a common molecular basis for SOC and CRAC channels.	NIDCR, Secret Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; CBR, Biomed Res Inst, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Dakota Grand Forks; University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Ambudkar, IS (corresponding author), NIDCR, Secret Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113,10 Ctr Dr, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Soboloff, Jonathan/I-6995-2012; Pani, Biswaranjan/GLT-9217-2022; Bandyopadhyay, Bidhan/AAC-6828-2022	Soboloff, Jonathan/0000-0001-5192-1297; Bandyopadhyay, Bidhan/0000-0003-2364-8945; Singh, Brij/0000-0003-0535-5997; Ong, Hwei Ling/0000-0002-7551-6883	NCRR NIH HHS [P20 RR017699, P20 RR017699-077011] Funding Source: Medline; NIDCR NIH HHS [R01 DE017102-06A1, R01 DE017102-05, R01 DE017102-01A1, DE017102, R01 DE017102-02, R01 DE017102-03, R01 DE017102] Funding Source: Medline; NIGMS NIH HHS [GM07525] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2006, TRENDS PHARMACOL SCI, V27, P25, DOI 10.1016/j.tips.2005.11.008; Beech DJ, 2005, PFLUG ARCH EUR J PHY, V451, P53, DOI 10.1007/s00424-005-1441-3; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOLOTINA VM, 2004, SCI STKE, pPE34; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Brownlow SL, 2005, THROMB HAEMOSTASIS, V94, P839, DOI 10.1160/TH05-06-0391; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; HISATSUNE C, 2005, SCI STKE, pPE53, DOI DOI 10.1126/STKE.3132005PE53; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Kiselyov K, 2005, PFLUG ARCH EUR J PHY, V451, P116, DOI 10.1007/s00424-005-1442-2; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu X, 2004, J MEMBRANE BIOL, V200, P93, DOI 10.1007/s00232-004-0698-3; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200	46	318	327	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9105	9116		10.1074/jbc.M608942200	http://dx.doi.org/10.1074/jbc.M608942200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17224452	hybrid, Green Accepted			2022-12-25	WOS:000245780300058
J	Tafreshi, NK; Hosseinkhani, S; Sadeghizadeh, M; Sadeghi, M; Ranjbar, B; Naderi-Manesh, H				Tafreshi, Narges Kh.; Hosseinkhani, Saman; Sadeghizadeh, Majid; Sadeghi, Mehdi; Ranjbar, Bijan; Naderi-Manesh, Hossein			The influence of insertion of a critical residue (Arg(356)) in structure and bioluminescence spectra of firefly luciferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAILROAD-WORM; BACTERIAL LUCIFERASE; SEQUENCE-ANALYSIS; PH-SENSITIVITY; CLICK BEETLE; IN-VIVO; LIGHT; COLORS; LUMINESCENCE; EXPRESSION	The firefly bioluminescence reaction, which uses luciferin, Mg-ATP, and molecular oxygen to yield an electronically excited oxyluciferin, is carried out by luciferase and visible light is emitted. The bioluminescence color of firefly luciferases is determined by the luciferase structure and assay conditions. Among different beetle luciferases, those from Phrixothrix railroad worm emit either yellow or red bioluminescence colors. Sequence alignment analysis shows that the red-emitter luciferase from Phrixothrix hirtus has an additional Arg residue at 353, which is absent in firefly luciferases. We report here the construction and purification of a mutant at residue Arg(356), which is not conserved in beetle luciferases. By insertion of an additional residue (Arg(356)) using site-specific insertion mutagenesis in a green-emitter luciferase (Lampyris turkestanicus) the color of emitted light was changed to red and the optimum temperature of activity was also increased. Insertion of this Arg in an important flexible loop showed changes of the bioluminescence color and the luciferase reaction took place with relatively retention of its basic kinetic properties such as K-m and relative activity. Comparison of native and mutant luciferases using homology modeling reveals a significant conformational change of the flexible loop in the red mutant. Movement of flexible loop brought about a new ionic interaction concomitant with a change in polarity of the emitter site, thereby leading to red emission. It is worthwhile to note that the increased optimum temperature and emission of red light might make mutant luciferase a suitable reporter for the study of gene expression and bioluminescence imaging.	Tarbiat Modares Univ, Fac Basic Sci, Dept Genet, Tehran 14115175, Iran; Tarbiat Modares Univ, Fac Basic Sci, Dept Biochem, Tehran 14115175, Iran; Natl Inst Genet Engn & Biotechnol, Tehran 141556346, Iran	Tarbiat Modares University; Tarbiat Modares University	Hosseinkhani, S (corresponding author), Tarbiat Modares Univ, Fac Basic Sci, Dept Genet, Tehran 14115175, Iran.	saman_h@modares.ac.ir		Naderi-Manesh, Hossein/0000-0002-4227-171X				Alipour BS, 2004, BIOCHEM BIOPH RES CO, V325, P215, DOI 10.1016/bbrc.2004.10.022; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baggett B, 2004, MOL IMAGING, V3, P324, DOI 10.1162/1535350042973553; BIGGLEY WH, 1967, J GEN PHYSIOL, V50, P1681, DOI 10.1085/jgp.50.6.1681; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branchini BR, 2004, BIOCHEMISTRY-US, V43, P7255, DOI 10.1021/bi036175d; CHINNUSAMY V, 2002, SCI STKE, pL10; COLEPICOLO NP, 1986, INSECT BIOCHEM, V16, P803; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DELUCA M, 1973, P NATL ACAD SCI USA, V70, P1664, DOI 10.1073/pnas.70.6.1664; DELUCA M, 1976, ADV ENZYMOL RAMB, V44, P37; DELUCA M, 1969, BIOCHEMISTRY-US, V8, P160, DOI 10.1021/bi00829a023; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hosseinkhani S, 2005, BIOCHEM J, V385, P575, DOI 10.1042/BJ20040863; Madvar AR, 2005, FEBS LETT, V579, P4701, DOI 10.1016/j.febslet.2005.07.040; McCapra F., 1994, BIOLUMINESCENCE CHEM, P387; MCCAPRA F, 1996, BIOLUMINESCENCE CHEM, P7; Nakatsu T, 2006, NATURE, V440, P372, DOI 10.1038/nature04542; Ohmiya Y, 1996, FEBS LETT, V384, P83; Orlova G, 2003, J AM CHEM SOC, V125, P6962, DOI 10.1021/ja021255a; Protasevich I, 1997, BIOCHEMISTRY-US, V36, P2017, DOI 10.1021/bi962538g; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rehemtulla A, 2002, MOL IMAGING, V1, P43, DOI 10.1162/153535002753395707; SCHIPPERS PH, 1981, ANAL CHEM, V53, P778, DOI 10.1021/ac00229a008; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SELIGER HH, 1964, P NATL ACAD SCI USA, V52, P75, DOI 10.1073/pnas.52.1.75; SELIGER HH, 1964, J GEN PHYSIOL, V48, P95, DOI 10.1085/jgp.48.1.95; Shin JH, 2003, ONCOL REP, V10, P2063; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; Ugarova NN, 2001, RUSS CHEM B+, V50, P1752, DOI 10.1023/A:1014365609421; Viviani VR, 2005, PHOTOCHEM PHOTOBIOL, V81, P843, DOI 10.1562/2004-12-09-RA-398R.1; Viviani VR, 2004, PROTEIN ENG DES SEL, V17, P113, DOI 10.1093/protein/gzh016; Viviani VR, 1997, ANN ENTOMOL SOC AM, V90, P389, DOI 10.1093/aesa/90.3.389; VIVIANI VR, 1993, PHOTOCHEM PHOTOBIOL, V58, P615, DOI 10.1111/j.1751-1097.1993.tb04941.x; Viviani VR, 1999, BIOCHEMISTRY-US, V38, P8271, DOI 10.1021/bi9900830; VIVIANI VR, 1995, PHOTOCHEM PHOTOBIOL, V62, P490, DOI 10.1111/j.1751-1097.1995.tb02373.x; Viviani VR, 2002, PHOTOCHEM PHOTOBIOL, V76, P538, DOI 10.1562/0031-8655(2002)076&lt;0538:TIOAGA&gt;2.0.CO;2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; WHITE E H, 1971, Bioorganic Chemistry, V1, P92, DOI 10.1016/0045-2068(71)90009-5; WHITE EH, 1975, J AM CHEM SOC, V97, P1243, DOI 10.1021/ja00838a049; WOOD KV, 1989, SCIENCE, V244, P700, DOI 10.1126/science.2655091; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x; Zhao H, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2032388	45	87	87	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8641	8647		10.1074/jbc.M609271200	http://dx.doi.org/10.1074/jbc.M609271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17197704	hybrid			2022-12-25	WOS:000245780300010
J	Xu, D; Song, DY; Pedersen, LC; Liu, J				Xu, Ding; Song, Danyin; Pedersen, Lars C.; Liu, Jian			Mutational study of heparan sulfate 2-0-sulfotransferase and chondroitin sulfate 2-0-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DERMATAN SULFATE; ESTROGEN SULFOTRANSFERASE; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; STRUCTURAL-ANALYSIS; IN-VIVO; DROSOPHILA; 2-O-SULFOTRANSFERASE; 2-SULFOTRANSFERASE	Heparan sulfate (HS) and chondroitin sulfate (CS) are highly sulfated polysaccharides with a wide range of biological functions. Heparan sulfate 2-O-sulfotransferase (HS-2OST) transfers the sulfo group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the 2-OH position of the hexauronic acid that is adjacent to N-sulfated glucosamine, whereas chondroitin sulfate 2-O-sulfotransferase (CS-2OST) transfers the sulfo group to the hexauronic acid that is adjacent to N-acetylated galactosamine. Here we report a systematic mutagenesis study of HS-2OST and CS-2OST based on their structural homology to estrogen sulfotransferase and HS 3-O-sulfotransferase isoform 3 (3-OST3), for which crystal structures exist. We have identified six residues possibly involved in binding to PAPS. HS-2OST carrying mutations of these residues lacks sulfotransferase activity and the ability to bind 3'-phosphoadenosine 5'-phosphate, a PAPS analogue, as determined by isothermal titration calorimetry. Similar residues involved in binding to PAPS were also identified in CS-20ST. Additional residues that participate in carbohydrate substrate binding were also identified in both enzymes. Mutations at these residues led to the loss of sulfotransferase activity but maintained the ability to bind to phosphoadenosine 5'-phosphate. The catalytic function of HS-2OST appears to involve two histidine residues (His(140) and His(142)), whereas only one histidine (His(168)) of CS 2-OST is likely to be critical. This unique feature of HS 2-OST catalytic residues directed us to characterize the Drosophila heparan sulfate 2-O-sulfotransferase. The results from this study provide insight into the differences and similarities various residues play in the biological roles of the HS-2OST and CS-20ST enzymes.	Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liu, J (corresponding author), Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Rm 309,Beard Hall, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Pedersen, Lars/C-6173-2019; Xu, Ding/B-2493-2009	Pedersen, Lars/0000-0002-4488-4077; Xu, Ding/0000-0001-9380-2712	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI50050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen JH, 2005, J BIOL CHEM, V280, P42817, DOI 10.1074/jbc.M504338200; Edavettal SC, 2004, J BIOL CHEM, V279, P25789, DOI 10.1074/jbc.M401089200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gutteridge A, 2005, TRENDS BIOCHEM SCI, V30, P622, DOI 10.1016/j.tibs.2005.09.006; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kamimura K, 2006, J CELL BIOL, V174, P773, DOI 10.1083/jcb.200603129; Khersonsky O, 2006, J BIOL CHEM, V281, P7649, DOI 10.1074/jbc.M512594200; Kinnunen T, 2005, P NATL ACAD SCI USA, V102, P1507, DOI 10.1073/pnas.0401591102; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mizuguchi H, 1999, J BIOL CHEM, V274, P2166, DOI 10.1074/jbc.274.4.2166; Moon AF, 2004, J BIOL CHEM, V279, P45185, DOI 10.1074/jbc.M405013200; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Ohtake S, 2005, J BIOL CHEM, V280, P39115, DOI 10.1074/jbc.M508816200; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Pinto DO, 2004, GLYCOBIOLOGY, V14, P529, DOI 10.1093/glycob/cwh070; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Sen J, 2000, DEVELOPMENT, V127, P5541; Sergeev P, 2001, DEV DYNAM, V220, P122, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1094>3.0.CO;2-A; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zhu XJ, 2005, DEVELOPMENT, V132, P3813, DOI 10.1242/dev.01962	43	21	21	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8356	8367		10.1074/jbc.M608062200	http://dx.doi.org/10.1074/jbc.M608062200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227754	hybrid, Green Published			2022-12-25	WOS:000245081000069
J	Jacobson, DA; Weber, CR; Bao, SZ; Turk, J; Philipson, LH				Jacobson, David A.; Weber, Christopher R.; Bao, Shunzhong; Turk, John; Philipson, Louis H.			Modulation of the pancreatic islet beta-cell-delayed rectifier potassium channel Kv2.1 by the polyunsaturated fatty acid arachidonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDEPENDENT PHOSPHOLIPASE A(2); TRANSFECTED INSULINOMA CELLS; K+ CHANNELS; INTRACELLULAR CA-2+; SECRETORY RESPONSES; OVEREXPRESS GROUP; GLUCOSE; CALCIUM; METABOLISM; INHIBITION	Glucose stimulates both insulin secretion and hydrolysis of arachidonic acid (AA) esterified in membrane phospholipids of pancreatic islet P-cells, and these processes are amplified by muscarinic agonists. Here we demonstrate that nonesterified AA regulates the biophysical activity of the pancreatic islet beta-cell-delayed rectifier channel, Kv2.1. Recordings of Kv2.1 currents from INS-1 insulinoma cells incubated with AA (5 mu M) and subjected to graded degrees of depolarization exhibit a significantly shorter time-to-peak current interval than do control cells. AA causes a rapid decay and reduced peak conductance of delayed rectifier currents from INS-1 cells and from primary beta-cells isolated from mouse, rat, and human pancreatic islets. Stimulating mouse islets with AA results in a significant increase in the frequency of glucose-induced [Ca2+] oscillations, which is an expected effect of Kv2.1 channel blockade. Stimulation with concentrations of glucose and carbachol that accelerate hydrolysis of endogenous AA from islet phosphoplipids also results in accelerated Kv2.1 inactivation and a shorter time-to-peak current interval. Group VIA phospholipase A(2) (iPLA(2)beta) hydrolyzes beta-cell membrane phospholipids to release nonesterified fatty acids, including AA, and inhibiting iPLA(2)beta prevents the muscarinic agonist-induced accelerated Kv2.1 inactivation. Furthermore, glucose and carbachol do not significantly affect Kv2.1 inactivation in beta-cells from iPLA(2)beta(-/-) mice. Stably transfected INS-1 cells that overexpress iPLA(2)beta hydrolyze phospholipids more rapidly than control INS-1 cells and also exhibit an increase in the inactivation rate of the delayed rectifier currents. These results suggest that Kv2.1 currents could be dynamically modulated in the pancreatic islet beta-cell by phospholipase-catalyzed hydrolysis of membrane phospholipids to yield non-esterified fatty acids, such as AA, that facilitate Ca2+ entry and insulin secretion.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Med Dept Mass Spectrometry Facil, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Mateab & Lipid Res, St Louis, MO 63110 USA	University of Chicago; University of Chicago; Washington University (WUSTL); Washington University (WUSTL)	Philipson, LH (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.	l-philipson@uchicago.edu		Weber, Christopher/0000-0002-2117-3184; Jacobson, David A./0000-0003-1816-5375	NCRR NIH HHS [P41 RR000954-30, P41 RR000954] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-07, P60 DK020595, R01 DK063493, R01 DK048494, P60-DK20579, DK63493, P60 DK020579, R37 DK034388, P60 DK020579-269005, P30 DK020595, P30-DK56341, R37 DK034388-23, DK44840, R37-DK34388, DK48494, DK20595, P30 DK056341-06, P30 DK056341-069003, P30 DK056341] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048494, P60DK020579, P30DK020595, P01DK044840, R37DK034388, P30DK056341, P60DK020595, R01DK063493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; CHAUDHRY A, 1987, J BIOL CHEM, V262, P17426; Dixon G, 2004, CLIN SCI, V106, P191, DOI 10.1042/CS20030261; DIXON JF, 1984, J BIOL CHEM, V259, P4418; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; DUKES ID, 1990, J PHARMACOL EXP THER, V254, P560; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; El-Kholy W, 2003, FASEB J, V17, P720, DOI 10.1096/fj.02-0802fje; Feng DD, 2006, ENDOCRINOLOGY, V147, P674, DOI 10.1210/en.2005-0225; Gubitosi-Klug RA, 2005, P NATL ACAD SCI USA, V102, P5964, DOI 10.1073/pnas.0501999102; GubitosiKlug RA, 1996, J BIOL CHEM, V271, P32519, DOI 10.1074/jbc.271.51.32519; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Juhl K, 2003, BIOCHEM BIOPH RES CO, V310, P274, DOI 10.1016/j.bbrc.2003.09.018; KONRAD RJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P215, DOI 10.1016/0167-4889(92)90139-3; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; LAYCHOCK SG, 1983, DIABETES, V32, P6, DOI 10.2337/diabetes.32.1.6; Ma ZM, 2001, LIPIDS, V36, P689, DOI 10.1007/s11745-001-0774-9; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008; MCGEE R, 1988, J MEMBRANE BIOL, V102, P21, DOI 10.1007/BF01875350; McKay MC, 2001, AM J PHYSIOL-CELL PH, V281, pC1277, DOI 10.1152/ajpcell.2001.281.4.C1277; METZ SA, 1987, BIOCHEM BIOPH RES CO, V142, P251, DOI 10.1016/0006-291X(87)90478-5; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; O'Connell KMS, 2005, J CELL SCI, V118, P2155, DOI 10.1242/jcs.02348; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; Owada S, 1999, J BIOL CHEM, V274, P2000, DOI 10.1074/jbc.274.4.2000; PELIKANOVA T, 1991, METABOLISM, V40, P175, DOI 10.1016/0026-0495(91)90170-2; Pelikanova T, 2001, METABOLISM, V50, P1472, DOI 10.1053/meta.2001.27195; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; SALOMAA V, 1990, METABOLISM, V39, P1285, DOI 10.1016/0026-0495(90)90185-F; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song HW, 2006, BIOCHEMISTRY-US, V45, P1061, DOI 10.1021/bi052065q; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Tamarina NA, 2005, DIABETES, V54, P3073, DOI 10.2337/diabetes.54.11.3073; Tamarina NA, 2005, AM J PHYSIOL-ENDOC M, V289, pE578, DOI 10.1152/ajpendo.00054.2005; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; TURK J, 1993, DIABETES, V42, P367, DOI 10.2337/diabetes.42.3.367; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P110, DOI 10.1016/0005-2760(84)90304-7; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V835, P1, DOI 10.1016/0005-2760(85)90023-2; TURK J, 1988, DIABETES, V37, P992, DOI 10.2337/diabetes.37.7.992; TURK J, 1986, BIOCHEM J, V237, P259, DOI 10.1042/bj2370259; TURK J, 1992, BIOCHIM BIOPHYS ACTA, V1125, P280, DOI 10.1016/0005-2760(92)90057-3; TURK J, 2006, COMMENTARIES PERSPEC, V2, P10; VACHER P, 1989, AM J PHYSIOL, V257, pE203, DOI 10.1152/ajpendo.1989.257.2.E203; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WOLF BA, 1986, J BIOL CHEM, V261, P3501	69	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7442	7449		10.1074/jbc.M607858200	http://dx.doi.org/10.1074/jbc.M607858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17197450	Green Accepted			2022-12-25	WOS:000245080900056
J	Liang, S; Wang, M; Tapping, RI; Stepensky, V; Nawar, HF; Triantafilou, M; Triantafilou, K; Connell, TD; Hajishengallis, G				Liang, Shuang; Wang, Min; Tapping, Richard I.; Stepensky, Vitaly; Nawar, Hesharn F.; Triantafilou, Martha; Triantafilou, Kathy; Connell, Terry D.; Hajishengallis, George			Ganglioside GD1 a is an essential coreceptor for toll-like receptor 2 signaling in response to the B subunit of type IIb enterotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXINS; AIRWAY EPITHELIAL-CELLS; INNATE IMMUNE-SYSTEM; PATTERN-RECOGNITION; LT-IIB; PORPHYROMONAS-GINGIVALIS; REQUIRES COEXPRESSION; ADAPTER MOLECULE; CHOLERA-TOXIN; POLYOMA-VIRUS	Innate recognition and signaling by Toll-like receptors (TLRs) is facilitated by functionally associated coreceptors, although the cooperativity mechanisms involved are poorly understood. As a model we investigated TLR2 interactions with the GD1a ganglioside binding subunit of type IIb Escherichia coli enterotoxin (LT-IIb-B-5). Both LT-IIb-B-5 and a GD1a binding-defective mutant (LT-IIb-B-5(T13I)) could modestly bind to TLR2, but only the wild-type molecule displayed a dramatic increase in TLR2 binding activity in the presence of GD1a (although not in the presence of irrelevant gangliosides). Moreover, fluorescence resonance energy transfer experiments indicated that LT-IIb-B-5 induces lipid raft recruitment of TLR2 and TLR1 and their clustering with GD1a, in contrast to the GD1a binding-defective mutant, which moreover fails to activate TLR2 signaling. LT-IIb-B-5-induced cell activation was critically dependent upon the Toll/IL-1 receptor domain-containing adaptor protein, which was induced to colocalize with TLR2 and GD1a, as shown by confocal imaging. Therefore, GD1a provides TLR2 coreceptor function by enabling the ligand to recruit, bind, and activate TLR2. These findings establish a model of TLR2 coreceptor function and, moreover, suggest novel mechanisms of adjuvanticity by non-toxic derivatives of type II enterotoxins dependent upon GD1a/TLR2 cooperative activity.	Univ Louisville, Hlth Sci Ctr, Ctr Oral Hlth Syst Dis, Louisville, KY 40292 USA; Univ Louisville, Hlth Sci Ctr, Dept Periodont, Louisville, KY 40292 USA; Univ Louisville, Hlth Sci Ctr, Dept Microbiol Immunol, Louisville, KY 40292 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; SUNY Buffalo, Dept Microbiol & Immunol, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA; Univ Sussex, Sch Life Sci, Infect & Immun Grp, Brighton BN1 9QG, E Sussex, England	University of Louisville; University of Louisville; University of Louisville; University of Illinois System; University of Illinois Urbana-Champaign; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Sussex	Hajishengallis, G (corresponding author), Univ Louisville, Hlth Sci Ctr, Ctr Oral Hlth Syst Dis, 501 S Preston St,Room 206, Louisville, KY 40292 USA.	g0haji01@louisville.edu	Hajishengallis, George N./K-1117-2019	Hajishengallis, George N./0000-0001-7392-8852	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052344, R21AI052344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017138, R01DE015254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013833] Funding Source: NIH RePORTER; NIAID NIH HHS [AI052344] Funding Source: Medline; NIDCR NIH HHS [DE017138, DE13833, DE015254] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adamo R, 2004, AM J RESP CELL MOL, V30, P627, DOI 10.1165/rcmb.2003-0260OC; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Christian AE, 1997, J LIPID RES, V38, P2264; Du JW, 2006, INVEST OPHTH VIS SCI, V47, P4810, DOI 10.1167/iovs.06-0250; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fraser SA, 2003, INFECT IMMUN, V71, P1527, DOI 10.1128/IAI.71.3.1527-1537.2003; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; Galvan EM, 2004, J INFECT DIS, V189, P1556, DOI 10.1086/383349; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Hajishengallis G, 2005, J DENT RES, V84, P1104, DOI 10.1177/154405910508401205; Hajishengallis G, 2005, J BIOL CHEM, V280, P38902, DOI 10.1074/jbc.M507326200; Hajishengallis G, 2005, INFECT IMMUN, V73, P1343, DOI 10.1128/IAI.73.3.1343-1349.2005; Hajishengallis G, 2004, INFECT IMMUN, V72, P6351, DOI 10.1128/IAI.72.11.6351-6358.2004; Hajishengallis G, 2006, CELL MICROBIOL, V8, P1557, DOI 10.1111/j.1462-5822.2006.00730.x; Harokopakis E, 2005, EUR J IMMUNOL, V35, P1201, DOI 10.1002/eji.200425883; Harokopakis E, 2006, J IMMUNOL, V176, P7645, DOI 10.4049/jimmunol.176.12.7645; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Holmes RK, 1995, BACTERIAL TOXINS VIR, P225; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Massari P, 2006, J IMMUNOL, V176, P2373, DOI 10.4049/jimmunol.176.4.2373; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Ogushi K, 2004, J BIOL CHEM, V279, P12213, DOI 10.1074/jbc.M307944200; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Omueti KO, 2005, J BIOL CHEM, V280, P36616, DOI 10.1074/jbc.M504320200; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; Schilling D, 2002, J IMMUNOL, V169, P5874, DOI 10.4049/jimmunol.169.10.5874; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; Sorice M, 2001, FEBS LETT, V506, P55, DOI 10.1016/S0014-5793(01)02830-7; Tachado SD, 2007, J LEUKOCYTE BIOL, V81, P205, DOI 10.1189/jlb.1005580; Takebayashi M, 2004, SYNAPSE, V53, P90, DOI 10.1002/syn.20041; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Tinker JK, 2003, INFECT IMMUN, V71, P4093, DOI 10.1128/IAI.71.7.4093-4101.2003; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; vandenAkker F, 1996, STRUCTURE, V4, P665, DOI 10.1016/S0969-2126(96)00073-1; Velupillai P, 2006, J IMMUNOL, V176, P1148, DOI 10.4049/jimmunol.176.2.1148; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yoshimura A, 1999, J IMMUNOL, V163, P1	59	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7532	7542		10.1074/jbc.M611722200	http://dx.doi.org/10.1074/jbc.M611722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17227759	hybrid			2022-12-25	WOS:000245080900066
J	Sriburi, R; Bommiasamy, H; Buldak, GL; Robbins, GR; Frank, M; Jackowski, S; Brewer, JW				Sriburi, Rungtawan; Bommiasamy, Hemamalini; Buldak, Gerald L.; Robbins, Gregory R.; Frank, Matthew; Jackowski, Suzanne; Brewer, Joseph W.			Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1 (S)-induced endoplasmic reticulum biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PLASMA-CELL DIFFERENTIATION; RIBOSOME RECEPTOR; PHOSPHATIDYLCHOLINE SYNTHESIS; ER STRESS; CLONING; LIPIN; IRE1; OVEREXPRESSION	Development of the expansive endoplasmic reticulum (ER) present in specialized secretory cell types requires X-box-binding protein-1 (Xbp-1). Enforced expression of XBP-1(S), a transcriptional activator generated by unfolded protein response-mediated splicing of Xbp-1 mRNA, is sufficient to induce proliferation of rough ER. We previously showed that XBP-1(S)induced ER biogenesis in fibroblasts correlates with increased production of phosphatidylcholine (PtdCho), the primary phospholipid of the ER membrane, and enhanced activities of the choline cytidylyltransferase (CCT) and cholinephosphotransferase enzymes in the cytidine diphosphocholine (CDP-choline) pathway of PtdCho biosynthesis. Here, we report that the level and synthesis of CCT, the rate-limiting enzyme in the CDPcholine pathway, is elevated in fibroblasts overexpressing XBP-1(S). Furthermore, overexpression experiments demonstrated that raising the activity of CCT, but not cholinephosphotransferase, is sufficient to augment PtdCho biosynthesis in fibroblasts, indicating that XBP-1(S) increases the output of the CDP-choline pathway primarily via its effects on CCT. Finally, fibroblasts overexpressing CCT up-regulated PtdCho synthesis to a level similar to that in XBP-1(S)-transduced cells but exhibited only a small increase in rough ER and no induction of secretory pathway genes. The more robust XBP-1(S)-induced ER expansion was accompanied by induction of a wide array of genes encoding proteins that function either in the ER or at other steps in the secretory pathway. We propose that XBP-1(S) regulates ER abundance by coordinately increasing the supply of membrane phospholipids and ER proteins, the key ingredients for ER biogenesis.	Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	Loyola University Chicago; St Jude Children's Research Hospital	Brewer, JW (corresponding author), Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, 2160 S 1st Ave, Maywood, IL 60153 USA.	jbrewer@lumc.edu	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429; sriburi, Rungtawan/0000-0002-8900-9233; Frank, Matthew/0000-0002-4914-1440	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061970, R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIAID NIH HHS [T32 AI007508] Funding Source: Medline; NIGMS NIH HHS [GM 61970, R01 GM061970, GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Federovitch CM, 2005, CURR OPIN CELL BIOL, V17, P409, DOI 10.1016/j.ceb.2005.06.010; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; GRASSO JA, 1978, J CELL SCI, V31, P165; Gunn KE, 2004, MOL IMMUNOL, V41, P919, DOI 10.1016/j.molimm.2004.04.023; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 2005, J BIOL CHEM, V280, P853, DOI 10.1074/jbc.R400031200; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Langley R, 1998, DNA CELL BIOL, V17, P449, DOI 10.1089/dna.1998.17.449; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2005, DRUG NEWS PERSPECT, V18, P5, DOI 10.1358/dnp.2005.18.1.877165; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ridsdale R, 2004, J BIOL CHEM, V279, P55946, DOI 10.1074/jbc.M407670200; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; RUSH JS, 1991, ARCH BIOCHEM BIOPHYS, V284, P63, DOI 10.1016/0003-9861(91)90264-J; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; SHOHAT M, 1973, EUR J IMMUNOL, V3, P680, DOI 10.1002/eji.1830031106; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tirosh B, 2005, J EXP MED, V202, P505, DOI 10.1084/jem.20050575; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161; Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	54	181	191	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7024	7034		10.1074/jbc.M609490200	http://dx.doi.org/10.1074/jbc.M609490200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213183	hybrid			2022-12-25	WOS:000245080900014
J	Snyers, L; Vlcek, S; Dechat, T; Skegro, D; Korbei, B; Gajewski, A; Mayans, O; Schofer, C; Foisner, R				Snyers, Luc; Vlcek, Sylvia; Dechat, Thomas; Skegro, Darko; Korbei, Barbara; Gajewski, Andreas; Mayans, Olga; Schoefer, Christian; Foisner, Roland			Lamina-associated polypeptide 2-alpha forms homo-trimers via its C terminus, and oligomerization is unaffected by a disease-causing mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-STRUCTURE DYNAMICS; A-TYPE LAMINS; CHROMOSOME ASSOCIATION; LAP2-ALPHA; PROTEIN; BAF; CHROMATIN; ENVELOPE; REGION; DOMAIN	The nucleoplasmic protein, Lamina-associated polypeptide (LAP) 2 alpha, is one of six alternatively spliced products of the LAP2gene, which share a common N-terminal region. In contrast to the other isoforms, which also share most of their C termini, LAP2 alpha has a large unique C-terminal region that contains binding sites for chromatin, A-type lamins, and retinoblastorna protein. By immunoprecipitation analyses of LAP2a complexes from cells expressing differently tagged LAP2 alpha proteins and fragments, we demonstrate that LAP21y forms higher order structures containing multiple LAP2 alpha molecules in vivo and that complex formation is mediated by the C terminus. Solid phase binding assays using recombinant and in vitro translated LAP2 alpha fragments showed direct interactions of LAP2 alpha C termini. Cross-linking of LAP2 alpha complexes and multiangle light-scattering of purified LAP2 alpha revealed the existence of stable homo-trimers in vivo and in vitro. Finally, we show that, in contrast to the LAP2 alpha-lamin A interaction, its self-association is not affected by a disease-linked single point mutation in the LAP2 alpha C terminus.	Med Univ Vienna, Max F Perutz Labs, A-1030 Vienna, Austria; Med Univ Vienna, Ctr Anat & Cell Biol, A-1090 Vienna, Austria; Univ Basel, Biozentrum, Div Marine Biol, CH-4056 Basel, Switzerland	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; University of Basel	Foisner, R (corresponding author), Med Univ Vienna, Max F Perutz Labs, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	roland.foisner@meduniwien.ac.at	Foisner, Roland/AAD-1833-2019; Mayans, Olga/A-3954-2008	Foisner, Roland/0000-0003-4734-4647; Korbei, Barbara/0000-0002-0439-0435; Mayans, Olga/0000-0001-6876-8532; Schofer, Christian/0000-0001-9570-5692	Austrian Science Fund FWF [P 17871] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Dechat T, 2000, J CELL SCI, V113, P3473; Dechat T, 2000, J STRUCT BIOL, V129, P335, DOI 10.1006/jsbi.2000.4212; Dechat T, 2004, J CELL SCI, V117, P6117, DOI 10.1242/jcs.01529; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Dorner D, 2006, J CELL BIOL, V173, P83, DOI 10.1083/jcb.200511149; Foisner R, 2001, J CELL SCI, V114, P3791; Gajewski A, 2004, J BIOL CHEM, V279, P35813, DOI 10.1074/jbc.M402546200; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gotzmann J, 2006, HISTOCHEM CELL BIOL, V125, P33, DOI 10.1007/s00418-005-0050-8; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104-1062; Markiewicz E, 2002, MOL BIOL CELL, V13, P4401, DOI 10.1091/mbc.E02-07-0450; Prufert K, 2004, J CELL SCI, V117, P6105, DOI 10.1242/jcs.01532; Segura-Totten M, 2004, TRENDS CELL BIOL, V14, P261, DOI 10.1016/j.tcb.2004.03.004; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Suzuki Y, 2004, EMBO J, V23, P4670, DOI 10.1038/sj.emboj.7600452; Taylor MRG, 2005, HUM MUTAT, V26, P566, DOI 10.1002/humu.20250; Vlcek S, 1999, EMBO J, V18, P6370, DOI 10.1093/emboj/18.22.6370; Vlcek S, 2002, J BIOL CHEM, V277, P18898, DOI 10.1074/jbc.M200048200	22	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6308	6315		10.1074/jbc.M605782200	http://dx.doi.org/10.1074/jbc.M605782200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17213199	hybrid			2022-12-25	WOS:000244867200037
J	Gelain, F; Bottai, D; Vescovi, A; Zhang, SG				Gelain, Fabrizio; Bottai, Daniele; Vescovi, Angleo; Zhang, Shuguang			Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures	PLOS ONE			English	Article								Biomedical researchers have become increasingly aware of the limitations of conventional 2-dimensional tissue cell culture systems, including coated Petri dishes, multi-well plates and slides, to fully address many critical issues in cell biology, cancer biology and neurobiology, such as the 3-D microenvironment, 3-D gradient diffusion, 3-D cell migration and 3-D cell-cell contact interactions. In order to fully understand how cells behave in the 3-D body, it is important to develop a well-controlled 3-D cell culture system where every single ingredient is known. Here we report the development of a 3-D cell culture system using a designer peptide nanofiber scaffold with mouse adult neural stem cells. We attached several functional motifs, including cell adhesion, differentiation and bone marrow homing motifs, to a self-assembling peptide RADA16 (Ac-RADARADARADARADA-COHN2). These functionalized peptides undergo self-assembly into a nanofiber structure similar to Matrigel. During cell culture, the cells were fully embedded in the 3-D environment of the scaffold. Two of the peptide scaffolds containing bone marrow homing motifs significantly enhanced the neural cell survival without extra soluble growth and neurotrophic factors to the routine cell culture media. In these designer scaffolds, the cell populations with beta-Tubulin(+), GFAP(+) and Nestin(+) markers are similar to those found in cell populations cultured on Matrigel. The gene expression profiling array experiments showed selective gene expression, possibly involved in neural stem cell adhesion and differentiation. Because the synthetic peptides are intrinsically pure and a number of desired function cellular motifs are easy to incorporate, these designer peptide nanofiber scaffolds provide a promising controlled 3-D culture system for diverse tissue cells, and are useful as well for general molecular and cell biology.	[Gelain, Fabrizio; Zhang, Shuguang] MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; [Gelain, Fabrizio; Bottai, Daniele; Vescovi, Angleo] Fdn Ctr San Raffaele Monte Tabor, Dept Biol & Technol Res, Stem Cell Res Inst, Milan, Italy; [Gelain, Fabrizio; Vescovi, Angleo] Univ Milano Bicocca, Dept Biosci & Biotechnol, Milan, Italy; [Bottai, Daniele] Univ Milan, Dept Med Surg & Dent, Fac Med, Milan, Italy	Massachusetts Institute of Technology (MIT); University of Milano-Bicocca; University of Milan	Zhang, SG (corresponding author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	shuguang@mit.edu	Bottai, Daniele/O-2586-2017; Gelain, Fabrizio G/K-5069-2012	Bottai, Daniele/0000-0002-7951-9512; Gelain, Fabrizio G/0000-0002-2624-5853; Zhang, Shuguang/0000-0002-3856-3752	Cross fellowship from CARIPLO and Hospital S. Raffaele, Milano, Italy; Olympus Corp; NIH BRP [EB003805]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003805] Funding Source: NIH RePORTER	Cross fellowship from CARIPLO and Hospital S. Raffaele, Milano, Italy; Olympus Corp; NIH BRP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	F. G. was supported by the Cross fellowship from CARIPLO and Hospital S. Raffaele, Milano, Italy. This work was supported in part by grants from Olympus Corp and by NIH BRP Grant EB003805. We also received free RADA16 (Puramatrix) samples from 3DM, an MIT startup, instead of purchasing the RADA16 (Puramatrix) from BD Biosciences.	Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bokhari MA, 2005, BIOMATERIALS, V26, P5198, DOI 10.1016/j.biomaterials.2005.01.040; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Durselen L, 2001, J BIOMED MATER RES, V58, P666, DOI 10.1002/jbm.1067; Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103; Galli R, 2000, DEV NEUROSCI-BASEL, V22, P86, DOI 10.1159/000017430; Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097-4644(19970601)65:3<359::AID-JCB6>3.0.CO;2-R; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756-3282(96)00223-2; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Kreis T, 1999, GUIDE BOOK EXTRACELL; Lanza R.P., 2000, PRINCIPLES TISSUE EN; LEBEAU JM, 1994, EXP NEUROL, V127, P1, DOI 10.1006/exnr.1994.1074; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; Mikhailova A, 2003, REGUL PEPTIDES, V114, P183, DOI 10.1016/S0167-0115(03)00123-X; Narmoneva DA, 2005, BIOMATERIALS, V26, P4837, DOI 10.1016/j.biomaterials.2005.01.005; Nowakowski GS, 2004, STEM CELLS, V22, P1030, DOI 10.1634/stemcells.22-6-1030; Palou E, 2000, TISSUE ANTIGENS, V55, P118, DOI 10.1034/j.1399-0039.2000.550203.x; Palsson B, 2003, TISSUE ENG PRINCIPLE; Petrov RV, 1997, BIOPOLYMERS, V43, P139; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RANIERI JP, 1995, J BIOMED MATER RES, V29, P779, DOI 10.1002/jbm.820290614; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sarkar S, 2006, BIOMATERIALS, V27, P4775, DOI 10.1016/j.biomaterials.2006.04.038; Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Spancake KM, 1999, CANCER RES, V59, P6042; Tuzlakoglu K, 2004, MACROMOL BIOSCI, V4, P811, DOI 10.1002/mabi.200300100; Twal WO, 2001, J CELL SCI, V114, P4587; Wallquist W, 2002, J COMP NEUROL, V454, P284, DOI 10.1002/cne.10434; WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021; Zhang S., 2005, SCAFFOLDING TISSUE E, P217, DOI 10.1201/9781420027563; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375	42	484	519	5	115	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e119	10.1371/journal.pone.0000119	http://dx.doi.org/10.1371/journal.pone.0000119			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205123	Green Published, gold			2022-12-25	WOS:000207443700013
J	Kim, D; Rath, O; Kolch, W; Cho, KH				Kim, D.; Rath, O.; Kolch, W.; Cho, K-H			A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways	ONCOGENE			English	Article						signaling pathways; crosstalk; positive feed-back loop; Wnt pathway; ERK pathway; colorectal cancer	BETA-CATENIN; SIGNALING PATHWAYS; NEGATIVE FEEDBACK; UP-REGULATION; OKADAIC ACID; EXPRESSION; MUTATIONS; TRANSACTIVATION; OVEREXPRESSION; APOPTOSIS	The Wnt and the extracellular signal regulated-kinase (ERK) pathways are both involved in the pathogenesis of various kinds of cancers. Recently, the existence of crosstalk between Wnt and ERK pathways was reported. Gathering all reported results, we have discovered a positive feedback loop embedded in the crosstalk between the Wnt and ERK pathways. We have developed a plausible model that represents the role of this hidden positive feedback loop in the Wnt/ERK pathway crosstalk based on the integration of experimental reports and employing established basic mathematical models of each pathway. Our analysis shows that the positive feedback loop can generate bistability in both the Wnt and ERK signaling pathways, and this prediction was further validated by experiments. In particular, using the commonly accepted assumption that mutations in signaling proteins contribute to cancerogenesis, we have found two conditions through which mutations could evoke an irreversible response leading to a sustained activation of both pathways. One condition is enhanced production of beta-catenin, the other is a reduction of the velocity of MAP kinase phosphatase(s). This enables that high activities of Wnt and ERK pathways are maintained even without a persistent extracellular signal. Thus, our study adds a novel aspect to the molecular mechanisms of carcinogenesis by showing that mutational changes in individual proteins can cause fundamental functional changes well beyond the pathway they function in by a positive feedback loop embedded in crosstalk. Thus, crosstalk between signaling pathways provides a vehicle through which mutations of individual components can affect properties of the system at a larger scale.	Seoul Natl Univ, Bio MAX Inst, Seoul 151818, South Korea; Seoul Natl Univ, Coll Med, Seoul, South Korea; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Seoul National University (SNU); Seoul National University (SNU); Beatson Institute; University of Glasgow	Cho, KH (corresponding author), Seoul Natl Univ, Bio MAX Inst, 3rd Floor,IVI,San 4-8,Bongcheon 7 Dong, Seoul 151818, South Korea.	w.kolch@beatson.gla.ac.uk; ckh-sb@snu.ac.kr	Cho, Kwang-Hyun/C-1684-2011; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Rath, Oliver/D-6523-2018	Rath, Oliver/0000-0001-7986-591X; Kolch, Walter/0000-0001-5777-5016				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Aust DE, 2005, INT J CANCER, V115, P673, DOI 10.1002/ijc.20925; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cho KH, 2003, LECT NOTES COMPUT SC, V2602, P127; Cho KH, 2006, FEBS LETT, V580, P3665, DOI 10.1016/j.febslet.2006.05.053; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Kim CJ, 2005, WORLD J GASTROENTERO, V11, P5006, DOI 10.3748/wjg.v11.i32.5006; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kolch Walter, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004386; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Loda M, 1996, AM J PATHOL, V149, P1553; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rottinger E, 2004, DEVELOPMENT, V131, P1075, DOI 10.1242/dev.01000; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; TAKATA K, 2000, BREED RES, V2, P11; Wolkenhauer O, 2005, BIOCHEM SOC T, V33, P507, DOI 10.1042/BST0330507; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601	36	113	120	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4571	4579		10.1038/sj.onc.1210230	http://dx.doi.org/10.1038/sj.onc.1210230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237813				2022-12-25	WOS:000247836100011
J	Busa, R; Paronetto, MP; Farini, D; Pierantozzi, E; Botti, F; Angelini, DF; Attisani, F; Vespasiani, G; Sette, C				Busa, R.; Paronetto, M. P.; Farini, D.; Pierantozzi, E.; Botti, F.; Angelini, D. F.; Attisani, F.; Vespasiani, G.; Sette, C.			The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; Sam68; cell proliferation; apoptosis; RNA metabolism	CYCLE PROGRESSION; TYROSINE KINASES; KH DOMAIN; SRC; RECEPTOR; ACTIVATION; PHOSPHORYLATION; INHIBITION; EXPRESSION; VARIANT	The tyrosine kinase Src is frequently activated in advanced human prostate carcinomas and its activation correlates with tyrosine phosphorylation of the RNA-binding protein Sam68. Herein, we have investigated the expression and function of Sam68 in human prostate cancer cells. Analysis of speci mens obtained from 20 patients revealed that Sam68 is upregulated at the protein level in 35% of the samples. Real-time polymerase chain reaction con. firmed the results at the mRNA level in most patients. Downregulation of Sam68 by RNAi in LNCaP prostate cancer cells delayed cell cycle progression and reduced the proliferation rate. Moreover, depletion of Sam68 sensitized cells to apoptosis induced by DNA-damaging agents. Similarly, stable cell lines expressing a truncated GFP-Sam68(GSG) protein displayed reduced growth rates and higher sensitivity to cisplatin-induced apoptosis. Microarray analyses revealed that a subset of genes involved in proliferation and apoptosis were altered when Sam68 was knocked down in LNCaP cells. Our results indicate that Sam68 expression supports prostate cancer cells proliferation and survival to cytotoxle agents.	Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Urol, Rome, Italy; IRCCS, Inst Neurosci, Fdn Santa Lucia, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Via Montpellier 1, I-00133 Rome, Italy.	claudio.sette@uniroma2.it	Paronetto, Maria Paola/A-9578-2012; Angelini, Daniela F/J-8001-2018; Sette, Claudio/S-4307-2019	Paronetto, Maria Paola/0000-0001-5324-0903; Angelini, Daniela F/0000-0003-4552-9226; Sette, Claudio/0000-0003-2864-8266; FARINI, DONATELLA/0000-0002-1991-3956; PIERANTOZZI, Enrico/0000-0003-2925-7339				Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li HR, 2006, CANCER RES, V66, P4079, DOI 10.1158/0008-5472.CAN-05-4264; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Palapattu GS, 2005, CARCINOGENESIS, V26, P1170, DOI 10.1093/carcin/bgh317; Paronetto MP, 2006, MOL BIOL CELL, V17, P14, DOI 10.1091/mbc.e05-06-0548; Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002-9440(10)63212-9; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Zhang CL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-202; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	29	140	145	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4372	4382		10.1038/sj.onc.1210224	http://dx.doi.org/10.1038/sj.onc.1210224			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237817				2022-12-25	WOS:000247620000005
J	Singh, B; Berry, JA; Shoher, A; Ayers, GD; Wei, C; Lucci, A				Singh, B.; Berry, J. A.; Shoher, A.; Ayers, G. D.; Wei, C.; Lucci, A.			COX-2 involvement in breast cancer metastasis to bone	ONCOGENE			English	Article						breast cancer; COX-2; mouse model; MF-tricyclic; bone metastasis; cancer prevention	CYCLOOXYGENASE-2 INHIBITOR; OSTEOCLAST FORMATION; PROSTAGLANDIN E-2; IL-11 PRODUCTION; KNOCKOUT MICE; MURINE MODEL; CELL-LINES; EXPRESSION; CELECOXIB; GROWTH	Cyclooxygenase-2 (COX- 2) is expressed in 40% of human invasive breast cancers. Bone is the predominant site of metastasis in case of breast cancer. We investigated the role of COX- 2 in a suitable mouse model of breast cancer metastasis to bone using the whole-body luciferase imaging of cancer cells. We provide several lines of evidence that COX- 2 produced in breast cancer cells is important for bone metastasis in this model including (1) COX- 2 transfection enhanced the bone metastasis of MDA-435S cells and (2) breast cancer cells isolated and cultured from the bone metastases produced significantly more prostaglandin E-2 (an important mediator of COX- 2) than the parental injected cell populations of breast cancer cells. Next, we found that a COX- 2 inhibitor, MF-tricyclic, inhibited bone metastasis caused by a bone-seeking clone both in prevention regimen (in which case mice started receiving MF-tricyclic 1 week before the injection of cancer cells) and in treatment regimen (in which case mice received MF-tricyclic after the development of bone metastasis). These studies indicate that COX- 2 produced in breast cancer cells may be vital to the development of osteolytic bone metastases in patients with breast cancer, and that COX- 2 inhibitors may be useful in halting this process.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Adv Res Ctr Microscop Dis, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lucci, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, 1515 Holcombe Blvd, Houston, TX 77030 USA.	alucci@mdanderson.org		Lucci, Anthony/0000-0003-4039-174X; Berry, Jacob/0000-0002-5241-1720	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067682] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK067682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGUELLO F, 1988, CANCER RES, V48, P6876; Basu GD, 2004, MOL CANCER RES, V2, P632; Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756-3282(03)00086-3; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; D Basu G, 2006, J IMMUNOL, V177, P2391, DOI 10.4049/jimmunol.177.4.2391; Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952-3278(03)00027-9; Gilhooly EM, 1999, INT J ONCOL, V15, P267; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Harms JF, 2003, CLIN EXP METASTAS, V20, P327, DOI 10.1023/A:1024062911144; Harris RE, 2000, CANCER RES, V60, P2101; Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008-5472.CAN-05-2012; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Howe LR, 2002, CANCER RES, V62, P5405; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; Kundu N, 2005, CANCER IMMUNOL IMMUN, V54, P981, DOI 10.1007/s00262-005-0669-2; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Lal G, 2001, CANCER RES, V61, P6131; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774; Ristimaki A, 2002, CANCER RES, V62, P632; Roche-Nagle G, 2004, BRIT J CANCER, V91, P359, DOI 10.1038/sj.bjc.6601967; Shaheen NJ, 2002, CANCER-AM CANCER SOC, V94, P950, DOI 10.1002/cncr.10333; Singh B, 2006, J SURG RES, V131, P267, DOI 10.1016/j.jss.2005.11.582; Singh B, 2005, INT J ONCOL, V26, P1393; Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532; Singh B, 2006, J SURG RES, V134, P44, DOI 10.1016/j.jss.2006.03.018; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Wang HS, 2004, ASSAY DRUG DEV TECHN, V2, P31, DOI 10.1089/154065804322966298; Zhang S, 2004, BREAST CANCER RES TR, V87, P111, DOI 10.1023/B:BREA.0000041593.69178.57	37	104	107	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3789	3796		10.1038/sj.onc.1210154	http://dx.doi.org/10.1038/sj.onc.1210154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213821				2022-12-25	WOS:000247026400003
J	Hey, S; Mayerhofer, H; Halford, NG; Dickinson, JR				Hey, Sandra; Mayerhofer, Hubert; Halford, Nigel G.; Dickinson, J. Richard			DNA sequences from arabidopsis, which encode protein kinases and function as upstream regulators of Snf1 in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON METABOLISM; PHOSPHORYLATION; ACTIVATION; REDUCTASE; PLANTS; SNRK1; CELLS; BETA	Sucrose nonfermenting-1 ( Snf1)-related protein kinase-1 ( SnRK1) of plants is a global regulator of carbon metabolism through the modulation of enzyme activity and gene expression. It is structurally and functionally related to the yeast protein kinase, Snf1, and to mammalian AMP-activated protein kinase. Two DNA sequences from Arabidopsis thaliana, previously known only by their data base accession numbers of NM_125448.3 ( protein ID NP_200863) and NM_114393.3 ( protein ID NP_ 566876) each functionally complemented a Saccharomyces cerevisiae elm1 sak1 tos3 triple mutant. This indicates that the Arabidopsis proteins are able to substitute for one of the missing yeast upstream kinases, which are required for activity of Snf1. Both plant proteins were shown to phosphorylate a peptide with the amino acid sequence of the phosphorylation site in the T-loop of SnRK1 and by inference SnRK1 in Arabidopsis. The proteins encoded by NM_125448.3 and NM_114393.3 have been named AtSnAK1 and AtSnAK2 ( Arabidopsis thaliana SnRK1-activating kinase), respectively. We believe this is the first time that upstream activators of SnRK1 have been described in any plant species.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, Wales; Rothamsted Res, Dept Crop Performance & Improvement, Harpenden AL5 2JQ, Herts, England	Cardiff University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Dickinson, JR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, POB 915, Cardiff CF10 3TL, Wales.	Dickinson@cardiff.ac.uk	Halford, Nigel/B-3872-2009	Halford, Nigel/0000-0001-6488-2530; Mayerhofer, Hubert/0000-0002-3291-2376	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004150] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Halford NG, 2006, ADV BOT RES, V43, P93, DOI 10.1016/S0065-2296(05)43002-5; Halford NG, 2003, PLANT BIOTECHNOL J, V1, P381, DOI 10.1046/j.1467-7652.2003.00046.x; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Harthill JE, 2006, PLANT J, V47, P211, DOI 10.1111/j.1365-313X.2006.02780.x; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kulma A, 2004, PLANT J, V37, P654, DOI 10.1111/j.1365-313X.2003.01992.x; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; McKibbin RS, 2006, PLANT BIOTECHNOL J, V4, P409, DOI 10.1111/j.1467-7652.2006.00190.x; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Rubenstein EM, 2006, EUKARYOT CELL, V5, P620, DOI 10.1128/EC.5.4.620-627.2006; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; Sugden C, 1999, PLANT PHYSIOL, V120, P257, DOI 10.1104/pp.120.1.257; Tiessen A, 2003, PLANT J, V35, P490, DOI 10.1046/j.1365-313X.2003.01823.x; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005	22	37	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10472	10479		10.1074/jbc.M611244200	http://dx.doi.org/10.1074/jbc.M611244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17237223	hybrid, Green Published			2022-12-25	WOS:000245941000039
J	Mohsenin, A; Burdick, MD; Molina, JG; Keane, MP; Blackburn, MR				Mohsenin, Amir; Burdick, Marie D.; Molina, Jose G.; Keane, Michael P.; Blackburn, Michael R.			Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease	FASEB JOURNAL			English	Article						chemokine; asthma; macrophage; adenosine deaminase	DEAMINASE-DEFICIENT MICE; HUMAN ENDOTHELIAL-CELLS; AIRWAY INFLAMMATION; PULMONARY-FIBROSIS; MALIGNANT-MELANOMA; A(2B) RECEPTORS; ASTHMA; INTERLEUKIN-8; CHEMOKINES; EXPRESSION	Angiogenesis is a feature of chronic lung diseases such as asthma and pulmonary fibrosis; however, the pathways controlling pathological angiogenesis during lung disease are not completely understood. Adenosine is a signaling molecule that has been implicated in the exacerbation of chronic lung disease and in the regulation of angiogenesis; however, the relationship between these factors has not been investigated. The current study utilized adenosine deaminase (ADA)-deficient mice to determine whether chronic elevations in adenosine in vivo result in pulmonary angiogenesis. Results demonstrate substantial angiogenesis in the tracheas of ADA-deficient mice in association with adenosine elevations. ADA replacement enzyme therapy resulted in a lowering of adenosine levels and reversal of tracheal angiogenesis, indicating that the increases in vessel number are dependent on adenosine elevations. Levels of the angiogenic chemokine CXCL1 (mouse functional homologue of human IL-8) were found to be elevated in an adenosine-dependent manner in the lungs of ADA-deficient mice. Neutralization of CXCL1 and its receptor, CXCR2, resulted in the inhibition of angiogenic activity, which suggests that CXCL1 signaling through the CXCR2 receptor mediated the observed increases in angiogenesis. Our findings suggest that adenosine plays an important role, via CXCL1, in the induction of pulmonary angiogenesis.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90024 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of California System; University of California Los Angeles	Blackburn, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	Keane, Michael/R-6329-2019	Blackburn, Michael/0000-0002-1394-9966	NHLBI NIH HHS [P50HL67665, HL087186, HL-70952] Funding Source: Medline; NIAID NIH HHS [AI-43572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070952, P50HL067665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Belperio JA, 2005, J IMMUNOL, V175, P6931, DOI 10.4049/jimmunol.175.10.6931; Belperio JA, 2005, J CLIN INVEST, V115, P1150, DOI 10.1172/JCI200524233; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; Bobryshev YV, 2006, MICRON, V37, P208, DOI 10.1016/j.micron.2005.10.007; Burdick MD, 2005, AM J RESP CRIT CARE, V171, P261, DOI 10.1164/rccm.200409-1164OC; Cavaillon JM, 2005, CRIT CARE MED, V33, pS506, DOI 10.1097/01.CCM.0000185502.21012.37; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Csoma Z, 2005, EUR RESPIR J, V25, P873, DOI 10.1183/09031936.05.00110204; Desai A, 2005, MOL PHARMACOL, V67, P1406, DOI 10.1124/mol.104.007807; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; DUSSEAU JW, 1986, CIRC RES, V59, P163, DOI 10.1161/01.RES.59.2.163; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Huszar E, 2002, EUR RESPIR J, V20, P1393, DOI 10.1183/09031936.02.00005002; Jabs CM, 1998, SURGERY, V124, P65, DOI 10.1067/msy.1998.87894; Keane MP, 1997, J IMMUNOL, V159, P1437; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; Kocher AA, 2006, J MOL CELL CARDIOL, V40, P455, DOI 10.1016/j.yjmcc.2005.11.013; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MEININGER CJ, 1988, AM J PHYSIOL, V255, P554; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004; Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002-9440(10)63749-2; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Reid DW, 2003, EUR RESPIR J, V21, P994, DOI 10.1183/09031936.03.00109702; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; TORRY RJ, 1992, AM J PHYSIOL, V262, pH980, DOI 10.1152/ajpheart.1992.262.4.H980; TURNER-WARWICK MARGARET, 1963, THORAX, V18, P225, DOI 10.1136/thx.18.3.225; Varney ML, 2006, AM J CLIN PATHOL, V125, P209, DOI 10.1309/VPL5R.JR7F1D6V03; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; WEBER J, 1989, AM REV RESPIR DIS, V140, P1450, DOI 10.1164/ajrccm/140.5.1450; Xaus J, 1999, J IMMUNOL, V162, P3607; Young HWJ, 2004, J IMMUNOL, V173, P1380, DOI 10.4049/jimmunol.173.2.1380	55	25	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1026	1036		10.1096/fj.06-7301com	http://dx.doi.org/10.1096/fj.06-7301com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227950				2022-12-25	WOS:000245650400007
J	Wang, L; Maher, TJ; Wurtman, RJ				Wang, Lei; Maher, Timothy J.; Wurtman, Richard J.			Oral L-glutamine increases GABA levels in striatal tissue and extracellular fluid	FASEB JOURNAL			English	Article						microdialysis; glutamate; neurotransmitter precursor; hepatic encephalopathy	GAMMA-AMINOBUTYRIC-ACID; INDUCED HEPATIC-ENCEPHALOPATHY; BLOOD-BRAIN-BARRIER; RAT-BRAIN; IN-VIVO; METABOLIC COMPARTMENTATION; TRYPTOPHAN LEVELS; TRANSPORT; RELEASE; AMMONIA	We explored the possibility that circulating glutamine affects gamma-aminobutyric acid (GABA) levels in rat striatal tissue and GABA concentrations in striatal extracellular fluid (ECF). Striatal microdialysates, each collected over a 20 min interval, were obtained after no treatment, oral L-glutamine (0.5 g/kg), or glutamine followed by NMDA ( administered via the microdialysis probe). GABA concentrations were measured by HPLC using a stable OPA/sulfite precolumn derivatization and an electrochemical detection method. L-Glutamine administration significantly increased ECF GABA concentrations by 30%, and enhanced the response evoked by NMDA alone (70%) to 120% over baseline (all P < 0.05). Striatal GABA levels increased significantly 2.5 h after oral L-glutamine ( e. g., from 1.76 +/- 0.04 mu mol/g in vehicle-treated rats to 2.00 +/- 0.15 mu mol/g in those receiving 2.0 g/kg of glutamine). Striatal glutamine levels also increased significantly, but not those of glutamate. These data suggest that GABA synthesis in, and release from, rat striatum may be regulated in part by circulating glutamine. Hence, glutamine administration may provide a useful adjunct for treating disorders ( e. g., anxiety, seizures) when enhanced GABAergic transmission is desired. Moreover, the elevation in plasma and brain glutamine associated with hepatic failure may, by increasing brain GABA release, produce some of the manifestations of hepatic encephalopathy.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Masachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Boston, MA USA	Massachusetts Institute of Technology (MIT)	Wurtman, RJ (corresponding author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,46-5023B, Cambridge, MA 02139 USA.	dick@mit.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH028783] Funding Source: NIH RePORTER; NIMH NIH HHS [2 R01 MH028783-31] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACWORTH IN, 1988, BRAIN RES BULL, V21, P473, DOI 10.1016/0361-9230(88)90161-X; Anagnostaras SG, 1999, NAT NEUROSCI, V2, P780, DOI 10.1038/12146; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; Basile AS, 2002, NEUROCHEM INT, V41, P115, DOI 10.1016/S0197-0186(02)00032-3; BATTAGLIOLI G, 1991, NEUROCHEM RES, V16, P151, DOI 10.1007/BF00965703; Battaglioli G, 1996, NEUROSCI LETT, V209, P129, DOI 10.1016/0304-3940(96)12606-9; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DECHELOTTE P, 1991, AM J PHYSIOL, V260, pG677, DOI 10.1152/ajpgi.1991.260.5.G677; DEJONG CHC, 1992, J NEUROCHEM, V59, P1071, DOI 10.1111/j.1471-4159.1992.tb08349.x; DONZANTI BA, 1988, LIFE SCI, V43, P913, DOI 10.1016/0024-3205(88)90267-6; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; FUNOVICS JM, 1978, J NEURAL TRANSM, P61; GRIPPON P, 1986, HEPATOLOGY, V6, P682, DOI 10.1002/hep.1840060424; HILGIER W, 1994, J NEUROCHEM, V62, P197; Kanamori K, 2005, J NEUROCHEM, V94, P74, DOI 10.1111/j.1471-4159.2005.03170.x; Kanamori K, 2004, J NEUROCHEM, V90, P203, DOI 10.1111/j.1471-4159.2004.02478.x; KEEP RF, 1995, J NEUROCHEM, V65, P2571; Kohling R, 2002, SCIENCE, V298, P1350; Lacey Janet M., 1996, Journal of Parenteral and Enteral Nutrition, V20, P74, DOI 10.1177/014860719602000174; LARSSON OM, 1985, INT J DEV NEUROSCI, V3, P177, DOI 10.1016/0736-5748(85)90008-5; LAVOIE J, 1987, J NEUROCHEM, V49, P692, DOI 10.1111/j.1471-4159.1987.tb00949.x; LIEBSCHUTZ J, 1977, BIOCHEM PHARMACOL, V26, P443, DOI 10.1016/0006-2952(77)90206-4; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; MELAMED E, 1980, P NATL ACAD SCI-BIOL, V77, P4305, DOI 10.1073/pnas.77.7.4305; Pardridge WM, 1979, GLUTAMIC ACID ADV BI, P125; Patel AB, 2001, BRAIN RES, V919, P207, DOI 10.1016/S0006-8993(01)03015-3; PATEL AJ, 1974, J NEUROCHEM, V23, P1271; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Rae C, 2003, J NEUROCHEM, V85, P503, DOI 10.1046/j.1471-4159.2003.01713.x; SCHAECHTER JD, 1990, BRAIN RES, V532, P203, DOI 10.1016/0006-8993(90)91761-5; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; SMITH S, 1994, J CHROMATOGR B, V652, P228, DOI 10.1016/0378-4347(93)E0391-3; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; VANLEEUWEN PAM, 1991, SURGERY, V110, P169; Vogels BAPM, 1997, J HEPATOL, V26, P387, DOI 10.1016/S0168-8278(97)80057-8; Waagepetersen HS, 1999, J NEUROCHEM, V73, P1335, DOI 10.1046/j.1471-4159.1999.0731335.x; WEISER M, 1978, J NEURAL TRANSM, P95; WHITE HL, 1981, MOL CELL BIOCHEM, V39, P253, DOI 10.1007/BF00232578; WURTMAN RJ, 1980, PHARMACOL REV, V32, P315; WYSMYK U, 1992, NEUROCHEM RES, V17, P1187, DOI 10.1007/BF00968397; ZENEROLI ML, 1982, J NEUROCHEM, V38, P1219, DOI 10.1111/j.1471-4159.1982.tb07893.x	44	41	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1227	1232		10.1096/fj.06-7495com	http://dx.doi.org/10.1096/fj.06-7495com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218538				2022-12-25	WOS:000245650400026
J	Han, Y; Joosten, HJ; Niu, WL; Zhao, ZM; Mariano, PS; McCalman, M; van Kan, J; Schaap, PJ; Dunaway-Mariano, D				Han, Ying; Joosten, Henk-Jan; Niu, Weiling; Zhao, Zhiming; Mariano, Patrick S.; McCalman, Melisa; van Kan, Jan; Schaap, Peter J.; Dunaway-Mariano, Debra			Oxaloacetate hydrolase, the C-C bond lyase of oxalate secreting fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXALIC-ACID BIOSYNTHESIS; PETAL DEATH PROTEIN; ASPERGILLUS-NIGER; CRYSTAL-STRUCTURE; ISOCITRATE LYASE; MYCOBACTERIUM-TUBERCULOSIS; SCLEROTINIA-SCLEROTIORUM; 2-METHYLISOCITRATE LYASE; OXALACETATE; CATALYSIS	Oxalate secretion by fungi is known to be associated with fungal pathogenesis. In addition, oxalate toxicity is a concern for the commercial application of fungi in the food and drug industries. Although oxalate is generated through several different biochemical pathways, oxaloacetate acetylhydrolase (OAH)-catalyzed hydrolytic cleavage of oxaloacetate appears to be an especially important route. Below, we report the cloning of the Botrytis cinerea oahA gene and the demonstration that the disruption of this gene results in the loss of oxalate formation. In addition, through complementation we have shown that the intact B. cinerea oahA gene restores oxalate production in an Aspergillus niger mutant strain, lacking a functional oahA gene. These observations clearly indicate that oxalate production in A. niger and B. cinerea is solely dependent on the hydrolytic cleavage of oxaloacetate catalyzed by OAH. In addition, the B. cinera oahA gene was overexpressed in Escherichia coli and the purified OAH was used to define catalytic efficiency, substrate specificity, and metal ion activation. These results are reported along with the discovery of the mechanism-based, tight binding OAH inhibitor 3,3-difluorooxaloacetate (K-i = 68 nm). Finally, we propose that cellular uptake of this inhibitor could reduce oxalate production.	Univ Wageningen & Res Ctr, Microbiol Lab, Sect Fungal Genom, NL-6703 HA Wageningen, Netherlands; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Univ Wageningen & Res Ctr, Lab Phytopathol, NL-6709 PD Wageningen, Netherlands	Wageningen University & Research; University of New Mexico; Wageningen University & Research	Schaap, PJ (corresponding author), Univ Wageningen & Res Ctr, Microbiol Lab, Sect Fungal Genom, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.	peter.schaap@wur.nl; dd39@unm.edu	Han, Ying/G-3278-2012; Niu, Weiling/B-2997-2011	van Kan, Jan/0000-0003-3563-1550; Schaap, Peter/0000-0002-4346-6084	NIGMS NIH HHS [GM 28688] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERG DG, 1992, J AM CHEM SOC, V114, P3535, DOI 10.1021/ja00035a058; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BALMFORTH AJ, 1984, BIOCHEM J, V218, P113, DOI 10.1042/bj2180113; BRILEY PA, 1977, BIOCHEM J, V161, P383, DOI 10.1042/bj1610383; Britton KL, 2000, STRUCTURE, V8, P349, DOI 10.1016/S0969-2126(00)00117-9; CHANG CC, 1968, PLANT PHYSIOL, V43, P1821, DOI 10.1104/pp.43.11.1821; Chaudhuri BN, 2003, STRUCTURE, V11, P753, DOI 10.1016/S0969-2126(03)00106-0; Chen CCH, 2006, BIOCHEMISTRY-US, V45, P11491, DOI 10.1021/bi061208l; DEGRAAFF L, 1992, CURR GENET, V22, P21, DOI 10.1007/BF00351737; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; EMLY M, 1981, J AM CHEM SOC, V103, P628, DOI 10.1021/ja00393a022; ERLICK HA, 1992, PCR TECHNOLOGY PRINC; Gadd GM, 1999, ADV MICROB PHYSIOL, V41, P47, DOI 10.1016/S0065-2911(08)60165-4; GODOY G, 1990, PHYSIOL MOL PLANT P, V37, P179, DOI 10.1016/0885-5765(90)90010-U; Grimm C, 2003, J MOL BIOL, V328, P609, DOI 10.1016/S0022-2836(03)00358-9; Guimaraes RL, 2004, PLANT PHYSIOL, V136, P3703, DOI 10.1104/pp.104.049650; GUO Z, 1999, PLANT PHYSIOL BIOCH, V41, P47; HAMMEL KE, 1994, BIOCHEMISTRY-US, V33, P13349, DOI 10.1021/bi00249a022; HAN Y, 2006, THESIS U NEW MEXICO; HOMBERG U, 1995, CELL TISSUE RES, V279, P249, DOI 10.1007/s004410050280; HOUCK DR, 1987, ARCH BIOCHEM BIOPHYS, V259, P58, DOI 10.1016/0003-9861(87)90470-X; Huang K, 1999, STRUCT FOLD DES, V7, P539, DOI 10.1016/S0969-2126(99)80070-7; Kars I, 2005, MOL PLANT PATHOL, V6, P641, DOI [10.1111/j.1364-3703.2005.00312.x, 10.1111/J.1364-3703.2005.00312.X]; Kirkland BH, 2005, J MED ENTOMOL, V42, P346, DOI 10.1603/0022-2585(2005)042[0346:OAAAFA]2.0.CO;2; KUBICEK CP, 1988, APPL ENVIRON MICROB, V54, P633, DOI 10.1128/AEM.54.3.633-637.1988; LENZ H, 1976, EUR J BIOCHEM, V65, P225, DOI 10.1111/j.1432-1033.1976.tb10409.x; Liu SJ, 2005, BIOCHEMISTRY-US, V44, P2949, DOI 10.1021/bi0479712; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P16365, DOI 10.1021/bi051776l; MAO HK, 1981, INORG CHEM, V20, P4240, DOI 10.1021/ic50226a042; MAXWELL DP, 1968, PHYTOPATHOLOGY, V58, P1635; MILLERD A, 1963, BIOCHEM J, V88, P281, DOI 10.1042/bj0880281; Munir E, 2001, P NATL ACAD SCI USA, V98, P11126, DOI 10.1073/pnas.191389598; Nakagawa Y., 1999, J Infect Chemother, V5, P97, DOI 10.1007/s101560050016; Pedersen H, 2000, MOL GEN GENET, V263, P281, DOI 10.1007/s004380051169; Pedersen H, 2000, METAB ENG, V2, P34, DOI 10.1006/mben.1999.0136; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Ruijter GJG, 1999, MICROBIOL-SGM, V145, P2569, DOI 10.1099/00221287-145-9-2569; SAXTY BA, 1991, EUR J BIOCHEM, V202, P889, DOI 10.1111/j.1432-1033.1991.tb16448.x; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; Teplyakov A, 2005, BIOCHEMISTRY-US, V44, P16377, DOI 10.1021/bi051779y; VANDENHOMBERGH JPTW, 1995, CURR GENET, V28, P299, DOI 10.1007/BF00326427; Weir TL, 2006, PLANTA, V223, P785, DOI 10.1007/s00425-005-0192-x	43	78	89	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9581	9590		10.1074/jbc.M608961200	http://dx.doi.org/10.1074/jbc.M608961200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244616	Green Submitted, hybrid			2022-12-25	WOS:000245421700031
J	Mancuso, DJ; Han, XL; Jenkins, CM; Lehman, JJ; Sambandam, N; Sims, HF; Yang, JY; Yan, W; Yang, K; Green, K; Abendschein, DR; Saffitz, JE; Gross, RW				Mancuso, David J.; Han, Xianlin; Jenkins, Christopher M.; Lehman, John J.; Sambandam, Nandakumar; Sims, Harold F.; Yang, Jingyue; Yan, Wei; Yang, Kui; Green, Karen; Abendschein, Dana R.; Saffitz, Jeffrey E.; Gross, Richard W.			Dramatic accumulation of triglycerides and precipitation of cardiac hemodynamic dysfunction during brief caloric restriction in transgenic myocardium expressing human calcium-independent phospholipase A(2)gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; DIACYLGLYCEROL ACYLTRANSFERASE; DOCOSAHEXAENOIC ACID; TRIACYLGLYCEROL SYNTHESIS; CELLULAR LIPIDOMES; INSULIN-RESISTANCE; SHOTGUN LIPIDOMICS; BIOLOGICAL SAMPLES; MASS-SPECTROMETRY; IDENTIFICATION	Previously, we identified calcium-independent phospholipase A(2)gamma (iPLA(2)gamma) with multiple translation initiation sites and dual mitochondrial and peroxisomal localization motifs. To determine the role of iPLA(2)gamma in integrating lipid and energy metabolism, we generated transgenic mice containing the a-myosin heavy chain promoter (alpha MHC) placed proximally to the human iPLA(2)gamma coding sequence that resulted in cardiac myocyte-restricted expression of iPLA(2)gamma (TGiPLA(2)gamma). TGiPLA(2)gamma mice possessed multiple phenotypes including: 1) a dramatic -35% reduction in myocardial phospholipid mass in both the fed and mildly fasted states; 2) a marked accumulation of triglycerides during brief caloric restriction that represented 50% of total myocardial lipid mass; and 3) acute fasting-induced hemodynamic dysfunction. Biochemical characterization of the TGiPLA(2)gamma protein expressed in cardiac myocytes demonstrated over 25 distinct isoforms by two-dimensional SDS-PAGE Western analysis. Immunohistochemistry identified iPLA(2)gamma in the peroxisomal and mitochondrial compartments in both wild type and transgenic myocardium. Electron microscopy revealed the presence of loosely packed and disorganized mitochondrial cristae in TGiPLA(2)gamma mice that were accompanied by defects in mitochondrial function. Moreover, markedly elevated levels of 1-hydroxyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-hydroxyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine were prominent in the TGiPLA(2)gamma myocardium identifying the production of signaling metabolites by this enzyme in vivo. Collectively, these results identified the participation of iPLA(2)gamma in the remarkable lipid plasticity of myocardium, its role in generating signaling metabolites, and its prominent effects in modulating energy storage and utilization in myocardium in different metabolic contexts.	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovasc Res, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.	rgross@wustl.edu			NHLBI NIH HHS [5P01HL57278-10] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-07, P30 DK056341-06, P30 DK056341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; Ashmarina LI, 1996, BIOCHEM J, V315, P71, DOI 10.1042/bj3150071; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Bian F, 2005, J BIOL CHEM, V280, P9265, DOI 10.1074/jbc.M412850200; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Boehm EA, 2001, AM J PHYSIOL-HEART C, V280, pH977, DOI 10.1152/ajpheart.2001.280.3.H977; Bray GA, 2006, ENDOCRINE, V29, P109, DOI 10.1385/ENDO:29:1:109; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; DiMarzo V, 1996, BIOCHEM BIOPH RES CO, V227, P281, DOI 10.1006/bbrc.1996.1501; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Elphick MR, 2001, PHILOS T R SOC B, V356, P381, DOI 10.1098/rstb.2000.0787; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; Farooqui AA, 2003, ADV EXP MED BIOL, V544, P335; Gadd ME, 2006, J BIOL CHEM, V281, P6931, DOI 10.1074/jbc.M510845200; Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001; Glomset J.A., 2006, SCI STKE, V2006, ppe6, DOI DOI 10.1126/STKE.3212006PE6; GROSS RW, 1984, BIOCHIM BIOPHYS ACTA, V802, P197, DOI 10.1016/0304-4165(84)90161-2; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; Han XL, 2000, BIOCHEM J, V352, P79, DOI 10.1042/0264-6021:3520079; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Han XL, 2005, EXPERT REV PROTEOMIC, V2, P253, DOI 10.1586/14789450.2.2.253; Han XL, 2004, BIOCHEMISTRY-US, V43, P15584, DOI 10.1021/bi048307o; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Hesselink MKC, 2003, OBES RES, V11, P1429, DOI 10.1038/oby.2003.192; Hirafuji M, 2003, J PHARMACOL SCI, V92, P308; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kwong KF, 1998, CIRC RES, V82, P604, DOI 10.1161/01.RES.82.5.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin TM, 2003, BBA-MOL CELL BIOL L, V1634, P63, DOI 10.1016/j.bbalip.2003.09.006; Mancuso DJ, 2004, EUR J BIOCHEM, V271, P4709, DOI 10.1111/j.1432-1033.2004.04435.x; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; McGavock JM, 2006, ANN INTERN MED, V144, P517, DOI 10.7326/0003-4819-144-7-200604040-00011; Murakami M, 2005, J BIOL CHEM, V280, P14028, DOI 10.1074/jbc.M413766200; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; Raz I, 2005, DIABETES-METAB RES, V21, P3, DOI 10.1002/dmrr.493; Saffitz JE, 2000, AM J PHYSIOL-HEART C, V278, pH1662, DOI 10.1152/ajpheart.2000.278.5.H1662; Strokin M, 2004, INT J DEV NEUROSCI, V22, P551, DOI 10.1016/j.ijdevneu.2004.07.002; Su X, 2005, BIOCHEMISTRY-US, V44, P5234, DOI 10.1021/bi047773a; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200; Yang JY, 2003, FEBS LETT, V546, P247, DOI 10.1016/S0014-5793(03)00581-7; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	47	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9216	9227		10.1074/jbc.M607307200	http://dx.doi.org/10.1074/jbc.M607307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17213206	hybrid			2022-12-25	WOS:000245780300068
J	Berro, R; de la Fuente, C; Klase, Z; Kehn, K; Parvin, L; Pumfery, A; Agbottah, E; Vertes, A; Nekhai, S; Kashanchi, F				Berro, Reem; de la Fuente, Cynthia; Klase, Zachary; Kehn, Kylene; Parvin, Lida; Pumfery, Anne; Agbottah, Emmanuel; Vertes, Akos; Nekhai, Sergei; Kashanchi, Fatah			Identifying the membrane proteome of HIV-1 latently infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BRUTONS TYROSINE KINASE; FACTOR-KAPPA-B; LIPID RAFTS; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN INHIBITOR; RNA EXPRESSION; LIVING CELLS; P-TEFB	Profiling integral plasma membrane proteins is of particular importance for the identification of new biomarkers for diagnosis and for drug development. We report in this study the identification of surface markers by performing comparative proteomics of established human immunodeficiency virus-1 (HIV-1) latent cell models and parental cell lines. To this end we isolated integral membrane proteins using a biotin-directed affinity purification method. Isolated proteins were separated by two-dimensional get electrophoresis and identified by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) after in gel digestion. Seventeen different proteins were found to vary on the surface of T-cells due to HIV-1 infection. Of these proteins, 47% were integral membrane proteins, and 18% were membrane-associated. Through the use of complementary techniques such as Western blotting and fluorescent staining, we confirmed the differential expression of some of the proteins identified by MALDI-TOF including Bruton's tyrosine kinase and X-linked inhibitor of apoptosis. Finally, using phosphatidylinositol 3-kinase inhibitors and flavopiridol to inhibit Bruton's tyrosine kinase localization at the membrane and X-linked inhibitor of apoptosis protein expression, respectively, we showed that HIV-1 latently infected cells are more sensitive to these drugs than uninfected cells. This suggests that HIV-1 latently infected cells may be targeted with drugs that alter several pathways that are essential for the establishment and maintenance of latency.	George Washington Univ, Sch Med, Genet Program, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Immunol, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Chem, Washington, DC 20037 USA; Howard Univ, Dept Biochem, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Inst Genom Res, Rockville, MD 20850 USA	George Washington University; George Washington University; George Washington University; George Washington University; Howard University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Genet Program, 2300 1St,NW,Ross Hall,Rm 551, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	, nekhai/AAW-3105-2021; , nekhai/AFO-2652-2022; Kehn-Hall, Kylene/I-5752-2013; Vertes, Akos/B-7159-2008	Vertes, Akos/0000-0001-5186-5352; Kehn-Hall, Kylene/0000-0001-8036-7213	NIAID NIH HHS [R21 AI056973-02, AI043894, AI065236, R21 AI056973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI065236, R01AI043894, R21AI056973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010; Berro R, 2006, J VIROL, V80, P3189, DOI 10.1128/JVI.80.7.3189-3204.2006; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P420, DOI 10.4161/cbt.1.4.21; Bobe R, 2001, BLOOD, V97, P678, DOI 10.1182/blood.V97.3.678; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUTERA ST, 1994, J VIROL, V68, P2726, DOI 10.1128/JVI.68.4.2726-2730.1994; Carlson B. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P424; Carlson KA, 2004, J NEUROIMMUNOL, V147, P35, DOI 10.1016/j.jneuroim.2003.10.039; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fernandez-Figueras MT, 2000, MODERN PATHOL, V13, P438, DOI 10.1038/modpathol.3880075; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fuchigami T, 2002, BIOCHEM BIOPH RES CO, V293, P1107, DOI 10.1016/S0006-291X(02)00329-7; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Islam TC, 2000, IMMUNOL REV, V178, P49, DOI 10.1034/j.1600-065X.2000.17811.x; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; KEKOW J, 1990, P NATL ACAD SCI USA, V87, P8321, DOI 10.1073/pnas.87.21.8321; Lam LT, 2001, GENOME BIOL, V2; Li XD, 1996, VIROLOGY, V225, P196, DOI 10.1006/viro.1996.0588; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Peirce MJ, 2004, MOL CELL PROTEOMICS, V3, P56, DOI 10.1074/mcp.M300064-MCP200; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Pocernich CB, 2005, MOL BRAIN RES, V133, P307, DOI 10.1016/j.molbrainres.2004.10.023; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Rosato R, 2004, LEUKEMIA, V18, P1780, DOI 10.1038/sj.leu.2403491; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Ross TM, 2001, LEUKEMIA, V15, P332, DOI 10.1038/sj.leu.2402028; Schlaifer D, 1996, AM J PATHOL, V149, P177; Shapiro GI, 2004, CLIN CANCER RES, V10, p4270S, DOI 10.1158/1078-0432.CCR-040020; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wittmann S, 2003, CANCER RES, V63, P93; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Zhang W, 2003, ELECTROPHORESIS, V24, P2855, DOI 10.1002/elps.200305569; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004	51	52	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8207	8218		10.1074/jbc.M606324200	http://dx.doi.org/10.1074/jbc.M606324200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237230	hybrid			2022-12-25	WOS:000245081000053
J	Gao, YT; Panda, SP; Roman, LJ; Martasek, P; Ishimura, Y; Masters, BSS				Gao, Ying Tong; Panda, Satya Prakash; Roman, Linda J.; Martasek, Pavel; Ishimura, Yuzuru; Masters, Bettie Sue S.			Oxygen metabolism by neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENASE/FMN DOMAIN CONSTRUCTS; THYROID PLASMA-MEMBRANE; HYDROXY-L-ARGININE; ELECTRON-TRANSFER; SUPEROXIDE ANION; NITROXYL HNO; ISOCITRATE DEHYDROGENASE; HORSERADISH-PEROXIDASE; BIOLOGICAL-ACTIVITY; REDUCTASE DOMAIN	Nitric-oxide synthases (NOS) catalyze nitric oxide (NO) formation from the amino acid L-arginine. NOS is known to catalyze more than one reaction: the NO-producing reaction is considered to be the coupled reaction, and the uncoupled reactions are those that produce reactive (reduced) oxygen species (ROS), such as superoxide anion II and/or hydrogen peroxide (H2O2). As an oxygenase, NOS has been known for more than two decades, yet there is no complete description of oxygen stoichiometry. The present paper is focused on oxygen stoichiometry and the effects of cofactor binding on the neuronal isoform (nNOS) on oxygen uptake and product formation. Products of the uncoupled reactions are analyzed using diacetyldeuteroheme-substituted horseradish peroxidase as a trapping agent for both O-2(-) and H2O2. The addition of calmodulin not only stimulated the oxygen uptake rate but also changed the product of the uncoupled reaction, supporting the possibility of two different sites for electron leakage to molecular oxygen. Quantitative analysis of the uncoupled (substrate-free) reaction revealed a stoichiometry close to the theoretical value, and adding L-arginine not only initiates the coupled reaction, but also inhibits oxygen uptake. The presence of tetrahydrobiopterin affects oxygen metabolism by lowering the apparent K. value of nNOS for oxygen in the uncoupled reaction.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Charles Univ Prague, Sch Med, Dept Biol, Prague 2, Czech Republic; Charles Univ Prague, Sch Med, Dept Pediat, Prague 2, Czech Republic; Keio Univ, Sch Med, Dept Biochem & Integrated Biol, Tokyo 1088345, Japan	University of Texas System; University of Texas Health San Antonio; Charles University Prague; Charles University Prague; Keio University	Masters, BSS (corresponding author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	masters@uthscsa.edu	Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Cunningham MA, 1998, BIOPHYS J, V74, pA133; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DESANDRO V, 1991, EUR J BIOCHEM, V201, P507; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Fridovich I, 1998, J EXP BIOL, V201, P1203; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Fukuto JM, 2005, ANNU REV PHARMACOL, V45, P335, DOI 10.1146/annurev.pharmtox.45.120403.095959; Fukuto JM, 2005, CHEM RES TOXICOL, V18, P790, DOI 10.1021/tx0496800; Fukuto JM, 2005, CHEMBIOCHEM, V6, P612, DOI 10.1002/cbic.200400271; Fukuto JM, 1997, ACCOUNTS CHEM RES, V30, P149, DOI 10.1021/ar960010y; Gao YT, 2004, J BIOL CHEM, V279, P18759, DOI 10.1074/jbc.M308936200; Ghosh DK, 2006, J BIOL CHEM, V281, P14173, DOI 10.1074/jbc.M509937200; Gorren ACF, 2005, METHOD ENZYMOL, V396, P456, DOI 10.1016/S0076-6879(05)96038-2; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HAYAISHI O, 1970, OXGENASES; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; Ishimura Y, 2005, BIOCHEM BIOPH RES CO, V338, P543, DOI 10.1016/j.bbrc.2005.07.202; KLUG D, 1972, J BIOL CHEM, V247, P4839; KORTH HG, 1994, J BIOL CHEM, V269, P17776; KWON NS, 1989, J BIOL CHEM, V264, P20496; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MAKINO R, 1972, J BIOCHEM-TOKYO, V72, P655, DOI 10.1093/oxfordjournals.jbchem.a129943; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1991, FASEB J, V5, pA864; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Miller RT, 1997, FASEB J, V11, pA787; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAKAMURA Y, 1989, J BIOL CHEM, V264, P4759; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; Porasuphatana S, 2003, COMP BIOCHEM PHYS C, V134, P281, DOI 10.1016/S1532-0456(02)00271-5; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Poulos TL, 1999, CURR OPIN CHEM BIOL, V3, P131, DOI 10.1016/S1367-5931(99)80024-6; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reif A, 2001, FREE RADICAL BIO MED, V30, P803, DOI 10.1016/S0891-5849(01)00477-4; Reif A, 2004, FREE RADICAL BIO MED, V37, P988, DOI 10.1016/j.freeradbiomed.2004.07.005; Roman LJ, 2006, J BIOL CHEM, V281, P23111, DOI 10.1074/jbc.M603671200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 2006, NITRIC OXIDE-BIOL CH, V14, pA15, DOI 10.1016/j.niox.2006.04.052; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Smith SME, 2006, NITRIC OXIDE-BIOL CH, V14, pA70, DOI 10.1016/j.niox.2006.04.231; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Song HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI 10.1124/jpet.104.074401; Sono M, 1999, BIOCHEMISTRY-US, V38, P15853, DOI 10.1021/bi991580j; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Tsai P, 2005, BIOCHEM PHARMACOL, V69, P971, DOI 10.1016/j.bcp.2004.12.009; Tsikas D, 2005, FREE RADICAL RES, V39, P797, DOI 10.1080/10715760500053651; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Weaver J, 2005, BBA-GEN SUBJECTS, V1726, P302, DOI 10.1016/j.bbagen.2005.08.012; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; WINK DA, 1996, METHODS NITRIC OXIDE, P403; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200	81	28	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7921	7929		10.1074/jbc.M609814200	http://dx.doi.org/10.1074/jbc.M609814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229730	hybrid			2022-12-25	WOS:000245081000022
J	Immel, F; Jiang, Y; Wang, YQ; Marchal, C; Maillet, L; Perrett, S; Cullin, C				Immel, Francoise; Jiang, Yi; Wang, Yi-Qian; Marchal, Christelle; Maillet, Laurent; Perrett, Sarah; Cullin, Christophe			In vitro analysis of SpUre2p, a prion-related protein, exemplifies the relationship between amyloid and prion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 PROTEIN; URE3 PRION; STRUCTURAL-CHARACTERIZATION; GLUTATHIONE-PEROXIDASE; YEAST URE2P; DOMAIN; CONSERVATION; STABILITY; FILAMENTS	The yeast Saccharomyces cerevisiae contains in its proteome at least three prion proteins. These proteins (Ure2p, Sup35p, and Rnq1p) share a set of remarkable properties. In vivo, they form aggregates that self-perpetuate their aggregation. This aggregation is controlled by Hsp104, which plays a major role in the growth and severing of these prions. In vitro, these prion proteins form amyloid fibrils spontaneously. The introduction of such fibrils made from Ure2p or Sup35p into yeast cells leads to the prion phenotypes [URE3] and [PSI], respectively. Previous studies on evolutionary biology of yeast prions have clearly established that [URE3] is not well conserved in the hemiasco-mycetous yeasts and particularly in S. paradoxus. Here we demonstrated that the S. paradoxus Ure2p is able to form infectious amyloid. These fibrils are more resistant than S. cerevisiae Ure2p fibrils to shear force. The observation, in vivo, of a distinct aggregation pattern for GFP fusions confirms the higher propensity of SpUre2p to form fibrillar structures. Our in vitro and in vivo analysis of aggregation propensity of the S. paradoxus Ure2p provides an explanation for its loss of infective properties and suggests that this protein belongs to the non-prion amyloid world.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Bordeaux 2, CNRS, IBGC, UMR 5095, F-33077 Bordeaux, France; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Perrett, S (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	sarah.perrett@iname.com; Christophe.Cullin@ibgc.u-bordeaux2.fr	Immel, Françoise/N-7079-2019; MAILLET, Laurent/K-7959-2015; Perrett, Sarah/AAS-9483-2020; Immel, Françoise/GNP-4167-2022; cullin, christophe/AAM-2179-2020	MAILLET, Laurent/0000-0002-8169-060X; Perrett, Sarah/0000-0003-0137-0997; Immel, Françoise/0000-0002-2028-902X; cullin, christophe/0000-0003-4110-4677				Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baudin-Baillieu A, 2003, MOL BIOL CELL, V14, P3449, DOI 10.1091/mbc.e03-01-0007; Baxa U, 2005, J STRUCT BIOL, V150, P170, DOI 10.1016/j.jsb.2005.02.007; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Brachmann A, 2005, EMBO J, V24, P3082, DOI 10.1038/sj.emboj.7600772; CARPENTER JF, 1988, CRYOBIOLOGY, V25, P244, DOI 10.1016/0011-2240(88)90032-6; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Fay N, 2005, J BIOL CHEM, V280, P37149, DOI 10.1074/jbc.M506917200; Fernandez-Bellot E, 2000, EMBO J, V19, P3215, DOI 10.1093/emboj/19.13.3215; Fernandez-Bellot E, 1999, BIOCHEM J, V338, P403, DOI 10.1042/0264-6021:3380403; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Komar AA, 1997, FEBS LETT, V415, P6, DOI 10.1016/S0014-5793(97)01082-X; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Pierce MM, 2005, BIOCHEMISTRY-US, V44, P321, DOI 10.1021/bi047964d; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Resende C, 2002, MICROBIOL-SGM, V148, P1049, DOI 10.1099/00221287-148-4-1049; Ripaud L, 2004, J BIOL CHEM, V279, P50962, DOI 10.1074/jbc.M408792200; Ripaud L, 2003, EMBO J, V22, P5251, DOI 10.1093/emboj/cdg488; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Shorter J, 2006, MOL CELL, V23, P425, DOI 10.1016/j.molcel.2006.05.042; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Talarek N, 2005, GENETICS, V171, P23, DOI 10.1534/genetics.105.043489; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tanaka M, 2006, NATURE, V442, P585, DOI 10.1038/nature04922; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; VUILLARD L, 1995, BIOCHEM J, V305, P337, DOI 10.1042/bj3050337; Zhu L, 2003, J MOL BIOL, V328, P235, DOI 10.1016/S0022-2836(03)00249-3	44	13	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7912	7920		10.1074/jbc.M608652200	http://dx.doi.org/10.1074/jbc.M608652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234629	hybrid			2022-12-25	WOS:000245081000021
J	Peterson, FC; Deng, Q; Zettl, M; Prehoda, KE; Lim, WA; Way, M; Volkman, BF				Peterson, Francis C.; Deng, Qing; Zettl, Markus; Prehoda, Kenneth E.; Lim, Wendell A.; Way, Michael; Volkman, Brian F.			Multiple WASP-interacting protein recognition motifs are required for a functional interaction with N-WASP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; X-LINKED THROMBOCYTOPENIA; DOMAIN-PEPTIDE COMPLEX; ACTIN NUCLEATION; ARP2/3 COMPLEX; CHEMICAL-SHIFT; WIP COMPLEX; CHEMOTAXIS; ACTIVATION; MUTATIONS	The WASP-interacting protein (WIP) targets WASP/WAVE proteins through a constitutive interaction with an amino-terminal enabled/VASP homology (EVH1) domain. Parallel investigations had previously identified two distinct N-WASP binding motifs corresponding to WIP residues 451-461 and 461-485, and we determined the structure of a complex between WIP-(461485) and the N-WASP EVH1 domain (Volkman, B. F., Prehoda, K. E., Scott, J. A., Peterson, F. C., and Lim, W. A. (2002) Cell 111, 565-576). The present results show that, when combined, the WIP-(451-485) sequence wraps further around the EVH1 domain, extending the interface observed previously. Specific contacts with three WIP epitopes corresponded to regions of high sequence conservation in the verprolin family. A central polyproline motif occupied the canonical binding site but in a reversed orientation relative to other EVH1 complexes. This interaction was augmented in the amino- and carboxyl-terminal directions by additional hydrophobic contacts involving WIP residues 454-459 and 475-478, respectively. Disruption of any of the three WIP epitopes reduced N-WASP binding in cells, demonstrating a functional requirement for the entire binding domain, which is significantly longer than the polyproline motifs recognized by other EVH1 domains.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; MRC, Cambridge CB2 2QH, England; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; London Res Inst, Canc Res UK, Cell Motil Lab, London WC2A 3PX, England	Medical College of Wisconsin; University of Oregon; University of California System; University of California San Francisco; Cancer Research UK	Volkman, BF (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	bvolkman@mcw.edu	Deng, Qing/G-3923-2011; Deng, Qing/AAC-1123-2020; Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020	Deng, Qing/0000-0002-9254-9951; Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; Way, Michael/0000-0001-7207-2722	NIGMS NIH HHS [GM55940, GM62583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055940, R01GM062583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspenstrom P, 2005, FEBS LETT, V579, P5253, DOI 10.1016/j.febslet.2005.08.053; Aspenstrom P, 2004, EXP CELL RES, V298, P485, DOI 10.1016/j.yexcr.2004.04.050; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Bhattacharyya RP, 2006, SCIENCE, V311, P822, DOI 10.1126/science.1120941; Calle Y, 2004, J PATHOL, V204, P460, DOI 10.1002/path.1651; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; Jones GE, 2002, INT J BIOCHEM CELL B, V34, P806, DOI 10.1016/S1357-2725(01)00162-5; Krzewski K, 2006, J CELL BIOL, V173, P121, DOI 10.1083/jcb.200509076; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Luthi JN, 2003, EXP HEMATOL, V31, P150, DOI 10.1016/S0301-472X(02)01023-8; Lutskiy MI, 2005, J IMMUNOL, V175, P1329, DOI 10.4049/jimmunol.175.2.1329; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Notarangelo LD, 2005, CURR OPIN ALLERGY CL, V5, P485, DOI 10.1097/01.all.0000191243.25757.ce; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rong SB, 2000, J MOL MED, V78, P530, DOI 10.1007/s001090000136; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Savoy DN, 2000, J IMMUNOL, V164, P2866, DOI 10.4049/jimmunol.164.6.2866; Sawa M, 2006, BIOCHEM BIOPH RES CO, V340, P709, DOI 10.1016/j.bbrc.2005.12.056; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Tsuboi S, 2006, J IMMUNOL, V176, P6576, DOI 10.4049/jimmunol.176.11.6576; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zettl M, 2002, CURR BIOL, V12, P1617, DOI 10.1016/S0960-9822(02)01112-0; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	37	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8446	8453		10.1074/jbc.M609902200	http://dx.doi.org/10.1074/jbc.M609902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229736	hybrid			2022-12-25	WOS:000245081000077
J	Goulah, CC; Read, LK				Goulah, Christopher C.; Read, Laurie K.			Differential effects of arginine methylation on RBP16 mRNA binding, guide RNA (gRNA) binding, and gRNA-containing ribonucleoprotein complex (gRNP) formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; COLD-SHOCK DOMAIN; Y-BOX PROTEINS; XENOPUS-OOCYTES; VACCINIA VIRUS; SM PROTEINS; IN-VITRO; TRANSCRIPTION; TRANSLATION; FAMILY	Mitochondrial gene expression in Trypanosoma brucei involves the coordination of multiple events including polycistronic transcript cleavage, polyadenylation, RNA stability, and RNA editing. Arg methylation of RNA binding proteins has the potential to influence many of these processes via regulation of protein-protein and protein-RNA interactions. Here we demonstrate that Arg methylation differentially regulates the RNA binding capacity and macromolecular interactions of the mitochondrial gene regulatory protein, RBP16. We show that, in T brucei mitochondria, RBP16 forms two major stable complexes: a 5 S multiprotein complex and an 11 S complex consisting of the 5 S complex associated with guide RNA (gRNA). Expression of a non-methylatable RBP16 mutant protein demonstrates that Arg methylation of RBP16 is required to maintain the protein-protein interactions necessary for assembly and/or stability of both complexes. Down-regulation of the major trypanosome type I protein arginine methyltransferase, TbPRMT1, disrupts formation of both the 5 and 11 S complexes, indicating that TbPRMT1-catalyzed methylation of RBP16 Arg-78 and Arg-85 is critical for complex formation. We also show that Arg methylation decreases the capacity of RBP16 to associate with gRNA. This is not a general effect on RBP16 RNA binding, however, since methylation conversely increases the association of the protein with mRNA. Thus, TbPRMT1-catalyzed Arg methylation has distinct effects on RBP16 gRNA and mRNA association and gRNA-containing ribonucleoprotein complex (gRNP) formation.	SUNY Buffalo, Sch Med, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Read, LK (corresponding author), SUNY Buffalo, Sch Med, Dept Microbiol & Immunol, 138 Farber Hall, Buffalo, NY 14214 USA.	lread@acsu.buffalo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060260] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI060260] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRUN R, 1979, ACTA TROP, V36, P289; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Goulah CC, 2006, RNA, V12, P1545, DOI 10.1261/rna.90106; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hayman ML, 1999, J BIOL CHEM, V274, P12067, DOI 10.1074/jbc.274.17.12067; Hayman ML, 2001, NUCLEIC ACIDS RES, V29, P5216, DOI 10.1093/nar/29.24.5216; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lukes J, 2005, CURR GENET, V48, P277, DOI 10.1007/s00294-005-0027-0; Lukong KE, 2004, NAT STRUCT MOL BIOL, V11, P914, DOI 10.1038/nsmb1004-914; MASLOV DA, 1994, MOL CELL BIOL, V14, P8174, DOI 10.1128/MCB.14.12.8174; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; McBride AE, 2005, J BIOL CHEM, V280, P30888, DOI 10.1074/jbc.M505831200; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Militello KT, 2000, INT J PARASITOL, V30, P643, DOI 10.1016/S0020-7519(00)00041-2; Militello KT, 1999, NUCLEIC ACIDS RES, V27, P1377, DOI 10.1093/nar/27.5.1377; Miller MM, 2006, RNA, V12, P1292, DOI 10.1261/rna.2331506; Miller MM, 2003, EXP PARASITOL, V105, P140, DOI 10.1016/j.exppara.2003.12.002; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Pelletier M, 2005, MOL BIOCHEM PARASIT, V144, P206, DOI 10.1016/j.molbiopara.2005.08.015; Pelletier M, 2000, NUCLEIC ACIDS RES, V28, P1266, DOI 10.1093/nar/28.5.1266; Pelletier M, 2003, RNA, V9, P457, DOI 10.1261/rna.2160803; Pelletier M, 2001, MOL BIOCHEM PARASIT, V118, P49, DOI 10.1016/S0166-6851(01)00367-X; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; RILEY GR, 1994, J BIOL CHEM, V269, P6101; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Stetler A, 2006, HUM MOL GENET, V15, P87, DOI 10.1093/hmg/ddi429; Stuart K, 2002, MOL MICROBIOL, V45, P591, DOI 10.1046/j.1365-2958.2002.03028.x; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Vondruskova E, 2005, J BIOL CHEM, V280, P2429, DOI 10.1074/jbc.M405933200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yurkova MS, 1997, J BIOL CHEM, V272, P10870	49	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7181	7190		10.1074/jbc.M609485200	http://dx.doi.org/10.1074/jbc.M609485200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17229732	hybrid			2022-12-25	WOS:000245080900030
J	Milgrom, E; Diab, H; Middleton, F; Kane, PM				Milgrom, Elena; Diab, Heba; Middleton, Frank; Kane, Patricia M.			Loss of vacuolar proton-translocating ATPase activity in yeast results in chronic oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; GENOME-WIDE ANALYSIS; SACCHAROMYCES-CEREVISIAE; H+-ATPASE; GENE-EXPRESSION; PROTEIN OXIDATION; LIFE-SPAN; IRON; TRANSPORT; MUTANTS	Yeast mutants lacking vacuolar proton-translocating ATPas (V-ATPase) subunits (vma mutants) were sensitive to several different oxidants in a recent genomic screen (Thorpe, G. W. Fong, C. S., Alic, N., Higgins, V. J., and Dawes, 1. W. (2004) Proc Natl. Acad. Sci. U. S.A. 10 1, 6564 - 6569). We confirmed that mutants lacking a V, subunit (vma2 Delta), V. subunit, or either of the two V. a subunit isoforms are acutely sensitive to H2O2 and more sensitive to menadione and diamide than wild-type cells The vma2 Delta mutant contains elevated levels of reactive oxygen species and high levels of oxidative protein damage even in the absence of an applied oxidant, suggesting an endogenous source of oxidative stress. vma2 Delta mutants lacking mitochondrial DNA showed neither improved growth nor decreased sensitivity to peroxide, excluding respiration as the major source of the endogenous reactive oxygen species in the mutant. Double mutants lacking both VAM2 and components of the major cytosolic defense systems exhibited synthetic sensitivity to H2O2. Microarray analysis comparing wild-type and vma2 Delta mutant cells grown at pH 5, permissive conditions for the vma2 Delta mutant, indicated high level up-regulation of several iron uptake and metabolism genes that are part of the Aft1/Aft2 regulon. TSA2, which encodes an isoform of the cytosolic thioredoxin peroxidase, was strongly induced, but other oxidative stress defense systems were not induced. The results indicate that V-ATPase activity helps to protect cells from endogenous oxidative stress.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Neurosci, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu		Middleton, Frank/0000-0002-3107-7188	NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barros MH, 2004, J BIOL CHEM, V279, P49883, DOI 10.1074/jbc.M408918200; Belli G, 2004, J BIOL CHEM, V279, P12386, DOI 10.1074/jbc.M311879200; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Bonawitz ND, 2006, MOL CELL BIOL, V26, P4818, DOI 10.1128/MCB.02360-05; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANG EC, 1991, J BIOL CHEM, V266, P4417; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Drakulic T, 2005, FEMS YEAST RES, V5, P1215, DOI 10.1016/j.femsyr.2005.06.001; Eide DJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r77; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Grant CM, 1997, FEBS LETT, V410, P219, DOI 10.1016/S0014-5793(97)00592-9; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Haarer BK, 2004, MOL BIOL CELL, V15, P4522, DOI 10.1091/mbc.E04-06-0445; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kaplan J, 2006, BBA-MOL CELL RES, V1763, P646, DOI 10.1016/j.bbamcr.2006.03.008; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mimmack ML, 2004, BIOL PSYCHIAT, V55, P337, DOI 10.1016/j.biopsych.2003.09.007; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Outten CE, 2005, BIOCHEM J, V388, P93, DOI 10.1042/BJ20041914; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Sambrook J, 2001, MOL CLONING LAB MANU, P45; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; SUPEK F, 1994, J BIOL CHEM, V269, P26479; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; van Bakel H, 2005, PHYSIOL GENOMICS, V22, P356, DOI 10.1152/physiolgenomics.00055.2005; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	64	81	85	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7125	7136		10.1074/jbc.M608293200	http://dx.doi.org/10.1074/jbc.M608293200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215245	hybrid			2022-12-25	WOS:000245080900024
J	Rocher, G; Letourneux, C; Lenormand, P; Porteu, F				Rocher, Geraldine; Letourneux, Claire; Lenormand, Philippe; Porteu, Francoise			Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; KINASE-B; CELL-TRANSFORMATION; REGULATORY SUBUNIT; EPITHELIAL-CELLS; BETA-CATENIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; ERK	The importance of PP2A in the regulation of Akt/PKB activity has long been recognized but the nature of the holoenzyme involved and the mechanisms controlling dephosphorylation are not yet known. We identified IEX-1, an early gene product with proliferative and survival activities, as a specific inhibitor of B56 regulatory subunit-containing PP2A. IEX-1 inhibits B56PP2A activity by allowing the phosphorylation of B56 by ERK. This leads to sustained ERK activation. IEX-1 has no effect on PP2A containing other B family subunits. Thus, studying IEX-1 contribution to signaling should help the discovery of new pathways controlled by B56-PP2A. By using overexpression and RNA interference, we show here that IEX-1 increases Akt/PKB activity in response to various growth factors by preventing Akt dephosphorylation on both Thr(308) and Ser(473) residues. PP2A-B56 beta and gamma subunits have the opposite effect and reverse IEX-1-mediated Akt activation. The effect of IEX-1 on Akt is ERK-dependent. Indeed: (i) a IEX-1 mutant deficient in ERK binding had no effect on Akt; (ii) ERK dominant-negative mutants reduced IEX-1-mediated increase in pAkt; (iii) a B56 beta mutant that cannot be phosphorylated in the ERK-IEX-1 complex showed an enhanced ability to compete with IEX-1. These results identify B56-containing PP2A holoenzymes as Akt phosphatases. They suggest that IEX-1 behaves as a general inhibitor of B56 activity, enabling the control of both ERK and Akt signaling downstream of ERK.	Inst Cochin Genet Mol, Dept Hematol, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; CNRS, UMR 8104, F-75014 Paris, France; Univ Paris Descartes, Fac Med Rene Descartes, UMR S 8104, F-75014 Paris, France; CNRS, UMR 6543, Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc, F-06189 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Porteu, F (corresponding author), Hop Cochin, Bat G Roussy,27 Rue Fg St Jacques, F-75014 Paris, France.	Porteu@cochin.inserm.fr	PORTEU, Françoise/I-8445-2016; Lenormand, Philippe/N-5996-2018	PORTEU, Françoise/0000-0002-2403-4163; 				Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen JH, 2005, MOL CELL BIOL, V25, P525, DOI 10.1128/MCB.25.2.525-532.2005; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hamelin V, 2006, BLOOD, V107, P3106, DOI 10.1182/blood-2005-07-2953; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Remy I, 2004, MOL CELL BIOL, V24, P1493, DOI 10.1128/MCB.24.4.1493-1504.2004; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yamada T, 2001, J BIOL CHEM, V276, P5339, DOI 10.1074/jbc.M005685200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zhang YJ, 2003, ONCOGENE, V22, P6845, DOI 10.1038/sj.onc.1206707; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	64	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5468	5477		10.1074/jbc.M609712200	http://dx.doi.org/10.1074/jbc.M609712200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17200115	hybrid			2022-12-25	WOS:000244482300041
J	Vardavas, R; Blower, S				Vardavas, Raffaele; Blower, Sally			The Emergence of HIV Transmitted Resistance in Botswana: "When Will the WHO Detection Threshold Be Exceeded?''	PLOS ONE			English	Article								Background. The Botswana antiretroviral program began in 2002 and currently treats 42,000 patients, with a goal of treating 85,000 by 2009. The World Health Organization (WHO) has begun to implement a surveillance system for detecting transmitted resistance that exceeds a threshold of 5%. However, the WHO has not determined when this threshold will be reached. Here we model the Botswana government's treatment plan and predict, to 2009, the likely stochastic evolution of transmitted resistance. Methods. We developed a model of the stochastic evolution of drug-resistant strains and formulated a birth-death Master equation. We analyzed this equation to obtain an analytical solution of the probabilistic evolutionary trajectory for transmitted resistance, and used treatment and demographic data from Botswana. We determined the temporal dynamics of transmitted resistance as a function of: (i) the transmissibility (i.e., fitness) of the drug-resistant strains that may evolve and (ii) the rate of acquired resistance. Results. Transmitted resistance in Botswana will be unlikely to exceed the WHO's threshold by 2009 even if the rate of acquired resistance is high and the strains that evolve are half as fit as the wild-type strains. However, we also found that transmission of drug-resistant strains in Botswana could increase to similar to 15% by 2009 if the drug-resistant strains that evolve are as fit as the wild-type strains. Conclusions. Transmitted resistance will only be detected by the WHO (by 2009) if the strains that evolve are extremely fit and acquired resistance is high. Initially after a treatment program is begun a threshold lower than 5% should be used; and we advise that predictions should be made before setting a threshold. Our results indicate that it may be several years before the WHO's surveillance system is likely to detect transmitted resistance in other resource-poor countries that have significantly less ambitious treatment programs than Botswana.	[Vardavas, Raffaele; Blower, Sally] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Blower, S (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.	sblower@mednet.ucla.edu	Vardavas, Constantine I/G-7598-2011		NIH/NIAID [RO1 AI041935]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935] Funding Source: NIH RePORTER	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	NIH/NIAID (RO1 AI041935)	[Anonymous], 2004, MED NEWS TODAY; Baggaley RF, 2006, PLOS MED, V3, P493, DOI 10.1371/journal.pmed.0030124; Bailey N. T. J., 1964, ELEMENTS STOCHASTIC; Barbour JD, 2004, J INFECT DIS, V190, P251, DOI 10.1086/422036; Bertagnolio S, 2005, AIDS, V19, P1329, DOI 10.1097/01.aids.0000180107.19006.02; Blackham J, 2005, AIDS, V19, P487; Blower S, 2005, AIDS, V19, P1, DOI 10.1097/00002030-200501030-00001; Blower S., 2003, AIDS Reviews, V5, P113; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Blower SM, 2001, NAT MED, V7, P1016, DOI 10.1038/nm0901-1016; Bouchonnet F, 2005, J VIROL, V79, P812, DOI 10.1128/JVI.79.2.812-822.2005; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; French Martyn, 2002, HIV Clin Trials, V3, P177; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; KHAN AB, 2003, NATL HIV AIDS STRATE; Lloyd AL, 2004, THEOR POPUL BIOL, V65, P49, DOI 10.1016/j.tpb.2003.07.002; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; Mode CJ., 2000, STOCHASTIC PROCESSES; Myatt M, 2003, B WORLD HEALTH ORGAN, V81, P877; Porter K, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406002-00002; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Susman E, 2004, AIDS, V18, pN1, DOI 10.1097/00002030-200401230-00001; Tang JW, 2004, J CLIN VIROL, V30, P1, DOI 10.1016/j.jcv.2003.12.002; Vergne L, 2003, AIDS, V17, pS31, DOI 10.1097/00002030-200317003-00005; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; Wensing Annemarie M. J., 2003, AIDS Reviews, V5, P140; WHO, 2003, GUIDELINES SURVEILLA; *WHO, 2005, HIVRESNET PLEN M	35	47	49	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e152	10.1371/journal.pone.0000152	http://dx.doi.org/10.1371/journal.pone.0000152			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225857	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444000004
J	Hua, Z; Lv, Q; Ye, WB; Wong, CKA; Cai, GP; Gu, DY; Ji, YH; Zhao, C; Wang, JF; Yang, BB; Zhang, Y				Hua, Zhong; Lv, Qing; Ye, Wenbin; Wong, Chung-Kwun Amy; Cai, Guoping; Gu, Dayong; Ji, Yanhong; Zhao, Chen; Wang, Jifeng; Yang, Burton B.; Zhang, Yaou			MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia	PLOS ONE			English	Article							MICRORNA EXPRESSION; P53; MICROARRAYS; PREDICTION; BIOLOGY; RNAS	MicroRNAs (miRNAs) are a class of 20-24 nt non-coding RNAs that regulate gene expression primarily through post-transcriptional repression or mRNA degradation in a sequence-specific manner. The roles of miRNAs are just beginning to be understood, but the study of miRNA function has been limited by poor understanding of the general principles of gene regulation by miRNAs. Here we used CNE cells from a human nasopharyngeal carcinoma cell line as a cellular system to investigate miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia, and to explore the principles of gene regulation by miRNAs. Through computational analysis, 96 miRNAs were predicted as putative regulators of VEGF. But when we analyzed the miRNA expression profile of CNE and four other VEGF-expressing cell lines, we found that only some of these miRNAs could be involved in VEGF regulation, and that VEGF may be regulated by different miRNAs that were differentially chosen from 96 putative regulatory miRNAs of VEGF in different cells. Some of these miRNAs also co-regulate other angiogenic factors ( differential regulation and co-regulation principle). We also found that VEGF was regulated by multiple miRNAs using different combinations, including both coordinate and competitive interactions. The coordinate principle states that miRNAs with independent binding sites in a gene can produce coordinate action to increase the repressive effect of miRNAs on this gene. By contrast, the competitive principle states when multiple miRNAs compete with each other for a common binding site, or when a functional miRNA competes with a false positive miRNA for the same binding site, the repressive effects of miRNAs may be decreased. Through the competitive principle, false positive miRNAs, which cannot directly repress gene expression, can sometimes play a role in miRNA-mediated gene regulation. The competitive principle, differential regulation, multi-miRNA binding sites, and false positive miRNAs might be useful strategies in the avoidance of unwanted cross-action among genes targeted by miRNAs with multiple targets.	[Wong, Chung-Kwun Amy; Yang, Burton B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Hua, Zhong; Lv, Qing; Ye, Wenbin; Cai, Guoping; Gu, Dayong; Ji, Yanhong; Zhang, Yaou] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Shenzhen 518057, Peoples R China; [Zhao, Chen] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Xian 710049, Peoples R China; [Wang, Jifeng] Beijing Univ Chinese Med, Cell & Biochem Lab, Beijing, Peoples R China	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Xi'an Jiaotong University; Beijing University of Chinese Medicine	Yang, BB (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	byang@sri.utoronto.ca; zhangyo@sz.tsinghua.edu.cn	Lyu, Qing/AAF-5181-2021; Lyu, Qing/AAP-8387-2020; Hua, Zhong/J-8149-2014	Lyu, Qing/0000-0002-1325-6828; gu, dayong/0000-0002-9547-8474	National Natural Science Foundation of China [30611120519]; Canadian Institutes of Health Research [MOP-62729]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a China-Canada Joint Health Research Initiative grant from the National Natural Science Foundation of China (Grant No. 30611120519) and Canadian Institutes of Health Research to Yaou Zhang and Burton B. Yang, and Grant MOP-62729 from Canadian Institutes of Health Research to Burton B. Yang.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernhart SH, 2006, ALGORITHM MOL BIOL, V1, DOI 10.1186/1748-7188-1-3; Enright AJ, 2004, GENOME BIOL, V5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Karp X, 2005, SCIENCE, V310, P1288, DOI 10.1126/science.1121566; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Mallory AC, 2006, NAT GENET, V38, pS31, DOI 10.1038/ng1791; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Nakahara K, 2004, CURR OPIN CELL BIOL, V16, P127, DOI 10.1016/j.ceb.2004.02.006; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang MB, 2005, CURR OPIN PLANT BIOL, V8, P216, DOI 10.1016/j.pbi.2005.01.006; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu YJ, 2005, MATRIX BIOL, V24, P3, DOI 10.1016/j.matbio.2004.11.007; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010	40	520	559	1	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e116	10.1371/journal.pone.0000116	http://dx.doi.org/10.1371/journal.pone.0000116			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205120	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700010
J	Roato, I; Brunetti, G; Gorassini, E; Grano, M; Colucci, S; Bonello, L; Buffoni, L; Manfredi, R; Ruffini, E; Ottaviani, D; Ciuffreda, L; Mussa, A; Ferracini, R				Roato, Ilaria; Brunetti, Giacomina; Gorassini, Eva; Grano, Maria; Colucci, Silvia; Bonello, Lisa; Buffoni, Lucio; Manfredi, Roberto; Ruffini, Enrico; Ottaviani, Davide; Ciuffreda, Libero; Mussa, Antonio; Ferracini, Riccardo			IL-7 Up-Regulates TNF-alpha-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor	PLOS ONE			English	Article								Background. Interleukin-7 (IL-7) is a potent regulator of lymphocyte development, which has also significant effects on bone; in fact it is a potent osteoclastogenic factor. Some human solid tumors produce high IL-7 levels, suggesting a potential IL-7 role on tumor development and progression. Methodology. We studied 50 male patients affected by solid tumors, and their blood samples were collected at tumor diagnosis. PBMCs were isolated and cultured with/without IL-7 to study its influence on osteoclastogenesis. Serum and cell culture supernatant IL-7 levels were measured by ELISA. The quantitative analysis of IL-7 expression on T and B cells was performed by Real-Time PCR. Principal Findings. Serum IL-7 levels were highest in osteolytic cancer patients, followed by cancer patients without bone lesions, and then healthy controls. We showed the IL-7 production in PBMC cultures and particularly in monocyte and B cell co-cultures. A quantitative analysis of IL-7 expression in T and B cells confirmed that B cells had a high IL-7 expression. In all cell culture conditions, IL-7 significantly increased osteoclastogenesis and an anti-IL-7 antibody inhibited it. We demonstrated that IL-7 supports OC formation by inducing the TNF-alpha production and low RANKL levels, which synergize in promoting osteoclastogenesis. Conclusions. We demonstrated the presence of high serum IL-7 levels in patients with bone metastasis, suggesting the use of serum IL-7 level as a clinical marker of disease progression and of bone involvement. Moreover, we showed the capability of IL-7 to stimulate spontaneous osteoclastogenesis of bone metastatic patients and to induce osteoclastogenesis in cancer patients without bone involvement. These findings add further details to the disclosure of the mechanisms controlling bone metastasis in solid tumors.	[Roato, Ilaria; Gorassini, Eva; Bonello, Lisa] Univ Turin, CeRMS, Turin, Italy; [Brunetti, Giacomina; Grano, Maria; Colucci, Silvia] Univ Bari, Dept Human Anat & Histol, Bari, Italy; [Roato, Ilaria; Buffoni, Lucio; Ottaviani, Davide; Ciuffreda, Libero; Mussa, Antonio] Univ Turin, Dept Med Oncol, Turin, Italy; [Manfredi, Roberto] Osped Civile, Dept Med Oncol, Asti, Italy; [Ruffini, Enrico] AZO San Giovanni Battista, Dept Torac Surg, Turin, Italy; [Ferracini, Riccardo] AZO San Giovanni Battista, Dept Orthopaed, Turin, Italy; [Roato, Ilaria; Gorassini, Eva; Bonello, Lisa] AZO San Giovanni Battista, CeRMS, Turin, Italy; [Roato, Ilaria; Buffoni, Lucio; Ottaviani, Davide; Ciuffreda, Libero; Mussa, Antonio] AZO San Giovanni Battista, Dept Med Oncol, Turin, Italy	University of Turin; Universita degli Studi di Bari Aldo Moro; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Roato, I (corresponding author), Univ Turin, CeRMS, Turin, Italy.	roato78@libero.it	Giacomina, Brunetti/J-7692-2016; Ferracini, Riccardo/AAL-4622-2020	Giacomina, Brunetti/0000-0002-0681-1432; Grano, Maria/0000-0002-7121-5899; Colucci, Silvia/0000-0001-9970-3539; Roato, Ilaria/0000-0003-3029-4743; Ruffini, Enrico/0000-0002-7225-2456	Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS); Compagnia di San Paolo, "Special Project Oncology"	Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS); Compagnia di San Paolo, "Special Project Oncology"(Compagnia di San Paolo)	This work was mainly supported by a grant from Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS) and from Compagnia di San Paolo, "Special Project Oncology".	Al-Rawi MAA, 2004, EUR J CANCER, V40, P494, DOI 10.1016/j.ejca.2003.10.016; Al-Rawi MAA, 2003, HISTOL HISTOPATHOL, V18, P911, DOI 10.14670/HH-18.911; Appasamy PM, 1999, CYTOKINES CELL MOL T, V5, P25; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chopra V, 1997, J CANCER RES CLIN, V123, P167, DOI 10.1007/BF01214669; Chopra V, 1996, Cancer J Sci Am, V2, P279; Cosenza L, 2002, CELL SIGNAL, V14, P317, DOI 10.1016/S0898-6568(01)00245-5; DAMELIO P, 2006, BONE; DEBENEDETTI F, 1995, J RHEUMATOL, V22, P1581; EDER M, 1992, BLOOD, V79, P3274; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; FOSS HD, 1995, AM J PATHOL, V146, P33; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood-2002-04-1121; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee SK, 2003, ENDOCRINOLOGY, V144, P3524, DOI 10.1210/en.2002-221057; Li LQ, 2000, SCAND J IMMUNOL, V51, P361; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LONG BW, 1995, P NATL ACAD SCI USA, V92, P1416, DOI 10.1073/pnas.92.5.1416; Maeurer MJ, 1997, SCAND J IMMUNOL, V45, P182, DOI 10.1046/j.1365-3083.1997.d01-384.x; Miyaura C, 1997, P NATL ACAD SCI USA, V94, P9360, DOI 10.1073/pnas.94.17.9360; Okopien B, 2005, J CARDIOVASC PHARM, V46, P377, DOI 10.1097/01.fjc.0000175455.46245.c8; Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04-1823fje; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Sharma S, 1996, CANCER GENE THER, V3, P302; Szepietowski JC, 2000, CLIN EXP DERMATOL, V25, P643, DOI 10.1046/j.1365-2230.2000.00727.x; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100; Trinder P, 1999, INT J ONCOL, V14, P23; van Roon JAG, 2003, ANN RHEUM DIS, V62, P113, DOI 10.1136/ard.62.2.113; Varas A, 1998, BLOOD, V92, P93, DOI 10.1182/blood.V92.1.93.413a03_93_100; Wasilewska A, 2005, PEDIATR INT, V47, P424, DOI 10.1111/j.1442-200x.2005.02078.x; Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878; Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328; Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687	39	53	56	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e124	10.1371/journal.pone.0000124	http://dx.doi.org/10.1371/journal.pone.0000124			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205128	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700018
J	Chen, CH; Lu, PJ; Chen, YC; Fu, SL; Wu, KJ; Tsou, AP; Lee, YCG; Lin, TCE; Hsu, SL; Lin, WJ; Huang, CYF; Chou, CK				Chen, C-H; Lu, P-J; Chen, Y-C; Fu, S-L; Wu, K-J; Tsou, A-P; Lee, Y-C G.; Lin, T-C E.; Hsu, S-L; Lin, W-J; Huang, C-Y F.; Chou, C-K			FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway	ONCOGENE			English	Article						HCC; PI3K interaction protein; PI3K/AKT	HUMAN HEPATOCELLULAR-CARCINOMA; 3-KINASE PATHWAY; BETA-CATENIN; AURORA-A; C-MYC; EXPRESSION; PROTEIN; GENE; CANCER; PHOSPHORYLATION	A significant challenge in the post-genomic era is how to prioritize differentially expressed and uncharacterized novel genes found in hepatocellular carcinoma (HCC) microarray profiling. One such category is cell cycle regulated genes that have only evolved in higher organisms but not in lower eukaryotic cells. Characterization of these genes may reveal some novel human cancer-specific abnormalities. A novel transcript, FLJ10540 was identified. FLJ10540 is overexpressed in HCC as examined by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. The patients with higher FLJ10540 expression had a poor survival than those with lower FLJ10540 expression. Functional characterization indicates that FLJ10540 displays a number of characteristics associated with an oncogene, including anchorage-independent growth, enhanced cell growth at low serum levels and induction of tumorigenesis in nude mice. FLJ10540-elicited cell transformation is mediated by activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway. Moreover, FLJ10540 forms a complex with PI3K and can activate PI3K activity, which provides a mechanistic basis for FLJ10540-mediated oncogenesis. Together, using a combination of bioinformatics searches and empirical data, we have identified a novel oncogene, FLJ10540, which is conserved only in higher organisms. The finding raises the possibility that FLJ10540 is a potential new therapeutic target for HCC treatment. These findings may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in cancer cells.	Natl Hlth Res Inst, Canc Res Inst, Taipei 114, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli County, Taiwan; Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; Kaohsiung Vet Gen Hosp, Dept Surg, Div Gen Surg, Kaohsiung, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Taipei Med Univ, Grad Inst Med Informat, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan; Natl Yang Ming Univ, Inst Bio Pharmaceut Sci, Taipei 112, Taiwan; Chang Gung Univ, Dept Life Sci, Tao Yuan, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chang Gung University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Canc Res Inst, Room 9321,No 161,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	chiying@nhri.org.tw; ckchou@mail.cgu.edu.tw	Wu, Kou-Juey/P-4654-2015; Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YL, 2004, CANCER RES, V64, P8723, DOI 10.1158/0008-5472.CAN-03-3091; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Fu SL, 2005, BIOCHEM BIOPH RES CO, V338, P830, DOI 10.1016/j.bbrc.2005.10.045; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; Kim SA, 2006, CANCER LETT, V235, P53, DOI 10.1016/j.canlet.2005.04.003; Kobayashi N, 2003, BLOOD, V102, P3186, DOI 10.1182/blood-2003-02-0567; Kolligs FT, 2000, GENE DEV, V14, P1319; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Okano J, 2003, BIOCHEM BIOPH RES CO, V309, P298, DOI 10.1016/j.bbrc.2003.04.002; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Su LJ, 2006, GENE EXPRESSION, V13, P107, DOI 10.3727/000000006783991872; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu XD, 2004, ONCOL REP, V11, P25; Yang CW, 2005, BIOCHEM BIOPH RES CO, V330, P489, DOI 10.1016/j.bbrc.2005.03.005; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	29	71	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4272	4283		10.1038/sj.onc.1210207	http://dx.doi.org/10.1038/sj.onc.1210207			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237822				2022-12-25	WOS:000247619900010
J	Mussmann, R; Geese, M; Harder, F; Kegel, S; Andag, U; Lomow, A; Burk, U; Onichtchouk, D; Dohrmann, C; Austen, M				Mussmann, Rainer; Geese, Marcus; Harder, Friedrich; Kegel, Simone; Andag, Uwe; Lomow, Alexander; Burk, Ulrike; Onichtchouk, Daria; Dohrmann, Cord; Austen, Matthias			Inhibition of GSK3 promotes replication and survival of pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; EPIDERMAL-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASE-4; TYPE-2 DIABETES-MELLITUS; ISLET REGENERATION; IN-VITRO; GLUCOSE; PROLIFERATION; MASS; ACTIVATION	Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible. A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control. Here we report that the inactivation of GSK3 by small molecule inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells. Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concentrations of glucose and the saturated fatty acid palmitate on INS-1E cells. Furthermore, treatment of isolated rat islets with structurally diverse small molecule GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls. We propose that GSK3 is a regulator of beta cell replication and survival. Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.	DeveloGen AG, D-37079 Gottingen, Germany		Mussmann, R (corresponding author), DeveloGen AG, Marie Curie Str 7, D-37079 Gottingen, Germany.	mussmann@develogen.com; austen@develogen.com	Onichtchouk, Daria/E-1741-2012	Onichtchouk, Daria/0000-0001-6497-1445				Arulmozhi DK, 2006, EUR J PHARM SCI, V28, P96, DOI 10.1016/j.ejps.2006.01.003; Atkinson MA, 2005, DIABETES, V54, P1253, DOI 10.2337/diabetes.54.5.1253; Baggio LL, 2006, ANNU REV MED, V57, P265, DOI 10.1146/annurev.med.57.110104.115624; Beattie GM, 2002, DIABETES, V51, P3435, DOI 10.2337/diabetes.51.12.3435; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bernard-Kargar C, 2001, DIABETES, V50, pS30, DOI 10.2337/diabetes.50.2007.S30; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Boucher MJ, 2006, J BIOL CHEM, V281, P6395, DOI 10.1074/jbc.M511597200; Bouwens L, 2005, PHYSIOL REV, V85, P1255, DOI 10.1152/physrev.00025.2004; BRELJE TC, 1994, DIABETES, V43, P263, DOI 10.2337/diabetes.43.2.263; Brun T, 2004, J CELL BIOL, V167, P1123, DOI 10.1083/jcb.200405148; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen SY, 2006, P NATL ACAD SCI USA, V103, P8469, DOI 10.1073/pnas.0602921103; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cozar-Castellano I, 2004, DIABETES, V53, P149, DOI 10.2337/diabetes.53.1.149; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dokken BB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1188, DOI 10.1152/ajpendo.00547.2004; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; El-Assaad W, 2003, ENDOCRINOLOGY, V144, P4154, DOI 10.1210/en.2003-0410; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Gianani R, 2005, IMMUNOL REV, V204, P232, DOI 10.1111/j.0105-2896.2005.00248.x; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Jetton TL, 2005, DIABETES, V54, P2294, DOI 10.2337/diabetes.54.8.2294; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kaidanovich-Beilin O, 2006, J PHARMACOL EXP THER, V316, P17, DOI 10.1124/jpet.105.090266; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kunick C, 2004, BIOORG MED CHEM LETT, V14, P413, DOI 10.1016/j.bmcl.2003.10.062; Kypta RM, 2005, EXPERT OPIN THER PAT, V15, P1315, DOI 10.1517/13543776.15.10.1315; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Meier JJ, 2005, DIABETOLOGIA, V48, P2221, DOI 10.1007/s00125-005-1949-2; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Mu J, 2006, DIABETES, V55, P1695, DOI 10.2337/db05-1602; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Murtaugh LC, 2005, DEVELOPMENT, V132, P4663, DOI 10.1242/dev.02063; Ogawa N, 2004, DIABETES, V53, P1700, DOI 10.2337/diabetes.53.7.1700; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Papadopoulou S, 2005, DIABETES, V54, P2844, DOI 10.2337/diabetes.54.10.2844; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pospisilik JA, 2003, DIABETES, V52, P741, DOI 10.2337/diabetes.52.3.741; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Reimer MK, 2002, EUR J ENDOCRINOL, V146, P717, DOI 10.1530/eje.0.1460717; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Rooman I, 2004, DIABETOLOGIA, V47, P259, DOI 10.1007/s00125-003-1287-1; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Steffes MW, 2003, DIABETES CARE, V26, P832, DOI 10.2337/diacare.26.3.832; Suarez-Pinzon WL, 2005, J CLIN ENDOCR METAB, V90, P3401, DOI 10.1210/jc.2004-0761; Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339; Trucco M, 2005, J CLIN INVEST, V115, P5, DOI 10.1172/JCI200523935; Trumper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Tyrberg B, 2001, DIABETES, V50, P301, DOI 10.2337/diabetes.50.2.301; Vasavada RC, 2006, INT J BIOCHEM CELL B, V38, P931, DOI 10.1016/j.biocel.2005.08.003; von Herrath M, 2004, PEDIATR DIABETES, V5, P23, DOI 10.1111/j.1399-543X.2004.00076.x; Wagman AS, 2004, CURR PHARM DESIGN, V10, P1105, DOI 10.2174/1381612043452668; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Wente W, 2006, DIABETES, V55, P2470, DOI 10.2337/db05-1435; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Yoon KH, 2003, J CLIN ENDOCR METAB, V88, P2300, DOI 10.1210/jc.2002-020735	85	113	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12030	12037		10.1074/jbc.M609637200	http://dx.doi.org/10.1074/jbc.M609637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17242403	hybrid			2022-12-25	WOS:000245941900045
J	Ishibashi, Y; Nakasone, T; Kiyohara, M; Horibata, Y; Sakaguchi, K; Hijikata, A; Ichinose, S; Omori, A; Yasui, Y; Imamura, A; Ishida, H; Kiso, M; Okino, N; Ito, M				Ishibashi, Yohei; Nakasone, Toru; Kiyohara, Masashi; Horibata, Yasuhiro; Sakaguchi, Keishi; Hijikata, Atsushi; Ichinose, Sachiyo; Omori, Akira; Yasui, Yasuyuki; Imamura, Akihiro; Ishida, Hideharu; Kiso, Makoto; Okino, Nozomu; Ito, Makoto			A novel endoglycoceramidase hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHINOCOCCUS-MULTILOCULARIS; TRICHODERMA-VIRIDE; MOLECULAR-CLONING; RHODOCOCCUS SP; GLYCOSPHINGOLIPIDS; SEQUENCE; PURIFICATION; STRAIN; METACESTODES; EXPRESSION	Enzymes capable of hydrolyzing the beta-glycosidic linkage between oligosaccharides and ceramides in various glyco-sphingolipids has been found in microorganisms and invertebrates and designated endoglycoceramidase ( EC 3.2.1.123) or ceramide glycanase. Here we report the molecular cloning, characterization, and homology modeling of a novel endoglycoceramidase that hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides. The novel enzyme was purified from a culture supernatant of Rhodococcus equi, and the gene encoding 488 deduced amino acids was cloned using peptide sequences of the purified enzyme. Eight residues essential for the catalytic reaction in microbial and animal endoglycoceramidases were all conserved in the deduced amino acid sequence of the novel enzyme. Homology modeling of the enzyme using endocellulase E1 as a template revealed that the enzyme displays a (beta/alpha)(8) barrel structure in which Glu(234) at the end of beta-strand 4 and Glu(341) at the end of beta-strand 7 could function as an acid/base catalyst and a nucleophile, respectively. Site-directed mutagenesis of these glutamates resulted in a complete loss of the activity without a change in their CD spectra. The recombinant enzyme hydrolyzed the beta-galactosidic linkage between oligosaccharides and ceramides of 6-gala series glycosphingolipids that were completely resistant to hydrolysis by the enzymes reported so far. In contrast, the novel enzyme did not hydrolyze ganglio-, globo-, or lacto- series glycosphingolipids. The enzyme is therefore systematically named "oligogalactosyl-N-acylsphingosine 1,1'-beta-galactohydrolase" or tentatively designated " endogalactosylceramidase."	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Gifu Univ, Fac Appl Biol Sci, Gifu 5011193, Japan	Kyushu University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); RIKEN; Gifu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-ac.jp	Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818; Hijikata, Atsushi/0000-0003-4297-8368				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aoki K, 2004, J BIOL CHEM, V279, P32028, DOI 10.1074/jbc.M312918200; ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; Chisada S, 2005, BIOCHEM BIOPH RES CO, V333, P367, DOI 10.1016/j.bbrc.2005.05.110; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DENNIS RD, 1992, EUR J BIOCHEM, V207, P1053, DOI 10.1111/j.1432-1033.1992.tb17142.x; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HIGASHI H, 1990, ANAL BIOCHEM, V186, P355, DOI 10.1016/0003-2697(90)90094-P; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; International Union of Biochemistry and Molecular Biology, 1992, ENZ NOM; ISEGAWA Y, 1992, MOL CELL PROBE, V6, P467, DOI 10.1016/0890-8508(92)90043-W; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KAWAKAMI Y, 1993, J BIOCHEM-TOKYO, V114, P677, DOI 10.1093/oxfordjournals.jbchem.a124236; Kotake T, 2004, BIOCHEM J, V377, P749, DOI 10.1042/bj20031145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MATSUBARA T, 1981, J BIOCHEM-TOKYO, V89, P645, DOI 10.1093/oxfordjournals.jbchem.a133241; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; Noda N, 1996, CHEM PHARM BULL, V44, P895, DOI 10.1248/cpb.44.895; Okemoto K, 2003, CARBOHYD RES, V338, P219, DOI 10.1016/S0008-6215(02)00405-6; Persat F, 1996, INFECT IMMUN, V64, P3682, DOI 10.1128/IAI.64.9.3682-3687.1996; PERSAT F, 1992, J BIOL CHEM, V267, P8764; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sakaguchi K, 1999, BIOCHEM BIOPH RES CO, V260, P89, DOI 10.1006/bbrc.1999.0855; Sakaguchi K, 2000, J BIOCHEM-TOKYO, V128, P145, DOI 10.1093/oxfordjournals.jbchem.a022725; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sugita M, 1995, BBA-LIPID LIPID MET, V1259, P220, DOI 10.1016/0005-2760(95)00168-9; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	43	42	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11386	11396		10.1074/jbc.M608445200	http://dx.doi.org/10.1074/jbc.M608445200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17244618	hybrid			2022-12-25	WOS:000245941500061
J	Sohn, DH; Lee, KY; Lee, C; Oh, J; Chung, H; Jeon, SH; Seong, RH				Sohn, Dong H.; Lee, Kyoo Y.; Lee, Changjin; Oh, Jaehak; Chung, Heekyoung; Jeon, Sung H.; Seong, Rho H.			SRG3 interacts directly with the major components of the SWI/SNF chromatin remodeling complex and protects them from proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCED APOPTOSIS; RECEPTOR-DEPENDENT TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; SWIRM DOMAIN; EXPRESSION; PROTEINS; HOMOLOG; BINDING; DNA; TRANSACTIVATION	The mammalian SWI/SNF complex is an evolutionarily conserved ATP-dependent chromatin remodeling complex that consists of nine or more components. SRG3, a murine homologue of yeast SWI3, Drosophila MOIRA, and human BAF155, is a core component of the murine SWI/SNF complex required for the regulation of transcriptional processes associated with development, cellular differentiation, and proliferation. Here we report that SRG3 interacts directly with other components of the mammalian SWI/SNF complex such as SNF5, BRG1, and BAF60a. The SWIRM domain and the SANT domain were required for SRG3-SNF5 and SRG3-BRG1 interactions, respectively. In addition, SRG3 stabilized SNF5, BRG1, and BAF60a by attenuating their proteasomal degradation, suggesting its general role in the stabilization of the SWI/SNF complex. Such a stabilization effect of SRG3 was not only observed in the in vitro cell system, but also in cells isolated from SRG3 transgenic mice or knock-out mice haploinsufficient for the Srg3 gene. Taken together, these results suggest the critical role of SRG3 in the post-transcriptional stabilization of the major components of the SWI/SNF complex.	Seoul Natl Univ, Res Ctr Funct Cellulom, Seoul 151742, South Korea; Seoul Natl Univ, Dept Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; Hallym Univ, Dept Life Sci, Chunchon 200702, South Korea; Hallym Univ, Inst Biosci & Biotechnol, Chunchon 200702, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Hallym University; Hallym University	Seong, RH (corresponding author), Seoul Natl Univ, Res Ctr Funct Cellulom, Bldg 105,San 56-1, Seoul 151742, South Korea.	rhseong@snu.ac.kr		Seong, Rho/0000-0001-5699-0718				Biegel JA, 1999, CANCER RES, V59, P74; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; Da GP, 2006, P NATL ACAD SCI USA, V103, P2057, DOI 10.1073/pnas.0510949103; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Iyer L. M, 2002, GENOME BIOL, V3; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Qian CM, 2005, NAT STRUCT MOL BIOL, V12, P1078, DOI 10.1038/nsmb1022; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; Singh MV, 2004, MOL CELL BIOL, V24, P4929, DOI 10.1128/MCB.24.11.4929-4942.2004; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; Tochio N, 2006, STRUCTURE, V14, P457, DOI 10.1016/j.str.2005.12.004; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Treich I, 1997, MOL CELL BIOL, V17, P1768, DOI 10.1128/MCB.17.4.1768; Treich I, 1998, NUCLEIC ACIDS RES, V26, P3739, DOI 10.1093/nar/26.16.3739; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117	50	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10614	10624		10.1074/jbc.M610563200	http://dx.doi.org/10.1074/jbc.M610563200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17255092	hybrid			2022-12-25	WOS:000245941000055
J	Kumar, N; Robidoux, J; Daniel, KW; Guzman, G; Floering, LM; Collins, S				Kumar, Naresh; Robidoux, Jacques; Daniel, Kiefer W.; Guzman, Gabriel; Floering, Lisa M.; Collins, Sheila			Requirement of vimentin filament assembly for beta(3)-adrenergic receptor activation of ERK MAP kinase and lipolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; CYTOSKELETON; SRC; CLONING; CELLS; CDNA; GENE	Catecholamine stimulation of beta-adrenergic receptors (beta AR) in adipocytes activates the cAMP-dependent protein kinase to promote liberation of fatty acids as a fuel source. The adipocyte beta(3)AR also activates extracellular signal-regulated kinases (ERK)-1 and -2 through direct recruitment and activation of Src kinase. This pathway together with cAMP-dependent protein kinase contributes to maximal beta(3)AR-stimulated lipolysis. In a search for other molecules that might associate with beta(3)AR upon agonist stimulation, we identified vimentin using a proteomics approach. Immunoprecipitation of beta(3)AR from adipocytes in the absence or presence of the beta(3)AR agonist CL316,243, followed by Western blotting for vimentin confirmed this specific interaction. Since vimentin has also been identified on lipid droplets, the functional consequences of blocking the expression or structural integrity of vimentin intermediate filaments on beta(3)AR regulation of ERK activation and lipolysis was assessed. Following disruption of intermediate filaments with beta,beta'-iminodipropionitrile, as confirmed by confocal microscopy, beta(3)AR-stimulated ERK activation was blocked, and lipolysis was reduced by more than 40%. Independently, depletion of vimentin by small hairpin RNA (shRNA) completely inhibited beta(3)AR-mediated ERK activation and significantly reduced lipolysis. By contrast, disruption of actin-containing microfilaments by cytochalasin D or microtubules by nocodazole had no effect on either lipolysis or ERK activation. These results indicate that vimentin plays an essential role in the signal transduction pathway from beta(3)AR to the activation ERK and its contribution to lipolysis.	Hamner Inst Hlth Sci, Program Encocrine Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	The Hamner Institutes for Health Sciences; Duke University	Collins, S (corresponding author), Chem Ind Inst Toxicol, Ctr Hlth Res, 6 Davis Dr,Box 12137, Res Triangle Pk, NC 27709 USA.	scollins@thehamner.org		Robidoux, JAcques/0000-0002-4809-4734	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053092, R01DK057698] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53092, R01-DK57698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMANUMA K, 1986, VIRCHOWS ARCH A, V410, P231; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Helfand BT, 2005, TRENDS CELL BIOL, V15, P568, DOI 10.1016/j.tcb.2005.09.009; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Lieber JG, 1996, J CELL SCI, V109, P3047; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Martin NP, 2004, CELL SIGNAL, V16, P1397, DOI 10.1016/j.cellsig.2004.05.002; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Parker Carol E., 2005, V301, P117; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Robidoux J, 2006, J BIOL CHEM, V281, P37794, DOI 10.1074/jbc.M605572200; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605	27	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9244	9250		10.1074/jbc.M605571200	http://dx.doi.org/10.1074/jbc.M605571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17251187	hybrid			2022-12-25	WOS:000245780300071
J	Xie, ZJ; Bikle, DD				Xie, Zhongjian; Bikle, Daniel D.			The recruitment of phosphatidylinositol 3-kinase to the E-cadherin-catenin complex at the plasma membrane is required for calcium-induced phospholipase C-gamma 1 activation and human keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMAS; TYROSINE KINASE SUBSTRATE; BETA-CATENIN; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR CALCIUM; ADHESION COMPLEX; EPIDERMAL-CELLS; C-GAMMA; ULTRASTRUCTURAL-LOCALIZATION; MURINE KERATINOCYTES	Calcium induces epidermal keratinocyte differentiation, but the mechanism is not completely understood. We have previously demonstrated that calcium-induced human keratinocyte differentiation requires an intracellular calcium rise caused by phosphatidylinositol 3-kinase (PI3K)-dependent activation of phospholipase C-gamma 1. In this study we sought to identify the upstream signaling pathway necessary for calcium activation of PI3K and its subsequent activation of phospholipase C-gamma 1. We found that calcium induces the recruitment of PI3K to the E-cadherin-catenin complex at the plasma membrane of human keratinocytes. Knocking-down E-cadherin, beta-catenin, or p120-catenin expression blocked calcium activation of PI3K and phospholipase C-gamma 1 and calcium-induced keratinocyte differentiation. However, knocking-down gamma-catenin expression had no effect. Calcium-induced PI3K recruitment to E-cadherin stabilized by p120-catenin at the plasma membrane requires beta-catenin but not gamma-catenin. These data indicate that the recruitment of PI3K to the E-cadherin/beta-catenin/p120-catenin complex via beta-catenin at the plasma membrane is required for calcium-induced phospholipase C-gamma 1 activation and, ultimately, keratinocyte differentiation.	Vet Affairs Med Ctr, Endocrine Unit, N Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA	Northern California Institute for Research & Education; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Xie, ZJ (corresponding author), Vet Affairs Med Ctr, Endocrine Unit, N Calif Inst Res & Educ, 4150 Clement St 111N, San Francisco, CA 94121 USA.	Zhongjian.Xie@ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038386, P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR038386, P01AR39448] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andrews NA, 1997, BRIT J CANCER, V75, P1474, DOI 10.1038/bjc.1997.252; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Elias PM, 2002, J INVEST DERMATOL, V119, P1128, DOI 10.1046/j.1523-1747.2002.19512.x; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FURUKAWA F, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P802, DOI 10.1111/j.1346-8138.1994.tb03294.x; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lawlor MA, 2001, J CELL SCI, V114, P2903; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MATTIJSSEN V, 1993, INT J CANCER, V55, P580, DOI 10.1002/ijc.2910550411; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Posthaus H, 2002, J CELL SCI, V115, P4587, DOI 10.1242/jcs.00141; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; REISS M, 1991, J CELL PHYSIOL, V147, P281, DOI 10.1002/jcp.1041470213; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100; Troyanovsky S, 2005, EUR J CELL BIOL, V84, P225, DOI 10.1016/j.ejcb.2004.12.009; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Wu H, 2000, ANTICANCER RES, V20, P1385; XIAO K, 2003, J CELL BIOL, V163, P437; Xie ZJ, 2005, MOL BIOL CELL, V16, P3236, DOI 10.1091/mbc.E05-02-0109; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Young P, 2003, EMBO J, V22, P5723, DOI 10.1093/emboj/cdg560; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	60	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8695	8703		10.1074/jbc.M609135200	http://dx.doi.org/10.1074/jbc.M609135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242406	hybrid			2022-12-25	WOS:000245780300015
J	Raue, U; Oellerer, S; Rospert, S				Raue, Uta; Oellerer, Stefan; Rospert, Sabine			Association of protein biogenesis factors at the yeast ribosomal tunnel exit is affected by the translational status and nascent polypeptide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; RETRACTED ARTICLE. SEE; SACCHAROMYCES-CEREVISIAE; TRIGGER FACTOR; ESCHERICHIA-COLI; COMPLEX; CHAPERONES; HSP70; INTERACTS; REQUIRES	Ribosome-associated protein biogenesis factors (RPBs) act during a short but critical period of protein biogenesis. The action of RPBs starts as soon as a nascent polypeptide becomes accessible from the outside of the ribosome and ends upon termination of translation. In yeast, RPBs include the chaperones Ssb1/2 and ribosome-associated complex, signal recognition particle, nascent polypeptide-associated complex (NAC), the aminopeptidases Map1 and Map2, and the N-terminal acetyltransferase NatA. Here, we provide the first comprehensive analysis of RPB binding at the yeast ribosomal tunnel exit as a function of translational status and polypeptide sequence. We measured the ratios of RPBs to ribosomes in yeast cells and determined RPB occupation of translating and non-translating ribosomes. The combined results imply a requirement for dynamic and coordinated interactions at the tunnel exit. Exclusively, NAC was associated with the majority of ribosomes regardless of their translational status. All other RPBs occupied only ribosomal subpopulations, binding with increased apparent affinity to randomly translating ribosomes as compared with non-translating ones. Analysis of RPB interaction with homogenous ribosome populations engaged in the translation of specific nascent polypeptides revealed that the affinities of Ssb 1/2, NAC, and, as expected, signal recognition particle, were influenced by the amino acid sequence of the nascent polypeptide. Complementary cross-linking data suggest that not only affinity of RPBs to the ribosome but also positioning can be influenced in a nascent polypeptide-dependent manner.	Zentrum Biochem & Mol Zellforsch, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	University of Freiburg	Rospert, S (corresponding author), Zentrum Biochem & Mol Zellforsch, Inst Biochem & Mol Biol, Herrmann Herder Str 7, D-79104 Freiburg, Germany.	sabine.rospert@biochemie.uni-freiburg.de		Rospert, Sabine/0000-0002-3089-9614				Albanese V, 2006, CELL, V124, P75, DOI 10.1016/j.cell.2005.11.039; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BONVEN B, 1979, MOL GEN GENET, V170, P225, DOI 10.1007/BF00337800; CAPLAN S, 1991, GENETICS, V127, P299; Eisner G, 2006, J BIOL CHEM, V281, P7172, DOI 10.1074/jbc.M511388200; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; GARCIA PD, 1991, METHOD ENZYMOL, V194, P675; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Grallath S, 2006, EMBO REP, V7, P78, DOI 10.1038/sj.embor.7400551; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; Huang P, 2005, NAT STRUCT MOL BIOL, V12, P497, DOI 10.1038/nsmb942; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Maier T, 2005, CURR OPIN STRUC BIOL, V15, P204, DOI 10.1016/j.sbi.2005.03.005; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Polevoda B, 2003, BIOCHEM BIOPH RES CO, V308, P1, DOI 10.1016/S0006-291X(03)01316-0; Pool MR, 2005, MOL MEMBR BIOL, V22, P3, DOI 10.1080/09687860400026348; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rakwalska M, 2004, MOL CELL BIOL, V24, P9186, DOI 10.1128/MCB.24.20.9186-9197.2004; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; ROSPERT S, 2005, PROTEIN FOLDING HDB, V2, P429; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Ullers RS, 2006, J BIOL CHEM, V281, P13999, DOI 10.1074/jbc.M600638200; Vetro JA, 2002, J CELL BIOCHEM, V85, P678, DOI 10.1002/jcb.10161; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; Wegrzyn RD, 2006, J BIOL CHEM, V281, P2847, DOI 10.1074/jbc.M511420200; Wegrzyn RD, 2005, CELL MOL LIFE SCI, V62, P2727, DOI 10.1007/s00018-005-5292-z; Wild K, 2004, NAT STRUCT MOL BIOL, V11, P1049, DOI 10.1038/nsmb853; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809	50	91	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7809	7816		10.1074/jbc.M611436200	http://dx.doi.org/10.1074/jbc.M611436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229726	hybrid			2022-12-25	WOS:000245081000009
J	Rizzo, JM; Tarsio, M; Martinez-Munoz, GA; Kane, PM				Rizzo, Jason M.; Tarsio, Maureen; Martinez-Munoz, Gloria A.; Kane, Patricia M.			Diploids heterozygous for a vma13 Delta mutation in Saccharomyces cerevisiae highlight the importance of V-ATPase subunit balance in supporting vacuolar acidification and silencing cytosolic V-1-ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; GENETIC-ANALYSIS; DELTA-SUBUNIT; IN-VIVO; YEAST; MEMBRANE; LETHAL; PHENOTYPE; MUTANTS; PURIFICATION	The V-ATPase H subunit (encoded by the VMA13 gene) activates ATP-driven proton pumping in intact V-ATPase complexes and inhibits MgATPase activity in cytosolic V, sectors (Parra, K. J., Keenan, K. L., and Kane, P. M. (2000) J. Biol. Chem. 275, 21761-21767). Yeast diploids heterozygous for a vma13 Delta mutation show the pH- and calcium-dependent conditional lethality characteristic of mutants lacking V-ATPase activity, although they still contain one wild-type copy of VAM13. Vacuolar vesicles from this strain have similar to 50% of the ATPase activity of those from a wild-type diploid but do not support formation of a proton gradient. Compound heterozygotes with a second heterozygous deletion in another V-1 subunit gene exhibit improved growth, vacuolar acidification, and ATP-driven proton transport in vacuolar vesicles. In contrast, compound heterozygotes with a second deletion in a V-o subunit grow even more poorly than the vma13 Delta heterozygote, have very little vacuolar acidification, and have very low levels of V-ATPase subunits in isolated vacuoles. In addition, cytosolic V-1 sectors from this strain and from the strain containing only the heterozygous vma13 Delta mutation have elevated MgATPase activity. The results suggest that balancing levels of subunit H with those of other V-ATPase subunits is critical, both for allowing organelle acidification and for preventing unproductive hydrolysis of cytosolic ATP.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Syracuse University	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NIGMS NIH HHS [R01 GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali R, 2004, J BIOL CHEM, V279, P4498, DOI 10.1074/jbc.M307446200; Allan AK, 2005, PHYSIOL GENOMICS, V22, P128, DOI 10.1152/physiolgenomics.00233.2004; Borthwick KJ, 2002, CURR OPIN NEPHROL HY, V11, P563, DOI 10.1097/00041552-200209000-00013; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P16305, DOI 10.1074/jbc.M513805200; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FENG Y, 1992, J BIOL CHEM, V267, P19769; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Gruber G, 2001, J EXP BIOL, V204, P2597; Haghighi K, 2006, P NATL ACAD SCI USA, V103, P1388, DOI 10.1073/pnas.0510519103; HO MN, 1993, J BIOL CHEM, V268, P18286; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; KANE PM, 1995, J BIOL CHEM, V270, P17025; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Liu ML, 2005, J BIOL CHEM, V280, P36978, DOI 10.1074/jbc.M505296200; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Padilla-Lopez S, 2006, J BIOL CHEM, V281, P10273, DOI 10.1074/jbc.M510625200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Ramaesh T, 2006, INVEST OPHTH VIS SCI, V47, P1911, DOI 10.1167/iovs.05-1028; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; SHERMAN F, 1982, METHODS YEAST GENETI, P177; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200	42	16	17	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8521	8532		10.1074/jbc.M607092200	http://dx.doi.org/10.1074/jbc.M607092200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17234635	hybrid			2022-12-25	WOS:000245081000084
J	Stoj, CS; Augustine, AJ; Solomon, EI; Kosman, DJ				Stoj, Christopher S.; Augustine, Anthony J.; Solomon, Edward I.; Kosman, Daniel J.			Structure-function analysis of the cuprous oxidase activity in Fet3p from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMA-MEMBRANE; HUMAN CERULOPLASMIN; IRON UPTAKE; MULTICOPPER OXIDASES; NEURODEGENERATIVE DISEASE; FERROXIDASE ACTIVITY; ELECTRON-TRANSFER; ESCHERICHIA-COLI; COPPER OXIDASE; TRACE COPPER	The Fet3 protein from Saccharomyces cerevisiae is a multi-copper oxidase with specificity toward Fe(II) and Cu(I). Fet3p turnover of Fe(II) supports high affinity iron uptake across the yeast plasma membrane, whereas its turnover of Cu(I) contributes to copper resistance in yeast. The structure of Fet3p has been used to identify possible amino acid residues responsible for this protein's reactivity with Cu(I), and structure-function analyses have confirmed this assignment. Fet3p Met(345) is required for the enzyme's reactivity toward Cu(I). Although the Fet3pM345A mutant exhibits wild type spectral and electrochemical behavior, the kinetic constants for Cu(I) turnover and for single-turnover electron transfer from Cu(I) to the enzyme are significantly reduced. The specificity constant with Cu(I) as substrate is reduced by one-fifth, whereas the electron transfer rate from Cu(I) is reduced 50-fold. This mutation has little effect on the reactivity toward Fe(II), indicating that Met 345 contributes specifically to Fet3p reactivity with the cuprous ion. These kinetic defects render the Fet3pM345A unable to support wild type cellular copper resistance, suggesting that there is a finely tuned copper redox balance at the yeast plasma membrane.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Stanford University	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@buffalo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031450, R37DK031450, R01DK053820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31450, DK53820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; FREIDEN E, 1976, ADV EXP MED BIOL, V74, P505; Frieden E, 1974, Adv Exp Med Biol, V48, P235; Grass G, 2001, BIOCHEM BIOPH RES CO, V286, P902, DOI 10.1006/bbrc.2001.5474; Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Kosman DJ, 2002, ADV PROTEIN CHEM, V60, P221; Kwok EY, 2006, BIOCHEMISTRY-US, V45, P6317, DOI 10.1021/bi052173c; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; Machonkin TE, 2000, J AM CHEM SOC, V122, P12547, DOI 10.1021/ja002339r; Machonkin TE, 2001, J AM CHEM SOC, V123, P5507, DOI 10.1021/ja003975s; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; NAKANO M, 1993, EUR NEUROL, V33, P44, DOI 10.1159/000118537; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 2002, J NEUROSCI, V22, P6578; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Pierre JL, 1999, BIOMETALS, V12, P195, DOI 10.1023/A:1009252919854; Quintanar L, 2004, J AM CHEM SOC, V126, P6579, DOI 10.1021/ja049220t; Roberts SA, 2003, J BIOL CHEM, V278, P31958, DOI 10.1074/jbc.M302963200; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shi XL, 2003, J BIOL CHEM, V278, P50309, DOI 10.1074/jbc.M307019200; Singh A, 2006, J BIOL CHEM, V281, P13355, DOI 10.1074/jbc.M512042200; Singh SK, 2004, J BACTERIOL, V186, P7815, DOI 10.1128/JB.186.22.7815-7817.2004; Solomon EI, 2004, CHEM REV, V104, P419, DOI 10.1021/cr0206317; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stoj C, 2003, FEBS LETT, V554, P422, DOI 10.1016/S0014-5793(03)01218-3; Stoj C.S., 2006, ENCYCL INORG CHEM, DOI [10.1002/0470862106.ia055, DOI 10.1002/0470862106.IA055]; Stoj CS, 2006, BIOCHEMISTRY-US, V45, P12741, DOI 10.1021/bi061543+; Taylor AB, 2005, P NATL ACAD SCI USA, V102, P15459, DOI 10.1073/pnas.0506227102; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; Urbanski NK, 2000, ACTA BIOCHIM POL, V47, P951; Wang TP, 2003, J BIOL INORG CHEM, V8, P611, DOI 10.1007/s00775-003-0456-5; White AR, 2004, J BIOL INORG CHEM, V9, P269, DOI 10.1007/s00775-004-0521-8; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	47	18	19	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7862	7868		10.1074/jbc.M609766200	http://dx.doi.org/10.1074/jbc.M609766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17220296	hybrid			2022-12-25	WOS:000245081000015
J	Anderson, SG; Williams, CR; O'Donnell, M; Bloom, LB				Anderson, Stephen G.; Williams, Christopher R.; O'Donnell, Mike; Bloom, Linda B.			A function for the psi subunit in loading the Escherichia coli DNA polymerase sliding clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; III ACCESSORY PROTEINS; CELL NUCLEAR ANTIGEN; GAMMA-COMPLEX; LOADER COMPLEX; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; BETA-SUBUNIT; STRUCTURAL-ANALYSIS	Crystal structures of an Escherichia coli clamp loader have provided insight into the mechanism by which this molecular machine assembles ring-shaped sliding clamps onto DNA. The contributions made to the clamp loading reaction by two subunits, chi and psi, which are not present in the crystal structures, were determined by measuring the activities of three forms of the clamp loader, gamma(3)delta delta', gamma(3)delta delta'psi, and gamma(3)delta delta'psi chi. The psi subunit is important for stabilizing an ATP-induced conformational. state with high affinity for DNA, whereas the X subunit does not contribute directly to clamp loading in our assays lacking single-stranded DNA-binding protein. The psi subunit also increases the affinity of the clamp loader for the clamp in assays in which ATP gamma S is substituted for ATP. Interestingly, the affinity of the gamma(3)delta delta' complex for beta is no greater in the presence than in the absence of ATP gamma S. A role for psi in stabilizing or promoting ATP- and ATP gamma S-induced conformational changes may explain why large conformational differences were not seen in gamma(3)delta delta' structures with and without bound ATP gamma S. The beta clamp partially compensates for the activity of psi when this subunit is not present and possibly serves as a scaffold on which the clamp loader adopts the appropriate conformation for DNA binding and clamp loading. Results from our work and others suggest that the psi subunit may introduce a temporal order to the clamp loading reaction in which clamp binding precedes DNA binding.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	lbloom@ufl.edu	Bloom, Linda B/F-3684-2014		NIGMS NIH HHS [GM055596, R01 GM055596, GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 2004, EUR J BIOCHEM, V271, P439, DOI 10.1046/j.1432-1033.2003.03944.x; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Jarvis TC, 2005, J BIOL CHEM, V280, P40465, DOI 10.1074/jbc.M508310200; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; Johnson A, 2006, J BIOL CHEM, V281, P35531, DOI 10.1074/jbc.M606090200; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; Kazmirski SL, 2004, P NATL ACAD SCI USA, V101, P16750, DOI 10.1073/pnas.0407904101; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; MAKI S, 1988, J BIOL CHEM, V263, P6555; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; Miyata T, 2005, P NATL ACAD SCI USA, V102, P13795, DOI 10.1073/pnas.0506447102; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; O'Donnell M, 2006, CURR OPIN STRUC BIOL, V16, P35, DOI 10.1016/j.sbi.2005.12.004; O'Donnell M, 2006, J BIOL CHEM, V281, P10653, DOI 10.1074/jbc.R500028200; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Podobnik M, 2003, STRUCTURE, V11, P253, DOI 10.1016/S0969-2126(03)00027-3; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Snyder AK, 2004, J BIOL CHEM, V279, P4386, DOI 10.1074/jbc.M310430200; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Williams CR, 2004, J BIOL CHEM, V279, P4376, DOI 10.1074/jbc.M310429200; WILLIAMS CR, 2003, THESIS U FLORIDA GAI; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Zhuang Z, 2004, NAT STRUCT MOL BIOL, V11, P580, DOI 10.1038/nsmb0704-580	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7035	7045		10.1074/jbc.M610136200	http://dx.doi.org/10.1074/jbc.M610136200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210572	hybrid			2022-12-25	WOS:000245080900015
J	Hou, ZB; He, LS; Qi, RZ				Hou, Zhibo; He, Lisheng; Qi, Robert Z.			Regulation of S6 kinase 1 activation by phosphorylation at Ser-411	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; MAMMALIAN TARGET; IN-VIVO; RAPAMYCIN; P70(S6K); MTOR; CDK5; SITES	Ribosomal S6 kinase 1 (S6K1), as a key regulator of mRNA translation, plays an important role in cell cycle progression through the G, phase of proliferating cells and in the synaptic plasticity of terminally differentiated neurons. Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus. Phosphorylation at Thr-389 is also a crucial event in S6K1 activation. Here, we report that S6K1 phosphorylation at Ser-411 is required for the rapamycin-sensitive phosphorylation of Thr-389 and the subsequent activation of S6KI. Mutation of Ser-411 to Ala ablated insulin-induced Thr-389 phosphorylation and S6K1 activation, whereas mutation mimicking Ser-411 phosphorylation did not show any effect. Furthermore, phosphomimetic mutation of Thr-389 overcame the inhibitory effect of the mutation S411A. Thus, Ser-411 phosphorylation regulates S6K1 activation via the control of Thr-389 phosphorylation. In nervous system neurons, Cdk5-p35 kinase associates with S6K1 via the direct interaction between p35 and S6K1 and catalyzes S6KI phosphorylation specifically at Ser-411. Inhibition of the Cdk5 activity or suppression of Cdk5 expression blocked S6K1 phosphorylation at Ser-411 and Thr-389, resulting in S6K1 inactivation. Similar results were obtained by treating asynchronous populations of proliferating cells with the CDK inhibitor compound roscovitine. Altogether, our findings suggest a novel mechanism by which the CDK-mediated phosphorylation regulates the activation of S6K1.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Qi, RZ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	qirz@ust.hk		Qi, Robert Zhong/0000-0001-5596-8172				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FERRARI S, 1993, J BIOL CHEM, V268, P16091; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Johnson K, 2005, J NEUROCHEM, V93, P538, DOI 10.1111/j.1471-4159.2004.03004.x; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lim ACB, 2004, J BIOL CHEM, V279, P46668, DOI 10.1074/jbc.M404760200; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621	40	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6922	6928		10.1074/jbc.M607836200	http://dx.doi.org/10.1074/jbc.M607836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17220300	hybrid			2022-12-25	WOS:000245080900003
J	Liu, CX; Ranganathan, S; Robinson, S; Strickland, DK				Liu, Chun-Xiang; Ranganathan, Sripriya; Robinson, Susan; Strickland, Dudley K.			gamma-secretase-mediated release of the low density lipoprotein receptor-related protein 1B intracellular domain suppresses anchorage-independent growth of neuroglioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; REGULATED INTRAMEMBRANE PROTEOLYSIS; PRESENILIN/GAMMA-SECRETASE; NUCLEAR-LOCALIZATION; CYTOPLASMIC DOMAIN; F-SPONDIN; CLEAVAGE; LRP1B; NOTCH; GENE	The low density lipoprotein receptor related protein 1B (LRP1B) is a large endocytic receptor that was first identified as a candidate tumor suppressor gene. In the current investigation we demonstrate that LRP1B undergoes regulated intramembrane proteolysis in gamma-secretase-dependent process. The released intracellular domain (ICD) then translocates to the nucleus via a nuclear localization signal that is present within this domain. ICD release first requires shedding of the LRP1B ectodomain, which appears to be catalyzed by a member of the metalloproteinase family. Employing site-directed mutagenesis studies, we identified lysine residues 4432 and 4435 and arginine 4442 as key amino acids important for ectodomain shedding of LRP1B. We also demonstrate that an LRP1B minireceptor as well as the ICD domain alone suppresses anchorage-independent growth of LRP1B-deficient neuroglioma cells (H4 cells). Interestingly, abrogating ectodomain shedding resulted in a loss of the ability of LRP1B minireceptors to suppress anchorage-independent growth. Together, these studies reveal that LRP1B has tumor suppression function that is mediated by proteolytic processing of the receptor resulting in ICD release.	Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Strickland, DK (corresponding author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 W Baltimore St, Baltimore, MD 21201 USA.	dstrickland@som.umaryland.edu			NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Hirai Y, 2004, AM J OBSTET GYNECOL, V191, P1173, DOI 10.1016/j.ajog.2004.04.015; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Langbein S, 2002, LAB INVEST, V82, P639, DOI 10.1038/labinvest.3780458; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Li YH, 2005, BIOCHEM BIOPH RES CO, V333, P868, DOI 10.1016/j.bbrc.2005.05.170; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Marschang P, 2004, MOL CELL BIOL, V24, P3782, DOI 10.1128/MCB.24.9.3782-3793.2004; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pastrana DV, 2005, BBA-MOL BASIS DIS, V1741, P234, DOI 10.1016/j.bbadis.2005.06.007; Pineau P, 2003, HEPATOLOGY, V37, P852, DOI 10.1053/jhep.2003.50138; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tanaga K, 2004, ARTERIOSCL THROM VAS, V24, P1422, DOI 10.1161/01.ATV.0000133607.80554.09; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; Yoon IS, 2005, J BIOL CHEM, V280, P20140, DOI 10.1074/jbc.M413729200; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200	46	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7504	7511		10.1074/jbc.M608088200	http://dx.doi.org/10.1074/jbc.M608088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17227771	hybrid			2022-12-25	WOS:000245080900063
J	Radcliffe, CM; Arnold, JN; Suter, DM; Wormald, MR; Harvey, DJ; Royle, L; Mimura, Y; Kimura, Y; Sim, RB; Inoges, S; Rodriguez-Calvillo, M; Zabalegui, N; de Cerio, ALD; Potter, KN; Mockridge, CI; Dwek, RA; Bendandi, M; Rudd, PM; Stevenson, FK				Radcliffe, Catherine M.; Arnold, James N.; Suter, David M.; Wormald, Mark R.; Harvey, David J.; Royle, Louise; Mimura, Yusuke; Kimura, Yoshinobu; Sim, Robert B.; Inoges, Susana; Rodriguez-Calvillo, Mercedes; Zabalegui, Natalia; Lopez-Diaz de Cerio, Ascension; Potter, Kathleen N.; Mockridge, C. Ian; Dwek, Raymond A.; Bendandi, Maurizio; Rudd, Pauline M.; Stevenson, Freda K.			Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; C-TYPE LECTINS; RHEUMATOID-ARTHRITIS; GLYCOSYLATION SITES; DENDRITIC CELLS; IMMUNE-SYSTEM; SURFACE-IMMUNOGLOBULIN; BURKITTS-LYMPHOMA; VARIABLE REGION; FAB FRAGMENT	Expression of surface immunoglobulin appears critical for the growth and survival of B-cell lymphomas. In follicular lymphoma, we found previously that the Ig variable (V) regions in the B-cell receptor express a strikingly high incidence of N-glycosylation sequons, NX(S/T). These potential glycosylation sites are introduced by somatic mutation and are lymphoma-specific, pointing to their involvement in tumor pathogenesis. Analysis of the V region sugars from lymphoma-derived IgG/IgM reveals that they are mostly oligomannose and, remarkably, are located in the antigen-binding site, possibly precluding conventional antigen binding. The Fc region contains complex glycans, confirming that the normal glycan processing pathway is intact. Binding studies indicate that the oligomannose glycans occupying the V regions are accessible to mannose-binding lectin. These findings suggest a potential contribution to lymphoma pathogenesis involving antigen-independent interaction of surface immunoglobulin of the B-cell receptor with mannose-binding molecules of innate immunity in the germinal center.	Univ Oxford, Glycobiol Inst, Oxford OX1 3QU, England; Univ Oxford, Med Res Council Immunochem Unit, Dept Biochem, Oxford OX1 3QU, England; Okayama Univ, Dept Biofunct Chem, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan; Univ Clin Navarre, Pamplona 31008, Spain; Ctr Appl Med Res, Pamplona 31008, Spain; Univ Southampton, Hosp Trust, Mol Immunol Grp, Tenovus Lab,Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Oxford; University of Oxford; Okayama University; University of Navarra; University of Navarra; University of Southampton	Rudd, PM (corresponding author), Univ Coll Dublin, Conway Inst, NIBRT, Dublin Oxford Glycobiol Lab, Dublin 4, Ireland.	pauline.rudd@nibrt.ie	Wormald, Mark R/G-2785-2011; Inogés, Susana/AAW-6785-2021; Arnold, James/ABE-3900-2021; Sim, Bob/A-1354-2008; Suter, David/S-9210-2019; Harvey, David/A-5579-2013	Wormald, Mark R/0000-0002-4853-2773; Arnold, James/0000-0002-6949-0613; Sim, Bob/0000-0002-2855-7455; Suter, David/0000-0001-5644-4899; Stevenson, Freda/0000-0002-0933-5021; Harvey, David/0000-0003-0544-771X				Arnold JN, 2005, J BIOL CHEM, V280, P29080, DOI 10.1074/jbc.M504528200; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berney C, 1999, J EXP MED, V190, P851, DOI 10.1084/jem.190.6.851; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; CHANG SC, 1993, THESIS U OXFORD; CHAPMAN A, 1979, J BIOL CHEM, V254, P824; Chapman CJ, 1996, BLOOD, V88, P3562, DOI 10.1182/blood.V88.9.3562.bloodjournal8893562; Choe J, 2000, J IMMUNOL, V164, P56, DOI 10.4049/jimmunol.164.1.56; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; DEWK RA, 1996, CHEM REV, V96, P683; Downing I, 2003, IMMUNOLOGY, V109, P360, DOI 10.1046/j.1365-2567.2003.01675.x; ENDO T, 1995, MOL IMMUNOL, V32, P931, DOI 10.1016/0161-5890(95)00078-S; Fukuta K, 2000, ARCH BIOCHEM BIOPHYS, V378, P142, DOI 10.1006/abbi.2000.1806; Gala FA, 2004, J IMMUNOL, V172, P5489, DOI 10.4049/jimmunol.172.9.5489; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Goodarzi MT, 1998, GLYCOCONJUGATE J, V15, P469, DOI 10.1023/A:1006930902625; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; Inoges S, 2003, HAEMATOLOGICA, V88, P1438; Kabat EA, 1991, SEQUENCES PROTEINS I; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Manser T, 2004, J IMMUNOL, V172, P3369, DOI 10.4049/jimmunol.172.6.3369; McGreal EP, 2004, MOL IMMUNOL, V41, P1109, DOI 10.1016/j.molimm.2004.06.013; MirShekari SY, 1997, J BIOL CHEM, V272, P4027, DOI 10.1074/jbc.272.7.4027; MIZUTANI R, 1995, J MOL BIOL, V254, P208, DOI 10.1006/jmbi.1995.0612; PAREKH R, 1988, J EXP MED, V167, P1731, DOI 10.1084/jem.167.5.1731; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAREKH RB, 1988, LANCET, V1, P966; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Rodriguez-Calvillo M, 2004, CRIT REV ONCOL HEMAT, V52, P1, DOI 10.1016/j.critrevonc.2004.05.002; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Smith SH, 2004, MOL CELL, V14, P696, DOI 10.1016/j.molcel.2004.06.015; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TANDAI M, 1991, ARCH BIOCHEM BIOPHYS, V291, P339, DOI 10.1016/0003-9861(91)90144-8; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wang LD, 2003, IMMUNOLOGY, V110, P411, DOI 10.1111/j.1365-2567.2003.01756.x; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; Zabalegui N, 2004, HAEMATOLOGICA, V89, P541; ZELENETZ AD, 1992, J EXP MED, V176, P1137, DOI 10.1084/jem.176.4.1137; Zhu D, 2003, BRIT J HAEMATOL, V120, P217, DOI 10.1046/j.1365-2141.2003.04064.x; Zhu DL, 2002, BLOOD, V99, P2562, DOI 10.1182/blood.V99.7.2562	57	100	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7405	7415		10.1074/jbc.M602690200	http://dx.doi.org/10.1074/jbc.M602690200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17197448	Green Published, hybrid			2022-12-25	WOS:000245080900052
J	Clizbe, DB; Owens, ML; Masuda, KR; Shackelford, JE; Krisans, SK				Clizbe, Daun B.; Owens, Michelle L.; Masuda, Kimberly R.; Shackelford, Janis E.; Krisans, Skaidrite K.			IDI2, a second lsopentenyl diphosphate isomerase in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENTENYL PYROPHOSPHATE ISOMERASE; ISOPRENOID BIOSYNTHESIS; REDUCTASE DEGRADATION; STEROL-METABOLISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SKELETAL-MUSCLE; GENE-EXPRESSION; ENZYME; PEROXISOMES	We recently described the identification of a novel isopentenyl diphosphate isomerase, IDI2 in humans and mice. Our current data indicate that, in humans, IDI2 is expressed only in skeletal muscle. Expression constructs of human IDI2 in Saccharomyces cerevisiae can complement isomerase function in an idi1-deficient yeast strain. Furthermore, IDI2 has the ability to catalyze the isomerization of [C-14]IPP to [C-14]DMAPP. Enzyme kinetic analysis of partially purified IDI2 demonstrate the novel isozyme has a maximal relative specific activity of 1.2 X 10(-1) +/- 0.3 mu mol min(-1) mg(-1) at pH 8.0 with a K-m(IPP) value of 22.8 mu m IPP. Both isozymes, IDI1 and IDI2 are localized to the peroxisome by a PTS1-dependent pathway. Finally, our data suggest that IDI2 is regulated independently from IDI1, by a mechanism that may involve PPAR alpha.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Krisans, SK (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	skrisans@sciences.sdsu.edu			NIDDK NIH HHS [DK58238, DK58040] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058040, R01DK058238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aboushadi N, 1998, J LIPID RES, V39, P1781; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Breitling R, 2003, J MOL EVOL, V57, P282, DOI 10.1007/s00239-003-2476-8; BRUENGER E, 1986, ARCH BIOCHEM BIOPHYS, V248, P620, DOI 10.1016/0003-9861(86)90516-3; Brunmair B, 2004, J PHARMACOL EXP THER, V311, P109, DOI 10.1124/jpet.104.068312; Cameron-Smith D, 2003, AM J CLIN NUTR, V77, P313, DOI 10.1093/ajcn/77.2.313; Carrigan CN, 2003, J AM CHEM SOC, V125, P9008, DOI 10.1021/ja0350381; Durbecq V, 2001, EMBO J, V20, P1530, DOI 10.1093/emboj/20.7.1530; ELGERSMA Y, 1996, J BIOL CHEM, V271, P26357; Engfelt WH, 1997, J BIOL CHEM, V272, P24579, DOI 10.1074/jbc.272.39.24579; Fliesler SJ, 1999, INVEST OPHTH VIS SCI, V40, P1792; Fliesler SJ, 2000, LIPIDS, V35, P289, DOI 10.1007/s11745-000-0525-y; Hahn FM, 1996, ARCH BIOCHEM BIOPHYS, V332, P30, DOI 10.1006/abbi.1996.0312; Hahn FM, 1999, J BACTERIOL, V181, P4499, DOI 10.1128/JB.181.15.4499-4504.1999; HAHN FM, 1995, J BIOL CHEM, V270, P11298, DOI 10.1074/jbc.270.19.11298; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Holstein SA, 2004, LIPIDS, V39, P293, DOI 10.1007/s11745-004-1233-3; Kovacs WJ, 2002, PROG LIPID RES, V41, P369, DOI 10.1016/S0163-7827(02)00002-4; Landrier JF, 2004, J BIOL CHEM, V279, P45512, DOI 10.1074/jbc.M407461200; LYNEN F, 1959, ANGEW CHEM INT EDIT, V71, P657, DOI 10.1002/ange.19590712102; Maynard EL, 2004, PROTEINS, V55, P856, DOI 10.1002/prot.20112; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; Murthy S, 2005, J BIOL CHEM, V280, P41793, DOI 10.1074/jbc.M504101200; Nakamura A, 2001, FEBS LETT, V506, P61, DOI 10.1016/S0014-5793(01)02870-8; Neuberger G, 2003, J MOL BIOL, V328, P581, DOI 10.1016/S0022-2836(03)00319-X; Paton VG, 1997, J BIOL CHEM, V272, P18945, DOI 10.1074/jbc.272.30.18945; POPJAK G, 1970, NATURAL SUBSTANCES F, P17; SAGAMI H, 1983, J BIOCHEM-TOKYO, V94, P975, DOI 10.1093/oxfordjournals.jbchem.a134441; SATTERWHITE DM, 1985, METHOD ENZYMOL, V110, P92; Spriet LL, 2004, J APPL PHYSIOL, V96, P2082, DOI 10.1152/japplphysiol.01318.2003; SPURGEON SL, 1981, BIOSYNTHESIS ISOPREN, V1, P2; STREET IP, 1994, BIOCHEMISTRY-US, V33, P4212, DOI 10.1021/bi00180a014; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; Wouters J, 2004, PROTEINS, V54, P216, DOI 10.1002/prot.10573	36	13	14	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6668	6676		10.1074/jbc.M610922200	http://dx.doi.org/10.1074/jbc.M610922200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202134	hybrid			2022-12-25	WOS:000244867200076
J	Wrighton, KH; Liang, M; Bryan, B; Luo, KX; Liu, MY; Feng, XH; Lin, X				Wrighton, Katharine H.; Liang, Min; Bryan, Brad; Luo, Kunxin; Liu, Mingyao; Feng, Xin-Hua; Lin, Xia			Transforming growth factor-beta-independent regulation of myogenesis by SnoN sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SKI PROTOONCOGENE; MUSCLE DIFFERENTIATION; SKELETAL-MUSCLE; CDNA-CLONES; MICE; TRANSCRIPTION; DEGRADATION; ACTIVATION; INHIBITOR	Recent progress has been made on the role of oncoproteins c-Ski and related SnoN in the control of cellular transformation. c-Ski/SnoN potently repress transforming growth factor-beta (TGF-beta) antiproliferative signaling through physical interaction with signal transducers called Smads. Overexpression of c-Ski/SnoN also induces skeletal muscle differentiation, but how c-Ski/SnoN function in myogenesis is largely unknown. During our investigation on the role of sumoylation in TGF-beta signaling, we inadvertently found that SnoN is modified by small ubiquitin-like modifier-1 (SUMO-1). Here, we biochemically characterize SnoN sumoylation in detail and report the physiological function of the modification. Sumoylation occurs primarily at lysine 50 (Lys-50). PIAS1 and PIASx proteins physically interact with SnoN to stimulate its surnoylation, thus serving as SUMO-protein isopeptide ligases (E3) for SnoN surnoylation. SnoN surnoylation does not alter its metabolic stability or its ability to repress TGF-beta signaling. Notably, loss of surnoylation in the Lys-50 site (via a Lys-to-Arg point mutation) potently activates muscle-specific gene expression and enhances myotube formation. Our study suggests a novel role for SUMO modification in the regulation of myogenic differentiation.	Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Univ Calif Berkeley, Dept Mol Cell Biol, Berkeley, CA 94720 USA	Baylor College of Medicine; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of California System; University of California Berkeley	Lin, X (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.	xialin@bcm.edu		Liu, Mingyao/0000-0001-7339-5048; Wrighton, Katharine/0000-0001-7075-3399	NCI NIH HHS [R21CA11293, R01CA108454] Funding Source: Medline; NHLBI NIH HHS [R01HL06792] Funding Source: Medline; NIDDK NIH HHS [P50DK064233] Funding Source: Medline; NIGMS NIH HHS [R01GM63773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Colmenares C, 2002, NAT GENET, V30, P106, DOI 10.1038/ng770; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Hsu YHR, 2006, J BIOL CHEM, V281, P33008, DOI 10.1074/jbc.M604380200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Stroschein SL, 2001, GENE DEV, V15, P2822; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3	18	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6517	6524		10.1074/jbc.M610206200	http://dx.doi.org/10.1074/jbc.M610206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202138	hybrid			2022-12-25	WOS:000244867200059
J	Murashov, AK; Chintalgattu, V; Islamov, RR; Lever, TE; Pak, ES; Sierpinski, PL; Katwa, LC; Van Scott, MR				Murashov, Alexander K.; Chintalgattu, Vishnu; Islamov, Rustem R.; Lever, Teresa E.; Pak, Elena S.; Sierpinski, Paulina L.; Katwa, Laxmansa C.; Van Scott, Michael R.			RNAi pathway is functional in peripheral nerve axons	FASEB JOURNAL			English	Article						RNA interference; axonal protein synthesis; SiRNA; sciatic nerve; DRG	SPINAL MOTOR-NEURONS; FRAGILE-X-SYNDROME; MESSENGER-RNA; PROTEIN-SYNTHESIS; SCIATIC-NERVE; SYMPATHETIC NEURONS; LOCAL TRANSLATION; MAMMALIAN NEURONS; INTERFERING RNAS; SENSORY NEURONS	Recent observations demonstrated that translation of mRNAs may occur in axonal processes at sites that are long distances away from the neuronal perikaria. While axonal protein synthesis has been documented in several studies, the mechanism of its regulation remains unclear. The aim of this study was to investigate whether RNA interference (RNAi) may be one of the pathways that control local protein synthesis in axons. Here we show that sciatic nerve contains Argonaute2 nuclease, fragile X mental retardation protein, p100 nuclease, and Gemin3 helicase-components of the RNA-induced silencing complex (RISC). Application of short-interfering RNAs against neuronal beta-tubulin to the sciatic nerve initiated RISC formation, causing a decrease in levels of neuronal P-tubulin III mRNA and corresponding protein, as well as a significant reduction in retrograde labeling of lumbar motor neurons. Our observations indicate that RNAi is functional in peripheral mammalian axons and is independent from the neuronal cell body or Schwann cells. We introduce a concept of local regulation of axonal translation via RNAi.	E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC 27834 USA; E Carolina Univ, Brody Sch Med, Dept Commun Sci & Disorders, Greenville, NC 27834 USA; Kazan VI Lenin State Univ, Dept Histol, Kazan 420008, Russia	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Kazan Federal University	Murashov, AK (corresponding author), E Carolina Univ, Brody Sch Med, Dept Physiol, 600 Moye Blvd, Greenville, NC 27834 USA.	murashoval@ecu.edu	Islamov, Rustem R/H-8722-2015; Islamov, Rustem R/A-3581-2019; Katwa, Laxmansa C/AID-0012-2022; Murashov, Alexander K/F-2241-2011	Islamov, Rustem R/0000-0002-6632-4636; Katwa, Laxmansa C/0000-0001-7479-4630; Murashov, Alexander K/0000-0002-8912-5891; Van Scott, Michael/0000-0003-1782-1334				Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Cerutti H, 2003, TRENDS GENET, V19, P39, DOI 10.1016/S0168-9525(02)00010-0; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chintalgattu V, 2003, J MOL CELL CARDIOL, V35, P277, DOI 10.1016/S0022-2828(03)00006-3; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Eberwine J, 2002, NEUROCHEM RES, V27, P1065, DOI 10.1023/A:1020956805307; GAUDY AA, 2002, GENE DEV, V16, P2491; Ginty DD, 2002, CURR OPIN NEUROBIOL, V12, P268, DOI 10.1016/S0959-4388(02)00326-4; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Guo SC, 2005, HUM GENE THER, V16, P1097, DOI 10.1089/hum.2005.16.1097; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hengst U, 2006, J NEUROSCI, V26, P5727, DOI 10.1523/JNEUROSCI.5229-05.2006; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Islamov RR, 2004, NEUROREPORT, V15, P2117, DOI 10.1097/00001756-200409150-00024; Islamov RR, 2003, MOL BRAIN RES, V116, P163, DOI 10.1016/S0169-328X(03)00258-4; Keenan TW, 2000, BBA-GEN SUBJECTS, V1523, P84, DOI 10.1016/S0304-4165(00)00106-9; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; Lee SK, 2003, J CELL SCI, V116, P4467, DOI 10.1242/jcs.00745; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Mader K, 2004, J NEUROTRAUM, V21, P956, DOI 10.1089/0897715041526113; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McMurray R, 2003, BRAIN RES, V980, P140, DOI 10.1016/S0006-8993(03)02984-6; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Murashov AK, 2004, AM J PHYSIOL-CELL PH, V287, pC320, DOI 10.1152/ajpcell.00542.2003; Murashov AK, 1996, MOL BRAIN RES, V37, P85, DOI 10.1016/0169-328X(95)00288-4; Murashov AK, 1998, MOL BRAIN RES, V63, P14, DOI 10.1016/S0169-328X(98)00258-7; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Scherr M, 2004, CURR OPIN MOL THER, V6, P129; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sharifi N, 2002, ENDOCRINOLOGY, V143, P2503, DOI 10.1210/en.143.7.2503; Sharp PA, 2000, SCIENCE, V287, P2431, DOI 10.1126/science.287.5462.2431; Shen YP, 2002, J NEUROSCI, V22, P239, DOI 10.1523/JNEUROSCI.22-01-00239.2002; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Wagey R, 2001, NEUROSCIENCE, V103, P257, DOI 10.1016/S0306-4522(00)00551-0; Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001	69	77	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					656	670		10.1096/fj.06-6155com	http://dx.doi.org/10.1096/fj.06-6155com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17209129				2022-12-25	WOS:000244686400005
J	Hafezi-Moghadam, A; Noda, K; Almulki, L; Ilmaki, EF; Poulaki, V; Thomas, KL; Nakazawa, T; Hisatomi, T; Miller, JW; Gragoudas, ES				Hafezi-Moghadam, A.; Noda, K.; Almulki, L.; Ilmaki, E. F.; Poulaki, V.; Thomas, K. L.; Nakazawa, T.; Hisatomi, T.; Miller, J. W.; Gragoudas, E. S.			VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation	FASEB JOURNAL			English	Article						EIU; VCAM-1; autoperfused microflow chamber; leukocyle-endothelial interaction	EXPERIMENTAL AUTOIMMUNE UVEITIS; ADHESION MOLECULES; CELL-ADHESION; MONOCLONAL-ANTIBODIES; P-SELECTIN; LEUKOCYTE; INFLAMMATION; DISEASE; NEUTROPHIL; ICAM-1	Leukocyte adhesion to the vascular wall is a critical early step in the pathogenesis of inflammatory diseases and is mediated in part by the leukocyte integrin, VLA-4, which binds to endothelial vascular cell adhesion molecule (VCAM) -1. Here, we investigate VLA-4's role in endotoxin-induced uveitis (EIU). At various time points (6-48 h) after EIU induction, the severity of the inflammation was evaluated by quantifying cell and protein content in the aqueous fluid, firm leukocyte adhesion in the retinal vessels, and the number of extravasated leukocytes into the vitreous. Functional activation of VLA-4 in vivo was investigated in our previously introduced autoperfused micro flow chamber assay. Firm adhesion of EIU leukocytes to immobilized VCAM-1 under physiological blood flow conditions was significantly increased compared with normal controls (P < 0.05), suggesting an important role for VLA-4 in EIU. VLA-4 blockade in vivo significantly suppressed all uveitis-related inflammatory parameters studied, decreasing the clinical score by 45% (P < 0.01), protein content in the aqueous fluid by 21% (P < 0.01), retinal leukostasis by 68% (P < 0.01), and leukocyte accumulation in the vitreous by 75% (P < 0.01). Our data provide novel evidence for functional up-regulation of VLA-4 during EIU and suggest VLA-4 blockade as a promising therapeutic strategy for treatment of acute inflammatory eye diseases.	Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Hafezi-Moghadam, A (corresponding author), Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ahm@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [EY14104] Funding Source: Medline; NIAID NIH HHS [AI050775] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamus G, 2006, INVEST OPHTH VIS SCI, V47, P2555, DOI 10.1167/iovs.05-1242; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Avunduk MC, 2004, EXP EYE RES, V79, P357, DOI 10.1016/j.exer.2004.06.001; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chaney E, 2005, INC, V27, P50; Ciardella Antonio P, 2004, Curr Opin Ophthalmol, V15, P519; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dunn James P, 2004, Curr Opin Ophthalmol, V15, P293, DOI 10.1097/00055735-200408000-00003; Durrani OM, 2004, OPHTHALMOLOGICA, V218, P223, DOI 10.1159/000078612; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FORRESTER JV, 1991, LANCET, V338, P1498, DOI 10.1016/0140-6736(91)92309-P; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Holt PG, 1999, NATURE, V402, pB12; Honjo M, 2003, P NATL ACAD SCI USA, V100, P1274, DOI 10.1073/pnas.0337528100; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Issekutz AC, 1996, IMMUNOLOGY, V88, P569, DOI 10.1046/j.1365-2567.1996.d01-695.x; Issekutz TB, 1996, J EXP MED, V183, P2175, DOI 10.1084/jem.183.5.2175; Kiely JM, 1999, METH MOL B, V96, P131; La Heij E, 1998, BRIT J OPHTHALMOL, V82, P432; Leger Olivier J. P., 1997, Human Antibodies, V8, P3; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lightman S, 1997, EYE, V11, P222, DOI 10.1038/eye.1997.56; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; Martin AP, 2005, INVEST OPHTH VIS SCI, V46, P2056, DOI 10.1167/iovs.04-0418; MARX JL, 1982, SCIENCE, V215, P1380, DOI 10.1126/science.6278589; MCMENAMIN PG, 1995, INVEST OPHTH VIS SCI, V36, P1949; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moorthy RS, 1997, SURV OPHTHALMOL, V41, P361, DOI 10.1016/S0039-6257(97)00006-4; Planck SR, 1998, CURR EYE RES, V17, P941, DOI 10.1076/ceyr.17.9.941.5139; ROSENBAUM JT, 1993, CURR EYE RES, V12, P827, DOI 10.3109/02713689309020387; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; WHITCUP SM, 1993, CLIN IMMUNOL IMMUNOP, V67, P143, DOI 10.1006/clin.1993.1057; WHITCUP SM, 1995, EXP EYE RES, V60, P597, DOI 10.1016/S0014-4835(05)80001-6; WHITCUP SM, 1993, INVEST OPHTH VIS SCI, V34, P673; WHITCUP SM, 1992, ARCH OPHTHALMOL-CHIC, V110, P662, DOI 10.1001/archopht.1992.01080170084029; Whitcup SM, 1997, CLIN IMMUNOL IMMUNOP, V83, P45, DOI 10.1006/clin.1996.4324; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	49	26	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					464	474		10.1096/fj.06-6390com	http://dx.doi.org/10.1096/fj.06-6390com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202250				2022-12-25	WOS:000244686300020
J	Okabe, H; Lee, SH; Phuchareon, J; Albertson, DG; McCormick, F; Tetsu, O				Okabe, Hiroshi; Lee, Sang-Hyun; Phuchareon, Janyaporn; Albertson, Donna G.; McCormick, Frank; Tetsu, Osamu			A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation	PLOS ONE			English	Article								Cyclin D1 regulates G1 progression. Its transcriptional regulation is well understood. However, the mechanism underlying cyclin D1 ubiquitination and its subsequent degradation is not yet clear. We report that cyclin D1 undergoes increased degradation in the cytoplasm during S phase in a variety of cancer cells. This is mediated by phosphorylation at Thr286 through the activity of the Ras/Raf/MEK/ERK cascade and the F-box protein FBXW8, which is an E3 ligase. The majority of FBXW8 is expressed in the cytoplasm during G1 and S phase. In contrast, cyclin D1 accumulates in the nucleus during G1 phase and exits into the cytoplasm in S phase. Increased cyclin D1 degradation is linked to association with FBXW8 in the cytoplasm, and enhanced phosphorylation of cyclin D1 through sustained ERK1/2 signaling. Depletion of FBXW8 caused a significant accumulation of cyclin D1, as well as sequestration of CDK1 in the cytoplasm. This resulted in a severe reduction of cell proliferation. These effects could be rescued by constitutive nuclear expression of cyclin D1-T286A. Thus, FBXW8 plays an essential role in cancer cell proliferation through proteolysis of cyclin D1. It may present new opportunities to develop therapies targeting destruction of cyclin D1 or its regulator E3 ligase selectively.	[Okabe, Hiroshi; Phuchareon, Janyaporn; Tetsu, Osamu] Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; [Lee, Sang-Hyun; Albertson, Donna G.; McCormick, Frank] Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA; [Okabe, Hiroshi; Lee, Sang-Hyun; Phuchareon, Janyaporn; Albertson, Donna G.; McCormick, Frank; Tetsu, Osamu] Univ Calif San Francisco, Sch Med, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Tetsu, O (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA.	tetsu@cc.ucsf.edu	高, 雨莉/HGU-8187-2022	Tetsu, Osamu/0000-0003-1820-7539	American Cancer Society; Concern Foundation; Daiichi Pharmaceuticals; UCSF Research-Evaluation Allocation Committee; V Foundation; National Institutes of Health [R01 CA101359]; Wood Foundation; NATIONAL CANCER INSTITUTE [R01CA101359] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Concern Foundation; Daiichi Pharmaceuticals(Daiichi Sankyo Company Limited); UCSF Research-Evaluation Allocation Committee; V Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wood Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the American Cancer Society, the Concern Foundation, the Daiichi Pharmaceuticals, the UCSF Research-Evaluation Allocation Committee, and the V Foundation to O.T., the National Institutes of Health (R01 CA101359) to D. G. A., and the Wood Foundation to F. M.	Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Guo Y, 2005, ONCOGENE, V24, P2599, DOI 10.1038/sj.onc.1208326; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MACDONALD SG, 1997, RAS RAF ERK SIGNALIN, P121; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	33	155	157	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e128	10.1371/journal.pone.0000128	http://dx.doi.org/10.1371/journal.pone.0000128			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205132	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443700022
J	Hatch, T; Derijck, AAHA; Black, PD; van der Heijden, GW; de Boer, P; Dubrova, YE				Hatch, T.; Derijck, A. A. H. A.; Black, P. D.; van der Heijden, G. W.; de Boer, P.; Dubrova, Y. E.			Maternal effects of the scid mutation on radiation-induced transgenerational instability in mice	ONCOGENE			English	Article						radiation; transgenerational instability; maternal effects; scid; NHEJ; mouse	DEPENDENT PROTEIN-KINASE; DNA-REPAIR; CATALYTIC SUBUNIT; GENOME STABILITY; GERM-LINE; DAMAGE; SPERM; RATES; DEFICIENCY; EXPRESSION	The results of a number of recent studies show that mutation rates in the offspring of irradiated parents are substantially elevated, however, the effect of parental genotype on transgenerational instability remains poorly understood. Here, we have analysed the mutation frequency at an expanded simple tandem repeat (ESTR) locus in the germline and bone marrow of the first-generation male offspring of control and irradiated male mice. The frequency of ESTR mutation was studied in the offspring of two reciprocal matings male scid x female BALB/c and male BALB/c x female scid, which were compared with that in BALB/c mice. In the offspring of the BALB/c x BALB/c and male scid x female BALB/c matings, which were conceived after paternal sperm irradiation, the frequency of ESTR mutation was significantly elevated in both tissues. In contrast, ESTR mutation frequency was only slightly elevated in the offspring of male BALB/c x female scid mating conceived after paternal irradiation. The results of this study suggest that the oocytes of scid females are unable to fully support the repair of double-strand breaks induced in paternal sperm which may in turn result in the elimination of cells/embryos containing high levels of DNA damage, thus partially preventing the manifestation of genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, Nijmegen, Netherlands	University of Leicester; Radboud University Nijmegen	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020; van der Heijden, Godfried/ABC-5623-2021	van der Heijden, Godfried/0000-0001-5894-7027; Dubrova, Yuri/0000-0001-5281-7539	MRC [G0300477, G9806740] Funding Source: UKRI; Medical Research Council [G9806740, G0300477] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahmadi A, 1999, J EXP ZOOL, V284, P696, DOI 10.1002/(SICI)1097-010X(19991101)284:6&lt;696::AID-JEZ11&gt;3.0.CO;2-E; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2006, ONCOGENE, V25, P7336, DOI 10.1038/sj.onc.1209723; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Barton TS, 2005, P NATL ACAD SCI USA, V102, P7865, DOI 10.1073/pnas.0501200102; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Derijck AAHA, 2006, DNA REPAIR, V5, P959, DOI 10.1016/j.dnarep.2006.05.043; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Festing MF, 1996, GENETIC VARIANTS STR, P1537; Fiorenza MT, 2001, DEV BIOL, V233, P214, DOI 10.1006/dbio.2001.0199; GENEROSO WM, 1979, P NATL ACAD SCI USA, V76, P435, DOI 10.1073/pnas.76.1.435; Harrouk W, 2000, MUTAT RES-DNA REPAIR, V461, P229, DOI 10.1016/S0921-8777(00)00053-7; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Marchetti Francesco, 2005, Birth Defects Res C Embryo Today, V75, P112, DOI 10.1002/bdrc.20040; MATSUDA Y, 1989, MUTAT RES, V210, P35, DOI 10.1016/0027-5107(89)90042-0; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Okayasu R, 2000, CANCER RES, V60, P4342; Olsen Ann-Karin, 2005, Toxicol Appl Pharmacol, V207, P521, DOI 10.1016/j.taap.2005.01.060; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yu YJ, 2001, CANCER RES, V61, P1820; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	32	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4720	4724		10.1038/sj.onc.1210253	http://dx.doi.org/10.1038/sj.onc.1210253			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237807	Green Submitted			2022-12-25	WOS:000248037900012
J	Cras, A; Darsin-Bettinger, D; Balitrand, N; Cassinat, B; Soulie, A; Toubert, ME; Delva, L; Chomienne, C				Cras, A.; Darsin-Bettinger, D.; Balitrand, N.; Cassinat, B.; Soulie, A.; Toubert, M-E; Delva, L.; Chomienne, C.			Epigenetic patterns of the retinoic acid receptor beta(2) promoter in retinoic acid-resistant thyroid cancer cells	ONCOGENE			English	Article						RAR beta(2) promoter; RA; resistance; thyroid cells; histone acetylation	RECEPTOR-BETA GENE; REDIFFERENTIATION THERAPY; SODIUM/IODIDE SYMPORTER; MYELOID CELLS; RAR-ALPHA; EXPRESSION; CARCINOMA; LINES; TRANSCRIPTION; METHYLATION	Treatment with retinoic acid ( RA) is effective to restore radioactive iodine uptake in metastases of a small fraction of thyroid cancer patients. In order to find predictive markers of response, we took advantage of two thyroid cancer cell lines, FTC133 and FTC238, with low RA-receptor ( RAR)beta expression but differing in their response to RA. We report that in both cell lines, RA signalling pathways are functional, as transactivation of an exogenous RAR beta(2) promoter is effective in the presence of pharmacological concentrations of all-trans RA, and enhanced in RA-resistant FTC238 cells after ectopical expression of RAR beta, suggesting a defective endogenous RAR beta(2) promoter in these cells. Further analyses show that whereas the RAR beta(2) promoter is in an unmethylated permissive status in both FTC133 and FTC238 cells, it failed to be associated with acetylated forms of histones H3 or H4 in FTC238 cells upon RA treatment. Incubation with a histone deacetylase inhibitor, alone or in combination with RA, restored histone acetylation levels and reactivated RAR beta and differentiation marker Na+/I- symporter gene expression. Thus, histone modi. cation patterns may explain RA-refractoriness in differentiated thyroid cancer patients and suggest a potential benefit of combined transcriptional and differentiation therapies.	Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, F-75010 Paris, France; Univ Paris 07, INSERM, UMR S 718, Inst Univ Hematol, Paris, France; Hop St Louis, Nucl Med Serv, AP HP, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chomienne, C (corresponding author), Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.	christine.chomienne@sls.ap-hop-paris.fr	Cras, Audrey/Q-8784-2017; CASSINAT, BRUNO/N-2752-2017	Cras, Audrey/0000-0002-6894-9584; CASSINAT, BRUNO/0000-0002-6514-3905; CHOMIENNE, Christine/0000-0001-5513-5752; DELVA, Laurent/0000-0002-1086-3964				Bastie JN, 2004, MOL ENDOCRINOL, V18, P2685, DOI 10.1210/me.2003-0412; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Carpentier AF, 1999, ANTICANCER RES, V19, P3189; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Delva L, 1999, MOL CELL BIOL, V19, P7158; deThe H, 1996, FASEB J, V10, P955, DOI 10.1096/fasebj.10.9.8801177; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Filetti S, 1999, EUR J ENDOCRINOL, V141, P443, DOI 10.1530/eje.0.1410443; Goretzki P E, 1990, Recent Results Cancer Res, V118, P48; Grunwald F, 1998, J NUCL MED, V39, P1903; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Idres N, 2002, J BIOL CHEM, V277, P31491, DOI 10.1074/jbc.M205016200; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; PINEDA JD, 1995, J CLIN ENDOCR METAB, V80, P1488, DOI 10.1210/jc.80.5.1488; Rochaix P, 1998, HISTOPATHOLOGY, V33, P337, DOI 10.1046/j.1365-2559.1998.00486.x; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schmutzler C, 1998, INT J CANCER, V76, P368; Schmutzler C, 1997, BIOCHEM BIOPH RES CO, V240, P832, DOI 10.1006/bbrc.1997.7715; Schmutzler C, 2000, THYROID, V10, P393, DOI 10.1089/thy.2000.10.393; SCHRECK R, 1994, J CLIN ENDOCR METAB, V79, P791, DOI 10.1210/jc.79.3.791; Simon D, 2002, EUR J NUCL MED MOL I, V29, P775, DOI 10.1007/s00259-001-0737-6; Suh YA, 2002, CANCER RES, V62, P3945; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4018	4024		10.1038/sj.onc.1210178	http://dx.doi.org/10.1038/sj.onc.1210178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213810				2022-12-25	WOS:000247144500012
J	McColl, BK; Paavonen, K; Karnezis, T; Harris, NC; Davydova, N; Rothacker, J; Nice, EC; Harder, KW; Roufail, S; Hibbs, ML; Rogers, PAW; Alitalo, K; Stacker, SA; Achen, MG				McColl, Bradley K.; Paavonen, Karri; Karnezis, Tara; Harris, Nicole C.; Davydova, Natalia; Rothacker, Julie; Nice, Edouard C.; Harder, Kenneth W.; Roufail, Sally; Hibbs, Margaret L.; Rogers, Peter A. W.; Alitalo, Kari; Stacker, Steven A.; Achen, Marc G.			Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2	FASEB JOURNAL			English	Article						furin; PC5; PC7; angiogenesis; lymphatic	ENDOTHELIAL GROWTH-FACTOR; LYMPHATIC ENDOTHELIUM; CANCER METASTASIS; TYROSINE KINASES; TUMOR-METASTASIS; TRANSGENIC MICE; BREAST-CANCER; FURIN; LYMPHANGIOGENESIS; EXPRESSION	Vascular endothelial growth factor ( VEGF)-D is a secreted glycoprotein that induces angiogenesis and lymphangiogenesis. It consists of a central domain, containing binding sites for VEGF receptor-2 (VEGFR-2) and VEGFR-3, and N- and C-terminal propeptides. It is secreted from the cell as homodimers of the full-length form that can be proteolytically processed to remove the propeptides. It was recently shown, using adenoviral gene delivery, that fully processed VEGF-D induces angiogenesis in vivo, whereas full-length VEGF-D does not. To better understand these observations, we monitored the effect of VEGF-D processing on receptor binding using a full-length VEGF-D mutant that cannot be processed. This mutant binds VEGFR-2, the receptor signaling for angiogenesis, with similar to 17,000-fold lower affinity than mature VEGF-D, indicating the importance of processing for interaction with this receptor. Further, we show that members of the proprotein convertase ( PC) family of proteases promote VEGF-D processing, which facilitates the VEGF-D/VEGFR-2 interaction. The PCs furin and PC5 promote cleavage of both propeptides, whereas PC7 promotes cleavage of the C-terminal propeptide only. The finding that PCs promote activation of VEGF-D and other proteins with roles in cancer such as matrix metalloproteinases, emphasizes the importance of these enzymes as potential regulators of tumor progression and metastasis.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Univ Helsinki, Ludwig Inst Canc Res, Mol Canc Biol Lab, Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Monash University; Ludwig Institute for Cancer Research; University of Helsinki	Achen, MG (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	marc.achen@ludwig.edu.au	Rogers, Peter AW/C-2651-2008; Nice, Edouard C/B-1026-2011; Stacker, Steven A/J-2205-2012; Alitalo, Kari K/J-5013-2014; Hibbs, Margaret L/D-7013-2011	Rogers, Peter AW/0000-0002-7399-8997; Stacker, Steven A/0000-0003-4096-9273; Alitalo, Kari K/0000-0002-7331-0902; Hibbs, Margaret L/0000-0002-3751-6751; Rothacker, Julie/0000-0001-7560-4982; Achen, Marc/0000-0002-3791-803X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Baldwin ME, 2005, MOL CELL BIOL, V25, P2441, DOI 10.1128/MCB.25.6.2441-2449.2005; Baldwin ME, 2001, J BIOL CHEM, V276, P44307, DOI 10.1074/jbc.M106188200; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Joukov V, 1996, EMBO J, V15, P290; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Lehmann M, 1998, ENDOCRINOLOGY, V139, P3763, DOI 10.1210/en.139.9.3763; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McColl BK, 2003, J EXP MED, V198, P863, DOI 10.1084/jem.20030361; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Von Marschall Z, 2005, INT J ONCOL, V27, P669; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	54	80	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1088	1098		10.1096/fj.06-7060com	http://dx.doi.org/10.1096/fj.06-7060com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242158				2022-12-25	WOS:000245650400013
J	Dwyer, JR; Sever, N; Carlson, M; Nelson, SF; Beachy, PA; Parhami, F				Dwyer, Jennifer R.; Sever, Navdar; Carlson, Marc; Nelson, Stanley F.; Beachy, Philip A.; Parhami, Farhad			Oxysterols pathway in are novel activators of the hedgehog pluripotent mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SONIC-HEDGEHOG; OSTEOBLASTIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; BONE; PROLIFERATION; EXPRESSION; STIMULATE; SENSORS; ROLES; ACTS	Pluripotent mesenchymal cells form a population of precursors to a variety of cell types, including osteoblasts and adipocytes. Aging tilts the balance in favor of adipocyte differentiation at the expense of osteoblast differentiation, resulting in reduced bone formation and osteopenic disorders, including osteoporosis, in humans and animals. Understanding the mechanisms involved in causing this apparent shift in differentiation and identifying factors that stimulate osteoblast formation while inhibiting adipogenesis are of great therapeutic interest. In this study we report that specific, naturally occurring oxysterols, previously shown to direct pluripotent mesenchymal cells toward an osteoblast lineage, exert their osteoinductive effects through activation of Hedgehog signaling pathway. This was demonstrated by 1) oxysterol-induced expression of the Hh target genes Gli-1 and Patched, 2) oxysterol-induced activation of a luciferase reporter driven by a multimerized Gli-responsive element, 3) inhibition of oxysterol effects by the hedgehog pathway inhibitor, cyclopamine, and 4) unresponsiveness of Smoothened(-/-) mouse embryonic fibroblasts to oxysterols. Using Patched(-/-) cells that possess high baseline Gli activity, we found that oxysterols did not dramatically shift the IC50 concentration of cyclopamine needed to inhibit Gli activity in these cells. Furthermore, binding studies showed that oxysterols did not compete with fluorescently labeled cyclopamine, BODIPY-cyclopamine, for direct binding to Smoothened. These findings demonstrate that oxysterols stimulate hedgehog pathway activity by indirectly activating the seven-transmembrane pathway component Smoothened. Osteoinductive oxysterols are, therefore, novel activators of the hedgehog pathway in pluripotent mesenchymal cells, and they may be important modulators of this critical signaling pathway that regulates numerous developmental and postdevelopmental processes.	Univ Calif Los Angeles, Hlth Sci Ctr, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University	Parhami, F (corresponding author), Univ Calif Los Angeles, Hlth Sci Ctr, David Geffen Sch Med, Dept Med, BH-307,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	fparhami@mednet.ucla.edu	Sever, Navdar/AAB-7906-2022; Nelson, Stanley F/D-4771-2009	Sever, Navdar/0000-0001-9462-7979; Nelson, Stanley F/0000-0002-2082-3114; Dwyer, Jennifer/0000-0002-5893-6026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568] Funding Source: Medline; NIAMS NIH HHS [R01AR050426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cooper MK, 2003, NAT GENET, V33, P508, DOI 10.1038/ng1134; Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Edwards PA, 2002, J LIPID RES, V43, P2; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115; Krishnan V, 2001, ENDOCRINOLOGY, V142, P940, DOI 10.1210/en.142.2.940; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Li C., 2003, ANAL GENE EXPRESSION, P120; Lin YY, 2003, J STEROID BIOCHEM, V85, P57, DOI 10.1016/S0960-0760(03)00137-7; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Parhami F, 2002, J BONE MINER RES, V17, P1997, DOI 10.1359/jbmr.2002.17.11.1997; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199; RICHARDSON JA, 2006, IN PRESS J CELL BIOC; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; Zhou QH, 2006, GENETICS, V173, P2049, DOI 10.1534/genetics.106.061036	42	228	244	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8959	8968		10.1074/jbc.M611741200	http://dx.doi.org/10.1074/jbc.M611741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17200122	hybrid			2022-12-25	WOS:000245780300042
J	Shi, YL; Dodson, GE; Mukhopadhyay, PS; Shanware, NP; Trinh, AT; Tibbetts, RS				Shi, Yuling; Dodson, Gerald E.; Mukhopadhyay, Partha S.; Shanware, Naval P.; Trinh, Anthony T.; Tibbetts, Randal S.			Identification of carboxyl-terminal MCM3 phosphorylation sites using polyreactive phosphospecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; HUMAN SMG-1; ACTIVATION; REPLICATION; COMPLEX; BINDING	The functionally related ATM (ataxia telangiectasia-mutated) and ATR (ATM-Rad3-related) protein kinases are critical regulators of DNA damage responses in mammalian cells. ATM and ATR share highly overlapping substrate specificities and show a strong preference for the phosphorylation of Ser or Thr residues followed by Gln. In this report we used a polyreactive phosphospecific antibody (alpha-pDSQ) that recognizes a subset of phosphorylated AspSer-Gln sequences to purify candidate ATM/ATR substrates. This led to the identification of phosphorylation sites in the carboxyl terminus of the minichromosome maintenance protein 3 (MCM3), a component of the hexameric MCM DNA helicase. We show that the alpha-DSQ antibody recognizes tandem DSQ phosphorylation sites (Ser-725 and Ser-732) in the carboxyl terminus of murine MCM3 (mMCM3) and that ATM phosphorylates both sites in vitro. ATM phosphorylated the carboxyl termini of mMCM3 and human MCM3 in vivo and the phosphorylated form of MCM3 retained association with the canonical MCM complex. Although DNA damage did not affect steady-state levels of chromatin-bound MCM3, the ATM-phosphorylated form of MCM3 was preferentially localized to the soluble, nucleoplasmic fraction. This finding suggests that the carboxyl terminus of chromatin-loaded MCM3 may be sequestered from ATM-dependent checkpoint signals. Finally, we show that ATM and ATR jointly contribute to UV light-induced MCM3 phosphorylation, but that ATM is the predominant UV-activated MCM3 kinase in vivo. The carboxyl-terminal ATM phosphorylation sites are conserved in vertebrate MCM3 orthologs suggesting that this motif may serve important regulatory functions in response to DNA damage. Our findings also suggest that DSQ motifs are common phosphoacceptor motifs for ATM family kinases.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NIGMS NIH HHS [GM067868-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Livingstone M, 2005, CANCER RES, V65, P7533, DOI 10.1158/0008-5472.CAN-04-3729; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sheu YJ, 2006, MOL CELL, V24, P101, DOI 10.1016/j.molcel.2006.07.033; Shi YL, 2005, J BIOL CHEM, V280, P40195, DOI 10.1074/jbc.C500400200; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	59	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9236	9243		10.1074/jbc.M609256200	http://dx.doi.org/10.1074/jbc.M609256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244605	hybrid			2022-12-25	WOS:000245780300070
J	Boura, E; Silhan, J; Herman, P; Vecer, J; Sulc, M; Teisinger, J; Obsilova, V; Obsil, T				Boura, Evzen; Silhan, Jan; Herman, Petr; Vecer, Jaroslav; Sulc, Miroslav; Teisinger, Jan; Obsilova, Veronika; Obsil, Tomas			Both the N-terminal loop and wing W2 of the forkhead domain of transcription factor FoxO4 are important for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DOUBLE-STRANDED DNA; HELIX PROTEIN; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; LIGAND-BINDING; CELL-CYCLE; FACTOR AFX; PHOSPHORYLATION	FoxO4 belongs to the "O" subset of forkhead transcription factors, which participate in various cellular processes. The forkhead DNA binding domain (DBD) consists of three-helix bundle resting on a small antiparallel beta-sheet from which two extended loops protrude and create two wing-like structures. The wing W2 of FoxO factors contains a 14-3-3 protein-binding motif that is phosphorylated by protein kinase B in response to insulin or growth factors. In this report, we investigated the role of the N-terminal loop (portion located upstream of first helix H I) and the C-terminal region (loop known as wing W2) of the forkhead domain of transcription factor FoxO4 in DNA binding. Although the deletion of either portion partly reduces the FoxO4-DBD binding to the DNA, the simultaneous deletion of both regions inhibits DNA binding significantly. Forser resonance energy transfer measurements and molecular dynamics simulations suggest that both studied N- and C-terminal regions of FoxO4-DBD directly interact with DNA. In the presence of the N-terminal loop the protein kinase B-induced phosphorylation of wing W2 by itself has negligible effect on DNA binding. On the other hand, in the absence of this loop the phosphorylation of wing W2 significantly inhibits the FoxO4-DBD binding to the DNA. The binding of the 14-3-3 protein efficiently reduces DNA-binding potential of phosphorylated FoxO4-DBD regardless of the presence of the N-terminal loop. Our results show that both N- and C-terminal regions of forkhead domain are important for stability of the FoxO4-DBD-DNA complex.	Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843, Czech Republic; Charles Univ Prague, Inst Phys, Fac Math & Phys, CR-12116 Prague, Czech Republic; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Charles University Prague; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic.	obsil@natur.cuni.cz	Sulc, Miroslav/K-1029-2014; Obsil, Tomas/B-7142-2012; Herman, Petr/A-2626-2008; Boura, Evzen/G-5275-2014; Teisinger, Jan/B-7122-2012; Boura, Evzen/I-2626-2012; Obsilova, Veronika/B-7116-2012	Sulc, Miroslav/0000-0002-2659-0489; Obsil, Tomas/0000-0003-4602-1272; Herman, Petr/0000-0001-6918-2576; Obsilova, Veronika/0000-0003-4887-0323; Boura, Evzen/0000-0002-9652-4065				Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BIRMACHU W, 1989, BIOCHEMISTRY-US, V28, P3940, DOI 10.1021/bi00435a047; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kohler JJ, 2001, BIOCHEMISTRY-US, V40, P130, DOI 10.1021/bi001881p; Kovarova H, 2002, PROTEOMICS, V2, P85, DOI 10.1002/1615-9861(200201)2:1<85::AID-PROT85>3.3.CO;2-J; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Obsilova V, 2004, J BIOL CHEM, V279, P4531, DOI 10.1074/jbc.M306939200; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Silhan J, 2004, J BIOL CHEM, V279, P49113, DOI 10.1074/jbc.M408671200; Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Wolberger C, 2000, NAT STRUCT BIOL, V7, P261, DOI 10.1038/74004; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	49	62	65	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8265	8275		10.1074/jbc.M605682200	http://dx.doi.org/10.1074/jbc.M605682200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244620	hybrid			2022-12-25	WOS:000245081000059
J	Ciulli, A; Chirgadze, DY; Smith, AG; Blundell, TL; Abell, C				Ciulli, Alessio; Chirgadze, Dimitri Y.; Smith, Alison G.; Blundell, Tom L.; Abell, Chris			Crystal structure of Escherichia coli ketopantoate reductase in a ternary complex with NADP(+) and pantoate bound - Substrate recognition, conformational change, and cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; COENZYME-A; DEHYDROGENASE; BIOSYNTHESIS; INSIGHTS; SPECIFICITY; RESOLUTION; PROTEINS; TOOLS	Ketopantoate reductase (KPR, EC 1.1.1.169) catalyzes the NADPH-dependent reduction of ketopantoate to pantoate, an essential step for the biosynthesis of pantothenate (vitamin B.). Inhibitors of the enzymes of this pathway have been proposed as potential antibiotics or herbicides. Here we present the crystal structure of Escherichia coli KPR in a precatalytic ternary complex with NADP(+) and pantoate bound, solved to 2.3 angstrom of resolution. The asymmetric unit contains two protein molecules, each in a ternary complex; however, one is in a more closed conformation than the other. A hinge bending between the N- and C-terminal domains is observed, which triggers the switch of the essential Lys(176) to form a key hydrogen bond with the C2 hydroxyl of pantoate. Pantoate forms additional interactions with conserved residues Ser(244), Asn(98), and Asn(180) and with two conservatively varied residues, Asn(194) and Asn(241). The steady-state kinetics of active site mutants R31A, K72A, N98A, K176A, S244A, and E256A implicate Asn(98) as well as Lys(176) and Glu(256) in the catalytic mechanism. Isothermal titration calorimetry studies with these mutants further demonstrate the importance of Ser244 for substrate binding and of Arg(31) and Lys(72) for cofactor binding. Further calorimetric studies show that KPR discriminates binding of ketopantoate against pantoate only with NADPH bound. This work provides insights into the roles of active site residues and conformational changes in substrate recognition and catalysis, leading to the proposal of a detailed molecular mechanism for KPR activity.	Univ Chem Lab, Cambridge CB2 1EW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	University of Cambridge; University of Cambridge; University of Cambridge	Abell, C (corresponding author), Univ Chem Lab, Lensfield Rd, Cambridge CB2 1EW, England.	ca26@cam.ac.uk	Ciulli, Alessio/A-6279-2011	Ciulli, Alessio/0000-0002-8654-1670; Chirgadze, Dimitri/0000-0001-9942-0993; Smith, Alison Gail/0000-0001-6511-5704	BBSRC [BB/D005817/1, BB/D006104/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D005817/1, BB/D006104/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; Begley TP, 2001, VITAM HORM, V61, P157; Biou V, 1997, EMBO J, V16, P3405, DOI 10.1093/emboj/16.12.3405; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; Branden C I, 1980, Experientia Suppl, V36, P40; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciulli A, 2005, BIOCHEM SOC T, V33, P767, DOI 10.1042/BST0330767; Ciulli A, 2006, J MED CHEM, V49, P4992, DOI 10.1021/jm060490r; Ciulli A, 2007, ACTA CRYSTALLOGR D, V63, P171, DOI 10.1107/S0907444906044465; COLONNACESARI F, 1986, J BIOL CHEM, V261, P5273; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faehnle CR, 2006, J BIOL CHEM, V281, P31031, DOI 10.1074/jbc.M605926200; FERSHT A, 1999, STRUCTURE MECH PROTE, P458; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Jackowski S, 1996, CELLULAR MOL BIOL, P687; KING HL, 1974, J BIOL CHEM, V249, P4689; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LAMZIN VS, 1994, J MOL BIOL, V236, P759, DOI 10.1006/jmbi.1994.1188; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Lobley CMC, 2005, BIOCHEMISTRY-US, V44, P8930, DOI 10.1021/bi0502036; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Matak-Vinkovic D, 2001, BIOCHEMISTRY-US, V40, P14493, DOI 10.1021/bi011020w; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nocek B, 2005, J MOL BIOL, V354, P91, DOI 10.1016/j.jmb.2005.08.036; Ottenhof HH, 2004, PLANT J, V37, P61, DOI 10.1046/j.1365-313X.2003.01940.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765; Scapin G, 1998, BIOCHEMISTRY-US, V37, P3278, DOI 10.1021/bi9727949; SIEGEL JM, 1959, ARCH BIOCHEM BIOPHYS, V82, P288, DOI 10.1016/0003-9861(59)90124-9; Stillman TJ, 1999, J MOL BIOL, V285, P875, DOI 10.1006/jmbi.1998.2335; Sun W, 2006, J BIOL CHEM, V281, P12919, DOI 10.1074/jbc.M511986200; TAHILIANI AG, 1991, VITAM HORM, V46, P165; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Webb ME, 2004, NAT PROD REP, V21, P695, DOI 10.1039/b316419p; Zheng RJ, 2003, BIOCHEMISTRY-US, V42, P11289, DOI 10.1021/bi030101k; Zheng RJ, 2000, BIOCHEMISTRY-US, V39, P16244, DOI 10.1021/bi002134v; Zheng RJ, 2000, BIOCHEMISTRY-US, V39, P3708, DOI 10.1021/bi992676g	47	32	33	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8487	8497		10.1074/jbc.M611171200	http://dx.doi.org/10.1074/jbc.M611171200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17229734	hybrid			2022-12-25	WOS:000245081000081
J	Decca, MB; Carpio, MA; Bosc, C; Galiano, MR; Job, D; Andrieux, A; Hallak, ME				Decca, Maria B.; Carpio, Marcos A.; Bosc, Christophe; Galiano, Mauricio R.; Job, Didier; Andrieux, Annie; Hallak, Marta E.			Post-translational arginylation of calreticulin - A new isospecies of calreticulin component of stress granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN TRANSFERASE; MESSENGER-RNA; RAT-BRAIN; CALCIUM; BINDING; EXPRESSION; INCREASES; ARGININE; GENE; RECEPTOR	Post-translational arginylation consists of the covalent union of an arginine residue to a Glu, Asp, or Cys amino acid at the N-terminal position of proteins. This reaction is catalyzed by the enzyme arginyl-tRNA. protein transferase. Using mass spectrometry, we have recently demonstrated in vitro the post-translational incorporation of arginine into the calcium-binding protein calreticulin (CRT). To further study arginylated CRT we raised an antibody against the peptide (RDPAIYFK) that contains an arginine followed by the first 7 N-terminal amino acids of mature rat CRT. This antibody specifically recognizes CRT obtained from rat soluble fraction that was arginylated in vitro and also recognizes endogenous arginylated CRT from NIH 3T3 cells in culture, indicating that CRT arginylation takes place in living cells. Using this antibody we found that arginylation of CRT is Ca2+ -regulated. In vitro and in NIH 3T3 cells in culture, the level of arginylated CRT increased with the addition of a Ca2+ chelator to the medium, whereas a decreased arginine incorporation into CRT was found in the presence of Ca2+. The arginylated CRT was observed in the cytosol, in contrast to the non-arginylated CRT that is in the endoplasmic reticulum. Under stress conditions, arginylated CRT was found associated to stress granules. These results suggest that CRT arginylation occurs in the cytosolic pool of mature CRT (defined by an Asp acid N-terminal) that is probably retrotranslocated from the endoplasmic reticulum.	Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba, CIQUIBIC,Fac Ciencias Quim, CONICET,Dept Quim Biol, RA-5000 Cordoba, Argentina; CEA, INSERM U366, Lab Cytosquelette, F-38054 Grenoble, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hallak, ME (corresponding author), Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba, CIQUIBIC,Fac Ciencias Quim, CONICET,Dept Quim Biol, RA-5000 Cordoba, Argentina.	mhallak@mail.fcq.unc.edu.ar	Bosc, Christophe/P-3401-2017; Bosc, Christophe/Q-8877-2019; ANDRIEUX, ANNIE/B-2134-2017	Bosc, Christophe/0000-0002-3195-6692; Bosc, Christophe/0000-0002-3195-6692; ANDRIEUX, ANNIE/0000-0002-4022-6405; Galiano, Mauricio/0000-0002-8245-1715				Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005; Anderson P, 2002, J CELL SCI, V115, P3227; ATREYA CD, 1995, J VIROL, V69, P3848, DOI 10.1128/JVI.69.6.3848-3851.1995; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOHLEY P, 1991, BIOMED BIOCHIM ACTA, V50, P343; Bongiovanni G, 1995, NEUROREPORT, V7, P326, DOI 10.1097/00001756-199512000-00078; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chen MH, 1999, J VIROL, V73, P3386, DOI 10.1128/JVI.73.4.3386-3403.1999; Cheng ST, 1996, J IMMUNOL, V156, P4484; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Decca MB, 2006, NEUROCHEM RES, V31, P401, DOI 10.1007/s11064-005-9037-z; Denning GM, 1997, BLOOD, V90, P372; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HALLAK ME, 1991, J NEUROCHEM, V57, P1735, DOI 10.1111/j.1471-4159.1991.tb06375.x; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; KAJI H, 1963, BIOCHIM BIOPHYS ACTA, V76, P477; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Kwon YT, 1999, MOL CELL BIOL, V19, P182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; LIU NG, 1994, J BIOL CHEM, V269, P28635; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Pugachev KV, 1998, J VIROL, V72, P641, DOI 10.1128/JVI.72.1.641-650.1998; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Shaffer KL, 2005, DEV CELL, V9, P545, DOI 10.1016/j.devcel.2005.09.001; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SOFFER RL, 1968, BIOCHIM BIOPHYS ACTA, V155, P228, DOI 10.1016/0005-2787(68)90352-3; SOFFER RL, 1971, J BIOL CHEM, V246, P1602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8237	8245		10.1074/jbc.M608559200	http://dx.doi.org/10.1074/jbc.M608559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17197444	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000245081000056
J	Singh, I; Knezevic, N; Ahmmed, GU; Kini, V; Malik, AB; Mehta, D				Singh, Itender; Knezevic, Nebojsa; Ahmmed, Gias U.; Kini, Vidisha; Malik, Asrar B.; Mehta, Dolly			G alpha(q)-TRPC6-mediated Ca2+ entry induces RhoA activation and resultant endothelial cell shape change in response to thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR POTENTIAL CHANNELS; CALCIUM-ENTRY; DEPENDENT ACTIVATION; TRPC1 EXPRESSION; BARRIER FUNCTION; CATION CHANNELS; FUNCTIONAL-ROLE; P115 RHOGEF; ALPHA	RhoA activation and increased intracellular Ca2+ concentration mediated by the activation of transient receptor potential channels (TRPC) both contribute to the thrombin-induced increase in endothelial cell contraction, cell shape change, and consequently to the mechanism of increased endothelial permeability. Herein, we addressed the possibility that TRPC signals RhoA activation and thereby contributes in actinomyosin-mediated endothelial cell contraction and increased endothelial permeability. Transduction of a constitutively active G alpha(q) mutant in human pulmonary arterial endothelial cells induced RhoA activity. Preventing the increase in intracellular Ca2+ concentration by the inhibitor of Gaq or phospholipase C and the Ca2+ chelator, BAPTA-AM, abrogated thrombin-induced RhoA activation. Depletion of extracellular Ca2+ also inhibited RhoA activation, indicating the requirement of Ca2+ entry in the response. RhoA activation could not be ascribed to store-operated Ca2+ (SOC) entry because SOC entry induced with thapsigargin or small interfering RNA-mediated inhibition of TRPC1 expression, the predominant SOC channel in these endothelial cells, failed to alter RhoA activity. However, activation of receptor-operated Ca2+ entry by oleoyl-2-acetyl-sn-glycerol, the membrane permeable analogue of the Ga-q-phospholipase C product diacylglycerol, induced RhoA activity. Receptor-operated Ca2+ activation was mediated by TRPC6 because small interfering RNA-induced TRPC6 knockdown significantly reduced Ca2+ entry. TRPC6 knockdown also prevented RhoA activation, myosin light chain phosphorylation, and actin stress fiber formation as well as inter-endothelial-junctional gap formation in response to either oleoyl-2-acetyl-snglycerol or thrombin. TRPC6-mediated RhoA activity was shown to be dependent on PKC alpha activation. Our results demonstrate that Gaq activation of TRPC6 signals the activation of PKC alpha, and thereby induces RhoA activity and endothelial cell contraction.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu	Knezevic, Nebojsa Nick/H-9921-2019	Knezevic, Nebojsa Nick/0000-0001-8028-1495; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [R01 HL084153, R01 HL071794, HL 45638] Funding Source: Medline; PHS HHS [71794, 084153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045638, R01HL071794, R01HL084153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z; Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Albert AP, 2003, J PHYSIOL-LONDON, V552, P789, DOI 10.1113/jphysiol.2003.052977; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955; Cheng HW, 2006, ARTERIOSCL THROM VAS, V26, P1768, DOI 10.1161/01.ATV.0000231518.86795.0f; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Cioffi DL, 2005, CIRC RES, V97, P1164, DOI 10.1161/01.RES.0000193597.65217.00; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Gamberucci A, 2002, BIOCHEM J, V364, P245, DOI 10.1042/bj3640245; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Kim JY, 2005, J BIOL CHEM, V280, P32035, DOI 10.1074/jbc.M500429200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Leung PC, 2006, J VASC RES, V43, P367, DOI 10.1159/000094096; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Moers A, 2004, J BIOL CHEM, V279, P45354, DOI 10.1074/jbc.M408962200; Moore T, 1998, CHEST, V114, p36S, DOI 10.1378/chest.114.1_Supplement.36S; Moore TM, 2000, AM J PHYSIOL-LUNG C, V279, pL691, DOI 10.1152/ajplung.2000.279.4.L691; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004; Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200; Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Reither G, 2006, J CELL BIOL, V174, P521, DOI 10.1083/jcb.200604033; Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Soboloff J, 2005, J BIOL CHEM, V280, P39786, DOI 10.1074/jbc.M506064200; Thebault S, 2005, J CELL PHYSIOL, V204, P320, DOI 10.1002/jcp.20301; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Yao XQ, 2005, CIRC RES, V97, P853, DOI 10.1161/01.RES.0000187473.85419.3e; Yip H, 2004, HISTOCHEM CELL BIOL, V122, P553, DOI 10.1007/s00418-004-0720-y; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	51	162	167	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7833	7843		10.1074/jbc.M608288200	http://dx.doi.org/10.1074/jbc.M608288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17197445	hybrid			2022-12-25	WOS:000245081000012
J	Zhao, YG; Conze, DB; Hanover, JA; Ashwell, JD				Zhao, Yongge; Conze, Dietrich B.; Hanover, John A.; Ashwell, Jonathan D.			Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; UP-REGULATION; TNF-ALPHA; T-CELLS; IN-VIVO; APOPTOSIS; TRAF2; DEGRADATION; LIGASE; MICE	TRAF2 and ASK1 play essential roles in tumor necrosis factor alpha (TNF-alpha)-induced mitogen-activated protein kinase signaling. Stimulation through TNF receptor 2 (TNFR2) leads to TRAF2 ubiquitination and subsequent proteasomal degradation. Here we show that TNFR2 signaling also leads to selective ASK1 ubiquitination and degradation in proteasomes. c-IAP1 was identified as the ubiquitin protein ligase for ASK1 ubiquitination, and studies with primary B cells from c-IAP1 knock-out animals revealed that c-IAP1 is required for TNFR2-induced TRAF2 and ASK1 degradation. Moreover, in the absence of c-IAP1 TNFR2-mediated p38 and JNK activation was prolonged. Thus, the ubiquitin protein ligase activity of c-IAP1 is responsible for regulating the duration of TNF signaling in primary cells expressing TNFR2.	NCI, Lab Immune Cell Biol, Canc Res Ctr, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, Canc Res Ctr, Bethesda, MD 20892 USA.	jda@pop.nci.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010779, Z01BC010779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK060102, Z01DK060102, ZIADK060101, Z01DK060101] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alsalameh S, 1999, J RHEUMATOL, V26, P645; Bette M, 2003, J COMP NEUROL, V465, P417, DOI 10.1002/cne.10877; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Holtmann MH, 2002, EUR J IMMUNOL, V32, P3142, DOI 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4; Huang HK, 2000, J BIOL CHEM, V275, P26661; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kuranaga E, 2002, NAT CELL BIOL, V4, P705, DOI 10.1038/ncb842; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Munitic I, 2005, J IMMUNOL, V174, P4010, DOI 10.4049/jimmunol.174.7.4010; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ryan PE, 2006, TRENDS BIOCHEM SCI, V31, P79, DOI 10.1016/j.tibs.2005.12.004; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Weiss T, 1997, J IMMUNOL, V158, P2398; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	39	68	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7777	7782		10.1074/jbc.M609146200	http://dx.doi.org/10.1074/jbc.M609146200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17220297	hybrid			2022-12-25	WOS:000245081000005
J	Contreras, L; Gomez-Puertas, P; Iijima, M; Kobayashi, K; Saheki, T; Satrustegui, J				Contreras, Laura; Gomez-Puertas, Paulino; Iijima, Mikio; Kobayashi, Keiko; Saheki, Takeyori; Satrustegui, Jorgina			Ca2+ activation kinetics of the two aspartate-glutamate mitochondrial carriers, aralar and citrin - Role in the heart malate-aspartate NADH shuttle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; RAT-LIVER MITOCHONDRIA; CARDIAC MITOCHONDRIA; FUNCTIONAL-CHARACTERIZATION; CALMODULIN SUPERFAMILY; METABOLITE TRANSPORT; BACTERIAL EXPRESSION; REDUCING EQUIVALENTS; TISSUE DISTRIBUTION; MOLECULAR-CLONING	Ca2+ regulation of the Ca2+ binding mitochondrial carriers for aspartate/glutamate (AGCs) is provided by their N-terminal extensions, which face the intermembrane space. The two mammalian AGCs, aralar and citrin, are members of the malate-aspartate NADH shuttle. We report that their N-terminal extensions contain up to four pairs of EF-hand motifs plus a single vestigial EF-hand, and have no known homolog. Aralar and citrin contain one fully canonical EF-hand pair and aralar two additional halfpairs, in which a single EF-hand is predicted to bind Ca2+. Shuttle activity in brain or skeletal muscle mitochondria, which contain aralar as the major AGC, is activated by Ca2+ with S-0.5 values of 280-350 nM; higher than those obtained in liver mitochondria (100-150 nM) that contain citrin as the major AGC. We have used aralar- and citrin-deficient mice to study the role of the two isoforms in heart, which expresses both AGCs. The S-0.5 for Ca2+ activation of the shuttle in heart mitochondria is about 300 nm, and it remains essentially unchanged in citrin-deficient mice, although it undergoes a drastic reduction to about 100 nm in aralar-deficient mice. Therefore, aralar and citrin, when expressed as single isoforms in heart, confer differences in Ca2+ activation of shuttle activity, probably associated with their structural differences. In addition, the results reveal that the two AGCs fully account for shuttle activity in mouse heart mitochondria and that no other glutamate transporter can replace the AGCs in this pathway.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, CSIC, E-28049 Madrid, Spain; Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol Metab & Biochem Genet, Kagoshima 8908544, Japan	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Kagoshima University	Satrustegui, J (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, CSIC, E-28049 Madrid, Spain.	jsatrustegui@cbm.uam.es	Gomez-Puertas, Paulino/G-8821-2014; Satrustegui, Jorgina/R-6732-2019; Contreras, Laura/A-2296-2015; Contreras, Laura/ABG-7620-2021	Gomez-Puertas, Paulino/0000-0003-3131-729X; Contreras, Laura/0000-0003-1157-4942; Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667				APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; APRILLE JR, 1993, J BIOENERG BIOMEMBR, V25, P473, DOI 10.1007/BF01108404; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Brette F, 2003, CIRC RES, V92, P1182, DOI 10.1161/01.RES.0000074908.17214.FD; CEDERBAU.AI, 1973, ARCH BIOCHEM BIOPHYS, V158, P763, DOI 10.1016/0003-9861(73)90571-7; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; Cuezva JM, 2002, CANCER RES, V62, P6674; del Arco A, 2005, BIOCHEM J, V389, P647, DOI 10.1042/BJ20050283; del Arco A, 2004, J BIOL CHEM, V279, P24701, DOI 10.1074/jbc.M401417200; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; Fiermonte G, 2004, J BIOL CHEM, V279, P30722, DOI 10.1074/jbc.M400445200; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Griffin JL, 2000, AM J PHYSIOL-CELL PH, V279, pC1704, DOI 10.1152/ajpcell.2000.279.6.C1704; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; Ikura M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI 10.1073/pnas.0508640103; Jalil MA, 2005, J BIOL CHEM, V280, P31333, DOI 10.1074/jbc.M505286200; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; LANOUE KF, 1974, J BIOL CHEM, V249, P7522; LANOUE KF, 1974, J BIOL CHEM, V249, P7514; LANOUE KF, 1971, METABOLISM, V20, P119, DOI 10.1016/0026-0495(71)90087-4; LANOUE KF, 1973, J BIOL CHEM, V248, P7171; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; Mackenzie L, 2004, J CELL SCI, V117, P6327, DOI 10.1242/jcs.01559; MARTINEZ A, 1988, NEUROSCI LETT, V88, P336, DOI 10.1016/0304-3940(88)90234-0; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; Mashima H, 2003, J BIOL CHEM, V278, P9520, DOI 10.1074/jbc.M208398200; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Pardo B, 2006, J BIOL CHEM, V281, P1039, DOI 10.1074/jbc.M507270200; Ralphe JC, 2004, J MOL CELL CARDIOL, V37, P33, DOI 10.1016/j.yjmcc.2004.04.008; Ralphe JC, 2005, AM J PHYSIOL-HEART C, V288, pH2521, DOI 10.1152/ajpheart.00991.2004; Reifschneider NH, 2006, J PROTEOME RES, V5, P1117, DOI 10.1021/pr0504440; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Rupert BE, 2000, J MOL CELL CARDIOL, V32, P2287, DOI 10.1006/jmcc.2000.1257; SAFER B, 1971, J MOL CELL CARDIOL, V2, P111, DOI 10.1016/0022-2828(71)90065-4; Satrustegui J, 2007, PHYSIOL REV, V87, P29, DOI 10.1152/physrev.00005.2006; Scholz TD, 1998, AM J PHYSIOL-CELL PH, V274, pC780, DOI 10.1152/ajpcell.1998.274.3.C780; SCHOLZ TD, 1995, PEDIATR RES, V38, P221, DOI 10.1203/00006450-199508000-00015; Scholz TD, 2000, J MOL CELL CARDIOL, V32, P1, DOI 10.1006/jmcc.1999.1047; Seguchi H, 2005, CELL CALCIUM, V38, P1, DOI 10.1016/j.ceca.2005.03.004; Sinasac DS, 2004, MOL CELL BIOL, V24, P527, DOI 10.1128/MCB.24.2.527-536.2004; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; TISCHLER ME, 1976, ARCH BIOCHEM BIOPHYS, V173, P448, DOI 10.1016/0003-9861(76)90282-4; Truong K, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-1; Vogel F, 2006, J CELL BIOL, V175, P237, DOI 10.1083/jcb.200605138; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Yamasaki Y, 1997, ANAT REC, V248, P70; Yu X, 1996, BIOCHEMISTRY-US, V35, P6963, DOI 10.1021/bi960199l; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	68	75	76	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7098	7106		10.1074/jbc.M610491200	http://dx.doi.org/10.1074/jbc.M610491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17213189	hybrid			2022-12-25	WOS:000245080900021
J	Menon, S; Lee, J; Abplanalp, WA; Yoo, SE; Agui, T; Furudate, S; Kim, PS; Arvan, P				Menon, Shekar; Lee, Jaemin; Abplanalp, William A.; Yoo, Sung-Eun; Agui, Takashi; Furudate, Sen-ichi; Kim, Paul S.; Arvan, Peter			Oxidoreductase interactions include a role for ERp72 engagement with mutant thyroglobulin from the rdw/rdw rat dwarf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CONGENITAL HYPOTHYROID GOITER; RETICULUM STORAGE DISEASES; MISSENSE MUTATION G2320R; ER QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; RDW RATS; HEREDITARY DWARFISM; COMMON MECHANISM	Newly synthesized thyroglobulin (Tg), the secretory glycoprotein that serves as precursor in thyroid hormone synthesis, normally forms transient covalent protein complexes with oxidoreductases of the endoplasmic reticulum (ER). The Tg-G2320R mutation is responsible for congenital hypothyroidism in rdw/rdw rats, in which a lack of secondary thyroid enlargement (goiter) implicates death of thyrocytes as part of disease pathogenesis. We found that mutant Tg-G2320R was retained within the ER with no detectable synthesis of thyroxine, had persistent exposure of free cysteine thiols, and was associated with activated ER stress response but incomplete ER-associated degradation (ERAD). Tg-G2320R associated with multiple ER resident proteins, most notably ERp72, including covalent Tg-ERp72 interactions. In PC C13 thyrocytes, inducible overexpression of ERp72 increased the ability of cells to maintain Tg cysteines in a reduced state. Noncovalent interactions of several ER chaperones with newly synthesized Tg-G2320R diminished over time in parallel with ERAD of the mutant protein, yet a small ERAD-resistant Tg fraction remained engaged in covalent association with ERp72 even 2 days post-synthesis. Such covalent protein aggregates may set the stage for apoptotic thyrocyte cell death, preventing thyroid goiter formation in rdw/rdw rats.	Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, Med Ctr, Ann Arbor, MI 48109 USA; Univ Cincinnati, Cell & Mol Biol Program, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Endocrinol, Cincinnati, OH 45267 USA; Hokkaido Univ, Grad Sch Vet Med, Lab Expt Anim Sci, Sapporo, Hokkaido 0600818, Japan; Kitasato Univ, Sch Med, Dept Lab Anim Sci, Sagamihara, Kanagawa 2288555, Japan	University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Hokkaido University; Kitasato University	Arvan, P (corresponding author), Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, Med Ctr, 5560 MSRB2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Lee, Jaemin/AAP-4875-2021; Kim, Paul/GYV-3258-2022	Kim, Paul/0000-0003-0943-4924; Lee, Jaemin/0000-0002-0224-7141	NIDDK NIH HHS [R01 DK040344, DK52076, DK40344, R01 DK040344-20] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK052076, R01DK040344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlbom BE, 2002, HUM GENET, V110, P145, DOI 10.1007/s00439-002-0680-z; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Baryshev M, 2004, J MOL ENDOCRINOL, V32, P903, DOI 10.1677/jme.0.0320903; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Carelli S, 1997, SCIENCE, V277, P1681, DOI 10.1126/science.277.5332.1681; Chen Y, 2005, HUM MOL GENET, V14, P2559, DOI 10.1093/hmg/ddi259; Di Jeso B, 2005, MOL CELL BIOL, V25, P9793, DOI 10.1128/MCB.25.22.9793-9805.2005; Di Jeso B, 2003, BIOCHEM J, V370, P449, DOI 10.1042/BJ20021257; DIJESO B, 2004, THYROID; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fagioli C, 2001, J BIOL CHEM, V276, P40962, DOI 10.1074/jbc.M107456200; Forster ML, 2006, J CELL BIOL, V173, P853, DOI 10.1083/jcb.200602046; Hishinuma A, 2000, ENDOCRINOLOGY, V141, P4050, DOI 10.1210/en.141.11.4050; KIM PS, 1991, J BIOL CHEM, V266, P12412; Kim PS, 2000, MOL ENDOCRINOL, V14, P1944, DOI 10.1210/me.14.12.1944; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; KOTO M, 1988, EXP ANIM TOKYO, V37, P21, DOI 10.1538/expanim1978.37.1_21; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; Labat-Moleur F, 1999, THYROID, V9, P483, DOI 10.1089/thy.1999.9.483; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; McCracken AA, 2005, CURR TOP MICROBIOL, V300, P17; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068; Oh-Ishi M, 1998, ENDOCRINOLOGY, V139, P1288, DOI 10.1210/en.139.3.1288; Park YN, 2004, J BIOL CHEM, V279, P17085, DOI 10.1074/jbc.M314042200; Perlmutter David H, 2003, Methods Mol Biol, V232, P39; RUPP K, 1994, J BIOL CHEM, V269, P2501; Russell TA, 2003, J CLIN INVEST, V112, P1697, DOI 10.1172/JCI200318616; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Sakai Y, 2000, ANAT REC, V259, P60; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Umezu M, 1998, LAB ANIM SCI, V48, P496; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840	48	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6183	6191		10.1074/jbc.M608863200	http://dx.doi.org/10.1074/jbc.M608863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17200118	hybrid, Green Accepted			2022-12-25	WOS:000244867200024
J	Babel, AR; Bruce, J; Young, JAT				Babel, Angeline Rose; Bruce, James; Young, John A. T.			The hr1 and Fusion Peptide Regions of the Subgroup B Avian Sarcoma and Leukosis Virus Envelope Glycoprotein Influence Low pH-Dependent Membrane Fusion	PLOS ONE			English	Article								The avian sarcoma and leukosis virus (ASLV) envelope glycoprotein (Env) is activated to trigger fusion by a two-step mechanism involving receptor-priming and low pH fusion activation. In order to identify regions of ASLV Env that can regulate this process, a genetic selection method was used to identify subgroup B (ASLV-B) virus-infected cells resistant to low pH-triggered fusion when incubated with cells expressing the cognate TVB receptor. The subgroup B viral Env (envB) genes were then isolated from these cells and characterized by DNA sequencing. This led to identification of two frequent EnvB alterations which allowed TVB receptor-binding but altered the pH-threshold of membrane fusion activation: a 13 amino acid deletion in the host range 1 (hr1) region of the surface (SU) EnvB subunit, and the A32V amino acid change within the fusion peptide of the transmembrane (TM) EnvB subunit. These data indicate that these two regions of EnvB can influence the pH threshold of fusion activation.	[Young, John A. T.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; [Babel, Angeline Rose] Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; [Bruce, James] Univ Wisconsin, Bock Labs, Inst Mol Virol, Madison, WI 53706 USA	Salk Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Young, JAT (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jyoung@salk.edu		Young, John/0000-0003-1824-2561	NIH [CA70810, AI053668]; NSRA [T32 CA009135, P01-CA22443]; NATIONAL CANCER INSTITUTE [R01CA070810, P01CA022443, T32CA009135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053668] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grants CA70810 and AI053668 to J.A.T.Y and NSRA T32 CA009135 and P01-CA22443 to A. R. B.	Adkins HB, 1997, P NATL ACAD SCI USA, V94, P11617, DOI 10.1073/pnas.94.21.11617; Adkins HB, 2000, J VIROL, V74, P3572, DOI 10.1128/JVI.74.8.3572-3578.2000; Adkins HB, 2001, J VIROL, V75, P3520, DOI 10.1128/JVI.75.8.3520-3526.2001; Balliet JW, 2000, J VIROL, V74, P3731, DOI 10.1128/JVI.74.8.3731-3739.2000; Barnard RJO, 2006, VIROLOGY, V344, P25, DOI 10.1016/j.virol.2005.09.021; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Boerger AL, 1999, P NATL ACAD SCI USA, V96, P9867, DOI 10.1073/pnas.96.17.9867; BOVA CA, 1988, J VIROL, V62, P75, DOI 10.1128/JVI.62.1.75-83.1988; BOVA CA, 1986, VIROLOGY, V152, P343, DOI 10.1016/0042-6822(86)90137-6; Brojatsch J, 2000, J VIROL, V74, P11490, DOI 10.1128/JVI.74.24.11490-11494.2000; Bruce JW, 2005, J VIROL, V79, P12969, DOI 10.1128/JVI.79.20.12969-12978.2005; Chai N, 2006, P NATL ACAD SCI USA, V103, P5531, DOI 10.1073/pnas.0509785103; Damico R, 1999, J VIROL, V73, P3087, DOI 10.1128/JVI.73.4.3087-3094.1999; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; Delos SE, 2000, J VIROL, V74, P9738, DOI 10.1128/JVI.74.20.9738-9741.2000; Delos SE, 2005, J VIROL, V79, P3488, DOI 10.1128/JVI.79.6.3488-3499.2005; Delos SE, 2000, J VIROL, V74, P1686, DOI 10.1128/JVI.74.4.1686-1693.2000; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Earp LJ, 2003, J VIROL, V77, P3058, DOI 10.1128/JVI.77.5.3058-3066.2003; Elleder D, 2005, J VIROL, V79, P10408, DOI 10.1128/JVI.79.16.10408-10419.2005; Hernandez LD, 1998, J VIROL, V72, P3259, DOI 10.1128/JVI.72.4.3259-3267.1998; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Holmen SL, 2000, VIROLOGY, V273, P364, DOI 10.1006/viro.2000.0424; Holmen SL, 2001, J VIROL, V75, P726, DOI 10.1128/JVI.75.2.726-737.2001; Jonah G, 2003, J VIROL, V77, P6709, DOI 10.1128/JVI.77.12.6709-6719.2003; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; Markosyan RM, 2004, BIOPHYS J, V87, P3291, DOI 10.1529/biophysj.104.047696; Matsuyama S, 2004, J VIROL, V78, P8201, DOI 10.1128/JVI.78.15.8201-8209.2004; Melder DC, 2003, J VIROL, V77, P10504, DOI 10.1128/JVI.77.19.10504-10514.2003; Melikyan GB, 2005, P NATL ACAD SCI USA, V102, P8728, DOI 10.1073/pnas.0501864102; Melikyan GB, 2004, J VIROL, V78, P3753, DOI 10.1128/JVI.78.7.3753-3762.2004; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; Netter RC, 2004, J VIROL, V78, P13430, DOI 10.1128/JVI.78.24.13430-13439.2004; Rong LJ, 1997, J VIROL, V71, P3458, DOI 10.1128/JVI.71.5.3458-3465.1997; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; Taplitz RA, 1997, J VIROL, V71, P7814, DOI 10.1128/JVI.71.10.7814-7819.1997; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	39	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2007	2	1							e171	10.1371/journal.pone.0000171	http://dx.doi.org/10.1371/journal.pone.0000171			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DG	17245447	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444100008
J	Carling, MD; Brumfield, RT				Carling, Matthew D.; Brumfield, Robb T.			Gene Sampling Strategies for Multi-Locus Population Estimates of Genetic Diversity (theta)	PLOS ONE			English	Article								Background. Theoretical work suggests that data from multiple nuclear loci provide better estimates of population genetic parameters than do single loci, but just how many loci are needed and how much sequence is required from each has been little explored. Methodology/Principle Findings. To investigate how much data is required to estimate the population genetic parameter theta (4N(e)mu) accurately under ideal circumstances, we simulated datasets of DNA sequences under three values of theta per site (0.1, 0.01, 0.001), varying in both the total number of base pairs sequenced per individual and the number of equal-length loci. From these datasets we estimated theta using the maximum likelihood coalescent framework implemented in the computer program MIGRATE. Our results corroborated the theoretical expectation that increasing the number of loci impacted the accuracy of the estimate more than increasing the sequence length at single loci. However, when the value of theta was low (0.001), the per-locus sequence length was also important for estimating theta accurately, something that has not been emphasized in previous work. Conclusions/Significance. Accurate estimation of theta required data from at least 25 independently evolving loci. Beyond this, there was little added benefit in terms of decreasing the squared coefficient of variation of the coalescent estimates relative to the extra effort required to sample more loci.	[Carling, Matthew D.; Brumfield, Robb T.] Louisiana State Univ, Museum Nat Sci, Baton Rouge, LA 70803 USA; [Carling, Matthew D.] Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University	Carling, MD (corresponding author), Louisiana State Univ, Museum Nat Sci, Baton Rouge, LA 70803 USA.	mcarli1@lsu.edu	Brumfield, Robb T/K-6108-2015	Brumfield, Robb T/0000-0003-2307-0688	NSF [DEB-0332093]	NSF(National Science Foundation (NSF))	This work was funded by NSF grant DEB-0332093 to RTB.	Beerli P, 1999, GENETICS, V152, P763; BEGUN DJ, 1991, GENETICS, V129, P1147; BERRY AJ, 1991, GENETICS, V129, P1111; Congdon BC, 2000, EVOLUTION, V54, P974; Crawford AJ, 2003, MOL ECOL, V12, P2525, DOI 10.1046/j.1365-294X.2003.01910.x; DRUMMOND AJ, 2003, BEAST V1 0; Edwards SV, 2000, EVOLUTION, V54, P1839; Emerson BC, 2001, TRENDS ECOL EVOL, V16, P707, DOI 10.1016/S0169-5347(01)02305-9; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Felsenstein J, 2006, MOL BIOL EVOL, V23, P691, DOI 10.1093/molbev/msj079; FELSENSTEIN J, 1992, GENET RES, V59, P139, DOI 10.1017/S0016672300030354; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; Ford MJ, 1998, EVOLUTION, V52, P539, DOI 10.1111/j.1558-5646.1998.tb01653.x; FU YX, 1993, GENETICS, V133, P693; Fu YX, 1999, THEOR POPUL BIOL, V56, P1, DOI 10.1006/tpbi.1999.1421; FU YX, 1993, GENETICS, V134, P1261; Grassly NC, 1999, GENETICS, V151, P427; Hare MP, 2002, EVOLUTION, V56, P804; Hare MP, 2001, TRENDS ECOL EVOL, V16, P700, DOI 10.1016/S0169-5347(01)02326-6; Hedrick PW, 1999, EVOLUTION, V53, P313, DOI 10.1111/j.1558-5646.1999.tb03767.x; Kliman RM, 2000, GENETICS, V156, P1913; Knowles LL, 2002, MOL ECOL, V11, P2623, DOI 10.1046/j.1365-294X.2002.01637.x; Kuhner MK, 2000, GENETICS, V156, P439; KUHNER MK, 1995, GENETICS, V140, P1421; Lercher MJ, 2002, TRENDS GENET, V18, P337, DOI 10.1016/S0168-9525(02)02669-0; Llopart A, 2005, GENETICS, V171, P197, DOI 10.1534/genetics.104.033597; Moore WS, 1997, EVOLUTION, V51, P627, DOI 10.1111/j.1558-5646.1997.tb02452.x; MOORE WS, 1995, EVOLUTION, V49, P718, DOI 10.1111/j.1558-5646.1995.tb02308.x; Nachman MW, 1997, GENETICS, V147, P1303; Nachman MW, 2002, CURR OPIN GENET DEV, V12, P657, DOI 10.1016/S0959-437X(02)00358-1; Nachman MW, 1998, GENETICS, V150, P1133; Nachman MW, 2001, TRENDS GENET, V17, P481, DOI 10.1016/S0168-9525(01)02409-X; Nielsen R, 2000, GENETICS, V154, P931; Page RDM, 1998, BIOINFORMATICS, V14, P819, DOI 10.1093/bioinformatics/14.9.819; Patterson N, 2006, NATURE, V441, P1103, DOI 10.1038/nature04789; Pluzhnikov A, 1996, GENETICS, V144, P1247; Pogson GH, 2003, MOL ECOL, V12, P63, DOI 10.1046/j.1365-294X.2003.01713.x; Primmer CR, 2002, MOL ECOL, V11, P603, DOI 10.1046/j.0962-1083.2001.01452.x; Rokas A, 2003, NATURE, V425, P798, DOI 10.1038/nature02053; Rosenberg NA, 2002, NAT REV GENET, V3, P380, DOI 10.1038/nrg795; Saillant E, 2004, MOL ECOL, V13, P2947, DOI 10.1111/j.1365-294X.2004.02303.x; Sokal RR, 1995, BIOMETRY; Strasburg JL, 2005, MOL ECOL, V14, P2755, DOI 10.1111/j.1365-294X.2005.02627.X; TAKAHATA N, 1995, THEOR POPUL BIOL, V48, P198, DOI 10.1006/tpbi.1995.1026; Wakeley J, 2004, J HERED, V95, P397, DOI 10.1093/jhered/esh062; Wakeley J, 1997, GENETICS, V145, P847; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Yang ZH, 1997, GENET RES, V69, P111, DOI 10.1017/S001667239700270X; Zhang DX, 2003, MOL ECOL, V12, P563, DOI 10.1046/j.1365-294X.2003.01773.x	49	52	53	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e160	10.1371/journal.pone.0000160	http://dx.doi.org/10.1371/journal.pone.0000160			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225863	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444000011
J	Khonsari, RH; Calvez, V				Khonsari, Roman H.; Calvez, Vincent			The Origins of Concentric Demyelination: Self-Organization in the Human Brain	PLOS ONE			English	Article								Balo's concentric sclerosis is a rare atypical form of multiple sclerosis characterized by striking concentric demyelination patterns. We propose a robust mathematical model for Balo's sclerosis, sharing common molecular and cellular mechanisms with multiple sclerosis. A reconsideration of the analogies between Balo's sclerosis and the Liesegang periodic precipitation phenomenon led us to propose a chemotactic cellular model for this disease. Rings of demyelination appear as a result of self-organization processes, and closely mimic Balo lesions. According to our results, homogeneous and concentric demyelinations may be two different macroscopic outcomes of a single fundamental immune disorder. Furthermore, in chemotactic models, cellular aggressivity appears to play a central role in pattern formation.	[Khonsari, Roman H.] CHU Nantes, Serv Chirurg Maxillofaciale, F-44035 Nantes 01, France; [Khonsari, Roman H.] Hop La Pitie Salpetriere, Lab Neuropathol R Escourolle, F-75651 Paris, France; [Calvez, Vincent] Ecole Normale Super, Dept Math & Applicat, F-75231 Paris, France	Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Khonsari, RH (corresponding author), CHU Nantes, Serv Chirurg Maxillofaciale, F-44035 Nantes 01, France.	hossein.khonsari@ens.fr	Calvez, Vincent/D-1119-2014; Khonsari, Roman Hossein/H-7460-2017	Calvez, Vincent/0000-0002-3674-1965; Khonsari, Roman Hossein/0000-0002-0649-1432	Department de Mathematiques of the Ecole normale superieure in Paris; Agence Nationale de la Recherche	Department de Mathematiques of the Ecole normale superieure in Paris; Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was funded by the Department de Mathematiques of the Ecole normale superieure in Paris and has been partially financed by the MACBAC project of the Agence Nationale de la Recherche.	Aboul-Enein F, 2005, ACTA NEUROPATHOL, V109, P49, DOI 10.1007/s00401-004-0954-8; Anschel DJ, 2006, EUR NEUROL, V55, P111, DOI 10.1159/000092788; Balo J, 1927, MAGY ORVOSI ARCH, V28, P108; Barnett FH, 2004, NEUROSURGERY, V55, P468, DOI 10.1227/00006123-200408000-00083; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CALVEZ V, 2006, J MATH PURE APPL, V86, P2; Chen CJ, 1999, ANN NEUROL, V46, P651, DOI 10.1002/1531-8249(199910)46:4<651::AID-ANA15>3.0.CO;2-Y; Chen CJ, 2001, J COMPUT ASSIST TOMO, V25, P713, DOI 10.1097/00004728-200109000-00008; COURVILLE CB, 1970, MULTIPLE SCLEROSIS O, P437; Dolbeault J, 2004, CR MATH, V339, P611, DOI 10.1016/j.crma.2004.08.011; Droz M, 2000, J STAT PHYS, V101, P509, DOI 10.1023/A:1026489416640; Ferraro A, 1933, PSYCHIAT QUART, V7, P267, DOI 10.1007/BF01572459; Gajewski H, 1998, MATH NACHR, V195, P77, DOI 10.1002/mana.19981950106; Genain CP, 1997, J MOL MED, V75, P187, DOI 10.1007/s001090050103; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Hallervorden J, 1933, ARCH PSYCHIAT NERVEN, V98, P641, DOI 10.1007/BF01814664; Hatschek E, 1925, KOLLOID Z, V37, P297, DOI 10.1007/BF01424995; HENISCH HK, 1986, CRYSTALS GELS LIESEG, P137; ITOYAMA Y, 1984, ANN NEUROL, V17, P481; JAGER W, 1992, T AM MATH SOC, V329, P819, DOI 10.2307/2153966; Kastrup O, 2002, J NEUROL, V249, P811, DOI 10.1007/s00415-002-0718-0; KELLER EF, 1971, J THEOR BIOL, V30, P225, DOI 10.1016/0022-5193(71)90050-6; Krug HJ, 1996, GEOL RUNDSCH, V85, P19, DOI 10.1007/s005310050047; Krug HJ, 1999, J PHYS CHEM A, V103, P7811, DOI 10.1021/jp991092l; Lassmann H, 2005, BRAIN PATHOL, V15, P217; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lumsden CE, 1970, HDB CLINICAL NEUROLO, P217; Markiewicz D, 1977, Neuropatol Pol, V15, P491; MICHALAK S, 2004, STUDIA PHILOS TARTU, V4, P139; Moore GRW, 2001, MULT SCLER J, V7, P375, DOI 10.1177/135245850100700606; MOORE GRW, 1985, ANN NEUROL, V17, P604, DOI 10.1002/ana.410170614; Nagai T., 1995, ADV MATH SCI APPL, V5, P581; NANJUNDIAH V, 1973, J THEOR BIOL, V42, P63, DOI 10.1016/0022-5193(73)90149-5; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ostwald W., 1897, Z PHYS CHEM, V22, P289; Painter K. J., 2002, CANADIAN APPL MATH Q, V10, P501; PATLAK CLIFFORD S., 1953, BULL MATH BIOPHYS, V15, P311, DOI 10.1007/BF02476407; Pohl D, 2005, J NEUROL NEUROSUR PS, V76, P1723, DOI 10.1136/jnnp.2004.062331; Stadelmann C, 2005, BRAIN, V128, P979, DOI 10.1093/brain/awh457; Stadelmann C, 2004, NEUROL SCI, V25, pS319, DOI 10.1007/s10072-004-0333-1; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; VENZL G, 1982, J CHEM PHYS, V77, P1302, DOI 10.1063/1.443952; Wiendl H, 2005, EUR NEUROL, V53, P42, DOI 10.1159/000084264; YAO DL, 1994, ANN NEUROL, V35, P18, DOI 10.1002/ana.410350105; ZEMAN W, 1949, ARCH PSYCHIAT NERVEN, V181, P187	47	31	33	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e150	10.1371/journal.pone.0000150	http://dx.doi.org/10.1371/journal.pone.0000150			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225855	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444000002
J	Dean, SO; Spudich, JA				Dean, Sara O.; Spudich, James A.			Rho Kinase's Role in Myosin Recruitment to the Equatorial Cortex of Mitotic Drosophila S2 Cells Is for Myosin Regulatory Light Chain Phosphorylation	PLOS ONE			English	Article								Background. Myosin II recruitment to the equatorial cortex is one of the earliest events in establishment of the cytokinetic contractile ring. In Drosophila S2 cells, we previously showed that myosin II is recruited to the furrow independently of F-actin, and that Rho1 and Rok are essential for this recruitment [1]. Rok phosphorylates several cellular proteins, including the myosin regulatory light chain (RLC). Methodology/Principal Findings. Here we express phosphorylation state mimic constructs of the RLC in S2 cells to examine the role of RLC phosphorylation involving Rok in the localization of myosin. Phosphorylation of the RLC is required for myosin localization to the equatorial cortex during mitosis, and the essential role of Rok in this localization and for cytokinesis is to maintain phosphorylation of the RLC. The ability to regulate the RLC phosphorylation state spatio-temporally is not essential for the myosin localization. Furthermore, the essential role of Citron in cytokinesis is not phosphorylation of the RLC. Conclusions/Significance. We conclude that the Rho1 pathway leading to myosin localization to the future cytokinetic furrow is relatively straightforward, where only Rok is needed, and it is only needed to maintain phosphorylation of the myosin RLC.	[Dean, Sara O.; Spudich, James A.] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Spudich, JA (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	jspudich@stanford.edu			National Institutes of Health [GM07276, HG00044, GM46551]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000044, T32HG000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007276, R01GM033289, R37GM046551, R01GM046551] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health Cell and Molecular Biology Training Grant GM07276 and Genome Training Grant HG00044 (to S.O.D.) and National Institutes of Health Grant GM46551 (to J.A.S.).	Afshar K, 2000, DEVELOPMENT, V127, P1887; Bement WM, 2005, J CELL BIOL, V170, P91, DOI 10.1083/jcb.200501131; Chodagam S, 2005, CURR BIOL, V15, P1308, DOI 10.1016/j.cub.2005.06.024; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; D'Avino PP, 2004, J CELL BIOL, V166, P61, DOI 10.1083/jcb.200402157; Dean SO, 2005, P NATL ACAD SCI USA, V102, P13473, DOI 10.1073/pnas.0506810102; DeBiasio RL, 1996, MOL BIOL CELL, V7, P1259, DOI 10.1091/mbc.7.8.1259; Echard A, 2004, CURR BIOL, V14, P1685, DOI 10.1016/j.cub.2004.08.063; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hickson GRX, 2006, CURR BIOL, V16, P359, DOI 10.1016/j.cub.2005.12.043; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; Kamijo K, 2006, MOL BIOL CELL, V17, P43, DOI 10.1091/mbc.e05-06-0569; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mizuno T, 1999, GENE, V238, P437, DOI 10.1016/S0378-1119(99)00351-0; Naim V, 2004, MOL BIOL CELL, V15, P5053, DOI 10.1091/mbc.E04-06-0536; Piekny AJ, 2002, J CELL SCI, V115, P2271; Rogers SL, 2004, CURR BIOL, V14, P1827, DOI 10.1016/j.cub.2004.09.078; Royou A, 2004, MOL BIOL CELL, V15, P838, DOI 10.1091/mbc.E03-06-0440; Royou A, 2002, J CELL BIOL, V158, P127, DOI 10.1083/jcb.200203148; Sabry JH, 1997, MOL BIOL CELL, V8, P2605, DOI 10.1091/mbc.8.12.2605; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Ueda K, 2002, ONCOGENE, V21, P5852, DOI 10.1038/sj.onc.1205747; Vereshchagina N, 2004, MOL BIOL CELL, V15, P4395, DOI 10.1091/mbc.E04-02-0139; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427	40	56	56	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e131	10.1371/journal.pone.0000131	http://dx.doi.org/10.1371/journal.pone.0000131			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205135	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443700025
J	Happonen, P; Voutilainen, S; Tuomainen, TP; Salonen, JT				Happonen, Pertti; Voutilainen, Sari; Tuomainen, Tomi-Pekka; Salonen, Jukka T.			Catechol-O-Methyltransferase Gene Polymorphism Modifies the Effect of Coffee Intake on Incidence of Acute Coronary Events	PLOS ONE			English	Article								Background. The role of coffee intake as a risk factor for coronary heart disease (CHD) has been debated for decades. We examined whether the relationship between coffee intake and incidence of CHD events is dependent on the metabolism of circulating catecholamines, as determined by functional polymorphism of the catechol-O-methyltransferase (COMT) gene. Methodology/Principal Findings. In a cohort of 773 men who were 42 to 60 years old and free of symptomatic CHD at baseline in 1984-89, 78 participants experienced an acute coronary event during an average follow-up of 13 years. In logistic regression adjusting for age, smoking, family history of CHD, vitamin C deficiency, blood pressure, plasma cholesterol concentration, and diabetes, the odds ratio (90% confidence interval) comparing heavy coffee drinkers with the low activity COMT genotype with those with the high activity or heterozygotic genotypes was 3.2 (1.2-8.4). Urinary adrenaline excretion increased with increasing coffee intake, being over two-fold in heavy drinkers compared with nondrinkers (p = 0.008 for trend). Conclusions/Significance. Heavy coffee consumption increases the incidence of acute coronary events in men with low but not high COMT activity. Further studies are required to determine to which extent circulating catecholamines mediate the relationship between coffee intake and CHD.	[Happonen, Pertti; Salonen, Jukka T.] Univ Kuopio, Dept Publ Hlth, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland; [Voutilainen, Sari; Tuomainen, Tomi-Pekka; Salonen, Jukka T.] Univ Kuopio, Publ Hlth Res Inst, FIN-70211 Kuopio, Finland; [Tuomainen, Tomi-Pekka] Univ Kuopio, Clin Res Ctr, Atherosclerosis Unit, FIN-70211 Kuopio, Finland; [Salonen, Jukka T.] Oy Jurilab Ltd, Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland	Happonen, P (corresponding author), Univ Kuopio, Dept Publ Hlth, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland.	pertti.happonen@uku.fi			Academy of Finland [201688, 80185]; Ministry of Education of Finland; city of Kuopio; National Heart, Lung, and Blood Institute of the United States; Juho Vainio Foundation; Finnish Cultural Fund/North Savo Fund; Yrjo Jahnsson Foundation; Finnish Foundation for Medical Science	Academy of Finland(Academy of Finland); Ministry of Education of Finland; city of Kuopio; National Heart, Lung, and Blood Institute of the United States(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Juho Vainio Foundation; Finnish Cultural Fund/North Savo Fund; Yrjo Jahnsson Foundation; Finnish Foundation for Medical Science	This study was supported in part by grants from the Academy of Finland (201688 and 80185 for S. V.), the Ministry of Education of Finland, the city of Kuopio, and the National Heart, Lung, and Blood Institute of the United States. Additional support was provided to P. H. by the Juho Vainio Foundation, the Finnish Cultural Fund/North Savo Fund, the Yrjo Jahnsson Foundation, and the Finnish Foundation for Medical Science.	Boekschoten MV, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-8; Brandin L, 2003, J HYPERTENS, V21, P1695, DOI 10.1097/00004872-200309000-00019; Cornelis MC, 2006, JAMA-J AM MED ASSOC, V295, P1135, DOI 10.1001/jama.295.10.1135; Corti R, 2002, CIRCULATION, V106, P2935, DOI 10.1161/01.CIR.0000046228.97025.3A; Eisenhofer G, 2001, Rev Endocr Metab Disord, V2, P297, DOI 10.1023/A:1011572617314; Gidron Y, 2002, CARDIOVASC RES, V56, P15, DOI 10.1016/S0008-6363(02)00537-0; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; GYNTELBERG F, 1995, J INTERN MED, V237, P55, DOI 10.1111/j.1365-2796.1995.tb01140.x; Hammar N, 2003, J INTERN MED, V253, P653, DOI 10.1046/j.1365-2796.2003.01142.x; Happonen P, 2004, J NUTR, V134, P2381, DOI 10.1093/jn/134.9.2381; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393; KUMADA Y, 1976, J ANTIBIOT, V29, P882, DOI 10.7164/antibiotics.29.882; LACROIX AZ, 1986, NEW ENGL J MED, V315, P977, DOI 10.1056/NEJM198610163151601; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LANE JD, 1990, PSYCHOSOM MED, V52, P320, DOI 10.1097/00006842-199005000-00006; Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840; NISTRUPMADSEN S, 1978, BRIT J SURG, V65, P191, DOI 10.1002/bjs.1800650315; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Panagiotakos DB, 2003, J NUTR, V133, P3228, DOI 10.1093/jn/133.10.3228; PINCOMB GA, 1988, AM J CARDIOL, V61, P798, DOI 10.1016/0002-9149(88)91069-7; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; ROSENBERG L, 1988, AM J EPIDEMIOL, V128, P570, DOI 10.1093/oxfordjournals.aje.a115004; Saboury AA, 2003, ACTA BIOCHIM POL, V50, P849; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SMITS P, 1986, CLIN PHARMACOL THER, V40, P431, DOI 10.1038/clpt.1986.203; Stevens RD, 2003, ANESTH ANALG, V97, P623, DOI 10.1213/01.ANE.0000074795.68061.16; Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562; Syvanen AC, 1997, PHARMACOGENETICS, V7, P65; Tavani A, 2001, EUR J EPIDEMIOL, V17, P1131, DOI 10.1023/A:1021276932160; Thelle Dag S., 1995, Current Opinion in Lipidology, V6, P25, DOI 10.1097/00041433-199502000-00006; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; WHITSETT TL, 1984, AM J CARDIOL, V53, P918, DOI 10.1016/0002-9149(84)90525-3; Willett WC, 1996, JAMA-J AM MED ASSOC, V275, P458, DOI 10.1001/jama.275.6.458; WILSON PWF, 1989, ARCH INTERN MED, V149, P1169, DOI 10.1001/archinte.149.5.1169; Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481; Zhu BT, 2002, HISTOL HISTOPATHOL, V17, P1283, DOI 10.14670/HH-17.1283	42	32	34	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e117	10.1371/journal.pone.0000117	http://dx.doi.org/10.1371/journal.pone.0000117			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205121	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700011
J	Li, Y; Roycewicz, P; Smith, E; Borevitz, JO				Li, Yan; Roycewicz, Peter; Smith, Evadne; Borevitz, Justin O.			Genetics of Local Adaptation in the Laboratory: Flowering Time Quantitative Trait Loci under Geographic and Seasonal Conditions in Arabidopsis	PLOS ONE			English	Article								Flowering time in Arabidopsis thaliana is controlled by a large number of genes and various environmental factors, such as light and temperature. The objective of this study was to identify flowering time quantitative trait loci (QTL) under growth conditions simulating seasonal conditions from native geographic locations. Our growth chambers were set to simulate the spring conditions in Spain and Sweden, with appropriate changes in light color, intensity and day length, as well as temperature and relative humidity. Thus the Sweden-like spring conditions changed more dramatically compared to Spain-like spring conditions across the duration of our experiment. We have used these conditions to map QTL responsible for flowering time in the Kas-1/Col-gl1 recombinant inbred lines (RILs) across two replicate blocks. A linkage map from 96 RILs was established using 119 markers including 64 new SNPs markers. One major QTL, mapping to the FRIGIDA (FRI) locus, was detected on the top of chromosome 4 that showed significant gene x seasonal environment interactions. Three other minor QTL also were detected. One QTL mapping near FLOWERING LOCUS M(FLM) showed an epistatic interaction with the QTL at FRI. These QTL x environment and QTL x QTL interactions suggest that subtle ecologically relevant changes in light, temperature, and relative humidity are differentially felt by alleles controlling flowering time and may be responsible for adaptation to regional environments.	[Li, Yan; Smith, Evadne; Borevitz, Justin O.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; [Roycewicz, Peter; Borevitz, Justin O.] Univ Chicago, Comm Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Borevitz, JO (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.	borevitz@uchicago.edu	Borevitz, Justin/B-5423-2012; Li, Yan/AAF-5886-2019	Borevitz, Justin/0000-0001-8408-3699; Li, Yan/0000-0002-1627-7763	NIH [R01 GM073822]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073822] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Startup fund to Justin Borevitz supported this work; Yan Li was supported by NIH R01 GM073822 to Justin Borevitz.	Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Amasino RM, 2005, CURR OPIN BIOTECH, V16, P154, DOI 10.1016/j.copbio.2005.02.004; Balasubramanian S, 2006, PLOS GENET, V2, P980, DOI 10.1371/journal.pgen.0020106; Balasubramanian S, 2006, NAT GENET, V38, P711, DOI 10.1038/ng1818; Blazquez M, 2001, EMBO REP, V2, P1078, DOI 10.1093/embo-reports/kve254; Blazquez MA, 2003, NAT GENET, V33, P168, DOI 10.1038/ng1085; Borevitz JO, 2002, GENETICS, V160, P683; Caicedo AL, 2004, P NATL ACAD SCI USA, V101, P15670, DOI 10.1073/pnas.0406232101; CHURCHILL GA, 1994, GENETICS, V138, P963; Grini PE, 1999, GENETICS, V151, P849; Harushima Y, 1996, THEOR APPL GENET, V92, P145, DOI 10.1007/BF00223368; HOLLOWAY JL, 1994, GMENDEL 3 0 USERS GU; Howden R, 1998, GENETICS, V149, P621; Lempe J, 2005, PLOS GENET, V1, P109, DOI 10.1371/journal.pgen.0010006; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; Scortecci KC, 2001, PLANT J, V26, P229, DOI 10.1046/j.1365-313x.2001.01024.x; Searle I, 2004, EMBO J, V23, P1217, DOI 10.1038/sj.emboj.7600117; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Stinchcombe JR, 2004, P NATL ACAD SCI USA, V101, P4712, DOI 10.1073/pnas.0306401101; Stinchcombe JR, 2005, AM J BOT, V92, P1701, DOI 10.3732/ajb.92.10.1701; Sung SB, 2004, CURR OPIN PLANT BIOL, V7, P4, DOI 10.1016/j.pbi.2003.11.010; Voorrips RE, 2002, J HERED, V93, P77, DOI 10.1093/jhered/93.1.77; Weinig C, 2003, GENETICS, V165, P321; Weinig C, 2002, GENETICS, V162, P1875; Werner JD, 2005, GENETICS, V170, P1197, DOI 10.1534/genetics.104.036533; Werner JD, 2005, P NATL ACAD SCI USA, V102, P2460, DOI 10.1073/pnas.0409474102; Wilson IW, 2001, GENETICS, V158, P1301; Wolyn DJ, 2004, GENETICS, V167, P907, DOI 10.1534/genetics.103.024810; Xu Y, 1997, MOL GEN GENET, V253, P535, DOI 10.1007/s004380050355	30	40	41	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e105	10.1371/journal.pone.0000105	http://dx.doi.org/10.1371/journal.pone.0000105			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205109	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443700001
J	Oikonomou, N; Harokopos, V; Zalevsky, J; Valavanis, C; Kotanidou, A; Szymkowski, DE; Kollias, G; Aidinis, V				Oikonomou, Nikos; Harokopos, Vaggelis; Zalevsky, Jonathan; Valavanis, Christos; Kotanidou, Anastasia; Szymkowski, David E.; Kollias, George; Aidinis, Vassilis			Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis	PLOS ONE			English	Article								Background. Fibrosis, the replacement of functional tissue with excessive fibrous tissue, can occur in all the main tissues and organ systems, resulting in various pathological disorders. Idiopathic Pulmonary Fibrosis is a prototype fibrotic disease involving abnormal wound healing in response to multiple sites of ongoing alveolar epithelial injury. Methodology/Principal Findings. To decipher the role of TNF and TNF-mediated inflammation in the development of fibrosis, we have utilized the bleomycin-induced animal model of Pulmonary Fibrosis and a series of genetically modified mice lacking components of TNF signaling. Transmembrane TNF expression is shown to be sufficient to elicit an inflammatory response, but inadequate for the transition to the fibrotic phase of the disease. Soluble TNF expression is shown to be crucial for lymphocyte recruitment, a prerequisite for TGF-b1 expression and the development of fibrotic lesions. Moreover, through a series of bone marrow transfers, the necessary TNF expression is shown to originate from the non-hematopoietic compartment further localized in apoptosing epithelial cells. Conclusions. These results suggest a primary detrimental role of soluble TNF in the pathologic cascade, separating it from the beneficial role of transmembrane TNF, and indicate the importance of assessing the efficacy of soluble TNF antagonists in the treatment of Idiopathic Pulmonary Fibrosis.	[Oikonomou, Nikos; Harokopos, Vaggelis; Kollias, George; Aidinis, Vassilis] Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Athens, Greece; [Zalevsky, Jonathan; Szymkowski, David E.] Xencor Inc, Monrovia, CA USA; [Valavanis, Christos] Metaxa Canc Hosp, Dept Pathol, Mol Pathol Unit, Piraeus, Greece; [Kotanidou, Anastasia] Univ Athens, Sch Med, Dept Crit Care 1, GR-11527 Athens, Greece	Alexander Fleming Biomedical Sciences Research Center; Athens Medical School; National & Kapodistrian University of Athens	Aidinis, V (corresponding author), Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Athens, Greece.	V.Aidinis@Fleming.gr	Kotanidou, Anastasia/AAB-4731-2020; Aidinis, Vassilis/AAF-5380-2021; Kollias, George/A-7079-2012	Kollias, George/0000-0003-1867-3150; Aidinis, Vassilis/0000-0001-9531-7729; Szymkowski, David/0000-0002-8934-7902	EC [QLRT-CT-2001-01407, LSHG-CT-2005-005203]	EC(European CommissionEuropean Commission Joint Research Centre)	This work was supported in part by the EC grants QLRT-CT-2001-01407 and LSHG-CT-2005-005203.	Alexopoulou L, 2006, EUR J IMMUNOL, V36, P2768, DOI 10.1002/eji.200635921; Allen JT, 2001, RESP RES, V3, DOI 10.1186/rr162; ANTONIOU KM, 2006, EUR RESP J; Artis D, 1999, J EXP MED, V190, P953, DOI 10.1084/jem.190.7.953; BARGAGLI E, 2005, RESPIRATION; Boylen, 2002, AM J RESP CRIT CARE, V165, pA728; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fremond C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-136; Fujita M, 2001, AM J PHYSIOL-LUNG C, V280, pL39, DOI 10.1152/ajplung.2001.280.1.L39; Fujita M, 2003, AM J RESP CELL MOL, V29, P669, DOI 10.1165/rcmb.2002-0046OC; Gauldie J, 2001, RESP RES, V3; Gauldie J, 2002, AM J RESP CRIT CARE, V165, P1205, DOI 10.1164/rccm.2202054; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Hao ZY, 2004, J EXP MED, V199, P1355, DOI 10.1084/jem.20032196; Hardie WD, 2004, AM J PHYSIOL-LUNG C, V286, pL741, DOI 10.1152/ajplung.00208.2003; Hasegawa M, 1997, J RHEUMATOL, V24, P663; HOYT DG, 1992, AM J RESP CELL MOL, V7, P645, DOI 10.1165/ajrcmb/7.6.645; Huaux F, 2003, J IMMUNOL, V171, P5470, DOI 10.4049/jimmunol.171.10.5470; Huaux F, 2003, J IMMUNOL, V170, P2083, DOI 10.4049/jimmunol.170.4.2083; Izbicki G, 2002, INT J EXP PATHOL, V83, P111, DOI 10.1046/j.1365-2613.2002.00220.x; KAPANCI Y, 1995, AM J RESP CRIT CARE, V152, P2163, DOI 10.1164/ajrccm.152.6.8520791; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kollias G, 2004, Autoimmun Rev, V3 Suppl 1, pS24; Kollias G, 1999, IMMUNOL REV, V169, P175, DOI 10.1111/j.1600-065X.1999.tb01315.x; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kuroki M, 2003, J IMMUNOL, V170, P567, DOI 10.4049/jimmunol.170.1.567; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; Kuwano K, 1996, AM J RESP CRIT CARE, V154, P477, DOI 10.1164/ajrccm.154.2.8756825; Kuwano K, 2001, AM J PHYSIOL-LUNG C, V280, pL316, DOI 10.1152/ajplung.2001.280.2.L316; Lake-Bullock MHV, 1999, J LEUKOCYTE BIOL, V65, P187, DOI 10.1002/jlb.65.2.187; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Liu JY, 1998, AM J PATHOL, V153, P1839, DOI 10.1016/S0002-9440(10)65698-2; Liu JY, 2001, AM J RESP CELL MOL, V25, P3, DOI 10.1165/ajrcmb.25.1.4481; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; LUNDBLAD LK, 2005, AM J RESP CRIT CARE; Maeyama T, 2001, EUR RESPIR J, V17, P180, DOI 10.1183/09031936.01.17201800; Mauviel A, 2005, METH MOLEC MED, V117, P69; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NASH JRG, 1993, HISTOPATHOLOGY, V22, P343, DOI 10.1111/j.1365-2559.1993.tb00133.x; Nathan SD, 2004, RESPIRATION, V71, P77, DOI 10.1159/000075653; OHMORI Y, 1993, AM J PATHOL, V142, P861; Okudela K, 1999, AM J PATHOL, V155, P1341, DOI 10.1016/S0002-9440(10)65236-4; Ortiz LA, 1998, EXP LUNG RES, V24, P721, DOI 10.3109/01902149809099592; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 1999, AM J PHYSIOL-LUNG C, V277, pL1239, DOI 10.1152/ajplung.1999.277.6.L1239; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; PIGUET PF, 1994, EUR RESPIR J, V7, P515, DOI 10.1183/09031936.94.07030515; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; PIGUET PF, 1994, INT J EXP PATHOL, V75, P321; PIGUET PF, 1993, AM J PATHOL, V143, P651; Plataki M, 2005, CHEST, V127, P266, DOI 10.1378/chest.127.1.266; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Saunders BM, 2005, J IMMUNOL, V174, P4852, DOI 10.4049/jimmunol.174.8.4852; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Sheppard D, 2001, J CLIN INVEST, V107, P1501, DOI 10.1172/JCI13318; Sime PJ, 1998, AM J PATHOL, V153, P825, DOI 10.1016/S0002-9440(10)65624-6; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Strieter RM, 2002, AM J RESP CRIT CARE, V165, P1206, DOI 10.1164/rccm.2202055; Strieter Robert M., 2001, Chest, V120, p77S, DOI 10.1378/chest.120.1_suppl.S77-a; Thrall RS, 1997, AM J PATHOL, V151, P1303; Torres D, 2005, AM J PATHOL, V167, P1677, DOI 10.1016/S0002-9440(10)61250-3; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1192, DOI 10.1152/ajplung.1998.275.6.L1192; Uhal BD, 1995, AM J PHYSIOL-LUNG C, V269, pL819, DOI 10.1152/ajplung.1995.269.6.L819; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Vassallo Robert, 2002, Chest, V122, P1093, DOI 10.1378/chest.122.3.1093; VLADUTIU AO, 1993, CLIN EXP IMMUNOL, V93, P1; Vuillemenot BR, 2004, AM J RESP CELL MOL, V30, P438, DOI 10.1165/rcmb.2003-0062OC; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Whyte M, 2000, AM J RESP CRIT CARE, V162, P755, DOI 10.1164/ajrccm.162.2.9909053; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zhang K, 1997, J IMMUNOL, V158, P954; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zhu J, 1996, ANN NY ACAD SCI, V796, P194, DOI 10.1111/j.1749-6632.1996.tb32581.x; Ziegenhagen MW, 1998, J INVEST MED, V46, P223	84	95	99	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e108	10.1371/journal.pone.0000108	http://dx.doi.org/10.1371/journal.pone.0000108			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205112	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443700003
J	Saito, H; Yoshida, T; Yamazaki, H; Suzuki, N				Saito, H.; Yoshida, T.; Yamazaki, H.; Suzuki, N.			Conditional N-rasG12V expression promotes manifestations of neuro. bromatosis in a mouse model	ONCOGENE			English	Article						neurofibromatosis type 1; neurofibromatosis type 2; N-Ras	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS; RAS; INHIBITION; MERLIN; DEFICIENCY; PROTEIN; GROWTH; NF1; P53	Human clinical neurofibromatosis type 1 (NF1) and type 2 (NF2) result from mutations and inactivation of neurofibromin and merlin genes, respectively, which negatively regulate Ras pathways. To evaluate the contribution of N-Ras activity to the development of NF, we generated a novel transgenic mouse expressing oncogenic N-ras specifically in central nerve cells, neural crest-derived cells and lens epithelial cells. Soon after birth, the mouse skin showed hyperpigmentation of the epidermis and melanin-laden macrophages in the dermis, as observed in the cafe-au-lait spots of human cases. At 3 months of age, all the mice had neurofibromas in the skin and neurofibroma-like tumors with structure similar to Wagner Meissner bodies in the adrenal medulla. At 4 months of age, all the mice developed subcapsular cataract. In the 5th month, some developed protruding dermal neurofibromas involving subcutaneous fat. However, plexiform neurofibroma, schwannoma, astrocytoma and pheochromocytoma were not observed in the mice, suggesting a requirement for signal(s) other than the activated N-Ras pathway to induce these tumors. Thus, the activated N-Ras signal may be a main pathway for the development of the disease phenotypes characteristic of NF.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Dept Pathol & Matrix Biol, Tsu, Mie 514, Japan; Mie Univ, Grad Sch Med, Dept Physiol & Regenerat Med, Tsu, Mie 514, Japan	Mie University; Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Buchanan J.M., 1990, CONST POLITICAL ECON, V1, P1, DOI DOI 10.1007/BF02393031; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; ENZINGER FM, 1988, SOFT TISSUE TUMOR, P852; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Giovannini M, 2000, GENE DEV, V14, P1617; Hogan B, 1994, MANIPULATING MOUSE E; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Lakkis MM, 1999, DEV BIOL, V212, P80, DOI 10.1006/dbio.1999.9327; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; SATO N, 1992, J CELL SCI, V103, P131; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	26	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4714	4719		10.1038/sj.onc.1210250	http://dx.doi.org/10.1038/sj.onc.1210250			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237809				2022-12-25	WOS:000248037900011
J	Nagai, H; Sugito, N; Matsubara, H; Tatematsu, Y; Hida, T; Sekido, Y; Nagino, M; Nimura, Y; Takahashi, T; Osada, H				Nagai, H.; Sugito, N.; Matsubara, H.; Tatematsu, Y.; Hida, T.; Sekido, Y.; Nagino, M.; Nimura, Y.; Takahashi, T.; Osada, H.			CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells	ONCOGENE			English	Article						CLCP1; SEMA4B; lung cancer	POSTSYNAPTIC DENSITY PROTEIN; SUPPRESSES TUMOR-FORMATION; LINE NCI-H460-LNM35; ENDOCYTOSIS; METASTASIS; GENE	We previously established a highly metastatic subline, LNM35, from the NCI-H460 lung cancer cell line, and demonstrated upregulation of a novel gene, CLCP1 ( CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), in LNM35 and lung cancer specimens. In this study, we focused on the potential roles of that gene in cancer metastasis. First, we established stable LNM35 RNAi clones, in which CLCP1 expression was suppressed by RNAi, and found that their motility was significantly reduced, although growth rates were not changed. Next, in vitro selection of a phage display library demonstrated that a phage clone displaying a peptide similar to a sequence within the Sema domain of semaphorin 4B ( SEMA4B) interacted with LNM35. Immunoprecipitation experiments confirmed interaction of CLCP1 with SEMA4B, regulation of CLCP1 protein by ubiquitination and proteasome degradation enhanced in the presence of SEMA4B. These results are the first to indicate that CLCP1 plays a role in cell motility, whereas they also showed that at least one of its ligands is SEMA4B and that their interaction mediates proteasome degradation by CLCP1. Although the physiological role of the interaction between CLCP1 and SEMA4B remains to be investigated, this novel gene may become a target of therapy to inhibit metastasis of lung cancers.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc, Grad Sch Med, Nagoya, Aichi, Japan; Nagoya Univ, Div Surg Oncol, Dept Surg, Grad Sch Med, Nagoya, Aichi, Japan; Aichi Canc Ctr Hosp, Dept Pulm Med, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	Nagino, Masato/I-7342-2014; Sekido, Yoshitaka/P-9756-2015; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				Bachelder RE, 2003, CANCER RES, V63, P5230; Burkhardt C, 2005, FEBS LETT, V579, P3821, DOI 10.1016/j.febslet.2005.05.079; Castellani V, 2004, MOL CELL NEUROSCI, V26, P89, DOI 10.1016/j.mcn.2004.01.010; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Herold C, 1996, J IMMUNOL, V157, P5262; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Tse C, 2002, CANCER RES, V62, P542; Xiang RH, 2002, CANCER RES, V62, P2637; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591	19	48	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4025	4031		10.1038/sj.onc.1210183	http://dx.doi.org/10.1038/sj.onc.1210183			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213806				2022-12-25	WOS:000247144500013
J	Tai, KY; Shiah, SG; Shieh, YS; Kao, YR; Chi, CY; Huang, E; Lee, HS; Chang, LC; Yang, PC; Wu, CW				Tai, K-Y; Shiah, S-G; Shieh, Y-S; Kao, Y-R; Chi, C-Y; Huang, E.; Lee, H-S; Chang, L-C; Yang, P-C; Wu, C-W			DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression	ONCOGENE			English	Article						Ep-CAM; invasion; promoter methylation	EP-CAM; LUNG ADENOCARCINOMA; BREAST-CANCER; EXPRESSION; CARCINOMA; EPCAM; ANTIGEN; MARKERS; TARGET; INHIBITION	Epithelial cell adhesion molecule ( Ep-CAM) is believed to have a critical role in carcinogenesis and cell proliferation. However, the association of Ep-CAM with cancer invasion and progression is less clear. We found that EpCAM was highly expressed on low-invasive cells compared with highly invasive cells. Forced expression of Ep-CAM decreased cancer invasiveness, and silencing Ep-CAM expression elevated cancer invasiveness. EpCAM expression was associated with promoter methylation. Treatment with a demethylating agent, and/or the histone deacetylase inhibitor reactivated Ep-CAM expression in Ep-CAM-negative cells and inhibited cancer invasiveness. Using a promoter-reporter construct, we demonstrated methylation of the promoter fragment drive Ep-CAM-silenced transcription. Additionally, silenced Ep-CAM gene in cancer cells was enriched for hyper-methylated histone 3 lysine 9. When unmethylated and active, this promoter was associated with acetylated histone 3 lysine 9. Furthermore, we observed an increased association of Ep-CAM promoter with repression components as tumor invasiveness increased. In cancer tissues, Ep-CAM expression significantly correlated with tumor progression and associated with promoter methylation. Our data support the idea that modulation of Ep-CAM plays a pivotal role in tumor invasion and progression. Moreover, aberrant DNA methylation of Ep-CAM is implicated in enhancing invasive/metastatic proclivity of tumors.	Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan; Natl Def Med Ctr, Sch Dent, Taipei, Taiwan; Natl Def Med Ctr, Canc Epigenet Lab, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Oral Diag, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Pathol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Tri-Service General Hospital; National Taiwan University; National Taiwan University Hospital	Wu, CW (corresponding author), Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan.	ken@nhri.org.tw	Yang, Pan-Chyr/B-8808-2009; Shiah, Shine-Gwo/D-2087-2010	Tai, Kang-Yu/0000-0001-6867-3365; YANG, PAN-CHYR/0000-0001-6330-6048; Shiah, Shine-Gwo/0000-0002-1003-973X				Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Jojovic M, 1998, HISTOCHEM J, V30, P723, DOI 10.1023/A:1003486630314; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joo M, 2005, J GASTROEN HEPATOL, V20, P1039, DOI 10.1111/j.1440-1746.2005.03842.x; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; McLaughlin PMJ, 2004, CANCER GENE THER, V11, P603, DOI 10.1038/sj.cgt.7700725; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Rao CG, 2005, INT J ONCOL, V27, P49; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002; Takes RP, 2001, J PATHOL, V194, P298, DOI 10.1002/1096-9896(200107)194:3<298::AID-PATH900>3.0.CO;2-Q; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went P, 2005, AM J SURG PATHOL, V29, P83, DOI 10.1097/01.pas.0000.146028.70868.7a; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5	29	53	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3989	3997		10.1038/sj.onc.1210176	http://dx.doi.org/10.1038/sj.onc.1210176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213811				2022-12-25	WOS:000247144500009
J	Morrow, M; Samanta, A; Kioussis, D; Brady, HJM; Williams, O				Morrow, M.; Samanta, A.; Kioussis, D.; Brady, H. J. M.; Williams, O.			TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL	ONCOGENE			English	Article						leukemia; translocation; ETV6-RUNX1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; RUNT DOMAIN; NUCLEAR-MATRIX; TRANSCRIPTIONAL REPRESSION; AML1/PEBP2-ALPHA-B GENE; ADULT HEMATOPOIESIS; MUTATION ANALYSIS; POINT MUTATIONS; FUSION PROTEIN	The t(12;21)(p13;q22) translocation generates the TEL-AML1 (TEL, translocation-Ets-leukemia; AML1, acute myeloid leukemia-1) (ETV6-RUNX1) fusion product and is the most common chromosomal abnormality in pediatric leukemia. Our previous studies using a murine fetal liver transplantation model demonstrated that TEL-AML1 promotes the self-renewal of B-cell precursors in vitro and enhances the expansion of hematopoietic stem cells (HSCs) in vivo. This is consistent with the hypothesis that TEL-AML1 induces expansion of a preleukemic clone. Several studies have described domains within TEL-AML1 involved in the transcriptional regulation of specific target genes. However, it is unclear which of these domains is important for the activity of TEL-AML1 in preleukemic hematopoiesis. In order to examine this, we have generated a panel of deletion mutants and expressed them in HSCs. These experiments demonstrate that TEL-AML1 requires multiple domains from both TEL and AML1 to alter hematopoiesis. Furthermore, mutation of a single amino-acid residue within the runt homology domain of AML1, required for DNA binding, was sufficient to abrogate TEL-AML1 activity. These data suggest that TEL-AML1 acts as an aberrant transcription factor to perturb multiple pathways during hematopoiesis.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England	University of London; University College London; MRC National Institute for Medical Research	Williams, O (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	owen.williams@ich.ucl.ac.uk	Williams, Owen/B-5003-2013	Williams, Owen/0000-0002-1760-6880; Morrow, Michelle/0000-0002-4565-2008; Brady, Hugh/0000-0002-3152-067X	Medical Research Council [MC_U117512796] Funding Source: Medline; MRC [MC_U117512796] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bernardin F, 2002, CANCER RES, V62, P3904; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; CAMERON ER, 2001, GENE CHROMOSOME CANC, V30, P407; Cin Paola Dal, 2001, Genes Chromosomes and Cancer, V30, P407; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischer M, 2005, ONCOGENE, V24, P7579, DOI 10.1038/sj.onc.1208931; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Guidez F, 2000, BLOOD, V96, P2557; Gunji H, 2004, BIOCHEM BIOPH RES CO, V322, P623, DOI 10.1016/j.bbrc.2004.07.169; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Javed A, 2000, J CELL SCI, V113, P2221; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Quack I, 1999, AM J HUM GENET, V65, P1268, DOI 10.1086/302622; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Rho JK, 2002, BIOCHEM BIOPH RES CO, V297, P91, DOI 10.1016/S0006-291X(02)02075-2; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	57	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4404	4414		10.1038/sj.onc.1210227	http://dx.doi.org/10.1038/sj.onc.1210227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237815				2022-12-25	WOS:000247620000008
J	Bengrine, A; Li, JQ; Awayda, MS				Bengrine, Abderrahmane; Li, Jinqing; Awayda, Mouhamed S.			The A-kinase anchoring protein 15 regulates feedback inhibition of the epithelial Na+ channel	FASEB JOURNAL			English	Article						PKA; ENaC activity; intracellular Na+; AKAP15	RENAL PRINCIPAL CELLS; ENAC TRAFFICKING; CALCIUM-CHANNELS; SODIUM-CHANNEL; ION CHANNELS; IDENTIFICATION; AQUAPORIN-2; ASSOCIATION; ACTIVATION; ISOFORMS	Protein kinase A anchoring proteins or AKAPs regulate the activity of many ion channels. Protein kinase A (PKA) is a well-recognized target of AKAPs, with other kinases now emerging as additional targets. We examined the roles of epithelial-expressed AKAPs in regulating the epithelial Na+ channel ( ENaC). Experiments used heterologous expression with AKAP15, AKAP-KL, and AKAP79 in Xenopus oocytes. Experiments were carried out under high and low Na+ conditions, as Na+ loading is known to affect the baseline activity of ENaC in a PKC-dependent mechanism. ENaC activity was unaffected by AKAP79 and AKAP-KL expression. However, oocytes coexpressing AKAP15 exhibited an 80% and 91% reduction in the amiloride-sensitive, whole-cell conductance in high and low Na+ conditions, respectively. The reduced channel activity was unaffected by PKA activation or inhibition, indicating a PKA-independent mechanism. Expression with a membrane-targeting domain, mutant form of AKAP15 (AKAP15m) prevented the decrease of ENaC activity, but only under low Na+ conditions. In high sodium conditions, coexpression with AKAP15m led to an increase of ENaC activity to levels similar to those observed under low Na+. These results indicate that membrane- associated AKAP15 reduces ENaC activity whereas the cytoplasmically associated one may participate in the channel's feedback inhibition by intracellular Na+, a process known to involve PKC. This hypothesis was further confirmed in coexpression experiments, which demonstrated functional and physical interaction between AKAP15 and PKC alpha. We propose that AKAP15 regulates ENaC via a novel PKA-independent pathway.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Awayda, MS (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall,3435 Main St, Buffalo, NY 14214 USA.	awayda@buffalo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 2001, CELL PHYSIOL BIOCHEM, V11, P135, DOI 10.1159/000047801; Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; Awayda Mouhamed S., 2006, V337, P101; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; Awayda MS, 2004, J GEN PHYSIOL, V123, P709, DOI 10.1085/jgp.200308983; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Awayda MS, 2002, AM J PHYSIOL-CELL PH, V283, pC1122, DOI 10.1152/ajpcell.00142.2002; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; Butterworth MB, 2005, AM J PHYSIOL-RENAL, V289, pF969, DOI 10.1152/ajprenal.00390.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chraibi A, 2001, J MEMBRANE BIOL, V183, P15, DOI 10.1007/s00232-001-0049-6; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; ELS WJ, 1991, J GEN PHYSIOL, V98, P1197, DOI 10.1085/jgp.98.6.1197; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gorski JA, 2005, MOL BIOL CELL, V16, P3574, DOI 10.1091/mbc.E05-02-0134; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Henn V, 2004, J BIOL CHEM, V279, P26654, DOI 10.1074/jbc.M312835200; Higashida H, 2005, NEUROSCI RES, V51, P231, DOI 10.1016/j.neures.2004.11.009; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Khundmiri SJ, 2003, J BIOL CHEM, V278, P10134, DOI 10.1074/jbc.M211775200; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klussmann E, 2001, KIDNEY INT, V60, P446, DOI 10.1046/j.1523-1755.2001.060002446.x; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; McSorley T, 2006, EUR J CELL BIOL, V85, P673, DOI 10.1016/j.ejcb.2006.01.005; Peters KW, 2001, PFLUG ARCH EUR J PHY, V443, pS65, DOI 10.1007/s004240100647; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Schnizler M, 2001, J COMP PHYSIOL B, V171, P369; Schnizler M, 2000, PFLUG ARCH EUR J PHY, V439, P579, DOI 10.1007/s004240050981; Scott JD, 1997, SOC GEN PHY, V52, P227; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Wang HY, 2006, EUR J CELL BIOL, V85, P643, DOI 10.1016/j.ejcb.2005.12.003; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Xie GF, 2001, AM J PHYSIOL-GASTR L, V281, pG1051, DOI 10.1152/ajpgi.2001.281.4.G1051	48	14	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1189	1201		10.1096/fj.06-6046com	http://dx.doi.org/10.1096/fj.06-6046com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17244820				2022-12-25	WOS:000245650400023
J	Takahashi, H; Kumagai, T; Kitani, K; Mori, M; Matoba, Y; Sugiyama, M				Takahashi, Hitoshi; Kumagai, Takanori; Kitani, Kyoko; Mori, Miwako; Matoba, Yasuyuki; Sugiyama, Masanori			Cloning and characterization of a Streptomyces single module type non-ribosomal peptide synthetase catalyzing a blue pigment synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATION DOMAINS; CRYSTAL-STRUCTURE; BIOSYNTHESIS; INDIGOIDINE; BLEOMYCIN; DNA; POLYKETIDE; EPOTHILONE; BACTERIUM; OXIDATION	In the present study, we cloned a gene, designated bpsA, which encodes a single module type non-ribosomal peptide synthetase (NRPS) from a D-cycloserine (DCS)-producing Streptomyces lavendulae ATCC11924. A putative oxidation domain is significantly integrated into the adenylation domain of the NRPS, and the condensation domain is absent from the module. When S. lividans was transformed with a plasmid carrying bpsA, the transformed cells produced a blue pigment, suggesting that bpsA is responsible for the blue pigment synthesis. However, to produce the blue pigment in Escherichia coli, the existence of the 4'-phosphopantetheinyl transferase (PPTase) gene from Streptomyces was necessary, in addition to bpsA. The chemical structure of the pigment was determined as 5,5'-diamino-4,4'dihydroxy-3,3'-diazadiphenoquinone-(2,2'), called indigoidine. The bpsA gene product, designated BPSA, was overproduced in an E. coli host-vector system and purified to homogeneity, demonstrating that the recombinant enzyme prefers L-Gln as a substrate. The in vitro experiment using L-Gln also showed that the blue pigment was formed by the purified BPSA only when the enzyme was phosphopantetheinylated by adding a Streptomyces PPTase purified from E. coli cells. Each site-directed mutagenesis experiment of Lys(598), Tyr(601), Ser(603), and Tyr6os, which are seen in the oxidation domain of BPSA, suggests that these residues are essential for the binding of FMN to the protein and the synthesis of the blue pigment.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Frontier Ctr Microbiol, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp						Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Challis GL, 2004, CURR OPIN STRUC BIOL, V14, P748, DOI 10.1016/j.sbi.2004.10.005; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Chen HW, 2001, CHEM BIOL, V8, P899, DOI 10.1016/S1074-5521(01)00064-3; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Du LC, 2003, BIOCHEMISTRY-US, V42, P9731, DOI 10.1021/bi034817r; Du LC, 2000, FEMS MICROBIOL LETT, V189, P171, DOI 10.1016/S0378-1097(00)00274-3; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; Ehmann DE, 2000, P NATL ACAD SCI USA, V97, P2509, DOI 10.1073/pnas.040572897; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; Hughes MS, 1997, FEMS MICROBIOL LETT, V156, P31, DOI 10.1016/S0378-1097(97)00398-4; Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1111/j.1574-6968.1999.tb13576.x; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; KUHN R, 1965, ARCH MIKROBIOL, V51, P71, DOI 10.1007/BF00406851; Levin I, 2005, PROTEINS, V59, P864, DOI 10.1002/prot.20420; MORTIMER PS, 1966, APPL MICROBIOL, V14, P870; PINSKER KL, 1976, AM J HOSP PHARM, V33, P275, DOI 10.1093/ajhp/33.3.275; Reverchon S, 2002, J BACTERIOL, V184, P654, DOI 10.1128/JB.184.3.654-665.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez C, 2001, CHEM BIOL, V8, P725, DOI 10.1016/S1074-5521(01)00047-3; Schneider TL, 2003, BIOCHEMISTRY-US, V42, P9722, DOI 10.1021/bi034792w; Schwarzer D, 2002, P NATL ACAD SCI USA, V99, P14083, DOI 10.1073/pnas.212382199; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wietzorrek A, 1997, MOL MICROBIOL, V25, P1181, DOI 10.1046/j.1365-2958.1997.5421903.x; YANAGIMOTO M, 1983, J FERMENT TECHNOL, V61, P545	31	83	89	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9073	9081		10.1074/jbc.M611319200	http://dx.doi.org/10.1074/jbc.M611319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237222	Green Published, hybrid			2022-12-25	WOS:000245780300054
J	Mustafa, T; Grimaldi, M; Eiden, LE				Mustafa, Tomris; Grimaldi, Maurizio; Eiden, Lee E.			The hop cassette of the PAC1 receptor confers coupling to Ca2+ elevation required for pituitary adenylate cyclase-activating polypeptide-evoked neurosecretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CATECHOLAMINE RELEASE; 4 SPLICE VARIANTS; CHROMAFFIN CELLS; SIGNALING PATHWAYS; PAC(1) RECEPTOR; GENE-TRANSCRIPTION; MOLECULAR-CLONING; CALCIUM-CHANNELS; EXPRESSION; SECRETION	We have identified the single PAC1 receptor variant responsible for Ca2+ mobilization from intracellular stores and influx through voltage-gated Ca2+ channels in bovine chromaffin cells and the domain of this receptor variant that confers coupling to [Ca2+](i) elevation. This receptor (bPAC1(hop)) contains a 28-amino acid "hop" insertion in the third intracellular loop, with a full-length 171-amino acid N terminus. Expression of the bPAC1(hop) receptor in NG108-15 cells, which lack endogenous PAC1 receptors, reconstituted high affinity PACAP binding and PACAP-dependent elevation of both cAMP and intracellular Ca2+ concentrations ([Ca2+](i)). Removal of the hop domain and expression of this receptor (bPAC1(null)) in NG108-15 cells reconstituted high affinity PACAP binding and PACAP-dependent cAMP generation but without a corresponding [Ca2+](i) elevation. PC12-G cells express sufficient levels of PAC1 receptors to provide PACAP-saturable coupling to adenylate cyclase and to drive PACAP-dependent differentiation but do not express PAC1 receptors at levels found in postmitotic neuronal and endocrine cells and do not support PACAP-mediated neurosecretion. Expression of bPAC1(hop), but not bPAC1(null), at levels comparable with those of bPAC1(hop) in bovine chromaffin cells resulted in acquisition by PC12-G cells of PACAP-dependent [Ca2+]i increase and extracellular Ca2+ influx. In addition, PC12-G cells expressing bPAC1(hop) acquired the ability to release [3 H]norepinephrine in a Ca2+ influx-dependent manner in response to PACAP. Expression of PACAP receptors in neuroendocrine rather than nonneuroendocrine cells reveals key differences between PAC1(hop) and PAC1(null) coupling, indicating an important and previously unrecognized role of the hop cassette in PAC1-mediated Ca2+ signaling in neuroendocrine cells.	NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA; So Res Inst, Neuropharmacol Lab, Dept Biochem, Drug Discovery Div, Birmingham, AL 35205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Eiden, LE (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bldg 49,Rm 5A-68,9000 Rockville Pike, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov		Eiden, Lee/0000-0001-7524-944X; Grimaldi, Maurizio/0000-0002-7331-7055; Mustafa, Tomris/0000-0002-0836-2159	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002386] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 MH002386-22, ZIA MH002386-23, Z01 MH002386-21] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aoyagi K, 2001, BIOCHEM BIOPH RES CO, V286, P646, DOI 10.1006/bbrc.2001.5443; Babinski K, 1996, NEUROPEPTIDES, V30, P572, DOI 10.1016/S0143-4179(96)90041-4; Baldelli P, 2004, MOL NEUROBIOL, V29, P73, DOI 10.1385/MN:29:1:73; Beaudet MM, 1998, J NEUROBIOL, V36, P325, DOI 10.1002/(SICI)1097-4695(19980905)36:3<325::AID-NEU2>3.0.CO;2-Y; Beaudet MM, 2000, J NEUROSCI, V20, P7353; Braas KM, 1999, J BIOL CHEM, V274, P27702, DOI 10.1074/jbc.274.39.27702; Braas KM, 1996, ANN NY ACAD SCI, V805, P204; Brandish PE, 2005, NEURON, V45, P861, DOI 10.1016/j.neuron.2005.02.006; Carbone E, 2001, PFLUG ARCH EUR J PHY, V442, P801, DOI 10.1007/s004240100607; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; CAVALLARO S, 1995, MOL PHARMACOL, V48, P56; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Daniel PB, 2001, J BIOL CHEM, V276, P12938, DOI 10.1074/jbc.M009941200; Dautzenberg FM, 1999, J NEUROENDOCRINOL, V11, P941; Dennis E., 2003, HDB CELL SIGNALING, P375; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Dziema H, 2002, J NEUROPHYSIOL, V88, P1374, DOI 10.1152/jn.2002.88.3.1374; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; EIDEN LE, 1984, P NATL ACAD SCI-BIOL, V81, P3949, DOI 10.1073/pnas.81.13.3949; FENWICK EM, 1978, J CELL BIOL, V76, P12, DOI 10.1083/jcb.76.1.12; Fukushima Y, 2001, AM J PHYSIOL-REG I, V281, pR495, DOI 10.1152/ajpregu.2001.281.2.R495; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Geng GJ, 1997, AM J PHYSIOL-REG I, V273, pR1339, DOI 10.1152/ajpregu.1997.273.4.R1339; Grimaldi M, 2003, J NEUROSCI, V23, P4737; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hahm SH, 1998, J MOL NEUROSCI, V11, P43, DOI 10.1385/JMN:11:1:43; Hamelink C, 2002, J NEUROSCI, V22, P5310; Hamelink C, 2002, P NATL ACAD SCI USA, V99, P461, DOI 10.1073/pnas.012608999; Hamelink C., 2003, PITUITARY ADENYLATE, P227, DOI [10.1007/978-1-4615-0243-2_10, DOI 10.1007/978-1-4615-0243-2_10]; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; Lamouche S, 1999, AM J PHYSIOL-REG I, V276, pR162, DOI 10.1152/ajpregu.1999.276.1.R162; Lee HW, 1999, J NEUROCHEM, V73, P1769, DOI 10.1046/j.1471-4159.1999.731769.x; Lee J, 2004, BIOTECHNIQUES, V36, P398, DOI 10.2144/04363BM04; Marley PD, 2003, PHARMACOL THERAPEUT, V98, P1, DOI 10.1016/S0163-7258(03)00002-0; Marley PD, 1996, J AUTONOM NERV SYST, V60, P141, DOI 10.1016/0165-1838(96)00044-6; May V, 1998, ANN NY ACAD SCI, V865, P164, DOI 10.1111/j.1749-6632.1998.tb11175.x; Mazzocchi G, 2002, J CLIN ENDOCR METAB, V87, P2575, DOI 10.1210/jc.87.6.2575; McCulloch DA, 2001, MOL PHARMACOL, V59, P1523, DOI 10.1124/mol.59.6.1523; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; MOTULSKY HJ, 2003, PRACTICAL GUIDE CURV, P222; Mustafa T, 2001, J NEUROCHEM, V76, P1679, DOI 10.1046/j.1471-4159.2001.00166.x; Mustafa T, 2006, HDB NEUROCHEMISTRY M, P463; OFarrell M, 1997, N-S ARCH PHARMACOL, V356, P536, DOI 10.1007/PL00005088; Osipenko ON, 2000, J BIOL CHEM, V275, P16626, DOI 10.1074/jbc.M909636199; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Pisegna JR, 1996, ANN NY ACAD SCI, V805, P54; Powelka AM, 2001, FEBS LETT, V501, P47; Przywara DA, 1996, J BIOL CHEM, V271, P10545, DOI 10.1074/jbc.271.18.10545; RAUSCH DM, 1988, MOL ENDOCRINOL, V2, P921, DOI 10.1210/mend-2-10-921; Ravni A, 2006, J NEUROCHEM, V98, P1229, DOI 10.1111/j.1471-4159.2006.03962.x; Ronaldson E, 2002, REGUL PEPTIDES, V109, P193, DOI 10.1016/S0167-0115(02)00204-5; Sabban EL, 1995, ANN NY ACAD SCI, V771, P327, DOI 10.1111/j.1749-6632.1995.tb44692.x; Shibuya I, 1998, J NEUROENDOCRINOL, V10, P31, DOI 10.1046/j.1365-2826.1998.00168.x; Shioda S, 2000, ANN NY ACAD SCI, V921, P211; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Tanaka K, 1996, ENDOCRINOLOGY, V137, P956, DOI 10.1210/en.137.3.956; Tanaka K, 1997, ENDOCRINOLOGY, V138, P4086, DOI 10.1210/en.138.10.4086; Taupenot L, 1996, NEUROSCIENCE, V72, P377, DOI 10.1016/0306-4522(96)83172-1; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Turquier V, 2001, MOL PHARMACOL, V60, P42, DOI 10.1124/mol.60.1.42; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wallace DJ, 2002, J PHYSIOL-LONDON, V540, P921, DOI 10.1113/jphysiol.2001.013370; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; Wong AOL, 2005, ENDOCRINOLOGY, V146, P5407, DOI 10.1210/en.2005-0294; MINI HDB, P31	69	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8079	8091		10.1074/jbc.M609638200	http://dx.doi.org/10.1074/jbc.M609638200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17213203	Green Accepted, hybrid			2022-12-25	WOS:000245081000040
J	Tippens, AL; Lee, A				Tippens, Alyssa L.; Lee, Amy			Caldendrin, a neuron-specific modulator of Ca(v)1.2 (L-type) Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; VISININ-LIKE PROTEIN-2; LONG-TERM DEPRESSION; CA2+-DEPENDENT INACTIVATION; CALMODULIN-BINDING; CA(V)2.1 CHANNELS; CA2+-BINDING PROTEIN-1; HIPPOCAMPAL-NEURONS; SPLICE ISOFORMS; IQ DOMAIN	EF-hand Ca2+-binding proteins such as calmodulin and CaBP1 have emerged as important regulatory subunits of voltage-gated Ca2+ channels. Here, we show that caldendrin, a variant of CaBP1 enriched in the brain, interacts with and distinctly modulates Ca(v)1.2 (L-type) voltage-gated Ca2+ channels relative to other Ca2+-binding proteins. Caldendrin binds to the C-terminal IQ-domain of the pore-forming alpha(1)-subunit of Ca(v)1.2 (alpha(1),1.2) and competitively displaces calmodulin and CaBP1 from this site. Compared with CaBP1, caldendrin causes a more modest suppression of Ca2+-dependentin activation of Ca(v)1.2 through a different subset of molecular determinants. Caldendrin does not bind to the N-terminal domain of alpha(1)1.2, a site that is critical for functional interactions of the channel with CaBP1. Deletion of the N-terminal domain inhibits CaBPI, but spares caldendrin modulation of Ca(v)1.2 inactivation. In contrast, mutations of the IQ-domain abolish physical and functional interactions of caldendrin and Ca(v)1.2, but do not prevent channel modulation by CaBP1. Using antibodies specific for caldendrin and Ca(v)1.2, we show that caldendrin coimmunoprecipitates with Ca(v)1.2 from the brain and colocalizes with Ca(v)1.2 in somatodendritic puncta of cortical neurons in culture. Our findings reveal functional diversity within related Ca2+-binding proteins, which may enhance the specificity of Ca2+ signaling by Ca(v)1.2 channels in different cellular contexts.	Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University	Lee, A (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, 5123 Rollins Res Bldg,1510 Clifton Rd, Atlanta, GA 30322 USA.	alee@pharm.emory.edu		Lee, Amy/0000-0001-8021-0443	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044922] Funding Source: NIH RePORTER; NINDS NIH HHS [NS044922] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernstein HG, 2003, J HISTOCHEM CYTOCHEM, V51, P1109, DOI 10.1177/002215540305100816; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHRISTIE BR, 1994, NEUROSCI LETT, V167, P41, DOI 10.1016/0304-3940(94)91023-5; Christie BR, 1996, HIPPOCAMPUS, V6, P17, DOI 10.1002/(SICI)1098-1063(1996)6:1<17::AID-HIPO4>3.0.CO;2-4; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fallon JL, 2005, STRUCTURE, V13, P1881, DOI 10.1016/j.str.2005.09.021; Ferreira G, 1997, J GEN PHYSIOL, V109, P449, DOI 10.1085/jgp.109.4.449; Few AP, 2005, J NEUROSCI, V25, P7071, DOI 10.1523/JNEUROSCI.0452-05.2005; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Haverkamp S, 2000, J COMP NEUROL, V424, P1; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; HUANG YY, 1993, J NEUROSCI, V13, P568; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; JOHNSON BD, 1994, PFLUG ARCH EUR J PHY, V429, P14, DOI 10.1007/BF02584025; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; Landwehr M, 2003, FEBS LETT, V547, P189, DOI 10.1016/S0014-5793(03)00713-0; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lautermilch NJ, 2005, J NEUROSCI, V25, P7062, DOI 10.1523/JNEUROSCI.0447-05.2005; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; Menger N, 1999, CELL TISSUE RES, V298, P21, DOI 10.1007/s004419900060; Meuth S, 2002, EUR J NEUROSCI, V15, P1603, DOI 10.1046/j.1460-9568.2002.01999.x; Obermair GJ, 2004, EUR J NEUROSCI, V19, P2109, DOI 10.1111/j.0953-816X.2004.03272.x; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Schultz K, 2004, J COMP NEUROL, V479, P84, DOI 10.1002/cne.20314; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; Seldenbecher CI, 2004, J MOL BIOL, V336, P957, DOI 10.1016/j.jmb.2003.12.054; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Smalla KH, 2003, MOL BRAIN RES, V116, P159, DOI 10.1016/S0169-328X(03)00235-3; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Stewart AE, 2001, J NEUROPHYSIOL, V85, P1412, DOI 10.1152/jn.2001.85.4.1412; Stout AK, 1996, J PHYSIOL-LONDON, V492, P641, DOI 10.1113/jphysiol.1996.sp021334; Thibault O, 2001, J NEUROSCI, V21, P9744, DOI 10.1523/JNEUROSCI.21-24-09744.2001; Van Petegem F, 2005, NAT STRUCT MOL BIOL, V12, P1108, DOI 10.1038/nsmb1027; Wingard JN, 2005, J BIOL CHEM, V280, P37461, DOI 10.1074/jbc.M508541200; Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x; Zhou H, 2005, J BIOL CHEM, V280, P29612, DOI 10.1074/jbc.M504167200; Zhou H, 2004, J NEUROSCI, V24, P4698, DOI 10.1523/JNEUROSCI.5523-03.2004; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	58	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8464	8473		10.1074/jbc.M611384200	http://dx.doi.org/10.1074/jbc.M611384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17224447	hybrid			2022-12-25	WOS:000245081000079
J	Kang, HR; Cho, SJ; Lee, CG; Homer, RJ; Elias, JA				Kang, Hye-Ryun; Cho, Soo Jung; Lee, Chun Geun; Homer, Robert J.; Elias, Jack A.			Transforming growth factor (TGF)-beta(1) stimulates pulmonary fibrosis and inflammation via a bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; MICE LACKING SMAD3; TGF-BETA; EPITHELIAL-CELLS; DEFICIENT MICE; DEATH; EXPRESSION; TGF-BETA-1; PROTEINS; EMPHYSEMA	Fibrosis, apoptosis, and the exaggerated production of transforming growth factor (TGF)-beta(1) are juxtaposed in a variety of pulmonary diseases including the interstitial lung diseases and asthma. In these disorders, the relationships between these responses are not well defined. In addition, the apoptosis pathways that contribute to these responses and the mechanism(s) of their contribution have not been described. We hypothesized that BH3 domain-only protein-induced apoptosis plays an important role in the pathogenesis of TGF-beta(1)-induced pulmonary responses. To test this hypothesis, we characterized the effects of transgenic TGF-beta(1) in mice with wild type (WT) and null Bax loci. To investigate the mechanisms of Bax activation and its effector functions, we also compared the effects of TGF-beta(1), in mice with WT and null Bid and matrix metalloproteinase (MMP)-12 loci, respectively. These studies demonstrate that TGF-beta(1) is a potent stimulator of Bax, Bid, and MMP-12. The studies also demonstrate that Bax and Bid play key roles in the pathogenesis of TGF-beta(1)-induced inflammation, fibrosis, and apoptosis; that TGF-beta(1) stimulates MMP-12, TIMP-1, and cathepsins and inhibits MMP-9 and p21. via Bax- and Bid-dependent mechanisms; and that TGF-beta(1) stimulated pulmonary fibrosis is ameliorated in MMP-12-deficient animals. Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Baxmediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Yale Univ, Sch Med, Sect Pulm & Crit Care Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Sect Pulm & Crit Care Med, New Haven, CT 06520 USA.	jack.elias@yale.edu	Lee, Chun Geun/AAC-2838-2021; homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658	NHLBI NIH HHS [HL-064242, HL-078744, HL-084225, HL-56389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078744, R01HL084225, P01HL056389, R01HL064242, P50HL056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; ANTONIOU KM, 2006, IN PRESS PULM PHARM; Antoshina Elena, 1997, In Vitro Cellular and Developmental Biology Animal, V33, P212; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; Baskin-Bey ES, 2005, AM J PHYSIOL-GASTR L, V289, pG987, DOI 10.1152/ajpgi.00371.2005; Bergeron A, 2003, EUR RESPIR J, V22, P69, DOI 10.1183/09031936.03.00014703; Boxall C, 2006, EUR RESPIR J, V27, P208, DOI 10.1183/09031936.06.00130004; Budinger GRS, 2006, P NATL ACAD SCI USA, V103, P4604, DOI 10.1073/pnas.0507604103; Calabrese F, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-14; Chen P, 2006, AM J RESP CELL MOL, V34, P464, DOI 10.1165/rcmb.2005-0344OC; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Edwards DR, 2004, J PATHOL, V202, P391, DOI 10.1002/path.1548; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Gajewska M, 2004, COMP BIOCHEM PHYS C, V139, P65, DOI 10.1016/j.cca.2004.09.006; Hagimoto N, 2002, J IMMUNOL, V168, P6470, DOI 10.4049/jimmunol.168.12.6470; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Homer RJ, 2005, PHYSIOLOGY, V20, P28, DOI 10.1152/physiol.00035.2004; Howell JE, 2006, CURR DRUG TARGETS, V7, P547, DOI 10.2174/138945006776818692; Jiang DH, 2004, J CLIN INVEST, V114, P291, DOI 10.1172/JCI200416861; Joza N, 2002, TRENDS GENET, V18, P142, DOI 10.1016/S0168-9525(01)02618-X; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kandasamy K, 2003, CANCER RES, V63, P1712; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; Khalil N, 2001, THORAX, V56, P907, DOI 10.1136/thorax.56.12.907; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lagente V, 2005, BRAZ J MED BIOL RES, V38, P1521, DOI 10.1590/S0100-879X2005001000009; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee JH, 2002, CURR EYE RES, V25, P147, DOI 10.1076/ceyr.25.3.147.13475; Lee VY, 2005, AM J PHYSIOL-LUNG C, V289, pL521, DOI 10.1152/ajplung.00340.2004; Li XP, 2004, J APPL PHYSIOL, V97, P1535, DOI 10.1152/japplphysiol.00519.2004; Ling EM, 2002, CLIN EXP ALLERGY, V32, P175, DOI 10.1046/j.1365-2222.2002.01287.x; Lu Qing, 2005, Keio Journal of Medicine, V54, P184, DOI 10.2302/kjm.54.184; Ma B, 2005, J CLIN INVEST, V115, P3460, DOI 10.1172/JCI24858; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC; Massague J, 1999, NAT CELL BIOL, V1, pE117, DOI 10.1038/12944; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Noble PW, 2006, CLIN CHEST MED, V27, pS11, DOI 10.1016/j.ccm.2005.08.003; Noble PW, 2004, CLIN CHEST MED, V25, P749, DOI 10.1016/j.ccm.2004.04.003; Pardo Annie, 2006, Proc Am Thorac Soc, V3, P383, DOI 10.1513/pats.200601-012TK; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Quan Timothy E, 2006, Curr Rheumatol Rep, V8, P145, DOI 10.1007/s11926-006-0055-x; RAGHU G, 1998, FISHMANS PULMONARY D, P1035; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Selman M, 2006, AM J RESP CRIT CARE, V173, P188, DOI 10.1164/rccm.200504-644OC; Senior RM, 1998, FISHMANS PULMONARY D, P659; Steen V, 2006, AUTOIMMUN REV, V5, P122, DOI 10.1016/j.autrev.2005.09.003; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tan RJ, 2006, AM J RESP CELL MOL, V35, P289, DOI 10.1165/rcmb.2005-0471OC; Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wallach-Dayan SB, 2006, AM J PHYSIOL-LUNG C, V290, pL790, DOI 10.1152/ajplung.00300.2004; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yehualaeshet T, 2000, AM J RESP CELL MOL, V23, P204, DOI 10.1165/ajrcmb.23.2.4089; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zheng T, 2005, J IMMUNOL, V174, P8106, DOI 10.4049/jimmunol.174.12.8106	65	147	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7723	7732		10.1074/jbc.M610764200	http://dx.doi.org/10.1074/jbc.M610764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209037	hybrid			2022-12-25	WOS:000245080900084
J	Rainaldi, M; Yamniuk, AP; Murase, T; Vogel, HJ				Rainaldi, Mario; Yamniuk, Aaron P.; Murase, Tomohiko; Vogel, Hans J.			Calcium-dependent and -independent binding of soybean calmodulin isoforms to the calmodulin binding domain of tobacco MAPK phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ENTHALPY-ENTROPY COMPENSATION; C-TERMINAL DOMAIN; TARGET RECOGNITION; PEPTIDE INTERACTION; GLUTAMATE-DECARBOXYLASE; STRUCTURAL BASIS; PROTEIN-BINDING; APO-CALMODULIN; SIDE-CHAINS	The recent finding of an interaction between calmodulin (CaM) and the tobacco mitogen-activated protein kinase phosphatase-1 (NtMKP1) establishes an important connection between Ca2+ signaling and the MAPK cascade, two of the most important signaling pathways in plant cells. Here we have used different biophysical techniques, including fluorescence and NMR spectroscopy as well as microcalorimetry, to characterize the binding of soybean CaM isoforms, SCaM-1 and -4, to synthetic peptides derived from the CaM binding domain of NtMKP1. We find that the actual CaM binding region is shorter than what had previously been suggested. Moreover, the peptide binds to the SCaM C-terminal domain even in the absence of free Ca2+ with the single Trp residue of the NtMKP1 peptides buried in a solvent-inaccessible hydrophobic region. In the presence of Ca2+, the peptides bind first to the C-terminal lobe of the SCaMs with a nanomolar affinity, and at higher peptide concentrations, a second peptide binds to the N-terminal domain with lower affinity. Thermodynamic analysis demonstrates that the formation of the peptide-bound complex with the Ca2+-loaded SCaMs is driven by favorable binding enthalpy due to a combination of hydrophobic and electrostatic interactions. Experiments with CaM proteolytic fragments showed that the two domains bind the peptide in an independent manner. To our knowledge, this is the first report providing direct evidence for sequential binding of two identical peptides of a target protein to CaM. Discussion of the potential biological role of this interaction motif is also provided.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						Akyol Z, 2004, J BIOL CHEM, V279, P2166, DOI 10.1074/jbc.M302542200; Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bouche N, 2005, ANNU REV PLANT BIOL, V56, P435, DOI 10.1146/annurev.arplant.56.032604.144224; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; Carafoli E, 2005, FEBS J, V272, P1073, DOI 10.1111/j.1742-4658.2005.04546.x; Censarek P, 2004, FEBS LETT, V577, P465, DOI 10.1016/j.febslet.2004.10.048; Censarek P, 2002, BIOCHEMISTRY-US, V41, P8598, DOI 10.1021/bi025681k; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Csiszar A, 2006, BIOESSAYS, V28, P465, DOI 10.1002/bies.20411; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Faria TQ, 2004, J BIOL CHEM, V279, P48680, DOI 10.1074/jbc.M408806200; Gomes AV, 2000, ARCH BIOCHEM BIOPHYS, V379, P28, DOI 10.1006/abbi.2000.1827; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Hu HT, 2004, J BIOL CHEM, V279, P50895, DOI 10.1074/jbc.M404233200; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; Ishida H, 2006, PROTEIN PEPTIDE LETT, V13, P455, DOI 10.2174/092986606776819600; ITAKURA M, 1992, J BIOCHEM, V112, P183, DOI 10.1093/oxfordjournals.jbchem.a123875; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Katou S, 2005, J BIOL CHEM, V280, P39569, DOI 10.1074/jbc.M508115200; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kranz JK, 2002, J BIOL CHEM, V277, P16351, DOI 10.1074/jbc.C200139200; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Ligterink W, 2001, INT REV CYTOL, V201, P209, DOI 10.1016/S0074-7696(01)01004-X; LKURA M, 1992, SCIENCE, V256, P632; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAKHATADZE GI, 1995, NAT STRUCT BIOL, V2, P852, DOI 10.1038/nsb1095-852; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Mori M, 2003, BIOCHEM BIOPH RES CO, V307, P290, DOI 10.1016/S0006-291X(03)01183-5; Perozzo R, 2004, J RECEPT SIG TRANSD, V24, P1, DOI 10.1081/RRS-120037896; Reddy VS, 2004, PHYTOCHEMISTRY, V65, P1745, DOI 10.1016/j.phytochem.2004.04.033; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Schumacher MA, 2004, STRUCTURE, V12, P849, DOI 10.1016/S0969-2126(04)00112-1; Sheehan JH, 2006, J BIOL CHEM, V281, P2876, DOI 10.1074/jbc.M509886200; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; Yamakawa H, 2004, J BIOL CHEM, V279, P928, DOI 10.1074/jbc.M310277200; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900; Yamniuk AP, 2005, BIOCHEMISTRY-US, V44, P3101, DOI 10.1021/bi047770y; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yamniuk AP, 2004, J BIOL CHEM, V279, P7698, DOI 10.1074/jbc.M310763200; Yap KL, 2003, J MOL BIOL, V328, P193, DOI 10.1016/S0022-2836(03)00271-7; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; Yuan T, 1999, BIOCHEMISTRY-US, V38, P1446, DOI 10.1021/bi9816453; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1994, J MOL BIOL, V239, P545, DOI 10.1006/jmbi.1994.1393; Zhang MJ, 1997, PROTEIN PEPTIDE LETT, V4, P291; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901	68	28	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6031	6042		10.1074/jbc.M608970200	http://dx.doi.org/10.1074/jbc.M608970200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202149	hybrid			2022-12-25	WOS:000244867200008
J	Wlodarski, P; Zhang, Q; Liu, XB; Kasprzycka, M; Marzec, M; Wasik, MA				Wlodarski, Pawel; Zhang, Qian; Liu, Xiaobin; Kasprzycka, Monika; Marzec, Michal; Wasik, Mariusz A.			PU.1 activates transcription of SHP-1 gene in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MACROPHAGE DEVELOPMENT; MOTH-EATEN; EXPRESSION; MUTATIONS; ETS-2; DEPHOSPHORYLATION; DIFFERENTIATION; METHYLATION; MYB	Protein-tyrosine phosphatase SHP-1 is the key negative regulator of numerous signaling pathways. SHP-1 is expressed in the hematopietic and epithelial cells as two structurally similar mRNA transcripts controlled by two different promoters designated P2 and P1, respectively. Whereas the transcriptional regulation of the SHP-1 gene P1 promoter has been partially elucidated, the structure and functional control of the P2 promoter remain unknown despite the critical role played by SHP-1 in the normal and malignant lymphoid and other hematopoetic cells. Using luciferase reporter assays with the set of constructs that contained a gradually truncated intron 1 of the SHP-1 gene, we identified the minimal (< 120 bp) fragment that is able to fully activate expression of the reporter gene. Furthermore, we found that PU.1 (a member of the Ets transcription factor family that plays a crucial role in differentiation and function of the lymphoid and myeloid cells) binds to the identified P2 promoter both in vitro and in vivo. PUA also activates the promoter in the sequence specific manner and is critical for its expression as evidenced by the profound supression of the SHP-1 gene transcription upon the siRNA-mediated depletion of PU.1. These findings provide an insight into the structure of the hematopoietic cell-specific P2 promoter of the SHP-1 gene and identify PUA as the transcriptional activator of the P2 promoter.	Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Lab Med, Philadelphia, PA 19104 USA; Warsaw Med Univ, Dept Histol & Embryol, PL-02004 Warsaw, Poland; Warsaw Med Univ, Dept Clin Immunol, PL-02004 Warsaw, Poland	University of Pennsylvania; University of Pennsylvania; Medical University of Warsaw; Medical University of Warsaw	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01-CA89194, R01-CA96856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Frank C, 2004, J BIOL CHEM, V279, P11375, DOI 10.1074/jbc.M309096200; Gregory DJ, 2005, PARASITOLOGY, V130, pS27, DOI 10.1017/S0031182005008139; Hagman J, 2006, CURR OPIN IMMUNOL, V18, P127, DOI 10.1016/j.coi.2006.01.007; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; McIvor Z, 2003, EXP HEMATOL, V31, P39, DOI 10.1016/S0301-472X(02)01017-2; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mena-Duran AV, 2005, BRIT J HAEMATOL, V129, P791, DOI 10.1111/j.1365-2141.2005.05516.x; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oka T, 2002, CANCER RES, V62, P6390; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Tsui HW, 2002, EUR J BIOCHEM, V269, P3057, DOI 10.1046/j.1432-1033.2002.02986.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Xue HH, 2004, NAT IMMUNOL, V5, P1036, DOI 10.1038/ni1117; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; Zhang Q, 2000, AM J PATHOL, V157, P1137, DOI 10.1016/S0002-9440(10)64629-9; Zou GM, 2005, P NATL ACAD SCI USA, V102, P13236, DOI 10.1073/pnas.0506218102	28	22	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6316	6323		10.1074/jbc.M607526200	http://dx.doi.org/10.1074/jbc.M607526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17218319	hybrid			2022-12-25	WOS:000244867200038
J	Butchart, SHM; Akcakaya, HR; Chanson, J; Baillie, JEM; Collen, B; Quader, S; Turner, WR; Amin, R; Stuart, SN; Hilton-Taylor, C				Butchart, Stuart H. M.; Akcakaya, H. Resit; Chanson, Janice; Baillie, Jonathan E. M.; Collen, Ben; Quader, Suhel; Turner, Will R.; Amin, Rajan; Stuart, Simon N.; Hilton-Taylor, Craig			Improvements to the Red List Index	PLOS ONE			English	Article								The Red List Index uses information from the IUCN Red List to track trends in the projected overall extinction risk of sets of species. It has been widely recognised as an important component of the suite of indicators needed to measure progress towards the international target of significantly reducing the rate of biodiversity loss by 2010. However, further application of the RLI (to non-avian taxa in particular) has revealed some shortcomings in the original formula and approach: It performs inappropriately when a value of zero is reached; RLI values are affected by the frequency of assessments; and newly evaluated species may introduce bias. Here we propose a revision to the formula, and recommend how it should be applied in order to overcome these shortcomings. Two additional advantages of the revisions are that assessment errors are not propagated through time, and the overall level extinction risk can be determined as well as trends in this over time.	[Butchart, Stuart H. M.] BirdLife Int, Cambridge, England; [Akcakaya, H. Resit] Setauket, Appl Biomath, New York, NY USA; [Chanson, Janice; Stuart, Simon N.] Conservat Int, Ctr Appl Biodivers Sci, IUCN Species Programme, World Conservat Union IUCN,Species Survival Commi, Washington, DC USA; [Baillie, Jonathan E. M.; Collen, Ben; Amin, Rajan] Zool Soc London, Inst Zool, London NW1 4RY, England; [Quader, Suhel] Univ Cambridge, Dept Zool, Cambridge, England; [Hilton-Taylor, Craig] World Conservat Union IUCN Species Programme, Cambridge, England; [Quader, Suhel] Royal Soc Protect Birds, Sandy SG19 2DL, Beds, England	BirdLife International; Conservation International; Zoological Society of London; University of Cambridge; Royal Society for Protection of Birds	Butchart, SHM (corresponding author), BirdLife Int, Cambridge, England.	stuart.butchart@birdlife.org	Akcakaya, H. Resit/A-7830-2008; Collen, Ben/D-5055-2011; Butchart, Stuart/AAJ-1852-2021; Butchart, Stuart HM/Y-2711-2018; Collen, Ben/F-2543-2016; Quader, Suhel/D-4454-2011; Mace, Georgina M/I-3072-2016	Akcakaya, H. Resit/0000-0002-8679-5929; Butchart, Stuart/0000-0002-1140-4049; Collen, Ben/0000-0003-2564-4243; Mace, Georgina M/0000-0001-8965-5211				Akcakaya HR, 2000, CONSERV BIOL, V14, P1001, DOI 10.1046/j.1523-1739.2000.99125.x; [Anonymous], 2005, EC HUM WELL BEING WE; *BIRDLIFE INT, 2006, SPEC FACTSH TRICH RU; Brooks T, 2004, NATURE, V431, P1046, DOI 10.1038/4311046a; Butchart SHM, 2006, CONSERV BIOL, V20, P579, DOI 10.1111/j.1523-1739.2006.00410.x; Butchart SHM, 2005, PHILOS T R SOC B, V360, P255, DOI 10.1098/rstb.2004.1583; Butchart SHM, 2004, PLOS BIOL, V2, P2294, DOI 10.1371/journal.pbio.0020383; de Grammont PC, 2006, CONSERV BIOL, V20, P14, DOI 10.1111/j.1523-1739.2006.00352.x; *EUR COUNC, 2001, PRES CONCL GOT EUR C; Ferson S., 2001, RAMAS RED LIST THREA; Gregory RD, 2005, PHILOS T R SOC B, V360, P269, DOI 10.1098/rstb.2004.1602; Hambler C., 2004, CONSERVATION; *INT UN CONS NAT, 2012, IUCN RED LIST CAT CR; *IUCN, 2006, 2006 IUCN RED LIST T; IUCN, 2006, IUCN RED LIST THREAT; IUCN Red List Standards and Petitions Subcommittee, 2006, GUID US IUCN RED LIS; Keith DA, 2004, ECOL LETT, V7, P1101, DOI 10.1111/j.1461-0248.2004.00663.x; Lamoreux J, 2003, TRENDS ECOL EVOL, V18, P214, DOI 10.1016/S0169-5347(03)00090-9; Loh J, 2005, PHILOS T R SOC B, V360, P289, DOI 10.1098/rstb.2004.1584; Mace GM, 2005, NATURE, V434, P32, DOI 10.1038/434032a; Pereira HM, 2006, TRENDS ECOL EVOL, V21, P123, DOI 10.1016/j.tree.2005.10.015; Regan TJ, 2005, CONSERV BIOL, V19, P1969, DOI 10.1111/j.1523-1739.2005.00235.x; Rodrigues ASL, 2006, TRENDS ECOL EVOL, V21, P71, DOI 10.1016/j.tree.2005.10.010; Secretariat of the Convention on Biological Diversity, 2006, GLOB BIOD OUTL 2; Secretariat of the Convention on Biological Diversity, 2003, HDB CONV BIOL DIV; UNEP, 2006, GLOB ENV OUTL YB 200	26	178	196	1	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e140	10.1371/journal.pone.0000140	http://dx.doi.org/10.1371/journal.pone.0000140			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206275	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443800002
J	Noranate, N; Durand, R; Tall, A; Marrama, L; Spiegel, A; Sokhna, C; Pradines, B; Cojean, S; Guillotte, M; Bischoff, E; Ekala, MT; Bouchier, C; Fandeur, T; Ariey, F; Patarapotikul, J; Le Bras, J; Trape, JF; Rogier, C; Mercereau-Puijalon, O				Noranate, Nitchakarn; Durand, Remy; Tall, Adama; Marrama, Laurence; Spiegel, Andre; Sokhna, Cheikh; Pradines, Bruno; Cojean, Sandrine; Guillotte, Micheline; Bischoff, Emmanuel; Ekala, Marie-Therese; Bouchier, Christiane; Fandeur, Thierry; Ariey, Frederic; Patarapotikul, Jintana; Le Bras, Jacques; Trape, Jean Francois; Rogier, Christophe; Mercereau-Puijalon, Odile			Rapid Dissemination of Plasmodium falciparum Drug Resistance Despite Strictly Controlled Antimalarial Use	PLOS ONE			English	Article								Background. Inadequate treatment practices with antimalarials are considered major contributors to Plasmodium falciparum resistance to chloroquine, pyrimethamine and sulfadoxine. The longitudinal survey conducted in Dielmo, a rural Senegalese community, offers a unique frame to explore the impact of strictly controlled and quantified antimalarial use for diagnosed malaria on drug resistance. Methodology/Principal Findings. We conducted on a yearly basis a retrospective survey over a ten-year period that included two successive treatment policies, namely quinine during 1990-1994, and chloroquine (CQ) and sulfadoxine/pyrimethamine (SP) as first and second line treatments, respectively, during 1995-1999. Molecular beacon-based genotyping, gene sequencing and microsatellite analysis showed a low prevalence of Pfcrt and Pfdhfr-ts resistance alleles of Southeast Asian origin by the end of 1994 and their effective dissemination within one year of CQ and SP implementation. The Pfcrt resistant allele rose from 9% to 46% prevalence during the first year of CQ reintroduction, i.e., after a mean of 1.66 CQ treatment courses/person/year. The Pfdhfr-ts triple mutant rose from 0% to 20% by end 1996, after a mean of 0.35 SP treatment courses/person in a 16-month period. Both resistance alleles were observed at a younger age than all other alleles. Their spreading was associated with enhanced in vitro resistance and rapidly translated in an increased incidence of clinical malaria episodes during the early post-treatment period. Conclusion/Significance. In such a highly endemic setting, selection of drug-resistant parasites took a single year after drug implementation, resulting in a rapid progression of the incidence of clinical malaria during the early post-treatment period. Controlled antimalarial use at the community level did not prevent dissemination of resistance haplotypes. This data pleads against reintroduction of CQ in places where resistant allele frequency has dropped to a very low level after CQ use has been discontinued, unless drastic measures are put in place to prevent selection and spreading of mutants during the post-treatment period.	[Noranate, Nitchakarn; Guillotte, Micheline; Bischoff, Emmanuel; Ekala, Marie-Therese; Mercereau-Puijalon, Odile] Inst Pasteur, CNRS, URA 2581, Unite Immunol Mol Parasites, Paris, France; [Durand, Remy] Hop Avicenne, AP HP, F-93009 Bobigny, France; [Tall, Adama; Marrama, Laurence; Spiegel, Andre; Rogier, Christophe] Inst Pasteur, Unite Epidemiol, Dakar, Senegal; [Sokhna, Cheikh; Trape, Jean Francois] IRD, Lab Paludol Zool Med, Dakar, Senegal; [Pradines, Bruno; Rogier, Christophe] Inst Trop Med, Serv Sante Armees, Marseille, France; [Cojean, Sandrine; Le Bras, Jacques] Univ R Descartes, Paris, France; [Cojean, Sandrine; Le Bras, Jacques] Hop Bichat Claude Bernard, AP HP, F-75877 Paris 18, France; [Fandeur, Thierry; Ariey, Frederic] Inst Pasteur Cambodge, Phnom Penh, Cambodia; [Noranate, Nitchakarn; Patarapotikul, Jintana] Mahidol Univ, Fac Trop Med, Bangkok, Thailand	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Mahidol University	Mercereau-Puijalon, O (corresponding author), Inst Pasteur, CNRS, URA 2581, Unite Immunol Mol Parasites, Paris, France.	omp@pasteur.fr	ariey, frederic/P-1185-2017; Bischoff, Emmanuel/F-1197-2011; ROGIER, Christophe/C-2550-2008; Mercereau-Puijalon, Odile/AAA-2242-2020	ariey, frederic/0000-0002-0680-1090; Bischoff, Emmanuel/0000-0003-4655-4247; Cojean, Sandrine/0000-0001-6914-7957; Pradines, Bruno/0000-0002-2360-3803	Royal Golden Jubilee, Thailand Research Fund; EU [QLK2-CT-2002-01503]	Royal Golden Jubilee, Thailand Research Fund; EU(European Commission)	NN was supported by a fellowship from the Royal Golden Jubilee, Thailand Research Fund and from the EU-funded grant QLK2-CT-2002-01503 (RESMALCHIP). This work was funded by the Prix Louis D of the French Academy of Sciences and the EU-funded grant QLK2-CT-2002-01503 (RESMALCHIP).	Anderson TJC, 2003, TROP MED INT HEALTH, V8, P1068, DOI 10.1046/j.1360-2276.2003.01144.x; Ariey F, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-34; Basco LK, 1997, B SOC PATHOL EXOT, V90, P90; Chusacultanachai S, 2002, MOL BIOCHEM PARASIT, V120, P61, DOI 10.1016/S0166-6851(01)00440-6; Contamin H, 1996, AM J TROP MED HYG, V54, P632, DOI 10.4269/ajtmh.1996.54.632; CONTAMIN H, 1995, J CLIN MICROBIOL, V33, P944, DOI 10.1128/JCM.33.4.944-951.1995; Cortese JF, 2002, J INFECT DIS, V186, P999, DOI 10.1086/342946; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; Depoortere E, 2005, TROP MED INT HEALTH, V10, P139, DOI 10.1111/j.1365-3156.2004.01363.x; Depoortere E, 2004, TROP MED INT HEALTH, V9, P62, DOI 10.1046/j.1365-3156.2003.01157.x; Dieye A, 1997, PARASITOL TODAY, V13, P48, DOI 10.1016/S0169-4758(96)20062-6; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Durand R, 2002, ANTIMICROB AGENTS CH, V46, P2684, DOI 10.1128/AAC.46.8.2684-2686.2002; Durand R, 2000, ANTIMICROB AGENTS CH, V44, P3461, DOI 10.1128/AAC.44.12.3461-3464.2000; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X; Goudet J, 1995, J HERED, V86, P485, DOI 10.1093/oxfordjournals.jhered.a111627; Goudet J, 1996, GENETICS, V144, P1933; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; Khim N, 2005, ANTIMICROB AGENTS CH, V49, P3147, DOI 10.1128/AAC.49.8.3147-3152.2005; Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032; Mabuza A, 2005, SAMJ S AFR MED J, V95, P346; Mita T, 2003, AM J TROP MED HYG, V68, P413, DOI 10.4269/ajtmh.2003.68.413; Mita T, 2004, MOL BIOCHEM PARASIT, V135, P159, DOI 10.1016/j.molbiopara.2004.01.011; Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162; Ndiaye D, 2006, ACTA TROP, V99, P106, DOI 10.1016/j.actatropica.2006.07.002; Ndiaye D, 2005, TROP MED INT HEALTH, V10, P1176, DOI 10.1111/j.1365-3156.2005.01506.x; NEI M, 1978, GENETICS, V89, P583; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Nzila AM, 2000, ANTIMICROB AGENTS CH, V44, P991, DOI 10.1128/AAC.44.4.991-996.2000; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; Pradines B, 1999, ANTIMICROB AGENTS CH, V43, P418, DOI 10.1128/AAC.43.2.418; Pradines B, 1998, J ANTIMICROB CHEMOTH, V42, P333, DOI 10.1093/jac/42.3.333; Pradines B, 1996, Med Trop (Mars), V56, P141; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Rogier C, 1999, AM J TROP MED HYG, V60, P410, DOI 10.4269/ajtmh.1999.60.410; Rogier C, 2003, T ROY SOC TROP MED H, V97, P193, DOI 10.1016/S0035-9203(03)90116-7; Rogier C, 1996, T ROY SOC TROP MED H, V90, P175, DOI 10.1016/S0035-9203(96)90128-5; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876; Sokhna CS, 2000, AM J TROP MED HYG, V62, P266, DOI 10.4269/ajtmh.2000.62.266; Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092; Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249; Trape JF, 2002, TRENDS PARASITOL, V18, P224, DOI 10.1016/S1471-4922(02)02249-3; TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; Wellems TE, 2004, NAT MED, V10, P1169, DOI 10.1038/nm1104-1169; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	54	46	46	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e139	10.1371/journal.pone.0000139	http://dx.doi.org/10.1371/journal.pone.0000139			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206274	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443800001
J	Bulone, D; Masino, L; Thomas, DJ; Biagio, PLS; Pastore, A				Bulone, Donatella; Masino, Laura; Thomas, David J.; Biagio, Pier Luigi San; Pastore, Annalisa			The Interplay between PolyQ and Protein Context Delays Aggregation by Forming a Reservoir of Protofibrils	PLOS ONE			English	Article								Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by the expansion of CAG codon repeats, which code for polyQ in the corresponding gene products. These diseases are associated with the presence of amyloid-like protein aggregates, induced by polyQ expansion. It has been suggested that the soluble aggregates rather than the mature fibrillar aggregates are the toxic species, and that the aggregation properties of polyQ can be strongly modulated by the surrounding protein context. To assess the importance of the protein carrier in polyQ aggregation, we have studied the misfolding pathway and the kinetics of aggregation of polyQ of lengths above (Q41) and below (Q22) the pathological threshold fused to the well-characterized protein carrier glutathione S-transferase (GST). This protein, chosen as a model system, is per se able to misfold and aggregate irreversibly, thus mimicking the behaviour of domains of naturally occurring polyQ proteins. We prove that, while it is generally accepted that the aggregation kinetics of polyQ depend on its length and are faster for longer polyQ tracts, the presence of GST alters the polyQ aggregation pathway and reverses this trend. Aggregation occurs through formation of a reservoir of soluble intermediates whose populations and kinetic stabilities increase with polyQ length. Our results provide a new model that explains the toxicity of expanded polyQ proteins, in which the interplay between polyQ regions and other aggregation-prone domains plays a key role in determining the aggregation pathway.	[Masino, Laura; Pastore, Annalisa] Natl Inst Med Res, London NW7 1AA, England; [Bulone, Donatella; Biagio, Pier Luigi San] Ist Biofis, CNR, Palermo, Italy; [Thomas, David J.] Sci Software Solut, Paisley, Renfrew, Scotland	MRC National Institute for Medical Research; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Pastore, A (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	apastor@nimr.mrc.ac.uk	bulone, donatella/AAB-6116-2022	bulone, donatella/0000-0002-5841-9133; Masino, Laura/0000-0002-5326-7003; SAN BIAGIO, PIER LUIGI/0000-0002-4622-7361	EUROSCA European network of excellence; Medical Research Council [MC_U117584256] Funding Source: researchfish; MRC [MC_U117584256] Funding Source: UKRI	EUROSCA European network of excellence; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the EUROSCA European network of excellence.	Bhattacharyya A, 2006, J MOL BIOL, V355, P524, DOI 10.1016/j.jmb.2005.10.053; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrotta R, 2006, FASEB J, V20, P1916, DOI 10.1096/fj.06-5716fje; Carrotta R, 2005, J BIOL CHEM, V280, P30001, DOI 10.1074/jbc.M500052200; Caughey B, 2003, ANNU REV NEUROSCI, V9, P9; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Ignatova Z, 2006, J BIOL CHEM, V281, P12959, DOI 10.1074/jbc.M511523200; Kaplan W, 1997, PROTEIN SCI, V6, P399; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KLEIN F, 2006, J BIOL CHEM UNPUB; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Masino L, 2004, J MOL BIOL, V344, P1021, DOI 10.1016/j.jmb.2004.09.065; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; MENON RP, 2006, CELL MOL LI IN PRESS; Mukai H, 2005, P NATL ACAD SCI USA, V102, P10887, DOI 10.1073/pnas.0409283102; Nozaki K, 2001, NEUROREPORT, V12, P3357, DOI 10.1097/00001756-200110290-00042; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tanaka M, 2003, J BIOL CHEM, V278, P34717, DOI 10.1074/jbc.M209852200; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Weydt P, 2006, EXPERT OPIN THER TAR, V10, P505, DOI 10.1517/14728222.10.4.505; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6	39	48	49	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e111	10.1371/journal.pone.0000111	http://dx.doi.org/10.1371/journal.pone.0000111			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205115	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443700005
J	Zhu, Q; Wani, G; Yao, J; Patnaik, S; Wang, QE; El-Mahdy, MA; Praetorius-Ibba, M; Wani, AA				Zhu, Q.; Wani, G.; Yao, J.; Patnaik, S.; Wang, Q-E; El-Mahdy, M. A.; Praetorius-Ibba, M.; Wani, A. A.			The ubiquitin-proteasome system regulates p53-mediated transcription at p21(waf1) promoter	ONCOGENE			English	Article						ubiquitin; proteasome; degradationtranscription; p53	RNA-POLYMERASE-II; HORMONE-RECEPTOR; HUMAN HOMOLOG; DNA-REPAIR; P53; ACTIVATION; PROTEIN; COACTIVATOR; DEGRADATION; RECRUITMENT	The ubiquitin (Ub)-proteasome system (UPS) promotes the proteasomal degradation of target proteins by decorating them with Ub labels. Emerging evidence indicates a role of UPS in regulating gene transcription. In this study, we provided evidence for the involvement of UPS in the transcriptional activation function of tumor suppressor p53. We showed that both ubiquitylation and proteasomal functions are required for efficient transcription mediated by p53. Disruption of transcription by actinomycin D, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimadazole or alpha-amanitin leads to accumulation of cellular p53 protein. Proteasome inhibition by MG132 increases the occupancy of p53 protein at p53-responsive p21(waf1) promoter. In addition, the Sug-1 component of 19S proteasome physically interacts with p53 in vitro and in vivo. Moreover, in response to ultraviolet-induced DNA damage, both the 19S proteasomal components, Sug1 and S1, are recruited to p21(waf1) promoter region in a kinetic pattern similar to that of p53. These results suggested that UPS positively regulates p53-mediated transcription at p21(waf1) promoter.	Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.	wani.2@osu.edu	Zhu, Qianzheng/A-4902-2013		NATIONAL CANCER INSTITUTE [R01CA093413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991] Funding Source: NIH RePORTER; NCI NIH HHS [CA93413] Funding Source: Medline; NIEHS NIH HHS [R01 ES012991, ES12991, ES02388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin L, 2005, ONCOGENE, V24, P3385, DOI 10.1038/sj.onc.1208554; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; O'Hagan HM, 2004, ONCOGENE, V23, P5505, DOI 10.1038/sj.onc.1207709; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VOM BE, 1996, EMBO J, V15, P110; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu QZ, 2004, FEBS LETT, V556, P19, DOI 10.1016/S0014-5793(03)01347-4	50	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4199	4208		10.1038/sj.onc.1210191	http://dx.doi.org/10.1038/sj.onc.1210191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17224908				2022-12-25	WOS:000247619900002
J	Trapp, C; Reite, K; Klungland, A; Epe, B				Trapp, C.; Reite, K.; Klungland, A.; Epe, B.			Deficiency of the Cockayne syndrome B (CSB) gene aggravates the genomic instability caused by endogenous oxidative DNA base damage in mice	ONCOGENE			English	Article						oxidative DNA damage; spontaneous mutations; DNA repair; OGG1	BIG BLUE(R); MAMMALIAN-CELLS; REPAIR; ACCUMULATION; MUTATIONS; TISSUE; AGE; 8-HYDROXYGUANINE; PREDISPOSITION; 8-OXOGUANINE	The Cockayne syndrome B protein ( CSB) has long been known to be involved in the repair of DNA modi. cations that block the RNA polymerase in transcribed DNA sequences ( transcription-coupled repair). Recent evidence suggests that it also has a more general role in the repair of oxidative DNA base modi. cations such as 7,8-dihydro-8-oxo-2'-deoxyguanosine ( 8-oxoG). In mammalian cells, 8-oxoG is a substrate of the repair glycosylase OGG1. Mice without this enzyme accumulate 8-oxoG in the genome and have elevated spontaneous mutation rates. To elucidate the role of CSB in the prevention of mutations by oxidative DNA base damage, we have generated mice that are deficient in Csb or Ogg1 or both genes and carry a non-transcribed bacterial lacI gene for mutation analysis ( Big Blue mice). Our results indicate that the overall spontaneous mutation frequencies in the livers of Csb(m/m)/Ogg1(-/-)-mice are elevated not only compared with heterozygous control mice ( factor 3.3), but also with Ogg1(-/-)-animals ( factor 1.6). Sequence analysis revealed that the additional mutations caused by CSB deficiency in an Ogg1(-/-) background are mostly G: C to T: A transversions and small deletions. For all mouse strains, the background levels of oxidative purine modi. cations in the livers correlate linearly with the numbers of G: C to T: A transversions observed. The data indicate that CSB is involved in the inhibition of mutations caused by spontaneous oxidative DNA base damage in a non-transcribed gene.	Johannes Gutenberg Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Rikshosp Radiumhosp, Ctr Mol Biol & Neurosci, Oslo, Norway; Rikshosp Radiumhosp, Inst Med Microbiol, Oslo, Norway	Johannes Gutenberg University of Mainz; University of Oslo; University of Oslo	Epe, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.	epe@uni-mainz.de	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Collins A, 2003, FREE RADICAL BIO MED, V34, P1089, DOI 10.1016/s0891-5849(03)00041-8; Collins A, 2002, CARCINOGENESIS, V23, P2129, DOI 10.1093/carcin/23.12.2129; Dolle MET, 2006, MUTAT RES-FUND MOL M, V596, P22, DOI 10.1016/j.mrfmmm.2005.11.008; Flohr C, 2003, NUCLEIC ACIDS RES, V31, P5332, DOI 10.1093/nar/gkg715; Halangoda A, 2001, ENVIRON MOL MUTAGEN, V37, P311, DOI 10.1002/em.1038; Heinmoller PW, 2000, MUTAT RES-FUND MOL M, V453, P97, DOI 10.1016/S0027-5107(00)00091-9; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; YOUNG RR, 1995, MUTAT RES-FUND MOL M, V327, P67, DOI 10.1016/0027-5107(94)00080-O	31	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4044	4048		10.1038/sj.onc.1210167	http://dx.doi.org/10.1038/sj.onc.1210167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213818				2022-12-25	WOS:000247144500016
J	Mrosek, M; Labeit, D; Witt, S; Heerklotz, H; von Castelmur, E; Labeit, S; Mayans, O				Mrosek, Michael; Labeit, Dietmar; Witt, Stephanie; Heerklotz, Heiko; von Castelmur, Eleonore; Labeit, Siegfried; Mayans, Olga			Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin	FASEB JOURNAL			English	Article						elastic filament titin; muscle atrophy; X-ray crystallography; binding studies	KINASE DOMAIN; PROTEIN TITIN; IG TANDEMS; MUSCLE; IDENTIFICATION; ACTIVATION; INTERACTS; DYNAMICS; SYSTEM; MODEL	Titin forms an intrasarcomeric filament system in vertebrate striated muscle, which has elastic and signaling properties and is thereby central to mechanotransduction. Near its C-terminus and directly preceding a kinase domain, titin contains a conserved pattern of Ig and FnIII modules ( Ig(A168)- Ig(A169)-FnIII(A170), hereby A168-A170) that recruits the E3 ubiquitinligase MuRF-1 to the filament. This interaction is thought to regulate myofibril turnover and the trophic state of muscle. We have elucidated the crystal structure of A168-A170, characterized MuRF-1 variants by circular dichroism ( CD) and SEC-MALS, and studied the interaction of both components by isothermal calorimetry, SPOTS blots, and pull- down assays. This has led to the identification of the molecular determinants of the binding. A168-A170 shows an extended, rigid architecture, which is characterized by a shallow surface groove that spans its full length and a distinct loop protrusion in its middle point. In MuRF-1, a C- terminal helical domain is sufficient to bind A168-A170 with high affinity. This helical region predictably docks into the surface groove of A168-A170. Furthermore, pull- down assays demonstrate that the loop protrusion in A168-A170 is a key mediator of MuRF-1 recognition. Our findings indicate that this region of titin could serve as a target to attempt therapeutic inhibition of MuRF-1-mediated muscle turnover, where binding of small molecules to its distinctive structural features could block MuRF-1 access.	Univ Basel, Biozentrum, Div Struct Biol, CH-4056 Basel, Switzerland; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intesivmed, Mannheim, Germany	University of Basel; Ruprecht Karls University Heidelberg	Mayans, O (corresponding author), Univ Basel, Biozentrum, Div Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	olga.mayans@unibas.ch	Mayans, Olga/A-3954-2008	von Castelmur, Eleonore/0000-0001-7061-4890; Mayans, Olga/0000-0001-6876-8532; Heerklotz, Heiko/0000-0003-4615-7022				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dai KS, 2001, J BIOL CHEM, V276, P23992, DOI 10.1074/jbc.M011208200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; Grater F, 2005, BIOPHYS J, V88, P790, DOI 10.1529/biophysj.104.052423; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marino M, 2005, J MUSCLE RES CELL M, V26, P355, DOI 10.1007/s10974-005-9017-6; Marino M, 2006, STRUCTURE, V14, P1437, DOI 10.1016/j.str.2006.07.009; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Strelkov SV, 2004, J MOL BIOL, V343, P1067, DOI 10.1016/j.jmb.2004.08.093; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Witt CC, 1998, J STRUCT BIOL, V122, P206, DOI 10.1006/jsbi.1998.3993; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zou PJ, 2006, NATURE, V439, P229, DOI 10.1038/nature04343	33	75	75	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1383	1392		10.1096/fj.06-7644com	http://dx.doi.org/10.1096/fj.06-7644com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17215480				2022-12-25	WOS:000246117000014
J	Vincent, SG; Waddell, AE; Caron, MG; Walker, JKL; Fisher, JT				Vincent, Sandra G.; Waddell, Andrea E.; Caron, Marc G.; Walker, Julia K. L.; Fisher, John T.			A murine model of hyperdopaminergic state displays altered respiratory control	FASEB JOURNAL			English	Article						DAT; hypoxia; ADHD; chemoreception; respiration; circadian rhythm; body temperature	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER; CAROTID-BODY; VENTILATORY SENSITIVITY; AFFERENT PATHWAY; CHRONIC HYPOXIA; MESSENGER-RNA; RECEPTORS; MICE; HYPERACTIVITY	The dopamine transporter (DAT) protein plays an important role in the termination of dopamine signaling. We addressed the hypothesis that loss of DAT function would result in a distinctive cardiorespiratory phenotype due to the significant role of dopamine in the control of breathing, especially with respect to chemical control, metabolism, and thermoregulation. The DAT knockout mouse ( DAT(-/-)) displays a state of functional hyperdopaminergia characterized by marked novelty driven hyperactivity. Certain behavioral and drug responses in these mice are reminiscent of endophenotypes of individuals with attention deficit hyperactivity disorders ( ADHD). We performed experiments on conscious, unrestrained DAT(-/-) mice ( KO) and littermate DAT(+/+) wild- type ( WT) controls. Ventilation was measured by the barometric technique during normoxia, hypoxia, or hypercapnia. We measured core body temperature and CO2 production as an index of metabolism. DAT(-/-) mice displayed a significantly lower respiratory frequency than WT mice, reflecting a prolonged inspiratory time. DAT(-/-) mice exhibited a reduced ventilatory response to hypoxia characterized by an attenuation of both the respiratory frequency and tidal volume responses. Both groups showed similar metabolic responses to hypoxia. Circadian measurements of body temperature were significantly lower in DAT(-/-) mice than WT mice during inactive periods. We conclude that loss of the DAT protein in this murine model of altered dopaminergic neurotransmission results in a significant respiratory and thermal phenotype that has possible implications for understanding of conditions associated with altered dopamine regulation.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat & Med, Kingston, ON K7L 3N6, Canada; Duke Univ, Dept Med, Durham, NC 27706 USA; Duke Univ, Dept Cell Biol, Durham, NC 27706 USA	Queens University - Canada; Queens University - Canada; Duke University; Duke University	Fisher, JT (corresponding author), Queens Univ, Dept Physiol, 4th Floor,Botterell Hall, Kingston, ON K7L 3N6, Canada.	fisherjt@post.queensu.ca	Walker, Julia/R-7585-2017; Fisher, John/E-2568-2012; Waddell, Andrea/ABA-9390-2020	Fisher, John/0000-0001-6185-5940; Waddell, Andrea/0000-0003-1155-6015				Barros RCH, 2002, J APPL PHYSIOL, V92, P975, DOI 10.1152/japplphysiol.00852.2001; BISGARD GE, 1979, RESP PHYSIOL, V37, P61, DOI 10.1016/0034-5687(79)90092-6; Bradley JDD, 2001, CLIN PSYCHOL REV, V21, P907, DOI 10.1016/S0272-7358(00)00073-8; Brown TE, 2001, ANN NY ACAD SCI, V931, P271; Chervin RD, 2002, PEDIATRICS, V109, P449, DOI 10.1542/peds.109.3.449; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; Davids E, 2003, BRAIN RES REV, V42, P1, DOI 10.1016/S0165-0173(02)00274-6; FRAPPELL P, 1992, AM J PHYSIOL, V262, pR1040, DOI 10.1152/ajpregu.1992.262.6.R1040; Gainetdinov RR, 1999, BIOL PSYCHIAT, V46, P303, DOI 10.1016/S0006-3223(99)00122-5; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; Gainetdinov RR, 2001, J AM ACAD CHILD PSY, V40, P380, DOI 10.1097/00004583-200103000-00020; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GOINY M, 1991, J APPL PHYSIOL, V70, P2395, DOI 10.1152/jappl.1991.70.6.2395; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; HSIAO C, 1989, RESP PHYSIOL, V76, P327, DOI 10.1016/0034-5687(89)90073-X; Huey KA, 2000, RESP PHYSIOL, V123, P177, DOI 10.1016/S0034-5687(00)00175-4; Huey KA, 2000, J APPL PHYSIOL, V89, P1142, DOI 10.1152/jappl.2000.89.3.1142; Jackson DM, 2000, PULM PHARMACOL THER, V13, P39, DOI 10.1006/pupt.2000.0229; LAWRENCE AJ, 1995, BRIT J PHARMACOL, V114, P1329, DOI 10.1111/j.1476-5381.1995.tb13352.x; LIN MT, 1982, AM J PHYSIOL, V242, pR471, DOI 10.1152/ajpregu.1982.242.5.R471; Madras BK, 2005, BIOL PSYCHIAT, V57, P1397, DOI 10.1016/j.biopsych.2004.10.011; Mortola JP, 2000, J APPL PHYSIOL, V88, P365, DOI 10.1152/jappl.2000.88.2.365; NIELSEN AM, 1984, EUR J PHARMACOL, V106, P69, DOI 10.1016/0014-2999(84)90679-4; NIELSEN AM, 1983, RESP PHYSIOL, V53, P71, DOI 10.1016/0034-5687(83)90017-8; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; OLSON LG, 1982, AM REV RESPIR DIS, V126, P783; Pedersen MEF, 1999, J APPL PHYSIOL, V86, P222, DOI 10.1152/jappl.1999.86.1.222; Pliszka SR, 2005, BIOL PSYCHIAT, V57, P1385, DOI 10.1016/j.biopsych.2004.08.026; Sapru HN, 1996, ADV EXP MED BIOL, V410, P357; Serebrovskaya TV, 2000, RESPIRATION, V67, P253, DOI 10.1159/000029507; SMATRESK NJ, 1983, J APPL PHYSIOL, V54, P1567, DOI 10.1152/jappl.1983.54.6.1567; Wisor JP, 2001, J NEUROSCI, V21, P1787, DOI 10.1523/JNEUROSCI.21-05-01787.2001; ZAPATA P, 1984, NEUROSCI LETT, V51, P359, DOI 10.1016/0304-3940(84)90403-8	36	23	25	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1463	1471		10.1096/fj.06-7248com	http://dx.doi.org/10.1096/fj.06-7248com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255472				2022-12-25	WOS:000246117000021
J	Hwang, SR; Garza, C; Mosier, C; Toneff, T; Wunderlich, E; Goldsmith, P; Hook, V				Hwang, Shin-Rong; Garza, Christina; Mosier, Charles; Toneff, Thomas; Wunderlich, Eric; Goldsmith, Paul; Hook, Vivian			Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE THIOL PROTEASE; INHIBITORY PEPTIDE CATESTATIN; ADRENAL CHROMAFFIN GRANULES; PROCESSING ENZYME; PC12 CELLS; CATECHOLAMINE RELEASE; ALZHEIMERS-DISEASE; AMINOPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; ENDOGENOUS OPIOIDS	Proteases within secretory vesicles are required for conversion of neuropeptide precursors into active peptide neurotransmitters and hormones. This study demonstrates the novel cellular role of the cysteine protease cathepsin L for producing the (Met)enkephalin peptide neurotransmitter from proenkephalin (PE) in the regulated secretory pathway of neuroendocrine PC12 cells. These findings were achieved by coexpression of PE and cathepsin L cDNAs in PC12 cells with analyses of PE-derived peptide products. Expression of cathepsin L resulted in highly increased cellular levels of (Met)enkephalin, resulting from the conversion of PE to enkephalin-containing intermediates of 23, 18-19, 8-9, and 4.5 kDa that were similar to those present in vivo. Furthermore, expression of cathepsin L with PE resulted in increased amounts of nicotine-induced secretion of (Met)enkephalin. These results indicate increased levels of (Met)enkephalin within secretory vesicles of the regulated secretory pathway. Importantly, cathespin L expression was directed to secretory vesicles, demonstrated by colocalization of cathepsin L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secretory vesicles. In vivo studies also showed that cathepsin L in vivo was colocalized with enkephalin. The newly defined secretory vesicle function of cathepsin L for biosynthesis of active enkephalin opioid peptide contrasts with its function in lysosomes for protein degradation. These findings demonstrate cathepsin L as a distinct cysteine protease pathway for producing the enkephalin member of neuropeptides.	Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Sch Med, La Jolla, CA 92093 USA; Buck Inst, Novato, CA 94545 USA; Touro Univ, Coll Pharm, Vallejo, CA 94592 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Buck Institute for Research on Aging; Touro University California	Hook, V (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Sch Med, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA.	vhook@ucsd.edu						AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; AWAGURI S, 1995, EUR J CELL BIOL, V67, P308; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; Balogh A, 1998, J CELL SCI, V111, P161; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BLOOM FE, 1983, PSYCHIAT CLIN N AM, V6, P365; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; Cool DR, 1996, ENDOCRINOLOGY, V137, P5441, DOI 10.1210/en.137.12.5441; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; DAS B, 1992, J NEUROCHEM, V59, P2263; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DOCHERTY K, 1984, J BIOL CHEM, V259, P6041; DOCHERTY K, 1983, P NATL ACAD SCI-BIOL, V80, P3245, DOI 10.1073/pnas.80.11.3245; Dohrman DP, 2003, ALCOHOL CLIN EXP RES, V27, P1846, DOI 10.1097/01.ALC.0000095923.41707.C8; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; GAINER H, 1984, FEBS LETT, V175, P135, DOI 10.1016/0014-5793(84)80586-4; HILL RM, 1995, J NEUROCHEM, V65, P2318; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Hook V, 2004, BIOL CHEM, V385, P473, DOI 10.1515/BC.2004.055; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1987, NEUROPEPTIDES, V9, P263, DOI 10.1016/0143-4179(87)90001-1; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Hwang SR, 2007, J NEUROCHEM, V100, P1340, DOI 10.1111/j.1471-4159.2006.04325.x; Hwang SR, 2002, BIOCHEMISTRY-US, V41, P10397, DOI 10.1021/bi020088o; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Jiang QJ, 2001, J BIOL CHEM, V276, P25022, DOI 10.1074/jbc.M101545200; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Jutras I, 1999, FEBS LETT, V443, P48, DOI 10.1016/S0014-5793(98)01672-X; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; Li HY, 2005, NEURON, V48, P619, DOI 10.1016/j.neuron.2005.09.033; LODISH H, 2000, MOL CELL BIOL, P691; Mahapatra NR, 2006, J HYPERTENS, V24, P895, DOI 10.1097/01.hjh.0000222760.99852.e0; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Miller R, 2003, NEUROPEPTIDES, V37, P140, DOI 10.1016/S0143-4179(03)00027-1; Neves FAR, 1996, HYPERTENSION, V27, P514, DOI 10.1161/01.HYP.27.3.514; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sharp BM, 2006, BRAIN BEHAV IMMUN, V20, P9, DOI 10.1016/j.bbi.2005.02.002; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; Taupenot L, 2005, J BIOL CHEM, V280, P3885, DOI 10.1074/jbc.M408197200; Taylor CV, 2000, J BIOL CHEM, V275, P22905, DOI 10.1074/jbc.M001232200; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; UCHIYAMA Y, 1999, J HISTOCHEM CYTOCHEM, V5, P633; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; Yasothornsrikul S, 1999, BIOCHEMISTRY-US, V38, P7421, DOI 10.1021/bi990239w; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	55	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9556	9563		10.1074/jbc.M605510200	http://dx.doi.org/10.1074/jbc.M605510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244622	hybrid			2022-12-25	WOS:000245421700028
J	Baehr, W; Karan, S; Maeda, T; Luo, DG; Li, S; Bronson, JD; Watt, CB; Yau, KW; Frederick, JM; Palczewski, K				Baehr, Wolfgang; Karan, Sukanya; Maeda, Tadao; Luo, Dong-Gen; Li, Sha; Bronson, J. Darin; Watt, Carl B.; Yau, King-Wai; Frederick, Jeanne M.; Palczewski, Krzysztof			The function of guanylate cyclase 1 and guanylate cyclase 2 in rod and cone photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEINS; LEBER CONGENITAL AMAUROSIS; GUANYLATE-CYCLASE; CGMP-PHOSPHODIESTERASE; KNOCKOUT MICE; RETINAL DEGENERATION; IN-VIVO; ARRESTIN TRANSLOCATION; RHODOPSIN KINASE; DARK-ADAPTATION	Retinal guanylate cyclases 1 and 2 (GC1 and GC2) are responsible for synthesis of cyclic GMP in rods and cones, but their individual contributions to phototransduction are unknown. We report here that the deletion of both GC1 and GC2 rendered rod and cone photoreceptors nonfunctional and unstable. In the rod outer segments of GC double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cyclic GMP phosphodiesterase were undetectable, although rhodopsin and transducin alpha-subunit were mostly unaffected. Outer segment membranes of GC1(-/-) and GC double knock-out cones were destabilized and devoid of cone transducin (alpha- and gamma-subunits), cone phosphodiesterase, and G protein-coupled receptor kinase 1, whereas cone pigments were present at reduced levels. Real time reverse transcription-PCR analyses demonstrated normal RNA transcript levels for the downregulated proteins, indicating that down-regulation is posttranslational. We interpret these results to demonstrate an intrinsic requirement of GCs for stability and/or transport of a set of membrane-associated phototransduction proteins.	Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Anat & Neurobiol, Salt Lake City, UT 84132 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Case Western Reserve University; Johns Hopkins University	Baehr, W (corresponding author), Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 N Med Dr, Salt Lake City, UT 84132 USA.	wbaehr@hsc.utah.edu	Luo, Donggen/D-5990-2011		NEI NIH HHS [P30 EY014800, R01 EY008123, R01 EY009339-18, P30 EY11373, EY09339, R01 EY014596-05, R01 EY006837, R01 EY009339, P30 EY011373, F32 EY006837, P30 EY011373-119005, R01 EY006837-20A1, R01 EY014596-02, R01 EY014596-04, R01 EY006837-16A1, EY06837, R37 EY006837, R01 EY006837-17, R01 EY014596-01, R01 EY014596-03, R01 EY014596, R01 EY006837-18, EY08123, R01 EY006837-19] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904-03, R01 DC006904-01, R01 DC006904-02, R01 DC006904] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014800, R01EY009339, R37EY006837, F32EY006837, R01EY008123, R01EY006837, R01EY014596, P30EY011373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019; Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Cao LX, 2000, VISUAL NEUROSCI, V17, P319, DOI 10.1017/S0952523800173018; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Coleman JE, 2005, INVEST OPHTH VIS SCI, V46, P12, DOI 10.1167/iovs.04-0691; Coleman JE, 2004, INVEST OPHTH VIS SCI, V45, P3397, DOI 10.1167/iovs.04-0392; Deretic D, 1998, EYE, V12, P526, DOI 10.1038/eye.1998.141; Deretic D, 2005, P NATL ACAD SCI USA, V102, P3301, DOI 10.1073/pnas.0500095102; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Duda T, 2002, MOL CELL BIOCHEM, V230, P107, DOI 10.1023/A:1014290531357; Frederick JM, 2001, INVEST OPHTH VIS SCI, V42, P826; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Haire SE, 2006, INVEST OPHTH VIS SCI, V47, P3745, DOI 10.1167/iovs.06-0086; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hisatomi O, 1999, BIOCHEM BIOPH RES CO, V255, P216, DOI 10.1006/bbrc.1999.0165; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Imanishi Y, 2004, J MOL EVOL, V59, P204, DOI 10.1007/s00239-004-2614-y; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Koch KW, 2002, ADV EXP MED BIOL, V514, P349; Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849; Lem J, 2004, TRENDS MOL MED, V10, P150, DOI 10.1016/j.molmed.2004.02.009; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Luo DG, 2005, J GEN PHYSIOL, V126, P263, DOI 10.1085/jgp.200509342; Lyubarsky AL, 2000, J NEUROSCI, V20, P2209; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; Milam AH, 2003, OPHTHALMOLOGY, V110, P549, DOI 10.1016/S0161-6420(02)01757-8; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; NOLL GN, 1994, NEUROPHARMACOLOGY, V33, P1407, DOI 10.1016/0028-3908(94)90042-6; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Pennesi ME, 2003, P NATL ACAD SCI USA, V100, P6783, DOI 10.1073/pnas.1130102100; Pepperberg DR, 1997, VISUAL NEUROSCI, V14, P73, DOI 10.1017/S0952523800008774; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1994, J BIOL CHEM, V269, P3265; Rozet JM, 2001, INVEST OPHTH VIS SCI, V42, P1190; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Seebacher T, 1999, HEARING RES, V127, P95, DOI 10.1016/S0378-5955(98)00176-2; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Sung CH, 2000, INT REV CYTOL, V195, P215; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tucker CL, 2004, MOL VIS, V10, P297; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Yang RB, 1999, J NEUROSCI, V19, P5889, DOI 10.1523/JNEUROSCI.19-14-05889.1999; Yang RB, 1996, GENOMICS, V31, P367, DOI 10.1006/geno.1996.0060; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	55	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8837	8847		10.1074/jbc.M610369200	http://dx.doi.org/10.1074/jbc.M610369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255100	Green Accepted, hybrid			2022-12-25	WOS:000245780300031
J	Into, T; Kanno, Y; Dohkan, J; Nakashima, M; Inomata, M; Shibata, K; Lowenstein, CJ; Matsushita, K				Into, Takeshi; Kanno, Yosuke; Dohkan, Jun-ichi; Nakashima, Misako; Inomata, Megumi; Shibata, Ken-ichiro; Lowenstein, Charles J.; Matsushita, Kenji			Pathogen recognition by toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; BRUTONS TYROSINE KINASE; PHOSPHOLIPASE C-GAMMA; STAPHYLOCOCCUS-AUREUS; LIPOTEICHOIC ACID; INNATE IMMUNITY; BACTERIAL LIPOPOLYSACCHARIDE; SIGNAL-TRANSDUCTION; PROTEIN	The endothelial cell-specific granule Weibel-Palade body releases vasoactive substances capable of modulating vascular inflammation. Although innate recognition of pathogens,by Toll-like receptors (TLRs) is thought to play a crucial role in promotion of inflammatory responses, the molecular basis for early-phase responses of endothelial cells to bacterial pathogens has not fully been understood. We here report that human aortic endothelial cells respond to bacterial lipoteichoic acid (LTA) and synthetic bacterial lipopeptides, but not lipopolysaccharide or peptidoglycan, to induce Weibel-Palade body exocytosis, accompanied by release or externalization of the storage components von Willebrand factor and P-selectin. LTA could activate rapid Weibel-Palade body exocytosis through a TLR2- and MyD88-dependent mechanism without de novo protein synthesis. This process was at least mediated through MyD88-dependent phosphorylation and activation of phospholipase C gamma. Moreover, LTA activated interleukin-1 receptor-associated kinase-1-dependent delayed exocytosis with de novo protein synthesis and phospholipase C gamma-dependent activation of the NF-kappa B pathway. Increased TLR2 expression by transfection or interferon-gamma treatment increased TLR2-mediated Weibel-Palade body exocytosis, whereas reduced TLR2 expression under laminar flow decreased the response. Thus, we propose a novel role for TLR2 in induction of a primary proinflammatory event in aortic endothelial cells through Weibel-Palade body exocytosis, which may be an important step for linking innate recognition of bacterial pathogens to vascular inflammation.	Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Oral Dis Res, Obu, Aichi 4748522, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Lab Oral Mol Microbiol, Sapporo, Hokkaido 0608586, Japan; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	National Center for Geriatrics & Gerontology; Hokkaido University; Johns Hopkins University; Johns Hopkins University	Into, T (corresponding author), Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Oral Dis Res, Obu, Aichi 4748522, Japan.	into@nils.go.jp	Shibata, Ken-ichiro/A-4814-2012	Lowenstein, Charles/0000-0003-0485-7514				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bermpohl D, 2005, J CLIN INVEST, V115, P1607, DOI 10.1172/JCI23223; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Chun J, 2006, J IMMUNOL, V177, P1330, DOI 10.4049/jimmunol.177.2.1330; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Danesh J, 1999, AM HEART J, V138, pS434, DOI 10.1016/S0002-8703(99)70270-X; Davis CN, 2006, P NATL ACAD SCI USA, V103, P2953, DOI 10.1073/pnas.0510802103; Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Doran KS, 2005, J CLIN INVEST, V115, P2499, DOI 10.1172/JCI23829; Dunzendorfer S, 2004, CIRC RES, V95, P684, DOI 10.1161/01.RES.0000143900.19798.47; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2006, CELL MICROBIOL, V8, P1059, DOI 10.1111/j.1462-5822.2006.00726.x; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Fujita M, 2003, J IMMUNOL, V171, P3675, DOI 10.4049/jimmunol.171.7.3675; Gray P, 2006, J BIOL CHEM, V281, P10489, DOI 10.1074/jbc.M508892200; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Into T, 2005, CELL MICROBIOL, V7, P1305, DOI 10.1111/j.1462-5822.2005.00558.x; Into T, 2004, CELL MICROBIOL, V6, P187, DOI 10.1046/j.1462-5822.2003.00356.x; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Jeannin P, 2005, IMMUNITY, V22, P551, DOI 10.1016/j.immuni.2005.03.008; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Law CL, 1996, MOL CELL BIOL, V16, P1305; Lee CW, 2004, AM J PHYSIOL-LUNG C, V286, pL921, DOI 10.1152/ajplung.00124.2003; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; Manukyan M, 2005, EUR J IMMUNOL, V35, P911, DOI 10.1002/eji.200425336; Martin M, 2003, J IMMUNOL, V171, P717, DOI 10.4049/jimmunol.171.2.717; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Michelsen KS, 2004, J IMMUNOL, V173, P5901, DOI 10.4049/jimmunol.173.10.5901; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Mullaly SC, 2004, CIRC RES, V95, P657, DOI 10.1161/01.RES.0000144806.19585.5b; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; Reed KA, 2002, J BIOL CHEM, V277, P13346, DOI 10.1074/jbc.M200149200; Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Sekine Y, 2006, J IMMUNOL, V176, P380, DOI 10.4049/jimmunol.176.1.380; Shibata K, 2000, J IMMUNOL, V165, P6538, DOI 10.4049/jimmunol.165.11.6538; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Talreja J, 2004, IMMUNOLOGY, V113, P224, DOI 10.1111/j.1365-2567.2004.01946.x; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Tobias P, 2005, J LIPID RES, V46, P404, DOI 10.1194/jlr.R400015-JLR200; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yipp BG, 2002, J IMMUNOL, V168, P4650, DOI 10.4049/jimmunol.168.9.4650	55	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8134	8141		10.1074/jbc.M609962200	http://dx.doi.org/10.1074/jbc.M609962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227763	hybrid			2022-12-25	WOS:000245081000045
J	Leon, S; Subramani, S				Leon, Sebastien; Subramani, Suresh			A conserved cysteine residue of Pichia pastoris Pex20p is essential for its recycling from the peroxisome to the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TYPE-1 RECEPTOR; PROTEIN IMPORT; MATRIX; MECHANISM; UBIQUITINATION; BIOGENESIS; PEX5P	We identified a cysteine residue, conserved near the N terminus of Pex5p- and Pex20p-like proteins, that is essential for the cytosolic relocation of peroxisomal Pex20p. Surprisingly, this residue is not completely essential for the function of the protein; its point mutation into a serine in Pex20p(C8S) causes the accumulation of the protein at the peroxisome membrane, but this is quickly followed by its subsequent degradation by an ubiquitin-dependent quality control pathway called RADAR (receptor accumulation and degradation in the absence of recycling). This degradative pathway allows partial growth of the Pex20p(C8S) mutant on peroxisome-requiring medium. Mutation of cysteine 8 (C8S) and lysine 19 (K19R), the target residue of the RADAR pathway within Pex20p, leads to a stable but non-functional protein because it fails to recycle to the cytosol. This suggests a role for Cys-8 in Pex20p recycling and that constitutive degradation of peroxisomal receptors can be a partially functional alternative to receptor recycling. In addition, expression of this mutant protein in wild-type cells confers a dominant-negative, oleate-specific growth defect, which is a useful tool for a better understanding of peroxisomal receptor recycling.	Univ Calif San Diego, Sect Mol Biol, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Leon, S (corresponding author), Inst Jacques Monod, CNRS, UMR 7592, 2 Pl Jussieu, F-75251 Paris 05, France.	leon@ijm.jussieu.fr; ssubramani@ucsd.edu	LEON, Sebastien/A-5441-2008	LEON, Sebastien/0000-0002-2536-8595	NIDDK NIH HHS [R37 DK041737-16, DK41737, R56 DK041737, R37 DK041737, R01 DK041737] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041737, R01DK041737, R56DK041737] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Erdmann R, 2005, NAT REV MOL CELL BIO, V6, P738, DOI 10.1038/nrm1710; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Kiel JAKW, 2005, BBA-MOL CELL RES, V1745, P176, DOI 10.1016/j.bbamcr.2005.01.004; Kiel JAKW, 2005, J BIOL CHEM, V280, P1921, DOI 10.1074/jbc.M403632200; Kragt A, 2005, J BIOL CHEM, V280, P7867, DOI 10.1074/jbc.M413553200; Kunau WH, 2001, CURR BIOL, V11, pR659, DOI 10.1016/S0960-9822(01)00386-4; Leon S, 2006, J CELL BIOL, V172, P67, DOI 10.1083/jcb.200508096; Leon S, 2006, BBA-MOL CELL RES, V1763, P1552, DOI 10.1016/j.bbamcr.2006.08.037; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Purdue PE, 2001, J BIOL CHEM, V276, P47684, DOI 10.1074/jbc.M106823200; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; THOMS S, 2006, BIOCHIM BIOPHYS ACTA, V1763, P1621; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	19	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7424	7430		10.1074/jbc.M611627200	http://dx.doi.org/10.1074/jbc.M611627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209040	hybrid, Green Accepted			2022-12-25	WOS:000245080900054
J	Yoshida, Y; Murakami, A; Iwai, K; Tanaka, K				Yoshida, Yukiko; Murakami, Arisa; Iwai, Kazuhiro; Tanaka, Keiji			A neural-specific F-box protein Fbs1 functions as a chaperone suppressing glycoprotein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNIZES SUGAR CHAINS; SCF UBIQUITIN-LIGASE; QUALITY-CONTROL; STRUCTURAL BASIS; COMPLEX; PROTEOLYSIS; KINETOCHORE; DEGRADATION; RHODOPSIN; AUTOPHAGY	Fbs1 is an F-box protein present abundantly in the nervous system. Similar to the ubiquitously expressed Fbs2, Fbs1 recognizes N-glycans at the innermost position as a signal for unfolded glycoproteins, probably in the endoplasmic reticulum-associated degradation pathway. Here, we show that the in vivo majority of Fbs1 is present as Fbs1-Skp1 heterodimers or Fbs1 monomers but not SCFFbs1 complex. The inefficient SCF complex formation of Fbs1 and the restricted presence of SCFFbs1 bound on the endoplasmic reticulum membrane were due to the short linker sequence between the F-box domain and the sugar-binding domain. In vitro, Fbsl prevented the aggregation of the glycoprotein through the N-terminal unique sequence of Fbs1. Our results suggest that Fbsl assists clearance of aberrant glycoproteins in neuronal cells by suppressing aggregates formation, independent of ubiquitin ligase activity, and thus functions as a unique chaperone for those proteins.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan	Tokyo Metropolitan Institute of Medical Science; Osaka Metropolitan University	Yoshida, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	yyosida@rinshoken.or.jp	IWAI, KAZUHIRO/GSN-7385-2022; Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Iwai, Kazuhiro/0000-0001-5620-5951				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Ilyin GP, 2002, GENE, V296, P11, DOI 10.1016/S0378-1119(02)00867-3; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Mizushima T, 2004, NAT STRUCT MOL BIOL, V11, P365, DOI 10.1038/nsmb732; Nelson RF, 2006, J BIOL CHEM, V281, P20242, DOI 10.1074/jbc.M602423200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Paquet ME, 2005, METHODS, V35, P338, DOI 10.1016/j.ymeth.2004.10.005; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Saliba RS, 2002, J CELL SCI, V115, P2907; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; Yoshida Y, 2005, EMBO REP, V6, P239, DOI 10.1038/sj.embor.7400351; Yoshida Y, 2005, METHOD ENZYMOL, V398, P159, DOI 10.1016/S0076-6879(05)98014-2	30	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7137	7144		10.1074/jbc.M611168200	http://dx.doi.org/10.1074/jbc.M611168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17215248	hybrid			2022-12-25	WOS:000245080900025
J	Zhao, LY; Santiago, A; Liu, JL; Liao, DQ				Zhao, Lisa Y.; Santiago, Aleixo; Liu, Jilin; Liao, Daiqing			Repression of p53-mediated transcription by adenovirus E1B 55-kDa does not require corepressor mSin3A and histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; DNA-DAMAGE; 55-KILODALTON ONCOPROTEIN; ACTIVATION; PROTEIN; APOPTOSIS; DOMAIN; MDM2; IDENTIFICATION; TRANSFORMATION	The Ad EIB 55-kDa protein (E1B) is a potent transcriptional repressor. In vitro biochemical studies revealed that direct p53E1B interaction is essential for E1B to block p53-activated transcription and a corepressor may be involved. To understand how E1B represses p53-mediated transcription in vivo, we expressed E1B in several tumor cell lines that express wild type p53. Here we show that E1B strongly suppresses the expression of p53 target genes such as p21 and Puma-alpha in normal growth conditions or after cells were treated with p53-activating chemotherapeutic agents, suggesting that E1B-mediated gene repression is dominant and cannot be reversed via p53 activation. Interestingly, we found that E1B binds to corepressor mSin3A. Mutagenesis analysis indicated that the sequence motif "LHLLA" near the NH2 terminus of E1B is responsible for mSin3A binding, and this motif is conserved among E1B proteins from different Ad serotypes. The conserved paired amphipathic helix domain 1 of mSin3A is critical for mSin3A-E1B interaction. Surprisingly, E1B mutants that cannot bind to mSin3A can still repress p53 target genes, indicating that it is not the corepressor required for E1B-mediated gene repression. In support of this notion, repression of p53 target genes by E1B is insensitive to HDAC inhibitor trichostatin A. We further show that both the NH2- and COOH-terminal domains of E1B are required for the repression function. Therefore, E1B employs a unique repression mechanism to block p53-mediated transcription.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Shands Canc Ctr, Program Canc Genet, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Shands Canc Ctr, Program Epigenet, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Shands Canc Ctr, Program Tumor Virol, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Shands Canc Ctr, Program Cell Signaling Apoptosis & Canc, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Liao, DQ (corresponding author), 1376 Mowry Rd, Gainesville, FL 32611 USA.	dliao@ufl.edu	Liao, Daiqing/A-8941-2008		NATIONAL CANCER INSTITUTE [R01CA092236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Brubaker K, 2000, CELL, V103, P655, DOI 10.1016/S0092-8674(00)00168-9; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cowley SM, 2004, MOL CELL BIOL, V24, P2698, DOI 10.1128/MCB.24.7.2698-2709.2004; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; James P, 1996, GENETICS, V144, P1425; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Le Guezennec X, 2006, NUCLEIC ACIDS RES, V34, P3929, DOI 10.1093/nar/gkl537; Liao DQ, 1996, J BACTERIOL, V178, P4089, DOI 10.1128/jb.178.14.4089-4098.1996; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Nead MA, 1998, HUMAN TUMOR VIRUSES, P225; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Nomura M, 2005, J MOL BIOL, V354, P903, DOI 10.1016/j.jmb.2005.10.008; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiio Y, 2006, MOL CELL BIOL, V26, P1386, DOI 10.1128/MCB.26.4.1386-1397.2006; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trepel M, 1998, J NEURO-ONCOL, V39, P19, DOI 10.1023/A:1005910323338; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; White E, 2006, CELL DEATH DIFFER, V13, P1371, DOI 10.1038/sj.cdd.4401941; Wu SY, 2006, GENE DEV, V20, P2383, DOI 10.1101/gad.1448206; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhao LY, 2006, CANCER RES, V66, P9445, DOI 10.1158/0008-5472.CAN-06-1713; Zhao LY, 2004, J BIOL CHEM, V279, P50566, DOI 10.1074/jbc.M406743200; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	51	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7001	7010		10.1074/jbc.M610749200	http://dx.doi.org/10.1074/jbc.M610749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209038	hybrid			2022-12-25	WOS:000245080900012
J	Zito, CI; Qin, H; Blenis, J; Bennett, AM				Zito, Christina I.; Qin, Hui; Blenis, John; Bennett, Anton M.			SHP-2 regulates cell growth by controlling the mTOR/S6 kinase 1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P70 S6 KINASE; TYROSINE PHOSPHATASE SHP-2; MAMMALIAN TARGET; CYCLE PROGRESSION; RAPAMYCIN MTOR; ELONGATION-FACTOR-2 KINASE; SIGNALING PATHWAY; PHOSPHORYLATION; TRANSLATION	Cell growth (accumulation in cell mass) ensues through the promotion of macromolecular biosynthesis. S 6 ribosomal kinase 1 (S6K1), which is activated by the mammalian target of rapamycin, is critical for cell growth. The early events that control S6K1 signaling remain unclear. Here we show that SHP-2 suppresses S6K1 activity under conditions of growth factor deprivation. We show that under conditions of growth factor deprivation, S6K1 activity was increased in fibroblasts lacking functional SHP-2 and in cells where knock down of SHP-2 expression was established by small interference RNA. Consistent with these findings, fibroblasts lacking functional SHP-2 exhibited increased cell size as compared with wild type cells. Growth factor deprivation reduces cellular energy, and the energy-sensing 5'-AMP-activated protein kinase (AMPK) negatively regulates S6K1. We found that SHP-2 promoted AMPK activity under conditions of growth factor deprivation (low energy), suggesting that SHP-2 negatively regulates S6K1 via an AMPK-dependent pathway. These results implicate SHP-2 as an early mediator in the S6K1 signaling pathway to limit cell growth in low energy states.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Yale University; Harvard University; Harvard Medical School	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B226D,333 Cedar St, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599	NIAMS NIH HHS [AR46504] Funding Source: Medline; NIGMS NIH HHS [GM51405] Funding Source: Medline; NINDS NIH HHS [T32 NS07136] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007136] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gottlieb E, 2002, P NATL ACAD SCI USA, V99, P12801, DOI 10.1073/pnas.202477599; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Marin P, 1997, J NEUROSCI, V17, P3445; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Uhlen P, 2006, P NATL ACAD SCI USA, V103, P2160, DOI 10.1073/pnas.0510876103; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	50	12	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6946	6953		10.1074/jbc.M608338200	http://dx.doi.org/10.1074/jbc.M608338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17229738	hybrid			2022-12-25	WOS:000245080900006
J	Dey, M; Cao, C; Sicheri, F; Dever, TE				Dey, Madhusudan; Cao, Chune; Sicheri, Frank; Dever, Thomas E.			Conserved intermolecular salt bridge required for activation of protein kinases PKR, GCN2, and PERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FUNCTIONALLY SUBSTITUTE; TRANSLATIONAL CONTROL; EIF-2-ALPHA KINASE; UNFOLDED-PROTEIN; DIMERIZATION; BINDING; YEAST; AUTOPHOSPHORYLATION; ELF2-ALPHA	The protein kinases PKR, GCN2, and PERK phosphorylate translation initiation factor eIF2 alpha to regulate general and gene-specific protein synthesis under various cellular stress conditions. Recent x-ray crystallographic structures of PKR and GCN2 revealed distinct dimeric configurations of the kinase domains. Whereas PKR kinase domains dimerized in a back-to-back and parallel orientation, the GCN2 kinase domains displayed an antiparallel orientation. The dimerization interfaces on PKR and GCN2 were localized to overlapping surfaces on the N-terminal lobes of the kinase domains but utilized different intermolecular contacts. A key feature of the PKR dimerization interface is a salt bridge interaction between Arg(262) from one protomer and Asp(266) from the second protomer. Interestingly, these two residues are conserved in all eIF2 alpha kinases, although in the GCN2 structure, the two residues are too remote to interact. To test the importance of this potential salt bridge interaction in PKR, GCN2, and PERK, the residues constituting the salt bridge were mutated either independently or together to residues with the opposite charge. Single mutations of the Asp (or Glu) and Arg residues blocked kinase function both in yeast cells and in vitro. However, for all three kinases, the double mutation designed to restore the salt bridge interaction with opposite polarity resulted in a functional kinase. Thus, the salt bridge interaction and dimer interface observed in the PKR structure is critical for the activity of all three eIF2 alpha kinases. These results are consistent with the notion that the PKR structure represents the active state of the eIF2 alpha kinase domain, whereas the GCN2 structure may represent an inactive state of the kinase.	NICHD, Lab Gene Regulat & Dev, NICHD, Bethesda, MD 20892 USA; Mt Sinai Hosp, Program Mol Biol & Canc, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Dever, TE (corresponding author), NICHD, Lab Gene Regulat & Dev, NICHD, Bldg 6A,Rm B1A-03, Bethesda, MD 20892 USA.	tdever@nih.gov	Dever, Thomas/GSE-0966-2022; Sicheri, Frank/F-8856-2013	Dever, Thomas/0000-0001-7120-9678	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dar AC, 2002, MOL CELL, V10, P295, DOI 10.1016/S1097-2765(02)00590-7; DeLano WL, 2004, PYMOL USERS MANUAL; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; HARASHIMA S, 1987, GENETICS, V117, P409; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Padyana AK, 2005, J BIOL CHEM, V280, P29289, DOI 10.1074/jbc.M504096200; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; YANG JM, 1992, J BIOL CHEM, V267, P20519; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	33	45	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6653	6660		10.1074/jbc.M607897200	http://dx.doi.org/10.1074/jbc.M607897200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202131	hybrid			2022-12-25	WOS:000244867200074
J	Li, T; Chalifour, LE; Paudel, HK				Li, Tong; Chalifour, Lorraine E.; Paudel, Hernant K.			Phosphorylation of protein phosphatase 1 by cyclin-dependent protein kinase 5 during nerve growth factor-induced PC12 cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GENE ZIF268; GLYCOGEN-SYNTHASE KINASE-3-BETA; BOVINE BRAIN; NEURITE OUTGROWTH; CATALYTIC SUBUNIT; KINASE KINASE; INDUCTION; CDK5; P35; EXPRESSION	The transcription factor Egr-1 activates cyclin-dependent protein kinase 5 (Cdk5) during nerve growth factor (NGF)-induced differentiation of PC12 cells into neurons (Harada, T. Morooka, T., Ogawa, S., and Nishida, E. (2001) Nat. Cell Biol. 3, 453-459). The downstream target of Cdk5 in the Egr-1/Cdk5 pathway is not clear. In this study, we observed that phosphorylation of protein phosphatase 1 (PP1) on Thr(320) is reduced in brain extracts from Egr-1(-/-) mice, indicating that a kinase downstream of Egr-1 phosphorylates PP1. In HEK 293 cells co-transfected with PP1. and Cdk5, Cdk5 phosphorylates PP1. In vitro, Cdk5 purified from bovine brain phosphorylates bacterially expressed recombinant PP1. In NGF-treated PC12 cells, inhibition of Cdk5 by olomoucine or silencing Cdk5 expression by small interfering RNA strategy, suppresses PP1 phosphorylation. Silencing Cdk5 expression by small interfering RNA also blocks NGF-induced neurite outgrowth. Overexpression of PP1 (wild type) promotes NGF-induced differentiation of PC12 cells, whereas that of PP1 (T320A) has no effect. Our data indicate that PP1 is a downstream target of the NGF/Egr-1/Cdk5 pathway during NGF-induced differentiation of PC12 cells and suggest that PP1 phosphorylation promotes neuronal differentiation.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Paudel, HK (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca						Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3; Bozon B, 2002, HIPPOCAMPUS, V12, P570, DOI 10.1002/hipo.10100; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Hallows JL, 2003, J NEUROSCI, V23, P10633; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; Li T, 2006, BIOCHEMISTRY-US, V45, P3134, DOI 10.1021/bi051635j; Li T, 2006, BIOCHEMISTRY-US, V45, P3125, DOI 10.1021/bi051634r; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Munton RP, 2004, FEBS LETT, V567, P121, DOI 10.1016/j.febslet.2004.03.121; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Puntoni F, 1997, ARCH BIOCHEM BIOPHYS, V340, P177, DOI 10.1006/abbi.1997.9889; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Schipper HM, 1999, NEUROSCIENCE, V93, P585, DOI 10.1016/S0306-4522(99)00120-7; Shirane M, 2006, SCIENCE, V314, P818, DOI 10.1126/science.1134027; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; YAN GZ, 1995, J NEUROSCI, V15, P6200	48	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6619	6628		10.1074/jbc.M606347200	http://dx.doi.org/10.1074/jbc.M606347200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17202132	hybrid			2022-12-25	WOS:000244867200071
J	Lee, HJ; Kim, KS; Park, IH; Kim, SU				Lee, Hong J.; Kim, Kwang S.; Park, In H.; Kim, Seung U.			Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke Model	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; BRAIN TRANSPLANTATION; HIPPOCAMPAL-NEURONS; RAT-BRAIN; PROLIFERATION; DIFFERENTIATE; PERMEABILITY; MIGRATE; CULTURE	Background. Intracerebral hemorrhage (ICH) is a lethal stroke type. As mortality approaches 50%, and current medical therapy against ICH shows only limited effectiveness, an alternative approach is required, such as stem cell-based cell therapy. Previously we have shown that intravenously transplanted human neural stem cells (NSCs) selectively migrate to the brain and induce behavioral recovery in rat ICH model, and that combined administration of NSCs and vascular endothelial growth factor (VEGF) results in improved structural and functional outcome from cerebral ischemia. Methods and Findings. We postulated that human NSCs overexpressing VEGF transplanted into cerebral cortex overlying ICH lesion could provide improved survival of grafted NSCs, increased angiogenesis and behavioral recovery in mouse ICH model. ICH was induced in adult mice by unilateral injection of bacterial collagenase into striatum. HB1.F3.VEGF human NSC line produced an amount of VEGF four times higher than parental F3 cell line in vitro, and induced behavioral improvement and 2-3 fold increase in cell survival at two weeks and eight weeks post-transplantation. Conclusions. Brain transplantation of F3 human NSCs over-expressing VEGF near ICH lesion sites provided differentiation and survival of grafted human NSCs and renewed angiogenesis of host brain and functional recovery of ICH animals. These results suggest a possible application of the human neural stem cell line, which is genetically modified to over-express VEGF, as a therapeutic agent for ICH-stroke.	[Lee, Hong J.; Kim, Kwang S.; Park, In H.; Kim, Seung U.] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 441749, South Korea; [Lee, Hong J.] Korea Univ, Coll Biosci & Biotechnol, Seoul, South Korea; [Lee, Hong J.; Kim, Kwang S.; Kim, Seung U.] Univ British Columbia, Dept Med, Div Neurol, Univ British Columbia Hosp, Vancouver, BC V6T 1W5, Canada	Ajou University; Korea University; University of British Columbia	Kim, SU (corresponding author), Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 441749, South Korea.	sukim@interchange.ubc.ca			Korean Science and Engineering Foundation/Brain Disease Research Center-Ajou University; Canadian Myelin Research Initiative	Korean Science and Engineering Foundation/Brain Disease Research Center-Ajou University(Korea Science and Engineering Foundation); Canadian Myelin Research Initiative	The study was supported by the Korean Science and Engineering Foundation/Brain Disease Research Center-Ajou University and the Canadian Myelin Research Initiative.	BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Cho T, 2002, NEUROREPORT, V13, P1447, DOI 10.1097/00001756-200208070-00020; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fagan SC, 2004, STROKE, V35, P2220, DOI 10.1161/01.STR.0000138023.60272.9e; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Friguls B, 2001, NEUROREPORT, V12, P3381, DOI 10.1097/00001756-200110290-00046; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gebel JM, 2000, NEUROL CLIN, V18, P419, DOI 10.1016/S0733-8619(05)70200-0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Harrigan MR, 2003, ACTA NEUROCHIR, V145, P49, DOI 10.1007/s00701-002-1035-1; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Inagawa T, 2002, NEUROSURG REV, V25, P237, DOI 10.1007/s10143-002-0222-0; Ishibashi S, 2004, J NEUROSCI RES, V78, P215, DOI 10.1002/jnr.20246; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kim SU, 2006, NEUROPATHOLOGY, V26, P129, DOI 10.1111/j.1440-1789.2006.00688.x; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; KIM SU, 1983, BRAIN RES, V274, P79, DOI 10.1016/0006-8993(83)90522-X; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Marti HH, 2002, ADV EXP MED BIOL, V513, P375; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Meng XL, 2003, J NEUROSCI RES, V74, P266, DOI 10.1002/jnr.10764; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Paxinos G., 2003, RAT BRAIN STEREOTAXI; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Puurunen K, 2001, NEUROPHARMACOLOGY, V40, P597, DOI 10.1016/S0028-3908(00)00182-9; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Ryu JK, 2004, NEUROBIOL DIS, V16, P68, DOI 10.1016/j.nbd.2004.01.016; Ryu JK, 2003, J NEUROSCI RES, V72, P352, DOI 10.1002/jnr.10507; Sharp Frank R, 2004, NeuroRx, V1, P26, DOI 10.1602/neurorx.1.1.26; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170, DOI 10.1097/01.wcb.0000037988.07114.98; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	50	158	180	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e156	10.1371/journal.pone.0000156	http://dx.doi.org/10.1371/journal.pone.0000156			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225860	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444000007
J	Raymond, CS; Soriano, P				Raymond, Christopher S.; Soriano, Philippe			High-Efficiency FLP and Phi C31 Site-Specific Recombination in Mammalian Cells	PLOS ONE			English	Article							MOUSE ES CELLS; DNA RECOMBINATION; TRANSGENIC MICE; CRE; INTEGRASE; EXPRESSION	DNA site-specific recombinases (SSRs) such as Cre, FLPe, and Phi C31, are powerful tools for analyzing gene function in vertebrates. While the availability of multiple high-efficiency SSRs would facilitate a wide array of genomic engineering possibilities, efficient recombination in mammalian cells has only been observed with Cre recombinase. Here we report the de novo synthesis of mouse codon-optimized FLP (FLPo) and Phi C31 (Phi C31o) SSRs, which result in recombination efficiencies similar to Cre.	[Raymond, Christopher S.; Soriano, Philippe] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Dev Biol, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Dev Biol, 1124 Columbia St, Seattle, WA 98104 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Raymond, Christopher/0000-0003-1128-8524	Chromosome and Metabolism Training Grant [CA09657]; National Institute of Child Health and Human Development [HD24875]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER	Chromosome and Metabolism Training Grant; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	R. was supported by the Chromosome and Metabolism Training Grant (CA09657). This work was supported by grant HD24875 from the National Institute of Child Health and Human Development to P. S.	Andreas S, 2002, NUCLEIC ACIDS RES, V30, P2299, DOI 10.1093/nar/30.11.2299; Awatramani R, 2001, NAT GENET, V29, P257, DOI 10.1038/ng1101-257; Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787; Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; Liu J, 2006, GENE THER, V13, P1188, DOI 10.1038/sj.gt.3302789; MCLEOD M, 1986, MOL CELL BIOL, V6, P3357, DOI 10.1128/MCB.6.10.3357; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schaft J, 2001, GENESIS, V31, P6, DOI 10.1002/gene.1076; Schumacher A, 2000, J BIOL CHEM, V275, P37915, DOI 10.1074/jbc.M004839200; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007	16	259	307	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e162	10.1371/journal.pone.0000162	http://dx.doi.org/10.1371/journal.pone.0000162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225864	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444000012
J	Theisen, H; Syed, A; Nguyen, BT; Lukacsovich, T; Purcell, J; Srivastava, GP; Iron, D; Gaudenz, K; Nie, Q; Wan, FYM; Waterman, ML; Marsh, JL				Theisen, Heidi; Syed, Adeela; Nguyen, Baochi T.; Lukacsovich, Tamas; Purcell, Judith; Srivastava, Gyan Prakash; Iron, David; Gaudenz, Karin; Nie, Qing; Wan, Frederic Y. M.; Waterman, Marian L.; Marsh, J. Lawrence			Wingless Directly Represses DPP Morphogen Expression via an Armadillo/TCF/Brinker Complex	PLOS ONE			English	Article								Background. Spatially restricted morphogen expression drives many patterning and regeneration processes, but how is the pattern of morphogen expression established and maintained? Patterning of Drosophila leg imaginal discs requires expression of the DPP morphogen dorsally and the wingless (WG) morphogen ventrally. We have shown that these mutually exclusive patterns of expression are controlled by a self-organizing system of feedback loops that involve WG and DPP, but whether the feedback is direct or indirect is not known. Methods/Findings. By analyzing expression patterns of regulatory DNA driving reporter genes in different genetic backgrounds, we identify a key component of this system by showing that WG directly represses transcription of the dpp gene in the ventral leg disc. Repression of dpp requires a tri-partite complex of the WG mediators armadillo ( ARM) and dTCF, and the co-repressor Brinker, (BRK), wherein ARMNdTCF and BRK bind to independent sites within the dpp locus. Conclusions/Significance. Many examples of dTCF repression in the absence of WNT signaling have been described, but few examples of signal-driven repression requiring both ARM and dTCF binding have been reported. Thus, our findings represent a new mode of WG mediated repression and demonstrate that direct regulation between morphogen signaling pathways can contribute to a robust self-organizing system capable of dynamically maintaining territories of morphogen expression.	[Theisen, Heidi; Syed, Adeela; Lukacsovich, Tamas; Purcell, Judith; Gaudenz, Karin; Marsh, J. Lawrence] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA; [Nguyen, Baochi T.; Iron, David; Nie, Qing; Wan, Frederic Y. M.] Univ Calif Irvine, Dept Math, Irvine, CA 92717 USA; [Waterman, Marian L.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; [Theisen, Heidi; Syed, Adeela; Lukacsovich, Tamas; Purcell, Judith; Srivastava, Gyan Prakash; Gaudenz, Karin; Marsh, J. Lawrence] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Marsh, JL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA.	jlmarsh@uci.edu			NIH [RO1 HD36081, RO1 HD36049, CA83982, GM067247, GM75309]; NSF SCREMS [DMS0112416, P20GM066051]; Chao Family Comprehensive Cancer Center Functional Genomics Program; PHS [5T32 GM07311-17]; University of California, Irvine. [CA-62203]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036081, R01HD036049] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083982, P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075309, P20GM066051, T32GM007311, R01GM067247] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF SCREMS(National Science Foundation (NSF)); Chao Family Comprehensive Cancer Center Functional Genomics Program; PHS(United States Department of Health & Human ServicesUnited States Public Health Service); University of California, Irvine.(University of California System); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants RO1 HD36081 and RO1 HD36049 to JLM and NIH CA83982 to MLW, by NIH GM067247 and GM75309 to QN and FW through the Joint NSF/NIGMS Initiative to Support Research in the Area of Mathematical Biology, by NSF SCREMS Grant #DMS0112416, P20GM066051 JLM, QN, FW and by the Chao Family Comprehensive Cancer Center Functional Genomics Program. HT was supported in part by a PHS training grant 5T32 GM07311-17. This work was made possible, in part, through access to the confocal facility and Biacore facility of the Optical Biology Shared Resource of the Cancer Center Support Grant (CA-62203) at the University of California, Irvine.	Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGSTROM DE, 1995, GENETICS, V139, P1331; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BRYANT PJ, 1985, DEV BIOL, V107, P355, DOI 10.1016/0012-1606(85)90317-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 2002, DEVELOPMENT, V129, P3393; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Eldar A, 2004, CURR OPIN GENET DEV, V14, P435, DOI 10.1016/j.gde.2004.06.009; Fall CP., 2002, COMPUTATIONAL CELL B; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Heslip TR, 1997, DEVELOPMENT, V124, P1069; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Johnston LA, 1996, DEVELOPMENT, V122, P3519; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Lander AD, 2002, DEV CELL, V2, P785, DOI 10.1016/S1534-5807(02)00179-X; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Marsh JL, 1999, SEMIN CELL DEV BIOL, V10, P365, DOI 10.1006/scdb.1999.0323; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Piepenburg O, 2000, MOL CELL, V6, P203, DOI 10.1016/S1097-2765(00)00022-8; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Saller E, 2001, EMBO REP, V2, P298, DOI 10.1093/embo-reports/kve068; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Theisen H, 1996, DEVELOPMENT, V122, P3939; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Yang X, 2000, DEVELOPMENT, V127, P3695; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	61	33	34	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2007	2	1							e142	10.1371/journal.pone.0000142	http://dx.doi.org/10.1371/journal.pone.0000142			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DD	17206277	gold, Green Published			2022-12-25	WOS:000207443800004
J	Zachariah, R; Harries, AD; Manzi, M; Gomani, P; Teck, R; Phillips, M; Firmenich, P				Zachariah, Rony; Harries, Anthony David; Manzi, Marcel; Gomani, Patrick; Teck, Roger; Phillips, Mit; Firmenich, Peter			Acceptance of Anti-Retroviral Therapy among Patients Infected with HIV and Tuberculosis in Rural Malawi Is Low and Associated with Cost of Transport	PLOS ONE			English	Article								Background. A study was conducted among newly registered HIV-positive tuberculosis ( TB) patients systematically offered anti-retroviral treatment (ART) in a district hospital in rural Malawi in order to a) determine the acceptance of ART b) conduct a geographic mapping of those placed on ART and c) examine the association between "cost of transport'' and ART acceptance. Methodology/Principal Findings. A retrospective cross-sectional analysis was performed on routine program data for the period of February 2003 to July 2004. Standardized registers and patient cards were used to gather data. The place of residence was used to determine road distances to the Thyolo district hospital. Cost of transport from different parts of the district was based on the known cost for public transport to the road-stop closest to the patient's residence. Of 1,290 newly registered TB patients, 1,003(78%) underwent HIV-testing of whom 770 (77%) were HIV-positive. 742 of these individuals (pulmonary TB = 607; extra-pulmonary TB = 135) were considered eligible for ART of whom only 101(13.6%) accepted ART. Cost of transport to the hospital ART site was significantly associated with ART acceptance and there was a linear trend in association between cost and ART acceptance (X(2) for trend = 25.4, P<0.001). Individuals who had to pay 50 Malawi Kwacha (1 United States Dollar = 100 Malawi Kwacha, MW) or less for a one-way trip to the Thyolo hospital were four times more likely to accept ART than those who had to pay over 100 MW (Adjusted Odds ratio = 4.0, 95% confidence interval: 2.0-8.1, P<0.001). Conclusions/Significance. ART acceptance among TB patients in a rural district in Malawi is low and associated with cost of transport to the centralized hospital based ART site. Decentralizing the ART offer from the hospital to health centers that are closer to home communities would be an essential step towards reducing the overall cost and burden of travel.	[Zachariah, Rony; Manzi, Marcel] Brussels Operat Ctr, Med Dept Operat Res, Brussels, Belgium; [Harries, Anthony David] HIV Care & Support, Minist Hlth, Lilongwe, Malawi; [Gomani, Patrick] Thyolo Dist Hlth Serv, Minist Hlth & Populat, Thyolo, Malawi; [Teck, Roger] Medecins Sans Frontieres, Thyolo, Malawi; [Phillips, Mit] Medecins Sans Frontieres, Access Hlth, Brussels, Belgium; [Firmenich, Peter] Brussels Operat Ctr, Operat Dept, Luxembourg, Luxembourg	Doctors Without Borders	Zachariah, R (corresponding author), Brussels Operat Ctr, Med Dept Operat Res, Brussels, Belgium.	zachariah@internet.lu		zachariah, rony/0000-0002-2915-9328	Medecins sans Frontieres-Brussels; Family Health International, USA; Department for International Development (DFID); Norwegian Agency for Technical Cooperation (NORAD); Royal Dutch TB Association (KNCV); USAID; STOP-TB; WHO; CIFF	Medecins sans Frontieres-Brussels; Family Health International, USA; Department for International Development (DFID); Norwegian Agency for Technical Cooperation (NORAD); Royal Dutch TB Association (KNCV); USAID(United States Agency for International Development (USAID)); STOP-TB; WHO(World Health Organization); CIFF	The joint TB-HIV support program, including ART in Thyolo, is supported by Medecins sans Frontieres-Brussels. We are grateful to Family Health International, USA, the Department for International Development (DFID), the Norwegian Agency for Technical Cooperation (NORAD), the Royal Dutch TB Association (KNCV), USAID, STOP-TB, WHO, and CIFF for supporting TB and TB-HIV control country-wide in Malawi.	Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29; Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002; Harries AD, 2000, SCOT MED J, V45, P47, DOI 10.1177/00369330000450S122; KAPULULA PK, 2001, INT J TUBERC LUNG S1, V5, P167; Kwanjana JK, 2001, MALAWI MED J, V13, P7; MANN GH, 2005, 36 WORLD C LUNG HLTH; *MOHP, 2003, GUID US ANT THER MAL; *MOHP, 2003, MAL HLTH FAC SURV RE; *NAC, 2003, NAT EST HIV AIDS MAL; RAVIGLIONE MC, 1997, AIDS, V11, P115; Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7; SALANIPONI FM, 2003, INT J TUBERC LUNG S1, V7, P167; *UNAIDS WHO, 1997, WKLY EPIDEMIOL REC, V72, P81; Zachariah R, 2001, INT J TUBERC LUNG D, V5, P843; Zachariah R, 2006, T ROY SOC TROP MED H, V100, P167, DOI 10.1016/j.trstmh.2005.07.008; Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238; Zachariah R, 2002, INT J TUBERC LUNG D, V6, P1046	18	88	88	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e121	10.1371/journal.pone.0000121	http://dx.doi.org/10.1371/journal.pone.0000121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205125	Green Accepted, Green Published, gold, Green Submitted			2022-12-25	WOS:000207443700015
J	Swaminathan, G; Feshchenko, EA; Tsygankov, AY				Swaminathan, G.; Feshchenko, E. A.; Tsygankov, A. Y.			c-Cbl-facilitated cytoskeletal effects in v-Abl-transformed. broblasts are regulated by membrane association of c-Cbl	ONCOGENE			English	Article						c-Cbl; SLAP; adaptor protein; membrane localization; cell spreading; cell migration	INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; ADAPTER PROTEIN SLAP; NIH 3T3 FIBROBLASTS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; CELL MORPHOLOGY; LIPID RAFTS; SRC	The multi-functional protein c-Cbl is an important modulator of actin cytoskeletal dynamics in diverse biological systems. We had previously reported that c-Cbl facilitates cell spreading and adhesion and suppresses anchorage-independent growth of v-Abl-transformed fibroblasts. To assess the importance of membrane localization of c-Cbl for the observed effects of c-Cbl in v-Abl-3T3 cells, we. rst mapped the membrane interactive domain(s) of c-Cbl. Our studies indicate that localization of c-Cbl to the membrane is likely to be mediated by the tyrosine kinase binding (TKB) domain and the proline-rich region of c-Cbl, whereas C-terminal tyrosine phosphorylation does not play a role. The association of v-Cbl, which encompasses the TKB domain, with the membrane was unusual as it was not entirely dependent on SH2-phosphotyrosine interactions. Our studies further demonstrate that Src-like adaptor protein (SLAP), which binds to v-Cbl in a tyrosine phosphorylation-independent manner, facilitates membrane association of Cbl. The interaction between c-Cbl and SLAP in v-Abl-3T3 cells positively influenced c-Cbl-mediated spreading and adhesion of these cells. SLAP appears to exert its effects not simply by increasing the amount of c-Cbl in the membrane but by facilitating binding of p85-phosphatidylinositol-3-kinase (PI3K) with membrane-associated c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017		NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER; NCI NIH HHS [CA78499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Klapper LN, 2000, CANCER RES, V60, P3384; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; MARAKOVA O, 2000, BIOTECHNIQUES, V29, P970; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Scaife RM, 2000, J CELL SCI, V113, P215; Scaife RM, 2003, MOL BIOL CELL, V14, P4605, DOI 10.1091/mbc.E02-11-0739; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Teckchandani AM, 2005, EXP CELL RES, V306, P114, DOI 10.1016/j.yexcr.2005.02.014; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	38	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4095	4105		10.1038/sj.onc.1210184	http://dx.doi.org/10.1038/sj.onc.1210184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237826				2022-12-25	WOS:000247252700005
J	Karni-Schmidt, O; Friedler, A; Zupnick, A; McKinney, K; Mattia, M; Beckerman, R; Bouvet, P; Sheetz, M; Fersht, A; Prives, C				Karni-Schmidt, O.; Friedler, A.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Bouvet, P.; Sheetz, M.; Fersht, A.; Prives, C.			Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus	ONCOGENE			English	Article						p53; nucleolus; DNA damage; NoLS	TUMOR-SUPPRESSOR; DNA-DAMAGE; SUBCELLULAR LOCATION; BINDING PROTEIN; CELLULAR STRESS; NUCLEAR EXPORT; STABILIZES P53; CANCER-CELLS; HELA-CELLS; MDM2	The p53 tumor suppressor is a nucleocytoplasmic shuttling protein that is found predominantly in the nucleus of cells. In addition to mutation, abnormal p53 cellular localization is one of the mechanisms that inactivate p53 function. To further understand features of p53 that contribute to the regulation of its trafficking within the cell, we analysed the subnuclear localization of wild-type and mutant p53 in human cells that were either permeabilized with detergent or treated with the proteasome inhibitor MG132. We, here, show that either endogenously expressed or exogenously added p53 protein localizes to the nucleolus in detergent-permeabilized cells in a concentration- and ATP hydrolysis-dependent manner. Two discrete regions within the carboxyl terminus of p53 are essential for nucleolar localization in permeabilized cells. Similarly, localization of p53 to the nucleolus after proteasome inhibition in unpermeabilized cells requires sequences within the carboxyl terminus of p53. Interestingly, genotoxic stress markedly decreases the association of p53 with the nucleolus, and phosphorylation of p53 at S392, a site that is modified by such stress, partially impairs its nucleolar localization. The possible significance of these findings is discussed.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; MRC, Ctr Prot Engn, Dept MRC CPE, Cambridge CB2 2BB, England; Hebrew Univ Jerusalem, Dept Organ Chem, IL-91010 Jerusalem, Israel; Ecole Normale Super Lyon, UMR 5161, Lab Biol Mol Cellule, F-69364 Lyon, France	Columbia University; University of Cambridge; Hebrew University of Jerusalem; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, 816 Fairchild, New York, NY 10027 USA.	clp3@columbia.edu	, Bouvet/AAC-8779-2020; Fersht, Alan R/B-2189-2008	Bouvet, Philippe/0000-0003-4524-2233	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline; NCI NIH HHS [CA58316, CA87497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316, P01CA087497] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Benninghoff J, 1999, CANCER LETT, V144, P55, DOI 10.1016/S0304-3835(99)00187-1; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Carmo-Fonseca M, 2002, TRENDS CELL BIOL, V12, P491, DOI 10.1016/S0962-8924(02)02387-5; Chan PK, 1996, CANCER LETT, V100, P191, DOI 10.1016/0304-3835(95)04100-1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; DUNDR M, 1995, J CELL SCI, V108, P2811; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Horky M, 2001, J CELL SCI, V114, P663; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lamond AI, 2003, CURR BIOL, V13, pR825, DOI 10.1016/j.cub.2003.10.012; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; MOGAKI M, 1993, CARCINOGENESIS, V14, P2589, DOI 10.1093/carcin/14.12.2589; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROKAEUS N, 2006, ONCOGENE; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Stros M, 1998, EUR J BIOCHEM, V251, P427, DOI 10.1046/j.1432-1327.1998.2510427.x; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P752, DOI 10.1016/S0955-0674(00)00165-4; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; ZATSEPINA OV, 1989, EXP CELL RES, V181, P94, DOI 10.1016/0014-4827(89)90185-7; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	62	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3878	3891		10.1038/sj.onc.1210162	http://dx.doi.org/10.1038/sj.onc.1210162			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17237827				2022-12-25	WOS:000247026400011
J	Plata, C; Sussman, CR; Sindic, A; Liang, JO; Mount, DB; Josephs, ZM; Chang, MH; Romero, MF				Plata, Consuelo; Sussman, Caroline R.; Sindic, Aleksandra; Liang, Jennifer O.; Mount, David B.; Josephs, Zara M.; Chang, Min-Hwang; Romero, Michael F.			Zebrafish Slc5a12 encodes an electroneutral sodium monocarboxylate transporter (SMCTn) - A comparison with the electrogenic SMCT (SMCTe/Slc5a8)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; DEPOLARIZATION-INDUCED ALKALINIZATION; SUPPRESSOR GENE SLC5A8; CENTRAL-NERVOUS-SYSTEM; SPECTRUM LIPID DRUG; CHAIN FATTY-ACIDS; NICOTINIC-ACID; TUMOR-SUPPRESSOR; LACTATE TRANSPORT; GLUTAMATE TRANSPORTER	We have identified and characterized two different sodium-coupled monocarboxylate cotransporters ( SMCT) from zebrafish ( Danio rerio), electrogenic ( zSMCTe) and electroneutral ( zSMCTn). zSMCTn is the 12th member of the zebrafish Slc5 gene family ( zSlc5a12). Both zSMCT sequences have similar to 50% homology to human SLC5A8 ( hSMCT). Transport function and kinetics were measured in Xenopus oocytes injected with zSMCTcRNAs by measurement of intracellular Na+ concentration ([ Na+](i)) and membrane potential. Both zSMCTs oocytes increased [ Na+](i) with addition of monocarboxylates ( MC) such as lactate, pyruvate, nicotinate, and butyrate. By using two electrode voltage clamp experiments, we measured currents elicited from zSMCTe after MC addition. MC-elicited currents from zSMCTe were similar to hSMCT currents. In contrast, we found no significant MC-elicited current in either zSMCTn or control oocytes. Kinetic data show that zSMCTe has a higher affinity for lactate, nicotinate, and pyruvate ( K-m(L-lactate) = 0.17 +/- 0.02 mM, K-m(nicotinate) = 0.54 +/- 0.12 mM at -150 mV) than zSMCTn ( K-m(L-lactate) = 1.81 +/- 0.19 mM, K-m(nicotinate) = 23.68 +/- 4.88 mM). In situ hybridization showed that 1-, 3-, and 5-day-old zebrafish embryos abundantly express both zSMCTs in the brain, eyes, intestine, and kidney. Within the kidney, zSMCTn mRNA is expressed in pronephric tubules, whereas zSMCTe mRNA is more distal in pronephric ducts. zSMCTn is expressed in exocrine pancreas, but zSMCTe is not. Roles for Na+-coupled monocarboxylate cotransporters have not been described for the brain or eye. In summary, zSMCTe is the zebrafish SLC5A8 ortholog, and zSMCTn is a novel, electroneutral SMCT ( zSlc5a12). Slc5a12 in higher vertebrates is likely responsible for the electroneutral Na+/lactate cotransport reported in mammalian and amphibian kidneys.	Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biol, Cleveland, OH 44106 USA; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Nefrol & Metab Mineral, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Div Gen Internal Med, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA	Mayo Clinic; Case Western Reserve University; Case Western Reserve University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System	Romero, MF (corresponding author), Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, 200 1st St SW,Guggenheim 9-21D, Rochester, MN 55905 USA.	romero.michael@mayo.edu	Dugandzic, Aleksandra/AAL-7581-2020; Plata, Consuelo/M-4482-2015; Plata, Consuelo/M-6461-2019	Plata, Consuelo/0000-0001-9340-8950; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056218, R01DK057708, R21DK060845, R01DK059985] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56218, DK-57708, DK-60845, DK-59985] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARACNIETO M, 1980, AM J PHYSIOL, V239, pF496, DOI 10.1152/ajprenal.1980.239.5.F496; BARBARAT B, 1988, J BIOL CHEM, V263, P12190; Becker HM, 2004, J BIOL CHEM, V279, P28057, DOI 10.1074/jbc.M402401200; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Carlson LA, 2005, J INTERN MED, V258, P94, DOI 10.1111/j.1365-2796.2005.01528.x; Carlson LA, 2004, INT J CLIN PRACT, V58, P706, DOI 10.1111/j.1368-5031.2004.00233.x; CHANG MH, 2004, J AM SOC NEPHROL, V15, P75; Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859; Costa RMB, 2003, GENE EXPR PATTERNS, V3, P509, DOI 10.1016/S1567-133X(03)00086-3; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; Dinour D, 2004, J BIOL CHEM, V279, P52238, DOI 10.1074/jbc.M406591200; Frayling TM, 2003, DIABETES, V52, P872, DOI 10.2337/diabetes.52.3.872; Furuta A, 2003, AM J PATHOL, V163, P779, DOI 10.1016/S0002-9440(10)63705-4; Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237; GEIBISH G, 2003, MED PHYSL, P790; Gerhart DZ, 1999, NEUROSCIENCE, V92, P367, DOI 10.1016/S0306-4522(98)00699-X; Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916; Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Hertz L, 2005, J NEUROSCI RES, V79, P11, DOI 10.1002/jnr.20294; Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048; JORGENSEN KE, 1986, BIOCHIM BIOPHYS ACTA, V860, P632, DOI 10.1016/0005-2736(86)90563-8; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; Lindgren CM, 2002, AM J HUM GENET, V70, P509, DOI 10.1086/338629; MANGANEL M, 1985, AM J PHYSIOL, V249, pF400, DOI 10.1152/ajprenal.1985.249.3.F400; MENGUAL R, 1990, J BIOL CHEM, V265, P292; MENGUAL R, 1989, J MEMBRANE BIOL, V108, P197, DOI 10.1007/BF01871734; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Naoumova RP, 2003, ARTERIOSCL THROM VAS, V23, P2070, DOI 10.1161/01.ATV.0000095975.35247.9F; NORD E, 1982, AM J PHYSIOL, V243, pF456, DOI 10.1152/ajprenal.1982.243.5.F456; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pike Nicholas B, 2004, Curr Opin Investig Drugs, V5, P271; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394; Rodriguez AM, 2002, J CLIN ENDOCR METAB, V87, P3500, DOI 10.1210/jc.87.7.3500; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Shepherd J, 2005, CURR MED RES OPIN, V21, P665, DOI 10.1185/030079905X43677; Shoulders CC, 2004, HUM MOL GENET, V13, pR149, DOI 10.1093/hmg/ddh069; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF342, DOI 10.1152/ajprenal.1989.256.2.F342; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; Soengas JL, 2002, COMP BIOCHEM PHYS B, V131, P271, DOI 10.1016/S1096-4959(02)00022-2; Srinivas SR, 2005, BIOCHEM J, V392, P655, DOI 10.1042/BJ20050927; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Thirumurugan A, 2004, NEPHROL DIAL TRANSPL, V19, P1767, DOI 10.1093/ndt/gfh213; THISSE C, 1993, DEVELOPMENT, V119, P1203; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; Wright EM, 2004, PHYSIOLOGY, V19, P370, DOI 10.1152/physiol.00026.2004; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588	62	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11996	12009		10.1074/jbc.M609313200	http://dx.doi.org/10.1074/jbc.M609313200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17255103	hybrid			2022-12-25	WOS:000245941900042
J	Roy, A; Lin, YN; Agno, JE; DeMayo, FJ; Matzuk, MM				Roy, Angshumoy; Lin, Yi-Nan; Agno, Julio E.; DeMayo, Francesco J.; Matzuk, Martin M.			Absence of tektin 4 causes asthenozoospermia and subfertility in male mice	FASEB JOURNAL			English	Article						coiled-coil; axoneme; outer dense fiber; knockout mice	OUTER DENSE FIBERS; INNER-ARM DYNEIN; FLAGELLAR MICROTUBULES; MAMMALIAN SPERMATOZOA; RODENT SPERMATOZOA; PROTEOMIC ANALYSIS; REDUCED FERTILITY; MOLECULAR-CLONING; SPERM FLAGELLUM; HUMAN-DISEASE	Sperm flagellar motion is the outcome of a dynamic interplay between the axonemal cytoskeleton, the peri-axonemal accessory structures, and multiple regulatory networks that coordinate to produce flagellar beat and waveform. Tektins are conserved components of the flagellar proteome in evolutionarily diverse species and are believed to play essential roles in the mechanics of sperm motility. Using database mining, we identified multiple new paralogs of previously annotated tektins, including tektin 4 (TEKT4), which shares 77.1% identity with its nearest human homologue. Mouse Tekt4 is a germ cell-enriched gene, most abundantly expressed in haploid round spermatids in the testis, and the protein is localized to the sperm flagella. Male mice lacking TEKT4 on a 129S5/SvEvBrd inbred background are subfertile. Tekt4-null sperm exhibit drastically reduced forward progressive velocity and uncoordinated waveform propagation along the flagellum. In Tekt4-null sperm, flagellar ultrastructure is grossly unaltered as revealed by transmission electron microscopy. However, the ineffective flagellar strokes lead to similar to 10-fold higher consumption of intracellular ATP in Tekt4-null sperm as compared to wild-type, and null spermatozoa rapidly lose progressive motility when incubated for >= 1.5 h. Our studies demonstrate that TEKT4 is necessary for the proper coordinated beating of the sperm flagellum and male reproductive physiology.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Pl, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019; Lin, Yi-Nan/B-4986-2009	DeMayo, Francesco/0000-0002-9480-7336; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD-07495] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 2001, MOL HUM REPROD, V7, P513, DOI 10.1093/molehr/7.6.513; Afzelius BA, 2004, J PATHOL, V204, P470, DOI 10.1002/path.1652; AMOS WB, 1986, J CELL SCI, P55; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Brody SL, 2004, AM J RESP CELL MOL, V30, P435, DOI 10.1165/rcmb.2004-0004PS; BURFEIND P, 1993, EUR J BIOCHEM, V216, P497, DOI 10.1111/j.1432-1033.1993.tb18168.x; Cao WL, 2006, MOL CELL PROTEOMICS, V5, P801, DOI 10.1074/mcp.M500322-MCP200; Eddy EM, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P3; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; Henkel R, 2005, FERTIL STERIL, V84, P1430, DOI 10.1016/j.fertnstert.2005.05.020; Henkel R, 1999, FERTIL STERIL, V71, P1138, DOI 10.1016/S0015-0282(99)00141-7; HOYERFENDER S, 1995, CYTOGENET CELL GENET, V70, P200, DOI 10.1159/000134033; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; Iguchi N, 2002, MOL HUM REPROD, V8, P525, DOI 10.1093/molehr/8.6.525; Iida H, 2006, MOL REPROD DEV, V73, P342, DOI 10.1002/mrd.20419; Iida H, 2006, MOL REPROD DEV, V73, P929, DOI 10.1002/mrd.20486; Kleene KC, 2003, CYTOGENET GENOME RES, V103, P217, DOI 10.1159/000076807; Larsson M, 2000, EUR J CELL BIOL, V79, P718, DOI 10.1078/0171-9335-00097; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Linck R.W., 1982, Progress in Clinical and Biological Research, V80, P127; LINCK RW, 1985, J CELL BIOL, V100, P126, DOI 10.1083/jcb.100.1.126; LINCK RW, 1982, J CELL SCI, V58, P1; Lindemann CB, 1996, CELL MOTIL CYTOSKEL, V34, P258, DOI 10.1002/(SICI)1097-0169(1996)34:4<258::AID-CM1>3.0.CO;2-4; Matsuyama T, 2005, MOL REPROD DEV, V72, P120, DOI 10.1002/mrd.20331; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Miki K, 2002, DEV BIOL, V248, P331, DOI 10.1006/dbio.2002.0728; Mortimer ST, 1997, HUM REPROD UPDATE, V3, P403, DOI 10.1093/humupd/3.5.403; Nayernia K, 2002, MOL CELL BIOL, V22, P3046, DOI 10.1128/MCB.22.9.3046-3052.2002; Norrander J, 1998, J NEUROSCI, V18, P8912; OLSON GE, 1986, J ULTRA MOL STRUCT R, V94, P131, DOI 10.1016/0889-1605(86)90059-5; OLSON GE, 1990, J STRUCT BIOL, V103, P13, DOI 10.1016/1047-8477(90)90081-M; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Pearse RV, 1997, P NATL ACAD SCI USA, V94, P7555, DOI 10.1073/pnas.94.14.7555; PIRNER MA, 1994, J BIOL CHEM, V269, P31800; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Roy A, 2004, MOL REPROD DEV, V67, P295, DOI 10.1002/mrd.20025; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Tanaka H, 2004, MOL CELL BIOL, V24, P7958, DOI 10.1128/MCB.24.18.7958-7964.2004; Yan W, 2002, MOL ENDOCRINOL, V16, P1168, DOI 10.1210/me.16.6.1168; Yanagisawa H, 2004, MOL BIOL CELL, V15, P2105, DOI 10.1091/mbc.E03-11-0854; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683	43	75	80	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1013	1025		10.1096/fj.06-7035com	http://dx.doi.org/10.1096/fj.06-7035com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17244819				2022-12-25	WOS:000245650400006
J	Sun, HY; Lin, SW; Ko, TP; Pan, JF; Liu, CL; Lin, CN; Wang, AHJ; Lin, CH				Sun, Han-Yu; Lin, Sheng-Wei; Ko, Tzu-Ping; Pan, Jia-Fu; Liu, Chia-Ling; Lin, Chun-Nan; Wang, Andrew H. -J.; Lin, Chun-Hung			Structure and mechanism of Helicobacter pylori fucosyltransferase - A basis for lipopolysaccharide variation and inhibitor design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; CRYSTAL-STRUCTURE; HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE; BIOSYNTHETIC-PATHWAY; PERSISTENT INFECTION; ULCER DISEASE; LEWIS-Y; EXPRESSION; GLUCOSYLTRANSFERASE; GLYCOSYLTRANSFERASES	Helicobacter pylori alpha 1,3-fucosyltransferase (FucT) is involved in catalysis to produce the Lewis x trisaccharide, the major component of the bacteria's lipopolysaccharides, which has been suggested to mimic the surface sugars in gastric epithelium to escape host immune surveillance. We report here three x-ray crystal structures of FucT, including the FucT-GDPfucose and FucT center dot GDP complexes. The protein structure is typical of the glycosyltransferase-B family despite little sequence homology. We identified a number of catalytically important residues, including Glu-95, which serves as the general base, and Glu-249, which stabilizes the developing oxonium ion during catalysis. The residues Arg-195, Tyr-246, Glu-249, and Lys-250 serve to interact with the donor substrate, GDP-fucose. Variations in the protein and ligand conformations, as well as a possible FucT dimer, were also observed. We propose a catalytic mechanism and a model of polysaccharide binding not only to explain the observed variations in H. pylori lipopolysaccharides, but also to facilitate the development of potent inhibitors.	Natl Taiwan Univ, Inst Biochem Sci, Taipei 10642, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; Acad Sinica, Natl Core Facil HIgh Throughput Prog Crystallog, Taipei 11529, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Wang, AHJ (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Taipei 10642, Taiwan.	ahjwang@gate.sinica.edu.tw; chunhung@gate.sinica.edu.tw	Lin, Sheng-Wei/G-8142-2015; Lin, Chun-Hung/AAM-9711-2021	Lin, Sheng-Wei/0000-0001-7777-2090; Lin, Chun-Hung/0000-0002-6795-8825				BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; Hallet B, 2001, CURR OPIN MICROBIOL, V4, P570, DOI 10.1016/S1369-5274(00)00253-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee LV, 2003, J AM CHEM SOC, V125, P9588, DOI 10.1021/ja0302836; Lin SW, 2006, BIOCHEMISTRY-US, V45, P8108, DOI 10.1021/bi0601297; Lozniewski A, 2003, INFECT IMMUN, V71, P2902, DOI 10.1128/IAI.71.5.2902-2906.2003; Ma B, 2006, J BIOL CHEM, V281, P6385, DOI 10.1074/jbc.M511320200; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Mulichak AM, 2004, BIOCHEMISTRY-US, V43, P5170, DOI 10.1021/bi036130c; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; Ni LS, 2006, BIOCHEMISTRY-US, V45, P2139, DOI 10.1021/bi0524013; Nilsson C, 2006, P NATL ACAD SCI USA, V103, P2863, DOI 10.1073/pnas.0511119103; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsonnet J, 1996, NEW ENGL J MED, V335, P278, DOI 10.1056/NEJM199607253350411; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996	40	93	97	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9973	9982		10.1074/jbc.M610285200	http://dx.doi.org/10.1074/jbc.M610285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251184	hybrid, Green Published			2022-12-25	WOS:000245421700072
J	Fujikawa, T; Shiraha, H; Ueda, N; Takaoka, N; Nakanishi, Y; Matsuo, N; Tanaka, S; Nishina, SI; Suzuki, M; Takaki, A; Sakaguchi, K; Shiratori, Y				Fujikawa, Tatsuya; Shiraha, Hidenori; Ueda, Naoki; Takaoka, Nobuyuki; Nakanishi, Yutaka; Matsuo, Noriyuki; Tanaka, Shigetomi; Nishina, Shin-ichi; Suzuki, Mayumi; Takaki, Akinobu; Sakaguchi, Kohsaku; Shiratori, Yasushi			Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR; INCREASED EXPRESSION; ALPHA-FETOPROTEIN; CLINICAL-SIGNIFICANCE; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; TYROSINE KINASE; VEGF RECEPTOR-1; VENOUS INVASION	Des-gamma-carboxyl prothrombin (DCP) is a well recognized tumor marker for hepatocellular carcinoma. Previously, we have demonstrated that DCP stimulates cell proliferation in hepatocellular carcinoma cell lines through Met-Janus kinase 1 signal transducer and activator of transcription 3 signaling pathway. In the present study, we demonstrated that DCP induces both cell proliferation and migration in human umbilical vein endothelial cells. DCP was found to bind with the kinase insert domain receptor (KDR), alternatively referred to as vascular endothelial growth factor receptor-2. Furthermore, DCP induced autophosphorylation of KDR and its downstream effector phospholipase C-gamma and mitogen-activated protein kinase (MAPK). To support these results, we showed that DCP-induced cell proliferation and cell migration were inhibited by KDR short interfering RNA, KDR kinase inhibitor, or MAPK inhibitor. In conclusion, these results indicate that DCP is a novel type of vascular endothelial growth factor that possesses potent mitogenic and migrative activities.	Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, Okayama 7008558, Japan	Okayama University	Shiraha, H (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	hshiraha@md.okayama-u.ac.jp	Fujikawa, Tatsuya/P-1972-2018	Fujikawa, Tatsuya/0000-0003-3819-224X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Deli G, 2005, WORLD J GASTROENTERO, V11, P960, DOI 10.3748/wjg.v11.i7.960; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ding SL, 2003, BLOOD, V101, P4816, DOI 10.1182/blood-2002-06-1731; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gotoh M, 2003, JPN J CLIN ONCOL, V33, P522, DOI 10.1093/jjco/hyg096; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; INOUE S, 1994, AM J GASTROENTEROL, V89, P2222; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Ji-no K, 1998, CANCER-AM CANCER SOC, V82, P1260; Joukov V, 1996, EMBO J, V15, P290; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim HK, 2003, EUR J CANCER, V39, P184, DOI 10.1016/S0959-8049(02)00596-8; Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Li B, 2002, HYPERTENSION, V39, P1095, DOI 10.1161/01.HYP.0000018588.56950.7A; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mise K, 1998, CLIN CANCER RES, V4, P1475; Mise M, 1996, HEPATOLOGY, V23, P455; Miura H, 1997, J HEPATOL, V27, P854, DOI 10.1016/S0168-8278(97)80323-6; Moon WS, 2003, MODERN PATHOL, V16, P552, DOI 10.1097/01.MP.0000071841.17900.69; Mulcahy Mary F, 2005, Curr Treat Options Oncol, V6, P423, DOI 10.1007/s11864-005-0045-7; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park YN, 2000, ARCH PATHOL LAB MED, V124, P1061; Poon RTP, 2001, AM J SURG, V182, P298, DOI 10.1016/S0002-9610(01)00708-5; Poon RTP, 2001, J CLIN ONCOL, V19, P1207, DOI 10.1200/JCO.2001.19.4.1207; Poon RTP, 2001, ANN SURG, V233, P227, DOI 10.1097/00000658-200102000-00012; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Roncalli M, 1999, HEPATOLOGY, V30, P1174, DOI 10.1002/hep.510300507; SAKON M, 1992, AM J SURG, V163, P251, DOI 10.1016/0002-9610(92)90111-4; Shimada M, 1996, CANCER, V78, P2094, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2094::AID-CNCR9>3.0.CO;2-O; SUEHIRO T, 1995, SURGERY, V117, P682, DOI 10.1016/S0039-6060(95)80013-1; Sugimachi K, 2002, SURGERY, V131, pS135, DOI 10.1067/msy.2002.119365; Suzuki K, 1996, CANCER RES, V56, P3004; Suzuki M, 2005, J BIOL CHEM, V280, P6409, DOI 10.1074/jbc.M406714200; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tamano M, 2002, HEPATOL RES, V22, P261, DOI 10.1016/S1386-6346(01)00150-4; TERADA T, 1995, HISTOPATHOLOGY, V27, P333, DOI 10.1111/j.1365-2559.1995.tb01523.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Torimura T, 1998, HUM PATHOL, V29, P986, DOI 10.1016/S0046-8177(98)90205-2; UEDA K, 1992, HUM PATHOL, V23, P619, DOI 10.1016/0046-8177(92)90316-U; Uehara S, 1999, CLIN CHIM ACTA, V289, P33, DOI 10.1016/S0009-8981(99)00152-7; Van Belle E, 1998, CIRCULATION, V97, P381; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yamaguchi R, 2000, ONCOL REP, V7, P725; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zisch AH, 2001, J CONTROL RELEASE, V72, P101, DOI 10.1016/S0168-3659(01)00266-8	61	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8741	8748		10.1074/jbc.M609358200	http://dx.doi.org/10.1074/jbc.M609358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255102	hybrid			2022-12-25	WOS:000245780300020
J	Novinec, M; Grass, RN; Stark, WJ; Turk, V; Baici, A; Lenarcic, B				Novinec, Marko; Grass, Robert N.; Stark, Wendelin J.; Turk, Vito; Baici, Antonio; Lenarcic, Brigita			Interaction between human cathepsins K, L, and S and elastins - Mechanism of elastinolysis and inhibition by macromolecular inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; CYSTATIN-C DEFICIENCY; CYSTEINE PROTEASE; ESCHERICHIA-COLI; REDUCES ATHEROSCLEROSIS; ALVEOLAR MACROPHAGES; INCREASED EXPRESSION; PROTEINASES; ELASTOLYSIS; COLLAGEN	Proteolytic degradation of elastic fibers is associated with a broad spectrum of pathological conditions such as atherosclerosis and pulmonary emphysema. We have studied the interaction between elastins and human cysteine cathepsins K, L, and S, which are known to participate in elastinolytic activity in vivo. The enzymes showed distinctive preferences in degrading elastins from bovine neck ligament, aorta, and lung. Different susceptibility of these elastins to proteolysis was attributed to morphological differences observed by scanning electron microscopy. Kinetics of cathepsin binding to the insoluble substrate showed that the process occurs in two steps. The enzyme is initially adsorbed on the elastin surface in a nonproductive manner and then rearranges to form a catalytically competent complex. In contrast, soluble elastin is bound directly in a catalytically productive manner. Studies of enzyme partitioning between the phases showed that cathepsin K favors adsorption on elastin; cathepsin L prefers the aqueous environment, and cathepsin S is equally distributed among both phases. Our results suggest that elastinolysis by cysteine cathepsins proceeds in cycles of enzyme adsorption, binding of a susceptible peptide moiety, hydrolysis, and desorption. Alternatively, the enzyme may also form a new catalytic complex without prior desorption and re-adsorption. In both cases the active center of the enzymes remains at least partly accessible to inhibitors. Elastinolytic activity was readily abolished by cystatins, indicating that, unlike enzymes such as leukocyte elastase, pathological elastinorlytic cysteine cathepsins might represent less problematic drug targets. In contrast, thyropins were relatively inefficient in preventing elastincilysis by cysteine cathepsins.	Univ Ljubljana, Fac Chem & Chem Technol, Dept Chem & Biochem, SI-1000 Ljubljana, Slovenia; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; ETH, Dept Chem & Appl Biosci, Inst Chem & Bioengn, CH-8093 Zurich, Switzerland; Jozef Stefan Inst, Dept Biochem & Mol Biol, SI-1000 Ljubljana, Slovenia	University of Ljubljana; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute	Lenarcic, B (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Dept Chem & Biochem, Jamova 39, SI-1000 Ljubljana, Slovenia.	brigita.lenarcic@fkkt.uni-lj.si	Grass, Robert N/A-5607-2008; Novinec, Marko/J-9789-2019; Stark, Wendelin J./A-8680-2008	Grass, Robert N/0000-0001-6968-0823; Novinec, Marko/0000-0003-1824-1649; Baici, Antonio/0000-0002-2980-0541; Lenarcic, Brigita/0000-0002-2508-3776				Altiok O, 2006, AM J RESP CRIT CARE, V173, P318, DOI 10.1164/rccm.200503-425OC; BAICI A, 1990, BIOCHIM BIOPHYS ACTA, V1040, P355, DOI 10.1016/0167-4838(90)90133-Z; BAICI A, 1992, CURR T REH, P81; BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363; Bengtsson E, 2005, ARTERIOSCL THROM VAS, V25, P2151, DOI 10.1161/01.ATV.0000179600.34086.7d; BERG OG, 2002, INTERFACIAL ENZYME K, P47; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Buhling F, 2004, AM J PATHOL, V164, P2203, DOI 10.1016/S0002-9440(10)63777-7; Buhling F, 1999, AM J RESP CELL MOL, V20, P612; CARDOSO WV, 1993, AM REV RESPIR DIS, V147, P975, DOI 10.1164/ajrccm/147.4.975; Cheng XW, 2006, HYPERTENSION, V48, P979, DOI 10.1161/01.HYP.0000242331.99369.2f; Cheng XW, 2004, AM J PATHOL, V164, P243, DOI 10.1016/S0002-9440(10)63114-8; D'Alessio KJ, 1999, PROTEIN EXPRES PURIF, V15, P213, DOI 10.1006/prep.1998.1013; Dehrmann FM, 1995, ARCH BIOCHEM BIOPHYS, V324, P93, DOI 10.1006/abbi.1995.9924; DOLINAR M, 1995, BIOL CHEM H-S, V376, P385; Fiebiger E, 2002, J EXP MED, V196, P1263, DOI 10.1084/jem.20020762; Filippov S, 2003, J EXP MED, V198, P925, DOI 10.1084/jem.20030626; Helske S, 2006, ARTERIOSCL THROM VAS, V26, P1791, DOI 10.1161/01.ATV.0000228824.01604.63; HORNEBECK W, 1984, ADV EXP MED BIOL, V167, P111; HORNEBECK W, 1982, H-S Z PHYSIOL CHEM, V363, P455; JANOFF A, 1985, ANNU REV MED, V36, P207; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; Kielty CM, 2002, J CELL SCI, V115, P2817; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; Kopitar G, 1996, EUR J BIOCHEM, V236, P558, DOI 10.1111/j.1432-1033.1996.00558.x; KRAMPS JA, 1987, SCAND J CLIN LAB INV, V47, P405; LENARCIC B, 1991, FEBS LETT, V280, P211, DOI 10.1016/0014-5793(91)80295-E; Lenarcic B, 1998, BIOL CHEM, V379, P105; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Liu J, 2006, ATHEROSCLEROSIS, V184, P302, DOI 10.1016/j.atherosclerosis.2005.05.012; Liu J, 2006, ATHEROSCLEROSIS, V186, P411, DOI 10.1016/j.atherosclerosis.2005.08.001; Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; Meh P, 2005, BIOL CHEM, V386, P75, DOI 10.1515/BC.2005.010; MORRISON HM, 1990, AM J RESP CELL MOL, V2, P263, DOI 10.1165/ajrcmb/2.3.263; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; RAO NV, 1991, J BIOL CHEM, V266, P9540; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; ROBERT B, 1974, BIOCHIMIE, V56, P239, DOI 10.1016/S0300-9084(74)80383-4; Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3; Rodgers KJ, 2006, ARTERIOSCL THROM VAS, V26, P851, DOI 10.1161/01.ATV.0000203526.75772.4b; ROSENBLOOM J, 1984, LAB INVEST, V51, P605; Russell REK, 2002, AM J PHYSIOL-LUNG C, V283, pL867, DOI 10.1152/ajplung.00020.2002; SCHWABE C, 1973, ANAL BIOCHEM, V53, P484, DOI 10.1016/0003-2697(73)90098-5; Segel I. H, 1975, ENZYME KINETICS, P106; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; STARKEY PM, 1976, BIOCHEM J, V155, P273, DOI 10.1042/bj1550273; Sukhova GK, 2005, CIRC RES, V96, P368, DOI 10.1161/01.RES.0000155964.34150.F7; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; TAKAHASHI H, 1993, AM REV RESPIR DIS, V147, P1562, DOI 10.1164/ajrccm/147.6_Pt_1.1562; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200; Ying QL, 2002, AM J RESP CELL MOL, V26, P356, DOI 10.1165/ajrcmb.26.3.4704	62	76	76	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7893	7902		10.1074/jbc.M610107200	http://dx.doi.org/10.1074/jbc.M610107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227755	hybrid			2022-12-25	WOS:000245081000019
J	Vogel, RO; Dieteren, CEJ; van den Heuvel, LPWJ; Willems, PHGM; Smeitink, JAM; Koopman, WJH; Nijtmans, LGJ				Vogel, Rutger O.; Dieteren, Cindy E. J.; van den Heuvel, Lambert P. W. J.; Willems, Peter H. G. M.; Smeitink, Jan A. M.; Koopman, Werner J. H.; Nijtmans, Leo G. J.			Identification of mitochondrial complex I assembly intermediates by tracing tagged NDUFS3 demonstrates the entry point of mitochondrial subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; BLUE-NATIVE-ELECTROPHORESIS; BOVINE HEART-MITOCHONDRIA; DNA-ENCODED SUBUNITS; RESPIRATORY NADH; STRUCTURAL ORGANIZATION; OXIDATIVE-PHOSPHORYLATION; DEHYDROGENASE; ENZYME; DEFICIENCY	Biogenesis of human mitochondrial complex I (CI) requires the coordinated assembly of 45 subunits derived from both the mitochondrial and nuclear genome. The presence of CI subcomplexes in CI-deficient cells suggests that assembly occurs in distinct steps. However, discriminating between products of assembly or instability is problematic. Using an inducible NDUFS3-green fluorescent protein (GFP) expression system in HEK293 cells, we here provide direct evidence for the stepwise assembly of CI. Upon induction, six distinct NDUFS3-GFP-containing subcomplexes gradually appeared on a blue native Western blot also observed in wild type HEK293 mitochondria. Their stability was demonstrated by differential solubilization and heat incubation, which additionally allowed their distinction from specific products of CI instability and breakdown. Inhibition of mitochondrial translation under conditions of steady state labeling resulted in an accumulation of two of the NDUFS3-GFP-containing subcomplexes (100 and 150 kDa) and concomitant disappearance of the fully assembled complex. Lifting inhibition reversed this effect, demonstrating that these two subcomplexes are true assembly intermediates. Composition analysis showed that this event was accompanied by the incorporation of at least one mitochondrial DNA-encoded subunit, thereby revealing the first entry point of these subunits.	Radboud Univ Nijmegen, Med Ctr, Dept Paediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Membrane Biochem, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Microscopial Imaging Ctr, Nijmegen Mol Life Sci, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Nijtmans, LGJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Paediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.	l.nijtmans@cukz.umcn.nl	Smeitink, Jan/C-1351-2013; van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel, Lambertus/AAM-1772-2021; Koopman, Werner J.H./D-3592-2009; Dieteren, Cindy E.J./D-6042-2011; Willems, P.H.G.M./L-4759-2015; Nijtmans, L.G.J./L-4549-2015; Smeitink, Jan A.M./D-6064-2011; Koopman, Werner J.H./AAC-9668-2020	van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727; Koopman, Werner J.H./0000-0002-5340-6747; Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747				Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539; Braun M, 1998, BIOCHEMISTRY-US, V37, P1861, DOI 10.1021/bi971176p; Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; Clark MA, 1998, CURR MICROBIOL, V37, P356, DOI 10.1007/s002849900392; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Galante Y M, 1978, Methods Enzymol, V53, P15; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; HALL RE, 1990, J BIOL CHEM, V265, P16484; Hedderich R, 2004, J BIOENERG BIOMEMBR, V36, P65, DOI 10.1023/B:JOBB.0000019599.43969.33; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787; Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5; Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020; Potluri P, 2004, EUR J BIOCHEM, V271, P3265, DOI 10.1111/j.1432-1033.2004.04260.x; Prommeenate P, 2004, J BIOL CHEM, V279, P28165, DOI 10.1074/jbc.M401107200; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHULTE U, 1994, BBA-BIOENERGETICS, V1187, P121, DOI 10.1016/0005-2728(94)90096-5; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; TUSCHEN G, 1990, J MOL BIOL, V213, P845, DOI 10.1016/S0022-2836(05)80268-2; Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; Vogel R, 2004, CURR OPIN NEUROL, V17, P179, DOI 10.1097/00019052-200404000-00016; Vogel RO, 2005, FEBS J, V272, P5317, DOI 10.1111/j.1742-4658.2005.04928.x; Yadava N, 2004, J BIOL CHEM, V279, P12406, DOI 10.1074/jbc.M313588200	41	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7582	7590		10.1074/jbc.M609410200	http://dx.doi.org/10.1074/jbc.M609410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17209039	hybrid, Green Published			2022-12-25	WOS:000245080900071
J	Yoo, YD; Wu, XY; Guan, JL				Yoo, Youngdong; Wu, Xiaoyang; Guan, Jun-Lin			A novel role of the actin-nucleating Arp2/3 complex in the regulation of RNA polymerase II-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; N-WASP; MESSENGER-RNA; FILAMENT NUCLEATION; INTERPHASE NUCLEI; BETA-ACTIN; PROTEIN; LOCALIZATION; MOTILITY; FAMILY	It has been well documented that actin is present in the nucleus and involved in numerous nuclear functions including regulation of transcription. The actin-nucleating Arp2/3 complex is an essential, evolutionarily conserved seven-subunit protein complex that promotes actin cytoskeleton assembly in the cytoplasm upon stimulation by WASP family proteins. Our recent study indicates that the nuclear localized neural Wiskott-Aldrich syndrome protein (N-WASP) can induce de novo actin polymerization in the nucleus, and this function is important for the role of N-WASP in the regulation of RNA polymerase II-dependent transcription. Here, we have presented evidence to show that the Arp2/3 complex is also localized in the nucleus and plays an essential role in mediating nuclear actin polymerization induced by N-WASP. We have also demonstrated that the Arp2/3 complex physically associates with RNA polymerase 11 and is involved in the RNA polymerase II-dependent transcriptional regulation both in vivo and in vitro. Together, these data provide strong support for the hypothesis that N-WASP and the Arp2/3 complex regulate transcription, at least in part, through the regulation of nuclear actin polymerization in a manner similar to their function in the cytoplasm.	Univ Michigan, Sch Med, Div Med & Mol Genet, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Cornell Univ, Dept Mol Med, New York, NY 14853 USA	University of Michigan System; University of Michigan; Cornell University	Guan, JL (corresponding author), Univ Michigan, Sch Med, Div Med & Mol Genet, Dept Internal Med, Ann Arbor, MI 48109 USA.	jlguan@umich.edu			NIGMS NIH HHS [GM48050] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANKWAH KS, 1994, EXP CELL RES, V210, P315, DOI 10.1006/excr.1994.1044; Archer SK, 2005, BIOESSAYS, V27, P388, DOI 10.1002/bies.20200; Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Chhabra D, 2005, BIOPHYS J, V89, P1902, DOI 10.1529/biophysj.105.062083; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Deeks MJ, 2005, NAT REV MOL CELL BIO, V6, P954, DOI 10.1038/nrm1765; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Hu P, 2004, GENE DEV, V18, P3010, DOI 10.1101/gad.1250804; Huff T, 2004, J CELL SCI, V117, P5333, DOI 10.1242/jcs.01404; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Kiseleva E, 2004, J CELL SCI, V117, P2481, DOI 10.1242/jcs.01098; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; McDonald D, 2006, J CELL BIOL, V172, P541, DOI 10.1083/jcb.200507101; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Reutzel R, 2004, J STRUCT BIOL, V146, P291, DOI 10.1016/j.jsb.2003.12.006; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SAHLAS DJ, 1993, J CELL SCI, V105, P347; Schoenenberger CA, 2005, J STRUCT BIOL, V152, P157, DOI 10.1016/j.jsb.2005.09.003; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takenawa T, 2001, J CELL SCI, V114, P1801; Van Impe K, 2003, J BIOL CHEM, V278, P17945, DOI 10.1074/jbc.M209946200; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Wu XY, 2006, NAT CELL BIOL, V8, P756, DOI 10.1038/ncb1433; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	59	91	96	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7616	7623		10.1074/jbc.M607596200	http://dx.doi.org/10.1074/jbc.M607596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17220302	hybrid			2022-12-25	WOS:000245080900074
J	McCool, KW; Xu, XJ; Singer, DB; Murdoch, FE; Fritsch, MK				McCool, Kevin W.; Xu, Xiaojie; Singer, Don B.; Murdoch, Fern E.; Fritsch, Michael K.			The role of histone acetylation in regulating early gene expression patterns during early embryonic stem cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; ERYTHROID-DIFFERENTIATION; CHROMATIN DOMAIN; X-INACTIVATION; TRANSCRIPTION; MOUSE; CODE; ENHANCERS; PROTEINS; ELEMENTS	We have examined the role of histone acetylation in the very earliest steps of differentiation of mouse embryonic stem cells in response to withdrawal of leukemia inhibitory factor (LIF) as a differentiation signal. The cells undergo dramatic changes in morphology and an ordered program of gene expression changes representing differentiation to all three germ layers over the first 3-5 days of LIF withdrawal. We observed a global increase in acetylation on histone H4 and to a lesser extent on histone H3 over this time period. Treatment of the cells with trichostatin A (TSA), a histone deacetylase inhibitor, induced changes in morphology, gene expression, and histone acetylation that mimicked differentiation induced by withdrawal of LIF. We examined localized histone acetylation in the regulatory regions of genes that were transcriptionally either active in undifferentiated cells, induced during differentiation, or inactive under all treatments. There was striking concordance in the histone acetylation patterns of specific genes induced by both TSA and LIF withdrawal. Increased histone acetylation in local regions correlated best with induction of gene expression. Finally, TSA treatment did not support the maintenance or progression of differentiation. Upon removal of TSA, the cells reverted to the undifferentiated phenotype. We concluded that increased histone acetylation at specific genes played a role in their expression, but additional events are required for maintenance of differentiated gene expression and loss of the pluripotent state.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fritsch, MK (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 5250 MSC,1300 Univ Ave, Madison, WI 53706 USA.	mkfritsch@wisc.edu		MURDOCH, FERN/0000-0001-5724-9681	NIDDK NIH HHS [R01DK64243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; Cerny J, 2004, J CELL PHYSIOL, V201, P1, DOI 10.1002/jcp.20071; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; CULLEN KE, 1993, SCIENCE, V261, P203, DOI 10.1126/science.8327891; Dasen JS, 1999, CURR OPIN GENET DEV, V9, P566, DOI 10.1016/S0959-437X(99)00015-5; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Gadue P, 2005, EXP HEMATOL, V33, P955, DOI 10.1016/j.exphem.2005.06.009; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Gregory RI, 2002, J BIOL CHEM, V277, P11728, DOI 10.1074/jbc.M105775200; Hu X, 2003, P NATL ACAD SCI USA, V100, P1111, DOI 10.1073/pnas.0337404100; Huang D, 1998, DEVELOPMENT, V125, P3235; Huang DY, 2002, DEV DYNAM, V223, P353, DOI 10.1002/dvdy.10057; Huang MC, 2002, DNA CELL BIOL, V21, P561, DOI 10.1089/104454902320308933; Huebert DJ, 2005, CURR OPIN GENET DEV, V15, P476, DOI 10.1016/j.gde.2005.08.001; Im H, 2002, BIOCHEMISTRY-US, V41, P15152, DOI 10.1021/bi026786q; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Langston AW, 1997, J BIOL CHEM, V272, P2167, DOI 10.1074/jbc.272.4.2167; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Levings PP, 2006, FEBS J, V273, P746, DOI 10.1111/j.1742-4658.2005.05107.x; Lin WC, 2006, CURR OPIN GENET DEV, V16, P137, DOI 10.1016/j.gde.2006.02.002; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Long LY, 2004, GENOMICS, V83, P694, DOI 10.1016/j.ygeno.2003.09.009; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Luster TA, 2003, GENE, V323, P163, DOI 10.1016/j.gene.2003.09.019; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Ovitt CE, 1998, MOL HUM REPROD, V4, P1021, DOI 10.1093/molehr/4.11.1021; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rasmussen Theodore P, 2003, Reprod Biol Endocrinol, V1, P100, DOI 10.1186/1477-7827-1-100; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Sauter CN, 2005, EXP CELL RES, V311, P251, DOI 10.1016/j.yexcr.2005.09.005; Solter D, 2006, NAT REV GENET, V7, P319, DOI 10.1038/nrg1827; Szutorisz H, 2005, BIOESSAYS, V27, P1286, DOI 10.1002/bies.20330; Thompson JR, 1998, CELL GROWTH DIFFER, V9, P969; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041; WILES MV, 1991, DEVELOPMENT, V111, P259; Wu H, 2006, PEDIATR RES, V59, p21R, DOI 10.1203/01.pdr.0000203565.76028.2a; Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003	54	47	51	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6696	6706		10.1074/jbc.M609519200	http://dx.doi.org/10.1074/jbc.M609519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204470	hybrid			2022-12-25	WOS:000244867200079
J	Nasser, MW; Raghuwanshi, SK; Malloy, KM; Gangavarapu, P; Shim, JY; Rajarathnam, K; Richardson, RM				Nasser, Mohd W.; Raghuwanshi, Sandeep K.; Malloy, Kimberly M.; Gangavarapu, Pavani; Shim, Joong-Youn; Rajarathnam, Krishna; Richardson, Ricardo M.			CXCR1 and CXCR2 activation and regulation - Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; INTERLEUKIN-8 RECEPTOR; SIGNAL-TRANSDUCTION; CHEMOATTRACTANT RECEPTORS; CHEMOKINE RECEPTORS; CROSS-REGULATION; PHOSPHOLIPASE-D; BETA-ARRESTIN; NADPH OXIDASE; C-TERMINUS	CXCL8 (interleukin-8) interacts with two receptors, CXCR1 and CXCR2, to activate leukocytes. Upon activation, CXCR2 internalizes very rapidly relative to CXCR1 (similar to 90% versus similar to 10% after 5 min). The C termini of the receptors have been shown to be necessary for internalization but are not sufficient to explain the distinct kinetics of down-regulation. To determine the structural determinant(s) that modulate receptor internalization, various chimeric and point mutant receptors were generated by progressively exchanging specific domains or amino acids between CXCR1 and CXCR2. The receptors were stably expressed in rat basophilic leukemia 2H3 cells and characterized for receptor binding, intracellular Ca2+ mobilization, phosphoinositide hydrolysis, phosphorylation, internalization, and MAPK activation. The data herein indicate that the second extracellular loop (2ECL) of the receptors is critical for the distinct rate of internalization. Replacing the 2ECL of CXCR2 with that of CXCR1 (B(2ECL)A) or Asp(199) with its CXCR1 valine counterpart (B(D199V)A) delayed CXCR2 internalization similarly to CXCR1. Replacing Asp(199) with Asn (B-D199N) restored CXCR2 rapid internalization. Structure modeling of the 2ECL of the receptors also suggested that Asp(199) plays a critical role in stabilizing and modulating CXCR2 rapid internalization relative to CXCR1. BD199N internalized rapidly but migrated as a single phosphorylated form like CXCR1 (similar to 75 kDa), whereas B(2ECL)A and B(D199V)A showed slow and fast migrating forms like CXCR2 (similar to 45 and similar to 65 kDa, respectively) but internalized like CXCR1. These data further undermine the role of receptor oligomerization in CXCL8 receptor internalization. Like CXCR1, B(D199V)A also induced sustained ERK activation and cross-desensitized Ca2+ mobilization to CCR5 relative to BD199N and CXCR2. Altogether, the data suggest that the 2ECL of the CXCL8 receptors is important in modulating their distinct rate of down-regulation and thereby signal length and post-internalization activities.	N Carolina Cent Univ, L Chambers Biomed Biotechnol Res Inst, Durham, NC 27707 USA; N Carolina Cent Univ, Dept Biol, Durham, NC 27707 USA; Univ Texas, Dept Biochem & Mol Biol, Med Branch, Galveston, TX 77555 USA	University of North Carolina; North Carolina Central University; University of North Carolina; North Carolina Central University; University of Texas System; University of Texas Medical Branch Galveston	Richardson, RM (corresponding author), N Carolina Cent Univ, L Chambers Biomed Biotechnol Res Inst, 1801 Fayetteville St, Durham, NC 27707 USA.	mrrichardson@nccu.edu	Sawant, Kirti V/H-3778-2013; Nasser, Mohd/Y-3355-2019		NIAID NIH HHS [R01 AI069152, AI-38910, AI-069152] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069152, R01AI038910, R29AI038910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Ali H, 1996, J BIOL CHEM, V271, P3200, DOI 10.1074/jbc.271.6.3200; ALI H, 1993, J BIOL CHEM, V268, P24247; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baggiolini M, 2000, IMMUNOL REV, V177, P5, DOI 10.1034/j.1600-065X.2000.17722.x; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; Brown SL, 2006, J IMMUNOL, V177, P3242, DOI 10.4049/jimmunol.177.5.3242; Catusse J, 2003, BIOCHEM PHARMACOL, V65, P813, DOI 10.1016/S0006-2952(02)01619-2; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DING HQ, 1992, J CHEM PHYS, V97, P4309, DOI 10.1063/1.463935; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Kara E, 2006, MOL ENDOCRINOL, V20, P3014, DOI 10.1210/me.2006-0098; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Ludwig A, 2000, J IMMUNOL, V165, P1044, DOI 10.4049/jimmunol.165.2.1044; MAPLE JR, 1994, ISRAEL J CHEM, V34, P195; Matityahu E, 2002, EUR J IMMUNOL, V32, P3525, DOI 10.1002/1521-4141(200212)32:12<3525::AID-IMMU3525>3.0.CO;2-1; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nasser MW, 2005, J IMMUNOL, V174, P6927, DOI 10.4049/jimmunol.174.11.6927; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Sai JQ, 2006, J BIOL CHEM, V281, P35931, DOI 10.1074/jbc.M605883200; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; Trettel F, 2003, J BIOL CHEM, V278, P40980, DOI 10.1074/jbc.M306815200; Vaidehi N, 2006, J BIOL CHEM, V281, P27613, DOI 10.1074/jbc.M601389200; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Wilson S, 2005, J BIOL CHEM, V280, P28663, DOI 10.1074/jbc.M413475200; Zhao M, 2004, J BIOL CHEM, V279, P49259, DOI 10.1074/jbc.M405118200	48	37	37	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6906	6915		10.1074/jbc.M610289200	http://dx.doi.org/10.1074/jbc.M610289200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204468	hybrid			2022-12-25	WOS:000244867200100
J	Storm, MP; Bone, HK; Beck, CG; Bourillot, PY; Schreiber, V; Damiano, T; Nelson, A; Savatier, P; Welham, MJ				Storm, Mike P.; Bone, Heather K.; Beck, Craig G.; Bourillot, Pierre-Yves; Schreiber, Valerie; Damiano, Teresa; Nelson, Adam; Savatier, Pierre; Welham, Melanie J.			Regulation of nanog expression by phosphoinositide 3-kinase-dependent signaling in murine embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-RENEWAL; TRANSCRIPTIONAL REGULATION; MOUSE; PLURIPOTENCY; ACTIVATION; DIFFERENTIATION; PROLIFERATION; MAINTENANCE; 3-KINASE; KINASES	Embryonic stem (ES) cell pluripotency is regulated by a combination of extrinsic and intrinsic factors. Previously we have demonstrated that phosphoinositide 3-kinase (PI3K)dependent signaling is required for efficient self-renewal of murine ES cells. In the study presented here, we have investigated the downstream molecular mechanisms that contribute to the ability of PI3Ks to regulate pluripotency. We show that inhibition of PI3K activity with either pharmacological or genetic tools results in decreased expression of RNA for the homeodomain transcription factor Nanog and decreased Nanog protein levels. Inhibition of glycogen synthase kinase 3 (GSK-3) activity by PI3Ks plays a key role in regulation of Nanog expression, because blockade of GSK-3 activity effectively reversed the effects of PI3K inhibition on Nanog RNA, and protein expression and self-renewal under these circumstances were restored. Furthermore, GSK-3 mutants mimicked the effects of PI3K or GSK-3 inhibition on Nanog 'expression. Importantly, expression of an inducible form of Nanog prevented the loss of self-renewal observed upon inhibition of PI3Ks, supporting a functional relationship between PI3Ks and Nanog expression. In addition, expression of a number of putative Nanog target genes was sensitive to PI3K inhibition. Thus, the new evidence provided in this study shows that PI3K-dependent regulation of ES cell self-renewal is mediated, at least in part, by the ability of PI3K signaling to maintain Nanog expression. Regulation of GSK-3 activity by PI3Ks appears to play a key role in this process.	Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Univ Bath, Ctr Regenerat Med, Bath BA2 7AY, Avon, England; Univ Lyon, F-69003 Lyon, France; INSERM, U846, F-69500 Bron, France; Univ Leeds, Sch Chem, Leeds LS2 9JT, W Yorkshire, England	University of Bath; University of Bath; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Leeds	Welham, MJ (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.	M.J.Welham@bath.ac.uk	Storm, Mike/AAC-8733-2020; Bourillot, Pierre-Yves/M-6956-2014; SAVATIER, Pierre/J-4663-2014	Bourillot, Pierre-Yves/0000-0003-1657-8555; Nelson, Adam/0000-0003-3886-363X	Biotechnology and Biological Sciences Research Council [BB/C516528/1] Funding Source: Medline; Engineering and Physical Sciences Research Council [GR/S99419/01] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Anastassiadis K, 2002, GENE, V298, P159, DOI 10.1016/S0378-1119(02)00979-4; Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Branford WW, 2004, CURR BIOL, V14, pR341, DOI 10.1016/j.cub.2004.04.020; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Hallmann D, 2003, J BIOL CHEM, V278, P5099, DOI 10.1074/jbc.M208451200; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kuo GH, 2003, J MED CHEM, V46, P4021, DOI 10.1021/jm030115o; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nur-E-Kamal A, 2006, STEM CELLS, V24, P426, DOI 10.1634/stemcells.2005-0170; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Pritsker M, 2006, P NATL ACAD SCI USA, V103, P6946, DOI 10.1073/pnas.0509861103; Pyle AD, 2006, NAT BIOTECHNOL, V24, P344, DOI 10.1038/nbt1189; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Vallier L, 2001, P NATL ACAD SCI USA, V98, P2467, DOI 10.1073/pnas.041617198; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	54	103	118	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6265	6273		10.1074/jbc.M610906200	http://dx.doi.org/10.1074/jbc.M610906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204467	hybrid			2022-12-25	WOS:000244867200032
J	Zhang, XM; Boot-Handford, RP; Huxley-Jones, J; Forse, LN; Mould, AP; Robertson, DL; Li, L; Athiyal, M; Sarras, MP				Zhang, Xiaoming; Boot-Handford, Raymond P.; Huxley-Jones, Julie; Forse, Lorna N.; Mould, A. Paul; Robertson, David L.; Li, Li; Athiyal, Matthews; Sarras, Michael P., Jr.			The collagens of hydra provide insight into the evolution of metazoan extracellular matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE FIBRILLAR COLLAGEN; EXPRESSION; INVERTEBRATE; MORPHOGENESIS; ADHESION; LAMININ; FAMILY; FORM	A collagen-based extracellular matrix is one defining feature of all Metazoa. The thick sheet-like extracellular matrix (mesoglia) of the diploblast, hydra, has characteristics of both a basement membrane and an interstitial matrix. Several genes associated with mesoglea have been cloned including a basement membrane and fibrillar collagen and an A and B chain of laminin. Here we report the characterization of a further three fibrillar collagen genes (Hcol2, Hcol3, and Hcol5) and the partial sequence of a collagen gene with a unique structural organization consisting of multiple von Willebrand factor A domains interspersed with interrupted collagenous triple helices (Hcol6) from Hydra vulgaris. Hcol2 and -5 have major collagenous domains of classical length (similar to 1020 amino acid residues), whereas the equivalent domain in Hcol3 is shorter (969 residues). The N-propeptide of Hcol2 contains a whey acid protein four-cysteine repeat (WAP) domain, and the equivalent domain of Hcol3 contains two WAP and two von Willebrand factor A domains. Phylogenetic analyses reveal that the hydra fibrillar collagen genes form a distinct clade that appears related to the protostome/deuterostome A clade of fibrillar collagens. Data base searches reveal Hcol2, -5, and -6 are highly conserved in Hydra magnipapillata, which also provided preliminary evidence for the expression of a B-clade fibrillar collagen. All four of the H, vulgaris collagens are expressed specifically by the ectoderm. The expression pattern for Hcol2 is similar to that previously reported for Hcol1 (Deutzmann, R., Fowler, S., Zhang, X., Boone, K., Dexter, S., Boot-Handford, R. P., Rachel, R., and Sarras, M. P., Jr. (2000) Development 127, 4669 - 4680) but distinct from the pattern shared by Hcol3 and Hcol5. The characterization of multiple collagen genes in relatively simple diploblastic organisms provides new insights into the molecular evolution of collagens and the origins of the collagen-based extracellular matrix found throughout the multicellular animal kingdom.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Rosalind Franklin Univ Med & Sci, Dept Cell Biol & Anat, N Chicago, IL 60064 USA	University of Manchester; University of Kansas; University of Kansas Medical Center; Rosalind Franklin University Medical & Science	Boot-Handford, RP (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.	ray.boot-handford@manchester.ac.uk		Boot-Handford, Raymond/0000-0002-6167-8419; Mould, Paul/0000-0003-0076-6228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK065123] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK065123] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aouacheria A, 2004, J BIOL CHEM, V279, P47711, DOI 10.1074/jbc.M408950200; Aouacheria A, 2006, MOL BIOL EVOL, V23, P2288, DOI 10.1093/molbev/msl100; Ayad S, 1998, EXTRACELLULAR MATRIX, V2nd, P69; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; FELSENSTEIN JP, 1993, PHYLOGENETIC ANAL US; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; Huelsenbeck J. P., 2000, MRBAYES BAYESIAN INF; Huxley-Jones J, 2007, MATRIX BIOL, V26, P2, DOI 10.1016/j.matbio.2006.09.008; Jackson GC, 2004, J MED GENET, V41, P52, DOI 10.1136/jmg.2003.011429; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lenhoff H.M., 1983, P29; Mizuno K, 2001, MICRON, V32, P317, DOI 10.1016/S0968-4328(00)00036-6; Nichols SA, 2006, P NATL ACAD SCI USA, V103, P12451, DOI 10.1073/pnas.0604065103; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SARRAS MP, 1991, DEV BIOL, V148, P481, DOI 10.1016/0012-1606(91)90266-6; SARRAS MP, 1993, DEV BIOL, V157, P383, DOI 10.1006/dbio.1993.1143; Sarras MP, 2001, BIOESSAYS, V23, P716, DOI 10.1002/bies.1101; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; Sasaki T, 2004, J CELL BIOL, V164, P959, DOI 10.1083/jcb.200401058; Shimizu H, 2002, DEVELOPMENT, V129, P1521; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vargas-Albores F, 2004, COMP BIOCHEM PHYS B, V138, P415, DOI 10.1016/j.cbpc.2004.05.007; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; WOOD RL, 1961, BIOLOGY HYDRA, P51; Zhang XM, 2002, DEV GENES EVOL, V212, P159, DOI 10.1007/s00427-002-0225-4	32	37	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6792	6802		10.1074/jbc.M607528200	http://dx.doi.org/10.1074/jbc.M607528200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17204477	hybrid			2022-12-25	WOS:000244867200089
J	de Wit, H; Cornelisse, LN; Toonen, RFG; Verhage, M				de Wit, Heidi; Cornelisse, L. Niels; Toonen, Ruud F. G.; Verhage, Matthijs			Docking of Secretory Vesicles Is Syntaxin Dependent	PLOS ONE			English	Article								Secretory vesicles dock at the plasma membrane before they undergo fusion. Molecular docking mechanisms are poorly defined but believed to be independent of SNARE proteins. Here, we challenged this hypothesis by acute deletion of the target SNARE, syntaxin, in vertebrate neurons and neuroendocrine cells. Deletion resulted in fusion arrest in both systems. No docking defects were observed in synapses, in line with previous observations. However, a drastic reduction in morphologically docked secretory vesicles was observed in chromaffin cells. Syntaxin-deficient chromaffin cells showed a small reduction in total and plasma membrane staining for the docking factor Munc18-1, which appears insufficient to explain the drastic reduction in docking. The sub-membrane cortical actin network was unaffected by syntaxin deletion. These observations expose a docking role for syntaxin in the neuroendocrine system. Additional layers of regulation may have evolved to make syntaxin redundant for docking in highly specialized systems like synaptic active zones.	[Verhage, Matthijs] Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Funct Genom, Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Verhage, M (corresponding author), Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Funct Genom, Amsterdam, Netherlands.	matthijs@cncr.vu.nl		Toonen, Ruud/0000-0002-9900-4233; Cornelisse, Lennart Niels/0000-0001-9425-2935; verhage, matthijs/0000-0002-6085-7503	Netherlands Organization for Scientific Research (ZonMW Veni) [016-066-101, 970-10-036, 916-036-043, MW-PIO 900-01-001]; NeuroBsik Mouse Phenomics Consortium [BSIK03053]; European Commission (EU) [LSHM-CT-2005-019055]	Netherlands Organization for Scientific Research (ZonMW Veni)(Netherlands Organization for Scientific Research (NWO)); NeuroBsik Mouse Phenomics Consortium; European Commission (EU)(European CommissionEuropean Commission Joint Research Centre)	This research was supported by grants from the Netherlands Organization for Scientific Research (ZonMW Veni grant 016-066-101 to RFGT, GpD 970-10-036 to MV and HdW, ZonMW Veni Grant 916-036-043 to HdW, ZonMW Pionier MW-PIO 900-01-001 to MV), the NeuroBsik Mouse Phenomics Consortium (BSIK03053) and by the European Commission (EU Synapse project, LSHM-CT-2005-019055).	AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Borisovska M, 2005, EMBO J, V24, P2114, DOI 10.1038/sj.emboj.7600696; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Capogna M, 1997, J NEUROSCI, V17, P7190; Chieregatti E, 2002, TRAFFIC, V3, P496, DOI 10.1034/j.1600-0854.2002.30706.x; Deak F, 2004, NAT CELL BIOL, V6, P1102, DOI 10.1038/ncb1185; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Kittel RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/science.1126308; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Marsal J, 1997, P NATL ACAD SCI USA, V94, P14871, DOI 10.1073/pnas.94.26.14871; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Raciborska DA, 1998, EUR J NEUROSCI, V10, P2617, DOI 10.1046/j.1460-9568.1998.00270.x; Reist NE, 1998, J NEUROSCI, V18, P7662; Rickman C, 2004, J BIOL CHEM, V279, P12574, DOI 10.1074/jbc.M310710200; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Schutz D, 2005, EUR J NEUROSCI, V21, P2419, DOI 10.1111/j.1460-9568.2005.04095.x; Sherry DM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-54; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2006, EMBO J, V25, P955, DOI 10.1038/sj.emboj.7601003; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Toonen RF, 2006, EMBO J, V25, P3725, DOI 10.1038/sj.emboj.7601256; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Watanabe M, 2005, MOL BIOL CELL, V16, P4519, DOI 10.1091/mbc.E05-03-0252; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Weimer RM, 2006, J NEUROSCI, V26, P8040, DOI 10.1523/JNEUROSCI.2350-06.2006; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang CM, 2001, J CLIN INVEST, V107, P1311, DOI 10.1172/JCI12274; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	48	88	90	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e126	10.1371/journal.pone.0000126	http://dx.doi.org/10.1371/journal.pone.0000126			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205130	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443700020
J	McAllister, BF; Evans, AL				McAllister, Bryant F.; Evans, Amy L.			Increased Nucleotide Diversity with Transient Y Linkage in Drosophila americana	PLOS ONE			English	Article							SEXUALLY ANTAGONISTIC GENES; BACKGROUND SELECTION; GENOME EVOLUTION; SEX-CHROMOSOMES; X-CHROMOSOME; RECOMBINATION; HITCHHIKING; POLYMORPHISM; PATTERNS; MELANOGASTER	Recombination shapes nucleotide variation within genomes. Patterns are thought to arise from the local recombination landscape, influencing the degree to which neutral variation experiences hitchhiking with selected variation. This study examines DNA polymorphism along Chromosome 4 (element B) of Drosophila americana to identify effects of hitchhiking arising as a consequence of Y-linked transmission. A centromeric fusion between the X and 4(th) chromosomes segregates in natural populations of D. americana. Frequency of the X-4 fusion exhibits a strong positive correlation with latitude, which has explicit consequences for unfused 4(th) chromosomes. Unfused Chromosome 4 exists as a non-recombining Y chromosome or as an autosome proportional to the frequency of the X-4 fusion. Furthermore, Y linkage along the unfused 4 is disrupted as a function of the rate of recombination with the centromere. Inter-population and intra-chromosomal patterns of nucleotide diversity were assayed using six regions distributed along unfused 4(th) chromosomes derived from populations with different frequencies of the X-4 fusion. No difference in overall level of nucleotide diversity was detected among populations, yet variation along the chromosome exhibits a distinct pattern in relation to the X-4 fusion. Sequence diversity is inflated at loci experiencing the strongest Y linkage. These findings are inconsistent with the expected reduction in nucleotide diversity resulting from hitchhiking due to background selection or selective sweeps. In contrast, excessive polymorphism is accruing in association with transient Y linkage, and furthermore, hitchhiking with sexually antagonistic alleles is potentially responsible.	[McAllister, Bryant F.] Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA; Univ Iowa, Roy J Carver Ctr Comparat Genom, Iowa City, IA USA	University of Iowa; University of Iowa	McAllister, BF (corresponding author), Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA.	bryant-mcallister@uiowa.edu	McAllister, Bryant/A-3015-2008		National Science Foundation [DEB-0075295/0228832]; Roy J. Carver Charitable Trust [05-2045]	National Science Foundation(National Science Foundation (NSF)); Roy J. Carver Charitable Trust	This article is based upon work supported by the National Science Foundation under grant Nos. DEB-0075295/0228832 and the Roy J. Carver Charitable Trust under grant No. 05-2045.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bachtrog D, 2000, CURR BIOL, V10, P1025, DOI 10.1016/S0960-9822(00)00656-4; Bachtrog D, 2004, NAT GENET, V36, P518, DOI 10.1038/ng1347; Bachtrog D, 2002, NATURE, V416, P323, DOI 10.1038/416323a; Barton NH, 2002, GENET RES, V79, P129, DOI 10.1017/S0016672301005493; Baudry E, 2001, GENETICS, V158, P1725; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; Berlin S, 2004, P NATL ACAD SCI USA, V101, P15967, DOI 10.1073/pnas.0405126101; BLIGHT WC, 1955, THESIS WASHINGTON U; Charlesworth B, 1997, GENETICS, V145, P989; Charlesworth B, 1996, GENET RES, V68, P131, DOI 10.1017/S0016672300034029; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; Charlesworth B, 1998, MOL BIOL EVOL, V15, P538, DOI 10.1093/oxfordjournals.molbev.a025953; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Charlesworth D, 2005, HEREDITY, V95, P118, DOI 10.1038/sj.hdy.6800697; Charlesworth D, 2006, PLOS GENET, V2, P379, DOI 10.1371/journal.pgen.0020064; Cutter AD, 2003, MOL BIOL EVOL, V20, P665, DOI 10.1093/molbev/msg072; ENDLER JA, 1973, SCIENCE, V179, P243, DOI 10.1126/science.179.4070.243; Fay JC, 2000, GENETICS, V155, P1405; FELSENSTEIN J, 1974, GENETICS, V78, P737; Filatov DA, 2000, NATURE, V404, P388, DOI 10.1038/35006057; Filatov DA, 2001, MOL BIOL EVOL, V18, P1442, DOI 10.1093/oxfordjournals.molbev.a003930; FU YX, 1993, GENETICS, V133, P693; Gibson JR, 2002, P ROY SOC B-BIOL SCI, V269, P499, DOI 10.1098/rspb.2001.1863; Greenberg AJ, 2006, MOL BIOL EVOL, V23, P401, DOI 10.1093/molbev/msj045; GUBENKO IS, 1984, GENETICA, V65, P127, DOI 10.1007/BF00135277; Harr B, 2002, P NATL ACAD SCI USA, V99, P12949, DOI 10.1073/pnas.202336899; Haukoos JS, 2005, ACAD EMERG MED, V12, P360, DOI 10.1197/j.aem.2004.11.018; Hellborg L, 2004, MOL BIOL EVOL, V21, P158, DOI 10.1093/molbev/msh008; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HUDSON RR, 1992, MOL BIOL EVOL, V9, P138; HUDSON RR, 1995, GENETICS, V141, P1605; HUDSON RR, 1988, GENETICS, V120, P831; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; Innan H, 2003, GENETICS, V165, P2307; Jensen MA, 2002, GENETICS, V160, P493; Kennison J, 2000, DROSOPHILA PROTOCOLS, P111; KIKKAWA H., 1935, CYTOLOGIA, V6, P190, DOI 10.1508/cytologia.6.190; Kim Y, 2000, GENETICS, V155, P1415; KREITMAN M, 1991, GENETICS, V127, P565; Lenormand T, 2002, TRENDS ECOL EVOL, V17, P183, DOI 10.1016/S0169-5347(02)02497-7; LOZOVSKAYA ER, 1993, CHROMOSOMA, V102, P253, DOI 10.1007/BF00352399; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; McAllister BF, 1999, GENETICS, V153, P221; McAllister BF, 2000, GENETICS, V154, P1711; McAllister BF, 2003, GENETICS, V165, P1317; McAllister BF, 2002, GENOME, V45, P13, DOI 10.1139/g01-112; Nachman MW, 2001, TRENDS GENET, V17, P481, DOI 10.1016/S0168-9525(01)02409-X; Navarro A, 2002, GENETICS, V161, P849; Nordborg M, 1996, GENET RES, V67, P159, DOI 10.1017/S0016672300033619; Nordborg M, 1997, GENETICS, V146, P1501; Nurminsky DI, 1996, MOL BIOL EVOL, V13, P132, DOI 10.1093/oxfordjournals.molbev.a025551; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; RICE WR, 1987, GENETICS, V116, P161; RICE WR, 1987, EVOLUTION, V41, P911, DOI 10.1111/j.1558-5646.1987.tb05864.x; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Schafer MA, 2006, HEREDITY, V97, P291, DOI 10.1038/sj.hdy.6800860; Schlotterer C, 2002, GENETICS, V160, P753; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Scotti I, 2006, EVOLUTION, V60, P1793; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Stephan W, 1998, P NATL ACAD SCI USA, V95, P5649, DOI 10.1073/pnas.95.10.5649; Stokes ME, 2000, CATEGORICAL DATA ANA; TAJIMA F, 1989, GENETICS, V123, P597; TAJIMA F, 1989, GENETICS, V123, P585; TAJIMA F, 1983, GENETICS, V105, P437; TOMINAGA H, 1995, GENETICA, V96, P293, DOI 10.1007/BF01439583; Vieira J, 1997, CHROMOSOMA, V106, P99, DOI 10.1007/s004120050229; Vieira J, 2001, GENETICS, V158, P279; Wang W, 2004, GENETICS, V166, P1783, DOI 10.1534/genetics.166.4.1783; Wang W, 2002, SCIENCE, V295, P134, DOI 10.1126/science.1064521; WIEHE THE, 1993, MOL BIOL EVOL, V10, P842, DOI 10.1093/oxfordjournals.molbev.a040046; Yi SJ, 2000, MOL BIOL EVOL, V17, P703, DOI 10.1093/oxfordjournals.molbev.a026349; Zurovcova M, 1999, GENETICS, V153, P1709	76	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e112	10.1371/journal.pone.0000112	http://dx.doi.org/10.1371/journal.pone.0000112			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205116	gold, Green Published			2022-12-25	WOS:000207443700006
J	Appierto, V; Villani, MG; Cavadini, E; Gariboldi, M; De Cecco, L; Pierotti, MA; Lambert, JR; Reid, J; Tiberio, P; Colombo, N; Formelli, F				Appierto, V.; Villani, M. G.; Cavadini, E.; Gariboldi, M.; De Cecco, L.; Pierotti, M. A.; Lambert, J. R.; Reid, J.; Tiberio, P.; Colombo, N.; Formelli, F.			Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells	ONCOGENE			English	Article						4-HPR; retinoids; PLAB; ovarian cancer; cDNA microarray	LUNG-CARCINOMA CELLS; DRUG-ACTIVATED GENE; TUMOR AGGRESSIVENESS; RANDOMIZED-TRIAL; INDUCTION; P53; N-(4-HYDROXYPHENYL)RETINAMIDE; LINES; 4-OXO-FENRETINIDE; ASSOCIATION	Fenretinide ( 4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes. To identify genes contributing to its apoptotic activity in ovarian cancer cells, we monitored, by cDNA arrays, gene expression changes after 4-HPR exposure in A2780, a human ovarian carcinoma cell line sensitive to the retinoid. Among the differentially expressed transcripts, PLAcental Bone morphogenetic protein ( PLAB), a proapoptotic gene, was the most highly induced. In a panel of ovarian carcinoma cell lines with different 4-HPR sensitivities, PLAB upregulation was associated with cellular response to 4-HPR, its overexpression increased basal apoptosis and its silencing by small interfering RNA decreased the ability of 4-HPR to induce apoptosis. PLAB induction by 4-HPR was p53- and EGR-1 independent and was regulated, at least in part, by increased stability of PLAB mRNA. PLAB up-modulation by 4-HPR also occurred in vivo: in ascitic cells collected from patients with ovarian cancer before and after 4-HPR treatment, PLAB was upmodulated in 2/4 patients. Our results in certain ovarian cancer cell lines indicate a role for PLAB as a mediator of 4-HPR-induced apoptosis. The correlation of increased PLAB in vivo with antitumor activity remains to be established.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Fdn Ist FIRC Oncol Mol, Mol Canc Genet Grp, Milan, Italy; Univ Colorado, Dept Pathol, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO USA; Univ Milano Bicocca, Div Gynecol Oncol, European Inst Oncol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; University of Colorado System; University of Colorado Denver; IRCCS European Institute of Oncology (IEO); University of Milano-Bicocca	Formelli, F (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	franca.formelli@istitutotumori.mi.it	Appierto, Valentina/B-9325-2017; De Cecco, Loris/K-7036-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Colombo, Nicoletta/AAB-8319-2019; Gariboldi, Manuela/K-4744-2016	Appierto, Valentina/0000-0002-8726-6981; De Cecco, Loris/0000-0002-7066-473X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Gariboldi, Manuela/0000-0001-8406-165X; Reid, James/0000-0001-6997-2850				Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Appierto V, 2004, CELL DEATH DIFFER, V11, P270, DOI 10.1038/sj.cdd.4401349; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Clifford JL, 1999, CANCER RES, V59, P14; Colombo N, 2006, CANCER EPIDEM BIOMAR, V15, P1914, DOI 10.1158/1055-9965.EPI-06-0183; Cui WC, 2001, MOL BIOL REP, V28, P123, DOI 10.1023/A:1015288412047; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; FORMELLI F, 1993, CANCER RES, V53, P5374; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kadara H, 2006, CANCER BIOL THER, V5, P518, DOI 10.4161/cbt.5.5.2602; Lovat PE, 2004, ANN NY ACAD SCI, V1028, P81, DOI 10.1196/annals.1322.009; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Modlich O, 2004, CLIN CANCER RES, V10, P6418, DOI 10.1158/1078-0432.CCR-04-1031; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; OConnor PM, 1997, CANCER RES, V57, P4285; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; Perego P, 1996, CANCER RES, V56, P556; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Sharma A, 2005, GYNECOL ONCOL, V99, P58, DOI 10.1016/j.ygyno.2005.05.024; Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008-5472.CAN-05-1585; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Villani MG, 2006, CANCER RES, V66, P3238, DOI 10.1158/0008-5472.CAN-05-3362; Villani MG, 2004, CLIN CANCER RES, V10, P6265, DOI 10.1158/1078-0432.CCR-04-0655; Wang HT, 2001, CANCER RES, V61, P5102; Wei JS, 2005, ONCOGENE, V24, P7976, DOI 10.1038/sj.onc.1208947; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226	41	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3952	3962		10.1038/sj.onc.1210171	http://dx.doi.org/10.1038/sj.onc.1210171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213814				2022-12-25	WOS:000247144500005
J	Scholl, I; Ackermann, U; Ozdemir, C; Blumer, N; Dicke, T; Sel, S; Sel, S; Wegmann, M; Szalai, K; Knittelfelder, R; Untersmayr, E; Scheiner, O; Garn, H; Jensen-Jarolim, E; Renz, H				Schoell, Isabella; Ackermann, Ute; Ozdemir, Cevdet; Bluemer, Nicole; Dicke, Tanja; Sel, Serdar; Sel, Sarper; Wegmann, Michael; Szalai, Krisztina; Knittelfelder, Regina; Untersmayr, Eva; Scheiner, Otto; Garn, Holger; Jensen-Jarolim, Erika; Renz, Harald			Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring	FASEB JOURNAL			English	Article						sensitization against food; sucralfate; digestion; children; lactation	BREAST-MILK; HYPERSENSITIVITY; IMMUNIZATION; SUCRALFATE; CHEMOKINES; EXPOSURE; PROTEIN; CELLS; MICE	The treatment of dyspeptic disorders with anti-acids leads to an increased risk of sensitization against food allergens. As these drugs are taken by 30-50% of pregnant women due to reflux and heartburn, we aimed here to investigate the impact of maternal therapy with anti-acids on the immune response in the offspring in a murine model. Codfish extract as model allergen was fed with or without sucralfate, an anti-acid drug, to pregnant BALB/c mice during pregnancy and lactation. These mothers developed a codfish-specific allergic response shown as high IgG1 and IgE antibody levels and positive skin tests. In the next step we analyzed whether this maternal sensitization impacts a subsequent sensitization in the offspring. Indeed, in stimulated splenocytes of these offspring we found a relative Th2-dominance, because the Th1- and T-regulatory cytokines were significantly suppressed. Our data provide evidence that the anti-acid drug sucralfate supports sensitization against food in pregnant mice and favors a Th2-milieu in their offspring. From these results we propose that anti-acid treatment during pregnancy could be responsible for the increasing number of sensitizations against food allergens in young infants.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Hosp Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; Marmara Univ, Sch Med, Pediat Allergy & Immunol Div, Istanbul, Turkey	Medical University of Vienna; Marmara University	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Dept Pathophysiol, Wahringer Gurtel, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Ozdemir, Cevdet/X-5856-2018; Jensen-Jarolim, Erika/C-5120-2018; Untersmayr, Eva/GRY-4470-2022	Ozdemir, Cevdet/0000-0002-9284-4520; Jensen-Jarolim, Erika/0000-0003-4019-5765; Garn, Holger/0000-0002-5178-4023; Wegmann, Michael/0000-0002-1658-1554; Untersmayr, Eva/0000-0002-1963-499X	Austrian Science Fund FWF [H 220, F 1808] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; BARON TH, 1993, ANN INTERN MED, V118, P366, DOI 10.7326/0003-4819-118-5-199303010-00008; Bauer M, 2002, AM J OBSTET GYNECOL, V186, P117, DOI 10.1067/mob.2002.118306; Bednar-Tantscher E, 2001, INT ARCH ALLERGY IMM, V126, P300, DOI 10.1159/000049527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Cogswell JJ, 2000, CLIN EXP ALLERGY, V30, P1; FISHER RS, 1978, AM J PHYSIOL, V234, pE243, DOI 10.1152/ajpendo.1978.234.3.E243; Hawrylowicz CM, 2005, J EXP MED, V202, P1459, DOI 10.1084/jem.20052211; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Keski-Nisula L, 2003, J REPROD IMMUNOL, V60, P25, DOI 10.1016/S0165-0378(03)00079-2; Kruse A, 2002, BIOL REPROD, V66, P333, DOI 10.1095/biolreprod66.2.333; Michie CA, 1998, EUR CYTOKINE NETW, V9, P123; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P117; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P103; Ranchet GGO., 1990, G ITAL OBSTET GINECO, P1; Richter JE, 2005, ALIMENT PHARM THER, V22, P749, DOI 10.1111/j.1365-2036.2005.02654.x; Richter JE, 2003, GASTROENTEROL CLIN N, V32, P235, DOI 10.1016/S0889-8553(02)00065-1; Schoell I., 2002, Clinical and Experimental Allergy, V32, P1583, DOI 10.1046/j.1365-2222.2002.01527.x; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Takahata Y, 2003, ACTA PAEDIATR, V92, P659, DOI 10.1080/08035250310002614; Thornton CA, 2003, CLIN EXP ALLERGY, V33, P306, DOI 10.1046/j.1365-2222.2003.01614.x; Thornton Catherine A., 2002, Clinical and Experimental Allergy, V32, P1537, DOI 10.1046/j.1365-2222.2002.01543.x; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39; WALDEGRAVE W, 1986, J OFFICIEL COMMUNA L, V358, P1; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	35	57	60	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1264	1270		10.1096/fj.06-7223com	http://dx.doi.org/10.1096/fj.06-7223com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227952	Green Accepted			2022-12-25	WOS:000245650400030
J	El-Hallous, E; Sasaki, T; Hubmacher, D; Getie, M; Tiedemann, K; Brinckmann, J; Batge, B; Davis, EC; Reinhardt, DP				El-Hallous, Ehab; Sasaki, Takako; Hubmacher, Dirk; Getie, Melkamu; Tiedemann, Kerstin; Brinckmann, Juergen; Baetge, Boris; Davis, Elaine C.; Reinhardt, Dieter P.			Fibrillin-1 interactions with fibulins depend on the first hybrid domain and provide an adaptor function to tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; HONEYCOMB RETINAL DYSTROPHY; MARFAN-SYNDROME; CALCIUM-BINDING; CUTIS LAXA; ELASTIC FIBERS; IN-VIVO; GENE; MICROFIBRILS; EXPRESSION	Fibrillin-containing microfibrils in elastic and nonelastic extracellular matrices play important structural and functional roles in various tissues, including blood vessels, lung, skin, and bone. Microfibrils are supramolecular aggregates of several protein and nonprotein components. Recently, a large region in the N-terminal portion of fibrillin-1 was characterized as a multifunctional protein interaction site, including binding sites for fibulin-2 and -5 among others. Using a panel of recombinant fibrillin-1 swapped domain and deletion fragments, we demonstrate here that the conserved first hybrid domain in fibrillin-1 is essential for binding to fibulin-2, -4, and -5. Fibulin-3 and various isoforms of fibulin-1 did not interact with fibrillin-1. Although the first hybrid domain in fibrillin-1 is located in close vicinity to the self-assembly epitope, binding of fibulin-2, -4, and -5 did not interfere with self-assembly. However, these fibulins can associate with microfibrils at various levels of maturity. Formation of ternary complexes between fibrillin-1, fibulins, and tropoelastin demonstrated that fibulin-2 and -5 but much less fibulin-4, are able to act as molecular adaptors between fibrillin-1 and tropoelastin.	Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Div Biomed Sci, Montreal, PQ H3A 2B2, Canada; Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	McGill University; University of Lubeck; University of Lubeck; Max Planck Society	Reinhardt, DP (corresponding author), Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada.	dieter.reinhardt@mcgill.ca	Hubmacher, Dirk/AAE-1875-2020; Reinhardt, Dieter P/A-3102-2008; Davis, Elaine/F-3449-2012; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; Hubmacher, Dirk/0000-0003-1569-9451; El-Hallous, Ehab/0000-0003-0189-3720				Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Brinckmann J, 2005, ARTHRITIS RES THER, V7, pR1221, DOI 10.1186/ar1813; Cain SA, 2005, J BIOL CHEM, V280, P30526, DOI 10.1074/jbc.M501390200; Carta L, 2006, J BIOL CHEM, V281, P8016, DOI 10.1074/jbc.M511599200; Chaudhry SS, 2001, HUM MOL GENET, V10, P835, DOI 10.1093/hmg/10.8.835; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Freeman LJ, 2005, BIOCHEM J, V388, P1, DOI 10.1042/BJ20050368; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Katsanis N, 2000, HUM GENET, V106, P66, DOI 10.1007/s004390051011; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KIELTY CM, 1994, MATRIX BIOL, V14, P191, DOI 10.1016/0945-053X(94)90008-6; Kielty CM, 2002, J CELL SCI, V115, P2817; Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Raghunath M, 1999, J INVEST DERMATOL, V112, P97, DOI 10.1046/j.1523-1747.1999.00483.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Robinson PN, 2006, J MED GENET, V43, P769, DOI 10.1136/jmg.2005.039669; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Tiedemann K, 2005, J BIOL CHEM, V280, P11404, DOI 10.1074/jbc.M409882200; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHENG Q, 2006, IN PRESS J INVEST DE	65	89	95	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8935	8946		10.1074/jbc.M608204200	http://dx.doi.org/10.1074/jbc.M608204200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255108	hybrid, Green Published			2022-12-25	WOS:000245780300040
J	Koizumi, S; Gong, PF; Suzuki, K; Murata, M				Koizumi, Shinji; Gong, Pengfei; Suzuki, Kaoru; Murata, Mie			Cadmium-responsive element of the human heme oxygenase-1 gene mediates heat shock factor 1-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MTF-1; METAL RESPONSE; HUMAN-CELLS; EXPRESSION; PROMOTER; IDENTIFICATION; REPRESSOR; INTERACTS; BINDING; BACH1	Transcription of a number of mammalian genes is activated by heavy metals, but mechanisms of signaling and transcriptional regulation are not well understood. From a comparison of heavy metal responses of several human genes, it was noted that the heme oxygenase-1 (HO-1) gene is quite similar in the spectrum of metal response and induction kinetics to the heat shock protein 70 (HSP70) gene, suggesting a common regulatory mechanism shared by these genes. The cadmium-responsive element (CdRE) known to be responsible for the metal regulation of ho-1 formed complexes with proteins from heavy metal-treated HeLa cells in an electrophoretic mobility shift assay (EMSA). These complexes were indistinguishable in mobility from those formed by the heat shock factor 1 (HSF1) and the heat shock element involved in hsp70 regulation, suggesting the involvement of HSF1 also in the CdRE complexes. Competitive EMSA and supershift analysis with an anti-HSF1 antibody revealed that HSF1 was in fact a component of the CdRE complexes. A fine analysis on the affinity of HSF1 to a series of mutant CdRE sequences showed that HSF1 recognizes a sequence motif TnCTAGA. Transient transfection analysis with overexpressed recombinant HSF1 demonstrated that CdRE has HSF1-dependent enhancer-like activity that requires direct binding of HSF1. In the absence of overexpressed HSF1, however, CdRE by itself was insufficient to mediate heavy metal-induced transcription, suggesting requirement of additional regulatory sequences. The finding that HSF1 is directly involved in the regulation of ho-1 with an anti-oxidative role revealed a new aspect of the biological defense mechanism.	Natl Inst Occupat Safety & Hlth, Mechanism Hlth Effect Res Grp, Tama Ku, Kawasaki, Kanagawa 2148585, Japan		Koizumi, S (corresponding author), Natl Inst Occupat Safety & Hlth, Mechanism Hlth Effect Res Grp, Tama Ku, 6-21-1,Ngao, Kawasaki, Kanagawa 2148585, Japan.	koizumi@h.jniosh.go.jp						Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EPNER DE, 1991, J CELL PHYSIOL, V148, P68, DOI 10.1002/jcp.1041480109; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; Murata M, 1999, J CELL PHYSIOL, V180, P105, DOI 10.1002/(SICI)1097-4652(199907)180:1<105::AID-JCP12>3.0.CO;2-5; PEI J, 1990, J BIOL CHEM, V265, P14061; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2003, J BIOL CHEM, V278, P31879, DOI 10.1074/jbc.M302138200; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Sikorski EM, 2006, J BIOL CHEM, V281, P24423, DOI 10.1074/jbc.M602287200; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Uenishi R, 2006, BIOCHEM BIOPH RES CO, V341, P1072, DOI 10.1016/j.bbrc.2006.01.066; Uenishi R, 2005, J HEALTH SCI, V51, P242, DOI 10.1248/jhs.51.242; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Yamada H, 2002, IND HEALTH, V40, P159, DOI 10.2486/indhealth.40.159	23	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8715	8723		10.1074/jbc.M609427200	http://dx.doi.org/10.1074/jbc.M609427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244614	hybrid			2022-12-25	WOS:000245780300017
J	Bouzakri, K; Zierath, JR				Bouzakri, Karim; Zierath, Juleen R.			MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; RNA INTERFERENCE; KINASE; ACTIVATION; CELLS; RISK; IDENTIFICATION; PATHOGENESIS; EXPRESSION; GLUCOSE	Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-alpha-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-a-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-a-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-alpha. Depletion of MAP4K4 also prevented TNF-alpha-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-alpha-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-a-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAIP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake.	Karolinska Univ Hosp, Dept Mol Med & Surg, Karolinska Inst, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Zierath, JR (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Sect Integrat Physiol, Von Eulers Vag 4,4th Fl, S-17177 Stockholm, Sweden.	Juleen.Zierath@ki.se		Zierath, Juleen/0000-0001-6891-7497				Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Bouzakri K, 2004, DIABETOLOGIA, V47, P1314, DOI 10.1007/s00125-004-1428-1; Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEINGOLD KR, 1992, DIABETES, V41, P97, DOI 10.2337/diab.41.2.S97; Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; Mack KD, 2005, IMMUNOL LETT, V96, P129, DOI 10.1016/j.imlet.2004.08.004; Mishima Y, 2001, DIABETES RES CLIN PR, V52, P119, DOI 10.1016/S0168-8227(00)00247-3; Plomgaard P, 2005, DIABETES, V54, P2939, DOI 10.2337/diabetes.54.10.2939; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Winkler G, 1998, DIABETES CARE, V21, P1778, DOI 10.2337/diacare.21.10.1778; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; YKIJARVINEN H, 1995, DIABETOLOGIA, V38, P1378, DOI 10.1007/BF00400597; Zohn IE, 2006, CELL, V125, P957, DOI 10.1016/j.cell.2006.03.048	26	98	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7783	7789		10.1074/jbc.M608602200	http://dx.doi.org/10.1074/jbc.M608602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227768	hybrid			2022-12-25	WOS:000245081000006
J	Fiala, KA; Hypes, CD; Suo, ZC				Fiala, Kevin A.; Hypes, Cameron D.; Suo, Zucai			Mechanism of abasic lesion bypass catalyzed by a Y-family DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS P2; NUCLEOTIDE INCORPORATION OPPOSITE; DUPLEX DNA; DEOXYRIBONUCLEIC ACID; ALPHA-DEOXYADENOSINE; LOW FIDELITY; SITE; ETA; IV; CONFORMATION	The 3 million-base pair genome of Sulfolobus solfataricus likely undergoes depurination/depyrimidination frequently in vivo. These unrepaired abasic lesions are expected to be bypassed by Dpo4, the only Y-family DNA polymerase from S. solfataricus. Interestingly, these error-prone Y-family enzymes have been shown to be physiologically vital in reducing the potentially negative consequences of DNA damage while paradoxically promoting carcinogenesis. Here we used Dpo4 as a model Y-family polymerase to establish the mechanistic basis for DNA lesion bypass. While showing efficient bypass, Dpo4 paused when incorporating nucleotides directly opposite and one position downstream from an abasic lesion because of a drop of several orders of magnitude in catalytic efficiency. Moreover, in disagreement with a previous structural report, Dpo4-catalyzed abasic bypass involves robust competition between the A-rule and the lesion loop-out mechanism and is governed by the local DNA sequence. Analysis of the strong pause sites revealed biphasic kinetics for incorporation indicating that Dpo4 primarily formed a nonproductive complex with DNA that converted slowly to a productive complex. These strong pause sites are mutational hot spots with the embedded lesion even affecting the efficiency of five to six downstream incorporations. Our results suggest that abasic lesion bypass requires tight regulation to maintain genomic stability.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Suo, ZC (corresponding author), 740 Biol Sci,484 W 12th Ave, Columbus, OH 43210 USA.	suo.3@osu.edu						Ayadi L, 1999, BIOPHYS J, V77, P3218, DOI 10.1016/S0006-3495(99)77152-3; Barsky D, 2000, NUCLEIC ACIDS RES, V28, P2613, DOI 10.1093/nar/28.13.2613; Batra VK, 2006, STRUCTURE, V14, P757, DOI 10.1016/j.str.2006.01.011; Beger RD, 1998, J BIOL CHEM, V273, P15565, DOI 10.1074/jbc.273.25.15565; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carlson KD, 2005, MOL CELL BIOL, V25, P2169, DOI 10.1128/MCB.25.6.2169-2176.2005; Cramer J, 2005, J BIOL CHEM, V280, P40552, DOI 10.1074/jbc.M504481200; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Fiala KA, 2007, J MOL BIOL, V365, P590, DOI 10.1016/j.jmb.2006.10.008; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; GROLJER I, 1995, J BIOL CHEM, V270, P22980; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; IDE H, 1995, BIOCHEMISTRY-US, V34, P6947, DOI 10.1021/bi00021a006; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shimizu H, 1997, NUCLEIC ACIDS RES, V25, P597, DOI 10.1093/nar/25.3.597; STRAUSS B, 1982, BIOCHIMIE, V64, P829, DOI 10.1016/S0300-9084(82)80138-7; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; Washington MT, 2003, P NATL ACAD SCI USA, V100, P12093, DOI 10.1073/pnas.2134223100; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; WILDE JA, 1989, J AM CHEM SOC, V111, P1894, DOI 10.1021/ja00187a062; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2002, J BIOL CHEM, V277, P44582, DOI 10.1074/jbc.M207297200	42	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8188	8198		10.1074/jbc.M610718200	http://dx.doi.org/10.1074/jbc.M610718200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17210571	hybrid			2022-12-25	WOS:000245081000051
J	Gioannini, TL; Teghanemt, A; Zhang, DS; Prohinar, P; Levis, EN; Munford, RS; Weiss, JP				Gioannini, Theresa L.; Teghanemt, Athmane; Zhang, DeSheng; Prohinar, Polonca; Levis, Erika N.; Munford, Robert S.; Weiss, Jerrold P.			Endotoxin-binding proteins modulate the susceptibility of bacterial endotoxin to deacylation by acyloxyacyl hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; ESCHERICHIA-COLI; EXTRACELLULAR COMPONENTS; NEISSERIA-MENINGITIDIS; MONOMERIC ENDOTOXIN; LEUKOCYTE ENZYME; CELL ACTIVATION; LPS; MD-2; COMPLEXES	Acyloxyacyl hydrolase (AOAH) is an eukaryotic lipase that partially deacylates and detoxifies Gram-negative bacterial lipopolysaccharides and lipooligosaccharides (LPSs or LOSs, endotoxin) within intact cells and inflammatory fluids. In cell lysates or as purified enzyme, in contrast, detergent is required for AOAH to act on LPS or LOS (Erwin, A. L., and Munford, R. S. (1990) J. BioL Chem. 265, 16444-16449 and Katz, S. S., Weinrauch, Y., Munford, R. S., Elsbach, P., and Weiss, J. (1999) 1. BioL Chem. 274, 36579-36584). We speculated that the sequential interactions of endotoxin (E) with endotoxin-binding proteins (lipopolysaccharide-binding protein (LBP), CD14, and MD-2) might produce changes in endotoxin presentation that would allow AOAH greater access to its substrate, lipid A. To test this hypothesis, we measured the activity of purified AOAH against isolated, metabolically labeled meningococcal LOS and Escherichia coli LPS that were presented either as aggregates (LOSagg or LPSagg) +/- LBP or as monomeric protein (sCD14 or MD-2)-endotoxin complexes. Up to 100-fold differences in the efficiency of endotoxin deacylation by AOAH were observed, with the following rank order of susceptibility to AOAH: E:sCD14 >= endotoxin aggregates (E-agg):LBP (molar ratio of E/LBP 100:1) >> E-agg, E-agg:LBP (E/LBP similar to 1, mol/mol), or E:MD-2. AOAH treatment of LOS-sCD14 produced partially deacylated LOS still complexed with sCD14. The underacylated LOS complexed to sCD14 transferred to MD-2 and thus formed a complex capable of preventing TLR4 activation. These findings strongly suggest that LBP- and CD14-dependent extraction and transfer of endotoxin monomers are accompanied by increased exposure of fatty acyl chains within lipid A and that the acyl chains are then sequestered when LOS binds MD-2. The susceptibility of the monomeric endotoxin-CD14 complex to AOAH may help constrain endotoxin-induced TLR4 activation when endotoxin and membrane CD14 are present in excess of MD-2/TLR-4.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Coralville, IA 52241 USA; Vet Affairs Med Ctr, Inflammat Program, Coralville, IA 52241 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gioannini, TL (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Oakdale Res Campus,2501 Crosspk Rd, Coralville, IA 52241 USA.	theresa-gioannini@uiowa.edu		Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059372, R56AI018188, R01AI018188, R37AI018188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI59372, AI18188] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Coats SR, 2005, J IMMUNOL, V175, P4490, DOI 10.4049/jimmunol.175.7.4490; Darveau RP, 1998, CURR OPIN MICROBIOL, V1, P36, DOI 10.1016/S1369-5274(98)80140-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; Feulner JA, 2004, INFECT IMMUN, V72, P3171, DOI 10.1128/IAI.72.6.3171-3178.2004; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; Gioannini TL, 2005, J ENDOTOXIN RES, V11, P117, DOI 10.1179/096805105X35198; Gioannini TL, 2003, J ENDOTOXIN RES, V9, P401, DOI 10.1179/096805103225002773; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Gutsmann T, 2001, BIOL CHEM, V382, P425, DOI 10.1515/BC.2001.052; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; Hamann L, 2005, INFECT IMMUN, V73, P193, DOI 10.1128/IAI.73.1.193-200.2005; Iovine N, 2002, J BIOL CHEM, V277, P7970, DOI 10.1074/jbc.M109622200; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lu MF, 2005, NAT IMMUNOL, V6, P989, DOI 10.1038/ni1246; Lu MF, 2003, J EXP MED, V197, P1745, DOI 10.1084/jem.20030420; LUCHI M, 1993, J IMMUNOL, V151, P959; MUNFORD RS, 1986, METHOD FIND EXP CLIN, V8, P63; Munford RS, 2005, J ENDOTOXIN RES, V11, P69, DOI 10.1179/096805105X35161; MUNFORD RS, 1992, METHOD ENZYMOL, V209, P485; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; Post DMB, 2005, J BIOL CHEM, V280, P38383, DOI 10.1074/jbc.M508063200; Prohinar P, 2007, J BIOL CHEM, V282, P1010, DOI 10.1074/jbc.M609400200; RIEDO FX, 1990, J IMMUNOL, V144, P3506; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; STAAB JF, 1994, J BIOL CHEM, V269, P23736; Teghanemt A, 2005, J IMMUNOL, V175, P4669, DOI 10.4049/jimmunol.175.7.4669; Thompson PA, 2003, J BIOL CHEM, V278, P28367, DOI 10.1074/jbc.M302921200; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; Weiss J, 2003, BIOCHEM SOC T, V31, P785, DOI 10.1042/BST0310785; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	46	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7877	7884		10.1074/jbc.M605031200	http://dx.doi.org/10.1074/jbc.M605031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17227775	hybrid			2022-12-25	WOS:000245081000017
J	Sharma, M; Henderson, BR				Sharma, Manisha; Henderson, Beric R.			IQ-domain GTPase-activating protein 1 regulates beta-catenin at membrane ruffles and its role in macropinocytosis of N-cadherin and adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; IQGAP1; APC; ENDOCYTOSIS; CDC42; RAC1; LOCALIZATION; ADHESION; FIBROBLASTS; EXPRESSION	beta-Catenin is an integral component of E-cadherin dependent cell-cell junctions. Here we show that beta-catenin co-localizes with IQ-domain GTPase-activating protein 1 (IQGAP1), adenomatous polyposis coli (APC), and N-cadherin at actin-positive membrane ruffles in NIH 3T3 fibroblasts. We used deletion mapping to identify the membrane ruffle-targeting region of beta-catenin, localizing it to amino acids 47-217, which overlap the IQGAP1 binding site. Knockdown by small interference RNA (siRNA) revealed IQGAP I-dependent membrane targeting of beta-catenin, APC, and N-cadherin. Transient overexpression of IQGAP1 or N-cadherin increased beta-catenin at membrane ruffles. IQGAP1/APC regulates cell migration, and using a wound healing assay we demonstrate that siRNA-mediated loss of beta-catenin also caused a modest reduction in the rate of cell migration. More significantly, we discovered that beta-catenin is internalized by Arf6-dependent macropinocytosis near sites of membrane ruffling. The beta-catenin macropinosomes co-stained for APC, N-cadherin, and to a lesser extent IQGAP1, and internalization of each binding partner was abrogated by siRNA-dependent knockdown of beta-catenin. In addition, beta-catenin macropinosomes co-localized with the lysosomal marker, lysosome associated membrane protein 1, consistent with their recycling by the late endosomal machinery. Our findings expand on current knowledge of beta-catenin function. We propose that in motile cells beta-catenin is recruited by IQGAP1 and N-cadherin to active membrane ruffles, wherein beta-catenin mediates the internalization and possible recycling of the membrane-associated proteins N-cadherin and APC.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au		Sharma, Manisha/0000-0003-1892-9865				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Cardelli J, 2001, TRAFFIC, V2, P311, DOI 10.1034/j.1600-0854.2001.002005311.x; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Le Stunff H, 2000, BIOCHEM J, V352, P491, DOI 10.1042/0264-6021:3520491; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Pece S, 2002, NAT CELL BIOL, V4, pE72, DOI 10.1038/ncb0402-e72; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schafer DA, 2000, TRAFFIC, V1, P892; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	50	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8545	8556		10.1074/jbc.M610272200	http://dx.doi.org/10.1074/jbc.M610272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17255093	hybrid			2022-12-25	WOS:000245081000086
J	Whittaker, MM; Pan, HY; Yukl, ET; Whittaker, JW				Whittaker, Mei M.; Pan, Heng-Yen; Yukl, Erik T.; Whittaker, James W.			Burst kinetics and redox transformations of the active site manganese ion in oxalate oxidase - Implications for the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; BACILLUS-SUBTILIS; DECARBOXYLASE REACTION; ESCHERICHIA-COLI; PHOTOSYSTEM-II; CARBON-DIOXIDE; MN CLUSTER; METAL-ION; BARLEY; PURIFICATION	Oxalate oxidase (EC 1.2.3.4) catalyzes the oxidative cleavage of oxalate to carbon dioxide and hydrogen peroxide. In this study, unusual nonstoichiometric burst kinetics of the steady state reaction were observed and analyzed in detail, revealing that a reversible inactivation process occurs during turnover, associated with a slow isomerization of the substrate complex. We have investigated the underlying molecular mechanism of this kinetic behavior by preparing recombinant barley oxalate oxidase in three distinct oxidation states (Mn(II), Mn(III), and Mn(IV)) and producing a nonglycosylated variant for detailed biochemical and spectroscopic characterization. Surprisingly, the fully reduced Mn(II) form, which represents the majority of the as-isolated native enzyme, lacks oxalate oxidase activity, but the activity is restored by oxidation of the metal center to either Mn(III) or Mn(IV) forms. All three oxidation states appear to interconvert under turnover conditions, and the steady state activity of the enzyme is determined by a balance between activation and inactivation processes. In O-2-saturated buffer, a turnover-based redox modification of the enzyme forms a novel superoxidized mononuclear Mn(IV) biological complex. An oxalate activation role for the catalytic metal ion is proposed based on these results.	Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA	Oregon Health & Science University	Whittaker, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	jim@ebs.ogi.edu		Yukl, Erik/0000-0001-6519-6938	NIGMS NIH HHS [GM42680] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042680] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALBERTY RA, 1995, J PHYS CHEM-US, V99, P11028, DOI 10.1021/j100027a051; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Badarau A, 2006, BIOCHEMISTRY-US, V45, P11012, DOI 10.1021/bi0610146; Bernier F, 2001, PLANT PHYSIOL BIOCH, V39, P545, DOI 10.1016/S0981-9428(01)01285-2; Campbell KA, 2000, J AM CHEM SOC, V122, P3754, DOI 10.1021/ja000142t; Chang CH, 2004, J BIOL CHEM, V279, P52840, DOI 10.1074/jbc.M402345200; Cho M, 2004, APPL ENVIRON MICROB, V70, P1129, DOI 10.1128/AEM.70.2.1129-1134.2004; Escutia MR, 2005, APPL ENVIRON MICROB, V71, P3608, DOI 10.1128/AEM.71.7.3608-3616.2005; Gennaro A, 1996, J AM CHEM SOC, V118, P7190, DOI 10.1021/ja960605o; GREENWOOD NN, 1984, CHEM ELEMENTS, P8; HAYNES LV, 1967, ANAL CHEM, V39, P332, DOI 10.1021/ac60247a013; Hislop KA, 1999, ENVIRON SCI TECHNOL, V33, P3119, DOI 10.1021/es9810134; IVANCICH A, 1995, BIOCHEMISTRY-US, V34, P6628, DOI 10.1021/bi00020a008; Just VJ, 2004, J BIOL CHEM, V279, P19867, DOI 10.1074/jbc.M313820200; KESSISSOGLOU DP, 1987, INORG CHEM, V26, P2487, DOI 10.1021/ic00262a030; Kotsira VP, 1997, ARCH BIOCHEM BIOPHYS, V340, P239, DOI 10.1006/abbi.1997.9896; KOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P743; LANE BG, 1994, FASEB J, V8, P294, DOI 10.1096/fasebj.8.3.8143935; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCELVOY JP, 2006, CHEM REV, V106, P4455; Messinger J, 2000, BBA-BIOENERGETICS, V1459, P481, DOI 10.1016/S0005-2728(00)00187-0; Muthusamy M, 2006, BIOCHEMISTRY-US, V45, P10667, DOI 10.1021/bi060460q; OHLSSON JT, 1974, BIOCHIM BIOPHYS ACTA, V350, P48, DOI 10.1016/0005-2744(74)90201-0; Opaleye O, 2006, J BIOL CHEM, V281, P6428, DOI 10.1074/jbc.M510256200; PAGE MGP, 1993, BIOCHEM J, V295, P295, DOI 10.1042/bj2950295; Parsell TH, 2006, J AM CHEM SOC, V128, P8728, DOI 10.1021/ja062332v; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; REISFELD MJ, 1971, J MOL SPECTROSC, V39, P8, DOI 10.1016/0022-2852(71)90270-0; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; SEGEL IH, 1975, ENZYME KINETICS, P28; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; Svedruzic D, 2005, ARCH BIOCHEM BIOPHYS, V433, P176, DOI 10.1016/j.abb.2004.08.032; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; Vineyard D, 2006, BIOCHEMISTRY-US, V45, P11432, DOI 10.1021/bi060809+; WAGMAN DD, 1982, J PHYS CHEM REF D S2, V11, P83; WALEY SG, 1991, BIOCHEM J, V279, P87, DOI 10.1042/bj2790087; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4466; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker MM, 1996, BIOCHEMISTRY-US, V35, P6762, DOI 10.1021/bi960088m; Whittaker MM, 2003, EUR J BIOCHEM, V270, P1102, DOI 10.1046/j.1432-1033.2003.03459.x; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; Woo EJ, 1998, FEBS LETT, V437, P87, DOI 10.1016/S0014-5793(98)01203-4; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; Zhou FS, 1998, PLANT PHYSIOL, V117, P33, DOI 10.1104/pp.117.1.33	47	29	30	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7011	7023		10.1074/jbc.M609374200	http://dx.doi.org/10.1074/jbc.M609374200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17210574	hybrid			2022-12-25	WOS:000245080900013
J	Dahl, R; Iyer, SR; Owens, KS; Cuylear, DD; Simon, MC				Dahl, Richard; Iyer, Sangeeta R.; Owens, Kristin S.; Cuylear, Dorothy D.; Simon, M. Celeste			The transcriptional repressor GFI-1 antagonizes PU.1 activity through protein-protein lnteraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; COLONY-STIMULATING FACTOR; T-CELL LYMPHOMAGENESIS; C-JUN; LINEAGE COMMITMENT; FACTOR-RECEPTOR; C/EBP-ALPHA; DNA-BINDING; EXPRESSION; DIFFERENTIATION	Mice lacking the zinc finger transcriptional repressor protein GFI-1 are neutropenic. These mice generate abnormal immature myeloid cells exhibiting characteristics of both macrophages and granulocytes. Furthermore, Gfi-1(-/-) mice are highly susceptible to bacterial infection. Interestingly, Gfi-1(-/-) myeloid cells overexpress target genes of the PU. I transcription factor such as the macrophage colony-stimulating factor receptor and PU.1 itself. We therefore determined whether GFI-1 modulates the transcriptional activity of PU.1. Our data demonstrate that GFI-1 physically interacts with PU.1, repressing PU.1-dependent transcription. This repression is functionally significant, as GFI-1 blocked PU.1-induced macrophage differentiation of a multipotential hematopoietic progenitor cell line. Retroviral expression of GFI-1 in primary murine hematopoietic progenitors increased granulocyte differentiation at the expense of macrophage differentiation. We interbred Gfi-1(+/-) and PU.1(+/-) mice and observed that heterozygosity at the PU.I locus partially rescued the Gfi-1(-/-) mixed myeloid lineage phenotype, but failed to restore granulocyte differentiation. Our data demonstrate that GFI-1 represses PUA activity and that lack of this repression in Gfi-1(-/-) myeloid cells contributes to the observed mixed lineage phenotype.	Univ New Mexico, Canc Res Facil, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of New Mexico; University of New Mexico's Health Sciences Center; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Dahl, R (corresponding author), Univ New Mexico, Canc Res Facil, Dept Internal Med, Hlth Sci Ctr, 915 Camino Salud,CRF 117, Albuquerque, NM 87131 USA.	RDahl@salud.unm.edu	Simon, Celeste/AAG-3941-2021	Dahl, Richard/0000-0002-6341-5604	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL076595] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [T32HL076595, T35 HL076595] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aittomaki S, 2002, BLOOD, V100, P1078, DOI 10.1182/blood-2001-12-0236; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Fiolka K, 2006, EMBO REP, V7, P326, DOI 10.1038/sj.embor.7400618; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Perkel JM, 1998, J IMMUNOL, V160, P241; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Yucel R, 2004, J BIOL CHEM, V279, P40906, DOI 10.1074/jbc.M400808200; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	40	62	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6473	6483		10.1074/jbc.M607613200	http://dx.doi.org/10.1074/jbc.M607613200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197705	hybrid, Green Accepted			2022-12-25	WOS:000244867200055
J	Kimura, Y; Alric, J; Vermeglio, A; Masuda, S; Hagiwara, Y; Matsuura, K; Shimada, K; Nagashima, KVP				Kimura, Yasuaki; Alric, Jean; Vermeglio, Andre; Masuda, Shinji; Hagiwara, Yuuki; Matsuura, Katsumi; Shimada, Keizo; Nagashima, Kenji V. P.			A new membrane-bound cytochrome c works as an electron donor to the photosynthetic reaction center complex in the purple bacterium, Rhodovulum sulfidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RHODOBACTER-SPHAEROIDES; RUBRIVIVAX-GELATINOSUS; RHODOPSEUDOMONAS-VIRIDIS; INTERACTION SITE; UNUSUAL TRIHEME; SUBUNIT; SEQUENCE; GROWTH; GENES	A new type of membrane-bound cytochrome c was found in a marine purple photosynthetic bacterium, Rhodovulum sulfidophilum. This cytochrome c was significantly accumulated in cells growing under anaerobic photosynthetic conditions and showed an apparent molecular mass of similar to 100 kDa when purified and analyzed by SDS-PAGE. The midpoint potential of this cytochrome c was 369 mV. Flash-induced kinetic measurements showed that this new cytochrome c can work as an electron donor to the photosynthetic reaction center. The gene coding for this cytochrome c was cloned and analyzed. The deduced molecular mass was nearly equal to 50 kDa. Its C-terminal heme-containing region showed the highest sequence identity to the water-soluble cytochrome c, although its predicted secondary structure resembles that of cytochrome c(y). Phylogenetic analyses suggested that this new cytochrome c has evolved from cytochrome c, We, thus, propose its designation as cytochrome C-2m. Mutants lacking this cytochrome or cytochrome c(2) showed the same growth rate as the wild type. However, a double mutant lacking both cytochrome c(2) and c(2). showed no growth under photosynthetic conditions. It was concluded that either the membrane-bound cytochrome c(2). or the water-soluble cytochrome c(2) work as a physiological electron carrier in the photosynthetic electron transfer pathway of Rvu. sulfidophilum.	Tokyo Metropolitan Univ, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; CNRS, UMR 7141, Inst Biol Physicochim, F-75005 Paris, France; CEA Aix Marseille II, CNRS, UMR 6191, DEVM,Lab Bioenerget Cellulaire,CEA Cadarache, F-13108 St Paul Les Durance, France; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Tokyo Metropolitan University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Tokyo Institute of Technology	Nagashima, KVP (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, 1-1 Hachioji, Hachioji, Tokyo 1920397, Japan.	nagashima-kenji@c.metro-u.ac.jp	Alric, Jean/E-3538-2013; Masuda, Shinji/A-2703-2014; Nagashima, Kenji V. P./M-2208-2017	Alric, Jean/0000-0003-3574-2234; Masuda, Shinji/0000-0002-5349-4927; Nagashima, Kenji V. P./0000-0002-4526-6625				Alric J, 2004, J BIOL CHEM, V279, P26090, DOI 10.1074/jbc.M400361200; Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; BOTT M, 1991, J BACTERIOL, V173, P6766, DOI 10.1128/jb.173.21.6766-6772.1991; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; DRACHEVA S, 1991, BIOCHEMISTRY-US, V30, P11451, DOI 10.1021/bi00112a012; GAY P, 1985, J BACTERIOL, V164, P918, DOI 10.1128/JB.164.2.918-921.1985; JENNEY FE, 1993, EMBO J, V12, P1283, DOI 10.1002/j.1460-2075.1993.tb05773.x; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KUROWSKI B, 1987, J BIOL CHEM, V262, P13805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER CRD, 1995, ANOXYGENIC PHOTOSYNT; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; Masuda S, 1999, J BACTERIOL, V181, P4205, DOI 10.1128/JB.181.14.4205-4215.1999; Masuda S, 2002, BIOCHEMISTRY-US, V41, P11211, DOI 10.1021/bi0258492; MATSUURA K, 1986, BIOCHIM BIOPHYS ACTA, V852, P9, DOI 10.1016/0005-2728(86)90050-2; MATSUURA K, 1994, J PLANT RES, V107, P191, DOI 10.1007/BF02346017; Menin L, 1999, BIOCHEMISTRY-US, V38, P15238, DOI 10.1021/bi991146h; Meyer TE, 1995, ANOXYGENIC PHOTOSYNT, P725; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Osyczka A, 2001, J BIOL CHEM, V276, P24108, DOI 10.1074/jbc.M101141200; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; SCHOEPP B, 1995, BIOCHEMISTRY-US, V34, P11736, DOI 10.1021/bi00037a010; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Tsukatani Y, 2004, PHOTOSYNTH RES, V79, P83, DOI 10.1023/B:PRES.0000011922.56394.92; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yamada M, 2005, J BACTERIOL, V187, P1702, DOI 10.1128/JB.187.5.1702-1709.2005; Yoshida MT, 2001, BBA-BIOENERGETICS, V1506, P23, DOI 10.1016/S0005-2728(01)00177-3; Zeng XH, 2003, J BACTERIOL, V185, P6171, DOI 10.1128/JB.185.20.6171-6184.2003	39	5	6	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6463	6472		10.1074/jbc.M604452200	http://dx.doi.org/10.1074/jbc.M604452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197696	hybrid			2022-12-25	WOS:000244867200054
J	Malo, ME; Li, L; Fliegel, L				Malo, Mackenzie E.; Li, Liang; Fliegel, Larry			Mitogen-activated protein kinase-dependent activation of the Na+/H+ exchanger is mediated through phosphorylation of amino acids Ser(770) and Ser(771)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SEGMENT-IV; NHE1; IDENTIFICATION; MECHANISM; MYOCARDIUM; EXPRESSION; INHIBITORS; ISOFORM-1; THERAPY; DOMAIN	We investigated regulation of the type I isoform of the Na+/H+ exchanger by phosphorylation. Four specific groups of serine and threonine residues in the regulatory carboxyl-terminal tail were mutated to alanine residues: group 1, S693A; group 2, T718A and S723A/S726A/S729A; group 3, S766A/S770A/ S771A; and group 4, T779A and S785A. The proteins were expressed in Na+/H+ exchanger-deficient cells, and the activity was characterized. All of the mutants had proper expression, localization, and normal basal activity relative to wild type NHEI. Sustained intracellular acidosis was used to activate NHE1 via an ERK-dependent pathway that could be blocked with the MEK inhibitor U0126. Immunoprecipitation of 32p-labeled Na+/H+ exchanger from intact cells showed that sustained intracellular acidosis increased Na+/H+ exchanger phosphorylation in vivo. This was blocked by U0126. The Na+/H+ exchanger activity of mutants 1 and 2 was stimulated similar to wild type Na+/H+ exchanger. Mutant 4 showed a partially reduced level of activation. However, mutant 3 was not stimulated by sustained intracellular acidosis, and loss of stimulation of activity correlated to a loss of sustained acidosis-mediated phosphorylation in vivo. Mutation of the individual amino acids within mutant 3, Ser766, Ser171, and Ser771, showed that Ser770 and Ser771 are responsible for mediating increases in NHE1 activity through sustained acidosis. Both intact Ser770 and Ser771 were required for sustained acidosis-mediated activation of NHEL Our results suggest that amino acids Ser770 and Ser771 mediate ERK-dependent activation of the Na+/H+ exchanger in vivo.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Fliegel, L (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	lfliegel@ualberta.ca	Li, Liang/D-1822-2011	E Malo, Mackenzie/0000-0002-9118-0806				Avkiran M, 2001, BASIC RES CARDIOL, V96, P306, DOI 10.1007/s003950170037; Avkiran M, 2002, J AM COLL CARDIOL, V39, P747, DOI 10.1016/S0735-1097(02)01693-5; Baldursson O, 2000, AM J PHYSIOL-LUNG C, V279, pL835, DOI 10.1152/ajplung.2000.279.5.L835; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fliegel L, 2005, INT J BIOCHEM CELL B, V37, P33, DOI 10.1016/j.biocel.2004.02.006; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hayashi H, 2002, J BIOL CHEM, V277, P11090, DOI 10.1074/jbc.M111868200; KARMAZYN M, 2005, HAEMATOL DISORD, V5, P323; Khaled AR, 2001, MOL CELL BIOL, V21, P7545, DOI 10.1128/MCB.21.22.7545-7557.2001; LAZDUNSKI M, 1985, J MOL CELL CARDIOL, V17, P1029, DOI 10.1016/S0022-2828(85)80119-X; Liu HZ, 2004, ANAL CHEM, V76, P4223, DOI 10.1021/ac035231d; Martin SW, 2006, CELL CALCIUM, V39, P275, DOI 10.1016/j.ceca.2005.11.002; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Moor AN, 2001, J BIOL CHEM, V276, P16113, DOI 10.1074/jbc.M100519200; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Slepkov ER, 2005, J BIOL CHEM, V280, P17863, DOI 10.1074/jbc.M409608200; Slepkov ER, 2004, BIOCHEM J, V379, P31, DOI 10.1042/BJ20030884; Smith JA, 2005, CANCER RES, V65, P1027; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Van Linden AA, 2005, BIOCHEMISTRY-US, V44, P6980, DOI 10.1021/bi050058w; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Zeymer U, 2001, J AM COLL CARDIOL, V38, P1644	29	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6292	6299		10.1074/jbc.M611073200	http://dx.doi.org/10.1074/jbc.M611073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17209041	hybrid			2022-12-25	WOS:000244867200035
J	Valdivia, ER; Wu, Y; Li, LC; Cosgrove, DJ; Stephenson, AG				Valdivia, Elene R.; Wu, Yajun; Li, Lian-Chao; Cosgrove, Daniel J.; Stephenson, Andrew G.			A Group-1 Grass Pollen Allergen Influences the Outcome of Pollen Competition in Maize	PLOS ONE			English	Article							IGE-EPITOPES; PERFORMANCE; TUBE; CLONING; GENE; GERMINATION; POPULATION; EXPRESSION; EXPANSINS; PROTEINS	Worldwide, 400 million people suffer from hay fever and seasonal asthma. The major causative agents of these allergies are pollen specific proteins called the group-1 grass pollen allergens. Although details of their antigenicity have been studied for 40 years with an eye towards immunotherapy, their function in the plant has drawn scant attention. Zea m 1 constitutes a class of abundant grass pollen allergens coded for by several genes that loosen the walls of grass cells, including the maize stigma and style. We have examined the impact of a transposon insertion into one of these genes (EXPB1, the most abundant isoform of Zea m 1) on the production of Zea m 1 protein, pollen viability, and pollen tube growth, both in vitro and in vivo. We also examined the effect of the insertional mutation on the competitive ability of the pollen by experimentally varying the sizes of the pollen load deposited onto stigmas using pollen from heterozygous plants and then screening the progeny for the presence of the transposon using PCR. We found that the insertional mutation reduced the levels of Zea m 1 in maize pollen, but had no effect on pollen viability, in vitro pollen tube growth or the proportion of progeny sired when small pollen loads are deposited onto stigmas. However, when large pollen loads are deposited onto the stigmas, the transposon mutation is vastly underrepresented in the progeny, indicating that this major pollen allergen has a large effect on pollen tube growth rates in vivo, and plays an important role in determining the outcome of the pollen-pollen competition for access to the ovules. We propose that the extraordinary abundance (4% of the extractable protein in maize pollen) of this major pollen allergen is the result of selection for a trait that functions primarily in providing differential access to ovules.	[Valdivia, Elene R.; Wu, Yajun; Cosgrove, Daniel J.; Stephenson, Andrew G.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Valdivia, Elene R.; Wu, Yajun; Cosgrove, Daniel J.; Stephenson, Andrew G.] Penn State Univ, Plant Physiol Grad Program, University Pk, PA 16802 USA; [Li, Lian-Chao] Penn State Univ, Huck Inst Life Sci, Prote & Mass Spectrometry Core Facil, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Stephenson, AG (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.	as4@psu.edu	/AAE-9630-2019	Valdivia, Elene/0000-0001-6773-0583	NSF [DEB 02-35217]; USDA [2005-35320-15251]; NIH [GM060397]; DOE [DE-FG02-84ER13179]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060397] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); USDA(United States Department of Agriculture (USDA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOE(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported by an NSF grant DEB 02-35217 and USDA grant 2005-35320-15251 to A. G. S. and by NIH grant GM060397 and DOE grant DE-FG02-84ER13179 to D.J.C.; E. R. V. was supported in part by an NSF Graduate Research Training grant to D.J.C.	Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Arthur KM, 2003, GENETICS, V165, P2137; Ashman TL, 2004, ECOLOGY, V85, P2408, DOI 10.1890/03-8024; Ball T, 2005, FEBS J, V272, P217, DOI 10.1111/j.1432-1033.2004.04403.x; BARNABAS B, 1984, ACTA BOT HUNG, V30, P329; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Bernasconi G, 2004, PERSPECT PLANT ECOL, V6, P149, DOI 10.1078/1433-8319-00075; Bernasconi G, 2004, SCIENCE, V303, P971, DOI 10.1126/science.1092180; Brutnell TP, 2002, FUNCT INTEGR GENOMIC, V2, P4, DOI 10.1007/s10142-001-0044-0; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Cosgrove DJ, 2002, PLANT CELL PHYSIOL, V43, P1436, DOI 10.1093/pcp/pcf180; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; COSTANUNES JD, 2003, GENOME BIOL, V5; Delph LF, 1997, ECOLOGY, V78, P1632, DOI 10.1890/0012-9658(1997)078[1632:HEFAPP]2.0.CO;2; Falque M, 2005, GENETICS, V170, P1957, DOI 10.1534/genetics.104.040204; GORLA MS, 1994, POLLEN PISTIL INTERA, P230; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; Knox B, 1996, TRENDS PLANT SCI, V1, P156, DOI 10.1016/S1360-1385(96)80051-3; KNOX RB, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P31; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; Li LC, 2003, PLANT PHYSIOL, V132, P2073, DOI 10.1104/pp.103.020024; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; MARTIN FW, 1959, STAIN TECHNOL, V34, P125, DOI 10.3109/10520295909114663; MCQUEENMASON S, 1994, P NATL ACAD SCI USA, V91, P6574, DOI 10.1073/pnas.91.14.6574; Meeley B., 1995, Maize Genetics Cooperation Newsletter, P82; OTTAVIANO E, 1988, THEOR APPL GENET, V76, P601, DOI 10.1007/BF00260915; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; QUESADA M, 1993, AM NAT, V142, P694, DOI 10.1086/285564; RICH PM, 1989, MANUAL MICROCOMPUTER; Rodriguez-Riano T, 2000, SEX PLANT REPROD, V12, P241, DOI 10.1007/s004970050008; Sampedro J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-242; SCHIEFELBEIN J, 1993, PLANT PHYSIOL, V103, P979, DOI 10.1104/pp.103.3.979; Schreiber S, 2003, Z GASTROENTEROL, V41, P21, DOI 10.1055/s-2003-36662; SHCHERBAN TY, 1995, P NATL ACAD SCI USA, V92, P9245, DOI 10.1073/pnas.92.20.9245; SNOW AA, 1993, ANNU REV ECOL SYST, V24, P331, DOI 10.1146/annurev.es.24.110193.001555; STEPHENSON AG, 1992, ECOLOGY AND EVOLUTION OF PLANT REPRODUCTION, P119; Stephenson AG, 2001, SEX PLANT REPROD, V14, P77, DOI 10.1007/s004970100081; Stephenson AG, 2003, PHILOS T R SOC B, V358, P1009, DOI 10.1098/rstb.2003.1290; STEPHENSON AG, 1981, ANNU REV ECOL SYST, V12, P253, DOI 10.1146/annurev.es.12.110181.001345; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; Travers SE, 2000, AM J BOT, V87, P1091, DOI 10.2307/2656645; VALDIVIA ER, 2005, THESIS PENNSYLVANIA; Vejlupkova Z., 2003, Maize Genetics Cooperation Newsletter, P24; Wang W, 2004, SEX PLANT REPROD, V17, P41, DOI 10.1007/s00497-004-0207-y; WILLING RP, 1988, THEOR APPL GENET, V75, P751, DOI 10.1007/BF00265600; Winsor JA, 2000, AM J BOT, V87, P527, DOI 10.2307/2656596; Wu YJ, 2001, PLANT PHYSIOL, V126, P222, DOI 10.1104/pp.126.1.222; Xu ZN, 2006, GENETICS, V172, P1251, DOI 10.1534/genetics.105.050237; ZAMIR D, 1982, GENETICS, V101, P129; ZAMIR D, 1981, THEOR APPL GENET, V59, P235, DOI 10.1007/BF00265501	54	38	41	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2007	2	1							e154	10.1371/journal.pone.0000154	http://dx.doi.org/10.1371/journal.pone.0000154			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DF	17225858	Green Published, gold			2022-12-25	WOS:000207444000005
J	Chen, L; Jha, P; Stirling, B; Sgaier, SK; Daid, T; Kaul, R; Nagelkerke, N				Chen, Li; Jha, Prabhat; Stirling, Bridget; Sgaier, Sema K.; Daid, Tina; Kaul, Rupert; Nagelkerke, Nico		Int Studies HIV AIDS ISHA Investig	Sexual Risk Factors for HIV Infection in Early and Advanced HIV Epidemics in Sub-Saharan Africa: Systematic Overview of 68 Epidemiological Studies	PLOS ONE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX VIRUS-2; DAR-ES-SALAAM; REPRODUCTIVE-TRACT INFECTIONS; DISTANCE TRUCK-DRIVERS; GENITAL-ULCER-DISEASE; BASE-LINE SURVEY; TRANSMITTED-DISEASES; MALE CIRCUMCISION; PREGNANT-WOMEN	Background. It is commonly assumed that sexual risk factors for heterosexual HIV transmission in sub-Saharan Africa, such as multi-partner sex, paid sex and co-infections, become less important as HIV epidemics mature and prevalence increases. Methods and Findings. We conducted a systematic review of 68 African epidemiological studies from 1986 to 2006 involving 17,000 HIV positive adults and 73,000 controls. We used random-effects methods and stratified results by gender, time, background HIV prevalence rates and other variables. The number of sex partners, history of paid sex, and infection with herpes simplex virus (HSV-2) or other sexually-transmitted infections (STIs) each showed significant associations with HIV infection. Among the general population, the odds ratio (OR) of HIV infection for women reporting 3+ sex partners versus 0-2 was 3.64 (95% CI [2.87-4.62]), with similar risks for men. About 9% of infected women reported ever having been paid for sex, versus 4% of control women (OR = 2.29, [1.45-3.62]). About 31% of infected men reported ever paying for sex versus 18% of uninfected men (OR = 1.75, [1.30-2.36]). HSV-2 infection carried the largest risk of HIV infection: OR = 4.62, [2.85-7.47] in women, and OR = 6.97, [4.68-10.38] in men. These risks changed little over time and stratification by lower and higher HIV background prevalence showed that risk ratios for most variables were larger in high prevalence settings. Among uninfected controls, the male-female differences in the number of sex partners and in paid sex were more extreme in the higher HIV prevalence settings than in the lower prevalence settings. Significance. Multi-partner sex, paid sex, STIs and HSV-2 infection are as important to HIV transmission in advanced as in early HIV epidemics. Even in high prevalence settings, prevention among people with high rates of partner change, such as female sex workers and their male clients, is likely to reduce transmission overall.	[Chen, Li; Jha, Prabhat; Stirling, Bridget; Sgaier, Sema K.; Daid, Tina] Univ Toronto, St Michaels Hosp, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada; [Stirling, Bridget] Univ Victoria, Div Med Sci, Isl Med Program, Victoria, BC, Canada; [Kaul, Rupert] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; [Kaul, Rupert] Univ Toronto, Dept Med, Univ Hlth Network, Toronto, ON, Canada; [Nagelkerke, Nico] Al Ain Univ, Dept Community Med, Al Ain, U Arab Emirates	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Victoria; University of Nairobi; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Jha, P (corresponding author), Univ Toronto, St Michaels Hosp, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada.	prabhat.jha@utoronto.ca		Kaul, Rupert/0000-0002-1586-4093; Wang, Yu/0000-0001-7935-9902	Canadian Institutes of Health Research [123821]; Bill and Melinda Gates Foundation [39922]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Supported in part by research grants from the Canadian Institutes of Health Research (no 123821), and the Bill and Melinda Gates Foundation (no 39922). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams KR, 2000, METHODS METAANALYSIS; Alary M, 2002, AIDS, V16, P463, DOI 10.1097/00002030-200202150-00019; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; Ao TTH, 2006, SEX TRANSM DIS, V33, P163, DOI 10.1097/01.olq.0000187204.57006.b3; Aseffa A, 1998, EPIDEMIOL INFECT, V120, P171, DOI 10.1017/S0950268897008595; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009; BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016; BASSETT MT, 1992, J ACQ IMMUN DEF SYND, V5, P556; Bassett MT, 1996, J ACQ IMMUN DEF SYND, V13, P287, DOI 10.1097/00042560-199611010-00012; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; Boerma JT, 2003, SEX TRANSM DIS, V30, P779, DOI 10.1097/01.OLQ.0000078820.62897.A6; Bogaerts J, 1998, INT J STD AIDS, V9, P706, DOI 10.1258/0956462981921242; Breslow NE, 1980, IARC SCI PUBL, V32; BULTERYS M, 1994, AIDS, V8, P1585, DOI 10.1097/00002030-199411000-00010; BWAYO J, 1994, ARCH INTERN MED, V154, P1391, DOI 10.1001/archinte.154.12.1391; BWAYO JJ, 1991, E AFR MED J, V68, P425; CARAEL M, 1988, AIDS, V2, P201; Carpenter LM, 2002, J ACQ IMMUN DEF SYND, V29, P174, DOI 10.1097/00042560-200202010-00011; CARSWELL JW, 1989, AIDS, V3, P759, DOI 10.1097/00002030-198911000-00013; CHAO A, 1994, INT J EPIDEMIOL, V23, P371, DOI 10.1093/ije/23.2.371; Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005; Cleland J, 2004, SEX TRANSM INFECT, V80, P1, DOI 10.1136/sti.2004.013151; Clift S, 2003, SEX TRANSM INFECT, V79, P307, DOI 10.1136/sti.79.4.307; Coffee MP, 2005, J INFECT DIS, V191, pS159, DOI 10.1086/425270; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; COSSA HA, 1994, INT J STD AIDS, V5, P117, DOI 10.1177/095646249400500208; Cote AM, 2004, AIDS, V18, P917, DOI [10.1097/01.aids.0000111475.61782.98, 10.1097/00002030-200404090-00009]; Cowan FM, 2005, JAIDS-J ACQ IMM DEF, V40, P371, DOI 10.1097/01.qai.0000162420.93243.ff; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Egger M., 2008, SYSTEMATIC REV HLTH; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Gomo E., 1997, Central African Journal of Medicine, V43, P350; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; GROSSKURTH H, 1995, AIDS, V9, P927, DOI 10.1097/00002030-199508000-00015; Gwanzura L, 1998, J INFECT DIS, V177, P481, DOI 10.1086/517381; Hargreaves JR, 2002, TROP MED INT HEALTH, V7, P793, DOI 10.1046/j.1365-3156.2002.00943.x; Hearst N, 1997, AIDS, V11, pS1; HIRA SK, 1990, J INFECT DIS, V161, P584, DOI 10.1093/infdis/161.3.584; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HUNTER DJ, 1994, AIDS, V8, P93, DOI 10.1097/00002030-199401000-00014; Jha P, 2001, SCIENCE, V292, P224, DOI 10.1126/science.1058187; Kapiga S H, 2000, Afr J Reprod Health, V4, P88, DOI 10.2307/3583246; Kapiga SH, 2003, SEX TRANSM DIS, V30, P187, DOI 10.1097/00007435-200303000-00001; Kapiga SH, 2002, J ACQ IMMUN DEF SYND, V29, P409, DOI 10.1097/00126334-200204010-00013; Kapiga SH, 1998, AIDS, V12, P75, DOI 10.1097/00002030-199801000-00009; KAPIGA SH, 1994, J ACQ IMMUN DEF SYND, V7, P301; Kaul R, 2004, JAMA-J AM MED ASSOC, V291, P2555, DOI 10.1001/jama.291.21.2555; Kelly R, 1999, AIDS, V13, P399, DOI 10.1097/00002030-199902250-00013; Kelly RJ, 2003, JAIDS-J ACQ IMM DEF, V32, P446, DOI 10.1097/00126334-200304010-00016; Keou FXM, 1999, AIDS, V13, P536, DOI 10.1097/00002030-199903110-00021; Korenromp EL, 2001, SEX TRANSM DIS, V28, P613, DOI 10.1097/00007435-200111000-00001; Kumwenda NI, 2002, SEX TRANSM DIS, V29, P366, DOI 10.1097/00007435-200206000-00010; Lagarde E, 2004, INT J STD AIDS, V15, P395, DOI 10.1258/095646204774195254; Lagarde E, 2003, INT J EPIDEMIOL, V32, P744, DOI 10.1093/ije/dyg111; Langeland N, 1998, INT J STD AIDS, V9, P104, DOI 10.1258/0956462981921765; Lankoande S, 1998, INT J STD AIDS, V9, P146, DOI 10.1258/0956462981921909; LEROY V, 1995, GENITOURIN MED, V71, P207; LINDAN C, 1991, AIDS, V5, P993, DOI 10.1097/00002030-199108000-00011; Lurie MN, 2003, SEX TRANSM DIS, V30, P149, DOI 10.1097/00007435-200302000-00011; Lurie MN, 2003, AIDS, V17, P2245, DOI 10.1097/00002030-200310170-00013; MacDonald KS, 2001, AIDS, V15, P635, DOI 10.1097/00002030-200103300-00014; MAGGWA BN, 1993, AIDS, V7, P733, DOI 10.1097/00002030-199305000-00019; MANN JM, 1988, AIDS, V2, P249, DOI 10.1097/00002030-198808000-00002; Marcelin AG, 2002, J MED VIROL, V68, P164, DOI 10.1002/jmv.10184; Mbizvo EM, 2002, INT J STD AIDS, V13, P343, DOI 10.1258/0956462021925171; Mbizvo EM, 2001, INT J STD AIDS, V12, P524, DOI 10.1258/0956462011923624; Mbizvo M. T., 1996, Central African Journal of Medicine, V42, P14; Mbopi-Keou FX, 2000, J INFECT DIS, V182, P1090, DOI 10.1086/315836; MCCARTHY MC, 1989, AIDS, V3, P725, DOI 10.1097/00002030-198911000-00006; MCCARTHY MC, 1995, J MED VIROL, V46, P18, DOI 10.1002/jmv.1890460105; McFarland W, 1999, J INFECT DIS, V180, P1459, DOI 10.1086/315076; MEDA N, 1995, INT J STD AIDS, V6, P273, DOI 10.1177/095646249500600410; Mihret W, 2002, SEX TRANSM DIS, V29, P175, DOI 10.1097/00007435-200203000-00008; MIOTTI PG, 1990, AIDS, V4, P733, DOI 10.1097/00002030-199008000-00003; Mnyika KS, 1996, J ACQ IMMUN DEF SYND, V11, P484, DOI 10.1097/00042560-199604150-00009; Msuya SE, 2003, SEX TRANSM DIS, V30, P588, DOI 10.1097/00007435-200307000-00011; Msuya SE, 2002, ACTA OBSTET GYN SCAN, V81, P886, DOI 10.1034/j.1600-0412.2002.810916.x; Nagelkerke NJD, 2002, B WORLD HEALTH ORGAN, V80, P89; Nagot N, 2005, JAIDS-J ACQ IMM DEF, V39, P454, DOI 10.1097/01.qai.0000152399.54648.b9; NdinyaAchola JO, 1997, INT J STD AIDS, V8, P506, DOI 10.1258/0956462971920668; NSUBUGA P, 1990, J ACQ IMMUN DEF SYND, V3, P1002; Nunn AJ, 1996, INT J STD AIDS, V7, P123, DOI 10.1258/0956462961917320; Nyambi P, 2002, JAIDS-J ACQ IMM DEF, V31, P506, DOI 10.1097/00126334-200212150-00008; NZILA N, 1991, AIDS, V5, P715, DOI 10.1097/00002030-199106000-00011; Obisesan KA, 1997, INT J GYNECOL OBSTET, V56, P271, DOI 10.1016/S0020-7292(96)02821-4; Petry KU, 1996, INT J STD AIDS, V7, P265, DOI 10.1258/0956462961917942; Pettifor AE, 2004, AIDS, V18, P1435, DOI 10.1097/01.aids.0000131338.61042.b8; PISON G, 1993, J ACQ IMMUN DEF SYND, V6, P196; PLOURDE PJ, 1992, J INFECT DIS, V166, P86, DOI 10.1093/infdis/166.1.86; PUJADES RMM, 2002, AIDS, V16, P451; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; Quigley MA, 2000, J ACQ IMMUN DEF SYND, V23, P418, DOI 10.1097/00042560-200004150-00009; Ramjee G, 2005, JAIDS-J ACQ IMM DEF, V39, P333, DOI 10.1097/01.qai.0000144445.44518.ea; Riedner G, 2003, SEX TRANSM INFECT, V79, P382, DOI 10.1136/sti.79.5.382; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Sagay AS, 2005, INT J GYNECOL OBSTET, V90, P61, DOI 10.1016/j.ijgo.2005.03.030; SAMOAHADU C, 2001, J ACQ IMMUN DEF SYND, V28, P358; SassanMorokro M, 1996, J ACQ IMMUN DEF SYND, V11, P183, DOI 10.1097/00042560-199602010-00010; Seber G., 2003, LINEAR REGRESSION AN; SEED J, 1995, J ACQ IMMUN DEF SYND, V8, P83; Sentjens REJH, 2002, EPIDEMIOL INFECT, V128, P221, DOI 10.1017/S0950268801006604; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; Siegfried N, 2005, LANCET INFECT DIS, V5, P165, DOI 10.1016/S1473-3099(05)01309-5; Siegfried N, 2005, BRIT MED J, V331, P742, DOI 10.1136/bmj.331.7519.742; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; Simooya OO, 2001, AIDS, V15, P1741, DOI 10.1097/00002030-200109070-00023; Sinei SKA, 1996, INT J STD AIDS, V7, P65, DOI 10.1258/0956462961917104; Siziya S., 1996, Central African Journal of Medicine, V42, P114; Smith J, 1999, INT J STD AIDS, V10, P452, DOI 10.1258/0956462991914456; Stringer EM, 2004, JAIDS-J ACQ IMM DEF, V35, P60, DOI 10.1097/00126334-200401010-00009; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sutcliffe S, 2002, JAIDS-J ACQ IMM DEF, V31, P90, DOI 10.1097/00126334-200209010-00012; Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019; Tengia-Kessy A, 1998, E AFR MED J, V75, P528; TERMEULEN J, 1992, E AFR MED J, V69, P688; Thior I, 1997, Afr J Reprod Health, V1, P26, DOI 10.2307/3583374; Todd J, 2006, J INFECT DIS, V193, P458, DOI 10.1086/499313; *UNAIDS, 2006, AIDS EP UPD; *UNAIDS, 2005, AIDS EP UPD SPEC SEC; Urassa M, 1997, AIDS, V11, P73, DOI 10.1097/00002030-199701000-00011; VANDEPERRE P, 1987, AIDS, V1, P207; Wawer M., 2005, 12 C RETR OPP INF BO; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8; *WHO UNAIDS, 2002, 13 WHOUNAIDS; *WHO UNAIDS, CONS STI IN IN PRESS; Zaba BW, 2000, AIDS, V14, P2741, DOI 10.1097/00002030-200012010-00014; Zuma K, 2003, INT J STD AIDS, V14, P814, DOI 10.1258/095646203322556147	130	199	208	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2007	2	10							e1001	10.1371/journal.pone.0001001	http://dx.doi.org/10.1371/journal.pone.0001001			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HU	17912340	Green Published, gold			2022-12-25	WOS:000207455900037
J	Chen, SX; Wang, Y; Chen, FY; Yang, HC; Gan, MH; Zheng, SJ				Chen, Shixi; Wang, Yu; Chen, Fuyong; Yang, Hanchun; Gan, Menghou; Zheng, Shijun J.			A Highly Pathogenic Strain of Staphylococcus sciuri Caused Fatal Exudative Epidermitis in Piglets	PLOS ONE			English	Article							HYICUS SUBSP HYICUS; EXFOLIATIVE TOXIN; MOLECULAR CHARACTERIZATION; MEMBERS; PIGS; SKIN; IDENTIFICATION; MASTITIS	Staphylococcus sciuri are important human pathogens responsible for endocarditis, peritonitis, septic shock, urinary tract infection, pelvic inflammatory disease and wound infections. However, little information is known regarding the pathogenicity of S. sciuri to animals. From the pericardial fluid of a diseased piglet with exudative epidermitis (EE), we isolated a strain of Staphylococcus in pure culture. Surprisingly, this isolate was a member of S. sciuri rather than S. hyicus as identified by its biochemical traits and also by analysis of 23S ribosomal DNA using Internal Transcribed Spacer PCR. In addition, inoculation of newborn piglets with 1x10(10) CFU of the isolate by oral feeding or intra-muscular injection successfully reproduced EE in piglets, which suggested that the oral intake of the pathogen by the animals is one of the major routes of exposure. These unexpected findings prioritized S. sciuri as important zoonotic agents, which may have ramifications for human medicine.	[Chen, Shixi; Wang, Yu; Chen, Fuyong; Yang, Hanchun; Gan, Menghou; Zheng, Shijun J.] China Agr Univ, Coll Vet Med, Minist Agr, Key Lab Prevent Vet Med, Beijing 100094, Peoples R China	China Agricultural University; Ministry of Agriculture & Rural Affairs	Zheng, SJ (corresponding author), China Agr Univ, Coll Vet Med, Minist Agr, Key Lab Prevent Vet Med, Beijing 100094, Peoples R China.	sjzheng@cau.edu.cn		Kaul, Rupert/0000-0002-1586-4093; Wang, Yu/0000-0001-7935-9902	National Basic Research Program (Project 973) of China [2006CB504300]	National Basic Research Program (Project 973) of China(National Basic Research Program of China)	This work was supported by a grant from the National Basic Research Program (Project 973) of China (Grant 2006CB504300).	Ahrens P, 2004, J BACTERIOL, V186, P1833, DOI 10.1128/JB.186.6.1833-1837.2004; Amtsberg G, 1973, Dtsch Tierarztl Wochenschr, V80, P496; Andresen LO, 1998, FEMS IMMUNOL MED MIC, V20, P301, DOI 10.1111/j.1574-695X.1998.tb01140.x; Andresen LO, 2005, VET REC, V157, P376, DOI 10.1136/vr.157.13.376; Andresen LO, 2005, VET MICROBIOL, V105, P291, DOI 10.1016/j.vetmic.2004.12.006; Andresen LO, 2004, J APPL MICROBIOL, V96, P1265, DOI 10.1111/j.1365-2672.2004.02258.x; ANDRESEN LO, 1993, MICROB PATHOGENESIS, V15, P217, DOI 10.1006/mpat.1993.1072; Couto I, 1996, MICROB DRUG RESIST, V2, P377, DOI 10.1089/mdr.1996.2.377; Couto I, 2000, J CLIN MICROBIOL, V38, P1136, DOI 10.1128/JCM.38.3.1136-1143.2000; Couto I, 2001, J CLIN MICROBIOL, V39, P3099, DOI 10.1128/JCM.39.9.3099-3103.2001; Dakic I, 2005, J CLIN MICROBIOL, V43, P4875, DOI 10.1128/JCM.43.9.4875-4876.2005; Gianneechini R, 2002, ACTA VET SCAND, V43, P221, DOI 10.1186/1751-0147-43-221; Hanakawa Y, 2002, J CLIN INVEST, V110, P53, DOI 10.1172/JCI200215766; Hedin G, 1998, EUR J CLIN MICROBIOL, V17, P673, DOI 10.1007/s100960050157; Hill BD, 1996, AUST VET J, V73, P179, DOI 10.1111/j.1751-0813.1996.tb10022.x; Horii T, 2001, SCAND J INFECT DIS, V33, P930, DOI 10.1080/00365540110076750; LAMMLER C, 1990, BERL MUNCH TIERARZTL, V103, P60; ONET GE, 1991, J AM VET MED ASSOC, V199, P362; PHILLIPS WE, 1980, AM J VET RES, V41, P274; POUTREL B, 1984, AM J VET RES, V45, P2084; Rahman MT, 2005, MICROB DRUG RESIST, V11, P205, DOI 10.1089/mdr.2005.11.205; Sato H, 1990, Kitasato Arch Exp Med, V63, P119; Sato H, 2000, J BACTERIOL, V182, P4096, DOI 10.1128/JB.182.14.4096-4100.2000; SCHULZ W, 1969, Archiv fuer Experimentelle Veterinaermedizin, V23, P415; Shittu A, 2004, J MED MICROBIOL, V53, P51, DOI 10.1099/jmm.0.05294-0; Stepanovic S, 2005, INT J STD AIDS, V16, P452, DOI 10.1258/0956462054093999; Stepanovic S, 2005, SYST APPL MICROBIOL, V28, P353, DOI 10.1016/j.syapm.2005.02.001; Stepanovic S, 2005, J CLIN MICROBIOL, V43, P956, DOI 10.1128/JCM.43.2.956-958.2005; Stepanovic S, 2003, J CLIN MICROBIOL, V41, P5262, DOI 10.1128/JCM.41.11.5262-5264.2003; Stepanovic S, 2002, SCAND J INFECT DIS, V34, P685, DOI 10.1080/00365540110076949; Stepanovic S, 2001, VET MICROBIOL, V82, P177, DOI 10.1016/S0378-1135(01)00377-7; Stepanovic S, 2001, FEMS MICROBIOL LETT, V199, P47, DOI 10.1016/S0378-1097(01)00150-1; TAKEUCHI S, 1987, VET MICROBIOL, V14, P47, DOI 10.1016/0378-1135(87)90051-4; Waage S, 1999, J DAIRY SCI, V82, P712, DOI 10.3168/jds.S0022-0302(99)75288-4; Wallet F, 2000, SCAND J INFECT DIS, V32, P697, DOI 10.1080/003655400459667; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	36	199	208	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2007	2	1							e147	10.1371/journal.pone.0000147	http://dx.doi.org/10.1371/journal.pone.0000147			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DE	17912340	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443900001
